<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="fedregister.xsl"?>
<FEDREG xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="FRMergedXML.xsd">
    <VOL>91</VOL>
    <NO>145</NO>
    <DATE>Thursday, July 30, 2026</DATE>
    <UNITNAME>Contents</UNITNAME>
    <CNTNTS>
        <AGCY>
            <EAR>
                Agency Health
                <PRTPAGE P="iii"/>
            </EAR>
            <HD>Agency for Healthcare Research and Quality</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals, </DOC>
                    <PGS>48112-48115</PGS>
                    <FRDOCBP>2026-15324</FRDOCBP>
                      
                    <FRDOCBP>2026-15326</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Agriculture</EAR>
            <HD>Agriculture Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Natural Resources Conservation Service</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals, </DOC>
                    <PGS>48059</PGS>
                    <FRDOCBP>2026-15433</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>AIRFORCE</EAR>
            <HD>Air Force Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Licenses; Exemptions, Applications, Amendments, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Joint Ownership Agreement with an Exclusive Patent, </SJDOC>
                    <PGS>48091-48092</PGS>
                    <FRDOCBP>2026-15350</FRDOCBP>
                      
                    <FRDOCBP>2026-15351</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Centers Disease</EAR>
            <HD>Centers for Disease Control and Prevention</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>National Center for Health Statistics, ICD-10 Coordination and Maintenance Committee, </SJDOC>
                    <PGS>48116</PGS>
                    <FRDOCBP>2026-15323</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Centers Medicare</EAR>
            <HD>Centers for Medicare &amp; Medicaid Services</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Medicare Program:</SJ>
                <SJDENT>
                    <SJDOC>Updates to the Master List of Items Potentially Subject to Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements; etc., </SJDOC>
                    <PGS>47972-47978</PGS>
                    <FRDOCBP>2026-15446</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Children</EAR>
            <HD>Children and Families Administration</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <DOCENT>
                    <DOC>Administrative Costs for Children in Title IV-E Foster Care, </DOC>
                    <PGS>48058</PGS>
                    <FRDOCBP>2026-15403</FRDOCBP>
                </DOCENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Single-Source Grants:</SJ>
                <SJDENT>
                    <SJDOC>Multiple Recipients for Necessary Expenses Directly Related to the Consequences of Hurricanes Fiona and Ian, </SJDOC>
                    <PGS>48117-48118</PGS>
                    <FRDOCBP>2026-15413</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Civil Rights</EAR>
            <HD>Civil Rights Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Tennessee Advisory Committee, </SJDOC>
                    <PGS>48060</PGS>
                    <FRDOCBP>2026-15373</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Commerce</EAR>
            <HD>Commerce Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Economic Development Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Foreign-Trade Zones Board</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>International Trade Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Oceanic and Atmospheric Administration</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Committee for Purchase</EAR>
            <HD>Committee for Purchase From People Who Are Blind or Severely Disabled</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Procurement List; Additions and Deletions, </DOC>
                    <PGS>48089-48090</PGS>
                    <FRDOCBP>2026-15348</FRDOCBP>
                      
                    <FRDOCBP>2026-15349</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Corporation</EAR>
            <HD>Corporation for National and Community Service</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>AmeriCorps VISTA Application and Reporting Forms, </SJDOC>
                    <PGS>48090-48091</PGS>
                    <FRDOCBP>2026-15322</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Defense Department</EAR>
            <HD>Defense Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Air Force Department</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Drug</EAR>
            <HD>Drug Enforcement Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Decision and Order:</SJ>
                <SJDENT>
                    <SJDOC>Joan Rubinger, N.P., </SJDOC>
                    <PGS>48190-48197</PGS>
                    <FRDOCBP>2026-15328</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Economic Development</EAR>
            <HD>Economic Development Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Non-Infrastructure Metrics, </SJDOC>
                    <PGS>48060-48061</PGS>
                    <FRDOCBP>2026-15432</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Energy Department</EAR>
            <HD>Energy Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Energy Regulatory Commission</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>229 Boundary for the Princeton Plasma Physics Laboratory, </DOC>
                    <PGS>48092-48093</PGS>
                    <FRDOCBP>2026-15358</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Environmental Protection</EAR>
            <HD>Environmental Protection Agency</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Air Quality State Implementation Plans; Approvals and Promulgations:</SJ>
                <SJDENT>
                    <SJDOC>California; San Joaquin Valley Air Pollution Control District, </SJDOC>
                    <PGS>47962-47965</PGS>
                    <FRDOCBP>2026-15377</FRDOCBP>
                </SJDENT>
                <SJ>Operating Permit Program Approval:</SJ>
                <SJDENT>
                    <SJDOC>New Hampshire; Revised Definitions, </SJDOC>
                    <PGS>47965-47966</PGS>
                    <FRDOCBP>2026-15363</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Air Quality State Implementation Plans; Approvals and Promulgations:</SJ>
                <SJDENT>
                    <SJDOC>Missouri; Construction Permit Exemptions, </SJDOC>
                    <PGS>48032-48033</PGS>
                    <FRDOCBP>2026-15371</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Pennsylvania; Redesignation of the Warren County Nonattainment Area to Attainment and Approval of the Area's Maintenance Plan for the 2010 1-Hour Primary Sulfur Dioxide NAAQS, </SJDOC>
                    <PGS>48034-48042</PGS>
                    <FRDOCBP>2026-15372</FRDOCBP>
                </SJDENT>
                <SJ>Clean Air Act Operating Permit Program Revisions:</SJ>
                <SJDENT>
                    <SJDOC>California; Amador County Air Pollution Control District, Calaveras County Air Pollution Control District, Great Basin Unified Air Pollution Control District, Northern Sierra Air Quality Management District, </SJDOC>
                    <PGS>48042-48044</PGS>
                    <FRDOCBP>2026-15362</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Significant New Use Rules on Certain Chemical Substances (26-4), </DOC>
                    <PGS>48044-48058</PGS>
                    <FRDOCBP>2026-15352</FRDOCBP>
                </DOCENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Application for Registration and Pesticide Report for Pesticide-Producing and Device-Producing Establishments, </SJDOC>
                    <PGS>48107-48108</PGS>
                    <FRDOCBP>2026-15364</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Facility Ground-Water Monitoring Requirements, </SJDOC>
                    <PGS>48106-48107</PGS>
                    <FRDOCBP>2026-15392</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Final Authorization for Hazardous Waste Management Programs, </SJDOC>
                    <PGS>48101-48102</PGS>
                    <FRDOCBP>2026-15376</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Generator Standards Applicable to Laboratories Owned by Eligible Academic Entities, </SJDOC>
                    <PGS>48105-48106</PGS>
                    <FRDOCBP>2026-15393</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Land Disposal Restrictions, </SJDOC>
                    <PGS>48107</PGS>
                    <FRDOCBP>2026-15379</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Management Standards for Hazardous Waste Pharmaceuticals, </SJDOC>
                    <PGS>48100-48101</PGS>
                    <FRDOCBP>2026-15387</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>National Pollutant Discharge Elimination System Program, </SJDOC>
                    <PGS>48102-48103</PGS>
                    <FRDOCBP>2026-15394</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Recordkeeping and Reporting—Solid Waste Disposal Facilities and Practices, </SJDOC>
                    <PGS>48104-48105</PGS>
                    <FRDOCBP>2026-15388</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <PRTPAGE P="iv"/>
                    <DOC>Multi-Agency Radiation Survey and Site Investigation Manual, Revision 2, </DOC>
                    <PGS>48103-48104</PGS>
                    <FRDOCBP>2026-15390</FRDOCBP>
                </DOCENT>
                <SJ>Proposed Settlement Agreement, Stipulation, Order, and Judgment, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Bliss Corner Neighborhood Site, Dartmouth, MA, CERCLA Administrative Cost Recovery, </SJDOC>
                    <PGS>48099-48100</PGS>
                    <FRDOCBP>2026-15391</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>CERCLA Administrative Settlement Agreement with Prospective Purchaser and Covenants Not to Sue, McCormick and Baxter Creosoting Company Superfund Site, Portland, OR, </SJDOC>
                    <PGS>48101</PGS>
                    <FRDOCBP>2026-15395</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Equal</EAR>
            <HD>Equal Employment Opportunity Commission</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Removal of Reporting Requirements, </SJDOC>
                    <PGS>48027-48028</PGS>
                    <FRDOCBP>2026-15340</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Executive Office</EAR>
            <HD>Executive Office for Immigration Review</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <DOCENT>
                    <DOC>Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority, </DOC>
                    <PGS>47979-47994</PGS>
                    <FRDOCBP>2026-15458</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Aviation</EAR>
            <HD>Federal Aviation Administration</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Airworthiness Directives:</SJ>
                <SJDENT>
                    <SJDOC>Airbus Canada Limited Partnership (Type Certificate Previously Held by C Series Aircraft Limited Partnership (CSALP); Bombardier, Inc.) Airplanes, </SJDOC>
                    <PGS>47951-47953</PGS>
                    <FRDOCBP>2026-15411</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Airbus SAS Airplanes, </SJDOC>
                    <PGS>47938-47940, 47948-47951</PGS>
                    <FRDOCBP>2026-15410</FRDOCBP>
                      
                    <FRDOCBP>2026-15455</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Bell Textron Canada Limited Helicopters, </SJDOC>
                    <PGS>47953-47956</PGS>
                    <FRDOCBP>2026-15365</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Bombardier, Inc., Airplanes, </SJDOC>
                    <PGS>47933-47936</PGS>
                    <FRDOCBP>2026-15409</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Leonardo S.p.a. Helicopters, </SJDOC>
                    <PGS>47936-47938</PGS>
                    <FRDOCBP>2026-15370</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>MHI RJ Aviation ULC (Type Certificate Previously Held by Bombardier, Inc.) Airplanes, </SJDOC>
                    <PGS>47946-47948</PGS>
                    <FRDOCBP>2026-15412</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Pilatus Aircraft Ltd. Airplanes, </SJDOC>
                    <PGS>47931-47933</PGS>
                    <FRDOCBP>2026-15467</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Safran Helicopter Engines, S.A. (Type Certificate Previously Held by Turbomeca, S.A.) Engines, </SJDOC>
                    <PGS>47942-47946</PGS>
                    <FRDOCBP>2026-15369</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Stemme GmbH Gliders, </SJDOC>
                    <PGS>47940-47942</PGS>
                    <FRDOCBP>2026-15466</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Airworthiness Directives:</SJ>
                <SJDENT>
                    <SJDOC>Airbus Helicopters Deutschland GmbH (AHD) Helicopters, </SJDOC>
                    <PGS>47994-47997</PGS>
                    <FRDOCBP>2026-15374</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Waiver of Specified Statutory Requirements for Commercial Space Launch and Reentry Actions, </DOC>
                    <PGS>47997-48002</PGS>
                    <FRDOCBP>2026-15415</FRDOCBP>
                </DOCENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Environmental Assessments; Availability, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Finding of No Significant Impact/Record of Decision, </SJDOC>
                    <PGS>48208</PGS>
                    <FRDOCBP>2026-15417</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Communications</EAR>
            <HD>Federal Communications Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Prohibiting the Importation and Marketing of Certain Covered UAS and UAS Critical Components and Equipment Listed in Section 1709 of Fiscal Year 2025 National Defense Authorization Act, </DOC>
                    <PGS>48108-48111</PGS>
                    <FRDOCBP>2026-15418</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Emergency</EAR>
            <HD>Federal Emergency Management Agency</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Application for Surplus Federal Real Property Public Benefit Conveyance and BRAC Program for Emergency Management Use, </SJDOC>
                    <PGS>48174-48175</PGS>
                    <FRDOCBP>2026-15333</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Energy</EAR>
            <HD>Federal Energy Regulatory Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Combined Filings, </DOC>
                    <PGS>48094-48096</PGS>
                    <FRDOCBP>2026-15404</FRDOCBP>
                      
                    <FRDOCBP>2026-15405</FRDOCBP>
                </DOCENT>
                <SJ>Environmental Assessments; Availability, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Oswego Hydro Partners, LP, </SJDOC>
                    <PGS>48097</PGS>
                    <FRDOCBP>2026-15442</FRDOCBP>
                </SJDENT>
                <SJ>Licenses; Exemptions, Applications, Amendments, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Domtar Paper Co., LLC, </SJDOC>
                    <PGS>48093-48094</PGS>
                    <FRDOCBP>2026-15444</FRDOCBP>
                </SJDENT>
                <SJ>Request under Blanket Authorization:</SJ>
                <SJDENT>
                    <SJDOC>Southern Star Central Gas Pipeline, Inc., </SJDOC>
                    <PGS>48096-48097</PGS>
                    <FRDOCBP>2026-15445</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Tennessee Gas Pipeline Co., LLC, </SJDOC>
                    <PGS>48098-48099</PGS>
                    <FRDOCBP>2026-15443</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Motor</EAR>
            <HD>Federal Motor Carrier Safety Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Exemption Application:</SJ>
                <SJDENT>
                    <SJDOC>Hours of Service of Drivers; Precision Fireworks LLC, </SJDOC>
                    <PGS>48209-48210</PGS>
                    <FRDOCBP>2026-15430</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Parts and Accessories Necessary for Safe Operation; Charles Machine Works, Inc., </SJDOC>
                    <PGS>48208</PGS>
                    <FRDOCBP>2026-15431</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Parts and Accessories Necessary for Safe Operation; Transit Solutions, LLC, </SJDOC>
                    <PGS>48210-48212</PGS>
                    <FRDOCBP>2026-15414</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Reserve</EAR>
            <HD>Federal Reserve System</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Change in Bank Control:</SJ>
                <SJDENT>
                    <SJDOC>Acquisitions of Shares of a Bank or Bank Holding Company, </SJDOC>
                    <PGS>48111-48112</PGS>
                    <FRDOCBP>2026-15367</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Food and Drug</EAR>
            <HD>Food and Drug Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2027, </DOC>
                    <PGS>48128-48134</PGS>
                    <FRDOCBP>2026-15339</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027, </DOC>
                    <PGS>48149-48154</PGS>
                    <FRDOCBP>2026-15341</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Biosimilar User Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48166-48170</PGS>
                    <FRDOCBP>2026-15346</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48118-48121</PGS>
                    <FRDOCBP>2026-15336</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Food Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027, </DOC>
                    <PGS>48145-48149</PGS>
                    <FRDOCBP>2026-15337</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027, </DOC>
                    <PGS>48125-48127</PGS>
                    <FRDOCBP>2026-15345</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Generic Drug User Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48154-48160</PGS>
                    <FRDOCBP>2026-15343</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Medical Device User Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48134-48142</PGS>
                    <FRDOCBP>2026-15335</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Outsourcing Facility Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48142-48145</PGS>
                    <FRDOCBP>2026-15342</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48121-48124</PGS>
                    <FRDOCBP>2026-15344</FRDOCBP>
                </DOCENT>
                <DOCENT>
                    <DOC>Prescription Drug User Fee Rates for Fiscal Year 2027, </DOC>
                    <PGS>48160-48166</PGS>
                    <FRDOCBP>2026-15334</FRDOCBP>
                </DOCENT>
                <SJ>Request for Information:</SJ>
                <SJDENT>
                    <SJDOC>Butylated Hydroxytoluene, </SJDOC>
                    <PGS>48127-48128</PGS>
                    <FRDOCBP>2026-15429</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Foreign Assets</EAR>
            <HD>Foreign Assets Control Office</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Sanctions Action, </DOC>
                    <PGS>48224-48228</PGS>
                    <FRDOCBP>2026-15356</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Foreign Trade</EAR>
            <HD>Foreign-Trade Zones Board</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Proposed Production Activity:</SJ>
                <SJDENT>
                    <SJDOC>Aptera Motors Corp., Foreign-Trade Zone 153, Carlsbad, CA, </SJDOC>
                    <PGS>48061</PGS>
                    <FRDOCBP>2026-15422</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Omega Holdings, Foreign-Trade Zone 126, Sparks, NV, </SJDOC>
                    <PGS>48062</PGS>
                    <FRDOCBP>2026-15401</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>
                General Services
                <PRTPAGE P="v"/>
            </EAR>
            <HD>General Services Administration</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>General Services Property Management Regulation:</SJ>
                <SJDENT>
                    <SJDOC>Nondiscrimination on the Basis of the Age Act regulation for Programs or Activities Receiving Federal Financial Assistance; Technical Amendment, </SJDOC>
                    <PGS>47966-47972</PGS>
                    <FRDOCBP>2026-15368</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Health and Human</EAR>
            <HD>Health and Human Services Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Agency for Healthcare Research and Quality</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Centers for Disease Control and Prevention</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Centers for Medicare &amp; Medicaid Services</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Children and Families Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Food and Drug Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Health Resources and Services Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Institutes of Health</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Health Resources</EAR>
            <HD>Health Resources and Services Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Health Center Program Forms, </SJDOC>
                    <PGS>48170-48172</PGS>
                    <FRDOCBP>2026-15419</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Homeland</EAR>
            <HD>Homeland Security Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Emergency Management Agency</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Housing</EAR>
            <HD>Housing and Urban Development Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Privacy Act; Systems of Records, </DOC>
                    <PGS>48175-48181</PGS>
                    <FRDOCBP>2026-15421</FRDOCBP>
                      
                    <FRDOCBP>2026-15428</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Indian Affairs</EAR>
            <HD>Indian Affairs Bureau</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Advisory Board for Exceptional Children, </SJDOC>
                    <PGS>48187-48188</PGS>
                    <FRDOCBP>2026-15361</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Rate Adjustments for Indian Irrigation Projects, </DOC>
                    <PGS>48181-48187</PGS>
                    <FRDOCBP>2026-15360</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Interior</EAR>
            <HD>Interior Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Indian Affairs Bureau</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Park Service</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>International Trade Adm</EAR>
            <HD>International Trade Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Antidumping or Countervailing Duty Investigations, Orders, or Reviews:</SJ>
                <SJDENT>
                    <SJDOC>Hydrofluorocarbon Blends from the People's Republic of China, </SJDOC>
                    <PGS>48079-48081</PGS>
                    <FRDOCBP>2026-15398</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Large Diameter Graphite Electrodes from India, </SJDOC>
                    <PGS>48081-48083</PGS>
                    <FRDOCBP>2026-15396</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Large Diameter Graphite Electrodes from the People's Republic of China, </SJDOC>
                    <PGS>48076-48079</PGS>
                    <FRDOCBP>2026-15397</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Large Diameter Welded Pipe from the Republic of Korea, </SJDOC>
                    <PGS>48071-48074</PGS>
                    <FRDOCBP>2026-15399</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Raw Honey from Argentina; Correction, </SJDOC>
                    <PGS>48070-48071</PGS>
                    <FRDOCBP>2026-15436</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Ripe Olives from Spain, </SJDOC>
                    <PGS>48062-48063</PGS>
                    <FRDOCBP>2026-15400</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Steel Concrete Reinforcing Bar from Egypt, </SJDOC>
                    <PGS>48068-48070</PGS>
                    <FRDOCBP>2026-15439</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam, </SJDOC>
                    <PGS>48074-48076</PGS>
                    <FRDOCBP>2026-15437</FRDOCBP>
                </SJDENT>
                <SJ>Sales at Less Than Fair Value; Determinations, Investigations, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Steel Concrete Reinforcing Bar from Bulgaria, </SJDOC>
                    <PGS>48084-48085</PGS>
                    <FRDOCBP>2026-15441</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Steel Concrete Reinforcing Bar from Egypt, </SJDOC>
                    <PGS>48066-48068</PGS>
                    <FRDOCBP>2026-15440</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam, </SJDOC>
                    <PGS>48063-48066</PGS>
                    <FRDOCBP>2026-15438</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>International Trade Com</EAR>
            <HD>International Trade Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Investigations; Determinations, Modifications, and Rulings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Certain TOPCon Solar Cells, Modules, Panels, Components Thereof, and Products Containing Same, </SJDOC>
                    <PGS>48189-48190</PGS>
                    <FRDOCBP>2026-15426</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Fiberglass Door Panels from China, </SJDOC>
                    <PGS>48188-48189</PGS>
                    <FRDOCBP>2026-15423</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Justice Department</EAR>
            <HD>Justice Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Drug Enforcement Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Executive Office for Immigration Review</P>
            </SEE>
            <CAT>
                <HD>RULES</HD>
                <DOCENT>
                    <DOC>Procedures for Submission and Consideration of Petitions for Rulemaking, </DOC>
                    <PGS>47956-47960</PGS>
                    <FRDOCBP>2026-15434</FRDOCBP>
                </DOCENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Proposed Consent Decree:</SJ>
                <SJDENT>
                    <SJDOC>Clean Air Act, </SJDOC>
                    <PGS>48197</PGS>
                    <FRDOCBP>2026-15402</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Labor Department</EAR>
            <HD>Labor Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Workers Compensation Programs Office</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Attestation for Employers Seeking to Employ H-2B Nonimmigrant Workers under Section 105 of Division G, Title I of the Further Consolidated Appropriations Act, </SJDOC>
                    <PGS>48197-48198</PGS>
                    <FRDOCBP>2026-15424</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Maritime</EAR>
            <HD>Maritime Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Application and Reporting Elements for Participation in the Tanker Security Program, </SJDOC>
                    <PGS>48216</PGS>
                    <FRDOCBP>2026-15378</FRDOCBP>
                </SJDENT>
                <SJ>Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade:</SJ>
                <SJDENT>
                    <SJDOC>M/V Aperitivo, </SJDOC>
                    <PGS>48212-48213</PGS>
                    <FRDOCBP>2026-15382</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>M/V White Star, </SJDOC>
                    <PGS>48216-48217</PGS>
                    <FRDOCBP>2026-15385</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>S/V Cormorant, </SJDOC>
                    <PGS>48215-48216</PGS>
                    <FRDOCBP>2026-15384</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>S/V Dos Para Uno, </SJDOC>
                    <PGS>48214-48215</PGS>
                    <FRDOCBP>2026-15383</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>S/V Lynx, </SJDOC>
                    <PGS>48213-48214</PGS>
                    <FRDOCBP>2026-15386</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Highway</EAR>
            <HD>National Highway Traffic Safety Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>National Emergency Medical Services Advisory Council, </SJDOC>
                    <PGS>48217-48218</PGS>
                    <FRDOCBP>2026-15332</FRDOCBP>
                </SJDENT>
                <SJ>Petition for Decision of Inconsequential Noncompliance:</SJ>
                <SJDENT>
                    <SJDOC>Toyota Motor North America, </SJDOC>
                    <PGS>48218-48220</PGS>
                    <FRDOCBP>2026-15347</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Institute</EAR>
            <HD>National Institutes of Health</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Center for Scientific Review, </SJDOC>
                    <PGS>48173</PGS>
                    <FRDOCBP>2026-15330</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Office of the Director, </SJDOC>
                    <PGS>48173-48174</PGS>
                    <FRDOCBP>2026-15329</FRDOCBP>
                      
                    <FRDOCBP>2026-15427</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Office of the Secretary, </SJDOC>
                    <PGS>48172-48173</PGS>
                    <FRDOCBP>2026-15425</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Oceanic</EAR>
            <HD>National Oceanic and Atmospheric Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>New England Fishery Management Council, </SJDOC>
                    <PGS>48085-48086</PGS>
                    <FRDOCBP>2026-15380</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>North Pacific Fishery Management Council, </SJDOC>
                    <PGS>48086</PGS>
                    <FRDOCBP>2026-15319</FRDOCBP>
                </SJDENT>
                <SJ>Request for Information:</SJ>
                <SJDENT>
                    <SJDOC>Identifying Aquaculture Opportunity Areas in U.S. Waters, </SJDOC>
                    <PGS>48086-48089</PGS>
                    <FRDOCBP>2026-15435</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>
                National Park
                <PRTPAGE P="vi"/>
            </EAR>
            <HD>National Park Service</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <DOCENT>
                    <DOC>First State National Historical Park; Bicycling, </DOC>
                    <PGS>48028-48032</PGS>
                    <FRDOCBP>2026-15406</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Resources</EAR>
            <HD>Natural Resources Conservation Service</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Environmental Impact Statements; Availability, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Clarke County Water Supply Project Final Plan, Clarke County, IA, </SJDOC>
                    <PGS>48059-48060</PGS>
                    <FRDOCBP>2026-15381</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Nuclear Regulatory</EAR>
            <HD>Nuclear Regulatory Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Environmental Assessments; Availability, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Crow Butte Resources, Inc.; Crow Butte Project and Marsland Expansion Area, </SJDOC>
                    <PGS>48198-48200</PGS>
                    <FRDOCBP>2026-15338</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Postal Regulatory</EAR>
            <HD>Postal Regulatory Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>New Postal Products, </DOC>
                    <PGS>48200-48201</PGS>
                    <FRDOCBP>2026-15366</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Postal Service</EAR>
            <HD>Postal Service</HD>
            <CAT>
                <HD>RULES</HD>
                <DOCENT>
                    <DOC>Duty Collection for Domestic Mail Arriving from Certain Insular Possessions and Territories, </DOC>
                    <PGS>47960-47962</PGS>
                    <FRDOCBP>2026-15420</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Securities</EAR>
            <HD>Securities and Exchange Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Application:</SJ>
                <SJDENT>
                    <SJDOC>Securities Industry and Financial Markets Association, </SJDOC>
                    <PGS>48201-48204</PGS>
                    <FRDOCBP>2026-15320</FRDOCBP>
                </SJDENT>
                <SJ>Self-Regulatory Organizations; Proposed Rule Changes:</SJ>
                <SJDENT>
                    <SJDOC>The Nasdaq Stock Market LLC, </SJDOC>
                    <PGS>48204-48207</PGS>
                    <FRDOCBP>2026-15327</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>State Department</EAR>
            <HD>State Department</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Exchange Visitor Program:</SJ>
                <SJDENT>
                    <SJDOC>Termination of Program Participation, Extension of Program and Reinstatement to Valid Program Status, </SJDOC>
                    <PGS>48021-48027</PGS>
                    <FRDOCBP>2026-15450</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Transportation Department</EAR>
            <HD>Transportation Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Aviation Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Motor Carrier Safety Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Maritime Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Highway Traffic Safety Administration</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Privacy Act; Systems of Records, </DOC>
                    <PGS>48220-48224</PGS>
                    <FRDOCBP>2026-15359</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Treasury</EAR>
            <HD>Treasury Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Foreign Assets Control Office</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Veteran Affairs</EAR>
            <HD>Veterans Affairs Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Appointment of Veterans Service Organization as Claimant's Representative and Appointment of Individual as Claimant's Representative, </SJDOC>
                    <PGS>48228</PGS>
                    <FRDOCBP>2026-15375</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Financial Status Report, </SJDOC>
                    <PGS>48229-48230</PGS>
                    <FRDOCBP>2026-15355</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Medical Expense Report, </SJDOC>
                    <PGS>48230</PGS>
                    <FRDOCBP>2026-15353</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>PayVA (Pay Now Enter Info Page), </SJDOC>
                    <PGS>48228-48229</PGS>
                    <FRDOCBP>2026-15354</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Workers'</EAR>
            <HD>Workers Compensation Programs Office</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Black Lung Benefits Act:</SJ>
                <SJDENT>
                    <SJDOC>Authorization of Self-Insurers, </SJDOC>
                    <PGS>48002-48021</PGS>
                    <FRDOCBP>2026-15325</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AIDS>
            <HD SOURCE="HED">Reader Aids</HD>
            <P>Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, and notice of recently enacted public laws.</P>
            <P>To subscribe to the Federal Register Table of Contents electronic mailing list, go to https://public.govdelivery.com/accounts/USGPOOFR/subscriber/new, enter your e-mail address, then follow the instructions to join, leave, or manage your subscription.</P>
        </AIDS>
    </CNTNTS>
    <VOL>91</VOL>
    <NO>145</NO>
    <DATE>Thursday, July 30, 2026</DATE>
    <UNITNAME>Rules and Regulations</UNITNAME>
    <RULES>
        <RULE>
            <PREAMB>
                <PRTPAGE P="47931"/>
                <AGENCY TYPE="F">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-0015; Project Identifier MCAI-2025-01528-A; Amendment 39-23419; AD 2026-15-07]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Pilatus Aircraft Ltd. Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is adopting a new airworthiness directive (AD) for certain Pilatus Aircraft Ltd. (Pilatus) Model PC-12/47E airplanes. This AD was prompted by a report that, during an engine start on the ground, the airplane battery voltage dropped to a value that resulted in an avionic system shutdown. This AD requires incorporating a temporary revision (TR) into the existing pilot's operating handbook (POH) for the affected airplanes to provide operators with instructions for an enhanced engine start procedure. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-0015; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                </ADD>
                <HD SOURCE="HD1">Material Incorporated by Reference</HD>
                <P>
                    • For European Union Aviation Safety Agency (EASA) material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                    <E T="03">ADs@easa.europa.eu;</E>
                     website: 
                    <E T="03">easa.europa.eu.</E>
                     You may find this material on the EASA website at 
                    <E T="03">ad.easa.europa.eu.</E>
                </P>
                <P>
                    • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 1100 Main, Kansas City, MO 64105. For information on the availability of this material at the FAA, call (817) 222-5110. It is also available at 
                    <E T="03">regulations.gov</E>
                    under Docket No. FAA-2026-0015.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Doug Rudolph, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (816) 329-4059; email: 
                        <E T="03">doug.rudolph@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to certain Pilatus Model PC-12/47E airplanes. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on January 21, 2026 (91 FR 2510). The NPRM was prompted by EASA AD 2025-0201, dated September 18, 2025 (EASA AD 2025-0201) (also referred to as the MCAI), issued by EASA, which is the Technical Agent for the Member States of the European Union. The MCAI states that there was an occurrence reported where during an engine start on the ground, the airplane battery voltage dropped to a value that resulted in an avionic system shutdown. As a result, the engine parameters, including the interstage turbine temperature (ITT) indications were undetectable, and the ITT exceedance protection during the engine ground start procedure was deactivated. Under these conditions, an ITT exceedance could occur with the aircrew having no means to detect it. This condition, if not addressed, could result in reduced turbine blade structural integrity with possible engine failure and loss of thrust.
                </P>
                <P>In the NPRM, the FAA proposed to require incorporating a TR into the existing POH for the affected airplanes to provide operators with instructions for an enhanced engine start procedure. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-0015.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD2">Comments</HD>
                <P>The FAA received comments from the Air Line Pilots Association, International (ALPA) and an individual commenter who supported the NPRM without change.</P>
                <P>The FAA received additional comments from an individual commenter. The following presents the comments received on the NPRM and the FAA's response to each comment.</P>
                <HD SOURCE="HD2">Request To Revise Location of TR</HD>
                <P>An individual commenter stated that paragraph (h) of the proposed AD specified revising the Normal Procedures section of the existing POH by inserting a copy of the TR. The commenter noted that Pilatus PC-12/47E POH TR No. 31, dated July 16, 2025 (TR No. 31), instructs operators to insert the TR at the front of the POH. The commenter expressed concern that, with the TR inserted at the front of the POH, a pilot using the checklist in Section 4, Normal Procedures, might not see the revised note or the revised text in step 11. The commenter suggested that inserting TR No. 31 in Section 4-5-01, Engine Start (With or Without External Power), would ensure that pilots using the checklist are aware of the revision and are not required to rely on memory of changes located elsewhere in the manual.</P>
                <P>
                    The FAA notes that paragraph (h)(2) of the proposed AD stated that TR No. 31 be inserted into the Normal Procedures section of the POH instead of at the front of the POH. Further, as explained in the Differences Between this AD and the MCAI section of this final rule, FAA regulations require operators to furnish pilots with any changes to the POH (for example, 14 CFR 135.21). Therefore, no changes to the final rule are necessary in response to this comment.
                    <PRTPAGE P="47932"/>
                </P>
                <HD SOURCE="HD2">Request To Revise Level of Emphasis in TR</HD>
                <P>An individual commenter stated that the revised text in TR No. 31 is presented with the same level of emphasis as the original POH content, using a “Note.” The commenter referenced the definitions provided in the POH for “Warning,” “Caution,” and “Note,” and indicated that, given the FAA's determination that an AD is necessary, the revised text warrants a higher level of emphasis. The commenter suggested that the “Note” should be elevated to either a “Caution,” to indicate that damage to the airplane could result, or a “Warning,” to indicate that personal injury or loss of life is possible if the procedure is not strictly followed.</P>
                <P>The FAA disagrees. The State of Design and the type certificate holder have determined through their safety assessments that the use of a “Note” provides an appropriate level of emphasis for the revised text. The FAA has reviewed this determination and finds it acceptable.</P>
                <P>The FAA notes that the critical aspect of TR No. 31 is the inclusion of additional procedural steps within the checklist, which must be followed in the same manner as all other procedures in the POH. The FAA further notes that the manufacturer's conventions for the use of “Warnings” and “Cautions” are applied consistently and are generally not used for standard airmanship actions addressed through normal procedures.</P>
                <P>The FAA has determined that the actions required by this AD adequately address the identified unsafe condition by ensuring that the revised procedures are incorporated and followed, thereby preventing operation of the airplane with a compromised engine condition.</P>
                <P>The FAA has made no changes to the final rule in response to this comment.</P>
                <HD SOURCE="HD2">Request To Update Electronic and Paper Checklists</HD>
                <P>An individual commenter stated that the electronic and paper checklists have not been revised to include the same text as TR No. 31. The commenter noted that there is no indication within those checklists to alert the pilot that a change has been made and acknowledged that the airplane flight manual POH is the FAA-approved document. The FAA infers that the commenter is requesting that the electronic and paper checklists be updated or otherwise revised to reflect the changes in TR No. 31 to ensure pilots are aware of the revised procedures.</P>
                <P>The FAA disagrees. Paragraph (h)(2) of this AD requires revising the Normal Procedures section of the existing POH, which requires any checklists to be updated to match the revised POH. Pilatus is updating their provided checklist that is inside the Quick Reference Handbook. If operators develop their own checklists, they must update them to match this POH change. As was explained in the Differences Between this AD and the MCAI section of the NPRM and this final rule, FAA regulations require operators to furnish pilots with any changes to the POH (for example, 14 CFR 135.21) and require pilots to comply with the POH (14 CFR 91.9). Therefore, the FAA has made no changes to this AD in response to this comment.</P>
                <HD SOURCE="HD2">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>
                    The FAA reviewed EASA AD 2025-0201, which specifies procedures for incorporating TR No. 31 into the POH and allows for the incorporation of a later POH revision that includes the same POH amendment content. This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Differences Between This AD and the MCAI</HD>
                <P>The MCAI requires operators to “inform all flight crew” of the revisions to the POH and thereafter to “operate the airplane accordingly.” However, this AD does not specifically require those actions as those actions are already required by FAA regulations. FAA regulations require operators to furnish pilots with any changes to the POH (for example, 14 CFR 135.21) and require pilots to comply with the POH (14 CFR 91.9). As with any other flight crew training requirement, training on the updated POH content is tracked by the operators and recorded in each pilot's training record, which is available for the FAA to review. FAA regulations also require pilots to follow the procedures in the existing POH including all updates. Therefore, including a requirement in this AD to inform the flight crew and operate the airplane according to the revised POH would be redundant and unnecessary.</P>
                <HD SOURCE="HD2">Interim Action</HD>
                <P>The FAA considers this AD an interim action. This unsafe condition is still under investigation by the manufacturer and, depending on the results of that investigation, the FAA may consider further rulemaking action.</P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 265 airplanes of U.S. registry. The FAA estimates the following costs to comply with this:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s25,r50,12,12,12">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">Cost on U.S. operators</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Revise POH</ENT>
                        <ENT>1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$22,525</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>
                    The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA 
                    <PRTPAGE P="47933"/>
                    with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.
                </P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-07 Pilatus Aircraft Ltd.:</E>
                             Amendment 39-23419; Docket No. FAA-2026-0015; Project Identifier MCAI-2025-01528-A.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to Pilatus Aircraft Ltd Model PC-12/47E airplanes, manufacturer serial numbers 1720 and 2001 through 2999, certificated in any category.</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Joint Aircraft System Component (JASC) Code 7720, Engine Temp. Indicating System.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by a report that during an engine start on the ground, the airplane battery voltage dropped to a value that resulted in an avionic system shutdown. The FAA is issuing this AD to prevent takeoff when an undetected interstage turbine temperature exceedance occurs during engine start. The unsafe condition, if not addressed, could result in reduced turbine blade structural integrity with possible engine failure and loss of thrust.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Required Actions</HD>
                        <P>(1) Except as specified in paragraph (h) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, European Union Aviation Safety Agency AD 2025-0201, dated September 18, 2025 (EASA AD 2025-0201).</P>
                        <P>(2) The actions required by paragraph (g)(1) of this AD may be performed by the owner/operator (pilot) holding at least a private pilot certificate and must be entered into the aircraft records showing compliance with this AD in accordance with 14 CFR 43.9(a) and 91.417(a)(2)(v). The record must be maintained as required by 14 CFR 91.417, 121.380, or 135.439.</P>
                        <HD SOURCE="HD1">(h) Exceptions to EASA AD 2025-0201</HD>
                        <P>(1) Where EASA AD 2025-0201 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(2) Where paragraph (1) of EASA AD 2025-0201 specifies to “implement the POH TR, as defined in this AD”, this AD requires replacing that text with “revise the Normal Procedures Section of the existing POH for your airplane by inserting a copy of the POH TR as defined in EASA AD 2025-0201”.</P>
                        <P>(3) Where paragraph (1) of EASA AD 2025-0201 specifies to inform all flight crews and, thereafter, operate the [airplane] accordingly, this AD does not require those actions (see 14 CFR 91.9, 91.103, and 135.21).</P>
                        <P>(4) This AD does not adopt the “Remarks” section of EASA AD 2025-0201.</P>
                        <HD SOURCE="HD1">(i) Alternative Methods of Compliance (AMOCs)</HD>
                        <P>
                            (1) The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (j) of this AD and email to: 
                            <E T="03">AMOC@faa.gov.</E>
                        </P>
                        <P>(2) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office/certificate holding district office.</P>
                        <HD SOURCE="HD1">(j) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Doug Rudolph, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (816) 329-4059; email: 
                            <E T="03">doug.rudolph@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(k) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                        <P>(i) European Union Aviation Safety Agency (EASA) AD 2025-0201, dated September 18, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For EASA material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                            <E T="03">ADs@easa.europa.eu;</E>
                             website: 
                            <E T="03">easa.europa.eu.</E>
                             You may find this EASA AD on the EASA website at 
                            <E T="03">ad.easa.europa.eu.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 1100 Main, Kansas City, MO 64105. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 16, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15467 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-3864; Project Identifier MCAI-2022-01215-T; Amendment 39-23421; AD 2026-15-09]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Bombardier, Inc., Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The FAA is adopting a new airworthiness directive (AD) for certain Bombardier, Inc. Model BD-700-1A10 and BD-700-1A11 airplanes. This AD was prompted by an in-service event where a main landing gear tire burst 
                        <PRTPAGE P="47934"/>
                        upon landing. This AD requires an inspection to determine if an affected brake control unit (BCU) is installed and replacement of affected BCUs. This AD also prohibits the installation of affected parts. The FAA is issuing this AD to address the unsafe condition on these products.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3864; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario K1A 0N5, Canada; telephone 888-663-3639; email 
                        <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca.</E>
                         You may find this material on the Transport Canada website at 
                        <E T="03">tc.canada.ca/en/aviation.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3864.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Elizabeth Dowling, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                        <E T="03">Elizabeth.M.Dowling@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to certain Bombardier, Inc. Model BD-700-1A10, BD-700-1A11 airplanes. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on April 23, 2026 (91 FR 21747). The NPRM was prompted by Transport Canada AD CF-2022-53, dated September 8, 2022 (Transport Canada AD CF-2022-53) (also referred to as the MCAI), issued by Transport Canada, which is the aviation authority for Canada. The MCAI states an in-service event occurred where a main landing gear tire burst upon landing. The investigation into the event found that with the loss of a 5V power supply in the BCU wheel control card, a residual current may build within the brake control valve (BCV) driver circuit. This residual current may result in uncommanded brake pressure during landing. If not corrected, this can cause one or more tires to burst due to a dragging brake or a locked brake, unexpected deceleration, degraded braking performance, directional difficulties, or brake(s) overheating.
                </P>
                <P>In the NPRM, the FAA proposed to require an inspection to determine if an affected BCU is installed, replacement of affected BCUs, and prohibit the installation of affected parts, as specified in Transport Canada AD CF-2022-53. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-3864.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received a comment from NetJets Aviation. The following presents the comment received on the NPRM and the FAA's response to the comment.</P>
                <HD SOURCE="HD1">Request To Allow the Use of Maintenance Records</HD>
                <P>NetJets Aviation requested that the FAA revise the proposed AD to allow logbook research as an acceptable method of compliance for Part I, “Verification of Installed Parts,” of Transport Canada AD CF-2022-53. NetJets Aviation stated that determining whether BCU part number GW415-7125-7 is installed can be reliably accomplished through review of aircraft maintenance records and component installation history when documentation is complete and traceable, without requiring a physical inspection. NetJets Aviation also stated that allowing this approach would reduce unnecessary maintenance burden while maintaining an equivalent level of safety.</P>
                <P>The FAA agrees. The FAA has determined that a review of airplane maintenance records is acceptable in lieu of the inspection to determine the BCU part number, provided the BCU part number can be conclusively determined from that review. The FAA has added an exception to paragraph (h)(2) of this AD accordingly.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, and any other changes described previously, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>Transport Canada AD CF-2022-53 specifies procedures for an inspection to determine if BCUs with part number (P/N) GW415-7125-7 (Crane P/N 42-965-3) are installed and replacement of affected parts with BCU P/N GW415-7125-9 (Crane P/N 42-965-4). Transport Canada AD CF-2022-53 also prohibits the installation of affected parts.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>
                    The FAA estimates that this AD affects 42 airplanes of U.S. registry. The FAA estimates the following costs to comply with this AD:
                    <PRTPAGE P="47935"/>
                </P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,12C,12C,12C">
                    <TTITLE>Estimated Costs for Required Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">2 work-hours × $85 per hour = $170</ENT>
                        <ENT>$0</ENT>
                        <ENT>$170</ENT>
                        <ENT>$7,140</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA estimates the following costs to do any necessary on-condition action that would be required based on the results of any required actions. The FAA has no way of determining the number of aircraft that might need this on-condition action:</P>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s100,r50,r50">
                    <TTITLE>Estimated Costs of On-Condition Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">Cost per product</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">2 work-hours × $85 per hour = $170</ENT>
                        <ENT>Up to $430,089</ENT>
                        <ENT>Up to $430,259.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA has included all known costs in its cost estimate. According to the manufacturer, however, some or all of the costs of this AD may be covered under warranty, thereby reducing the cost impact on affected operators.</P>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-09 Bombardier, Inc.:</E>
                             Amendment 39-23421; Docket No. FAA-2026-3864; Project Identifier MCAI-2022-01215-T.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to Bombardier, Inc. Model BD-700-1A10 and BD-700-1A11 airplanes, certificated in any category, as identified in Transport Canada AD CF-2022-53, dated September 8, 2022 (Transport Canada AD CF-2022-53).</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Air Transport Association (ATA) of America Code 32, Landing Gear.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by an in-service event where a main landing gear tire burst upon landing. The investigation into the event found that with the loss of a 5V power supply in the brake control unit (BCU) wheel control card, a residual current may build within the brake control valve (BCV) driver circuit. This residual current may result in uncommanded brake pressure during landing. The unsafe condition, if not addressed, could result in one or more tires to burst due to a dragging brake or a locked brake, unexpected deceleration, degraded braking performance, directional difficulties, or brake(s) overheating.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Requirements</HD>
                        <P>Except as specified in paragraphs (h) and (i) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, Transport Canada AD CF-2022-53.</P>
                        <HD SOURCE="HD1">(h) Exception to Transport Canada AD CF-2022-53</HD>
                        <P>(1) Where Transport Canada AD CF-2022-53 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(2) Where Part I, “Verification of Installed Parts”, of Transport Canada AD CF-2022-53 specifies to inspect whether BCU part number (P/N) GW415-7125-7 (Crane P/N 42-965-3) is installed, for this AD, a review of airplane maintenance records is acceptable in lieu of the inspection, provided the BCU part number can be conclusively determined from that review.</P>
                        <HD SOURCE="HD1">(i) No Reporting Requirement and No Return of Parts</HD>
                        <P>Although the material referenced in Transport Canada AD CF-2022-53 specifies to submit certain information and return parts to the manufacturer, this AD does not include those requirements.</P>
                        <HD SOURCE="HD1">(j) Additional AD Provisions</HD>
                        <P>The following provisions also apply to this AD:</P>
                        <P>
                            (1) 
                            <E T="03">Alternative Methods of Compliance (AMOCs):</E>
                             The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. 
                            <PRTPAGE P="47936"/>
                            In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (k) of this AD and email to: 
                            <E T="03">AMOC@faa.gov</E>
                            . Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office.
                        </P>
                        <P>
                            (2) 
                            <E T="03">Contacting the Manufacturer:</E>
                             For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, International Validation Branch, FAA; or Transport Canada; or Bombardier, Inc's Transport Canada Design Approval Organization (DAO). If approved by the DAO, the approval must include the DAO-authorized signature.
                        </P>
                        <HD SOURCE="HD1">(k) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Elizabeth Dowling, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                            <E T="03">Elizabeth.M.Dowling@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(l) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless this AD specifies otherwise.</P>
                        <P>(i) Transport Canada AD CF-2022-53, dated September 8, 2022.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario K1A 0N5, Canada; telephone 888-663-3639; email 
                            <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca.</E>
                             You may find this material on the Transport Canada website at 
                            <E T="03">tc.canada.ca/en/aviation.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 20, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15409 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-3869; Project Identifier MCAI-2025-00429-R; Amendment 39-23427; AD 2026-15-15]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Leonardo S.p.a. Helicopters</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is adopting a new airworthiness directive (AD) for all Leonardo S.p.a. Model AW189 helicopters. This AD was prompted by reports of cracking on the ejector ducts. This AD requires repetitively inspecting the left-hand (LH) side and right-hand (RH) side ejector ducts, including the exhaust bracket reinforcements and reinforcement plates, and, depending on the results, replacing any affected ejector duct. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3869; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For European Union Aviation Safety Agency (EASA) material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                        <E T="03">ADs@easa.europa.eu;</E>
                         website: 
                        <E T="03">easa.europa.eu.</E>
                         You may find this material on the EASA website at 
                        <E T="03">ad.easa.europa.eu.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 10101 Hillwood Parkway, Fort Worth, TX 76177. For information on the availability of this material at the FAA, call (817) 222-5110. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3869.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        David Enns, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (316) 946-4147; email: 
                        <E T="03">david.enns@faa.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to all Leonardo S.p.a. Model AW189 helicopters. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on April 29, 2026 (91 FR 23031). The NPRM was prompted by EASA AD 2025-0064, dated March 25, 2025 (EASA AD 2025-0064) (also referred to as the MCAI), issued by EASA, which is the Technical Agent for the Member States of the European Union. The MCAI states that there have been reports of cracking on ejector duct part number (P/N) 8G7810P00131 (LH side) and P/N 8G7810P00231 (RH side) of the rear sliding cowling, where the engine exhaust ducts are installed. The MCAI also states that investigation of the cracks, which developed around the engine exhaust duct boundary reinforcement plate, is ongoing to identify the root cause of the occurrences, and the inspection area needs to be extended to the area of the exhaust bracket reinforcements.
                </P>
                <P>Additionally, the MCAI states that, due to reasons still under investigation, any Leonardo S.p.a. Model AW189 helicopter having manufacturer serial number 49018, 49019, 49025, or 49028 is subject to shorter compliance times due to higher likelihood of cracking. This condition, if not detected and corrected, could lead to detachment of a part of the ejector duct, which could impact the helicopter tailplane or the tail rotor with consequent loss of control of the helicopter.</P>
                <P>In the NPRM, the FAA proposed to require repetitively inspecting the LH side and RH side ejector ducts, including the exhaust bracket reinforcements and reinforcement plates, and, depending on the results, replacing any affected ejector duct. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>
                    The FAA received no comments on the NPRM or on the determination of the costs.
                    <PRTPAGE P="47937"/>
                </P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed EASA AD 2025-0064, which specifies procedures for repetitively inspecting the LH and RH ejector ducts P/N 8G7810P00131 (LH side) and P/N 8G7810P00231 (RH side) and the exhaust bracket reinforcements and reinforcement plates. Depending on the results of the inspection, EASA AD 2025-0064 specifies procedures for replacing the ejector duct and reporting inspection results to Leonardo if any discrepancy is detected as a result of the inspection.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Interim Action</HD>
                <P>The FAA considers that this AD is an interim action. The manufacturer is still investigating the root cause of the unsafe condition identified in this AD. If final action is later identified, the FAA might consider further rulemaking.</P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects four helicopters of U.S. registry.</P>
                <P>The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s75,r50,10,r30,r30">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">Cost per product</CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Visually inspect each ejector duct including the exhaust bracket reinforcements and reinforcement plates</ENT>
                        <ENT>2 work-hours × $85 per hour = $170 per inspection</ENT>
                        <ENT>$0</ENT>
                        <ENT>$170 per inspection</ENT>
                        <ENT>$680 per inspection.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA estimates the following costs to do any replacements or corrections that would be required based on the results of the inspection. The agency has no way of determining the number of helicopters that might need these replacements or corrections.</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s40,r50,10,16">
                    <TTITLE>On-Condition Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">Cost per product</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Replace an ejector duct</ENT>
                        <ENT>2 work-hours × $85 per hour = $170</ENT>
                        <ENT>$32,007</ENT>
                        <ENT>$32,177</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT> [Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-15 Leonardo S.p.a.:</E>
                             Amendment 39-23427; Docket No. FAA-2026-3869; Project Identifier MCAI-2025-00429-R.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to all Leonardo S.p.a. Model AW189 helicopters, certificated in any category.</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>
                            Joint Aircraft System Component (JASC) Code 7800, Engine exhaust system.
                            <PRTPAGE P="47938"/>
                        </P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by reports of cracking on the ejector duct. The FAA is issuing this AD to detect and address cracking around the engine exhaust duct boundary reinforcement plate. The unsafe condition, if not addressed, could lead to detachment of a part of the ejector duct, which could impact the helicopter tailplane or the tail rotor with consequent loss of control of the helicopter.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Required Actions</HD>
                        <P>Except as specified in paragraphs (h) and (i) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, European Union Aviation Safety Agency AD 2025-0064, dated March 25, 2025 (EASA AD 2025-0064).</P>
                        <HD SOURCE="HD1">(h) Exceptions to EASA AD 2025-0064</HD>
                        <P>(1) Where EASA AD 2025-0064 refers to its effective date, or July 26, 2023 [the effective date of EASA AD 2023-0149], this AD requires using the effective date of this AD.</P>
                        <P>(2) Where EASA AD 2025-0064 requires compliance in terms of flight hours, this AD requires using hours time-in-service.</P>
                        <P>(3) This AD does not adopt the “Remarks” section of EASA AD 2025-0064.</P>
                        <HD SOURCE="HD1">(i) No Reporting or Returning of Parts Requirement</HD>
                        <P>Although EASA AD 2025-0064 and the material referenced in EASA AD 2025-0064 specifies reporting certain information or to return any parts to the manufacturer, this AD does not require those actions.</P>
                        <HD SOURCE="HD1">(j) Alternative Methods of Compliance (AMOCs)</HD>
                        <P>
                            (1) The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (k) of this AD and email to: 
                            <E T="03">AMOC@faa.gov.</E>
                        </P>
                        <P>(2) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.</P>
                        <HD SOURCE="HD1">(k) Additional Information</HD>
                        <P>
                            For more information about this AD, contact David Enns, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (316) 946-4147; email: 
                            <E T="03">david.enns@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(l) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                        <P>(i) European Union Aviation Safety Agency (EASA) AD 2025-0064, dated March 25, 2025.</P>
                        <P>(ii) Reserved</P>
                        <P>
                            (3) For EASA material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                            <E T="03">ADs@easa.europa.eu;</E>
                             website: 
                            <E T="03">easa.europa.eu.</E>
                             You may find the EASA material on the EASA website at 
                            <E T="03">ad.easa.europa.eu.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 10101 Hillwood Parkway, Fort Worth, TX 76177. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 24, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15370 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-4639; Project Identifier MCAI-2025-01360-T; Amendment 39-23422; AD 2026-15-10]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Airbus SAS Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is adopting a new airworthiness directive (AD) for all Airbus SAS Model A330-841 and Model A330-941 airplanes. This AD was prompted by reports of crack findings on the sloping rib. This AD requires a repetitive inspection of the external surface of each sloping rib and each slat 1 inboard seal, and applicable corrective actions. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-4639; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For European Union Aviation Safety Agency (EASA) material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; telephone +49 221 8999 000; email 
                        <E T="03">ADs@easa.europa.eu.</E>
                         You may find this material on the EASA website at 
                        <E T="03">ad.easa.europa.eu.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-4639.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Bill Ashforth, Aviation Safety Engineer, FAA, 2200 South 216th St., Des Moines, WA 98198; phone: 206-231-3520; email: 
                        <E T="03">Bill.ashforth@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to all Airbus SAS Model A330-841 and Model A330-941 airplanes. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on May 20, 2026 (91 FR 29389). The NPRM was prompted by EASA AD 2025-0179, dated August 13, 2025 (EASA AD 2025-0179) (also referred to as the MCAI), issued by EASA, which is the Technical Agent for the Member States of the European Union. The MCAI states that occurrences of crack findings on the sloping rib were reported. This condition, if not addressed, could affect the handling qualities of the airplane, which could result in reduced controllability of the airplane.
                </P>
                <P>
                    In the NPRM, the FAA proposed to require a repetitive inspection of the external surface of each sloping rib and each slat 1 inboard seal, and applicable corrective actions, as specified in EASA AD 2025-0179. The FAA is issuing this AD to address the unsafe condition on these products.
                    <PRTPAGE P="47939"/>
                </P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-4639.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received a comment from the Air Line Pilots Association, International (ALPA) who supported the NPRM without change.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>EASA AD 2025-0179 specifies procedures for repetitive general visual inspection of the external surface of each left-hand (LH) and right-hand (RH) sloping rib for damage (which includes cracking, dents, and corrosion) and each LH and RH slat 1 inboard seal for damaged and missing seals, and applicable corrective actions. Corrective actions include contacting Airbus for repair instructions and doing the repair, and replacing or reinstalling any damaged or missing seal. EASA AD 2025-0179 also specifies procedures for an alternative method of compliance for any repetitive inspection by accomplishing a certain inspection or replacement.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 37 airplanes of U.S. registry. The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,12C,12C,12C">
                    <TTITLE>Estimated Costs for Required Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$3,145</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA has received no definitive data on which to base the cost estimates for the on-condition repairs specified in this AD.</P>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P>49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-10 Airbus SAS:</E>
                             Amendment 39-23422; Docket No. FAA-2026-4639; Project Identifier MCAI-2025-01360-T.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to all Airbus SAS Model A330-841 and Model A330-941 airplanes.</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Air Transport Association (ATA) of America Code 57, Wings.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by reports of crack findings on the sloping rib. The FAA is issuing this AD to address cracking on the sloping rib. The unsafe condition, if not addressed, could affect the handling qualities of the airplane, which could result in reduced controllability of the airplane.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Requirements</HD>
                        <P>Except as specified in paragraph (h) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, European Union Aviation Safety Agency (EASA) AD 2025-0179, dated August 13, 2025 (EASA AD 2025-0179).</P>
                        <HD SOURCE="HD1">(h) Exceptions to EASA AD 2025-0179</HD>
                        <P>(1) Where EASA AD 2025-0179 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>
                            (2) Where paragraph (2) of EASA AD 2025-0179 specifies “If any damage is found on a 
                            <PRTPAGE P="47940"/>
                            sloping rib, before next flight, contact Airbus for approved repair instructions and, within the compliance time specified therein, accomplish those instructions accordingly”, this AD requires replacing that text with “If any cracking is detected on a sloping rib during any inspection required by this AD, the cracking must be repaired before further flight using a method approved by the Manager, AIR-520, Continued Operational Safety Branch, FAA; or EASA; or Airbus SAS's EASA Design Organization Approval (DOA). If approved by the DOA, the approval must include the DOA-authorized signature. If any damage other than cracking is detected on a sloping rib during any inspection required by this AD, before next flight, contact Airbus for approved instructions and, within the compliance time identified therein, accomplish those instructions accordingly.”
                        </P>
                        <P>(3) This AD does not adopt the “Remarks” section of EASA AD 2025-0179.</P>
                        <HD SOURCE="HD1">(i) Additional AD Provisions</HD>
                        <P>The following provisions also apply to this AD:</P>
                        <P>
                            (1) 
                            <E T="03">Alternative Methods of Compliance (AMOCs):</E>
                             The Manager, AIR-520, Continued Operational Safety Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the Continued Operational Safety Branch, send it to the attention of the person identified in paragraph (j) of this AD and email to: 
                            <E T="03">AMOC@faa.gov</E>
                            . Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards office.
                        </P>
                        <P>
                            (2) 
                            <E T="03">Contacting the Manufacturer:</E>
                             For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, Continued Operational Safety Branch, FAA; or EASA; or Airbus SAS's EASA DOA. If approved by the DOA, the approval must include the DOA-authorized signature.
                        </P>
                        <P>
                            (3) 
                            <E T="03">Required for Compliance (RC):</E>
                             Except as required by paragraph (i)(2) of this AD, if any material referenced in EASA AD 2025-0179 contains paragraphs that are labeled as RC, the instructions in RC paragraphs, including subparagraphs under an RC paragraph, must be done to comply with this AD; any paragraphs, including subparagraphs under those paragraphs, that are not identified as RC are recommended. The instructions in paragraphs, including subparagraphs under those paragraphs, not identified as RC may be deviated from using accepted methods in accordance with the operator's maintenance or inspection program without obtaining approval of an AMOC, provided the instructions identified as RC can be done and the airplane can be put back in an airworthy condition. Any substitutions or changes to instructions identified as RC require approval of an AMOC.
                        </P>
                        <HD SOURCE="HD1">(j) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Bill Ashforth, Aviation Safety Engineer, FAA, 2200 South 216th St., Des Moines, WA 98198; phone: 206-231-3520; email: 
                            <E T="03">Bill.ashforth@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(k) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless this AD specifies otherwise.</P>
                        <P>(i) European Union Aviation Safety Agency (EASA) AD 2025-0179, dated August 13, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For EASA material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; telephone +49 221 8999 000; email 
                            <E T="03">ADs@easa.europa.eu;</E>
                             website 
                            <E T="03">easa.europa.eu.</E>
                             You may find this material on the EASA website at 
                            <E T="03">ad.easa.europa.eu.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 20, 2026.</DATED>
                    <NAME>Brian Knaup,</NAME>
                    <TITLE>Acting Deputy Director, Integrated Certificate Management Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15410 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-4637; Project Identifier MCAI-2025-01226-G; Amendment 39-23420; AD 2026-15-08]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Stemme GmbH Gliders</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is adopting a new airworthiness directive (AD) for all Stemme GmbH (Stemme) Model Stemme S 12 gliders. This AD was prompted by reports of fuel leaking around certain copper sealing rings within the fuel system. This AD requires repetitive visual checks of the fuel system for fuel leakage, and replacement of the affected copper sealing ring. This AD also prohibits the installation of affected parts. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-4637; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-91, West Building Fifth Floor, Room W58-213, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                </ADD>
                <HD SOURCE="HD1">Material Incorporated by Reference</HD>
                <P>
                    • For Stemme material identified in this AD, contact Stemme, Flugplatzstrasse F2 Nr. 6-7, Strausberg, Germany 15344; phone: +49 (0) 3341 3612; email: 
                    <E T="03">airworthiness@stemme.com;</E>
                     website: 
                    <E T="03">stemme.com</E>
                    .
                </P>
                <P>
                    • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 1100 Main, Kansas City, MO 64105. For information on the availability of this material at the FAA, call (817) 222-5110. It is also available at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-4637.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        George Weir, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (817) 222-4045; email: 
                        <E T="03">george.a.weir@faa.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to all Stemme Model Stemme S 12 gliders. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on May 15, 2026 (91 FR 27876). The NPRM was prompted by European Union Aviation Safety Agency (EASA) AD 2025-0155, dated July 21, 2025, issued by EASA, which is the Technical Agent for the Member States of the European Union (EASA AD 2025-0155) (referred to as the MCAI). The MCAI states that occurrences of fuel leaks at multiple locations within the fuel system have 
                    <PRTPAGE P="47941"/>
                    been reported. To address the unsafe condition, Stemme published service material to provide replacement instructions for affected copper sealing rings, and a parts installation restriction. This condition, if not addressed, could result in an in-flight fire.
                </P>
                <P>In the NPRM, the FAA proposed to require repetitive visual checks of the fuel system for fuel leakage (staining, wetness, dripping, etc.), and replacement of the affected copper sealing rings if leakage is detected. In addition, the FAA proposed to prohibit the installation of affected parts. The owner/operator (pilot) holding at least a private pilot certificate may perform the visual check and must enter compliance with the applicable paragraph of this AD into the glider maintenance records in accordance with 14 CFR 43.9(a) and 91.417(a)(2)(v). The pilot may perform this action because it only involves visually checking affected locations for fuel leakage. This action could be performed equally well by a pilot or a mechanic. This is an exception to the FAA's standard maintenance regulations. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-4637.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD2">Comments</HD>
                <P>The FAA received no comments on the NPRM or on the determination of the costs.</P>
                <HD SOURCE="HD2">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed Stemme Service Bulletin (SB) P062-980082, Revision 01, dated July 15, 2025. This material specifies procedures for replacement of affected copper sealing rings within the fuel pump set assembly and drainer complete assembly.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 31 gliders of U.S. registry. The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,r50,12,12,12">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Visual check of fuel system</ENT>
                        <ENT>1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$2,635</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Replacement of copper sealing rings</ENT>
                        <ENT>2 work-hours × $85 per hour = $170</ENT>
                        <ENT>150</ENT>
                        <ENT>320</ENT>
                        <ENT>9,920</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-08 Stemme GmbH:</E>
                             Amendment 39-23420; Docket No. FAA-2026-4637; Project Identifier MCAI-2025-01226-G.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to all Stemme GmbH Model Stemme S 12 gliders, certificated in any category.</P>
                        <NOTE>
                            <HD SOURCE="HED">Note 1 to paragraph (c): </HD>
                            <P>All of the affected airplanes were produced and delivered with the affected copper sealing rings installed.</P>
                        </NOTE>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Joint Aircraft System Component (JASC) Code 2800, Aircraft Fuel System.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>
                            This AD was prompted by reports of fuel leaking around certain copper sealing rings within the fuel system. The FAA is issuing this AD to prevent fuel leakage in the fuel 
                            <PRTPAGE P="47942"/>
                            system. The unsafe condition, if not addressed, could result in an in-flight fire.
                        </P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Definitions</HD>
                        <P>For the purpose of this AD, the definitions in paragraphs (g)(1) through (4) of this AD apply.</P>
                        <P>(1) An “affected location” is any of the following:</P>
                        <P>(i) The copper sealing ring within the fuel pump set assembly having part number (P/N) 128201, between the screw-in adapter having P/N 831099 and the fuel distributor having P/N 128229, and between the screw-in adapter having P/N 831099 and the fuel distributor having P/N 128228. The fuel pump set assembly P/N 128201 is located at the front left area of the middle fuselage and may be accessed from below when the main landing gear is extended. (Location defined in Stemme Service Bulletin (SB) P062-980082, Revision 01, dated July 15, 2025, Page 1 of 3, Action 2 and Figure 1).</P>
                        <P>(ii) The copper sealing ring within the drainer complete having P/N 128207, between the screw-in adapter having P/N 831099 and the drainer attachment having P/N 128271. The drainer complete P/N 128207 is located at the main landing gear bay and may be accessed from below when the main landing gear is extended. (Location defined in Stemme SB P062-980082, Revision 01, dated July 15, 2025, Page 2 of 3, Action 3 and Page 3 of 3 Figure 2).</P>
                        <P>(2) An “affected part” is a copper sealing ring having P/N D7603-12016-CU.</P>
                        <P>(3) “Group 1 gliders” are gliders that have an affected part installed.</P>
                        <P>(4) “Group 2 gliders” are gliders that do not have an affected part installed.</P>
                        <HD SOURCE="HD1">(h) Required Actions</HD>
                        <P>(1) For Group 1 gliders, before further flight after the effective date of this AD and thereafter before each flight until the replacement required by paragraph (h)(2) is accomplished, perform a visual check using a light source of the affected locations for indications of fuel leakage (staining, wetness, dripping, etc.). The owner/operator (pilot) holding at least a private pilot certificate may perform the visual check and must enter compliance with the applicable paragraph of this AD into the glider maintenance records in accordance with 14 CFR 43.9(a) and 91.417(a)(2)(v). The record must be maintained as required by 14 CFR 91.417.</P>
                        <P>(2) For Group 1 gliders, at whichever compliance time in paragraph (h)(2)(i) or (ii) that occurs first, replace the affected part at each affected location with a sealing ring having P/N 831984 in accordance with the instructions of Action 2 or Action 3 of Stemme SB P062-980082, Revision 01, dated July 15, 2025, as applicable.</P>
                        <P>(i) Before further flight if any leakage is detected during any preflight check required by paragraph (h)(1) of this AD.</P>
                        <P>(ii) Within 100 hours time-in-service after the effective date of this AD.</P>
                        <HD SOURCE="HD1">(i) Installation Prohibition</HD>
                        <P>For Group 1 and Group 2 gliders: As of the effective date of this AD, do not install an affected part as defined in paragraph (g)(2) of this AD on any glider.</P>
                        <HD SOURCE="HD1">(j) Alternative Methods of Compliance (AMOCs)</HD>
                        <P>
                            The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (k) of this AD and email to: 
                            <E T="03">AMOC@faa.gov.</E>
                             Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.
                        </P>
                        <HD SOURCE="HD1">(k) Additional Information</HD>
                        <P>
                            For more information about this AD, contact George Weir, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (817) 222-4045; email: 
                            <E T="03">george.a.weir@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(l) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference (IBR) of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                        <P>(i) Stemme Service Bulletin P062-980082, Revision 01, dated July 15, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For Stemme material identified in this AD, contact Stemme GmbH, Flugplatzstrasse F2 Nr. 6-7, Strausberg, Germany 15344; phone: +49 (0) 3341 3612; email: 
                            <E T="03">airworthiness@stemme.com;</E>
                             website: 
                            <E T="03">stemme.com</E>
                            .
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 1100 Main, Kansas City, MO 64105. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 24, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15466 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2025-2557; Project Identifier MCAI-2025-00533-E; Amendment 39-23415; AD 2026-15-03]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Safran Helicopter Engines, S.A. (Type Certificate Previously Held by Turbomeca, S.A.) Engines</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is adopting a new airworthiness directive (AD) for all Safran Helicopter Engines, S.A. (Safran) Model Arriel 2E engines. This AD was prompted by the determination that new or more restrictive airworthiness limitations are necessary. This AD requires revising the existing maintenance or inspection program to incorporate the airworthiness limitations section (ALS) of the existing approved aircraft maintenance program (AMP), as applicable. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2025-2557; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For European Union Aviation Safety Agency (EASA) material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                        <E T="03">ADs@easa.europa.eu;</E>
                         website: 
                        <E T="03">easa.europa.eu.</E>
                         You may find this material on the EASA website at 
                        <E T="03">ad.easa.europa.eu.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, 
                        <PRTPAGE P="47943"/>
                        Operational Safety Branch, 1200 District Avenue, Burlington, MA 01803. For information on the availability of this material at the FAA, call (817) 222-5110. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2025-2557.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        David Bergeron, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (860) 386-1805; email: 
                        <E T="03">david.j.bergeron@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to all Safran Model Arriel 2E engines. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on September 26, 2025 (90 FR 46368). The NPRM was prompted by EASA AD 2025-0079, dated April 10, 2025 (EASA AD 2025-0079) (also referred to as the MCAI), issued by EASA, which is the Technical Agent for the Member States of the European Union. The MCAI states that new or more restrictive airworthiness limitations have been developed, and the restrictive limitations include replacing life-limited parts before exceeding the applicable life limit, performing applicable maintenance tasks, and revising the approved aircraft maintenance program.
                </P>
                <P>In the NPRM, the FAA proposed to require revising the existing maintenance or inspection program to incorporate the ALS of the existing approved AMP, as applicable. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2025-2557.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received comments from the Citizens Rulemaking Alliance. The following presents the comments received on the NPRM and the FAA's response to each comment.</P>
                <HD SOURCE="HD1">Request To Issue an NPRM or Justify Forgoing Notice</HD>
                <P>The Citizens Rulemaking Alliance requested that the FAA either provide its justification for finding good cause to bypass notice and comment procedures or convert this action to an NPRM with a delayed 30-day effective date. The commenter asserted the FAA has not adequately justified use of the good cause exemption to bypass notice and comment and the 30-day delayed effective date.</P>
                <P>
                    The FAA notes the comment was submitted in response to an NPRM for which the FAA provided a 45-day comment period. This final rule is effective 35 days after its publication in the 
                    <E T="04">Federal Register</E>
                    . Therefore, the FAA did not change this AD as a result of this comment.
                </P>
                <HD SOURCE="HD1">Request To Make Incorporation by Reference (IBR) Materials Reasonably Available</HD>
                <P>
                    The Citizens Rulemaking Alliance requested that the FAA make IBR material available and free to the public during the comment period. Alternatively, they requested that material be published in the 
                    <E T="04">Federal Register</E>
                    . The commenter asserted that this AD incorporates by reference manufacturer service information.
                </P>
                <P>
                    The FAA notes that this AD incorporates by reference EASA AD 2025-0079, not the manufacturer service information referenced in that EASA AD. The FAA posted EASA AD 2025-0079 to the AD docket when the NPRM was published in the 
                    <E T="04">Federal Register</E>
                    . The material referenced in EASA AD 2025-0079 may only be posted before the final rule's publication if it is already publicly available or if there is written consent from the owner of that material. Additionally, the FAA provided notice in the NPRM that the material referenced in EASA AD 2025-0079 will be available in the AD docket after this AD is published. The FAA did not change this AD as a result of this comment.
                </P>
                <HD SOURCE="HD1">Request To Consider Impact on Small Entities</HD>
                <P>The Citizens Rulemaking Alliance requested that the FAA either provide the factual basis for its Regulatory Flexibility Act (RFA) certification that the AD will not have a significant economic impact on a substantial number of small entities or prepare an initial regulatory flexibility analysis.</P>
                <P>FAA has considered the AD's impact on small businesses and provides the following factual basis for its RFA certification.</P>
                <P>The Regulatory Flexibility Act of 1980, Public Law 96-354, 94 Stat. 1164 (5 U.S.C. 601-612), as amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121, 110 Stat. 857, Mar. 29, 1996) and the Small Business Jobs Act of 2010 (Pub. L. 111-240, 124 Stat. 2504, Sept. 27, 2010), requires Federal agencies to consider the effects of the regulatory action on small business and other small entities and to minimize any significant economic impact. The term “small entities” comprises small businesses and not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.</P>
                <HD SOURCE="HD2">Small Entities to Which This AD Applies</HD>
                <P>The FAA used the definition of small entities in the RFA for this analysis. The RFA defines small entities as small businesses, small governmental jurisdictions, or small organizations. In 5 U.S.C. 601(3), the RFA defines “small business” to have the same meaning as “small business concern” under section 3 of the Small Business Act. The Small Business Act authorizes the Small Business Administration (SBA) to define “small business” by issuing regulations.</P>
                <P>The SBA has established size standards for various types of economic activities, or industries, under the North American Industry Classification System (NAICS). These size standards generally define small businesses based on the number of employees or annual receipts. The following table provides the SBA size standards for all industries with at least one known entity impacted by this AD. Note that the SBA definition of a small business applies to the parent company and all affiliates as a single entity.</P>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s35,r100,r50">
                    <TTITLE>Small Business Size Standards</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            NAICS
                            <LI>code</LI>
                        </CHED>
                        <CHED H="1">NAICS category</CHED>
                        <CHED H="1">Size standard</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">221121</ENT>
                        <ENT>Electric Bulk Power Transmission and Control</ENT>
                        <ENT>950 Employees.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">221122</ENT>
                        <ENT>Electric Power Distribution</ENT>
                        <ENT>1,100 Employees.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">481211</ENT>
                        <ENT>Nonscheduled Chartered Passenger Air Transportation</ENT>
                        <ENT>1,500 Employees.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">481212</ENT>
                        <ENT>Nonscheduled Chartered Freight Air Transportation</ENT>
                        <ENT>1,500 Employees.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="47944"/>
                        <ENT I="01">488190</ENT>
                        <ENT>Other Support Activities for Air Transportation</ENT>
                        <ENT>$40,000,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">518210</ENT>
                        <ENT>Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services</ENT>
                        <ENT>$40,000,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">523910</ENT>
                        <ENT>Miscellaneous Intermediation</ENT>
                        <ENT>$47,000,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">531120</ENT>
                        <ENT>Lessors of Nonresidential Buildings (except Mini-warehouses)</ENT>
                        <ENT>$34,000,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">531390</ENT>
                        <ENT>Other Activities Related to Real Estate</ENT>
                        <ENT>$19,500,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">532411</ENT>
                        <ENT>Commercial Air, Rail, and Water Transportation Equipment Rental and Leasing</ENT>
                        <ENT>$45,500,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">541611</ENT>
                        <ENT>Administrative Management and General Management Consulting Services</ENT>
                        <ENT>$24,500,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">551112</ENT>
                        <ENT>Offices of Other Holding Companies</ENT>
                        <ENT>$45,500,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">611512</ENT>
                        <ENT>Flight Training</ENT>
                        <ENT>$34,000,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">621910</ENT>
                        <ENT>Ambulance Services</ENT>
                        <ENT>$22,500,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">622110</ENT>
                        <ENT>General Medical and Surgical Hospitals</ENT>
                        <ENT>$47,000,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">921110</ENT>
                        <ENT>Law Enforcement</ENT>
                        <ENT>50,000 Population.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    To identify small entities, the FAA first identified the primary NAICS of the entity or parent company, and then used data from different sources (
                    <E T="03">e.g.,</E>
                     company annual reports, Bureau of Transportation Statistics) to determine whether the entity meets the applicable size standard. This AD affects 24 identifiable domestic entities, of which 11 are small entities. The following table displays the industries of the small entities, their average annual revenue, and the AD's estimated cost burden relative to average annual revenue.
                </P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s35,r100,12,12,12">
                    <TTITLE>Number of Small Entities Affect by Industry and Cost Significance</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            NAICS
                            <LI>code</LI>
                        </CHED>
                        <CHED H="1">Description</CHED>
                        <CHED H="1">
                            Number of
                            <LI>affected</LI>
                            <LI>small entities</LI>
                        </CHED>
                        <CHED H="1">
                            Average
                            <LI>annual</LI>
                            <LI>revenue</LI>
                        </CHED>
                        <CHED H="1">
                            Cost per
                            <LI>AD/annual</LI>
                            <LI>revenue</LI>
                            <LI>(%)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">481211</ENT>
                        <ENT>Nonscheduled Chartered Passenger Air Transportation</ENT>
                        <ENT>1</ENT>
                        <ENT>$428,180</ENT>
                        <ENT>0.02</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">481211</ENT>
                        <ENT>Nonscheduled Chartered Passenger Air Transportation</ENT>
                        <ENT>1</ENT>
                        <ENT>15,290,000</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">481212</ENT>
                        <ENT>Nonscheduled Chartered Freight Air Transportation</ENT>
                        <ENT>1</ENT>
                        <ENT>12,510,000</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">488190</ENT>
                        <ENT>Other Support Activities for Air Transportation</ENT>
                        <ENT>1</ENT>
                        <ENT>4,690,000</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">518210</ENT>
                        <ENT>Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services</ENT>
                        <ENT>1</ENT>
                        <ENT>137,080</ENT>
                        <ENT>0.06</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">531120</ENT>
                        <ENT>Lessors of Nonresidential Buildings (except Mini-warehouses)</ENT>
                        <ENT>1</ENT>
                        <ENT>90,500</ENT>
                        <ENT>0.09</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">531390</ENT>
                        <ENT>Other Activities Related to Real Estate</ENT>
                        <ENT>1</ENT>
                        <ENT>151,760</ENT>
                        <ENT>0.06</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">532411</ENT>
                        <ENT>Commercial Air, Rail, and Water Transportation Equipment Rental and Leasing</ENT>
                        <ENT>1</ENT>
                        <ENT>850,000</ENT>
                        <ENT>0.01</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">541611</ENT>
                        <ENT>Administrative Management and General Management Consulting Services</ENT>
                        <ENT>1</ENT>
                        <ENT>1,050,000</ENT>
                        <ENT>0.01</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">611512</ENT>
                        <ENT>Flight Training</ENT>
                        <ENT>1</ENT>
                        <ENT>3,480,000</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">921110</ENT>
                        <ENT>Law Enforcement</ENT>
                        <ENT>1</ENT>
                        <ENT>143,650,000</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">RFA Conclusions</HD>
                <P>While FAA has determined that this final AD affects a substantial number of identifiable small entities, the compliance cost of the AD relative to each small entity's annual revenue is minimal. The FAA estimates the total cost per affected entity to be $85 (1 work-hour × $85 per work-hour), which is 0.02% of the average small entity's total annual revenue. Therefore, as provided in section 605(b), the FAA certifies this AD will not result in a significant economic impact on a substantial number of small entities. The FAA did not change this AD as a result of this comment.</P>
                <HD SOURCE="HD1">Request To Comply With the Paperwork Reduction Act (PRA)</HD>
                <P>The Citizens Rulemaking Alliance requested that the FAA revise the proposed AD to comply with the PRA if reporting is required. If reporting is not required, the commenter requested the FAA clarify that in the AD.</P>
                <P>The FAA notes this AD does not require reporting. If an AD were to require reporting, the preamble of the AD would include a paragraph titled “Paperwork Reduction Act” that would provide the applicable OMB control number, required PRA statements, and the estimated time to collect the required information (burden). Any costs associated with the reporting requirement would be included in the Costs of Compliance section in the preamble of the AD. Therefore, the FAA did not change this AD as a result of this comment.</P>
                <HD SOURCE="HD1">Request To Consider Compliance Alternatives</HD>
                <P>The Citizens Rulemaking Alliance requested that, if the proposed AD requires parts replacement or shop visits, the FAA adjust compliance times or provide alternative method of compliance (AMOC) pathways to reflect parts availability and maintenance capacity constraints, while maintaining an appropriate margin of safety.</P>
                <P>
                    The FAA disagrees with the request. The FAA notes that this AD requires revising the existing maintenance or inspection program, which requires neither replacement parts nor a shop visit. Furthermore, AMOC pathways already exist under the provisions of paragraph (j) of this AD. The FAA will 
                    <PRTPAGE P="47945"/>
                    consider requests for approval of an extension of the compliance time or other AMOCs if sufficient data are submitted to substantiate that the new compliance time or alternative method would provide an acceptable level of safety. The commenter did not provide specific data regarding parts availability or maintenance capacity constraints for the FAA to consider. Therefore, the FAA did not change this AD as a result of this comment.
                </P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed EASA AD 2025-0079, which specifies procedures for replacing components before exceeding their life limits and accomplishing all applicable maintenance tasks within thresholds and intervals specified in the ALS as defined in EASA AD 2025-0079. Depending on the results of the maintenance tasks, EASA AD 2025-0079 requires accomplishing corrective action(s) or contacting Safran Helicopters for approved instructions and accomplishing those instructions.</P>
                <P>Additionally, EASA AD 2025-0079 specifies procedures for accomplishing the actions specified in the applicable ALS, including performing maintenance tasks, replacing life-limited parts, and specifies procedures for revising the AMP by incorporating the limitations, tasks, and associated thresholds and intervals described in the specified ALS, as applicable. Revising the AMP constitutes terminating action for the requirement to record accomplishment of the actions of replacing components before exceeding their life limits and accomplishing maintenance tasks within thresholds and intervals specified in the applicable ALS as required by EASA AD 2025-0079 for demonstration of AD compliance on a continued basis.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Differences Between This AD and the MCAI</HD>
                <P>EASA AD 2025-0079 applies to Safran Model Arriel 2D, 2E, 2H, 2L2, and 2N engines, whereas this AD applies to Safran Model Arriel 2E engines. The ALS revisions required by this AD do not include Safran Model Arriel 2D engines, and Safran Model Arriel 2H, 2L2, and 2N engines do not have an FAA type certificate.</P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 136 engines installed on helicopters of U.S. registry.</P>
                <P>The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,r50,12,12,12">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Revise the ALS and the existing approved AMP</ENT>
                        <ENT>1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$11,560</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT> [Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-03 Safran Helicopter Engines, S.A. (Type Certificate Previously Held by Turbomeca S.A.):</E>
                             Amendment 39-23415; Docket No. FAA-2025-2557; Project Identifier MCAI-2025-00533-E.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>
                            This AD applies to all Safran Helicopter Engines, S.A. (type certificate previously 
                            <PRTPAGE P="47946"/>
                            held by Turbomeca S.A.) Model Arriel 2E engines.
                        </P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Joint Aircraft System Component (JASC) Code 7250, Turbine Section.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by the determination that new or more restrictive airworthiness limitations are necessary. The FAA is issuing this AD to prevent failure of life-limited parts. The unsafe condition, if not addressed, could result in failure of one or more engines, loss of thrust control, and consequent reduced control of the helicopter.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Required Actions</HD>
                        <P>(1) Except as specified in paragraphs (h) and (i) of this AD, perform all required actions within the compliance times specified in, and in accordance with, European Union Aviation Safety Agency AD 2025-0079, dated April 10, 2025 (EASA AD 2025-0079).</P>
                        <P>(2) The action required by paragraph (g)(1) of this AD may be performed by the owner/operator (pilot) holding at least a private pilot certificate and must be entered into the aircraft records showing compliance with this AD in accordance with 14 CFR 43.9(a) and 91.417(a)(2)(v). The record must be maintained as required by 14 CFR 91.417, 121.380, or 135.439.</P>
                        <HD SOURCE="HD1">(h) Exceptions to EASA AD 2025-0079</HD>
                        <P>(1) Where EASA AD 2025-0079 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(2) This AD does not require compliance with paragraphs (1), (2), (4), and (5) of EASA AD 2025-0079.</P>
                        <P>(3) Where paragraph (3) of EASA AD 2025-0079 requires revising the approved aircraft maintenance program (AMP) within 12 months after the effective date of EASA AD 2025-0079, this AD requires incorporating the actions and associated thresholds and intervals, including life limits and maintenance tasks, into the existing approved maintenance or inspection program, as applicable, within 90 days after the effective date of this AD.</P>
                        <P>(4) This AD does not adopt the “Remarks” section of EASA AD 2025-0079.</P>
                        <HD SOURCE="HD1">(i) Provisions for Alternative Actions and Intervals</HD>
                        <P>After performing the actions required by paragraph (g) of this AD, no alternative actions and associated thresholds and intervals, including life limits, are allowed unless they are approved as specified in the provisions of the “Ref. Publications” section of EASA AD 2025-0079.</P>
                        <HD SOURCE="HD1">(j) Alternative Methods of Compliance (AMOCs)</HD>
                        <P>
                            (1) The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (k) of this AD and email to: 
                            <E T="03">AMOC@faa.gov.</E>
                        </P>
                        <P>(2) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local Flight Standards District Office/certificate holding district office.</P>
                        <HD SOURCE="HD1">(k) Additional Information</HD>
                        <P>
                            For more information about this AD, contact David Bergeron, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (860) 386-1805; email: 
                            <E T="03">david.j.bergeron@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(l) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                        <P>(i) European Union Aviation Safety Agency (EASA) AD 2025-0079, dated April 10, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For EASA material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                            <E T="03">ADs@easa.europa.eu;</E>
                             website: 
                            <E T="03">easa.europa.eu.</E>
                             You may find this EASA AD on the EASA website at 
                            <E T="03">ad.easa.europa.eu.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 1200 District Avenue, Burlington, MA 01803. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 14, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15369 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-2714; Project Identifier MCAI-2025-00827-T; Amendment 39-23428; AD 2026-15-16]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; MHI RJ Aviation ULC (Type Certificate Previously Held by Bombardier, Inc.) Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is adopting a new airworthiness directive (AD) for all MHI RJ Aviation ULC Model CL-600-2C10 (Regional Jet Series 700, 701 &amp; 702), CL-600-2C11 (Regional Jet Series 550), CL-600-2D15 (Regional Jet Series 705), and CL-600-2D24 (Regional Jet Series 900) airplanes. This AD was prompted by a determination that new or more restrictive airworthiness limitations are necessary. This AD requires revising the existing maintenance or inspection program, as applicable, to incorporate new or more restrictive airworthiness limitations. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-2714; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario K1A 0N5, Canada; telephone 888-663-3639; email 
                        <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca.</E>
                         You may find this material on the 
                        <PRTPAGE P="47947"/>
                        Transport Canada website at 
                        <E T="03">tc.canada.ca/en/aviation.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-2714.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Isabel Saltzman, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                        <E T="03">9-avs-nyaco-cos@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to all MHI RJ Aviation ULC Model CL-600-2C10 (Regional Jet Series 700, 701 &amp; 702), CL-600-2C11 (Regional Jet Series 550), CL-600-2D15 (Regional Jet Series 705), and CL-600-2D24 (Regional Jet Series 900) airplanes. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on March 17, 2026 (91 FR 12695). The NPRM was prompted by Transport Canada AD CF-2025-26, dated May 6, 2025 (Transport Canada AD CF-2025-26) (also referred to as the MCAI), issued by Transport Canada, which is the aviation authority for Canada. The MCAI states that new or more restrictive airworthiness limitations have been developed. The manufacturer introduced changes to four airworthiness limitation items (ALIs) and added four new ALIs to Maintenance Requirements Manual (MRM) CSP B-053, Part 2, Section 2, “Structural Inspections,” and Section 3, “Safe Life Components,” Revision 28, dated June 25, 2024. These changes are the result of the latest damage tolerance analyses that revealed the need for more restrictive inspections than initially assumed.
                </P>
                <P>In the NPRM, the FAA proposed to require revising the existing maintenance or inspection program, as applicable, to incorporate new or more restrictive airworthiness limitations, as specified in Transport Canada AD CF-2025-26. The FAA is issuing this AD to address the potential failure of certain life-limited parts. The unsafe condition, if not addressed, could result in the loss of structural integrity of the airplane.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-2714.
                </P>
                <HD SOURCE="HD1">Other Related Rulemaking</HD>
                <P>The FAA issued AD 2025-25-03, Amendment 39-23211 (90 FR 57680, December 12, 2025) (AD 2025-25-03), which applies to all MHI RJ Aviation ULC Model CL-600-2C10 (Regional Jet Series 700, 701 &amp; 702), CL-600-2C11 (Regional Jet Series 550), CL-600-2D15 (Regional Jet Series 705), CL-600-2D24 (Regional Jet Series 900), and CL-600-2E25 (Regional Jet Series 1000) airplanes. AD 2025-25-03 requires revising the existing maintenance or inspection program, as applicable, to incorporate new or more restrictive airworthiness limitations. Accomplishing the actions in this AD terminates the corresponding requirements of AD 2025-25-03 for the tasks identified in the material referenced in Transport Canada AD CF-2025-26 only.</P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received a comment from the Air Line Pilots Association, International (ALPA) who supported the NPRM without change.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>
                    Transport Canada AD CF-2025-26 specifies new or more restrictive airworthiness limitations for airplane structures and safe life limits. This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 589 airplanes of U.S. registry. The FAA estimates the following costs to comply with this AD:</P>
                <P>The FAA has determined that revising the existing maintenance or inspection program takes an average of 90 work-hours per operator, although the agency recognizes that this number may vary from operator to operator. Since operators incorporate maintenance or inspection program changes for their affected fleet(s), the FAA has determined that a per-operator estimate is more accurate than a per-airplane estimate. Therefore, the agency estimates the average total cost per operator to be $7,650 (90 work-hours × $85 per work-hour).</P>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>
                    Accordingly, under the authority delegated to me by the Administrator, 
                    <PRTPAGE P="47948"/>
                    the FAA amends 14 CFR part 39 as follows:
                </P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority: </HD>
                        <P>49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-16 MHI RJ Aviation ULC (Type Certificate Previously Held by Bombardier, Inc.):</E>
                             Amendment 39-23428; Docket No. FAA-2026-2714; Project Identifier MCAI-2025-00827-T.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>This AD affects AD 2025-25-03, Amendment 39-23211 (90 FR 57680, December 12, 2025) (AD 2025-25-03).</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to all MHI RJ Aviation ULC (Type Certificate previously held by Bombardier, Inc.) airplanes identified in paragraphs (c)(1) through (4) of this AD, certificated in any category.</P>
                        <P>(1) Model CL-600-2C10 (Regional Jet Series 700, 701 &amp; 702) airplanes.</P>
                        <P>(2) Model CL-600-2C11 (Regional Jet Series 550) airplanes.</P>
                        <P>(3) Model CL-600-2D15 (Regional Jet Series 705) airplanes.</P>
                        <P>(4) Model CL-600-2D24 (Regional Jet Series 900) airplanes.</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Air Transport Association (ATA) of America Code 05, Time Limits/Maintenance Checks.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by a determination that new or more restrictive airworthiness limitations are necessary. The FAA is issuing this AD to address the potential failure of certain life-limited parts. The unsafe condition, if not addressed, could result in the loss of structural integrity of the airplane.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Requirements</HD>
                        <P>Within 30 days after the effective date of this AD: Comply with all required actions specified in, and in accordance with, Transport Canada AD CF-2025-26, dated May 6, 2025 (Transport Canada AD CF-2025-26), except as specified in paragraph (h) of this AD.</P>
                        <HD SOURCE="HD1">(h) Exception to Transport Canada AD CF-2025-26</HD>
                        <P>(1) Where the “Corrective Actions” section of Transport Canada AD CF-2025-26 specifies to “Within the thresholds and repeat intervals identified within the tasks, or discard time, as applicable, complete the new or more restrictive limitations contained in the ALI sections of the MHIRJ MRM Part 2 publication identified in Table 1 below, as applicable to the aeroplane model and configuration.”, this AD requires replacing that text with “Revise the existing maintenance or inspection program, as applicable, by incorporating the new and revised ALI tasks identified in Table 1 of Transport Canada AD CF-2025-26.”</P>
                        <P>(2) The initial compliance time for doing the tasks specified in Table 1 of Transport Canada AD CF-2025-26 is at the applicable threshold and discard time as specified in the material referenced in Transport Canada AD CF-2025-26, or within 30 days after the effective date of this AD, whichever occurs later.</P>
                        <HD SOURCE="HD1">(i) Provisions for Alternative Actions and Intervals</HD>
                        <P>
                            After the existing maintenance or inspection program has been revised as required by paragraph (g) of this AD, no alternative actions (
                            <E T="03">e.g.,</E>
                             inspections) and intervals are allowed unless they are approved as specified in the provisions of the “Corrective Actions” section of Transport Canada AD CF-2025-26.
                        </P>
                        <HD SOURCE="HD1">(j) Terminating Action for Certain Tasks Required by AD 2025-25-03</HD>
                        <P>Accomplishing the actions required by this AD terminates the corresponding requirements of AD 2025-25-03 for the tasks identified in the material referenced in Transport Canada AD CF-2025-26 only.</P>
                        <HD SOURCE="HD1">(k) Additional AD Provisions</HD>
                        <P>The following provisions also apply to this AD:</P>
                        <P>
                            (1) 
                            <E T="03">Alternative Methods of Compliance (AMOCs):</E>
                             The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (l) of this AD and email to: 
                            <E T="03">AMOC@faa.gov.</E>
                             Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office.
                        </P>
                        <P>
                            (2) 
                            <E T="03">Contacting the Manufacturer:</E>
                             For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, International Validation Branch, FAA; or Transport Canada; or MHI RJ Aviation ULC's Transport Canada Design Approval Organization (DAO). If approved by the DAO, the approval must include the DAO-authorized signature.
                        </P>
                        <HD SOURCE="HD1">(l) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Isabel Saltzman, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                            <E T="03">9-avs-nyaco-cos@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(m) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless this AD specifies otherwise.</P>
                        <P>(i) Transport Canada AD CF-2025-26, dated May 6, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario K1A 0N5, Canada; telephone 888-663-3639; email 
                            <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca.</E>
                             You may find this material on the Transport Canada website at 
                            <E T="03">tc.canada.ca/en/aviation.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 24, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15412 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-3873; Project Identifier MCAI-2025-00197-T; Amendment 39-23413; AD 2026-15-01]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Airbus SAS Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The FAA is adopting a new airworthiness directive (AD) for certain Airbus SAS Model A330-200 and A330-300 series airplanes modified by a certain supplemental type certificate (STC). This AD was prompted by a finding that, for airplanes with a flightcrew oxygen system supplied by a single oxygen cylinder, the oxygen supply would not be sufficient under all circumstances for extended operations 
                        <PRTPAGE P="47949"/>
                        (ETOPS) with a maximum diversion time of 180 minutes (ETOPS-180) with four flightcrew members. This AD requires revising the existing Airplane Flight Manual Supplement (AFM-S) to limit ETOPS-180 operations to three flightcrew members, as applicable, and correct minimum oxygen dispatch pressure information. The FAA is issuing this AD to address the unsafe condition on these products.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3873; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For European Union Aviation Safety Agency (EASA) material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; telephone +49 221 8999 000; email 
                        <E T="03">ADs@easa.europa.eu.</E>
                         You may find this material on the EASA website at 
                        <E T="03">ad.easa.europa.eu.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3873.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Joseph Catanzaro, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Westbury, NY 11590; phone: 516-228-7366; email: 
                        <E T="03">Joseph.Catanzaro@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 by adding an AD that would apply to certain Airbus SAS Model A330-200 and A330-300 series airplanes converted from passenger to freighter airplanes in accordance with EASA STC S10063798, which was issued to Elbe Flugzeugwerke GmbH (EFW). EASA STC S10063798 corresponds to FAA STC ST04038NY for those same modified airplane models operating in the U.S. The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on April 29, 2026 (91 FR 23034). The NPRM was prompted by EASA AD 2025-0047, dated February 20, 2025 (EASA AD 2025-0047) (also referred to as the MCAI), issued by EASA, which is the Technical Agent for the Member States of the European Union. The MCAI states it was identified that, for airplanes with a flightcrew oxygen system supplied by a single oxygen cylinder, the oxygen supply will not be sufficient under all circumstances for ETOPS-180 operation with four flightcrew members, when considering the modified procedures for airplanes that have EASA STC S10063798 (FAA STC ST04038NY) embodied. It was also identified that the minimum oxygen dispatch pressure information in the Flight Crew Operating Manual Supplement (FCOM-S) was not properly referenced by the AFM-S. This condition, if not corrected, could lead to insufficient oxygen supply in emergency situations during ETOPS-180 operation with four flightcrew members.
                </P>
                <P>In the NPRM, the FAA proposed to require revising the existing AFM-S to limit ETOPS-180 operations to three flightcrew members, as applicable, and correct minimum oxygen dispatch pressure information, as specified in EASA AD 2025-0047. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-3873.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received a comment from the Air Line Pilots Association, International, (ALPA) who supported the NPRM without change.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>
                    EASA AD 2025-0047 specifies procedures for implementing the AFM-S update to limit ETOPS-180 operations to three flightcrew members on airplanes with a flightcrew oxygen system supplied by a single 115 ft
                    <SU>3</SU>
                     oxygen cylinder and to update the minimum oxygen dispatch pressure information for all airplanes. This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 11 airplanes of U.S. registry. The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,12C,12C,12C">
                    <TTITLE>Estimated Costs for Required Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$935</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>
                    The FAA is issuing this rulemaking under the authority described in 
                    <PRTPAGE P="47950"/>
                    Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.
                </P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-01 Airbus SAS:</E>
                             Amendment 39-23413; Docket No. FAA-2026-3873; Project Identifier MCAI-2025-00197-T.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>None.</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to Airbus SAS airplanes identified in paragraphs (c)(1) and (2) of this AD, certificated in any category, modified in accordance with FAA Supplemental Type Certificate (STC) ST04038NY.</P>
                        <P>(1) Model A330-201, -202, -203, -223, and -243 airplanes.</P>
                        <P>(2) Model A330-301, -302, -303, -321, -322, -323, -341, -342, and -343 airplanes.</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Air Transport Association (ATA) of America Code 35, Oxygen.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by a finding that, for airplanes with a flightcrew oxygen system supplied by a single oxygen cylinder, the oxygen supply would not be sufficient under all circumstances for extended operations (ETOPS) with a maximum diversion time of 180 minutes (ETOPS-180) with four flightcrew members. The FAA is issuing this AD to limit ETOPS-180 operations to three flightcrew members on airplanes with a flightcrew oxygen system supplied by a single oxygen cylinder and to address incorrect minimum oxygen dispatch pressure information in the airplane flight manual supplement (AFM-S). The unsafe condition, if not addressed, could result in insufficient oxygen supply in emergency situations during ETOPS-180 operation with four flightcrew members.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Requirements</HD>
                        <P>Except as specified in paragraph (h) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, European Union Aviation Safety Agency (EASA) AD 2025-0047, dated February 20, 2025 (EASA AD 2025-0047).</P>
                        <HD SOURCE="HD1">(h) Exceptions to EASA AD 2025-0047</HD>
                        <P>(1) Where EASA AD 2025-0047 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(2) Where EASA AD 2025-0047 defines the AFM-S update as, “Aeroplane Flight Manual Supplement (AFM-S) Limitations update, as defined in Appendix 1 of this AD; and Elbe Flugzeugwerke GmbH (EFW) A330 P2F Flight Crew Operating Manual Supplement (FCOM-S) ENV-Temporary Revision No. 00-007 (Based on the Apr 01/23)”, this AD requires replacing that text with “Airplane Flight Manual Supplement (AFM-S) Limitations update, as defined in Appendix 1 of this AD”.</P>
                        <P>(3) Where paragraph (1) of EASA AD 2025-0047 says to “implement the AFM-S update”, this AD requires replacing that text with “revise the “Appendices and Supplements” section of the existing AFM Supplement to incorporate the applicable limitations in the AFM-S update”.</P>
                        <P>(4) Where paragraph (1) of EASA AD 2025-0047 specifies to “inform all flight crews, and, thereafter, operate the aeroplane accordingly,” this AD does not require those actions as those actions are already required by existing FAA operating regulations (see 14 CFR 91.9, 91.505, and 121.137).</P>
                        <P>(5) This AD does not adopt the “Remarks” section of EASA AD 2025-0047.</P>
                        <HD SOURCE="HD1">(i) Additional AD Provisions</HD>
                        <P>The following provisions also apply to this AD:</P>
                        <P>
                            (1) 
                            <E T="03">Alternative Methods of Compliance (AMOCs):</E>
                             The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the Internal Validation Branch, send it to the attention of the person identified in paragraph (j) of this AD and email to: 
                            <E T="03">AMOC@faa.gov</E>
                            . Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office.
                        </P>
                        <P>
                            (2) 
                            <E T="03">Contacting the Manufacturer:</E>
                             For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, International Validation Branch, FAA; or EASA; or Airbus SAS's EASA Design Organization Approval (DOA). If approved by the DOA, the approval must include the DOA-authorized signature.
                        </P>
                        <HD SOURCE="HD1">(j) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Joseph Catanzaro, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Westbury, NY 11590; phone: 516-228-7366; email: 
                            <E T="03">Joseph.Catanzaro@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(k) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless this AD specifies otherwise.</P>
                        <P>(i) European Union Aviation Safety Agency (EASA) AD 2025-0047, dated February 20, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For EASA material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; telephone +49 221 8999 000; email 
                            <E T="03">ADs@easa.europa.eu.</E>
                             You may find this material on the EASA website at 
                            <E T="03">ad.easa.europa.eu.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <PRTPAGE P="47951"/>
                    <DATED>Issued on July 28, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15455 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-1336; Project Identifier MCAI-2025-00254-T; Amendment 39-23426; AD 2026-15-14]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Airbus Canada Limited Partnership (Type Certificate Previously Held by C Series Aircraft Limited Partnership (CSALP); Bombardier, Inc.) Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is superseding Airworthiness Directive (AD) 2025-06-01, which applied to all Airbus Canada Limited Partnership Model BD-500-1A10 and BD-500-1A11 airplanes. AD 2025-06-01 required revising the existing airplane flight manual (AFM) to incorporate the procedures for the flightcrew to manually isolate the opposite functional engine in the event of an engine bleed duct large leak condition. Since the FAA issued AD 2025-06-01, an electronic engine control (EEC) software update has been developed to address the unsafe condition. This AD continues to require the actions in AD 2025-06-01 and requires installing a certain EEC software update on both engines. This AD also removes airplanes from the applicability. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-1336; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario K1A 0N5, Canada; telephone 888-663-3639; email 
                        <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca.</E>
                         You may find this material on the Transport Canada website at 
                        <E T="03">tc.canada.ca/en/aviation.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-1336.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Erica Bayles, Aviation Safety Engineer, FAA, 2200 South 216th St., Des Moines, WA 98198; phone: 907-271-5844; email: 
                        <E T="03">erica.e.bayles@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 to supersede AD 2025-06-01, Amendment 39-22989 (90 FR 12457, March 18, 2025) (AD 2025-06-01). AD 2025-06-01 applied to all Airbus Canada Limited Partnership Model BD-500-1A10 and BD-500-1A11 airplanes. AD 2025-06-01 required revising the existing AFM to incorporate the procedures for the flightcrew to manually isolate the opposite functional engine in the event of an engine bleed duct large leak condition. The FAA issued AD 2025-06-01 to address partially impaired software protection logic for potential large leaks from the engine bleed duct inside the engine core compartments, which could result in dual engine failure.</P>
                <P>
                    The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on February 23, 2026 (91 FR 8390). The NPRM was prompted by Transport Canada AD CF-2025-12, dated March 4, 2025 (Transport Canada AD CF-2025-12) (also referred to as the MCAI), issued by Transport Canada, which is the aviation authority for Canada. The MCAI states that Pratt &amp; Whitney developed an EEC software update (version 2.12.1, part number 5324158-15) to address the detection and protection for potential large leaks. Installation of EEC software version 2.12.1 on both engines is a terminating action to the AFM revision specified in the MCAI. The MCAI also removes production airplanes from the applicability that will have an equivalent modification incorporated before delivery.
                </P>
                <P>In the NPRM, the FAA proposed to continue to require the actions in AD 2025-06-01 and require installing a certain EEC software update on both engines, as specified in Transport Canada AD CF-2025-12. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-1336.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received a comment from Air Line Pilots Association, International (ALPA) who supported the NPRM without change.</P>
                <P>The FAA received additional comments from Delta Air Lines (Delta). The following presents the comments received on the NPRM and the FAA's response to each comment.</P>
                <HD SOURCE="HD1">Request To Allow Replacement of the EEC</HD>
                <P>Delta requested that the FAA revise paragraph (h)(4) of the proposed AD to allow either replacement or modification of the EEC to a software version eligible for installation, for added operator flexibility. Delta stated that Transport Canada AD CF-2025-12 mandates installation of EEC software version V2.12.1 either through replacement or modification of the EEC as terminating action of the Transport Canada AD. Delta suggested that the ability to either modify or replace the EEC would allow operators additional flexibility in AD implementation.</P>
                <P>Replacement of an EEC is an optional method of compliance. The FAA has revised paragraph (h)(4) of this AD to specify replacement of an EEC with an EEC that has EEC software version 2.12.1 or later approved version as an optional method of compliance for this AD.</P>
                <HD SOURCE="HD1">Request To Allow Later Software Versions</HD>
                <P>
                    Delta requested that the FAA revise the proposed AD to allow later EEC software versions. Delta recommended that the FAA add a new paragraph to the proposed AD titled “Definitions” and define “EEC Software Version Eligible for Installation” as “EEC Software Version V2.12.1 or later” to accommodate future EEC software 
                    <PRTPAGE P="47952"/>
                    version releases. Delta noted that other FAA ADs for these aircraft that have mandated installation of a specific EEC software version have allowed for future EEC software versions to be considered as AD-compliant. Delta suggested that defining an EEC software version eligible for installation as V2.12.1 or later would accommodate future EEC software versions released by the manufacturer for continued fleet reliability improvements and would align with previous ADs with EEC software version mandates.
                </P>
                <P>The FAA agrees to allow later EEC software versions. The FAA coordinated with Transport Canada regarding the acceptability of specifying later versions of EEC software for this aircraft. While the FAA has not revised this AD to add a definitions paragraph, the FAA has revised paragraph (h)(4) of this AD to allow later versions of the EEC software.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, and any other changes described previously, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>
                    Transport Canada AD CF-2025-12 specifies procedures for revising the “Non-Normal Procedure” of the AFM to incorporate the procedures for the flightcrew to manually isolate the opposite functional engine in the event of an engine bleed duct large leak condition, and the installation of a certain EEC software update on both engines, which terminates the AFM revision. The installation consists of updating the EEC software to version 2.12.1 by either replacing or modifying the EEC to include software version 2.12.1. This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates this AD affects 152 airplanes of U.S. registry. The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s100,r100,12,12,12">
                    <TTITLE>Estimated Costs for Required Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Retained actions from AD 2025-06-01</ENT>
                        <ENT>1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$12,920</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">New actions (software upgrade)</ENT>
                        <ENT>10 work-hours × $85 per hour = $850</ENT>
                        <ENT>0</ENT>
                        <ENT>850</ENT>
                        <ENT>129,200</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,r50,12,12">
                    <TTITLE>Estimated Costs for Optional Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Replace EEC</ENT>
                        <ENT>9 work-hours × $85 per hour = $765</ENT>
                        <ENT>$1,291,050</ENT>
                        <ENT>$1,291,815</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA has determined that it is not likely that operators would need to replace the EEC in order to complete the software upgrade; therefore, the rule is not significant.</P>
                <P>The FAA has included all known costs in its cost estimate. According to the manufacturer, however, some or all of the costs of this AD may be covered under warranty, thereby reducing the cost impact on affected operators.</P>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>This AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority: </HD>
                        <P>49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <PRTPAGE P="47953"/>
                    <SECTNO>§ 39.13 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by:</AMDPAR>
                    <AMDPAR>a. Removing Airworthiness Directive (AD) AD 2025-06-01, Amendment 39-22989 (90 FR 12457, March 18, 2025); and</AMDPAR>
                    <AMDPAR>b. Adding the following new AD:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-14 Airbus Canada Limited Partnership (Type Certificate Previously Held by C Series Aircraft Limited Partnership (CSALP); Bombardier, Inc.):</E>
                             Amendment 39-23426; Docket No. FAA-2026-1336; Project Identifier MCAI-2025-00254-T.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>This AD replaces AD 2025-06-01, Amendment 39-22989 (90 FR 12457, March 18, 2025) (AD 2025-06-01).</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to Airbus Canada Limited Partnership (Type Certificate previously held by C Series Aircraft Limited Partnership (CSALP); Bombardier, Inc.) Model BD-500-1A10 and BD-500-1A11 airplanes, certificated in any category, as identified in Transport Canada AD CF-2025-12, dated March 4, 2025 (Transport Canada AD CF-2025-12).</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Air Transport Association (ATA) of America Code 73, Engine fuel and control.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>
                            This AD was prompted by a design review that discovered software protection logic for potential large leaks from the engine bleed duct inside the engine core compartments was partially impaired. Under certain large leak conditions (
                            <E T="03">e.g.,</E>
                             a duct burst at a specific portion of the engine's bleed ducting), Pratt &amp; Whitney's PW1500G engine's electronic engine control (EEC) would not transmit the necessary information to the aircraft controller to automatically isolate the opposite engine from the leak path in the bleed system. In addition, since AD 2025-06-01 was issued, the FAA determined the installation of an engine EEC software update must be done to address the unsafe condition. The FAA is issuing this AD to address the unsafe condition which, if not addressed, could result in dual engine failure.
                        </P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Requirements</HD>
                        <P>Except as specified in paragraph (h) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, Transport Canada AD CF-2025-12.</P>
                        <HD SOURCE="HD1">(h) Exceptions to Transport Canada AD CF-2025-12</HD>
                        <P>(1) Where Transport Canada AD CF-2025-12 refers to September 10, 2024 (the effective date of Transport Canada AD CF-2024-30, dated August 27, 2024), this AD requires using April 22, 2025 (the effective date of AD 2025-06-01).</P>
                        <P>(2) Where Transport Canada AD CF-2025-12 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(3) Where paragraph B. of part I of Transport Canada AD CF-2025-12 specifies to “inform all flight crews of these changes in the AFM procedures and thereafter operate the aeroplane accordingly,” this AD does not require those actions as those actions are already required by existing FAA operating regulations (see 14 CFR 91.9, 14 CFR 91.505, and 14 CFR 121.137).</P>
                        <P>(4) Where the material referenced in Transport Canada AD CF-2025-12 specifies to replace or modify the EEC to update the EEC software to version 2.12.1, this AD requires modifying or replacing the EEC to update the EEC software to version 2.12.1 or later approved version.</P>
                        <HD SOURCE="HD1">(i) No Reporting Requirement</HD>
                        <P>Although the material referenced in Transport Canada AD CF-2025-12 specifies to submit certain information to the manufacturer, this AD does not include that requirement.</P>
                        <HD SOURCE="HD1">(j) Additional AD Provisions</HD>
                        <P>The following provisions also apply to this AD:</P>
                        <P>
                            (1) 
                            <E T="03">Alternative Methods of Compliance (AMOCs):</E>
                             The Manager, AIR-520, Continued Operational Safety Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the Continued Operational Safety Branch, send it to the attention of the person identified in paragraph (k) of this AD and email to: 
                            <E T="03">AMOC@faa.gov</E>
                            .
                        </P>
                        <P>(i) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office.</P>
                        <P>(ii) AMOCs approved previously for AD 2025-06-01 are approved as AMOCs for the corresponding provisions of Transport Canada AD CF-2025-12 that are required by paragraph (g) of this AD.</P>
                        <P>
                            (2) 
                            <E T="03">Contacting the Manufacturer:</E>
                             For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, AIR-520, Continued Operational Safety Branch, FAA; or Transport Canada; or Airbus Canada Limited Partnership's Transport Canada Design Approval Organization (DAO). If approved by the DAO, the approval must include the DAO-authorized signature.
                        </P>
                        <HD SOURCE="HD1">(k) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Erica Bayles, Aviation Safety Engineer, FAA, 2200 South 216th St., Des Moines, WA 98198; phone: 907-271-5844; email: 
                            <E T="03">erica.e.bayles@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(l) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless this AD specifies otherwise.</P>
                        <P>(i) Transport Canada AD CF-2025-12, dated March 4, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario K1A 0N5, Canada; telephone 888-663-3639; email 
                            <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca.</E>
                             You may find this material on the Transport Canada website at 
                            <E T="03">tc.canada.ca/en/aviation.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov.</E>
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 23, 2026.</DATED>
                    <NAME>Brian Knaup,</NAME>
                    <TITLE>Acting Deputy Director, Integrated Certificate Management Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15411 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-3477; Project Identifier MCAI-2025-01195-R; Amendment 39-23418; AD 2026-15-06]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Bell Textron Canada Limited Helicopters</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The FAA is superseding Airworthiness Directive (AD) 2024-02-55, which applies to certain Bell Textron Canada Limited (BTCL) Model 505 helicopters. AD 2024-02-55 required initial and recurring inspections of the vertical stabilizer top end cap assembly and corrective action if a crack is found. Since the FAA issued AD 2024-02-55, the manufacturer introduced a new one-
                        <PRTPAGE P="47954"/>
                        piece vertical stabilizer machined top end cap assembly, which is implemented during production, and designed a new replacement for the vertical stabilizer machined top end cap assembly currently in service. This AD continues to require the inspection requirements of AD 2024-02-55 and would limit the applicability to exclude certain serial numbered BTCL Model 505 helicopters with an improved design vertical stabilizer top end cap installed at production. This AD also requires replacing the vertical stabilizer top end cap assembly with an improved design top end cap assembly, which constitutes a terminating action for the recurring detailed visual inspections. The FAA is issuing this AD to address the unsafe condition on these products.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective September 3, 2026.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of September 3, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3477; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For Transport Canada material identified in this AD, contact Transport Canada, Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario, K1A 0N5, Canada; telephone 888-663-3639; email: 
                        <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca;</E>
                         internet 
                        <E T="03">tc.canada.ca/en/aviation.</E>
                         You may find the Transport Canada material on the Transport Canada website at 
                        <E T="03">wwwapps.tc.gc.ca/Saf-Sec-Sur/2/cawis-swimn/ad_qs1.aspx.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 10101 Hillwood Parkway, Fort Worth, TX 76177. For information on the availability of this material at the FAA, call (817) 222-5110. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-3477.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Promita Dey, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (913) 563-8269; email: 
                        <E T="03">promita.dey@faa.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 to supersede AD 2024-02-55, Amendment 39-22674 (89 FR 14576, February 28, 2024) (AD 2024-02-55). AD 2024-02-55 applied to certain BTCL Model 505 helicopters. AD 2024-02-55 required accomplishing initial and recurring inspections of the vertical stabilizer top end cap assembly, and if a crack is found, replacement of the top end cap. The FAA issued AD 2024-02-55 to address cracking in the vertical stabilizer top end cap assembly. This condition, if not addressed, could result in the antenna or tuning weight departing from the helicopter and impacting and damaging the tail rotor, which could result in the loss of directional control of the helicopter.</P>
                <P>
                    The NPRM was published in the 
                    <E T="04">Federal Register</E>
                     on April 8, 2026 (91 FR 17772). The NPRM was prompted by Transport Canada AD CF-2025-32, dated July 2, 2025 (Transport Canada AD CF-2025-32) (also referred to as the MCAI), issued by Transport Canada, which is the aviation authority for Canada. The MCAI states that a new one-piece vertical stabilizer machined top end cap assembly, having part number (P/N) SLS-030-701-149, was implemented into the Bell 505 production line, and a new machined top end cap assembly, P/N SLS-704-701-101, was developed as a replacement for the top end cap assembly P/N SLS-030-701-125 that is currently in service. The MCAI requires repetitive inspections of the vertical stabilizer top end cap assembly until the required replacement with a new machined top end cap assembly, P/N SLS-704-701-101, which is considered terminating action for the repetitive inspections.
                </P>
                <P>In the NPRM, the FAA proposed to continue to require the inspection requirements of AD 2024-02-55 and proposed to limit the applicability to exclude certain serial numbered BTCL Model 505 helicopters with an improved design vertical stabilizer top end cap installed at production. In the NPRM, the FAA also proposed to require replacing the vertical stabilizer top end cap assembly with an improved design top end cap assembly, which would constitute a terminating action for the recurring detailed visual inspections.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-3477.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received no comments on the NPRM or on the determination of the costs.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the civil aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data, considered any comments received, and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. Except for minor editorial changes, this AD is adopted as proposed in the NPRM. None of the changes will increase the economic burden on any operator.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed Transport Canada AD CF-2025-32, which specifies procedures for accomplishing a one-time detailed visual inspection of the vertical stabilizer top end cap assembly for cracking; replacing any cracked vertical stabilizer top end cap assembly; repetitively inspecting vertical stabilizer top end cap assembly P/N SLS-030-701-125; and replacing vertical stabilizer top end cap assembly P/N SLS-030-701-125 with vertical stabilizer top end cap assembly P/N SLS-704-701-101.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">Differences Between This AD and the MCAI</HD>
                <P>
                    Where the material referenced in Transport Canada AD CF-2025-32 specifies to contact the manufacturer if the drilled holes can no longer go beyond the allowable dimensions, this AD requires corrective action to be done in accordance with a method approved by the Manager, International Validation Branch, FAA; or Transport Canada; or Bell Textron Canada Limited Transport Canada Design Approval Organization (DAO). If approved by the DAO, the approval must include the DAO-authorized signature.
                    <PRTPAGE P="47955"/>
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 150 helicopters of U.S. registry.</P>
                <P>The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,r50,12,12,13">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">
                            Cost on U.S.
                            <LI>operators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Initial inspection of vertical stabilizer top end assembly</ENT>
                        <ENT>2 work-hours × $85 per hour = $170</ENT>
                        <ENT>$0</ENT>
                        <ENT>$170</ENT>
                        <ENT>$25,500</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Recurring inspections of vertical stabilizer top end assembly</ENT>
                        <ENT>1 work-hour × $85 per hour = $85</ENT>
                        <ENT>0</ENT>
                        <ENT>85</ENT>
                        <ENT>12,750</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Replacement of the vertical stabilizer top end assembly</ENT>
                        <ENT>6 work-hours (not including 16 hours to cure) × $85 per hour = $510</ENT>
                        <ENT>2,000</ENT>
                        <ENT>2,510</ENT>
                        <ENT>376,500</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA has included all known costs in its cost estimate. According to the manufacturer, however, some of the costs of this AD may be covered under warranty, thereby reducing the cost impact on affected operators.</P>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>The FAA has determined that this AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT> [Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by:</AMDPAR>
                    <AMDPAR>a. Removing Airworthiness Directive 2024-02-55, Amendment 39-22674 (89 FR 14576, February 28, 2024); and</AMDPAR>
                    <AMDPAR>b. Adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <FP SOURCE="FP-2">
                            <E T="04">2026-15-06 Bell Textron Canada Limited:</E>
                             Amendment 39-23418; Docket No. FAA-2026-3477; Project Identifier MCAI-2025-01195-R.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective September 3, 2026.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>This AD replaces AD 2024-02-55, Amendment 39-22674 (89 FR 14576, February 28, 2024).</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to Bell Textron Canada Limited Model 505 helicopters, certificated in any category, as identified in Transport Canada AD CF-2025-32, dated July 2, 2025 (Transport Canada AD CF-2025-32).</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Joint Aircraft System Component (JASC) Code: 5530, Vertical stabilizer structure.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by multiple occurrences of the vertical stabilizer top end cap assembly being found cracked, with some cases including the departure of the navigation/very high frequency omni-directional range/glide slope antenna and tuning weight from the helicopter during flight. The FAA is issuing this AD to address cracking in the vertical stabilizer top end cap assembly. The unsafe condition, if not addressed, could result in the antenna or tuning weight departing from the helicopter and impacting and damaging the tail rotor, which could result in the loss of directional control of the helicopter.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Requirements</HD>
                        <P>Except as specified in paragraphs (h) and (i) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, Transport Canada AD CF-2025-32.</P>
                        <HD SOURCE="HD1">(h) Exceptions to Transport Canada AD CF-2025-32</HD>
                        <P>(1) Where Transport Canada AD CF-2025-32 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(2) Where Transport Canada AD CF-2025-32 requires compliance in terms of hours air time, this AD requires using hours time-in-service.</P>
                        <P>(3) Where the material referenced in Transport Canada AD CF-2025-32 specifies discarding parts, this AD requires removing those parts from service.</P>
                        <P>(4) Where the material referenced in Transport Canada AD CF-2025-32 specifies damage, for the purposes of this AD, damage can be indicated by, but not limited to, cracking.</P>
                        <P>
                            (5) Where the material referenced in Transport Canada AD CF-2025-32 specifies to contact the manufacturer if the drilled holes can no longer go beyond the allowable dimensions, this AD requires corrective action in accordance with a method approved by the Manager, International Validation Branch, FAA; or Transport Canada; or Bell Textron Canada Limited Transport Canada Design Approval Organization (DAO). If approved by the DAO, 
                            <PRTPAGE P="47956"/>
                            the approval must include the DAO-authorized signature.
                        </P>
                        <HD SOURCE="HD1">(i) No Reporting Requirement</HD>
                        <P>Although the material referenced in Transport Canada AD CF-2025-32 specifies submitting certain information to the manufacturer, this AD does not include that action.</P>
                        <HD SOURCE="HD1">(j) Credit for Previous Actions</HD>
                        <P>This paragraph provides credit for the actions required by paragraph 1. of Transport Canada AD CF-2025-32, if those actions were performed before the effective date of this AD using Bell Textron Canada Limited Alert Service Bulletin (ASB) 505-24-38, dated January 24, 2024.</P>
                        <HD SOURCE="HD1">(k) Alternative Methods of Compliance (AMOCs)</HD>
                        <P>
                            (1) The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (l)(1) of this AD and email to: 
                            <E T="03">AMOC@faa.gov.</E>
                        </P>
                        <P>(2) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.</P>
                        <HD SOURCE="HD1">(l) Additional Information</HD>
                        <P>
                            (1) For more information about this AD, contact Promita Dey, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (913) 563-8269; email: 
                            <E T="03">promita.dey@faa.gov.</E>
                        </P>
                        <P>(2) Material identified in this AD that is not incorporated by reference is available at the address specified in paragraph (m)(3) of this AD.</P>
                        <HD SOURCE="HD1">(m) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                        <P>(i) Transport Canada AD CF-2025-32, dated July 2, 2025.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For Transport Canada material identified in this AD, contact Transport Canada National Aircraft Certification, 159 Cleopatra Drive, Nepean, Ontario, K1A 0N5, Canada; phone 888-663-3639; email 
                            <E T="03">TC.AirworthinessDirectives-Consignesdenavigabilite.TC@tc.gc.ca;</E>
                             internet 
                            <E T="03">tc.canada.ca/en/aviation.</E>
                             You may find the Transport Canada material on the Transport Canada website at 
                            <E T="03">wwwapps.tc.gc.ca/Saf-Sec-Sur/2/cawis-swimn/ad_qs1.aspx.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 10101 Hillwood Parkway, Fort Worth, TX 76177. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov</E>
                            .
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on July 16, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15365 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF JUSTICE</AGENCY>
                <SUBAGY>Office of the Attorney General</SUBAGY>
                <CFR>28 CFR Part 50</CFR>
                <DEPDOC>[Docket No. OAG187; AG Order No. 7028-2026]</DEPDOC>
                <RIN>RIN 1105-AB84</RIN>
                <SUBJECT>Procedures for Submission and Consideration of Petitions for Rulemaking</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Interim final rule; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the Administrative Procedure Act, the Department of Justice (“the Department”) is adopting a process for considering petitions submitted by interested persons requesting that the Department issue, amend, or repeal a rule.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P/>
                    <P>
                        <E T="03">Effective date:</E>
                         This rule is effective July 31, 2026.
                    </P>
                    <P>
                        <E T="03">Comments:</E>
                         Comments are due on or before September 29, 2026.
                    </P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>If you wish to provide comments regarding this rulemaking, you must submit comments, identified by the agency name and referencing this rule's Regulatory Identification Number (“RIN”) “1105-AB84”, by one of the two methods below:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                          
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the website instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail/Commercial Courier:</E>
                         Paper comments that duplicate an electronic submission are unnecessary. If you wish to submit a paper comment in lieu of electronic submission, please direct themail/shipment to: Docket Clerk, Office of Legal Policy, U.S. Department of Justice, RFK Main Justice Building, 950 Pennsylvania Avenue NW, Room 4234, Washington, DC 20530.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the agency name and RIN for this rulemaking. Paper comments that duplicate an electronic submission are unnecessary. All comments received may be posted without change to 
                        <E T="03">https://www.regulations.gov,</E>
                         including any personal information provided. For detailed instructions on sending comments and additional information on the rulemaking process, see the “Public Participation” heading of the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section of this document.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Christina Greer, Senior Counsel, Office of Legal Policy, U.S. Department of Justice, RFK Main Justice Building, 950 Pennsylvania Avenue NW, Washington, DC 20530. Telephone: (202) 514-5739.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Public Participation</HD>
                <P>Interested persons are invited to participate in this rulemaking by submitting written data, views, or arguments on all aspects of this rule through one of the two methods identified above and by the deadline stated above.</P>
                <P>
                    Please note that all comments received are considered part of the public record and made available for public inspection at 
                    <E T="03">https://www.regulations.gov.</E>
                     Such information includes personally identifiable information (such as your name, address, etc.) voluntarily submitted by the commenter.
                </P>
                <P>
                    The Department may withhold from public viewing information provided in comments that it determines is offensive, that may adversely impact the privacy of a third party, or for other legitimate reasons. For additional information, please read the privacy notice that is available through the link in the footer of 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <HD SOURCE="HD1">II. Background</HD>
                <P>
                    The Administrative Procedure Act (“APA”) requires that each agency give interested persons the right to petition that agency to issue, amend, or repeal a rule. 
                    <E T="03">See</E>
                     5 U.S.C. 553(e). Such a petition is known as a “petition for rulemaking.” The APA generally does not establish procedures that agencies must follow in connection with petitions for rulemaking, leaving the specific procedures to agency discretion. 
                    <E T="03">See</E>
                     Adoption of Recommendations, Admin. Conf. of the U.S., Recommendation 2014-6, Petitions for Rulemaking, 79 FR 75114, 75117 (Dec. 17, 2014) (“ACUS Recommendation 2014-6”); Maeve P. Carey, Cong. Rsch. Serv., R46190, 
                    <PRTPAGE P="47957"/>
                    <E T="03">Petitions for Rulemaking: An Overview</E>
                     5 (2020), 
                    <E T="03">https://perma.cc/2L7C-ZJND</E>
                     (“CRS, 
                    <E T="03">Petitions for Rulemaking”</E>
                    ). Other Federal agencies have enacted petition procedures. 
                    <E T="03">See, e.g.,</E>
                     6 CFR part 3 (Department of Homeland Security); 10 CFR 2.802, 2.803 (Nuclear Regulatory Commission); 14 CFR 11.61-11.103 (Federal Aviation Administration); 24 CFR 10.20 (Department of Housing and Urban Development); 43 CFR part 14 (Department of the Interior); 49 CFR 389.33 (Department of Transportation).
                </P>
                <HD SOURCE="HD1">III. Description</HD>
                <P>
                    The Department's rulemaking components have previously received and responded to petitions for rulemaking from members of the public. Until now, however, there has not been a Department-wide set of procedures addressing how the public should submit petitions for rulemaking, or how the Department considers and responds to those petitions. This rule seeks both to enhance public accessibility to the petitioning process and to establish a standard process by which the Department can efficiently manage petitions for rulemaking. Accordingly, the rule presents the requirements for prospective petitioners in a step-by-step process and explains the Department's internal procedure for receiving, tracking, considering, and responding to such petitions. 
                    <E T="03">See</E>
                     Attorney General's Manual on the Administrative Procedure Act 38 (1947) (“APA Manual”) (encouraging agencies to issue “procedural rules governing the receipt, consideration and disposition of petitions” for rulemaking).
                </P>
                <P>The rule adds to part 50 of title 28 of the Code of Federal Regulations (“Statements of Policy”) a new § 50.18, entitled “Petitions for rulemaking.” Section 50.18 is composed of paragraphs (a) through (h), which set forth: (a) the applicability of the rule; (b) pertinent definitions; (c) requirements for documents to be treated as petitions for rulemaking; (d) recommended petition content; (e) information regarding public display of petitions; (f) internal Department procedures for logging, routing, and tracking petitions; (g) Department considerations when evaluating a petition; and (h) the process for, effect of, and timing of Department responses to petitions.</P>
                <HD SOURCE="HD2">A. General Provisions (Paragraphs (a) and (b))</HD>
                <P>
                    New § 50.18 begins by setting forth general information about the section in paragraphs (a) and (b). Paragraph (a)(1) provides that § 50.18 describes the exclusive process for submitting a petition for rulemaking to the Department and any of its components as well as the Department's exclusive process for considering such petitions. Paragraph (a)(2) excepts from this exclusivity provision any petitions submitted to the Drug Enforcement Administration under the Controlled Substances Act regarding the classification of substances, 
                    <E T="03">see</E>
                     21 U.S.C. 811. Such petitions are instead governed by 21 CFR 1308.43 and 1310.02(d) through (h). Because § 50.18 only governs petitions for rulemaking, whether submitted under the APA or other law, it does not cover petitions requesting that the Department or a component take action other than issuing, amending, or appealing a rule or regulation. Paragraph (a)(3) provides that, although the Department retains discretion to treat documents that do not meet the requirements of paragraph (c) as petitions for rulemaking, the Department will only do so in exceptional circumstances.
                </P>
                <P>
                    Paragraph (b) provides definitions for the following terms used in the section: “component”, “Department”, “petition for rulemaking”, and “petitioner.” “Component” means each separate entity within the Department listed in 28 CFR 0.1, while “Department” is defined to refer to the Department or a component of it. 28 CFR 50.18(b). “Petitioner” is defined as an individual or entity that has submitted a written request for the Department to issue, adopt, amend, or repeal a Department rule. 
                    <E T="03">Id.</E>
                     Finally, “petition for rulemaking” is defined as a written request from a petitioner to issue, adopt, amend, or repeal a Department rule as provided in 5 U.S.C. 553(e). The Department further clarifies that a document not meeting the requirements in paragraph (c) is not considered to be a “petition for rulemaking” under § 50.18 unless the Department deems it to be excepted from those requirements pursuant to paragraph (a)(3).
                </P>
                <HD SOURCE="HD2">B. Requirements and Recommendations for Petitions for Rulemaking (Paragraphs (c) and (d))</HD>
                <P>Paragraphs (c) and (d) set forth the features the Department requires for a document to be considered a petition for rulemaking, as well as suggestions for the content of petitions. Pursuant to paragraph (c), to be treated as a petition for rulemaking, a document must:</P>
                <P>• include in a prominent location on the first page the words “Petition for Rulemaking”, 28 CFR 50.18(c)(1)(i);</P>
                <P>• include in a prominent location on the first page the petitioner's name and mailing address, 28 CFR 50.18(c)(1)(ii);</P>
                <P>• be addressed to the Attorney General and submitted by mail to “Attorney General, U.S. Department of Justice, 950 Pennsylvania Avenue NW, Washington, DC 20530” 28 CFR 50.18(c)(2); and</P>
                <P>• include the following specific content: (i) if requesting that the Department amend or repeal an existing rule, a citation to that rule; (ii) if requesting that the Department issue a new rule or amend an existing rule, the language the petitioner recommends for the new or amended rule; (iii) the reasons supporting the proposed action, including the factual or legal problem the petitioner seeks to address; (iv) an explanation of how the proposed action would address the problem or problems identified; (v) an explanation of why the proposed action would be in the public interest; and (vi) the interest of each petitioner in the action sought. 28 CFR 50.18(c)(3).</P>
                <P>If a document meets the requirements in paragraph (c), the Department may decline to treat it as a petition for rulemaking if its apparent purpose is to advocate for a regulatory change on behalf of a party to pending or completed adversarial proceedings before the Department and the substance of the document relates to such proceedings. 28 CFR 50.18(c)(4). Such documents may be better treated as filings in the pending or completed proceedings and may raise ex parte communication concerns if the opposing party to those proceedings is not served. To avoid such concerns, the Department may decline to treat these documents as petitions for rulemaking and may decline to address the merits of any arguments made in them.</P>
                <P>
                    The Department has determined that having a basic set of submission requirements is necessary to ensure that the Department recognizes petitions for rulemaking when submitted and handles them appropriately. 
                    <E T="03">See</E>
                     APA Manual at 38 (stating that agency procedural rules governing petitions for rulemaking “may call, for example, for . . . compliance with reasonable formal requirements”); ACUS Recommendation 2014-6, 79 FR 75118 (recommending that agencies “designate a particular person or office to receive and distribute all petitions for rulemaking to ensure that each petition for rulemaking is expeditiously directed to the appropriate agency personnel for consideration and disposition”). In the absence of such basic requirements, the Department has determined that components currently have different ways of treating documents requesting changes to Department regulations and that the public is confused about the 
                    <PRTPAGE P="47958"/>
                    proper addressee for rulemaking petitions. Additionally, the content requirements ensure that documents treated as petitions are petitions in substance, and not just in form, warranting a Departmental response. Without content requirements, the Department is concerned that it may have to allocate significant resources to respond to vague requests for rulemaking and that such reallocation of resources could cause delays in other important Department activities. 
                    <E T="03">See</E>
                     CRS, 
                    <E T="03">Petitions for Rulemaking</E>
                     at 11 (discussing the potential disadvantages of rulemaking petitions); Revisions to the Petition for Rulemaking Process, 78 FR 25886, 25887-88 (May 3, 2013) (proposed rule from the Nuclear Regulatory Commission discussing the difficulties the agency faced in processing petitions for rulemaking and the need for early screening to reduce the number of petitions that must receive full consideration and response); Revisions to the Petition for Rulemaking Process, 80 FR 60513, 60515 (Oct. 7, 2015) (final rule adopting without change the proposed rule's requirements that petitions be docketed and receive full consideration).
                </P>
                <P>
                    In addition to the requirements above, the Department includes in paragraph (d) recommendations for members of the public to consider when drafting petitions. 
                    <E T="03">See</E>
                     CRS, 
                    <E T="03">Petitions for Rulemaking</E>
                     at 12 (“Individual agencies may provide guidance, or even requirements, for petitioners . . . in their regulations.”). These recommendations are materially similar to recommendations provided by other agencies and non-governmental organizations. 
                    <E T="03">See generally id.</E>
                     (describing suggestions from the Center for Effective Government, some of which are derived from related Federal Aviation Administration regulations). In the Department's experience, the information identified in paragraph (d) helps the Department and its components better understand and consider petitions for rulemaking. 
                    <E T="03">See</E>
                     ACUS Recommendation 2014-6, 79 FR 75118 (recommending that agency procedures “explain what type of data, argumentation, and other information make a petition more useful and easier for the agency to evaluate”).
                </P>
                <HD SOURCE="HD2">C. Internal Department Processing and Procedures (Paragraphs (e) Through (h))</HD>
                <P>In paragraphs (e), (f), (g), and (h), the Department sets out its internal processes and considerations with respect to petitions for rulemaking.</P>
                <P>Paragraph (e) alerts the public that the Department may make publicly available any petition for rulemaking and its response. If the Department and relevant component make such documents public, they retain the discretion not to post information designated by the petitioner as inappropriate for public disclosure. Accordingly, petitioners should be careful to note in their submissions if there is information included that they do not wish to be made publicly available. Additionally, the Department and relevant component retain discretion not to post content that they determine is inappropriate for public disclosure. Content inappropriate for public disclosure generally includes information that may impact the privacy of an individual, confidential business information, sexually graphic content, and content that promotes violence.</P>
                <P>
                    Paragraph (f) codifies the Department's internal processes for routing petitions for rulemaking and responses. When a petition is received by mail as provided in § 50.18(c)(2), it will be logged by the Justice Management Division (“JMD”) and a copy will be sent to the Department's Regulatory Policy Officer in the Office of Legal Policy (“OLP”). 
                    <E T="03">See</E>
                     ACUS Recommendation 2014-6, 79 FR 75118 (recommending that agencies “designate a particular person or office to receive and distribute all petitions for rulemaking to ensure that each petition for rulemaking is expeditiously directed to the appropriate agency personnel for consideration and disposition”). JMD will assign the petition to the appropriate component for a response and will track both the petition and response. 
                    <E T="03">See id.</E>
                     OLP will maintain a log that tracks each petition for rulemaking and will coordinate internal Department review and clearance of draft responses prior to their issuance. 
                    <E T="03">See id.</E>
                     at 75119 (“Agencies should maintain a summary log or report listing all petitions, the date each was received, and the date of disposition or target timeline for disposition[.]”).
                </P>
                <P>Paragraph (g) describes the criteria that the Department may consider when evaluating a petition for rulemaking. The Department provides this information in addition to the requirements in paragraph (c)(3) and the recommended petition content in paragraph (d) to aid interested persons when they are drafting petitions for rulemaking.</P>
                <P>
                    Paragraph (h) describes the nature and timing of a response to a petition for rulemaking. First, upon granting or denying a petition, the Department (or the relevant component) will notify the petitioner of the resolution at the contact information the petitioner provided under paragraph (c)(1)(ii). 28 CFR 50.18(h)(1). If the petition is denied in whole or in part, the Department's response will provide a brief statement of the grounds for denying it. 
                    <E T="03">See</E>
                     5 U.S.C. 555(e) (“Except in affirming a prior denial or when the denial is self-explanatory, the notice shall be accompanied by a brief statement of the grounds for denial.”). Denying a petition does not preclude the Department (or a relevant component) from considering one or more of the issues raised in the petition in future actions.
                </P>
                <P>Second, the head of a component may deny a petition for rulemaking relating to matters within its jurisdiction. 28 CFR 50.18(h)(2). By this rule, the Attorney General is delegating this authority to component heads to better allow for timely resolution of petitions. However, the requirement that denials be coordinated with OLP will ensure that any denials are cleared by Department leadership and represent the Department's positions on the issues involved.</P>
                <P>
                    Third, when the Department grants a petition, the Department will initiate a rulemaking action under 5 U.S.C. 553, as appropriate, although taking such an action does not mean that the Department will ultimately adopt the petition's proposals or that the Department will complete the rulemaking. 28 CFR 50.18(h)(3). 
                    <E T="03">See</E>
                     CRS, 
                    <E T="03">Petitions for Rulemaking</E>
                     at 5 (“[T]he granting of the petition merely serves as a starting point for the agency to take an action. If the nature of the action requires notice-and-comment rulemaking, for example, the agency must still engage in those procedures.”). The Attorney General is not delegating general authority in this rule to grant petitions for rulemaking, because such actions often involve issuing a notice of proposed rulemaking and delegations to propose rules have typically been made through more specific delegations, generally by topic and by component.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See, e.g.,</E>
                         28 CFR 0.96(n) through (o), 0.99 (delegating to the Director of the Bureau of Prisons authority to issue specific types of rules and regulations); Att'y Gen. Order No. 6260-2025 (May 8, 2025) (delegating authority to the Director of the Executive Office for Immigration Review to issue regulations related to immigration matters within that office's jurisdiction); Att'y Gen. Order No. 6353-2025 (Aug. 4, 2025) (delegating authority to the Director of the Bureau of Alcohol, Tobacco, Firearms, and Explosives to issue regulations related to matters within that bureau's jurisdiction).
                    </P>
                </FTNT>
                <P>
                    Finally, the Department will endeavor to consider all petitions submitted as time and resources permit but specifies that nothing in § 50.18 binds the Department to act within a certain time period when making a determination on a petition, providing notice of such determination to the petitioner, or 
                    <PRTPAGE P="47959"/>
                    undertaking a rulemaking after granting a petition. 8 CFR 50.18(h)(4).
                </P>
                <HD SOURCE="HD1">IV. Regulatory Certifications</HD>
                <HD SOURCE="HD2">A. Administrative Procedure Act</HD>
                <P>
                    This rule relates to a matter of agency management or personnel and is a rule of agency organization, procedure, or practice. This rule describes how an interested person may petition the Department to issue, amend, or repeal a rule and explains the procedures that the Department will follow to respond to rulemaking petitions it receives. As such, this rule is exempt from the usual requirements of prior notice and comment, and from a 30-day delay in effective date. 
                    <E T="03">See</E>
                     5 U.S.C. 553(a)(2), (b)(A), (d). Although the APA does not require the Department to provide a period of advance notice nor an opportunity for public comment, the Department invites public comment on this rule.
                </P>
                <HD SOURCE="HD2">B. Regulatory Flexibility Act</HD>
                <P>
                    A regulatory flexibility analysis under the Regulatory Flexibility Act is not required for this interim final rule because the Department was not required to publish a general notice of proposed rulemaking for this matter. 
                    <E T="03">See</E>
                     5 U.S.C. 601(2), 604(a).
                </P>
                <HD SOURCE="HD2">C. Executive Orders 12866 (Regulatory Planning and Review) and 14192 (Unleashing Prosperity Through Deregulation)</HD>
                <P>
                    This rule is limited to agency organization, management, or personnel matters and is therefore not subject to review by the Office of Management and Budget, pursuant to section 3(d)(3) of Executive Order 12866, and section 5(b) of Executive Order 14192. 
                    <E T="03">See</E>
                     E.O. 12866, 58 FR 51735, 51737 (Sept. 30, 1993); E.O. 14192, 90 FR 9065, 9066 (Jan. 31, 2025).
                </P>
                <HD SOURCE="HD2">D. Executive Order 14294 (Overcriminalization of Federal Regulations)</HD>
                <P>
                    Executive Order 14294 requires agencies promulgating regulations with criminal regulatory offenses potentially subject to criminal enforcement to explicitly describe the conduct subject to criminal enforcement, the authorizing statutes, and the mens rea standard applicable to each element of those offenses. 
                    <E T="03">See</E>
                     E.O. 14294, 90 FR 20363, 20363 (May 9, 2025). This rule does not promulgate a regulation potentially subject to criminal enforcement and is thus exempt from Executive Order 14924's requirements.
                </P>
                <HD SOURCE="HD2">E. Executive Order 12988 (Civil Justice Reform)</HD>
                <P>
                    This rule meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 to specify provisions in clear language. 
                    <E T="03">See</E>
                     E.O. 12988, 61 FR 4729, 4730-32 (Feb. 5, 1996).
                </P>
                <HD SOURCE="HD2">F. Executive Order 13132 (Federalism)</HD>
                <P>
                    This rule will not have substantial direct effects on the States, on the relationship between the Federal government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with section 6 of Executive Order 13132, the Department has determined that this rule does not have sufficient federalism implications to warrant preparing a federalism summary impact statement. 
                    <E T="03">See</E>
                     E.O. 13132, 64 FR 43255, 43257-58 (Aug. 4, 1999).
                </P>
                <HD SOURCE="HD2">G. Unfunded Mandates Reform Act of 1995</HD>
                <P>
                    This rule will not result in the expenditure of $100 million or more (adjusted for inflation) in any one year by State, local, and Tribal governments in the aggregate or by the private sector, and it will not significantly or uniquely affect small governments. Therefore, no actions are necessary under the provisions of the Unfunded Mandates Reform Act of 1995, 2 U.S.C. 1501 
                    <E T="03">et seq.</E>
                </P>
                <HD SOURCE="HD2">H. Congressional Review Act</HD>
                <P>
                    This rule is not a “major rule” as defined by the Congressional Review Act (“CRA”), 5 U.S.C. 804(2). This action pertains to agency management and to matters of agency organization, procedure, or practice, and does not substantially affect the rights or obligations of non-agency parties. Accordingly, it is also not a “rule” as that term is defined in the CRA, 
                    <E T="03">see</E>
                     5 U.S.C. 804(3), and the reporting requirement of 5 U.S.C. 801 does not apply.
                </P>
                <HD SOURCE="HD2">I. Paperwork Reduction Act of 1995</HD>
                <P>This rule does not impose any new reporting or recordkeeping requirements under the Paperwork Reduction Act of 1995, 44 U.S.C. 3501-3521.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 28 CFR Part 50</HD>
                    <P>Administrative practice and procedure, Crime, News media, Search warrants.</P>
                </LSTSUB>
                <P>Accordingly, by virtue of the authority vested in me as Attorney General, including by 5 U.S.C. 301 and 28 U.S.C. 509-510, part 50 of title 28 of the Code of Federal Regulations is amended as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 50—STATEMENTS OF POLICY</HD>
                </PART>
                <REGTEXT TITLE="28" PART="50">
                    <AMDPAR>1. The authority citation for part 50 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P>
                             5 U.S.C. 301; 18 U.S.C. 1162; 28 U.S.C. 509, 510, 516, and 519; 42 U.S.C. 1921 
                            <E T="03">et seq.,</E>
                             1973c; and Public Law 107-273, 116 Stat. 1758, 1824.
                        </P>
                    </AUTH>
                </REGTEXT>
                  
                <REGTEXT TITLE="28" PART="50">
                    <AMDPAR>2. Section 50.18 is added to read as follows:</AMDPAR>
                    <SECTION>
                        <SECTNO>§ 50.18 </SECTNO>
                        <SUBJECT>Petitions for rulemaking.</SUBJECT>
                        <P>
                            (a) 
                            <E T="03">Applicability of this section.</E>
                             (1) 
                            <E T="03">General.</E>
                             Except as provided in paragraph (a)(2) of this section, this section prescribes the exclusive process for submitting to the Department of Justice or any of its components a petition requesting that the Department issue, amend, or repeal a Department rule as provided in 5 U.S.C. 553(e), or other statutory provision, and the process by which the Department will consider and respond to such petitions.
                        </P>
                        <P>
                            (2) 
                            <E T="03">Exception.</E>
                             This section does not apply to any petition submitted regarding the classification of substances pursuant to the Controlled Substances Act, 21 U.S.C. 811. Such petitions are governed by 21 CFR 1308.43 and 1310.02(d) through (h).
                        </P>
                        <P>
                            (3) 
                            <E T="03">Department discretion.</E>
                             The Department retains the discretion to treat documents that do not meet the requirements of paragraph (c) of this section as petitions for rulemaking. However, the Department will exercise that discretion only in exceptional circumstances.
                        </P>
                        <P>
                            (b) 
                            <E T="03">Definitions.</E>
                        </P>
                        <P>
                            <E T="03">Component.</E>
                             Each separate organizational entity within the U.S. Department of Justice listed in 28 CFR 0.1.
                        </P>
                        <P>
                            <E T="03">Department.</E>
                             The U.S. Department of Justice or a component thereof.
                        </P>
                        <P>
                            <E T="03">Petition for rulemaking.</E>
                             Any written request from a petitioner to issue, adopt, amend, or repeal a Department rule, pursuant to 5 U.S.C. 553(e), that is submitted in accordance with the requirements in paragraph (c) of this section or that the Department deems to be excepted from those requirements under paragraph (a)(3) and treats as a petition for rulemaking under that paragraph.
                        </P>
                        <P>
                            <E T="03">Petitioner.</E>
                             An individual or entity that has submitted a written request that the Department issue, adopt, amend, or repeal a Department rule.
                        </P>
                        <P>
                            (c) 
                            <E T="03">Formatting and submission requirements.</E>
                             The Department will not treat a document as a petition for rulemaking unless it meets the following requirements.
                            <PRTPAGE P="47960"/>
                        </P>
                        <P>
                            (1) 
                            <E T="03">Format.</E>
                             The document must be typewritten and include in a prominent location on the first page—
                        </P>
                        <P>(i) The words “Petition for Rulemaking”; and</P>
                        <P>(ii) The petitioner's name and mailing address, in addition to any other contact information (such as telephone number or email address) that the petitioner chooses to include.</P>
                        <P>
                            (2) 
                            <E T="03">Submission.</E>
                             The document must be addressed to the Attorney General and submitted by mail to: “Attorney General, U.S. Department of Justice, 950 Pennsylvania Avenue NW, Washington, DC 20530”.
                        </P>
                        <P>
                            (3) 
                            <E T="03">Content.</E>
                             The document must include:
                        </P>
                        <P>(i) If requesting that the Department amend or repeal an existing rule or regulation, a citation to that rule or provision in the Code of Federal Regulations;</P>
                        <P>(ii) If requesting that the Department issue a new rule or amend an existing rule or regulation, the language the petitioner recommends for the new or amended rule or regulatory text;</P>
                        <P>(iii) The reasons supporting the proposed action, including the factual or legal problem the petitioner seeks to address;</P>
                        <P>(iv) An explanation of how the proposed action would address the problem or problems identified;</P>
                        <P>(v) An explanation of why the proposed action would be in the public interest; and</P>
                        <P>(vi) The interest that each petitioner has in the action sought.</P>
                        <P>
                            (4) 
                            <E T="03">Submissions by parties to proceedings before the Department.</E>
                             A document meeting the requirements in paragraphs (c)(1) through (3) of this section may not be treated as a petition for rulemaking if the document's apparent purpose is to advocate on behalf of a party to pending or completed adversarial proceedings before the Department and the substance of the document relates to the substance of the proceedings.
                        </P>
                        <P>
                            (d) 
                            <E T="03">Additional recommended content for a petition for rulemaking.</E>
                             The Department and its components will be in a better position to understand, consider, and respond to a petition for rulemaking if the petition identifies and directly addresses the petitioner's particular concerns and the specific changes requested. Thus, in addition to the requirements listed in paragraph (c) of this section, the Department recommends that any petition for rulemaking also identify:
                        </P>
                        <P>(1) Sources in support of the petitioner's request as well as those counseling against it;</P>
                        <P>(2) The legal authority pursuant to which the Department may issue, amend, or repeal the rule in question;</P>
                        <P>(3) The name of the component, if known, under whose authority the rule exists or would exist if the petition requests that the Department issue a rule;</P>
                        <P>(4) An explanation of why rulemaking is the most appropriate means to address the problem identified in the petition, and why other ways to resolve the problem, such as adjudication or agency guidance, are insufficient; and</P>
                        <P>(5) An analysis of reasons for not adopting possible alternative rulemaking approaches to achieve the intended result.</P>
                        <P>
                            (e) 
                            <E T="03">Docketing and public display.</E>
                             The Department may make a petition for rulemaking, and the Department's response to the petition, publicly available. The Department retains discretion not to post information identified by the petitioner as being inappropriate for public disclosure or which the Department determines is inappropriate for public disclosure.
                        </P>
                        <P>
                            (f) 
                            <E T="03">Logging and internal Department review of response.</E>
                             (1) When the Department receives a petition for rulemaking, the Justice Management Division must log it and send a copy to the Department's Regulatory Policy Officer in the Office of Legal Policy. The Justice Management Division will assign the petition to the appropriate component to prepare a response and will notify the Department's Regulatory Policy Officer of the assignment.
                        </P>
                        <P>(2) The Office of Legal Policy will maintain a log that tracks each petition for rulemaking that the Department receives and the status of each such petition, in addition to any similar logs maintained by the Justice Management Division and the component tasked with drafting a response.</P>
                        <P>(3) The component tasked with drafting a response to a petition shall submit the draft response to the Office of Legal Policy for appropriate review and clearance and shall coordinate with the Office of Legal Policy on the appropriate means for issuing the response.</P>
                        <P>
                            (g) 
                            <E T="03">Determination.</E>
                             The Department's determination on a petition for rulemaking may be based upon, but is not limited to, the following considerations:
                        </P>
                        <P>(1) The merits of the petition;</P>
                        <P>(2) Whether addressing the issues raised in the petition is consistent with the Department's policy preferences and priorities;</P>
                        <P>(3) The immediacy of the concern raised;</P>
                        <P>(4) The availability of resources and the priority of the issues raised in relation to other Department rulemaking actions;</P>
                        <P>(5) Whether the problems or issues raised are already under consideration by the Department in other actions; and</P>
                        <P>(6) Whether rulemaking is the appropriate means to address the problems or issues raised.</P>
                        <P>
                            (h) 
                            <E T="03">Resolution.</E>
                             (1) 
                            <E T="03">Notification.</E>
                             Upon granting or denying a petition, the Department will notify the petitioner at themailing address provided by the petitioner under paragraph (c)(1)(ii) of this section. If the Department denies the petition in whole or in part, the Department will also provide a brief statement to the petitioner of the grounds for denying it.
                        </P>
                        <P>
                            (2) 
                            <E T="03">Delegation of authority for denying petitions.</E>
                             The head of a component may deny a petition for rulemaking that relates to matters within the component's jurisdiction after consultation with the Office of Legal Policy as described in paragraph (f)(3) of this section.
                        </P>
                        <P>
                            (3) 
                            <E T="03">Effect of grant of petition for rulemaking.</E>
                             In general, when the Department grants a petition for rulemaking in whole or in part, it will initiate a rulemaking action under 5 U.S.C. 553, as appropriate. However, such a grant does not mean that the Department will ultimately adopt the petition's proposals or that it will complete any initiated rulemaking action relating to the petition.
                        </P>
                        <P>
                            (4) 
                            <E T="03">Timing.</E>
                             The Department will endeavor to consider all petitions submitted pursuant to this section as time and resources permit, given its other obligations and responsibilities. However, nothing in this section binds the Department to act within a certain time period when making a determination on a petition, providing notice of such determination to a petitioner, or undertaking a rulemaking (if a petition is granted).
                        </P>
                    </SECTION>
                </REGTEXT>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Todd Blanche,</NAME>
                    <TITLE>Acting Attorney General.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15434 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-BB-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">POSTAL SERVICE</AGENCY>
                <CFR>39 CFR Part 111</CFR>
                <SUBJECT>Duty Collection for Domestic Mail Arriving From Certain Insular Possessions and Territories</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Postal Service.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Interim final rule.</P>
                </ACT>
                <SUM>
                    <PRTPAGE P="47961"/>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Postal Service is revising 
                        <E T="03">Mailing Standards of the United States Postal Service,</E>
                         Domestic Mail Manual (DMM®), section 608, to provide instructions for customs clearance and the prepayment of applicable customs duties, taxes, and fees for certain goods mailed from American Samoa, Guam, Northern Mariana Islands, and U.S. Virgin Islands destined to the customs territory of the United States (CTUS), which is defined in 19 Code of Federal Regulations (CFR) 101.1 as the fifty States, the District of Columbia, and Puerto Rico.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Effective:</E>
                         July 30, 2026.
                    </P>
                    <P>Comments must be received by August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Mail or deliver comments to the manager of Product Classification, U.S. Postal Service, 475 L'Enfant Plaza SW, RM 4446, Washington, DC 20260-5015. You may inspect and photocopy all written comments at USPS Headquarters Library, 475 L'Enfant Plaza SW, 11th Floor N, Washington, DC by appointment only between the hours of 9 a.m. and 4 p.m. ET, Monday through Friday, by calling (202) 268-2906 in advance. Email comments, including the name and address of the commenter, to: 
                        <E T="03">PCFederalRegister@usps.gov,</E>
                         with a subject line of “Duty Collection for Domestic Mail.” Faxed comments will not be accepted.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Michelle Lassiter at (202) 268-2914.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Pursuant to the Executive Order 14324 of July 30, 2025 (“Suspending Duty-Free De Minimis Treatment for All Countries”), as amended, duty-free 
                    <E T="03">de minimis</E>
                     treatment under 19 U.S.C. 1321(a)(2)(C) was suspended on a global basis effective August 29, 2025.
                </P>
                <P>
                    On June 24, 2026, U.S. Customs and Border Protection (CBP) published an interim final rule which implemented an immediate indefinite suspension of the 
                    <E T="03">de minimis</E>
                     administrative exemption for merchandise valued at $800 or less and imported through the international postal network (91 FR 37801). As a result, goods imported by mail that are valued at $2,500 or less, and are eligible for informal entry, may be entered under the new informal entry process which was also established by CBP's interim final rule, effective July 24, 2026.
                </P>
                <P>
                    The U.S. Postal Service® has coordinated with a licensed customs broker to enablemailers to prepay duties, taxes, and fees, and obtain proof of payment, for articles valued up to $2,500 entering the customs territory of the United States (CTUS) from the following insular possessions and territories: American Samoa, Guam, Northern Mariana Islands, and U.S. Virgin Islands. The DMM is hereby updated to reflect the additional steps mailers must follow before presenting their items at a Post Office
                    <E T="51">TM</E>
                     retail service counter.
                </P>
                <P>The Postal Service is implementing these requirements immediately to avoid a delay or suspension of service for items being sent from the affected insular possessions and territories to the CTUS. Although exempt from the notice and comment requirements of the Administrative Procedure Act (5 U.S.C. 553(b), (c)) regarding proposed rulemaking by 39 U.S.C. 410(a), the Postal Service invites public comments on the described revisions.</P>
                <P>The Postal Service adopts the described changes to Mailing Standards of the United States Postal Service, Domestic Mail Manual (DMM), incorporated by reference in the Code of Federal Regulations. We will publish an appropriate amendment to 39 CFR part 111 to reflect these changes.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 39 CFR Part 111</HD>
                    <P>Administrative practice and procedure, Postal Service.</P>
                </LSTSUB>
                <P>Accordingly, the Postal Service amends Mailing Standards of the United States Postal Service, Domestic Mail Manual (DMM), incorporated by reference in the Code of Federal Regulations as follows (see 39 CFR 111.1):</P>
                <PART>
                    <HD SOURCE="HED">PART 111—[AMENDED]</HD>
                </PART>
                <REGTEXT TITLE="39" PART="111">
                    <AMDPAR>1. The authority citation for 39 CFR Part 111 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority: </HD>
                        <P>5 U.S.C. 552(a); 13 U.S.C. 301-307; 18 U.S.C. 1692-1737; 39 U.S.C. 101, 401-404, 414, 416, 3001-3018, 3201-3220, 3401-3406, 3621, 3622, 3626, 3629, 3631-3633, 3641, 3681-3685, and 5001.</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="39" PART="111">
                    <AMDPAR>
                        2. Revise 
                        <E T="03">Mailing Standards of the United States Postal Service,</E>
                         Domestic Mail (DMM), as follows:
                    </AMDPAR>
                    <HD SOURCE="HD1">Mailing Standards of the United States Postal Service, Domestic Mail Manual (DMM)</HD>
                    <STARS/>
                    <HD SOURCE="HD1">600 Basic Standards for All Mailing Services</HD>
                    <STARS/>
                    <HD SOURCE="HD1">608 Postal Information and Resources</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.0 Domestic Mail</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.3 Customs Forms Required</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.3.2 Items Containing Goods</HD>
                    <P>[Delete 2.3.2 and renumber current 2.3.3 and 2.3.4 as 2.3.2 and 2.3.3, respectively. Renumber 2.3.5 as 2.3.4 and revise the first paragraph to read as follows:]</P>
                    <HD SOURCE="HD1">2.3.4 Items Eligible for Deposit or Pickup</HD>
                    <P>
                        Except for items covered by 2.6.3, items bearing a computer-generated customs form (
                        <E T="03">e.g.,</E>
                         using Click-N-Ship service, an authorized PC Postage vendor, or the USPS API) may be deposited through any of the following methods, provided postage is paid by a means other than using postage stamps.
                    </P>
                    <STARS/>
                    <P>[Renumber 2.3.6 as 2.3.5 and revise the text by adding a new item d. to read as follows:]</P>
                    <HD SOURCE="HD1">2.3.5 Items Not Eligible for Deposit or Pickup</HD>
                    <STARS/>
                    <P>d. Any item requiring prepayment of customs duties, taxes, and fees, see 2.6.3.</P>
                    <STARS/>
                    <P>[Renumber current 2.3.7 and 2.3.8 as 2.3.6 and 2.3.7, respectively.]</P>
                    <STARS/>
                    <P>[Add new section 2.6 and renumber current 2.6 as 2.7 to read as follows:]</P>
                    <HD SOURCE="HD1">2.6 Items Sent to the Customs Territory of the United States (CTUS)</HD>
                    <HD SOURCE="HD1">2.6.1 Duty Collection for Certain Domestic Mail</HD>
                    <P>U.S. Customs and Border Protection (CBP) has the authority to collect duties, taxes, and fees for items entering the customs territory of the United States (CTUS), which is defined as the fifty States, the District of Columbia, and Puerto Rico (19 CFR 101.1). Insular possessions of the United States other than Puerto Rico are American territory but, because they are outside the CTUS, goods mailed from these locations are subject to duties unless exempted (see 19 CFR 7.2 and 7.3).</P>
                    <HD SOURCE="HD1">2.6.2 Preparation and Acceptance of Electronically Generated Customs Forms</HD>
                    <P>
                        Regardless of mail class or weight, items containing goods must bear a properly completed, computer-generated customs form produced through an approved USPS system capable of electronically transmitting the associated customs data when the items are sent into the CTUS from an APO/FPO/DPO location abroad (see 703.2.7.3), from the possessions and territories listed in 2.1 (except Puerto Rico), or from a Freely Associated State 
                        <PRTPAGE P="47962"/>
                        listed in 2.2. The following are mandatory and conditional data elements.
                    </P>
                    <P>
                        a. 
                        <E T="03">Mandatory Data Elements:</E>
                         The following data elements are mandatory for all customs forms regardless of mail class:
                    </P>
                    <P>1. Sender's full name and address.</P>
                    <P>2. Recipient's full name and address.</P>
                    <P>
                        3. Category of items (
                        <E T="03">e.g.,</E>
                         document, gift, merchandise, etc.).
                    </P>
                    <P>4. A detailed qualitative description of contents, as well as the quantity, net weight, and value for each item in the package.</P>
                    <P>5. For all goods, all applicable tariff codes from the Harmonized Tariff Schedule of the United States (including all 10-digits codes and 8-digit codes, if applicable).</P>
                    <P>6. Country(ies) of origin of goods.</P>
                    <P>7. Sender's signature and date.</P>
                    <P>
                        b. 
                        <E T="03">Conditional Data Elements:</E>
                         The following data elements may be required based on the contents of the package and other nonpostal rules and regulations (
                        <E T="03">Note:</E>
                         this is not an all-inclusive list.):
                    </P>
                    <P>1. Sender's phone number or email address, if available.</P>
                    <P>2. Recipient's phone number or email address, if available.</P>
                    <P>3. License/Permit number, if applicable.</P>
                    <P>
                        4. AES ITN or exemption citation (NOEEI) (see 
                        <E T="03">520</E>
                        -
                        <E T="03">527</E>
                        ), if applicable.
                    </P>
                    <HD SOURCE="HD1">2.6.3 Proof of Customs Duty Payment or Recording of Duty Exemption</HD>
                    <P>
                        Mailers sending dutiable goods valued up to $2,500 from the U.S. possessions and territories listed in Exhibit 2.6.3 are required to ensure payment of all applicable duties, taxes, and fees before presenting the item to an employee at a Post Office retail service counter. Proof of duty payment or confirmation of the duty exemption status (
                        <E T="03">e.g.,</E>
                         declaration ID, QR Code®, etc.) must be presented at the time of mailing. Deposit and pickup methods listed under 2.3.5 are prohibited.
                    </P>
                    <NOTE>
                        <HD SOURCE="HED">Note: </HD>
                        <P>
                            Mailers sending items containing only documents that have no monetary value are not required to provide proof of duty payment or proof of duty exemption. For more information about goods that qualify for duty exemptions, see 
                            <E T="03">https://www.cbp.gov/trade/basic-import-export/e-commerce/faqs.</E>
                        </P>
                    </NOTE>
                    <HD SOURCE="HD1">Exhibit 2.6.3 Proof of Customs Duty Payment or Duty Exemption Record</HD>
                    <FP SOURCE="FP-1">American Samoa</FP>
                    <FP SOURCE="FP-1">Guam</FP>
                    <FP SOURCE="FP-1">Northern Mariana Islands</FP>
                    <FP SOURCE="FP-1">U.S. Virgin Islands</FP>
                    <HD SOURCE="HD1">2.6.4 Preparation by the Sender</HD>
                    <P>Before mailing, when using the Zonos Prepay app, the sender should complete the following steps:</P>
                    <P>
                        a. Download the Zonos Prepay mobile app, which is available for iOS devices through the App Store at 
                        <E T="03">https://apps.apple.com/us/app/zonos-prepay/id6747267592</E>
                         and for Android devices through Google Play at 
                        <E T="03">https://play.google.com/store/apps/details?id=com.zonos.zonosprepay&amp;hl=fr.</E>
                    </P>
                    <P>b. Use the mobile app to pay any applicable duties, taxes, and fees, and obtain a declaration ID and QR Code®. </P>
                    <NOTE>
                        <HD SOURCE="HED">Note: </HD>
                        <P>As a licensed customs broker, Zonos may charge a fee for its services.</P>
                    </NOTE>
                    <P>c. Present the item along with the declaration ID to an employee at a Post Office retail service counter. Alternatively, themailer may present the Zonos Prepay QR Code® at a Post Office location where scanning technology is available at the time of acceptance.</P>
                    <HD SOURCE="HD1">2.6.5 Preparation by Acceptance Employee</HD>
                    <P>Postal Service acceptance employees must comply with all requirements set forth in the most recent applicable training materials and standard operating procedures. For mailpieces containing dutiable goods and items where themailer used the services of a licensed customs broker, the following steps should be completed:</P>
                    <P>a. Obtain the customer's proof of duty payment or duty exemption. This may be in the form of a declaration ID or QR Code®.</P>
                    <P>b. Complete the data entry for customs form information, if necessary, and obtain the USPS tracking number.</P>
                    <P>c. Link the proof of duty payment or proof of exemption record to the USPS tracking number by following the instructions in the standard operating procedures. </P>
                    <NOTE>
                        <HD SOURCE="HED">Note: </HD>
                        <P>This step may require the acceptance employee to access a third-party website.</P>
                    </NOTE>
                    <STARS/>
                    <P>[Revise the title of 608.7 to read as follows:]</P>
                    <HD SOURCE="HD1">7.0 Trademarks and Copyrights</HD>
                    <STARS/>
                    <P>[Add new 7.3 to read as follows:]</P>
                    <HD SOURCE="HD1">7.3 Third-Party Trademarks</HD>
                    <P>The following are third-party registered trademarks and service marks that appear throughout the DMM.</P>
                    <P>• QR Code® is a registered trademark of Denso Wave, Inc.</P>
                    <STARS/>
                </REGTEXT>
                <SIG>
                    <NAME>Jeffrey Boblick,</NAME>
                    <TITLE>Attorney, Ethics and Legal Compliance.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15420 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7710-12-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Part 52</CFR>
                <DEPDOC>[EPA-R09-OAR-2025-1938; FRL-13058-02-R9]</DEPDOC>
                <SUBJECT>Air Plan Approval; California; San Joaquin Valley Air Pollution Control District</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Environmental Protection Agency (EPA) is taking final action to approve a revision to the San Joaquin Valley Air Pollution Control District (SJVAPCD or “District”) portion of the California State Implementation Plan (SIP) concerning two rules submitted to address section 185 of the Clean Air Act (CAA or the “Act”) with respect to the 2008 and 2015 8-hour ozone National Ambient Air Quality Standards (NAAQS or “standards”).</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This rule is effective August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The EPA has established a docket for this action under Docket ID No. EPA-R09-OAR-2025-1938. All documents in the docket are listed on the 
                        <E T="03">https://www.regulations.gov</E>
                         website. Some information is not publicly available, 
                        <E T="03">e.g.,</E>
                         Confidential Business Information (CBI) or other 
                    </P>
                    <PRTPAGE P="47963"/>
                    <FP>
                        information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the internet and will be publicly available only in hard copy form. Publicly available docket materials are available through 
                        <E T="03">https://www.regulations.gov,</E>
                         or please contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section for additional availability information. If you need assistance in a language other than English or if you are a person with a disability who needs a reasonable accommodation at no cost to you, please contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section.
                    </FP>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Tom Kelly, EPA Region IX, 75 Hawthorne St, San Francisco, CA 94105; telephone number: (415) 972-3856; email address: 
                        <E T="03">kelly.thomasp@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Throughout this document, “we,” “us,” and “our” refer to the EPA.</P>
                <HD SOURCE="HD1">Table of Contents </HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Proposed Action</FP>
                    <FP SOURCE="FP-2">II. Public Comments and EPA Responses</FP>
                    <FP SOURCE="FP-2">III. EPA Action</FP>
                    <FP SOURCE="FP-2">IV. Incorporation by Reference</FP>
                    <FP SOURCE="FP-2">V. Statutory and Executive Order Reviews</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Proposed Action</HD>
                <P>
                    On December 11, 2025, the EPA proposed to approve the rules in Table 1 into the California SIP.
                    <SU>1</SU>
                    <FTREF/>
                     We proposed to approve these rules because we determined that the rules comply with the relevant CAA requirements. Our proposed action contains more information on the rules and our evaluation.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         90 FR 57414 (December 11, 2025).
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="xs60,12,r50,12,12">
                    <TTITLE>Table 1—Submitted Rules</TTITLE>
                    <BOXHD>
                        <CHED H="1">Local agency</CHED>
                        <CHED H="1">Rule No.</CHED>
                        <CHED H="1">Rule title</CHED>
                        <CHED H="1">Adopted</CHED>
                        <CHED H="1">Submitted</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">SJVAPCD</ENT>
                        <ENT>3172</ENT>
                        <ENT>Federally Mandated Ozone Nonattainment Fee—2008 8-Hour Standard</ENT>
                        <ENT>12/21/23</ENT>
                        <ENT>03/13/24</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SJVAPCD</ENT>
                        <ENT>3173</ENT>
                        <ENT>Federally Mandated Ozone Nonattainment Fee—2015 8-Hour Standard</ENT>
                        <ENT>12/21/23</ENT>
                        <ENT>03/13/24</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">II. Public Comments and EPA Responses</HD>
                <P>The EPA's proposed action provided a 30-day public comment period (90 FR 57414 (December 11, 2025). During this period, we received one comment letter from the Committee for a Better Arvin, Medical Advocates for Healthy Air, and the Sierra Club, which is included in the docket for this rulemaking. The following paragraphs summarize the substantive comments objecting to our proposed action and provide our responses.</P>
                <P>
                    <E T="03">Comment 1:</E>
                     Commenters point to the CAA section 185(a) requirement that fees be paid “for each calendar year beginning after the attainment date, until the area is redesignated as an attainment area for ozone.” They claim that the rule language providing that “[t]he fees established by this rule shall cease to be applicable” when the EPA redesignates the area to attainment means that the rules do not require payment of fees that have accrued and become due but have not yet been paid when the area is redesignated.
                </P>
                <P>
                    <E T="03">Response:</E>
                     The EPA does not agree with Commenters' reading of the rules. The EPA understands that the provision providing that “[t]he fees established by this rule shall cease to be applicable” upon redesignation simply prevents new fees from accruing—but does not excuse payment of monies already due.
                </P>
                <P>There are multiple reasons why the EPA believes this is the best reading. First, as a textual matter, if, for example, a tax or fee “ceases to be applicable” in a specific year, a natural reading of such provision is that the tax is not incurred for years beginning with the specified year. It does not retroactively excuse non-payment of taxes already owed. If, for example, a vehicle registration fee ceases to be applicable in 2027, a common sense reading of that provision would not excuse past due fees from 2026; it would simply not impose new fees for 2027. The EPA believes that a similar reading is indicated here.</P>
                <P>
                    Second, when comparing the applicability provisions of the rules themselves, section 2.1 of the rules provides that “This rule shall become applicable” if and when the EPA makes a finding that the area has failed to attain the applicable NAAQS by the attainment date. By contrast, the provision cited by Commenters provides that “The fees established by this rule shall cease to be applicable” when the EPA redesignates the area. It does not state that “the rule” becomes inapplicable upon redesignation. The reading suggested by the Commenters does not give meaning to the distinction between “the rule” becoming applicable and “the fees established by this rule” becoming inapplicable.
                    <SU>2</SU>
                    <FTREF/>
                     The EPA believes that the best reading of the rule—one that gives meaning to the distinction between “the rule” and “the fees”—is that the rule continues to require payment of past-due amounts following redesignation. It is simply new fees that do not accrue.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         The EPA need not opine here on whether “the rule” becoming inapplicable at a particular time would necessarily forgive amounts already due.
                    </P>
                </FTNT>
                <P>
                    Finally, EPA communications with the District confirm that the District understands the requirements of the rule in this manner as well. Specifically, the District has clarified, “when read in context of the entirety of the rules, the District interprets section 2.4 to end the rules' prospective applicability once EPA redesignates the San Joaquin Valley Air Basin as attainment for the 2008 8-hour ozone standard or 2015 8-hour ozone standard, respectively. It does not forgive, vacate, or otherwise eliminate fees already assessed or owed for prior years.” 
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Email from Nick Pierce, Permit Services Manager, SJVAPCD, to Tom Kelly, EPA, dated April 13, 2026.
                    </P>
                </FTNT>
                <P>
                    <E T="03">Comment 2:</E>
                     Commenters state that Rules 3172 and 3173 do not compel payment of all fees and give the District enforcement discretion to take no further action against a noncompliant major stationary source. Commenters support this assertion with a hypothetical scenario in which multiple years of fees are not collected and then excused upon redesignation.
                </P>
                <P>
                    <E T="03">Response:</E>
                     The EPA disagrees that Rules 3172 and 3173 do not require payment of all fees. Paragraph 5.1.2 states that each agency or person “shall remit” the assessed fees to the District. Payment of the fees is thus required under the rule, and failure to do so would constitute a violation of the rule. The fact that the rule specifies that late payment will result in an additional fee increase and could result in suspension of a facility's permit to operate does not make the initial obligation to pay the fee any less of an obligation.
                </P>
                <P>
                    The fact that States possess a degree of enforcement discretion with respect to their rules is not a basis for rule disapproval. The District has implemented a CAA section 185 fee rule for the 1-hour ozone NAAQS since 2011, and the EPA has no basis to conclude that the District lacks the 
                    <PRTPAGE P="47964"/>
                    personnel, funding, and legal authority to implement the rule.
                    <SU>4</SU>
                    <FTREF/>
                     Moreover, the Act provides recourse in the event that a state does not sufficiently implement its section 185 fee program. Section 185(d) of the CAA provides authority to the EPA to collect unpaid fees in the event that the Administrator makes a finding that the State is not administering and enforcing the required fee.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         See CAA section 110(a)(2)(E).
                    </P>
                </FTNT>
                <P>In addition, Sections 113 and 304 of the Act provide that once the rules are approved into the SIP, they become enforceable not just by the District, but also by the Federal government and private citizens. Because section 5.1.2 of the rule provides an enforceable requirement for the payment of fees, this requirement may also be enforced by the EPA and via citizen suits once the rule is approved into the SIP.</P>
                <P>Accordingly, the EPA disagrees that the rules do not compel payment of all fees and disagrees that the rules are not enforceable. Under CAA section 110(k)(3), the EPA shall approve a SIP submittal if it meets the applicable requirements of the Act. The Act provides a set of tools for addressing potential future enforcement shortcomings if they were to occur. Commenter's concerns about potential future enforcement shortcomings do not provide a basis for rule disapproval.</P>
                <HD SOURCE="HD1">III. EPA Action</HD>
                <P>The EPA did not receive comments that changed its assessment of the approvability of the rules as described in our proposal. Accordingly, under CAA section 110(k)(3) and for the reasons explained in our proposed rule and responses to comments, we are finalizing approval of SJVAPCD Rules 3172 and 3173.</P>
                <HD SOURCE="HD1">IV. Incorporation by Reference</HD>
                <P>
                    In this document, the EPA is finalizing regulatory text that includes incorporation by reference. In accordance with requirements of 1 CFR 51.5, the EPA is finalizing the incorporation by reference of SJVAPCD Rule 3172, Federally Mandated Ozone Nonattainment Fee—2008 8-Hour Standard and SJVAPCD Rule 3173, Federally Mandated Ozone Nonattainment Fee—2015 8-Hour Standard. Both rules were adopted on December 21, 2023, and fulfill, respectively, the CAA section 185 requirements for the 2008 and 2015 ozone NAAQS. The EPA has made, and will continue to make, these documents available through 
                    <E T="03">https://www.regulations.gov</E>
                     and at the EPA Region IX Office (please contact the person identified in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this preamble for more information).
                </P>
                <HD SOURCE="HD1">V. Statutory and Executive Order Reviews</HD>
                <P>Under the CAA, the Administrator is required to approve a SIP submission that complies with the provisions of the Act and applicable Federal regulations. 42 U.S.C. 7410(k); 40 CFR 52.02(a). Thus, in reviewing SIP submissions, the EPA's role is to approve State choices, provided that they meet the criteria of the Clean Air Act. Accordingly, this action merely approves State law as meeting Federal requirements and does not impose additional requirements beyond those imposed by State law. For that reason, this action:</P>
                <P>• Is not a significant regulatory action subject to review by the Office of Management and Budget under Executive Order 12866 (58 FR 51735, October 4, 1993);</P>
                <P>• Is not an Executive Order 14192 (90 FR 9065, February 6, 2025) regulatory action because this action is not significant under Executive Order 12866;</P>
                <P>
                    • Does not impose an information collection burden under the provisions of the Paperwork Reduction Act (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>
                    • Is certified as not having a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>• Does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4);</P>
                <P>• Does not have federalism implications as specified in Executive Order 13132 (64 FR 43255, August 10, 1999);</P>
                <P>• Is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997) because it approves a State program;</P>
                <P>• Is not a significant regulatory action subject to Executive Order 13211 (66 FR 28355, May 22, 2001); and</P>
                <P>• Is not subject to requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) because application of those requirements would be inconsistent with the CAA.</P>
                <P>In addition, the SIP is not approved to apply on any Indian reservation land or in any other area where the EPA or an Indian Tribe has demonstrated that a Tribe has jurisdiction. In those areas of Indian country, the rule does not have Tribal implications and will not impose substantial direct costs on Tribal governments or preempt Tribal law as specified by Executive Order 13175 (65 FR 67249, November 9, 2000).</P>
                <P>This action is subject to the Congressional Review Act, and the EPA will submit a rule report to each House of the Congress and to the Comptroller General of the United States. This action is not a “major rule” as defined by 5 U.S.C. 804(2).</P>
                <P>Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by September 28, 2026. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this action for the purposes of judicial review, nor does it extend the time within which a petition for judicial review may be filed and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements (See CAA section 307(b)(2)).</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 40 CFR Part 52</HD>
                    <P>Environmental protection, Air pollution control, Incorporation by reference, Intergovernmental relations, Nitrogen oxides, Ozone, Reporting and recordkeeping requirements, Volatile organic compounds.</P>
                </LSTSUB>
                <SIG>
                    <DATED>Dated: July 23, 2026.</DATED>
                    <NAME>Michael Martucci,</NAME>
                    <TITLE>Acting Regional Administrator, Region IX.</TITLE>
                </SIG>
                <P>For the reasons stated in the preamble, the Environmental Protection Agency amends part 52, chapter I, title 40 of the Code of Federal Regulations as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 52—APPROVAL AND PROMULGATION OF IMPLEMENTATION PLANS</HD>
                </PART>
                <REGTEXT TITLE="40" PART="52">
                    <AMDPAR>1. The authority citation for part 52 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority: </HD>
                        <P>
                             42 U.S.C. 7401 
                            <E T="03">et seq.</E>
                              
                        </P>
                    </AUTH>
                </REGTEXT>
                <SUBPART>
                    <HD SOURCE="HED">Subpart F—California</HD>
                </SUBPART>
                <REGTEXT TITLE="40" PART="52">
                    <AMDPAR>2. Section 52.220 is amended by adding paragraph (c)(632) to read as follows:</AMDPAR>
                    <SECTION>
                        <SECTNO>§ 52.220 </SECTNO>
                        <SUBJECT>Identification of plan—in part.</SUBJECT>
                        <STARS/>
                        <P>(c) * * *</P>
                        <P>(632) The following regulations were submitted electronically on March 13, 2024, by the Governor's designee as an attachment to a letter dated March 7, 2024.</P>
                        <P>
                            (i) 
                            <E T="03">Incorporation by reference.</E>
                             (A) San Joaquin Valley Unified Air Pollution Control District.
                            <PRTPAGE P="47965"/>
                        </P>
                        <P>
                            (
                            <E T="03">1</E>
                            ) Rule 3172, “Federally Mandated Ozone Nonattainment Fee—2008 8-Hour Standard,” adopted on December 21, 2023.
                        </P>
                        <P>
                            (
                            <E T="03">2</E>
                            ) Rule 3173, “Federally Mandated Ozone Nonattainment Fee—2015 8-Hour Standard,” adopted on December 21, 2023.
                        </P>
                        <P>(B) [Reserved]</P>
                        <P>(ii) [Reserved]</P>
                    </SECTION>
                </REGTEXT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15377 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Part 70</CFR>
                <DEPDOC>[EPA-R01-OAR-2025-1608; FRL-13018-02-R1]</DEPDOC>
                <SUBJECT>Operating Permit Program Approval; New Hampshire; Revised Definitions</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Environmental Protection Agency (EPA) approves revisions to the State of New Hampshire's Clean Air Act (CAA) title V operating permit program. These revisions amend the definitions of “hazardous air pollutant” and “regulated air pollutant” in New Hampshire regulations to remain consistent with Federal permitting and air toxics requirements in accordance with the CAA.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This rule is effective on August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The EPA has established a docket for this action under Docket Identification No. EPA-R01-OAR-2025-1608. All documents in the docket are listed on the 
                        <E T="03">https://www.regulations.gov</E>
                         website. Although listed in the index, some information is not publicly available, 
                        <E T="03">i.e.,</E>
                         CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the internet and will be publicly available only in hard copy form. Publicly available docket materials are available at 
                        <E T="03">https://www.regulations.gov</E>
                         or at the U.S. Environmental Protection Agency, EPA Region 1 Regional Office, Air and Radiation Division, 5 Post Office Square—Suite 100, Boston, MA. The EPA requests that if at all possible, you contact the contact listed in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section to schedule your inspection.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Jessica Kilpatrick, Air Permits, Toxics, and Indoor Programs Branch, Air and Radiation Division, U.S. Environmental Protection Agency, Region 1, 5 Post Office Square, Mail Code: 5-MI, Boston, MA 02109-0287. Telephone number: 617-918-1652. Email address: 
                        <E T="03">kilpatrick.jessica@epa.gov.</E>
                    </P>
                    <HD SOURCE="HD1">Table of Contents</HD>
                    <EXTRACT>
                        <FP SOURCE="FP-2">I. Background and Purpose</FP>
                        <FP SOURCE="FP-2">II. Response to Comments</FP>
                        <FP SOURCE="FP-2">III. Final Action</FP>
                        <FP SOURCE="FP-2">IV. Statutory and Executive Order Reviews</FP>
                    </EXTRACT>
                    <HD SOURCE="HD1">I. Background and Purpose</HD>
                    <P>On June 12, 2025, and July 31, 2025, the New Hampshire Department of Environmental Services (NHDES) submitted to the EPA revisions to the State's title V operating permit program. Specifically, the revisions incorporate the amended definitions of “hazardous air pollutant (HAP)” and “regulated air pollutant (RAP)” in the New Hampshire Code of Administrative Rules, Chapter Env-A—Air Related Programs to remain consistent with Federal definitions at CAA section 112(b) and 40 CFR 70.2. On November 20, 2025 (90 FR 52318), the EPA published a Notice of Proposed Rulemaking (NPRM), proposing to approve the revisions. The rationale for the EPA's proposed action is explained in the NPRM and will not be restated here.</P>
                    <HD SOURCE="HD1">II. Response to Comments</HD>
                    <P>The NPRM provided a 30-day public comment period, which concluded on December 22, 2025. The EPA received two comments in response to the NPRM, one of which was supportive in nature and one of which was adverse in nature to the EPA's proposed approval of the action. A summary of the adverse comment and the EPA's response to the comment is provided below.</P>
                    <P>
                        <E T="03">Comment 1a:</E>
                         The EPA gave inadequate notice and record under the Administrative Procedure Act (APA) and the NPRM was missing required program revision materials under 40 CFR part 70. The commentor suggested that the EPA withdraw the direct final approach and reissue the action as a proposed rule with a minimum 30-day comment period after the docket is complete. The commentor suggested that the EPA supplement the docket with: (a) the specific revised definitions; (b) a redline/crosswalk against previously approved text and part 70; (c) a technical support document explaining the EPA's evaluation of each change; and (d) any legal authority statements relied upon.
                    </P>
                    <P>
                        <E T="03">Response 1a:</E>
                         The EPA disagrees with the commentor. On November 20, 2025, the EPA published an NPRM for this action with a 30-day comment period. The notice was not a direct final rulemaking. The NPRM contained the NHDES's revised definition of “HAP” at Env-A 103.41 and revised definition of “RAP” at Env-A 104.47. The revised definitions comply with the CAA, requiring the NHDES to incorporate all current and future HAPs into its title V operating permit program. The EPA's basis for proposing to approve these revisions is clearly and completely delineated in the NPRM. There is no need for supplemental materials in the rulemaking docket such as revised definitions, a redline/crosswalk, a technical support document, or legal authority statements, because this information would be duplicative of the NPRM. The EPA has provided a proper record and notice period in this action and is not missing any required materials related to 40 CFR part 70.
                    </P>
                    <P>
                        <E T="03">Comment 1b:</E>
                         The NPRM had a deficient or unsupported analysis under the Regulatory Flexibility Act (RFA), 5 U.S.C. 601 
                        <E T="03">et seq.,</E>
                         as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA) and failed to provide a factual basis for a certification under 5 U.S.C. 605(b). The commentor suggested that the EPA provide a reasoned, record-based factual statement addressing the number and types of small entities affected and the expected cost effects of the definitional change or should prepare an Initial Regulatory Flexibility Analysis and allow comment.
                    </P>
                    <P>
                        <E T="03">Response 1b:</E>
                         The RFA/SBREFA is inapplicable to this rulemaking. The regulatory analysis provisions of the RFA/SBREFA are only triggered by a threshold determination by the Agency that this rule would have a significant economic impact on a substantial number of small entities. Because the Agency has certified that this rule will not have a significant economic impact on a substantial number of small entities, section 603 and 604 of the RFA/SBREFA do not apply to this rulemaking. 5 U.S.C. 605(b).
                    </P>
                    <P>
                        <E T="03">Comment 1c:</E>
                         The NPRM did not address implications of the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 
                        <E T="03">et seq.,</E>
                         for Part 70 information collection requests (ICR). The commentor suggested that the EPA address PRA implications by explaining whether the action changes the respondent universe or burden under the Operating Permits Program ICR (OMB Control No. 2060-0243; EPA ICR No. 1587) and, if so, submit the appropriate ICR change request to OMB and place burden calculations in the docket.
                    </P>
                    <P>
                        <E T="03">Response 1c:</E>
                         The EPA has complied with the PRA by certifying that the PRA does not apply to this rule because the 
                        <PRTPAGE P="47966"/>
                        action does not involve an information collection burden as defined by the Act.
                    </P>
                    <P>
                        <E T="03">Comment 1d:</E>
                         The NPRM lacked a supporting basis for an Unfunded Mandates Reform Act (UMRA), 2 U.S.C. 1501 
                        <E T="03">et seq.,</E>
                         statement that was tailored to the definitional changes. The commentor suggested that the EPA provide a tailored UMRA statement that briefly quantifies or explains the expected change (if any) in private-sector expenditures due to the definitional changes.
                    </P>
                    <P>
                        <E T="03">Response 1d:</E>
                         The EPA has complied with UMRA by making its own determination that this rule will not result in expenditures of $100M+, and therefore the Agency does not need to complete a statement under 2 U.S.C. 1532.
                    </P>
                    <P>
                        <E T="03">Comment 1e:</E>
                         The EPA may have invoked good cause to waive the 30-day delayed effective date for this action. The commentor suggested that the EPA rescind the waiver or provide a particularized justification.
                    </P>
                    <P>
                        <E T="03">Response 1e:</E>
                         This is factually inaccurate. The EPA did not include a good cause waiver in this action. The effective date of this action is 30 days after its date of publication in the 
                        <E T="04">Federal Register</E>
                        .
                    </P>
                    <HD SOURCE="HD1">III. Final Action</HD>
                    <P>The EPA approves the NHDES's title V operating permit program revisions to incorporate the definitions for “hazardous air pollutant” and “regulated air pollutant” at the New Hampshire Code of Administrative Rules, Chapter Env-A—Air Related Programs.</P>
                    <P>• N.H. Admin. Code § Env-A 103.41: “Hazardous air pollutant” means any air pollutant listed pursuant to section 112(b) of the Act.</P>
                    <P>• N.H. Admin. Code § Env-A 104.47: “Regulated air pollutant” means “regulated air pollutant” as defined in 40 CFR 70.2, reprinted in Appendix D.</P>
                    <HD SOURCE="HD1">IV. Statutory and Executive Order Reviews</HD>
                    <P>Under the CAA, the Administrator is required to approve title V operating permit program revisions that comply with the provisions of the CAA and applicable Federal regulations. Thus, in reviewing revisions, the EPA's role is to approve state choices provided that they meet the criteria of the CAA. Accordingly, this action merely approves state law as meeting Federal requirements and does not impose additional requirements beyond those imposed by state law. For that reason, this proposed action:</P>
                    <P>• Is not a significant regulatory action subject to review by the Office of Management and Budget under Executive Orders 12866 (58 FR 51735, October 4, 1993);</P>
                    <P>• Is not subject to an Executive Order 14192 (90 FR 9065, February 6, 2025) regulatory action because this action is not significant under Executive Order 12866;</P>
                    <P>
                        • Does not impose an information collection burden under the provisions of the PRA (44 U.S.C. 3501 
                        <E T="03">et seq.</E>
                        );
                    </P>
                    <P>
                        • Is certified as not having a significant economic impact on a substantial number of small entities under the RFA (5 U.S.C. 601 
                        <E T="03">et seq.</E>
                        );
                    </P>
                    <P>• Does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the UMRA of 1995 (Pub. L. 104-4);</P>
                    <P>• Does not have federalism implications as specified in Executive Order 13132 (64 FR 43255, August 10, 1999);</P>
                    <P>• Is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997) because it approves a state program;</P>
                    <P>• Is not a significant regulatory action subject to Executive Order 13211 (66 FR 28355, May 22, 2001); and</P>
                    <P>• Is not subject to requirements of Section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) because application of those requirements would be inconsistent with the CAA.</P>
                    <P>In addition, this action is not approved to apply on any Indian reservation land or in any other area where the EPA or an Indian tribe has demonstrated that a tribe has jurisdiction. In those areas of Indian country, the action does not have tribal implications and will not impose substantial direct costs on tribal governments or preempt tribal law as specified by Executive Order 13175 (65 FR 67249, November 9, 2000).</P>
                    <P>This action is subject to the Congressional Review Act, and the EPA will submit a rule report to each House of the Congress and to the Comptroller General of the United States. This action is not a “major rule” as defined by 5 U.S.C. 804(2).</P>
                    <P>Under section 307(b)(1) of the CAA, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by September 28, 2026. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this action for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2)).</P>
                    <LSTSUB>
                        <HD SOURCE="HED">List of Subjects in 40 CFR Part 70</HD>
                        <P>Environmental protection, Air pollution control, Acid rain, Administrative practice and procedure, Hazardous substances, Intergovernmental relations, Licensing and registration, Reporting and recordkeeping requirements.</P>
                    </LSTSUB>
                    <AUTH>
                        <HD SOURCE="HED">Authority: </HD>
                        <P>
                            42 U.S.C. 7401 
                            <E T="03">et seq.</E>
                        </P>
                    </AUTH>
                    <SIG>
                        <DATED>Dated: July 16, 2026.</DATED>
                        <NAME>Mark Sanborn,</NAME>
                        <TITLE>Regional Administrator, EPA Region 1.</TITLE>
                    </SIG>
                    <P>For the reasons stated in the preamble the Environmental Protection Agency amends part 70 of chapter I, title 40 of the Code of Federal Regulations to read as follows:</P>
                    <PART>
                        <HD SOURCE="HED">PART 70—STATE OPERATING PERMIT PROGRAMS</HD>
                    </PART>
                    <REGTEXT TITLE="40" PART="70">
                        <AMDPAR>1. The authority citation for part 70 continues to read as follows:</AMDPAR>
                        <AUTH>
                            <HD SOURCE="HED">Authority:</HD>
                            <P>
                                 42 U.S.C. 7401 
                                <E T="03">et seq.</E>
                            </P>
                        </AUTH>
                    </REGTEXT>
                    <REGTEXT TITLE="40" PART="70">
                        <AMDPAR>2. Appendix A to part 70 is amended under “New Hampshire” by adding paragraph (d) to read as follows:</AMDPAR>
                        <HD SOURCE="HD1">Appendix A to Part 70—Approval Status of State and Local Operating Permits Programs</HD>
                        <EXTRACT>
                            <STARS/>
                            <HD SOURCE="HD1">New Hampshire</HD>
                            <STARS/>
                            <P>(d) The New Hampshire Department of Environmental Services submitted program revisions on June 12, 2025, and July 31, 2025. The revisions incorporate the definitions of hazardous air pollutant and regulated air pollutant. The EPA hereby grants full approval effective on August 31, 2026.</P>
                        </EXTRACT>
                    </REGTEXT>
                </FURINF>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15363 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">GENERAL SERVICES ADMINISTRATION</AGENCY>
                <CFR>41 CFR Parts 101-8 and 105-9</CFR>
                <DEPDOC>[GSPMR Case 2026-01; Docket No. GSA-GSA-2026-0067 Sequence No.1]</DEPDOC>
                <RIN>RIN 3090-AK12</RIN>
                <SUBJECT>General Services Administration Property Management Regulation (GSPMR); Nondiscrimination on the Basis of the Age Act Regulation for Programs or Activities Receiving Federal Financial Assistance; Technical Amendment</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Government-Wide Policy (OGP), U.S. General Services Administration (GSA).</P>
                </AGY>
                <ACT>
                    <PRTPAGE P="47967"/>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Technical amendment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The General Services Administration (GSA) is publishing a technical amendment to effectuate the rule published March 6, 2026. That published rule required clarifying edits in the amendatory instructions in order to facilitate the removal of GSA's regulations from the government-wide Federal Property Management Regulation (FPMR) and the addition of those regulations into the General Services Administration Property Management Regulations (GSPMR).</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This technical amendment is effective July 30, 2026. The subject GSPMR case continues to be effective March 6, 2026.</P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For clarification of content, contact Lisa Lee Anderson, Supervisory Equal Opportunity Specialist, Office of Civil Rights (OCR), at 202-501-0767 or 
                        <E T="03">Lisa.Anderson@gsa.gov.</E>
                         Please cite GSPMR Case 2026-01-Technical Amendment.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Purpose of Amendments</HD>
                <P>GSA is issuing this technical amendment to the final rule, published on March 6, 2026, at 91 FR 10971, to make clarifying edits in the words of issuance, authority citations, amendatory instructions, CFR unit headings, and section numbering. These edits are purely administrative in nature. They have no impact on the substance of the regulations, which remain unchanged.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of subjects in 41 CFR Parts 101-8 and 105-9</HD>
                    <P>Administrative practice and procedure, Aged, Civil rights, Government property management, Individuals with disabilities, Reporting and recordkeeping requirements.</P>
                </LSTSUB>
                <SIG>
                    <NAME>Edward Forst,</NAME>
                    <TITLE>Administrator.</TITLE>
                </SIG>
                <P>For the reasons set forth in the preamble, GSA amends 41 CFR part 101-8 and chapter 105 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 101-8—NONDISCRIMINATION IN PROGRAMS RECEIVING FEDERAL FINANCIAL ASSISTANCE</HD>
                </PART>
                <REGTEXT TITLE="41" PART="101-8">
                    <AMDPAR>1. The authority citation for part 101-8 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> Sec. 205(c), 63 Stat. 390; 40 U.S.C. 486(c).</P>
                    </AUTH>
                </REGTEXT>
                <SUBPART>
                    <HD SOURCE="HED">Subpart 101-8.7 [Removed]</HD>
                </SUBPART>
                <REGTEXT TITLE="41" PART="101-8">
                    <AMDPAR>
                        2. Under the authority of 42 U.S.C. 6101 
                        <E T="03">et seq.,</E>
                         remove subpart 101-8.7, consisting of §§ 101-8.700 through 101-8.725.
                    </AMDPAR>
                </REGTEXT>
                <HD SOURCE="HD1">CHAPTER 105—GENERAL SERVICES ADMINISTRATION</HD>
                <AMDPAR>3. Add part 105-9 to read as follows:</AMDPAR>
                <REGTEXT TITLE="41" PART="105-9">
                    <PART>
                        <HD SOURCE="HED">PART 105-9—DISCRIMINATION PROHIBITED ON THE BASIS OF AGE</HD>
                        <CONTENTS>
                            <SECHD>Sec.</SECHD>
                            <SECTNO>105-9.101</SECTNO>
                            <SUBJECT>Purpose of the Age Discrimination Act of 1975.</SUBJECT>
                            <SECTNO>105-9.102</SECTNO>
                            <SUBJECT>Scope of General Services Administration's age discrimination regulation (this part).</SUBJECT>
                            <SECTNO>105-9.103</SECTNO>
                            <SUBJECT>Applicability.</SUBJECT>
                            <SECTNO>105-9.104</SECTNO>
                            <SUBJECT>Definitions of terms.</SUBJECT>
                            <SECTNO>105-9.105</SECTNO>
                            <SUBJECT>Rules against age discrimination.</SUBJECT>
                            <SECTNO>105-9.106</SECTNO>
                            <SUBJECT>Exceptions to the rules against age discrimination</SUBJECT>
                            <SECTNO>105-9.107</SECTNO>
                            <SUBJECT>Reasonable factors other than age.</SUBJECT>
                            <SECTNO>105-9.108</SECTNO>
                            <SUBJECT>Burden of proof.</SUBJECT>
                            <SECTNO>105-9.109</SECTNO>
                            <SUBJECT>Affirmative action by recipient.</SUBJECT>
                            <SECTNO>105-9.110</SECTNO>
                            <SUBJECT>Special benefits for children and the elderly.</SUBJECT>
                            <SECTNO>105-9.111</SECTNO>
                            <SUBJECT>Age distinctions contained in General Services Administration regulations generally.</SUBJECT>
                            <SECTNO>105-9.112</SECTNO>
                            <SUBJECT>General responsibilities.</SUBJECT>
                            <SECTNO>105-9.113</SECTNO>
                            <SUBJECT>Notice to subrecipients and beneficiaries.</SUBJECT>
                            <SECTNO>105-9.114</SECTNO>
                            <SUBJECT>Assurance of compliance and recipient assessment of age distinctions.</SUBJECT>
                            <SECTNO>105-9.115</SECTNO>
                            <SUBJECT>Information requirements.</SUBJECT>
                            <SECTNO>105-9.116</SECTNO>
                            <SUBJECT>Compliance reviews.</SUBJECT>
                            <SECTNO>105-9.117</SECTNO>
                            <SUBJECT>Complaints.</SUBJECT>
                            <SECTNO>105-9.118</SECTNO>
                            <SUBJECT>Mediation.</SUBJECT>
                            <SECTNO>105-9.119</SECTNO>
                            <SUBJECT>Investigation.</SUBJECT>
                            <SECTNO>105-9.120</SECTNO>
                            <SUBJECT>Prohibition against intimidation or retaliation.</SUBJECT>
                            <SECTNO>105-9.121</SECTNO>
                            <SUBJECT>Compliance procedure.</SUBJECT>
                            <SECTNO>105-9.122</SECTNO>
                            <SUBJECT>Hearings.</SUBJECT>
                            <SECTNO>105-9.123</SECTNO>
                            <SUBJECT>Decisions and notices.</SUBJECT>
                            <SECTNO>105-9.124</SECTNO>
                            <SUBJECT>Remedial action by recipient.</SUBJECT>
                            <SECTNO>105-9.125</SECTNO>
                            <SUBJECT>Exhaustion of administrative remedies.</SUBJECT>
                            <SECTNO>105-9.126</SECTNO>
                            <SUBJECT>Alternate funds disbursal</SUBJECT>
                        </CONTENTS>
                        <AUTH>
                            <HD SOURCE="HED">Authority:</HD>
                            <P>
                                 42 U.S.C. 6101 
                                <E T="03">et seq.</E>
                            </P>
                        </AUTH>
                        <SECTION>
                            <SECTNO>§ 105-9.101</SECTNO>
                            <SUBJECT> Purpose of the Age Discrimination Act of 1975.</SUBJECT>
                            <P>The Age Discrimination Act of 1975, as amended, prohibits discrimination on the basis of age in programs or activities receiving Federal financial assistance.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.102</SECTNO>
                            <SUBJECT> Scope of General Services Administration's age discrimination regulation (this part).</SUBJECT>
                            <P>This part sets out General Services Administration's (GSA) policies and procedures under the Age Discrimination Act of 1975, as amended, in accordance with 45 CFR part 90 (implementing regulations). The Act and implementing regulations permit Federally assisted programs or activities to continue to use certain age distinctions and factors other than age which meet the requirements of the Act and implementing regulations.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.103</SECTNO>
                            <SUBJECT> Applicability.</SUBJECT>
                            <P>(a) This part applies to each GSA recipient and to each program or activity operated by the recipient.</P>
                            <P>(b) This part does not apply to:</P>
                            <P>(1) An age distinction contained in that part of Federal, State, local statute or ordinance adopted by an elected, general purpose legislative body that:</P>
                            <P>(i) Provides any benefits or assistance to persons based on age;</P>
                            <P>(ii) Establishes criteria for participation in age-related terms; or</P>
                            <P>(iii) Describes intended beneficiaries or target groups in age related terms.</P>
                            <P>(2) Any employment practice of any employer, employment agency, labor organization or any labor-management apprenticeship training program, except for any program or activity receiving Federal financial assistance for public service employment.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.104</SECTNO>
                            <SUBJECT> Definitions of terms.</SUBJECT>
                            <P>As used in this part, the term:</P>
                            <P>
                                <E T="03">Act</E>
                                 means the Age Discrimination Act of 1975, as amended (Title III of Pub. L. 94-135).
                            </P>
                            <P>
                                <E T="03">Action</E>
                                 means any act, activity, policy, rule, standard, or method of administration.
                            </P>
                            <P>
                                <E T="03">Age</E>
                                 means how old a person is, or the number of years from the date of a person's birth.
                            </P>
                            <P>
                                <E T="03">Age distinction</E>
                                 means any action using age or an age-related term.
                            </P>
                            <P>
                                <E T="03">Age-related term</E>
                                 means a word or words that imply a particular age or range or ages (for example, 
                                <E T="03">children, adults, older person,</E>
                                 but not 
                                <E T="03">student</E>
                                ).
                            </P>
                            <P>
                                <E T="03">Agency</E>
                                 means a Federal department or agency empowered to extend Federal financial assistance.
                            </P>
                            <P>
                                <E T="03">Agency Responsible Official</E>
                                 means:
                            </P>
                            <P>
                                (1) 
                                <E T="03">Administrator</E>
                                 means the Administrator of General Services.
                            </P>
                            <P>
                                (2) 
                                <E T="03">Director, Office of Civil Rights</E>
                                 means the individual responsible for managing the agency's nondiscrimination Federal financial assistance policy, or his or her designee.
                            </P>
                            <P>
                                <E T="03">Federal financial assistance</E>
                                 means—
                            </P>
                            <P>(1) Grants and loans of Federal funds;</P>
                            <P>(2) The grant or donation of Federal property and interests in property;</P>
                            <P>(3) The services of Federal personnel;</P>
                            <P>(4) The sale and lease of, and the permission to use (on other than a casual or transient basis), Federal property or any interest in such property without consideration or at a nominal consideration, or at a consideration which is reduced for the purposes of assisting the recipient, or in recognition of the public interest to be served by such sale or lease to the recipient; and</P>
                            <P>
                                (5) Any Federal agreement, arrangement, or other contract which 
                                <PRTPAGE P="47968"/>
                                has as one of its purposes the provision of assistance.
                            </P>
                            <P>
                                <E T="03">GSA</E>
                                 means the United States General Services Administration.
                            </P>
                            <P>
                                <E T="03">Normal operation</E>
                                 means the operation of a program or activity without significant changes that would inhibit meeting objectives.
                            </P>
                            <P>
                                <E T="03">Primary recipient</E>
                                 means any recipient which is authorized or required to extend Federal financial assistance to another recipient.
                            </P>
                            <P>
                                <E T="03">Program or activity</E>
                                 means all of the operations of any entity described in paragraphs (1) through (4) of this definition, any part of which is extended Federal financial assistance:
                            </P>
                            <P>(1)(i) A department, agency, special purpose district, or other instrumentality of a State or of a local government;</P>
                            <P>(ii) The entity of such State and local government that distributes such assistance and each such department or agency (and each other state or local government entity) to which the assistance is extended, in the case of assistance to a State or local government;</P>
                            <P>(2)(i) A college, university, or other postsecondary institution, or a public system of higher education; or</P>
                            <P>(ii) A local educational agency (as defined in 20 U.S.C. 7801), system of vocational education, or other school system;</P>
                            <P>(3)(i) An entire corporation, partnership, or other private organization, or an entire sole proprietorship—</P>
                            <P>(A) If assistance is extended to such corporation, partnership, private organization, or sole proprietorship as a whole; or</P>
                            <P>(B) Which is principally engaged in the business of providing education, health care, housing, social services, or parks and recreation; or</P>
                            <P>(ii) The entire plant or other comparable, geographically separate facility to which Federal financial assistance is extended, in the case of any other corporation, partnership, private organization, or sole proprietorship; or</P>
                            <P>(4) Any other entity which is established by two or more of the entities described in paragraph (1), (2), or (3) of this definition.</P>
                            <P>
                                <E T="03">Recipient</E>
                                 means any State, political subdivision of any State, or instrumentality of any State or political subdivision, any public or private agency, institution, or organization, or any other entity, or any individual, in any State, to whom Federal financial assistance is extended, directly or through another recipient, including any successor, assign, or transferee thereof, but such term does not include any ultimate beneficiary.
                            </P>
                            <P>
                                <E T="03">Statutory objective</E>
                                 means any purpose of a program or activity expressly stated in any Federal, State, or local statute or ordinance adopted by an elected, general purpose legislative body.
                            </P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.105</SECTNO>
                            <SUBJECT> Rules against age discrimination.</SUBJECT>
                            <P>The rules stated in this section are limited by the exceptions contained in §§ 105-9.106 and 105-9.107.</P>
                            <P>
                                (a) 
                                <E T="03">General rule.</E>
                                 No person in the United States may on the basis of age, be excluded from participation, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance from GSA.
                            </P>
                            <P>
                                (b) 
                                <E T="03">Specific rules.</E>
                                 A recipient may not, in any program or activity receiving Federal financial assistance, directly or through contractual licensing, or other arrangement, use age distinctions or take any other actions that have the effect on the basis of age, of:
                            </P>
                            <P>(1) Excluding individuals from participating in, denying them the benefits of, or subjecting them to discrimination under a program or activity receiving Federal financial assistance; or</P>
                            <P>(2) Denying or limiting individual opportunity to participate in any program or activity receiving Federal financial assistance.</P>
                            <P>
                                (c) 
                                <E T="03">Qualification of rules.</E>
                                 The forms of age discrimination listed in paragraph (b) of this section are not necessarily a complete list.
                            </P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.106</SECTNO>
                            <SUBJECT> Exceptions to the rules against age discrimination.</SUBJECT>
                            <P>A recipient is permitted to take an action, otherwise prohibited, if the action reasonably takes into account age as a factor necessary to the normal operation or achievement of any statutory objective of a program or activity. An action reasonably takes into account age as a factor if:</P>
                            <P>(a) Age is used as a measure or approximation of one or more other characteristics; and</P>
                            <P>(b) The other characteristic must be measured or approximated for the normal operation of the program or activity to continue, or to achieve any statutory objective of the program or activity; and</P>
                            <P>(c) The other characteristic can be reasonably measured or approximated by the use of age; and</P>
                            <P>(d) The other characteristic is impractical to measure directly on an individual basis</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.107</SECTNO>
                            <SUBJECT> Reasonable factors other than age.</SUBJECT>
                            <P>(a) A recipient is permitted to take an action, otherwise prohibited by § 105-9.106, which is based on something other than age, even though the action may have a disproportionate effect on persons of different ages.</P>
                            <P>(b) An action may be based on a factor other than age only if the factor bears a direct and substantial correlation to the normal operation of the program or activity or to the achievement of a statutory objective.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.108</SECTNO>
                            <SUBJECT> Burden of proof.</SUBJECT>
                            <P>The recipient has the burden of proving that an age distinction or other action falls within the exceptions outlined in §§ 105-9.106 and 105-9.107.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.109</SECTNO>
                            <SUBJECT> Affirmative action by recipient.</SUBJECT>
                            <P>Even in the absence of a finding of age discrimination, a recipient may take affirmative action to overcome the effects resulting in limited participation in the recipient's program or activity.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.110</SECTNO>
                            <SUBJECT> Special benefits for children and the elderly.</SUBJECT>
                            <P>If a recipient's program or activity provides special benefits to the elderly or to children, such use of age distinctions is presumed to be necessary to the normal operation of the program or activity.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.111</SECTNO>
                            <SUBJECT> Age distinctions contained in General Services Administration regulations generally.</SUBJECT>
                            <P>Any age distinctions contained in a rule or regulation issued by GSA are presumed to be necessary to the achievement of a statutory objective of the program or activity to which the rule or regulation applies.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.112</SECTNO>
                            <SUBJECT> General responsibilities.</SUBJECT>
                            <P>Each recipient of Federal financial assistance from GSA is responsible for ensuring that its programs or activities comply with the Act and this part and must take steps to eliminate violations of the Act. A recipient is also responsible for maintaining records, providing information, and affording GSA access to its records to the extent GSA finds necessary to determine whether the recipient is complying with the Act and this part.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.113</SECTNO>
                            <SUBJECT> Notice to subrecipients and beneficiaries.</SUBJECT>
                            <P>
                                (a) If a primary recipient passes on Federal financial assistance from GSA to subrecipients, the primary recipient provides to subrecipients, written notice of their obligations under the Act and this part.
                                <PRTPAGE P="47969"/>
                            </P>
                            <P>(b) Each recipient makes necessary information about the Act and this part available to its beneficiaries to inform them about the protections against discrimination provided by the Act and this part.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.114</SECTNO>
                            <SUBJECT> Assurance of compliance and recipient assessment of age distinctions.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">Assurance of compliance.</E>
                                 Each recipient of Federal financial assistance from GSA signs a written assurance as specified by GSA that it intends to comply with the Act and this part.
                            </P>
                            <P>
                                (b) 
                                <E T="03">Recipient assessment of age distinctions.</E>
                                 (1) As part of a compliance review under § 105-82.715 of this chapter or complaint investigation under § 105-82.718 of this chapter, GSA may require a recipient employing the equivalent of 15 or more employees to complete a written self-evaluation of any age distinction imposed in its program or activity receiving Federal financial assistance from GSA to assess the recipient's compliance with the Act.
                            </P>
                            <P>(2) If an assessment indicates a violation of the Act and this part, the recipient takes corrective action.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.115</SECTNO>
                            <SUBJECT> Information requirements.</SUBJECT>
                            <P>Each recipient must:</P>
                            <P>(a) Keep records in a form and containing information that GSA determines necessary to ensure that the recipient is complying with the Act and this part.</P>
                            <P>(b) Provide to GSA upon request, information and reports that GSA determines necessary to find out whether the recipient is complying with the Act and this part.</P>
                            <P>(c) Permit reasonable access by GSA to books, records, accounts, facilities, and other sources of information to the extent GSA finds it necessary to find out whether the recipient is complying with the Act and this part.</P>
                            <P>(d) In accordance with the Paperwork Reduction Act of 1980 (Pub. L. 59-511), the reporting and record keeping provisions included in this part will be submitted, for approval, to the Office of Management and Budget (OMB). No data collection or record keeping requirement will be imposed on recipients or donees without the required OMB approval number.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.116</SECTNO>
                            <SUBJECT> Compliance reviews.</SUBJECT>
                            <P>(a) GSA may conduct compliance reviews and use similar procedures to investigate and correct violations of the Act and this part. GSA may conduct the reviews even in the absence of a complaint against a recipient. The reviews may be as comprehensive as necessary to determine whether a violation of the Act and this part has occurred.</P>
                            <P>(b) If a compliance review indicates a violation of the Act or this part, GSA attempts to achieve voluntary compliance with the Act. If compliance cannot be achieved, GSA arranges for enforcement as described in § 105-9.121.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.117</SECTNO>
                            <SUBJECT> Complaints.</SUBJECT>
                            <P>(a) Any person, individually or as a member of a class (defined at § 105-9.104 or on behalf of others, may file a complaint with GSA alleging discrimination prohibited by the Act or this part based on an action occurring after July 1, 1979. A complainant must file a complaint within 80 days from the date the complainant first has knowledge of the alleged act of discrimination. However, for good cause shown, GSA may extend this time limit.</P>
                            <P>(b) GSA considers the date a complaint is filed to be the date upon which the complaint is sufficient to be processed.</P>
                            <P>(c) GSA attempts to facilitate the filing of complaints if possible, including taking the following measures:</P>
                            <P>(1) Accepting as a sufficient complaint, any written statement that identifies the parties involved and the date the complainant first had knowledge of the alleged violation, describes the action or practice complained of, and is signed by the complainant;</P>
                            <P>(2) Freely permitting a complainant to add information to the complaint to meet the requirements of a sufficient complaint; and</P>
                            <P>(3) Notifying the complainant and the recipient (or their representative) of their right to contact GSA for information and assistance regarding the complaint resolution process.</P>
                            <P>(d) GSA returns to the complainant any complaint outside the jurisdiction of this part and states the reason(s) why it is outside the jurisdiction of this part.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.118</SECTNO>
                            <SUBJECT> Mediation.</SUBJECT>
                            <P>(a) GSA promptly refers to the mediation agency designated by the Secretary, HHS, all sufficient complaints that:</P>
                            <P>(1) Fall within the jurisdiction of the Act and this part, unless the age distinction complained of is clearly within an exception; and</P>
                            <P>(2) Contain the information needed for further processing.</P>
                            <P>(b) Both the complainant and the recipient must participate in the mediation process to the extent necessary to reach an agreement or make an informed judgement that an agreement is not possible. Both parties need not meet with the mediator at the same time.</P>
                            <P>(c) If the complainant and the recipient agree, the mediator will prepare a written statement of the agreement and have the complainant and the recipient sign it. The mediator must send a copy of the agreement to GSA. GSA takes no further action on the complaint unless the complainant or the recipient fails to comply with the agreement.</P>
                            <P>(d) The mediator must protect the confidentiality of all information obtained in the course of the mediation. No mediator may testify in any adjudicative proceeding, produce any document, or otherwise disclose any information obtained in the course of the mediation process without prior approval of the head of the mediation agency.</P>
                            <P>(e) The mediation proceeds for a maximum of 60 calendar days after a complaint is filed with GSA. Mediation ends if:</P>
                            <P>(1) 60 calendar days elapse from the time the complaint is filed; or</P>
                            <P>(2) Before the end of the 60 calendar-day period an agreement is reached; or</P>
                            <P>(3) Before the end of that 60 calendar-day period, the mediator finds that an agreement cannot be reached.</P>
                            <P>(f) The 60 calendar-day period may be extended by the mediator, with the concurrence of GSA, for not more than 30 calendar days if the mediator determines that agreement is likely to be reached during the extension period.</P>
                            <P>(g) The mediator must return unresolved complaints to GSA.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.119</SECTNO>
                            <SUBJECT> Investigation.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">Informal investigation.</E>
                                 GSA investigates complaints that are unresolved after mediation or are reopened because of a violation of a mediation agreement. As part of the initial investigation, GSA uses informal fact-finding methods, including joint or separate discussions with the complainant and the recipient, to establish the fact and, if possible, settle the complaint on terms that are mutually agreeable to the parties. GSA may seek the assistance of any involved State agency. GSA puts any agreement in writing and has it signed by the parties and an authorized official designated by the Administrator or the Director, Office of Organization and Personnel. The settlement may not affect the operation of any other enforcement efforts of GSA, including compliance reviews and investigation of other complaints that may involve the recipient. The settlement is not a finding of discrimination against a recipient.
                            </P>
                            <P>
                                (b) 
                                <E T="03">Formal investigation.</E>
                                 If GSA cannot resolve the complaint through 
                                <PRTPAGE P="47970"/>
                                informal investigation, it begins to develop formal findings through further investigation of the complaint. If the investigation indicates a violation of this part, GSA attempts to obtain voluntary compliance. If GSA cannot obtain voluntary compliance, it begins enforcement as described in § 105-9.121.
                            </P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.120</SECTNO>
                            <SUBJECT> Prohibition against intimidation or retaliation.</SUBJECT>
                            <P>A recipient may not engage in acts of intimidation or retaliation against any person who:</P>
                            <P>(a) Attempts to assert a right protected by the Act of this part; or</P>
                            <P>(b) Cooperates in any mediation, investigation, hearing, conciliation, and enforcement process.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.121</SECTNO>
                            <SUBJECT> Compliance procedure.</SUBJECT>
                            <P>(a) GSA may enforce the Act and this part through:</P>
                            <P>(1) Termination of a recipient's Federal financial assistance from GSA under the program or activity involved where the recipient has violated the Act or this part. The determination of the recipient's violation may be made only after a recipient has had an opportunity for a hearing on the record before an administrative law judge.</P>
                            <P>(2) Any other means authorized by law including, but not limited to:</P>
                            <P>(i) Referral to the Department of Justice for proceeding to enforce any rights of the United States or obligations of the recipients created by the Act or this part; or</P>
                            <P>(ii) Use of any requirement of or referral to any Federal, State, or local government agency that has the effect of correcting a violation of the Act or this part.</P>
                            <P>(b) GSA limits any termination to the particular recipient and program or activity or part of such program or activity GSA finds in violation of this part. GSA does not base any part of a termination on a finding with respect to any program or activity of the recipient that does not receive Federal financial assistance from GSA.</P>
                            <P>(c) GSA takes no action under paragraph (a) of this section until:</P>
                            <P>(1) The administrator advises the recipient of its failure to comply with the Act and this part and determines that voluntary compliance cannot be obtained; and</P>
                            <P>(2) 30 calendar days elapse after the Administrator sends a written report of the grounds of the action to the committees of Congress having legislative jurisdiction over the program or activity involved. The Administrator files a report if any action is taken under paragraph (a) of this section.</P>
                            <P>(d) GSA may also defer granting new Federal financial assistance from GSA to a recipient when a hearing under § 105-9.122 is initiated.</P>
                            <P>(1) New Federal financial assistance from GSA includes all assistance for which GSA requires an application or approval, including renewal or continuation of existing activities, or authorization of new activities, during the deferral period. New Federal financial assistance from GSA does not include assistance approved before the beginning of a hearing.</P>
                            <P>(2) GSA does not begin a deferral until the recipient receives notice of an opportunity for a hearing under § 105-9.122. GSA does not continue a deferral for more than 60 calendar days unless a hearing begins within that time or the time for beginning the hearing is extended by mutual consent of the recipient and the Administrator. GSA does not continue a deferral for more than 30 calendar days after the close of the hearing, unless the hearing results in a finding against the recipient.</P>
                            <P>(3) GSA limits any deferral to the particular recipient and program or activity or part of such program or activity GSA finds in violation of this part. GSA does not base any part of a deferral on a finding with respect to any program or activity of the recipient which does not, and would not, receive Federal financial assistance from GSA.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.122</SECTNO>
                            <SUBJECT> Hearings.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">Opportunity for hearing.</E>
                                 Whenever an opportunity for a hearing is required, reasonable notice shall be given by registered or certified mail, return receipt requested, to the affected applicant or recipient. This notice shall advise the applicant or recipient of the action proposed to be taken, the specific provision under which the proposed action against it is to be taken, and the matters of fact or law asserted as the basis for this action; and either fix a date not less than 20 days after the date of such notice within which the applicant or recipient may request of the responsible GSA official that the matter be scheduled for hearing or advise the applicant or recipient that the matter in question has been set down for hearing at a stated place and time. The time and place so fixed shall be reasonable and shall be subject to change for cause. The complainant, if any, shall be advised of the time and place of the hearing. An applicant or recipient may waive a hearing and submit written information and argument for the record. The failure of an applicant or recipient to request a hearing for which a date has been set shall be deemed to be a waiver of the right to a hearing under section 602 of the Act, and consent to the making of a decision on the basis of such information as may be filed as the record.
                            </P>
                            <P>
                                (b) 
                                <E T="03">Time and place of hearing.</E>
                                 Hearings shall be held at GSA in Washington, DC, at a time fixed by GSA's Associate Administrator, for the Office of Civil Rights unless he or she determines that the convenience of the applicant or recipient or of GSA requires that another place be selected. Hearings/Virtual hearings shall be held before a hearing examiner designated in accordance with 5 U.S.C. 3105 and 3344 (section 11 of the Administrative Procedure Act).
                            </P>
                            <P>
                                (c) 
                                <E T="03">Right to counsel.</E>
                                 In all proceedings under this section, the applicant or recipient and GSA shall have the right to be represented by counsel.
                            </P>
                            <P>
                                (d) 
                                <E T="03">Procedures, evidence, and record.</E>
                                 (1) The hearing, decision, and any administrative review thereof shall be conducted in conformity with secs. 5 through 8 of the Administrative Procedure Act, and in accordance with such rules of procedure as are proper (and not inconsistent with this section) relating to the conduct of the hearing, giving of notices subsequent to those provided for in paragraph (a) of this section, taking of testimony, exhibits, arguments and briefs, requests for findings, and other related matters. Both GSA and the applicant or recipient shall be entitled to introduce all relevant evidence on the issues as stated in the notice for hearing or as determined by the Officer conducting the hearing at the outset of or during the hearings. Any person (other than a Government employee considered to be on official business) who, having been invited or requested to appear and testify as a witness on the Government's behalf, attends at a time and place scheduled for a hearing provided for by this part, may be reimbursed for his or her travel and actual expenses of attendance in an amount not to exceed the amount payable under the standardized travel regulations to a Government employee traveling on official business.
                            </P>
                            <P>
                                (2) Technical rules of evidence shall not apply to hearings conducted pursuant to this part, but rules or principles designed to assure production of the most credible evidence available and to subject testimony to test by cross-examination shall be applied where reasonably necessary by the officer conducting the hearing. The hearing officer may exclude irrelevant, immaterial, or unduly repetitious evidence. All documents and other evidence offered or taken for the record shall be open to examination by the parties and 
                                <PRTPAGE P="47971"/>
                                opportunity shall be given to refute facts and arguments advanced on either side of the issues. A transcript shall be made of the oral evidence except to the extent the substance thereof is stipulated for the record. All decisions shall be based upon the hearing record and written findings shall be made.
                            </P>
                            <P>
                                (e) 
                                <E T="03">Consolidated joint hearings.</E>
                                 In cases in which the same or related facts are asserted to constitute non-compliance with this part with respect to two or more Federal statutes, authorities, or other means by which Federal financial assistance is extended and to which this part applies, or noncompliance with this part, and the regulations of one or more other Federal departments or agencies issued under Title VI of the Civil Rights Act of 1964, the responsible GSA official may, by agreement with such other departments or agencies where applicable, provide for the conduct of consolidated or joint hearings, and for the application to such hearings of rules of procedures not inconsistent with this part. Final decisions in such cases, insofar as this part is concerned, shall be made in accordance with § 105-9.123.
                            </P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.123</SECTNO>
                            <SUBJECT> Decisions and notices.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">Decisions by hearing examiners.</E>
                                 After a hearing is held by a hearing examiner such hearing examiner shall either make an initial decision, if so authorized, or certify the entire record including his recommended findings and proposed decision to the Agency designated reviewing authority for final decision. A copy of such initial decision or certification shall be mailed to the applicant or recipient and to the complainant, if any. Where the initial decision referred to in this paragraph (a) or in paragraph (c) of this section is made by the hearing examiner, the applicant or recipient or the counsel for GSA may, within the period provided for in the rules of procedure issued by GSA official, file with the reviewing authority exceptions to the initial decision, with his or her reasons therefore. Upon the filing of such exceptions the reviewing authority shall review the initial decision and issue a decision including the reasons therefore. In the absence of exceptions the initial decision shall constitute the final decision, subject to the provisions of paragraph (e) of this section.
                            </P>
                            <P>
                                (b) 
                                <E T="03">Decisions on record or review by the reviewing authority.</E>
                                 Whenever a record is certified to the reviewing authority for decision or it reviews the decision of a hearing examiner pursuant to paragraph (a) or (c) of this section, the applicant or recipient shall be given reasonable opportunity to file with it briefs or other written statements of its contentions, and a copy of the final decision of the reviewing authority shall be given in writing to the applicant or recipient and to the complainant, if any.
                            </P>
                            <P>
                                (c) 
                                <E T="03">Decisions on record where a hearing is waived.</E>
                                 Whenever a hearing is waived pursuant to § 105-9.122(a) the reviewing authority shall make its final decision on the record or refer the matter to a hearing examiner for an initial decision to be made on the record. A copy of such decision shall be given in writing to the applicant or recipient, and to the complainant, if any.
                            </P>
                            <P>
                                (d) 
                                <E T="03">Rulings required.</E>
                                 Each decision of a hearing examiner or reviewing authority shall set forth a ruling on each findings, conclusion, or exception presented, and shall identify the requirement or requirements imposed by or pursuant to this part with which it is found that the applicant or recipient has failed to comply.
                            </P>
                            <P>
                                (e) 
                                <E T="03">Review in certain cases by the Administrator.</E>
                                 If the Administrator has not personally made the final decision referred to in paragraph (a), (b), or (c) of this section, a recipient or applicant or the counsel for GSA may request the Administrator to review a decision of the Reviewing Authority in accordance with rules of procedure issued by the responsible GSA official. Such review is not a matter of right and shall be granted only where the Administrator determines there are special and important reasons therefore. The Administrator may grant or deny such request, in whole or in part. He or she may also review such a decision in accordance with rules of procedure issued by the responsible GSA official. In the absence of a review under this paragraph (e), a final decision referred to in paragraph (a), (b), or (c) of this section shall become the final decision of GSA when the Administrator transmits it as such to Congressional committees with the report required under section 602 of the Act. Failure of an applicant or recipient to file an exception with the Reviewing Authority or to request review under this paragraph (e) shall not be deemed a failure to exhaust administrative remedies for the purpose of obtaining judicial review.
                            </P>
                            <P>
                                (f) 
                                <E T="03">Content of orders.</E>
                                 The final decision may provide for suspension or termination of, or refusal to grant or continue Federal financial assistance, in whole or in part, to which this part applies, and may contain such terms, conditions and other provisions as are consistent with and will effectuate the purposes of the Act and this part, including provisions designed to assure that no Federal financial assistance to which this part applies will thereafter be extended under such law or laws to the applicant or recipient determined by such decision to be in default in its performance of an assurance given by it pursuant to this part, or to have otherwise failed to comply with this part unless and until it corrects its noncompliance and satisfies the responsible GSA official that it will fully comply with this part.
                            </P>
                            <P>
                                (g) 
                                <E T="03">Post-termination proceedings.</E>
                                 (1) An applicant or recipient adversely affected by an order issued under paragraph (f) of this section shall be restored to full eligibility to receive Federal financial assistance if it satisfies the terms and conditions of that order for such eligibility or if it brings itself into compliance with this part and provides reasonable assurance that it will fully comply with this part.
                            </P>
                            <P>(2) Any applicant or recipient adversely affected by an order entered pursuant to paragraph (f) of this section may at any time request the responsible GSA official to restore fully its eligibility to receive Federal financial assistance. Any such request shall be supported by information showing that the applicant or recipient has met the requirements of paragraph (g)(1) of this section. If the responsible GSA official determines that those requirements have been satisfied, he or she shall restore such eligibility.</P>
                            <P>(3) If the responsible GSA official denies any such request, the applicant or recipient may submit a request for a hearing in writing, specifying why it believes such official to have been in error. It shall therefore be given an expeditious hearing, with a decision on the record, in accordance with rules of procedure issued by the responsible GSA official. The applicant or recipient will be restored to such eligibility if it proves at such hearing that it satisfied the requirements of paragraph (g)(1) of this section. While proceedings under this paragraph (g)(3) are pending, the sanctions imposed by the order issued under paragraph (f) of this section shall remain in effect.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105-9.124</SECTNO>
                            <SUBJECT> Remedial action by recipient.</SUBJECT>
                            <P>If GSA finds a recipient discriminated against on the basis of age, the recipient must take any remedial action that GSA may require to overcome the effects of the discrimination. If another recipient exercises control over the recipient that discriminated, GSA may require both recipients to take remedial action.</P>
                        </SECTION>
                        <SECTION>
                            <PRTPAGE P="47972"/>
                            <SECTNO>§ 105-9.125</SECTNO>
                            <SUBJECT> Exhaustion of administrative remedies.</SUBJECT>
                            <P>(a) A complainant may file a civil action following the exhaustion of administrative remedies under the Act. Administrative remedies are exhausted if:</P>
                            <P>(1) 180 calendar days elapse after the complainant files the complaint and GSA makes no finding with regard to the complaint; or</P>
                            <P>(2) GSA issues a finding in favor of the recipient.</P>
                            <P>(b) If GSA fails to make a finding within 180 days or issues a finding in favor of the recipient, GSA must:</P>
                            <P>(1) Promptly advise the complainant of this fact;</P>
                            <P>(2) Advise the complainant of his or her right to bring civil action for injunctive relief; and</P>
                            <P>(3) Inform the complainant:</P>
                            <P>(i) That the complainant may bring civil action only in a United States district court for the district in which the recipient is located or transacts business;</P>
                            <P>(ii) That a complainant prevailing in a civil action has the right to be awarded the costs of the action, including reasonable attorney's fees, but that the complainant must demand these costs in the complaint;</P>
                            <P>(iii) That before commencing the action the complainant must give 30 calendar days notice by registered mail to the Secretary, HHS, The Administrator, the Attorney General of the United States, and the recipient;</P>
                            <P>(iv) That the notice must state the alleged violation of the Act, the relief requested, the court in which the complainant is bringing the action, and whether or not attorney's fees are demanded in the event the complainant prevails; and</P>
                            <P>(v) That the complainant may not bring an action if the same alleged violation of the Act by the same recipient is the subject of a pending action in any court of the United States.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 105.9-126 </SECTNO>
                            <SUBJECT>Alternate funds disbursal.</SUBJECT>
                            <P>If GSA withholds Federal financial assistance from a recipient under this part, the Administrator may disburse the assistance to an alternate recipient; any public or nonprofit private organization; or agency or State or political subdivision of the State. The Administrator requires any alternate recipient to demonstrate:</P>
                            <P>(a) The ability to comply with this part; and</P>
                            <P>(b) The ability to achieve the goals of the Federal Statutes authorizing the Federal financial assistance.</P>
                        </SECTION>
                    </PART>
                </REGTEXT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15368 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6820-UP-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Centers for Medicare &amp; Medicaid Services</SUBAGY>
                <CFR>42 CFR Parts 410 and 414</CFR>
                <DEPDOC>[CMS-6109-N]</DEPDOC>
                <RIN>RIN 0938-ZC04</RIN>
                <SUBJECT>Medicare Program; Updates to the Master List of Items Potentially Subject to Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements; Updates to the Required Face-to-Face Encounter and Written Order Prior to Delivery List; and Updates to the Required Prior Authorization List</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Centers for Medicare &amp; Medicaid Services (CMS), Department of Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Updates to the Master List of Items Potentially Subject to Face-To-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements (the “Master List”); Updates to the Required Face-to-Face Encounter and Written Order Prior to Delivery List; and Updates to the Required Prior Authorization List.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This document announces updates to the Healthcare Common Procedure Coding System (HCPCS) codes on the Master List. It also announces updates to the HCPCS codes on the Required Face-to-Face Encounter and Written Order Prior to Delivery List and the Required Prior Authorization List.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Implementation of updates to the Master List, the Required Face-to-Face Encounter and Written Order Prior to Delivery List, and the Required Prior Authorization List, excluding upper limb orthoses, are effective October 28, 2026.</P>
                    <P>Prior authorization requirements for the upper limb orthoses will be implemented in three phases. Phase one includes New York, Michigan, Florida, and California and is effective October 28, 2026. Phase two includes the States in phase one and Pennsylvania, Massachusetts, Ohio, Illinois, Texas, Georgia, Arizona, and Oregon and is effective January 26, 2027. Phase three includes all States and territories not included in phases one and two and is effective April 26, 2027.</P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>For information related to the Required Face-to-Face Encounter and Written Order Prior to Delivery List, contact Jennifer Phillips, (410) 786-1023; Misty Whitaker, (410) 786-4975; or Olufemi Shodeke, (410) 786-1649.</P>
                    <P>For information related to the Master List or Required Prior Authorization List, contact Justin Carlisle, (410) 786-4265; Karen Leban, (410) 786-2476; or Jessica Martindale, (410) 786-1558.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>On November 8, 2019, the Centers for Medicare &amp; Medicaid Services (CMS) published a final rule titled, “Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Fee Schedule Amounts, DMEPOS Competitive Bidding Program (CBP) Amendments, Standard Elements for a DMEPOS Order, and Master List of DMEPOS Items Potentially Subject to a Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements” (the November 2019 final rule) (84 FR 60648). The rule became effective January 1, 2020, harmonizing the lists of DMEPOS items created by former rules and establishing one “Master List of DMEPOS Items Potentially Subject to Face-to-Face Encounter and Written Orders Prior to Delivery and/or Prior Authorization Requirements” (the “Master List”).</P>
                <P>
                    The Master List serves as a library of items, that have been identified as potential vulnerabilities to the Trust Fund based on criteria outlined in 42 CFR 414.234(b), from which items may be selected to be placed on either the Required Face-to-Face Encounter and Written Orders Prior to Delivery List (the “F2F/WOPD List”) and/or Required Prior Authorization List under the authority provided under sections 1834(a)(1)(E)(iv), 1834(a)(11)(B), and 1834(a)(15) of the Social Security Act (the Act). Only those items that are selected and announced via 
                    <E T="04">Federal Register</E>
                     notice are subject to such regulatory conditions of payment. The November 2019 final rule provided that the 
                    <E T="04">Federal Register</E>
                     notice would be for a period of no less than 60 days. It also clarified that certain items (that is, power mobility devices (PMDs)) require a face-to-face encounter per statute and would remain on both the Master List and the F2F/WOPD List.
                </P>
                <P>
                    The requirements in the November 2019 final rule related to face-to-face encounters, written orders prior to delivery, and standard written orders for specified DMEPOS items were codified in 42 CFR 410.38. The information in 
                    <PRTPAGE P="47973"/>
                    the November 2019 final rule related to the creation and maintenance of the Master List is codified at 42 CFR 414.234. The November 2019 final rule also includes information related to the prior authorization process, as initially outlined in the December 30, 2015, final rule titled “Medicare Program; Prior Authorization Process for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies” (80 FR 81674).
                </P>
                <P>
                    The Master List was last updated via the document published in the January 13, 2026 
                    <E T="04">Federal Register</E>
                     (91 FR 1250 through 1252) and currently includes 530 items. The Master List is available on the CMS website at: 
                    <E T="03">http://go.cms.gov/DMEPOSPA.</E>
                </P>
                <P>
                    The January 2026 
                    <E T="04">Federal Register</E>
                     document (91 FR 1252 and 1253) also included the most recent iteration of the Required Face-to-Face Encounter and Written Order Prior to Delivery List. There are currently 83 items on the list, including 46 PMDs that were included per statute. This list is also available on the CMS website at: 
                    <E T="03">http://go.cms.gov/DMEPOSF2F.</E>
                </P>
                <P>
                    The Required Prior Authorization List was last updated via the January 2026 
                    <E T="04">Federal Register</E>
                     document (91 FR 1253 and 1254) and currently includes 74 items. All the lists discussed in this notice are available on the CMS website at: 
                    <E T="03">http://go.cms.gov/DMEPOSPA.</E>
                </P>
                <HD SOURCE="HD1">II. Provisions of the Document</HD>
                <P>This document serves to update three separate lists. First, it provides an update to the Master List. Next, this document updates the items included on the Required Face-to-Face Encounter and Written Order Prior to Delivery List. Finally, this document updates items on the Required Prior Authorization List.</P>
                <HD SOURCE="HD2">A. Master List</HD>
                <P>The Master List includes items that appear on the DMEPOS Fee Schedule and meet one of the following criteria, as stated in 42 CFR 414.234(b)(1):</P>
                <P>• Have an average purchase fee of $500 or greater that is adjusted annually for inflation, or an average monthly rental fee schedule of $50 or greater that is adjusted annually for inflation, or items identified as accounting for at least 1.5 percent of Medicare expenditures for all DMEPOS items over a recent 12-month period, that are also—</P>
                <P>++ Identified in a Government Accountability Office (GAO) or Department of Health and Human Services Office of Inspector General (OIG) report that is national in scope and published in 2015 or later as having a high rate of fraud or unnecessary utilization; or</P>
                <P>++ Listed in the 2018 or subsequent year Comprehensive Error Rate Testing (CERT) Medicare Fee-for-Service Supplemental Improper Payment Data report as having a high improper payment rate.</P>
                <P>• Any items with at least 1,000 claims and $1 million in payments during a recent 12-month period that are determined to have aberrant billing patterns and lack explanatory contributing factors (for example, new technology or coverage policies that may require time for providers and suppliers to be educated on billing policies). Items with aberrant billing patterns would be identified as those items with payments during a 12-month timeframe that exceed payments made during the preceding 12 months by the greater of—</P>
                <P>++ Double the percentage change of all DMEPOS claim payments for items that meet the previous claim and payment criteria, from the preceding 12-month period; or</P>
                <P>++ Exceeding a 30 percent increase in payments for the items from the preceding 12-month period.</P>
                <P>• Any items statutorily requiring a face-to-face encounter, a written order prior to delivery, or prior authorization.</P>
                <P>In the regulation at § 414.234(b) and in the November 2019 final rule, the maintenance process of the Master List is described as follows:</P>
                <P>• The Master List will be updated annually, and more frequently as needed (for example, to address emerging billing trends and to reflect the thresholds specified in the regulations).</P>
                <P>• Items on the DMEPOS Fee Schedule that meet the payment threshold criteria set forth in § 414.234(b)(1) are added to the list when the item is also listed in the CERT Medicare Fee-for-Service Supplemental Improper Payment Data report published after 2020, or in an OIG or GAO report published after 2020, and items not meeting the cost thresholds (originally set at $500 for purchases and $50 for rentals and adjusted for inflation) may still be added based on findings of aberrant billing patterns.</P>
                <P>• Items are removed from the Master List 10 years after the date the item was added, unless the item was identified in an OIG report, GAO report, or having been identified in the CERT Medicare Fee-for-Service Supplemental Improper Payment Data report as having a high improper payment rate, within the 5-year period preceding the anticipated date of expiration.</P>
                <P>• Items are removed from the list sooner than 10 years if the purchase amount drops below the payment threshold.</P>
                <P>• Items already on the Master List that are identified on a subsequent OIG, GAO, or CERT report will remain on the list for 10 years from the publication date of the new report.</P>
                <P>• Items on the Master List are updated when the HCPCS codes representing an item have been discontinued and cross walked to an equivalent item.</P>
                <P>
                    • We will notify the public of any additions and deletions from the Master List by posting a notification in the 
                    <E T="04">Federal Register</E>
                     and on the website at: 
                    <E T="03">http://go.cms.gov/DMEPOSPA.</E>
                </P>
                <P>This document updates the Master List of DMEPOS Items Potentially Subject to a Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements stated in the November 2019 final rule (84 FR 60648). As noted previously, we adjust the “payment threshold” each year for inflation. Specifically, in accordance with 42 CFR 414.234(b)(1)(i) the $500 average purchase fee threshold and the $50 average monthly rental fee threshold is adjusted using the Consumer Price Index for All Urban Consumers (CPI-U), reduced by the 10-year moving average of changes in annual economy-wide private nonfarm business multifactor productivity as projected by the Secretary for the 10-year period ending with the applicable fiscal year, year, cost reporting period, or other annual period.</P>
                <P>
                    In accordance with sections 1834(a)(14), 1834(h)(4) and 1842(s)(1)(B) of the Act, we updated certain DMEPOS fee schedule amounts for calendar year (CY) 2026,
                    <SU>1</SU>
                    <FTREF/>
                     by the percentage increase in the CPI-U for the 12-month period ending June 30, 2025, adjusted by the change in the economy-wide productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business multi-factor productivity (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, year, cost reporting period, or other annual period) (the “productivity adjustment”). The U.S. Department of Labor's Bureau of Labor Statistics (BLS) publishes the official measures of productivity for the U.S. economy. The productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act is 
                    <PRTPAGE P="47974"/>
                    published by BLS as private nonfarm business total factor productivity (TFP), previously referred to as multifactor productivity.
                    <SU>2</SU>
                    <FTREF/>
                     Please see 
                    <E T="03">https://www.bls.gov/productivity/</E>
                     for the BLS historical published TFP data. For CY 2026, the productivity adjustment is estimated to be 0.7 percent and the CPI-U percentage increase is 2.7 percent. Thus, the 2.7 percentage increase in the CPI-U is reduced by a 0.7 percentage point productivity adjustment resulting in a net increase of 2.0 percent for the update factor for CY 2026.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         2026 DMEPOS Fee Schedule; available at 
                        <E T="03">https://www.cms.gov/medicare/payment/fee-schedules/dmepos/dmepos-fee-schedule/dme26</E>
                        .
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">https://www.bls.gov/productivity/notices/2021/mfp-to-tfp-term-change.htm</E>
                        .
                    </P>
                </FTNT>
                <P>For CY 2026, the adjusted purchase price threshold is $614, and the adjusted monthly rental fee threshold is $62. We calculated this by applying the 2.0 percent update factor to the CY 2025 average price threshold of $602, resulting in a CY 2026 adjusted payment threshold of $614.02 ($602 × 1.02), and to the CY 2025 average monthly rental fee of $61, resulting in an adjusted payment threshold of $62.22 ($61 × 1.02). Rounding to the nearest whole dollar, these figures are $614 and $62.</P>
                <P>We are adding a total of 20 HCPCS codes (see Table 1) meeting the criteria outlined previously to the Master List. Of these 20 HCPCS codes, A4239, A6022, A6197, K0831, L0456, L0486, L1833, and L3916 are being added for aberrant billing patterns. These codes represent items for which data shows suppliers submitted at least 1,000 claims and received at least $1 million in payments during the 12 months from July 2024 to June 2025. There was more than a 30 percent increase in payments for each item from the preceding 12-month period. CMS did not identify explanatory contributing factors for the aberrant billing. The remaining 12 codes are added because these items meet the updated payment threshold and are listed in an OIG or GAO report of a national scope or a CERT Medicare Fee-for-Service Supplemental Improper Payment Data report, or both.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="xs66,r150">
                    <TTITLE>Table 1—Additions to the Master List</TTITLE>
                    <BOXHD>
                        <CHED H="1">HCPCS</CHED>
                        <CHED H="1">Description</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">A4239</ENT>
                        <ENT>Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (CGM) including all supplies and accessories (1 month supply = 1 unit of service).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">A4594</ENT>
                        <ENT>Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">A6022</ENT>
                        <ENT>Collagen dressing, sterile, size more than 16 square (sq) inches (in) but less than or equal to 48 sq in each.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">A6197</ENT>
                        <ENT>Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 square (sq) inches (in) but less than or equal to 48 sq.in., each dressing.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0658</ENT>
                        <ENT>Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full arms and chest.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0659</ENT>
                        <ENT>Segmental pneumatic appliance for use with pneumatic compressor, integrated, head, neck, and chest.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0683</ENT>
                        <ENT>Non-pneumatic, non-sequential, peristaltic wave compression pump.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0734</ENT>
                        <ENT>External upper limb tremor stimulator of the peripheral nerves of the wrist.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0738</ENT>
                        <ENT>Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including a microprocessor, all components, and accessories.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0739</ENT>
                        <ENT>Rehabilitation system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E2001</ENT>
                        <ENT>Suction pump, home model, portable or stationary, electric, any type, for use with an external urine and/or fecal management system.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E2298</ENT>
                        <ENT>Complex rehabilitative power wheelchair accessory, power seat elevation system, any type.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0831</ENT>
                        <ENT>Power wheelchair, group 2 standard, seat elevator, captain's chair, patient weight capacity up to and including 300 pounds.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0456</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0486</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, triplanar control, two piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1833</ENT>
                        <ENT>Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1933</ENT>
                        <ENT>Ankle foot orthosis, rigid anterior tibial section, total carbon fiber or equal material, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1952</ENT>
                        <ENT>Ankle foot orthosis, spiral, (Institute of rehabilitative medicine type), plastic or other material, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L3916</ENT>
                        <ENT>Wrist hand orthosis, includes one or more nontorsion joint(s), elastic bands, turnbuckles, may include soft interface, straps, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L5827</ENT>
                        <ENT>Endoskeletal knee-shin system, single axis, electromechanical swing and stance phase control, with or without shock absorption and stance extension damping.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Items are removed from the Master List 10 years after the date the item was added, unless the item was identified in an OIG report, GAO report, or has been identified in the CERT Medicare Fee-for-Service Supplemental Improper Payment Data report as having a high improper payment rate, within the 5-year period preceding the anticipated date of expiration. Additionally, items are removed from the list sooner than a 10-year timeframe if the purchase or monthly rental amount drops below the payment threshold. There are no HCPCS codes being removed from the Master List for the CY 2026 update.</P>
                <P>
                    The full updated Master List is available on the CMS website at: 
                    <E T="03">http://go.cms.gov/DMEPOSPA.</E>
                </P>
                <HD SOURCE="HD2">B. Items Subject to Face-to-Face Encounter and Written Order Prior to Delivery Requirements</HD>
                <P>
                    The F2F/WOPD List includes PMDs that are required by statutory obligation. For the other DMEPOS items, we consider factors such as operational limitations, item utilization, cost-benefit analysis (for example, comparing the cost of review versus the anticipated amount of improper payment 
                    <PRTPAGE P="47975"/>
                    identified), emerging trends (for example, billing patterns, medical review findings), vulnerabilities identified in official agency reports, or other analysis.
                </P>
                <P>When selecting these items, we balance our program integrity goals with the needs of beneficiaries to ensure the appropriate application and oversight of the face-to-face encounter requirements. In consideration of access issues, we note that the regulation 42 CFR 410.38 allows for use of telehealth, as defined in 42 CFR 410.78 and 414.65, when appropriate to meet our coverage requirements for beneficiaries.</P>
                <P>Consistent with § 410.38(d), the face-to-face encounter must be documented in the pertinent portion of the medical record (for example, history, physical examination, diagnostic tests, summary of findings, progress notes, treatment plans or other sources of information that may be appropriate). The supporting documentation must include subjective and objective beneficiary-specific information used for diagnosing, treating, or managing a clinical condition for which the DMEPOS item(s) is ordered. Upon request by CMS or its review contractors, a supplier must submit additional documentation to support and substantiate the medical necessity for the DMEPOS item.</P>
                <P>
                    Prior to publication of this 
                    <E T="04">Federal Register</E>
                     notice, 83 items have been included on the F2F/WOPD List. We have not been notified of any issues related to beneficiary access, and billing trends have been consistent with anticipated volumes.
                </P>
                <P>
                    Based on our regulatory authority at 42 CFR 410.38, this 
                    <E T="04">Federal Register</E>
                     notice is adding the following 22 additional HCPCS codes to the F2F/WOPD List (See Table 2).
                </P>
                <P>We have selected three codes for lumbar-sacral orthoses, four codes for lower limb orthoses, two codes for upper limb orthoses, eight wheelchair codes, three codes for home ventilators, one code related to oxygen and its delivery system, and one code for an air-fluidized bed. Lumbar-sacral orthoses, lower limb orthoses, upper limb orthoses, ventilators, oxygen supplies/equipment and hospital bed/accessories were identified by CMS' Comprehensive Error Rate Testing (CERT) program as being within the top 20 DMEPOS service types with improper payments in 2025. Several of these codes were also identified by HHS program integrity experts, including our contractors performing medical review as being vulnerable to fraud.</P>
                <P>We continue to believe additional practitioner oversight of beneficiaries in need of items included on the F2F/WOPD List will help further our program integrity goals of reducing fraud, waste, and abuse. It helps ensure beneficiary receipt of items specific to their medical needs, as the written order/prescription must be communicated to the supplier prior to delivery. For such items, we continue to require the treating practitioner to have a face-to-face encounter with the beneficiary within the 6 months preceding the date of the written order/prescription.</P>
                <P>The proposed items were selected based on the clinical appropriateness of requiring a practitioner encounter within the preceding 6 months, jurisdictionally identified billing vulnerabilities, and data analysis, including our analysis of the CERT improper payment information.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="xs66,r150">
                    <TTITLE>Table 2—Additions to the F2F/WOPD List—New Non-Statutorily Required Items</TTITLE>
                    <BOXHD>
                        <CHED H="1">HCPCS</CHED>
                        <CHED H="1">Description</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">E0194</ENT>
                        <ENT>Air fluidized bed.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0466</ENT>
                        <ENT>Home ventilator, any type, used with non-invasive interface, (for example, mask, chest shell).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0467</ENT>
                        <ENT>Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E0468</ENT>
                        <ENT>Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">E1161</ENT>
                        <ENT>Manual adult size wheelchair, includes tilt in space.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0002</ENT>
                        <ENT>Standard hemi (low seat) wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0003</ENT>
                        <ENT>Lightweight wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0004</ENT>
                        <ENT>High strength, lightweight wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0005</ENT>
                        <ENT>Ultralightweight wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0006</ENT>
                        <ENT>Heavy duty wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0007</ENT>
                        <ENT>Extra heavy-duty wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0738</ENT>
                        <ENT>Portable gaseous oxygen system, rental; home compressor used to fill portable oxygen cylinders; includes portable containers, regulator, flowmeter, humidifier, cannula or mask, and tubing.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0831</ENT>
                        <ENT>Power wheelchair, group 2 standard, seat elevator, captain's chair, patient weight capacity up to and including 300 pounds.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0486</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, triplanar control, two piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0456</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0457</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1833</ENT>
                        <ENT>Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1906</ENT>
                        <ENT>Ankle foot orthosis, multi-ligamentous ankle support, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1933</ENT>
                        <ENT>Ankle foot orthoses, rigid anterior tibial section, total carbon fiber or equal material, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1952</ENT>
                        <ENT>Ankle foot orthosis, spiral, (Institute of rehabilitative medicine type), plastic or other material, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L3761</ENT>
                        <ENT>Elbow orthosis, with adjustable position locking joint(s), prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="47976"/>
                        <ENT I="01">L3916</ENT>
                        <ENT>Wrist hand orthosis, includes one or more nontorsion joint(s), elastic bands, turnbuckles, may include soft interface, straps, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    The F2F/WOPD List is available on the CMS website at: 
                    <E T="03">http://go.cms.gov/DMEPOSF2F.</E>
                </P>
                <HD SOURCE="HD2">C. Items Subject to Prior Authorization Requirements</HD>
                <P>
                    The Required Prior Authorization List specified in § 414.234(c)(1) is selected from the Master List (as described in § 414.234(b)), and those selected items require prior authorization as a condition of payment. As stated in § 414.234(c), we inform the public of those DMEPOS items on the Required Prior Authorization List in the 
                    <E T="04">Federal Register</E>
                     with no less than 60 days' notice before implementation, and post notification on the CMS website. Additionally, § 414.234 (c)(1)(ii) states that CMS may elect to limit the prior authorization requirement to a particular region of the country if claims data analysis shows that unnecessary utilization of the selected item(s) is concentrated in a particular region.
                </P>
                <P>We are updating the Required Prior Authorization List to include the addition of eight HCPCS codes (See Table 3). To assist stakeholders in preparing for implementation of the prior authorization program, we are providing at least 90 days' notice as further described as follows.</P>
                <P>The following HCPCS codes for a pressure-reducing support surface, manual wheelchair base, knee orthosis, thoracic-lumbar-sacral orthoses, and upper-limb orthoses are being added to the Required Prior Authorization List:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="xs66,r150">
                    <TTITLE>Table 3—Additions to the Required Prior Authorization List</TTITLE>
                    <BOXHD>
                        <CHED H="1">HCPCS</CHED>
                        <CHED H="1">Description</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">E0194</ENT>
                        <ENT>Air fluidized bed.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">K0005</ENT>
                        <ENT>Ultralightweight wheelchair.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L1833</ENT>
                        <ENT>Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0456</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0457</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, flexible, provides trunk support, thoracic region, rigid posterior panel and soft anterior apron, extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, restricts gross trunk motion in the sagittal plane, produces intracavitary pressure to reduce load on the intervertebral disks, includes straps and closures, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L0486</ENT>
                        <ENT>Thoracic-lumbar-sacral orthosis, triplanar control, two piece rigid plastic shell with interface liner, multiple straps and closures, posterior extends from sacrococcygeal junction and terminates just inferior to scapular spine, anterior extends from symphysis pubis to sternal notch, lateral strength is enhanced by overlapping plastic, restricts gross trunk motion in the sagittal, coronal, and transverse planes, includes a carved plaster or CAD-CAM model, custom fabricated.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L3761</ENT>
                        <ENT>Elbow orthosis, with adjustable position locking joint(s), prefabricated, off-the-shelf.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">L3916</ENT>
                        <ENT>Wrist hand orthosis, includes one or more nontorsion joint(s), elastic bands, turnbuckles, may include soft interface, straps, prefabricated, off-the-shelf.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    We believe prior authorization of these eight additional HCPCS codes will help further our program integrity goals of reducing fraud, waste, and abuse, while also protecting access to care. In addition, recent enforcement actions by the U.S. Department of Justice have continued to demonstrate broader program integrity risks, including fraudulent billing schemes involving medically unnecessary equipment, the submission of claims lacking documentation of medical necessity, and the use of telemarketing arrangements targeting Medicare beneficiaries.
                    <SU>3</SU>
                    <FTREF/>
                     Additionally, the CMS Fraud Defense Operations Center has reported over $1.5 billion in payments suspended for DMEPOS items associated with suspected fraudulent billing.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         DOJ July 2025 Press Release; available at 
                        <E T="03">www.justice.gov/opa/pr/durable-medical-equipment-owner-sentenced-12-years-61-million-medicare-fraud-scheme</E>
                        .
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Fraud Defense Operations Center Fast Facts; available at 
                        <E T="03">https://www.cms.gov/files/document/fdoc-fact-sheet-updated.pdf</E>
                        .
                    </P>
                </FTNT>
                <P>
                    Orthoses have been identified by the CERT program as one of the top DMEPOS service types with improper payments over the past several years. From 2023 to 2025, improper payment rates remained consistently elevated, ranging from approximately 40 percent to 48 percent for upper limb orthoses and 35 percent to 47 percent for lower limb orthoses. The improper payment rate for manual wheelchairs ranged from 22.1 percent to 42 percent over that same time period.
                    <E T="51">5 6 7</E>
                    <FTREF/>
                     Additionally, claims for certain pressure-reducing support surfaces have been denied through medical reviews for not meeting Medicare requirements for payment.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         2023 CMS Medicare Fee for Service (FFS) Supplemental and Improper Payment Data (CERT); available at 
                        <E T="03">https://www.cms.gov/files/document/2023medicarefee-servicesupplementalimproperpaymentdatapdf.pdf</E>
                        .
                    </P>
                    <P>
                        <SU>6</SU>
                         2024 CMS Medicare FFS Supplemental and Improper Payment Data (CERT); available at 
                        <E T="03">https://www.cms.gov/files/document/2024-medicare-fee-service-supplemental-improper-payment-data.pdf</E>
                        .
                    </P>
                    <P>
                        <SU>7</SU>
                         2025 CMS Medicare FFS Supplemental and Improper Payment Data (CERT); available at 
                        <E T="03">https://www.cms.gov/files/document/nov-2025-medicare-ffs-supplemental-improper-payment-data-2025922.pdf</E>
                        .
                    </P>
                </FTNT>
                <P>
                    Upon implementation, these codes will be subject to the requirements of the prior authorization program for certain DMEPOS items as outlined in § 414.234. We will implement a prior authorization program for the newly added pressure-reducing support surface, manual wheelchair, knee 
                    <PRTPAGE P="47977"/>
                    orthosis, and thoracic-lumbar-sacral orthoses codes beginning on the date specified in the 
                    <E T="02">DATES</E>
                     section. We will implement a prior authorization program for the two newly added upper limb orthoses codes (L3761 and L3916) in three phases beginning on the dates specified in the 
                    <E T="02">DATES</E>
                     section. This phased-in approach will allow us to identify and resolve any unforeseen issues by using smaller claim volumes in phase one and phase two before nationwide implementation occurs in phase three.
                </P>
                <P>
                    In phase one of the implementation, which begins on the date specified in the 
                    <E T="02">DATES</E>
                     section, we will limit the prior authorization requirement of the upper limb orthoses to four states (one in each DME MAC jurisdiction) as follows: New York, Michigan, Florida, and California.
                </P>
                <P>
                    In phase two, which begins on the date specified in the 
                    <E T="02">DATES</E>
                     section, the prior authorization requirement of the upper limb orthoses items will expand to Pennsylvania, Massachusetts, Ohio, Illinois, Texas, Georgia, Arizona, and Oregon.
                </P>
                <P>
                    In phase three, which begins on the date specified in the 
                    <E T="02">DATES</E>
                     section, the prior authorization requirement of the upper limb orthoses items will expand nationally to all remaining states and territories not included in the first two phases.
                </P>
                <P>The prior authorization program for the remaining 74 HCPCS codes currently subject to the DMEPOS prior authorization requirement will continue uninterrupted.</P>
                <P>Prior to providing an item on the Required Prior Authorization List to the beneficiary and submitting the claim for processing, a requester must submit a prior authorization request. The request must include evidence that the item complies with all applicable Medicare coverage, coding, and payment rules. Consistent with § 414.234(d), such evidence must include the written order/prescription, relevant information from the beneficiary's medical record, and relevant supplier-produced documentation. After receipt of all applicable required Medicare documentation, CMS or one of its review contractors will conduct a medical review and communicate a decision that provisionally affirms or non-affirms the request.</P>
                <P>We will issue specific prior authorization guidance for these additional items in sub-regulatory communications, final timelines customized for the DMEPOS item subject to prior authorization and for communicating a provisionally affirmed or non-affirmed decision to the requester. In the December 30, 2015, final rule (80 FR 81674), we stated that this approach to final timelines provides flexibility to develop a process that involves fewer days, as may be appropriate, and allows us to safeguard beneficiary access to care. If at any time we become aware that the prior authorization process is creating barriers to care, we can suspend the program. For example, we will review questions and complaints from consumers and providers that come through regular sources such as 1-800-Medicare.</P>
                <P>
                    The updated Required Prior Authorization List is available on the CMS website at: 
                    <E T="03">http://go.cms.gov/DMEPOSPA.</E>
                </P>
                <HD SOURCE="HD1">III. Collection of Information Requirements</HD>
                <P>This document provides updates to the Master List, the Required Face-to-Face and Written Order Prior to Delivery List, and the Required Prior Authorization List.</P>
                <P>A total of 20 HCPCS codes (see Table 1) meeting the criteria outlined previously are added to the Master List. Of these 20 HCPCS codes, 12 are added because these items meet the updated payment threshold and are listed in an OIG or GAO report of a national scope, a CERT Medicare Fee-for-Service Supplemental Improper Payment Data report, or both; and 8 are being added for aberrant billing patterns. There are no HCPCS codes being removed from the Master List for the CY 2026 update.</P>
                <P>
                    Twenty-two HCPCS codes (see Table 2) are being added to the F2F/WOPD List. These codes include three for lumbar-sacral orthoses, four for lower limb orthoses, two for upper limb orthoses, eight for wheelchairs, three for home ventilators, one related to oxygen delivery, and one for air-fluidized beds. The 83 codes currently subject to the F2F/WOPD requirements will continue to remain on the Required F2F/WOPD List. Therefore, a total of 105 codes will be subject to face-to-face encounter and written order prior to delivery as a condition of payment. The updates to the F2F/WOPD List do not constitute information collections requirements, that is, reporting, recordkeeping or third-party disclosure requirements. Consequently, there is no need for review by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ).
                </P>
                <P>A total of eight HCPCS codes (see Table 3) are selected for addition to the Required Prior Authorization List. Of these eight HCPCS codes, one is a pressure reducing support surface, one is a manual wheelchair, and six are orthoses. The remaining 74 HCPCS codes currently subject to the DMEPOS prior authorization requirement will continue uninterrupted.</P>
                <P>
                    The information collection burden associated with the DMEPOS prior authorization program is currently approved by OMB under control number 0938-1293 (CMS-10524). The control number accounts for the burden associated with the addition of items to the Required Prior Authorization Lists and assumes an annual burden of approximately $4.8 million for providers to comply with the prior authorization requirement. The burden associated with the additions to the Required Prior Authorization List has been assessed in the PRA package referenced previously and is included in this 
                    <E T="04">Federal Register</E>
                     notice as required under the Paperwork Reduction Act of 1995.
                </P>
                <HD SOURCE="HD1">IV. Regulatory Impact Statement</HD>
                <P>We have examined the impacts of this regulatory notice as required by Executive Order 12866, “Regulatory Planning and Review”; Executive Order 13132, “Federalism“; Executive Order 13563, “Improving Regulation and Regulatory Review”; Executive Order 14192, “Unleashing Prosperity Through Deregulation”; the Regulatory Flexibility Act (RFA) (Pub. L. 96-354); section 1102(b) of the Social Security Act; section 202 of the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4); and the Congressional Review Act (5 U.S.C. 804(2)).</P>
                <P>
                    Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select those regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; as well as the distributive impacts). Section 3(f) of Executive Order 12866 defines a “significant regulatory action” as any regulatory action that is likely to result in a regulatory notice that may: (1) have an annual effect on the economy of $100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities; (2) create a serious inconsistency or otherwise interfere with an action taken or planned by another agency; (3) materially alter the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or (4) raise novel 
                    <PRTPAGE P="47978"/>
                    legal or policy issues arising out of legal mandates, or the President's priorities.
                </P>
                <P>A regulatory impact analysis (RIA) must be prepared for a regulatory action that is significant under section 3(f)(1) of E.O. 12866. This regulatory notice is not significant and does not reach the economic threshold and thus is not considered a major regulatory notice.</P>
                <P>Per our analysis, the additional items being added to the prior authorization program have an estimated net savings of $15.8 million after deducting implementation costs from gross savings. Gross savings were estimated by reducing the estimated total amount paid for these items in CY 2025 by a reduction in the items' improper payment rates.</P>
                <P>The Regulatory Flexibility Act (RFA) requires agencies to analyze options for regulatory relief of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. Most hospitals and other providers and suppliers are small entities, either by nonprofit status or by having revenues of less than $9.0 million to $47.0 million in any 1 year. Individuals and States are not included in the definition of a small entity. We are not preparing an analysis for the RFA because we have determined, and the Secretary certifies, that this regulatory notice will not have a significant economic impact on a substantial number of small entities.</P>
                <P>In addition, section 1102(b) of the Act requires us to prepare an RIA if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a Metropolitan Statistical Area for Medicare payment regulations and has fewer than 100 beds. We are not preparing an analysis for section 1102(b) of the Act because we have determined, and the Secretary certifies that this regulatory notice will not have a significant impact on the operations of a substantial number of small rural hospitals.</P>
                <P>Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. In 2026, that threshold is approximately $193 million. This regulatory notice will have no consequential effect on State, local, or tribal governments or on the private sector.</P>
                <P>Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule or other regulatory document) that imposes substantial direct requirement costs on State and local governments, preempts State law, or otherwise has Federalism implications. Since this regulatory notice does not impose any costs on State or local governments, the requirements of Executive Order 13132 are not applicable.</P>
                <P>In accordance with the provisions of Executive Order 12866, this notice was reviewed by the Office of Management and Budget.</P>
                <P>
                    The Administrator of the Centers for Medicare &amp; Medicaid Services (CMS), Dr. Mehmet Oz, having reviewed and approved this document, authorizes Chyana Woodyard, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Chyana Woodyard,</NAME>
                    <TITLE>Federal Register Liaison, Centers for Medicare &amp; Medicaid Services.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15446 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4120-01-P</BILCOD>
        </RULE>
    </RULES>
    <VOL>91</VOL>
    <NO>145</NO>
    <DATE>Thursday, July 30, 2026</DATE>
    <UNITNAME>Proposed Rules</UNITNAME>
    <PRORULES>
        <PRORULE>
            <PREAMB>
                <PRTPAGE P="47979"/>
                <AGENCY TYPE="F">DEPARTMENT OF JUSTICE</AGENCY>
                <SUBAGY>Executive Office for Immigration Review</SUBAGY>
                <CFR>8 CFR Parts 1003 and 1103</CFR>
                <DEPDOC>[Docket No. EOIR-26-AB02; Dir. Order No. 07-2026]</DEPDOC>
                <RIN>RIN 1125-AB02</RIN>
                <SUBJECT>Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Executive Office for Immigration Review, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed rulemaking.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This notice of proposed rulemaking (“NPRM”) would implement a provision of the Immigration and Nationality Act (“INA” or “the Act”) that authorizes Immigration Judges, under regulations prescribed by the Attorney General, to sanction by civil money penalty any action (or inaction) in contempt of the proper exercise of their authority by certain individuals. The rule would: define the scope of the contempt authority; provide procedures for contempt findings, penalty determinations, and penalty payment; establish an appellate process; and implement oversight of the use of contempt authority. The rule would also make conforming changes to the grounds for practitioner discipline.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        Electronic comments must be submitted on or before September 28, 2026. The electronic Federal Docket Management System at 
                        <E T="03">https://www.regulations.gov</E>
                         will accept electronic comments until 11:59 p.m. Eastern Time on that date.
                    </P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        If you wish to provide comments regarding this proposed rulemaking, you must submit your comments, identified by the agency name and reference RIN 1125-AB02 or EOIR Docket No. EOIR-26-AB02, via the Federal eRulemaking Portal at 
                        <E T="03">https://www.regulations.gov.</E>
                         The electronic Federal Docket Management System (“FDMS”) at 
                        <E T="03">https://www.regulations.gov</E>
                         will accept electronic comments until September 28, 2026. Follow the website instructions for submitting comments. Comments must be submitted in English, or an English translation must be provided.
                    </P>
                    <P>
                        Comments submitted in a manner other than via 
                        <E T="03">https://www.regulations.gov</E>
                         will not be considered comments on the proposed rule and may not receive a response from EOIR. EOIR is not accepting mailed comments at this time.
                    </P>
                    <P>
                        If you cannot submit your comment by using 
                        <E T="03">https://www.regulations.gov,</E>
                         please contact Jamee E. Comans, Assistant Director for Policy, Office of Policy, Executive Office for Immigration Review, by telephone at (703) 305-0289 (not a toll-free call) for alternate instructions.
                    </P>
                    <P>
                        Pursuant to 5 U.S.C. 553(b)(4), a plain language summary of the proposed rule is available in the rulemaking docket at 
                        <E T="03">https://www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Jamee E. Comans, Assistant Director, Office of Policy, Executive Office for Immigration Review, 5107 Leesburg Pike, Suite 2500, Falls Church, Virginia 22041, telephone (703) 305-0289 (not a toll-free call).</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Public Participation</HD>
                <P>Interested persons are invited to participate in this rulemaking by submitting written data, views, or arguments on all aspects of the proposed rule via the method and by the deadline stated above. The Department of Justice (“Department”) also invites comments that relate to the economic, environmental, or federalism effects that might result from the proposed rule. Comments that will provide the most assistance to the Department will reference a specific portion of the proposed rule, explain the reason for any recommended change; and include data, information, or authority that supports such recommended change.</P>
                <P>
                    Please note that all comments received are considered part of the public record and made available for public inspection at 
                    <E T="03">https://www.regulations.gov.</E>
                     Such information includes personally identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.
                </P>
                <P>If you want to submit personally identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online, you must include the phrase “PERSONALLY IDENTIFYING INFORMATION” in the first paragraph of your comment and identify what information you want redacted.</P>
                <P>
                    If you want to submit confidential business information as part of your comment, but do not want it to be posted online, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You also must prominently identify the confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted on 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <P>
                    Personally identifying information located as set forth above will be placed in the agency's public docket file but not posted online. Confidential business information identified and located as set forth above will not be placed in the public docket file. The Department may withhold from public viewing information provided in comments that it determines may impact the privacy of an individual or is offensive. For additional information, please read the Privacy Act notice that is available via the link in the footer of 
                    <E T="03">https://www.regulations.gov.</E>
                     To inspect the agency's public docket file in person, you must make an appointment with the agency. Please see the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     paragraph above for agency contact information.
                </P>
                <HD SOURCE="HD1">II. Legal Authority</HD>
                <P>
                    The Department is issuing this NPRM pursuant to section 103(g) of the INA, 8 U.S.C. 1103(g), as amended by the Homeland Security Act of 2002 (“HSA”), Public Law 107-296, 116 Stat. 2135. Under the HSA, the Attorney General retains the authority to “establish such regulations, . . . issue such instructions, review such administrative determinations in immigration proceedings, delegate such authority, and perform such other acts as the Attorney General determines to be necessary for carrying out” the Attorney General's duties under the 
                    <PRTPAGE P="47980"/>
                    INA. HSA 1102, 116 Stat. at 2273-74; INA 103(g)(2), 8 U.S.C. 1103(g)(2).
                </P>
                <P>Further, the INA explicitly authorizes the Attorney General to prescribe regulations related to Immigration Judges' authority to issue civil money penalties for any contemptuous action or inaction during the course of removal proceedings under section 240 of the INA, 8 U.S.C. 1229a. INA 240(b)(1), 8 U.S.C. 1229a(b)(1).</P>
                <HD SOURCE="HD1">III. Background</HD>
                <P>
                    In 1996, Congress codified Immigration Judges' authority to sanction contemptuous action or inaction by imposing civil money penalties. Illegal Immigration Reform and Immigrant Responsibility Act of 1996, Public Law 104-208,  304, 110 Stat. 3009, 3009-589; 
                    <E T="03">see</E>
                     INA 240(b)(1), 8 U.S.C. 1229a(b)(1). The statute requires, however, that the Attorney General promulgate regulations to define and delineate that statutory authority.
                </P>
                <P>
                    In 2006, then-Attorney General Alberto Gonzales announced measures designed to improve the performance of the Immigration Courts and the Board of Immigration Appeals (“Board”). One measure directed EOIR to “draft a new proposed rule that creates a strictly defined and clearly delineated authority to sanction by civil money penalty an action (or inaction) in contempt of an immigration judge's proper exercise of authority.” 
                    <SU>1</SU>
                    <FTREF/>
                     Attorney General Gonzales announced this measure because “Immigration judges should have the tools necessary to control their courtrooms and to protect the adjudicatory system from fraud and abuse.” 
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Memorandum from the Attorney General for the Deputy Attorney General, Assistant Attorney General for Legal Policy, Director of the Executive Office for Immigration Review, and Acting Chief Immigration Judge (Aug. 9, 2006), 
                        <E T="03">https://www.justice.gov/sites/default/files/ag/legacy/2009/02/10/ag-080906.pdf</E>
                         [
                        <E T="03">https://perma.cc/V79E-T87Q</E>
                        ].
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Despite Attorney General Gonzales's instruction and Departmental efforts over time, the Department has not published a rulemaking implementing “a strictly defined and clearly delineated authority” for Immigration Judges to impose a civil money penalty as a sanction for contemptuous conduct. The Department has adopted regulations establishing rules of professional conduct for practice before EOIR, 
                    <E T="03">see</E>
                     8 CFR 1003.101-.111, but that disciplinary process is initiated and led by the EOIR disciplinary counsel. 
                    <E T="03">See generally</E>
                     8 CFR 1003.105 (detailing discipline process). Thus, there are no existing mechanisms for Immigration Judges presiding over proceedings to impose sanctions when an individual engages in contemptuous conduct; if an attorney or accredited representative engages in contemptuous conduct, the Immigration Judge is limited to filing a disciplinary complaint in the same manner as members of the general public. 
                    <E T="03">See</E>
                     8 CFR 1003.104(a)(1).
                </P>
                <P>Now, the Department is issuing this NPRM, which, if finalized, would implement the contempt authority provided for Immigration Judges under section 240(b)(1) of the INA, 8 U.S.C. 1229a(b)(1). The implementation of Immigration Judges' authority to sanction contemptuous conduct by civil money penalty will honor the framework envisioned by Congress for Immigration Judges to control the proceedings before them and help deter detrimental conduct that may affect such proceedings.</P>
                <HD SOURCE="HD1">IV. Description of the Proposed Rule</HD>
                <P>The Department proposes to add Subpart H—Civil Money Penalty for Contemptuous Conduct Before an Immigration Judge to Title 8, Chapter V, Part 1003 of the Code of Federal Regulations. Within this subpart, the Department proposes to: (1) explain the purpose and exceptional nature of the civil money penalty; (2) describe individuals who may be ordered to pay a civil money penalty; (3) outline the types of contemptuous conduct that may result in the imposition of a civil money penalty; (4) provide procedural standards for the Immigration Judge, the individual, and the Chief Immigration Judge to follow in the consideration of contempt matters; (5) authorize and provide standards for appeals to the Board; (6) provide guidelines for the payment of civil money penalties, including consequences for failure to pay; and (7) ensure oversight by EOIR management—primarily by the Chief Immigration Judge—of Immigration Judges' use of their contempt authority.</P>
                <HD SOURCE="HD2">A. Purpose of the Proposed Rule</HD>
                <P>
                    This rule proposes regulations that would allow Immigration Judges to use the contempt authority Congress provided for nearly 30 years ago. 
                    <E T="03">See</E>
                     INA 240(b)(1), 8 U.S.C. 1229a(b)(1); 8 CFR 1003.121 (proposed). It continues to be the case that Immigration Judges should have this important tool “to control their courtrooms and to protect the adjudicatory system from fraud and abuse.” 
                    <SU>3</SU>
                    <FTREF/>
                     Despite Congress's decision to provide contempt authority as a tool for Immigration Judges, the absence of implementing regulations means that Immigration Judges are currently unable to use this contempt authority to aid in efficiently conducting and managing removal proceedings. While the Department's intent to issue regulations to define and delineate the contempt authority is longstanding,
                    <SU>4</SU>
                    <FTREF/>
                     it is now imperative to do so to ensure Immigration Judges can exercise contempt authority to efficiently manage removal proceedings. Indeed, EOIR currently has a backlog of over 3.5 million cases.
                    <SU>5</SU>
                    <FTREF/>
                     Given the scope of this backlog, it is crucial for Immigration Judges to have every tool available—including the authority to impose civil money penalties—to control the proceedings before them and address and deter conduct that prevents efficient completion of removal proceedings.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Memorandum from the Attorney General for the Deputy Attorney General, Assistant Attorney General for Legal Policy, Director of the Executive Office for Immigration Review, and Acting Chief Immigration Judge 5 (Aug. 9, 2006), 
                        <E T="03">https://www.justice.gov/sites/default/files/ag/legacy/2009/02/10/ag-080906.pdf</E>
                         [
                        <E T="03">https://perma.cc/V79E-T87Q</E>
                        ].
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority, RIN 1125-AB02, 
                        <E T="03">https://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202004&amp;RIN=1125-AB02</E>
                         [
                        <E T="03">https://perma.cc/7YFD-PXTV</E>
                        ] (showing inclusion of this rulemaking in the Spring 2020 Unified Agenda, which identifies the Department's planned regulatory actions).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         EOIR, 
                        <E T="03">Adjudication Statistics: Pending Cases, New Cases, and Total Completions</E>
                         (Apr. 22, 2026), 
                        <E T="03">https://www.justice.gov/eoir/media/1344791/dl?inline</E>
                         [
                        <E T="03">https://perma.cc/J5L7-EGLV</E>
                        ].
                    </P>
                </FTNT>
                <P>
                    Further, in addition to implementing an Immigration Judge's statutory authority, such a measure is consistent with the Administration's goal of combatting fraud and abuse of legal processes, including in the immigration system, which may lead to delays in the adjudication of cases before the agency.
                    <SU>6</SU>
                    <FTREF/>
                     Accordingly, if finalized, the proposed rule will help to promote the fair, efficient, and consistent adjudication of immigration proceedings by allowing Immigration Judges to use civil money penalties to deter behavior that delays, disrupts, or obstructs the due course of immigration proceedings. 8 CFR 1003.122(a) (proposed).
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Presidential Memorandum, Preventing Abuses of the Legal System and the Federal Court (Mar. 22, 2025), 
                        <E T="03">https://www.whitehouse.gov/presidential-actions/2025/03/preventing-abuses-of-the-legal-system-and-the-federal-court/</E>
                         [
                        <E T="03">https://perma.cc/KVC6-FE7F</E>
                        ].
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Covered Individuals</HD>
                <P>
                    The proposed rule defines the three categories of individuals upon whom a civil money penalty may be imposed. 
                    <E T="03">See</E>
                     8 CFR 1003.123(a) (proposed). Specifically, the proposed rule would allow for a civil money penalty to be 
                    <PRTPAGE P="47981"/>
                    imposed upon the following individuals directly affiliated with proceedings before the Immigration Court: (1) an attorney (as defined at 8 CFR 1001.1(f)) or representative (as defined at 8 CFR 1001.1(j)) who has filed with the Immigration Court either a Notice of Entry of Appearance as Attorney or Representative before the Immigration Court (Form EOIR-28) or a Notice of Entry of Limited Appearance for Document Assistance before the Immigration Court (Form EOIR-61); (2) aliens who are the subject of the proceedings before the Immigration Judge; and (3) witnesses in any court proceedings before the Immigration Judge,
                    <SU>7</SU>
                    <FTREF/>
                     other than witnesses who are current employees or contractors of the Federal government acting in their official capacity. 
                    <E T="03">Id.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         This includes witnesses who are present in the courtroom, either physically or remotely through telephone or video-teleconferencing equipment, including during internet-based hearings. 8 CFR 1003.123(a)(3) (proposed).
                    </P>
                </FTNT>
                <P>
                    Under the proposed rule, an Immigration Judge would not be able to propose a civil money penalty on any other category of individual, including attorneys acting in their official capacity representing the Federal Government. 
                    <E T="03">See</E>
                     8 CFR 1003.123(b) (“Individuals not subject to civil money penalties.”) (proposed). This exclusion is analogous to the approach of the EOIR disciplinary rules. 
                    <E T="03">See</E>
                     8 CFR 1003.101(b) (excluding practitioners who represent the government from EOIR's authority to impose disciplinary sanctions for attorney misconduct). Importantly, government attorneys who appear in Immigration Court are subject to the jurisdiction of the Office of the Inspector General for the Department of Homeland Security (“DHS”) and, if warranted, will be disciplined pursuant to DHS's attorney discipline procedures. 
                    <E T="03">See</E>
                     8 CFR 292.3(i). Moreover, the Department is wary of creating a regulatory structure where one Executive agency may impose money sanctions on individuals engaging in official representation of another Executive agency. 
                    <E T="03">See</E>
                     5 CFR 2635.106(b) (“It is the responsibility of the employing agency to initiate appropriate disciplinary or corrective action in individual cases.”).
                </P>
                <P>For the same reasons, the Department does not propose to apply civil money penalties on witnesses who are current employees or contractors of the Federal government acting in their official capacity. Any otherwise contemptuous conduct made by such Federal employees or contractors in their official capacity is more properly addressed by their employing or contracting agency.</P>
                <HD SOURCE="HD2">C. Covered Conduct</HD>
                <P>
                    The Department proposes to authorize Immigration Judges to propose a civil money penalty as a sanction only for specified types of contemptuous conduct. 
                    <E T="03">See</E>
                     8 CFR 1003.124 (proposed). Specifically, the only five types of conduct that would be subject to a civil money penalty under the proposed rule are: (1) attorneys' and representatives' repeated failure to appear or to appear on time for scheduled hearings or pre-hearing conferences, including those held via telephone or video conferencing, without good cause; (2) repeated failure to comply with Immigration Judge orders to timely file pleadings, applications, pre-hearing statements, evidentiary submissions, or any other filings, without good cause; (3) disorderly or abusive behavior or language in and around the courtroom and before the Immigration Judge or abusive language in any filing with the Immigration Court; (4) knowingly or recklessly making a false statement of material fact or law, or knowingly or recklessly offering false evidence, and for attorneys and representatives, failing to take appropriate remedial measures after becoming aware of the falsity of previous material statements or evidence; and (5) willfully misleading, misinforming, threatening, or deceiving any person (including a party to a case or an officer or employee of the Department), concerning any relevant matter relating to a case. 8 CFR 1003.124(a)(1)-(5) (proposed). Both actions and inactions may constitute contemptuous conduct. 
                    <E T="03">See</E>
                     8 CFR 1003.124(b) (proposed).
                </P>
                <P>
                    When determining whether good cause exists for the failure to appear or to appear on time, 8 CFR 1003.124(a)(1) (proposed), or for the failure to comply with filing orders, 8 CFR 1003.124(a)(2) (proposed), the proposed rule would require the adjudicator to consider all relevant information, similar to other uses of the “good cause” standard in immigration proceedings. 
                    <E T="03">See, e.g., Dugboe</E>
                     v. 
                    <E T="03">Holder,</E>
                     644 F.3d 462, 471 (6th Cir. 2011) (applying a multi-factor balancing test when adjudicating a change of venue request under the “good cause” standard); 
                    <E T="03">Matter of L-A-B-R-,</E>
                     27 I&amp;N Dec. 405, 406 (A.G. 2018) (applying a “multifactor analysis” when adjudicating a continuance request under the “good cause” standard).
                </P>
                <P>In considering whether an attorney or representative is repeatedly failing to appear or timely appear at hearings, as stated in 8 CFR 1003.124(a)(1) (proposed), likely relevant factors would include, but not be limited to, whether proper notice of the hearing was provided; whether there were technical difficulties if appearing by telephone or videoconferencing; emergency medical or familial issues; or transportation issues beyond normal traffic, such as issues resulting from severe weather, among others. In considering whether an individual is repeatedly failing to timely file documents pursuant to an Immigration Judge's order, as stated in 8 CFR 1003.124(a)(2) (proposed), likely relevant factors would include, but not be limited to, technical difficulties with filing if filing electronically; emergency medical or familial issues; or other similar, external factors that repeatedly prevented the individual from filing documents pursuant to the Immigration Judge's order.</P>
                <P>
                    Similarly, the term “repeated failure,” as used in 8 CFR 1003.124(a)(1) and (2) (proposed), is intended to capture persistent and sustained failures that delay, disrupt, or obstruct the adjudicatory process. Immigration Judges would consider the total number of failures, their proximity to each other, the severity of the failures (
                    <E T="03">e.g.,</E>
                     whether the failure is being a few minutes late versus not appearing at all), and the degree of actual prejudice to the conduct of the proceedings, as well as any other relevant factors. The Department expects that, ordinarily, an attorney or representative will not confront these types of external factors on a regular basis such that it would result in repeated inexcusable delays or absences.
                </P>
                <P>
                    Additionally, “disorderly or abusive behavior or language in and around the courtroom and before the Immigration Judge,” as stated in 8 CFR 1003.124(a)(3) (proposed), includes, but is not limited to, behavior or language that impugns the integrity of the court, unfairly maligns the competence or impartiality of the presiding Immigration Judge, is defamatory or slanderous, or inappropriately accosts any individual in the courtroom.
                    <FTREF/>
                    <SU>8</SU>
                      
                    <E T="03">See</E>
                     8 CFR 1003.124(a)(3) (proposed). These types of abusive language in any filing with the Immigration Court also constitute sanctionable conduct. 
                    <E T="03">Id.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         To the extent that an attorney or representative has concerns about an Immigration Judge's conduct, they may raise such concerns by filing a complaint with EOIR's Judicial Conduct and Professionalism Unit. 
                        <E T="03">See</E>
                         EOIR PM 26-03, 
                        <E T="03">Judicial Conduct and Professionalism</E>
                         (Mar. 20, 2026), 
                        <E T="03">https://www.justice.gov/eoir/media/1432036/dl?inline</E>
                         [
                        <E T="03">https://perma.cc/HZ6F-EJSN</E>
                        ].
                    </P>
                </FTNT>
                <P>
                    The fourth type of sanctionable conduct includes knowingly or recklessly making a false statement of material fact or law or offering false evidence. 
                    <E T="03">See</E>
                     8 CFR 1003.124(a)(4) 
                    <PRTPAGE P="47982"/>
                    (proposed). Importantly, for attorneys and representatives, failing to take appropriate remedial measures after receiving notice of such falsity, or when the attorney or representative reasonably should have known of the falsity, of either a previous statement of material law or fact or previously offered material evidence, encompasses the same conduct that is sanctionable for practitioners under 8 CFR 1003.102(c).
                    <SU>9</SU>
                    <FTREF/>
                     Id.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         Currently, 8 CFR 1003.102(c) notes a practitioner's obligation to take remedial measures regarding false evidence, but not regarding false statements of material law or fact. That distinction has no basis in the professional responsibility obligations of practitioners. 
                        <E T="03">See, e.g.,</E>
                         Model Rule of Prof. Conduct 3.3(a)(1) (“A lawyer shall not knowingly make a false statement of fact or law to a tribunal or 
                        <E T="03">fail to correct a false statement of material fact or law previously made to the tribunal by the lawyer.</E>
                        ” (emphasis added)). Accordingly, and consistent with the bases for contemptuous conduct subject to a civil money penalty, the proposed rule would correct that oversight. 
                        <E T="03">See</E>
                         8 CFR 1003.102(c) (proposed).
                    </P>
                </FTNT>
                <P>The last type of sanctionable conduct proposed by the rule includes willfully misleading, misinforming, threatening, or deceiving any person (including a party to a case or an officer or employee of the Department), concerning any relevant matter relating to a case, and applies to any individual who may be subject to sanctions by civil money penalty. 8 CFR 1003.124(a)(5) (proposed).</P>
                <P>Overall, these sanctionable forms of conduct directly interfere with the Immigration Courts' ability to conduct proceedings in a fair and efficient manner. To ensure that the contempt authority works to promote the efficient and fair adjudication of proceedings, the proposed rule specifies that an Immigration Judge will only be able to initiate the proposed civil money penalty process if the Immigration Judge makes a prima facie determination, based on the circumstances of the case, that the charged conduct did, in fact, delay, disrupt, or obstruct the adjudicatory process. 8 CFR 1003.124(a) (proposed).</P>
                <P>
                    Like the standards applied in Federal courts, these standards are applicable to conduct that occurs inside or outside of the courtroom. 
                    <E T="03">See</E>
                     18 U.S.C. 401 (authorizing a court to sanction misbehavior that occurs “in its presence or so near thereto as to obstruct the administration of justice,” for “[m]isbehavior of any of its officers in their official transactions,” and for “[d]isobedience or resistance to its lawful writ, process, order, rule, decree, or command”); 
                    <E T="03">see also Int'l Union, United Mine Workers of Am.</E>
                     v. 
                    <E T="03">Bagwell,</E>
                     512 U.S. 821, 833 (1994) (explaining that certain contemptuous conduct occurring outside of the courtroom “impede[s] the court's ability to adjudicate the proceedings before it and thus touch[es] upon the core justification for the contempt power”). In this proposed rule, for example, the disorderly or abusive behavior may occur in the court waiting room, hallway, or at the filing window. Disorderly or abusive language in written filings may also serve as the basis for sanctions.
                </P>
                <HD SOURCE="HD2">D. Process for Sanctioning by Civil Money Penalty</HD>
                <P>
                    The Department is also proposing a detailed process for Immigration Judges to follow to impose sanctions for contemptuous conduct by civil money penalty. 
                    <E T="03">See</E>
                     8 CFR 1003.125 (“Required warning before initiating the civil money penalty process.”); 1003.126 (“Initiation of the civil money penalty process.”); and 1003.127 (“Decision by the Chief Immigration Judge or designee.”) (proposed). These proposed procedures ensure that the imposition of a civil money penalty is used as an exceptional tool that should be rarely invoked. 
                    <E T="03">See, e.g., Nelson</E>
                     v. 
                    <E T="03">Steiner,</E>
                     279 F.2d 944, 948 (7th Cir. 1960) (“The power to punish for contempt is to be sparingly used . . . .” (citation omitted)).
                </P>
                <HD SOURCE="HD3">1. Warning of Violation Before Imposition of Civil Money Penalty</HD>
                <P>
                    In general, the proposed rule requires the Immigration Judge to provide the covered individual with a clear and unambiguous warning that a violation has occurred before initiating the civil money penalty process. 8 CFR 1003.125(a) (proposed); 
                    <E T="03">cf.</E>
                     Fed. R. Crim. P. 42(a)(1) (notice requirement applies). If the covered individual engages in the same misconduct within one year from the date of issuance of the warning, no further warning is required before initiating the civil money penalty process. 8 CFR 1003.125(a), 1003.126(a) (proposed).
                </P>
                <P>
                    Procedurally, the Immigration Judge will provide either an oral or written warning, depending on whether the individual is present before the Immigration Judge when the conduct occurs. 8 CFR 1003.125(b) (proposed). If an oral warning is given, the Immigration Judge must memorialize the warning in writing as soon as practicable. 
                    <E T="03">Id.</E>
                     Any written warning or written memorialization of an oral warning will then be served on the individual. 
                    <E T="03">Id.</E>
                </P>
                <P>Substantively, the warning must describe the specific conduct; explain why the conduct is sanctionable under the applicable contempt regulations; notify the individual that continuing to engage in the same conduct may result in the initiation of contempt proceedings and the imposition of a civil money penalty; and notify the individual that they may respond to the warning within 10 days of issuance of the warning. 8 CFR 1003.125(c), (d) (proposed).</P>
                <P>
                    This warning will ensure that the individual is provided clear and unambiguous notice of their conduct and the potential effects of continuing that conduct. 8 CFR 1003.125(a), (c) (proposed). To achieve this purpose, the Immigration Judge should provide the warning as close in time as reasonably possible to the contemptuous conduct. 8 CFR 1003.125(a)-(b) (proposed). Moreover, the Immigration Judge's warning must detail the specific conduct that has occurred, and a standing order or a generic discussion not tied to the specific conduct at issue does not satisfy the requirement of a warning under this proposed rule.
                    <SU>10</SU>
                    <FTREF/>
                     8 CFR 1003.125(c)(1) (proposed).
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Nothing in this proposed rule would prohibit an Immigration Judge from issuing a standing order regulating conduct within his or her courtroom, as long as the order is consistent with applicable law and policy. 
                        <E T="03">See</E>
                         EOIR Policy Memorandum 20-09, 
                        <E T="03">The Immigration Court Practice Manual and Orders</E>
                         (Feb. 13, 2020), 
                        <E T="03">https://www.justice.gov/eoir/reference-materials/OOD2009/dl</E>
                         [
                        <E T="03">https://perma.cc/76TJ-TMKP</E>
                        ]. Nonetheless, while the violation of a standing order may serve as evidence of contemptuous conduct, the presence of a standing order itself is insufficient to constitute a warning necessary prior to seeking to impose a civil money penalty.
                    </P>
                </FTNT>
                <P>
                    Once a warning has been issued, an individual may, but is not required to, respond to the Immigration Judge's warning, either on the record orally at the time of the warning or in writing within 10 days of the issuance of the warning. 8 CFR 1003.125(d) (proposed). Such response, if any, will be included in the Record of Proceeding for the relevant case in which the contemptuous conduct occurred, as well as the separate contempt Record of Proceeding if a civil money penalty process is subsequently initiated.
                    <FTREF/>
                    <SU>11</SU>
                      
                    <E T="03">Id.</E>
                     Any contemptuous response to a warning may also be sufficient to 
                    <PRTPAGE P="47983"/>
                    initiate the civil money penalty process. 
                    <E T="03">Id.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         When an Immigration Judge initiates a civil money penalty process based on a contempt allegation, the Immigration Court will create a contempt Record of Proceeding, separate from the underlying case Record of Proceeding, and ensure that relevant matters in the underlying immigration proceeding(s) that gave rise to the initiation of the civil money penalty are entered or described in the contempt Record of Proceeding. 8 CFR 1003.126(e) (proposed). Any oral statements given on the record, including any oral response to the Immigration Judge's warning, will be transcribed for inclusion in the contempt Record of Proceeding. 
                        <E T="03">Id.</E>
                         Any oral statements that were not recorded must be summarized in writing by the Immigration Judge for inclusion in the contempt Record of Proceeding. 
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>If the individual continues to engage in the same contemptuous conduct after the warning is given, the proposed rule requires the Immigration Judge to make a finding on the record—which can be an oral statement on the record or a written statement added to the Record of Proceeding—that such conduct has continued to occur. 8 CFR 1003.125(e) (proposed).</P>
                <P>
                    Additionally, the warning would not be limited to the particular proceeding in which the initial contemptuous conduct occurred but, rather, would apply across all future proceedings. 8 CFR 1003.125(a) (proposed). For example, if an Immigration Judge issues a warning to an individual for engaging in contemptuous conduct and that case then changes venue to another Immigration Court, that warning—which will have been made or memorialized in writing and contained within the Record of Proceeding of the underlying case—would still be a valid foundation for the initiation of the civil money penalty process in the new Immigration Court if the individual continues to engage in the same contemptuous conduct that was the subject of the warning. 
                    <E T="03">See id.</E>
                     Similarly, as another example, if an individual is warned about the use of abusive language under § 1003.124(a)(3) (proposed) in a specific proceeding, that warning would be effective for any further abusive conduct under § 1003.124(a)(3) (proposed) by that individual in any other proceedings, even proceedings unrelated to the initial one.
                </P>
                <P>Furthermore, under § 1003.125(a) (proposed), the Immigration Judge will not be required to issue a warning where a previous order imposing a civil money penalty had been issued on a covered individual for continuing to engage in the same type of contemptuous conduct. In such instances, the previous order will serve as a warning for the imposition of future civil money penalties if the individual continues to engage in the same conduct within one year of the previous order.</P>
                <HD SOURCE="HD3">2. Notice of Intent To Impose Civil Money Penalty</HD>
                <P>
                    If, after issuing a warning, the Immigration Judge makes a finding of continued contemptuous conduct on the record, the Immigration Judge may initiate the civil money penalty process. 
                    <E T="03">See</E>
                     8 CFR 1003.126(a) (proposed).
                </P>
                <P>
                    Under the proposed rule, the Immigration Judge initiates the civil money penalty process by serving a Notice of Intent to Impose Civil Money Penalty (“CMP Notice”) on the individual. 8 CFR 1003.126(b)(1) (proposed). The CMP Notice may be served on the individual by personal service or mail, and if the individual is a practitioner before EOIR, the CMP Notice may also be served electronically using the practitioner's email address provided through eRegistry. 
                    <E T="03">Id.</E>
                     This process must be initiated as soon as practicable after a finding on the record of continued contemptuous conduct, and in no case later than one year after the most recent related warning. 8 CFR 1003.126(a) (proposed).
                </P>
                <P>The CMP Notice must include the following items: (1) the name and address of the individual; (2) a factual description of the conduct in question; (3) the alleged charge or charges of contemptuous conduct; (4) an explanation of how the conduct in question delayed, disrupted, or obstructed the adjudicatory process; (5) a brief description of any warning(s) provided; and (6) the Immigration Judge's proposed civil money penalty amount. 8 CFR 1003.126(b)(2) (proposed).</P>
                <P>
                    The CMP Notice will also inform the individual of the procedures for the civil money penalty process. 8 CFR 1003.126(b)(3) (proposed). This will include informing the individual that the matter is being referred to the Chief Immigration Judge for a decision and that he or she has the right to file a response with the Chief Immigration Judge within 30 days of issuance of the CMP Notice; the right to file one motion to extend the time to respond for up to 7 days for good cause; and the right to be represented at the individual's own expense. 8 CFR 1003.126(b)(3)(i)-(iv) (proposed). The individual's response will be required to include the following information: (1) the individual's name; (2) the contempt proceeding case number; (3) the individual's A-number 
                    <SU>12</SU>
                    <FTREF/>
                     or EOIR identification number (if any); 
                    <SU>13</SU>
                    <FTREF/>
                     (4) the individual's current physical and email addresses; (5) the individual's position on the charge(s) in the CMP Notice; and (6) any written or documentary evidence that the individual wishes to provide in support of the individual's position. 8 CFR 1003.126(d) (proposed). The CMP Notice, any responses to the CMP Notice, and related filings will be included in the contempt Record of Proceeding. 8 CFR 1003.126(e) (proposed).
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         An Alien Registration Number (“A-number”) is a unique identification number that DHS assigns to an alien.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         An EOIR identification number (“EOIR ID”) is an identifier used by EOIR for attorneys and fully accredited representatives to indicate that such an individual has registered with EOIR. EOIR requires attorneys and fully accredited representatives to register with the agency to practice before the Immigration Courts and the Board. To receive an EOIR ID, attorneys and fully accredited representatives must (1) register online through the eRegistry portal, and (2) appear in person at an approved location to present photo identification for identity validation. Upon completion of both steps, EOIR issues a unique EOIR ID to the individual by email. For further information, see EOIR, Attorneys and Fully Accredited Reps—How to Register (Feb. 2024), 
                        <E T="03">https://www.justice.gov/eoir/media/1358206/dl?inline</E>
                         [
                        <E T="03">https://perma.cc/F3M3-N3SM</E>
                        ].
                    </P>
                </FTNT>
                <P>
                    The proposed rule's inclusion of this 30-day response period, as well as the earlier warning and CMP Notice requirements, will ensure that the individual is provided notice of the contemptuous behavior and an opportunity to be heard. 
                    <E T="03">See generally Mullane</E>
                     v. 
                    <E T="03">Cent. Hanover Bank &amp; Trust Co.,</E>
                     339 U.S. 306, 313 (1950) (explaining that notice and an opportunity to be heard must be “appropriate to the nature of the case”). These contempt proceedings are not “required by statute to be determined on the record after opportunity for an agency hearing” and, thus, are not subject to the Administrative Procedure Act's requirements for formal adjudications under 5 U.S.C. 554, 556-57. 
                    <E T="03">Accord</E>
                     INA 240(b)(1), 8 U.S.C. 1229a(b)(1) (not requiring specific hearing procedures for Immigration Judges' contempt authority). However, the proposed rule comports with general due process principles, which require, at a minimum, notice and an opportunity to respond. 
                    <E T="03">See Mullane,</E>
                     339 U.S. at 314. The CMP Notice will ensure that the individual is made aware of the allegations against him or her. The CMP Notice will also inform the individual that he or she has the right to representation at no expense to the government by an attorney or other representative. 8 CFR 1003.126(b)(3)(iv) (proposed).
                </P>
                <P>
                    Additionally, to determine the penalty amount for the CMP Notice, the proposed rule provides a penalty schedule and relevant factors for the Immigration Judge to consider. 
                    <E T="03">See</E>
                     8 CFR 1003.126(c) (proposed).
                </P>
                <P>
                    Lastly, the proposed rule requires all filings by the individual to comply with existing Immigration Court filing procedures. 
                    <E T="03">See</E>
                     8 CFR 1003.126(f) (proposed); 
                    <E T="03">see also</E>
                     8 CFR 1003.31-33 (requiring certain document sizes and English language usage or translation, among other requirements).
                </P>
                <HD SOURCE="HD3">3. Decision by the Chief Immigration Judge or Designee</HD>
                <P>
                    Under the proposed rule, decisions on civil money penalties would be made by the Chief Immigration Judge or his or her designee. Jurisdiction vests, 
                    <PRTPAGE P="47984"/>
                    including over all motions filed, with the Chief Immigration Judge once the CMP Notice is referred to him or her. 8 CFR 1003.127(a) (proposed). The Chief Immigration Judge may not remand the CMP Notice to the Immigration Judge. 8 CFR 1003.127(b) (proposed).
                </P>
                <P>
                    Once the individual files a response to the CMP Notice, or the 30-day response period expires, the Chief Immigration Judge will then issue a written decision determining whether there is clear and convincing evidence that the individual engaged in contemptuous conduct that delayed, disrupted, or obstructed the adjudicatory process. 
                    <E T="03">See</E>
                     8 CFR 1003.127(b)-(d) (proposed). The Chief Immigration Judge will only be able to issue an order finding the individual in contempt and imposing a civil money penalty if clear and convincing evidence demonstrates: (1) that the person charged is a covered individual against whom a civil money penalty may be imposed; (2) the conduct described in the CMP Notice did in fact occur; (3) the conduct described in the CMP Notice falls within the scope of 8 CFR 1003.124(a) (proposed); and (4) the Immigration Judge properly provided a warning, time to respond to the warning, and the CMP Notice. 8 CFR 1003.127(d)(1) (proposed).
                </P>
                <P>In making this decision, the proposed rule limits the ability of the Chief Immigration Judge to engage in additional factfinding by only allowing for the consideration of the contempt Record of Proceeding as described in § 1003.126(e) (proposed). 8 CFR 1003.127(b) (proposed).</P>
                <P>If the Chief Immigration Judge determines that these requirements were met, the order is required to specify the civil money penalty amount imposed and provide instructions regarding the payment of the penalty. 8 CFR 1003.127(d)(2) (proposed). If, on the other hand, the Chief Immigration Judge determines that the evidence is insufficient to impose a civil money penalty, the Chief Immigration Judge will issue an order dismissing the CMP Notice with prejudice, and no further review is provided. 8 CFR 1003.127(d)(3)-(4) (proposed).</P>
                <P>
                    The Chief Immigration Judge or the designee must serve a copy of his or her order on the individual or, if represented, the individual's attorney or representative. 8 CFR 1003.127(d)(5) (proposed). If the individual is represented by an attorney or representative, the Chief Immigration Judge's order will be served electronically using the email address that the individual's attorney or representative has provided through eRegistry. 
                    <E T="03">Id.</E>
                     If the individual is not represented, the Chief Immigration Judge's order may be served on the individual by personal service or mail. 
                    <E T="03">Id.</E>
                     If the unrepresented individual is a practitioner before EOIR, service may also be made electronically using the practitioner's email address provided through eRegistry. 
                    <E T="03">Id.</E>
                     These methods of service are consistent with general EOIR practice. 
                    <E T="03">See</E>
                     8 CFR 1003.32(b); 8 CFR 1003.37.
                </P>
                <P>
                    The Chief Immigration Judge also may designate a permanent Deputy Chief Immigration Judge to conduct such a review in his or her place, provided that such designee (1) is not the present first-line supervisor of the Immigration Judge who issued the CMP Notice; and (2) is not conducting a review involving an alien who has previously appeared in immigration proceedings before the designee. 8 CFR 1003.127(a) (proposed). If the Chief Immigration Judge is the Immigration Judge who issued the CMP Notice, the EOIR Director will designate a senior adjudicator outside of the Office of the Chief Immigration Judge to make a decision. 
                    <E T="03">Id.</E>
                </P>
                <HD SOURCE="HD3">4. Amount of the Civil Money Penalty</HD>
                <P>
                    In all cases, the civil money penalty ordered will be based on the penalty schedule included in the proposed rule. 
                    <E T="03">See</E>
                     8 CFR 1003.126(c)(1) (proposed). After considering all relevant factors, the Chief Immigration Judge will be able to issue a penalty of an amount according to the following ranges: $1,000 to $1,500 for a first contempt order; $1,500 to $2,500 for a second contempt order; and $2,500 to $3,500 for any subsequent contempt orders. 
                    <E T="03">Id.</E>
                     The Department believes these amounts properly account for the important purposes served by the statutory contempt authority; are sufficient, in combination with other sanctions and procedures that may be available under existing laws and regulations, to deter the types of contemptuous conduct covered in this proposed rule; and are only issuable in the context of the significant procedural protections put into place, including official warnings, a civil penalty process, and administrative appeal availability.
                </P>
                <P>These ranges will also allow the penalty amount to be properly tailored to the conduct in question. Relevant factors to be considered include the number of offenses, the harm resulting from the sanctionable conduct, the remarkable nature of the conduct, and the deterrent effect of the penalty. 8 CFR 1003.126(c)(2) (proposed). In ordering a civil money penalty, the Chief Immigration Judge will not be able to increase the penalty amount stated in the CMP Notice. 8 CFR 1003.127(d)(2) (proposed).</P>
                <P>
                    The Department considered leaving the civil money penalty amounts to the Immigration Judge's discretion, similar to the discretion afforded to Federal court judges. 
                    <E T="03">See generally Paramedics Electromedicina Comercial, Ltda</E>
                     v. 
                    <E T="03">GE Med. Sys. Info. Techs., Inc.,</E>
                     369 F.3d 645, 657 (2d Cir. 2004) (noting that, for civil contempt purposes, judges have “broad discretion” to set a penalty to coerce compliance). However, the Department determined that providing a generally applicable penalty schedule will better promote consistency amongst the Immigration Courts.
                </P>
                <P>
                    Separately, the Department notes that, in the future, it will review the penalty amounts for any potential further adjustment, including periodically to account for inflation. 
                    <E T="03">Accord</E>
                     Federal Civil Monetary Penalties Inflation Adjustment Act of 1990, Public Law 101-410, sec. 4, as amended, (28 U.S.C. 2461 note) (requiring Federal agencies to adjust statutory penalties for inflation annually to maintain their deterrent effect).
                </P>
                <HD SOURCE="HD2">E. Appeals</HD>
                <P>
                    The rule proposes to include an appeal process to provide an additional layer of procedural protection to individuals found in contempt. 
                    <E T="03">See</E>
                     8 CFR 1003.128 (“Appeals.”) (proposed). Following the Chief Immigration Judge's order imposing a civil money penalty, the individual found in contempt will be able to challenge that order by filing an appeal with the Board. 
                    <E T="03">Id.</E>
                     The Board will review the Chief Immigration Judge's decision consistent with 8 CFR 1003.1(d)(3), similar to how it reviews decisions of adjudicating officials in disciplinary proceedings involving practitioners or recognized organizations. 
                    <E T="03">See</E>
                     8 CFR 1003.1(b)(13); 8 CFR 1003.106(c). The Chief Immigration Judge's decision dismissing the CMP Notice with prejudice is not subject to appeal. 8 CFR 1003.127(d)(4) (proposed). The Chief Immigration Judge's order becomes a final agency decision unless the individual files a timely notice of appeal. 8 CFR 1003.127(e) (proposed). The appeal is subject to a proposed $675 filing fee, 8 CFR 1103.7(b)(1) (proposed), which is the same amount as the fee currently charged for appeals from a decision of an adjudicating official in a practitioner disciplinary case under section 286(m) of the INA, 8 U.S.C. 1356(m), as discussed in Section V.C of this preamble. To be timely, the appeal must be filed within 10 days from the date of the order and include the required filing 
                    <PRTPAGE P="47985"/>
                    fee or fee waiver form. 8 CFR 1003.128(a) (proposed).
                </P>
                <P>
                    As part of the proposed appeal process, the individual is required to simultaneously serve a copy of the appeal and other related filings on the EOIR General Counsel. 8 CFR 1003.128(a) (proposed). EOIR's General Counsel, or the EOIR disciplinary counsel where so designated, will represent the agency on appeal and will be permitted to submit a brief under the briefing schedule issued by the Board. 
                    <E T="03">Id.;</E>
                     8 CFR 1003.3(c)(1) (proposed). The Board will set a simultaneous briefing schedule with briefs due from both parties within 20 days of the Board order setting the schedule and in no case more than 35 days after the appeal was filed. 8 CFR 1003.3(c)(1) (proposed). Following review, the Board will issue a written decision affirming, modifying, or vacating with prejudice the civil money penalty. 
                    <E T="03">See</E>
                     8 CFR 1003.128(d)(2) (proposed). The Board will not be permitted to set a penalty amount above the amount stated in the CMP Notice or to remand the case for further proceedings.
                    <FTREF/>
                    <SU>14</SU>
                      
                    <E T="03">Id.</E>
                     The Board's order will become the final agency decision on the date the order is issued. 
                    <E T="03">Id.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         If the individual subject to a civil money penalty is an alien described in 8 CFR 1003.123(a)(2) (proposed) and either the Chief Immigration Judge or his or her designee or the Board receives information that the alien has been removed prior to the issuance of a decision, then, as appropriate, the Chief Immigration Judge or his or her designee will dismiss the CMP Notice or the Board will vacate the civil money penalty. 8 CFR 1003.127(d)(3), 1003.128(d)(2) (proposed).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">F. Other Provisions</HD>
                <HD SOURCE="HD3">1. Limited Sanction</HD>
                <P>
                    The proposed rule includes instructions to EOIR's adjudicators that the contempt authority is an exceptional tool that should be used sparingly. 
                    <E T="03">See</E>
                     8 CFR 1003.122(b) (proposed). The proposed rule also explains that Immigration Judges should attempt to deter or redress contemptuous conduct through other reasonably available means, resorting to the initiation of the civil money penalty process only after other reasonably available means have failed to restore proper courtroom conduct. 8 CFR 1003.122(b) (proposed).
                </P>
                <P>
                    The proposed rule also explains that the contempt authority is independent of other sanctions or procedures. 8 CFR 1003.122(c) (proposed). Those include, but are not limited to, attorney or representative discipline pursuant to subpart G of 8 CFR part 1003; admitting evidence described in a pre-hearing statement as unopposed when evidentiary objections to the pre-hearing statement are required but not timely received, as provided in 8 CFR 1003.21(c); and deeming the opportunity to file an application or document as waived or abandoned, 
                    <E T="03">see, e.g.,</E>
                     8 CFR 1003.31(h).
                </P>
                <P>Lastly, the proposed rule explicitly states that contempt authority under proposed subpart H of 8 CFR part 1003, does not apply to subpoena enforcement pursuant to 8 CFR 1003.35(b). 8 CFR 1003.122(d) (proposed).</P>
                <HD SOURCE="HD3">2. Payment of the Civil Money Penalty</HD>
                <P>
                    The proposed rule includes instructions regarding the deadline for paying civil money penalties and the consequences of failing to pay a civil money penalty as ordered. 8 CFR 1003.129 (proposed). An individual found in contempt will be required to pay the penalty within 30 days of the Board's order becoming final. 8 CFR 1003.129(a) (proposed). In other words, if an individual does not file an appeal, the individual will be required to pay the penalty within 30 days of the Chief Immigration Judge's order becoming final, or if an individual files an appeal, within 30 days of the Board's decision affirming or modifying a civil money penalty.
                    <FTREF/>
                    <SU>15</SU>
                      
                    <E T="03">Id</E>
                    .
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         If the individual seeks further Federal court review of the Board's order imposing a civil money penalty for contempt, the payment would then be due within 30 days of a final court decision upholding the civil money penalty.
                    </P>
                </FTNT>
                <P>If a practitioner (attorney or accredited representative) fails to timely pay a required civil money penalty, the EOIR disciplinary counsel will move to immediately suspend the practitioner from practice before EOIR. 8 CFR 1003.129(c) (proposed). Upon proof of payment of the penalty, the practitioner will then be able to move to have the suspension set aside. 8 CFR 1003.129(c)(4) (proposed).</P>
                <HD SOURCE="HD3">3. Oversight</HD>
                <P>
                    The proposed rule specifically instructs the Chief Immigration Judge to maintain oversight over Immigration Judges' use of the civil money penalty authority afforded by section 240(b)(1) of the INA, 8 U.S.C. 1229a(b)(1), and proposed subpart H of 8 CFR part 1003. 
                    <E T="03">See</E>
                     8 CFR 1003.130 (proposed).
                </P>
                <P>
                    Consistent with preexisting regulatory provisions, Immigration Judges will also receive appropriate training and guidance on the proper use of their authority to sanction by civil money penalty. 
                    <E T="03">See, e.g.,</E>
                     8 CFR 1003.0(b)(1)(vii) (establishing that the Director shall have the authority to “[p]rovide for comprehensive, continuing training and support for Board members, immigration judges, and EOIR staff in order to promote the quality and consistency of adjudications”), 1003.9(b)(2). Further, the proposed rule reiterates that an Immigration Judge's exercise of the authority to issue a CMP Notice is subject to the supervision of the Chief Immigration Judge; that the Chief Immigration Judge must conduct periodic reviews of that authority; and that, after consultation with the Director, the Chief Immigration Judge may suspend any Immigration Judge's exercise of that authority for up to 30 days if that Immigration Judge has improperly applied or misused that authority. 8 CFR 1003.130 (proposed). These provisions are consistent with the Chief Immigration Judge's general authority to oversee Immigration Court operations and the authority to make reports and inspections and take corrective action. 8 CFR 1003.9(b)(4). Any such suspension of an Immigration Judge's contempt authority by the Chief Immigration Judge will be conducted through a standing order.
                    <SU>16</SU>
                    <FTREF/>
                     8 CFR 1003.130 (proposed).
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         The Chief Immigration Judge's use of the authority to issue a CMP Notice will be subject to the supervision of the Director. 8 CFR 1003.0(b); 28 CFR 0.115(a). The Director will conduct periodic reviews of that authority by the Chief Immigration Judge and may suspend the Chief Immigration Judge's exercise of that authority for up to 30 days if the authority has been improperly applied or misused. The proposed rule authorizes the Director to issue a standing order to memorialize any such suspension of the Chief Immigration Judge's contempt authority. 8 CFR 1003.130 (proposed).
                    </P>
                </FTNT>
                <P>
                    To ensure further oversight, the proposed rule makes clear that complaints or allegations of misconduct regarding the threat or exercise of authority by an Immigration Judge should be directed to the Immigration Judge's supervisor, EOIR's Judicial Conduct and Professionalism Unit, or the Department of Justice Office of Professional Responsibility (“OPR”). 
                    <E T="03">See</E>
                     8 CFR 1003.109 (proposed). In doing so, the proposed rule revises 8 CFR 1003.109 to make clear that complaints regarding the behavior of EOIR adjudicators, including Immigration Judges, need not be directed solely to OPR and may be directed to the adjudicator's supervisor or to EOIR's Judicial Conduct and Professionalism Unit. 
                    <E T="03">Id.</E>
                     This clarification is consistent with longstanding practice; 
                    <SU>17</SU>
                    <FTREF/>
                     guidance from former Attorney General Alberto 
                    <PRTPAGE P="47986"/>
                    Gonzales; 
                    <SU>18</SU>
                    <FTREF/>
                     and other regulatory authority.
                    <SU>19</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">See</E>
                         EOIR, 
                        <E T="03">Judicial Complaint Process</E>
                         (Feb. 2023), 
                        <E T="03">https://www.justice.gov/eoir/page/file/1100946/download</E>
                         [
                        <E T="03">https://perma.cc/Q4H9-SG9Q</E>
                        ].
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         Memorandum from the Attorney General for the Deputy Attorney General, Assistant Attorney General for Legal Policy, Director of the Executive Office for Immigration Review, and the Acting Chief Immigration Judge (Aug. 9, 2006) (directing EOIR to develop an adjudicator complaint process that clearly defines the roles of EOIR, OPR, and the Office of the Inspector General in handling adjudicator complaints), 
                        <E T="03">https://www.justice.gov/sites/default/files/ag/legacy/2009/02/10/ag-080906.pdf</E>
                         [
                        <E T="03">https://perma.cc/V79E-T87Q</E>
                        ].
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See, e.g.,</E>
                         8 CFR 1003.0(b)(1)(viii) (instructing the Director to “[i]mplement a process for receiving, evaluating, and responding to complaints of inappropriate conduct by EOIR adjudicators”).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Professional Conduct for Practitioners</HD>
                <P>
                    “Engag[ing] in contumelious or otherwise obnoxious conduct” is already a ground for practitioner discipline. 8 CFR 1003.102(g). The proposed rule clarifies—consistent with the Department's previous statements regarding contempt proceedings and practitioner discipline 
                    <SU>20</SU>
                    <FTREF/>
                    —that contumelious conduct includes conduct for which a civil money penalty has been assessed under proposed subpart H of 8 CFR part 1003. 8 CFR 1003.102(g) (proposed). The rule also proposes to add a ground for practitioner discipline for repeatedly failing to pay any ordered civil money penalty to promote compliance with such orders. 8 CFR 1003.102(x) (proposed).
                </P>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         Professional Conduct for Practitioners—Rules and Procedures, 65 FR 39513, 39518-19 (Jun. 27, 2000) (“It is expected that the contempt regulations, once published, will provide that a practitioner can be disciplined under the Professional Conduct Rules when the practitioner has been sanctioned for contemptuous conduct by an Immigration Judge pursuant to 8 U.S.C. 1229a(b)(1). A finding of contempt will become a prerequisite to the imposition of disciplinary action pursuant to this subsection.”).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">G. Effective Date</HD>
                <P>The provisions of the proposed rule would apply only to conduct in the Immigration Courts on or after the effective date of the final rule.</P>
                <HD SOURCE="HD1">V. Regulatory Requirements</HD>
                <HD SOURCE="HD2">A. Regulatory Flexibility Act</HD>
                <P>
                    The Department has reviewed this proposed regulation in accordance with the Regulatory Flexibility Act (“RFA”). 
                    <E T="03">See</E>
                     5 U.S.C. 605(b). As proposed, this rule regulates attorneys and accredited representatives, which qualify as “small entities” under the RFA. 
                    <E T="03">See</E>
                     5 U.S.C. 601(3)-(4), (6). However, the Department has determined that the proposed rule will not have a significant economic impact on a substantial number of small entities. As indicated in the proposed rule, the imposition of a civil money penalty is intended to be an extraordinary sanction that is used infrequently in response to misconduct occurring before an Immigration Judge.
                </P>
                <HD SOURCE="HD2">B. Unfunded Mandates Reform Act of 1995</HD>
                <P>
                    The proposed rule will not result in the expenditure by State, local, and Tribal governments, in the aggregate, or by the private sector, of $100 million or more in any one year (adjusted for inflation), and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995, codified at 2 U.S.C. 1501 
                    <E T="03">et seq.</E>
                </P>
                <HD SOURCE="HD2">C. Executive Orders 12866 (Regulatory Planning and Review) and 13563 (Improving Regulation and Regulatory Review)</HD>
                <P>The Office of Information and Regulatory Affairs has determined that the proposed rule is a “significant regulatory action” under section 3(f) of Executive Order 12866. Accordingly, the proposed regulation has been submitted to the Office of Management and Budget (“OMB”) for review. The Department certifies that the proposed regulation has been drafted in accordance with the principles of Executive Order 12866, section 1(b), and Executive Order 13563. Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health, and safety effects). Executive Order 13563 emphasizes the importance of using the best available methods to quantify costs and benefits, reducing costs, harmonizing rules, and promoting flexibility.</P>
                <P>
                    The Department believes that the proposed rule will provide significant benefits relating to EOIR proceedings. 
                    <E T="03">See</E>
                     Section 1(b)(6) of E.O. 12866. The proposed rule will help ensure the efficiency and integrity of these proceedings by setting out enforcement mechanisms for the sanctionable conduct of individuals appearing before the Immigration Court system. The Department anticipates that allowing Immigration Judges to warn and institute the civil money penalty process against those individuals who are disruptive to the proceedings will encourage those appearing before the Immigration Courts to act with decorum and will have a deterrent effect on overall sanctionable conduct, thereby reducing the time Immigration Judges spend attempting to enforce courtroom decorum instead of adjudicating cases.
                </P>
                <P>
                    In contrast, the costs on the public that the proposed rule will impose are the individual liabilities for individuals who may be subject to a civil money penalty for actions or inactions in contempt of the Immigration Judge's authority, as well as the filing fee for any appeals of the Chief Immigration Judge's civil money penalty order. The Department is proposing a $675 appeal filing fee to match the cost recovery portion of the Form EOIR-45, Notice of Appeal from a Decision of an Adjudicating Official in Practitioner Disciplinary Case.
                    <SU>21</SU>
                    <FTREF/>
                     The Department anticipates that the Board's adjudication of an appeal in contempt proceedings will be substantially similar to that in attorney discipline cases, such that the filing fees should be consistent.
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         On July 4, 2025, President Trump signed the One Big Beautiful Bill Act (H.R. 1) (“OBBBA”), which added an additional $1,325 fee for attorney discipline appeals. 
                        <E T="03">See</E>
                         Public Law 119-21, 139 Stat. 72 at sec. 100013(f). OBBBA did not include any additional fees relating to contempt, so the Department is comparing its contempt appeal fee to the preexisting $675 EOIR fee for attorney discipline cases, which itself was based on a 2018 fee study of relevant adjudication costs. 
                        <E T="03">See</E>
                         Executive Office for Immigration Review; Fee Review, 85 FR 11866, 11870 (Feb. 28, 2020).
                    </P>
                </FTNT>
                <P>
                    Because the Department intends for the civil money penalty to be an “extraordinary” sanction, 
                    <E T="03">see</E>
                     8 CFR 1003.122(b) (proposed), the Department does not anticipate that a significant number of individuals will ultimately be subject to such a penalty (for example, in Section V.F of this preamble, the Department estimates an approximate 50 appeals per year for Paperwork Reduction Act purposes).
                    <SU>22</SU>
                    <FTREF/>
                     Rather, the Department expects that, in most cases, warnings issued under this proposed rule will be sufficient to deter contemptuous conduct without having to initiate the civil money penalty process.
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See</E>
                         EOIR, List of Currently Disciplined Practitioners (July 13, 2026), 
                        <E T="03">https://www.justice.gov/eoir/list-of-currently-disciplined-practitioners</E>
                         [
                        <E T="03">https://perma.cc/XQ6Y-LKAG</E>
                        ] (showing immediate suspension or final disciplinary action (not including reinstatement) imposed on approximately 46 practitioners in 2025 and 37 practitioners in 2026 to date). The Department acknowledges that the individuals subject to a civil money penalty under this proposed rule, 
                        <E T="03">see</E>
                         8 CFR 1003.123 (proposed), is a broader group of individuals than practitioners subject to EOIR's professional conduct rules, 
                        <E T="03">see</E>
                         8 CFR 1003.101(b), which may result in more individuals receiving or appealing a civil money penalty than individuals subject to discipline. Nonetheless, the Department believes this is an appropriate analogy.
                    </P>
                </FTNT>
                <P>
                    Otherwise, the Department does not believe that, broadly speaking, the proposed rule could be said to burden the parties in EOIR proceedings, as the proposed rule simply provides for civil money penalties where misconduct 
                    <PRTPAGE P="47987"/>
                    prevents efficiencies. Moreover, any burden would only be held by a covered individual who engaged in contemptuous conduct that delayed, disrupted, or obstructed the adjudicatory process, which holds comparatively little weight in balancing the costs and benefits of the proposed rule.
                </P>
                <HD SOURCE="HD2">D. Executive Order 13132 (Federalism)</HD>
                <P>The proposed rule will not have substantial direct effects on the States, on the relationship between the National Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with section 6 of Executive Order 13132, the proposed rule does not have sufficient federalism implications to warrant the preparation of a federalism summary impact statement.</P>
                <HD SOURCE="HD2">E. Executive Order 12988 (Civil Justice Reform)</HD>
                <P>The proposed rule meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988.</P>
                <HD SOURCE="HD2">F. Paperwork Reduction Act</HD>
                <P>
                    Under the procedures established by the Paperwork Reduction Act of 1995 (“PRA”) (44 U.S.C. 3501, 
                    <E T="03">et seq.</E>
                    ), Federal agencies must obtain approval from OMB for each collection of information they conduct, sponsor, or require through regulations. A person is not required to respond to a collection of information by a Federal agency unless the collection displays a valid OMB control number. The Information Collection Requests (“ICRs”) for the proposed new and revised information collections described below have been forwarded to OMB for review and comment. In compliance with these requirements, the Department asks for public comments on the following proposed collections of information for which the agency is seeking approval from OMB.
                </P>
                <P>
                    If you have any comments or suggestions, especially on the estimated public burden or associated response time, or if you need a copy of the proposed new or revised information collection instruments with instructions or additional information, please contact the Department as noted in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this preamble. Written comments and suggestions from the public and affected agencies concerning the proposed information collection instruments are encouraged. Comments should be directed to the address listed in the 
                    <E T="02">ADDRESSES</E>
                     section at the beginning of this preamble. Comments should also be submitted to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention: Desk Officer for EOIR, New Executive Building, 725 17th Street NW, Washington, DC 20053. This process complies with 5 CFR 1320.11.
                </P>
                <P>
                    Your comments should address one or more of the following four points: (1) whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the collection of information, including the validity of the methodology and assumptions used; (3) how the Department could enhance the quality, utility, and clarity of the information to be collected; or (4) how the Department could minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology (
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses).
                </P>
                <HD SOURCE="HD3">1. New Information Collection</HD>
                <P>The proposed rule includes one new collection of information: Form EOIR-86, Notice of Appeal of a Civil Money Penalty for Contempt. The proposed new information collection is intended to be used by individuals to appeal to the Board an order of the Chief Immigration Judge finding the individual in contempt and issuing a civil money penalty. An individual is required to complete the form to exercise the appeal rights afforded to the individual under the proposed rule. The proposed new collection of information will help the Board differentiate appeals of decisions involving civil money penalties for contempt from other types of appeals, such as appeals of Immigration Judge decisions in removal proceedings.</P>
                <P>The proposed new collection of information is modeled on the current approved Forms EOIR-26, Notice of Appeal from a Decision of an Immigration Judge, and EOIR-45, Notice of Appeal from a Decision of an Adjudicating Official in a Practitioner Disciplinary Case. Like the Forms EOIR-26 and EOIR-45, the proposed new collection will require the appellant to identify himself or herself, to state the decision being appealed, and to explain the basis for the appeal. The proposed new form will also provide the appellant with instructions as to where and how to serve the EOIR General Counsel as a party to contempt proceedings. Individuals will be able to download and complete the form either electronically or by printing and handwriting responses. Individuals will be able to submit completed forms to EOIR by email, electronically when available, or by regular mail, overnight mail, or hand-delivery.</P>
                <P>The Department estimates that up to 50 individuals will submit an average of one form per year. The Department estimates that the average time to review the proposed form, gather necessary materials, complete the proposed form, and assemble any attachments will be one hour in total. The total public burden of the proposed new collection is estimated to be 50 burden hours (50 respondents × 1 response per respondent × 1 hour per response = 50 burden hours). The Department estimates the upper bound for aggregate costs for all respondents at $39,278 annually, accounting for the following types of estimated costs to members of the public.</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,tp0,p7,7/8,i1" CDEF="s50,r50,10,xs48">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Type of cost</CHED>
                        <CHED H="1">Estimated per response</CHED>
                        <CHED H="1">
                            Estimated
                            <LI>total</LI>
                            <LI>responses</LI>
                            <LI>per year</LI>
                        </CHED>
                        <CHED H="1">Total</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Filing Fee</ENT>
                        <ENT>$675</ENT>
                        <ENT>50</ENT>
                        <ENT>$33,750 per year.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Printing</ENT>
                        <ENT>$0.10 per page × 5 pages × 2 copies = $1.00 per response</ENT>
                        <ENT>50</ENT>
                        <ENT>50 per year.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Postage</ENT>
                        <ENT>$10.10 per response × 2 copies = $20.20 per response</ENT>
                        <ENT>50</ENT>
                        <ENT>1,010 per year.</ENT>
                    </ROW>
                    <ROW RUL="n,n,s">
                        <ENT I="01">Professional Legal Assistance to Complete Form</ENT>
                        <ENT>$89.35 per hour × 1 hour per response = $89.35 per response</ENT>
                        <ENT>50</ENT>
                        <ENT>4,468 per year.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">AGGREGATE ESTIMATED ANNUAL COST TO PUBLIC</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT>39,278 per year.</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="47988"/>
                <P>
                    The aggregate estimated annual cost to the public is the upper bound of estimated costs. There are no capital or start-up costs associated with the form. There is a maximum estimated labor cost of $89.35 per form, based on the national average hourly wage for attorneys as estimated by the Bureau of Labor Statistics. 
                    <E T="03">See</E>
                     BLS, Occupational Employment and Wage Statistics (OEWS) Profiles, Lawyers (May 2025), 
                    <E T="03">https://data.bls.gov/oesprofile/?major_group=230000&amp;occupation=231011&amp;measure=03&amp;areas=INDUSTRY,STATE,MSA</E>
                     [
                    <E T="03">https://perma.cc/AW2X-GKSN</E>
                    ].
                </P>
                <P>The lower bound of aggregate estimated annual cost to the public is $33,750 because printing and postage costs may be avoided if an individual completes the form electronically and submits the form via email and because professional legal assistance is not required to complete the form.</P>
                <HD SOURCE="HD3">2. Revisions to Approved Collections of Information</HD>
                <P>The proposed rule also includes revisions to two currently approved collections of information: Form EOIR-27, Notice of Entry of Appearance as an Attorney or Representative before the Board of Immigration Appeals; and EOIR-28, Notice of Entry of Appearance as an Attorney or Representative before the Immigration Court. These forms were previously approved by OMB under the provisions of the PRA, and the information collections were assigned OMB Control Number 1125-0005 for Form EOIR-27 and 1125-0006 for Form EOIR-28.</P>
                <P>Under the proposed rule, Forms EOIR-27 and EOIR-28 are being revised so that the forms may be used by practitioners to enter an appearance to represent an individual in contempt proceedings before the Chief Immigration Judge or Board. Specifically, the Department proposes to update the forms by adding fields for the contempt proceeding case number and the relevant service of process locations. The Forms EOIR-27 and EOIR-28 are required to represent an individual in proceedings before the Immigration Courts or Board. The proposed revisions do not change the underlying purpose of the forms or how individuals can submit the forms to EOIR, and the proposed revisions minimally affect the substance of the forms. Therefore, the Department believes that these proposed revisions will not increase the average time required to complete the forms, which was previously estimated at six minutes.</P>
                <P>
                    • 
                    <E T="03">Form EOIR-27, Notice of Entry of Appearance as an Attorney or Representative before the Board of Immigration Appeals.</E>
                     The Department estimates that an average of 42,176 individuals will submit one form per year, spending an estimated average of six minutes to prepare and submit the form. The total public burden of this revised collection is estimated at 4,213 burden hours annually (42,126 respondents × 1 response per respondent × 6 minutes per response = 4,213 burden hours). The Department estimates the aggregate costs for all respondents at $314,681. There are no capital or start-up costs or filing fees associated with the form. Assuming the form is included in the samemailed envelope as any filings submitted by mail, there is no additional postage cost. The estimated printing cost is $0.20 per form. Printing and postage costs may be avoided by completing and submitting the form electronically. There is an estimated labor cost of $8.94 per form, based on the current median hourly wage for attorneys as set by the Bureau of Labor Statistics ($89.35 per hour × 0.1 hour to complete = $8.94 per form).
                </P>
                <P>
                    • 
                    <E T="03">Form EOIR-28, Notice of Entry of Appearance as an Attorney or Representative before the Immigration Court.</E>
                     The Department estimates that 1,536,921 individuals will submit one form per year, spending an estimated average of six minutes to prepare and submit the form. The total public burden of this revised collection is estimated at 153,692 burden hours annually (1,536,921 respondents × 1 response per respondent × 6 minutes per response = 153,692 burden hours). The Department estimates the aggregate costs for all respondents at $11,480,800. There are no capital or start-up costs or filing fees associated with the form. Assuming the form is included in the samemailed envelope as any filings submitted by mail, there is no additional postage cost. The estimated printing cost is $0.20 per form. Printing and postage costs may be avoided by completing and submitting the form electronically. There is an estimated labor cost of $8.94 per form, based on the current median hourly wage for attorneys as set by the Bureau of Labor Statistics ($89.35 per hour × 0.1 hour to complete = $8.94 per form).
                </P>
                <GPOTABLE COLS="4" OPTS="L2,nj,tp0,i1" CDEF="s100,12,12,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">
                            Approx.
                            <LI>number of</LI>
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Average 
                            <LI>response time</LI>
                            <LI>(minutes)</LI>
                        </CHED>
                        <CHED H="1">
                            Total burden
                            <LI>(hours)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">EOIR-27</ENT>
                        <ENT>42,126</ENT>
                        <ENT>6 </ENT>
                        <ENT>4,213</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">EOIR-28</ENT>
                        <ENT>1,536,921</ENT>
                        <ENT>6 </ENT>
                        <ENT>153,692 </ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">G. Executive Order 14192 (Unleashing Prosperity Through Deregulation)</HD>
                <P>The proposed rule is a “regulation[ ] issued with respect to a[n] . . . immigration-related function of the United States” and is therefore exempt from the requirements of Executive Order 14192 under section 5(a) of that Order.</P>
                <HD SOURCE="HD2">H. Executive Order 14219 (Ensuring Lawful Governance and Implementing the President's “Department of Government Efficiency” Deregulatory Initiative)</HD>
                <P>The proposed rule is “an[ ] action related to a[n] . . . immigration-related function of the United States” and is therefore exempt from the requirements of Executive Order 14219 under section 7(a) of that Order.</P>
                <HD SOURCE="HD2">I. Executive Order 14294 (Overcriminalization of Federal Regulations)</HD>
                <P>Executive Order 14294 requires agencies promulgating regulations with criminal regulatory offenses potentially subject to criminal enforcement to explicitly describe the conduct subject to criminal enforcement, the authorizing statutes, and the mens rea standard applicable to each element of those offenses. This proposed rule will not create a criminal regulatory offense and is thus exempt from Executive Order 14294 requirements.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects</HD>
                    <CFR>8 CFR Part 1003</CFR>
                    <P>Administrative practice and procedure, Aliens, Immigration, Legal Services, Organization and functions (Government agencies).</P>
                    <CFR>8 CFR Part 1103</CFR>
                    <P>Administrative practice and procedure, Authority delegations (Government agencies), Fees, Reporting and recordkeeping requirements.</P>
                </LSTSUB>
                <PRTPAGE P="47989"/>
                <P>Accordingly, for the reasons set forth in the preamble, and by the authority vested in the Acting Director, Executive Office for Immigration Review, by the Attorney General Order Number 6260-2025, the Department proposes to amend parts 1003 and 1103 of chapter V of title 8 of the Code of Federal Regulations as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 1003—EXECUTIVE OFFICE FOR IMMIGRATION REVIEW</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 1003 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>5 U.S.C. 301; 6 U.S.C. 521; 8 U.S.C. 1101, 1103, 1154, 1155, 1158, 1182, 1226, 1229, 1229a, 1229b, 1229c, 1231, 1254a, 1255, 1324d, 1330, 1361, 1362, 1801, 1802, 1808, 1812; 28 U.S.C. 509, 510, 1746; sec. 2 Reorg. Plan No. 2 of 1950; 3 CFR, 1949-1953 Comp., p. 1002.</P>
                </AUTH>
                <AMDPAR>2. Amend § 1003.1 by adding new paragraph (b)(15) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 1003.1</SECTNO>
                    <SUBJECT>Organization, jurisdiction, and powers of the Board of Immigration Appeals.</SUBJECT>
                    <STARS/>
                    <P>(b) * * *</P>
                    <P>(15) Decisions on the imposition of a civil money penalty under subpart H of this part.</P>
                    <STARS/>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.3</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <AMDPAR>3. Amend § 1003.3(c)(1) by adding a new sentence after the third sentence that reads “For appeals of orders in contempt proceedings under subpart H of this part, briefs shall be due to the Board simultaneously from both parties within 20 days of the Board order setting the schedule and in no case more than 35 days after the appeal was filed.”</AMDPAR>
                <AMDPAR>4. Amend § 1003.9 by:</AMDPAR>
                <AMDPAR>a. Removing the word “and” in paragraph (b)(5);</AMDPAR>
                <AMDPAR>b. Redesignating paragraph (b)(6) as (b)(7); and</AMDPAR>
                <AMDPAR>c. Adding new paragraph (b)(6) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 1003.9</SECTNO>
                    <SUBJECT>Office of the Chief Immigration Judge.</SUBJECT>
                    <STARS/>
                    <P>(b) * * *</P>
                    <P>(6) Issue orders imposing a civil money penalty, in accordance with 8 CFR part 1003, subpart H; and</P>
                    <STARS/>
                </SECTION>
                <AMDPAR>5. Amend § 1003.102 by:</AMDPAR>
                <AMDPAR>a. Revising the last sentence of paragraph (c);</AMDPAR>
                <AMDPAR>b. Revising paragraph (g);</AMDPAR>
                <AMDPAR>c. Removing the period at the end of paragraph (v) and adding in its place a semicolon;</AMDPAR>
                <AMDPAR>d. Removing the period at the end of paragraph (w) and adding in its place “; or”; and</AMDPAR>
                <AMDPAR>e. Adding paragraph (x).</AMDPAR>
                <P>The revisions and addition read as follows:</P>
                <SECTION>
                    <SECTNO>§ 1003.102</SECTNO>
                    <SUBJECT>Grounds.</SUBJECT>
                    <STARS/>
                    <P>(c) * * * If a practitioner has offered material evidence or made a false statement of material fact or law and receives notice, or reasonably should have known, of the falsity, the practitioner shall take appropriate remedial measures, and a failure to take such remedial measures shall subject the practitioner to disciplinary sanctions in the public interest under this paragraph (c);</P>
                    <STARS/>
                    <P>(g) Engages in contumelious or otherwise obnoxious conduct, with regard to a case in which he or she acts in a representative capacity, which would constitute contempt of court in a judicial proceeding or a proceeding under subpart H of this part. The assessment of a final order for a civil money penalty in proceedings under subpart H of this part, and the conduct underlying such an order, are factors that may be considered when determining if contumelious or otherwise obnoxious conduct has occurred;</P>
                    <STARS/>
                    <P>(x) Repeatedly fails to pay a civil money penalty as described in § 1003.129.</P>
                </SECTION>
                <AMDPAR>6. Revise § 1003.103 by adding new paragraph (d) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 1003.103</SECTNO>
                    <SUBJECT>Immediate suspension and summary disciplinary proceedings; duty of practitioner to notify EOIR of conviction or discipline.</SUBJECT>
                    <STARS/>
                    <P>
                        (d) 
                        <E T="03">Contempt civil money penalty.</E>
                         For procedures relating to the immediate suspension of practitioners for failure to pay a civil money penalty for contempt, see § 1003.129.
                    </P>
                </SECTION>
                <AMDPAR>7. Revise § 1003.109, including the section heading, to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 1003.109</SECTNO>
                    <SUBJECT>Discipline of EOIR adjudicators.</SUBJECT>
                    <P>Complaints regarding the conduct or behavior of Immigration Judges, Appellate Immigration Judges, or Administrative Law Judges shall be directed to an appropriate supervisor, the EOIR Judicial Conduct and Professionalism Unit, or the Office of Professional Responsibility, United States Department of Justice. If disciplinary action is warranted, it shall be administered pursuant to the Department's attorney discipline procedures and, for Administrative Law Judges, pursuant to 5 CFR 930.211.</P>
                </SECTION>
                <AMDPAR>8. Amend part 1003 by adding a new Subpart H, to read as follows:</AMDPAR>
                <SUBPART>
                    <HD SOURCE="HED">SUBPART H—CIVIL MONEY PENALTY FOR CONTEMPTUOUS CONDUCT BEFORE AN IMMIGRATION JUDGE</HD>
                </SUBPART>
                <CONTENTS>
                    <SECHD>Sec.</SECHD>
                    <SECTNO>1003.121</SECTNO>
                    <SUBJECT>Authority to impose civil money penalties for contemptuous conduct.</SUBJECT>
                    <SECTNO>1003.122</SECTNO>
                    <SUBJECT>General statement of principles.</SUBJECT>
                    <SECTNO>1003.123</SECTNO>
                    <SUBJECT>Covered individuals.</SUBJECT>
                    <SECTNO>1003.124</SECTNO>
                    <SUBJECT>Contemptuous conduct for which a civil money penalty may be imposed.</SUBJECT>
                    <SECTNO>1003.125</SECTNO>
                    <SUBJECT>Required warning before initiating the civil money penalty process.</SUBJECT>
                    <SECTNO>1003.126</SECTNO>
                    <SUBJECT>Initiation of the civil money penalty process.</SUBJECT>
                    <SECTNO>1003.127</SECTNO>
                    <SUBJECT>Decision by the Chief Immigration Judge or designee.</SUBJECT>
                    <SECTNO>1003.128</SECTNO>
                    <SUBJECT>Appeals.</SUBJECT>
                    <SECTNO>1003.129</SECTNO>
                    <SUBJECT>Payment of the civil money penalty.</SUBJECT>
                    <SECTNO>1003.130</SECTNO>
                    <SUBJECT>Oversight.</SUBJECT>
                </CONTENTS>
                <SECTION>
                    <SECTNO>§ 1003.121</SECTNO>
                    <SUBJECT>Authority to impose civil money penalties for contemptuous conduct.</SUBJECT>
                    <P>Under section 240(b)(1) of the Act and the provisions of this subpart, an Immigration Judge has the authority to propose, and the Chief Immigration Judge or designee has the authority to impose, a civil money penalty on an individual, as set forth in § 1003.123, who engages in conduct, as set forth in § 1003.124, in contempt of the Immigration Judge's proper exercise of authority under the Act during the course of proceedings conducted under section 240 of the Act.</P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.122</SECTNO>
                    <SUBJECT>General statement of principles.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Purpose of the civil money penalty.</E>
                         The purpose of imposing civil money penalties for contemptuous conduct before an Immigration Judge is to promote the fair, efficient, and consistent adjudication of immigration proceedings; to uphold the dignity and authority of such proceedings; and to deter behavior that delays, disrupts, or obstructs the due course of those proceedings.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Exceptional use.</E>
                         The imposition of a civil money penalty for contemptuous conduct is an extraordinary sanction. The civil money penalty sanction under this subpart exists to allow Immigration Judges to conduct proceedings without improper interference. Immigration Judges generally should make a reasonable attempt to deter or redress contemptuous conduct through other available means, resorting to the proposal of a civil money penalty only after other reasonably available means have failed to restore proper conduct. A 
                        <PRTPAGE P="47990"/>
                        civil money penalty should be imposed only upon clearly identifiable behavior that constitutes misconduct under this subpart.
                    </P>
                    <P>
                        (c) 
                        <E T="03">Relationship of the civil money penalty to other sanctions.</E>
                         The procedures in this subpart are independent of other sanctions or procedures that may be available under the immigration laws and this chapter. The availability or imposition of a civil money penalty under this subpart does not preclude the use of other sanctions or procedures with regard to misconduct that are available.
                    </P>
                    <P>
                        (d) 
                        <E T="03">Inapplicability of the civil money penalty to the enforcement of subpoenas.</E>
                         Contempt authority and procedures under this subpart do not apply to the enforcement of a subpoena pursuant to § 1003.35(b).
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.123 </SECTNO>
                    <SUBJECT>Covered individuals.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Individuals subject to civil money penalties.</E>
                         Civil money penalties under this subpart may only be imposed on the following individuals:
                    </P>
                    <P>(1) An attorney or representative, as defined in § 1001.1(f) and (j), who has filed a Notice of Entry of Appearance as Attorney or Representative before the Immigration Court (Form EOIR-28) or a Notice of Entry of Limited Appearance for Document Assistance before the Immigration Court (Form EOIR-61);</P>
                    <P>(2) An alien who is the subject of proceedings before the Immigration Judge; and,</P>
                    <P>(3) Witnesses, except as described in paragraph (b) of this section, in any proceedings before the Immigration Judge, whether physically present in the courtroom or whose presence in the courtroom is effectuated through telephonic or videoconferencing equipment.</P>
                    <P>
                        (b) 
                        <E T="03">Individuals not subject to civil money penalties.</E>
                         Civil money penalties may only be imposed on individuals described in paragraph (a) of this section, which does not include attorneys or witnesses who are employees or contractors of the federal government acting in their official capacity.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.124 </SECTNO>
                    <SUBJECT>Contemptuous conduct for which a civil money penalty may be imposed.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Contemptuous conduct subject to a civil money penalty.</E>
                         Subject to the requirements of § 1003.125 and § 1003.126, an Immigration Judge may issue a Notice of Intent to Impose Civil Money Penalty on a covered individual, as defined in § 1003.123, if the Immigration Judge makes a prima facie determination that the individual has engaged in one or more of the following types of conduct, and that the conduct delayed, disrupted, or obstructed the adjudicatory process:
                    </P>
                    <P>(1) For attorneys and representatives, the repeated failure to appear or to appear in a timely manner, including by telephone or by videoconferencing, for scheduled hearings or pre-hearing conferences, without good cause.</P>
                    <P>(2) Repeated failure to comply with Immigration Judge orders to timely file pleadings, applications, pre-hearing statements, evidentiary submissions, or any other filings, without good cause.</P>
                    <P>(3) Disorderly or abusive behavior or language in and around the courtroom and before the Immigration Judge or abusive language in any filing with the court.</P>
                    <P>(4) Knowingly or recklessly making a false statement of material fact or law or offering false evidence. For attorneys and representatives, such conduct includes failing to take appropriate remedial measures after receiving notice of the falsity, or when the attorney or representative reasonably should have known of the falsity, of either a previous statement of material law or fact or previously offered material evidence.</P>
                    <P>(5) Willfully misleading, misinforming, threatening, or deceiving any person (including a party to a case or an officer or employee of the Department of Justice), concerning any relevant matter relating to a case.</P>
                    <P>
                        (b) 
                        <E T="03">Action and inaction.</E>
                         Both actions and inactions may constitute contemptuous conduct if they satisfy the requirements of paragraph (a) of this section.
                    </P>
                    <P>
                        (c) 
                        <E T="03">Exclusive list of contemptuous conduct.</E>
                         A civil money penalty may not be imposed for conduct that is not described in this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.125 </SECTNO>
                    <SUBJECT>Required warning before initiating the civil money penalty process.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Warning requirement.</E>
                         If an Immigration Judge believes a covered individual, as set forth in § 1003.123, has engaged in contemptuous conduct for which a civil money penalty may be imposed, as set forth in § 1003.124, the Immigration Judge must provide the individual with a clear and unambiguous warning before initiating the civil money penalty process under this subpart. The Immigration Judge is required to issue only one warning before initiating the civil money penalty process for continued engagement in the same contemptuous conduct; and such warning is not limited to a single proceeding. The warning remains in effect for one year from the date of issuance of the warning. Any previous order imposing a civil money penalty on a covered individual, as set forth in § 1003.123, for contemptuous conduct, shall also serve as a warning for the imposition of future civil money penalties if the same type of contemptuous conduct continues or is repeated within one year of the previous order.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Form of warning.</E>
                         If the individual is present before the Immigration Judge when the conduct occurs, the Immigration Judge must provide an oral warning on the record and memorialize the warning in writing as soon as practicable. If the individual is not present before the Immigration Judge when the conduct occurs, the Immigration Judge must provide a written warning. In all cases, the warning should be made as close in time to the occurrence of the conduct as reasonably possible. The written warning or a written memorialization of an oral warning must be served on the individual either in person or at the individual's physical or email address in EOIR's case management system, and a copy shall be maintained in the Record of Proceeding for the relevant case in which the contemptuous conduct occurred. If the individual's name and address(es) are not in EOIR's case management system, the Immigration Judge must request on the record that the individual provide such information.
                    </P>
                    <P>
                        (c) 
                        <E T="03">Contents of the warning.</E>
                         The warning must:
                    </P>
                    <P>(1) Describe the specific conduct that resulted in the warning;</P>
                    <P>(2) Explain why the Immigration Judge believes the conduct is within the scope of § 1003.124;</P>
                    <P>(3) Notify the individual that, if he or she continues to engage in such conduct, the Immigration Judge may initiate the process to hold the individual in contempt and impose a civil money penalty on the individual; and</P>
                    <P>(4) Notify the individual that he or she may respond to the warning and, if responding, must do so within the time specified in paragraph (d) of this section.</P>
                    <P>
                        (d) 
                        <E T="03">Response to the warning.</E>
                         An individual may, but is not required to, respond to the Immigration Judge's warning, either on the record orally at the time of the warning or in writing within 10 days of the issuance of the warning. Such response, if any, must be included in the Record of Proceeding of the relevant case in which the contemptuous conduct occurred. Any response demonstrating further contemptuous conduct within the scope of § 1003.124 that the individual was warned about may form the basis for 
                        <PRTPAGE P="47991"/>
                        initiation of the civil money penalty process.
                    </P>
                    <P>
                        (e) 
                        <E T="03">Continued contemptuous conduct following warning.</E>
                         If, after receiving a warning, the individual continues to engage in the same contemptuous conduct that the individual was warned about, the Immigration Judge must make a finding on the record that the individual has continued to engage in the specified conduct despite being warned before initiating the civil money penalty process under § 1003.126. In all cases, the finding of continued contemptuous conduct should be made as close in time to the occurrence of the conduct as reasonably possible.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.126 </SECTNO>
                    <SUBJECT>Initiation of the civil money penalty process.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Generally.</E>
                         The civil money penalty process is the sole means of imposing a civil money penalty for contemptuous conduct under § 1003.124. The civil money penalty process must be initiated as soon as practicable after the finding of continued contemptuous conduct under § 1003.125(e), but in no case later than one year after the most recent related warning issued pursuant to § 1003.125. No civil money penalty proceedings initiated against an alien described in § 1003.123(a)(2) may stay or otherwise interfere with the proceedings before the Immigration Judge or, as appropriate, the removal of the alien.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Initiating the civil money penalty process.</E>
                         (1) To initiate the civil money penalty process, the Immigration Judge will serve the individual with a Notice of Intent to Impose Civil Money Penalty (CMP Notice). The CMP Notice may be served on the individual by personal service or mail. If the individual is a practitioner before EOIR, the CMP Notice may also be served electronically using the practitioner's email address provided through eRegistry. The Immigration Judge shall also refer the CMP Notice to the Chief Immigration Judge or his or her designee for adjudication.
                    </P>
                    <P>(2) The CMP Notice must include:</P>
                    <P>(i) The name and address of the individual subject to the civil money penalty;</P>
                    <P>(ii) A factual description of the conduct in question, including the date(s), time(s), and place(s) of the conduct, as relevant;</P>
                    <P>(iii) The specific alleged charge(s) of conduct under § 1003.124;</P>
                    <P>(iv) An explanation of how the conduct in question delayed, disrupted, or obstructed the adjudicatory process;</P>
                    <P>(v) A brief description of any warning(s) provided; and</P>
                    <P>(vi) The amount of the proposed civil money penalty consistent with paragraph (c) of this section.</P>
                    <P>(3) The CMP Notice must inform the individual of the following:</P>
                    <P>(i) That the matter is being referred to the Chief Immigration Judge for decision as provided in § 1003.127;</P>
                    <P>(ii) That the individual may file a response to the CMP Notice with the Chief Immigration Judge in accordance with paragraph (d) of this section within 30 days of issuance of the CMP Notice, and the location where the response to the CMP Notice must be filed;</P>
                    <P>(iii) That the individual may file one motion with the Chief Immigration Judge to extend the time to respond to the CMP Notice for a maximum of 7 days, for good cause; and</P>
                    <P>(iv) That the individual may be represented at their own expense by an attorney, as defined in § 1001.1(f), or another representative allowed under § 1292.1.</P>
                    <P>
                        (c) 
                        <E T="03">Determining proposed penalty amount.</E>
                         To determine the proposed penalty amount for the CMP Notice, the Immigration Judge must first determine the appropriate penalty range based on the penalty schedule provided in paragraph (c)(1) of this section. Once the penalty range is determined, the specific amount of the proposed penalty is then determined by considering all relevant factors as provided in paragraph (c)(2) of this section.
                    </P>
                    <P>
                        (1) 
                        <E T="03">Penalty schedule.</E>
                         A civil money penalty must be determined according to the following schedule:
                    </P>
                    <P>(i) First contempt order: not less than $1,000 and not more than $1,500;</P>
                    <P>(ii) Second contempt order: not less than $1,500 and not more than $2,500; and</P>
                    <P>(iii) Any subsequent contempt order: not less than $2,500 and not more than $3,500.</P>
                    <P>
                        (2) 
                        <E T="03">Relevant factors.</E>
                         The factors an Immigration Judge must consider when proposing a civil money penalty include, but are not limited to:
                    </P>
                    <P>(i) The harm from the conduct, including any resulting administrative delays or additional costs or burdens;</P>
                    <P>(ii) The egregiousness of the individual's contemptuous conduct during the proceedings before the Immigration Judge;</P>
                    <P>(iii) The pervasiveness of the individual's contemptuous conduct during the proceedings before the Immigration Judge;</P>
                    <P>(iv) The probable deterrent effect of the penalty; and</P>
                    <P>(v) The number of prior offenses or warnings.</P>
                    <P>
                        (d) 
                        <E T="03">Response to the CMP Notice.</E>
                         An individual served a CMP Notice under paragraph (b) of this section may submit a written response to the CMP Notice to the Chief Immigration Judge. Such response must be filed within 30 days of the date of issuance of the CMP Notice. An individual may file one motion with the Chief Immigration Judge to extend the time to respond to the CMP Notice for a maximum of 7 days, for good cause. The response must include the individual's name, contempt case number, A-number or EOIR identification number (if any), current physical and email addresses, the individual's position on the charge(s) set forth in the CMP Notice, and any written or documentary evidence in support of the individual's position. If the individual is represented, his or her attorney or representative must file a Notice of Entry of Appearance as Attorney or Representative before the Immigration Court (Form EOIR-28) with the Chief Immigration Judge.
                    </P>
                    <P>
                        (e) 
                        <E T="03">Record of Proceeding.</E>
                         If the civil money penalty process is initiated under this section, the Immigration Court shall create a contempt Record of Proceeding, separate and apart from any underlying case Record of Proceeding(s). The Immigration Court shall ensure that all relevant evidence in the underlying case proceeding(s) that gave rise to the initiation of the civil money penalty process, such as any oral statements or documents capturing or giving rise to the contemptuous conduct, related warnings and warning responses under § 1003.125, and CMP Notices, responses to CMP Notices, and related filings under paragraphs (b) and (d) of this section, are entered or described in the contempt Record of Proceeding. Any oral statements, warnings, or warning responses given on the record must be transcribed for inclusion in the contempt Record of Proceeding. Any oral statements, warnings, or warning responses that were not recorded must be summarized in writing by the Immigration Judge for inclusion in the contempt Record of Proceeding.
                    </P>
                    <P>
                        (f) 
                        <E T="03">Filing requirements.</E>
                         All filings by an individual must comply with the document filing requirements in §§ 1003.31 through 1003.33, including that all filings submitted under this subpart must be submitted in English or accompanied by a certified English translation.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.127 </SECTNO>
                    <SUBJECT>Decision by the Chief Immigration Judge or designee.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Adjudicator.</E>
                         Upon referral of the CMP Notice by the Immigration Judge, jurisdiction over a civil money penalty process initiated under § 1003.126 vests 
                        <PRTPAGE P="47992"/>
                        with the Chief Immigration Judge to make the final decision. The Chief Immigration Judge may designate a permanent Deputy Chief Immigration Judge to make the decision, provided that such designee is not the present first-line supervisor of the Immigration Judge who issued the CMP Notice and is not conducting a review involving an alien who has previously appeared in immigration proceedings before the designee. If the Chief Immigration Judge is the Immigration Judge who issued the CMP Notice, the EOIR Director will designate a senior adjudicator outside of the Office of the Chief Immigration Judge to adjudicate the CMP Notice and make a decision.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Adjudication procedures.</E>
                         After reviewing the CMP Notice and the response to the CMP Notice, if any, as well as all supporting materials, the Chief Immigration Judge or the designee will issue a written decision under paragraph (d) of this section. The Chief Immigration Judge or the designee may only consider the contempt Record of Proceeding as described in § 1003.126(e). The Chief Immigration Judge or the designee will consider and rule on all motions. The Chief Immigration Judge or the designee may not remand a CMP Notice to the Immigration Judge for further clarification or proceedings.
                    </P>
                    <P>
                        (c) 
                        <E T="03">Motion to extend time to respond.</E>
                         A maximum of one time per case, upon a motion filed to extend the time to respond to the CMP Notice, the Chief Immigration Judge or the designee may extend the date by which the response must be filed by a maximum of 7 days upon good cause shown.
                    </P>
                    <P>
                        (d) 
                        <E T="03">Decision.</E>
                         (1) The Chief Immigration Judge or the designee shall issue a decision finding the individual in contempt and imposing a civil money penalty if clear and convincing evidence supports the following:
                    </P>
                    <P>(i) The person charged in the CMP Notice is a covered individual under § 1003.123;</P>
                    <P>(ii) The conduct set forth in the CMP Notice occurred;</P>
                    <P>(iii) The conduct falls within the scope of § 1003.124(a); and</P>
                    <P>(iv) The Immigration Judge properly provided the required warning, time to respond to the warning, and the CMP Notice under §§ 1003.125 and 1003.126.</P>
                    <P>(2) If the Chief Immigration Judge or the designee issues an order imposing a civil money penalty, the order must specify the amount of the civil money penalty consistent with § 1003.126(c); provided, however, that the order may not set a penalty amount above the amount stated in the CMP Notice. The order must include instructions for payment, including where payment is to be made and the form of such payment. The order must also inform the individual of the right to file an appeal with the Board under § 1003.128 within 10 days from the date of the order.</P>
                    <P>(3) The Chief Immigration Judge or the designee must issue an order dismissing the CMP Notice with prejudice if:</P>
                    <P>(i) He or she does not find clear and convincing evidence to support the findings required in paragraph (d)(1) of this section, or</P>
                    <P>(ii) The CMP Notice was issued against an alien described in § 1003.123(a)(2) and the Chief Immigration Judge or the designee receives information indicating that the alien has been removed from or has departed the United States prior to the issuance of a decision.</P>
                    <P>(4) An order dismissing the CMP Notice is final and not subject to further review.</P>
                    <P>(5) The Chief Immigration Judge or the designee must serve a copy of his or her order on the individual or, if represented, the individual's attorney or representative. If the individual is represented by an attorney or representative, the Chief Immigration Judge's order will be served electronically using the email address that the individual's attorney or representative has provided through eRegistry. If the individual is not represented, the Chief Immigration Judge's order may be served on the individual by personal service or mail. If the unrepresented individual is a practitioner before EOIR, service may also be made electronically using the practitioner's email address provided through eRegistry.</P>
                    <P>
                        (e) 
                        <E T="03">Finality of order.</E>
                         The order of the Chief Immigration Judge or the designee becomes a final agency decision unless the individual files a timely appeal with the Board under § 1003.128. Where the individual has filed a timely appeal, the Board's decision shall become a final agency decision in accordance with § 1003.128(d)(2). Filing an appeal automatically stays the order and the requirement to pay the penalty pending the outcome of the appeal.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.128 </SECTNO>
                    <SUBJECT>Appeals.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Generally.</E>
                         An individual who has been issued an order finding the individual in contempt and imposing a civil money penalty pursuant to § 1003.127 may appeal the order to the Board by filing a Notice of Appeal of a Civil Money Penalty for Contempt (Form EOIR-86). A copy of the Notice of Appeal of a Civil Money Penalty for Contempt must be simultaneously served on the General Counsel. The General Counsel or the EOIR disciplinary counsel, where so designated, will represent the Office of the Chief Immigration Judge in this appeal process. The Notice of Appeal of a Civil Money Penalty for Contempt must be filed within 10 days from the date of the order issued under § 1003.127 and include the required filing fee or fee waiver form pursuant to § 1103.7.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Notice of appeal and briefs.</E>
                         The Notice of Appeal of a Civil Money Penalty for Contempt must state the basis for the appeal. A brief in support of an appeal shall be filed directly with the Board, follow the briefing schedules contained in § 1003.3(c)(1), and include proof of service on the General Counsel. All filings to the Board must include: the individual's name, case number, A-number or EOIR identification number (if any), current physical and email addresses, and a designation of the type of filing.
                    </P>
                    <P>
                        (c) 
                        <E T="03">Representation.</E>
                         An individual may be represented on appeal, at no expense to the government, by an attorney, as defined in § 1001.1(f), or another individual authorized under § 1292.1 to provide representation before EOIR. The attorney or representative must file a Notice of Entry of Appearance as Attorney or Representative before the Board of Immigration Appeals (Form EOIR-27) and serve a copy on the General Counsel.
                    </P>
                    <P>
                        (d) 
                        <E T="03">Appellate processes before the Board.</E>
                         (1) Upon receipt of a timely filed Notice of Appeal of a Civil Money Penalty for Contempt, the Chief Immigration Judge or the designee will promptly forward the contempt Record of Proceeding to the Board to conduct a review pursuant to § 1003.1(d)(3).
                    </P>
                    <P>
                        (2) Following its review, the Board must issue a written decision affirming, modifying, or vacating with prejudice the civil money penalty, provided that the Board may neither set a penalty amount above the amount stated in the CMP Notice nor remand the case to the Chief Immigration Judge or the designee for further proceedings. If a civil money penalty was imposed against an alien described in § 1003.123(a)(2) and the Board receives information that the alien has been removed from or has departed the United States prior to issuing its decision, the Board shall vacate the civil money penalty. A copy of the Board's written decision will be served on the General Counsel, the individual, and, if the individual is represented, the individual's attorney or representative. The Board's decision becomes the final agency order on the date issued.
                        <PRTPAGE P="47993"/>
                    </P>
                    <P>(3) The Board may publish decisions in proceedings conducted under this subpart consistent with its authority in § 1003.1(g). Such decisions will serve as precedents in all proceedings involving the same issue(s). The Board shall refer cases under this subpart to the Attorney General for review in accordance with § 1003.1(h).</P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.129</SECTNO>
                    <SUBJECT>Payment of the civil money penalty.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Deadline.</E>
                         Payment of the civil money penalty must be made in a manner and form authorized by EOIR. If no appeal is filed, payment of the civil money penalty is due within 30 days of the order of the Chief Immigration Judge or the designee becoming final under § 1003.127(e). If an appeal is filed, payment of the civil money penalty is due within 30 days of the issuance of the final agency decision under § 1003.128(d). If review of the Board decision is sought in federal court, payment of the civil money penalty is due within 30 days of the issuance of a final court decision upholding the civil money penalty.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Collection of unpaid civil money penalty.</E>
                         If the individual upon whom a civil money penalty has been imposed fails to pay the penalty in the timeframe provided in paragraph (a) of this section, the civil money penalty may be collected under the provisions in 28 CFR part 11 or any other applicable federal law.
                    </P>
                    <P>
                        (c) 
                        <E T="03">Suspension of a practitioner for failure to pay.</E>
                         (1) If the individual who fails to pay the imposed civil money penalty within 30 days as provided in paragraph (a) of this section is a practitioner subject to sanctions in § 1003.101(b), the EOIR disciplinary counsel will send the practitioner a notice that the disciplinary counsel will file a petition with the Board to suspend that practitioner from practice before the Board and the Immigration Courts immediately, unless the practitioner pays the civil money penalty and a late fee of $50 within 15 days from the date of issuance of the notice. Service of this notice will be made upon the practitioner either by certified mail to his or her last known address as defined in § 1003.105(a)(2) or by personal delivery.
                    </P>
                    <P>(2) If the practitioner fails to pay the civil money penalty and the applicable late fee or otherwise send proof of payment thereof to the EOIR disciplinary counsel within 15 days of issuance of the notice, the EOIR disciplinary counsel shall file a petition with the Board to suspend that practitioner immediately from practice before the Board and the Immigration Courts. Service of the petition for immediate suspension will be made upon the practitioner either by certified mail to his or her last known address as defined in § 1003.105(a)(2) or by personal delivery.</P>
                    <P>(3) Upon the filing of a petition for immediate suspension by the EOIR disciplinary counsel, together with a certified copy of the relevant final order imposing a civil money penalty and a copy of the notice described in this section, the Board may enter an order immediately suspending the practitioner from practice before the Board and the Immigration Courts. If an immediate suspension is imposed upon a practitioner, the Board may require that notice of such suspension be posted at the Board and the Immigration Courts.</P>
                    <P>(4) A suspended practitioner may file a motion with the Board to set aside the immediate suspension order upon proof that the civil money penalty and the late fee were paid in full.</P>
                    <P>(5) Nothing in this section prohibits the EOIR disciplinary counsel from taking any other appropriate action consistent with subpart G of this part.</P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 1003.130</SECTNO>
                    <SUBJECT>Oversight.</SUBJECT>
                    <P>An Immigration Judge's exercise of the authority set forth in this subpart is subject to the supervision of the Chief Immigration Judge. The Chief Immigration Judge's exercise of the authority set forth in this subpart is subject to the supervision of the Director. The Chief Immigration Judge must conduct periodic reviews of this authority and, after consultation with the Director, may suspend any Immigration Judge's exercise of the authority for up to 30 days if the authority has been improperly applied or misused. The Director will review the Chief Immigration Judge's exercise of the authority set forth in this subpart and may suspend the Chief Immigration Judge's exercise of the authority for up to 30 days if the authority has been improperly applied or misused. Any suspension of an Immigration Judge's authority under this paragraph shall be communicated through a standing order issued by the Chief Immigration Judge or, as appropriate, the Director. Complaints or allegations of misconduct by an Immigration Judge regarding the threat or exercise of authority under this subpart should be directed to the Immigration Judge's supervisor, EOIR's Judicial Conduct and Professionalism Unit, or the Department of Justice Office of Professional Responsibility.</P>
                </SECTION>
                <PART>
                    <HD SOURCE="HED">PART 1103—APPEALS, RECORDS, AND FEES</HD>
                </PART>
                <AMDPAR>9. The authority citation for part 1103 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>8 U.S.C. 1101, 1103, 1304, 1356, 1801, 1802, 1808, 1812; 31 U.S.C. 9701; 28 U.S.C. 509, 510.</P>
                </AUTH>
                <AMDPAR>10. In § 1103.7, amend table 1 to paragraph (b)(1) by adding an entry for Form EOIR-86, Notice of Appeal of a Civil Money Penalty for Contempt, in numerical order by form number to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 1103.7</SECTNO>
                    <SUBJECT>Fees.</SUBJECT>
                    <STARS/>
                    <P>(b) * * *</P>
                    <P>(1) * * *</P>
                    <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s100,12C,12C,12C">
                        <TTITLE>
                            Table 1 to Paragraph (
                            <E T="01">b</E>
                            )(1)
                        </TTITLE>
                        <BOXHD>
                            <CHED H="1">Immigration fee type</CHED>
                            <CHED H="1">
                                Current EOIR
                                <LI>(section 286(m) of the</LI>
                                <LI>Immigration</LI>
                                <LI>and Nationality Act) fee</LI>
                            </CHED>
                            <CHED H="1">
                                Current
                                <LI>One Big</LI>
                                <LI>Beautiful</LI>
                                <LI>Bill Act (OBBBA) fee</LI>
                            </CHED>
                            <CHED H="1">
                                Current EOIR total fees
                                <LI>except any</LI>
                                <LI>biometrics fees</LI>
                            </CHED>
                        </BOXHD>
                        <ROW>
                            <ENT I="01">Form EOIR-86, Notice of Appeal of a Civil Money Penalty for Contempt</ENT>
                            <ENT>$675</ENT>
                            <ENT>$0</ENT>
                            <ENT>$675</ENT>
                        </ROW>
                    </GPOTABLE>
                    <PRTPAGE P="47994"/>
                    <STARS/>
                </SECTION>
                <SIG>
                    <NAME>Sirce E. Owen,</NAME>
                    <TITLE>Acting Director, Executive Office for Immigration Review, Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15458 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-30-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2026-7230; Project Identifier MCAI-2026-00185-R]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Airbus Helicopters Deutschland GmbH (AHD) Helicopters</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed rulemaking (NPRM).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA proposes to supersede Airworthiness Directive (AD) 2024-04-10, which applies to all Airbus Helicopters Deutschland GmbH (AHD) Model EC135P1, EC135P2, EC135P2+, EC135P3, EC135T1, EC135T2, EC135T2+, EC135T3, and EC635T2+ helicopters. AD 2024-04-10 requires repetitively inspecting certain part-numbered tail rotor (T/R) blades for a crack and, depending on the results, removing any cracked T/R blade from service. AD 2024-04-10 also prohibits installing certain T/R blades on any helicopter unless certain requirements are met. Since AD 2024-04-10 was issued, it was determined that inspection Method A should be discontinued and that additional limitations shall be provided. This proposed AD would retain the actions of AD 2024-04-10 and would require repetitively inspecting a certain tail rotor blade (TRB) assembly for cracks and, depending on the results, removing any cracked TRB assembly from service and replacing an affected part as terminating action for the repetitive inspections. This proposed AD would also prohibit installing an affected TRB assembly on any helicopter unless certain requirements are met. The FAA is proposing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The FAA must receive comments on this NPRM by September 14, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may send comments, using the procedures found in 14 CFR 11.43 and 11.45, by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">regulations.gov</E>
                        . Follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         (202) 493-2251.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery:</E>
                         Deliver to Mail address above between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                    </P>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2026-7230; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this NPRM, the mandatory continuing airworthiness information (MCAI) any comments received, and other information. The street address for Docket Operations is listed above.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For European Union Aviation Safety Agency (EASA) material identified in this proposed AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                        <E T="03">ADs@easa.europa.eu;</E>
                         website: 
                        <E T="03">easa.europa.eu.</E>
                    </P>
                    <P>• You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 10101 Hillwood Parkway, Fort Worth, TX 76177. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Soban Saeed, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (316) 946-4123; email: 
                        <E T="03">soban.saeed@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Comments Invited</HD>
                <P>
                    The FAA invites you to send any written relevant data, views, or arguments about this proposal. Send your comments using a method listed under 
                    <E T="02">ADDRESSES</E>
                    . Include “Docket No. FAA-2026-7230; Project Identifier MCAI-2026-00185-R” at the beginning of your comments. The most helpful comments reference a specific portion of the proposal, explain the reason for any recommended change, and include supporting data. The FAA will consider all comments received by the closing date and may amend the proposal because of those comments.
                </P>
                <P>
                    Except for Confidential Business Information (CBI) as described in the following paragraph, and other information as described in 14 CFR 11.35, the FAA will post all comments received, without change, to 
                    <E T="03">regulations.gov</E>
                    , including any personal information you provide. The agency will also post a report summarizing each substantive verbal contact received about this NPRM.
                </P>
                <HD SOURCE="HD1">Confidential Business Information</HD>
                <P>CBI is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (FOIA) (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments responsive to this NPRM contain commercial or financial information that is customarily treated as private, that you actually treat as private, and that is relevant or responsive to this NPRM, it is important that you clearly designate the submitted comments as CBI. Please mark each page of your submission containing CBI as “PROPIN.” The FAA will treat such marked submissions as confidential under the FOIA, and they will not be placed in the public docket of this NPRM. Submissions containing CBI should be sent to Soban Saeed, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590. Any commentary that the FAA receives which is not specifically designated as CBI will be placed in the public docket for this rulemaking.</P>
                <HD SOURCE="HD1">Background</HD>
                <P>The FAA issued AD 2024-04-10, Amendment 39-22689 (89 FR 15431, March 4, 2024) (AD 2024-04-10), for all AHD Model EC135P1, EC135P2, EC135P2+, EC135P3, EC135T1, EC135T2, EC135T2+, EC135T3, and EC635T2+ helicopters. AD 2024-04-10 was prompted by EASA Emergency AD 2024-0028-E, dated January 25, 2024, (EASA Emergency AD 2024-0028-E) originated by EASA, which is the Technical Agent for the Member States of the European Union. EASA issued EASA Emergency AD 2024-0028-E to correct an unsafe condition identified as cracks in affected T/R blades. EASA then superseded EASA Emergency AD 2024-0028-E and issued EASA AD 2024-0028R1, dated April 22, 2024 (EASA AD 2024-0028R1), to allow an optional visual inspection (Method E). The FAA did not issue an AD corresponding to EASA AD 2024-0028R1.</P>
                <P>
                    AD 2024-04-10 requires repetitively inspecting T/R blades having part number (P/N) L642A2002111 or P/N L642A2002112 installed for a crack and, depending on the results, removing any cracked T/R blade from service. AD 2024-04-10 also prohibits installing certain T/R blades on any helicopter unless certain requirements are met. 
                    <PRTPAGE P="47995"/>
                    The FAA issued AD 2024-04-10 to detect and address cracks in affected T/R blades. The unsafe condition, if not addressed, could result in separation of a T/R blade assembly and subsequent reduced control of the helicopter.
                </P>
                <HD SOURCE="HD1">Actions Since AD 2024-04-10 Was Issued</HD>
                <P>Since the FAA issued AD 2024-04-10, EASA superseded EASA AD 2024-0028R1 and issued EASA AD 2026-0032, dated February 19, 2026 (EASA AD 2026-0032) (also referred to as the MCAI). The MCAI states that a determination was made by the manufacturer that a previously approved inspection method (Method A), should be discontinued. Method A consisted of a dye-penetrant (with increased temperature) inspection.</P>
                <P>In addition, since the FAA issued AD 2024-04-10, it has been determined that TRB assemblies with P/N L642A2002121 installed, may also be subject to intergranular corrosion and could contain or develop the same unsafe condition. The FAA may publish a separate rulemaking to address this part number.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2026-7230.
                </P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed EASA AD 2026-0032, which specifies procedures for repetitively inspecting the affected TRB assembly for cracks and, if any crack is detected, replacing the affected TRB assembly with a serviceable part. EASA AD 2026-0032 prohibits installing a certain TRB assembly on any helicopter unless certain requirements are met and specifies that replacing an affected TRB assembly with an eligible TRB assembly that is not an affected part is terminating action for certain repetitive inspections.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">FAA's Determination</HD>
                <P>These products have been approved by the civil aviation authority (CAA) of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, that authority has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA is issuing this NPRM after determining that the unsafe condition described previously is likely to exist or develop on other products of the same type design.</P>
                <HD SOURCE="HD1">Proposed AD Requirements in This NPRM</HD>
                <P>This proposed AD would retain the requirements of AD 2024-04-10 and would also require accomplishing the actions specified in EASA AD 2026-0032, described previously, as incorporated by reference, except for any differences identified as exceptions in the regulatory text of this AD. See “Differences Between this Proposed AD and the MCAI” for a discussion of the general differences included in this proposed AD.</P>
                <HD SOURCE="HD1">Differences Between This Proposed AD and the MCAI</HD>
                <P>The MCAI applies to Airbus Helicopters Model EC635 P2+, EC635 P3, EC635 T1, and EC635 T3 helicopters, whereas this proposed AD does not because those models do not have an FAA type certificate.</P>
                <P>The MCAI specifies inspecting for cracks by performing a visual inspection, dye-penetrant inspection, eddy current inspection, or fluorescent penetrant inspection, whereas this proposed AD would require inspection methods under certain scenarios as outlined in the regulatory text of this proposed AD, which are also described in a Note in the regulatory text of this proposed AD.</P>
                <HD SOURCE="HD1">Explanation of Required Compliance Information</HD>
                <P>
                    In the FAA's ongoing efforts to improve the efficiency of the AD process, the FAA developed a process to use some CAA ADs as the primary source of information for compliance with requirements for corresponding FAA ADs. The FAA has been coordinating this process with manufacturers and CAAs. As a result, the FAA proposes to incorporate EASA AD 2026-0032 by reference in the FAA final rule. This proposed AD would, therefore, require compliance with EASA AD 2026-0032 in its entirety through that incorporation, except for any differences identified as exceptions in the regulatory text of this proposed AD. Using common terms that are the same as the heading of a particular section in EASA AD 2026-0032 does not mean that operators need comply only with that section. For example, where the AD requirement refers to “all required actions and compliance times,” compliance with this AD requirement is not limited to the section titled “Required Action(s) and Compliance Time(s)” in EASA AD 2026-0032. Material required by EASA AD 2026-0032 for compliance will be available at 
                    <E T="03">regulations.gov</E>
                    under Docket No. FAA-2026-7230 after the FAA final rule is published.
                </P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD, if adopted as proposed, would affect 359 helicopters of U.S. registry.</P>
                <P>The FAA estimates the following costs to comply with this proposed AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s75,r50,8,r35,r40">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">Cost per product</CHED>
                        <CHED H="1">Cost on U.S. operators</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Inspect one affected TRB assembly (up to 10 per helicopter)</ENT>
                        <ENT>3 work-hours × $85 per hour = $255</ENT>
                        <ENT>$50</ENT>
                        <ENT>Up to $305</ENT>
                        <ENT>Up to $109,495.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA estimates the following costs to do any replacements that would be required based on the results of the proposed inspection. The agency has no way of determining the number of helicopters that might need this replacement:</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s75,r75,r50,r35">
                    <TTITLE>On-Condition Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">Cost per product</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Replace one TRB assembly (up to 10 per helicopter)</ENT>
                        <ENT>3 work-hours × $85 per hour = $255</ENT>
                        <ENT>$4,900 per TRB assembly</ENT>
                        <ENT>Up to $51,550.</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="47996"/>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII, Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>The FAA determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that the proposed regulation:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Would not affect intrastate aviation in Alaska, and</P>
                <P>(3) Would not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Proposed Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>49 U.S.C. 106(g), 40113, 44701.</P>
                </AUTH>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <AMDPAR>2. The FAA amends § 39.13 by:</AMDPAR>
                <AMDPAR>a. Removing Airworthiness Directive 2024-04-10, Amendment 39-22689 (89 FR 15431, March 4, 2024); and</AMDPAR>
                <AMDPAR>b. Adding the following new airworthiness directive:</AMDPAR>
                <EXTRACT>
                    <FP SOURCE="FP-2">
                        <E T="04">Airbus Helicopters Deutschland GmbH (AHD):</E>
                         Docket No. FAA-2026-7230; Project Identifier MCAI-2026-00185-R.
                    </FP>
                    <HD SOURCE="HD1">(a) Comments Due Date</HD>
                    <P>The FAA must receive comments on this airworthiness directive (AD) by September 14, 2026.</P>
                    <HD SOURCE="HD1">(b) Affected ADs</HD>
                    <P>This AD replaces AD 2024-04-10, Amendment 39-22689 (89 FR 15431, March 4, 2024) (AD 2024-04-10).</P>
                    <HD SOURCE="HD1">(c) Applicability</HD>
                    <P>This AD applies to all Airbus Helicopters Deutschland GmbH (AHD) Model EC135P1, EC135P2, EC135P2+, EC135P3, EC135T1, EC135T2, EC135T2+, EC135T3, and EC635T2+ helicopters, certificated in any category.</P>
                    <HD SOURCE="HD1">(d) Subject</HD>
                    <P>Joint Aircraft System Component (JASC) Code 6410, Tail rotor blades.</P>
                    <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                    <P>This AD was prompted by a report of a separated tail rotor blade (TRB) assembly due to a crack in the TRB assembly caused by intergranular corrosion. The FAA is issuing this AD to detect and address cracks in the TRB assembly. The unsafe condition, if not addressed, could result in separation of the TRB assembly and reduced control of the helicopter.</P>
                    <HD SOURCE="HD1">(f) Compliance</HD>
                    <P>Comply with this AD within the compliance times specified, unless already done.</P>
                    <HD SOURCE="HD1">(g) Requirements</HD>
                    <P>Except as specified in paragraphs (h) and (i) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, European Union Aviation Safety Agency AD 2026-0032, dated February 19, 2026 (EASA AD 2026-0032).</P>
                    <HD SOURCE="HD1">(h) Exceptions to EASA AD 2026-0032</HD>
                    <P>(1) Where EASA AD 2026-0032 refers to its effective date, this AD requires using the effective date of this AD.</P>
                    <P>(2) Where EASA AD 2026-0032 refers to January 29, 2024 (the effective date of EASA Emergency AD 2024-0028-E), this AD requires using March 19, 2024 (the effective date of AD 2024-04-10).</P>
                    <P>(3) Where EASA AD 2026-0032 refers to flight hours, this AD requires using hours time-in-service (TIS).</P>
                    <P>(4) Where paragraph (1) of EASA AD 2026-0032 specifies “Before an affected part exceeds 685 FH [flight hours] since first installation on a helicopter”, this AD requires replacing that text with “Before an affected part accumulates 685 hours TIS since first installation on a helicopter, or within 10 hours TIS after March 19, 2024 (the effective date of AD 2024-04-10), whichever occurs later”.</P>
                    <P>(5) Where paragraph 4.3 of the material referenced in EASA AD 2026-0032 recommends type II visible dye inspections, this AD requires the inspection methods in paragraphs (h)(5)(i), (ii), or (iii) of this AD, as applicable:</P>
                    <P>(i) If the affected part has previously been inspected using a type II visible dye method, perform type II visible dye (Method B of the material referenced in EASA AD 2026-0032) or eddy current inspections, instead of fluorescent penetrant inspections.</P>
                    <P>(ii) If the affected part has not previously been inspected using a type II visible dye inspection, perform eddy current or fluorescent penetrant inspections, instead of type II visible dye inspections.</P>
                    <P>(iii) If you cannot determine whether the affected part has previously been inspected by a type II visible dye method, clean all surfaces to be inspected and perform an eddy current or a fluorescent penetrant inspection, instead of a type II visible dye inspection.</P>
                    <P>
                        <E T="04">Note 1 to paragraph (h)(5):</E>
                         The FAA reminds operators of the airworthiness concern regarding type II visible dye inspections of critical parts discussed in FAA Special Airworthiness Information Bulletin (SAIB) CE-18-26R1, dated October 30, 2018 (SAIB CE-18-26R1). SAIB CE-18-26R1 explains the risks associated with using type II visible dye inspection methods, including the prohibition in ASTM E1417 on the use of type II visible dye penetrant prior to the use of type I fluorescent penetrant on the same surface. SAIB CE-18-26R1 also advises of the importance of pre- and post-inspection cleaning to ensure proper detection of cracks. You can find SAIB CE-18-26R1 at 
                        <E T="03">drs.faa.gov.</E>
                    </P>
                    <P>
                        <E T="04">Note 2 to paragraph (h)(5):</E>
                         The material referenced in EASA AD 2026-0032 identifies a type II visible dye inspection as Method A (not allowed), or Method B, eddy current inspection as Method C; and fluorescent penetrant inspection as Method D.
                    </P>
                    <P>
                        <E T="04">Note 3 to paragraph (h)(5):</E>
                         When entering compliance with the applicable paragraph of the AD into the helicopter maintenance records, documenting that a type II visible dye inspection was performed improves the accuracy of maintenance records.
                    </P>
                    <P>(6) This AD does not adopt paragraph (3) of EASA AD 2026-0032.</P>
                    <P>(7) This AD does not adopt the “Remarks” section of EASA AD 2026-0032.</P>
                    <HD SOURCE="HD1">(i) No Reporting or Returning of Parts</HD>
                    <P>Where the material referenced in EASA AD 2026-0032 specifies to submit certain information and to send removed parts to the manufacturer, this AD does not include those actions.</P>
                    <HD SOURCE="HD1">(j) Special Flight Permits</HD>
                    <P>Special flight permits, as described in 14 CFR 21.197 and 21.199, are not allowed.</P>
                    <HD SOURCE="HD1">(k) Alternative Methods of Compliance (AMOCs)</HD>
                    <P>
                        (1) The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards District Office, 
                        <PRTPAGE P="47997"/>
                        as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (l) of this AD and email to 
                        <E T="03">AMOC@faa.gov.</E>
                    </P>
                    <P>(2) Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.</P>
                    <HD SOURCE="HD1">(l) Additional Information</HD>
                    <P>
                        For more information about this AD, contact Soban Saeed, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (316) 946-4123; email: 
                        <E T="03">soban.saeed@faa.gov.</E>
                    </P>
                    <HD SOURCE="HD1">(m) Material Incorporated by Reference</HD>
                    <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                    <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                    <P>(i) European Union Aviation Safety Agency (EASA) AD 2026-0032, dated February 19, 2026.</P>
                    <P>(ii) [Reserved]</P>
                    <P>
                        (3) For EASA material identified in this AD, contact EASA, Konrad-Adenauer-Ufer 3, 50668 Cologne, Germany; phone: +49 221 8999 000; email: 
                        <E T="03">ADs@easa.europa.eu;</E>
                         website: 
                        <E T="03">easa.europa.eu.</E>
                         You may find the EASA material on the EASA website at 
                        <E T="03">ad.easa.europa.eu.</E>
                    </P>
                    <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 10101 Hillwood Parkway, Fort Worth, TX 76177. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                    <P>
                        (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                        <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                         or email 
                        <E T="03">fr.inspection@nara.gov.</E>
                    </P>
                </EXTRACT>
                <SIG>
                    <DATED>Issued on July 28, 2026.</DATED>
                    <NAME>Steven W. Thompson,</NAME>
                    <TITLE>Acting Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15374 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Parts 400, 420, 433, 437, 450</CFR>
                <DEPDOC>[Docket No. FAA-2026-8614; Notice No. 26-11]</DEPDOC>
                <RIN>RIN 2120-AM51</RIN>
                <SUBJECT>Waiver of Specified Statutory Requirements for Commercial Space Launch and Reentry Actions</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed rulemaking (NPRM).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>FAA proposes to amend its commercial space licensing regulations to streamline the licensing process and reduce regulatory burden for applicants. Specifically, FAA proposes to invoke the Secretary of Transportation's statutory authority to waive requirements of laws of the U.S. for a license or permit, after consultation with the head of the appropriate executive agency, when the requirement is not necessary to protect the public health and safety, safety of property, and national security and foreign policy interests of the United States. FAA proposes waiving requirements under 13 laws for commercial space licenses and permits to operate a launch site, licenses to operate a reentry site, experimental permits, and licenses to operate a launch or reentry vehicle.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Send comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Send comments identified by docket number FAA-2026-8614 using any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">www.regulations.gov</E>
                         and follow the online instructions for sending your comments electronically.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Send comments to Docket Operations: U.S. Department of Transportation (DOT), 1200 New Jersey Avenue SE, West Building, 5th Floor (W58-213), Washington, DC 20590-0001.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery or Courier:</E>
                         Take comments to Docket Operations in Room W58-213 of the West Building, 5th Floor, at 1200 New Jersey Avenue SE, Washington, DC 20590 between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         Fax comments to Docket operations at (202) 493-2251.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         Background documents or comments received may be read at 
                        <E T="03">www.regulations.gov</E>
                         at any time. Follow the online instructions for accessing the docket or go to the Docket Operations in Room W58-213 of the West Building 5th Floor at 1200 New Jersey Avenue SE, Washington, DC 20590 between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Randy Repcheck, Federal Aviation Administration, 800 Independence Avenue SW, Washington, DC 20591; telephone (202) 267-9677; email 
                        <E T="03">9-FAA-Waiver-NPRM@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Executive Summary</HD>
                <HD SOURCE="HD2">A. Executive Order 14335</HD>
                <P>
                    On August 13, 2025, President Trump signed Executive Order “
                    <E T="03">Enabling Competition in the Commercial Space Industry”</E>
                     (E.O. 14335).
                    <SU>1</SU>
                    <FTREF/>
                     As detailed in E.O. 14335, the U.S. must facilitate efficient launches, reentries, and missions in space to continue enhancing economic growth, national security, and accomplish Federal space objectives. To achieve this objective and maintain American leadership in the commercial space industry, the U.S. will streamline approvals for commercial space licenses and permits.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         90 FR 40219 (Aug. 19, 2025).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Statement of the Problem</HD>
                <P>In accordance with section 3(a) of E.O. 14335, FAA is exploring the use of all available authorities to eliminate or expedite environmental reviews and other obstacles from licenses to operate launch and reentry vehicles, licenses to launch and reentry sites, and experimental permits. Specifically, under section 50905(b)(2)(C) of title 51 of the United States Code (U.S.C.) the Secretary of Transportation may prescribe by regulation that a requirement of a law of the U.S. not be a requirement for a license or permit if the Secretary, after consulting with the head of the appropriate executive agency, decides the requirement is not necessary to protect the public health and safety, safety of property, and national security and foreign policy interests of the United States.</P>
                <HD SOURCE="HD1">II. Authority for This Rulemaking</HD>
                <P>The Commercial Space Launch Act of 1984, as amended and codified at 51 U.S.C. 50901-50924, authorizes the Secretary of Transportation to oversee, license, and regulate commercial launch and reentry activities, and the operation of launch and reentry sites within the United States (U.S.) or as carried out by U.S. citizens. Section 50905 directs the Secretary to exercise this responsibility consistent with public health and safety, safety of property, and the national security and foreign policy interests of the United States. In addition, section 50903 requires the Secretary to encourage, facilitate, and promote commercial space launches and reentries by the private sector. As codified in 49 CFR 1.83(b), the Secretary has delegated authority to the FAA Administrator to carry out these functions.</P>
                <P>
                    Finally, under 51 U.S.C. 50905(b)(2)(C), the Secretary of Transportation may prescribe by 
                    <PRTPAGE P="47998"/>
                    regulation that a requirement of a law of the U.S. not be a requirement for a license or permit if the Secretary, after consulting with the head of the appropriate executive agency, decides the requirement is not necessary to protect the public health and safety, safety of property, and national security and foreign policy interests of the United States.
                </P>
                <HD SOURCE="HD1">III. Background</HD>
                <P>
                    Chapter III of title 14 of the Code of Federal Regulations (14 CFR) sets forth the procedures and requirements applicable to the authorization and supervision under 51 U.S.C. subtitle V, chapter 509, of commercial space transportation activities conducted in the United States or by a U.S. citizen, with certain exceptions.
                    <SU>2</SU>
                    <FTREF/>
                     The issuance of licenses to operate a launch site (part 420), licenses to operate a reentry site (part 433), experimental permits (part 437), and licenses for the operation of launch and reentry vehicles (part 450), respectively, constitutes a major Federal action under NEPA, which triggers an environmental review that may be extensive.
                    <SU>3</SU>
                    <FTREF/>
                     In accordance with §§ 420.15, 433.7, 437.21, and 450.47, an applicant must provide the FAA with information needed to show that the FAA complies with the procedures and policies of NEPA and other applicable environmental laws, regulations, and Executive Orders. These respective sections also require that, if a Categorical Exclusion (CATEX) 
                    <SU>4</SU>
                    <FTREF/>
                     does not apply to the proposed action, an applicant must prepare an Environmental Assessment (EA), assume financial responsibility for preparation of an Environmental Impact Statement (EIS), or provide information to support a written re-evaluation of a previously submitted EA or EIS, when directed by the FAA. While FAA strives to complete these environmental reviews expeditiously, these environmental reviews for each license to operate a launch site, license to operate a reentry site, experimental permit, and license to operate a launch or reentry vehicle can involve multiple statutes and agencies, sometimes leading to duplicative processes and delay for near-term launch operations.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         14 CFR 400.2(a) through (c) set forth the exceptions to the scope of Chapter III.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         These four types of authorizations are collectively referred to in this document as “commercial space license(s) or permit(s).”
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         National Environmental Policy Act of 1969, as amended, defines a categorical exclusion as a category of actions that a Federal agency has determined normally does not significantly affect the quality of the human environment within the meaning of 42 U.S.C. 4332(2)(C). 42 U.S.C. 4336(e).
                    </P>
                </FTNT>
                <P>
                    As the Supreme Court explained in 
                    <E T="03">Seven County Infrastructure Coal</E>
                     v. 
                    <E T="03">Eagle County</E>
                    , 
                </P>
                <EXTRACT>
                    <P>
                        NEPA has transformed from a modest procedural requirement into a blunt and haphazard tool employed by project opponents (who may not always be entirely motivated by concern for the environment) to try to stop or at least slow down new infrastructure and construction projects. . . . All of that has led to more agency analysis of separate projects, more consideration of attenuated effects, more exploration of alternatives to proposed agency action, more speculation and consultation and estimation and litigation. Delay upon delay, so much so that the process sometimes seems to “borde[r] on the Kafkaesque.” Vermont Yankee, 435 U. S., at 557. Fewer projects make it to the finish line. Indeed, fewer projects make it to the starting line. Those that survive often end up costing much more than is anticipated or necessary, both for the agency preparing the EIS and for the builder of the project. And that in turn means fewer and more expensive railroads, airports, wind turbines, transmission lines, dams, housing developments, highways, bridges, subways, stadiums, arenas, data centers, and the like. And that also means fewer jobs, as new projects become difficult to finance and build in a timely fashion.
                        <SU>5</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>5</SU>
                             
                            <E T="03">Seven County Infrastructure Coal</E>
                             v. 
                            <E T="03">Eagle County</E>
                            , 605 U.S. 168, 183 (2025).
                        </P>
                    </FTNT>
                </EXTRACT>
                <P>
                    And just as the Supreme Court recognized a need for a “course correction” in the judicial review of NEPA,
                    <SU>6</SU>
                    <FTREF/>
                     so too has DOT and FAA identified a need for course correction in application of NEPA and other related laws to the commercial space licensing and permitting process.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">Id. at 184.</E>
                    </P>
                </FTNT>
                <P>
                    Therefore, FAA proposes to exercise the Secretary's statutory authority to reduce regulatory barriers to obtaining a commercial space license or permit and eliminate environmental review processing while protecting public health and safety, safety of property, and national security interests and foreign policy interests of the U.S. Because the Secretary of Transportation's authority to waive certain laws under 51 U.S.C. 50905 applies broadly to commercial space licenses or permits, the Secretary finds this authority extends to waive laws applicable to licenses to operate a launch site, licenses to operate a reentry site, experimental permits, and licenses to operate launch and reentry vehicles.
                    <SU>7</SU>
                    <FTREF/>
                     The Secretary proposes that the identified provisions of the following 13 laws may not be necessary in some or all licensing circumstances to protect public health and safety, safety of property, national security, or foreign policy interests of the United States in the context of commercial space licenses and permits.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         The authority under paragraph (b)(2)(C) authorizes waiver via regulation of requirements for a “license or permit. . .” Therefore, FAA finds that licenses to operate a launch site and reentry site, experimental permits, and licenses to operate launch and reentry vehicles fall squarely within the Secretary's jurisdiction to waive under section 50905(b)(2)(C).
                    </P>
                </FTNT>
                <P>
                    1. 42 U.S.C. 4321 
                    <E T="03">et seq.</E>
                     (National Environmental Policy Act);
                </P>
                <P>2. 49 U.S.C. 303(f) (U.S. Department of Transportation Act);</P>
                <P>
                    3. 16 U.S.C. 1531 
                    <E T="03">et seq.</E>
                     (Endangered Species Act);
                </P>
                <P>
                    4. 33 U.S.C. 1251 
                    <E T="03">et seq.</E>
                     (Clean Water Act);
                </P>
                <P>
                    5. 16 U.S.C. 1451 
                    <E T="03">et seq.</E>
                     (Coastal Zone Management Act);
                </P>
                <P>
                    6. 42 U.S.C. 7401 
                    <E T="03">et seq.</E>
                     (Clean Air Act);
                </P>
                <P>
                    7. 54 U.S.C. 300101 
                    <E T="03">et seq.</E>
                     (National Historic Preservation Act);
                </P>
                <P>
                    8. 16 U.S.C. 1361 
                    <E T="03">et seq.</E>
                     (Marine Mammal Protection Act);
                </P>
                <P>
                    9. 16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                     (Magnuson-Stevens Fishery Conservation and Management Act);
                </P>
                <P>
                    10. 16 U.S.C. 1271 
                    <E T="03">et seq.</E>
                     (Wild and Scenic Rivers Act);
                </P>
                <P>
                    11. 42 U.S.C. 4901 
                    <E T="03">et seq.</E>
                     (Noise Control Act of 1972);
                </P>
                <P>
                    12. 33 U.S.C. 401 
                    <E T="03">et seq.</E>
                     (Rivers and Harbors Act); and
                </P>
                <P>
                    13. 16 U.S.C. 1431 
                    <E T="03">et seq.</E>
                     (National Marine Sanctuaries Act).
                </P>
                <P>
                    Other Federal agencies may take actions that authorize and facilitate launch and reentry operations, subject to the CSLA and subject to NEPA, and are required to support an FAA license or permit and the resulting operations. For example, many commercial space launch and reentry operations take place at Federal sites owned or operated by the Federal Government such as the National Aeronautics and Space Administration (NASA), the U.S. Department of the Air Force (DAF), and other agencies. To operate from a Federal site, operators must first enter into an agreement, such as a real property agreement, with the Federal custodian (
                    <E T="03">e.g.,</E>
                     NASA or DAF). The execution of a real property agreement or other instrument that allows substantial modification of a site or commercial space launch and reentry operations is often a major Federal action subject to NEPA given the Federal agency's substantial Federal control and responsibility over the action and the potential for significant impacts to the human environment.
                    <SU>8</SU>
                    <FTREF/>
                     Waiving NEPA only for the commercial space licensing and permitting actions covered under Chapter 509 would merely shift the responsibility for leading the NEPA review and ensuring 
                    <PRTPAGE P="47999"/>
                    compliance with other requirements from one executive agency to another. Therefore, the Secretary proposes that the requirements associated with the provisions of the prior 13 laws also may not be necessary to protect public health and safety, safety of property, national security, or foreign policy interests of the United States in the context of commercial space licenses and permits in the following licensing or permitting circumstances including, but not limited to:
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         14 CFR 1216.302(c).
                    </P>
                </FTNT>
                <P>(1) Issuance, renewal, or modification of Chapter 509 Licenses or Experimental Permits;</P>
                <P>(2) Authorizing airspace closures in accordance with FAA Order 7400.2R, Procedures for Handling Airspace Matters;</P>
                <P>(3) Unconditional or mixed Airport Layout Plan (ALP) approval of airport development for which the FAA has ALP approval authority under 49 U.S.C. 47107(a)(16) and § 47107(x).);</P>
                <P>(4) Lease of land to operator from a Federal site.</P>
                <P>Pursuant to the procedural requirements of 51 U.S.C. 50905(b)(2)(C), during the pendency of this rulemaking, the FAA will consult with the heads of appropriate executive agencies, including the Council on Environmental Quality, the Environmental Protection Agency, the Department of the Interior, the Department of Commerce, NASA, Department of War, and the Advisory Council on Historic Preservation, as applicable, on the Secretary's determination that the enumerated requirements are not necessary to protect the public health and safety, safety of property, and national security and foreign policy interests of the United States.</P>
                <P>
                    To effectuate the waiver of these laws to the commercial space licenses and permits across several FAA parts (
                    <E T="03">i.e.,</E>
                     parts 420, 433, 437, and 450), FAA proposes a new 14 CFR 400.3, titled General Waiver,
                    <SU>9</SU>
                    <FTREF/>
                     which would set forth the applicability provision (
                    <E T="03">i.e.,</E>
                     parts 420, 433, 437, and 450) of the waiver in proposed § 400.3(a), identify the specific laws that will no longer be a requirement for such licenses and permits in proposed § 400.3(b), and apply waiver of the laws in paragraph (b) to related actions outside of 14 CFR chapter III (
                    <E T="03">i.e.,</E>
                     the preceding list of four licensing or permitting circumstances) in proposed § 400.3(c). FAA also proposes conforming amendments to §§ 420.15(b), 433.7, 437.21(b)(1), and 450.47, to cross-reference the exceptions that would be set forth in proposed § 400.3.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         While the authority in 51 U.S.C. 50905(b)(2)(C) may colloquially be referred to as a general waiver authority, the Secretary has separate authority to waive a requirement as long as the Secretary determines the waiver is in the public interest and will not jeopardize public health and safety, safety of property, and national security and foreign policy interests of the United States. 51 U.S.C. 50905(b)(3); 
                        <E T="03">see also</E>
                         14 CFR part 404. These are two distinct waiver authorities with distinct implementation processes.
                    </P>
                </FTNT>
                <P>
                    FAA invites comments on the Secretary's proposed waiver of these laws. FAA also invites comment on other requirements not included that are not necessary, for example: Ocean Dumping Act (33 U.S.C. 1401-1445; 40 CFR 220-229); Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) (42 U.S.C. 9601 
                    <E T="03">et seq.</E>
                    ); Safe Drinking Water Act (42 U.S.C. 300f-300j-26; 40 CFR 141-143); Resource Conservation and Recovery Act (42 U.S.C. 6901-6992k; 40 CFR 239-282); Toxic Substances Control Act (15 U.S.C. 2601-2692; 40 CFR 700-799); Bald and Golden Eagle Protection Act (16 U.S.C. 668 
                    <E T="03">et seq.</E>
                    ); Migratory Bird Treaty Act (16 U.S.C. 703 
                    <E T="03">et seq.</E>
                    ); and National Wildlife Refuge System Administration Act (16 U.S.C. 668dd 
                    <E T="03">et seq.</E>
                    ).
                </P>
                <P>Further, FAA seeks comment on the following specific areas of interest:</P>
                <P>a. Should applicability be scoped to specific Federal sites, licensed launch and reentry sites, or exclusive use sites?</P>
                <P>b. Are any specific launch and reentry sites so differently situated that they warrant different treatment?</P>
                <P>c. How have the 13 laws identified for waiver in this proposed rule applied, in the launch and reentry site/launch and reentry context, to reduce a legally cognizable environmental harm? FAA encourages providing quantifiable, technical data to support a response.</P>
                <P>
                    d. How would application of these waivers further Congress's purpose to “promote economic growth and entrepreneurial activity through use of the space environment”? 
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         51 U.S.C. 50901(b)(1).
                    </P>
                </FTNT>
                <P>
                    e. Would exempting launch and reentry/launch and reentry site development from these laws fulfill Congress's mandate to “simplify and expedit[e] the issuance and transfer of commercial licenses”? 
                    <SU>11</SU>
                    <FTREF/>
                     If so, how?
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         51 U.S.C. 50905(b)(2).
                    </P>
                </FTNT>
                <P>
                    f. Would exempting launch and reentry/launch and reentry site development from these laws fulfill Congress's mandate to “facilitate the strengthening and expansion of the United States space transportation infrastructure”? 
                    <SU>12</SU>
                    <FTREF/>
                     If so, how?
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         51 U.S.C. 50905(b)(4).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Regulatory Notices and Analyses</HD>
                <HD SOURCE="HD2">A. Regulatory Impact Analysis</HD>
                <P>E.O. 12866 (“Regulatory Planning and Review”) and E.O. 13563 (“Improving Regulation and Regulatory Review”) require agencies to regulate in the “most cost-effective manner,” to make a “reasoned determination that the benefits of the intended regulation justify its costs,” and to develop regulations that “impose the least burden on society.” The Office of Management and Budget has determined that this proposed rulemaking is a significant regulatory action as defined in section (3)(f) of E.O. 12866.</P>
                <P>FAA expects the streamlining of its commercial space licensing regulations would significantly reduce the time required to obtain commercial space licenses and permits. Furthermore, there would be significant reductions in costs and time to draft and obtain the necessary approvals related to developing the currently required EAs and EISs. The FAA invites comments on the expected savings from these proposals, as well as any other costs or cost savings.</P>
                <HD SOURCE="HD2">B. Regulatory Flexibility Act</HD>
                <P>The Regulatory Flexibility Act (RFA) of 1980, (5 U.S.C. 601-612), as amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121) and the Small Business Jobs Act of 2010 (Pub. L. 111-240,), requires Federal agencies to consider the effects of the regulatory action on small business and other small entities and to minimize any significant economic impact. The term “small entities” comprises small businesses and not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.</P>
                <P>This proposed rule would amend commercial space licensing and permitting regulations to streamline the licensing and permitting process and reduce regulatory burden for applicants. Therefore, there are no significant economic impacts to small entities.</P>
                <P>
                    If an agency determines that a rulemaking will not result in a significant economic impact on a substantial number of small entities, the head of the agency may so certify under section 605(b) of the RFA. Therefore, as provided in section 605(b) and based on the foregoing, the head of FAA certifies that this rulemaking would not result in a significant economic impact on a substantial number of small entities.
                    <PRTPAGE P="48000"/>
                </P>
                <HD SOURCE="HD2">C. International Trade Impact Assessment</HD>
                <P>The Trade Agreements Act of 1979 (Pub. L. 96-39), as amended by the Uruguay Round Agreements Act (Pub. L. 103-465), prohibits Federal agencies from establishing standards or engaging in related activities that create unnecessary obstacles to the foreign commerce of the United States. Pursuant to these Acts, the establishment of standards is not considered an unnecessary obstacle to the foreign commerce of the United States, so long as the standard has a legitimate domestic objective, such as the protection of safety, and does not operate in a manner that excludes imports that meet this objective. The statute also requires consideration of international standards and, where appropriate, they be the basis for U.S. standards.</P>
                <P>FAA has assessed the potential effect of this proposed rule and determined that it would not create unnecessary obstacles to the foreign commerce of the United States.</P>
                <HD SOURCE="HD2">D. Unfunded Mandates Assessment</HD>
                <P>The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531-1538) governs the issuance of Federal regulations that require unfunded mandates. An unfunded mandate is a regulation that requires a State, local, or Tribal government or the private sector to incur direct costs without the Federal Government having first provided the funds to pay those costs. FAA determined the proposed rule would not result in the expenditure of $193,000,000 or more ($100,000,000 adjusted for inflation using the most current Implicit Price Deflator for the Gross Domestic Product) by State, local, or Tribal governments, in the aggregate, or the private sector, in any one year.</P>
                <HD SOURCE="HD2">E. Paperwork Reduction Act</HD>
                <P>The Paperwork Reduction Act of 1995 (44 U.S.C. 3507(d)) requires FAA consider the impact of paperwork and other information collection burdens imposed on the public. FAA has determined there would be no new requirement for information collection associated with this proposed rule.</P>
                <HD SOURCE="HD2">F. International Compatibility</HD>
                <P>In keeping with U.S. obligations under the Convention on International Civil Aviation, the FAA generally seeks to conform to International Civil Aviation Organization (ICAO) Standards and Recommended Practices (SARPs) to the maximum extent practicable. As part of the final rule, the FAA anticipates determining whether this rule affects FAA's conformity with any SARPs or other international obligations and invites public comments on this question.</P>
                <HD SOURCE="HD2">G. Environmental Analysis</HD>
                <P>The National Environmental Policy Act of 1969 (NEPA) (42 U.S.C. 4321-4347) requires Federal agencies to consider the environmental impacts of their actions in the decision-making process. DOT Order 5610.1D, DOT's Procedures for Considering Environmental Impacts (90 FR 29621, July 3, 2025), establishes DOT's procedures and practices for implementing NEPA. In addition, FAA Order 1050.1G, FAA National Environmental Policy Act Implementing Procedures (90 FR 29615, July 3, 2025), establishes FAA's policies and procedures for the evaluation of environmental impacts under NEPA. Appendix B of FAA Order 1050.1G identifies FAA's categorical exclusions. Categorical exclusions are categories of actions that the agency has determined normally do not significantly affect the quality of the human environment within the meaning of section 102(2)(C) of NEPA and therefore do not require either an environmental assessment (EA) or environmental impact statement (EIS). See NEPA § 4336e(1) and DOT Order 5610.1D § 9. In analyzing the applicability of a categorical exclusion, the agency must also consider whether extraordinary circumstances are present that would warrant the preparation of an EA or EIS. See DOT Order 5610.1D § 9(b). FAA has evaluated this NPRM in accordance with NEPA, DOT Order 5610.1D, and FAA Order 1050.1G. The FAA has determined that this NPRM does not constitute a major Federal action significantly affecting the quality of the human environment. A detailed environmental analysis is not required because this NPRM qualifies for the categorical exclusion identified in FAA Order 1050.1G, Appendix B, Paragraph B-2.6(d) for notices of proposed regulations and do not involve any extraordinary circumstances. The publication of a regulatory proposal is procedural, informational, and without environmental effects; it is not operative and does not normally have a significant effect on the environment. By its nature, a proposed rule is not the type of final action to which NEPA attaches. A final decision on the level of NEPA analysis required will be made at the final rule stage.</P>
                <HD SOURCE="HD1">V. E.O. Determinations</HD>
                <HD SOURCE="HD2">A. E.O. 13132, Federalism</HD>
                <P>FAA has analyzed this proposed rule under the principles and criteria of E.O. 13132, Federalism. FAA has determined this action would not have a substantial direct effect on the States, or the relationship between the Federal Government and the States, or on the distribution of power and responsibilities among the various levels of government, and, therefore, would not have federalism implications.</P>
                <HD SOURCE="HD2">B. E.O. 13175, Consultation and Coordination With Indian Tribal Governments</HD>
                <P>
                    Consistent with E.O. 13175, Consultation and Coordination with Indian Tribal Governments,
                    <SU>13</SU>
                    <FTREF/>
                     and FAA Order 1210.20, American Indian and Alaska Native Tribal Consultation Policy and Procedures,
                    <SU>14</SU>
                    <FTREF/>
                     FAA ensures Federally Recognized Tribes (Tribes) are given the opportunity to provide meaningful and timely input regarding proposed Federal actions that have the potential to affect uniquely or significantly their respective Tribes. During the pendency of the rulemaking and comment period to inform the final rule, FAA will identify any unique or significant effects, environmental or otherwise, on Tribes and engage as necessary.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         65 FR 67249 (November 6, 2000).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         FAA Order No. 1210.20 (January 28, 2004), available at 
                        <E T="03">www.faa.gov/documentLibrary/media/1210.pdf.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. E.O. 13211, Regulations That Significantly Affect Energy Supply, Distribution, or Use</HD>
                <P>FAA analyzed this proposed rule under E.O. 13211, Actions Concerning Regulations that Significantly Affect Energy Supply, Distribution, or Use (May 18, 2001). FAA has determined it would not be a “significant energy action” under the E.O. and would not be likely to have a significant adverse effect on the supply, distribution, or use of energy.</P>
                <HD SOURCE="HD2">D. E.O. 13609, Promoting International Regulatory Cooperation</HD>
                <P>
                    E.O. 13609, Promoting International Regulatory Cooperation, promotes international regulatory cooperation to (1) meet shared challenges involving health, safety, labor, security, environmental, and other issues and to reduce, eliminate, or (2) prevent unnecessary differences in regulatory requirements. FAA has analyzed this action under the policies and agency responsibilities of E.O. 13609 and has determined this action may effect 
                    <PRTPAGE P="48001"/>
                    international regulatory cooperation; FAA will address those effects during the pendency of this rulemaking and the final rule stage.
                </P>
                <HD SOURCE="HD2">E. E.O. 14192, Unleashing Prosperity Through Deregulation</HD>
                <P>This proposed rule, if finalized as proposed, is expected to be an E.O. 14192 deregulatory action.</P>
                <HD SOURCE="HD1">VI. Additional Information</HD>
                <HD SOURCE="HD2">A. Comments Invited</HD>
                <P>FAA invites interested persons to participate in this rulemaking by submitting written comments, data, or views. FAA also invites comments relating to the economic, environmental, or federalism impacts that might result from adopting the proposals in this document. The most helpful comments reference a specific portion of the proposal, explain the reason for any recommended change, and include supporting data. To ensure the docket does not contain duplicate comments, commenters should submit only one time if comments are filed electronically, or commenters should send only one copy of written comments if comments are filed in writing.</P>
                <P>FAA will file in the docket all comments it receives, as well as a report summarizing each substantive public contact with FAA personnel concerning this proposed rule. Before acting on this proposal, FAA will consider all comments it receives on or before the closing date for comments. FAA will consider comments filed after the comment period has closed if it is possible to do so without incurring expense or delay. FAA may change this proposal in light of the comments it receives.</P>
                <P>
                    <E T="03">Privacy:</E>
                     In accordance with 5 U.S.C. 553(c), DOT solicits comments from the public to inform its rulemaking process better. DOT posts these comments, without edit, including any personal information the commenter provides, to 
                    <E T="03">www.regulations.gov</E>
                    , as described in the system of records notice (DOT/ALL-14 FDMS), which can be reviewed at 
                    <E T="03">www.dot.gov/privacy.</E>
                </P>
                <HD SOURCE="HD2">B. Confidential Business Information</HD>
                <P>
                    Confidential Business Information (CBI) is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (FOIA) (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments responsive to this NPRM contain commercial or financial information that is customarily treated as private, that you actually treat as private, and is relevant or responsive to this NPRM, it is important you clearly designate the submitted comments as CBI. Please mark each page of your submission containing CBI as “PROPIN.” FAA will treat such marked submissions as confidential under the FOIA, and they will not be placed in the public docket of this NPRM. Submissions containing CBI should be sent to the person in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this document. Any commentary FAA receives which is not specifically designated as CBI will be placed in the public docket for this rulemaking.
                </P>
                <HD SOURCE="HD2">C. Electronic Access and Filing</HD>
                <P>
                    A copy of this NPRM, a plain language summary of the proposed rule, all comments received, any final rule, and all background material may be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     using the docket number listed above. Electronic retrieval help and guidelines are available on the website. It is available 24 hours each day, 365 days each year. An electronic copy of this document may also be downloaded from the Office of the Federal Register's website at 
                    <E T="03">www.federalregister.gov</E>
                     and the Government Publishing Office's website at 
                    <E T="03">www.govinfo.gov.</E>
                     A copy may also be found at FAA's Regulations and Policies website at 
                    <E T="03">www.faa.gov/regulations_policies.</E>
                </P>
                <P>Copies may also be obtained by sending a request to the Federal Aviation Administration, Office of Rulemaking, ARM-1, 800 Independence Avenue SW, Washington, DC 20591, or by calling (202) 267-9677. Requests must identify the docket or notice number of this rulemaking.</P>
                <P>All documents FAA considered in developing this proposed rule, including economic analyses and technical reports, may be accessed in the electronic docket for this rulemaking.</P>
                <HD SOURCE="HD2">D. Small Business Regulatory Enforcement Fairness Act</HD>
                <P>
                    The Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104 121, 110 Stat. 857, Mar. 29, 1996) requires FAA to comply with small entity requests for information or advice about compliance with statutes and regulations within its jurisdiction. A small entity with questions regarding this document may contact its local FAA official, or the person listed under the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     heading at the beginning of the preamble. To find out more about SBREFA on the internet, visit 
                    <E T="03">www.faa.gov/regulations_policies/rulemaking/sbre_act/.</E>
                </P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects</HD>
                    <CFR>14 CFR Part 400</CFR>
                    <P>Space transportation and exploration.</P>
                    <CFR>14 CFR Part 420</CFR>
                    <P>Environmental protection, Reporting and recordkeeping requirements, Space transportation and exploration.</P>
                    <CFR>14 CFR Part 433</CFR>
                    <P>Aviation safety, Environmental protection, Investigations, Reporting and recordkeeping requirements, Space transportation and exploration.</P>
                    <CFR>14 CFR Part 437</CFR>
                    <P>Aircraft, Aviation safety, Reporting and recordkeeping requirements, Space transportation and exploration.</P>
                    <CFR>14 CFR Part 450</CFR>
                    <P>Aircraft, Aviation safety, Environmental protection, Investigations, Reporting and recordkeeping requirements, Space transportation and exploration.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Proposed Amendments</HD>
                <P>For the reasons discussed in the preamble, the Federal Aviation Administration proposes to amend chapter III of title 14, Code of Federal Regulations as follows:</P>
                <PART>
                    <HD SOURCE="HED">[PART 400—BASIS AND SCOPE</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 400 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P> 51 U.S.C. 50901-50923.</P>
                </AUTH>
                <AMDPAR>2. Add a new § 400.3 to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 400.3</SECTNO>
                    <SUBJECT>General Waiver.</SUBJECT>
                    <P>(a) This section applies to licenses to operate a launch site under part 420 of this chapter, licenses to operate a reentry site under part 433 of this chapter, experimental permits under part 437 of this chapter, and licenses to operate a launch or reentry vehicle under part 450 of this chapter issued or modified on or after [EFFECTIVE DATE OF FINAL RULE].</P>
                    <P>(b) The requirements of the following Federal laws and associated implementing regulations shall not apply to a license or permit as set forth in paragraph (a) of this section:</P>
                    <P>(1) 42 U.S.C. 4321, et seq (National Environmental Policy Act);</P>
                    <P>(2) 49 U.S.C. 303(f) (U.S. Department of Transportation Act);</P>
                    <P>(3) 16 U.S.C. 1536 (Endangered Species Act);</P>
                    <P>
                        (4) 33 U.S.C. 1341, 1344 (Clean Water Act);
                        <PRTPAGE P="48002"/>
                    </P>
                    <P>(5) 16 U.S.C. 1456 (Coastal Zone Management Act);</P>
                    <P>(6) 42 U.S.C. 7506(c) (Clean Air Act);</P>
                    <P>(7) 54 U.S.C. 306108 (Section 106 of the National Historic Preservation Act);</P>
                    <P>(8) 16 U.S.C. 1371, 1374 (Marine Mammal Protection Act);</P>
                    <P>(9) 16 U.S.C. 1855(b)(2) (Magnuson-Stevens Fishery Conservation and Management Act);</P>
                    <P>(10) 16 U.S.C. 1276(d)(1); 1283(a) (Wild and Scenic Rivers Act);</P>
                    <P>(11) 42 U.S.C. 4903 (Noise Control Act of 1972);</P>
                    <P>(12) 33 U.S.C. 403 (Rivers and Harbors Act); and</P>
                    <P>(13) 16 U.S.C. 1434(d) (National Marine Sanctuaries Act).</P>
                    <P>(c) The requirements of Federal laws and any implementing regulations as set forth in paragraph (b) of this section shall not apply to a license or permit requirement associated with:</P>
                    <P>(1) Issuance, renewal, or modification of Chapter 509 Licenses or Experimental Permits;</P>
                    <P>(2) Authorizing airspace closures in accordance with FAA Order 7400.2R, Procedures for Handling Airspace Matters;</P>
                    <P>(3) Unconditional or mixed Airport Layout Plan (ALP) approval of airport development for which the FAA has ALP approval authority under 49 U.S.C. 47107(a)(16) and § 47107(x); and</P>
                    <P>(4) Lease of land to operator from a Federal site.</P>
                </SECTION>
                <PART>
                    <HD SOURCE="HED">PART 420—LICENSE TO OPERATE A LAUNCH SITE</HD>
                </PART>
                <AMDPAR>3. The authority citation for part 420 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>51 U.S.C. 50901-50923.</P>
                </AUTH>
                <AMDPAR>4. Amend § 420.15 by revising paragraph (b) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 420.15</SECTNO>
                    <SUBJECT>Information requirements.</SUBJECT>
                    <STARS/>
                    <P>
                        (b) 
                        <E T="03">Environmental.</E>
                         Except as provided in § 400.3 of this chapter, the FAA is responsible for complying with the procedures and policies of the National Environmental Policy Act (NEPA) and other applicable environmental laws, regulations, and Executive Orders prior to issuing a launch site operator license. An applicant must provide the FAA with information needed to comply with such requirements. The FAA will consider and document the potential environmental effects associated with issuing a launch site operator license.
                    </P>
                    <STARS/>
                </SECTION>
                <PART>
                    <HD SOURCE="HED">PART 433—LICENSE TO OPERATE A REENTRY SITE</HD>
                </PART>
                <AMDPAR>5. The authority citation for part 433 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>51 U.S.C. 50901-50923.</P>
                </AUTH>
                <AMDPAR>6. Amend § 433.7 by revising paragraph (a) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 433.7</SECTNO>
                    <SUBJECT>Environmental.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">General.</E>
                         Except as provided in § 400.3 of this chapter, the FAA is responsible for complying with the procedures and policies of the National Environmental Policy Act (NEPA) and other applicable environmental laws, regulations, and Executive Orders prior to issuing a reentry site operator license. An applicant must provide the FAA with information needed to comply with such requirements. The FAA will consider and document the potential environmental effects associated with issuing a reentry site operator license.
                    </P>
                    <STARS/>
                </SECTION>
                <PART>
                    <HD SOURCE="HED">PART 437—EXPERIMENTAL PERMITS</HD>
                </PART>
                <AMDPAR>7. The authority citation for part 437 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>51 U.S.C. 50901-50923.</P>
                </AUTH>
                <AMDPAR>8. Amend § 437.21 by revising paragraph (b)(1)(i) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 437.21</SECTNO>
                    <SUBJECT>General.</SUBJECT>
                    <STARS/>
                    <P>
                        (b) 
                        <E T="03">Other regulations</E>
                        —(1) 
                        <E T="03">Environmental</E>
                        —(i) 
                        <E T="03">General.</E>
                         Except as provided in § 400.3 of this chapter, the FAA is responsible for complying with the procedures and policies of the National Environmental Policy Act (NEPA) and other applicable environmental laws, regulations, and Executive Orders prior to considering and documenting the potential environmental effects associated with proposed reusable suborbital vehicle launches or reentries. An applicant must provide the FAA with information needed to comply with such requirements. The FAA will consider and document the potential environmental effects associated with proposed reusable suborbital vehicle launches or reentries.
                    </P>
                    <STARS/>
                </SECTION>
                <PART>
                    <HD SOURCE="HED">PART 450—LAUNCH AND REENTRY LICENSE REQUIREMENTS</HD>
                </PART>
                <AMDPAR>9. The authority citation for part 450 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>51 U.S.C. 50901-50923.</P>
                </AUTH>
                <AMDPAR>10. Amend § 450.47 by revising paragraph (a) to read as follows</AMDPAR>
                <SECTION>
                    <SECTNO>§ 450.47 </SECTNO>
                    <SUBJECT>Environmental review.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">General.</E>
                         Except as provided in § 400.3 of this chapter, the FAA is responsible for complying with the procedures and policies of the National Environmental Policy Act (NEPA) and other applicable environmental laws, regulations, and Executive Orders prior to issuing a launch or reentry license. An applicant must provide the FAA with information needed to comply with such requirements. The FAA will consider and document the potential environmental effects associated with issuing a vehicle operator license consistent with paragraph (b) of this section.
                    </P>
                    <STARS/>
                </SECTION>
                <SIG>
                    <P>Issued in Washington, DC.</P>
                    <NAME>Sean P. Duffy,</NAME>
                    <TITLE>Secretary of Transportation.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15415 Filed 7-28-26; 4:15 pm]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF LABOR</AGENCY>
                <SUBAGY>Office of Workers' Compensation Programs</SUBAGY>
                <CFR>20 CFR Part 726</CFR>
                <RIN>RIN 1240-AA16</RIN>
                <SUBJECT>Black Lung Benefits Act: Authorization of Self-Insurers</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Workers' Compensation Programs, Department of Labor.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed rulemaking; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department is proposing revisions to regulations under the Black Lung Benefits Act (BLBA or the Act) governing authorization of self-insurers. These rules will determine the process for coal mine operators to apply for authorization to self-insure, the requirements operators must meet to qualify to self-insure, the amount of security self-insured operators must provide, and the types of security accepted for operators to self-insure.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The Department invites written comments on the proposed regulations from interested parties. Written comments must be received by September 28, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit written comments by any of the following methods. To facilitate receipt and processing of comments, the Office of Workers' Compensation Programs (OWCP) encourages interested parties to submit their comments electronically.</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                          
                        <E T="03">http://www.regulations.gov.</E>
                         Follow the instructions on the website for submitting comments. Pursuant to the Administrative Procedure Act at 5 U.S.C. 553(b)(4), a plain language summary of the rule may also be found on the Federal eRulemaking Portal.
                        <PRTPAGE P="48003"/>
                    </P>
                    <P>
                        • 
                        <E T="03">Facsimile:</E>
                         (202) 693-1395 (this is not a toll-free number). Only comments of ten or fewer pages, including a fax cover sheet and attachments, if any, will be accepted by fax.
                    </P>
                    <P>
                        • 
                        <E T="03">Regular Mail/Hand Delivery/Courier:</E>
                         Submit comments on paper to the Division of Coal Mine Workers' Compensation Programs, Office of Workers' Compensation Programs, U.S. Department of Labor, 200 Constitution Avenue NW, Suite C3520-DCWMC, Washington, DC 20210. The Department's receipt of U.S. mail may be significantly delayed due to security procedures. You must take this into consideration when preparing to meet the deadline for submitting comments.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         Your submission must include the agency name and the Regulatory Information Number (RIN) for this rulemaking. 
                        <E T="03">Caution:</E>
                         All comments received will be posted without change to 
                        <E T="03">http://www.regulations.gov.</E>
                         Please do not include any personally identifiable or confidential business information you do not want publicly disclosed.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to the rulemaking docket and to read background documents or comments received, go to 
                        <E T="03">http://www.regulations.gov.</E>
                         Although some information (
                        <E T="03">e.g.,</E>
                         copyrighted material) may not be available through the website, the entire rulemaking record, including any copyrighted material, will be available for inspection at OWCP. Please contact the individual named below if you would like to inspect the record.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Ryan Jansen, Acting Director, Division of Coal Mine Workers' Compensation, Office of Workers' Compensation Programs, U.S. Department of Labor, 200 Constitution Avenue NW, Suite C3520-DCWMC, Washington, DC 20210. Telephone: 1-800-347-2502. This is a toll-free number. TTY/TDD callers may dial toll-free 1-877-889-5627 for further information.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background of This Rulemaking</HD>
                <P>
                    The BLBA, 30 U.S.C. 901-944, provides for the payment of benefits to coal miners and certain of their dependent survivors for total disability or death due to pneumoconiosis, commonly known as black lung disease. 30 U.S.C. 901(a); 
                    <E T="03">Usery</E>
                     v. 
                    <E T="03">Turner Elkhorn Mining Co.,</E>
                     428 U.S. 1, 5 (1976). The Act places the primary responsibility for paying benefits on coal mine operators. 30 U.S.C. 932(b). When a coal miner is determined to be eligible for benefits, the operator responsible for paying benefits (the responsible operator) is generally the one that most recently employed the miner for a period of at least one year and is financially capable of paying benefits. 20 CFR 725.495(a)(1).
                </P>
                <P>
                    If a responsible operator cannot be determined, is unable to pay, or defaults on its obligation to pay, the responsibility for paying benefits falls to the Black Lung Disability Trust Fund, which is primarily financed by an excise tax on coal mined for domestic use. 30 U.S.C. 932(j), 934(b); 26 U.S.C. 4121, 9501. If the black lung excise tax revenue is not sufficient to finance the Black Lung benefits due, the trust fund may borrow from the general fund of the Treasury. As of September 30, 2024, the Fund reported a $6.6 billion deficit 
                    <SU>1</SU>
                    <FTREF/>
                     and has borrowed from the U.S. Treasury's general fund nearly every year since 1979 to make needed expenditures.
                    <SU>2</SU>
                    <FTREF/>
                     In FY24, OWCP's Black Lung Program paid compensation and medical benefits for 12,911 beneficiaries, totaling approximately $140 million under Part C of title IV of the Act.
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">https://www.dol.gov/sites/dolgov/files/OPA/reports/2024annualreport.pdf</E>
                        .
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         U.S. Government Accountability Office, 
                        <E T="03">Federal Black Lung Benefits Program: Improved Oversight of Coal Mine Operator Insurance is Needed,</E>
                         at 13 (Feb. 2020), available at 
                        <E T="03">https://www.gao.gov/products/gao-20-21</E>
                        .
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">https://www.dol.gov/agencies/owcp/dcmwc/statistics/PartsBandCBeneficiaries</E>
                        .
                    </P>
                </FTNT>
                <P>
                    Because coal mine operators are principally responsible for paying benefits, the Act requires every operator to secure the payment of benefits for which it may be found liable. 30 U.S.C. 932(b). Each operator must secure the payment of benefits either by purchasing commercial insurance or by qualifying as a self-insurer “in accordance with regulations prescribed by the Secretary.” 30 U.S.C. 933(a); 
                    <E T="03">see also</E>
                     20 CFR 726.1. At the end of FY24, there were 709 Responsible Mine Operators (RMOs) covered by commercial insurance policies containing a Federal Black Lung endorsement. In comparison, 15 RMOs were authorized to self-insure their Federal Black Lung liabilities, which is only two percent of RMOs that could potentially be affected by this rulemaking. There were 10,139 covered beneficiaries being paid by RMOs, either through commercial insurance policies or self-insurance authorization, during this timeframe.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">https://www.dol.gov/sites/dolgov/files/OWCP/OWCPFY23-24AnnualReporttoCongress.pdf</E>
                        .
                    </P>
                </FTNT>
                <P>Regulations—20 CFR part 726 Subpart B—establish the standards for a coal mine operator to qualify as a self-insurer. They provide that, to qualify as a self-insurer, an operator must meet certain minimum requirements, including “obtain[ing] security . . . in a form approved by OWCP . . . and in an amount to be determined by OWCP.” 20 CFR 726.101(b)(2). The regulations identify four forms of security that an operator may use alone or in concert: (1) indemnity bonds; (2) deposits of negotiable securities; (3) letters of credit; or (4) trust funds under Section 501(c)(21) of the Internal Revenue Code. 20 CFR 726.104(b).</P>
                <P>
                    Historically, the Department did “not require self-insured operators to post . . . security with a face value that would cover all of the operator's expected black lung liability.” 
                    <E T="03">See</E>
                     62 FR 3338, 3370 (Jan. 22, 1997). The Department relied in part on a company's size as evidence of its ability to make future benefits payments. 
                    <E T="03">Id.</E>
                </P>
                <P>
                    A number of insolvencies in the mining industry revealed weaknesses in that process and demonstrated that a more substantial security amount would be required to adequately protect the Trust Fund. Specifically, beginning in 2014, three large self-insured operators filed for bankruptcy. Because these operators had insufficient securities to cover the full amount of expected benefits, an estimated $865 million in liabilities will ultimately transfer to the Trust Fund. 
                    <E T="03">See</E>
                     U.S. Government Accountability Office, 
                    <E T="03">Federal Black Lung Benefits Program: Improved Oversight of Coal Mine Operator Insurance is Needed,</E>
                     at 13 (Feb. 2020), available at 
                    <E T="03">https://www.gao.gov/products/gao-20-21</E>
                    .
                </P>
                <P>
                    In response, OWCP developed revised guidelines and procedures for authorizing coal mine operators to self-insure, which it began to implement in 2019. These guidelines were intended to standardize the process by which applicants provide financial and actuarial information to OWCP. OWCP required each company to calculate and report its projected black lung liabilities through actuarial reports using a set of standardized assumptions, including discount rate, claim cost trends, and the probability of awards. OWCP also developed a set of financial metrics and a methodology to assess each operator's solvency, profitability, and risk of default. This assessment determined the proportion of the operator's projected liabilities it would be required to post as security. Operators determined to be at less risk of not meeting their obligations would be required to provide smaller amounts of security, while operators at higher risk would be required to provide larger amounts of security. These guidelines were summarized in a December 2020 
                    <PRTPAGE P="48004"/>
                    bulletin, 
                    <E T="03">see</E>
                     BLBA Bulletin No. 21-01 (Dec. 7, 2020).
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         OWCP published a notice in the 
                        <E T="04">Federal Register</E>
                         seeking comment on the Bulletin in January 2021, pursuant to then-operative Executive Order 13891 and the Department's implementing regulation. 86 FR 1529 (Jan. 8, 2021). OWCP later withdrew the notice after the Executive Order and the Department's regulation were rescinded and the incoming Administration imposed a temporary regulatory freeze. 86 FR 8806 (Feb. 9, 2021).
                    </P>
                </FTNT>
                <P>In 2021, the then-new administration withdrew enforcement of these guidelines, and began work on revised rulemaking that culminated in the current regulations.</P>
                <P>The Department promulgated new regulations in 2024 (89 FR 100304, December 12, 2024), providing that “[a]ny operator approved to self-insure must submit security equal to 100 percent of the actuarially estimated liabilities (all present and future liabilities), as determined by OWCP based on the actuarial report or reports submitted with the operator's application or on file with OWCP, other information submitted with the operator's application, and any other materials or information that OWCP deems relevant.” 20 CFR 726.105.</P>
                <P>
                    The 2024 regulations implemented the practice of basing a self-insured operator's security requirement on an actuarial assessment of its total present and future black lung liability. 20 CFR 726.105, 89 FR at 100320. The regulations eliminated the process of assessing each operator's financial strength and risk of default, and required all self-insured operators to post security equal to 100 percent of their projected black lung liabilities. 
                    <E T="03">Id.</E>
                     Coal mine operators were instructed to post this security within one year of promulgation. “Operators that are required to submit an initial or increased security deposit may do so in quarterly increments over the course of one year. Such operators must deposit at least 25 percent of the newly required security amount within thirty days of OWCP issuing the notification provided in paragraphs (d) and (e) of this section, followed by at least 50 percent of their required security within four months, at least 75 percent within eight months, and 100 percent within one year. If an operator fails to timely submit any one of these security installments, OWCP will revoke its self-insurance authorization and the operator will be subject to the civil penalty provisions in subpart D of this part.” 20 CFR 726.104(c), 89 FR at 100319. The 2024 regulations also removed the option to establish new Internal Revenue Code Section 501(c)(21) trust funds for securing a mine operator's estimated liabilities, but continued to allow existing funds to serve as security. 26 U.S.C. 501(c)(21), 20 CFR 726.104(b)(4), 89 FR at 100308, 100319.
                </P>
                <P>The Department now believes that the current 2024 rule is prohibitive and potentially detrimental to the coal industry by requiring operators to secure 100% of actuarial estimated liabilities in a short period of time, regardless of the operator's financial strength. The rule was informed by prior self-insured operator bankruptcies that transferred an estimated $865 million to the Trust Fund, as outlined in the February 2020 GAO report referenced above.</P>
                <P>The requirement for 100% of actuarial estimated liabilities within one year of the operator's security determination is a substantial increase in collateral in a short period of time that now risks a negative economic impact on the coal mining industry. The financial impact to individual operators is the cost of the change in securities to meet 100% actuarial estimated liabilities within one year, an amount that ranges between $136 thousand to $343 million per operator. Meeting such a sizeable increase in a short amount of time will require operators to place more liquid assets in the approved security options, such as treasury bills or letters of credit, resulting in less working capital. That change in available assets potentially impairs their operating ability and ability to adjust to strategic changes, such as current industry growth as a result of the increased need for electricity to power AI data centers, or emergent situations where a mine becomes unable to produce due to a full or partial collapse, equipment malfunction, or maintenance.</P>
                <P>Such a heavy-handed approach to self-insurance security requirements fails to promote the stated goal of increasing domestic energy production, including coal, announced by President Donald J. Trump (Executive Order 14261, April 8, 2025). OWCP believes that this rule would best balance the needs of the Trust Fund with ensuring that miners receive the benefits to which they are entitled. As was outlined in the 2020 GAO report referenced above, prior security requirements for self-insurance authorizations were inadequate, and resulted in the $865 million transfer of liability to the Trust Fund. Further disruptions in the industry could have an equally dire effect on the Trust Fund. The 2024 rule would place an excessive burden on coal mine operators by requiring self-insured operators to pledge over $500 million in security within twelve months. This diversion of capital from operations to security would have negative impacts on both the companies operating coal mines as well as national energy requirements. This proposed rule supports growth in a critical sector and balances national security and energy interests while adequately protecting the Trust Fund. Self-insured operators would need to pledge additional security to protect the Trust Fund (over $300 million) but they would be permitted to make these allotments over a lengthier period of time, and in a manner that is most appropriate for their operations.</P>
                <P>Accordingly, the Department removed the 60-day deadline it had set by letter in January 2025 for self-insured operators to submit applications for renewal authorization under the 2024 rule. The Department sent follow-up letters to the operators in February 2025, informing them that the 60-day deadline no longer applied and they would receive further guidance after OWCP consulted with new Department leadership. In the meantime, OWCP has evaluated current self-insured operators and determined that although not all are secured at 100%, they are not currently at high risk of bankruptcy.</P>
                <HD SOURCE="HD1">II. Statutory Authority</HD>
                <P>Section 426(a) of the BLBA, 30 U.S.C. 936(a), authorizes the Secretary of Labor to prescribe rules and regulations necessary for the administration and enforcement of the Act.</P>
                <HD SOURCE="HD1">III. Summary of the Proposed Rule</HD>
                <P>
                    The Department proposes this rule to balance the need to protect the Trust Fund and benefits owed to disabled miners with vital energy and national security interests. 
                    <E T="03">Id.</E>
                     The proposed rule intends to allow self-insured coal mine operators greater flexibility in securing their estimated black lung liabilities for the benefit of disabled miners. The proposed rule would establish a graduated system of security levels based on an operator's risk of default, to reflect the economic realities of the mining industry. The rule would also allow operators an extended period to post this security in order to avoid constraining vital capital that could be used in mining operations. Lastly, the Department proposes to introduce new methods for operators to post required security, while continuing to recognize existing methods. These new methods could be employed individually or in combination with other options, affording the coal mine operators the greatest flexibility in determining how they can utilize their assets to secure their liabilities. By allowing multiple options, coal mine operators can select 
                    <PRTPAGE P="48005"/>
                    the method or methods that best fit their business operations, and OWCP can ensure that the Trust Fund is protected in the event of default.
                </P>
                <P>The Department invites comments on the proposed rule from all interested parties. The Department is particularly interested in comments addressing the impact of the proposed rulemaking on coal mine operators currently participating in the self-insurance program and any resulting impact on their ability to continue participating in the program.</P>
                <HD SOURCE="HD2">A. General Provisions</HD>
                <P>The Department is proposing a number of changes to advance the goal of protecting the Black Lung Disability Trust Fund against future insolvencies of mine operators in the coal industry. During the comment period following publication of a previous Notice of Proposed Rulemaking on this subject (88 FR 3349, January 19, 2023), the Department received a number of comments from stakeholders. Those comments have been taken into consideration during development of this proposed rule.</P>
                <P>The Department proposes to establish security levels for self-insured coal mine operators at levels that account for the financial health of the operator and accurately reflect the risk of default for the Trust Fund. The Department also proposes to allow operators to fully secure the appropriate amount of their established liabilities over the course of three years following promulgation of a Final Rule.</P>
                <P>The Department proposes to allow self-insured coal mine operators to secure their estimated liabilities through a number of new methods. These new methods provide operators with expanded options that can be tailored to specific business needs and resources. The Department expects that operators will utilize a combination of multiple methods to arrive at their total security requirement. We note that the option to use multiple instruments to secure liability is not a new authority for self-insured operators. The Department also notes that the methods proposed are merely options. Operators will not be required or encouraged to utilize any particular instrument. The Department is retaining all existing methods of securing liability, with certain limitations about how much liability may be secured through each method, as detailed below.</P>
                <P>The Department proposes to allow operators to designate a hierarchy to prioritize which method of security should be utilized first in the event of default. This new authority is intended to allow operators flexibility when purchasing security, and may result in cost savings for the purchase of particular instruments.</P>
                <P>The Department retains the ability to adjust security amounts between annual reviews when presented with material change(s) to evidence submitted after the application process is completed and prior to the next scheduled annual review. The operator will receive notification of any security requirement adjustments.</P>
                <HD SOURCE="HD2">B. Section-by-Section Explanation</HD>
                <HD SOURCE="HD3">20 CFR 726.101 Who May File and Be Authorized To Self-Insure</HD>
                <P>Current § 726.101 describes the minimum requirements established by the Secretary for determining whether any particular coal mine operator may be authorized to self-insure or to renew authorization to self-insure.</P>
                <P>Current paragraph (a) is retained in its entirety.</P>
                <P>
                    OWCP proposes revising paragraph (b), to update the minimum requirements that must be met by an operator seeking authorization or reauthorization to self-insure. OWCP proposes adding a new requirement that first-time applicants provide, at minimum, $400,000 in security in order to be authorized to self-insure their liabilities.
                    <SU>6</SU>
                    <FTREF/>
                     If the present and future estimated liabilities of the operator exceed $400,000 at the time of application or during annual reviews in the first three years of the operator's self-insurance authorization, the operator will be required to provide 100% of their present and future estimated liabilities as security. If the estimated liabilities are less than $400,000 or if OWCP determines that the estimated liabilities cannot be reasonably estimated due to limited historical claims experience and exposure data, the operator will be required to provide $400,000 in security. This requirement will only apply to the first three years in which the new applicant is authorized to self-insure. After three years, the operator will be subject to the requirements outlined in § 726.105 below and required to post security at a level based on the operator's risk of default; they may withdraw any excess security that was required from them in the first three years of their self-insurance authorization. Previously, operators were not permitted to self-insure within the first three years of commencing mining operations. These revisions will allow new operators to self-insure, provided that they secure a minimum of $400,000 of estimated liabilities. This change allows flexibility to new operators to determine the best methods for securing liabilities, while protecting the Trust Fund.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         Based on historical practices and its experience administering the self-insurance program under the Black Lung Benefits Act, OWCP has determined a $400,000 minimum security requirement is appropriate given the financial profile of companies it typically authorizes for self-insurance.
                    </P>
                </FTNT>
                <P>Given the foregoing changes, OWCP proposes to retain in its entirety and renumber current paragraph (b)(1) as paragraph (b)(2), and current paragraph (b)(2) as paragraph (b)(3).</P>
                <P>Current paragraphs (c) and (d) are retained in their entirety.</P>
                <P>OWCP also proposes to add a new paragraph (e), which will specify which entities may apply for authorization to self-insure or to renew authorization to self-insure. OWCP proposes using the same language for this paragraph as appears in current § 726.102(c), and will remove the language from that section. New paragraph (e) also provides that if a parent corporation's self-insurance authorization includes subsidiary corporations, the parent will remain liable for claims based on employment with such subsidiaries regardless of any sale or transfer of the subsidiaries.</P>
                <HD SOURCE="HD3">20 CFR 726.102 Application for Authority To Become a Self-Insurer; How Filed; Information To Be Submitted</HD>
                <P>Current § 726.102 provides requirements for filing an application for authorization to self-insure or renew authorization to self-insure, detailing what information must be submitted with an application and how to file it.</P>
                <P>Current paragraphs (a) and (b)(1) through (b)(6) are retained in their entirety.</P>
                <P>
                    OWCP proposes revising paragraph (b)(7). Current paragraph (b)(7) grants OWCP discretion to request additional information or evidence from an applicant. OWCP proposes deleting and replacing current paragraph (b)(7) to identify the exact financial documentation that must be submitted in order to calculate security requirements under § 726.105. OWCP's proposed paragraph (b)(7) will require an applicant to include the most recent long-term credit rating report issued by a nationally recognized statistical rating organization within the past 18 months at the time of application, if such a report exists. This change is intended to provide OWCP with an independent and standardized assessment of the applicant's creditworthiness, to use in conjunction with other information requested in paragraph (b).
                    <PRTPAGE P="48006"/>
                </P>
                <P>
                    OWCP proposes to add a new paragraph (b)(8). The proposed paragraph (b)(8) provides the documentation an applicant must submit for OWCP to use in accordance with the financial scoring systems known as the Altman Z-score 
                    <SU>7</SU>
                    <FTREF/>
                     and Ohlson O-score.
                    <SU>8</SU>
                    <FTREF/>
                     OWCP proposes to use the Altman Z-score and Ohlson O-Score as part of its calculations to determine the amount of security the applicant must submit under § 726.105. To calculate these scores, OWCP will require audited financial statements for the most recent and prior fiscal years, including balance sheets, income statements, cash flow statements, financial statement notes, and market capitalization data for publicly traded companies. OWCP performed a retrospective analysis on previous bankruptcies that discharged unsecured liabilities to the Black Lung Disability Trust Fund (BLDTF). The proposed methodology would have been successful in identifying the growing risk of default and would have resulted in requiring higher levels of security at the critical time.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         The Altman Z-score is a financial metric used to predict the likelihood of a company entering bankruptcy within the next two years and is widely used in the financial industry. This score uses information directly from the company's balance sheets and income statements. Retrospective studies have shown that it is a reasonably efficient predictor of financial distress, particularly for manufacturing and similar industries. The formula considers: short-term liquidity; reliance on debt financing; operating efficiency; leverage; and revenue generation.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         The Ohlson O-Score is a credit scoring system that is used to predict the likelihood of a company going bankrupt within the next two years. The Ohlson O-Score uses a formula derived from nine variables: total assets; total liabilities; working capital; current liabilities; current assets; total liabilities to total assets; net income; funds from operations; and if a net loss has occurred for the last two years.
                    </P>
                </FTNT>
                <P>OWCP proposes to add a new paragraph (b)(9) that will allow OWCP to request additional information or evidence not outlined in paragraphs (b)(1) through (b)(8). OWCP may request additional information related to the supporting documentation submitted by the applicant as provided by paragraphs (b)(1) through (b)(8). OWCP's request will detail the reasons for requesting additional information. An example of this would be OWCP's request for additional information because there is a note in the financial statement that necessitates clarification before review of the application can continue.</P>
                <P>OWCP proposes retaining the language contained in current § 726.102(c) in its entirety and renumbering current § 726.102(c) as the new § 726.101(e).</P>
                <HD SOURCE="HD3">20 CFR 726.103 Application for Authority To Self-Insure; Effect of Regulations Contained in This Part</HD>
                <P>Current § 726.103 provides that each of the regulations, interpretations and requirements contained in this part 726, including those described in subpart C related to insurance contracts, are binding upon each applicant for self-insurance authorization, and the applicant's consent to be bound by all requirements of the regulations in this part are deemed to be included in and a part of the application, as fully as though written therein.</P>
                <P>
                    OWCP proposes revising this section for clarification in response to a court decision that called into question OWCP's ability to hold liable a parent company based on its self-insurance of a subsidiary when the miner last worked there, if the parent later sold the subsidiary. (
                    <E T="03">See Hobet Mining Co.</E>
                     v. 
                    <E T="03">Director, OWCP and Horace Meredith,</E>
                     156 F.4th 385 (4th Cir. 2025). OWCP proposes to add a new sentence clarifying that an applicant's consent to be bound by all requirements in this part includes, but is not limited to, § 726.203's insurance endorsement, which applies to any self-insurer. For instance, a parent company whose self-insurance authorization includes a subsidiary company shall remain liable for federal black lung claims based on employment with that subsidiary, regardless of any sale or transfer of the subsidiary.
                </P>
                <HD SOURCE="HD3">20 CFR 726.104 Action by OWCP Upon Application of Operator</HD>
                <P>OWCP proposes revising § 726.104 to focus on the actions OWCP will take upon receipt of applications and how much time operators will have to phase in their required security amounts. OWCP proposes to move references to the forms of security that operators may use from § 726.104 to § 726.106.</P>
                <P>Current paragraph (a) is retained in its entirety. OWCP proposes to make stylistic changes to paragraph (a). No alteration in meaning either results from or is intended by these changes.</P>
                <P>OWCP proposes retaining the portion of paragraph (b) that provides that OWCP will notify an operator that it may give security in an amount fixed by OWCP. OWCP proposes removing paragraphs (b)(1), (b)(2), (b)(3), and (b)(4), which list the acceptable types of security in the current rule, and will instead provide this information in § 726.106.</P>
                <P>
                    OWCP proposes to substantially revise paragraph (c) to change the period of time and process through which operators may phase in their security, after the initial self-insurance review under these new regulations. Current paragraph (c) requires operators to phase in their security within one year. OWCP proposes to revise this phased approach by allowing approved operators to reach full security over the course of three years commencing with OWCP's acceptance of the first security deposit. The first security deposit for year one will be equal to at least 34% of the operator's overall security amount. For the following year, designated as year two, the second annual security deposit will be at least 33%, bringing the total security submitted to at least 67% of the operator's total security requirement. At year three, the remaining balance or 33% of security will be submitted, bringing the operator to its total calculated security. OWCP will notify the operator of the amounts and submission deadline for each security deposit after the initial review under these revised regulations. In this notification, OWCP will typically provide operators thirty calendar days to submit their payments, which can be extended for good cause. This change to the phase-in period is in recognition that some self-insured mine operators are currently severely under-secured and requiring them to attain even a low-level tier of security could put a strain on their financial capital at a time when both coal mine expansion is crucial and the industry continues to shoulder significant regulatory burdens elsewhere. In response to prior self-insurance rulemaking, operators have opposed the narrow timeframes allotted for submission of additional securities, arguing that anything less than a three-year phased in approach is not only unworkable, but arbitrary and capricious. Therefore, developing a longer phase-in approach and providing coal mine operators an established annual period to scale up their security would reduce that burden for entities that are not already at their required security level. This approach will also allow OWCP to take into account various factors that may affect the amount of security required each year of the three-year period, including the operator's assessed risk of default and the amount of security that the operator has already deposited. Furthermore, allowing operators a reasonable time to reach full security will protect the Trust Fund from absorbing the consequences of any potential default caused by operators being unable to reach full security on a truncated timeline. The three-year phase-in approach is only applicable for submitting security to 
                    <PRTPAGE P="48007"/>
                    attain total security after the initial review conducted under these revised regulations. Operators will not be afforded additional years to attain total security with each review of a subsequent application for reauthorization.
                </P>
                <P>OWCP proposes to revise paragraph (d) to provide that initial self-insurance authorization is contingent upon and effective upon receipt of either the full security amount or the first security deposit under paragraph (c) of this section, in addition to a completed form OWCP-1 Agreement and Undertaking.</P>
                <P>OWCP proposes to revise paragraph (e)(2) to provide that renewed self-insurance authorization is contingent upon and effective upon receipt of either the full security amount or the first security deposit under paragraph (c) of this section, in addition to a completed form OWCP-1 Agreement and Undertaking. The rest of current paragraph (e) is retained in its entirety. OWCP proposes to make stylistic changes to the rest of paragraph (e). No alteration in meaning either results from or is intended by these changes.</P>
                <P>OWCP proposes to revise paragraph (f) to clarify that an applicant who cannot satisfy its security requirements has 30 calendar days after OWCP issues notification of its decision to obtain and submit proof of a commercial policy or contract of insurance.</P>
                <HD SOURCE="HD3">20 CFR 726.105 Fixing the Amount of Security</HD>
                <P>Current § 726.105 provides that any operator approved to self-insure must submit security equal to 100 percent of its actuarial estimated liabilities (all present and future liabilities) as determined by OWCP based on the actuarial report or reports submitted by the applicant (or on file with OWCP), other information submitted with the operator's application, or any other materials or information that OWCP deems relevant.</P>
                <P>OWCP proposes to delete current § 726.105 and replace it with a new § 726.105. Proposed § 726.105 would provide that any operator approved to self-insure must submit security according to a multi-tiered risk-focused framework. This new model is designed around financial assessments based on accepted accounting standards and principles. This approach is also consistent with methodologies outlined in the National Association of Insurance Commissioners Financial Condition Examiners Handbook. OWCP will use the self-insured coal mine operator's financial strength to determine the percentage of their total estimated liability which would require security annually. By setting required security amounts at manageable levels, OWCP seeks to prevent a negative impact on coal mine operations while protecting the Trust Fund from absorbing the negative effects of coal-industry disruptions and insolvencies.</P>
                <P>New paragraph (a) describes the methodology used by OWCP to determine the amount of security an operator must provide to self-insure their liabilities under the Act. OWCP will determine the financial position of the applicant by the credit rating report submitted in accordance with new § 726.102, in conjunction with the financial metrics outlined in new paragraph (b) of this section. If no external credit rating exists, OWCP will perform an assessment based upon information submitted by the applicant. The risk assessment will place each operator within one of seven tiers with the most financially secure entities required to secure less of their liabilities, while operators who are financially riskier would be required to secure a higher percentage.</P>
                <P>OWCP proposes new paragraph (b), which will provide that the amount of required security is determined by calculating a Composite Solvency Score that evaluates the financial health of the operator using a combination of metrics in accordance with actuarial standards. OWCP shall calculate the Composite Solvency Score for each self-insured operator based upon three factors. OWCP proposes new paragraph (b)(2), which will list the three financial indicators it will use to determine the Composite Solvency Score: (i) the company's credit rating; (ii) the company's Altman Z-score; and (iii) and the company's Ohlson O-score.</P>
                <P>Subparagraph (b)(2)(i) explains that OWCP will review an operator's most recent long-term credit rating from a nationally recognized statistical rating organization, such as Fitch Ratings, Moody's Investors Service or Standard and Poor's.</P>
                <P>Subparagraphs (b)(2)(ii) and (b)(2)(iii) explain that OWCP will also factor the Altman Z-score and Ohlson O-score into its calculation of the Composite Solvency Score.</P>
                <P>New paragraph (c) provides the procedure OWCP will follow to calculate the Composite Solvency Score. New paragraph (c)(1) provides the formulas for calculating each of the metrics. New paragraph (c)(2) describes how the scores for each metric will be normalized so that the results can be weighted into a composite score. This step is necessary in the scoring process because each of the metrics is expressed on a different scale. A consistent, normalized, scale is applied to ensure that equivalent levels of risk are represented comparably across all metrics. New paragraph (c)(3) provides the final formula OWCP will use to calculate the Composite Solvency Score.</P>
                <P>New paragraph (d) provides that after calculating the Composite Solvency Score, OWCP will assign an operator to the appropriate tier of scores and will require the operator to secure the appropriate percentage of their estimated liability based on that tier. The tier structure outlined in paragraph (d) represents OWCP's planned structure for the first year of implementing any final rule arising from this proposed rule. OWCP will update this tier structure periodically by published subregulatory guidance. These adjustments will be based on actuarially assessed economic factors involving the industry.</P>
                <P>New paragraph (e) provides that OWCP reserves the right to conduct its own independent financial analysis.</P>
                <HD SOURCE="HD3">20 CFR 726.106 Type of Security</HD>
                <P>OWCP proposes amending § 726.106 to list the acceptable types of security, a change from where they appear in the current rule, § 726.104(b), and to allow operators to utilize new methods to secure liabilities.</P>
                <P>OWCP proposes to amend paragraph (a) to reiterate that multiple forms of security may be utilized to attain the fixed security amount.</P>
                <P>Current paragraph (b) is retained in its entirety.</P>
                <P>OWCP proposes to revise paragraph (c) to add that deposits of negotiable securities must be in compliance with § 726.107.</P>
                <P>OWCP proposes to add paragraph (d) to describe a letter of credit as an acceptable type of security. Letters of credit are described as acceptable types of security in the current rule at § 726.104(b)(3), but the current rule notes that letters of credit are not sufficient by themselves to satisfy an operator's security obligations. OWCP proposes to more definitively limit the portion of a self-insured operator's estimated liabilities that can be secured by a letter of credit, requiring that a letter of credit may only be used to secure fifty percent of an operator's estimated liability. In the event of an insolvency, a letter of credit does not provide priority over other creditors. In order to protect the Trust Fund while still allowing flexibility, OWCP would limit the amount of estimated liability that can be secured through a letter of credit.</P>
                <P>
                    OWCP proposes to add paragraph (e) to describe a Section 501(c)(21) trust as 
                    <PRTPAGE P="48008"/>
                    an acceptable type of security. OWCP proposes to reintroduce the option for operators to provide security in the form of a new 501(c)(21) trust. The 2024 rulemaking restricted the use of new trusts, and mandated that only trusts in existence prior to publication of the final rule would be allowed. 
                    <E T="03">See</E>
                     89 FR 100304, 100305 (December 12, 2024). In the 2024 rule, OWCP noted that 501(c)(21) trusts had proven to be a less reliable form of security. 
                    <E T="03">Id.</E>
                     A number of commenters expressed disagreement with this change. In part, commenters disputed the Department's authority to remove this kind of security instrument and noted that 501(c)(21) trusts are not inherently riskier to the Trust Fund. 
                    <E T="03">Id.</E>
                     at 100308. The Department explained in the 2024 Final Rule that while the Department is not concerned about the riskiness of investments in 501(c)(21) trusts, it is concerned about the risk that money in such trusts may fall below necessary security amounts because the trusts can be used to pay claims and other expenses. 
                    <E T="03">Id.; see also</E>
                     26 U.S.C. 501(c)(21)(A). OWCP now proposes to permit the use of new 501(c)(21) trusts as security, but to protect against the risk described here, OWCP proposes to require that an operator secure no more than fifty percent of its estimated liabilities using such a trust. The operator would be required to secure the remaining liabilities with another method or combination of methods.
                </P>
                <P>OWCP proposes to add paragraph (f) to allow self-insured operators to secure a portion of their liabilities using reinsurance policies. Reinsurance policies under this new subsection will be limited to stop-loss or catastrophic coverage, and must not exceed 90% of the operator's total security amount. A reinsurance policy must be utilized in conjunction with one or more other types of security, and those other types of security will act as the self-insured retention limit that must be exhausted before the reinsurance policy becomes responsible. Similar to other commercial insurance, as provided in 20 CFR 726.202, a reinsurance contract can be underwritten by any stock company or mutual company or association, or with any other person, or fund, including any State fund while such company, association, person, or fund is authorized under the law of any State to insure workers' compensation. All reinsurance contracts will be subject to the same requirements of commercial insurance contracts under the Act and regulations, including 30 U.S.C. 933(b) (required provisions of insurance contracts) and 933(c) (cancellation of insurance contracts), and 20 CFR 726.201-213. OWCP proposes to incorporate the provisions of 20 CFR 726.203-207 into § 726.106(f).</P>
                <P>OWCP proposes to add paragraph (g) to allow self-insured operators to secure their liabilities using a guaranty from a parent company. The parent company will irrevocably and unconditionally, and jointly and severally, guarantee self-insured obligations allocated to the operator under the Act, either in part or in full, as allowed by OWCP. The guaranty must be submitted on parent company letterhead and contain language as required by OWCP. The guaranty shall be continuous in form and remain in full force and effect until authorized cancellation or release by OWCP. The existence of a parental guaranty does not eliminate liability for a subsidiary company, nor does the absence of a parental guaranty alter the liability of a parent company under the Act and implementing regulations. Because the success of a parental guaranty as self-insurance security will depend on the parent company's risk of default, OWCP proposes to allow a parent company to secure more than 50% of its subsidiary's estimated liabilities if the parent company has a Composite Solvency Score of at least 90 under § 726.105(d), and to secure less than 50% of its subsidiary's estimated liabilities if the parent company has a Composite Solvency Score of at least 70. No parent company with a Composite Solvency Score under 70 will be permitted to guarantee its subsidiary's liabilities.</P>
                <P>OWCP proposes to add paragraph (h) to allow an operator to create a hierarchy to determine which security instrument is to be the primary payor, secondary payor, and so forth, in the event of a partial default. Allowing the operator to determine the order in which funds should be recovered may influence the price of the instrument. A hierarchy of this type would not alleviate the operator's responsibility to secure the required amount of estimated liabilities, and would pose no additional risks to the Black Lung Disability Trust Fund in the event of a default.</P>
                <HD SOURCE="HD3">20 CFR 726.107 How Negotiable Securities Are Handled</HD>
                <P>Current § 726.107 is retained in its entirety.</P>
                <HD SOURCE="HD3">20 CFR 726.108 Withdrawal of Securities</HD>
                <P>Current § 726.108 is retained with minor changes.</P>
                <HD SOURCE="HD3">20 CFR 726.109 Adjustments in the Amount of Security</HD>
                <P>Current paragraph (a) provides OWCP with discretion to increase security between annual reauthorization reviews when OWCP determines that the security on deposit is less than 100% of the self-insurer's estimated liabilities. OWCP proposes revising § 726.109(a) to reflect the change in percentage of estimated liabilities that will be required for security under § 726.105 and to allow OWCP to decrease, rather than only increase, an operator's security between annual reauthorization reviews.</P>
                <P>
                    OWCP proposes adding subparagraphs (1) and (2) to explain the conditions that would necessitate a security adjustment. Most notably, if evidence alters an operator's Composite Solvency Score, then OWCP may deem it necessary to adjust the amount of total security or scheduled phase-in deposits. 
                    <E T="03">See</E>
                     §§ 726.105, and 726.112.
                </P>
                <P>Current § 726.109(b) is retained in its entirety.</P>
                <HD SOURCE="HD3">20 CFR 726.110 Filing of Agreement and Undertaking</HD>
                <P>OWCP proposes revising § 726.110 to remove reporting requirements, which will instead be part of § 726.112. Current § 726.110 provides additional conditions that must be met prior to an operator receiving authorization to self-insure. Specifically, an operator must execute and file a form Agreement and Undertaking, in which the operator agrees to the terms of its self-insurance authorization. These requirements are set out in current paragraphs (a) and (b), which are retained in their entirety. OWCP proposes to make stylistic changes to paragraphs (a) and (b). No alteration in meaning either results from or is intended by these changes.</P>
                <P>OWCP proposes to remove paragraphs (c) and (d) from this section. These paragraphs provide requirements that operators notify OWCP of certain changes and allow OWCP to require certain information from operators. OWCP proposes moving these provisions to § 726.112, Reporting Required of Self-Insurer; Examination of Accounts of Self-Insurer.</P>
                <HD SOURCE="HD3">20 CFR 726.111 Notice of Authorization To Self-Insure</HD>
                <P>Current § 726.111 is retained in its entirety.</P>
                <HD SOURCE="HD3">20 CFR 726.112 Reporting Required of Self-Insurer; Examination of Accounts of Self-Insurer</HD>
                <P>
                    Current § 726.112 provides reporting requirements of authorized self-insurers, including the examination of books of 
                    <PRTPAGE P="48009"/>
                    account, records, and other documentation to verify evidence submitted as part of the application process.
                </P>
                <P>OWCP proposes revising the language contained within paragraphs (a) and (b) to better explain conditions that would require an operator to provide additional information or necessitate inspection of financial documentation. When evidence suggests that the operator is neglecting duties as required under 726.110, OWCP may request supplemental documentation confirming all benefits payable have been rendered when due and proper security limits as required under § 726.105 are being maintained.</P>
                <P>OWCP proposes retaining the language contained in current § 726.110(c) and renumbering as new § 726.112(c). New paragraph (c) will provide the requirements that operators notify OWCP of certain changes to operations covered under the self-insurance authorization. Also, OWCP proposes revising the language of current § 726.110(d) and renumbering as new § 726.112(d). New paragraph (d) will provide that OWCP may require an operator to provide supplemental information upon notification of changes under paragraph (c) of this section only if it determines that the operator's total security under 726.105 will be impacted.</P>
                <P>Given the foregoing changes, OWCP proposes to renumber current paragraph (c) as paragraph (e) and retain the language in its entirety.</P>
                <HD SOURCE="HD3">20 CFR 726.113 Disclosure of Confidential Information</HD>
                <P>Current § 726.113 is retained with non-substantive, editorial revisions to improve clarity.</P>
                <HD SOURCE="HD3">20 CFR 726.114 Authorization and Reauthorization Timeframes</HD>
                <P>Current § 726.114 is retained with non-substantive, editorial revisions to improve clarity.</P>
                <HD SOURCE="HD3">20 CFR 726.115 Revocation of Authorization To Self-Insure</HD>
                <P>Current § 726.115 is retained in its entirety.</P>
                <HD SOURCE="HD3">20 CFR 726.116 Appeal Process</HD>
                <P>Section 726.116 establishes the steps an applicant must undertake to appeal a self-insurance determination made by OWCP. Current paragraph (a) provides that an applicant may file an appeal in writing with the Director of OWCP in the form and manner prescribed by OWCP within 30 days of the issuance of a self-insurance determination. The 30-day deadline may not be extended. OWCP proposes to retain the substance of this paragraph but clarify that an appeal must be made within 30 calendar days of the issuance of a self-insurance determination.</P>
                <P>Current paragraph (b) provides that an applicant may submit a brief in support of its appeal, but no further evidence not provided with the initial application. OWCP proposes to amend this paragraph to allow applicants an opportunity to submit additional evidence in support of an appeal. Current paragraph (b) also provides that OWCP may extend an applicant's deadline to submit briefing for up to 30 days upon a showing of good cause, up to a maximum of two extensions. OWCP proposes revising paragraph (b) to allow OWCP to extend an applicant's deadline upon a showing of good cause, without limiting the extensions to 30 days or a maximum of two extensions. OWCP proposes these changes because the Department believes the current provisions do not allow enough opportunity for applicants to submit evidence or enough time to do so.</P>
                <P>Current paragraph (c) sets forth the process for requesting an informal conference on an appeal. Current subparagraph (c)(1) provides that an applicant may request in writing an informal conference when it submits its brief in support of an appeal. To provide greater flexibility to applicants, OWCP proposes slightly revising subparagraph (c)(1) to reflect that an applicant may request an informal conference when submitting its brief and evidence or when submitting any new evidence in support of its appeal. Current subparagraph (c)(2) is retained in its entirety.</P>
                <P>Current subparagraph (c)(3) provides that if an applicant does not request a conference, OWCP may decide the appeal without one or schedule an informal conference on its own initiative. Subparagraph (c)(3) is retained with stylistic changes.</P>
                <P>Current subparagraph (c)(4) provides that the informal conference will be limited to the issues an applicant identified in its written materials. Subparagraph (c)(4) is retained in its entirety.</P>
                <P>Current paragraph (d) sets forth OWCP's obligations in the review process and issuance of a final agency decision. Current paragraph (d) provides that OWCP will review its previous determination and issue a final agency decision. OWCP proposes to clarify that the division will review the previous determination in light of any new evidence and information submitted.</P>
                <P>Current subparagraph (d)(1) provides that the Director of OWCP will review the initial determination, the evidence of record, and arguments on appeal, and that the applicant may not submit any new evidence to the Director of OWCP. OWCP proposes revising subparagraph (d)(1) to clarify that an applicant may only submit evidence allowed in proposed 726.116(b).</P>
                <P>Current subparagraph (d)(2) provides that the Director of OWCP will have 60 days to take up the appeal and issue a final agency decision. Current subparagraph (d)(3) provides that if the Director of OWCP issues a final agency decision denying self-insurance authorization, any existing authorization will end and the applicant will have 30 days to obtain and submit proof of commercial insurance or face civil penalties for failure to secure benefits. OWCP proposes to retain the substance of subparagraphs (d)(2) and (d)(3), but clarify the deadlines in terms of calendar days. OWCP will also add that a final agency decision will be issued within 7 calendar days after review of appeal and evidence provided.</P>
                <HD SOURCE="HD2">C. Severability</HD>
                <P>The Department proposes to include a severability provision in Part 726 Subpart B, so that if one or more of the provisions of Part 726 are held invalid or stayed pending further agency action, the remaining provisions would remain effective and operative. The Department believes that the provisions of the proposed rule can operate independently and will improve the effectiveness of the self-insurance program, even if other provisions are deemed invalid.</P>
                <P>
                    It is the Department's intent that any final rule following this proposal apply to its greatest extent even if one or more provisions of such rule are invalidated or stayed. For example, it is the Department's intent that each of the minimum requirements that must be met by an operator under § 726.101(b)'s be effective even if one of those requirements is invalidated. Similarly, it is the Department's intent that each of the financial risk metrics relied on in § 726.105(b)(2) be effective even if the consideration of one of those metrics is invalidated. It is also the Department's intent that each form of security provided in § 726.106 be effective even if one of those forms of security is invalidated. This list is not exhaustive. In all circumstances, whether or not specifically discussed, it is the Department's intent that the provisions of any final rule be construed to give the maximum effect to the provisions permitted by law, and that any invalidated provisions be considered 
                    <PRTPAGE P="48010"/>
                    severable from Part 726 and not affect the remainder of any final rule.
                </P>
                <HD SOURCE="HD1">IV. Administrative Law Considerations</HD>
                <HD SOURCE="HD2">A. Information Collection Requirements</HD>
                <P>
                    The Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 
                    <E T="03">et seq.,</E>
                     and its implementing regulations, 5 CFR part 1320, require that the Department consider the impact of paperwork and other information collection burdens imposed on the public. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless it is approved by the Office of Management and Budget (OMB) under the PRA and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person may generally be subject to penalty for failing to comply with a collection of information that does not display a valid Control Number. 
                    <E T="03">See</E>
                     5 CFR 1320.5(a) and 1320.6.
                </P>
                <P>
                    The proposed rule contains information collections within the meaning of the PRA (
                    <E T="03">see</E>
                     proposed § 726.102), however, these collections are not new. They are currently approved for use in the Black Lung program by OMB under Control Number 1240-0057 (CM-2017 Application or Renewal of Self-Insurance Authority; and CM-2017b Report of Claims Information for Self-Insured Operators). The requirements for completion of the forms and the information collected on the forms will not change if this rule is adopted in final. In fact, as with the current rule, this proposed rule removes the previous requirement for OWCP to review self-insurers' quarterly financial reports.
                </P>
                <P>Consistent with the 2024 rule, the proposed rule requires applicants to submit an actuarial report of current and future liabilities utilizing actuarial assumptions provided by OWCP. This is not a new requirement of operators. The stipulated data points are based on historical, current, and future trend analysis experienced by the Trust Fund. Applicants will be afforded the opportunity to submit alternative actuarial reports based on their individual experience as a self-insurer.</P>
                <P>Although the proposed rule adds the requirement for applicants to submit the most recent long-term credit rating report (if available), as well as audited financial statements for the most recent and prior fiscal years, including balance sheets, income statements, cash flow statements, financial statement notes, and market capitalization data for publicly traded companies, the burden on applicants would be minimal. These financial documents are not unfamiliar to applicants and are, in fact, routinely created as part of standard operating procedures. Providing OWCP with copies of these existing documents will not be an arduous task for applicants, so the overall burden imposed by the information collections is negligible.</P>
                <HD SOURCE="HD2">B. Executive Order 12866: Regulatory Planning and Review; Executive Order 13563: Improving Regulation and Regulatory Review; and 14192 (Unleashing Prosperity Through Deregulation)</HD>
                <P>
                    Under Executive Order (E.O.) 12866, as amended by E.O. 14904, the Office of Information and Regulatory Affairs (OIRA) of OMB determines whether a regulatory action is significant and, therefore, subject to the requirements of the E.O. and review by OMB. Section 3(f) of E.O. 12866 defines a “significant regulatory action” as an action that is likely to result in a rule that (1) has an annual effect on the economy of $100 million or more, or adversely affects in a material way a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, territorial or tribal governments or communities; (2) create a serious inconsistency or otherwise interfere with an action taken or planned by another agency; (3) materially alter the budgetary impacts of entitlements, grants, user fees, or loan programs, or the rights and obligations of recipients thereof; or (4) raises legal or policy issues “for which centralized review would meaningfully further the President's priorities or the principles set forth in this Executive order.” 
                    <E T="03">See</E>
                     E.O. 12866, 58 FR 51735 (Oct. 4, 1993).
                </P>
                <P>
                    Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, reducing costs, harmonizing rules, and promoting flexibility. It also instructs agencies to review “rules that may be outmoded, ineffective, insufficient, or excessively burdensome, and to modify, streamline, expand, or repeal them.” 
                    <E T="03">See</E>
                     E.O. 13563, 76 FR 3821 (Jan. 21, 2011).
                </P>
                <P>The Department has considered the proposed rule with these principles in mind and has determined that the anticipated benefits outweigh the costs. The discussion below sets out the rule's anticipated economic impact and discusses economic factors favoring adoption of the proposal. OIRA has reviewed this rule and designated it as a significant regulatory action under Section 3(f) of Executive Order 12866, as amended.</P>
                <P>Executive Order 14192, titled “Unleashing Prosperity Through Deregulation,” was issued on January 31, 2025. This proposed rule, if finalized as proposed, is expected to be an E.O. 14192 deregulatory action.</P>
                <HD SOURCE="HD3">1. Economic Considerations</HD>
                <P>The proposed rule will have an economic impact on operators that currently participate in the self-insurance program, as well as any new applicants.</P>
                <P>
                    As explained in the preamble, prior security requirements have proven inadequate to protect the Trust Fund when a self-insured operator becomes insolvent. From 2014 to 2016, three self-insured coal operators entered bankruptcy with combined collateral of $27.4 million; the resulting transfer of black lung liabilities to the Trust Fund was eventually estimated to be $865 million. 
                    <E T="03">See</E>
                     U.S. Government Accountability Office, 
                    <E T="03">Federal Black Lung Benefits Program: Improved Oversight of Coal Mine Operator Insurance is Needed,</E>
                     at 13 (Feb. 2020), available at 
                    <E T="03">https://www.gao.gov/products/gao-20-21</E>
                    . In response to those inadequacies, the Department underwent additional rulemaking. The regulations, as amended in 2024 (89 FR 100304, December 12, 2024) required operators to secure 100 percent of the actuarially estimated liabilities (all present and future liabilities), over one year, regardless of the operator's financial strength. This proposed rule will balance the need to protect the Trust Fund and secure benefits for affected coal miners, while decreasing potential risks and disruptions to the coal industry.
                </P>
                <P>This analysis provides the Department's estimate of the economic impact of the proposed rule, both on the economy as a whole and on individual operators. The Department invites comments on this analysis from all interested parties. The Department is particularly interested in comments addressing the Department's evaluation of the impact of the proposed rule on operators that currently participate in the self-insurance program.</P>
                <HD SOURCE="HD3">a. Data Considered</HD>
                <P>To determine the proposed rule's general economic impact, the Department calculated how the rule will affect several stakeholder groups, including: (i) OWCP, (ii) taxpayers, (iii) commercially insured operators, and (iv) self-insured operators.</P>
                <HD SOURCE="HD3">i. OWCP</HD>
                <P>
                    The proposed rule does not impose significant additional demands on OWCP resources. In fact, as with the current rule, this proposed rule removes 
                    <PRTPAGE P="48011"/>
                    the previous requirement for OWCP to review self-insurers' quarterly financial reports. The proposed rule will require OWCP to review each operator's financial information each year and determine the resulting security percentage. OWCP will also review actuarial liability estimates every three years and monitor authorized self-insurers for compliance with eligibility requirements. The review of annual financial reports and calculation of the required security percentage represents a change from the 2024 rule, but does not pose a significant cost on OWCP due to OWCP's familiarity with this task and the relatively small number of affected operators.
                </P>
                <P>OWCP may incur a minimal cost to review financial statements of the parent corporations of self-insured coal mine operators that elect the parental guarantee security option. However, this would not be a significant expense for OWCP.</P>
                <HD SOURCE="HD3">ii. Taxpayers</HD>
                <P>The proposed rule will be of net benefit to taxpayers. The proposed rule will balance the need to protect the Trust Fund and secure benefits for affected coal miners, while decreasing potential risks and disruptions to the coal industry upon which Americans rely for domestic energy production. In comparison to the 2024 rule, the proposed rule reallocates a portion of the bankruptcy-related risk to the taxpayers, but the required security deposits are appropriately aligned with the associated risk of bankruptcy.</P>
                <HD SOURCE="HD3">iii. Commercially Insured Operators</HD>
                <P>
                    The proposed rule will not impose additional costs on operators that secure their BLBA liabilities through commercial insurance. The proposed rule affects only the eligibility criteria, security requirements, and other procedures for operators that secure their liabilities by qualifying to self-insure. At most, commercially insured operators might choose to reassess whether, in light of these changes, commercial insurance remains the most cost-effective option for securing their liabilities or, instead, whether to switch to self-insurance. The cost of any such assessment would be 
                    <E T="03">de minimis.</E>
                </P>
                <HD SOURCE="HD3">iv. Self-Insured Operators</HD>
                <P>The proposed rule may reduce costs for current operators that are self-insured. OWCP has identified a total of 15 operators that are, or recently have been, actively mining coal and participating in the self-insurance program. Of these 15 self-insured operators, four have commercial insurance for their current operations, but self-insure their legacy liabilities. Six secure both their current and legacy liabilities through self-insurance. The remaining five have hybrid coverage with self-insurance or commercial insurance for legacy and current operations, depending on mine site location and/or subsidiary operator.</P>
                <P>The proposed rule will apply to these 15 operators. Table 1 lists the estimated actuarial liabilities, securities currently on deposit, the estimated security requirement under the 2024 final rule, and estimated future security requirements under the proposed rule.</P>
                <BILCOD>BILLING CODE; P</BILCOD>
                <GPH SPAN="3" DEEP="233">
                    <GID>EP30JY26.000</GID>
                </GPH>
                <BILCOD>BILLING CODE; C</BILCOD>
                <P>
                    The proposed rule imposes small changes to the reporting or filing requirements on the operators currently utilizing self-insurance. Operators are required to continue updating their actuarial liability estimates on a three-year cycle and are required to provide annual financial reports rather than quarterly financial reports. OWCP will provide applicants with actuarial assumptions based on Trust Fund data, however, it is permissible for operators to submit alternative actuarial reports based on their individual experience administering self-insured claims. As part of the security percentage calculation, operators will also be required to provide their most recent credit rating, if available, and publicly-traded operators will be required to provide their market capitalization amount consistent with the date of their financial statements. These financial documents are routinely created as part of standard operating procedures and should be readily available to applicants. The cost to provide OWCP with copies of the existing documentation would be minimal. There will also be a cost to the operators for the time required to review and understand the rule. Because of the small number of affected establishments, the cost of the change in reporting requirements and rule 
                    <PRTPAGE P="48012"/>
                    familiarization is 
                    <E T="03">de minimis</E>
                     in aggregate and is not included in the rule's total cost estimate. OWCP requests comments on the reporting burden from affected stakeholders.
                </P>
                <P>The proposed rule allows self-insured operators to adjust the amount of their security deposits to reach the required security percent. Table 1 reflects that all of the 15 current self-insured operators will be allowed to decrease their required security deposits as a result of this proposed rule. For each operator, the cost savings of the decrease in required security deposits depends on which security deposit option the operator employs (since different security options have different costs) and the amount of the permissible reduction in required security.</P>
                <P>
                    Operators with security deposits in the form of surety bonds incur a premium cost determined by the commercial bond underwriters. OWCP does not have direct information on the cost of these bonds, as pricing is a function of multiple qualitative and quantitative attributes of each operator and is determined by underwriters on a case-by-case basis. Each underwriter has their own pricing formula and offers various payment options. To estimate the impacts of the proposed rule, an annual premium ranging from 2 percent to 12 percent of the additional security was used as an estimate. This range is based on a review of public data from several different surety companies; however, actual costs could be higher or lower.
                    <SU>9</SU>
                    <FTREF/>
                     OWCP seeks comments from the public regarding the costs of bonds for coal mine operators. Additionally, OWCP estimates that in most cases the surety companies will require the operator to maintain a certain amount of restricted cash in support of the surety obligations. Based on a review of the coal industry financial reports, OWCP estimates an average restricted cash requirement of 25% of the surety bond amount. The opportunity cost of holding the restricted cash is estimated at the company or industry-level Weighted Average Cost of Capital (WACC) minus interest earned on the restricted cash. The median WACC for the coal and related energy industry is currently 8.4 percent, although the WACC for coal mining companies specifically, and in particular for individual coal mining companies, may be higher or lower. Interest earned on the restricted cash is currently estimated at 3 percent. These assumptions translate into an additional annual cost of approximately 1.5 percent per dollar of increased security. Adding the cost of the restricted cash requirements to the estimated surety bond premium results in an estimated range of 3.5 percent to 13.5 percent annual cost. This analysis focuses solely on surety bonds because that is both the most widely used option among currently self-insured operators and the most cost-effective option. If operators do not wish to use surety bonds, however, they may obtain a different form—or multiple forms—of security, or commercial insurance. 
                    <E T="03">See</E>
                     20 CFR 726.104(b), 30 U.S.C. 933(a), and 20 CFR 726.1 and 726.201.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         In reaching this estimate, OWCP reviewed publicly available estimates of surety bond premiums from BondExchange; Bryant Surety Bonds; Insureon; JW Surety Bonds; Lance Surety Bond Associates, Inc.; NNA Surety Bonds; Surety Bonds Direct; Surety Solutions; and Value Penguin. Note that these are for surety bonds generally, not surety bonds for coal companies specifically. The 2 to 12 percent range was then developed based on this public data.
                    </P>
                </FTNT>
                <P>
                    For operators with security deposits in the form of negotiable securities, the savings would consist of the opportunity costs of the reduced deposits (
                    <E T="03">i.e.,</E>
                     the difference in return between funds held in such accounts and funds invested elsewhere, such as in higher-performing investments or reinvested into the operations of the business itself). The opportunity costs for these operators could be estimated by calculating the difference between their WACC and the annual return earned on their security deposit and multiplying that figure by the dollar decrease in their security requirement. OWCP has not quantified these costs for two principal reasons. First, as noted above, most self-insured operators use surety bonds as security. OWCP does not anticipate that these operators will begin using negotiable securities. Second, annual surety bond costs are likely to be lower than the one-time financing of negotiable securities and associated opportunity costs, making surety bonds the more cost-effective option. Furthermore, any operators that currently use negotiable securities to secure some or all of their liabilities can continue using those securities in combination with surety bonds or similarly approved security option to comply with the revised security requirement (
                    <E T="03">i.e.,</E>
                     some portion of the operator's liabilities could be secured with negotiable securities and the remainder could be secured with surety bonds).
                </P>
                <P>
                    Table 2 calculates the estimated savings from obtaining a a smaller surety bond for each operator and compares this figure to each operator's annual revenues. Annual revenues are represented by the most recent revenue available to OWCP, as reported by S&amp;P or operator-provided financial statements. Annual costs are estimated as the average of the maximum and minimum annual cost (
                    <E T="03">i.e.,</E>
                     the midpoint of the 3.5 percent to 13.5 percent range). As shown in Table 2, the estimated annual impact for operators as a percentage of annual revenue ranges from 0.0002 percent to 0.257 percent savings.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Surety bonds are generally paid for annually, and the premium is paid up front at the beginning of the year or charged a finance fee for a payment plan. Discounting is not presented in Table 2 because the average estimated cost represents one annual premium payment, rather than the total net present value of all future payments.
                    </P>
                </FTNT>
                <P>OWCP invites additional information and supporting documentation from commenters on the cost of these bonds; security levels required by the surety providers; and information regarding financing costs, borrowing costs, or capital constraints relevant for evaluating the financial and operational impact of the proposed security requirements.</P>
                <BILCOD>BILLING CODE; P</BILCOD>
                <GPH SPAN="3" DEEP="283">
                    <PRTPAGE P="48013"/>
                    <GID>EP30JY26.001</GID>
                </GPH>
                <BILCOD>BILLING CODE; C</BILCOD>
                <P>
                    As a result of these changes, some self-insured operators might choose to reassess whether, in light of these changes, self-insurance remains the most cost-effective option for securing their liabilities or, instead, whether to switch to commercial insurance. The cost of any such assessment would be 
                    <E T="03">de minimis.</E>
                </P>
                <HD SOURCE="HD3">v. New Coal Mine Operators</HD>
                <P>Under current practices, operators new to coal mining are not permitted to self-insure during the first three years after commencing mining operations. The proposed rule would remove this three-year restriction while continuing to require a minimum security amount of $400,000 during the operator's initial three years of self-insurance. This change would provide greater flexibility for new operators in determining the most appropriate method for securing the payment of black lung benefits for their employees, while maintaining a baseline level of financial protection for the Trust Fund.</P>
                <HD SOURCE="HD3">b. Economic Impact Summary</HD>
                <P>
                    The Department believes the proposed rule will not have a significant impact on the economy as a whole. OIRA has used a $100 million-dollar annual threshold for determining the proposed rule's economic significance. See, 
                    <E T="03">e.g.,</E>
                     E.O. 12866.
                </P>
                <P>
                    Based on this test, the self-insurance rule change is not “economically significant” because its estimated combined impact ranges from approximately $7 million to $28 million savings on an annual basis, with a mid-range estimate of $17 million.
                    <SU>11</SU>
                    <FTREF/>
                     In Table 2 above, the minimum and maximum estimated impacts of the change in security requirements are based on 3.5 percent and 13.5 percent, respectively, of the total change in secured position for each operator. OWCP used an annual cost ranging from 3.5 percent to 13.5 percent of the secured amount based on a review of public data from several different surety companies and operator financial statements. OWCP used estimates for surety bonds because that is both the most widely used option among currently self-insured operators and likely to be the most cost-effective option.
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         The annualized impact is $31 million at 3 and 7 percent discount rates.
                    </P>
                </FTNT>
                <P>The impact on the coal industry overall is smaller than that of the self-insured operator group because we do not estimate any impact on commercially insured operators.</P>
                <HD SOURCE="HD3">2. Regulatory Alternatives</HD>
                <P>The Department considered alternative options and methods before proposing these changes to the self-insurance program. Specifically, the Department considered the repeal of the 2024 rule and a return to the prior scheme, or a fixed industry-wide security requirement similar to the 2024 rule's 100% requirement, but at a lesser level. The Department continues to believe that greater security than currently on deposit is required, and that a simple repeal of the 2024 rule would have a negative impact on the Trust Fund, leaving operators severely under secured. The potential financial impact on the Trust Fund is measured by the change in unsecured operator liabilities for future black lung claims. Current unsecured liabilities equal $572 million (the total $688 million estimated operator liability minus the $116 million in current operator securities). Should a series of operators default, the Trust Fund could experience an influx of liabilities similar to the events outlined in the U.S. Government Accountability Office, Federal Black Lung Benefits Program: Improved Oversight of Coal Mine Operators Insurance is Needed (February 2020).</P>
                <P>
                    Alternatively, the Department considered maintaining the structure and form of the 2024 rule but applying a different uniform security requirement. While this approach would have mitigated the impact of the loss of liquidity in the form of working capital, it would not address the fact that the 2024 rule did not allow for any consideration of individual company's financial health. The 2024 rule acknowledges OWCP's ability to set security levels and then abdicates that responsibility by imposing a full 100% 
                    <PRTPAGE P="48014"/>
                    security mandate. The Department now feels that companies should have the opportunity to present evidence of their ongoing ability to cover liabilities and receive a level commensurate with their status.
                </P>
                <HD SOURCE="HD2">C. Regulatory Flexibility Act and Executive Order 13272 (Proper Consideration of Small Entities in Agency Rulemaking)</HD>
                <P>
                    The Regulatory Flexibility Act of 1980 (RFA), 5 U.S.C. 601 
                    <E T="03">et seq.,</E>
                     requires an agency to prepare a regulatory flexibility analysis when it proposes regulations that will have “a significant economic impact on a substantial number of small entities” or to certify that the proposed regulations will have no such impact, and to make the analysis or certification available for public comment.
                </P>
                <P>The Department certifies that this rule will not have a significant economic impact on a substantial number of small entities. For the mining industry, the Small Business Administration (SBA) uses two levels of employee counts to define small mining operations:</P>
                <FP SOURCE="FP1-2">NAICS 212114 Bituminous Coal and Lignite Surface Mining—1,250 employees NAICS 212115 Bituminous Coal Underground Mining—1,500 employees</FP>
                <FP SOURCE="FP1-2">For purposes of this analysis, operators were classified as Surface operations (NAICS = 212114) or Underground (NAICS = 212115) depending on their predominant method of coal mining. The SBA classification of small entities was applied according to the operator's NAICS code type of operations.</FP>
                <P>According to the SBA criteria, 6 of the 15 self-insured operators, or 40 percent, are considered small firms. Tables 3A and 3B show the impact on small and large self- insured operators. As explained above, the minimum and maximum estimated impact of the change in security requirements is based on 3.5 percent and 13.5 percent, respectively, of the total change in secured position for each operator.</P>
                <GPH SPAN="3" DEEP="126">
                    <GID>EP30JY26.002</GID>
                </GPH>
                <GPH SPAN="3" DEEP="161">
                    <GID>EP30JY26.003</GID>
                </GPH>
                <P>
                    Based on these facts, the Department certifies that this rule will not have a significant economic impact on a substantial number of small entities.
                    <SU>12</SU>
                    <FTREF/>
                     The Department, however, invites comments from members of the public who believe the regulations will have a significant economic impact on a substantial number of small operators. The Department has provided the Chief Counsel for Advocacy of the Small Business Administration with a copy of this certification. 
                    <E T="03">See</E>
                     5 U.S.C. 605.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         The RFA does not define “significant” or “substantial.” 5 U.S.C. 601. It is widely accepted, however, that “[t]he agency is in the best position to gauge the small entity impacts of its regulations.” SBA Office of Advocacy, “A Guide for Government Agencies: How to Comply with the Regulatory Flexibility Act,” at 18 (August 2017), available at 
                        <E T="03">https://cdn.advocacy.sba.gov/wp-content/uploads/2019/06/21110349/How-to-Comply-with-the-RFA.pdf.</E>
                         One measure for determining whether an economic impact is “significant” is the percentage of revenue affected. For this rule, the Department used as a standard of significant economic impact whether the costs for a small entity equal or exceed 3 percent of the entity's annual revenue.
                    </P>
                    <P>
                        The Department has used the threshold of 3 percent of revenues for the definition of significant economic impact in a number of recent rulemakings. 
                        <E T="03">See, e.g.,</E>
                         Wage and Hour Division, Establishing a Minimum Wage for Contractors, Notice of Proposed Rulemaking, 79 FR 34568, 34603 (June 17, 2014); Office of Federal Contract Compliance Programs, Government Contractors, Requirement To Report Summary Data on Employee Compensation, Notice of Proposed Rulemaking, 79 FR 46562, 46591 (Aug. 8, 2014). The 3 percent standard is also consistent with the standards utilized by various other Federal agencies in conducting their regulatory flexibility analyses. 
                        <E T="03">See, e.g.,</E>
                         Department of Health and Human Services, Centers for Medicare &amp; Medicaid Services, “Medicare and Medicaid Programs; Regulatory Provisions To Promote Program Efficiency, Transparency, and Burden Reduction; Part II; Final Rule,” 79 FR 27106, 27151 (May 12, 2014).
                    </P>
                </FTNT>
                <PRTPAGE P="48015"/>
                <HD SOURCE="HD3">Industry Profile and Analysis</HD>
                <HD SOURCE="HD3">Types of Operations</HD>
                <P>The United States coal mine industry consists of hundreds of mines controlled by hundreds of operators. Coal mine operators vary in size from owners of multiple mines to operators of single mines. The two main categories of coal mining operations are surface and underground, but many operators are also involved in other coal-related enterprises, including steel production, mining technology and support services, petroleum products, other mineral mining operations, and energy generation. Coal mining is the only focus of some operators, while for others it is only incidental to their main enterprise. For purposes of this analysis, operators engaged in surface mining or with multiple streams of revenue were classified as Surface operations (NAICS = 212114). Other operators were classified as Underground (NAICS = 212115) depending on their main source of revenues. The SBA classification of small entities was applied according to the operator's NAICS code type of operations.</P>
                <HD SOURCE="HD3">Revenues Versus Coal Production</HD>
                <P>Typically, coal operators are analyzed on the basis of measures such as coal production, coal reserves, and mine productivity. Among self-insured operators, there are differences in the proportion of coal mining operations covered by self-insurance, and the proportion of operators' total operations that are mining related (see Table 4 below). To determine the impact of the rule change, total company revenues were used, because an individual operator could have multiple revenue streams available to support their workers' compensation costs. As noted, 40 percent of the self-insured operators are classified as “small” using employee counts, under the SBA's definitions. Additionally, 47 percent are classified as “major” coal producers based on coal production. The “major” classification is based on the U.S. Energy Information Administration (“EIA”) criterion of producing more than 5 million short tons of coal per year.</P>
                <GPH SPAN="3" DEEP="343">
                    <GID>EP30JY26.004</GID>
                </GPH>
                <HD SOURCE="HD2">D. Unfunded Mandates Reform Act of 1995</HD>
                <P>
                    Title II of the Unfunded Mandates Reform Act of 1995, 2 U.S.C. 1531 
                    <E T="03">et seq.,</E>
                     directs agencies to assess the effects of Federal regulatory actions on state, local, and tribal governments, and the private sector, “other than to the extent that such regulations incorporate requirements specifically set forth in law.” The proposed rule does not include any Federal mandate that may result in increased expenditures by state, local, tribal governments, or increased expenditures by the private sector of more than $100 million, and therefore is not covered by the Unfunded Mandates Reform Act.
                </P>
                <HD SOURCE="HD2">E. Executive Order 13132 (Federalism)</HD>
                <P>
                    The Department has reviewed this proposed rule in accordance with Executive Order 13132 regarding federalism and has determined that it does not have “federalism implications.” E.O. 13132, 64 FR 43255 (Aug. 4, 1999). The proposed rule will not “have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various 
                    <PRTPAGE P="48016"/>
                    levels of government” if promulgated as a final rule. 
                    <E T="03">Id.</E>
                </P>
                <HD SOURCE="HD2">F. Executive Order 12988 (Civil Justice Reform)</HD>
                <P>The proposed rule meets the applicable standards in Sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 20 CFR Part 726</HD>
                    <P>Administrative practice and procedure, Black lung benefits, Coal miners, Mines, Penalties.</P>
                </LSTSUB>
                <P>For the reasons set forth in the preamble, the Department of Labor proposes to amend 20 CFR part 726 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 726—BLACK LUNG BENEFITS; REQUIREMENTS FOR COAL MINE OPERATOR'S INSURANCE</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 726 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>
                        5 U.S.C. 301; 30 U.S.C. 901 
                        <E T="03">et seq.,</E>
                         902(f), 925, 932, 933, 934, 936; 33 U.S.C. 901 
                        <E T="03">et seq.;</E>
                         28 U.S.C. 2461 note (Federal Civil Penalties Inflation Adjustment Act of 1990 (as amended by the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015)); Pub. L. 114-74 at sec. 701; Reorganization Plan No. 6 of 1950, 15 FR 3174; Secretary's Order 10-2009, 74 FR 58834.
                    </P>
                </AUTH>
                <AMDPAR>2. For the reasons set forth in the preamble, revise Subpart B as follows:</AMDPAR>
                <SUBPART>
                    <HD SOURCE="HED">Subpart B—Authorization of Self-Insurers</HD>
                    <SECTION>
                        <SECTNO>§ 726.101 </SECTNO>
                        <SUBJECT>Who May File and be Authorized to Self-Insure.</SUBJECT>
                        <P>(a) Pursuant to section 423 of part C of title IV of the Act, authorization to self-insure against liability incurred by coal mine operators on account of the total disability or death of miners due to pneumoconiosis may be granted or denied in the discretion of the Secretary. The provisions of this subpart describe the minimum requirements established by the Secretary for determining whether any particular coal mine operator may be authorized as a self-insurer.</P>
                        <P>(b) The minimum requirements which must be met by any operator seeking authorization to self-insure are as follows:</P>
                        <P>(1) First time applicants will be required to submit and maintain, at minimum, $400,000 in security for the first three years of their self-insurance authorization. If at the time of application or during subsequent annual reviews during these first three years, the operator's total present and future estimated liabilities exceed this amount, the operator will be required to secure 100% of its estimated liabilities. After three years, the operator is subject to the requirements outlined in § 726.105, and they may withdraw any excess security that was required from them in the first three years of their self-insurance authorization.</P>
                        <P>(2) The operator must demonstrate the administrative capacity to fully service such claims as may be filed against it; and,</P>
                        <P>(3) Such operator must obtain security, in a form approved by OWCP (see § 726.104) and in an amount to be determined by OWCP (see § 726.105).</P>
                        <P>(c) No application will be approved until OWCP receives security in the amount and in the form determined by OWCP. If the applicant is seeking authorization to self-insure for the first time, it is not authorized to self-insure while its application is under review.</P>
                        <P>(d) No operator whose application for authorization to self-insure or to renew authorization to self-insure is denied may reapply until 12 months after a final decision denying such application.</P>
                        <P>(e) An application for authorization to self-insure (including an application to renew authority to self-insure) may be filed by any parent or subsidiary corporation, partner or partnership, party to a joint venture or joint venture, individual, or other business entity which may be determined liable for the payment of black lung benefits under part C of title IV of the Act, regardless of whether such applicant is directly engaged in the business of mining coal. However, in each case for which authorization to self-insure is granted, the agreement and undertaking filed pursuant to § 726.110 and the security deposit must be respectively filed by and deposited in the name of the applicant only. A parent corporation that holds self-insurance authorization encompassing subsidiary companies shall remain liable for claims arising from employment with such subsidiaries, regardless of any sale or transfer of the subsidiaries.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.102</SECTNO>
                        <SUBJECT> Application for Authority to Become a Self-Insurer; How Filed; Information to be Submitted.</SUBJECT>
                        <P>(a) How filed. An application for authorization to self-insure or to renew authorization to self-insure must be submitted electronically in the manner prescribed by OWCP. Such application must be signed by the applicant and if the applicant is not an individual, by the principal officer of the applicant duly authorized to make such application.</P>
                        <P>(b) Information to be submitted. Each application for authority to self-insure or to renew authorization to self-insure must contain the following:</P>
                        <P>(1) Any application forms required by OWCP.</P>
                        <P>(2) An actuarial report using OWCP-mandated actuarial assumptions, unless the applicant has submitted such a report within the preceding 3 years. The operator may submit an additional actuarial report using alternate assumptions with an explanation of why it believes the alternative assumptions are appropriate.</P>
                        <P>(3) A statement of the employer's payroll report for each of the preceding 3 years.</P>
                        <P>(4) A statement of the average number of employees engaged in employment within the purview of the Act for each of the preceding 3 years.</P>
                        <P>(5) A list of the mine or mines to be covered by any particular self-insurance agreement. Each such mine or mines listed must be described by name and reference must be made to the Mine Identification Number assigned such mine by the Mine Safety and Health Administration, U.S. Department of Labor.</P>
                        <P>(6) A statement demonstrating the applicant's administrative capacity to provide or procure adequate servicing for a claim including both medical and dollar claims.</P>
                        <P>(7) The most recent long-term issuer credit rating report issued by a nationally recognized statistical rating organization. The issue date for the credit rating must be within the past 18 months and the credit rating agency must be registered as a nationally recognized statistical rating organization through the U.S. Securities and Exchange Commission (SEC).</P>
                        <P>(8) Audited financial statements for the most recent and prior fiscal years. The financial statements must include:</P>
                        <P>(i) Balance sheets</P>
                        <P>(ii) Income statements</P>
                        <P>(iii) Cash flow statements</P>
                        <P>(iv) Notes to the financial statements</P>
                        <P>(9) For publicly-traded companies, market capitalization data is required, reflecting the stock price and number of shares outstanding at the end of the most recent fiscal year.</P>
                        <P>(10) As an addition to the information required in paragraphs (b)(1) through (8) of this section, OWCP may request additional information related to the supporting documents submitted with the application. When requesting further information, OWCP will detail the type of information or evidence required and explain the need of any such supplemental information.</P>
                    </SECTION>
                    <SECTION>
                        <PRTPAGE P="48017"/>
                        <SECTNO>§ 726.103</SECTNO>
                        <SUBJECT> Application for Authority to Self-Insure; Effect of Regulations Contained in this Part.</SUBJECT>
                        <P>As appropriate, each of the regulations, interpretations and requirements contained in this part 726 including those described in subpart C of this part, are binding upon each applicant under this subpart B, and the applicant's consent to be bound by all requirements of the regulations in this part are deemed to be included in and a part of the application, as fully as though written therein. This provision encompasses, but is not limited to, the insurance endorsement specified in § 726.203, applicable to all self-insurers.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.104 </SECTNO>
                        <SUBJECT>Action by OWCP upon Application of Operator.</SUBJECT>
                        <P>(a) Within 30 calendar days after determining that an operator's application for authorization to self-insure or to renew authorization to self-insure is complete, OWCP will review and consider all relevant information submitted in the application and issue a written determination either denying the application or determining the amount of security which must be given by the applicant to guarantee the payment of benefits and the discharge of all other obligations which may be required of such applicant under the Act. OWCP may extend the 30-calendar day deadline if it determines that additional evidence is needed or that the applicant's evidence is not in compliance with OWCP's requirements in this subpart.</P>
                        <P>(b) Upon approval, the applicant will thereafter be notified that they may give security in the amount fixed by OWCP under § 726.105, utilizing one or more acceptable types of security described in § 726.106.</P>
                        <P>(c) Any operator authorized to self-insure will submit security in full or be allowed to phase in total security at specific percentages over a three-year period, at maximum, after the initial review under these revised regulations. Subsequent applications for reauthorization to self-insure will not be allotted additional periods or years to phase in total security after each annual review. Operators will be provided with advance notification, typically 30 calendar days, of the amounts due for each security submission and the dates upon which payments will be made. The deadline for payment can be extended with good cause. The three-year phase-in commences with the first security deposit, known as year one. The year one submission will be at least 34% of the overall security amount. For the following year, designated as year two, the security deposit will be at least 33%, bringing the total security submitted to at least 67% of the total security requirement. At year three, the remaining balance of 33% security will be submitted, bringing the operator to its total calculated security amount. Factors affecting the amount required each year include the level of assessed risk and the amount of security already provided by the operator for their estimated liabilities. Furthermore, any operators fully secured at the time of rule publication will not be permitted to withdraw existing security to less than their total calculated security amount to participate in the three-year phase in and must remain fully secured.</P>
                        <P>(d) If the applicant is receiving authorization to self-insure for the first time, OWCP will notify the applicant that:</P>
                        <P>(1) its authorization to self-insure is contingent upon submitting the required security (either the full amount or the first security deposit under paragraph (c) of this section) and completed form OWCP-1 Agreement and Undertaking; and</P>
                        <P>(2) the applicant's authorization to self-insure is effective for 12 months from the date such security (either the full amount or the first security deposit under paragraph (c) of this section) and completed form OWCP-1 Agreement and Undertaking are received by OWCP.</P>
                        <P>(e) If OWCP renews the applicant's authorization to self-insure, OWCP will notify the applicant that:</P>
                        <P>(1) If there are no changes in the required security amount, the applicant's authorization to self-insure is effective for 12 months from the date such renewal is granted and the applicant's completed form OWCP-1 Agreement and Undertaking is received by OWCP; or</P>
                        <P>(2) If changes are needed to the existing security amount, the applicant's authorization to self-insure is not granted until the applicant has submitted the required security (either the full amount or the annual security deposit under paragraph (c) of this section) and completed form OWCP-1 Agreement and Undertaking. The applicant's authorization to self-insure will be effective for 12 months from the date such updated security and completed form OWCP-1 Agreement and Undertaking are received by OWCP.</P>
                        <P>(f) Any applicant who cannot meet the security deposit requirements imposed by OWCP should proceed to obtain a commercial policy or contract of insurance and submit proof of such coverage within 30 calendar days after OWCP issues notification to the applicant of its decision. Any applicant for authorization to self-insure whose application has been denied or who believes that the security deposit requirements imposed by OWCP are excessive may appeal such determination in the manner set forth in § 726.116.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.105 </SECTNO>
                        <SUBJECT>Fixing the Amount of Security.</SUBJECT>
                        <P>(a) Purpose. Any operator approved to self-insure must secure their liabilities according to a risk-based system that uses the operator's financial strength to determine the percentage of their total present and future estimated liability which would require security. Following risk assessment, each operator will be placed within one of seven tiers with the most financially secure entities required to secure less of their liabilities, while operators who are financially weakest would be required to secure a higher percentage.</P>
                        <P>The financial position of the operator would be determined by an external expert financial assessment establishing a credit rating provided by the operator when possible, in conjunction with the financial metrics outlined in paragraph (b) of this section. Alternatively, if no external credit rating exists, OWCP will perform an assessment based upon information submitted by the operator to OWCP directly. This is necessary for privately held operators whose financial performance is not publicly available.</P>
                        <P>(b) Composite Solvency Score. The amount of required security is determined by calculating a Composite Solvency Score that evaluates the financial health of the operator using a weighted combination of metrics.</P>
                        <P>(1) The Department will calculate a Composite Solvency Score using the documentation submitted during the application process.</P>
                        <P>(2) The Department will calculate the Composite Solvency Score based on three financial risk metrics:</P>
                        <P>(i) The long-term credit rating from a nationally recognized statistical rating organization, such as Fitch Ratings, Moody's Investors Service or Standard and Poor's, if available;</P>
                        <P>(ii) The Altman Z-score; and</P>
                        <P>(iii) The Ohlson O-score.</P>
                        <P>(3) The Composite Solvency Score will determine the amount of security the operator must post, as a percentage of the operator's actuarial liability.</P>
                        <P>(c) Calculation and Normalization of Scores</P>
                        <P>(1) The three financial metrics will be calculated as:</P>
                        <P>(i) Credit rating. The most recent long-term credit rating issued by the rating agency will be used directly as the input for the normalized credit rating score, if such a rating exists.</P>
                        <P>
                            (ii) Altman Z-Score. The Department will calculate the Altman Z-Score (Z) for 
                            <PRTPAGE P="48018"/>
                            each operator using the following formula:
                        </P>
                        <FP SOURCE="FP-2">Z = (1.2 × A) + (1.4 × B) + (3.3 × C) + (0.6 × D) + (1.0 × E)</FP>
                        <EXTRACT>
                            <FP SOURCE="FP-2">Where:</FP>
                            <FP SOURCE="FP-2">A = Working Capital/Total Assets</FP>
                            <FP SOURCE="FP-2">B = Retained Earnings/Total Assets</FP>
                            <FP SOURCE="FP-2">C = Earnings Before Interest and Taxes/Total Assets</FP>
                            <FP SOURCE="FP-2">D = Market Value of Equity/Total Liability for publicly-traded companies and Book Value of Equity/Total Liability for privately-owned companies</FP>
                            <FP SOURCE="FP-2">E = Sales/Total Assets</FP>
                        </EXTRACT>
                        <P>(iii) Ohlson O-Score. The Department will calculate a modified Ohlson O Score (O) for each operator using the following formula:</P>
                        <FP SOURCE="FP-2">
                            O = −1.32−(0.407 × log(TA
                            <E T="52">t</E>
                            )) + (6.03 × TL
                            <E T="52">t</E>
                            /TA
                            <E T="52">t</E>
                            )−(1.43 × WC
                            <E T="52">t</E>
                            /TA
                            <E T="52">t</E>
                            ) + (0.0757 × CLt/CA
                            <E T="52">t</E>
                            )−(1.72 X)−(2.37 NI
                            <E T="52">t</E>
                            /TA
                            <E T="52">t</E>
                            )−(1.83 × (NI
                            <E T="52">t</E>
                             + DA
                            <E T="52">t</E>
                            )/TL
                            <E T="52">t</E>
                            ) + (0.285 × Y)−(0.521 × (NI
                            <E T="52">t</E>
                            −N
                            <E T="52">t-1</E>
                            )/(|NI
                            <E T="52">t</E>
                            | + |NI
                            <E T="52">t-1</E>
                            |))
                        </FP>
                        <EXTRACT>
                            <FP SOURCE="FP-2">Where:</FP>
                            <FP SOURCE="FP-2">TA = Total Assets</FP>
                            <FP SOURCE="FP-2">TL = Total Liabilities</FP>
                            <FP SOURCE="FP-2">WC = Working Capital (Current Assets−Current Liabilities)</FP>
                            <FP SOURCE="FP-2">X = 1 if TL &gt; TA, otherwise 0</FP>
                            <FP SOURCE="FP-2">NI = Net Income</FP>
                            <FP SOURCE="FP-2">DA = Depreciation and Amortization</FP>
                            <FP SOURCE="FP-2">Y = 1 if NI is negative for the last two years, otherwise 0</FP>
                        </EXTRACT>
                        <P>Any reference to Ohlson O-Score in this document is intended to reflect the modified Ohlson O-Score.</P>
                        <P>(2) After determining the credit rating, Altman Z-Score and Ohlson O-Score, the normalization scores shall be determined as follows:</P>
                        <P>(i) Credit rating normalization:</P>
                        <GPOTABLE COLS="3" OPTS="L2,tp0,i1" CDEF="s75,r75,10">
                            <TTITLE> </TTITLE>
                            <BOXHD>
                                <CHED H="1">FITCH/S&amp;P credit rating</CHED>
                                <CHED H="1">MOODY'S credit rating</CHED>
                                <CHED H="1">
                                    Credit
                                    <LI>rating</LI>
                                    <LI>normalized</LI>
                                    <LI>score</LI>
                                    <LI>(CRN)</LI>
                                </CHED>
                            </BOXHD>
                            <ROW>
                                <ENT I="01">AAA</ENT>
                                <ENT>Aaa</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">AA+</ENT>
                                <ENT>Aa1</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">AA</ENT>
                                <ENT>Aa2</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">AA−</ENT>
                                <ENT>Aa3</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">A+</ENT>
                                <ENT>A1</ENT>
                                <ENT>0.5</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">A</ENT>
                                <ENT>A2</ENT>
                                <ENT>0.5</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">A−</ENT>
                                <ENT>A3</ENT>
                                <ENT>0.5</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">BBB+</ENT>
                                <ENT>Baa1</ENT>
                                <ENT>1</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">BBB</ENT>
                                <ENT>Baa2</ENT>
                                <ENT>1</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">BBB−</ENT>
                                <ENT>Baa3</ENT>
                                <ENT>1</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">BB+</ENT>
                                <ENT>Ba1</ENT>
                                <ENT>2</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">BB</ENT>
                                <ENT>Ba2</ENT>
                                <ENT>3</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">BB−</ENT>
                                <ENT>Ba3</ENT>
                                <ENT>4</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">B+</ENT>
                                <ENT>B1</ENT>
                                <ENT>5</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">B</ENT>
                                <ENT>B2</ENT>
                                <ENT>6</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">B−</ENT>
                                <ENT>B3</ENT>
                                <ENT>11</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">CCC+</ENT>
                                <ENT>Caa1</ENT>
                                <ENT>23</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">CCC</ENT>
                                <ENT>Caa2</ENT>
                                <ENT>35</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">CCC−</ENT>
                                <ENT>Caa3</ENT>
                                <ENT>50</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">CC</ENT>
                                <ENT>Ca</ENT>
                                <ENT>50</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">C</ENT>
                                <ENT>Ca</ENT>
                                <ENT>50</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">DDD</ENT>
                                <ENT>C</ENT>
                                <ENT>100</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">DD</ENT>
                                <ENT>C</ENT>
                                <ENT>100</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">D</ENT>
                                <ENT>C</ENT>
                                <ENT>100</ENT>
                            </ROW>
                        </GPOTABLE>
                        <P>(ii) Altman Z-Score normalization:</P>
                        <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s75,10">
                            <TTITLE> </TTITLE>
                            <BOXHD>
                                <CHED H="1">Altman Z-Score</CHED>
                                <CHED H="1">
                                    Altman Z normalized score
                                    <LI>(AZN)</LI>
                                </CHED>
                            </BOXHD>
                            <ROW>
                                <ENT I="01">10-15</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">5-9.999</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">3-4.999</ENT>
                                <ENT>1</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">1.8-2.999</ENT>
                                <ENT>3</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">1.5-1.799</ENT>
                                <ENT>4</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">1-1.499</ENT>
                                <ENT>5</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">0.5-0.999</ENT>
                                <ENT>7</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">0-0.499</ENT>
                                <ENT>9</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−0.5 to −0.001</ENT>
                                <ENT>11</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−1.0 to −0.501</ENT>
                                <ENT>15</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−1.5 to −1.001</ENT>
                                <ENT>19</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−2.0 to −1.501</ENT>
                                <ENT>24</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−2.5 to −2.001</ENT>
                                <ENT>30</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−3 to −10.00</ENT>
                                <ENT>50</ENT>
                            </ROW>
                        </GPOTABLE>
                        <P>(iii) Ohlson O-score normalization:</P>
                        <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s75,10">
                            <TTITLE> </TTITLE>
                            <BOXHD>
                                <CHED H="1">Modified Ohlson O-Score</CHED>
                                <CHED H="1">
                                    Ohlson O normalized score
                                    <LI>(OON)</LI>
                                </CHED>
                            </BOXHD>
                            <ROW>
                                <ENT I="01">−15 to −10.001</ENT>
                                <ENT>0</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−10 to −7.501</ENT>
                                <ENT>1</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−7.5 to −5.001</ENT>
                                <ENT>2</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−5 to −2.501</ENT>
                                <ENT>3</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−2.5 to −1.251</ENT>
                                <ENT>4</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">−1.25 to −0.001</ENT>
                                <ENT>5</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">0-1.249</ENT>
                                <ENT>7</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">1.25-2.499</ENT>
                                <ENT>10</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">2.5-4.999</ENT>
                                <ENT>20</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">5 or more</ENT>
                                <ENT>50</ENT>
                            </ROW>
                        </GPOTABLE>
                        <P>(3) A Composite Solvency Score will then be calculated as:</P>
                        <FP SOURCE="FP-2">
                            Composite Solvency Score = [0.9−0.9 × (MIN((W
                            <E T="52">1</E>
                             × CRN) + (W
                            <E T="52">2</E>
                             × AZN) + (W
                            <E T="52">3</E>
                             × OON), 6)/6) ^ 0.585)] × 100
                        </FP>
                        <EXTRACT>
                            <FP SOURCE="FP-2">Where:</FP>
                            <FP SOURCE="FP-2">(i) CRN = normalized credit rating score</FP>
                            <FP SOURCE="FP-2">(ii) AZN = normalized Altman Z-score</FP>
                            <FP SOURCE="FP-2">(ii) OON = normalized Ohlson O-score</FP>
                        </EXTRACT>
                        <P>With weights according to the following structure:</P>
                        <PRTPAGE P="48019"/>
                        <GPOTABLE COLS="4" OPTS="L2,nj,tp0,i1" CDEF="s100,8,8,8">
                            <TTITLE> </TTITLE>
                            <BOXHD>
                                <CHED H="1"> </CHED>
                                <CHED H="1">
                                    W
                                    <E T="0732">1</E>
                                </CHED>
                                <CHED H="1">
                                    W
                                    <E T="0732">2</E>
                                </CHED>
                                <CHED H="1">
                                    W
                                    <E T="0732">3</E>
                                </CHED>
                            </BOXHD>
                            <ROW>
                                <ENT I="01">The entity has a credit rating issued by an NRSRO within the past 18 months, and is not an energy utility</ENT>
                                <ENT>0.50</ENT>
                                <ENT>0.35</ENT>
                                <ENT>0.15</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">The entity does not have a credit rating issued by an NRSRO within the past 18 months, and is not an energy utility</ENT>
                                <ENT>0</ENT>
                                <ENT>0.70</ENT>
                                <ENT>0.30</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">The entity is an Energy Utility</ENT>
                                <ENT>0.80</ENT>
                                <ENT>0</ENT>
                                <ENT>0.20</ENT>
                            </ROW>
                        </GPOTABLE>
                        <P>An “Energy Utility” means any entity, whether publicly or privately owned, that owns, operates, or controls facilities for the generation, transmission, or distribution of electricity, or for the transportation or distribution of natural gas, and that provides such services to the public under terms and conditions regulated by a federal or state authority.</P>
                        <P>The Composite Solvency Score shall be rounded to the nearest whole number. Higher Composite Solvency Scores indicate higher financial strength.</P>
                        <P>(d) The security percentage will be assigned based on the Composite Solvency Score. For the first year of implementing any final rule arising from this proposed rule, the tier structure will be as follows. This structure will remain in place until such time as OWCP makes and implements changes to the tier structure or values through subregulatory guidance.</P>
                        <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s100,12">
                            <TTITLE> </TTITLE>
                            <BOXHD>
                                <CHED H="1">Composite solvency score</CHED>
                                <CHED H="1">
                                    Security
                                    <LI>percentage</LI>
                                </CHED>
                            </BOXHD>
                            <ROW>
                                <ENT I="01">90</ENT>
                                <ENT>10</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">70-89</ENT>
                                <ENT>25</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">58-69</ENT>
                                <ENT>40</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">43-57</ENT>
                                <ENT>55</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">21-42</ENT>
                                <ENT>70</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">9-20</ENT>
                                <ENT>85</ENT>
                            </ROW>
                            <ROW>
                                <ENT I="01">0-8</ENT>
                                <ENT>100</ENT>
                            </ROW>
                        </GPOTABLE>
                        <P>(e) OWCP reserves the right to conduct its own independent financial analysis and to make discretionary adjustments where OWCP determines that unusual circumstances materially affect the reliability or appropriateness of the calculated results.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.106 </SECTNO>
                        <SUBJECT>Type of Security.</SUBJECT>
                        <P>(a) OWCP will determine the type or types of security, described in this section, which an applicant is authorized to procure. An operator may not provide any form of security other than those provided in this section. An operator can procure multiple types of security as allowed in the section to attain the total fixed security amount under § 726.105.</P>
                        <P>
                            (b) 
                            <E T="03">Indemnity Bond.</E>
                             In the event the indemnity bond option is selected, the bond must be in such form and contain such provisions as OWCP prescribes: 
                            <E T="03">Provided</E>
                             that only corporations may act as sureties on such indemnity bonds. In each case in which the surety on any such bond is a surety company, such company must be one approved by the U.S. Treasury Department under the laws of the United States and the applicable rules and regulations governing bonding companies (see Department of Treasury's Circular-570).
                        </P>
                        <P>
                            (c) 
                            <E T="03">Negotiable Security.</E>
                             If the form of negotiable securities is selected, the operator must deposit the amount fixed by OWCP in any negotiable securities acceptable as security for the deposit of public moneys of the United States under regulations issued by the Secretary of the Treasury in 31 CFR part 225., and in compliance with § 726.107. The approval, valuation, acceptance, and custody of such securities is hereby committed to the several Federal Reserve Banks and the Treasurer of the United States.
                        </P>
                        <P>
                            (d) 
                            <E T="03">Letter of Credit.</E>
                             A letter of credit issued by a financial institution, as authorized. Financial institutions are authorized to provide letters of credit to government agencies through their chartering authority and through designation by the U.S. Treasury Department Fiscal Service as a Depositary and Financial Agent of the Government. (See 31 CFR parts 202 and 203) The letter of credit cannot exceed 50% of the operators' total estimated liability under the Act, and must be employed in conjunction with another form of approved security.
                        </P>
                        <P>
                            (e) 
                            <E T="03">501(c)(21) Trust.</E>
                             A 501(c)(21) is a tax-exempt trust that can be established by coal operators through a financial institution. The Internal Revenue Service authorizes the establishment of such trusts under Internal Revenue Code 501(c)(21). Any financial institution acting as trustee for such trust is subject to regulatory oversight by its respective federal and state bodies, such as the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act (see 12 U.S.C). A 501(c)(21) trust may not be funded at an amount to exceed 50% of the operator's required security for present and future black lung claims liability, and must be employed in conjunction with another form of approved security.
                        </P>
                        <P>
                            (f) 
                            <E T="03">Reinsurance.</E>
                             OWCP may approve the use of a reinsurance contract, either stop-loss or catastrophic, not to exceed 90% of the total fixed security amount. This security instrument must be utilized in conjunction with another type of security or multiple securities; the other securities will act as the self-insured retention limit and must be exhausted before the reinsurance policy becomes responsible. A reinsurance contract must comply with the insurance provisions in 20 CFR 726.201-213, which are incorporated into this section.
                        </P>
                        <P>
                            (g) 
                            <E T="03">Parental Guaranty.</E>
                             OWCP may approve a parental guaranty, in part or in full, to secure the self-insured obligations of the subsidiary operator under the Act. The parent company will irrevocably and unconditionally, and jointly and severally, guarantee self-insured obligations allocated to the operator under the Act. OWCP will determine the financial strength of the guarantor and calculate a composite solvency score utilizing the methodologies described in § 726.105. Parent companies securing greater than 50% of the subsidiary's liabilities must have a composite solvency score of at least 90 on the chart under § 726.105(d). Parent companies securing less than 50% of subsidiary liabilities must have a composite solvency score of at least 70. Parent companies with a composite solvency score of less than 70 will not be permitted to guarantee subsidiary liabilities. The parental guaranty shall remain in force and effect until released, in writing, by OWCP.
                        </P>
                        <P>(h) If an operator procures more than one instrument to secure their estimated liabilities, the operator may designate which instrument is to be the primary payor, secondary payor, tertiary payor, etc. in the event of a default unless the order is specified within any provision of § 726.106.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.107 </SECTNO>
                        <SUBJECT>How Negotiable Securities Are Handled.</SUBJECT>
                        <P>(a) Deposits of securities provided for by the regulations in this part must be made with any Federal Reserve bank or any branch of a Federal Reserve bank designated by OWCP, or the Treasurer of the United States, and must be held in the name of the Department of Labor.</P>
                        <P>(b) If the self-insurer defaults on its obligations under the Act, OWCP has the power, in its discretion, to:</P>
                        <P>(1) collect the interest as it may become due;</P>
                        <P>(2) sell any or all of the securities; and</P>
                        <P>
                            (3) apply the collected interest or proceeds from the sale of securities to 
                            <PRTPAGE P="48020"/>
                            the payment of any benefits for which the self-insurer may be liable.
                        </P>
                        <P>(c) If a self-insurer with deposits of securities has neither defaulted nor appealed from a determination made by OWCP under § 726.104, OWCP may allow the self-insurer to collect interest on the security deposit.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.108 </SECTNO>
                        <SUBJECT>Withdrawal of Securities.</SUBJECT>
                        <P>(a) Withdrawal of any form of security as allowed under 726.106 is prohibited except upon express written authorization by OWCP.</P>
                        <P>(b) If a self-insurer wishes to withdraw securities, it must submit a written request, and must submit replacement securities in the amount and form approved by OWCP. If OWCP approves the operator's request to withdraw and replace its securities, the operator must provide the replacement securities before it withdraws its existing securities.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.109 </SECTNO>
                        <SUBJECT>Adjustments in the Amount of Security.</SUBJECT>
                        <P>(a) OWCP may increase or decrease the percentage of liabilities required for adequate security that is determined under 726.105, depending on evidence submitted under 726.112. OWCP will provide a written explanation for any adjustment.</P>
                        <P>(1) If an operator's Composite Solvency Score increases, OWCP may decrease the total security percentage or next scheduled phase-in deposit required under 726.105.</P>
                        <P>(2) If an operator's Composite Solvency score decreases, OWCP may increase the total security percentage or next scheduled phase-in deposit required under 726.105. An operator's security percentage will not fall below one level of the established tiering, unless the Composite Solvency Score decreases in excess of twenty points.</P>
                        <P>(b) OWCP will not require an operator to post greater than 100 percent of its estimated liabilities, based on the information prompting the increase in security.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.110 </SECTNO>
                        <SUBJECT>Filing of Agreement and Undertaking.</SUBJECT>
                        <P>(a) In addition to the requirement that adequate security be procured as set forth in this subpart, the applicant for the authorization to self-insure must, as a condition precedent to receiving such authorization, execute and file form OWCP-1 Agreement and Undertaking, in which the applicant must agree:</P>
                        <P>(1) To pay when due, as required by the Act, all benefits payable on account of total disability or death of any of its employee-miners;</P>
                        <P>(2) To furnish medical, surgical, hospital, and other attendance, treatment, and care as required by the Act;</P>
                        <P>(3) To provide security in a form approved by OWCP (see § 726.106) and in an amount established by OWCP (see § 726.105); and</P>
                        <P>(4) To authorize OWCP to sell any negotiable securities so deposited or any part thereof, and to pay from the proceeds thereof such benefits, medical, and other expenses and any accrued penalties imposed by law as OWCP may find to be due and payable.</P>
                        <P>(b) When an applicant has provided the requisite security, it must submit a completed and executed form OWCP-1 Agreement and Undertaking, together with satisfactory proof that its obligations and liabilities under the Act have been secured.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.111</SECTNO>
                        <SUBJECT> Notice of Authorization to Self-Insure.</SUBJECT>
                        <P>Upon receipt of a completed agreement and undertaking and satisfactory proof that adequate security has been provided, OWCP will notify an applicant for authorization to self-insure in writing that it is authorized to self-insure to meet the obligations imposed upon such operator by section 415 and part C of title IV of the Act. OWCP will also notify the applicant of the date on which its authorization is effective, the date on which such authorization will expire, and the date by which the applicant must apply to renew such authorization if the applicant intends to continue self-insuring its liabilities under the Act.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.112 </SECTNO>
                        <SUBJECT>Reporting Required of Self-Insurer; Examination of Accounts of Self-Insurer.</SUBJECT>
                        <P>(a) Upon request by OWCP, an operator who has been authorized to self-insure under this part is required to submit reports containing such information confirming all benefits payable, including medical treatment, are rendered when due. This may be in the form of an annual CM-908 report or ad hoc request when allegations of neglect are made by an eligible party.</P>
                        <P>(b) OWCP, or its duly authorized representative, may inspect or examine the books of account, records, and other papers of a self-insurer for the purpose of verifying any financial statement submitted under 726.102 or any other section of this part, if necessary. In lieu of this requirement OWCP may accept an adequate report of a certified public accountant.</P>
                        <P>(c) Any operator authorized to self-insure must notify OWCP of any changes to operations covered under the self-insurance authorization, including the purchase, sale, or lease of any coal mining operations that could affect the operator's liability for benefits under the Act. The operator must provide notification to OWCP within 30 days of such change. In all events, however, an operator's liability following a change or sale is governed by Subpart G of these regulations, 20 CFR 725.490-725.497.</P>
                        <P>(d) OWCP may require an operator to provide supplemental information upon notification of changes under subparagraph (c) of this section, if it is determined the operator's total security under 726.105 will be impacted.</P>
                        <P>(e) Failure to submit or make available any report or information requested by OWCP from an authorized self-insurer pursuant to this section may, in appropriate circumstances, result in a revocation of the authorization to self-insure.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.113</SECTNO>
                        <SUBJECT> Disclosure of Confidential Information.</SUBJECT>
                        <P>Any financial information or records, or other information relating to the business of an authorized self-insurer or applicant for the authorization of self-insurance obtained by OWCP is exempt from public disclosure to the extent provided in 5 U.S.C. 552(b) and the applicable regulations of the Department of Labor promulgated thereunder. (See 29 CFR part 70.)</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.114</SECTNO>
                        <SUBJECT> Authorization and Reauthorization Timeframes.</SUBJECT>
                        <P>(a) No initial or renewed authorization to self-insure may be granted for a period in excess of 12 months unless OWCP determines that extenuating circumstances exist to allow an extension.</P>
                        <P>(b) If an applicant is seeking to renew its authority to self-insure, the applicant must file its application no later than 90 calendar days before its existing authorization period ends.</P>
                        <P>(c) Each operator authorized to self-insure under this part must apply for reauthorization for any period during which it engages in the operation of a coal mine and for additional periods after it ceases operating a coal mine. Upon application by the operator, accompanied by proof that the security it has posted is sufficient to secure all benefits potentially payable to miners formerly employed by the operator, OWCP will issue a certification that the operator is exempt from the coal mine operator insurance requirements of this part based on its prior operation of a coal mine. The civil money penalty provisions of subpart D of this part will be applicable to any operator that fails to apply for reauthorization in accordance with the provisions of this section.</P>
                    </SECTION>
                    <SECTION>
                        <PRTPAGE P="48021"/>
                        <SECTNO>§ 726.115</SECTNO>
                        <SUBJECT> Revocation of Authorization to Self-Insure.</SUBJECT>
                        <P>OWCP may suspend or revoke the authorization of any self-insurer for good cause, including but not limited to:</P>
                        <P>(a) Failure by a self-insurer to comply with any provision or requirement of law or of the regulations in this part, or with any lawful order or request made by OWCP;</P>
                        <P>(b) The failure or insolvency of the surety on its indemnity bond, if such bond is used as security, or any other financial institution holding any form of security provided by an operator; or</P>
                        <P>(c) Impairment of financial responsibility of such self-insurer.</P>
                    </SECTION>
                    <SECTION>
                        <SECTNO>§ 726.116 </SECTNO>
                        <SUBJECT>Appeal Process.</SUBJECT>
                        <P>(a) How to appeal. Any applicant that wishes to appeal a self-insurance determination on an application must submit a written appeal to the Director of OWCP in the form and manner prescribed by OWCP within 30 calendar days of such determination. This deadline may not be extended.</P>
                        <P>(b) What to submit. Within 30 calendar days after filing a written appeal, the applicant must submit any evidence and/or briefing on which it intends to rely, including any arguments that the initial determination was erroneous. OWCP may extend this deadline at the applicant's request upon a showing of good cause.</P>
                        <P>(c) Conferences.</P>
                        <P>(1) The applicant may request an informal conference to present its position. Such request must be made in writing when the applicant submits evidence and briefing and/or any new timely evidence in support of its request for review.</P>
                        <P>(2) If the applicant requests a conference, the Director of OWCP will hold one with the applicant's representatives and the Department's Office of the Solicitor.</P>
                        <P>(3) If the applicant does not request a conference, OWCP may either decide the appeal on the record or schedule a conference on its own initiative.</P>
                        <P>(4) The conference will be limited to the issues identified in the applicant's written materials.</P>
                        <P>(d) Review by OWCP. OWCP will review the previous determination in light of any new evidence or additional information submitted and issue a final agency decision.</P>
                        <P>(1) The Director of OWCP will review the prior decision, evidence of record, and arguments submitted on appeal within 60 calendar days of acknowledging receipt of such. The applicant may not submit new evidence to the Director of OWCP outside of what is allowable under 726.116(b).</P>
                        <P>(2) The Director of OWCP will issue a final agency decision within 7 calendar days upon completion of review.</P>
                        <P>(3) If the Director of OWCP issues a final agency decision denying self-insurance, any existing self-insurance authorization of the applicant will end. The applicant will have 30 calendar days from issuance of the final agency decision to obtain and submit proof of commercial insurance or begin facing civil penalties for failure to secure benefits.</P>
                    </SECTION>
                </SUBPART>
                <SIG>
                    <P>Signed at Washington, DC.</P>
                    <NAME>James Macy,</NAME>
                    <TITLE>Director, Office of Workers' Compensation Programs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15325 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE;P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF STATE</AGENCY>
                <CFR>22 CFR Part 62</CFR>
                <DEPDOC>[Public Notice: 13087]</DEPDOC>
                <RIN>RIN: 1400-AF23</RIN>
                <SUBJECT>Exchange Visitor Program—Termination of Program Participation, Extension of Program and Reinstatement to Valid Program Status</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Department of State.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule with request for comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of State's (Department's) Bureau of Educational and Cultural Affairs administers the Exchange Visitor Program, as set forth at 22 CFR part 62, wherein exchange visitors on educational and cultural exchange programs travel to the United States in the J visa category. The Department tracks the status and geographic location of exchange visitors through the Student and Exchange Visitor Information System (SEVIS), a database administered by the Department of Homeland Security. This Notice of Proposed Rulemaking (Proposed Rule) seeks to clarify the conditions under which a sponsor must terminate an exchange visitor's program and authorizes the Department, in its discretion, to terminate an exchange visitor's program in limited circumstances; modifies Extension of Program and Reinstatement to valid program status in their entirety by eliminating outdated requirements and introducing updated procedures that make use of current SEVIS functionality; amends Definitions to include definitions for “Unauthorized Employment” and “Valid Program Status”; and rescinds the separate extension of program provision for au pairs.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The Department of State will accept comments from the public for 60 days from July 30, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments on this proposed rule by one of the following methods:</P>
                    <P>
                        <E T="03">Online:</E>
                         Go to 
                        <E T="03">www.regulations.gov.</E>
                         Enter Docket ID: DOS-2026-0859 in the search bar to locate this rule. As required by the Administrative Procedure Act at 5 U.S.C. 553(b)(4), you can also find a plain language summary of the proposed rule at this location.
                    </P>
                    <P>
                        <E T="03">Email:</E>
                         Send comments to 
                        <E T="03">JExchanges@state.gov.</E>
                         Include “RIN 1400-AF23” in the subject line of your email.
                    </P>
                    <P>All comments should include the commenter's name, the organization they represent (if applicable), and a mailing address. If the Department cannot read your comment or contact you for clarification, we may not be able to consider it. After the 60-day comment period closes, the Department will review all relevant feedback and publish a final rule as soon as possible.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Rebecca Pasini, Deputy Assistant Secretary for Private Sector Exchange, U.S. Department of State, SA-5, 5th Floor, 2200 C Street NW, Washington, DC 20522. Email: 
                        <E T="03">JExchanges@state.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The Secretary of State is authorized to promulgate such rules and regulations as may be necessary to carry out the functions of the Department of State. 22 U.S.C. 2651a(a)(4). The Mutual Educational and Cultural Exchange Act of 1961, as amended, authorized the Department of State (and the newly established Bureau of Education and Cultural Affairs) to carry out the purposes of and manage, coordinate, and oversee programs established pursuant to the Act. 22 U.S.C. 2451 
                    <E T="03">et seq.</E>
                     The Department of State is proposing modifications to Subpart C of the Code of Federal Regulations, Title 22: Foreign Relations, Part 62—Exchange Visitor Program (Subpart C—Status of Exchange Visitors). Subpart C governs the status of nonimmigrant exchange visitors who travel to the United States on J-1 visas and their accompanying spouses and/or dependents, if any, who travel to the United States on J-2 visas. This proposed rule specifically addresses termination of program participation under 22 CFR 62.40, extension of an exchange visitors' program under 22 CFR 62.43, and reinstatement of exchange visitor records to valid program status under 22 CFR 62.45. The 
                    <PRTPAGE P="48022"/>
                    status of any accompanying spouses and/or dependents mirrors the status of the exchange visitors they accompany. For purposes of this proposed rule, references to exchange visitor records include the records of accompanying spouses and/or dependents unless stated otherwise.
                </P>
                <P>
                    Subpart C was last modified in 1999, when the former U.S. Information Agency (USIA), which previously had oversight of the Exchange Visitor Program, issued an interim final rule with request for comment (64 FR 44123, Aug. 13, 1999). That rule replaced a prior policy statement published in the 
                    <E T="04">Federal Register</E>
                     on April 24, 1997. The 1999 regulations were developed for operation in a paper-based environment.
                </P>
                <P>The Illegal Immigration Reform and Immigrant Responsibility Act of 1996 (IIRIRA) directed the Attorney General to create an electronic system to collect information on F, M, and J nonimmigrants in response to concerns that such individuals could fall out of status and remain in the United States without authorization. In 2001, section 416 of the USA PATRIOT Act (Pub. L. 107-56) amended IIRIRA to mandate the expansion and implementation of that system. In January 2003, the Department of Homeland Security (DHS) and the Department launched SEVIS, a web-based platform for tracking and monitoring F, M, and J nonimmigrants throughout the duration of their participation in approved programs.</P>
                <HD SOURCE="HD1">Termination of Program Participation</HD>
                <P>This proposed rule addresses the termination of exchange visitor program participation under 22 CFR 62.40. The proposed rule provides an additional basis for which a sponsor must terminate an exchange visitor's participation in their exchange program; namely, when an exchange visitor falsifies or fails to provide a full and truthful response, information, or documents as part of his or her exchange visitor application or during the ongoing exchange program.</P>
                <P>The proposed rule also amends 22 CFR 62.40 to expand circumstances where the Department may exercise its discretionary authority to terminate exchange visitor program participation. Under the proposed rule, the Department may terminate an exchange visitor's status when the Department or DHS has revoked or cancelled a visa with immediate effect. In such cases, the individual must immediately leave the country or risk removal. The proposed rule also provides that the Department may terminate an exchange visitor's program when an exchange visitor falsifies or fails to provide a full and truthful response, information, or documents as part of his or her exchange visitor application or during the ongoing exchange program. For example, exchange visitors may be asked to provide proof of a U.S. address, educational qualifications, or attendance at the site of activity. Accurate information is necessary for the sponsors and the Department to assess whether exchange visitors continue to meet the conditions of their nonimmigrant status. A new procedure is also being proposed where an exchange visitor may challenge the Department's termination decision for unauthorized employment or falsifying information or documentation by submitting a statement in opposition within 10 business days of the Department's written notice. Exchange visitors may not appeal on the basis of hardship or other equitable considerations. These regulatory changes are intended to further support the program's objectives of ensuring visitor welfare, program integrity, and national security.</P>
                <HD SOURCE="HD1">Extension of Program</HD>
                <P>The proposed replacement of 22 CFR 62.43 (Extension of Program) streamlines and clarifies the processes for extensions, both within and beyond the maximum program duration, by integrating these procedures with SEVIS functionalities. Sponsors currently have the authority to extend exchange visitor programs up to the permitted duration of the category of exchange programs. However, consistent with existing regulations, if exchange visitors are seeking to extend beyond the permitted maximum duration, sponsors must obtain Department approval. This rule proposes to establish a deadline for submitting such extension requests. After submitting the electronic application for extension in SEVIS, the Department must receive the supporting documentation no later than three months prior to the new extension period. There will be no exceptions for late submissions.</P>
                <P>To ensure consistency across all program categories, this proposed rule deletes 22 CFR 62.31(o) extension of program under the Au pair category, which currently stateses: “Applications to the Department for extensions of six, nine, or 12 months, must be received by the Department not less than 30 calendar days prior to the expiration of the exchange visitor's initial authorized stay . . .” Under this proposed rule, extensions for au pairs will be governed by the general rules and timelines contained in the proposed 22 CFR 62.43, which will require submission 90 days prior to the expiration of the exchange visitor's program end date. These revisions align with Executive Order 14219 (“Ensuring Lawful Governance and Implementing the President's 'Department of Government Efficiency' Deregulatory Initiative”, 90 FR 10583, Feb. 19, 2025), which directs agencies to streamline obsolete regulatory provisions.</P>
                <HD SOURCE="HD1">Reinstatement to Valid Program Status</HD>
                <P>The Department monitors the valid program status of exchange visitors in SEVIS. Designated sponsors must use SEVIS to validate initial program participation, report failures to begin programs, and indicate the early completion or termination of programs (22 CFR 62.13). Whether an exchange visitor completes their program ahead of schedule, voluntarily ends their participation, or has their program involuntarily terminated, sponsors must promptly update the exchange visitor's record in SEVIS to reflect this change and keep the status of the exchange visitor's SEVIS record up to date. This proposed rule revises 22 CFR 62.2 by adding a definition for “Valid Program Status” as the current and accurate status of an exchange visitor's SEVIS record from the time designated sponsors issue a Form DS-2019 through the visitor's active participation in an exchange program and including the visitor's final status upon completion, cessation, graduation, termination, or other program conclusion. The definition relates to any current or future status as contained in the SEVIS record: Initial, Active, Inactive, Terminated, Transferred, Invalid, and No Show. The proposed rule also adds a definition for “Unauthorized Employment,” aligning it with existing U.S. Citizenship and Immigration Services (USCIS) policy language. DHS administers and enforces the Immigration and Nationality Act (INA), as amended. Other federal and state agencies rely on SEVIS data to determine compliance with laws and regulations.</P>
                <P>When SEVIS was implemented, designated sponsors transitioned from paper files to electronic reporting. Sponsors are required under 22 CFR 62.12(a)(2) to maintain accurate, current, and updated SEVIS records. They must also ensure that program participation matches the activities described in SEVIS and listed on the Form DS-2019 (22 CFR 62.10(d)).</P>
                <P>
                    Sponsors must report program status violations in SEVIS. When a record does not accurately reflect an exchange visitor's program status, whether through administrative oversight, 
                    <PRTPAGE P="48023"/>
                    inadvertence, or neglect on the part of the sponsors, exchange visitors, or both, or due to unexpected circumstances beyond their control, the sponsor must either correct the record or request a reinstatement.
                </P>
                <P>The current regulation categorizes violations into three types: (1) minor or technical infractions, (2) substantive violations, and (3) non-reinstatable violations. The proposed rule eliminates the distinction between minor or technical infractions and substantive violations, requiring that, within 30 days, sponsors fix an exchange visitor's record in SEVIS using the Correct SEVIS Status process for all but non-reinstatable violations. This proposed rule provides a simplified system to ensure data integrity by replacing the previous deadlines of 120 days for minor infractions and giving sponsors an easy way to ensure accurate SEVIS records without compromising the program or requiring Department approval. Thus, the “Correct SEVIS Status” action must be used when a sponsor mistakenly changes the status of an exchange visitor's SEVIS record to Active, Inactive, Terminated, Transferred, Invalid, and No Show due to administrative error, neglect, or circumstances beyond their control, or when the error is caused by system changes. The Correct SEVIS Status action must also be used if an exchange visitor fails to request a timely update, such as a transfer or program extension, causing their record to mistakenly reflect an incorrect status, or if a student fails to maintain a full course of study (as defined in § 62.2) without prior consultation with the sponsor and their academic advisor.</P>
                <P>Sponsors will have 30 days from the date the SEVIS record went into the incorrect status to use the Correct SEVIS Status action to return SEVIS records to Active or Inactive status with no application or fee to the Department of State. There is no time limit for changing records from Invalid or Active status to Initial status if the exchange visitor has not entered the United States.</P>
                <P>The “Correct SEVIS Status” action updates the status of the exchange visitor's record immediately. If the J-2 spouse and/or dependent's SEVIS record changed alongside the J-1, it will automatically update. If not, the J-2 record must be corrected separately. If a sponsor is unable to correct the SEVIS record using the 30-day window, a Reinstatement application must be submitted.</P>
                <P>Previously, the Department would not consider requests made after 270 days, as such delays were seen as a lack of program continuity. In an effort to align with the policies provided by DHS, the Department will evaluate requests to reinstate exchange visitor records to Active status if the exchange visitor has not been out of status for more than the time period DHS has set (currently five months). If the exchange visitor has been out of status for more than the time established in DHS's policy, the Department will only consider requests where the sponsor can demonstrate that the failure to file was due to exceptional circumstances and that the request was filed as promptly as possible under those circumstances. There is no time limit for requesting a reinstatement to update a record to Inactive status.</P>
                <P>Sponsors may not use the Correct SEVIS Status action or submit a Reinstatement application to update an exchange visitor's record to Active status if the exchange visitor:</P>
                <P>• Did not maintain their original program objective identified under their category in 22 CFR part 62 Subpart B (Specific Program Provisions);</P>
                <P>• Failed to maintain required insurance coverage required by 22 CFR 62.14;</P>
                <P>• Was involuntarily suspended or terminated by sponsor or host organization;</P>
                <P>• Received a favorable waiver recommendation under INA § 212(e);</P>
                <P>• Received DHS approval for a change of status to a different nonimmigrant class of admission; or</P>
                <P>• Failed to pay the fee mandated by Public Law 104-208.</P>
                <P>Reinstatement applications must be initiated in SEVIS and followed by submission of supporting documentation within ten (10) days to the Department. Sponsors must pay a non-refundable fee (listed in 62.17) and submit a written statement on official letterhead declaring:</P>
                <P>• The exchange visitor's continued pursuit of the original program objective;</P>
                <P>• That the lapse was due to oversight, inadvertence, or factors beyond the control of the sponsor;</P>
                <P>• That denial would impose unusual hardship on the exchange visitor;</P>
                <P>• That no unauthorized employment occurred; and,</P>
                <P>• The exchange visitor's accurate program end date.</P>
                <P>
                    The proposed rule relocates and updates the definition of “Unauthorized Employment” to § 62.2. It mirrors the language found in Volume 7, Part B, Chapter 6 of the U.S. Citizenship and Immigration Services (USCIS) Policy Manual,
                    <SU>1</SU>
                    <FTREF/>
                     which defines unauthorized employment as:
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         See Volume 7, Adjustment of Status, Part B, 245(a) Adjustment, Chapter 6, Unauthorized Employment (INA 245(c)(2) and INA 245(c)(8), Section A, Definitions, Subsection 1, Unauthorized Employment [7 USCIS-PM B.6(A)(1)].
                    </P>
                </FTNT>
                <P>
                    “[A]ny service or labor performed for an employer within the United States by an alien who is not authorized by the INA or USCIS to accept employment or who exceeds the scope or period of the alien's employment authorization.” 
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         See 8 CFR 274a.12(a)-(c) for examples of authorized employment.
                    </P>
                </FTNT>
                <P>
                    For purposes of this rule, unauthorized employment does not include activities that are normally approvable and appropriate for the visitor's category (
                    <E T="03">e.g.,</E>
                     honoraria for scholars giving lectures or consultations).
                </P>
                <HD SOURCE="HD1">Regulatory Analysis</HD>
                <HD SOURCE="HD1">Administrative Procedure Act</HD>
                <P>
                    The Department has historically determined that rulemakings regarding the Exchange Visitor Program involve a foreign affairs function of the United States and therefore are exempt from notice and comment (5 U.S.C. 553(a)).
                    <SU>3</SU>
                    <FTREF/>
                     However, due to the Department's interest in seeking public comment on this rule, the Department is soliciting comments during a 60-day comment period, to which it will respond in a final rule, should the Department choose to finalize all or part of this proposal.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Foreign governments seek to promote the ability of their foreign nationals to visit and study in the United States, and the Department of State establishes modified exchange programs pursuant to memoranda of understanding with foreign governments, based on the foreign policy needs of the United States. This practice reflects the flexibility needed for a program whose purpose is to promote the interests of the United States abroad and further “peaceful relations between the United States and the other countries of the world.” 22 U.S.C. 2451. In connection with that purpose, a major purpose of this rule is to protect the health, safety, and welfare of foreign nationals while they are in the United States on their programs. Failure to protect the health, safety and welfare of these foreign nationals can have direct and substantial adverse effects on the foreign affairs of the United States.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Unfunded Mandates Reform Act of 1995</HD>
                <P>
                    This proposed rule will not result in expenditures of $100 million or more in any one year by State, Local, or Tribal governments, or by the private sector. It also does not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the Unfunded Mandates Reform Act of 1995.
                    <PRTPAGE P="48024"/>
                </P>
                <HD SOURCE="HD1">Executive Order 13175—Consultation and Coordination With Indian Tribal Governments</HD>
                <P>The Department has determined that this proposed rule does not have Tribal implications, does not impose substantial direct compliance costs on Indian Tribal governments, and does not preempt Tribal law. Accordingly, the requirements of Executive Order 13175 do not apply to this rulemaking.</P>
                <HD SOURCE="HD1">Regulatory Flexibility Act/Executive Order 13272—Consideration of Small Entities</HD>
                <P>
                    While the Department of State considers this rule exempt from the notice-and-comment provisions of 5 U.S.C. 553, and thus not subject to the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    ) or Executive Order 13272, we are nonetheless providing an assessment of the potential burden on small entities.
                </P>
                <P>
                    <E T="03">Terminations:</E>
                     The Department estimates that approximately 1,400 designated sponsors operate under the Exchange Visitor Program. The Department anticipates the benefits resulting in changes to the termination of program section will significantly strengthen operational transparency and effectiveness without imposing additional economic burdens on sponsors or exchange visitors, ultimately advancing the program's foreign policy objectives. Any changes resulting from this proposed rule impose no new net regulatory costs. Expenses related to an exchange visitor submitting a statement of opposition and the review process conducted by the Deputy Assistant Secretary for Private Sector Exchange are expected to be minimal and rare.
                </P>
                <P>
                    <E T="03">Analysis of Fee Impact for Extensions:</E>
                     Under the existing regulations, designated sponsors must obtain Department approval for program extensions that exceed the maximum duration allowed for a specific Exchange Visitor Program category. This process requires Department resources for review and adjudication. The fee associated with this request is designed to cover these administrative costs.
                </P>
                <P>The current fee for filing an application for specific exchange visitor status changes is $367 per application (22 CFR 62.17(b)(2)). Based on program data provided for 2022 through 2024, the Department processed an average of approximately 14,563 “Program Extension beyond Maximum Duration” requests annually (calculated from 43,690 requests over three years). Applying the $367 fee results in an estimated total annual cost recovery of approximately $5,344,871 (14,563 requests * $367/request). This cost reflects the Department resources required to act on these requests, which involves verifying the justification for the extension against program regulations and participant eligibility. Unlike the reinstatement fee discussed previously (which designated sponsors can potentially avoid by maintaining timely updates to their records in SEVIS), this fee is required whenever a sponsor seeks an extension for an exchange visitor beyond the standard maximum program duration permitted by regulations for a category, necessitating Department review. The fee per request affects all designated sponsors submitting such requests, including small entities. The estimated total annual cost across all designated sponsors is noteworthy (~$5.34 million), driven by the high volume of extension requests (~14,563 annually).</P>
                <P>Unlike the reinstatement fee, which applies to a much smaller volume of requests and may be avoidable, the extension fee applies to a more common request. While the cost per individual request may not be significant, substantial cumulative costs arise from numerous extension requests. The Department also acknowledges that the number of extension requests has remained relatively consistent from 2022 to 2024, with a nominal increase in requests in 2024 compared to the prior year. The Department cannot forecast how the volume of these requests may change in the coming years.</P>
                <P>
                    <E T="03">Benefits:</E>
                     A primary benefit of the fee is cost recovery for the U.S. Government, ensuring that the administrative costs associated with processing these requests are borne by the entities requesting the service rather than the public or appropriated funds. The fee also implicitly underscores the nature of extensions beyond the maximum duration, which still represents a relatively small proportion of the total exchange visitor population annually.
                </P>
                <P>
                    <E T="03">Conclusion:</E>
                     Based on recent data, the established fee for Program Extension beyond Maximum Duration requests, which is applied to an average of approximately 14,563 requests annually, results in an estimated cost recovery of approximately $5.34 million annually. This fee allows the Department of State to cover the administrative expenses associated with providing the necessary services for these specific extension requests made by designated sponsors on behalf of exchange visitors.
                </P>
                <P>
                    <E T="03">Analysis of Fee Impact for Reinstatements:</E>
                     Available data shows that only 21 formal reinstatement requests were submitted in 2024. Preparing an extension or reinstatement request typically requires 1 hour of administrative time, resulting in an estimated total annual cost of approximately $2,100 for all affected sponsors combined. This low volume and minimal administrative burden support the Department's determination that the economic impact of this rule on small entities is minimal.
                </P>
                <P>The rule codifies existing SEVIS procedures, such as Correct SEVIS Status, that allow sponsors to fix most issues without Department intervention or fees. Fees only apply when designated sponsors fail to take timely action and reinstatement is necessary to correct SEVIS records.</P>
                <P>The rule is structured to promote preventative compliance: sponsors who maintain accurate and timely SEVIS records will not incur new fees. This helps reduce the financial burden, particularly for smaller sponsors with limited resources.</P>
                <P>This rule is also consistent with Executive Order 14192, Unleashing American Prosperity Through Deregulation, as it imposes no new net regulatory costs and codifies existing operational practices. The primary direct cost is the non-refundable fee for submitting reinstatement requests to the Department. This fee has consistently remained at $367 per application, as specified in the Exchange Visitor Program regulations at 22 CFR 62.17(b)(2). Program data from 2022 to 2024 indicates that the Department processed an average of 155 reinstatement requests annually (calculated from 465 requests over three years). Consequently, the estimated annual cost to designated sponsors for processing these requests totals $56,885 (155 requests * $367/request).</P>
                <P>
                    This proposed rule highlights the significance of quantifying costs and benefits, minimizing administrative burdens, aligning regulations, encouraging flexibility, promoting sponsor independence, and fostering self-reliance. The rule emphasizes the use of SEVIS, enabling designated sponsors to resolve many common record issues directly. This is expected to alleviate administrative burdens and save designated sponsors time when handling routine corrections. However, if designated sponsors fail to update records directly in SEVIS within designated timeframes, the sponsors must initiate the Reinstatement request in SEVIS and pay the non-refundable fee established under 22 CFR 62.17(b)(2). Reinstatement requests require review and processing by the 
                    <PRTPAGE P="48025"/>
                    Department of State. The cost per sponsor will significantly depend on the number of reinstatement applications sponsors submit annually due to not utilizing the corrective actions available in SEVIS that do not require prior Department approval. Given the relatively low total number of these specific applications requiring Department involvement among approximately 1,400 designated sponsors, along with the general preventability of such requests through timely actions in SEVIS, the Department believes that the fee is unlikely to impose a 
                    <E T="03">significant</E>
                     economic impact on a 
                    <E T="03">substantial</E>
                     number of designated sponsors. A more detailed analysis comparing potential costs to designated sponsors' revenues would require data on sponsor size distribution and reinstatement request frequency by size, which is not currently available.
                </P>
                <P>The Department recognizes that SEVIS functionality has evolved since it was first implemented in 2003. This rule reflects those developments and aligns the regulatory framework with current sponsor responsibilities and technological capabilities. To ensure clear and consistent program compliance, the Department intends to review and update relevant sponsor guidance as SEVIS tools continue to advance.</P>
                <P>The regulations outline streamlined procedures (Correct SEVIS Status) that allow designated sponsors to address many record issues directly in SEVIS within specified timeframes without requiring Department intervention or a fee. The annual estimate reflects the expenses incurred by designated sponsors who seek Department action rather than a rise in costs for designated sponsors using SEVIS as intended. Furthermore, the Department acknowledges that reinstatement requests declined yearly from 2022 to 2024. As such, the Department of State does not make projections regarding potential changes in the number of requests in the coming years.</P>
                <P>
                    <E T="03">Benefits:</E>
                     The primary benefits include: (1) Increased efficiency and reduced administrative burden for designated sponsors managing routine record corrections in SEVIS; (2) Enhanced accuracy and timeliness of SEVIS data, resulting from streamlined correction processes and the incentive structure established by the fee, which supports program administration and oversight; (3) Cost recovery for Department resources utilized to resolve more complex reinstatement cases that exceed standard corrections; (4) Clear regulatory standards for designated sponsors regarding record maintenance and corrections; and, (5) Indirect benefits for exchange visitors, of resolving their status issues more efficiently, in contrast to potential adverse impacts on exchange visitors if designated sponsors fail to correct records promptly.
                </P>
                <P>
                    <E T="03">Conclusion:</E>
                     The Department of State believes the proposed approach maximizes net benefits. The anticipated advantages—including enhanced sponsor efficiency, improved SEVIS data integrity, clearer regulatory standards, Department cost recovery, and potentially quicker resolutions for exchange visitors—are expected to outweigh the potential costs associated with the fee for reinstatement requests, which require direct Department involvement.
                </P>
                <HD SOURCE="HD1">Executive Orders 12866 and 13563—Regulatory Planning and Review</HD>
                <P>The Office of Information and Regulatory Affairs has determined that this proposed rule is significant within the meaning of section 3(f) of Executive Order 12866. The Department has reviewed this proposed rule to ensure consistency with the principles of cost-effectiveness, clarity, and regulatory flexibility described in these Executive Orders.</P>
                <P>In 2024, over 1,700 individual exchange visitor records were terminated. The top reasons were for breaking sponsor rules or regulations (975), failure to continue program activities (300), disciplinary reasons or criminal convictions (90), engaging in unauthorized employment (30), and reasons listed as “other” (450). The proposed modernization of 22 CFR 62.40 strengthens program administration by allowing for efficient electronic recording, tracking, and documentation of termination decisions, resulting in greater accuracy and timeliness of data while supporting proactive compliance monitoring. The new regulations also provide sponsors and exchange visitors with increased operational and regulatory clarity, while formalizing the Department's discretionary authority in the exchange visitor termination process through the introduction of defined procedural requirements. There are no new costs involved for updating the functionality in the SEVIS database. Sponsors shall continue the same monitoring and documentation of exchange visitors as is already expected. Exchange visitors who are terminated by the Department will be accorded the right to challenge the Department's termination.</P>
                <HD SOURCE="HD1">Executive Order 12988—Civil Justice Reform</HD>
                <P>The Department of State has reviewed this proposed rule in accordance with Sections 3(a) and 3(b)(2) of Executive Order 12988. The rule is written to minimize ambiguity, reduce litigation, and establish clear legal standards.</P>
                <HD SOURCE="HD1">Executive Orders 12372 and 13132—Federalism</HD>
                <P>The Department has determined that this proposed rule does not have substantial direct effects on the states, on the relationships between the national government and the states, or on the distribution of power and responsibilities among the various levels of government. In accordance with Section 6 of Executive Order 13132, the rule does not have sufficient federalism implications to require consultation or preparation of a federalism summary impact statement. Executive Order 12372, which governs intergovernmental review of federal programs, does not apply to this regulation.</P>
                <HD SOURCE="HD1">Paperwork Reduction Act</HD>
                <P>Under the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), agencies must obtain approval from the Office of Management and Budget (OMB) for any new collection of information. This proposed rule does not impose any new reporting or recordkeeping requirements on sponsors, and therefore, does not require approval under the PRA.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 22 CFR Part 62</HD>
                    <P>Cultural exchange programs, Reporting and recordkeeping requirements.</P>
                </LSTSUB>
                <P>Accordingly, 22 CFR part 62 is proposed to be amended to read as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 62—EXCHANGE VISITOR PROGRAM</HD>
                </PART>
                <AMDPAR>1. The authority citation for 22 CFR Part 62 is revised to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>
                        8 U.S.C. 1101(a)(15)(J), 1182, 1184, 1258; 22 U.S.C. 1431-1442, 2451 
                        <E T="03">et seq.;</E>
                         22 U.S.C. 2451; Foreign Affairs Reform and Restructuring Act of 1998, Pub. L. 105-277, Div. G, 112 Stat. 2681 
                        <E T="03">et seq.;</E>
                         Reorganization Plan No. 2 of 1977, 3 CFR, 1977 Comp., p. 200; E.O. 12048 of March 27, 1978, 3 CFR, 1978 Comp., p. 168; Illegal Immigration Reform and Immigrant Responsibility Act (IIRIRA) of 1996, Pub. L. 104-208, Div. C, 110 Stat. 3009-546, as amended; USA PATRIOT Act, Pub. L. 107-56, sec. 416, 115 Stat. 354; Enhanced Border Security and Visa Entry Reform Act of 2002, Pub. L. 107-173, 116 Stat. 543.
                    </P>
                </AUTH>
                <SECTION>
                    <PRTPAGE P="48026"/>
                    <SECTNO>§ 62.2 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <AMDPAR>2. Section 62.2 is amended to add the following definitions, in alphabetical order:</AMDPAR>
                <P>
                    <E T="03">Unauthorized employment:</E>
                     Any service or labor performed for an employer within the United States by foreign nationals who are not authorized by the Immigration and Nationality Act or the U.S. Citizenship and Immigration Services to accept employment, or who exceed the scope or period of their employment authorization. This definition also applies to accompanying J-2 spouses and/or dependents who perform such labor without prior Department of Homeland Security authorization.
                </P>
                <P>
                    <E T="03">Valid program status:</E>
                     The current and accurate status of an exchange visitor's SEVIS record from the time designated sponsors issue a Form DS-2019 through the visitor's active participation in an exchange program and including the visitor's final status upon completion, cessation, graduation, termination, or other program conclusion.
                </P>
                <SECTION>
                    <SECTNO>§ 62.31 </SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <AMDPAR>3. Remove and reserve paragraph (o).</AMDPAR>
                <AMDPAR>4. Amend § 62.40 by revising it to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 62.40 </SECTNO>
                    <SUBJECT>Termination of program participation.</SUBJECT>
                    <P>(a) A sponsor must terminate an exchange visitor's participation in his or her program when the exchange visitor:</P>
                    <P>(1) Fails to pursue the activities for which he or she was admitted to the United States;</P>
                    <P>(2) Is unable to continue the program unless otherwise exempted pursuant to these regulations;</P>
                    <P>(3) Violates the sponsor's rules governing the program, if, in the sponsor's discretion after reviewing Department of State guidance, termination is warranted;</P>
                    <P>(4) Fails to maintain the insurance coverage required under § 62.14 of these regulations; or</P>
                    <P>(5) Falsifies or fails to provide full and truthful response, information, or documents as part of his or her application or ongoing program.</P>
                    <P>(b) The Department of State may terminate an exchange visitor's participation in his or her program when:</P>
                    <P>(1) The Department of State or the Department of Homeland Security has revoked or canceled the exchange visitor's visa with immediate effect;</P>
                    <P>(2) An exchange visitor engages in unauthorized employment; or</P>
                    <P>(3) An exchange visitor falsifies or fails to provide full and truthful response, information, or documents as part of his or her application or ongoing program.</P>
                    <P>(c) Upon a finding of any of the acts set forth at paragraph (b)(2) or (3) of this section, the Office of Private Sector Exchange shall serve an exchange visitor with not less than thirty (30) days written notice of intent to terminate an exchange visitor's participation in his or her program. Such notice must specify the grounds for the proposed termination and its effective date, advise the exchange visitor that he or she may oppose the termination, and identify the procedures for submitting a statement of opposition thereto.</P>
                    <P>(d) Within ten (10) days after service of such written notice of intent to terminate, the exchange visitor may submit a statement in opposition to the proposed termination to the Deputy Assistant Secretary for Private Sector Exchange (Deputy Assistant Secretary). Exchange visitors may not appeal on the basis of hardship or other equitable considerations.</P>
                    <P>(e) The submission of such statement will stay the effective date of the proposed termination pending the decision of the Deputy Assistant Secretary.</P>
                    <P>(f) Upon consideration of such statement, the Deputy Assistant Secretary will issue a written decision confirming or withdrawing the proposed termination. The decision of the Deputy Assistant Secretary is not subject to administrative appeal.</P>
                </SECTION>
                <AMDPAR>5. Amend § 62.43 by revising it to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 62.43 </SECTNO>
                    <SUBJECT>Extension of program</SUBJECT>
                    <P>(a) Extension within the maximum duration.</P>
                    <P>(1) Sponsors may extend an exchange visitor's participation in the Exchange Visitor Program through SEVIS up to the maximum permissible period of participation authorized for his or her specific program category.</P>
                    <P>(2) A sponsor that extends an exchange visitor's program must:</P>
                    <P>(i) Issue the exchange visitor a duly executed Form DS-2019 reflecting the extension; and</P>
                    <P>(ii) Where the new program end date exceeds the exchange visitor's fixed period of admission, issue the Form DS-2019 before the exchange visitor applies for an extension of stay with the Department of Homeland Security.</P>
                    <P>(b) Extension beyond the maximum duration.</P>
                    <P>(1) The sponsor seeking a program extension on behalf of an exchange visitor in excess of that authorized for his or her specific category of participation must:</P>
                    <P>(i) Submit their extension request through SEVIS and email supporting documentation to the Department of State no later than three months prior to the beginning of the desired extension period for the exchange visitor;</P>
                    <P>(ii) Include proof of payment of the required non-refundable extension fee as set forth in § 62.17; and</P>
                    <P>(iii) Adequately document the reasons which justify such extension.</P>
                    <P>(2) For au pairs, sponsors may submit applications to the Department of State for extensions of six, nine, or 12 months and must include the following additional supporting documentation on the sponsor's organizational letterhead:</P>
                    <P>(i) Au pair's name, SEVIS identification number, date of birth, the length of the extension period being requested; and,</P>
                    <P>(ii) Verification that the au pair completed the educational requirements of the initial program.</P>
                    <P>(3) Upon Department of State approval, a sponsor that extends an exchange visitor's program must:</P>
                    <P>(i) Issue the exchange visitor a duly executed Form DS-2019 reflecting the extension; and</P>
                    <P>(ii) Where the new program end date exceeds the exchange visitor's fixed period of admission, issue the Form DS-2019 before the exchange visitor applies for an extension of stay with the Department of Homeland Security.</P>
                </SECTION>
                <AMDPAR>6. Revise § 62.45 by amending it to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 62.45 </SECTNO>
                    <SUBJECT>Reinstatement to valid program status.</SUBJECT>
                    <P>(a) Maintain valid program status.  Designated sponsors must maintain current and accurate SEVIS records. Failure to maintain an exchange visitor's valid program status may negatively affect that individual's ability to enter or remain in the United States. The Department of State may determine that a sponsor's failure to maintain valid program status endangers the welfare of the exchange visitor or U.S. national security. Sponsors must use one of the correction options outlined in this section to restore valid program status when necessary.</P>
                    <P>(b) Correct SEVIS status.</P>
                    <P>(1) Sponsors must use the “Correct SEVIS Status” action to address incorrect record statuses resulting from administrative oversight, inadvertence, or circumstances beyond the control of either the sponsor or exchange visitor.</P>
                    <P>
                        (2) Sponsors will have 30 days from the status change date to use this action to return SEVIS records to Active or Inactive status. Under this provision, sponsors can only correct Terminated records if the sponsor initiates the 
                        <PRTPAGE P="48027"/>
                        termination. After 30 days from the status change, a reinstatement application is required.
                    </P>
                    <P>(3) Sponsors must also use this action to change records from Active or Invalid status to Initial status if the exchange visitor has not entered the United States. There is no time limit for using this action if the Form DS-2019 has not been used for entry.</P>
                    <P>(c) Reinstatements.</P>
                    <P>(1) If sponsors cannot correct the status of the SEVIS record using the action above within the permitted 30-day timeframe, they must request a formal reinstatement from the Department of State.</P>
                    <P>(2) The Department of State will evaluate requests to reinstate exchange visitor records to Active status if submitted within the time period consistent with DHS policies (currently five months). Alternatively, if the sponsor can demonstrate that the failure to file was due to exceptional circumstances and that the request was filed as promptly as possible under those circumstances, the Department may consider the request. There is no time limit for requesting a reinstatement to update a record to reflect Inactive status.</P>
                    <P>(3) Sponsors must initiate the reinstatement application in SEVIS and, within 10 calendar days, email the Department of State the following:</P>
                    <P>(i) A signed statement on sponsor letterhead, including: </P>
                    <P>(A) That the exchange visitor is pursuing or intended to pursue their original activity;</P>
                    <P>(B) That the lapse was due to oversight, inadvertence, or circumstances beyond the control of the sponsor;</P>
                    <P>(C) That denial would cause unusual hardship to the exchange visitor;</P>
                    <P>(D) That no unauthorized employment occurred; and,</P>
                    <P>(E) The exchange visitor's accurate program end date.</P>
                    <P>
                        (ii) A copy of the 
                        <E T="03">pay.gov</E>
                         receipt and I-901 repayment proof;
                    </P>
                    <P>(iii) A copy of the exchange visitor's Form I-94, visa, and passport; and </P>
                    <P>(iv) Any other supporting documentation deemed necessary.</P>
                    <P>(4) Notification of Decision. The Department of State will notify sponsors of its decision. If approved, the SEVIS record will be updated, and an automated email will be sent to the sponsor. The sponsor should issue an updated Form DS-2019 to the exchange visitor reflecting the change. If denied, the sponsor will receive an email explaining the reason(s) for the denial.</P>
                    <P>(5) The Department of State will not consider reinstatement requests to Active status if the exchange visitor:</P>
                    <P>(i) Did not maintain their original program objective;</P>
                    <P>(ii) Failed to maintain required insurance coverage required by 22 CFR 62.14;</P>
                    <P>(iii) Engaged in unauthorized employment;</P>
                    <P>(iv) Was involuntarily suspended or terminated by sponsor or host site;</P>
                    <P>(v) Received a favorable waiver recommendation under INA § 212(e);</P>
                    <P>(vi) Received DHS approval for a change of status to a different nonimmigrant class of admission; or</P>
                    <P>(viii) Failed to pay the fee mandated by Public Law 104-208.</P>
                    <P>(e) Failure to maintain valid program status. Sponsors must routinely monitor and update SEVIS records. A sponsor's failure to take appropriate action using the correction of SEVIS status or reinstatement processes may be considered a violation of 22 CFR 62.13 (Notification requirements).</P>
                </SECTION>
                <SIG>
                    <NAME>Rebecca A. Pasini,</NAME>
                    <TITLE>Deputy Assistant Secretary, Bureau of Educational and Cultural Affairs, U.S. Department of State.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15450 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4710-05-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">EQUAL EMPLOYMENT OPPORTUNITY COMMISSION</AGENCY>
                <CFR>29 CFR Part 1602</CFR>
                <RIN>RIN 3046-AB37</RIN>
                <SUBJECT>Removal of Reporting Requirements; Public Hearing</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Equal Employment Opportunity Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule; public hearing.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Equal Employment Opportunity Commission has scheduled a public hearing to gather information and hear public comment on its proposed rulemaking—Rescission of EEO Reports (EEO-1, EEO-2, EEO-3, EEO-4, EEO-5, EEO-6) and related recordkeeping and record preservation requirements.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Tuesday, August 11, 2026, 10:00 a.m.-12:00 p.m. Eastern Time.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        131 M Street NE, Washington, DC 20507, Jacqueline A. Berrien Training Center. The hearing also may be observed as a listen-only audio. The public may attend in person or connect to the audio-only by following the instructions that will be posted on 
                        <E T="03">www.eeoc.gov</E>
                         at least 24 hours before the meeting. Due to technical limitations, those attending by audio-only will not be able to offer comments. ASL services will be available for those attending the meeting in person and a closed captioning link will be posted on our website prior to the meeting. A transcript of the hearing will be made available on the agency's website thereafter.
                    </P>
                    <P>
                        If you wish to attend the meeting in person, you must email 
                        <E T="03">commissionmeetingcomments@eeoc.gov</E>
                         to register by providing your name as it appears on your driver's license or other government-issued identification at least 24 hours prior to the meeting. You will be asked to show your ID upon arrival. If you additionally wish to speak at the hearing, please follow the instructions provided in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section of this document.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Raymond Windmiller, Executive Officer, Executive Secretariat, (202) 921-2705. Requests for this document in an alternative format should be made to the Office of Communications and Legislative Affairs at 202-921-3191 (voice), 1-800-669-6820 (TTY), or 1-844-234-5122 (ASL video phone).</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>On July 23, 2026, the Equal Employment Opportunity Commission (EEOC) published a notice of proposed rulemaking (NPRM), proposing to rescind and remove the requirements on certain employers and other entities to file workforce data reports to the EEOC contained at 29 CFR part 1602, and proposing to remove the recordkeeping and record preservation requirements related to those reports. 91 FR 46332. The July 23, 2026 document invited public comments on the NPRM.</P>
                <P>Section 709(c) of title VII of the Civil Rights Act also requires that, before imposing any new or changed recordkeeping or reporting requirements it deems “reasonable, necessary, or appropriate for the enforcement” of title VII, the Commission must hold a public hearing. 42 U.S.C. 2000e-8(c). Accordingly, the July 23, 2026 NPRM sets a hearing date for August 11, 2026, at 10 a.m. (Eastern).</P>
                <P>
                    Persons wishing to speak at the hearing must submit a written request to the EEOC of their desire to do so by August 7, 2026, with their contact information and a written summary of the remarks to be offered. Written requests to speak at the hearing must be submitted to the EEOC via one of the methods outlined in the July 23, 2026, NPRM. Because of time limitations, not all interested persons may be able to testify at the hearing, but the Commission will consider all written statements submitted regardless. You will be notified by close of business 
                    <PRTPAGE P="48028"/>
                    August 10 whether you have been selected to speak and the amount of time permitted for your comments.
                </P>
                <NOTE>
                    <HD SOURCE="HED">Note:</HD>
                    <P>
                        In addition to publishing announcements of Commission hearings in the 
                        <E T="04">Federal Register</E>
                        , the Commission also provides information about Commission hearings on its website, 
                        <E T="03">www.eeoc.gov,</E>
                         and provides a recorded announcement one week in advance of a Commission meeting or hearing. Observers seeking to take still photographs, video, or audio recordings of the hearing must seek permission by contacting the Executive Secretariat at 
                        <E T="03">commissionmeetingcomments@eeoc.gov</E>
                         at least 24 hours before the hearing to discuss the manner of recording and ensure it does not interfere with the meeting.
                    </P>
                </NOTE>
                <P>
                    Please telephone (202) 921-2705, or email 
                    <E T="03">commissionmeetingcomments@eeoc.gov</E>
                     at any time for information on this meeting.
                </P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Raymond D. Windmiller,</NAME>
                    <TITLE>Executive Officer, Executive Secretariat.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15340 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6570-01-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>National Park Service</SUBAGY>
                <CFR>36 CFR Part 7</CFR>
                <DEPDOC>[NPS-FRST-DTS#NPS0042641; 266-PPMPSPD1Z.YM0000-PPNEFRST00]</DEPDOC>
                <RIN>RIN 1024-AE95</RIN>
                <SUBJECT>First State National Historical Park; Bicycling</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Park Service, Interior.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The National Park Service (NPS) proposes to issue special regulations for First State National Historical Park to allow for bicycle use on approximately 25 miles of trails within the Brandywine Valley unit of the park.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the proposed rule must be received by 11:59 p.m. EDT on September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">Written comments:</E>
                         You may submit comments by one of the following methods:
                    </P>
                    <P>
                        (1) 
                        <E T="03">Electronically:</E>
                    </P>
                    <P>
                        ○ Go to the 
                        <E T="04">Federal Register</E>
                         website: 
                        <E T="03">https://www.federalregister.gov.</E>
                         In the search box, enter 1024-AE95, the regulation identifier number (RIN) for this rulemaking. Click on the green “Submit a Public Comment” button at the top of the document and follow the instructions for submitting comments; or
                    </P>
                    <P>
                        ○ Go to the 
                        <E T="03">Federal eRulemaking Portal: https://www.regulations.gov.</E>
                         In the Search box, enter 1024-AE95, the RIN for this rulemaking. On the resulting page, select the Dockets tab and then click on the title of the rule. Next, click the “Open for Comments” box, then click the blue “Comment” box and follow the instructions for submitting comments.
                    </P>
                    <P>
                        (2) 
                        <E T="03">By hard copy: Mail to:</E>
                         Superintendent, First State National Historical Park, 10 Market Street, New Castle, DE 19720.
                    </P>
                    <P>
                        <E T="03">Document Availability:</E>
                         The Brandywine Valley Trail Plan/Environmental Assessment, the Finding of No Significant Impact, and related project documents provide information and context for this proposed rule and are available online at 
                        <E T="03">https://parkplanning.nps.gov/frst</E>
                         by clicking the link entitled “BRVA-Comprehensive Trail Plan” and then clicking the link entitled “Document List.”
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         Comments will not be accepted by fax, email, or in any way other than those specified above. All submissions received must include the words “National Park Service” or “NPS” and must include the docket number or RIN (1024-AE95) for this rulemaking. Comments received may be posted without change to 
                        <E T="03">https://www.regulations.gov,</E>
                         including any personal information provided.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to the docket to view the proposed rule and comments received, go to 
                        <E T="03">https://www.regulations.gov</E>
                         and search for “1024-AE95.” Be sure to check the Dockets Tab, Documents Tab, and Comment Tab for possible results.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Joshua Boles, Superintendent, First State National Historical Park; (302)-300-7238; 
                        <E T="03">Joshua_Boles@nps.gov.</E>
                         Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States. In compliance with the Providing Accountability Through Transparency Act of 2023, the plain language summary of the proposal is available on 
                        <E T="03">Regulations.gov</E>
                         in the docket for this rulemaking.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <HD SOURCE="HD2">Purpose and Management Authority for the Park</HD>
                <P>First State National Monument was established by Presidential Proclamation 8944, signed by President Barack Obama on March 25, 2013, and redesignated by the U.S. Congress as First State National Historical Park on December 19, 2014. Public Law 113-291. The park is the first National Park System unit in the State of Delaware. Visitors to the park can explore the people, places, and stories that played a role in the early colonial history and settlement of the Delaware Valley. Congress established the park to preserve, protect, and interpret the nationally significant cultural and historic resources that are associated with early Dutch, Swedish, Finnish, and English settlers of the Colony of Delaware and portions of the Colony of Pennsylvania; and the role of Delaware in the birth of the United States and as the first state to ratify the Constitution. 16 U.S.C 410rrr. The park tells the unique story of those early settlers and their relationships with Native Americans.</P>
                <P>The park consists of six distinct units located in Delaware and southern Pennsylvania: the Brandywine Valley, Old Swedes Historic Site, Fort Christina, the New Castle Court House Museum, the Dover Green, and the John Dickinson Plantation. The NPS administers the Brandywine Valley unit and park's Welcome Center located in the historic Sheriff's House in New Castle, Delaware. The remaining sites are managed by NPS partners.</P>
                <P>The park's enabling legislation directs the NPS to administer the park in accordance with the enabling legislation and with the laws generally applicable to the National Park System, including the NPS Organic Act, which gives the NPS broad authority to regulate the use of the lands and waters within System units. See 54 U.S.C. 100101 and 100751(a).</P>
                <HD SOURCE="HD2">History and Establishment of the Brandywine Valley Unit</HD>
                <P>
                    The significant and varied historic resources that form First State National Historical Park include 1,359 acres of preserved natural and cultural landscapes in the Brandywine Valley. The Brandywine Valley unit is the largest of the six units that make up the park. On these lands lie evidence of the seasonal activities of the Lenape bands of Native Americans who utilized the abundant natural resources of the Brandywine Valley for hundreds of years prior to European settlement. The 
                    <PRTPAGE P="48029"/>
                    farms dotting the hills and valleys harken to the early eighteenth-century settlement of the landscape by industrious Quaker planters, who followed William Penn to his proprietary commonwealth formerly claimed by Dutch and Swedish traders. The mill remnants along the banks of Beaver Creek reveal some of the earliest industries of the American colonies associated with the remarkable Brandywine Creek corridor.
                </P>
                <P>In 1906, Quaker industrialist William P. Bancroft purchased this bucolic property to preserve the beauty of the Brandywine Valley. His conservation foresight, vision for community planning, and establishment of the Woodlawn Trustees to steward the rural landscape collectively ensured the preservation of this significant area for future generations. In 1959, the Woodlawn Trustees began building bridle paths to help their officers and guests explore more of the area. They used some existing farm roads and added new paths for recreational use. By 1968, these paths were open to the public for activities like hiking, biking, and horseback riding. The land served as a privately-owned park until it was donated to the NPS in 2013. The NPS conserves and interprets the natural and cultural landscape of the Brandywine Valley unit consistent with William Poole Bancroft's vision of an open space accessible to the public for their health and well-being.</P>
                <HD SOURCE="HD2">Bicycle Use in the Brandywine Valley Unit</HD>
                <P>The existing trail network in the Brandywine Valley unit consists of historical farm roads and single-track trails, all with natural or unpaved surfacing. The trail network is a popular year-round destination for hikers, mountain bikers, and equestrians, and numerous trails connect the Brandywine Valley unit to neighboring properties such as the Brandywine Creek State Park. As described above, bicycling was a popular recreational activity on the trail network in the Brandywine Vally unit before it became part of the National Park System and continues to be a popular form of recreation in and around the park. Today, bicycles are used on roads that are open to public motor vehicle traffic, on 4.3 miles of administrative roads that are closed to motor vehicle use by the public but open to motor vehicle use by the NPS for administrative purposes, and on all of the trails in the existing trail system, comprising approximately 15 miles of trails. Public roads, administrative roads, and trails that are open to traditional bicycles are also open to electric bicycles (e-bikes), which are defined in NPS regulations as two- or three-wheeled cycles with fully operable pedals and electric motors of not more than 750 watts that meet the requirements of one of three classes (36 CFR 1.4). Class 1 e-bikes are equipped with a motor that provides assistance only when the rider is pedaling, and that ceases to provide assistance when the bicycle reaches the speed of 20 miles per hour. Class 2 e-bikes are equipped with a motor that may be used exclusively to propel the bicycle, and that is not capable of providing assistance when the bicycle reaches the speed of 20 miles per hour. Class 3 e-bikes are equipped with a motor that provides assistance only when the rider is pedaling, and that ceases to provide assistance when the bicycle reaches the speed of 28 miles per hour. Class 1 and class 3 electric bicycles are allowed in the same locations where traditional bicycles are allowed. Class 2 electric bicycles are not allowed on the trail network.</P>
                <HD SOURCE="HD2">Brandywine Valley Trail Plan and Environmental Assessment</HD>
                <P>In 2022, the NPS completed a comprehensive trail inventory for the Brandywine Valley unit. The inventory identified approximately 27.4 miles of trails. Some of the trails are designated and maintained by the NPS. Others are social trails created by users for various purposes. Some were created to avoid designated trails that have been eroded or otherwise damaged. Others were created as a continuation of designated trails that end abruptly. Others have been converted to administrative roads. After reviewing the inventory, the NPS identified a need for a trail plan to establish a cohesive and sustainable trail network with more functionality and quality than currently exists.</P>
                <P>In July 2024, the NPS published a draft Brandywine Valley Trail Plan/Environmental Assessment for a 30-day public comment period. In November 2024, the NPS revised and reissued the Brandywine Valley Trail Plan/Environmental Assessment (EA), and the Regional Director for Interior Region 1, Northeast Region, signed a Finding of No Significant Impact (FONSI) that identified the preferred alternative in the EA as the selected action. Under the selected action, the NPS will construct approximately 8.5 miles of new shared-use trails and perform site-specific trail modifications and upgrades on 15 miles of existing trails. Trail modifications will focus on existing trail segments identified during the trail inventory as suffering from issues such as erosion, channeling, and saturation. By using trail alignment principles that will be used for new trail construction, modifications to existing trails will improve the durability of the trail surface and soil conditions to accommodate bicycling and other non-motorized uses. The NPS will close and restore to natural condition a total of 8.1 miles of trails that are in poor condition, contribute to erosion and runoff, are unsafe, dead-end at private property, or otherwise fail to provide a high-quality user experience. The EA contains a full description of the purpose and need for taking action, the alternatives considered, maps of the affected areas, and the environmental impacts associated with the project. As stated in the FONSI, the NPS believes the selected action will improve the sustainability of the trail system, better protect the resources of the park, and improve the visitor experience by providing additional trails that are sustainably designed for recreation, interpretation, and safety.</P>
                <HD SOURCE="HD1">Proposed Rule</HD>
                <P>
                    NPS regulations in 36 CFR part 7 contain special regulations that apply to individual units of the National Park System. The proposed rule would add a new § 7.99 to this part that establishes special regulations for the park. The rule would authorize the Superintendent to designate approximately 25 miles of trails for bicycle use in the Brandywine Valley unit. The proposed rule includes a table that identifies 12 named trails with approximate trail length and start and end points. The total mileage for these named trails includes existing trail segments, planned new trail construction, and certain segments of administrative roads used as part of the trail alignment. In addition to the 12 named trails, the trail network will include 51 connector trails that link the named trails together. Connector trails will be marked on park maps and serve as short linking segments that provide access between the named trails, trailheads, parking areas, viewpoints, and other features of the trail system. Their purpose is simply to facilitate movement within the trail network. Because connector trails are functional rather than recreational in nature, they are generally designed to be direct, clear, efficient, and minimally intrusive to the landscape. The average length of a connector trail is approximately 0.2 miles. The complexity of the trail network makes it difficult to identify and describe each of the connector trails in the proposed rule. As a result, the connector trails are included in the table as a set of trails labeled C1 through C51 with their cumulative mileage.
                    <PRTPAGE P="48030"/>
                </P>
                <P>The proposed rule would require the Superintendent to notify the public of designated trails through one or more of the methods identified in 36 CFR 1.7, including publication in the Superintendent's Compendium (or written compilation) of discretionary actions referred to § 1.7(b). The rule would require the Superintendent to identify the designated trails on maps available at visitor centers and on the park website. The proposed rule would authorize the Superintendent to limit, restrict, or impose conditions on bicycle use, or close any trail to bicycle use, or terminate such limits, restrictions, conditions or closures, after considering public health and safety, resources protection, and other management activities and objectives. Pursuant to 36 CFR 4.30(i), the Superintendent may allow electric bicycles on any trails that are open to traditional bicycles and will notify the public pursuant to 36 CFR 1.7 if electric bicycles are so allowed.</P>
                <HD SOURCE="HD2">Compliance With NPS Bicycle Regulations</HD>
                <P>
                    The EA constitutes the planning document and evaluates the criteria required by the NPS's general bicycle regulations at 36 CFR 4.30. Under the selected action in the FONSI, the NPS would allow bicycle use on an approximately 25 mile shared-use trail network.
                    <SU>1</SU>
                    <FTREF/>
                     The EA, informed by the comprehensive trail inventory, evaluates the suitability of each trail surface and soil conditions for accommodating bicycle use; and life cycle maintenance costs, safety considerations, methods to prevent or minimize user conflict, and methods to protect natural and cultural resources and mitigate impacts associated with bicycle use. The Superintendent of the park has signed a written determination that bicycle use on all of the trails identified in this proposed rule is consistent with the protection of the park's natural, scenic, and aesthetic values; safety considerations; management objectives; and will not disturb wildlife or park resources, as required by 36 CFR 4.30. This written determination is available on the park's planning website at the URL listed in the 
                    <E T="02">ADDRESSES</E>
                     section. The NPS is not publishing the written determination separately in the 
                    <E T="04">Federal Register</E>
                     but welcomes comments on the written determination during the public comment period for this proposed rule.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         During the NEPA process, the NPS evaluated the impacts of bicycle use on all of the trails identified in this rule for bicycle use. The NPS acknowledges minor trail mileage discrepancies between the FONSI and this rule. Small discrepancies in GIS estimates are reasonable and expected. The differing mileage estimates between documents are a result of minor addition and rounding errors as well as improved data quality, increased accuracy in GIS layers, and the inclusion of administrative road segments that also function as part of the trail system.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Compliance With Other Laws, Executive Orders and Department Policy</HD>
                <HD SOURCE="HD2">Regulatory Planning and Review E.O.s —12866 and 14192</HD>
                <P>This proposed rule has been determined to be not significant for purposes of E.O. 12866. This rule is a “one-time” enabling regulation that would authorize the Superintendent to expand consumption options for the American public by increasing opportunities for access and recreation at the park. As a result, this rule qualifies as an E.O. 14192 deregulatory action pursuant to M-25-20, “Guidance Implementing Section 3 of Executive Order 14192, Titled `Unleashing Prosperity Through Deregulation'” issued by the Office of Management and Budget, Office of Information and Regulatory Affairs, on March 26, 2025.</P>
                <HD SOURCE="HD2">Regulatory Flexibility Act</HD>
                <P>
                    This proposed rule will not have a significant economic effect on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    ). No small entities would be directly regulated by this rule, which would authorize the superintendent of First State National Historical Park to allow bicycle use on approximately 25 miles of trails within the Brandywine Valley unit. The action would not generate new costs for small businesses, organizations, or governmental jurisdictions, nor would it impose fees, operational requirements, training, recordkeeping, or other compliance burdens on small businesses or organizations. Trail construction and the subsequent authorization of bicycle use on new and upgraded existing trails would expand and improve bicycling opportunities, which is expected to increase recreational visitation and may benefit nearby small businesses through increased visitor spending. This action is not expected to have adverse economic effects on any sector, including small entities. For these reasons, the NPS certifies that this rule will not have a significant economic impact on a substantial number of small entities; therefore, a regulatory flexibility analysis is not required.
                </P>
                <HD SOURCE="HD2">Congressional Review Act</HD>
                <P>This proposed rule is not a major rule under 5 U.S.C. 804(2). This rule:</P>
                <P>(a) Would not have an annual effect on the economy of $100 million or more.</P>
                <P>(b) Would not cause a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions.</P>
                <P>(c) Would not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S.-based enterprises to compete with foreign-based enterprises.</P>
                <HD SOURCE="HD2">Unfunded Mandates Reform Act</HD>
                <P>
                    This proposed rule would not impose an unfunded mandate on State, local, or Tribal governments or the private sector of more than $100 million per year. This proposed rule would not have a significant or unique effect on State, local or Tribal governments or the private sector. It addresses public use of national park lands and imposes no requirements on other agencies or governments. A statement containing the information required by the Unfunded Mandates Reform Act (2 U.S.C. 1531 
                    <E T="03">et seq.</E>
                    ) is not required.
                </P>
                <HD SOURCE="HD2">Takings (Executive Order 12630)</HD>
                <P>This proposed rule would not effect a taking of private property or otherwise have takings implications under E.O. 12630. A takings implication assessment is not required.</P>
                <HD SOURCE="HD2">Federalism (Executive Order 13132)</HD>
                <P>Under the criteria in section 1 of E.O. 13132, this proposed rule would not have sufficient federalism implications to warrant the preparation of a Federalism summary impact statement. This rule would only affect use of federally administered lands and waters. It would have no direct effects on other areas. A Federalism summary impact statement is not required.</P>
                <HD SOURCE="HD2">Civil Justice Reform (Executive Order 12988)</HD>
                <P>This proposed rule complies with the requirements of E.O. 12988. This proposed rule:</P>
                <P>(a) Meets the criteria of section 3(a) requiring that all regulations be reviewed to eliminate errors and ambiguity and be written to minimize litigation; and</P>
                <P>(b) Meets the criteria of section 3(b)(2) requiring that all regulations be written in clear language and contain clear legal standards.</P>
                <HD SOURCE="HD2">Consultation With Indian Tribes (Executive Order 13175 and Department Policy)</HD>
                <P>
                    The Department of the Interior strives to strengthen its government-to-
                    <PRTPAGE P="48031"/>
                    government relationship with Indian Tribes through a commitment to consultation with Indian Tribes and recognition of their right to self-governance and Tribal sovereignty. The NPS has evaluated this proposed rule under the criteria in E.O. 13175 and under the Department's Tribal consultation policy and has determined that Tribal consultation is not required because this rule will have no substantial direct effect on federally recognized Indian Tribes. Nevertheless, in support of the Department of the Interior's and the NPS's commitment to government-to-government consultation, the NPS consulted with the Delaware Nation and the Delaware Tribe of Indians. The NPS executed a programmatic agreement (PA) outlining the ongoing consultation process to avoid, minimize, and, when necessary, mitigate adverse effects. The PA was signed by the Pennsylvania State Historic Preservation Office (SHPO) on September 23, 2024, and the Delaware SHPO on September 26, 2024. The Delaware Nation and Delaware Tribe of Indians concurred with the PA. The NPS will continue to consult with Tribes through the standard consultation process. The PA can be found in the EA under Appendix A.
                </P>
                <HD SOURCE="HD2">Paperwork Reduction Act</HD>
                <P>
                    This proposed rule contains no new information collections. All information collections require approval under the Paperwork Reduction Act of 1995 (PRA; 44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). The NPS may not conduct or sponsor and you are not required to respond to a collection of information unless it displays a currently valid OMB control number.
                </P>
                <HD SOURCE="HD2">National Environmental Policy Act</HD>
                <P>
                    The NPS has prepared the EA to determine whether this proposed rule will have a significant impact on the quality of the human environment under the National Environmental Policy Act of 1969. This proposed rule would not constitute a major Federal action significantly affecting the quality of the human environment. A detailed statement under the NEPA is not required because of the FONSI. A copy of the EA and FONSI are available online at 
                    <E T="03">https://parkplanning.nps.gov/frst</E>
                     by clicking the link entitled “BRVA-Comprehensive Trail Plan” and then clicking the link entitled “Document List.”
                </P>
                <P>Final trail alignments may vary slightly from the corridors analyzed in the EA (shown on Figure 12), based on additional field verification prior to construction, archeological field surveys, and Section 106 consultation. The park's natural and cultural resources experts will review final trail alignments to minimize impacts on sensitive resources. If the NPS needs to align a trail outside of an identified corridor, it would conduct additional environmental review of the alignment to avoid or minimize impacts to sensitive resources and would document the change as an amendment to the EA.</P>
                <HD SOURCE="HD2">Effects on the Energy Supply (Executive Order 13211)</HD>
                <P>This proposed rule is not a significant energy action under the definition in E.O. 13211; this proposed rule is not likely to have a significant adverse effect on the supply, distribution, or use of energy, and this proposed rule has not otherwise been designated by the Administrator of OIRA as a significant energy action. A Statement of Energy Effects in not required.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 36 CFR Part 7</HD>
                    <P>National parks, Reporting and Recordkeeping requirements.</P>
                </LSTSUB>
                <P>In consideration of the foregoing, the National Park Service proposes to amend 36 CFR part 7 as set forth below:</P>
                <PART>
                    <HD SOURCE="HED">PART 7—SPECIAL REGULATIONS, AREAS OF THE NATIONAL PARK SYSTEM</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 7 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>54 U.S.C. 100101, 100751, 320102; Sec. 7.96 also issued under DC Code 10-137 and DC Code 50-2201.07.</P>
                </AUTH>
                <AMDPAR>2. Add § 7.99 to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 7.99</SECTNO>
                    <SUBJECT> First State National Historical Park.</SUBJECT>
                    <P>(a) Bicycle Use.</P>
                    <P>(1) The Superintendent may designate for bicycle use all or a portion of the trails in the Brandywine Valley Unit that are identified in Table 1:</P>
                    <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,12,r50,r50">
                        <TTITLE>
                            Table 1 to Paragraph (
                            <E T="01">a</E>
                            )(1)
                        </TTITLE>
                        <BOXHD>
                            <CHED H="1">Trail name</CHED>
                            <CHED H="1">
                                Total 
                                <LI>approximate </LI>
                                <LI>distance (mi)</LI>
                            </CHED>
                            <CHED H="1">Start point</CHED>
                            <CHED H="1">End point</CHED>
                        </BOXHD>
                        <ROW>
                            <ENT I="01">Beaver Dam Trail</ENT>
                            <ENT>1.34</ENT>
                            <ENT>Smith Bridge Parking Lot (Lot 3)</ENT>
                            <ENT>Smith Bridge Parking Lot (Lot 3).</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Boundary Marker Trail</ENT>
                            <ENT>1.02</ENT>
                            <ENT>Lot 1</ENT>
                            <ENT>Delaware/Pennsylvania border near Woodlawn Trustees.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Chandler's Hollow Trail</ENT>
                            <ENT>0.96</ENT>
                            <ENT>Parking lot near the 3-way intersection on Beaver Valley Road</ENT>
                            <ENT>Boundary Marker Trail.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Coyote Ridge Trail</ENT>
                            <ENT>0.80</ENT>
                            <ENT>North of Ramsey Parking Lot (Lot 4)</ENT>
                            <ENT>Gate near the Ramsey Quarry.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Hurricane Run Loop Trail</ENT>
                            <ENT>0.96</ENT>
                            <ENT>500 Woodlawn Road</ENT>
                            <ENT>501 Woodlawn Road.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Lower Creek Trail</ENT>
                            <ENT>1.42</ENT>
                            <ENT>Smith Bridge Parking Lot (Lot 3)</ENT>
                            <ENT>Smith Bridge Parking Lot (Lot 3).</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">North Quarry Trail</ENT>
                            <ENT>1.70</ENT>
                            <ENT>Across the road from Lot 1</ENT>
                            <ENT>Smith Bridge Road.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Pasture Loop Trail</ENT>
                            <ENT>1.07</ENT>
                            <ENT>500 Woodlawn Road</ENT>
                            <ENT>501 Woodlawn Road.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Pipeline Ridge Loop</ENT>
                            <ENT>2.14</ENT>
                            <ENT>At the three way intersection of Beaver Valley Road and Dam Road</ENT>
                            <ENT>At the three way intersection of Beaver Valley Road and Dam Road.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Ramsey Loop</ENT>
                            <ENT>2.08</ENT>
                            <ENT>Ramsey Park Lot (Lot 4)</ENT>
                            <ENT>Ramsey Park Lot (Lot 4).</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Rocky Run Loop Trail</ENT>
                            <ENT>1.27</ENT>
                            <ENT>Marrit Hotel Parking Lot (Lot 5)</ENT>
                            <ENT>Marrit Hotel Parking Lot (Lot 5).</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Woodlawn Trail</ENT>
                            <ENT>1.05</ENT>
                            <ENT>Gate on Ramsey Road</ENT>
                            <ENT>Cross walk on Beaver Valley Road.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Connector Trails C1 through C51</ENT>
                            <ENT>9.0</ENT>
                        </ROW>
                    </GPOTABLE>
                    <P>(2) A map showing trails open to bicycle use will be available at park visitor centers and posted on the park website. The Superintendent will provide notice of all trails designated for bicycle use in accordance with §  1.7 of this chapter, including publication in the Superintendent's Compendium (or written compilation) of discretionary actions referred to § 1.7(b).</P>
                    <P>
                        (3) The Superintendent may limit, restrict, or impose conditions on bicycle use, or close any trail to bicycle use, or terminate such conditions, closures, limits, or restrictions in accordance with 
                        <PRTPAGE P="48032"/>
                        §  4.30 of this chapter. A violation of any such condition, closure, limit, or restriction is prohibited.
                    </P>
                    <P>(b) Reserved.</P>
                </SECTION>
                <SIG>
                    <NAME>Kevin J. Lilly,</NAME>
                    <TITLE>Principal Deputy Assistant Secretary Exercising the Delegated Authority of the Assistant Secretary for Fish and Wildlife and Parks</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15406 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4312-52-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Part 52</CFR>
                <DEPDOC>[EPA-R07-OAR-2026-5182; FRL-13486-01-R7]</DEPDOC>
                <SUBJECT>Air Plan Approval; Missouri; Construction Permit Exemptions</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Environmental Protection Agency (EPA) is proposing to approve revisions to the Missouri State Implementation Plan (SIP) received on February 10, 2026. The submission revises Missouri's regulation on construction permit exemptions in their Minor New Source Review (NSR) program. These revisions refine exemptions for emergency generators, update references to other rules, and update recordkeeping requirements. The EPA is proposing to approve this rule revision pursuant to the Clean Air Act (CAA).</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        You may send comments, identified by Docket ID No. EPA-R07-OAR-2026-5182 to 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the online instructions for submitting comments.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the Docket ID No. for this rulemaking. Comments received will be posted without change to 
                        <E T="03">https://www.regulations.gov,</E>
                         including any personal information provided. For detailed instructions on sending comments and additional information on the rulemaking process, see the “Written Comments” heading of the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section of this document.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        William Stone, Environmental Protection Agency, Region 7 Office, Air Quality Planning Branch, 11201 Renner Boulevard, Lenexa, Kansas 66219; telephone number: (913) 551-7714; email address: 
                        <E T="03">stone.william@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Throughout this document “we,” “us,” and “our” refer to the EPA.</P>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Written Comments</FP>
                    <FP SOURCE="FP-2">II. What is being addressed in this document?</FP>
                    <FP SOURCE="FP-2">III. Have the requirements for approval of a SIP revision been met?</FP>
                    <FP SOURCE="FP-2">IV. What action is the EPA taking?</FP>
                    <FP SOURCE="FP-2">V. Incorporation by Reference</FP>
                    <FP SOURCE="FP-2">VI. Statutory and Executive Order Reviews</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Written Comments</HD>
                <P>
                    Submit your comments, identified by Docket ID No. EPA-R07-OAR-2026-5182, at
                    <E T="03"> https://www.regulations.gov.</E>
                     Once submitted, comments cannot be edited or removed from 
                    <E T="03">Regulations.gov</E>
                    . The EPA may publish any comment received to its public docket. Do not submit electronically any information you consider to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Multimedia submissions (audio, video, etc.) must be accompanied by a written comment. The written comment is considered the official comment and should include discussion of all points you wish to make. The EPA will generally not consider comments or comment contents located outside of the primary submission (
                    <E T="03">i.e.,</E>
                     on the web, cloud, or other file sharing system). For additional submission methods, the full EPA public comment policy, information about CBI or multimedia submissions, and general guidance on making effective comments, please visit 
                    <E T="03">https://www.epa.gov/dockets/commenting-epa-dockets.</E>
                </P>
                <HD SOURCE="HD1">II. What is being addressed in this document?</HD>
                <P>The EPA is proposing to approve revisions to the Missouri SIP received on February 10, 2026. The revisions are to Title 10, Division 10 of the Missouri Code of State Regulations (CSR), 10 CSR 10-6.061 “Construction Permit Exemptions”. The purpose of the state regulation is to list specific construction or modification projects that are exempt from the requirement to obtain permits to construct under 10 CSR 10-6.060. Missouri made several revisions to the rule. These proposed revisions to the rule refine exemptions for emergency generators, update references within the rule and to other rules, and update recordkeeping requirements. The EPA proposes to find that these revisions meet the requirements of the CAA, do not interfere with any applicable requirement concerning attainment and reasonable further progress, and do not adversely impact air quality. The full text of the rule revisions as well as the EPA's analysis of the revisions are contained in the technical support document (TSD) included in the docket for this action.</P>
                <HD SOURCE="HD1">III. Have the requirements for approval of a SIP revision been met?</HD>
                <P>The State submission has met the public notice requirements for SIP submissions in accordance with 40 CFR 51.102. The submission also satisfied the completeness criteria of 40 CFR part 51, appendix V. The State provided public notice on this SIP revision from June 16, 2025, to August 7, 2025, and held a public hearing on July 31, 2025. Missouri received no comments.</P>
                <P>In addition, as explained above and in more detail in the TSD which is part of this docket, the revision meets the substantive SIP requirements of the CAA, including section 110 and implementing regulations.</P>
                <HD SOURCE="HD1">IV. What action is the EPA taking?</HD>
                <P>The EPA is proposing to amend the Missouri SIP by approving the State's request to revise 10 CSR 10-6.061 “Construction Permit Exemptions.” We are processing this as a proposed action because we are soliciting comments on this proposed action. Final rulemaking will occur after consideration of any comments.</P>
                <HD SOURCE="HD1">V. Incorporation by Reference</HD>
                <P>
                    In this document, the EPA is proposing to include regulatory text in an EPA final rule that includes incorporation by reference. In accordance with requirements of 1 CFR 51.5, the EPA is proposing to finalize the incorporation by reference of the Missouri rule 10 CSR 10-6.061 as described in section II. of this preamble and as set forth below in the proposed amendments to 40 CFR part 52. The EPA has made, and will continue to make, these materials generally available through 
                    <E T="03">https://www.regulations.gov</E>
                     and at the EPA Region 7 Office (please contact the person identified in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this preamble for more information).
                </P>
                <HD SOURCE="HD1">VI. Statutory and Executive Order Reviews</HD>
                <P>
                    Under the CAA, the Administrator is required to approve a SIP submission that complies with the provisions of the CAA and applicable Federal regulations. 42 U.S.C. 7410(k); 40 CFR 52.02(a). Thus, in reviewing SIP submissions, the EPA's role is to approve state choices, provided that they meet the criteria of the CAA. Accordingly, this action merely approves state law as meeting Federal requirements and does not 
                    <PRTPAGE P="48033"/>
                    impose additional requirements beyond those imposed by state law. For that reason, this action:
                </P>
                <P>• Is not a significant regulatory action subject to review by the Office of Management and Budget under Executive Order 12866 (58 FR 51735, October 4, 1993);</P>
                <P>• Is not an Executive Order 14192 (90 FR 9065, February 6, 2025) regulatory action because this action is not significant under Executive Order 12866;</P>
                <P>
                    • Does not impose an information collection burden under the provisions of the Paperwork Reduction Act (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>
                    • Is certified as not having a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>• Does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4);</P>
                <P>• Does not have federalism implications as specified in Executive Order 13132 (64 FR 43255, August 10, 1999);</P>
                <P>• Is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997) because it approves a state program;</P>
                <P>• Is not a significant regulatory action subject to Executive Order 13211 (66 FR 28355, May 22, 2001); and</P>
                <P>• Is not subject to requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) because application of those requirements would be inconsistent with the CAA.</P>
                <P>In addition, the SIP is not approved to apply on any Indian reservation land or in any other area where the EPA or an Indian Tribe has demonstrated that a Tribe has jurisdiction. In those areas of Indian country, the rule does not have Tribal implications and will not impose substantial direct costs on Tribal governments or preempt Tribal law as specified by Executive Order 13175 (65 FR 67249, November 9, 2000).</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 40 CFR Part 52</HD>
                    <P>Environmental protection, Air pollution control, Carbon monoxide, Incorporation by reference, Intergovernmental relations, Lead, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides, Volatile organic compounds.</P>
                </LSTSUB>
                <SIG>
                    <DATED>Dated: July 17, 2026.</DATED>
                    <NAME>James Macy,</NAME>
                    <TITLE>Regional Administrator, Region 7.</TITLE>
                </SIG>
                <P>For the reasons stated in the preamble, the EPA proposes to amend 40 CFR part 52 as set forth below:</P>
                <PART>
                    <HD SOURCE="HED">PART 52—APPROVAL AND PROMULGATION OF IMPLEMENTATION PLANS</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 52 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>
                         42 U.S.C. 7401 
                        <E T="03">et seq.</E>
                    </P>
                </AUTH>
                <SUBPART>
                    <HD SOURCE="HED">Subpart AA—Missouri</HD>
                </SUBPART>
                <AMDPAR>2. In § 52.1320, the table in paragraph (c) is amended by revising the entry “10-6.061” to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 52.1320</SECTNO>
                    <SUBJECT> Identification of plan.</SUBJECT>
                    <STARS/>
                    <P>(c) * * *</P>
                    <GPOTABLE COLS="5" OPTS="L1,nj,i1" CDEF="xs60,r30,r30,r75,r50">
                        <TTITLE>EPA—Approved Missouri Regulations</TTITLE>
                        <BOXHD>
                            <CHED H="1">
                                Missouri
                                <LI>citation</LI>
                            </CHED>
                            <CHED H="1">Title</CHED>
                            <CHED H="1">
                                State
                                <LI>effective</LI>
                                <LI>date</LI>
                            </CHED>
                            <CHED H="1">EPA approval date</CHED>
                            <CHED H="1">Explanation</CHED>
                        </BOXHD>
                        <ROW EXPSTB="04" RUL="s">
                            <ENT I="21">
                                <E T="02">Missouri Department of Natural Resources</E>
                            </ENT>
                        </ROW>
                        <ROW EXPSTB="00">
                            <ENT I="22"> </ENT>
                        </ROW>
                        <ROW RUL="s">
                            <ENT I="28">*         *         *         *         *         *         *</ENT>
                        </ROW>
                        <ROW EXPSTB="04" RUL="s">
                            <ENT I="21">
                                <E T="02">Chapter 6—Air Quality Standards, Definitions, Sampling and Reference Methods, and Air Pollution Control Regulations for the State of Missouri</E>
                            </ENT>
                        </ROW>
                        <ROW EXPSTB="00">
                            <ENT I="22"> </ENT>
                        </ROW>
                        <ROW RUL="s">
                            <ENT I="28">*         *         *         *         *         *         *</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">10-6.061</ENT>
                            <ENT>Construction Permit Exemptions</ENT>
                            <ENT>1/30/2026</ENT>
                            <ENT>
                                7/30/2026, 91 FR [
                                <E T="02">Federal Register</E>
                                 page where the document begins of the final rule]
                            </ENT>
                            <ENT>Sections (3)(A)2.D. and (3)(A)2.E.(II)(c) are not SIP-approved.</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="22"> </ENT>
                        </ROW>
                        <ROW>
                            <ENT I="28">*         *         *         *         *         *         *</ENT>
                        </ROW>
                    </GPOTABLE>
                    <STARS/>
                </SECTION>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15371 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <PRTPAGE P="48034"/>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Parts 52 and 81</CFR>
                <DEPDOC>[EPA-R03-OAR-2026-1685; FRL-13024-01-R3]</DEPDOC>
                <SUBJECT>Air Plan Approval; Pennsylvania; Redesignation of the Warren County Nonattainment Area to Attainment and Approval of the Area's Maintenance Plan for the 2010 1-Hour Primary Sulfur Dioxide National Ambient Air Quality Standard</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is proposing to approve a state implementation plan (SIP) revision and redesignation request submitted on September 19, 2025 by the Pennsylvania Department of Environmental Protection (PADEP). The SIP revision asks the EPA to redesignate the Warren County, Pennsylvania area from nonattainment to attainment for the 2010 1-hour primary sulfur dioxide (SO
                        <E T="52">2</E>
                        ) national ambient air quality standard (NAAQS). The revision also asks the EPA to approve into the SIP the Commonwealth's maintenance plan for the 2010 1-hour primary SO
                        <E T="52">2</E>
                         NAAQS for the Warren County area. Furthermore, Pennsylvania requests that the EPA correct source-specific requirements for United Refining Company within the Pennsylvania SIP that were previously included in error. This proposed action is being taken under the Clean Air Act (CAA).
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written comments must be received on or before August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, identified by Docket ID No. EPA-R03-OAR-2026-1685 at 
                        <E T="03">www.regulations.gov,</E>
                         or via email to 
                        <E T="03">gordon.mike@epa.gov.</E>
                         For comments submitted at 
                        <E T="03">Regulations.gov,</E>
                         follow the online instructions for submitting comments. Once submitted, comments cannot be edited or removed from 
                        <E T="03">Regulations.gov.</E>
                         For either manner of submission, the EPA may publish any comment received to its public docket. Do not submit electronically any information you consider to be confidential business information (CBI) or other information whose disclosure is restricted by statute. Multimedia submissions (audio, video, etc.) must be accompanied by a written comment. The written comment is considered the official comment and should include discussion of all points you wish to make. The EPA will generally not consider comments or comment contents located outside of the primary submission (
                        <E T="03">i.e.,</E>
                         on the web, cloud, or other file sharing system). For additional submission methods, please contact the person identified in the 
                        <E T="02">For Further Information Contact</E>
                         section. For the full EPA public comment policy, information about CBI or multimedia submissions, and general guidance on making effective comments, please visit 
                        <E T="03">www.epa.gov/dockets/commenting-epa-dockets.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Philip McGuire, Planning &amp; Implementation Branch (3AD30), Air &amp; Radiation Division, U.S. Environmental Protection Agency, Region III, 1600 John F Kennedy Boulevard, Philadelphia, Pennsylvania 19103. The telephone number is (215) 814-2251. Mr. McGuire can also be reached via electronic mail at 
                        <E T="03">mcguire.philip@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">I. Background</HD>
                <HD SOURCE="HD2">A. Nonattainment Designation</HD>
                <P>
                    On June 22, 2010, the EPA revised the primary SO
                    <E T="52">2</E>
                     NAAQS, establishing a new 1-hour primary standard of 75 parts per billion (ppb).
                    <SU>1</SU>
                    <FTREF/>
                     Under the EPA's regulations at title 40 of the Code of Federal Regulations (CFR) part 50, the 2010 1-hour SO
                    <E T="52">2</E>
                     NAAQS is met at a monitoring site when the design value 
                    <SU>2</SU>
                    <FTREF/>
                     is less than or equal to 75 ppb (based on the rounding convention in 40 CFR part 50, appendix T).
                    <SU>3</SU>
                    <FTREF/>
                     Ambient air quality monitoring data for the 3-year period must meet a data completeness requirement. A year meets data completeness requirements when all four quarters are complete, and a quarter is complete when at least 75 percent of the sampling days in the quarter have complete data. A sampling day has complete data if 75 percent of the hourly concentration values, including state-flagged data affected by exceptional events which have been approved for exclusion by the Administrator, are reported.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See</E>
                         75 FR 35520, June 22, 2010.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         For the 2010 1-hour SO
                        <E T="52">2</E>
                         NAAQS, the design value is calculated as the 3-year average of the annual 99th percentile of daily maximum 1-hour average concentrations of SO
                        <E T="52">2</E>
                        .
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         40 CFR 50.17.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         40 CFR part 50, appendix T, section 3.1(b).
                    </P>
                </FTNT>
                <P>
                    Upon promulgation of a new or revised NAAQS, the CAA requires the EPA to designate as nonattainment any area that does not meet (or that contributes to ambient air quality in a nearby area that does not meet) the NAAQS.
                    <SU>5</SU>
                    <FTREF/>
                     On August 5, 2013, the EPA designated a portion of Warren County, Pennsylvania (hereafter the “Warren County NAA”), as nonattainment for the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS, effective October 4, 2013.
                    <SU>6</SU>
                    <FTREF/>
                     The designation was based on violating air quality monitoring data for calendar years 2009-2011. The Warren County NAA consists of Conewango Township, Glade Township, Pleasant Township, and the City of Warren.
                    <SU>7</SU>
                    <FTREF/>
                     This proposed action established an attainment date five years after the effective date for the areas designated as nonattainment for the 2010 SO
                    <E T="52">2</E>
                     NAAQS (
                    <E T="03">i.e.,</E>
                     by October 4, 2018). The Commonwealth was also required to submit an attainment plan SIP revision for the Warren County NAA to the EPA that met the requirements of CAA sections 110, 172(c) and 191-192 within 18 months of the October 4, 2013, effective date of designation (
                    <E T="03">i.e.,</E>
                     by April 4, 2015).
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         CAA section 107(d)(1)(A)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         78 FR 47191, August 5, 2013.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         A list of Pennsylvania's attainment status designations is available at 40 CFR 81.339.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Relevant Historical SIP Actions</HD>
                <P>
                    The EPA did not receive an attainment plan SIP revision for the Warren County NAA by the deadline of April 4, 2015, and subsequently on March 18, 2016, the EPA published a finding of failure to submit indicating that Pennsylvania did not submit the required SO
                    <E T="52">2</E>
                     attainment plan.
                    <SU>8</SU>
                    <FTREF/>
                     This finding initiated a clock under CAA section 179(a) for the potential imposition of new source review sanctions 18 months after the effective date of the finding and the potential imposition of highway funding sanctions 6 months following that, in accordance with CAA section 179(b) and 40 CFR 52.31. Additionally, under CAA section 110(c), the finding triggered a requirement for the EPA to promulgate a Federal implementation plan (FIP) within two years of the effective date of the finding unless, by that time, Pennsylvania made the necessary complete submittal, and the EPA approved the submittal.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         81 FR 14736, March 18, 2016.
                    </P>
                </FTNT>
                <P>
                    Ultimately, Pennsylvania did submit an attainment plan SIP revision for the Warren County NAA on September 29, 2017. The EPA issued a letter to Pennsylvania on October 5, 2017, finding the attainment plan submittal complete and noting the stopping of the sanctions' deadline. As a result, these CAA section 179(b) sanctions were not imposed.
                    <SU>9</SU>
                    <FTREF/>
                     The EPA proposed approving the attainment plan SIP revision 
                    <PRTPAGE P="48035"/>
                    submittal on March 22, 2018,
                    <SU>10</SU>
                    <FTREF/>
                     and issued a final approval on October 12, 2018.
                    <SU>11</SU>
                    <FTREF/>
                     This approval ended the requirement for the EPA to promulgate a FIP under CAA section 110(c).
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         Both the 2017 attainment plan submittal and EPA completeness letter are available in the docket for this proposed rulemaking and are titled 
                        <E T="03">Warren_County_September_2017_Attainment_Plan</E>
                         and 
                        <E T="03">EPA_Letter_of_Completeness_dated_October_5,_2017,</E>
                         respectively.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         83 FR 12516, March 22, 2018.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         83 FR 51629, October 12, 2018.
                    </P>
                </FTNT>
                <P>
                    Relevant to this proposed action, on September 19, 2025, PADEP submitted a SIP revision to the EPA for the inclusion of a maintenance plan for the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS and requested a concurrent redesignation of the Warren County NAA to attainment for the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS.
                    <SU>12</SU>
                    <FTREF/>
                     The September 19, 2025 SIP revision also requested that the EPA correct source-specific requirements included in the Pennsylvania SIP. The October 12, 2018 final approval of Pennsylvania's attainment plan SIP revision incorporated by reference the entirety of a consent order and agreement between PADEP and United Refining Company,
                    <SU>13</SU>
                    <FTREF/>
                     rather than the intended redacted version and PADEP has provided updated language with the September 19, 2025 revision for inclusion in the SIP to replace the prior error.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         Available in the docket for this proposed rulemaking as 
                        <E T="03">Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP.</E>
                         The transmittal letter for this submittal is dated September 10, 2025, but the submittal was not received until September 19, 2025.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         United Refining Company may also be referred to as “United Refining Corporation” or “URC” within this proposed rulemaking or within the documents available in the docket for this proposed rulemaking.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Redesignation to Attainment Criteria</HD>
                <P>
                    After a state has submitted a redesignation request for a nonattainment area, the EPA must assess if the statutory criteria identified in CAA section 107(d)(3)(E) have been met to redesignate the area to attainment. These conditions include: (1) the EPA has determined that the applicable NAAQS has been attained; (2) the applicable SIP has been fully approved by the EPA under CAA section 110(k); (3) the EPA has determined that the improvement in the area's air quality is due to permanent and enforceable reductions in emissions; (4) the area has a fully approved maintenance plan, including a contingency plan, under CAA section 175A; and (5) the State has met all applicable requirements for the area under CAA section 110 and part D. The EPA has provided direction for how it would consider if these conditions have been met in the April 23, 2014 memorandum “Guidance for 1-Hour SO
                    <E T="52">2</E>
                     Nonattainment Area SIP Submissions” (2014 SO
                    <E T="52">2</E>
                     Guidance).
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         Available in the docket for this proposed rulemaking as 
                        <E T="03">2014_SO</E>
                        <E T="52">2</E>
                        <E T="03">_Guidance</E>
                         and at 
                        <E T="03">www.epa.gov/sites/default/files/2016-06/documents/20140423guidance_nonattainment_sip.pdf.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">D. Maintenance Plan Approval Criteria</HD>
                <P>
                    Section 175A of the CAA and additional EPA guidance, including the September 4, 1992 memorandum “Procedures for Processing Requests to Redesignate Areas to Attainment” (Calcagni Memo),
                    <SU>15</SU>
                    <FTREF/>
                     identify the required elements for an approvable maintenance plan for areas seeking redesignation from nonattainment to attainment. Under CAA section 175A, the plan must demonstrate continued attainment of the applicable NAAQS for at least 10 years after the EPA approves a redesignation request to attainment. Eight years after the redesignation, the State must submit a revised maintenance plan demonstrating that attainment will continue to be maintained for an additional 10 years following the initial 10-year period. To address the possibility of future NAAQS violations, the maintenance plan must contain contingency measures, as the EPA deems necessary, to assure prompt correction of any future NAAQS violations, in this case the 2010 1-hour SO
                    <E T="52">2</E>
                     NAAQS. The Calcagni Memo provides further guidance on the content of a maintenance plan, explaining that a maintenance plan should address five requirements: (1) an attainment emissions inventory that identifies the level of emissions in the area which is sufficient to attain the NAAQS; (2) a maintenance demonstration that shows future emissions of a pollutant will not exceed the level of the attainment inventory; (3) the continued operation of a monitoring network that conforms to 40 CFR part 58; (4) a means for verifying the continued attainment of the NAAQS; and (5) a contingency plan to correct any violation of the NAAQS in the area following redesignation of the area.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         Available in the docket for this proposed rulemaking as 
                        <E T="03">Calcagni_Memo</E>
                         and at 
                        <E T="03">www.epa.gov/sites/default/files/2016-03/documents/calcagni_memo_-_procedures_for_processing_requests_to_redesignate_areas_to_attainment_090492.pdf.</E>
                         Both the 2014 SO
                        <E T="52">2</E>
                         Guidance and Calcagni Memo provide similar guidance on redesignation requests and maintenance plans and these reference documents may be used interchangeably in this proposed rulemaking.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Summary of Redesignation Request and Maintenance Plan and EPA Analysis</HD>
                <P>
                    The EPA's evaluation of Pennsylvania's redesignation request and maintenance plan for the Warren County NAA is based on consideration of the five redesignation criteria provided under CAA section 107(d)(3)(E) and relevant guidance, including the aforementioned 2014 SO
                    <E T="52">2</E>
                     Guidance and Calcagni Memo. The summary and analysis of Pennsylvania's redesignation request and maintenance plan are discussed immediately below, while the summary and analysis of the source-specific requirements revision is discussed in section III in this document.
                </P>
                <HD SOURCE="HD2">
                    A. Criterion (1)—The Warren County SO2 Nonattainment Area Has Attained the 2010 1-Hour SO
                    <E T="52">2</E>
                     NAAQS
                </HD>
                <P>
                    Section 107(d)(3)(E)(i) of the CAA requires that the EPA determine that a nonattainment area has attained the applicable NAAQS in order to redesignate the area to attainment. In assessing if the area has attained the NAAQS, the 2014 SO
                    <E T="52">2</E>
                     Guidance stipulates that the EPA can interdependently consider two components to support an attainment determination: air quality monitoring data and air quality modeling data.
                    <SU>16</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See 2014_SO</E>
                        <E T="52">2</E>
                        <E T="03">_Guidance,</E>
                         at 62.
                    </P>
                </FTNT>
                <P>
                    The Warren County NAA contains two operational SO
                    <E T="52">2</E>
                     monitor sites: the Warren Overlook site (Air Quality System (AQS) Site ID 42-123-0004) and the Warren East site (AQS Site ID 42-123-0005). The Warren Overlook site is located in Conewango Township, while the Warren East site is located in the City of Warren. The Warren Overlook monitor has been in operation since 1996 and has been in attainment of the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS since 2017, with the most recent design value for the 2022-2024 period measuring 45 parts per billion (ppb). The Warren East monitor does not meet siting criteria established in 40 CFR part 58 and as such its data is not appropriate for assessing NAAQS compliance.
                    <SU>17</SU>
                    <FTREF/>
                     Since it began monitoring in 2012, the Warren East monitor has continuously recorded design values below the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS, with the most recent design value for the 2022-2024 period measuring 32 ppb. Design values for both the Warren Overlock and Warren East monitors are reported in table 1 in this document.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         The Warren East site data is presented for informational purposes only.
                    </P>
                </FTNT>
                <PRTPAGE P="48036"/>
                <GPOTABLE COLS="11" OPTS="L2,nj,p7,7/8,i1" CDEF="s40,10,10,10,10,10,10,10,10,10,10">
                    <TTITLE>
                        Table 1—2015-2024 SO
                        <E T="0732">2</E>
                         Design Values for Warren County Nonattainment Area Monitor Sites 
                    </TTITLE>
                    <TDESC>[Parts per billion]</TDESC>
                    <BOXHD>
                        <CHED H="1">Monitor site</CHED>
                        <CHED H="1">2013-2015</CHED>
                        <CHED H="1">2014-2016</CHED>
                        <CHED H="1">2015-2017</CHED>
                        <CHED H="1">2016-2018</CHED>
                        <CHED H="1">2017-2019</CHED>
                        <CHED H="1">2018-2020</CHED>
                        <CHED H="1">2019-2021</CHED>
                        <CHED H="1">2020-2022</CHED>
                        <CHED H="1">2021-2023</CHED>
                        <CHED H="1">2022-2024</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Warren Overlook</ENT>
                        <ENT>118</ENT>
                        <ENT>92</ENT>
                        <ENT>* 64</ENT>
                        <ENT>36</ENT>
                        <ENT>31</ENT>
                        <ENT>36</ENT>
                        <ENT>40</ENT>
                        <ENT>46</ENT>
                        <ENT>44</ENT>
                        <ENT>45</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Warren East</ENT>
                        <ENT>* 61</ENT>
                        <ENT>* 52</ENT>
                        <ENT>38</ENT>
                        <ENT>31</ENT>
                        <ENT>42</ENT>
                        <ENT>33</ENT>
                        <ENT>35</ENT>
                        <ENT>29</ENT>
                        <ENT>* 33</ENT>
                        <ENT>32</ENT>
                    </ROW>
                    <TNOTE>* Indicates year in which the design value did not meet data completeness requirements.</TNOTE>
                </GPOTABLE>
                <P>
                    Pennsylvania's 2017 attainment plan contained an attainment demonstration which utilized allowable SO
                    <E T="52">2</E>
                     emission limits from stationary sources within the Warren County NAA to inform several modeling analyses for SO
                    <E T="52">2</E>
                     emissions.
                    <SU>18</SU>
                    <FTREF/>
                     These modeling analyses were based on emissions limits for large, stationary sources of SO
                    <E T="52">2</E>
                    , which, when enacted, would ensure that the Warren County NAA would attain the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS. The 2014 SO
                    <E T="52">2</E>
                     Guidance states that the EPA may make a determination of attainment based on this attainment plan modeling, eliminating the need for separate actual emissions-based modeling to support a redesignation request—provided that the source characteristics are still reasonably represented and that the control strategy in the SIP has been fully implemented.
                    <SU>19</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See Warren_County_September_2017_Attainment_Plan,</E>
                         available in the docket for this proposed rulemaking.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See 2014_SO_Guidance,</E>
                         at 50.
                    </P>
                </FTNT>
                <P>
                    Since Pennsylvania's 2017 submittal of this attainment plan modeling—which EPA approved on October 12, 2018 
                    <SU>20</SU>
                    <FTREF/>
                    —source characteristics within the Warren County NAA remain reasonably represented. United Refining Company (URC) is still the largest SO
                    <E T="52">2</E>
                     emissions stationary source within the nonattainment area and remains relatively unchanged, with the exception of a boiler replacement, a stack height reduction, and the addition of a loading rack. The former boiler at URC was modeled with an SO
                    <E T="52">2</E>
                     emissions rate equivalent to 7.21 pounds per hour (lbs/hr), while the replacement boiler is limited to 1.7 lbs/hr of SO
                    <E T="52">2</E>
                     emissions. The stack that the new boiler exhausts through was shortened from the height of the prior boiler's exhaust stack, but the new boiler simultaneously was permitted at a lower emissions rate. The newly constructed loading rack is expected to produce minimal SO
                    <E T="52">2</E>
                     emissions, with a reported contribution of 0.0001 lbs/hr. The sources characteristics are still reasonably represented and overall, these operational changes lead to a modeled overestimation of actual emissions of SO
                    <E T="52">2</E>
                     sources within the Warren NAA.
                </P>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         83 FR 51629, October 12, 2018.
                    </P>
                </FTNT>
                <P>
                    The 2014 SO
                    <E T="52">2</E>
                     Guidance further states that a demonstration that the control strategy in the SIP has been fully implemented will also be pertinent for making the determination of attainment.
                    <SU>21</SU>
                    <FTREF/>
                     Pennsylvania has submitted information detailed in its redesignation request and maintenance plan to confirm that the control strategy outlined in the SIP has been fully implemented. Specific measures identified in the control strategy include a fuel switch to low sulfur fuel in 11 combustion units and heaters at URC, as well as the increased usage of an additive for preventing SO
                    <E T="52">2</E>
                     formation in the fluid catalytic cracking unit at URC. These implemented permanent and federally enforceable control measures have aided in reducing the actual total emissions from large, stationary SO
                    <E T="52">2</E>
                     sources in the Warren County NAA to 328 tons per year (as of 2018),
                    <SU>22</SU>
                    <FTREF/>
                     which is well below the revised total emissions limits proposed for Warren County NAA facilities in the 2017 attainment demonstration modeling (1,274 tons per year),
                    <SU>23</SU>
                    <FTREF/>
                     thus contributing to bringing the Warren County NAA into attainment.
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         Ibid.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP, at 29.</E>
                    </P>
                </FTNT>
                <P>
                    As the source characteristics within the Warren County NAA are still reasonably represented and the control strategy in the SIP has been fully implemented, the EPA may make a determination of attainment based on this attainment plan modeling. In this proposed rulemaking, the EPA proposes to find that the air quality modeling data demonstrate that the Warren County NAA has attained the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS, with the air quality monitoring data further supporting this conclusion.
                </P>
                <HD SOURCE="HD2">B. Criterion (2)—Pennsylvania Has a Fully Approved SIP Under Section 110(k)</HD>
                <P>
                    Section 107(d)(3)(E)(ii) of the CAA requires that the EPA fully approve the applicable implementation plan for the area under CAA section 110(k) in order to redesignate that area to attainment. An area cannot be redesignated to attainment if a required element of the SIP is the subject of a disapproval; a finding of failure to submit, or failure to implement the SIP; or a partial, conditional, or limited approval.
                    <SU>24</SU>
                    <FTREF/>
                     The 2017 attainment plan SIP was initially proposed for EPA approval on March 22, 2018 
                    <SU>25</SU>
                    <FTREF/>
                     and received final EPA approval on October 12, 2018.
                    <SU>26</SU>
                    <FTREF/>
                     The approved elements from the 2017 attainment plan include a 2011 base year emissions inventory, a control strategy and air quality modeling demonstration, a reasonable available control measures/reasonably available control technology (RACM/RACT) analysis, a reasonable further progress (RFP) analysis, and contingency measures. The EPA also concluded in the October 12, 2018 final approval that Pennsylvania's existing SIP-approved nonattainment new source review (NNSR) program meets the applicable requirements for SO
                    <E T="52">2</E>
                    .
                    <SU>27</SU>
                    <FTREF/>
                     As such, the EPA has fully approved the applicable Pennsylvania SIP for the Warren County NAA under section 110(k) of the CAA for all requirements applicable for purposes of redesignation.
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See 2014_SO</E>
                        <E T="52">2</E>
                        <E T="03">_Guidance,</E>
                         at 64.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         83 FR 12516, March 22, 2018.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         83 FR 51629, October 12, 2018.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         Pennsylvania has a NNSR program for criteria pollutants in 25 Pennsylvania Code Chapter 127, Subchapter E, which was approved into the Pennsylvania SIP on December 9, 1997 (62 FR 64722). On May 14, 2012 (77 FR 28261), the EPA approved a SIP revision pertaining to the preconstruction permitting requirements of Pennsylvania's NNSR program to update the regulations to meet the EPA's 2002 NSR reform regulations. The EPA then approved an update to Pennsylvania's NNSR regulations on July 13, 2012 (77 FR 41276). PADEP's current, SIP-approved NNSR program meets all of the requirements of CAA sections 175(c)(5) and 173 and 40 CFR 51.165 for SO
                        <E T="52">2</E>
                         sources undergoing construction or major modification in the Warren Area.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">
                    C. Criterion (3)—The Air Quality Improvement in the Warren County SO
                    <E T="52">2</E>
                     Nonattainment Area Is Due to Permanent and Enforceable Reductions in Emissions
                </HD>
                <P>
                    For redesignating a nonattainment area to attainment, CAA section 107(d)(3)(E)(iii) requires the EPA to determine that the air quality improvement in the area is due to permanent and enforceable reductions in emissions resulting from implementation of the SIP, applicable federal air pollution control regulations, 
                    <PRTPAGE P="48037"/>
                    and other permanent and enforceable reductions. The EPA proposes to find that Pennsylvania has demonstrated that the requirements of CAA section 107(d)(3)(E)(iii) have been met.
                </P>
                <P>
                    Collectively, a fuel switch to low sulfur fuel in 11 combustion units and heaters at URC, as well as the increased usage of an additive for preventing SO
                    <E T="52">2</E>
                     formation in the fluid catalytic cracking unit at URC resulted in an actual decrease of approximately 664 tons of SO
                    <E T="52">2</E>
                     emitted per year from 2011 to 2018.
                    <SU>28</SU>
                    <FTREF/>
                     This is approximately a 67% reduction from 2011 levels of 992 tons of SO
                    <E T="52">2</E>
                     emitted per year.
                    <SU>29</SU>
                    <FTREF/>
                     As this reduction is federally enforceable through permit-controlled emission limits,
                    <SU>30</SU>
                    <FTREF/>
                     the EPA proposes to find the air quality improvement in the Warren County NAA to be due to permanent and enforceable reductions in emissions.
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See Warren_County_September_2017_Attainment_Plan,</E>
                         at 8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         A copy of URC's title V operating permit, effective December 15, 2025 is available in the docket for this proposed rulemaking. See 
                        <E T="03">2025_URC_Title_V_Full.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">
                    D. Criterion (4)—The Warren County SO
                    <E T="52">2</E>
                     Nonattainment Area Has a Fully Approved Maintenance Plan Pursuant to Section 175A of the CAA
                </HD>
                <P>
                    To redesignate a NAA to attainment, CAA section 107(d)(3)(E)(iv) requires the EPA to determine that the area has a fully approved maintenance plan pursuant to section 175A of the CAA. In conjunction with its request to redesignate the Warren County NAA to attainment for the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS, the Commonwealth submitted a SIP revision to provide for the maintenance of the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS for at least 10 years after the effective date of redesignation to attainment. The EPA is proposing to find that this maintenance plan meets the requirements for approval under section 175A of the CAA.
                </P>
                <HD SOURCE="HD3">1. Maintenance Plan Requirements</HD>
                <P>
                    Section 175A of the CAA sets forth the elements of a maintenance plan. Under CAA section 175A, the plan must demonstrate continued attainment of the applicable NAAQS for at least 10 years after the Administrator approves a redesignation request to attainment. Eight years after the redesignation, the State must submit a revised maintenance plan demonstrating that attainment will continue to be maintained for an additional 10 years following the initial 10-year period. To address the possibility of future NAAQS violations, the maintenance plan must contain contingency measures as the EPA deems necessary to assure prompt correction of any future NAAQS violations, here the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS. As noted above, the Calcagni Memo provides further guidance on the content of a maintenance plan, explaining that a maintenance plan should address five requirements: (1) the attainment emissions inventory; (2) maintenance demonstration; (3) monitoring; (4) verification of continued attainment; and (5) a contingency plan.
                    <SU>31</SU>
                    <FTREF/>
                     As discussed in detail below, the EPA is proposing to determine that Pennsylvania's submitted maintenance plan meets the requirements in CAA section 175A and is thus proposing to approve it as a revision to the Warren County portion of the Pennsylvania SIP.
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         
                        <E T="03">See Calcagni_Memo,</E>
                         at pp. 8-13.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Attainment Emissions Inventory</HD>
                <P>
                    In a maintenance plan, states are required to submit an emissions inventory to identify the level of emissions in the area which is sufficient to attain and maintain the relevant NAAQS, which is called the attainment inventory. This inventory is used as the basis for future, projected emission inventories that are used to show the area will remain in attainment. Pennsylvania submitted a 2018 SO
                    <E T="52">2</E>
                     emissions inventory as the attainment inventory with its maintenance plan. This represented a year in which SO
                    <E T="52">2</E>
                     emissions were at levels required to demonstrate attainment of the 2010 SO
                    <E T="52">2</E>
                     NAAQS.
                </P>
                <P>
                    For the 2018 attainment year inventory, Pennsylvania directly used point source emissions reported to Pennsylvania for 2018, except for Warren General Hospital and Warren Airpark, which were projected from the 2017 National Emission Inventory (NEI).
                    <SU>32</SU>
                    <FTREF/>
                     The point source emissions for the Warren County NAA were verified against the EPA's emissions inventory system (EIS) and the EPA found them to be acceptable. Projected emissions for area sources in 2018 were estimated from the 2017 NEI emission data and growth factors developed by the Mid-Atlantic Regional Air Management Association (MARAMA), Inc. These growth factors are developed based on forecasts from various databases and tools, including the Energy Information Administration's 2019 and 2020 Annual Energy Outlook, the 2016 NEI Collaborative data for the rail and the oil and gas Source Classification Codes, and other sources that are detailed in the submitted maintenance plan.
                    <SU>33</SU>
                    <FTREF/>
                     Area source emissions were estimated based on the relative percentage of the Warren County population residing in the Warren County NAA and the resulting factor allocated the appropriate fraction of the County's total emissions to the Warren County NAA.
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         The NEI is a comprehensive and detailed estimate of air emissions of criteria pollutants, criteria precursors, and hazardous air pollutants from air emissions sources. The NEI is released every three years based primarily upon data provided by State, Local, and Tribal air agencies for sources in their jurisdictions and supplemented by data developed by the US EPA, available at 
                        <E T="03">www.epa.gov/air-emissions-inventories/national-emissions-inventory-nei.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 17.
                    </P>
                </FTNT>
                <P>Nonroad and onroad mobile source emissions for 2017 were obtained from the EPA's Motor Vehicle Emissions Simulator (MOVES) model, specifically the MOVES2014b version. PADEP executed the MOVES2014b modeling runs for nonroad mobile sources and utilized a contractor to run the model for onroad mobile source emissions.</P>
                <P>
                    Projected inventories from the attainment inventory demonstrate that the area will continue to remain in attainment throughout the first maintenance period. Pennsylvania developed 2028 and 2036 emission projections for the interim and maintenance plan end year, respectively. Projected emissions for these years—as well as the base year inventory—are available in table 2 in this document. Projected emissions for point and area sources were estimated, as previously described for area sources, from the 2017 NEI and growth factors developed by MARAMA. Nonroad and onroad mobile source emissions for the projected years 2028 and 2036 were estimated from the MOVES2014b version. MOVES2014b modeling runs were once again executed by PADEP for nonroad mobile source emissions and by the contractor for onroad mobile source emissions. Additional details on some of the assumptions and inputs to the model are available in the redesignation request and its associated Appendices C4, C5, and C6.
                    <SU>34</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 19-21; 
                        <E T="03">Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP_App_C4_Nonroad_Inventory; Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP_App_C5_Mobile_Inv_Method;</E>
                         and 
                        <E T="03">Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP_App_C6_Mobile_Inventory.</E>
                    </P>
                </FTNT>
                <PRTPAGE P="48038"/>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,15,15,15">
                    <TTITLE>Table 2—Emissions Inventories for the Warren County Nonattainment Area</TTITLE>
                    <TDESC>
                        [Tons of SO
                        <E T="52">2</E>
                         per year]
                    </TDESC>
                    <BOXHD>
                        <CHED H="1">Sector</CHED>
                        <CHED H="1">
                            2018 Actual
                            <LI>emissions</LI>
                            <LI>(base year)</LI>
                        </CHED>
                        <CHED H="1">
                            2028 Projected
                            <LI>emissions</LI>
                            <LI>(interim year)</LI>
                        </CHED>
                        <CHED H="1">
                            2036 Projected
                            <LI>emissions</LI>
                            <LI>(maintenance year)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Point Sources</ENT>
                        <ENT>328</ENT>
                        <ENT>424</ENT>
                        <ENT>420</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Area Sources</ENT>
                        <ENT>20</ENT>
                        <ENT>30</ENT>
                        <ENT>30</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Nonroad Mobile Sources</ENT>
                        <ENT>&lt; 1</ENT>
                        <ENT>&lt; 1</ENT>
                        <ENT>&lt; 1</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Onroad Mobile Sources</ENT>
                        <ENT>&lt; 1</ENT>
                        <ENT>&lt; 1</ENT>
                        <ENT>&lt; 1</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT>* 349</ENT>
                        <ENT>* 455</ENT>
                        <ENT>* 450</ENT>
                    </ROW>
                    <TNOTE>* Discrepancies in summed emissions are due to rounding.</TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD3">3. Maintenance Demonstration</HD>
                <P>
                    The Calcagni memo describes two ways for a state to demonstrate maintenance of the NAAQS for a period of at least 10 years following the redesignation of the area: (1) the State can show that future emissions of a pollutant will not exceed the level of the attainment inventory, or (2) the State can model to show that the future mix of sources and emission rates will not cause a violation of the standard.
                    <SU>35</SU>
                    <FTREF/>
                     Pennsylvania's projected actual emissions for the interim year of 2028 and for the maintenance year of 2036 are both below the modeled limits established in the 2017 attainment demonstration, which is acceptable for showing maintenance in the Warren County NAA.
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See Calcagni_Memo,</E>
                         at 9.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Monitoring Network</HD>
                <P>
                    The 2014 SO
                    <E T="52">2</E>
                     Guidance indicates that once an area has been redesignated to attainment, the state should continue to operate an appropriate air quality monitoring network as provided under 40 CFR part 58 to verify the attainment status of the area. Pennsylvania has committed to continued operation of its SO
                    <E T="52">2</E>
                     monitoring network in the Warren County NAA to verify the attainment status. Also, Pennsylvania will continue to submit an annual monitoring network plan to the EPA for approval, in accordance with 40 CFR 58.10. No monitoring sites will be retired from the existing network unless pre-approved by the EPA. The EPA proposes to find that these measures are sufficient for purposes of the maintenance plan.
                </P>
                <HD SOURCE="HD3">5. Verification of Continued Attainment</HD>
                <P>
                    The 2014 SO
                    <E T="52">2</E>
                     Guidance states that each air agency should ensure that it has the legal authority to implement and enforce all measures necessary to attain and maintain the 2010 SO
                    <E T="52">2</E>
                     NAAQS. The air agency's submittal should indicate how it will track the progress of the maintenance plan for the area either through air quality monitoring or modeling.
                </P>
                <P>
                    Pennsylvania Air Pollution Control Act (APCA) section 4(27) grants PADEP the legal authority to implement all measures necessary to enforce the APCA, including maintaining the 2010 1-hour primary SO
                    <E T="52">2</E>
                     NAAQS. In addition, PADEP has indicated it will track the progress of the maintenance plan through an integrated approach utilizing air quality monitoring data and emissions inventories.
                </P>
                <P>
                    As previously indicated, PADEP will continue to operate its SO
                    <E T="52">2</E>
                     monitoring network to verify the attainment status of the Warren County NAA. PADEP will also use emissions inventories—developed annually for major point sources and triennially for area and mobile sources—to assess emissions trends. PADEP has also committed to submitting an additional SIP revision 8 years following redesignation to establish the Commonwealth's plan for maintaining the 2010 SO
                    <E T="52">2</E>
                     NAAQS for an additional 10 years, as required by CAA section 175A(b).
                </P>
                <P>The EPA proposes to find that these proposed measures will provide for verifying continued attainment within the Warren County NAA.</P>
                <HD SOURCE="HD3">6. Contingency Measures</HD>
                <P>Section 175A(d) of the CAA requires that a maintenance plan include such contingency measures as the EPA deems necessary to assure that the state will promptly correct a violation of the NAAQS that occurs after redesignation. The maintenance plan should identify the contingency measures to be adopted, a schedule and procedure for adoption and implementation, and a time limit for action by the state. A State should also identify specific indicators to be used to determine when the contingency measures need to be implemented. The maintenance plan must also include a requirement that a State will continue to implement all measures with respect to control of the pollutant that were contained in the SIP before redesignation of the area to attainment.</P>
                <P>
                    Pennsylvania has committed to continuing implementation of all applicable measures indicated in the SIP after redesignation of the Warren County NAA.
                    <SU>36</SU>
                    <FTREF/>
                     Furthermore, Pennsylvania has identified triggering indicators for its contingency measures, a schedule for implementing these potential measures, and has specified potential options to correct any NAAQS violation.
                    <SU>37</SU>
                    <FTREF/>
                     These contingency measures include both URC- and PADEP-based contingency measures.
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 31.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 31-33.
                    </P>
                </FTNT>
                <P>
                    For URC, Pennsylvania has identified two separate triggering indicators for different contingency measures: (1) an exceedance of the permitted SO
                    <E T="52">2</E>
                     emission limit (131.5 lbs/hr) for the fluid catalytic cracking (FCC) unit at URC and (2) the occurrence of a third daily max 1-hour SO
                    <E T="52">2</E>
                     concentration that exceeds 75 ppb, as measured by PADEP's Warren Overlook SO
                    <E T="52">2</E>
                     ambient monitor.
                    <SU>38</SU>
                    <FTREF/>
                     If the FCC unit at URC exceeds its permitted emission limit, URC will initiate a system audit of the FCC unit—which includes a review of the SO
                    <E T="52">2</E>
                     emission-controlling additive components, continuous emissions monitoring system, and communications equipment. Within 45 days of the exceedance, URC shall furnish PADEP with a written report that details the operating parameters of the FCC unit and its emission control system. Alternatively, if PADEP's Warren Overlook SO
                    <E T="52">2</E>
                     ambient monitor measures a third daily max 1-hour SO
                    <E T="52">2</E>
                     concentration that exceeds 75 ppb, PADEP will provide written notice to 
                    <PRTPAGE P="48039"/>
                    URC that the facility must produce an “Ambient Action Level Report” within 90 days of the provided notice. This Ambient Action Level Report should identify if any URC sources were beyond their permitted emission limits, the reason for the non-compliance, and if any additional measures have been or will be implemented to reduce the possibility of future non-compliance. If no emission exceedances are identified by URC, then URC must conduct an analysis—which may include meteorological or photochemical modeling—to identify the source of the SO
                    <E T="52">2</E>
                     ambient monitor violation. If URC was found to be in compliance with all SO
                    <E T="52">2</E>
                     emission limits and no other parties are indicated as the source of the SO
                    <E T="52">2</E>
                     monitor violation or if the Ambient Action Level Report identifies that a URC source caused the SO
                    <E T="52">2</E>
                     monitor violation, then URC shall also assess if any changes in facility operations are required to avoid a future violation of the 2010 SO
                    <E T="52">2</E>
                     NAAQS.
                </P>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         PADEP has indicated that in the event of back-to-back (2 days) exceedances of the 75-ppb threshold, this occurrence will be counted as a single day in determining the third daily exceedance. In the event of a three-day exceedance of the 75-ppb threshold, this occurrence will be counted as two days in determining the third daily exceedance.
                    </P>
                </FTNT>
                <P>
                    Alongside the URC-based contingency measures, PADEP also has identified a PADEP-based contingency measure. If PADEP identifies a daily maximum SO
                    <E T="52">2</E>
                     concentration exceeding 75 ppb at the Warren Overlook SO
                    <E T="52">2</E>
                     monitor, PADEP will initiate an investigation and proceed with enforcement as appropriate. This process includes PADEP contacting the PADEP Air Resource Management Division Chief and the PADEP Northwest Regional Office Air Program Manager to report the exceeding monitored value within five business days of the identified exceedance. Within five business days of PADEP's notification, the Northwest Regional Office will contact URC in writing requesting an informal investigation into each observed daily exceedance at the Warren Overlook SO
                    <E T="52">2</E>
                     monitor, with a URC response due in writing within 30 days. This PADEP-initiated contingency measure takes effect with the first instance of a 1-hour daily maximum SO
                    <E T="52">2</E>
                     concentration at the Warren Overlook monitor exceeding 75 ppb and is intended to proactively identify any issue prior to a violation of the 2010 SO
                    <E T="52">2</E>
                     NAAQS. If three instances of daily exceedance events occur within a calendar year, the Ambient Action Level Report contingency measure associated with URC will be enacted to correct for any potential NAAQS violation.
                </P>
                <P>
                    As the 2036 projected inventory estimates approximately 450 tons of SO
                    <E T="52">2</E>
                     emissions per year compared to the approximately 1,275 tons of SO
                    <E T="52">2</E>
                     emissions per year permitted in the 2017 attainment plan modeling, it is not expected that there will be a future monitor exceedance in the Warren County NAA. Nevertheless, Pennsylvania has committed to adopting and implementing corrective actions, as necessary and appropriate.
                </P>
                <P>The EPA proposes to find that these contingency measures are sufficient. Consistent with the above proposed findings, the EPA proposes to find that Pennsylvania's submitted maintenance plan meets the requirements set forth in CAA section 175A and EPA guidance, and is proposing to approve the maintenance plan as a revision to the Pennsylvania SIP.</P>
                <HD SOURCE="HD2">E. Criterion (5)—Pennsylvania Has Met All Applicable Requirements Under Section 110 and Part D of Title I of the CAA</HD>
                <P>In accordance with section 107(d)(3)(E)(v) of the CAA, to redesignate the Warren County NAA to attainment, Pennsylvania must meet all requirements applicable to the Warren County NAA under CAA section 110 (general SIP requirements) and part D of title I of the CAA (SIP requirements for nonattainment areas).</P>
                <HD SOURCE="HD3">1. Section 110 General Requirements for SIPs</HD>
                <P>
                    Pursuant to CAA section 110(a)(1), whenever new or revised NAAQS are promulgated, the CAA requires states to submit a plan (
                    <E T="03">i.e.,</E>
                     SIP) for the implementation, maintenance, and enforcement of such NAAQS. Section 110(a)(2) of title I of the CAA contains the general requirements for a SIP, also known as “infrastructure” requirements. These requirements include, but are not limited to, the following: submittal of a SIP that has been adopted by the State after reasonable public notice and hearing; provisions for establishment and operation of appropriate procedures needed to monitor ambient air quality; implementation of a source permit program; provisions for the implementation of part C of title I of the Clean Air Act (CAA) requirements (Prevention of Significant Deterioration (PSD)) and provisions for the implementation of part D of title I of the Clean Air Act (CAA) requirements NNSR permit programs); provisions for air pollution modeling; and provisions for public and local agency participation in planning and emission control rule development.
                </P>
                <P>
                    Section 110(a)(2)(D) of the CAA requires that SIPs contain certain measures to prevent sources in a state from significantly contributing to air quality problems in another state. To implement this provision, the EPA has required certain states to establish programs to address the interstate transport of air pollutants.
                    <SU>39</SU>
                    <FTREF/>
                     The CAA section 110(a)(2)(D) requirements for a State are not linked with a particular nonattainment area's designation and classification in that state. The EPA has concluded that the requirements linked with a particular nonattainment area's designation and classifications are the relevant measures to evaluate in reviewing a redesignation request. The transport SIP submittal requirements, where applicable, continue to apply to a state regardless of the designation of any one particular area in the state. Thus, the EPA has concluded that the CAA's interstate transport requirements should not be construed to be applicable requirements for purposes of redesignation.
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         See Nitrogen Oxides (NO
                        <E T="52">X</E>
                        ) SIP Call and amendments to the NO
                        <E T="52">X</E>
                         SIP Call (64 FR 26298, May 14, 1999 and 65 FR 11222, March 2, 2000), and the Cross-State Air Pollution Rule (CSAPR) Update (81 FR 74504, October 26, 2016).
                    </P>
                </FTNT>
                <P>
                    In addition, the EPA has concluded other CAA section 110 elements—those that are neither connected with nonattainment plan submissions nor linked with an area's attainment status—are not applicable requirements for purposes of redesignation. The area will still be subject to these requirements after the area is redesignated. The CAA section 110 and part D requirements which are linked with a particular area's designation and classification are the relevant measures to evaluate in reviewing a redesignation request. This approach is consistent with the EPA's existing policy on applicability (
                    <E T="03">i.e.,</E>
                     for redesignations) of conformity and oxygenated fuels requirements, as well as with CAA section 184 ozone transport requirements. See Reading, Pennsylvania, proposed and final rules (61 FR 53174-53176, October 10, 1996), (62 FR 24826, May 7, 2008); Cleveland-Akron-Loraine, Ohio, final rule (61 FR 20458, May 7,1996); and Tampa, Florida, final rule (60 FR 62748, December 7, 1995). See also the discussion on this issue in the Cincinnati, Ohio, redesignation (65 FR 37890, June 19, 2000), and in the Pittsburgh, Pennsylvania, redesignation (66 FR 50399, October 19, 2001).
                </P>
                <P>
                    The EPA approved elements of Pennsylvania's June 15, 2014 SO
                    <E T="52">2</E>
                     infrastructure SIP submittal on August 5, 2015.
                    <SU>40</SU>
                    <FTREF/>
                     As explained previously, certain general requirements of CAA section 110(a)(2) are statewide requirements that are not linked to the nonattainment status of the Warren County NAA and are therefore not “applicable requirements” for the purpose of reviewing Pennsylvania's 
                    <PRTPAGE P="48040"/>
                    redesignation request. Because Pennsylvania satisfies the general SIP elements and requirements set forth in CAA section 110(a)(2) applicable to and necessary for SO
                    <E T="52">2</E>
                     redesignation with the EPA's August 5, 2015 (80 FR 46494) approval of the infrastructure SIP, the EPA proposes to conclude that Pennsylvania has satisfied the criterion of CAA section 107(d)(3)(E)(v) related to section 110(a)(2) of the CAA.
                </P>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         80 FR 46494, August 5, 2015.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Part D Requirements</HD>
                <P>
                    In addition to the CAA section 110 requirements, CAA section 107(d)(3)(E)(v) requires that the State meet all the requirements applicable to the nonattainment area “under part D of this subchapter” for the nonattainment area to be redesignated. Both CAA section 107 and part D are within title 1 of the CAA. Part D, of title I of the CAA, entitled “Plan Requirements for Nonattainment Areas,” consists of six subparts, of which only subparts 1 and 5 are applicable to SO
                    <E T="52">2</E>
                     nonattainment areas. Subpart 1 (sections 171 through 179B) contains provisions that can apply to all nonattainment areas for all criteria pollutants, while subpart 5 (sections 191 and 192) contains additional provisions for SO
                    <E T="52">2</E>
                    , NO
                    <E T="52">X</E>
                    , or lead nonattainment areas. The requirements applicable to this redesignation regarding the 2010 SO
                    <E T="52">2</E>
                     NAAQS are discussed below, as applicable to SO
                    <E T="52">2</E>
                    .
                </P>
                <HD SOURCE="HD3">a. Subpart 1 Requirements</HD>
                <HD SOURCE="HD3">1. Section 172 Requirements</HD>
                <P>
                    Section 172 of the CAA requires states with nonattainment areas to submit plans that provide for timely attainment of the NAAQS. More specifically, CAA section 172(c) contains general requirements for nonattainment plans. A thorough discussion of these requirements is found in the General Preamble for Implementation of title I.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         57 FR 13498, April 16, 1992.
                    </P>
                </FTNT>
                <P>As noted in the General Preamble, certain attainment-related planning requirements under CAA section 172(c) no longer have meaning for an area that is already attaining the NAAQS, and therefore are not applicable for purposes of redesignation. For example, for an area that is already attaining the NAAQS, there would be nothing for the State to provide to show reasonable further progress to attainment in that area. Similarly, the CAA section 172 requirements for the attainment demonstration, implementation of reasonably available control measures, including reasonably available control technology, and contingency measures that are triggered if an area fails to meet RFP or fails to attain are also not applicable for purposes of redesignation.</P>
                <P>
                    With respect to CAA section 172(c)(3), Pennsylvania was required to submit an actual current emissions inventory with its attainment plan.
                    <SU>42</SU>
                    <FTREF/>
                     Pennsylvania had submitted a base year inventory with its attainment plan SIP on September 29, 2017 and the EPA approved this element on October 12, 2018.
                    <SU>43</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         With respect to CAA section 172(c)(5), Pennsylvania is required to have a permit program for the construction and operation of new or modified major stationary sources within the nonattainment area. Discussion on this requirement is provided in “Section 173 Requirements,” in this document.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See</E>
                         83 FR 51629, October 12, 2018.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Section 173 Requirements</HD>
                <P>
                    Section 173 of the CAA includes requirements for permit programs that are required in a nonattainment area for new sources as required by CAA section 172(c)(5), known as NNSR. However, the EPA has a longstanding interpretation that because the NNSR permit program is replaced by the PSD permit program upon an area's redesignation to attainment, nonattainment areas seeking redesignation to attainment do not need a fully approved part D NNSR program to be redesignated. A more detailed rationale for this view is described in a memorandum from Mary Nichols, Assistant Administrator for Air and Radiation, dated October 14, 1994, entitled, “Part D New Source Review Requirements for Areas Requesting Redesignation to Attainment.” 
                    <SU>44</SU>
                    <FTREF/>
                     Nevertheless, the EPA notes that Pennsylvania's Code has SIP-approved NNSR and PSD programs found at 25 Pa. Code 127.201-127.218 for NNSR and at 25 Pa. Code 127.81-127.83 for PSD. Pennsylvania's PSD regulations merely incorporate by reference the Federal PSD regulations found at 40 CFR part 52. Warren County has therefore addressed all required provisions for the permitting of sources in NAAs, including NNSR. See 40 CFR 52.2020(c). Pennsylvania's PSD program will become applicable for SO
                    <E T="52">2</E>
                     in the Warren County NAA if redesignation to attainment is finalized.
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         Available in the docket for this proposed rulemaking as 
                        <E T="03">Nichols_Memo</E>
                         and at 
                        <E T="03">www.epa.gov/sites/default/files/2015-07/documents/101494m.pdf.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Section 175A Requirements</HD>
                <P>CAA section 175A requires that states seeking redesignation of an area to attainment submit a “maintenance plan” containing certain elements. Pennsylvania included a maintenance plan for the Warren County NAA with its September 19, 2025, redesignation request, which the EPA is proposing to approve in conjunction with the redesignation, and it is discussed in detail in section II.D., Criterion (4) of this document.</P>
                <HD SOURCE="HD3">4. Section 176 Requirements</HD>
                <P>
                    Section 176(c) of the CAA requires that Federal actions conform to the air quality planning goals in the applicable SIP. The requirement to determine conformity applies to transportation plans, programs, and projects that are developed, funded, or approved under title 23 of the United States Code and the Federal Transit Act (transportation conformity) as well as to all other Federally-supported or funded projects (general conformity). Section 176(c) of the CAA also requires that states establish criteria and procedures to ensure that Federally-supported or funded transportation plans, transportation improvement programs (TIPs) and projects conform to the goals of the applicable SIP. This is referred to as a transportation conformity SIP. In the preamble to the January 1993 proposed transportation conformity rule, the EPA stated that, “[b]ased on available emissions information, EPA believes highway and transit motor vehicles are not significant sources of lead or sulfur dioxide. Therefore, transportation plans, TIPs, and projects are presumed to conform to the applicable implementation plans for these pollutants.” 
                    <SU>45</SU>
                    <FTREF/>
                     In November 1993, the EPA finalized its transportation conformity regulations. One section of those regulations addressed the geographic applicability of the transportation conformity regulations. The regulation stated at that time that, “[t]he provisions of this subpart apply with respect to emissions of the following criteria pollutants: Ozone, carbon monoxide, nitrogen dioxide, and particles with an aerodynamic diameter less than or equal to a nominal 10 micrometers (PM
                    <E T="52">10</E>
                    ).” 
                    <SU>46</SU>
                    <FTREF/>
                     Based on this provision, transportation conformity does not apply in nonattainment or maintenance areas for SO
                    <E T="52">2</E>
                    . Therefore, a transportation conformity SIP is not required for SO
                    <E T="52">2</E>
                     nonattainment and maintenance areas and is not necessary for an SO
                    <E T="52">2</E>
                     nonattainment area to be redesignated to attainment, and the EPA's transportation conformity rules do not apply to SO
                    <E T="52">2</E>
                     for the Warren County NAA.
                </P>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         58 FR 3776, January 11, 1993.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         This provision has been revised to include particles with an aerodynamic diameter less than or equal to a nominal 2.5 micrometers (PM
                        <E T="52">2.5</E>
                        ). See 40 CFR 93.102(b)(1).
                    </P>
                </FTNT>
                <PRTPAGE P="48041"/>
                <HD SOURCE="HD3">5. Section 179 Requirements</HD>
                <P>Section 179(a) of the CAA addresses potential sanctions for the failure of a State to submit certain required SIP elements by statutory deadlines. The EPA is not aware of any missing or incomplete Warren County planning elements subject to section 179(a) of the CAA.</P>
                <HD SOURCE="HD3">b. Subpart 5 Requirements</HD>
                <P>
                    The subpart 5 requirements, which consist of sections 191 and 192 of the CAA, are specific provisions applicable to SO
                    <E T="52">2</E>
                    , NO
                    <E T="52">2</E>
                     or lead nonattainment areas. Section 191 of the CAA requires states with areas designated nonattainment for SO
                    <E T="52">2</E>
                    , NO
                    <E T="52">2</E>
                     or lead after November 15, 1990, to submit within 18 months of the designation an implementation plan meeting the requirements of part D.
                    <SU>47</SU>
                    <FTREF/>
                     The substance of the required plans is established by CAA section 172(c). Section 192 of the CAA sets forth attainment dates for nonattainment areas under CAA section 191.
                </P>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         Pennsylvania submitted this attainment plan on September 29, 2017, and EPA finalized approval of this SIP revision on October 1, 2019. Additional background on this process is provided in “
                        <E T="03">Relevant Historical SIP Actions,”</E>
                         in this preamble.
                    </P>
                </FTNT>
                <P>
                    For SO
                    <E T="52">2</E>
                    , CAA section 192(a) requires that attainment plans provide for attainment of the primary Standard as expeditiously as possible, but no later than five years from the date of the nonattainment designation. The EPA designated the Warren County NAA as nonattainment on August 5, 2013 (78 FR 47191), with an attainment date of October 4, 2018. However, because the EPA is reviewing a redesignation request under CAA section 107(d)(3)(E), rather than a determination of attainment under CAA section 179(c), the determination of whether the Area attained by the attainment date set forth in CAA section 192 is not applicable to this proposed action proposing approval of Pennsylvania's redesignation request.
                </P>
                <P>Based on the above, the EPA is proposing to find that Pennsylvania has satisfied the applicable requirements for the redesignation of the Warren County NAA under section 110 and part D of title I of the CAA.</P>
                <HD SOURCE="HD1">III. Summary of Source-Specific Requirements SIP Revision and EPA Analysis</HD>
                <P>
                    In the September 19, 2025 redesignation request and maintenance plan submittal, PADEP concurrently requested that the EPA correct source-specific requirements for URC in the Pennsylvania SIP.
                    <SU>48</SU>
                    <FTREF/>
                     With the final approval of the attainment plan for the Warren Nonattainment Area on October 12, 2018,
                    <SU>49</SU>
                    <FTREF/>
                     the EPA incorporated by reference the entirety of a consent order and agreement (COA) between PADEP and URC, as submitted by PADEP. However, a redacted version of the COA was intended to be included in the SIP. PADEP has requested that the previously unredacted language included in the Pennsylvania SIP be removed to align with the redacted version of the COA, as originally intended. Specifically, PADEP has requested that the EPA replace the unredacted COA with an excerpt of the title V permit for URC that contains the provisions identified by the COA.
                    <SU>50</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See Warren_SO</E>
                        <E T="52">2</E>
                        <E T="03">_RR_and_MP,</E>
                         at 8. PADEP further clarified this request and provided supplemental material via an email dated January 27, 2026. This email is available in the docket for this rulemaking as 
                        <E T="03">PADEP_Warren_Supplement_Email_260127.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         
                        <E T="03">See</E>
                         83 FR 51629, October 12, 2018.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         The excerpt of the title V permit for URC as well as the entirety of the title V permit issued on December 15, 2025 is available in the docket for this proposed rulemaking as 
                        <E T="03">2025_URC_Title_V_Excerpt</E>
                         and 
                        <E T="03">2025_URC_Title_V_Full,</E>
                         respectively.
                    </P>
                </FTNT>
                <P>
                    The EPA has reviewed the unredacted version of the COA as well as the title V permit excerpt containing the COA provisions and has determined that the title V permit excerpt contains all relevant emission limits, testing, and recordkeeping and reporting requirements as originally identified in the COA. The redacted COA information mainly pertains to historical context, background information on the facility, and details related to the development and execution of the COA. Notably, the title V permit excerpt removes an SO
                    <E T="52">2</E>
                     emission limit for Boiler 4 at the URC facility. However, this source was decommissioned on February 14, 2018 and the latest title V permit for URC—issued on December 15, 2025—does not permit operation of this source any longer.
                    <SU>51</SU>
                    <FTREF/>
                     All other emission limits, fuel sulfur content, testing, and recordkeeping and reporting requirements from the original COA remain intact. No emissions increases are anticipated as a result of this SIP revision.
                </P>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         PADEP email correspondence confirming the shutdown of this source is available in the docket for this proposed rulemaking as 
                        <E T="03">PADEP_Email_URC_Source_034_Shutdown.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Proposed Action</HD>
                <P>
                    The EPA's review of this material indicates that the Warren County NAA has met the criteria necessary under CAA section 107(d)(3)(E) for the EPA to redesignate the Warren County NAA from nonattainment to attainment for the 2010 SO
                    <E T="52">2</E>
                     NAAQS. Accordingly, the EPA is proposing to approve Pennsylvania's redesignation request for the Warren County NAA, which was submitted on September 19, 2025. Final approval of Pennsylvania's redesignation request would change the legal designation of the portion of Warren County designated nonattainment at 40 CFR 81.339 to attainment for the 2010 1-hour SO
                    <E T="52">2</E>
                     NAAQS. Essential to the potential redesignation, the EPA is also proposing to approve Pennsylvania's maintenance plan, which is designed to ensure that the potentially redesignated Warren County NAA will continue to maintain the SO
                    <E T="52">2</E>
                     NAAQS for ten years following potential redesignation.
                </P>
                <P>Simultaneously, the EPA is proposing to amend the Pennsylvania SIP by replacing the unredacted version of the 2017 COA between PADEP and URC with an excerpt of the 2025 title V permit for URC that contains the provisions identified by the COA. The entirety of the 2017 COA was initially incorporated into the SIP in error, and this proposed action proposes to correct this error. The title V permit excerpt contains all relevant emission limits, testing, and recordkeeping and reporting requirements as originally identified in the COA.</P>
                <P>The EPA is soliciting public comments on the issues discussed in this document. These comments will be considered before taking final action.</P>
                <HD SOURCE="HD1">V. Statutory and Executive Order Reviews</HD>
                <P>Under the Clean Air Act, the Administrator is required to approve a SIP submission that complies with the provisions of the Clean Air Act and applicable Federal regulations. 42 U.S.C. 7410(k); 40 CFR 52.02(a). Thus, in reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. Accordingly, this proposed action merely approves state law as meeting Federal requirements and does not impose additional requirements beyond those imposed by State law. For that reason, this proposed action:</P>
                <P>• Is not a significant regulatory action subject to review by the Office of Management and Budget under Executive Orders 12866 (58 FR 51735, October 4, 1993);</P>
                <P>• Is not an Executive Order 14192 (90 FR 9065, February 6, 2025) regulatory action because this proposed action is not significant under Executive Order 12866;</P>
                <P>
                    • Does not impose an information collection burden under the provisions of the Paperwork Reduction Act (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    );
                    <PRTPAGE P="48042"/>
                </P>
                <P>
                    • Is certified as not having a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>• Does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4);</P>
                <P>• Does not have federalism implications as specified in Executive Order 13132 (64 FR 43255, August 10, 1999);</P>
                <P>• Is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997) because it approves a State program;</P>
                <P>• Is not a significant regulatory action subject to Executive Order 13211 (66 FR 28355, May 22, 2001); and</P>
                <P>• Is not subject to requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) because application of those requirements would be inconsistent with the Clean Air Act.</P>
                <P>In addition, the SIP is not approved to apply on any Indian reservation land or in any other area where the EPA or an Indian Tribe has demonstrated that a Tribe has jurisdiction. In those areas of Indian country, the rule does not have Tribal implications and will not impose substantial direct costs on Tribal governments or preempt Tribal law as specified by Executive Order 13175 (65 FR 67249, November 9, 2000).</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects</HD>
                    <CFR>40 CFR Part 52</CFR>
                    <P>Environmental protection, Air pollution control, Incorporation by reference, Intergovernmental relations, Reporting and recordkeeping requirements, Sulfur oxides.</P>
                    <CFR>40 CFR Part 81</CFR>
                    <P>Environmental protection, Air pollution control, Carbon monoxide, Incorporation by reference, Intergovernmental relations, Lead, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides, Volatile organic compounds.</P>
                </LSTSUB>
                <SIG>
                    <NAME>Amy Van Blarcom-Lackey,</NAME>
                    <TITLE>Regional Administrator, Region III.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15372 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Part 70</CFR>
                <DEPDOC>[EPA-R09-OAR-2025-0166; FRL-12718-01-R9]</DEPDOC>
                <SUBJECT>Clean Air Act Operating Permit Program Revisions; California; Amador County Air Pollution Control District, Calaveras County Air Pollution Control District, Great Basin Unified Air Pollution Control District, Northern Sierra Air Quality Management District</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Environmental Protection Agency (EPA) is proposing to approve revisions to four State of California air districts' Clean Air Act title V program rules to remove emergency affirmative defense provisions. The four districts are the Amador County Air Pollution Control District (ACAPCD), the Calaveras County Air Pollution Control District (CCAPCD), the Great Basin Unified Air Pollution Control District (GBUAPCD), and the Northern Sierra Air Quality Management District (NSAQMD) (“Districts”). This proposed action is being taken in accordance with Federal regulations and the Clean Air Act (CAA or “Act”). We are taking comments on these proposed revisions and plan to follow with a final action.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written comments must be received on or before August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, identified by Docket ID No. EPA-R09-OAR-2025-0166 at 
                        <E T="03">https://www.regulations.gov.</E>
                         For comments submitted at 
                        <E T="03">https://www.regulations.gov,</E>
                         follow the online instructions for submitting comments. Once submitted, comments cannot be edited or removed from 
                        <E T="03">http://www.regulations.gov.</E>
                         The EPA may publish any comment received to its public docket. Do not submit electronically any information you consider to be confidential business information (CBI) or other information whose disclosure is restricted by statute. Multimedia submissions (audio, video, etc.) must be accompanied by a written comment. The written comment is considered the official comment and should include discussion of all points you wish to make. The EPA will generally not consider comments or comment contents located outside of the primary submission (
                        <E T="03">i.e.,</E>
                         on the web, cloud, or other file sharing system). For additional submission methods, please contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section. For the full EPA public comment policy, information about CBI or multimedia submissions, and general guidance on making effective comments, please visit 
                        <E T="03">https://www.epa.gov/dockets/commenting-epa-dockets.</E>
                         If you need assistance in a language other than English or if you are a person with disabilities who needs a reasonable accommodation at no cost to you, please contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Camille Cassar, EPA Region IX, 75 Hawthorne Street, San Francisco, CA 94105; telephone number: (415) 947-4164; email address: 
                        <E T="03">cassar.camille@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Throughout this document, “we,” “us,” and “our” refer to the EPA.</P>
                <HD SOURCE="HD1">TABLE OF CONTENTS</HD>
                <EXTRACT>
                    <FP SOURCE="FP-1">I. Title V Program Background</FP>
                    <FP SOURCE="FP-1">II. Requirements for Approval of Revisions to Title V Programs</FP>
                    <FP SOURCE="FP-1">III. What are the States' Proposed Title V Program Revisions?</FP>
                    <FP SOURCE="FP-1">IV. EPA Evaluation of Title V Revisions</FP>
                    <FP SOURCE="FP-1">V. Proposed Action</FP>
                    <FP SOURCE="FP-1">VI. Statutory and Executive Order Reviews</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Title V Program Background</HD>
                <P>The CAA Amendments of 1990 include title V, which requires States to develop an operating permits program that meets the Federal criteria codified in title 40 of the Code of Federal Regulations (CFR) part 70. The title V program requires certain sources of air pollution to obtain Federal operating permits from their respective States or air districts. These Federal operating permits improve enforcement and compliance by consolidating all applicable Federal requirements into one federally enforceable document. Before a State can issue permits under 40 CFR part 70 (which are referred to as “title V permits”), the EPA must approve its program under appendix A of 40 CFR part 70. States may submit revisions to their approved programs for EPA approval.</P>
                <HD SOURCE="HD1">II. Requirements for Approval of Revisions to Title V Programs</HD>
                <P>
                    Pursuant to 40 CFR 70.4(i), either the EPA or the State may initiate a title V program revision “when relevant Federal or State statutes or regulations are modified or supplemented.” It is the responsibility of the State to keep the EPA apprised of any proposed modifications to its basic statutory or regulatory authority or procedures. Revision of a State program shall be accomplished as follows:
                    <PRTPAGE P="48043"/>
                </P>
                <P>
                    (a) The State submits a modified program description, Attorney General's statement (if necessary for expanded or additional authority), or other documents as the EPA determines to be necessary. 
                    <E T="03">See</E>
                     40 CFR 70.4(i)(2)(i).
                </P>
                <P>
                    (b) After the EPA receives a proposed program revision, it will publish a notice of the proposed change in the 
                    <E T="04">Federal Register</E>
                     and provide for a public comment period of at least 30 days. 
                    <E T="03">See</E>
                     40 CFR 70.4(i)(2)(ii).
                </P>
                <P>
                    (c) The Administrator shall approve or disapprove program revisions based on the requirements of 40 CFR part 70 and the Act. 
                    <E T="03">See</E>
                     40 CFR 70.4(i)(2)(iii).
                </P>
                <P>
                    (d) The EPA must publish a notice of approval in the 
                    <E T="04">Federal Register</E>
                     for any substantial program revisions. 
                    <E T="03">See</E>
                     40 CFR 70.4(i)(2)(iv).
                </P>
                <P>
                    (e) Approval of nonsubstantial revisions may be given by a letter from the Administrator to the Governor or a designee. 
                    <E T="03">See</E>
                     40 CFR 70.4(i)(2)(iv).
                </P>
                <P>
                    (f) A program revision shall become effective upon the approval of the Administrator. 
                    <E T="03">See</E>
                     40 CFR 70.4(i)(2)(iv).
                </P>
                <HD SOURCE="HD1">III. What are the States' Proposed Title V Program Revisions?</HD>
                <P>Table 1 lists the rules submitted as part of the title V program revisions by the ACAPCD, the CCAPCD, the GBUAPCD, and the NSAQMD, and the dates they were adopted by the Districts and submitted by the California Air Resources Board (CARB), which is the governor's designee for California rule submittals.</P>
                <GPOTABLE COLS="5" OPTS="L2,i1" CDEF="xs60,12,r50,12,12">
                    <TTITLE>Table 1—Submitted Rules</TTITLE>
                    <BOXHD>
                        <CHED H="1">District</CHED>
                        <CHED H="1">
                            Rule
                            <LI>number</LI>
                        </CHED>
                        <CHED H="1">
                            Rule
                            <LI>title</LI>
                        </CHED>
                        <CHED H="1">
                            Amended
                            <LI>date</LI>
                        </CHED>
                        <CHED H="1">
                            Submitted
                            <LI>date</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">ACAPCD</ENT>
                        <ENT>500</ENT>
                        <ENT>Procedures for Issuing Permits to Operate for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990</ENT>
                        <ENT>1/21/2025</ENT>
                        <ENT>4/25/2025</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">CCAPCD</ENT>
                        <ENT>1002</ENT>
                        <ENT>Additional Procedures for Issuing Permits to Operate for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990—Definitions</ENT>
                        <ENT>08/12/2025</ENT>
                        <ENT>08/21/2025</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">CCAPCD</ENT>
                        <ENT>1006</ENT>
                        <ENT>Additional Procedures for Issuing Permits to Operate for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990—Permit Content Requirements</ENT>
                        <ENT>08/12/2025</ENT>
                        <ENT>08/21/2025</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">GBUAPCD</ENT>
                        <ENT>217</ENT>
                        <ENT>Additional Procedures for Issuing Operating Permits for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990</ENT>
                        <ENT>07/03/2025</ENT>
                        <ENT>08/21/2025</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NSAQMD</ENT>
                        <ENT>522</ENT>
                        <ENT>Title V Federal Operating Permits</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>2/4/2025</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    The ACAPCD Title V Operating Permit Program is implemented through its “Procedures for Issuing Permits to Operate for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990” rule, codified as ACAPCD Rule 500. On November 21, 2003, the EPA approved the ACAPCD Title V Operating Permit Program, which became effective January 1, 2004 (68 FR 65637, November 21, 2003). On January 21, 2025, the ACAPCD amended its Rule 500 and on April 25, 2025, CARB submitted the revision to Rule 500 for approval into the district's EPA-approved title V program.
                    <SU>1</SU>
                    <FTREF/>
                     The revision includes removal of emergency affirmative defense provisions in section 500.VI.B.12, “Emergency Provisions.”
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         April 25, 2025 electronic submittal to the EPA with a cover letter dated April 18, 2025, from CARB to the EPA.
                    </P>
                </FTNT>
                <P>
                    The CCAPCD Title V Operating Permit Program is implemented through the following two rules: its “Additional Procedures for Issuing Permits to Operate for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990—Definitions” rule, codified as CCAPCD Rule 1002, and its “Additional Procedures for Issuing Permits to Operate for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990—Permit Content Requirements” rule, codified as CCAPCD Rule 1006. On November 21, 2003, the EPA approved the CCAPCD Title V Operating Permit Program, which became effective January 1, 2004 (68 FR 65637, November 21, 2003). On August 12, 2025, the CCAPD amended their Rules 1002 and 1006, and on August 21, 2025, CARB submitted the revisions to Rules 1002 and 1006 for approval into the district's EPA-approved title V program.
                    <SU>2</SU>
                    <FTREF/>
                     The revisions include removal of emergency affirmative defense provisions in section 1 (M) of 1002, “Emergency” definition, and section B (12), “Emergency Provisions” of 1006.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         August 21, 2025 electronic submittal to the EPA with a cover letter dated August 21, 2025, from CARB to the EPA.
                    </P>
                </FTNT>
                <P>
                    The GBUAPCD Title V Operating Permit Program is implemented through its “Additional Procedures for Issuing Operating Permits for Sources Subject to Title V of the Federal Clean Air Act Amendments of 1990” rule, codified as GBUAPCD Rule 217. On November 21, 2003, the EPA approved the GBUAPCD Title V Operating Permit Program, which became effective January 1, 2004 (68 FR 65637, November 21, 2003). On July 3, 2025, the GBUAPCD amended its Rule 217, and on August 21, 2025, CARB submitted the revision to Rule 217 for approval into the district's EPA-approved title V program.
                    <SU>3</SU>
                    <FTREF/>
                     The revisions include removal of emergency affirmative defense provisions in section 2 (M), “Emergency” definition, and section I (12), “Emergency Provisions.”
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         August 21, 2025 electronic submittal to the EPA with a cover letter dated August 20, 2025, from CARB to the EPA.
                    </P>
                </FTNT>
                <P>
                    The NSAQMD Title V Operating Permit Program is implemented through its “Title V Federal Operating Permits” rule, codified as NSAQMD Rule 522. On November 21, 2003, the EPA approved the NSAQMD Title V Operating Permit Program, which became effective January 1, 2004 (68 FR 65637, November 21, 2003). On October 28, 2024, the NSAQMD amended its Rule 522, and on February 4, 2025, CARB submitted the revision of Rule 522 for approval into the district's EPA-approved title V program.
                    <SU>4</SU>
                    <FTREF/>
                     The revisions include removal of emergency affirmative defense provisions in Section 6.12, “Emergency Provisions.”
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         February 4, 2025 electronic submittal to the EPA with cover letter dated February 3, 2025, from CARB to the EPA.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. EPA Evaluation of Title V Revisions</HD>
                <P>
                    As mentioned above, the revisions to these rules include removing emergency affirmative defense provisions.
                    <SU>5</SU>
                    <FTREF/>
                     Our 
                    <PRTPAGE P="48044"/>
                    Technical Support Document (TSD) provides more details for each of these revisions and how they meet EPA requirements. The EPA finds these revisions acceptable as title V program revisions and consistent with part 70 provisions.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         On September 5, 2025, the Court of Appeals for the D.C. Circuit issued a decision in 
                        <E T="03">SSM Litigation Group</E>
                         v. 
                        <E T="03">EPA</E>
                         rejecting the legal bases for EPA's July 2023 final rule concerning “emergency” affirmative defense provisions in title V permits and reversing that final rule (88 FR 47029, July 21, 2023). 
                        <E T="03">SSM Litigation Group</E>
                         v. 
                        <E T="03">EPA, et al.,</E>
                         150 F.4th 593 (D.C. Cir. 2025), 
                        <E T="03">reh'g denied.</E>
                         Because 
                        <E T="03">SSM Litigation Group</E>
                         does not prohibit States from removing 
                        <PRTPAGE/>
                        affirmative defense provisions from their title V programs, we are proceeding with this proposal to remove these provisions from the ACAPCD's, CCAPCD's, GBUAPCD's and NSAQMD's Title V Operating Permit Programs consistent with their requests. For additional information, please see the TSD in the docket for this proposed action.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">V. Proposed Action</HD>
                <P>Pursuant to 40 CFR 70.4(i)(2), the EPA is proposing to approve the revisions to the ACAPCD Title V Operating Permit Program submitted on April 25, 2025, the CCAPCD Title V Operating Permit Program submitted on August 21, 2025, the GBUAPCD Title V Operating Permit Program submitted on July 3, 2025, and the NSAQMD Title V Operating Permit Program submitted on February 4, 2025. The revisions meet the requirements of section 502 of the CAA and 40 CFR 70.4. The EPA is soliciting public comments on the revisions discussed in this document.</P>
                <HD SOURCE="HD1">VI. Statutory and Executive Order Reviews</HD>
                <HD SOURCE="HD2">A. General Requirements</HD>
                <P>Under the CAA, the Administrator is required to approve title V operating permit program revisions that comply with the Act and applicable Federal regulations. See 42 U.S.C. 7661a(d). Thus, in reviewing title V permit program submissions, the EPA's role is to approve State choices, provided that they meet the criteria of the CAA. Accordingly, this proposed action merely approves State law as meeting Federal requirements and does not impose additional requirements beyond those imposed by State law. For that reason, this proposed action:</P>
                <P>• Is not a significant regulatory action subject to review by the Office of Management and Budget under Executive Order 12866 (58 FR 51735, October 4, 1993);</P>
                <P>• Is not an Executive Order 14192 (90 FR 9065, February 6, 2025) regulatory action because this proposed action is not significant under Executive Order 12866;</P>
                <P>
                    • Does not impose an information collection burden under the provisions of the Paperwork Reduction Act (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>
                    • Is certified as not having a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    );
                </P>
                <P>• Does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104-4);</P>
                <P>• Does not have federalism implications as specified in Executive Order 13132 (64 FR 43255, August 10, 1999);</P>
                <P>• Is not an economically significant regulatory action based on health or safety risks subject to Executive Order 13045 (62 FR 19885, April 23, 1997);</P>
                <P>• Is not a significant regulatory action subject to Executive Order 13211 (66 FR 28355, May 22, 2001); and</P>
                <P>• Is not subject to requirements of Section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) because application of those requirements would be inconsistent with the CAA.</P>
                <P>This proposed rule does not have Tribal implications as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), because the proposed title V action is not approved to apply in Indian country located in the State, and the EPA notes that it will not impose substantial direct costs on Tribal governments or preempt Tribal law.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 40 CFR Part 70</HD>
                    <P>Environmental protection, Administrative practice and procedure, Air pollution control, Carbon monoxide, Intergovernmental relations, Lead, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides, Volatile organic compounds.</P>
                </LSTSUB>
                <AUTH>
                    <HD SOURCE="HED">Authority: </HD>
                    <P>
                        42 U.S.C. 7401 
                        <E T="03">et seq.</E>
                    </P>
                </AUTH>
                <SIG>
                    <DATED>Dated: July 15, 2026.</DATED>
                    <NAME>Michael Martucci,</NAME>
                    <TITLE>Acting Regional Administrator, Region IX.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15362 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Part 721</CFR>
                <DEPDOC>[EPA-HQ-OPPT-2026-2707; FRL-13462-01-OCSPP]</DEPDOC>
                <RIN>RIN 2070-AB27</RIN>
                <SUBJECT>Significant New Use Rules on Certain Chemical Substances (26-4)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>EPA is proposing significant new use rules (SNURs) under the Toxic Substances Control Act (TSCA) for certain chemical substances that were the subject of premanufacture notices (PMNs) and are also subject to an Order issued by EPA pursuant to TSCA. Once finalized, the SNURs would require persons who intend to manufacture (defined by statute to include import) or process any of these chemical substances for an activity that is proposed as a significant new use by this rulemaking to notify EPA at least 90 days before commencing that activity. The required notification initiates EPA's evaluation of the conditions of that use for that chemical substance. In addition, the manufacture or processing for the significant new use may not commence until EPA has conducted a review of the required notification, made an appropriate determination regarding that notification, and taken such actions as required by that determination.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before August 31, 2026.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, identified by docket identification (ID) number EPA-HQ-OPPT-2026-2707, online at 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the online instructions for submitting comments. Do not submit electronically any information you consider to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Additional instructions on commenting and visiting the docket, along with more information about dockets generally, is available at 
                        <E T="03">https://www.epa.gov/dockets.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        <E T="03">For technical information:</E>
                         Darrell Stanley, New Chemicals Division (7405M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number: (202) 202-564-4770; email address: 
                        <E T="03">stanley.darrell@epa.gov.</E>
                    </P>
                    <P>
                        <E T="03">For general information on SNURs:</E>
                         Iliriana Mushkolaj, New Chemicals Division (7405M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number: (202) 564-6877; email address: 
                        <E T="03">mushkolaj.iliriana</E>
                        @epa.gov.
                    </P>
                    <P>
                        <E T="03">For general information on TSCA:</E>
                         The TSCA Assistance Information Service Hotline, Goodwill of the Finger Lakes, 422 South Clinton Ave., Rochester, NY 14620; telephone number: (800) 471-7127 or (202) 554-1404; email address: 
                        <E T="03">TSCA-Hotline@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">
                    SUPPLEMENTARY INFORMATION:
                    <PRTPAGE P="48045"/>
                </HD>
                <HD SOURCE="HD1">I. Executive Summary</HD>
                <HD SOURCE="HD2">A. What is the Agency's authority for taking this action?</HD>
                <P>TSCA section 5(a)(2) (15 U.S.C. 2604(a)(2)) authorizes EPA to determine that a use of a chemical substance is a “significant new use.” EPA must make this determination by rule after considering all relevant factors, including the factors in TSCA section 5(a)(2) (see also the discussion in Unit II.).</P>
                <HD SOURCE="HD2">B. What action is the Agency taking?</HD>
                <P>EPA is proposing SNURs for the chemical substances discussed in Unit III. These SNURs, if finalized as proposed, would require persons who intend to manufacture or process any of these chemical substances for an activity that is designated as a significant new use to notify EPA at least 90 days before commencing that activity.</P>
                <HD SOURCE="HD2">C. Does this action apply to me?</HD>
                <HD SOURCE="HD3">1. General Applicability</HD>
                <P>This action applies to you if you manufacture, process, or use the chemical substances contained in this proposed rule. The following list of North American Industrial Classification System (NAICS) codes is not intended to be exhaustive, but rather provides a guide to help readers determine whether this document applies to them. Potentially affected entities may include:</P>
                <P>
                    • Manufacturers or processors of one or more subject chemical substances (NAICS codes 325 and 324110), 
                    <E T="03">e.g.,</E>
                     chemical manufacturing and petroleum refineries.
                </P>
                <HD SOURCE="HD3">2. Applicability to Importers and Exporters</HD>
                <P>
                    This action may also apply to certain entities through pre-existing import certification and export notification requirements under TSCA (
                    <E T="03">https://www.epa.gov/tsca-import-export-requirements</E>
                    ).
                </P>
                <P>Chemical importers are subject to TSCA section 13 (15 U.S.C. 2612), the requirements in 19 CFR 12.118 through 12.127, 19 CFR 127.28, and 40 CFR 707.20. Importers of chemical substances in bulk form, as part of a mixture, or as part of an article (if required by rule) must certify that the shipment of the chemical substance complies with all applicable rules and orders under TSCA, including regulations issued under TSCA sections 5, 6, 7 and Title IV.</P>
                <P>Pursuant to 40 CFR 721.20, any persons who export or intend to export a chemical substance that is the subject of this proposed rule on or after August 31, 2026 are subject to TSCA section 12(b) (15 U.S.C. 2611(b)) and must comply with the export notification requirements in 40 CFR part 707, subpart D.</P>
                <HD SOURCE="HD2">D. What are the incremental economic impacts of this action?</HD>
                <P>EPA has evaluated the potential costs of establishing SNUN reporting requirements for potential manufacturers (including importers) and processors of the chemical substances subject to these proposed SNURs. This analysis, which is available in the docket, is briefly summarized here.</P>
                <HD SOURCE="HD3">1. Estimated Costs for SNUN Submissions</HD>
                <P>If a SNUN is submitted, costs are an estimated $45,496 per SNUN submission for large business submitters and $14,976 for small business submitters. These estimates include the cost to prepare and submit the SNUN (including registration for EPA's Central Data Exchange (CDX)), and the payment of a user fee. Businesses that submit a SNUN would be subject to either a $37,000 user fee required by 40 CFR 700.45(c)(2)(ii) and (d), or, if they are a small business as defined at 13 CFR 121.201, a reduced user fee of $6,480 (40 CFR 700.45(c)(1)(ii) and (d)). The costs of submission for SNUNs will not be incurred by any company unless a company decides to pursue a significant new use as defined in these SNURs. Additionally, these estimates reflect the costs and fees as they are known at the time of this rulemaking.</P>
                <HD SOURCE="HD3">2. Estimated Costs for Export Notifications</HD>
                <P>
                    EPA has also evaluated the potential costs associated with the export notification requirements under TSCA section 12(b) and the implementing regulations at 40 CFR part 707, subpart D. For persons exporting a substance that is the subject of a SNUR, a one-time notice to EPA must be provided for the first export or intended export to a particular country. The total costs of export notification will vary by chemical, depending on the number of required notifications (
                    <E T="03">i.e.,</E>
                     the number of countries to which the chemical is exported). While EPA is unable to make any estimate of the likely number of export notifications for the chemical substances covered by these SNURs, as stated in the accompanying economic analysis, the estimated cost of the export notification requirement on a per unit basis is approximately $106.
                </P>
                <HD SOURCE="HD2">E. What should I consider as I prepare my comments for EPA?</HD>
                <HD SOURCE="HD3">1. Submitting CBI</HD>
                <P>
                    Do not submit CBI to EPA through email or 
                    <E T="03">https://www.regulations.gov.</E>
                     If you wish to include CBI in your comment, please follow the applicable instructions at 
                    <E T="03">https://www.epa.gov/dockets/commenting-epa-dockets#rules</E>
                     and clearly mark the information that you claim to be CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR parts 2 and 703.
                </P>
                <HD SOURCE="HD3">2. Tips for Preparing Your Comments</HD>
                <P>
                    When preparing and submitting your comments, see the commenting tips at 
                    <E T="03">https://www.epa.gov/dockets/commenting-epa-dockets.</E>
                </P>
                <HD SOURCE="HD1">II. Background</HD>
                <P>
                    This unit provides general information about SNURs. For additional information about EPA's new chemical program go to 
                    <E T="03">https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca</E>
                    .
                </P>
                <HD SOURCE="HD2">A. Significant New Use Determination Factors</HD>
                <P>TSCA section 5(a)(2) states that EPA's determination that a use of a chemical substance is a significant new use must be made after consideration of all relevant factors, including:</P>
                <P>• The projected volume of manufacturing and processing of a chemical substance.</P>
                <P>• The extent to which a use changes the type or form of exposure of human beings or the environment to a chemical substance.</P>
                <P>• The extent to which a use increases the magnitude and duration of exposure of human beings or the environment to a chemical substance.</P>
                <P>• The reasonably anticipated manner and methods of manufacturing, processing, distribution in commerce, and disposal of a chemical substance.</P>
                <P>In determining what would constitute a significant new use for the chemical substances that are the subject of these SNURs, EPA considered relevant information about the toxicity of the chemical substances, and potential human exposures and environmental releases that may be associated with the substances, in the context of the four bulleted TSCA section 5(a)(2) factors listed in this Unit and discussed in Unit III.</P>
                <P>
                    These proposed SNURs are based on orders issued to certain companies for substances that were the subject of PMN submissions. Those orders were issued under TSCA section 5(e)(1)(A), as 
                    <PRTPAGE P="48046"/>
                    required by the determinations made under TSCA section 5(a)(3)(B). The TSCA orders require protective measures to limit exposures or otherwise mitigate the potential unreasonable risk. The proposed SNURs extend those protective measures to any person intending to manufacture, process, use, distribute in commerce, or dispose of the new chemical substances subject to orders and identify as significant new uses any manufacturing, processing, use, distribution in commerce, or disposal that does not conform to the restrictions imposed by the underlying TSCA orders, consistent with TSCA section 5(f)(4).
                </P>
                <HD SOURCE="HD2">B. Rationale and Objectives of the SNURs</HD>
                <HD SOURCE="HD3">1. Rationale</HD>
                <P>Under TSCA section 5(a)(1)(B), no person may manufacture a new chemical substance or manufacture or process a chemical substance for a significant new use until EPA makes a determination as described in TSCA section 5(a)(3) and takes any required action. The issuance of a SNUR is not a risk determination itself, only a notification requirement for “significant new uses,” so that the Agency has the opportunity to review the SNUN for the significant new use and make a TSCA section 5(a)(3) risk determination.</P>
                <P>During review of the PMNs submitted that identify chemical substances subject to these proposed SNURs, EPA concluded that regulation was warranted under TSCA section 5(e), pending the development of information sufficient to make reasoned evaluations of the health or environmental effects of the chemical substances. Based on the findings outlined in Unit III., TSCA section 5(e) Orders requiring the use of appropriate exposure controls were negotiated with the PMN submitters. As a general matter, EPA believes it is necessary to follow a TSCA order with a SNUR that identifies the absence of those protective measures as significant new uses to ensure that all manufacturers and processors—not just the party subject to a TSCA order are held to the same standard.</P>
                <HD SOURCE="HD3">2. Objectives</HD>
                <P>EPA is proposing these SNURs because the Agency has determined it is appropriate:</P>
                <P>• To identify as significant new uses any manufacturing, processing, use, distribution in commerce, or disposal that does not conform to the restrictions imposed by the underlying TSCA Orders, consistent with TSCA section 5(f)(4).</P>
                <P>• To have an opportunity to review and evaluate data submitted in a SNUN before the submitter begins manufacturing or processing a listed chemical substance for the described significant new use.</P>
                <P>• To be obligated to make a determination under TSCA section 5(a)(3) regarding the use described in the SNUN, under the conditions of use. The Agency will either determine under TSCA section 5(a)(3)(C) that the significant new use is not likely to present an unreasonable risk, including an unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant by the Administrator under the conditions of use, or make a determination under TSCA section 5(a)(3)(A) or (B) and take the required regulatory action associated with the determination, before manufacture or processing for the significant new use of the chemical substance can occur.</P>
                <P>
                    Issuance of a proposed SNUR for a chemical substance does not signify that the chemical substance is listed on the TSCA Chemical Substance Inventory (TSCA Inventory). Guidance on how to determine if a chemical substance is on the TSCA Inventory is available at 
                    <E T="03">https://www.epa.gov/tsca-inventory</E>
                    .
                </P>
                <HD SOURCE="HD2">C. Significant New Uses Claimed as CBI</HD>
                <P>
                    EPA is proposing to establish certain significant new uses which have been claimed as CBI subject to Agency confidentiality regulations at 40 CFR parts 2 and 703. Absent a final determination or other disposition of the confidentiality claim under these regulations, EPA is required to keep this information confidential. EPA promulgated a procedure at 40 CFR 721.11 to deal with the situation where a specific significant new use is CBI. Under these procedures, a manufacturer or processor may ask EPA to identify the confidential significant new use subject to the SNUR. The manufacturer or processor must show that it has a 
                    <E T="03">bona fide</E>
                     intent to manufacture or process the chemical substance. If EPA concludes that the person has shown a 
                    <E T="03">bona fide</E>
                     intent to manufacture or process the chemical substance, EPA will identify the confidential significant new use to that person. Since most of the chemical identities of the chemical substances subject to these SNURs are also CBI, manufacturers and processors can combine the 
                    <E T="03">bona fide</E>
                     submission under the procedure in 40 CFR 721.11 into a single step.
                </P>
                <HD SOURCE="HD2">D. Applicability of General Provisions</HD>
                <P>General provisions for SNURs appear in 40 CFR part 721, subpart A. These provisions describe persons subject to SNURs, recordkeeping requirements, exemptions to reporting requirements, and applicability of the rule to uses occurring before the effective date of the rule. Pursuant to 40 CFR 721.1(c), persons subject to SNURs must comply with the same requirements and EPA regulatory procedures as submitters of PMNs under TSCA section 5(a)(1)(A). In particular, these requirements include the information submission requirements of TSCA sections 5(b) and 5(d)(1), the exemptions authorized by TSCA sections 5(h)(1), 5(h)(2), 5(h)(3), and 5(h)(5), and the regulations at 40 CFR part 720. In addition, provisions relating to user fees appear at 40 CFR part 700.</P>
                <P>
                    Once EPA receives a SNUN, EPA must either determine that the significant new use is not likely to present an unreasonable risk of injury under the conditions of use for the chemical substance or take such regulatory action as is associated with an alternative determination under TSCA section 5 before the manufacture (including import) or processing for the significant new use can commence. If EPA determines that the significant new use of the chemical substance is not likely to present an unreasonable risk, EPA is required under TSCA section 5(g) to make public, and submit for publication in the 
                    <E T="04">Federal Register</E>
                    , a statement of EPA's findings.
                </P>
                <P>
                    As discussed in Unit I.C.2., persons who export or intend to export a chemical substance identified in a proposed or final SNUR are subject to the export notification provisions of TSCA section 12(b), and persons who import a chemical substance identified in a final SNUR are subject to the TSCA section 13 import certification requirements. See also 
                    <E T="03">https://www.epa.gov/tsca-import-export-requirements.</E>
                </P>
                <HD SOURCE="HD2">E. Applicability of the Proposed SNURs to Uses Occurring Before the Effective Date of the Final Rule</HD>
                <P>
                    To establish a significant new use, EPA must determine that the use is not ongoing. The chemical substances subject to this proposed rule have undergone premanufacture review and received determinations under TSCA section 5(a)(3)(C). TSCA Orders have been issued for these chemical substances and the PMN submitters are required by the TSCA Orders to submit a SNUN before undertaking activities that would be designated as significant new uses in these SNURs. Additionally, the identities of many of the chemical substances subject to this proposed rule have been claimed as confidential per 
                    <PRTPAGE P="48047"/>
                    40 CFR 720.85, further reducing the likelihood that another party would manufacture or process the substances for an activity that would be designated as a significant new use. Based on this, the Agency believes that it is highly unlikely that any of the significant new uses identified in Unit III. are ongoing.
                </P>
                <P>When the chemical substances identified in Unit III. are added to the TSCA Inventory, EPA recognizes that, before the rule is effective, other persons might engage in a use that has been identified as a significant new use. Persons who begin manufacture or processing of the chemical substances for a significant new use identified on or after the designated cutoff date specified in Unit III.A. would have to cease any such activity upon the effective date of the final rule. To resume their activities, these persons would have to first comply with all applicable SNUR notification requirements and EPA would have to take action under TSCA section 5 allowing manufacture or processing to proceed.</P>
                <HD SOURCE="HD2">F. Important Information About SNUN Submissions</HD>
                <HD SOURCE="HD3">1. SNUN Submissions</HD>
                <P>
                    SNUNs must be submitted on EPA Form No. 7710-25, generated using e-PMN software, and submitted to the Agency in accordance with the procedures set forth in 40 CFR 720.40 and 721.25. E-PMN software is available electronically at 
                    <E T="03">https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca.</E>
                </P>
                <HD SOURCE="HD3">2. Development and Submission of Information</HD>
                <P>
                    EPA recognizes that TSCA section 5 does not require development of any particular new information (
                    <E T="03">e.g.,</E>
                     generating test data) before submission of a SNUN. There is an exception: If a person is required to submit information for a chemical substance pursuant to a rule, order, or consent agreement under TSCA section 4, then TSCA section 5(b)(1)(A) requires such information to be submitted to EPA at the time of submission of the SNUN.
                </P>
                <P>In the absence of a rule, TSCA order, or consent agreement under TSCA section 4 covering the chemical substance, persons are required only to submit information in their possession or control and to describe any other information known to or reasonably ascertainable by them (see 40 CFR 720.50). However, upon review of PMNs and SNUNs, the Agency has the authority to require appropriate testing. To assist with EPA's analysis of the SNUN, submitters are encouraged, but not required, to provide the potentially useful information as identified for the chemical substance in Unit III.C.</P>
                <P>
                    EPA strongly encourages persons, before performing any testing, to consult with the Agency pertaining to protocol selection. Furthermore, pursuant to TSCA section 4(h), which pertains to reduction of testing in vertebrate animals, EPA encourages consultation with the Agency on the use of alternative test methods and strategies (also called New Approach Methodologies, or NAMs), if available, to generate the recommended test data. EPA encourages dialog with Agency representatives to help determine how best the submitter can meet both the data needs and the objective of TSCA section 4(h). For more information on alternative test methods and strategies to reduce vertebrate animal testing, 
                    <E T="03">visit https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/alternative-test-methods-and-strategies-reduce.</E>
                </P>
                <P>The potentially useful information described in Unit III. may not be the only means of providing information to evaluate the chemical substance associated with the significant new uses. However, submitting a SNUN without any test data may increase the likelihood that EPA will take action under TSCA sections 5(e) or 5(f). EPA recommends that potential SNUN submitters contact EPA early enough so that they will be able to conduct the appropriate tests.</P>
                <P>SNUN submitters should be aware that EPA will be better able to evaluate SNUNs that provide detailed information about human exposure and environmental release that may result from the significant new use of the chemical substances.</P>
                <HD SOURCE="HD1">III. Chemical Substances Subject to These Proposed SNURs</HD>
                <HD SOURCE="HD2">A. What is the designated cutoff date for ongoing uses?</HD>
                <P>EPA designates July 30, 2026 as the cutoff date for determining whether the new use is ongoing. This designation is explained in more detail in Unit II.E.</P>
                <HD SOURCE="HD2">B. What information is provided for each chemical substance?</HD>
                <P>For each chemical substance identified in Unit III.C., EPA provides the following information:</P>
                <P>• PMN number(s) (as well as the proposed CFR citation assigned in the regulatory text section of this document).</P>
                <P>• Chemical name (generic name, if the specific name is claimed as CBI).</P>
                <P>• Chemical Abstracts Service Registry Number (CASRN) or Accession Number (if assigned for confidential chemical identities).</P>
                <P>
                    • Basis for the SNUR (
                    <E T="03">e.g.,</E>
                     effective date of and basis for the corresponding TSCA Order).
                </P>
                <P>• Potentially useful information.</P>
                <P>The regulatory text section of the proposed rule specifies the activities designated as significant new uses. Certain new uses, including production volume limits and other uses designated in the proposed rules, may be claimed as CBI.</P>
                <P>These proposed SNURs include PMN substances that are subject to orders issued under TSCA section 5(e)(1)(A), as required by the determinations made under TSCA section 5(a)(3)(B). Those TSCA Orders require protective measures to limit exposures or otherwise mitigate the potential unreasonable risk. The proposed SNURs identify as significant new uses any manufacturing, processing, use, distribution in commerce, or disposal that does not conform to the restrictions imposed by the underlying TSCA Orders, consistent with TSCA section 5(f)(4).</P>
                <HD SOURCE="HD2">C. Which chemical substances are subject to these proposed SNURs?</HD>
                <P>The substances subject to the proposed SNURs in this document are as follows, listed by PMN number and with the proposed CFR citation:</P>
                <HD SOURCE="HD3">P-21-7 (40 CFR 721.12306) and P-21-8 (40 CFR 721.12307)</HD>
                <P>
                    <E T="03">Chemical Names:</E>
                     Reaction products of aluminoxanes, Me, Me group-terminated and (alkylcycloalkylene)dialkylzirconium (generic) (P-21-7) and reaction products of aluminoxanes, Me, Me group-terminated and cycloalkylene dialkyl tetrahydroindenyl zirconium (generic) (P-21-8).
                </P>
                <P>
                    <E T="03">CASRNs or Accession Nos.:</E>
                     Not available.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     March 20, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMNs state that the generic (non-confidential) use will be as catalysts. Based on pyrophoric nature (violent reactivity) of the PMN substances, EPA has identified concerns for corrosion to the skin, eyes, and respiratory tract. Based on test data for hydrolysis and oxidation products and components, EPA has also identified concerns for neurotoxicity, systemic, and developmental effects. Based on comparison to analogous aluminum compounds and zirconium compounds, EPA predicts toxicity to aquatic organisms may occur at 
                    <PRTPAGE P="48048"/>
                    concentrations that exceed 24 ppb (P-21-7) and 20 ppb (P-21-8). The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substances may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Manufacture, processing, and use of the PMN substances only in an enclosed process;</P>
                <P>• Disposal of the PMN substances, or waste streams containing the PMN substances, only by incineration;</P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• No release of the PMN substances, or any waste stream containing the PMN substances, to water; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of aquatic toxicity testing may be potentially useful to characterize the environmental effects of the PMN substances. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-21-36 (40 CFR 721.12308)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     5-Hexen-2-one, 1-bicyclo[2.2.1]hept-2-yl-.
                </P>
                <P>
                    <E T="03">CASRN:</E>
                     1352216-91-1.
                </P>
                <P>
                    <E T="03">Effective Date of modified TSCA Order:</E>
                     April 14, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the use will be as a fragrance in household consumer products. Based on submitted test data on the PMN substance, EPA has identified concerns for acute neurotoxicity, skin and eye irritation, and skin sensitization. Based on comparison to analogous chemical substances, EPA has also identified concerns for systemic effects. Based on submitted test data on the PMN substance, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 23 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Manufacture of the PMN substance only below an annual volume of 50,000 kilograms per year;</P>
                <P>• Processing for use and use of the PMN substance only as a fragrance ingredient;</P>
                <P>• Use of the PMN substance only if the concentration of the PMN substance does not exceed 1% by weight;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, resulting in surface water concentrations that exceed 23 ppb, except that waste streams from formulations containing 2% or less of the PMN substance by weight are exempt from this requirement; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>
                    The proposed SNUR would designate as a “significant new use” the absence of these protective measures. On April 1, 2026, EPA received a request from the PMN submitter to modify the language in Written Agreement and Exemptions sections of the Order. EPA approved the request and issued a modified Order, effective April 14, 2026, adding the wastewater treatment removal rate (
                    <E T="03">i.e.,</E>
                     percentage) used in the Agency's environmental and exposure assessments to the compliance criteria for the water release limit of 23 ppb.
                </P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of metabolism or pharmacokinetics, specific target organ toxicity, and chronic aquatic toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-21-59 (40 CFR 721.12309)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     Methanesulfonic acid,l,l,l-trifluoro-, ytterbium(3+) salt (3:1).
                </P>
                <P>
                    <E T="03">CASRN:</E>
                     54761-04-5.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     June 26, 2025.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the generic (non-confidential) use will be as a stabilizer. Based on comparison to analogous chemical substances, EPA has identified concerns for acute toxicity, irritation to the skin, eyes, and respiratory tract, and point-of-contact (glandular stomach, duodenum), neurological, and developmental effects. Based on comparison to analogous lanthanides or rare earth metals, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 9 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Processing for use or use of the PMN substance in a consumer product only if the concentration of the PMN substance does not exceed the confidential concentration by weight listed in the Order in final formulation in the consumer product;</P>
                <P>• Manufacture, processing, and use of the PMN substance only in a liquid formulation;</P>
                <P>• No manufacture, processing, or use of the PMN substance in any manner that results in inhalation exposure;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, to water; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of acute toxicity, developmental toxicity, eye irritation, neurotoxicity, pulmonary effects, skin irritation, and aquatic 
                    <PRTPAGE P="48049"/>
                    toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-21-185 (40 CFR 721.12310)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     Ethyl cyclohexenyl propionate, ethyl cyclohexenyl propionate (generic).
                </P>
                <P>
                    <E T="03">CASRN or Accession No.:</E>
                     Not available.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     February 26, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the use will be as a fragrance ingredient, being blended (mixed) with other fragrance ingredients to make fragrance oils that will be sold to industrial and commercial customers for their incorporation into soaps, detergents, cleaners and other similar household and consumer products. Based on submitted test data on the PMN substance, EPA has identified concerns for skin sensitization and reproductive and developmental effects. Based on submitted test data on the PMN substance, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 13 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• No manufacture of the PMN substance beyond the confidential combined annual production volume listed in the Order;</P>
                <P>• No processing for use or use of the PMN substance in consumer products where the combined concentration of the PMN substance exceeds 1% by weight;</P>
                <P>• Use of the PMN substance only as fragrance ingredients;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, resulting in surface water concentrations that exceed 13 ppb. Waste streams from formulations containing 1% or less of the PMN substance combined by weight are exempt from this restriction; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of chronic aquatic toxicity testing may be potentially useful to characterize the environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-24-27 (40 CFR 721.12311)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     Fatty acids, C8-14, 2,3-diesters with rel-(2R,3S)-2,3,4-trihydroxybutyl.beta.-D-mannopyranoside acetate.
                </P>
                <P>
                    <E T="03">CASRN:</E>
                     2711034-48-7.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     February 19, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the use will be as a surfactant. Based on the intended use as a surfactant, and a structural alert for nonionic surfactants, EPA has identified concerns for lung toxicity (surfactant effects). Based on comparison to analogous chemical substances, EPA has also identified concerns for skin irritation and eye corrosion. Based on comparison to analogous nonionic surfactants, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 550 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Use of a NIOSH-certified respirator with an APF of at least 50 where there is a potential for inhalation exposure;</P>
                <P>• No processing for use or use of the PMN substance in a consumer product;</P>
                <P>• Use of the PMN substance only as an industrial cleaner;</P>
                <P>• Use of the PMN substance only if the concentration of the PMN substance does not exceed 5% by weight;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, resulting in surface water concentrations that exceed 550 ppb; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of skin irritation, eye damage, pulmonary effects, skin corrosion, specific target organ toxicity, and aquatic toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-24-86 (40 CFR 721.12312) and P-24-87 (40 CFR 721.12313)</HD>
                <P>
                    <E T="03">Chemical Names:</E>
                     Graphene, turbostratic, 3-9 layers (P-24-86) and graphene, turbostratic, ~32 layers (P-24-87).
                </P>
                <P>
                    <E T="03">CASRNs or Accession Nos.:</E>
                     Not available.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     February 20, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMNs state that the use will be for various applications including in lubricants and oils, coatings, biosensors, energy storage, resins, thermosets, thermoplastics, hollow glass microspheres, printed inks, bullet proof armor and glass, and composites. Based on comparison to analogous chemical substances and physical/chemical properties of the PMN substances, EPA has identified concerns for lung effects (lung overload) and systemic effects. Due to insufficient information, EPA was unable to estimate the environmental hazard of the PMN substances. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substances may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                    <PRTPAGE P="48050"/>
                </P>
                <P>• Use of the PMN substance for battery, electronics, and alternative energy storage manufacture or as concrete and asphalt additives only in a manner that does not result in inhalation exposure;</P>
                <P>• Use of the PMN substances for battery, electronics, and alternative energy storage manufacture only if the amount of the PMN substances does not exceed the confidential percentage by weight listed in the Order in the electrode;</P>
                <P>• No processing for use or use of the PMN substances in a consumer product;</P>
                <P>• Use of a NIOSH-certified respirator with an APF of at least 50 where there is a potential for inhalation exposure. If the PMN substances are spray-applied or if the substances are at greater than 6% in formulation by weight and engineer controls reduce inhalation exposures by less than 94%, then the APF for the required respirator is at least 1,000;</P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• No release of the PMN substances, or any waste stream containing the PMN substances, to water; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of pulmonary effects, specific target organ toxicity, and aquatic toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substances. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-24-196 (40 CFR 721.12314)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     2-Pyrrolidinone, polymer with 2-oxepanone.
                </P>
                <P>
                    <E T="03">CASRN:</E>
                     25101-88-6.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     March 4, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the use will be as an additive for architectural paints (elongation improvers). Based on high molecular weight, negligible water solubility, and comparison to analogous respirable, poorly soluble particulates, EPA has identified concerns for lung toxicity via lung overload. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Use of a NIOSH-certified respirator with an APF of at least 50 where there is a potential for inhalation exposure;</P>
                <P>• Manufacture of the PMN substance only below an annual volume of 10,000 kilograms;</P>
                <P>• No processing for use or use of the PMN substance in a consumer product;</P>
                <P>• Use of the PMN substance only if the concentration of the PMN substance does not exceed 20% by weight in the final formulation; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of pulmonary effects testing may be potentially useful to characterize the health effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-25-15 (40 CFR 721.12315)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     Modified tall oil fatty acid polyamine condensate (generic).
                </P>
                <P>
                    <E T="03">CASRN or Accession No.:</E>
                     Not available.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     March 3, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the generic (non-confidential) use will be as an additive in paving applications. Based on the pH of the PMN substance, EPA has identified concerns for corrosion to skin, eyes, and respiratory tract. Based on structure, EPA has identified concerns for lung effects (surfactancy and cationic binding). Based on comparison to analogous chemical substances, EPA has also identified concerns for acute toxicity, skin sensitization, and systemic effects. Based on comparison to analogous aliphatic amines, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 3 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Manufacture, processing, and use of the PMN substance only in a manner that does not result in inhalation exposure to the PMN substance;</P>
                <P>• Use of the PMN substance only as a site-limited intermediate;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, resulting in surface water concentrations that exceed 3 ppb; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of acute toxicity, eye corrosion, pulmonary effects, skin corrosion, skin sensitization, specific target organ toxicity, and aquatic toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-25-25 (40 CFR 721.21316).</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     Carbomonocyclic alcohol, 4,4-[[6-(heteroatom-substituted carbomonocycle)- heteromonocycle-2,4-diyl]heteroatom-substituted]bis- (generic).
                    <PRTPAGE P="48051"/>
                </P>
                <P>
                    <E T="03">CASRN or Accession No.:</E>
                     Not available.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     March 9, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the generic (non-confidential) use will be in photolithography. Based on comparison to analogous chemical substances, EPA has identified concerns for skin sensitization, respiratory sensitization, carcinogenicity, and systemic effects. Based on comparison to analogous chemical substances, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 3 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• No manufacture, processing, or use of the PMN substance in any manner that generates a vapor, mist, dust, or aerosol containing the PMN substance unless in an enclosed process;</P>
                <P>• No processing for use or use of the PMN substance in a consumer product;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, resulting in surface water concentrations that exceed 3 ppb; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of carcinogenicity, skin sensitization, specific target organ toxicity, pulmonary effects, and aquatic toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-25-77 (40 CFR 721.12317)</HD>
                <P>
                    <E T="03">Chemical Name:</E>
                     Arsine, (1,1-dimethylethyl)-.
                </P>
                <P>
                    <E T="03">CASRN:</E>
                     4262-43-5.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     March 16, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMN states that the use will be as tertiarybutylarsine (TBA) used in semiconductor manufacturing. Based on submitted test data on the PMN substance and its reactivity, EPA has identified concerns for acute handling hazard. Based on comparison to analogous chemical substances, EPA has also identified concerns for neurotoxicity, immunotoxicity, genetic toxicity, carcinogenicity, and portal-of-entry, systemic, dermal, reproductive, and developmental effects. Based on reactivity of the PMN substance, EPA has also identified concerns for corrosion to the skin, eyes, and respiratory tract. Based on comparison to analogous chemical substances, EPA predicts toxicity to aquatic organisms may occur at concentrations that exceed 163 ppb. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substance may present an unreasonable risk of injury to human health and the environment. To protect against these risks, the Order requires:
                </P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Manufacture, processing, and use of the PMN substance only in an enclosed process;</P>
                <P>• No release of the PMN substance, or any waste stream containing the PMN substance, to water; and</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. EPA has determined that the results of skin corrosion, eye corrosion, and aquatic toxicity testing may be potentially useful to characterize the health and environmental effects of the PMN substance. Although the Order does not require these tests, the Order's restrictions remain in effect until the Order is modified or revoked by EPA based on submission of this or other relevant information.
                </P>
                <HD SOURCE="HD3">P-25-126 (40 CFR 721.12318) and P-25-127 (40 CFR 721.12319)</HD>
                <P>
                    <E T="03">Chemical Names:</E>
                     Carbomonocyclic substituted heteromonocyclic, salt with carbopolycyclic sulfocarboxylate (generic) (P-25-126) and carbomonocyclic sulfonium, salt with carbopolycyclic sulfocarboxylate (generic) (P-25-127).
                </P>
                <P>
                    <E T="03">CASRNs or Accession Nos.:</E>
                     Not available.
                </P>
                <P>
                    <E T="03">Effective Date of TSCA Order:</E>
                     March 4, 2026.
                </P>
                <P>
                    <E T="03">Basis for TSCA Order:</E>
                     The PMNs state that the generic (non-confidential) uses will be as ingredients used in the manufacture of photoresist. Based on the physical/chemical properties of the PMN substances (as described in the New Chemical Program's PBT category at 64 FR 60194; November 1999) and in the absence of data, the anions of the PMN substances, the cation photodegradation product of the P-25-127 PMN substance, and the cation of the P-25-126 PMN substance are potentially persistent, bioaccumulative, and toxic (PBT) chemicals. EPA estimates that the anions of the PMN substances and the cation of the P-25-126 PMN substance will persist in the environment for more than six months and that their potential to bioaccumulate is unknown. EPA estimates that the cation photodegradation product of the P-25-127 PMN substance will persist in the environment for more than six months and estimates a bioaccumulation factor of greater than or equal to 5,000. Based on comparison to analogous chemical substances, EPA has identified concerns for acute toxicity, irritation to the skin and respiratory tract, genetic toxicity, and neurological and systemic effects for the cations of the P-25-126 and P-25-127 PMN substances and eye corrosion for the cation of the P-25-127 PMN substance. Based on photoreactivity of the PMN substances, EPA has also identified concerns for photosensitization for the cations of the PMN substances. Due to insufficient information, EPA was unable to estimate the environmental hazard of the PMN substances. The Order was issued under TSCA sections 5(a)(3)(B)(ii)(I) and 5(e)(1)(A)(ii)(I), based on a finding that, in the absence of sufficient information to permit a reasoned evaluation, the substances may present an unreasonable risk of injury to human health and the environment. To 
                    <PRTPAGE P="48052"/>
                    protect against these risks, the Order requires:
                </P>
                <P>• No manufacture of the PMN substances beyond the time limits specified in the Order without submittal to EPA the results of certain testing described in the Testing section of the Order;</P>
                <P>• Use of personal protective equipment where there is a potential for dermal exposure;</P>
                <P>• Establishment of a hazard communication program, including human health and environmental precautionary statements on each label and in the SDS;</P>
                <P>• No processing of the PMN substances in any way that generates vapor, dust, mist, or aerosol in a non-enclosed process;</P>
                <P>• Use of the PMN substances only for the confidential use listed in the Order;</P>
                <P>
                    • No domestic manufacture of the PMN substances (
                    <E T="03">i.e.,</E>
                     import only);
                </P>
                <P>• Import of the PMN substances only in solution unless in sealed containers weighing 5 kilograms or less; and</P>
                <P>• No exceedance of the confidential annual importation volumes listed in the Order.</P>
                <P>The proposed SNUR would designate as a “significant new use” the absence of these protective measures.</P>
                <P>
                    <E T="03">Potentially Useful Information:</E>
                     EPA has determined that certain information about the physical/chemical properties, fate, bioaccumulation, environmental hazard, and human health effects of the PMN substances may be potentially useful in support of a request by the PMN submitter to modify the Order, or if a manufacturer or processor is considering submitting a SNUN for a significant new use that will be designated by this SNUR. The submitter has agreed not to exceed the time limits specified in the Order without performing the required Tier I and Tier II testing outlined in the Testing section of the Order.
                </P>
                <HD SOURCE="HD1">IV. Statutory and Executive Order Reviews</HD>
                <P>
                    Additional information about these statutes and Executive Orders can be found at 
                    <E T="03">https://www.epa.gov/laws-regulations-and-executive-orders.</E>
                </P>
                <HD SOURCE="HD2">A. Executive Order 12866: Regulatory Planning and Review</HD>
                <P>This action proposes to establish SNURs for new chemical substances that were the subject of PMNs. The Office of Management and Budget (OMB) has exempted these types of actions from review under Executive Order 12866 (58 FR 51735, October 4, 1993).</P>
                <HD SOURCE="HD2">B. Executive Order 14192: Unleashing Prosperity Through Deregulation</HD>
                <P>Executive Order 14192 (90 FR 9065, February 6, 2025) does not apply because significant new use rules for new chemicals under TSCA section 5 are exempted from review under Executive Order 12866.</P>
                <HD SOURCE="HD2">C. Paperwork Reduction Act (PRA)</HD>
                <P>
                    According to the PRA (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ), an agency may not conduct or sponsor, and a person is not required to respond to a collection of information that requires OMB approval under PRA, unless it has been approved by OMB and displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in title 40 of the CFR, after appearing in the 
                    <E T="04">Federal Register</E>
                    , are listed in 40 CFR part 9, and included on the related collection instrument or form, if applicable.
                </P>
                <P>The information collection requirements related to SNURs have already been approved by OMB pursuant to PRA under OMB control number 2070-0038 (EPA ICR No. 1188). This action does not impose any burden requiring additional OMB approval. If an entity were to submit a SNUN to the Agency, the annual burden is estimated to average between 30 and 170 hours per submission. This burden estimate includes the time needed to review instructions, search existing data sources, gather and maintain the data needed, and complete, review, and submit the required SNUN.</P>
                <P>EPA always welcomes your feedback on the burden estimates. When submitting comments on these proposed SNURs, include comments about the accuracy of the burden estimate, and any suggested methods for improving the collection instruments or instruction or minimizing respondent burden, including through the use of automated collection techniques.</P>
                <HD SOURCE="HD2">D. Regulatory Flexibility Act (RFA)</HD>
                <P>
                    I certify that this action will not have a significant economic impact on a substantial number of small entities under the RFA (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    ). The requirement to submit a SNUN applies to any person (including small or large entities) who intends to engage in any activity described in the final rule as a “significant new use.” Because these uses are “new,” based on all information currently available to EPA, EPA has concluded that no small or large entities presently engage in such activities.
                </P>
                <P>A SNUR requires that any person who intends to engage in such activity in the future must first notify EPA by submitting a SNUN. Although some small entities may decide to pursue a significant new use in the future, EPA cannot presently determine how many, if any, there may be. However, EPA's experience to date is that, in response to the promulgation of SNURs covering over 1,000 chemicals, the Agency receives only a small number of notices per year. For example, the number of SNUNs received was 23 in FY2023, 7 in FY2024, and 10 in FY2025, and only a fraction of these submissions were from small businesses.</P>
                <P>
                    In addition, the Agency currently offers relief to qualifying small businesses by reducing the SNUN submission fee from $37,000 to $6,480. This lower fee reduces the total reporting and recordkeeping cost of submitting a SNUN to about $14,967 per SNUN submission for qualifying small firms. Therefore, the potential economic impacts of complying with these proposed SNURs are not expected to be significant or adversely impact a substantial number of small entities. In a SNUR that published in the 
                    <E T="04">Federal Register</E>
                     of June 2, 1997 (62 FR 29684 (FRL-5597-1)), the Agency presented its general determination that SNURs are not expected to have a significant economic impact on a substantial number of small entities, which was provided to the Chief Counsel for Advocacy of the Small Business Administration.
                </P>
                <HD SOURCE="HD2">E. Unfunded Mandates Reform Act (UMRA)</HD>
                <P>This action does not contain an unfunded mandate of $100 million or more (in 1995 dollars) in any one year as described in UMRA, 2 U.S.C. 1531-1538, and does not significantly or uniquely affect small governments. Based on EPA's experience with proposing and finalizing SNURs, State, local, and Tribal governments have not been impacted by SNURs, and EPA does not have any reasons to believe that any State, local, or Tribal government will be impacted by these SNURs. In addition, the estimated costs of this action to the private sector do not exceed $183 million or more in any one year (the 1995 dollars are adjusted to 2023 dollars for inflation using the GDP implicit price deflator). The estimated costs for this action are discussed in Unit I.D.</P>
                <HD SOURCE="HD2">F. Executive Order 13132: Federalism</HD>
                <P>
                    This action will not have federalism implications as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it is not expected to have a substantial direct effect on States, on 
                    <PRTPAGE P="48053"/>
                    the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Accordingly, the requirements of Executive Order 13132 do not apply to this action.
                </P>
                <HD SOURCE="HD2">G. Executive Order 13175: Consultation and Coordination With Indian Tribal Governments</HD>
                <P>This action will not have Tribal implications as specified in Executive Order 13175 (65 FR 67249, November 9, 2000), because it is not expected to have substantial direct effects on Indian Tribes, significantly or uniquely affect the communities of Indian Tribal governments and does not involve or impose any requirements that affect Indian Tribes. Accordingly, the requirements of Executive Order 13175 do not apply to this action.</P>
                <HD SOURCE="HD2">H. Executive Order 13045: Protection of Children From Environmental Health Risks and Safety Risks</HD>
                <P>This action is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it does not concern an environmental health or safety risk. Since this action does not concern a human health risk, EPA's 2026 Policy on Children's Health also does not apply. Although the establishment of these SNURs do not address an existing children's environmental health concern because the chemical uses involved are not ongoing uses, SNURs require that persons notify EPA at least 90 days before commencing manufacture (defined by statute to include import) or processing of the identified chemical substances for an activity that is designated as a significant new use by the SNUR. This notification allows EPA to assess the intended uses to identify potential risks and take appropriate actions before the activities commence.</P>
                <HD SOURCE="HD2">I. Executive Order 13211: Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use</HD>
                <P>This action is not a “significant energy action” as defined in Executive Order 13211 (66 FR 28355, May 22, 2001), because it is not likely to have a significant adverse effect on the supply, distribution, or use of energy.</P>
                <HD SOURCE="HD2">J. National Technology Transfer and Advancement Act (NTTAA)</HD>
                <P>This action does not involve any technical standards subject to NTTAA section 12(d) (15 U.S.C. 272 note).</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 40 CFR Part 721</HD>
                    <P>Environmental protection, Chemicals, Hazardous substances, Reporting and recordkeeping requirements.</P>
                </LSTSUB>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Mary Elissa Reaves,</NAME>
                    <TITLE>Director, Office of Pollution Prevention and Toxics.</TITLE>
                </SIG>
                <P>For the reasons stated in the preamble, EPA proposes to amend 40 CFR chapter I as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 721—SIGNIFICANT NEW USES OF CHEMICAL SUBSTANCES</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 721 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P> 15 U.S.C. 2604, 2607, and 2625(c).</P>
                </AUTH>
                <AMDPAR>2. Add §§ 721.12306 through 721.12319 to subpart E to read as follows:</AMDPAR>
                <STARS/>
                <CONTENTS>
                    <SECHD>Sec.</SECHD>
                    <SECTNO>721.12306</SECTNO>
                    <SUBJECT> Reaction products of aluminoxanes, Me, Me group-terminated and (alkylcycloalkylene)dialkylzirconium (generic).</SUBJECT>
                    <SECTNO>721.12307</SECTNO>
                    <SUBJECT> Reaction products of aluminoxanes, Me, Me group-terminated and cycloalkylene dialkyl tetrahydroindenyl zirconium (generic).</SUBJECT>
                    <SECTNO>721.12308</SECTNO>
                    <SUBJECT> 5-Hexen-2-one, 1-bicyclo[2.2.1]hept-2-yl-.</SUBJECT>
                    <SECTNO>721.12309</SECTNO>
                    <SUBJECT> Methanesulfonic acid,l,l,l-trifluoro-, ytterbium(3+) salt (3:1).</SUBJECT>
                    <SECTNO>721.12310</SECTNO>
                    <SUBJECT> Ethyl cyclohexenyl propionate, ethyl cyclohexenyl propionate (generic).</SUBJECT>
                    <SECTNO>721.12311</SECTNO>
                    <SUBJECT> Fatty acids, C8-14, 2,3-diesters with rel-(2R,3S)-2,3,4-trihydroxybutyl .beta.-D-mannopyranoside acetate.</SUBJECT>
                    <SECTNO>721.12312</SECTNO>
                    <SUBJECT> Graphene, turbostratic, 3-9 layers.</SUBJECT>
                    <SECTNO>721.12313</SECTNO>
                    <SUBJECT> Graphene, turbostratic, ~32 layers.</SUBJECT>
                    <SECTNO>721.12314</SECTNO>
                    <SUBJECT> 2-Pyrrolidinone, polymer with 2-oxepanone.</SUBJECT>
                    <SECTNO>721.12315</SECTNO>
                    <SUBJECT> Modified tall oil fatty acid polyamine condensate (generic).</SUBJECT>
                    <SECTNO>721.12316</SECTNO>
                    <SUBJECT> Carbomonocyclic alcohol, 4,4-[[6-(heteroatom-substituted carbomonocycle)- heteromonocycle-2,4-diyl]heteroatom-substituted]bis- (generic).</SUBJECT>
                    <SECTNO>721.12317</SECTNO>
                    <SUBJECT> Arsine, (1,1-dimethylethyl)-.</SUBJECT>
                    <SECTNO>721.12318</SECTNO>
                    <SUBJECT> Carbomonocyclic substituted heteromonocyclic, salt with carbopolycyclic sulfocarboxylate (generic).</SUBJECT>
                    <SECTNO>721.12319</SECTNO>
                    <SUBJECT> Carbomonocyclic sulfonium, salt with carbopolycyclic sulfocarboxylate (generic).</SUBJECT>
                </CONTENTS>
                <STARS/>
                <SECTION>
                    <SECTNO>§ 721.12306 </SECTNO>
                    <SUBJECT> Reaction products of aluminoxanes, Me, Me group-terminated and (alkylcycloalkylene)dialkylzirconium (generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as reaction products of aluminoxanes, Me, Me group-terminated and (alkylcycloalkylene)dialkylzirconium (generic) (PMN P-21-7) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1) and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: skin corrosion, serious eye damage, reproductive toxicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(a) through (c).
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Disposal.</E>
                         Requirements as specified in § 721.85(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (v) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12307 </SECTNO>
                    <SUBJECT>Reaction products of aluminoxanes, Me, Me group-terminated and cycloalkylene dialkyl tetrahydroindenyl zirconium (generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as reaction products of aluminoxanes, Me, Me group-terminated and cycloalkylene dialkyl tetrahydroindenyl zirconium (PMN P-
                        <PRTPAGE P="48054"/>
                        21-8) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1) and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: skin corrosion, serious eye damage, reproductive toxicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(a) through (c).
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Disposal.</E>
                         Requirements as specified in § 721.85(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (v) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12308 </SECTNO>
                    <SUBJECT>5-Hexen-2-one, 1-bicyclo[2.2.1]hept-2-yl-.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as 5-hexen-2-one, 1-bicyclo[2.2.1]hept-2-yl- (PMN P-21-36; CASRN 1352216-91-1) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1) and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: skin irritation, eye irritation, skin sensitization, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(t). It is a significant new use to manufacture the substance unless below an annual volume of 50,000 kg/yr. It is a significant new use to process for use or use the substance other than as a fragrance ingredient. It is a significant new use to use the substance if the concentration of the substance exceeds 1% by weight.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(4), (b)(4), and (c)(4), where N = 23. Waste streams from formulations containing 2% or less of the substance by weight are exempt from this restriction. For the purposes of § 721.91(a)(7), the control technology is primary and secondary wastewater treatment as defined in 40 CFR part 133 and the percentage removal of the substance resulting from use of the specified control technology is 90%.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12309 </SECTNO>
                    <SUBJECT>Methanesulfonic acid,l,l,l-trifluoro-, ytterbium(3+) salt (3:1).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as methanesulfonic acid,l,l,l-trifluoro-, ytterbium(3+) salt (3:1) (PMN P-21-59; CASRN 54761-04-5) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or cured (
                        <E T="03">i.e.,</E>
                         the substance has been reacted or cured to the extent that no release of the substance can be detected).
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: acute toxicity, skin irritation, eye irritation, reproductive toxicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         It is a significant new use to manufacture, process, or use the substance other than in a liquid formulation. It is a significant new use to manufacture, process, or use the substance in any manner that results in inhalation exposure to the substance. It is a significant new use to process for use or use the substance in a consumer product unless the concentration of the substance does not exceed the confidential concentration by weight listed in the Order in final formulation in the consumer product.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <PRTPAGE P="48055"/>
                    <SECTNO>§ 721.12310 </SECTNO>
                    <SUBJECT>Ethyl cyclohexenyl propionate, ethyl cyclohexenyl propionate (generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as ethyl cyclohexenyl propionate, ethyl cyclohexenyl propionate (PMN P-21-185) are subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), the substance may cause: skin sensitization and reproductive toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(t). It is a significant new use to use the substance other than as a fragrance ingredient. It is a significant new use to process for use or use the substance in consumer products where the concentration of the substance exceeds 1% (by weight).
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(4), (b)(4), and (c)(4) where N = 13. Waste streams from formulations containing 1% or less of the substance by weight are exempt from these requirements. For the purposes of § 721.91(a)(7), the control technology is primary and secondary wastewater treatment as defined in 40 CFR part 133 and the percentage removal of the substance resulting from use of the specified control technology is 90%.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12311 </SECTNO>
                    <SUBJECT>Fatty acids, C8-14, 2,3-diesters with rel-(2R,3S)-2,3,4-trihydroxybutyl .beta.-D-mannopyranoside acetate.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as fatty acids, C8-14, 2,3-diesters with rel-(2R,3S)-2,3,4-trihydroxybutyl .beta.-D-mannopyranoside acetate (PMN P-24-27; CASRN 2711034-48-7) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (a)(3) through (6), and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1) and (4), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible. For purposes of § 721.63(a)(5), respirators must provide a National Institute for Occupational Safety and Health (NIOSH) assigned protection factor (APF) of at least 50.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: skin irritation, serious eye damage, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(o). It is a significant new use to use the substance other than as an industrial cleaner. It is a significant new use to use the substance if the concentration of the substance exceeds 5% by weight in the final product.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(4), (b)(4), and (c)(4), where N = 550.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12312 </SECTNO>
                    <SUBJECT>Graphene, turbostratic, 3-9 layers.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as graphene, turbostratic, 3-9 layers (PMN P-24-86) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or cured (
                        <E T="03">i.e.,</E>
                         the substance has been reacted or cured to the extent that no release of the substance can be detected).
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (3) through (6), and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1) and (4), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible. For purposes of § 721.63(a)(5), respirators must provide a National Institute for Occupational Safety and Health (NIOSH) assigned protection factor (APF) of at least 50. If the substance is used at greater than 6% in formulation by weight and engineering controls reduce inhalation exposures by less than 94%, or if the substance is spray applied at any concentration, then the APF for the required respirator is at least 1,000.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(o). It is a significant new use to use the substance other than for battery, electronics, and alternative energy storage manufacture or as concrete and asphalt additives. It is a significant new use to use the substance as concrete and asphalt additives in any manner that results in inhalation exposure to the substance. It is a significant new use to use the 
                        <PRTPAGE P="48056"/>
                        substance for battery, electronics, and alternative energy storage manufacture unless the amount of the substance does not exceed the confidential percentage by weight in the electrode listed in the Order.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12313 </SECTNO>
                    <SUBJECT>Graphene, turbostratic, ~32 layers.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as graphene, turbostratic, ~32 layers (PMN P-24-87) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or cured (
                        <E T="03">i.e.,</E>
                         the substance has been reacted or cured to the extent that no release of the substance can be detected).
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (a)(3) through (6), and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1) and (4), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible. For purposes of § 721.63(a)(5), respirators must provide a National Institute for Occupational Safety and Health (NIOSH) assigned protection factor (APF) of at least 50. If the substance is used at greater than 6% in formulation by weight and engineering controls reduce inhalation exposures by less than 94%, or the substance is spray applied at any concentration, then the APF for the required respirator is at least 1,000.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(o). It is a significant new use to use the substance other than for battery, electronics, and alternative energy storage manufacture or as concrete and asphalt additives. It is a significant new use to use the substance as concrete and asphalt additives in any manner that results in inhalation exposure to the substance. It is a significant new use to use the substance for battery, electronics, and alternative energy storage manufacture if the amount of the substance exceeds the confidential percentage by weight in the electrode listed in the Order.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12314 </SECTNO>
                    <SUBJECT>2-Pyrrolidinone, polymer with 2-oxepanone.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as 2-pyrrolidinone, polymer with 2-oxepanone (PMN P-24-196; CASRN 25101-88-6) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or cured (
                        <E T="03">i.e.,</E>
                         the substance has been reacted or cured to the extent that no release of the substance can be detected).
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (a)(3) through (6), and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1) and (4), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible. For purposes of § 721.63(a)(5), respirators must provide a National Institute for Occupational Safety and Health (NIOSH) assigned protection factor (APF) of at least 50.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1) and (5). For purposes of § 721.72(g)(1), this substance may cause: specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(o) and (t). It is a significant new use to manufacture the substance beyond an annual production volume of 10,000 kilograms. It is a significant new use to use the substance at a concentration of greater than 20% by weight in the final formulation.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12315 </SECTNO>
                    <SUBJECT>Modified tall oil fatty acid polyamine condensate (generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as modified tall oil fatty acid polyamine condensate (PMN P-25-15) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or cured (
                        <E T="03">i.e.,</E>
                         the substance has been reacted or cured to the extent that no release of the substance can be detected).
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1) and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be 
                        <PRTPAGE P="48057"/>
                        considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: acute toxicity, skin corrosion, serious eye damage, skin sensitization, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(h). It is a significant new use to manufacture, process, or use the substance in any manner that results in inhalation exposure to the substance.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(4), (b)(4), and (c)(4), where N = 3.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12316 </SECTNO>
                    <SUBJECT>Carbomonocyclic alcohol, 4,4-[[6-(heteroatom-substituted carbomonocycle)-heteromonocycle-2,4-diyl]heteroatom-substituted]bis-(generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as carbomonocyclic alcohol, 4,4-[[6-(heteroatom-substituted carbomonocycle)-heteromonocycle-2,4-diyl]heteroatom-substituted]bis-(PMN P-25-25) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1) and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: respiratory sensitization, skin sensitization, carcinogenicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(o). It is a significant new use to manufacture, process, or use the substance in any manner that generates a vapor, mist, dust, or aerosol containing the substance unless in an enclosed process.
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(4), (b)(4), and (c)(4) where N = 3.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12317 </SECTNO>
                    <SUBJECT>Arsine, (1,1-dimethylethyl)-.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified as arsine, (1,1-dimethylethyl)-(PMN P-25-77; CASRN 4262-43-5) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1) and (3) and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (d), (f), (g)(1), (g)(3)(iii), and (g)(5). For purposes of § 721.72(g)(1), this substance may cause: acute toxicity, skin corrosion, serious eye damage, genetic toxicity, carcinogenicity, reproductive toxicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(a) through (c).
                    </P>
                    <P>
                        (iv) 
                        <E T="03">Release to water.</E>
                         Requirements as specified in § 721.90(a)(1), (b)(1), and (c)(1).
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) and (k) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12318 </SECTNO>
                    <SUBJECT>Carbomonocyclic substituted heteromonocyclic, salt with carbopolycyclic sulfocarboxylate (generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as carbomonocyclic substituted heteromonocyclic, salt with carbopolycyclic sulfocarboxylate (PMN P-25-126) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or adhered (during photolithographic processes) onto a semiconductor wafer surface or similar manufactured article used in the production of semiconductor technologies.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (a)(2)(i) and (a)(2)(iii), (a)(3), and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (f), (g)(1), (g)(2)(i) through (iii) and (v), (g)(3)(i) and (ii), and (g)(5). For purposes of § 721.72(e), the concentration is set at 1.0%. For purposes of § 721.72(g)(1), this substance may cause: acute toxicity, skin irritation, skin sensitization, genetic toxicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the 
                        <PRTPAGE P="48058"/>
                        criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(f), (k), and (t). It is a significant new use to import the substance other than in solution, unless in sealed containers weighing 5 kilograms or less. It is a significant new use to process the substance in any way that generates vapor, dust, mist, or aerosol in a non-enclosed process. It is a significant new use to manufacture the substance longer than 18 months.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
                <SECTION>
                    <SECTNO>§ 721.12319 </SECTNO>
                    <SUBJECT>Carbomonocyclic sulfonium, salt with carbopolycyclic sulfocarboxylate (generic).</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Chemical substance and significant new uses subject to reporting.</E>
                         (1) The chemical substance identified generically as carbomonocyclic sulfonium, salt with carbopolycyclic sulfocarboxylate (PMN P-25-127) is subject to reporting under this section for the significant new uses described in paragraph (a)(2) of this section. The requirements of this section do not apply to quantities of the substance after they have been completely reacted or adhered (during photolithographic processes) onto a semiconductor wafer surface or similar manufactured article used in the production of semiconductor technologies.
                    </P>
                    <P>(2) The significant new uses are:</P>
                    <P>
                        (i) 
                        <E T="03">Protection in the workplace.</E>
                         Requirements as specified in § 721.63(a)(1), (2)(i) and (iii), (3), and (c). When determining which persons are reasonably likely to be exposed as required for § 721.63(a)(1), engineering control measures (
                        <E T="03">e.g.,</E>
                         enclosure or confinement of the operation, general and local ventilation) or administrative control measures (
                        <E T="03">e.g.,</E>
                         workplace policies and procedures) shall be considered and implemented to prevent exposure, where feasible.
                    </P>
                    <P>
                        (ii) 
                        <E T="03">Hazard communication.</E>
                         Requirements as specified in § 721.72(a) through (f), (g)(1), (g)(2)(i) through (iii) and (v), (g)(3)(i) and (ii), and (g)(5). For purposes of § 721.72(e), the concentration is set at 1.0%. For purposes of § 721.72(g)(1), this substance may cause: acute toxicity, skin irritation, serious eye damage, skin sensitization, genetic toxicity, and specific target organ toxicity. Alternative hazard and warning statements that meet the criteria of the Globally Harmonized System and OSHA Hazard Communication Standard may be used.
                    </P>
                    <P>
                        (iii) 
                        <E T="03">Industrial, commercial, and consumer activities.</E>
                         Requirements as specified in § 721.80(f), (k), and (t). It is a significant new use to import the substance other than in solution, unless in sealed containers weighing 5 kilograms or less. It is a significant new use to process the substance in any way that generates vapor, dust, mist, or aerosol in a non-enclosed process. It is a significant new use to manufacture the substance longer than 18 months.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Specific requirements.</E>
                         The provisions of subpart A of this part apply to this section except as modified by this paragraph (b).
                    </P>
                    <P>
                        (1) 
                        <E T="03">Recordkeeping.</E>
                         Recordkeeping requirements as specified in § 721.125(a) through (i) are applicable to manufacturers, importers, and processors of this substance.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Limitation or revocation of certain notification requirements.</E>
                         The provisions of § 721.185 apply to this section.
                    </P>
                </SECTION>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15352 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Administration for Children and Families</SUBAGY>
                <CFR>45 CFR Part 1356</CFR>
                <RIN>RIN 0970-AC14</RIN>
                <SUBJECT>Administrative Costs for Children in Title IV-E Foster Care</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Administration for Children and Families (ACF), Department of Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule; withdrawal.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        This document withdraws a proposed rule that was published in the 
                        <E T="04">Federal Register</E>
                         on January 31, 2005. The proposed rule would have amended the regulations for Child and Family Services with respect to title IV-E administrative costs and eligibility determinations and re-determinations for title IV-E foster care recipients and foster care “candidates” to implement title IV-E foster care eligibility and administrative cost provisions in sections 472 and 474 of the Social Security Act (the Act) and incorporates previously issued policy guidance.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The proposed rule published January 31, 2005 (70 FR 4803) is withdrawn, effective July 30, 2026.</P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Adam N. Jones, Deputy Chief of Staff, Immediate Office of the Assistant Secretary, Administration for Children and Families, Department of Health and Human Services, Washington, DC 202-417-0115 or 
                        <E T="03">Deregulation@acf.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    ACF published a notice of proposed rulemaking (NPRM) related to the administration of the title IV-E Program in the 
                    <E T="04">Federal Register</E>
                     on January 31, 2005 (70 FR 4803). The Notice of Proposed Rule Making (NPRM) proposed to amend the regulations for Child and Family Services with respect to title IV-E administrative costs and eligibility determinations and re-determinations for title IV-E foster care recipients and foster care “candidates.” This NPRM proposes rules to implement title IV-E foster care eligibility and administrative cost provisions in sections 472 and 474 of the Social Security Act (the Act) and incorporates previously issued policy guidance.
                </P>
                <P>
                    ACF does not intend to publish a final rule following the publication of this NPRM on January 31, 2005. This decision was made due to the fact that the NPRM was published over 20 years ago by a prior Administration, and its continued existence on the 
                    <E T="04">Federal Register</E>
                     as a proposed, but not finalized rule, serves to only confuse the public. There have been multiple Administrations spanning this timeframe, with none seeking to finalize this proposed rulemaking. This withdrawal represents good governance and will ease the understandability of current Administration priorities for the public.
                </P>
                <SIG>
                    <NAME>Robert F. Kennedy, Jr.,</NAME>
                    <TITLE>Secretary, Department of Health and Human Services.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15403 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4184-01-P</BILCOD>
        </PRORULE>
    </PRORULES>
    <VOL>91</VOL>
    <NO>145</NO>
    <DATE>Thursday, July 30, 2026</DATE>
    <UNITNAME>Notices</UNITNAME>
    <NOTICES>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48059"/>
                <AGENCY TYPE="F">DEPARTMENT OF AGRICULTURE</AGENCY>
                <SUBJECT>Submission for OMB Review; Comment Request</SUBJECT>
                <P>The Department of Agriculture has submitted the following information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104-13. Comments are required regarding; whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; the accuracy of the agency's estimate of burden including the validity of the methodology and assumptions used; ways to enhance the quality, utility and clarity of the information to be collected; and ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.</P>
                <P>
                    Comments regarding this information collection received by August 31, 2026 will be considered. Written comments and recommendations for the proposed information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                     Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                </P>
                <P>An agency may not conduct or sponsor a collection of information unless the collection of information displays a currently valid OMB control number and the agency informs potential persons who are to respond to the collection of information that such persons are not required to respond to the collection of information unless it displays a currently valid OMB control number.</P>
                <HD SOURCE="HD1">Farm Service Agency</HD>
                <P>
                    <E T="03">Title:</E>
                     7 CFR 765, Direct Loan Servicing—Regular.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     0560-0236.
                </P>
                <P>
                    <E T="03">Summary of Collection:</E>
                     FSA's Farm Loan Programs (FLP) provide loans to family farmers to purchase real estate and equipment, and finance agricultural production. Direct Loan Servicing—Regular, as specified in 7 CFR part 765, provides the requirements related to regular and routine servicing actions associated with direct loans. FSA is required to actively supervise its borrowers and provide credit counseling, management advice and financial guidance. Additionally, FSA must document that credit is not available to the borrower from commercial credit sources for borrowers to maintain eligibility for assistance. Information collections established in the regulation are necessary for FSA to monitor and account for loan security, including proceeds derived from the sale of security, and to process a borrower's request for subordination, partial release of security, or consent. Borrowers are required to provide financial information to determine graduation eligibility based on commercial lender standards provided to FSA.
                </P>
                <P>FSA is retiring form FSA-2060 “Application for Partial Release, Subordination (Real or Personal), or Consent”. The form FSA-2061 “Application for Partial Release or Consent,” and form FSA-2062 “Application for Subordination of Security for Commercial Credit” are new forms; both new forms captured the information previously requested on the FSA-2001 and FSA-2060 that will replace the FSA-2060 and eliminating the need for FSA-2001 for regular and routine servicing requests.</P>
                <P>
                    <E T="03">Need and Use of the Information:</E>
                     Information requested under this collection is submitted by borrowers to the local agency office serving the county in which their business is headquartered. The information is used by FLP to manage application of proceeds from the sale of agency security, consider whether a borrower is in compliance with their loan covenants, assist the borrower in achieving their business goals, conduct day-to-day management of the agency's loan portfolio, and ensure that the agency's interests are protected. Failure to collect the information or collecting it less frequently could result in the failure of the farm operation or loss of agency security, property or position.
                </P>
                <P>
                    <E T="03">Description of Respondents:</E>
                     Business or other for-profit; farms.
                </P>
                <P>
                    <E T="03">Number of Respondents:</E>
                     109,568.
                </P>
                <P>
                    <E T="03">Frequency of Responses:</E>
                     Reporting: On occasion; annually.
                </P>
                <P>
                    <E T="03">Total Burden Hours:</E>
                     36,275.
                </P>
                <SIG>
                    <NAME>Rachelle Ragland-Greene,</NAME>
                    <TITLE>Departmental Information Collection Clearance Officer.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15433 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3410-05-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF AGRICULTURE</AGENCY>
                <SUBAGY>Natural Resources Conservation Service</SUBAGY>
                <SUBJECT>Record of Decision on Clarke County Water Supply Project Final Plan-Environmental Impact Statement, Clarke County, Iowa</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Natural Resources Conservation Service (NRCS), United States Department of Agriculture (USDA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability; record of decision.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>NRCS announces the availability of the Record of Decision (ROD) for the Clarke County Water Supply Project Plan and Final Plan-Environmental Impact Statement (Final Plan-EIS) in Clarke County, Iowa. NRCS has selected the “Water Supply Reservoir with Dam at Site 4B Alternative” as the preferred alternative. This alternative includes constructing an earth-fill embankment dam with a reinforced concrete pressure-pipe principal spillway and vegetated auxiliary spillway; installing a water-supply pipeline (including a pumping station and ground storage reservoir) to transport water from the reservoir to the water-treatment plant; and relocating a segment of a local road (Truro Pavement).</P>
                </SUM>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The ROD and Final Plan-EIS are available on the NRCS project website at: 
                        <E T="03">https://www.nrcs.usda.gov/state-offices/iowa/clarke-county-water-supply-project.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Michael (Scott) Cagle, (515) 323-2211, 
                        <PRTPAGE P="48060"/>
                        <E T="03">michael.cagle2@usda.gov.</E>
                         Individuals with disabilities who require alternative means for communication should contact the USDA Target Center at (202) 720-2600 (voice and text telephone (TTY mode)) or dial 711 for Telecommunications Relay Service (both voice and text telephone users can initiate this call from any telephone).
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The ROD identifies NRCS's selected alternative for the Clarke County Water Supply Project, as described in the February 2026 Final Plan-EIS for Clarke County, Iowa. NRCS reached its decision after reviewing the Final Plan-EIS, which is available on the NRCS project website listed in the
                    <E T="02"> Addresses</E>
                     section of this notice and was announced on April 10, 2026, through a notice of availability (91 FR 18456), in accordance with the requirements of 7 CFR 650. The Final Plan-EIS evaluated the proposed action, the no-action alternative, and other alternatives. NRCS has selected the proposed action alternative titled “Water Supply Reservoir with Dam at Site 4B Alternative.”
                </P>
                <P>The ROD documents the basis for NRCS's decision on the selected alternative, including the mitigation measures that will be implemented and the environmental, social, and economic factors considered under the National Environmental Policy Act. NRCS concludes that the selected alternative provides the most balanced approach to meeting project objectives while minimizing adverse effects.</P>
                <P>NRCS reviewed and considered all substantive comments received on the Final Plan-EIS following publication of the notice of availability on April 10, 2026 (91 FR 18456). While the comments did not require changes to the Final Plan-EIS, a summary of the comments and NRCS's responses is available on the NRCS project website listed in the Addresses section of this notice. Watershed planning is authorized by the Watershed Protection and Flood Prevention Act of 1954 (Pub. L. 83-566), as amended, and the Flood Control Act of 1944 (Pub. L. 78-534).</P>
                <SIG>
                    <NAME>Jaia Fischer,</NAME>
                    <TITLE>Acting Iowa State Conservationist, Natural Resources Conservation Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15381 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3410-16-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">COMMISSION ON CIVIL RIGHTS</AGENCY>
                <SUBJECT>Notice of Public Meeting of the Tennessee Advisory Committee</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Commission on Civil Rights.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Announcement of virtual business meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act (FACA) that the Tennessee Advisory Committee to the U.S. Commission on Civil Rights will hold a virtual business meetings via Zoom on Monday, August 17, 2026; Monday, September 14, 2026 and Monday, October 19, 2026, from 3:00 p.m.-4:00 p.m. CT. For the purpose of discussing ideas for their first project.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The meetings will take place on:</P>
                </DATES>
                <HD SOURCE="HD1">Monday, August 17th from 3:00 p.m.-4:00 p.m. CT</HD>
                <P>
                    <E T="03">• Registration Link (Audio/Visual): https://www.zoomgov.com/webinar/register/WN_ZAIP4A_dQwSXafOP0furjg.</E>
                </P>
                <P>
                    • 
                    <E T="03">Join by Phone (Audio Only):</E>
                     1-833-435-1820 USA Toll Free; Webinar ID: #165 2974 150.
                </P>
                <HD SOURCE="HD1">Monday, September 14th from 3:00 p.m.-4:00 p.m. CT</HD>
                <P>
                    <E T="03">• Registration Link (Audio/Visual): https://www.zoomgov.com/webinar/register/WN_k7SITldQSLeOrOkXPhuRKA.</E>
                </P>
                <P>
                    • 
                    <E T="03">Join by Phone (Audio Only):</E>
                     1-833-435-1820 USA Toll Free; Webinar ID: #165 222 2525.
                </P>
                <HD SOURCE="HD1">Monday, October 19th from 3:00 p.m.-4:00 p.m. CT</HD>
                <P>
                    • 
                    <E T="03">Registration Link (Audio/Visual): https://www.zoomgov.com/webinar/register/WN_WkUl0p75QgO4THn2mlTbfA.</E>
                </P>
                <P>
                    • 
                    <E T="03">Join by Phone (Audio Only):</E>
                     1-833-435-1820 USA Toll Free; Webinar ID: #165 572 5099.
                </P>
                <P>
                    <E T="03">Agendas:</E>
                     (
                    <E T="03">note: final meeting agendas will be available prior to the meeting dates</E>
                    ).
                </P>
                <P>
                    • 8/17/26 
                    <E T="03">https://usccr.box.com/s/h8fql4wag318yakk1fffu3zuvzgtoe3g.</E>
                </P>
                <P>
                    • 9/14/26 
                    <E T="03">https://usccr.box.com/s/ctaaxwfpn4zmotmjpu8ojhzkrstdhzgy.</E>
                </P>
                <P>
                    • 10/19/26 
                    <E T="03">https://usccr.box.com/s/uxvst4owqbxho5tgy4l6tbqewli2yzes.</E>
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        Brooke Peery, Designated Federal Officer (DFO) at 
                        <E T="03">bpeery@usccr.gov</E>
                         or by phone at (202) 701-1376.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Committee meetings are available to the public through the videoconference link above. Any interested member of the public may listen to the meeting. An open comment period will be provided to allow members of the public to make a statement as time allows. Per the Federal Advisory Committee Act, public minutes of the meeting will include a list of persons who are present at the meeting. If joining via phone, callers can expect to incur regular charges for calls they initiate over wireless lines, according to their wireless plan. The Commission will not refund any incurred charges. Closed captioning will be available for individuals who are deaf, hard of hearing, or who have certain cognitive or learning impairments. To request additional accommodations, please email Corrine Sanders, Support Services Specialist, 
                    <E T="03">csanders@usccr.gov</E>
                     at least 10 business days prior to the meeting.
                </P>
                <P>
                    Members of the public are entitled to make comments during the open period at the end of the meeting. Members of the public may also submit written comments; the comments must be received in the Regional Programs Unit within 30 days following the meeting. Written comments can be sent via email to Brooke Peery (DFO) at 
                    <E T="03">bpeery@usccr.gov</E>
                    .
                </P>
                <P>
                    Records generated from this meeting may be inspected and reproduced at the Regional Programs Coordination Unit Office, as they become available, both before and after the meeting. Records of the meetings will be available via 
                    <E T="03">www.facadatabase.gov</E>
                     under the Commission on Civil Rights, Tennessee Advisory Committee link. Persons interested in the work of this Committee are directed to the Commission's website, 
                    <E T="03">http://www.usccr.gov,</E>
                     or may contact the Regional Programs Coordination Unit at 
                    <E T="03">csanders@usccr.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 28, 2026.</DATED>
                    <NAME>David Mussatt,</NAME>
                    <TITLE>Supervisory Chief, Regional Programs Unit.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15373 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>Economic Development Administration</SUBAGY>
                <SUBJECT>Agency Information Collection Activities; Submission for OMB Review; Comment Request; Non-Infrastructure Metrics</SUBJECT>
                <P>
                    The Department of Commerce will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. We invite the general public and other Federal agencies to comment on proposed, and continuing information collections, which helps us 
                    <PRTPAGE P="48061"/>
                    assess the impact of our information collection requirements and minimize the public's reporting burden. Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on May 15, 2026 during a 60-day comment period. This notice allows for an additional 30 days for public comments.
                </P>
                <P>
                    <E T="03">Agency:</E>
                     Economic Development Administration, Department of Commerce.
                </P>
                <P>
                    <E T="03">Title:</E>
                     Non-Infrastructure Metrics.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     0610-0098.
                </P>
                <P>
                    <E T="03">Form Number(s):</E>
                     ED-915, ED-916.
                </P>
                <P>
                    <E T="03">Type of Request:</E>
                     Regular submission (extension with revision).
                </P>
                <P>
                    <E T="03">Number of Respondents:</E>
                     750.
                </P>
                <P>
                    <E T="03">Average Hours per Response:</E>
                     2.5 hours.
                </P>
                <P>
                    <E T="03">Burden Hours:</E>
                     1,475.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     EDA-funded grantees: State, local and tribal governments; community organizations; non-profit organizations; Indian Tribes; Institution of Higher Education or a consortium of institutions of higher education.
                </P>
                <P>
                    <E T="03">Frequency:</E>
                     Annually.
                </P>
                <P>
                    <E T="03">Respondents' Obligation:</E>
                     Mandatory for all non-infrastructure and infrastructure award recipients.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Cost to Public:</E>
                     $96,878 (cost assumes application of U.S. Bureau of Labor Statistics 2025 mean hourly employer costs for employee compensation for professional and related occupations of $65.68).
                </P>
                <P>
                    <E T="03">Needs and Uses:</E>
                     EDA's expansive portfolio of programs, changing technology, and advances in the field of program evaluation require comprehensive and relevant data collection to increase EDA's transparency, accountability, and inform the effectiveness of its investments. Thus, EDA proposes revising forms ED-916, ED-917, and ED-918, which are currently used to collect performance information from EDA grantees, and extending the ED-915. This revision also includes consolidating the ED-916, ED-917, and ED-918 into one streamlined data collection (the ED-916) that reduces the number of questions in order to prioritize measurement of return on investment and decrease participant burden. For the ED-915, EDA proposes to extend the data collection with no revision to the current instrument. These data collection instruments cover EDA's infrastructure and non-infrastructure program portfolios thereby providing EDA with a comprehensive view and helping ensure investments are evidence-based, data-driven, and accountable to participants and the public.
                </P>
                <P>
                    <E T="03">Legal Authority:</E>
                     The Public Works and Economic Development Act of 1965 (42 U.S.C. 3121 
                    <E T="03">et seq.</E>
                    ).
                </P>
                <P>
                    This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view the Department of Commerce collections currently under review by OMB.
                </P>
                <P>
                    Written comments and recommendations for the proposed information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                     Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the collection or the OMB Control Number 0610-0098.
                </P>
                <SIG>
                    <NAME>Sheleen Dumas,</NAME>
                    <TITLE>Departmental PRA Compliance Officer, Office of the Under Secretary of Economic Affairs, Commerce Department.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15432 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-34-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>Foreign-Trade Zones Board</SUBAGY>
                <DEPDOC>[B-92-2026]</DEPDOC>
                <SUBJECT>Foreign-Trade Zone (FTZ) 153, Notification of Proposed Production Activity; Aptera Motors Corp; (Solar Electric Vehicles); Carlsbad, California</SUBJECT>
                <P>Aptera Motors Corp submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Carlsbad, California within Subzone 153P. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 23, 2026.</P>
                <P>
                    Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via 
                    <E T="03">www.trade.gov/ftz.</E>
                </P>
                <P>The proposed finished products include solar electric vehicles (duty rate is 2.5%).</P>
                <P>The proposed foreign-status materials/components include: cross car beams; vehicle interior headliners; i-shaft steering racks; airbags; airbag inflators; airbag modules; airbag covers; sun visors; fluid lines; fluid manifolds; collectors; floor mats; tempered safety glass; laminated windscreens; door hinge arms; door hinges; upper door hinge assemblies; lithium-ion battery cells; vehicle horns; telematics units; audio speakers; thermistors; busbars; cooling plates; photovoltaic cells; body inner panels; body outer panels; body panels; body structural tubs; exterior body panels; seat belt retractors; seat belt b-pillar anchorage; seat belt buckle; suspension control arms; side extrusions; control arm bushings; cross bars; engine castings; suspension rockers; suspension push rods; steering knuckles; suspension arms; rear suspension pillars; kick down rails; compressor supports; tie bars; subframes; rear suspension assemblies; steering yokes; center control units; tires; wheel bearing units; brake caliper and rotors; and brake calipers (duty rates range from duty-free to 5.5%).</P>
                <P>The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 (section 232), or section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable section 232 and section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign (PF) status (19 CFR 146.41). The request also indicates that aluminum extrusions, passenger vehicle tires, and tapered roller bearing units are subject to antidumping/countervailing duty (AD/CVD) orders/investigations if imported from China. The Board's regulations (15 CFR 400.13(c)(2)) require that merchandise subject to AD/CVD orders, or items which would be otherwise subject to suspension of liquidation under AD/CVD procedures if they entered U.S. customs territory, be admitted to the zone in PF status (19 CFR 146.41).</P>
                <P>
                    Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: 
                    <E T="03">ftz@trade.gov.</E>
                     The closing period for their receipt is September 8, 2026.
                </P>
                <P>A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.</P>
                <P>
                    For further information, contact Christopher Williams at 
                    <E T="03">christopher.williams@trade.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 24, 2026.</DATED>
                    <NAME>Elizabeth Whiteman,</NAME>
                    <TITLE>Executive Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15422 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48062"/>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>Foreign-Trade Zones Board</SUBAGY>
                <DEPDOC>[B-93-2026]</DEPDOC>
                <SUBJECT>Foreign-Trade Zone (FTZ) 126, Notification of Proposed Production Activity; Omega Holdings; (Aftermarket Air Conditioning Components); Sparks, Nevada</SUBJECT>
                <P>Omega Holdings submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Sparks, Nevada within FTZ 126. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 22, 2026.</P>
                <P>
                    Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via 
                    <E T="03">www.trade.gov/ftz.</E>
                </P>
                <P>The proposed finished products are parts of air conditioning units modified with domestic status internal components. These proposed finished products include: Air Conditioning Compressor Assemblies; Air Conditioning Electrical Pigtails; Air Conditioning Compressor Clutches; Air Conditioning Compressor Heads; Air Conditioning Compressor Bearings (duty rate ranges from duty free to 1.4%).</P>
                <P>The proposed foreign-status materials/components are parts of air conditioning units with unmodified internal components. These proposed foreign-status materials/components include: Air Conditioning Compressor Assemblies; Air Conditioning Electrical Pigtails; Air Conditioning Compressor Clutches; Air Conditioning Compressor Heads; Air Conditioning Compressor Bearings (duty rate ranges from duty free to 1.4%)</P>
                <P>The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 (section 232) or section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable section 232 and section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).</P>
                <P>
                    Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: 
                    <E T="03">ftz@trade.gov.</E>
                     The closing period for their receipt is September 8, 2026.
                </P>
                <P>A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.</P>
                <P>
                    For further information, contact John Frye at 
                    <E T="03">John.Frye@trade.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Elizabeth Whiteman,</NAME>
                    <TITLE>Executive Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15401 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[C-469-818]</DEPDOC>
                <SUBJECT>Ripe Olives From Spain: Final Results of Countervailing Duty Administrative Review; 2023</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that certain exporters/producers of ripe olives from Spain received countervailable subsidies during the period of review (POR) January 1, 2023, through December 31, 2023.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Ted Pearson or Stefan Smith, AD/CVD Operations, Office I, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-2631 or (202) 482-4342, respectively.</P>
                    <HD SOURCE="HD1">Background</HD>
                    <P>
                        On February 10, 2026, Commerce published the 
                        <E T="03">Preliminary Results</E>
                         of this administrative review in the 
                        <E T="04">Federal Register</E>
                        .
                        <SU>1</SU>
                        <FTREF/>
                         From March 9, 2026, through March 13 2026, Commerce conducted verification of the data and information submitted by Agro Sevilla Aceitunas, S.Coop.And. and Angel Camacho Alimentacion, S.L., as well as their unaffiliated olive growers.
                        <SU>2</SU>
                        <FTREF/>
                         Subsequently, on March 27, 2026, we invited interested parties to comment on the 
                        <E T="03">Preliminary Results</E>
                         and verification.
                        <SU>3</SU>
                        <FTREF/>
                         On June 3, 2026, Commerce extended the final results by 42 days.
                        <SU>4</SU>
                        <FTREF/>
                         Accordingly, the deadline for the final results is now July 22, 2026.
                        <SU>5</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>1</SU>
                             
                            <E T="03">See Ripe Olives from Spain: Preliminary Results and Partial Rescission of Countervailing Duty Administrative Review; 2023,</E>
                             91 FR 5918 (February 10, 2026) (
                            <E T="03">Preliminary Results</E>
                            ).
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>2</SU>
                             
                            <E T="03">See</E>
                             Memorandum, “Verification of the Questionnaire Responses of Angel Camacho Alimentacion, S.L.,” dated March 24, 2026; 
                            <E T="03">see also</E>
                             Memorandum, “Verification of Agro Sevilla Aceitunas, S.Coop.And,” dated March 23, 2026.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>3</SU>
                             
                            <E T="03">See</E>
                             Memorandum, “Briefing Schedule,” dated March 27, 2026.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>4</SU>
                             See Memorandum, “Extension of Deadline for Final Results of Countervailing Duty Administrative Review,” dated June 3, 2026.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>5</SU>
                             
                            <E T="03">Id.</E>
                        </P>
                    </FTNT>
                    <P>
                        For a complete description of the events that occurred since the 
                        <E T="03">Preliminary Results, see</E>
                         the Issues and Decision Memorandum.
                        <SU>6</SU>
                        <FTREF/>
                         The Issues and Decision Memorandum is a public document and is on file electronically via ACCESS. ACCESS is available to registered users at 
                        <E T="03">https://access.trade.gov.</E>
                         In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                        <E T="03">https://access.trade.gov/frnotices.</E>
                    </P>
                    <FTNT>
                        <P>
                            <SU>6</SU>
                             
                            <E T="03">See</E>
                             Memorandum, “Issues and Decision Memorandum for the Final Results of the Countervailing Duty Administrative Review of Ripe Olives from Spain; 2023,” dated concurrently with, and hereby adopted by, this notice (Issues and Decision Memorandum).
                        </P>
                    </FTNT>
                    <HD SOURCE="HD1">Scope of the Order</HD>
                    <P>
                        The products covered by the 
                        <E T="03">Order</E>
                         are ripe olives from Spain. For a complete description of the scope of the 
                        <E T="03">Order, see</E>
                         the Issues and Decision Memorandum.
                    </P>
                    <HD SOURCE="HD1">Analysis of Comments Received</HD>
                    <P>All issues raised by interested parties in their case and rebuttal briefs are addressed in the Issues and Decision Memorandum. The topics discussed and the issues raised by parties to which we responded in the Issues and Decision Memorandum are listed in the appendix to this notice.</P>
                    <HD SOURCE="HD1">Changes Since the Preliminary Results</HD>
                    <P>
                        Based on our analysis of comments received from interested parties and verification findings, we made changes to our denominator calculations, applications of adverse facts available, and programs determined to be countervailable from the 
                        <E T="03">Preliminary Results.</E>
                        <SU>7</SU>
                        <FTREF/>
                         For a discussion of these changes, 
                        <E T="03">see</E>
                         the Issues and Decision Memorandum.
                    </P>
                    <FTNT>
                        <P>
                            <SU>7</SU>
                             
                            <E T="03">See Preliminary Results.</E>
                        </P>
                    </FTNT>
                    <HD SOURCE="HD1">Methodology</HD>
                    <P>
                        Commerce conducted this administrative review in accordance with section 751(a)(1)(A) of the Act. For each of the subsidy programs found to be countervailable, we determine that there is a subsidy, 
                        <E T="03">i.e.,</E>
                         a government-provided financial contribution that gives rise to a benefit to the recipient, 
                        <PRTPAGE P="48063"/>
                        and that the subsidy is specific.
                        <SU>8</SU>
                        <FTREF/>
                         In these final results, Commerce relied, in part, on facts otherwise available, including with an adverse inference, pursuant to sections 776(a) and (b) of the Act. For a complete description of the methodology underlying all of Commerce's conclusions, 
                        <E T="03">see</E>
                         the Issues and Decision Memorandum.
                    </P>
                    <FTNT>
                        <P>
                            <SU>8</SU>
                             
                            <E T="03">See</E>
                             sections 771(5)(B) and (D) of the Act regarding financial contribution; section 771(5)(E) of the Act regarding benefit; and section 771(5A) of the Act regarding specificity.
                        </P>
                    </FTNT>
                    <HD SOURCE="HD1">Final Results of Review</HD>
                    <P>Commerce determined the following net countervailable subsidy rates exist for the period January 1, 2023, through December 31, 2023:</P>
                    <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s50,12">
                        <TTITLE> </TTITLE>
                        <BOXHD>
                            <CHED H="1">Producer/exporter</CHED>
                            <CHED H="1">
                                Subsidy rate
                                <LI>
                                    (percent 
                                    <E T="03">ad valorem</E>
                                    )
                                </LI>
                            </CHED>
                        </BOXHD>
                        <ROW>
                            <ENT I="01">Agro Sevilla Aceitunas S.Coop.And</ENT>
                            <ENT>4.80</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">
                                Angel Camacho Alimentación, S.L. and its cross-owned affiliates 
                                <SU>9</SU>
                            </ENT>
                            <ENT>25.21</ENT>
                        </ROW>
                    </GPOTABLE>
                    <HD SOURCE="HD1">
                        Disclosure
                        <FTREF/>
                    </HD>
                    <FTNT>
                        <P>
                            <SU>9</SU>
                             Commerce found the following companies to be cross-owned with Angel Camacho Alimentación, S.L.: Grupo Angel Camacho, S.L., Cuarterola S.L., and Cucanoche S.L.
                        </P>
                    </FTNT>
                    <P>
                        Commerce intends to disclose the calculations and analysis performed for these final results of review within five days of the date of publication of this notice in the 
                        <E T="04">Federal Register</E>
                        , in accordance with 19 CFR 351.224(b).
                    </P>
                    <HD SOURCE="HD1">Assessment</HD>
                    <P>
                        Pursuant to 19 CFR 351.212(b)(2), Commerce has determined, and U.S Customs and Border Protection (CBP) shall assess, countervailing duties on all appropriate entries covered by this review. Commerce intends to issue assessment instructions to CBP no earlier than 35 days after publication of the final results of this review in the 
                        <E T="04">Federal Register</E>
                        . If a timely summons is filed at the U.S. Court of International Trade, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired (
                        <E T="03">i.e.,</E>
                         within 90 days of publication).
                    </P>
                    <HD SOURCE="HD1">Cash Deposit Requirements</HD>
                    <P>
                        In accordance with section 751(a)(1) of the Act, we also intend to instruct CBP to collect cash deposits of estimated countervailing duties in the amounts shown above for the above-listed companies with regard to shipments of subject merchandise entered, or withdrawn from warehouse, for consumption on or after the date of publication of these final results of review. For all non-reviewed firms subject to the 
                        <E T="03">Order,</E>
                         we will instruct CBP to continue to collect cash deposits of estimated countervailing duties at the most recent company-specific rate or the all-others rate (
                        <E T="03">i.e.,</E>
                         11.08 percent), as appropriate.
                        <SU>10</SU>
                        <FTREF/>
                         These cash deposit requirements, when imposed, shall remain in effect until further notice.
                    </P>
                    <FTNT>
                        <P>
                            <SU>10</SU>
                             
                            <E T="03">See Ripe Olives from Spain: Implementation of Determination Under Section 129 of the Uruguay Round Agreements Act,</E>
                             88 FR 3384 (January 19, 2023).
                        </P>
                    </FTNT>
                    <HD SOURCE="HD1">Administrative Protective Order (APO)</HD>
                    <P>This notice also serves as a final reminder to parties subject to an APO of their responsibility concerning the disposition of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3). Timely written notification of the return or destruction of APO materials or conversion to judicial protective order, is hereby requested. Failure to comply with the regulations and terms of an APO is a sanctionable violation.</P>
                    <HD SOURCE="HD1">Notification to Interested Parties</HD>
                    <P>These final results are issued and published in accordance with sections 751(a)(1) and 777(i)(1) of the Act, and 19 CFR 351.221(b)(5).</P>
                    <SIG>
                        <DATED>Dated: July 22, 2026.</DATED>
                        <NAME>Christopher Abbott,</NAME>
                        <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                    </SIG>
                    <HD SOURCE="HD1">Appendix—List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <EXTRACT>
                        <FP SOURCE="FP-2">I. Summary</FP>
                        <FP SOURCE="FP-2">II. Background</FP>
                        <FP SOURCE="FP-2">
                            III. Scope of the 
                            <E T="03">Order</E>
                        </FP>
                        <FP SOURCE="FP-2">IV. Subsidies Valuation</FP>
                        <FP SOURCE="FP-2">V. Use of Facts Otherwise Available and Adverse Inferences</FP>
                        <FP SOURCE="FP-2">VI. Analysis of Programs</FP>
                        <FP SOURCE="FP-2">VII. Discussion of the Issues</FP>
                        <FP SOURCE="FP1-2">Comment 1: Whether Commerce Should Find Two Other Subsidy Programs Countervailable</FP>
                        <FP SOURCE="FP1-2">Comment 2: Whether Commerce Should Apply Adverse Facts Available to Benefits Provided as Minor Corrections</FP>
                        <FP SOURCE="FP1-2">Comment 3: Whether Commerce Should Apply Facts Available to Additional Growers</FP>
                        <FP SOURCE="FP1-2">Comment 4: Whether Commerce Should Assign Adverse Facts Available to Growers Who Reported No Benefits Under Certain Programs</FP>
                        <FP SOURCE="FP1-2">Comment 5: Whether Commerce Should Correct Camacho Supplier 2's Raw Olive Sales to Olive and Olive-Derived Product Sales</FP>
                        <FP SOURCE="FP1-2">Comment 6: Whether Commerce Should Correct the Volume for Camacho Grower 6.A for Certain Programs</FP>
                        <FP SOURCE="FP1-2">Comment 7: Whether Commerce Should Revise the Substantial Dependence Calculation</FP>
                        <FP SOURCE="FP1-2">Comment 8: Whether Commerce Should Revise its Facts Available Methodology for Growers that Provided Insufficient Information</FP>
                        <FP SOURCE="FP-2">VIII. Recommendation </FP>
                    </EXTRACT>
                </FURINF>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15400 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[A-552-853]</DEPDOC>
                <SUBJECT>Steel Concrete Reinforcing Bar From the Socialist Republic of Vietnam: Final Affirmative Determination of Sales at Less Than Fair Value</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that steel concrete reinforcing bar (rebar) from the Socialist Republic of Vietnam (Vietnam) is being, or is likely to be, sold in the United States at less than fair value (LTFV). The period of investigation (POI) is October 1, 2024, through March 31, 2025.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Kate Fracke, AD/CVD Operations, Office III, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-3299.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On March 13, 2026, Commerce published in the 
                    <E T="04">Federal Register</E>
                     its preliminary affirmative determination in the LTFV investigation of steel concrete reinforcing bar from Vietnam, in which it also postponed the final determination until July 27, 2026.
                    <SU>1</SU>
                    <FTREF/>
                     We invited interested parties to comment on the 
                    <E T="03">Preliminary Determination.</E>
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam: Preliminary Affirmative Determination of Sales at Less Than Fair Value, Postponement of Final Determination and Extension of Provisional Measures,</E>
                         91 FR 12359 (March 13, 2026) (
                        <E T="03">Preliminary Determination</E>
                        ), and accompanying Preliminary Decision Memorandum (PDM).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">Id.,</E>
                         91 FR 12360-61.
                    </P>
                </FTNT>
                <P>
                    A summary of the events that occurred since the 
                    <E T="03">Preliminary Determination,</E>
                     as well as a full discussion of the issues raised by 
                    <PRTPAGE P="48064"/>
                    interested parties for this final determination, may be found in the Issues and Decision Memorandum.
                    <SU>3</SU>
                    <FTREF/>
                     The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at 
                    <E T="03">http://access.trade.gov.</E>
                     In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Issues and Decision Memorandum for the Final Affirmative Determination in the Less-Than Fair-Value Investigation of Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam,” dated concurrently with, and hereby adopted by, this notice (Issues and Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The product covered by this investigation is rebar from Vietnam. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the preamble to Commerce's regulations,
                    <SU>4</SU>
                    <FTREF/>
                     the 
                    <E T="03">Initiation Notice</E>
                     set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>5</SU>
                    <FTREF/>
                     No interested party commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     Therefore, Commerce is not modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Algeria, Bulgaria, Egypt, and the Socialist Republic of Vietnam: Initiation of Less-Than-Fair-Value Investigations,</E>
                         90 FR 27846 (June 30, 2025) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Verification</HD>
                <P>Commerce conducted verification of the information relied upon in making its final determination in this investigation, in accordance with section 782(i) of the Tariff Act of 1930, as amended (the Act). Specifically, we conducted on-site verifications of sales and factors of production information submitted by Hoa Phat Dung Quat Steel Joint Stock Company (HPDQ), Hoa Phat Hai Duong Steel Joint Stock Company (HPHD), Hoa Phat Hung Yen Steel Limited Liability Company (HPHY), and Hoa Phat Prestressed Concrete Company Limited (HPPC) (collectively, Hoa Phat Steel), for use in our final determination. We used standard verification procedures, including an examination of relevant sales and accounting records, and original source documents provided by Hoa Phat Steel.</P>
                <HD SOURCE="HD1">Analysis of Comments Received</HD>
                <P>
                    All issues raised in the case and rebuttal briefs submitted by interested parties in this investigation are addressed in the Issues and Decision Memorandum. For a list of the issues raised by interested parties and addressed in the Issues and Decision Memorandum, 
                    <E T="03">see</E>
                     Appendix II to this notice.
                </P>
                <HD SOURCE="HD1">Changes Since the Preliminary Determination</HD>
                <P>
                    Based on Commerce's analysis of the comments received and findings at verification, we made certain changes since the 
                    <E T="03">Preliminary Determination.</E>
                     For a discussion of these changes, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <HD SOURCE="HD1">Vietnam-Wide Entity and Use of Adverse Facts Available</HD>
                <P>
                    Consistent with the 
                    <E T="03">Preliminary Determination,</E>
                     Commerce continues to find, pursuant to sections 776(a) and (b) of the Act, that the use of facts otherwise available, with adverse inferences (AFA), is warranted in determining the dumping rate for the Vietnam-wide entity. For this final determination, there is no new information on the record that would cause us to reconsider our preliminary decision.
                    <SU>6</SU>
                    <FTREF/>
                     As AFA, we assigned the rate of 136.57 percent to the Vietnam-wide entity. For a full description of the methodology underlying Commerce's final determination, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Preliminary Determination, 91 FR at 12360.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Separate Rates</HD>
                <P>
                    In the 
                    <E T="03">Preliminary Determination,</E>
                     we preliminarily granted a separate rate to Hoa Phat Steel. We received no comments from interested parties on Commerce's preliminary separate rate determination for Hoa Phat Steel. Accordingly, we continue to find that Hoa Phat Steel is eligible for a separate rate.
                </P>
                <HD SOURCE="HD1">Combination Rates</HD>
                <P>
                    Consistent with the 
                    <E T="03">Initiation Notice,</E>
                     the 
                    <E T="03">Preliminary Determination,</E>
                     and Policy Bulletin 05.1,
                    <SU>7</SU>
                    <FTREF/>
                     Commerce calculated a combination rate for Hoa Phat Steel, which is the sole respondent eligible for a separate rate in this investigation.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See</E>
                         Enforcement and Compliance's Policy Bulletin No. 05.1, regarding, “Separate-Rates Practice and Application of Combination Rates in Antidumping Investigations involving Non-Market Economy Countries,” dated April 5, 2005 (Policy Bulletin 05.1), available on Commerce's website at 
                        <E T="03">https://www.trade.gov/enforcement-and-compliance-policy-bulletins-0.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Final Determination</HD>
                <P>
                    Commerce determines that the following estimated weighted-average dumping margins exist:
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Commerce preliminarily determined that Hoa Phat Dung Quat Steel Joint Stock Company, Hoa Phat Hai Duong Steel Joint Stock Company, Hoa Phat Hung Yen Steel Limited Liability Company, and Hoa Phat Prestressed Concrete Company Limited (collectively, Hoa Phat Steel) are a single entity. 
                        <E T="03">See</E>
                         Preliminary Decision Memorandum. Because no party commented on Commerce's preliminary collapsing determination, we continue to find HPDQ, HPHD, HPHY, and HPPC, are a single entity.
                    </P>
                </FTNT>
                <GPOTABLE COLS="4" OPTS="L2,nj,tp0,i1" CDEF="s100,r100,12,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Producer</CHED>
                        <CHED H="1">Exporter</CHED>
                        <CHED H="1">
                            Weighted-
                            <LI>average</LI>
                            <LI>dumping</LI>
                            <LI>margin</LI>
                            <LI>(percent)</LI>
                        </CHED>
                        <CHED H="1">
                            Cash deposit
                            <LI>rate</LI>
                            <LI>(adjusted for</LI>
                            <LI>subsidy offsets</LI>
                            <LI>(percent)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">
                            Hoa Phat Dung Quat Steel Joint Stock Company; Hoa Phat Hai Duong Steel Joint Stock Company; Hoa Phat Hung Yen Steel Limited Liability Company; and Hoa Phat Prestressed Concrete Company Limited 
                            <SU>8</SU>
                        </ENT>
                        <ENT>Hoa Phat Dung Quat Steel Joint Stock Company; Hoa Phat Hai Duong Steel Joint Stock Company</ENT>
                        <ENT>128.53</ENT>
                        <ENT>123.49</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Vietnam-Wide Entity</ENT>
                        <ENT/>
                        <ENT>* 136.57</ENT>
                        <ENT>131.53</ENT>
                    </ROW>
                    <TNOTE>* Rate based on facts available with adverse inferences.</TNOTE>
                </GPOTABLE>
                <PRTPAGE P="48065"/>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    We intend to disclose the calculations and analysis performed to interested parties in this final determination within five days of its public announcement, or if there is no public announcement, within five days of the date of the publication of this notice in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b).
                </P>
                <HD SOURCE="HD1">Continuation of Suspension of Liquidation</HD>
                <P>
                    In accordance with section 735(c)(1)(B) of the Act, we will instruct U.S. Customs and Border Protection (CBP) to continue to suspend liquidation of all appropriate entries of subject merchandise, as described in Appendix I of this notice, which are entered, or withdrawn from warehouse, for consumption on or after March 13, 2026, the date of publication of the 
                    <E T="03">Preliminary Determination</E>
                     in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <P>Pursuant to section 735(c)(1)(B)(ii) of the Act and 19 CFR 351.210(d), Commerce will instruct CBP to require the following cash deposits of estimated antidumping duties for all appropriate entries: (1) for the producer/exporter combinations listed in the table above, the applicable cash deposit rate will be equal to the estimated weighted-average dumping margin listed in the table for that combination, adjusted for subsidy offsets, if appropriate; (2) for all combinations of Vietnamese producers/exporters of the subject merchandise that have not established eligibility for separate rates, the cash deposit rate will be equal to the estimated weighted-average dumping margin established for the Vietnam-wide entity, adjusted for subsidy offsets if appropriate; and (3) for all third country exporters of subject merchandise not listed in the table above, the cash deposit rate is the cash deposit rate applicable to the Vietnam producer/exporter combination (or Vietnam-wide entity) that supplied that third county exporter or, if the producer/exporter combination does not have its own rate, the cash deposit will be the cash deposit rate for the Vietnam-wide entity. These suspension of liquidation instructions and cash deposit requirements will remain in effect until further notice.</P>
                <P>
                    To determine the cash deposit rate, Commerce normally adjusts the estimated weighted average dumping margin by the amount of domestic pass-through and export subsidies countervailed in a companion countervailing duty (CVD) proceeding, when CVD provisional measures are in effect. Accordingly, where Commerce has made a final affirmative determination for domestic pass-through or export subsidies, Commerce offsets the estimated weighted-average dumping margin by the appropriate CVD rate. Commerce is adjusting the cash deposit rate for export subsidies found in the companion CVD investigation by the appropriate export subsidy rate; however, the suspension of liquidation of provisional measures in the companion CVD case has been discontinued.
                    <SU>9</SU>
                    <FTREF/>
                     Therefore, we are not instructing CBP to collect cash deposits based on the adjusted estimated weighted-average dumping margin for export subsidies at this time. If the U.S. International Trade Commission (ITC) makes a final affirmative determination of injury due to both dumping and subsidies, then the cash deposit rate will be revised effective on the date of publication of the ITC's final affirmative determination in the 
                    <E T="04">Federal Register</E>
                     to be the company-specific estimated weighted-average dumping margin adjusted for export subsidies.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination with Final Antidumping Duty Determination,</E>
                         91 FR 1265 (January 13, 2026); 
                        <E T="03">see also</E>
                         section 703(d) of the Act, which states that the provisional measures may not be in effect for more than four months, which in the companion CVD case is 120 days after the publication of the preliminary determination, or May 12, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">ITC Notification</HD>
                <P>In accordance with section 735(d) of the Act, Commerce will notify the ITC of its final affirmative determination of sales at LTFV. We will allow the ITC access to all privileged and business proprietary information in our files, provided the ITC confirms that it will not disclose such information, either publicly or under an administrative protective order (APO), without the written consent of the Assistant Secretary for Enforcement and Compliance.</P>
                <P>Because the final determination in this proceeding is affirmative, in accordance with section 735(b)(2) of the Act, the ITC will make its final determination as to whether the domestic industry in the United States is materially injured, or threatened with material injury, by reason of imports of steel concrete reinforcing bar from Vietnam no later than 45 days after our final determination. If the ITC determines that material injury or threat of material injury does not exist, the proceeding will be terminated, and all cash deposits will be refunded. If the ITC determines that such injury does exist, Commerce intends to issue an antidumping duty order, in accordance with section 736(a) of the Act, directing CBP to assess, upon further instruction by Commerce, antidumping duties on all imports of the subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation, as discussed above in the “Continuation of Suspension of Liquidation” section.</P>
                <HD SOURCE="HD1">Administrative Protective Order</HD>
                <P>This notice serves as a final reminder to parties subject to an APO of their responsibility concerning the disposition of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3). Timely written notification of the return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This determination is issued and published in accordance with sections 735(d) and 777(i) of the Act and 19 CFR 351.210(c).</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Scope of the Investigation</HD>
                    <P>The merchandise subject to this investigation is steel concrete reinforcing bar imported in either straight length or coil form (rebar) regardless of metallurgy, length, diameter, or grade or lack thereof.</P>
                    <P>The subject merchandise includes rebar that has been further processed in the subject countries or a third country, including but not limited to cutting, grinding, galvanizing, painting, coating, or any other processing that would not otherwise remove the merchandise from the scope of this investigation if performed in the country of manufacture of the rebar.</P>
                    <P>
                        Specifically excluded are plain rounds (
                        <E T="03">i.e.,</E>
                         nondeformed or smooth rebar).
                    </P>
                    <P>The subject merchandise is classifiable in the Harmonized Tariff Schedule of the United States (HTSUS) primarily under item numbers 7213.10.0000, 7214.20.0000, and 7228.30.8010. The subject merchandise may also enter under other HTSUS numbers including 7221.00.0017, 7221.00.0018, 7221.00.0030, 7221.00.0045, 7222.11.0001, 7222.11.0057, 7222.11.0059, 7222.30.0001, 7227.20.0080, 7227.90.6030, 7227.90.6035, 7227.90.6040, 7228.20.1000, and 7228.60.6000. HTSUS numbers are provided for convenience and customs purposes; however, the written description of the scope remains dispositive.</P>
                </EXTRACT>
                <PRTPAGE P="48066"/>
                <HD SOURCE="HD1">Appendix II</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">III. Adjustment to Cash Deposit Rate for Export Subsidies</FP>
                    <FP SOURCE="FP-2">
                        IV. Changes Since the 
                        <E T="03">Preliminary Determination</E>
                    </FP>
                    <FP SOURCE="FP-2">V. Application of Facts Available and Use of Adverse Inference</FP>
                    <FP SOURCE="FP-2">VI. Discussion of the Issues</FP>
                    <FP SOURCE="FP1-2">Comment 1: Whether To Apply Partial Adverse Facts Available (AFA) to Hoa Phat Steel's Unreported U.S. Sales</FP>
                    <FP SOURCE="FP1-2">Comment 2: Whether To Apply Partial AFA to Hoa Phat Steel's Unreported Water Consumption</FP>
                    <FP SOURCE="FP1-2">Comment 3: Whether To Value Crum Scrap Using Indonesian Harmonized System Number 7503.00</FP>
                    <FP SOURCE="FP1-2">Comment 4: Whether To Continue to Deny HPHY's and HPHD's By-Product Offsets</FP>
                    <FP SOURCE="FP1-2">Comment 5: Whether To Value Labor Using International Labor Organization Laborstat Data</FP>
                    <FP SOURCE="FP1-2">Comment 6: Whether To Rely on the Surrogate Companies Proposed by Hoa Phat Steel to Calculate Surrogate Financial Ratios</FP>
                    <FP SOURCE="FP1-2">Comment 7: Whether To Offset Stelling, General, and Administrative Expenses with Financial Income in the Surrogate Financial Ratios</FP>
                    <FP SOURCE="FP1-2">Comment 8: Whether To Include Gains on the Foreign Exchange in the Surrogate Profit Ratio</FP>
                    <FP SOURCE="FP1-2">Comment 9: Whether To Include Direct Labor in the Surrogate Financial Ratios</FP>
                    <FP SOURCE="FP1-2">Comment 10: Whether To Change the Surrogate Value for HPHD's GAS_GAS Input</FP>
                    <FP SOURCE="FP-2">VII. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15438 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[A-729-805]</DEPDOC>
                <SUBJECT>Steel Concrete Reinforcing Bar From Egypt: Final Affirmative Determination of Sales at Less Than Fair Value</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that steel concrete reinforcing bar (rebar) from Egypt is being, or is likely to be, sold in the United States at less than fair value (LTFV). The period of investigation is April 1, 2024, through March 31, 2025.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Anne Entz or Ajay Menon, AD/CVD Operations, Office IX, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-3845 or (202) 482-0208.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On March 13, 2026, Commerce published in the 
                    <E T="04">Federal Register</E>
                     the preliminary affirmative determination in the LTFV investigation of rebar from Egypt and postponed the final determination until 135 days after the date of publication of the 
                    <E T="03">Preliminary Determination.</E>
                    <SU>1</SU>
                    <FTREF/>
                     Accordingly, the deadline for this final determination is now July 27, 2026. We invited interested parties to comment on the 
                    <E T="03">Preliminary Determination.</E>
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Egypt: Preliminary Affirmative Determination of Sales at Less Than Fair Value, Postponement of Final Determination, and Extension of Provisional Measures,</E>
                         91 FR 12347 (March 13, 2026) (
                        <E T="03">Preliminary Determination</E>
                        ), and accompanying Preliminary Decision Memorandum.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See Preliminary Determination,</E>
                         91 FR at 12348.
                    </P>
                </FTNT>
                <P>
                    A summary of the events that occurred since Commerce published the 
                    <E T="03">Preliminary Determination,</E>
                     as well as a full discussion of the issues raised by parties for this final determination, may be found in the Issues and Decision Memorandum.
                    <SU>3</SU>
                    <FTREF/>
                     The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                     In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Issues and Decision Memorandum for the Final Determination in the Less-Than-Fair-Value Investigation of Steel Concrete Reinforcing Bar from Egypt,” dated concurrently with, and herby adopted by, this notice (Issues and Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The product covered by this investigation is rebar from Egypt. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the preamble to Commerce's regulations,
                    <SU>4</SU>
                    <FTREF/>
                     the 
                    <E T="03">Initiation Notice</E>
                     set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>5</SU>
                    <FTREF/>
                     No interested party commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     Therefore, Commerce is not modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Algeria, Bulgaria, Egypt, and the Socialist Republic of Vietnam: Initiation of Less-Than-Fair-Value Investigations,</E>
                         90 FR 27846 (June 30, 2025) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Verification</HD>
                <P>
                    Commerce was unable to conduct on-site verification of the information relied on in making its final determination in this investigation. However, in March and April 2026, we took additional steps in lieu of on-site verification to verify the information relied upon in making this final determination, in accordance with section 782(i) of the Tariff Act of 1930, as amended (the Act), by conducting virtual verifications of the mandatory respondent Al-Ezz Dekheila Steel Alexandria Company S.A.E, Ezz Steel Company S.A.E., Ezz Rolling Mills Company S.A.E, and Al-Ezz Flat Steel Company S.A.E. (collectively, the Ezz Group).
                    <SU>6</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Verification of the Sales Response of the Ezz Group in the Antidumping Investigation of Steel Concrete Reinforcing Bar from Egypt,” dated Jun 9, 2026; 
                        <E T="03">see also</E>
                         Memorandum, “Verification of the Cost Response of Al-Ezz Dekheila Steel Alexandria Company S.A.E. in the Less-Than-Fair-Value Investigation of Steel Concrete Reinforcing Bar from the Arab Republic of Egypt,” dated May 18, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Analysis of Comments Received</HD>
                <P>
                    All issues raised in the case and rebuttal briefs submitted by interested parties in this investigation are addressed in the Issues and Decision Memorandum. For a list of the issues addressed in the Issues and Decision Memorandum, 
                    <E T="03">see</E>
                     Appendix II.
                </P>
                <HD SOURCE="HD1">Changes Since the Preliminary Determination</HD>
                <P>
                    We made certain changes to our calculations in the 
                    <E T="03">Preliminary Determination;</E>
                     however, they did not change the weighted-average dumping margin calculated for the Ezz Group. For a discussion of these changes, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <HD SOURCE="HD1">All-Others Rate</HD>
                <P>
                    Section 735(c)(5)(A) of the Act provides that Commerce shall determine an estimated all-others rate for all exporters and producers not individually examined. This rate shall be an amount equal to the weighted average of the estimated weighted-average dumping margins established for exporters and producers individually investigated, excluding rates that are zero, 
                    <E T="03">de minimis</E>
                     margins, or determined entirely under section 776 of the Act. In this investigation, Commerce calculated an individual estimated weighted-average dumping 
                    <PRTPAGE P="48067"/>
                    margin for the Ezz Group. Because the Ezz Group's dumping margin is the only individually calculated dumping margin that is not zero, 
                    <E T="03">de minimis,</E>
                     or based entirely on facts otherwise, the rate calculated for the Ezz Group is also the rate assigned to all other producers and exporters.
                </P>
                <HD SOURCE="HD1">Final Determination</HD>
                <P>Commerce determines that the following estimated weighted-average dumping margins exist for the POI, April 1, 2024, through March 31, 2025:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s100,15">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Exporter/producer</CHED>
                        <CHED H="1">
                            Weighted-average dumping margin
                            <LI>(percent)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Al-Ezz Dekheila Steel Alexandria Company S.A.E; Ezz Steel Company S.A.E.; Ezz Rolling Mills Company S.A.E.; and Al-Ezz Flat Steel Company S.A.E</ENT>
                        <ENT>34.20</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">El Marakby Steel</ENT>
                        <ENT>* 52.73</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Suez Steel Company</ENT>
                        <ENT>* 52.73</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">All Others</ENT>
                        <ENT>34.20</ENT>
                    </ROW>
                    <TNOTE>* Rate based on facts available with adverse inferences.</TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    Commerce intends to disclose the calculations performed in connection with this final determination to interested parties within five days of any public announcement or, if there is no public announcement, within five days of the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b).
                </P>
                <HD SOURCE="HD1">Continuation of Suspension of Liquidation</HD>
                <P>
                    In accordance with section 735(c)(1)(B) of the Act, Commerce will instruct U.S. Customs and Border Protection (CBP) to continue to suspend liquidation of all entries of subject merchandise, as described in Appendix I of this notice, which were entered, or withdrawn from warehouse, for consumption on or after March 13, 2026, the date of publication of the 
                    <E T="03">Preliminary Determination</E>
                     in the 
                    <E T="04">Federal Register</E>
                    . These suspension of liquidation instructions will remain in effect until further notice.
                </P>
                <P>Pursuant to section 735(c)(1)(B)(ii) of the Act and 19 CFR 351.210(d), Commerce will instruct CBP to require a cash deposit equal to the estimated weighted-average antidumping margin or the estimated all-others rate, as follows: (1) the cash deposit rate for the companies listed in the table above will be equal to the company-specific estimated weighted-average dumping margin determined in this final determination; (2) if the exporter is not a respondent listed in the table above, but the producer is, then the cash deposit rate will be equal to the company-specific estimated weighted-average dumping margin listed for the producer of the subject merchandise; and (3) the cash deposit rate for all other producers and exporters will be equal to the estimated weighted-average dumping margin for all other producers and exporters listed in the table above.</P>
                <HD SOURCE="HD1">U.S. International Trade Commission (ITC) Notification</HD>
                <P>In accordance with section 735(d) of the Act, Commerce will notify the ITC of our final affirmative determination of sales at LTFV. Because the final determination in this proceeding is affirmative, in accordance with sections 735(b)(2) of the Act, the ITC will make its final determination as to whether the domestic industry in the United States is materially injured, or threatened with material injury, by reason of imports of rebar from Egypt no later than 45 days after this final determination. If the ITC determines that such injury does not exist, this proceeding will be terminated, all cash deposits posted will be refunded, and suspension of liquidation will be lifted. If the ITC determines that such injury does exist, Commerce will issue an antidumping duty order directing CBP to assess, upon further instruction by Commerce, antidumping duties on all imports of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation, as discussed in the “Continuation of Suspension of Liquidation” section above.</P>
                <HD SOURCE="HD1">Administrative Protective Order (APO)</HD>
                <P>This notice serves as a final reminder to parties subject to an APO of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3), which continues to govern business proprietary information in this segment of the proceeding. Timely written notification of the return or destruction of APO materials, or conversion to judicial protective order, is hereby requested. Failure to comply with the regulations and the terms of an APO is a violation subject to sanction.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This final determination is issued and published in accordance with sections 735(d) and 777(i) of the Act, and 19 CFR 351.210(c).</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Scope of the Investigation</HD>
                    <P>The merchandise subject to this investigation is steel concrete reinforcing bar imported in either straight length or coil form (rebar) regardless of metallurgy, length, diameter, or grade or lack thereof.</P>
                    <P>The subject merchandise includes rebar that has been further processed in the subject country or a third country, including but not limited to cutting, grinding, galvanizing, painting, coating, or any other processing that would not otherwise remove the merchandise from the scope of this investigation if performed in the country of manufacture of the rebar.</P>
                    <P>
                        Specifically excluded are plain rounds (
                        <E T="03">i.e.,</E>
                         nondeformed or smooth rebar).
                    </P>
                    <P>The subject merchandise is classifiable in the Harmonized Tariff Schedule of the United States (HTSUS) primarily under item numbers 7213.10.0000, 7214.20.0000, and 7228.30.8010. The subject merchandise may also enter under other HTSUS numbers including 7221.00.0017, 7221.00.0018, 7221.00.0030, 7221.00.0045, 7222.11.0001, 7222.11.0057, 7222.11.0059, 7222.30.0001, 7227.20.0080, 7227.90.6030, 7227.90.6035, 7227.90.6040, 7228.20.1000, and 7228.60.6000. HTSUS numbers are provided for convenience and customs purposes; however, the written description of the scope remains dispositive.</P>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">
                        III. Changes Since the 
                        <E T="03">Preliminary Determination</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        IV. Application of Facts Available with 
                        <PRTPAGE P="48068"/>
                        Adverse Inference
                    </FP>
                    <FP SOURCE="FP-2">V. Discussion of the Issues</FP>
                    <FP SOURCE="FP1-2">Comment 1: Whether to Apply Adverse Facts Available to Suez Steel</FP>
                    <FP SOURCE="FP1-2">Comment 2: The Ezz Group's Post-Sale Billing Adjustments</FP>
                    <FP SOURCE="FP1-2">Comment 3: Treatment of the Ezz Group's Home Market Bank Charges</FP>
                    <FP SOURCE="FP1-2">Comment 4: EZDK's General and Administrative Expense Ratio</FP>
                    <FP SOURCE="FP-2">VI. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15440 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[C-729-806]</DEPDOC>
                <SUBJECT>Steel Concrete Reinforcing Bar From Egypt: Final Affirmative Countervailing Duty Determination</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that countervailable subsidies are being provided to producers and exporters of steel concrete reinforcing bar (rebar) from Egypt during the period of investigation (POI), January 1, 2024, through December 31, 2024.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Roee Tenne or Lingjun Wang, AD/CVD Operations, Office VII, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-3996 or (202) 482-2316, respectively.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On January 13, 2026, Commerce published in the 
                    <E T="04">Federal Register</E>
                     the 
                    <E T="03">Preliminary Determination</E>
                     and invited comments from interested parties.
                    <SU>1</SU>
                    <FTREF/>
                     For a complete description of the events that occurred since Commerce published the 
                    <E T="03">Preliminary Determination,</E>
                     as well as a full discussion of the issues raised by parties for this final determination, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                    <SU>2</SU>
                    <FTREF/>
                     The Issues and Decision Memorandum is a public document and is on file electronically via ACCESS. ACCESS is available to registered users at 
                    <E T="03">http://access.trade.gov.</E>
                     In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Egypt: Preliminary Affirmative Countervailing Duty Determination, and Alignment of Final Determination with Final Antidumping Duty Determination,</E>
                         91 FR 1263 (January 13, 2026) (
                        <E T="03">Preliminary Determination</E>
                        ), and accompanying Preliminary Decision Memorandum.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Issues and Decision Memorandum for the Final Affirmative Determination of in the Countervailing Duty Investigation of Steel Concrete Reinforcing Bar from Egypt,” dated concurrently with, and hereby adopted by, this notice (Issues and Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The product covered by this investigation is rebar from Egypt. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the preamble to Commerce's regulations,
                    <SU>3</SU>
                    <FTREF/>
                     the 
                    <E T="03">Initiation Notice</E>
                     set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>4</SU>
                    <FTREF/>
                     No interested party commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     Therefore, Commerce is not modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Algeria, Bulgaria, Egypt, and the Socialist Republic of Vietnam: Initiation of Less-Than-Fair-Value Investigations,</E>
                         90 FR 27846 (June 30, 2025) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Verification</HD>
                <P>
                    Commerce conducted verification of the information relied upon in making its final determination in this investigation, in accordance with section 782(i) of the Tariff Act of 1930, as amended (the Act). Specifically, we conducted virtual verifications of the subsidy information reported by the Government of Egypt (GOE) and Ezz Group in April and May 2026 using standard verification procedures, including an examination of relevant sales and accounting records, and original source documents.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Verification of the Questionnaire Responses of the Government of Egypt,” dated May 27, 2026; 
                        <E T="03">see also</E>
                         Memorandum, “Verification of the Questionnaire Responses of Ezz Group,” dated May 27, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Analysis of Subsidy Programs and Comments Received</HD>
                <P>
                    The subsidy programs under investigation, and the issues raised in the case and rebuttal briefs that were submitted by parties in this investigation, are discussed in the Issues and Decision Memorandum. For a list of the issues raised by parties, and to which we responded in the Issues and Decision Memorandum, 
                    <E T="03">see</E>
                     Appendix II.
                </P>
                <HD SOURCE="HD1">Methodology</HD>
                <P>
                    Commerce conducted this investigation in accordance with section 701 the Act. For each of the subsidy programs found to be countervailable, Commerce determines that there is a subsidy, 
                    <E T="03">i.e.,</E>
                     a financial contribution by an “authority” that gives rise to a benefit to the recipient, and that the subsidy is specific.
                    <SU>6</SU>
                    <FTREF/>
                     For a full description of the methodology underlying our final determination, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         sections 771(5)(B) and (D) of the Act regarding financial contribution; 
                        <E T="03">see also</E>
                         section 771(5)(E) of the Act regarding benefit; and section 771(5A) of the Act regarding specificity.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Changes Since the Preliminary Determination</HD>
                <P>
                    We made certain changes to the countervailable subsidy rate calculations for Ezz Group. For a discussion of these changes, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <HD SOURCE="HD1">All-Others Rate</HD>
                <P>
                    Pursuant to section 705(c)(5)(A)(i) of the Act, Commerce will determine an all-others rate equal to the weighted average countervailable subsidy rates established for those exporters and/or producers individually investigated, excluding any zero and 
                    <E T="03">de minimis</E>
                     countervailable subsidy rates, and any rates based entirely under section 776 of the Act.
                </P>
                <P>
                    In this investigation, Commerce calculated an individual estimated countervailable subsidy rate for Ezz Group, the only individually examined exporter and producer in this investigation. Because the only individual calculated rate is not zero, 
                    <E T="03">de minimis,</E>
                     or based entirely on facts otherwise available, the rate calculated for Ezz Group is also assigned as the rate for all other producers and exporters, pursuant to section 705(c)(5)(A)(i) of the Act.
                </P>
                <HD SOURCE="HD1">Final Determination</HD>
                <P>
                    Commerce determines that the following estimated countervailable subsidy rates exist for the period January 1, 2024, through December 31, 2024:
                    <PRTPAGE P="48069"/>
                </P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s100,20">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Company</CHED>
                        <CHED H="1">
                            Subsidy rate
                            <LI>
                                (percent 
                                <E T="03">ad valorem</E>
                                )
                            </LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Al-Ezz Dekheila Steel Alexandria Company (SAE); Ezz Steel Company S.A.E.; Ezz Rolling Mills Company (SAE); Al-Ezz Flat Steel Company (SAE); Contra Steel Co.; Al-Ezz Group Holding Company for Industry &amp; Investment (collectively, Ezz Group)</ENT>
                        <ENT>23.27</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">All Others</ENT>
                        <ENT>23.27</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    Commerce intends to disclose its calculations and analysis performed to interested parties in this final determination within five days of its public announcement, or if there is no public announcement, within five days of the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b).
                </P>
                <HD SOURCE="HD1">Continuation of Suspension of Liquidation</HD>
                <P>
                    As a result of our 
                    <E T="03">Preliminary Determination,</E>
                     and pursuant to sections 703(d)(1)(B) and (d)(2) of the Act, we instructed U.S. Customs and Border Protection (CBP) to collect cash deposits and suspend liquidation of entries of subject merchandise, as described in the scope of the investigation section, that were entered, or withdrawn from warehouse, for consumption on or after January 13, 2026, the date of publication of the 
                    <E T="03">Preliminary Determination</E>
                     in the 
                    <E T="04">Federal Register</E>
                    , for entries produced and/or exported by Ezz Group and all other producers and exporters. In accordance with section 703(d) of the Act, we instructed CBP to discontinue the suspension of liquidation of all entries of subject merchandise entered or withdrawn from warehouse, on or after, May 13, 2026, but to continue the suspension of liquidation of all entries of subject merchandise that were subject to suspension of liquidation between January 13, 2026, and May 12, 2026.
                </P>
                <P>If the U.S. International Trade Commission (ITC) issues a final affirmative injury determination, we will issue a countervailing duty order, reinstate the suspension of liquidation under section 706(a) of the Act, and require a cash deposit of estimated countervailing duties for such entries of subject merchandise in the amounts indicated above, in accordance with section 706(a) of the Act. If the ITC determines that material injury, or threat of material injury, does not exist, this proceeding will be terminated, and all estimated duties deposited or securities posted as a result of the suspension of liquidation will be refunded or canceled.</P>
                <HD SOURCE="HD1">ITC Notification</HD>
                <P>In accordance with section 705(d) of the Act, Commerce will notify the ITC of its final affirmative determination that countervailable subsidies are being provided to producers and exporters of rebar from Egypt. Because the final determination is affirmative, in accordance with section 705(b) of the Act, the ITC will make its final determination as to whether the domestic industry in the United States is materially injured, or threatened with material injury, by reason of imports of rebar from Egypt no later than 45 days after this final determination. In addition, we are making available to ITC all non-privileged and nonproprietary information related to this investigation. We will allow the ITC access to all privileged and business proprietary information in our files, provided that the ITC confirms that it will not disclose such information, either publicly or under an administrative protective order (APO), without the written consent of the Assistant Secretary for Enforcement and Compliance. If the ITC determines that material injury or threat of material injury does not exist, this proceeding will be terminated, and all cash deposits will be refunded.</P>
                <P>If the ITC determines that such injury does exist, Commerce will issue a countervailing duty order directing CBP to assess, upon further instruction by Commerce, countervailing duties on all imports of the subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation, as discussed above in the “Continuation of Suspension of Liquidation” section.</P>
                <HD SOURCE="HD1">Administrative Protective Order</HD>
                <P>In the event that the ITC issues a final negative injury determination, this notice will serve as the only reminder to parties subject to an APO of their responsibility concerning the destruction of proprietary information disclosed under APO, in accordance with 19 CFR 351.305(a)(3). Timely written notification of the return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This determination is issued and published pursuant to sections 705(d) and 777(i) of the Act, and 19 CFR 351.210(c).</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Scope of the Investigation</HD>
                    <P>The merchandise subject to this investigation is steel concrete reinforcing bar imported in either straight length or coil form (rebar) regardless of metallurgy, length, diameter, or grade or lack thereof.</P>
                    <P>The subject merchandise includes rebar that has been further processed in the subject countries or a third country, including but not limited to cutting, grinding, galvanizing, painting, coating, or any other processing that would not otherwise remove the merchandise from the scope of this investigation if performed in the country of manufacture of the rebar.</P>
                    <P>
                        Specifically excluded are plain rounds (
                        <E T="03">i.e.,</E>
                         nondeformed or smooth rebar).
                    </P>
                    <P>The subject merchandise is classifiable in the Harmonized Tariff Schedule of the United States (HTSUS) primarily under item numbers 7213.10.0000, 7214.20.0000, and 7228.30.8010. The subject merchandise may also enter under other HTSUS numbers including 7221.00.0017, 7221.00.0018, 7221.00.0030, 7221.00.0045, 7222.11.0001, 7222.11.0057, 7222.11.0059, 7222.30.0001, 7227.20.0080, 7227.90.6030, 7227.90.6035, 7227.90.6040, 7228.20.1000, and 7228.60.6000. HTSUS numbers are provided for convenience and customs purposes; however, the written description of the scope remains dispositive.</P>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">
                        III. Changes Since the 
                        <E T="03">Preliminary Determination</E>
                         and Post-Preliminary Analysis
                    </FP>
                    <FP SOURCE="FP-2">IV. Subsidies Valuation Information</FP>
                    <FP SOURCE="FP-2">V. Analysis of Programs</FP>
                    <FP SOURCE="FP-2">VI. Discussion of the Issues</FP>
                    <FP SOURCE="FP1-2">Comment 1: Whether the Provision of Natural Gas for Less Than Adequate Remuneration (LTAR) Program is Specific</FP>
                    <FP SOURCE="FP1-2">
                        Comment 2: Whether to Modify the Benchmark for the Provision of Natural Gas for LTAR
                        <PRTPAGE P="48070"/>
                    </FP>
                    <FP SOURCE="FP1-2">Comment 3: Whether the Provision of Electricity for LTAR Program is Specific</FP>
                    <FP SOURCE="FP1-2">Comment 4: Whether to Modify the Benchmark for the Provision of Electricity for LTAR</FP>
                    <FP SOURCE="FP1-2">Comment 5: Whether Central Bank of Egypt Industrial Sector Initiative is Specific</FP>
                    <FP SOURCE="FP1-2">Comment 6: Whether EZDK and EFS Were Uncreditworthy</FP>
                    <FP SOURCE="FP-2">VII. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15439 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[A-357-823]</DEPDOC>
                <SUBJECT>Raw Honey From Argentina: Amended Final Results of Antidumping Duty Administrative Review and Notice of Correction; 2023-2024</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) is amending the final results of the administrative review of the antidumping duty (AD) order on raw honey from Argentina. The period of review (POR) is June 1, 2023, through May 31, 2024.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Thomas Martin, AD/CVD Operations, Office IV, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-3936.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On June 12, 2026, Commerce published the 
                    <E T="03">Final Results</E>
                     of the 2023-2024 administrative review of the AD order on raw honey from Argentina in the 
                    <E T="04">Federal Register</E>
                    .
                    <SU>1</SU>
                    <FTREF/>
                     On June 15, 2026, Commerce received a timely filed allegation of ministerial errors from Asociación de Cooperativas Argentinas C.L. (ACA) with regard to its final dumping margin calculation.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Raw Honey from Argentina: Final Results of the Antidumping Duty Administrative Review; 2023-2024,</E>
                         91 FR 35670 (June 12, 2026) (
                        <E T="03">Final Results</E>
                        ), and accompanying Issues and Decision Memorandum (IDM).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See</E>
                         ACA's Letter, “Ministerial Error Comments,” dated June 15, 2026 (ACA's Ministerial Error Comments).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Legal Framework</HD>
                <P>
                    Section 751(h) of the Tariff Act of 1930, as amended (the Act), defines a ministerial error as including “errors in addition, subtraction, or other arithmetic function, clerical errors resulting from inaccurate copying, duplication, or the like, and any other unintentional error which the administering authority considers ministerial.” 
                    <SU>3</SU>
                    <FTREF/>
                     With respect to final results of administrative reviews, 19 CFR 351.224(e) provides that Commerce “will analyze any comments received and, if appropriate, correct any . . . ministerial error by amending the final results of review . . . {.}”
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.224(f).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Ministerial Errors</HD>
                <P>
                    ACA alleges that Commerce inadvertently conducted certain dumping comparisons twice, leading to a duplication of the dumping calculated for certain transactions, which was a ministerial error.
                    <SU>4</SU>
                    <FTREF/>
                     We agree with ACA that we made a ministerial error regarding the duplication of certain comparisons that doubled the calculated amount of dumping for certain U.S. sales transactions. Pursuant to section 751(h) of the Act and 19 CFR 351.224(f), we have amended our calculations to correct this ministerial error.
                    <SU>5</SU>
                    <FTREF/>
                     Additionally, in the course of correcting the error identified by ACA, we found an error in the conversion of general and administrative expenses from kilograms to metric tons, in the calculation of constructed value.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See</E>
                         ACA Ministerial Error Comments at 2.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Analysis of Ministerial Error Allegations,” dated concurrently (ACA Ministerial Error Memorandum).
                    </P>
                </FTNT>
                <P>
                    Based on these corrections, ACA's final weighted-average dumping margin is 17.76 percent. As a result, we are also amending the rate for the companies not selected for individual examination in this review, from 21.35 to 17.76 percent, based on the weighted-average dumping margin calculated for ACA, the only calculated rate in this review that is not zero, 
                    <E T="03">de minimis</E>
                     or determined entirely under section 776 of the Act.
                </P>
                <P>
                    For a complete discussion of the ministerial error allegation, as well as Commerce's analysis, 
                    <E T="03">see</E>
                     the ACA Ministerial Error Memorandum.
                    <SU>6</SU>
                    <FTREF/>
                     The ACA Ministerial Error Memorandum is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS), which is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Antidumping Duty Administrative Review of Frozen Warmwater Shrimp from Thailand: Analysis of Ministerial Error Allegation; 2023-2024,” dated concurrently with, and hereby adopted by, this notice (Ministerial Error Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Correction</HD>
                <P>
                    Additionally, as discussed in the 
                    <E T="03">Preliminary Results,</E>
                    <SU>7</SU>
                    <FTREF/>
                     we rescinded, in part, the administrative review for eight companies, in accordance with 19 CFR 351.213(d)(3): (1) Algodonera Avellaneda S.A.; (2) Apicola Danangie; (3) Argentik LLC; (4) Camino de Circunvalancion y Calle; (5) Compania Inversora Platense S.A.; (6) Cooperativa Apicola La Colmena Ltda; (7) Industrial Haedo S.A; and (8) Mieles Cor Pam Srl).
                    <SU>8</SU>
                    <FTREF/>
                     However, we inadvertently listed Compania Inversora Platense S.A., and Cooperativa Apicola La Colmena Ltda, as non-examined companies receiving a review-specific rate.
                    <SU>9</SU>
                    <FTREF/>
                     A corrected list of these companies is included in an appendix to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Raw Honey from Argentina: Preliminary Results and Rescission, In Part, of Antidumping Duty Administrative Review; 2023-2024,</E>
                         90 FR 48035 (October 3, 2025).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">Id.</E>
                         at 48037.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Amended Final Results of Review</HD>
                <P>
                    As a result of correcting the ministerial error, determines the following estimated weighted-average dumping margins for the period of June 1, 2023, through May 31, 2024:
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         the appendix for a list of the non-selected companies receiving a review-specific rate.
                    </P>
                </FTNT>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s150,16">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Exporter/producer</CHED>
                        <CHED H="1">
                            Weighted-average
                            <LI>dumping margin</LI>
                            <LI>(percent)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Asociación de Cooperativas Argentinas C.L</ENT>
                        <ENT>17.76</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Review-Specific Rate for Non-Examined Companies 
                            <SU>10</SU>
                        </ENT>
                        <ENT>17.76</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="48071"/>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    Commerce intends to disclose the calculations performed in connection with these amended final results of review to interested parties within five days after public announcement of the final results or, if there is no public announcement, within five days of the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b).
                </P>
                <HD SOURCE="HD1">Assessment Rates</HD>
                <P>
                    Pursuant to section 751(a)(2)(C) of the Act and 19 CFR 351.212(b)(1), Commerce will determine, and U.S. Customs and Border Protection (CBP) shall assess, antidumping duties on all appropriate entries of subject merchandise in accordance with the amended final results of this review. The amended final results of this review shall be the basis for the assessment of antidumping duties on entries of merchandise covered by the amended final results of this review and for future deposits of estimated duties, where applicable.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         section 751(a)(2)(C) of the Act.
                    </P>
                </FTNT>
                <P>
                    Pursuant to 19 CFR 351.212(b)(1), we calculated importer-specific 
                    <E T="03">ad valorem</E>
                     duty assessment rates based on the ratio of the total amount of dumping calculated for each importer's examined sales and the total entered value of those sales. Where either the respondent's weighted-average dumping margin is zero or 
                    <E T="03">de minimis</E>
                     within the meaning of 19 CFR 351.106(c)(1), or an importer-specific assessment rate is 
                    <E T="03">de minimis</E>
                     (
                    <E T="03">i.e.,</E>
                     less than 0.5 percent), we will instruct CBP to liquidate the appropriate entries without regard to antidumping duties.
                </P>
                <P>For all non-selected companies listed in the appendix to this notice, we will instruct CBP to liquidate all entries of subject merchandise that entered the United States during the POR at the rate calculated for ACA as listed above.</P>
                <P>For entries of subject merchandise during the POR produced by ACA for which it did not know that its merchandise was destined for the United States, we will instruct CBP to liquidate such entries at the all-others rate established in the less-than-fair-value (LTFV) investigation, if there is no rate for the intermediate company(ies) involved in the transaction.</P>
                <P>
                    Commerce intends to issue assessment instructions to CBP no earlier than 35 days after the date of publication of these amended final results of this review in the 
                    <E T="04">Federal Register</E>
                    . If a timely summons is filed at the U.S. Court of International Trade, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired (
                    <E T="03">i.e.,</E>
                     within 90 days of publication).
                </P>
                <HD SOURCE="HD1">Cash Deposit Requirements</HD>
                <P>
                    The following amended cash deposit requirements will be effective for all shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after June 12, 2026, the publication date of the 
                    <E T="03">Final Results,</E>
                     as provided by section 751(a)(2)(C) of the Act: (1) the amended cash deposit rate for the companies listed above will be equal to the weighted-average dumping margin established in these amended final results of review; (2) for merchandise exported by producers or exporters not covered in this review but covered in a prior completed segment of the proceeding, the cash deposit rate will continue to be the company specific rate published in the completed segment for the most recent period; (3) if the exporter is not a firm covered in this review, a prior review, or the original investigation but the producer has been covered in a prior completed segment of this proceeding, then the cash deposit rate will be the rate established in the completed segment for the most recent period for the producer of the subject merchandise; and (4) the cash deposit rate for all other producers or exporters will continue to be 16.92 percent, the all-others rate established in the 
                    <E T="03">Section 129 Determination.</E>
                    <SU>12</SU>
                    <FTREF/>
                     The cash deposit requirements, when imposed, shall remain in effect until further notice.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See Section 129 Determination.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Notification to Importers</HD>
                <P>This notice serves as a final reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in Commerce's presumption that reimbursement of the antidumping duties occurred and the subsequent assessment of doubled antidumping duties.</P>
                <HD SOURCE="HD1">Administrative Protective Order (APO)</HD>
                <P>This notice also serves as a reminder to parties subject to APO of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3). Timely written notification of the return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>We are issuing and publishing these amended final results of administrative review in accordance with sections 751(h) and 777(i)(1) of the Act, and 19 CFR 351.224(e).</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Companies Not Selected for Individual Examination Receiving a Review-Specific Rate</HD>
                    <FP SOURCE="FP-2">1. Azul Agronegocios S.A.</FP>
                    <FP SOURCE="FP-2">2. Compania Apicola Argentina S.A.</FP>
                    <FP SOURCE="FP-2">3. D'Ambros Maria De Los Angeles D'Ambros Maria Daniela SRL.</FP>
                    <FP SOURCE="FP-2">4. D'Ambros Maria de los Angeles y D'Ambros Maria Daniela SRL.</FP>
                    <FP SOURCE="FP-2">5. Gasrroni Srl.</FP>
                    <FP SOURCE="FP-2">6. Gasrroni S.R.L.</FP>
                    <FP SOURCE="FP-2">7. Geomiel SA.</FP>
                    <FP SOURCE="FP-2">8. Gruas San Blas S.A.</FP>
                    <FP SOURCE="FP-2">9. Honey and Grains SRL.</FP>
                    <FP SOURCE="FP-2">10. Naiman S.A.</FP>
                    <FP SOURCE="FP-2">11. Newsan S.A.</FP>
                    <FP SOURCE="FP-2">12. Newsan Food S.A.</FP>
                    <FP SOURCE="FP-2">13. Osbo S.A.</FP>
                    <FP SOURCE="FP-2">14. Patagonik Food S.A.</FP>
                    <FP SOURCE="FP-2">15. Promiel Srl (Vicentin S.A.I.C.).</FP>
                    <FP SOURCE="FP-2">16. Terremare Foods S.A.S.</FP>
                    <FP SOURCE="FP-2">17. Villamora S.A</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15436 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[A-580-897]</DEPDOC>
                <SUBJECT>Large Diameter Welded Pipe From the Republic of Korea: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The U.S. Department of Commerce (Commerce) preliminarily determines that the individually-examined producers/exporters subject to this review did not make sales of subject merchandise at less than normal value (NV) during the period of review (POR), May 1, 2024, through April 30, 2025. In addition, we are rescinding the review with respect to 15 companies. 
                        <PRTPAGE P="48072"/>
                        Interested parties are invited to comment on these preliminary results of review.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Patrick Barton or Katerina Katsiadas, AD/CVD Operations, Office VIII, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-0012 or (202) 482-4929, respectively.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On June 25, 2025, based on timely requests for review, in accordance with 19 CFR 351.221(c)(1)(i), we initiated an administrative review of the antidumping duty order on large diameter welded pipe (welded pipe) from the Republic of Korea (Korea).
                    <SU>1</SU>
                    <FTREF/>
                     On August 27, 2025, Commerce selected Hyundai Steel Pipe Co., Ltd. (HSP) and SeAH Steel Corporation (SeAH) as the mandatory respondents in this review.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Initiation of Antidumping and Countervailing Duty Administrative Reviews,</E>
                         90 FR 26967 (June 25, 2025); 
                        <E T="03">see also Large Diameter Welded Pipe from the Republic of Korea: Amended Final Affirmative Antidumping Determination and Antidumping Duty Order,</E>
                         84 FR 18767 (May 2, 2019) (
                        <E T="03">Order</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Respondent Selection,” dated August 27, 2025.
                    </P>
                </FTNT>
                <P>
                    Due to the lapse in appropriations and Federal Government shutdown, on November 14, 2025, Commerce tolled all deadlines in administrative proceedings by 47 days.
                    <SU>3</SU>
                    <FTREF/>
                     Additionally, due to a backlog of documents that were electronically filed via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS) during the Federal Government shutdown, on November 24, 2025, Commerce tolled all deadlines in administrative proceedings by an additional 21 days.
                    <SU>4</SU>
                    <FTREF/>
                     On March 30, 2026, we extended the preliminary results of this review to no later than July 24, 2026.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Deadlines Affected by the Shutdown of the Federal Government,” dated November 14, 2025.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Tolling of all Case Deadlines,” dated November 24, 2025.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Extension of Deadline for Preliminary Results of Antidumping Duty Administrative Review,” dated March 30, 2026.
                    </P>
                </FTNT>
                <P>
                    For a complete description of the events that followed the initiation of this review, 
                    <E T="03">see</E>
                     the Preliminary Decision Memorandum.
                    <SU>6</SU>
                    <FTREF/>
                     A list of the topics discussed in the Preliminary Decision Memorandum is attached as Appendix I to this notice. The Preliminary Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                     In addition, a complete version of the Preliminary Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Decision Memorandum for the Preliminary Results of Antidumping Duty Administrative Review: Large Diameter Welded Pipe from the Republic of Korea; 2024-2025,” dated concurrently with, and hereby adopted by, this notice (Preliminary Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Order</HD>
                <P>
                    The merchandise subject to the 
                    <E T="03">Order</E>
                     is welded pipe from Korea. For a complete description of the scope of the 
                    <E T="03">Order, see</E>
                     the Preliminary Decision Memorandum.
                </P>
                <HD SOURCE="HD1">Rescission of Administrative Review, in Part</HD>
                <P>
                    Pursuant to 19 CFR 351.213(d)(3), it is Commerce's practice to rescind an administrative review of an antidumping duty order where it concludes that there were no suspended entries of subject merchandise during the POR.
                    <SU>7</SU>
                    <FTREF/>
                     Normally, upon completion of an administrative review, the suspended entries are liquidated at the antidumping duty assessment rate for the review period.
                    <SU>8</SU>
                    <FTREF/>
                     Therefore, for an administrative review to be conducted, there must be a reviewable, suspended entry that Commerce can instruct U.S. Customs and Border Protection (CBP) to liquidate at the antidumping duty assessment rate calculated for the POR.
                    <SU>9</SU>
                    <FTREF/>
                     Commerce notified all interested parties of its intent to rescind the instant review regarding the companies listed in Appendix II because there were no reviewable, suspended entries of subject merchandise from these companies during the POR, and invited interested parties to comment.
                    <SU>10</SU>
                    <FTREF/>
                     No party commented on this memorandum. In the absence of any suspended entries of subject merchandise from these companies during the POR, we are rescinding this administrative review for the companies listed in Appendix II, in accordance with 19 CFR 351.213(d)(3).
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See, e.g., Certain Carbon and Alloy Steel Cut-to Length Plate from the Federal Republic of Germany: Recission of Antidumping Administrative Review; 2020-2021,</E>
                         88 FR 4154 (January 24, 2023).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.212(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See, e.g., Shanghai Sunbeauty Trading Co.</E>
                         v. 
                        <E T="03">United States,</E>
                         380 F.Supp.3d 1328, 1337 (CIT 2019) (referring to section 751(a) of the Act, the U.S. Court of International Trade (CIT) held that “{w}hile the statute does not explicitly require that an entry be suspended as a prerequisite for establishing entitlement to a review, it does explicitly state the determined rate will be used as the liquidation rate for the reviewed entries. This result can only obtain if the liquidation of entries has been suspended”); 
                        <E T="03">see also Certain Frozen Fish Fillets from the Socialist Republic of Vietnam: Final Results of Antidumping Duty Administrative Review and Final Determination of No Shipments; 2018-2019,</E>
                         86 FR 36102, and accompanying Issues and Decision Memorandum at Comment 4; and 
                        <E T="03">Solid Fertilizer Grade Ammonium Nitrate from the Russian Federation: Notice of Rescission of Antidumping Duty Administrative Review,</E>
                         77 FR 65532 (October 29, 2012) (noting that “for an administrative review to be conducted, there must be a reviewable, suspended entry to be liquidated at the newly calculated assessment rate”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Notice of Intent to Rescind Review, In Part,” dated June 1, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Methodology</HD>
                <P>
                    Commerce is conducting this review in accordance with section 751(a) of the Tariff Act of 1930, as amended (the Act). Constructed export price is calculated in accordance with section 772 of the Act. NV is calculated in accordance with section 773 of the Act. For a full description of the methodology underlying our conclusions, 
                    <E T="03">see</E>
                     the Preliminary Decision Memorandum.
                </P>
                <HD SOURCE="HD1">Rate for Non-Individually Examined Companies</HD>
                <P>
                    The Act does not address the establishment of a rate to apply to companies not selected for individual examination when Commerce limits its examination in an administrative review pursuant to section 777A(c)(2) of the Act. However, Commerce's regulation at 19 CFR 351.109(g) states that Commerce will determine the rate for non-selected companies by following the process set forth in 19 CFR 351.109(f)(1), which generally parallels the process for determining the all-others rate in an investigation under section 735(c)(5) of the Act. Section 735(c)(5)(A) of the Act and 19 CFR 351.109(f)(1)(i) state that for companies not investigated, in general, Commerce will determine an all-others rate by weight averaging the estimated weighted-average dumping margins established for each of the individually investigated exporters and producers, excluding any zero and 
                    <E T="03">de minimis</E>
                     (
                    <E T="03">i.e.,</E>
                     less than 0.5 percent) margins, and any margins determined entirely under section 776 of the Act (
                    <E T="03">i.e.,</E>
                     based entirely on the facts available). Section 735(c)(5)(B) of the Act and 19 CFR 351.109(f)(2)(iii) elaborate that, where the estimated weighted-average dumping margins established for all individually investigated exporters and producers are zero, 
                    <E T="03">de minimis,</E>
                     or determined entirely under section 776 of the Act (
                    <E T="03">i.e.,</E>
                     based entirely on the facts available), Commerce may use any reasonable method to establish the estimated all-others rate for exporters 
                    <PRTPAGE P="48073"/>
                    and producers not individually investigated.
                </P>
                <P>
                    In this review, we calculated weighted-average dumping margins of zero for both HSP and SeAH. Therefore, consistent with section 735(c)(5) of the Act and 19 CFR 351.109(f), we are preliminarily assigning the most recent above-
                    <E T="03">de minimis</E>
                     rate calculated in this proceeding (
                    <E T="03">i.e.,</E>
                     0.80 percent) to the exporters and producers not individually examined.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See Large Diameter Welded Pipe from the Republic of Korea: Final Results of Antidumping Duty Administrative Review; 2023-2024,</E>
                         91 FR 23400 (May 1, 2026).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Preliminary Results of Review</HD>
                <P>As a result of this review, we preliminarily determine the following estimated weighted-average dumping margin exists for the period May 1, 2024, through April 30, 2025:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s25,9">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Producer/exporter</CHED>
                        <CHED H="1">
                            Weighted-
                            <LI>average</LI>
                            <LI>dumping</LI>
                            <LI>margin</LI>
                            <LI>(percent)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Hyundai Steel Pipe Co., Ltd</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SeAH Steel Corporation</ENT>
                        <ENT>0.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Companies Not Selected for Individual Review 
                            <SU>12</SU>
                        </ENT>
                        <ENT>0.80</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">
                    Disclosure
                    <FTREF/>
                </HD>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         The exporters or producers not selected for individual review are listed in Appendix III.
                    </P>
                </FTNT>
                <P>Commerce intends to disclose to interested parties its calculations performed for these preliminary results within five days of any public announcement or, if there is no public announcement, within five days of the date of publication of this notice in accordance with 19 CFR 351.224(b).</P>
                <HD SOURCE="HD1">Verification</HD>
                <P>As provided in section 782(i)(3) of the Act, Commerce intends to verify the information relied upon in making its final results.</P>
                <HD SOURCE="HD1">Public Comment</HD>
                <P>
                    Case briefs or other written comments may be submitted to the Assistant Secretary for Enforcement and Compliance no later than seven days after the date on which the last verification report is issued in this review.
                    <SU>13</SU>
                    <FTREF/>
                     Rebuttal briefs, limited to issues raised in the case briefs, may be filed not later than five days after the date for filing case briefs.
                    <SU>14</SU>
                    <FTREF/>
                     Interested parties who submit case briefs or rebuttal briefs in this proceeding must submit: (1) a table of contents listing each issue; and (2) a table of authorities.
                    <SU>15</SU>
                    <FTREF/>
                     All briefs must be filed electronically using ACCESS. An electronically filed document must be received successfully in its entirety in ACCESS by 5:00 p.m. Eastern Time on the established deadline.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(c)(1)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(d); 
                        <E T="03">see also Administrative Protective Order, Service, and Other Procedures in Antidumping and Countervailing Duty Proceedings,</E>
                         88 FR 67069, 67077 (September 29, 2023) (
                        <E T="03">APO and Service Procedures</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(c)(2) and (d)(2).
                    </P>
                </FTNT>
                <P>
                    As provided under 19 CFR 351.309(c)(2)(iii) and (d)(2)(iii), we request that interested parties provide at the beginning of their briefs a public executive summary for each issue raised in their briefs.
                    <SU>16</SU>
                    <FTREF/>
                     Further, we request that interested parties limit their public executive summary of each issue to no more than 450 words, not including citations. We intend to use the public executive summaries as the basis of the comment summaries included in the issues and decision memorandum that will accompany the final results in this administrative review. We request that interested parties include footnotes for relevant citations in the public executive summary of each issue. Note that Commerce has amended certain of its requirements pertaining to the service of documents in 19 CFR 351.303(f).
                    <SU>17</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         We use the term “issue” here to describe an argument that Commerce would normally address in a comment of the Issues and Decision Memorandum.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">See APO and Service Procedures,</E>
                         88 FR at 67069.
                    </P>
                </FTNT>
                <P>
                    Pursuant to 19 CFR 351.310(c), interested parties who wish to request a hearing must submit a written request to the Assistant Secretary for Enforcement and Compliance, filed electronically via ACCESS by 5:00 p.m. Eastern Time within 30 days after the date of publication of this notice. Requests should contain: (1) the party's name, address, and telephone number; (2) the number of participants and whether any participant is a foreign national; and (3) a list of issues to be discussed. Oral presentations at the hearing will be limited to issues raised in the briefs. If a request for a hearing is made, Commerce will inform parties of the scheduled date for the hearing.
                    <SU>18</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.310(d).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Assessment Rates</HD>
                <P>Pursuant to section 751(a)(2)(A) of the Act and 19 CFR 351.212(b)(1), Commerce will determine, and U.S. Customs and Border Protection (CBP) shall assess, antidumping duties on all appropriate entries of subject merchandise in accordance with the final results of this review.</P>
                <P>
                    If the weighted-average dumping margin for an individually examined respondent is not zero or 
                    <E T="03">de minimis</E>
                     (
                    <E T="03">i.e.,</E>
                     less than 0.50 percent) in the final results of this review, Commerce intends to calculate importer-specific assessment rates on the basis of the ratio of the total amount of dumping calculated for each importer's examined sales to the total entered value of those sales. Where we do not have entered values for all U.S. sales to a particular importer, we will calculate an importer-specific, per-unit assessment rate on the basis of the ratio of the total amount of dumping calculated for the importer's examined sales to the total quantity of those sales.
                    <SU>19</SU>
                    <FTREF/>
                     To determine whether an importer-specific, per-unit assessment rate is 
                    <E T="03">de minimis,</E>
                     in accordance with 19 CFR 351.106(c)(2), we also will calculate an importer-specific 
                    <E T="03">ad valorem</E>
                     ratio based on estimated entered values. If the weighted-average dumping margin for an individually examined respondent is zero or 
                    <E T="03">de minimis,</E>
                     or where an importer-specific 
                    <E T="03">ad valorem</E>
                     assessment rate is zero or 
                    <E T="03">de minimis,</E>
                     we will instruct CBP to liquidate appropriate entries without regard to antidumping duties.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.212(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.106(c)(2); 
                        <E T="03">see also Antidumping Proceeding: Calculation of the Weighted-Average Dumping Margin and Assessment Rate in Certain Antidumping Proceedings; Final Modification,</E>
                         77 FR 8101, 8103 (February 14, 2012).
                    </P>
                </FTNT>
                <P>
                    In accordance with Commerce's “automatic assessment” practice, for entries of subject merchandise during the POR produced by HSP and SeAH for which they did not know that the merchandise was destined for the United States, we intend to instruct CBP to liquidate those entries at the all-others rate calculated in the less-than-fair-value (LTFV) investigation if there is no rate for the intermediate companies involved in the transaction.
                    <SU>21</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         For a full discussion of this practice, 
                        <E T="03">see Antidumping and Countervailing Duty Proceedings: Assessment of Antidumping Duties,</E>
                         68 FR 23954 (May 6, 2003).
                    </P>
                </FTNT>
                <P>
                    For the companies listed in Appendix III which were not selected for individual review, we will assign an assessment rate based on the review-specific rate, calculated as noted in the “Rate for Non-Individually Examined Companies” section, above. The final results of this review shall be the basis for the assessment of antidumping duties on entries of merchandise covered by the final results of this review and for future deposits of estimated duties, where applicable.
                    <SU>22</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See</E>
                         section 751(a)(2)(C) of the Act.
                    </P>
                </FTNT>
                <P>
                    For the companies listed in Appendix II for which the review is being rescinded, Commerce will instruct CBP 
                    <PRTPAGE P="48074"/>
                    to assess antidumping duties on all appropriate entries. Antidumping duties shall be assessed at rates equal to the cash deposit rate for estimated antidumping duties required at the time of entry, or withdrawal from warehouse, for consumption, in accordance with 19 CFR 351.212(c)(1)(i). Commerce intends to issue rescission instructions to CBP no earlier than 35 days after the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    . If a timely summons is filed at the CIT, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired (
                    <E T="03">i.e.,</E>
                     within 90 days of publication).
                </P>
                <HD SOURCE="HD1">Cash Deposit Requirements</HD>
                <P>
                    The following deposit requirements will be effective for all shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the publication date of the final results of this administrative review, as provided by section 751(a)(2)(C) of the Act: (1) the cash deposit rate for the companies listed above will be that established in the final results of this review, except if the rate is less than 0.50 percent and, therefore, 
                    <E T="03">de minimis</E>
                     within the meaning of 19 CFR 351.106(c)(1), in which case the cash deposit rate will be zero; (2) for previously investigated or reviewed companies not covered by this review, the cash deposit rate will continue to be the company-specific cash deposit rate published for the most recently completed segment of this proceeding in which the company participated; (3) if the exporter is not a firm covered in this review, or the LTFV investigation, but the manufacturer is, then the cash deposit rate will be the rate established for the most recent segment for the manufacturer of the merchandise; and (4) the cash deposit rate for all other manufacturers or exporters will continue to be 7.08 percent, the all-others rate established in the LTFV investigation.
                    <SU>23</SU>
                    <FTREF/>
                     These cash deposit requirements, when imposed, shall remain in effect until further notice.
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See Order,</E>
                         84 FR at 18769.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Notification to Importers</HD>
                <P>This notice also serves as a preliminary reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping and/or countervailing duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in Commerce's presumption that reimbursement of antidumping and/or countervailing duties occurred and the subsequent assessment of double antidumping duties, and/or an increase in the amount of antidumping duties by the amount of the countervailing duties.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>We are issuing and publishing these preliminary results of review in accordance with sections 751(a)(1) and 777(i)(1) of the Act, and 19 CFR 351.221(b)(4).</P>
                <SIG>
                    <DATED>Dated: July 24, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I—List of Topics Discussed in the Preliminary Decision Memorandum</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">III. Scope of the Order</FP>
                    <FP SOURCE="FP-2">IV. Companies Not Selected for Individual Examination</FP>
                    <FP SOURCE="FP-2">V. Discussion of the Methodology</FP>
                    <FP SOURCE="FP-2">VI. Currency Conversion</FP>
                    <FP SOURCE="FP-2">VII. Recommendation</FP>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II—Companies With No Reviewable Entries Rescinded From Review</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">1. AJU Besteel Co., Ltd</FP>
                    <FP SOURCE="FP-2">2. Daiduck Piping Co., Ltd.</FP>
                    <FP SOURCE="FP-2">3. Dongbu Incheon Steel Co., Ltd.</FP>
                    <FP SOURCE="FP-2">4. EEW KHPC Co., Ltd.</FP>
                    <FP SOURCE="FP-2">5. Geumok Tech. Co., Ltd.</FP>
                    <FP SOURCE="FP-2">6. Hansol Metal Co. Ltd.</FP>
                    <FP SOURCE="FP-2">7. Husteel Co., Ltd.</FP>
                    <FP SOURCE="FP-2">8. Il Jin Nts Co. Ltd.</FP>
                    <FP SOURCE="FP-2">9. Kiduck Industries Co., Ltd.</FP>
                    <FP SOURCE="FP-2">10. Kum Kang Kind. Co., Ltd.</FP>
                    <FP SOURCE="FP-2">11. Kumsoo Connecting Co., Ltd.</FP>
                    <FP SOURCE="FP-2">12. Seonghwa Industrial Co., Ltd.</FP>
                    <FP SOURCE="FP-2">13. SIN-E B&amp;P Co., Ltd.</FP>
                    <FP SOURCE="FP-2">14. Steel Flower Co., Ltd.</FP>
                    <FP SOURCE="FP-2">15. WELTECH Co., Ltd.</FP>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix III—Companies not Selected for Individual Examination Receiving a Review-Specific Rate</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">1. Chang Won Bending Co., Ltd.</FP>
                    <FP SOURCE="FP-2">2. Dong Yang Steel Pipe Co., Ltd.</FP>
                    <FP SOURCE="FP-2">3. EEW Korea Co., Ltd.</FP>
                    <FP SOURCE="FP-2">4. Histeel Co., Ltd.</FP>
                    <FP SOURCE="FP-2">5. Hyundai RB Co., Ltd.</FP>
                    <FP SOURCE="FP-2">6. Nexteel Co., Ltd.</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15399 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[C-552-854]</DEPDOC>
                <SUBJECT>Steel Concrete Reinforcing Bar From the Socialist Republic of Vietnam: Final Affirmative Countervailing Duty Determination</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that countervailable subsidies are being provided to producers and exporters of steel concrete reinforcing bar (rebar) from the Socialist Republic of Vietnam (Vietnam) during the period of investigation (POI), January 1, 2024, through December 31, 2024.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Erin Howard or Thomas Schauer, AD/CVD Operations, Office I, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-3453 or (202) 482-0410, respectively.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On January 13, 2026, Commerce published in the 
                    <E T="04">Federal Register</E>
                     its 
                    <E T="03">Preliminary Determination</E>
                     and invited comments from interested parties.
                    <SU>1</SU>
                    <FTREF/>
                     In the 
                    <E T="03">Preliminary Determination,</E>
                     and in accordance with section 705(a)(1) of the Tariff Act of 1930, as amended (the Act), and 19 CFR 351.210(b)(4), Commerce aligned the final countervailing duty (CVD) determination with the final determination in the less-than-fair-value investigation of rebar from Vietnam.
                    <SU>2</SU>
                    <FTREF/>
                     Further, on May 13, 2026, Commerce issued its Post-Preliminary Analysis Memorandum.
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination With Final Antidumping Duty Determination,</E>
                         91 FR 1265 (January 13, 2026) (
                        <E T="03">Preliminary Determination</E>
                        ), and accompanying Preliminary Decision Memorandum (PDM).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See Preliminary Determination,</E>
                         91 FR at 1266.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Post-Preliminary Analysis,” dated May 13, 2026 (Post-Preliminary Analysis Memorandum).
                    </P>
                </FTNT>
                <P>
                    For a complete description of the events that occurred since Commerce published the 
                    <E T="03">Preliminary Determination,</E>
                     as well as a full discussion of the issues raised by parties for this final determination, 
                    <E T="03">see</E>
                     the 
                    <PRTPAGE P="48075"/>
                    Issues and Decision Memorandum.
                    <SU>4</SU>
                    <FTREF/>
                     The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                     In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Issues and Decision Memorandum for the Final Affirmative Determination in the Countervailing Duty Investigation of Steel Concrete Reinforcing Bar from the Socialist Republic of Vietnam,” dated concurrently with, and hereby adopted by, this notice (Issues and Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The product covered by this investigation is rebar from Vietnam. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the preamble to Commerce's regulations,
                    <SU>5</SU>
                    <FTREF/>
                     the 
                    <E T="03">Initiation Notice</E>
                     set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>6</SU>
                    <FTREF/>
                     No interested party commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     Therefore, Commerce is not modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Algeria, Bulgaria, Egypt, and the Socialist Republic of Vietnam: Initiation of Less-Than-Fair-Value Investigations,</E>
                         90 FR 27846 (June 30, 2025) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Verification</HD>
                <P>
                    Commerce conducted verification of the information relied upon in making its final determination in this investigation, in accordance with section 782(i) of the Act. Specifically, we conducted on-site verification of the subsidy information reported by Hoa Phat Group Joint Stock Company (HPG) in May 2026 using standard verification procedures, including an examination of relevant sales, accounting records and original source documents.
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Verification of the Questionnaire Responses of Hoa Phat Group Joint Stock Company and Its Cross-Owned Companies,” dated June 2, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Analysis of Subsidy Programs and Comments Received</HD>
                <P>
                    The subsidy programs under investigation, and the issues raised in the case and rebuttal briefs that were submitted by interested parties in this investigation are discussed in the Issues and Decision Memorandum. For a complete list of the issues raised by parties, and to which we responded in the Issues and Decision Memorandum, 
                    <E T="03">see</E>
                     Appendix II.
                </P>
                <HD SOURCE="HD1">Methodology</HD>
                <P>
                    Commerce conducted this investigation in accordance with section 701 of the Act. For each of the subsidy programs found to be countervailable, Commerce determines that there is a subsidy, 
                    <E T="03">i.e.,</E>
                     a financial contribution by an “authority” that gives rise to a benefit to the recipient, and that the subsidy is specific.
                    <SU>8</SU>
                    <FTREF/>
                     For a full description of the methodology underlying our final determination, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         sections 771(5)(B) and (D) of the Act regarding financial contribution; 
                        <E T="03">see also</E>
                         section 771(5)(E) of the Act regarding benefit; and section 771(5A) of the Act regarding specificity.
                    </P>
                </FTNT>
                <P>
                    In making this final determination, Commerce relied, in part, on facts otherwise available, with adverse inferences (AFA), pursuant to sections 776(a) and (b) of the Act. For a full discussion of our methodology, including our application of AFA, 
                    <E T="03">see</E>
                     the 
                    <E T="03">Preliminary Determination,</E>
                     Post-Preliminary Analysis Memorandum,
                    <SU>9</SU>
                    <FTREF/>
                     and Issues and Decision Memorandum.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See Post-Preliminary Analysis Memorandum</E>
                         at 5-11.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Changes Since the Preliminary Determination</HD>
                <P>
                    Based on our review of the information examined at verification and analysis of the comments received from interested parties, we made certain changes to the countervailable subsidy rate calculations for HPG which, in turn, impacted the rates assigned to all other producers/exporters. For a discussion of these changes, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <HD SOURCE="HD1">All-Others Rate</HD>
                <P>
                    Pursuant to section 705(c)(5)(A)(i) of the Act, Commerce will determine an all-others rate equal to the weighted average countervailable subsidy rates established for those exporters and/or producers individually examined, excluding any rates that are zero, 
                    <E T="03">de minimis,</E>
                     or based entirely under section 776 of the Act. If the rates established for all exporters and producers individually investigated are zero, 
                    <E T="03">de minimis,</E>
                     or determined entirely under facts available, Commerce may use any reasonable method to establish an all-others rate.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         sections 705(c)(5)(A)(i) and (ii) of the Act.
                    </P>
                </FTNT>
                <P>
                    In this investigation, Commerce calculated an individual estimated countervailable subsidy rate for HPG that is not zero, 
                    <E T="03">de minimis,</E>
                     or based entirely on the facts otherwise available. Therefore, Commerce calculated the all-others rate using the individual estimated subsidy rate calculated for the sole examined respondent, 
                    <E T="03">i.e.,</E>
                     HPG.
                </P>
                <HD SOURCE="HD1">Final Determination</HD>
                <P>
                    Commerce determines that the following estimated net countervailable subsidy rates exist for the period January 1, 2024, through December 31, 2024:
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Commerce continues to find the following companies to be cross-owned with Hoa Phat Group Joint Stock Company: Hoa Phat Dung Quat Steel Joint Stock Company, Hoa Phat Hai Duong Steel Joint Stock Company, Hoa Phat Hung Yen Steel Limited Liability Company, Hoa Phat Energy Joint Stock Company, An Thong Mineral Investment Joint Stock Company, Hoa Phat Iron and Steel Joint Stock Company, Hoa Phat Metal Producing Company Limited, Hoa Phat Prestressed Concrete One Member Limited Liability Company, and Hoa Phat Steel Products Joint Stock Company.
                    </P>
                </FTNT>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s100,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Company</CHED>
                        <CHED H="1">
                            Subsidy rate
                            <LI>(percent</LI>
                            <LI>
                                <E T="03">ad valorem</E>
                                )
                            </LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">
                            Hoa Phat Group Joint Stock Company 
                            <SU>11</SU>
                        </ENT>
                        <ENT>6.80</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">All Others</ENT>
                        <ENT>6.80</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    Commerce intends to disclose its calculations and analysis performed to interested parties in this final determination within five days of its public announcement or, if there is no public announcement, within five days of the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b).
                </P>
                <HD SOURCE="HD1">Continuation of Suspension of Liquidation</HD>
                <P>
                    As a result of our 
                    <E T="03">Preliminary Determination,</E>
                     and pursuant to sections 703(d)(1)(B) and (d)(2) of the Act, we instructed U.S. Customs and Border Protection (CBP) to collect cash deposits and suspend liquidation of entries of subject merchandise, as described in the scope of the investigation section, that were entered, or withdrawn from warehouse, for consumption on or after January 13, 2026, the date of publication of the 
                    <E T="03">Preliminary Determination</E>
                     in the 
                    <E T="04">Federal Register</E>
                    , for entries produced and/or exported by HSG and all other producers and exporters.
                    <SU>12</SU>
                    <FTREF/>
                     In accordance with section 703(d) of the Act, we instructed CBP to discontinue the suspension of liquidation of all entries of subject merchandise entered or withdrawn from warehouse, on or after May 13, 2026, the first day provisional measures were no longer in 
                    <PRTPAGE P="48076"/>
                    effect, but to continue the suspension of liquidation of all entries of subject merchandise on or before May 12, 2026.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See Post-Preliminary Analysis Memorandum.</E>
                    </P>
                </FTNT>
                <P>If the U.S. International Trade Commission (ITC) issues a final affirmative injury determination, we will issue a CVD order, reinstate the suspension of liquidation under section 706(a) of the Act, and require a cash deposit of estimated countervailing duties for such entries of subject merchandise in the amounts indicated above. Pursuant to section 705(c)(2) of the Act, if the ITC determines that material injury, or threat of material injury, does not exist, this proceeding will be terminated, and all estimated duties deposited or securities posted as a result of the suspension of liquidation will be refunded or cancelled.</P>
                <HD SOURCE="HD1">ITC Notification</HD>
                <P>In accordance with section 705(d) of the Act, Commerce will notify the ITC of its final affirmative determination that countervailable subsidies are being provided to producers and exporters of rebar from Vietnam. As Commerce's final determination is affirmative, in accordance with section 705(b) of the Act, the ITC will determine, within 45 days, whether the domestic industry in the United States is materially injured, or threatened with material injury, by reason of imports of rebar from Vietnam. In addition, we are making available to the ITC all non-privileged and non-proprietary information related to this investigation. We will allow the ITC access to all privileged and business proprietary information in our files, provided the ITC confirms that it will not disclose such information, either publicly or under administrative protective order (APO), without the written consent of the Assistant Secretary for Enforcement and Compliance. If the ITC determines that material injury or threat of material injury does not exist, this proceeding will be terminated and all cash deposits will be refunded.</P>
                <P>If the ITC determines that such injury does exist, Commerce will issue a CVD order directing CBP to assess, upon further instruction by Commerce, countervailing duties on all imports of the subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation, as discussed above in the “Continuation of Suspension of Liquidation” section.</P>
                <HD SOURCE="HD1">Administrative Protective Order (APO)</HD>
                <P>In the event that the ITC issues a final negative injury determination, this notice will serve as the only reminder to parties subject to the APO of their responsibility concerning the destruction of proprietary information disclosed under APO, in accordance with 19 CFR 351.305(a)(3). Timely written notification of the return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This determination is issued and published pursuant to sections 705(d) and 777(i) of the Act, and 19 CFR 351.210(c).</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Scope of the Investigation</HD>
                    <P>The merchandise subject to this investigation is steel concrete reinforcing bar imported in either straight length or coil form (rebar) regardless of metallurgy, length, diameter, or grade or lack thereof.</P>
                    <P>The subject merchandise includes rebar that has been further processed in the subject countries or a third country, including but not limited to cutting, grinding, galvanizing, painting, coating, or any other processing that would not otherwise remove the merchandise from the scope of this investigation if performed in the country of manufacture of the rebar.</P>
                    <P>
                        Specifically excluded are plain rounds (
                        <E T="03">i.e.,</E>
                         nondeformed or smooth rebar).
                    </P>
                    <P>The subject merchandise is classifiable in the Harmonized Tariff Schedule of the United States (HTSUS) primarily under item numbers 7213.10.0000, 7214.20.0000, and 7228.30.8010. The subject merchandise may also enter under other HTSUS numbers including 7221.00.0017, 7221.00.0018, 7221.00.0030, 7221.00.0045, 7222.11.0001, 7222.11.0057, 7222.11.0059, 7222.30.0001, 7227.20.0080, 7227.90.6030, 7227.90.6035, 7227.90.6040, 7228.20.1000, and 7228.60.6000. HTSUS numbers are provided for convenience and customs purposes; however, the written description of the scope remains dispositive.</P>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">III. Subsidies Valuation Information</FP>
                    <FP SOURCE="FP-2">IV. Analysis of Programs</FP>
                    <FP SOURCE="FP-2">V. Discussion of the Issues</FP>
                    <FP SOURCE="FP1-2">Comment 1: Which Benchmark Should Be Used for Iron Ore, Ferrous Scrap, and Ferroalloys</FP>
                    <FP SOURCE="FP1-2">Comment 2: Whether All of HPG's Iron Ore, Ferrous Scrap, and Ferroalloys Purchases Are Countervailable</FP>
                    <FP SOURCE="FP1-2">Comment 3: Whether the Provision of Coal and Coking Coal, Lime and Limestone, and Liquified Petroleum Gas for Less-Than-Adequate-Remuneration (LTAR) Programs Are Specific</FP>
                    <FP SOURCE="FP1-2">Comment 4: Whether the Direct Reduced Iron and Hot Briquetted Iron for LTAR Program Provides a Financial Contribution</FP>
                    <FP SOURCE="FP1-2">Comment 5: Whether HPG's Loans from State-Owned Commercial Banks Are Countervailable</FP>
                    <FP SOURCE="FP1-2">Comment 6: Which Benchmark Should Be Used for Electricity for LTAR</FP>
                    <FP SOURCE="FP1-2">Comment 7: Whether Verification Findings Should Be Corrected</FP>
                    <FP SOURCE="FP1-2">Comment 8: Whether HPG's Electricity Purchases Were for LTAR</FP>
                    <FP SOURCE="FP1-2">Comment 9: Whether HPG's Electricity Sales Were for More-Than-Adequate-Remuneration</FP>
                    <FP SOURCE="FP1-2">Comment 10: Whether HPG's Iron Ore, Ferrous Scrap, and Ferroalloys Purchases Were for LTAR</FP>
                    <FP SOURCE="FP-2">VI. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15437 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[C-570-221]</DEPDOC>
                <SUBJECT>Large Diameter Graphite Electrodes From the People's Republic of China: Preliminary Affirmative Countervailing Duty Determination, and Alignment of Final Determination With Final Antidumping Duty Determination</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) preliminarily determines that countervailable subsidies are being provided to producers and exporters of large diameter graphite electrodes (large graphite electrodes) from the People's Republic of China (China). The period of investigation is January 1, 2025, through December 31, 2025. Interested parties are invited to comment on this preliminary determination.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Joseph Molokwu, AD/CVD Operations, Office IV, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-8043.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    This preliminary determination is made in accordance with section 703(b) of the Tariff Act of 1930, as amended (the Act). Commerce published the 
                    <PRTPAGE P="48077"/>
                    notice of initiation of this investigation on March 20, 2026.
                    <SU>1</SU>
                    <FTREF/>
                     On May 6, 2026, Commerce postponed the preliminary determination of this investigation and the revised deadline is now July 24, 2026.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Large Diameter Graphite Electrodes From the People's Republic of China and India: Initiation of Countervailing Duty Investigations,</E>
                         91 FR 13577 (March 20, 2026) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See Large Diameter Graphite Electrodes From the People's Republic of China and India: Postponement of Preliminary Determinations in the Countervailing Duty Investigations,</E>
                         91 FR 24520 (May 6, 2026).
                    </P>
                </FTNT>
                <P>
                    For a complete description of the events that followed the initiation of this investigation, 
                    <E T="03">see</E>
                     the Preliminary Decision Memorandum.
                    <SU>3</SU>
                    <FTREF/>
                     A list of topics discussed in the Preliminary Decision Memorandum is included as Appendix II to this notice. The Preliminary Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System, which is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                     In addition, a complete version of the Preliminary Decision Memorandum can be accessed at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Decision Memorandum for the Preliminary Affirmative Determination in the Countervailing Duty Investigation of Large Diameter Graphite Electrodes from the People's Republic of China,” dated concurrently with, and hereby adopted by, this notice (Preliminary Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The products covered by this investigation are large graphite electrodes from China. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the 
                    <E T="03">Preamble</E>
                     to Commerce's regulations,
                    <SU>4</SU>
                    <FTREF/>
                     in the 
                    <E T="03">Initiation Notice</E>
                     we set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>5</SU>
                    <FTREF/>
                     Certain interested parties commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     For a summary of the product coverage comments and rebuttal responses submitted to the record for this preliminary determination, and accompanying discussion and analysis of all comments timely received, 
                    <E T="03">see</E>
                     the Preliminary Scope Decision Memorandum.
                    <SU>6</SU>
                    <FTREF/>
                     Commerce is preliminarily modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the revised scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997) (
                        <E T="03">Preamble</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See Initiation Notice,</E>
                         91 FR at 13577.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Less-Than-Fair-Value and Countervailing Duty Investigations of Large Diameter Graphite Electrodes from India and the People's Republic of China: Preliminary Scope Decision Memorandum,” dated concurrently with this notice (Preliminary Scope Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Methodology</HD>
                <P>
                    Commerce is conducting this investigation in accordance with section 701 of the Act. For each of the subsidy programs found countervailable, Commerce preliminarily determines that there is a subsidy, 
                    <E T="03">i.e.,</E>
                     a financial contribution by an “authority” that gives rise to a benefit to the recipient, and that the subsidy is specific.
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See</E>
                         sections 771(5)(B) and (D) of the Act regarding financial contribution; section 771(5)(E) of the Act regarding benefit; and section 771(5A) of the Act regarding specificity.
                    </P>
                </FTNT>
                <P>
                    Commerce notes that, in making these findings, it relied on facts available and, because we found that the respondents did not act to the best of their ability to respond to Commerce's requests for information, we drew an adverse inference where appropriate in selecting from among the facts otherwise available.
                    <SU>8</SU>
                    <FTREF/>
                     For further information, 
                    <E T="03">see</E>
                     the “Use of Facts Otherwise Available and Adverse Inferences” section in the Preliminary Decision Memorandum.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         sections 776(a) and (b) of the Act.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Alignment</HD>
                <P>
                    As noted in the Preliminary Decision Memorandum, in accordance with section 705(a)(1) of the Act and 19 CFR 351.210(b)(4), Commerce is aligning the final determination in this countervailing duty (CVD) investigation with the final determination in the companion less-than-fair-value (LTFV) investigation of large graphite electrodes from China based on a request made by the petitioners.
                    <SU>9</SU>
                    <FTREF/>
                     Consequently, the final determination in this CVD investigation will be issued on the same date as the final determination in the LTFV investigation of large graphite electrodes from China, which is currently scheduled to be issued no later than December 7, 2026, unless postponed.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         The petitioners are the Large Diameter Graphite Electrodes Fair Trade Coalition and its individual members, Resonac Graphite America Inc. and Tokai Carbon GE LLC. 
                        <E T="03">See</E>
                         Petitioner's Letter, “Petitioners' Request to Align Final Countervailing Duty Determinations with the Companion Antidumping Duty Final Determinations,” dated June 24, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">All-Others Rate</HD>
                <P>
                    Sections 703(d) and 705(c)(5)(A) of the Act provide that, in the preliminary determination, Commerce shall determine an estimated all-others rate for companies not individually examined. This rate shall be an amount equal to the weighted average of the estimated subsidy rates established for those companies individually examined, excluding any zero and 
                    <E T="03">de minimis</E>
                     rates and any rates based entirely under section 776 of the Act.
                </P>
                <P>
                    Pursuant to section 705(c)(5)(A)(ii) of the Act, if the individual estimated countervailable subsidy rates established for all exporters and producers individually examined are zero, 
                    <E T="03">de minimis,</E>
                     or determined based entirely on facts otherwise available, Commerce may use “any reasonable method” to establish the estimated subsidy rate for all other producers or exporters. In this investigation, Commerce preliminarily determined the estimated subsidy rate for each of the individually examined respondents based entirely on facts available under section 776 of the Act. Thus, this is the only rate available in this proceeding for deriving the all-others rate. Consequently, pursuant to sections 703(d) and 705(c)(5)(A)(ii) of the Act, Commerce established the all-others rate by applying the countervailable subsidy rate assigned to the non-responsive mandatory respondents.
                </P>
                <HD SOURCE="HD1">Preliminary Determination</HD>
                <P>Commerce preliminarily determines that the following estimated countervailable subsidy rates exist:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s25,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Company</CHED>
                        <CHED H="1">
                            Subsidy rate
                            <LI>(percent</LI>
                            <LI>
                                <E T="03">ad valorem</E>
                                )
                            </LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Dantan New Materials Co., Ltd</ENT>
                        <ENT>* 103.49</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Shanxi Juxian Graphite New Material Co., Ltd</ENT>
                        <ENT>* 103.49</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">All Others</ENT>
                        <ENT>103.49</ENT>
                    </ROW>
                    <TNOTE>* Rate is based on facts available with adverse inferences.</TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">Suspension of Liquidation</HD>
                <P>
                    In accordance with section 703(d)(2) of the Act, Commerce will direct U.S. Customs and Border Protection (CBP) to suspend liquidation of entries of subject merchandise as described in the scope of the investigation section entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    . Further, pursuant to section 703(d)(1)(B) of the Act and 19 CFR 351.107(e), Commerce will instruct CBP to require a cash deposit equal to the estimated company-specific countervailable subsidy rate or the estimated all-others rate, as follows: (1) the cash deposit rate for the respondents listed above will be equal to the company-specific estimated individual countervailable subsidy rates determined in this preliminary determination; (2) if both the producer 
                    <PRTPAGE P="48078"/>
                    and exporter of the subject merchandise have company-specific estimated subsidy rates determined in this preliminary determination, and their rates differ, then the applicable cash deposit rate will be the higher of these two rates; (3) if either the producer or the exporter, but not both, of the subject merchandise have a company-specific estimated subsidy rate determined in this preliminary determination, the applicable cash deposit rate will be that company's company-specific rate; and (4) the cash deposit rate for all other producers and exporters will be equal to the estimated all-others subsidy rate.
                </P>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>Normally, Commerce discloses its calculations and analysis performed in connection with the preliminary determination to interested parties within five days of its public announcement, or if there is no public announcement, within five days of the date of publication of this notice, in accordance with 19 CFR 351.224(b). However, because Commerce preliminarily relied on total adverse facts available (AFA) in the calculation of the benefit for the individually examined companies, Dantan New Materials Co., Ltd. and Shanxi Juxian Graphite New Material Co., Ltd. in this investigation, in accordance with section 776 of the Act, and the applied AFA rates are based on rates calculated in prior proceedings, there are no calculations to disclose.</P>
                <HD SOURCE="HD1">Verification</HD>
                <P>Because the examined respondents in this investigation did not provide information requested by Commerce and Commerce preliminarily determines each of the examined respondents to have been uncooperative, it will not conduct verification.</P>
                <HD SOURCE="HD1">Public Comment</HD>
                <P>The deadlines to submit scope case and rebuttal briefs are provided in the Preliminary Scope Decision Memorandum. For all scope case and rebuttal briefs, parties must file identical documents simultaneously on the records of the ongoing LTFV and CVD large graphite electrodes. No new factual information or business proprietary information may be included in either scope case or rebuttal briefs</P>
                <P>
                    Non-scope related case briefs or other written comments may be submitted to the Assistant Secretary for Enforcement and Compliance no later than 30 days after the date of publication of the preliminary determination.
                    <SU>10</SU>
                    <FTREF/>
                     Rebuttal briefs, limited to issues raised in the case briefs, may be filed not later than five days after the date for filing case briefs.
                    <SU>11</SU>
                    <FTREF/>
                     Interested parties who submit case or rebuttal briefs in this proceeding must submit: (1) a table of contents listing each issue; and (2) a table of authorities.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(c)(1)(i); 
                        <E T="03">see also</E>
                         19 CFR 351.303 (for general filing requirements).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(d); 
                        <E T="03">see also Administrative Protective Order, Service, and Other Procedures in Antidumping and Countervailing Duty Proceedings,</E>
                         88 FR 67069, 67077 (September 29, 2023) (
                        <E T="03">APO and Service Final Rule</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(c)(2) and (d)(2).
                    </P>
                </FTNT>
                <P>
                    As provided under 19 CFR 351.309(c)(2)(iii) and (d)(2)(iii), we request that interested parties provide at the beginning of their briefs a public, executive summary for each issue raised in their briefs.
                    <SU>13</SU>
                    <FTREF/>
                     Further, we request that interested parties limit their executive summary of each issue to no more than 450 words, not including citations. We intend to use the executive summaries as the basis of the comment summaries included in the issues and decision memorandum that will accompany the final determination in this investigation. We request that interested parties include footnotes for relevant citations in the executive summary of each issue. Note that Commerce has amended certain of its requirements pertaining to the service of documents in 19 CFR 351.303(f).
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         We use the term “issue” here to describe an argument that Commerce would normally address in a comment of the Issues and Decision Memorandum.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See APO and Service Final Rule.</E>
                    </P>
                </FTNT>
                <P>Pursuant to 19 CFR 351.310(c), interested parties who wish to request a hearing, limited to issues raised in the case and rebuttal briefs, must submit a written request to the Assistant Secretary for Enforcement and Compliance, U.S. Department of Commerce, within 30 days after the date of publication of this notice. Requests should contain (1) the party's name, address, and telephone number; (2) the number of participants and whether any participant is a foreign national; and (3) a list of the issues to be discussed. If a request for a hearing is made, Commerce intends to hold the hearing at a time and date to be determined. Parties should confirm by telephone the date, time, and location of the hearing two days before the scheduled date.</P>
                <HD SOURCE="HD1">U.S. International Trade Commission (ITC) Notification</HD>
                <P>In accordance with section 703(f) of the Act, Commerce will notify the ITC of its determination. If the final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after the final determination whether imports of large graphite electrodes from China are materially injuring, or threaten material injury to, the U.S. industry.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This determination is issued and published pursuant to sections 703(f) and 777(i) of the Act, and 19 CFR 351.205(c).</P>
                <SIG>
                    <DATED>Dated: July 24, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I—Scope of the Investigation</HD>
                <EXTRACT>
                    <P>The merchandise covered by this investigation includes all large diameter graphite electrodes of any length, whether or not finished, of a kind used in furnaces, with a nominal or actual diameter exceeding 425 millimeters (16.7 inches), and whether or not attached to a graphite pin joining system or any other type of joining system or hardware. The merchandise covered by the investigation also includes graphite pin joining systems (commonly referred to as pins or nipples) for large diameter graphite electrodes, of any length, and with a minimum diameter of 228.6 mm (9 inches) at its widest transverse cross-section, whether or not finished, of a kind used in furnaces, and whether or not the graphite pin joining system is attached to, sold with, or sold separately from, the large diameter graphite electrode. Unfinished large diameter graphite electrodes are graphitized electrodes that have not undergone final machining. For purposes of the investigation, the country of origin is determined by the country of graphitization.</P>
                    <P>
                        Excluded from the scope of the investigation are large diameter graphite electrodes that are subject to the existing antidumping duty order on Small Diameter Graphite Electrodes from the People's Republic of China. 
                        <E T="03">See Antidumping Duty Order: Small Diameter Graphite Electrodes from the People's Republic of China,</E>
                         74 FR 8775 (February 26, 2009) (
                        <E T="03">SDGE China AD Order</E>
                        ) due to an affirmative determination of circumvention that imports of graphite electrodes from the People's Republic of China, produced and/or exported by Sinosteel Jilin Carbon Co., Ltd. and Jilin Carbon Import &amp; Export Company (collectively, Jilin Carbon), with an actual or nominal diameter of 17 inches and otherwise meeting the description of the scope of the 
                        <E T="03">SDGE China AD Order</E>
                         constitute merchandise subject to the 
                        <E T="03">SDGE China AD Order. See Small Diameter Graphite Electrodes from the People's Republic of China: Affirmative Final Determination of Circumvention of the Antidumping Duty Order and Rescission of Later-Developed Merchandise Anticircumvention Inquiry,</E>
                         78 FR 56864 (September 16, 2013). In the case of graphite electrodes entering the United 
                        <PRTPAGE P="48079"/>
                        States determined to be subject to the 
                        <E T="03">SDGE China AD Order,</E>
                         such order controls. In the case of graphite electrodes entering the United States meeting the scope definition of the investigation and not covered by the scope of the 
                        <E T="03">SDGE China AD Order,</E>
                         the scope of the investigation controls.
                    </P>
                    <P>Large diameter graphite electrodes and graphite pin joining systems for large diameter graphite electrodes that are covered by the investigation are currently classified under the Harmonized Tariff Schedule of the United States (HTSUS) statistical reporting number 8545.11.0020. Merchandise covered by the investigation may also enter under HTSUS statistical reporting numbers 3801.10.5090 or 3801.90.0050. The HTSUS numbers are provided for convenience and customs purposes, but the written description of the scope is dispositive.</P>
                    <P>Excluded from the scope of the investigation are certain thermal energy storage (TES) graphite blocks. The excluded TES graphite blocks are machine-milled, non-cylindrical graphite blocks, which have: a coefficient of thermal expansion of 1.5 µm/(m·K) or greater, and an apparent (also known as bulk) density below 1.74 g/cm3, and which have an actual length of between 228.6 mm (9.0 inches) and 3010 mm (118.5 inches), an actual width between 228.6 mm (9.0 inches) and 560 mm (22.0 inches), an actual height between 228.6 mm (9.0 inches) and 560 mm (22.0 inches), and which have been machined to include two or more holes of at least 150 mm (5.9 inches) in depth and at least 35 mm (1.4 inches) in diameter.</P>
                    <P>The two or more 150 mm deep holes must be located: (i) along the longest centerline of the longest side of the block, each located on the same side of the block, (ii) spaced at intervals of no greater than 1000 mm (39.4 inches) apart as measured from the outer edge of the holes, and (iii) with the hole closest to each end of the longest centerline located within 1000 mm of the corresponding end of the block. Blocks may contain any number of additional holes, channels, or grooves in any configuration or location, provided that at least two or more holes of at least 150 mm depth are present as described above.</P>
                    <P>Further excluded from the scope of the investigation are certain TES graphite blocks, anchors, and pins, regardless of shape, which have a coefficient of thermal expansion of 1.5 µm/(m·K) or greater, and an apparent (also known as bulk) density below 1.74 g/cm3, with actual dimensions such that any one or more of the length, width, or height is less than 228.6 mm (9.0 inches).</P>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II—List of Topics Discussed in the Preliminary Decision Memorandum</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">III. Injury Test</FP>
                    <FP SOURCE="FP-2">IV. Analysis of China's Financial System</FP>
                    <FP SOURCE="FP-2">V. Diversification of China's economy</FP>
                    <FP SOURCE="FP-2">VI. Use of Facts Otherwise Available and Adverse Inferences</FP>
                    <FP SOURCE="FP-2">VII. Subsidies Valuation</FP>
                    <FP SOURCE="FP-2">VIII. Analysis of Programs</FP>
                    <FP SOURCE="FP-2">IX. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15397 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[A-570-028]</DEPDOC>
                <SUBJECT>Hydrofluorocarbon Blends From the People's Republic of China: Final Results of Antidumping Duty Administrative Review and Final Determination of No Shipments; 2023-2024</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that certain exporters of hydrofluorocarbon blends (HFC blends) from the People's Republic of China (China) sold subject merchandise at less than normal value during the period of review (POR), August 1, 2023, through July 31, 2024. Further, we also determine that Zhejiang Yonghe Refrigerant Co., Ltd. (Zhejiang Yonghe) had no shipments of subject merchandise to the United States during the POR.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Caroline Carroll, AD/CVD Operations, Office IX, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-4948.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On February 10, 2026, we published the 
                    <E T="03">Preliminary Results</E>
                     and invited interested parties to comment.
                    <SU>1</SU>
                    <FTREF/>
                     We received timely case and rebuttal briefs from the American HFC Coalition (the petitioner) and Zhejiang Sanmei Chemical Industry Co., Ltd. (Sanmei).
                    <SU>2</SU>
                    <FTREF/>
                     On May 20, 2026, and July 2, 2026, Commerce extended the deadline of the final results of this administrative review, in accordance with section 751(a)(3)(A) of the Tariff Act of 1930, as amended (the Act), and 19 CFR 351.213(h)(2); 
                    <SU>3</SU>
                    <FTREF/>
                     accordingly, the deadline is now July 24, 2026.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Hydrofluorocarbon Blends from the People's Republic of China: Preliminary Results of the Antidumping Duty Administrative Review and Preliminary Determination of No Shipments; 2023-2024,</E>
                         91 FR 5905 (February 10, 2026) (
                        <E T="03">Preliminary Results</E>
                        ), and accompanying Preliminary Decision Memorandum.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See</E>
                         Petitioner's Letter, “Petitioner's Case Brief,” dated March 6, 2026; 
                        <E T="03">see also</E>
                         Sanmei's Letter, “Case Brief,” dated March 3, 2026; Petitioner's Letter, “HFC Coalition's Rebuttal Brief,” dated March 13, 2026; and Sanmei's Letter, “Rebuttal Brief,” dated March 13, 2026.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Extension of Deadline for Final Results of 2023-2024 Antidumping Duty Administrative Review,” dated May 20, 2026; 
                        <E T="03">see also</E>
                         Memorandum, “Extension of Deadline for Final Results of 2023-2024 Antidumping Duty Administrative Review,” dated July 2, 2026.
                    </P>
                </FTNT>
                <P>
                    For details regarding the events that occurred since the 
                    <E T="03">Preliminary Results, see</E>
                     the Issues and Decision Memorandum.
                    <SU>4</SU>
                    <FTREF/>
                     The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                     In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                     Commerce conducted this administrative review in accordance with section 751 of the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Issues and Decision Memorandum for the Final Results of the Antidumping Duty Administrative Review of Hydrofluorocarbon Blends from the People's Republic of China and Final Determination of No Shipments; 2023-2024,” dated concurrently with, and hereby adopted by, this notice (Issues and Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">
                    Scope of the Order 
                    <SU>5</SU>
                    <FTREF/>
                </HD>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See Hydrofluorocarbon Blends from the People's Republic of China: Antidumping Duty Order,</E>
                         81 FR 55436 (August 19, 2016) (
                        <E T="03">Order</E>
                        ).
                    </P>
                </FTNT>
                <P>
                    The products covered by this 
                    <E T="03">Order</E>
                     are HFC blends from China. For a complete description of the scope of the 
                    <E T="03">Order, see</E>
                     the Issues and Decision Memorandum.
                </P>
                <HD SOURCE="HD1">Analysis of Comments Received</HD>
                <P>We addressed all the issues raised in the case and rebuttal briefs in the Issues and Decision Memorandum. A list of the issues that parties raised is provided in Appendix I of this notice.</P>
                <HD SOURCE="HD1">Final Determination of No Shipments</HD>
                <P>
                    In the 
                    <E T="03">Preliminary Results,</E>
                     we determined that Zhejiang Yonghe did not have shipments of subject merchandise during the POR.
                    <SU>6</SU>
                    <FTREF/>
                     We received no comments regarding Zhejiang Yonghe from interested parties. Therefore, we continue to find that Zhejiang Yonghe had no shipments of subject merchandise during the POR and we will issue appropriate liquidation instructions regarding this company consistent with our “automatic assessment” clarification for these final results.
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See Preliminary Results,</E>
                         91 FR at 5906.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Non-Market Economy Antidumping Proceedings: Assessment of Antidumping Duties,</E>
                         76 FR 65694 (October 24, 2011) (
                        <E T="03">Non-Market Economy Assessment Notice</E>
                        ).
                    </P>
                </FTNT>
                <PRTPAGE P="48080"/>
                <HD SOURCE="HD1">Separate Rate</HD>
                <P>
                    In the 
                    <E T="03">Preliminary Results,</E>
                     we found that that Sanmei, the only company individually examined in this review, is eligible to receive a separate rate. For the final results, we continue to find that Sanmei has demonstrated its eligibility for a separate rate in this review.
                </P>
                <HD SOURCE="HD1">China-Wide Entity</HD>
                <P>
                    Under Commerce's policy regarding conditional review of the China-wide entity,
                    <SU>8</SU>
                    <FTREF/>
                     the China-wide entity will not be under review unless a party specifically requests, or Commerce self-initiates, a review of the entity. Because no party requested a review of the China-wide entity, the entity is not under review, and the entity's rate (
                    <E T="03">i.e.,</E>
                     216.37 percent) 
                    <SU>9</SU>
                    <FTREF/>
                     is not subject to change. Commerce considers the companies under review listed in Appendix II to this notice, which did not file a separate rate application or demonstrate separate rate eligibility, to be part of the China-wide entity.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See Antidumping Proceedings: Announcement of Change in Department Practice for Respondent Selection in Antidumping Duty Proceedings and Conditional Review of the Nonmarket Economy Entity in NME Antidumping Duty Proceedings,</E>
                         78 FR 65963 (November 4, 2013).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See Order.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Final Results of Review</HD>
                <P>Commerce determines that the following estimated weighted-average dumping margin exists for the period August 1, 2023, through July 31, 2024:</P>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s50,9C">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Exporter</CHED>
                        <CHED H="1">weighted-average dumping margin (percent)</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Zhejiang Sanmei Chemical Industry Co., Ltd.; Jiangsu Sanmei Chemical Ind. Co., Ltd.; Fujian Qingliu Dongying Chemical Ind. Co., Ltd</ENT>
                        <ENT>182.61</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    Normally, Commerce discloses to interested parties the calculations of the final results of an administrative review within five days of a public announcement or, if there is no public announcement, within five days of the date of publication of the final results in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b). However, because we have made no changes from the 
                    <E T="03">Preliminary Results,</E>
                     there are no new calculations to disclose.
                </P>
                <HD SOURCE="HD1">Assessment Rates</HD>
                <P>
                    Pursuant to section 751(a)(2)(C) of the Act, and 19 CFR 351.212(b), Commerce will determine, and U.S. Customs and Border Protection (CBP) shall assess, antidumping duties on all appropriate entries of subject merchandise in accordance with the final results of this review. Commerce intends to issue assessment instructions to CBP no earlier than 35 days after the date of publication of the final results of this review in the 
                    <E T="04">Federal Register</E>
                    . If a timely summons is filed at the U.S. Court of International Trade, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired (
                    <E T="03">i.e.,</E>
                     within 90 days of publication).
                </P>
                <P>
                    For Sanmei, Commerce will calculate importer-specific assessment rates for antidumping duties, in accordance with 19 CFR 351.212(b)(1). Where the respondent reported reliable entered values, Commerce intends to calculate importer-specific ad valorem assessment rates by aggregating the amount of dumping calculated for all U.S. sales to the importer and dividing this amount by the total entered value of the merchandise sold to the importer.
                    <SU>10</SU>
                    <FTREF/>
                     Where the respondent did not report entered values, Commerce will calculate importer-specific assessment rates by dividing the amount of dumping for reviewed sales to the importer by the total quantity of those sales. Commerce will calculate an estimated ad valorem importer-specific assessment rate to determine whether the per-unit assessment rate is 
                    <E T="03">de minimis</E>
                     (
                    <E T="03">i.e.,</E>
                     0.50 percent or below); however, Commerce will use the per-unit assessment rate where entered values were not reported.
                    <SU>11</SU>
                    <FTREF/>
                     Where an importer-specific ad valorem assessment rate is not zero or 
                    <E T="03">de minimis,</E>
                     Commerce will instruct CBP to collect the appropriate duties at the time of liquidation. Where either the respondent's weighted-average dumping margin is zero or de minimis, or an importer-specific ad valorem assessment rate is zero or de minimis, Commerce will instruct CBP to liquidate appropriate entries without regard to antidumping duties.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.212(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.106(c)(2); 
                        <E T="03">see also Antidumping Proceeding: Calculation of the Weighted-Average Dumping Margin and Assessment Rate in Certain Antidumping Proceedings; Final Modification,</E>
                         77 FR 8101, 8103 (February 14, 2012).
                    </P>
                </FTNT>
                <P>
                    Pursuant to Commerce's assessment practice,
                    <SU>13</SU>
                    <FTREF/>
                     for entries that were not reported in the U.S. data submitted by Sanmei, we will instruct to CBP to liquidate such entries at the China-wide rate (
                    <E T="03">i.e.,</E>
                     216.37 percent).
                    <SU>14</SU>
                    <FTREF/>
                     Additionally, where Commerce determined that an exporter under review had no shipments of subject merchandise to the United States during the POR, any suspended entries of subject merchandise that entered under that exporter's CBP case number during the POR will be liquidated at the weighted-average dumping margin assigned to the China-wide entity.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See Non-Market Economy Assessment Notice,</E>
                         76 FR at 65694, for a full discussion of this practice.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See Order.</E>
                    </P>
                </FTNT>
                <P>For the companies listed in Appendix II found to be part of the China-wide entity, we will instruct CBP to liquidate all entries of subject merchandise during the POR exported by these companies at the China-wide assessment rate. Further, for Zhejiang Yonghe, the company determined to have no shipments, we will instruct CBP to assess antidumping duties on all appropriate entries at a rate equal to the cash deposit rate of estimated antidumping duties required at the time of entry, or withdrawal from warehouse, for consumption, in accordance with 19 CFR 351.212(c)(1)(i).</P>
                <HD SOURCE="HD1">Cash Deposit Requirements</HD>
                <P>
                    The following cash deposit requirements will be effective for shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the publication date for the final results of review, as provided for by section 751(a)(2)(C) of the Act: (1) for Sanmei, the cash deposit rate will be the rate established in the final results of this review; (2) for previously investigated or reviewed exporters not under review that have separate rates, the cash deposit rate will continue to be the existing exporter-specific rate published for the most recently-completed segment of this proceeding; (3) for all Chinese exporters of subject merchandise that have not been found to be entitled to a separate rate, the cash deposit rate will be the rate for the China-wide entity (
                    <E T="03">i.e.,</E>
                     216.37 percent); and (4) for all exporters of subject merchandise which are not located in China and have not received their own rate, the cash deposit rate will be the rate applicable to the Chinese exporter(s) that supplied that non-China exporter. These cash deposit requirements, when imposed, shall remain in effect until further notice.
                </P>
                <HD SOURCE="HD1">Notification to Importers</HD>
                <P>
                    This notice serves as a final reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping and/or countervailing 
                    <PRTPAGE P="48081"/>
                    duties prior to liquidation of the relevant entries during this POR. Failure to comply with this requirement could result in Commerce's presumption that reimbursement of antidumping and/or countervailing duties occurred and the subsequent assessment of double antidumping duties, and/or an increase in the amount of antidumping duties by the amount of the countervailing duties.
                </P>
                <HD SOURCE="HD1">Administrative Protective Order</HD>
                <P>This notice also serves as a reminder to parties subject to an administrative protective order (APO) of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3), which continues to govern business proprietary information in this segment of the proceeding. Timely written notification of the return or destruction of APO materials, or conversion to judicial protective order, is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>We are issuing these final results of administrative review and publishing this notice in accordance with sections 751(a)(1) and 777(i)(1) of the Act, and 19 CFR 351.213(h)(1) and 351.221(b)(5).</P>
                <SIG>
                    <DATED>Dated: July 24, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">
                        III. Scope of the 
                        <E T="03">Order</E>
                    </FP>
                    <FP SOURCE="FP-2">IV. Discussion of the Issues</FP>
                    <FP SOURCE="FP1-2">Comment 1: Selection of Primary Surrogate Country</FP>
                    <FP SOURCE="FP1-2">Comment 2: Selection of Surrogate Value for Fluorite Powder</FP>
                    <FP SOURCE="FP1-2">Comment 3: Reporting of By-Product Offsets</FP>
                    <FP SOURCE="FP-2">V. Recommendation</FP>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Companies Found to Be Part of the China-Wide Entity</HD>
                    <FP SOURCE="FP-2">1. Best Inc. Limited</FP>
                    <FP SOURCE="FP-2">2. Changzhou Vista Chemical Co., Ltd.</FP>
                    <FP SOURCE="FP-2">3. Daikin Fluorochemicals (China) Co., Ltd.</FP>
                    <FP SOURCE="FP-2">4. Dongyang Weihua Refrigerants Co., Ltd.</FP>
                    <FP SOURCE="FP-2">5. Hangzhou Icetop Refrigeration Co., Ltd.</FP>
                    <FP SOURCE="FP-2">6. ICool Chemical Co. Ltd.</FP>
                    <FP SOURCE="FP-2">7. Oasis Chemical Co., Limited</FP>
                    <FP SOURCE="FP-2">8. Qingdao Shingchem New Material Co.</FP>
                    <FP SOURCE="FP-2">9. Sinochem Environmental Protection Chemicals (Taicang) Co., Ltd.</FP>
                    <FP SOURCE="FP-2">10. Superfy Industrial Limited</FP>
                    <FP SOURCE="FP-2">11. Tianjin Synergy Gases Products, Co., Ltd.</FP>
                    <FP SOURCE="FP-2">12. Weitron International Refrigeration Equipment (Kunshan) Co., Ltd.</FP>
                    <FP SOURCE="FP-2">13. Weitron International Refrigeration Equipment Co., Ltd.</FP>
                    <FP SOURCE="FP-2">14. Yangfar Industry Co., Ltd.</FP>
                    <FP SOURCE="FP-2">15. Zhejiang Hoating Lighting Co., Ltd.</FP>
                    <FP SOURCE="FP-2">16. Zhejiang Lantian Environmental Protection Fluoro Material Co. Ltd.</FP>
                    <FP SOURCE="FP-2">17. Zhejiang Quzhou Lianzhou Refrigerants Co., Ltd.</FP>
                    <FP SOURCE="FP-2">18. Zhejiang Zhonglan Refrigeration Technology Co., Ltd.</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15398 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[C-533-949]</DEPDOC>
                <SUBJECT>Large Diameter Graphite Electrodes From India: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination With Final Antidumping Duty Determination</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) preliminarily determines that countervailable subsidies are being provided to producers and exporters of large diameter graphite electrodes (large graphite electrodes) from India. The period of investigation is January 1, 2025, through December 31, 2025. Interested parties are invited to comment on this preliminary determination.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Nathan James or Olivia Woolverton, AD/CVD Operations, Office V, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-5305 or (202) 482-7452, respectively.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    This preliminary determination is made in accordance with section 703(b) of the Tariff Act of 1930, as amended (the Act). Commerce published the notice of initiation of this investigation on March 20, 2026.
                    <SU>1</SU>
                    <FTREF/>
                     On May 6, 2026, Commerce postponed the preliminary determination of this investigation and the revised deadline is now July 24, 2026.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Large Diameter Graphite Electrodes from the People's Republic of China and India: Initiation of Countervailing Duty Investigations,</E>
                         91 FR 13577 (March 20, 2026) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See Large Diameter Graphite Electrodes from the People's Republic of China and India: Postponement of Preliminary Determinations in the Countervailing Duty Investigations,</E>
                         91 FR 24520 (May 6, 2026).
                    </P>
                </FTNT>
                <P>
                    For a complete description of the events that followed the initiation of this investigation, 
                    <E T="03">see</E>
                     the Preliminary Decision Memorandum.
                    <SU>3</SU>
                    <FTREF/>
                     A list of topics discussed in the Preliminary Decision Memorandum is included as Appendix II to this notice. The Preliminary Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System, which is available to registered users at 
                    <E T="03">https://access.trade.gov.</E>
                     In addition, a complete version of the Preliminary Decision Memorandum can be accessed at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Decision Memorandum for the Preliminary Affirmative Determination in the Countervailing Duty Investigation of Large Diameter Graphite Electrodes from India,” dated concurrently with, and hereby adopted by, this notice (Preliminary Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The products covered by this investigation are large graphite electrodes from India. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the 
                    <E T="03">Preamble</E>
                     to Commerce's regulations,
                    <SU>4</SU>
                    <FTREF/>
                     in the 
                    <E T="03">Initiation Notice</E>
                     we set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>5</SU>
                    <FTREF/>
                     Certain interested parties commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     For a summary of the product coverage comments and rebuttal responses submitted to the record for this preliminary determination, and accompanying discussion and analysis of all comments timely received, 
                    <E T="03">see</E>
                     the Preliminary Scope Decision Memorandum.
                    <SU>6</SU>
                    <FTREF/>
                     Commerce is preliminarily modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the revised scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997) (
                        <E T="03">Preamble</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See Initiation Notice,</E>
                         91 FR at 13577.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Less-Than-Fair-Value and Countervailing Duty Investigations of Large Diameter Graphite Electrodes from India and the People's Republic of China: Preliminary Scope Decision Memorandum,” dated concurrently with this notice (Preliminary Scope Decision Memorandum).
                    </P>
                </FTNT>
                <PRTPAGE P="48082"/>
                <HD SOURCE="HD1">Methodology</HD>
                <P>
                    Commerce is conducting this investigation in accordance with section 701 of the Act. For each of the subsidy programs found countervailable, Commerce preliminarily determines that there is a subsidy, 
                    <E T="03">i.e.,</E>
                     a financial contribution by an “authority” that gives rise to a benefit to the recipient, and that the subsidy is specific.
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See</E>
                         sections 771(5)(B) and (D) of the Act regarding financial contribution; section 771(5)(E) of the Act regarding benefit; and section 771(5A) of the Act regarding specificity.
                    </P>
                </FTNT>
                <P>
                    Commerce notes that, in making these findings, we relied, in part, on facts available and, because we found that one or more respondents did not act to the best of their ability to respond to Commerce's requests for information, we drew an adverse inference where appropriate in selecting from among the facts otherwise available.
                    <SU>8</SU>
                    <FTREF/>
                     For further information, 
                    <E T="03">see</E>
                     the “Use of Facts Otherwise Available and Adverse Inferences” section in the Preliminary Decision Memorandum.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         sections 776(a) and (b) of the Act.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Alignment</HD>
                <P>
                    As noted in the Preliminary Decision Memorandum, in accordance with section 705(a)(1) of the Act and 19 CFR 351.210(b)(4), Commerce is aligning the final determination in this countervailing duty (CVD) investigation with the final determination in the companion less-than-fair-value (LTFV) investigation of large graphite electrodes from India based on a request made by the petitioners.
                    <SU>9</SU>
                    <FTREF/>
                     Consequently, the final determination in this CVD investigation will be issued on the same date as the final determination in the LTFV investigation of large graphite electrodes from India, which is currently scheduled to be issued no later than December 7, 2026, unless postponed.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         The petitioners are the Large Diameter Graphite Electrodes Fair Trade Coalition and its individual members, Resonac Graphite America Inc. and Tokai Carbon GE LLC. 
                        <E T="03">See</E>
                         Petitioner's Letter, “Petitioners' Request to Align Final Countervailing Duty Determinations with the Companion Antidumping Duty Final Determinations,” dated June 24, 2026.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">All-Others Rate</HD>
                <P>
                    Sections 703(d) and 705(c)(5)(A) of the Act provide that, in the preliminary determination, Commerce shall determine an estimated all-others rate for companies not individually examined. This rate shall be an amount equal to the weighted average of the estimated subsidy rates established for those companies individually examined, excluding any zero and 
                    <E T="03">de minimis</E>
                     rates and any rates based entirely under section 776 of the Act.
                </P>
                <P>
                    In this investigation, Commerce calculated individual estimated countervailable subsidy rates for Graphite India Limited (GIL) and HEG Limited (HEG) that are not zero, 
                    <E T="03">de minimis,</E>
                     or based entirely on facts otherwise available. Commerce calculated the all-others rate using a weighted average of the individual estimated subsidy rates calculated for the examined respondents using each company's publicly-ranged values for the subject merchandise.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Pursuant to 19 CFR 351.109(f)(2)(ii), with two respondents under examination, Commerce normally calculates: (A) a weighted-average of the estimated subsidy rates calculated for the examined respondents; (B) a simple average of the estimated subsidy rates calculated for the examined respondents; and (C) a weighted-average of the estimated subsidy rates calculated for the examined respondents using each company's publicly-ranged U.S. sale values for the subject merchandise. Commerce then compares (B) and (C) to (A) and selects the rate closest to (A) as the most appropriate rate for all other producers and exporters. As complete publicly ranged sales data were available, and the weighted average calculated using the publicly-ranged data was closer to the actual weighted-average margin than a simple average, Commerce based the all-others rate on the publicly ranged sales data of the mandatory respondents. For a complete analysis of the data, 
                        <E T="03">see</E>
                         Memorandum, “Preliminary Calculation of the All Others Rate,” dated concurrently with this notice.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Preliminary Determination</HD>
                <P>Commerce preliminarily determines that the following estimated countervailable subsidy rates exist:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s25,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Company</CHED>
                        <CHED H="1">
                            Subsidy rate
                            <LI>(percent</LI>
                            <LI>
                                <E T="03">ad valorem</E>
                                )
                            </LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Graphite India Limited</ENT>
                        <ENT>3.68</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HEG Limited</ENT>
                        <ENT>6.99</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">All Others</ENT>
                        <ENT>5.87</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Suspension of Liquidation</HD>
                <P>
                    In accordance with section 703(d)(2) of the Act, Commerce will direct U.S. Customs and Border Protection (CBP) to suspend liquidation of entries of subject merchandise as described in the scope of the investigation section entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    . Further, pursuant to section 703(d)(1)(B) of the Act and 19 CFR 351.107(e), Commerce will instruct CBP to require a cash deposit equal to the estimated company-specific countervailable subsidy rate or the estimated all-others rate, as follows: (1) the cash deposit rate for the respondents listed above will be equal to the company-specific estimated individual countervailable subsidy rates determined in this preliminary determination; (2) if both the producer and exporter of the subject merchandise have company-specific estimated subsidy rates determined in this preliminary determination, and their rates differ, then the applicable cash deposit rate will be the higher of these two rates; (3) if either the producer or the exporter, but not both, of the subject merchandise have a company-specific estimated subsidy rate determined in this preliminary determination, the applicable cash deposit rate will be that company's company-specific rate; and (4) the cash deposit rate for all other producers and exporters will be equal to the estimated all-others subsidy rate.
                </P>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>Commerce intends to disclose its calculations and analysis performed to interested parties in this preliminary determination within five days of its public announcement, or if there is no public announcement, within five days of the date of this notice in accordance with 19 CFR 351.224(b).</P>
                <P>Consistent with 19 CFR 351.224(e), Commerce will analyze and, if appropriate, correct any timely allegations of significant ministerial errors by amending the preliminary determination. However, consistent with 19 CFR 351.224(d), Commerce will not consider incomplete allegations that do not address the significance standard under 19 CFR 351.224(g) following the preliminary determination. Instead, Commerce will address such allegations in the final determination together with issues raised in the case briefs or other written comments.</P>
                <HD SOURCE="HD1">Verification</HD>
                <P>As provided in section 782(i)(1) of the Act, Commerce intends to verify the information relied upon in making its final determination.</P>
                <HD SOURCE="HD1">Public Comment</HD>
                <P>The deadlines to submit scope case and rebuttal briefs are provided in the Preliminary Scope Decision Memorandum. For all scope case and rebuttal briefs, parties must file identical documents simultaneously on the records of the ongoing LTFV and CVD large graphite electrodes. No new factual information or business proprietary information may be included in either scope case or rebuttal briefs</P>
                <P>
                    Non-scope related case briefs or other written comments may be submitted to the Assistant Secretary for Enforcement and Compliance no later than seven days after the date on which the last verification report is issued in this investigation. Rebuttal briefs, limited to issues raised in the case briefs, may be 
                    <PRTPAGE P="48083"/>
                    filed not later than five days after the date for filing case briefs.
                    <SU>11</SU>
                    <FTREF/>
                     Interested parties who submit case briefs or rebuttal briefs in this proceeding must submit: (1) a table of contents listing each issue; and (2) a table of authorities.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(d); 
                        <E T="03">see also Administrative Protective Order, Service, and Other Procedures in Antidumping and Countervailing Duty Proceedings,</E>
                         88 FR 67069, 67077 (September 29, 2023) (
                        <E T="03">APO and Service Final Rule</E>
                        ).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.309(c)(2) and (d)(2).
                    </P>
                </FTNT>
                <P>
                    As provided under 19 CFR 351.309(c)(2)(iii) and (d)(2)(iii), we request that interested parties provide at the beginning of their briefs a public, executive summary for each issue raised in their briefs.
                    <SU>13</SU>
                    <FTREF/>
                     Further, we request that interested parties limit their executive summary of each issue to no more than 450 words, not including citations. We intend to use the executive summaries as the basis of the comment summaries included in the Issues and Decision Memorandum that will accompany the final determination in this investigation. We request that interested parties include footnotes for relevant citations in the executive summary of each issue. Note that Commerce has amended certain of its requirements pertaining to the service of documents in 19 CFR 351.303(f).
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         We use the term “issue” here to describe an argument that Commerce would normally address in a comment of the Issues and Decision Memorandum.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See APO and Service Final Rule.</E>
                    </P>
                </FTNT>
                <P>Pursuant to 19 CFR 351.310(c), interested parties who wish to request a hearing, limited to issues raised in the case and rebuttal briefs, must submit a written request to the Assistant Secretary for Enforcement and Compliance, U.S. Department of Commerce within 30 days after the date of publication of this notice. Requests should contain (1) the party's name, address, and telephone number, (2) the number of participants, and whether any participant is a foreign national, and (3) a list of the issues to be discussed. If a request for a hearing is made, Commerce intends to hold the hearing at a time and date to be determined. Parties should confirm by telephone the date, time, and location of the hearing two days before the scheduled date.</P>
                <HD SOURCE="HD1">U.S. International Trade Commission (ITC) Notification</HD>
                <P>In accordance with section 703(f) of the Act, Commerce will notify the ITC of its determination. If the final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after the final determination whether imports of large graphite electrodes from India are materially injuring, or threaten material injury to, the U.S. industry.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This determination is issued and published pursuant to sections 703(f) and 777(i) of the Act, and 19 CFR 351.205(c).</P>
                <SIG>
                    <DATED>Dated: July 24, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I—Scope of the Investigation</HD>
                <EXTRACT>
                    <P>The merchandise covered by this investigation includes all large diameter graphite electrodes of any length, whether or not finished, of a kind used in furnaces, with a nominal or actual diameter exceeding 425 millimeters (16.7 inches), and whether or not attached to a graphite pin joining system or any other type of joining system or hardware. The merchandise covered by the investigation also includes graphite pin joining systems (commonly referred to as pins or nipples) for large diameter graphite electrodes, of any length, and with a minimum diameter of 228.6 mm (9 inches) at its widest transverse cross-section, whether or not finished, of a kind used in furnaces, and whether or not the graphite pin joining system is attached to, sold with, or sold separately from, the large diameter graphite electrode. Unfinished large diameter graphite electrodes are graphitized electrodes that have not undergone final machining. For purposes of the investigation, the country of origin is determined by the country of graphitization.</P>
                    <P>
                        Excluded from the scope of the investigation are large diameter graphite electrodes that are subject to the existing antidumping duty order on Small Diameter Graphite Electrodes from the People's Republic of China. 
                        <E T="03">See Antidumping Duty Order: Small Diameter Graphite Electrodes from the People's Republic of China,</E>
                         74 FR 8775 (February 26, 2009) (
                        <E T="03">SDGE China AD Order</E>
                        ) due to an affirmative determination of circumvention that imports of graphite electrodes from the People's Republic of China, produced and/or exported by Sinosteel Jilin Carbon Co., Ltd. and Jilin Carbon Import &amp; Export Company (collectively, Jilin Carbon), with an actual or nominal diameter of 17 inches and otherwise meeting the description of the scope of the 
                        <E T="03">SDGE China AD Order</E>
                         constitute merchandise subject to the 
                        <E T="03">SDGE China AD Order. See Small Diameter Graphite Electrodes from the People's Republic of China: Affirmative Final Determination of Circumvention of the Antidumping Duty Order and Rescission of Later-Developed Merchandise Anticircumvention Inquiry,</E>
                         78 FR 56864 (September 16, 2013). In the case of graphite electrodes entering the United States determined to be subject to the 
                        <E T="03">SDGE China AD Order,</E>
                         such order controls. In the case of graphite electrodes entering the United States meeting the scope definition of the investigation and not covered by the scope of the 
                        <E T="03">SDGE China AD Order,</E>
                         the scope of the investigation controls.
                    </P>
                    <P>Large diameter graphite electrodes and graphite pin joining systems for large diameter graphite electrodes that are covered by the investigation are currently classified under the Harmonized Tariff Schedule of the United States (HTSUS) statistical reporting number 8545.11.0020. Merchandise covered by the investigation may also enter under HTSUS statistical reporting numbers 3801.10.5090 or 3801.90.0050. The HTSUS numbers are provided for convenience and customs purposes, but the written description of the scope is dispositive.</P>
                    <P>Excluded from the scope of the investigation are certain thermal energy storage (TES) graphite blocks. The excluded TES graphite blocks are machine-milled, non-cylindrical graphite blocks, which have: a coefficient of thermal expansion of 1.5 µm/(m·K) or greater, and an apparent (also known as bulk) density below 1.74 g/cm3, and which have an actual length of between 228.6 mm (9.0 inches) and 3010 mm (118.5 inches), an actual width between 228.6 mm (9.0 inches) and 560 mm (22.0 inches), an actual height between 228.6 mm (9.0 inches) and 560 mm (22.0 inches), and which have been machined to include two or more holes of at least 150 mm (5.9 inches) in depth and at least 35 mm (1.4 inches) in diameter.</P>
                    <P>The two or more 150 mm deep holes must be located: (i) along the longest centerline of the longest side of the block, each located on the same side of the block, (ii) spaced at intervals of no greater than 1000 mm (39.4 inches) apart as measured from the outer edge of the holes, and (iii) with the hole closest to each end of the longest centerline located within 1000 mm of the corresponding end of the block. Blocks may contain any number of additional holes, channels, or grooves in any configuration or location, provided that at least two or more holes of at least 150 mm depth are present as described above.</P>
                    <P>Further excluded from the scope of the investigation are certain TES graphite blocks, anchors, and pins, regardless of shape, which have a coefficient of thermal expansion of 1.5 µm/(m·K) or greater, and an apparent (also known as bulk) density below 1.74 g/cm3, with actual dimensions such that any one or more of the length, width, or height is less than 228.6 mm (9.0 inches).</P>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II—List of Topics Discussed in the Preliminary Decision Memorandum</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">III. Injury Test</FP>
                    <FP SOURCE="FP-2">IV. Diversification of India's Economy</FP>
                    <FP SOURCE="FP-2">V. Use of Facts Available and Adverse Inferences</FP>
                    <FP SOURCE="FP-2">VI. Subsidies Valuation</FP>
                    <FP SOURCE="FP-2">VII. Analysis of Programs</FP>
                    <FP SOURCE="FP-2">VIII. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15396 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48084"/>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[A-487-002]</DEPDOC>
                <SUBJECT>Steel Concrete Reinforcing Bar From Bulgaria: Final Affirmative Determination of Sales at Less Than Fair Value</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Enforcement and Compliance, International Trade Administration, Department of Commerce.</P>
                </AGY>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of Commerce (Commerce) determines that steel concrete reinforcing bar (rebar) from Bulgaria are being, or are likely to be, sold in the United States at less than fair value (LTFV) during the period of investigation (POI) April 1, 2024, through March 31, 2025.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Applicable July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Hermes Pinilla, AD/CVD Operations, Office I, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-3477.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    On March 13, 2026, Commerce published in the 
                    <E T="04">Federal Register</E>
                     its preliminary affirmative determination in the LTFV investigation of rebar from Bulgaria.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Bulgaria: Preliminary Affirmative Determination of Sales at Less Than Fair Value, Postponement of Final Determination,</E>
                         and 
                        <E T="03">Extension of Provisional Measures,</E>
                         91 FR 12351 (March 13, 2026) (
                        <E T="03">Preliminary Determination</E>
                        ), and accompanying Preliminary Decision Memorandum (PDM).
                    </P>
                </FTNT>
                <P>
                    A summary of the events that occurred since the 
                    <E T="03">Preliminary Determination,</E>
                     as well as a full discussion of the issues raised by parties for this final determination, may be found in the Issues and Decision Memorandum.
                    <SU>2</SU>
                    <FTREF/>
                     The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at 
                    <E T="03">http://access.trade.gov.</E>
                     In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at 
                    <E T="03">https://access.trade.gov/frnotices.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See</E>
                         Memorandum, “Issues and Decision Memorandum for the Final Affirmative Determination of Sales at Less Than Fair Value in the Investigation of Steel Concrete Reinforcing Bar from Bulgaria,” dated concurrently with, and hereby adopted by this notice (Issues and Decision Memorandum).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Scope of the Investigation</HD>
                <P>
                    The product covered by this investigation is rebar from Bulgaria. For a complete description of the scope of this investigation, 
                    <E T="03">see</E>
                     Appendix I.
                </P>
                <HD SOURCE="HD1">Scope Comments</HD>
                <P>
                    In accordance with the preamble to Commerce's regulations,
                    <SU>3</SU>
                    <FTREF/>
                     the 
                    <E T="03">Initiation Notice</E>
                     set aside a period of time for parties to raise issues regarding product coverage (
                    <E T="03">i.e.,</E>
                     scope).
                    <SU>4</SU>
                    <FTREF/>
                     No interested party commented on the scope of the investigation as it appeared in the 
                    <E T="03">Initiation Notice.</E>
                     Therefore, Commerce is not modifying the scope language as it appeared in the 
                    <E T="03">Initiation Notice. See</E>
                     the scope in Appendix I to this notice.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See Antidumping Duties; Countervailing Duties, Final Rule,</E>
                         62 FR 27296, 27323 (May 19, 1997).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See Steel Concrete Reinforcing Bar from Algeria, Bulgaria, Egypt, and the Socialist Republic of Vietnam: Initiation of Less-Than-Fair-Value Investigations,</E>
                         90 FR 27846 (June 30, 2025) (
                        <E T="03">Initiation Notice</E>
                        ).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Verification</HD>
                <P>Commerce conducted verifications of the information relied upon in making its final determination in this investigation, in accordance with section 782(i) of the Tariff Act of 1930, as amended (the Act). Specifically, we conducted on-site verifications of the sales and cost information submitted by Promet Steel JSC (Promet) for use in the final determination. We used standard verification procedures, including an examination of relevant sales and accounting records, and original source documents provided by Promet.</P>
                <HD SOURCE="HD1">Analysis of Comments Received</HD>
                <P>All issues raised in the case and rebuttal briefs submitted by interested parties in this investigation are addressed in the Issues and Decision Memorandum. A list of the issues addressed in the Issues and Decision Memorandum is attached to this notice as Appendix II.</P>
                <HD SOURCE="HD1">Changes Since the Preliminary Determination</HD>
                <P>
                    We made certain changes to the margin calculation for Promet since the 
                    <E T="03">Preliminary Determination.</E>
                     For a discussion of these changes, 
                    <E T="03">see</E>
                     the Issues and Decision Memorandum.
                </P>
                <HD SOURCE="HD1">All-Others Rate</HD>
                <P>
                    Section 735(c)(5)(A) of the Act provides that Commerce shall determine an estimated all-others rate for all exporters and producers not individually examined.
                    <SU>5</SU>
                    <FTREF/>
                     This rate shall be an amount equal to the weighted average of the estimated weighted-average dumping margins established for exporters and producers individually investigated, excluding any zero and 
                    <E T="03">de minimis</E>
                     margins, and any margins determined entirely under section 776 of the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.109(f).
                    </P>
                </FTNT>
                <P>
                    In this final determination, Commerce calculated an estimated weighted-average dumping margin for Promet that is not zero, 
                    <E T="03">de minimis,</E>
                     or based entirely on facts otherwise available.
                    <SU>6</SU>
                    <FTREF/>
                     Consequently, the rate calculated for Promet is assigned as the rate for all other producers and exporters.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         19 CFR 351.109(f)(2)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Final Determination</HD>
                <P>Commerce determines that the following estimated weighted-average dumping margins exist for the POI April 1, 2024, through March 31, 2025:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s25,9">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Exporter/producer</CHED>
                        <CHED H="1">
                            Weighted-
                            <LI>average</LI>
                            <LI>dumping</LI>
                            <LI>margin</LI>
                            <LI>(percent)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Promet Steel JSC</ENT>
                        <ENT>53.27</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">All Others</ENT>
                        <ENT>53.27</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Disclosure</HD>
                <P>
                    Commerce intends to disclose the calculations performed in connection with this final determination to interested parties within five days of any public announcement or, if there is no public announcement, within five days of the date of publication of this notice in the 
                    <E T="04">Federal Register</E>
                    , in accordance with 19 CFR 351.224(b).
                </P>
                <HD SOURCE="HD1">Continuation of Suspension of Liquidation</HD>
                <P>
                    In accordance with section 735(c)(1)(B) of the Act, Commerce will instruct U.S. Customs and Border Protection (CBP) to continue to suspend liquidation of all entries of subject merchandise, as described in Appendix I of this notice, which were entered, or withdrawn from warehouse, for consumption on or after March 13, 2026, the date of publication of the 
                    <E T="03">Preliminary Determination</E>
                     in the 
                    <E T="04">Federal Register</E>
                    , for Promet and all other producers and exporters.
                </P>
                <P>
                    Pursuant to section 735(c)(1)(B)(ii) of the Act and 735(c)(5)(A) of the Act, and 19 CFR 351.210(d), upon the publication of this notice, we will instruct CBP to require a cash deposit for estimated weighted-average dumping margin or the estimated all-others rate as follows: (1) the cash deposit rate for the respondent listed above will be equal to the company-specific estimated weighted-average dumping margins determined in this 
                    <PRTPAGE P="48085"/>
                    final determination; (2) if the exporter is not a respondent identified above, but the producer is, then the cash deposit rate will be equal to the company-specific estimated weighted-average dumping margin established for that producer of the subject merchandise; and (3) the cash deposit rate for all other producers and exporters will be equal to the estimated weighted-average dumping margin for all other producers and exporters. These suspension of liquidation instructions will remain in effect until further notice.
                </P>
                <HD SOURCE="HD1">U.S. International Trade Commission</HD>
                <P>In accordance with section 735(d) of the Act, Commerce will notify the U.S. International Trade Commission (ITC) of its final affirmative determination of sales at LTFV. Because Commerce's final determination is affirmative, in accordance with section 735(b)(2) of the Act, the ITC will make its final determination as to whether the domestic industry in the United States is materially injured, or threatened with material injury, by reason of imports or sales (or the likelihood of sales) for importation of subject merchandise no later than 45 days after this final determination. If the ITC determines that material injury or threat of material injury does not exist, the proceeding will be terminated and all cash deposits will be refunded or canceled, and suspension of liquidation will be lifted. If the ITC determines that such injury does exist, Commerce will issue an antidumping duty order directing CBP to assess, upon further instructions by Commerce, antidumping duties on all imports of the subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation, as discussed above in the “Continuation of Suspension of Liquidation” section above.</P>
                <HD SOURCE="HD1">Administrative Protective Order</HD>
                <P>This notice serves as the only reminder to parties subject to an administrative protective order (APO) of their responsibility concerning the disposition of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3), which continues to govern business proprietary information in this segment of the proceeding. Timely written notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a sanctionable violation.</P>
                <HD SOURCE="HD1">Notification to Interested Parties</HD>
                <P>This final determination is issued and published in accordance with sections 735(d) and 777(i) of the Act, and 19 CFR 351.210(c).</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Christopher Abbott,</NAME>
                    <TITLE>Deputy Assistant Secretary for Policy and Negotiations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Appendix I</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">Scope of the Investigation</HD>
                    <P>The merchandise subject to this investigation is steel concrete reinforcing bar imported in either straight length or coil form (rebar) regardless of metallurgy, length, diameter, or grade or lack thereof.</P>
                    <P>The subject merchandise includes rebar that has been further processed in the subject countries or a third country, including but not limited to cutting, grinding, galvanizing, painting, coating, or any other processing that would not otherwise remove the merchandise from the scope of this investigation if performed in the country of manufacture of the rebar.</P>
                    <P>
                        Specifically excluded are plain rounds (
                        <E T="03">i.e.,</E>
                         nondeformed or smooth rebar).
                    </P>
                    <P>The subject merchandise is classifiable in the Harmonized Tariff Schedule of the United States (HTSUS) primarily under item numbers 7213.10.0000, 7214.20.0000, and 7228.30.8010. The subject merchandise may also enter under other HTSUS numbers including 7221.00.0017, 7221.00.0018, 7221.00.0030, 7221.00.0045, 7222.11.0001, 7222.11.0057, 7222.11.0059, 7222.30.0001, 7227.20.0080, 7227.90.6030, 7227.90.6035, 7227.90.6040, 7228.20.1000, and 7228.60.6000. HTSUS numbers are provided for convenience and customs purposes; however, the written description of the scope remains dispositive.</P>
                </EXTRACT>
                <HD SOURCE="HD1">Appendix II</HD>
                <EXTRACT>
                    <HD SOURCE="HD1">List of Topics Discussed in the Issues and Decision Memorandum</HD>
                    <FP SOURCE="FP-2">I. Summary</FP>
                    <FP SOURCE="FP-2">II. Background</FP>
                    <FP SOURCE="FP-2">
                        III. Changes Since the 
                        <E T="03">Preliminary Determination</E>
                    </FP>
                    <FP SOURCE="FP-2">IV. Discussion of the Issues</FP>
                    <FP SOURCE="FP1-2">Comment 1: Whether To Use Promet's Revised Sales Databases</FP>
                    <FP SOURCE="FP1-2">Comment 2: Whether To Reject Petitioner's Comments Regarding Promet's Minor Corrections</FP>
                    <FP SOURCE="FP1-2">Comment 3: Whether To Revise the Major Input Adjustment</FP>
                    <FP SOURCE="FP1-2">Comment 4: Whether To Revise General &amp; Administrative Expense Ratio</FP>
                    <FP SOURCE="FP1-2">Comment 5: Whether To Revise Financial Expense Ratio</FP>
                    <FP SOURCE="FP1-2">Comment 6: Whether To Reject BAMI's Filing</FP>
                    <FP SOURCE="FP-2">V. Recommendation</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15441 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DS-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XF913]</DEPDOC>
                <SUBJECT>New England Fishery Management Council; Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of public meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The New England Fishery Management Council (Council) is scheduling a hybrid public meeting of its Habitat Joint Committee and Advisory Panel to consider actions affecting New England fisheries in the exclusive economic zone (EEZ). Recommendations from this group will be brought to the full Council for formal consideration and action, if appropriate.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        This webinar will be held on Thursday, August 20, 2026, at 9 a.m. Webinar registration URL information: 
                        <E T="03">https://nefmc-org.zoom.us/meeting/register/JPkr4NWtT9OLGt8OYpjZzQ.</E>
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>This meeting will take place at the Fairfield Inn &amp; Suites/Waypoint Event Center, 185 MacArthur Drive, New Bedford, MA 02740 Phone: (774) 634-2000.</P>
                    <P>
                        <E T="03">Council address:</E>
                         New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Cate O'Keefe, Ph.D., Executive Director, New England Fishery Management Council; telephone: (978) 465-0492.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Agenda</HD>
                <P>The Habitat Committee and Advisory Panel will meet to review the draft 2026 Essential Fish Habitat (EFH) Framework including EFH designation alternatives and identify a preferred alternative for Council consideration at the September 15-17 meeting. Species list: Acadian redfish, American plaice, Atlantic halibut, Atlantic sea scallop, Atlantic wolffish, haddock, ocean pout, offshore hake, pollock, red hake, silver hake, white hake, windowpane flounder, winter flounder, witch flounder, and yellowtail flounder. They will also review a draft report about the clam dredge exemption program within the Great South Channel Habitat Management Area. Other business will be discussed, if necessary.</P>
                <P>
                    Although non-emergency issues not contained on the agenda may come before this Council for discussion, those issues may not be the subject of formal 
                    <PRTPAGE P="48086"/>
                    action during this meeting. Council action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency. The public also should be aware that the meeting will be recorded. Consistent with 16 U.S.C. 1852, a copy of the recording is available upon request.
                </P>
                <HD SOURCE="HD1">Special Accommodations</HD>
                <P>This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Cate O'Keefe, Ph.D., Executive Director, at (978) 465-0492, at least 5 days prior to the meeting date.</P>
                <EXTRACT>
                    <FP>
                        (Authority: 16 U.S.C. 1801 
                        <E T="03">et seq.</E>
                        )
                    </FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: July 27, 2026. </DATED>
                    <NAME>Rey Israel Marquez,</NAME>
                    <TITLE>Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15380 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XF886]</DEPDOC>
                <SUBJECT>North Pacific Fishery Management Council; Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of web conference.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The North Pacific Fishery Management Council's (Council) Legislative Committee will meet on August 10, 2026.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The Council's Legislative Committee will begin at 1 to 5 p.m. on Monday, August 10, 2026, Alaska Time.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The meeting will be held via web conference. Join online through the link at 
                        <E T="03">https://meetings.npfmc.org/Meeting/Details/3125.</E>
                    </P>
                    <P>
                        <E T="03">Council address:</E>
                         North Pacific Fishery Management Council, 1007 W 3rd Ave., Suite 400, Anchorage, AK 99501-2252; telephone: (907) 271-2809. Instructions for attending the meeting via web conference are given under 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                        , below.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Diana Evans, Council staff; email: 
                        <E T="03">devans@npfmc.org;</E>
                         telephone: (907) 271-2809. For technical support please contact our Council administrative staff, email: 
                        <E T="03">support@npfmc.org.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Agenda</HD>
                <HD SOURCE="HD2">Monday, August 10, 2026</HD>
                <P>
                    <E T="03">Legislative Committee Agenda:</E>
                     The Legislative Committee agenda will include a review of recently introduced Federal legislation regarding fisheries management, and an evaluation of potential impacts of legislation on the Council's ability to perform the functions specified in its grant, fulfill its responsibilities under the Magnuson-Stevens Act, or affect the Council's ability to conserve and manage marine resources and resource users. The agenda is subject to change, and the latest version will be posted at 
                    <E T="03">https://meetings.npfmc.org/Meeting/Details/3125</E>
                     prior to the meeting, along with meeting materials.
                </P>
                <HD SOURCE="HD1">Connection Information</HD>
                <P>
                    You can attend the meeting online using a computer, tablet, or smart phone; or by phone only. Connection information will be posted online at: 
                    <E T="03">https://meetings.npfmc.org/Meeting/Details/3125.</E>
                     For technical support please contact our administrative staff, email: 
                    <E T="03">support@npfmc.org</E>
                     or by telephone: (907) 271-2809.
                </P>
                <HD SOURCE="HD1">Public Comment</HD>
                <P>
                    Public comment letters will be accepted and should be submitted electronically through the links at 
                    <E T="03">https://meetings.npfmc.org/Meeting/Details/3125.</E>
                     The written comment period closes at 5 p.m. Alaska Time on Friday, August 7, 2026.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 27, 2026. </DATED>
                    <NAME>Rey Israel Marquez,</NAME>
                    <TITLE>Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15319 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XF663]</DEPDOC>
                <SUBJECT>Identifying Aquaculture Opportunity Areas in U.S. Waters</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; request for information.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        NOAA is issuing this request for information (RFI) to collect information to help identify the next geographic region(s) of focus for Aquaculture Opportunity Areas (AOA) identification. On May 7, 2020, the White House issued an Executive Order (E.O.) on Promoting American Seafood Competitiveness and Economic Growth, which requires the Secretary of Commerce to identify geographic areas containing locations suitable for commercial aquaculture. These geographic areas are referred to as AOAs. NOAA requests data, comments, views, information, analysis, or suggestions from the public to support the identification of AOAs in U.S. waters, including geographic areas of focus. NOAA requests that interested parties provide relevant information on the identification of areas within U.S. waters for future AOAs. The public input provided in response to this RFI will inform NOAA as it works with other Federal agencies, Regional Fishery Management Councils, and in coordination with state, jurisdictional and tribal governments to identify AOAs nationally. NOAA will combine input received through consultation and coordination with Federal and non-Federal stakeholders, comments on this notice, and spatial analyses by NOAA's National Centers for Coastal Ocean Science (NCCOS), to help identify the next geographic area(s) to focus on for AOA identification. Please respond to the questions in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section, as appropriate.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Interested persons are invited to submit written comments on or before September 13, 2026. Three webinar-based listening sessions are scheduled. Comments on each topic area will be accepted at all meetings:</P>
                </DATES>
                <FP SOURCE="FP-2">1. August 6, 2026, 6 p.m. to 7 p.m. Pacific (PDT)</FP>
                <FP SOURCE="FP-2">2. August 13, 2026, 12 p.m. to 1 p.m. Hawaii (HST)</FP>
                <FP SOURCE="FP-2">3. August 31, 2026, 3 p.m. to 4 p.m. Eastern (EDT) (English and Spanish)</FP>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments on this document, identified by NOAA-NMFS-2026-2179, by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Electronic Submission:</E>
                         Submit all electronic public comments via the Federal e-Rulemaking Portal. Visit 
                        <E T="03">https://www.regulations.gov</E>
                         and type NOAA-NMFS-2026-2179 in the Search box. Click on the “Comment” icon, complete the required fields, and enter or attach your comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Submit written information to Brian Fredieu, Office of Aquaculture, NOAA Fisheries, Attn: Aquaculture 
                        <PRTPAGE P="48087"/>
                        Opportunity Area, 1315 East West Hwy., Silver Spring, MD 20910.
                    </P>
                    <P>
                        • 
                        <E T="03">Webinar:</E>
                         Comments on each topic area will be accepted at all webinar meetings. Links and toll-free phone numbers for each webinar can be found at:
                        <E T="03"> https://www.fisheries.noaa.gov/national/aquaculture/aquaculture-opportunity-areas.</E>
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         Comments sent by any other method, to any other address or individual, or received after the end of the comment period, may not be considered by NMFS. All comments received are a part of the public record and will generally be posted for public viewing on 
                        <E T="03">https://www.regulations.gov</E>
                         without change. All personal identifying information (
                        <E T="03">e.g.,</E>
                         name, address, 
                        <E T="03">etc.</E>
                        ), confidential business information, or otherwise sensitive information submitted voluntarily by the sender will be publicly accessible. NMFS will accept anonymous comments (enter“N/A” in the required fields if you wish to remain anonymous).
                    </P>
                    <P>
                        Please note that the U.S. Government will not pay for any costs that you may incur in responding to this RFI, or for the use of any information contained in the response. The documents and information submitted in response to this RFI become the property of the U.S. Government and will not be returned. If you are unable to provide electronic comments, please contact NOAA Fisheries at 
                        <E T="03">nmfs.aquaculture.info@noaa.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                         Brian Fredieu, NOAA Fisheries, Office of Aquaculture: 301-427-8578, 
                        <E T="03">nmfs.aquaculture.info@noaa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>On May 7, 2020, the President signed an E.O. on Promoting American Seafood Competitiveness and Economic Growth (E.O. 13921). The E.O. calls for the expansion of sustainable U.S. seafood production. Building on this foundation, the President issued additional executive orders in 2025 to further strengthen domestic seafood production and aquaculture development, including E.O. 14276, Restoring American Seafood Competitiveness, which reaffirms and expands the Federal commitment to growing the U.S. aquaculture industry and reducing the nation's seafood trade deficit. Together, these executive orders direct NOAA to continue the identification of AOAs across U.S. waters and streamline the processes that support sustainable commercial aquaculture. NOAA also has directives to promote sustainable aquaculture in the U.S., including through the National Aquaculture Act of 1980 and the Department of Commerce (DOC) and NOAA Marine Aquaculture Policies. NOAA has a variety of proven science-based tools and strategies that can support these directives and help communities thoughtfully consider how and where to sustainably develop aquaculture that will complement wild-capture fisheries, working waterfronts, and our nation's seafood processing and distribution infrastructure.</P>
                <P>Section 7 of E.O. 13921 directs the Secretary of Commerce to identify AOAs in consultation with the Secretary of Defense, the Secretary of the Interior, the Secretary of Agriculture, the Secretary of Homeland Security, the Administrator of the Environmental Protection Agency, other appropriate Federal officials, and appropriate Regional Fishery Management Councils, and in coordination with appropriate state, jurisdiction and tribal governments. This includes:</P>
                <P>1. Within 1 year of the E.O., identify at least two geographic areas containing locations suitable for commercial aquaculture;</P>
                <P>2. Within 2 years of identifying each area, complete a National Environmental Policy Act (NEPA) Programmatic Environmental Impact Statement (PEIS) for each area to assess the impact of siting aquaculture facilities there;</P>
                <P>3. For each of the following 4 years, identify two additional geographic areas containing locations suitable for commercial aquaculture and complete a PEIS for each within 2 years.</P>
                <P>Identifying AOAs is an opportunity to use the best available science to support sustainable aquaculture management, and support the “triple bottom line” of environmental, economic, and social sustainability. The areas identified as AOAs are defined geographic areas that NOAA has evaluated through both spatial analysis and a programmatic NEPA process that may be environmentally, economically, and socially suitable to support multiple commercial aquaculture operations.</P>
                <P>Identifying AOAs is a planning process. The areas identified as AOAs may be suitable to support aquaculture farms of varying types. Locations for individual operations within an AOA would be considered and evaluated during the permitting process and associated environmental reviews and consultations. Aquaculture operations proposed within an AOA would be subject to the same Federal and state/jurisdiction permitting and authorization requirements as those located elsewhere and would need to comply with all applicable Federal and state laws and regulations.</P>
                <P>NOAA has engaged in the science and public based AOA identification process since 2020. Following issuance of E.O. 13921, NOAA utilized a public comment period to solicit public feedback on identifying prospective regions of focus, selecting the Gulf of America and Southern California as the first regions (85 FR 67519, October 23, 2020). On September 19, 2025, NOAA identified 13 AOAs totaling more than 21,000 acres in U.S. Federal waters of the Gulf of America and off Southern California, after the National Centers for Coastal Ocean Science (NCCOS) published AOAs for these regions in November 2021. On February 19, 2026, the NCCOS published an Atlas for Alaska, identifying 77 options (50 to 2,000 acres) for potential AOA identification across 10 study areas in Gulf of Alaska state waters.</P>
                <HD SOURCE="HD1">AOA Identification Process</HD>
                <P>NOAA is requesting public input on areas that should be considered nationally for future AOA identification and will use the information received from this RFI to help determine where to focus continued efforts.</P>
                <P>To identify AOAs, NOAA will use a combination of spatial mapping approaches, scientific review, public input, and other relevant information. NOAA's National Centers for Coastal Ocean Science will use public input and the best available data to account for key environmental, economic, social, and cultural considerations to identify areas that may support sustainable aquaculture development. NOAA will then combine those results with input from other Federal and state/jurisdictional agencies, Regional Fishery Management Councils, Marine Fisheries Commissions, jurisdictional tribal governments and organizations, and the general public to identify areas that will be considered in more depth through the NEPA process.</P>
                <P>
                    Importantly, AOA identification is a planning process and does not, by itself, result in areas permitted for aquaculture. The AOA process is not a required prerequisite to understanding the impacts of aquaculture in a region. The absence of an AOA does not equate with a lack of scientific understanding of aquaculture's impacts in the region. For example, some forms of aquaculture have been practiced in coastal waters for decades, generating a substantial body of peer-reviewed scientific literature, state-level environmental reviews, and site-specific NEPA analyses. Federal agencies including NOAA, the U.S. Army Corps of Engineers, and the 
                    <PRTPAGE P="48088"/>
                    Environmental Protection Agency have conducted and reviewed numerous environmental assessments and environmental impact statements for aquaculture projects in various regions. The AOA process is a planning process and the absence of an AOA in a given region does not preclude aquaculture development there, nor does it indicate that the environmental impacts of aquaculture in that region are unknown or unexamined. The AOA process is designed to proactively identify suitable areas and improve efficiencies for future permitting.
                </P>
                <P>
                    All aquaculture operations are required to comply with applicable Federal and state laws, regulations and authorizations. Further, aquaculture operations proposed within an AOA would have the same Federal and State permitting and authorization requirements as anywhere else. Site-specific environmental surveys may be required for the permitting process. Additional NEPA analysis beyond the PEIS may be necessary as a part of permitting and authorization processes for individual operations. NOAA will work with the Federal agencies responsible for permitting aquaculture (
                    <E T="03">e.g.,</E>
                     the U.S. Army Corps of Engineers and the Environmental Protection Agency) throughout the AOA identification process to identify information NOAA can include in the PEIS to help inform future permitting needs.
                </P>
                <P>
                    Additional information on AOAs, including frequently asked questions, is available on NOAA's website at: 
                    <E T="03">https://www.fisheries.noaa.gov/insight/aquaculture-opportunity-areas.</E>
                </P>
                <HD SOURCE="HD1">Request for Information</HD>
                <P>NOAA requests data, comments, views, information, analysis, or suggestions from the public to support the identification of AOAs in U.S. waters, including siting parameters that can be used to select potential areas for further analysis. When providing input, please specify:</P>
                <P>• The question number(s) you are responding to;</P>
                <P>• The U.S. region(s) to which your comments apply; and</P>
                <P>
                    • Whether your comments apply to specific type(s) of aquaculture or gear/structure (
                    <E T="03">e.g.,</E>
                     finfish, shellfish, macroalgae/seaweed, or a combination of species).
                </P>
                <P>Responses to this request are voluntary. Respondents need not reply to all questions.</P>
                <HD SOURCE="HD1">Input Requested To Inform the Identification of Future AOAs, Nationally</HD>
                <HD SOURCE="HD2">Question 1</HD>
                <P>What regions of the country should next be considered for future AOAs?</P>
                <P>a. New England (Maine through Connecticut).</P>
                <P>b. Mid-Atlantic (New York through Virginia).</P>
                <P>c. South Atlantic (North Carolina through east coast Florida).</P>
                <P>d. U.S. Caribbean (Puerto Rico and U.S. Virgin Islands).</P>
                <P>e. Pacific Islands (American Samoa, Commonwealth of the Northern Mariana Islands, Guam, Hawaii, and U.S. Pacific Remote Island Areas).</P>
                <HD SOURCE="HD2">Question 2</HD>
                <P>Are there specific locations within those regions identified in response to Question 1 that should be considered for future AOAs? Please be as specific as possible and include latitude and longitude or defining landmarks.</P>
                <HD SOURCE="HD2">Question 3</HD>
                <P>NOAA is soliciting information on technical siting requirements for aquaculture operations to inform spatial analysis for future AOAs. For the region(s) identified in response to Question 1, please provide:</P>
                <P>a. Minimum and maximum depth needed to operate aquaculture farms.</P>
                <P>b. Minimum and maximum current conditions that could impact farm operation.</P>
                <P>c. Minimum and maximum wave climate that could impact farm operation. </P>
                <P>d. Proximity to shore, critical infrastructure and/or coastal communities.</P>
                <HD SOURCE="HD2">Question 4</HD>
                <P>Are there specific locations within U.S. waters in your region that should be considered for AOAs? Are there specific locations that should be avoided? Please be as specific as possible and include latitude and longitude or defining landmarks. Please indicate why such areas should be considered or avoided, for example:</P>
                <P>a. Favorable biological parameters.</P>
                <P>
                    b. Water quality (
                    <E T="03">e.g.,</E>
                     nutrients or other parameters that might make an area favorable or disfavored).
                </P>
                <P>
                    c. Proximity to infrastructure (
                    <E T="03">e.g.,</E>
                     ports, processing plants, hatcheries, or nurseries that could supply seed or fingerlings for grow-out) 
                </P>
                <FP SOURCE="FP-2">d. Relationships to other planned or ongoing activities.</FP>
                <P>e. Proximity to traditionally and culturally important locations or sacred sites.</P>
                <P>
                    f. Presence in or use of an area by protected species (
                    <E T="03">e.g.,</E>
                     large whales, sea turtles, dolphins, sea otters, sea lions, 
                    <E T="03">etc.</E>
                    ).
                </P>
                <HD SOURCE="HD2">Question 5</HD>
                <P>Within those regions identified in response to Question 1, what resource use conflicts should be considered as NOAA identifies future AOAs? Please describe specific considerations that might make an area unfavorable, including ongoing or planned activities or ocean uses.</P>
                <HD SOURCE="HD2">Question 6</HD>
                <P>
                    Are there size limitations NOAA should consider for AOAs (
                    <E T="03">e.g.,</E>
                     maximum or minimum size)? How many farms should fit within an AOA? Should the size of AOAs be aligned with regional or state/jurisdictional economic development goals for aquaculture?
                </P>
                <HD SOURCE="HD2">Question 7</HD>
                <P>
                    Are there aquaculture species or gear considerations that may result in optimized growth? This might include (but is not limited to): species or aquaculture gear depth thresholds, water current thresholds, temperature thresholds, salinity thresholds, 
                    <E T="03">etc.</E>
                     Are there any species or gear not currently being used that you would like to see considered in the future? Please be as specific as possible.
                </P>
                <HD SOURCE="HD2">Question 8</HD>
                <P>Is there ongoing environmental, economic, or social science research that would assist in the identification and implementation of future AOAs? If so, please describe in as much detail as is available.</P>
                <HD SOURCE="HD2">Question 9</HD>
                <P>Is there information that may not be readily available or accessible online that would be useful for AOA planning processes in your region? This includes spatial data or Geographic Information System (GIS) layers representing subsistence, environmental, and socioeconomic considerations, or a point of contact for these data, for the following categories:</P>
                <P>a. Biophysical/oceanographic (ice cover where applicable, temperature, ocean acidification indices, wave climate, currents, bathymetry).</P>
                <P>b. Natural resources (minerals, energy resources, fishes and other aquatic organisms, protected species and habitats, marine mammals, kelp beds, eelgrass beds, coral reefs, biodiversity).</P>
                <P>
                    c. Social, historical, and cultural resources (cultural and subsistence 
                    <PRTPAGE P="48089"/>
                    harvest, community subsistence activities, culturally important sites).
                </P>
                <P>d. Government boundaries. </P>
                <P>e. Industry (fishing, energy production, transportation, communication cables).</P>
                <P>f. Military.</P>
                <P>g. Navigation.</P>
                <P>
                    h. Recreational resources (fishing, hunting, 
                    <E T="03">etc.</E>
                    ).
                </P>
                <HD SOURCE="HD2">Question 10</HD>
                <P>Is there any additional information NOAA should consider?</P>
                <P>
                    <E T="03">Authority:</E>
                     E.O. 13921 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 28, 2026.</DATED>
                    <NAME>Danielle Blacklock,</NAME>
                    <TITLE>Director, Office of Aquaculture, National Marine Fisheries Service. </TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15435 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED</AGENCY>
                <SUBJECT>Procurement List; Additions and Deletions</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Committee for Purchase From People Who Are Blind or Severely Disabled.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Additions to and deletions from the procurement list.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This action adds product(s) and service(s) to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and deletes product(s) and service(s) from the Procurement List previously furnished by such agencies.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Date added to and deleted from the Procurement List:</E>
                         August 29, 2026.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Committee for Purchase From People Who Are Blind or Severely Disabled, 250 E Street SW, Suite 3100, Washington, DC 20024.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For further information or to submit comments contact: Michael R. Jurkowski, Telephone: (703) 489-1322, or email 
                        <E T="03">CMTEFedReg@AbilityOne.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Additions</HD>
                <P>On March 26, 2026 (91 FR 14684) and April 30, 2026 (91 FR 23247), the Committee for Purchase From People Who Are Blind or Severely Disabled (operating as the U.S. AbilityOne Commission) published an initial notice of proposed additions to the Procurement List. The Committee determined that the service(s) listed below are suitable for procurement by the Federal Government and has added these service(s) to the Procurement List as a mandatory purchase for the contracting activities listed. In accordance with 41 CFR 51-5.3(b), the mandatory purchase requirement is limited to the contracting activities at the locations listed, and in accordance with 41 CFR 51-5.2, the Committee has authorized the nonprofit agencies listed as the authorized source(s) of supply.</P>
                <P>On March 26, 2026 (91 FR 14684) and April 30, 2026 (91 FR 23247), the Committee for Purchase From People Who Are Blind or Severely Disabled published notice of proposed additions to the Procurement List. This notice is published pursuant to 41 U.S.C. 8503 (a)(2) and 41 CFR 51-2.3.</P>
                <P>After consideration of the material presented to it concerning capability of qualified nonprofit agencies to provide the service(s) and impact of the additions on the current or most recent contractors, the Committee has determined that the service(s) listed below are suitable for procurement by the Federal Government under 41 U.S.C. 8501-8506 and 41 CFR 51-2.4.</P>
                <HD SOURCE="HD1">Regulatory Flexibility Act Certification</HD>
                <P>I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:</P>
                <P>1. The action will not result in additional reporting, recordkeeping or other compliance requirements for small entities.</P>
                <P>2. The action may result in authorizing small entities to furnish the service(s) to the Government.</P>
                <P>3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 8501-8506) in connection with the service(s) added to the Procurement List.</P>
                <HD SOURCE="HD1">End of Certification</HD>
                <P>Accordingly, the following service(s) are added to the Procurement List:</P>
                <EXTRACT>
                    <HD SOURCE="HD2">Service(s)</HD>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Lawn care
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         NOAA, Atlantic Oceanographic &amp; Meteorological Laboratory, Miami, FL., 4301 Rickenbacker Causeway, Miami, FL
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         Goodwill Industries of South Florida, Inc., Miami, FL
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPARTMENT OF COMMERCE, NOAA
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Base Operations Services
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         US Air Force, Joint Base Elmendorf-Richardson, JBER, AK, 10480 Sijan Avenue, JBER, AK
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         Skookum Educational Programs, Bremerton, WA
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPT OF THE AIR FORCE, FA5000 673 CONS LGC
                    </FP>
                </EXTRACT>
                <P>
                    The Committee finds good cause to dispense with the 30-day delay in the effective date normally required by the Administrative Procedure Act. See 5 U.S.C. 553(d). This addition to the Committee's Procurement List is effectuated because of the expiration of the Department of the Air Force, Base Operations Maintenance Services (BOMS), Joint Base Elmendorf-Richardson (JBER), Anchorage, AK, contract. The Federal customer contacted and has worked diligently with the AbilityOne Program to fulfill this service need under the AbilityOne Program. To avoid performance disruption, and the possibility that the Department of the Air Force will refer its business elsewhere, this addition must be effective on August 9, 2026, ensuring timely execution for a August 9, 2026 start date. The Committee published an initial notice of proposed Procurement List addition in the 
                    <E T="04">Federal Register</E>
                     on March 26, 2026 (91 FR 14684) but did not receive any comments. This addition will not create a public hardship and has limited effect on the public at large. Rather, this addition will create new jobs for other affected parties—people with significant disabilities in the AbilityOne program who otherwise face challenges locating employment. Moreover, this addition enables the Federal customer to continue operations without interruption.
                </P>
                <SIG>
                    <NAME>Michael R. Jurkowski,</NAME>
                    <TITLE>Director, Business Operations.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15348 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6353-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED</AGENCY>
                <SUBJECT>Procurement List; Proposed Additions and Deletions</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Committee for Purchase From People Who Are Blind or Severely Disabled.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed additions to and deletions from the Procurement List.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Committee is proposing to add service(s) to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and delete product(s) and service(s) previously furnished by such agencies.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before: August 29, 2026.</P>
                </DATES>
                <ADD>
                    <PRTPAGE P="48090"/>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Committee for Purchase From People Who Are Blind or Severely Disabled, 250 E Street SW, Suite 3100, Washington, DC 20024.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For further information or to submit comments contact: Michael R. Jurkowski, Telephone: (703) 489-1322, or email 
                        <E T="03">CMTEFedReg@AbilityOne.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This notice is published pursuant to 41 U.S.C. 8503 (a)(2) and 41 CFR 51-2.3. Its purpose is to provide interested persons an opportunity to submit comments on the proposed actions.</P>
                <HD SOURCE="HD1">Additions</HD>
                <P>In accordance with 41 CFR 51-5.3(b), the Committee intends to add the service requirements listed below to the Procurement List as a mandatory purchase only for contracting activities at the locations listed with the proposed qualified nonprofit agency as the authorized source of supply. Prior to adding the service to the Procurement List, the Committee will consider other pertinent information, including information from Government personnel and relevant comments from interested parties regarding the Committee's intent to geographically limit this services requirement.</P>
                <P>The following service(s) are proposed for addition to the Procurement List for production by the nonprofit agencies listed:</P>
                <EXTRACT>
                    <HD SOURCE="HD2">Service(s)</HD>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Subsistence Prime Vendor
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         U.S. Army, Pennsylvania Army National Guard and Air National Guard, Fort Indiantown Gap, PA
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         Opportunity Center, Incorporated, New Castle, DE
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         Pennsylvania Army National Guard, Annville, PA
                    </FP>
                    <HD SOURCE="HD1">Deletions</HD>
                    <P>The following product(s) and service(s) are proposed for deletion from the Procurement List:</P>
                    <HD SOURCE="HD2">Product(s)</HD>
                    <FP SOURCE="FP-2">NSN(s)—Product Name(s):</FP>
                    <FP SOURCE="FP1-2">8465-01-524-7689—Foliage Green</FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         Travis Association for the Blind, Austin, TX
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPT OF DEFENSE, DLA TROOP SUPPORT
                    </FP>
                    <FP SOURCE="FP-2">NSN(s)—Product Name(s):</FP>
                    <FP SOURCE="FP1-2">8955-01-E10-1648—Beverage Base, Non-nutritive, Sweetened, Lemonade </FP>
                    <FP SOURCE="FP1-2">8955-01-E10-1650—Beverage Base, Non-nutritive, Sweetened, Raspberry Ice</FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         BOSMA Enterprises, Indianapolis, IN
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPT OF DEFENSE, DIR OF SUB DLA TROOP SUPPORT
                    </FP>
                    <HD SOURCE="HD2">Service(s)</HD>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Shelf Stocking, Custodial &amp; Warehousing
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         Defense Commissary Agency, Minot Air Force Base Commissary, Minot AFB, ND, 360 Missile Avenue, Bldg. 246, Minot AFB, ND
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         CW Resources, Inc., New Britain, CT
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPT OF DEFENSE, DEFENSE COMMISSARY AGENCY
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Janitorial
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         US Customs and Border Protection, Camp Grip, Wellton, AZ, Devil's Highway, Wellton, AZ
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         ACHIEVE Human Services. Inc., Yuma, AZ
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPARTMENT OF HOMELAND SECURITY, BORDER ENFORCEMENT CTR DIV
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Custodial and Refuse Removal Services
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         Bureau of Land Management, Las Cruces District Office, Upham and I-25 Parking Sites, Las Cruces, NM, 1800 Marquess St., Las Cruces, NM
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         Tresco, Inc., Las Cruces, NM
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPARTMENT OF THE INTERIOR, BLM ALBUQUERQUE DISTRICT OFFICE
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Service Type:</E>
                         Furnishing Management Service
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Mandatory For:</E>
                         US Air Force, Cannon Air Force Base (CAFB), Dormitory Campus, CAFB Fire Department, Base Confinement Area &amp; Fire Department Melrose AF Range, Cannon AFB, NM, 110 E Alison Avenue, Building 600, Cannon AFB, NM
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Authorized Source of Supply:</E>
                         ENMRSH, Inc., Clovis, NM
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Contracting Activity:</E>
                         DEPT OF DEFENSE, FA4855 27 SOCONS LGC
                    </FP>
                </EXTRACT>
                <SIG>
                    <NAME>Michael R. Jurkowski,</NAME>
                    <TITLE>Director, Business Operations.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15349 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6353-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">CORPORATION FOR NATIONAL AND COMMUNITY SERVICE</AGENCY>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; AmeriCorps VISTA Application and Reporting Forms</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Corporation for National and Community Service.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of information collection; request for comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Corporation for National and Community Service, operating as AmeriCorps, has submitted a public information collection request (ICR) for AmeriCorps VISTA application and reporting forms.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        Written comments must be submitted to the individual and office listed in the 
                        <E T="02">ADDRESSES</E>
                         section by August 31, 2026.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Copies of this ICR, with applicable supporting documentation, may be obtained by contacting Orlaith Duggan, AmeriCorps VISTA, 202-606-6658, 
                        <E T="03">ODuggan@americorps.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The OMB is particularly interested in comments which:</P>
                <P>• Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of CNCS, including whether the information will have practical utility;</P>
                <P>• Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions;</P>
                <P>• Propose ways to enhance the quality, utility, and clarity of the information to be collected; and</P>
                <P>• Propose ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.</P>
                <HD SOURCE="HD1">Comments</HD>
                <P>
                    A 60-day Notice requesting public comment on this information collection was published in the 
                    <E T="04">Federal Register</E>
                     on May 6, 2026 at 91 FR 23529. The comment period ended July 6, 2026. One public comment was received. A summary of the comments and AmeriCorps VISTA's responses are below:
                </P>
                <P>
                    • 
                    <E T="03">Comment:</E>
                     Concern that an intermediary project might find it difficult to fit all of the requested information for the concept paper and application into the page limit. 
                    <E T="03">Response:</E>
                     The suggested page limit for intermediary projects to concisely respond to the narrative questions is sufficient because the list of sites and performance measures does not count towards the narrative page limit.
                </P>
                <P>
                    • 
                    <E T="03">Comment:</E>
                     Request that requirements for the continuation application instructions be reduced for intermediary projects with a large number of Volunteers and/or service 
                    <PRTPAGE P="48091"/>
                    locations. 
                    <E T="03">Response:</E>
                     The continuation application is used to help evaluate and measure the success of a project, regardless of project type (single service location, muti-service location, or intermediary) or size. A project sponsor's answers help AmeriCorps assess whether a project is continuing to strive towards sustainability and their use of VISTA resources is compliant.
                </P>
                <P>• On the progress report instructions, the commenter suggested:</P>
                <P>
                    • Consolidating the VISTA Progress Report Supplement (VPRS) with the Project Process Report (PPR) to allow for one reporting period. 
                    <E T="03">Response:</E>
                     VISTA is working towards a single project progress report. However, we are still including the progress report supplement until the report consolidation is complete, which we expect to happen by FY2028.
                </P>
                <P>
                    • Making the Sustainability narrative section “not applicable” for intermediary projects. 
                    <E T="03">Response:</E>
                     Legislation and regulations governing AmeriCorps VISTA apply to all project models (single-site, multi-site, or intermediary), and accordingly, sustainability is a key factor in our determination of a project's success.
                </P>
                <P>
                    • Making the Partnership Collaboration and Development narrative “not applicable” for intermediary projects. 
                    <E T="03">Response:</E>
                     The PPR instructions were updated with clarifying language, so intermediaries do not have to list each partnership developed by every site, but are encouraged to provide three to five examples.
                </P>
                <P>
                    • Changing the due date for PPRs from 30 days to 60 days. 
                    <E T="03">Response:</E>
                     The instructions have been updated to reflect a deadline of no later than 90 calendar days for annual performance reports.
                </P>
                <P>
                    • Questioning how the agency uses the information in the Member Development section. 
                    <E T="03">Response:</E>
                     Volunteer (formally, “member”) development is a cornerstone of VISTA's legislation and a key component of the agency's new strategic plan. We use this information to review key metrics and identify possible training needs.
                </P>
                <P>
                    • Changing the “Demographics” title of the PPR and removing information on youth and veterans and military families. 
                    <E T="03">Response:</E>
                     AmeriCorps VISTA will continue to use “Demographics.” The term has specific meaning and is widely used, including across AmeriCorps programs. Youth, veterans, and military families are a high priority for the agency and the Administration, so we need to collect data about these populations. We do recognize that not all projects will serve these target populations. The instructions state that projects may enter “0” if it does not apply to them.
                </P>
                <P>
                    • Removing the Resource Development section. 
                    <E T="03">Response:</E>
                     We have added language to the instructions to clarify the more limited requirements for intermediary project responses. Intermediary projects only need to highlight successful projects. AmeriCorps frequently uses this information in outreach and reporting to Congress to demonstrate the success of the VISTA program and its partners in generating non-AmeriCorps resources.
                </P>
                <P>
                    • Removing information on the number of VISTA Volunteers serving under each performance measure. 
                    <E T="03">Response:</E>
                     We updated the PPR instructions to explain what to enter in the “# of Full Time VISTAS” field. We need to collect this information to determine the scope of VISTA Volunteer activities, where we may need to supplement training resources, and to pull data for information requests.
                </P>
                <P>
                    <E T="03">Title of Collection:</E>
                     AmeriCorps VISTA Application and Reporting Forms.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     3045-0038.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision.
                </P>
                <P>
                    <E T="03">Respondents/Affected Public:</E>
                     Businesses and Organizations, State, Local or Tribal Governments.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Annual Responses:</E>
                     750.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Annual Burden Hours:</E>
                     13,763.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     AmeriCorps seeks to revise the concept paper and project application instructions, continuation application instructions, project progress report instructions, and support grant budget instructions in the current information collection. The revisions streamline content, ensure use of plain English with use of the second person, separate systems instructions from content explanations, update terminology, and divide narrative fields into clearer subsections to organize content. No revisions are being made to the VISTA Progress Report Supplement (VPRS) instructions. The information collection will otherwise be used in the same manner as the existing application and reporting forms. AmeriCorps also seeks to continue using the current forms until the revised forms are approved by OMB. The currently approved information collection is due to expire on March 31, 2027.
                </P>
                <SIG>
                    <NAME>Brendan Murphy,</NAME>
                    <TITLE>Acting Director, AmeriCorps VISTA.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15322 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6050-28-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Department of the Air Force</SUBAGY>
                <SUBJECT>Notice of Intent To Grant a Joint Ownership Agreement With an Exclusive Patent License</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Department of the Air Force, Department of Defense.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of intent.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the Bayh-Dole Act and implementing regulations, the Department of the Air Force hereby gives notice of its intent to grant a joint ownership agreement with an exclusive (the field to include all fields) patent license to the University of Kansas Center for Technology Commercialization having a place of business at 2029 Becker Drive, Suite 142. Lawrence, Kansas 66047.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written objections must be filed no later than fifteen (15) calendar days after the date of publication of this Notice.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit objections to Robert Barnes, AFRL/RFYP, 2241 Avionics Way, Wright Patterson AFB, OH 45433-7304; Phone: (312) 713-8511; or Email: 
                        <E T="03">Robert.Barnes.36.ctr@us.af.mil.</E>
                         Include Docket No. 26-0006229-AFRL/RY in the subject line of the message.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Robert Barnes, AFRL/RFYP, 2241 Avionics Way, Wright Patterson AFB, OH 45433-7304; Phone: (312) 713-8511; or Email: 
                        <E T="03">Robert.Barnes.36.ctr@us.af.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Abstract of Patent Application(s)</HD>
                <P>
                    Systems, methods, and computer-readable storage media for generating and utilizing radar signals with embedded data are disclosed. Data is encoded onto a CPM waveform, which is then combined with a base radar waveform to produce a radar-embedded communication (REC) waveform. Both the CPM waveform and the base radar waveform may have a continuous phase and constant envelope, resulting in the REC waveform having a continuous phase and constant envelope. The changing (
                    <E T="03">e.g.,</E>
                     on a pulse-to-pulse basis) nature of the REC waveform causes RSM of clutter which may result in residual clutter after clutter cancellation, decreasing target detection performance of the radar system. In an aspect, various parameters may be utilized to dynamically adjust the performance of the radar system for a particular operating scenario, such as to enhance radar signal processing or enhance data communication capabilities.
                    <PRTPAGE P="48092"/>
                </P>
                <HD SOURCE="HD1">Intellectual Property</HD>
                <P>
                    U.S. Patent No. 12,625,246 issued on May 12, 2026, and entitled 
                    <E T="03">Continuous-Phase Modulation Based Power-Efficient Tunable Joint Radar/Communications System,</E>
                     and U.S. Continuation Patent Application No. 17/761,326 filed on March 17, 2022, and entitled 
                    <E T="03">Continuous-Phase Modulation Based Power-Efficient Tunable Joint Radar/Communications System.</E>
                </P>
                <P>The Department of the Air Force may grant the prospective license unless a timely objection is received that sufficiently shows the grant of the license would be inconsistent with the Bayh-Dole Act or implementing regulations. A competing application for a patent license agreement, completed in compliance with 37 CFR 404.8 and received by the Air Force within the period for timely objections, will be treated as an objection and may be considered as an alternative to the proposed license.</P>
                <EXTRACT>
                    <FP>(Authority: 35 U.S.C. 209; 37 CFR 404.)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Crystle C. Poge, </NAME>
                    <TITLE>Air Force Federal Register Liaison Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15351 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3911-44-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Department of the Air Force</SUBAGY>
                <SUBJECT>Notice of Intent To Grant a Joint Ownership Agreement With an Exclusive Patent License</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Department of the Air Force, Department of Defense.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of intent.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the Bayh-Dole Act and implementing regulations, the Department of the Air Force hereby gives notice of its intent to grant a joint ownership agreement with an exclusive (the field to include all fields) patent license to the Research Foundation for the State University of New York having a place of business at 4400 Vestal Parkway East, Binghamton, NY 13902-4600.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written objections must be filed no later than fifteen (15) calendar days after the date of publication of this Notice.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit objections to Ryan Toner, AFRL/RIBA, 525 Brooks Road, Rome Lab AFB, NY 13441; Phone: (312) 587-3340; or Email: 
                        <E T="03">Ryan.Toner@us.af.mil.</E>
                         Include Docket No. 26-0006369-AFRL/RI in the subject line of the message.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Ryan Toner, AFRL/RIBA, 525 Brooks Road, Rome Lab AFB, NY 13441; Phone: (312) 587-3340; or Email: Ryan,
                        <E T="03">Toner@us.af.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Abstract of Patent Application(s)</HD>
                <P>A metaverse system, comprising: an interface to at least one microchained Internet of Things network, each microchained Internet of Things network comprising sensing, computing, communication, and storage devices for monitoring and controlling a physical environment; a slicing layer comprising dedicated logic of a decentralized network configured to process data from the at least one Internet of Things network; a Microverse layer comprising at least one semantic model and at least one intelligent service, configured to implement a digitally twin model of the at least one Internet of Things network based on the slicing layer; and an application layer, configured to monitor and control the physical environment based on the Microverse layer.</P>
                <HD SOURCE="HD1">Intellectual Property</HD>
                <P>
                    U.S. Patent Application No. 63,757,781 filed on February 12, 2025, and entitled 
                    <E T="03">The Microverse: A Task-Oriented Edge Scale Metaverse.</E>
                </P>
                <P>The Department of the Air Force may grant the prospective license unless a timely objection is received that sufficiently shows the grant of the license would be inconsistent with the Bayh-Dole Act or implementing regulations. A competing application for a patent license agreement, completed in compliance with 37 CFR 404.8 and received by the Air Force within the period for timely objections, will be treated as an objection and may be considered as an alternative to the proposed license.</P>
                <EXTRACT>
                    <FP>(Authority: 35 U.S.C. 209; 37 CFR part 404.)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Crystle C. Poge, </NAME>
                    <TITLE>Air Force Federal Register Liaison Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15350 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3911-44-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF ENERGY</AGENCY>
                <SUBJECT>Notice of 229 Boundary for the Princeton Plasma Physics Laboratory</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Science, Department of Energy.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of 229 Boundary for the Princeton Plasma Physics Laboratory.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given that the U.S. Department of Energy, pursuant to the Atomic Energy Act of 1954, prohibits the unauthorized entry and the unauthorized introduction of weapons or dangerous materials, as provided in, into or upon the following described facilities and property of the Princeton Plasma Physics Laboratory of the U.S. Department of Energy.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This action is effective on July 30, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Mr. Tyler M. Walker, Real Estate Contracting Officer, 200 Administration Road, Oak Ridge, TN 37830, Email: 
                        <E T="03">tyler.walker@science.doe.gov;</E>
                         Telephone: (865) 469-1183.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This security boundary is designated pursuant to section 229 of the Atomic Energy Act of 1954 as amended, and as implemented by U.S. Department of Energy's regulations regarding Trespassing on Department of Energy Property at 10 CFR part 860.</P>
                <P>The following supplement is made:</P>
                <P>The U.S. Department of Energy installation known as the Princeton Plasma Physics Laboratory, is located in the Plainsboro Township, Middlesex County, New Jersey on Stellarator Road, just east of US Route 1, between College Road East, and Plainsboro Road (Route 614), with a physical address of 100 Stellarator Road, Princeton, NJ 08540. The site, consisting of approximately 90.919 acres, is controlled through a long-term ground lease between the United States Department of Energy by the Trustees of Princeton University. In addition to the ground lease area, the United States Department of Energy controls an area consisting of approximately 0.089 acres through an easement agreement, providing the area for the U.S. Department of Energy-owned Canal Pump House located at 26 Mapleton Road, Plainsboro, NJ. The Princeton Plasma Physics Laboratory consists of office, warehouse, laboratory, and research &amp; development buildings and other site improvements which are owned by the U.S. Department of Energy. The Princeton Plasma Physics Laboratory boundary is indicated by a combination of signage at entrances and along the perimeter, and chain link fencing, and other physical features which surround the facility.</P>
                <P>
                    <E T="03">Signing Authority:</E>
                     This document of the Department of Energy was signed on July 27, 2026, by Tyler M. Walker, Real Estate Contracting Officer, pursuant to delegated authority from the Secretary of Energy. That document with the original signature and date is maintained by DOE. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DOE Federal Register Liaison Officer has been 
                    <PRTPAGE P="48093"/>
                    authorized to sign and submit the document in electronic format for publication, as an official document of the Department of Energy. This administrative process in no way alters the legal effect of this document upon publication in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <DATED>Signed in Washington, DC, on July 28, 2026.</DATED>
                    <NAME>Treena V. Garrett,</NAME>
                    <TITLE>Federal Register Liaison Officer, U.S. Department of Energy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15358 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6450-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Project No. 2212-062]</DEPDOC>
                <SUBJECT>Domtar Paper Company, LLC; Notice of Application for Non-Capacity Amendment of License Accepted for Filing, Soliciting Comments, Motions To Intervene, and Protests</SUBJECT>
                <P>Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection:</P>
                <P>
                    a. 
                    <E T="03">Application Type:</E>
                     Non-Capacity Amendment of License.
                </P>
                <P>
                    b. 
                    <E T="03">Project No:</E>
                     2212-062.
                </P>
                <P>
                    c. 
                    <E T="03">Date Filed:</E>
                     April 30, 2026, and supplemented on June 30, 2026.
                </P>
                <P>
                    d. 
                    <E T="03">Applicant:</E>
                     Domtar Paper Company, LLC.
                </P>
                <P>
                    e. 
                    <E T="03">Name of Project:</E>
                     Rothschild Hydroelectric Project.
                </P>
                <P>
                    f. 
                    <E T="03">Location:</E>
                     The project is located on the Wisconsin River in Marathon County, Wisconsin. The project does not occupy any federal lands.
                </P>
                <P>
                    g. 
                    <E T="03">Filed Pursuant to:</E>
                     Federal Power Act, 16 U.S.C. 791a-825r.
                </P>
                <P>
                    h. 
                    <E T="03">Applicant Contact:</E>
                     Steven Lewens, Environmental Health and Safety Manager-Rothschild, Domtar Paper Company, LLC, 200 North Grand Avenue, Rothschild, WI 54474, 
                    <E T="03">Steven.lewens@domtar.com,</E>
                     (715) 355-6268.
                </P>
                <P>
                    i. 
                    <E T="03">FERC Contact:</E>
                     Aneela Mousam, (202) 502-8357, 
                    <E T="03">aneela.mousam@ferc.gov.</E>
                </P>
                <P>
                    j. 
                    <E T="03">Cooperating Agencies:</E>
                     With this notice, the Commission is inviting federal, state, local, and Tribal agencies with jurisdiction and/or special expertise with respect to environmental issues affected by the proposal, that wish to cooperate in the preparation of any environmental document, if applicable, to follow the instructions for filing such requests described in item k below. Cooperating agencies should note the Commission's policy that agencies that cooperate in the preparation of any environmental document cannot also intervene. 
                    <E T="03">See</E>
                     94 FERC ¶ 61,076 (2001).
                </P>
                <P>
                    k. 
                    <E T="03">Deadline for Filing Comments, Motions To Intervene, and Protests:</E>
                     August 26, 2026 5:00 p.m. Eastern Time.
                </P>
                <P>
                    The Commission strongly encourages electronic filing. Please file comments, motions to intervene, and protests using the Commission's eFiling system at 
                    <E T="03">http://www.ferc.gov/docs-filing/efiling.asp.</E>
                     Commenters can submit brief comments up to 6,000 characters, without prior registration, using the eComment system at 
                    <E T="03">http://www.ferc.gov/docs-filing/ecomment.asp.</E>
                     For assistance, please contact FERC Online Support at 
                    <E T="03">FERCOnlineSupport@ferc.gov,</E>
                     (866) 208-3676 (toll free), or (202) 502-8659 (TTY). In lieu of electronic filing, you may submit a paper copy. Submissions sent via the U.S. Postal Service must be addressed to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 888 First Street NE, Room 1A, Washington, DC 20426. Submissions sent via any other carrier must be addressed to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, MD 20852. The first page of any filing should include the docket number P-2212-062. Comments emailed to Commission staff are not considered part of the Commission record.
                </P>
                <P>The Commission's Rules of Practice and Procedure require all intervenors filing documents with the Commission to serve a copy of that document on each person whose name appears on the official service list for the project. Further, if an intervenor files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.</P>
                <P>
                    l. 
                    <E T="03">Description of Request:</E>
                     In 2022, Domtar Paper Company, LLC (licensee) retired, in place, five inoperable turbine-generator units (Units 1, 2, 4, 5, and 6). The other two turbine generating units at the project (Units 3 and 7) remain in service. Due to newly available energy incentives from the Focus on Energy program in the State of Wisconsin, the licensee proposes to return Unit 5 to service by repairing the unit and reconnecting the generator leads. The proposed upgrades would not result in any ground disturbance and would not require the licensee to deviate from the licensed reservoir elevations or required operations during construction or operation. With both the powerhouse and the spillway section of the dam releasing flows into the main channel of the Wisconsin River downstream, the proposal would result in an increased flow through the powerhouse and a reduced flow over the spillway. The proposal would increase the installed capacity of the project from 948 to 1,748 kilowatts and would increase the maximum hydraulic capacity from 1,100 to 1,850 cubic feet per second.
                </P>
                <P>
                    m. 
                    <E T="03">Locations of the Application:</E>
                     This filing may be viewed on the Commission's website at 
                    <E T="03">http://www.ferc.gov</E>
                     using the “eLibrary” link. Enter the docket number excluding the last three digits in the docket number field to access the document. You may also register online at 
                    <E T="03">http://www.ferc.gov/docs-filing/esubscription.asp</E>
                     to be notified via email of new filings and issuances related to this or other pending projects. For assistance, call 1-866-208-3676 or email 
                    <E T="03">FERCOnlineSupport@ferc.gov,</E>
                     for TTY, call (202) 502-8659. Agencies may obtain copies of the application directly from the applicant.
                </P>
                <P>n. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.</P>
                <P>
                    o. 
                    <E T="03">Comments, Protests, or Motions To Intervene:</E>
                     Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214, respectively. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.
                </P>
                <P>
                    p. 
                    <E T="03">Filing and Service of Documents:</E>
                     Any filing must (1) bear in all capital letters the title “COMMENTS”, “PROTEST”, or “MOTION TO INTERVENE” as applicable; (2) set forth in the heading the name of the applicant and the project number of the application to which the filing responds; and (3) otherwise comply with the requirements of 18 CFR 385.2001 through 385.2005. All comments, motions to intervene, or protests must set forth their evidentiary basis. Any filing made by an intervenor must be accompanied by proof of service on all persons listed in the service list prepared by the Commission in this proceeding, in accordance with 18 CFR 385.2010.
                    <PRTPAGE P="48094"/>
                </P>
                <P>
                    q. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 18 CFR 2.1)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15444 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <SUBJECT>Combined Notice of Filings</SUBJECT>
                <P>Take notice that the Commission has received the following Natural Gas Pipeline Rate and Refund Report filings:</P>
                <HD SOURCE="HD1">Filings Instituting Proceedings</HD>
                <P>
                    <E T="03">Docket Numbers:</E>
                     PR26-72-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Southern California Gas Company.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 284.123 Rate Filing: Offshore Delivery Service Rate Revision July 2026 to be effective 7/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5050.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/14/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-985-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Maritimes &amp; Northeast Pipeline, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Compliance filing: Order No. 587-AB (Docket No. RM96-1-044) Compliance Filing to be effective 1/1/2027.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/23/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260723-5155.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/4/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-986-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Texas Eastern Transmission, LP.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 4(d) Rate Filing: August 1 NJR NRAs to be effective 8/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5196.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/5/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-987-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Port Arthur Pipeline, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 4(d) Rate Filing: Filing of Non-Conforming Agreement 7.24.26 to be effective 8/26/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5268.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/5/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-988-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     El Paso Natural Gas Company, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 4(d) Rate Filing: Negotiated Rate Agreement Update (Shell Sep-Nov 2026) to be effective 9/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5318.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/5/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-989-000. 
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     ExxonMobil Oil Corporation, Pioneer Natural Resources USA, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Joint Petition for Limited Waiver of Capacity Release Regulations, et al. of ExxonMobil Oil Corporation, et al..
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5320.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/5/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-990-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Gillis Hub Pipeline, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 4(d) Rate Filing: Filing of Negotiated Rate FTSA to be effective 8/26/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5097.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/10/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP26-991-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Transcontinental Gas Pipe Line Company, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 4(d) Rate Filing: Rate Schedule S-2 Tracker Filing Eff 8/1/2026 to be effective 8/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5141.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/10/26.
                </P>
                <P>Any person desiring to intervene, to protest, or to answer a complaint in any of the above proceedings must file in accordance with Rules 211, 214, or 206 of the Commission's Regulations (18 CFR 385.211, 385.214, or 385.206) on or before 5:00 p.m. Eastern time on the specified comment date. Protests may be considered, but intervention is necessary to become a party to the proceeding.</P>
                <HD SOURCE="HD1">Filings in Existing Proceedings</HD>
                <P>
                    <E T="03">Docket Numbers:</E>
                     PR25-49-001. 
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Delta North Louisiana Gas Company, LLC. 
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 284.123 Rate Filing: Delta North Amended SOC to be effective 4/1/2025.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/23/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260723-5180.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/6/26.
                </P>
                <P>Any person desiring to protest in any the above proceedings must file in accordance with Rule 211 of the Commission's Regulations (18 CFR 385.211) on or before 5:00 p.m. Eastern time on the specified comment date.</P>
                <P>
                    The filings are accessible in the Commission's eLibrary system (
                    <E T="03">https://elibrary.ferc.gov/idmws/search/fercgensearch.asp</E>
                    ) by querying the docket number.
                </P>
                <P>
                    eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: 
                    <E T="03">http://www.ferc.gov/docs-filing/efiling/filing-req.pdf.</E>
                     For other information, call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.
                </P>
                <P>
                    For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Carlos D. Clay,</NAME>
                    <TITLE>Deputy Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15405 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <SUBJECT>Combined Notice of Filings #1</SUBJECT>
                <P>Take notice that the Commission received the following Accounting Request filings:</P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     AC26-37-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Duke Energy Florida, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Duke Energy Florida, LLC submits data response to request for additional information issued 07/09/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/21/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260721-5271.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/11/26.
                </P>
                <P>Take notice that the Commission received the following electric corporate filings:</P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EC25-101-001.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Vandolah Power Company L.L.C., Florida Power &amp; Light Company. 
                </P>
                <P>
                    <E T="03">Description:</E>
                     Notice of Non-Material Change in Circumstances of Vandolah Power Company L.L.C., et al.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/14/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260714-5194.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/4/26.
                </P>
                <P>Take notice that the Commission received the following exempt wholesale generator filings:</P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EG26-280-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Rush Springs Energy Storage II, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Rush Springs Energy Storage II, LLC submits Notice of Self-Certification of Exempt Wholesale Generator Status.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/22/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260722-5178.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/12/26.
                </P>
                <P>Take notice that the Commission received the following electric rate filings:</P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-2373-001.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Midcontinent Independent System Operator, Inc.
                    <PRTPAGE P="48095"/>
                </P>
                <P>
                    <E T="03">Description:</E>
                     Tariff Amendment: 2026-07-24_SA 4748 Deficiency Response Entergy Texas-Entergy Texas GIA (E0030) to be effective 6/29/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5336.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/14/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-2374-001.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Midcontinent Independent System Operator, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Tariff Amendment: 2026-07-24_SA 4749 Deficiency Resp. Entergy Texas-OTP-NSP-ITC-MEC JTIQ (E0030) to be effective 6/29/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5341.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/14/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-2749-001.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Atlas Solar IV, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Tariff Amendment: Certificate of Concurrence- 2d A&amp;R SFA- Sub #2 to be effective 6/8/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5124.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3249-001.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     PacifiCorp.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Tariff Amendment: Amendment to SLGIA (S.A. No. 1216) to be effective 7/24/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5332.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/14/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3274-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Portland General Electric Company.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: Portland General Electric EDAM Refinement OATT Revision to be effective 12/31/9998.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/24/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260724-5368.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/14/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3275-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Midcontinent Independent System Operator, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: 2026-07-27_SA 4808 NIPSCO-Swift Energy Storage GIA (J2215) to be effective 9/26/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5066.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3276-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Southwest Power Pool, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: 1276R43 Evergy Metro NITSA NOA) to be effective 7/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5068.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3277-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     American Transmission Systems, Incorporated.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: ATSI submits a new Construction Agmt—SA No. 7686 to be effective 9/26/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5069.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3278-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Buckeye Power, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: AEPSC submits an update to Attachment 1 of the ILDSA—SA No. 1336 to be effective 7/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5071.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3279-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Southwest Power Pool, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: 3211R9 North Iowa Municipal Electric Cooperative Association NITSA and NOA to be effective 7/1/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5072.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3280-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     PacifiCorp.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: DG&amp;T Engineering Services Agreement (R.S. No. 812) to be effective 9/26/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5078.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3281-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Public Service Company of Colorado.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: 2026-07-27 PSCo Concurrence to SPP Emergency Energy to be effective 6/24/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5101.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3282-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Flint Grid, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: Market-Based Rate Application and Request for Waivers and Blanket Approvals to be effective 10/27/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5105.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3283-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Tri-State Generation and Transmission Association, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: Initial Filing of Rate Schedule FERC No. 441 to be effective 9/27/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5113.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3284-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Duke Energy Ohio, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Compliance filing: DEO Compliance Filing to Implement Order on Remand to be effective 5/15/2022.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5120.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3285-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Atlas Solar II, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Initial Rate Filing: COC- 2d A&amp;R SFA Sub #2 to be effective 12/31/9998.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5129.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3286-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Mulqueeney Wind Energy LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Initial Rate Filing: Market-Based Rate Application to be effective 9/26/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5136.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3287-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     American Transmission Systems, Incorporated.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Compliance filing: ATSI submits Filing to Comply with Order on Remand Issued in No. EL22-34-000 to be effective 12/15/2022.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5137.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER26-3288-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Atlas Solar II, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     § 205(d) Rate Filing: COC- 3d A&amp;R SFA All to be effective 7/28/2026.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     7/27/26.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20260727-5139.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 8/17/26.
                </P>
                <P>
                    The filings are accessible in the Commission's eLibrary system (
                    <E T="03">https://elibrary.ferc.gov/idmws/search/fercgensearch.asp</E>
                    ) by querying the docket number.
                </P>
                <P>Any person desiring to intervene, to protest, or to answer a complaint in any of the above proceedings must file in accordance with Rules 211, 214, or 206 of the Commission's Regulations (18 CFR 385.211, 385.214, or 385.206) on or before 5:00 p.m. Eastern time on the specified comment date. Protests may be considered, but intervention is necessary to become a party to the proceeding.</P>
                <P>
                    eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: 
                    <E T="03">http://www.ferc.gov/docs-filing/efiling/filing-req.pdf.</E>
                     For other information, call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.
                </P>
                <P>
                    For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <SIG>
                    <PRTPAGE P="48096"/>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Carlos D. Clay,</NAME>
                    <TITLE>Deputy Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15404 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Docket No. CP26-554-000]</DEPDOC>
                <SUBJECT>Southern Star Central Gas Pipeline, Inc.; Notice of Request Under Blanket Authorization and Establishing Intervention and Protest Deadline</SUBJECT>
                <P>
                    Take notice that on July 15, 2026, Southern Star Central Gas Pipeline, Inc. (Southern Star), 4700 State Route 56, Owensboro, Kentucky 42301, filed in the above referenced docket, a prior notice request pursuant to sections 157.205 and 157.208 of the Commission's regulations under the Natural Gas Act (NGA), and Southern Star's blanket certificate issued in Docket No. CP82-479-000, for authorization to increase the maximum allowable operating pressure (MAOP) on a 13,100 foot segment of its 8-inch-diameter Line EU from 150 pounds per square inch gauge (psig) to 333 psig located in Leavenworth County, Kansas (Line EU MAOP Uprate Project).
                    <SU>1</SU>
                    <FTREF/>
                     The MAOP uprate will support the planned installation of facilities under automatic authorization authority, all as more fully set forth in the request which is on file with the Commission and open to public inspection.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         No increased capacity is expected to occur from the MAOP uprate of Line EU.
                    </P>
                </FTNT>
                <P>
                    In addition to publishing the full text of this document in the 
                    <E T="04">Federal Register</E>
                    , the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the internet through the Commission's Home Page (
                    <E T="03">http://www.ferc.gov</E>
                    ). From the Commission's Home Page on the internet, this information is available on eLibrary. The full text of this document is available on eLibrary in PDF and Microsoft Word format for viewing, printing, and/or downloading. To access this document in eLibrary, type the docket number excluding the last three digits of this document in the docket number field.
                </P>
                <P>
                    User assistance is available for eLibrary and the Commission's website during normal business hours from FERC Online Support at (202) 502-6652 (toll free at 1-866-208-3676) or email at 
                    <E T="03">ferconlinesupport@ferc.gov,</E>
                     or the Public Reference Room at (202) 502-8371, TTY (202) 502-8659. Email the Public Reference Room at 
                    <E T="03">public.referenceroom@ferc.gov.</E>
                </P>
                <P>
                    Any questions concerning this request should be directed to Jennifer Matthews, Manager, Regulatory, Southern Star Central Gas Pipeline, Inc., 4700 State Route 56, Owensboro, Kentucky 42301, by phone at (270) 316-2972 or by email at 
                    <E T="03">Jennifer.Matthews@southernstar.com.</E>
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <P>There are three ways to become involved in the Commission's review of this project: you can file a protest to the project, you can file a motion to intervene in the proceeding, and you can file comments on the project. There is no fee or cost for filing protests, motions to intervene, or comments. The deadline for filing protests, motions to intervene, and comments is 5:00 p.m. Eastern Time on September 25, 2026. How to file protests, motions to intervene, and comments is explained below.</P>
                <P>
                    For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation (OPP) at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <HD SOURCE="HD2">Protests</HD>
                <P>
                    Pursuant to section 157.205 of the Commission's regulations under the NGA,
                    <SU>2</SU>
                    <FTREF/>
                     any person 
                    <SU>3</SU>
                    <FTREF/>
                     or the Commission's staff may file a protest to the request. If no protest is filed within the time allowed or if a protest is filed and then withdrawn within 30 days after the allowed time for filing a protest, the proposed activity shall be deemed to be authorized effective the day after the time allowed for protest. If a protest is filed and not withdrawn within 30 days after the time allowed for filing a protest, the instant request for authorization will be considered by the Commission.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         18 CFR 157.205.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Persons include individuals, organizations, businesses, municipalities, and other entities. 18 CFR 385.102(d).
                    </P>
                </FTNT>
                <P>
                    Protests must comply with the requirements specified in section 157.205(e) of the Commission's regulations,
                    <SU>4</SU>
                    <FTREF/>
                     and must be submitted by the protest deadline, which is 5:00 p.m. Eastern Time on September 25, 2026. Filings that do not meet requirements of 18 CFR 157.205(e)(2) 
                    <SU>5</SU>
                    <FTREF/>
                     will not be considered protests by the Commission.
                    <SU>6</SU>
                    <FTREF/>
                     A protest may also serve as a motion to intervene so long as the protestor states it also seeks to be an intervenor.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         18 CFR 157.205(e).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         18 CFR 157.205(e)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">Cheniere Creole Trail Pipeline, L.P.,</E>
                         195 FERC ¶ 61,208, at P 8 n.16 (2026).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Interventions</HD>
                <P>Any person has the option to file a motion to intervene in this proceeding. Only intervenors have the right to request rehearing of Commission orders issued in this proceeding and to subsequently challenge the Commission's orders in the U.S. Circuit Courts of Appeal.</P>
                <P>
                    To intervene, you must submit a motion to intervene to the Commission in accordance with Rule 214 of the Commission's Rules of Practice and Procedure 
                    <SU>7</SU>
                    <FTREF/>
                     and the regulations under the NGA 
                    <SU>8</SU>
                    <FTREF/>
                     by the intervention deadline for the project, which is 5:00 p.m. Eastern Time on September 25, 2026. As described further in Rule 214, your motion to intervene must state, to the extent known, your position regarding the proceeding, as well as your interest in the proceeding. For an individual, this could include your status as a landowner, ratepayer, resident of an impacted community, or recreationist. You do not need to have property directly impacted by the project in order to intervene. For more information about motions to intervene, refer to the FERC website at 
                    <E T="03">https://www.ferc.gov/resources/guides/how-to/intervene.asp.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         18 CFR 385.214.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         18 CFR 157.10.
                    </P>
                </FTNT>
                <P>All timely, unopposed motions to intervene are automatically granted by operation of Rule 214(c)(1). Motions to intervene that are filed after the intervention deadline are untimely and may be denied. Any late-filed motion to intervene must show good cause for being late and must explain why the time limitation should be waived and provide justification by reference to factors set forth in Rule 214(d) of the Commission's Rules and Regulations. A person obtaining party status will be placed on the service list maintained by the Secretary of the Commission and will receive copies (paper or electronic) of all documents filed by the applicant and by all other parties.</P>
                <HD SOURCE="HD2">Comments</HD>
                <P>
                    Any person wishing to comment on the project may do so. The Commission considers all comments received about the project in determining the appropriate action to be taken. To ensure that your comments are timely and properly recorded, please submit your comments on or before 5:00 p.m. Eastern Time on September 25, 2026. The filing of a comment alone will not serve to make the filer a party to the 
                    <PRTPAGE P="48097"/>
                    proceeding. To become a party, you must intervene in the proceeding.
                </P>
                <HD SOURCE="HD2">How To File Protests, Interventions, and Comments</HD>
                <P>There are two ways to submit protests, motions to intervene, and comments. In both instances, please reference the Project docket number CP26-554-000 in your submission.</P>
                <P>
                    (1) You may file your protest, motion to intervene, and comments by using the Commission's eFiling feature, which is located on the Commission's website (
                    <E T="03">www.ferc.gov</E>
                    ) under the link to Documents and Filings. New eFiling users must first create an account by clicking on “eRegister.” You will be asked to select the type of filing you are making; first select “General” and then select “Protest”, “Intervention”, or “Comment on a Filing”; or 
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         Additionally, you may file your comments electronically by using the eComment feature, which is located on the Commission's website at 
                        <E T="03">www.ferc.gov</E>
                         under the link to Documents and Filings. Using eComment is an easy method for interested persons to submit brief, text-only comments on a project.
                    </P>
                </FTNT>
                <P>(2) You can file a paper copy of your submission by mailing it to the address below. Your submission must reference the Project docket number CP26-554-000.</P>
                <P>
                    <E T="03">To file via USPS:</E>
                     Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 888 First Street NE, Washington, DC 20426.
                </P>
                <P>
                    <E T="03">To file via any other method:</E>
                     Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland 20852.
                </P>
                <P>
                    The Commission encourages electronic filing of submissions (option 1 above) and has eFiling staff available to assist you at (202) 502-8258 or 
                    <E T="03">FercOnlineSupport@ferc.gov.</E>
                </P>
                <P>
                    Protests and motions to intervene must be served on the applicant either by mail at: Jennifer Matthews, Manager, Regulatory, Southern Star Central Gas Pipeline, Inc., 4700 State Route 56, Owensboro, Kentucky 42301, or by email (with a link to the document) at 
                    <E T="03">Jennifer.Matthews@southernstar.com.</E>
                     Any subsequent submissions by an intervenor must be served on the applicant and all other parties to the proceeding. Contact information for parties can be downloaded from the service list at the eService link on FERC Online.
                </P>
                <HD SOURCE="HD1">Tracking the Proceeding</HD>
                <P>
                    Throughout the proceeding, additional information about the project will be available from OPP at (202) 502-6595 or on the FERC website at 
                    <E T="03">www.ferc.gov</E>
                     using the “eLibrary” link as described above. The eLibrary link also provides access to the texts of all formal documents issued by the Commission, such as orders, notices, and rulemakings.
                </P>
                <P>
                    In addition, the Commission offers a free service called eSubscription which allows you to keep track of all formal issuances and submittals in specific dockets. This can reduce the amount of time you spend researching proceedings by automatically providing you with notification of these filings, document summaries, and direct links to the documents. For more information and to register, go to 
                    <E T="03">www.ferc.gov/docs-filing/esubscription.asp.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 18 CFR 2.1)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15445 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Project No. 4113-067]</DEPDOC>
                <SUBJECT>Oswego Hydro Partners, LP; Notice of Availability of Environmental Assessment</SUBJECT>
                <P>
                    In accordance with the National Environmental Policy Act of 1969 and the Federal Energy Regulatory Commission's (Commission) regulations, 18 CFR part 380, the Office of Energy Projects has reviewed the application for a new license to continue to operate and maintain the Phoenix Hydroelectric Project No. 4113 (project). The project is located on the Oswego, Oneida, and Seneca Rivers in Onondaga and Oswego counties, New York. Commission staff has prepared an Environmental Assessment (EA) for the project.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         For tracking purposes under the National Environmental Policy Act, the unique identification number for documents relating to this environmental review is EAXX-019-20-000-1753790446.
                    </P>
                </FTNT>
                <P>The EA contains staff's analysis of the potential environmental impacts of the project and concludes that licensing the project, with appropriate environmental protective measures, would not constitute a major federal action that would significantly affect the quality of the human environment.</P>
                <P>
                    A copy of the EA may be viewed on the Commission's website at 
                    <E T="03">http://www.ferc.gov/,</E>
                     using the “eLibrary” link. Enter the docket number, excluding the last three digits in the docket number field, to access the document. For assistance, contact FERC Online Support at 
                    <E T="03">FERCOnlineSupport@ferc.gov,</E>
                     or at (866) 208-3676 (toll-free), or (202) 502-8659 (TTY).
                </P>
                <P>
                    You may also register online at 
                    <E T="03">https://ferconline.ferc.gov/FERCOnline.aspx</E>
                     to be notified via email of new filings and issuances related to this or other pending projects. For assistance, contact FERC Online Support.
                </P>
                <P>Any comments should be filed on or before 5:00 p.m. Eastern Time on August 26, 2026.</P>
                <P>
                    The Commission strongly encourages electronic filing. Please file comments using the Commission's eFiling system at 
                    <E T="03">https://ferconline.ferc.gov/FERCOnline.aspx.</E>
                     Commenters can submit brief comments up to 10,000 characters, without prior registration, using the eComment system at 
                    <E T="03">https://ferconline.ferc.gov/QuickComment.aspx.</E>
                     For assistance, please contact FERC Online Support. In lieu of electronic filing, please send a paper copy via U.S. Postal Service to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 888 First Street NE, Room 1A, Washington, DC 20426. Submissions sent via any other carrier must be addressed to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland 20852. The first page of any filing should include docket number P-4113-067.
                </P>
                <P>
                    For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <P>
                    For further information, contact Joshua Dub by email at 
                    <E T="03">Joshua.Dub@ferc.gov</E>
                     or by telephone at (202) 502-8138.
                </P>
                <EXTRACT>
                    <FP>(Authority: 18 CFR 2.1)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15442 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48098"/>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Docket No. CP26-552-000]</DEPDOC>
                <SUBJECT>Tennessee Gas Pipeline Company, L.L.C.; Notice of Request Under Blanket Authorization and Establishing Intervention and Protest Deadline</SUBJECT>
                <P>
                    Take notice that on July 15, 2026, Tennessee Gas Pipeline Company, L.L.C. (TGP), 1001 Louisiana Street, Suite 1000, Houston, Texas 77002, filed in the above referenced docket, a prior notice request pursuant to sections 157.205, and 157.208, and 157.216 of the Commission's regulations under the Natural Gas Act (NGA), and TGP's blanket certificate issued in Docket No. CP82-413-000,
                    <SU>1</SU>
                    <FTREF/>
                     for authorization to: (1) replace 24-inch-diameter segments of two of TGP's existing natural gas pipelines (TGP Line Nos. 500-1 and 800-1) that cross the Cumberland River in Cheatham County, Tennessee with 30-inch-diameter natural gas pipeline segments; (2) abandon in place the existing 24-inch-diameter pipeline segments that are being replaced; and (3) replace TGP's existing 24-inch-diameter main line valves (MLVs) 561-1, 562-1, 862-1, and 863-1 with 30-inch-diameter MLVs on the north and south sides of the Cumberland River (Cumberland River HDD Project). The project will allow TGP to conduct certain integrity assessments, as required by a condition of a Special Permit from the U.S. Department of Transportation Pipeline and Hazardous Material Safety Administration (PHMSA).
                    <SU>2</SU>
                    <FTREF/>
                     The estimated cost for the project is $16,000,000, all as more fully set forth in the request which is on file with the Commission and open to public inspection., as more fully described in the Prior Notice Request.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">Tennessee Gas Pipeline Company,</E>
                         20 FERC ¶ 62,409 (1982).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="03">See</E>
                         Condition 5(b) Special Permit—Class 1 to 3 Location, U.S. Department of Transportation Pipeline and Hazardous Material Safety Administration (Docket No. PHMSA-2016-0004) (Issued Sept. 1, 2016; Renewed Mar. 17, 2023).
                    </P>
                </FTNT>
                <P>
                    In addition to publishing the full text of this document in the 
                    <E T="04">Federal Register</E>
                    , the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the internet through the Commission's Home Page (
                    <E T="03">http://www.ferc.gov</E>
                    ). From the Commission's Home Page on the internet, this information is available on eLibrary. The full text of this document is available on eLibrary in PDF and Microsoft Word format for viewing, printing, and/or downloading. To access this document in eLibrary, type the docket number excluding the last three digits of this document in the docket number field.
                </P>
                <P>
                    User assistance is available for eLibrary and the Commission's website during normal business hours from FERC Online Support at (202) 502-6652 (toll free at 1-866-208-3676) or email at 
                    <E T="03">ferconlinesupport@ferc.gov,</E>
                     or the Public Reference Room at (202) 502-8371, TTY (202) 502-8659. Email the Public Reference Room at 
                    <E T="03">public.referenceroom@ferc.gov.</E>
                </P>
                <P>
                    Any questions concerning this request should be directed to Tina Hardy, Director, Regulatory for Tennessee Gas Pipeline Company, L.L.C., 1001 Louisiana Street, Suite 1000, Houston, Texas 77002, by phone at (205) 325-3668, or by email at 
                    <E T="03">tina_hardy@kindermorgan.com.</E>
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <P>There are three ways to become involved in the Commission's review of this project: you can file a protest to the project, you can file a motion to intervene in the proceeding, and you can file comments on the project. There is no fee or cost for filing protests, motions to intervene, or comments. The deadline for filing protests, motions to intervene, and comments is 5:00 p.m. Eastern Time on September 25, 2026. How to file protests, motions to intervene, and comments is explained below.</P>
                <P>
                    For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation (OPP) at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <HD SOURCE="HD2">Protests</HD>
                <P>
                    Pursuant to section 157.205 of the Commission's regulations under the NGA,
                    <SU>3</SU>
                    <FTREF/>
                     any person 
                    <SU>4</SU>
                    <FTREF/>
                     or the Commission's staff may file a protest to the request. If no protest is filed within the time allowed or if a protest is filed and then withdrawn within 30 days after the allowed time for filing a protest, the proposed activity shall be deemed to be authorized effective the day after the time allowed for protest. If a protest is filed and not withdrawn within 30 days after the time allowed for filing a protest, the instant request for authorization will be considered by the Commission.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         18 CFR 157.205.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Persons include individuals, organizations, businesses, municipalities, and other entities. 18 CFR 385.102(d).
                    </P>
                </FTNT>
                <P>
                    Protests must comply with the requirements specified in section 157.205(e) of the Commission's regulations,
                    <SU>5</SU>
                    <FTREF/>
                     and must be submitted by the protest deadline, which is 5:00 p.m. Eastern Time on September 25, 2026. Filings that do not meet requirements of 18 CFR 157.205(e)(2) 
                    <SU>6</SU>
                    <FTREF/>
                     will not be considered protests by the Commission.
                    <SU>7</SU>
                    <FTREF/>
                     A protest may also serve as a motion to intervene so long as the protestor states it also seeks to be an intervenor.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         18 CFR 157.205(e).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         18 CFR 157.205(e)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">Cheniere Creole Trail Pipeline, L.P.,</E>
                         195 FERC ¶ 61,208, at P 8 n.16 (2026).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Interventions</HD>
                <P>Any person has the option to file a motion to intervene in this proceeding. Only intervenors have the right to request rehearing of Commission orders issued in this proceeding and to subsequently challenge the Commission's orders in the U.S. Circuit Courts of Appeal.</P>
                <P>
                    To intervene, you must submit a motion to intervene to the Commission in accordance with Rule 214 of the Commission's Rules of Practice and Procedure 
                    <SU>8</SU>
                    <FTREF/>
                     and the regulations under the NGA 
                    <SU>9</SU>
                    <FTREF/>
                     by the intervention deadline for the project, which is 5:00 p.m. Eastern Time on September 25, 2026. As described further in Rule 214, your motion to intervene must state, to the extent known, your position regarding the proceeding, as well as your interest in the proceeding. For an individual, this could include your status as a landowner, ratepayer, resident of an impacted community, or recreationist. You do not need to have property directly impacted by the project in order to intervene. For more information about motions to intervene, refer to the FERC website at 
                    <E T="03">https://www.ferc.gov/resources/guides/how-to/intervene.asp.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         18 CFR 385.214.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         18 CFR 157.10.
                    </P>
                </FTNT>
                <P>
                    All timely, unopposed motions to intervene are automatically granted by operation of Rule 214(c)(1). Motions to intervene that are filed after the intervention deadline are untimely and may be denied. Any late-filed motion to intervene must show good cause for being late and must explain why the time limitation should be waived and provide justification by reference to factors set forth in Rule 214(d) of the Commission's Rules and Regulations. A person obtaining party status will be placed on the service list maintained by the Secretary of the Commission and will receive copies (paper or electronic) of all documents filed by the applicant and by all other parties.
                    <PRTPAGE P="48099"/>
                </P>
                <HD SOURCE="HD2">Comments</HD>
                <P>Any person wishing to comment on the project may do so. The Commission considers all comments received about the project in determining the appropriate action to be taken. To ensure that your comments are timely and properly recorded, please submit your comments on or before 5:00 p.m. Eastern Time on September 25, 2026. The filing of a comment alone will not serve to make the filer a party to the proceeding. To become a party, you must intervene in the proceeding.</P>
                <HD SOURCE="HD2">How To File Protests, Interventions, and Comments</HD>
                <P>There are two ways to submit protests, motions to intervene, and comments. In both instances, please reference the Project docket number CP26-552-000 in your submission.</P>
                <P>
                    (1) You may file your protest, motion to intervene, and comments by using the Commission's eFiling feature, which is located on the Commission's website (
                    <E T="03">www.ferc.gov</E>
                    ) under the link to Documents and Filings. New eFiling users must first create an account by clicking on “eRegister.” You will be asked to select the type of filing you are making; first select “General” and then select “Protest”, “Intervention”, or “Comment on a Filing”; or 
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Additionally, you may file your comments electronically by using the eComment feature, which is located on the Commission's website at 
                        <E T="03">www.ferc.gov</E>
                         under the link to Documents and Filings. Using eComment is an easy method for interested persons to submit brief, text-only comments on a project.
                    </P>
                </FTNT>
                <P>(2) You can file a paper copy of your submission by mailing it to the address below. Your submission must reference the Project docket number CP26-552-000.</P>
                <P>
                    <E T="03">To file via USPS:</E>
                     Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 888 First Street NE, Washington, DC 20426.
                </P>
                <P>
                    <E T="03">To file via any other method:</E>
                     Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland 20852.
                </P>
                <P>
                    The Commission encourages electronic filing of submissions (option 1 above) and has eFiling staff available to assist you at (202) 502-8258 or 
                    <E T="03">FercOnlineSupport@ferc.gov.</E>
                </P>
                <P>
                    Protests and motions to intervene must be served on the applicant either by mail at: Tina Hardy, Director, Regulatory for Tennessee Gas Pipeline Company, L.L.C., 1001 Louisiana Street, Suite 1000, Houston, Texas 77002, or by email (with a link to the document) at 
                    <E T="03">tina_hardy@kindermorgan.com.</E>
                     Any subsequent submissions by an intervenor must be served on the applicant and all other parties to the proceeding. Contact information for parties can be downloaded from the service list at the eService link on FERC Online.
                </P>
                <HD SOURCE="HD1">Tracking the Proceeding</HD>
                <P>
                    Throughout the proceeding, additional information about the project will be available from OPP at (202) 502-6595 or on the FERC website at 
                    <E T="03">www.ferc.gov</E>
                     using the “eLibrary” link as described above. The eLibrary link also provides access to the texts of all formal documents issued by the Commission, such as orders, notices, and rulemakings.
                </P>
                <P>
                    In addition, the Commission offers a free service called eSubscription which allows you to keep track of all formal issuances and submittals in specific dockets. This can reduce the amount of time you spend researching proceedings by automatically providing you with notification of these filings, document summaries, and direct links to the documents. For more information and to register, go to 
                    <E T="03">www.ferc.gov/docs-filing/esubscription.asp.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 18 CFR 2.1)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15443 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[CERCLA-01-2026-0048; FRL-13537-01-R1]</DEPDOC>
                <SUBJECT>Proposed CERCLA Administrative Cost Recovery Settlement: Bliss Corner Neighborhood Site, Dartmouth, Massachusetts</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed settlement; request for public comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given of a proposed settlement regarding the Bliss Corner Neighborhood Site, located in Dartmouth, Bristol County, Massachusetts, with the Settling Parties: the City of New Bedford, Massachusetts, and the Town of Dartmouth, Massachusetts. The proposed settlement requires the Town to pay EPA $50,000 and provide in-kind services with an estimated value of $2.75 million and the City to pay EPA $1,000.00 to resolve the matter at the Bliss Corner Neighborhood Site, where EPA has incurred past response costs of $21,329,439.21 as of April 30, 2026. In exchange, EPA will provide the Settling Parties with a covenant not to sue or take administrative action relating to the site. The settlement has been approved by the Environmental and Natural Resources Division of the United States Department of Justice. For 30 days following the date of publication of this notice, the Agency will receive written comments relating to the settlement. The Agency will consider all comments received and may modify or withdraw its consent to this settlement if comments received disclose facts or considerations which indicate that the settlement is inappropriate, improper, or inadequate. The EPA's response to any comments received will be available for public inspection at the Environmental Protection Agency—Region 1, 5 Post Office Square, Suite 100, Boston, MA 02109-3912.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted by August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Comments should be addressed to Stacy Greendlinger, Senior Enforcement Coordinator, Superfund and Emergency Management Division, U.S. Environmental Protection Agency, 5 Post Office Square, Suite 100 (2-MI), Boston, MA 02109-3912, telephone number: (617) 918-1403, email address: 
                        <E T="03">greendlinger.stacy@epa.gov</E>
                         and should reference the Bliss Corner Neighborhood Site, U.S. EPA Docket No: CERCLA 01-2026-0048.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        A copy of the proposed settlement may be obtained from Stacy Greendlinger, Superfund and Emergency Management Division, U.S. Environmental Protection Agency, Region 1, 5 Post Office Square, Suite 100 (02-2), Boston, MA 02109-3912, telephone number: (617) 918-1403, email address: 
                        <E T="03">greendlinger.stacy@epa.gov.</E>
                         Direct technical questions to Stacy Greendlinger and legal questions to RuthAnn Sherman, Office of Regional Counsel, U.S. Environmental Protection Agency, Region 1, 5 Post Office Square, Suite 100 (4-WI), Boston, MA 02109-3912, telephone number: (617) 918-1886, email address: 
                        <E T="03">sherman.ruthann@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This proposed settlement regarding the Bliss Corner Neighborhood Site, located in Dartmouth, Bristol County, Massachusetts, is made in accordance with Section 122(h)(1) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) and the authority of the Attorney General of the United States to compromise and settle claims of the United States. EPA covenants not to sue 
                    <PRTPAGE P="48100"/>
                    or take administrative action against the Settling Parties, the City of New Bedford and the Town of Dartmouth, pursuant to Sections 106 and 107(a) of CERCLA, 42 U.S.C. 9606 and 9607(a), for performance of remedial work or recovery of response costs related to the Bliss Corner Neighborhood Site, subject to standard reservations of rights. In exchange, the Town of Dartmouth agrees to pay EPA $50,000.00 and provide in-kind services with an estimated value of $2.75 million and based on the determination of financial inability to settle EPA's claim, the City of New Bedford agrees to pay EPA $1,000.00. Payment of such amounts shall be due within thirty days after the Effective Date.
                </P>
                <P>For 30 days following the date of publication of this notice, the Agency will receive written comments relating to the settlement for recovery of response costs. The Effective Date of the Agreement is the date upon which EPA issues written notice to the City of New Bedford and the Town of Dartmouth that the public comment period has closed and that such comments, if any, do not require that EPA modify or withdraw from the Agreement.</P>
                <SIG>
                    <NAME>Bryan Olson,</NAME>
                    <TITLE>Director, Superfund and Emergency Management Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15391 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OLEM-2026-5414; FRL-13473-01-OLEM]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Management Standards for Hazardous Waste Pharmaceuticals ICR (Renewal), EPA ICR No. 2486.04, OMB Control No. 2050-0212</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Management Standards for Hazardous Waste Pharmaceuticals (Renewal)” (EPA ICR No. 2486.04, OMB Control No. 2050-0212) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act (PRA). Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section. This is a proposed extension of the ICR, which is currently approved through March 31, 2027. This document allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID No. EPA-HQ-OLEM-2026-5414, to EPA online using 
                        <E T="03">https://www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, U.S. Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Peggy Vyas, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-0453; email address: 
                        <E T="03">vyas.peggy@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through March 31, 2027. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This document allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">https://www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is (202) 566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     document to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Some pharmaceuticals are regulated as hazardous waste under the Resource Conservation and Recovery Act (RCRA) when discarded. In 2019 EPA promulgated regulations for the management of hazardous waste pharmaceuticals by healthcare facilities and reverse distributors (84 FR 5816, February 22, 2019). Healthcare facilities (for both humans and animals) and reverse distributors now manage their hazardous waste pharmaceuticals under a new set of sector-specific standards in lieu of the existing hazardous waste generator regulations. These regulations are found in 40 CFR part 266, subpart P, and are mandatory. The new requirements include labeling containers holding non-creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals with the words “Hazardous Waste Pharmaceuticals”. Healthcare facilities and reverse distributors must also track or manage rejected shipments by sending a copy of the manifest to the designated facility that returned or rejected the shipment. Additionally, healthcare facilities and reverse distributors must submit exception reports for a missing copy of a manifest. Reverse distributors are required to amend their contingency plan under 40 CFR part 262, subpart M. A reverse distributor must submit an unauthorized hazardous waste report if it receives waste it is not authorized to receive.
                </P>
                <P>
                    <E T="03">Form numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Entities potentially affected by this action are the private sector.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (RCRA section 3001).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     8,163.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Annual.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     40,045 hours per year. Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $3,580,140 (per year), includes $0 annualized capital or operation &amp; maintenance costs.
                    <PRTPAGE P="48101"/>
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     The burden hours are likely to stay substantially the same.
                </P>
                <SIG>
                    <DATED>Dated: July 21, 2026.</DATED>
                    <NAME>Andrew Baca,</NAME>
                    <TITLE>Director, Office of Resource Conservation and Recovery.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15387 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-R10-SFUND-2026-2674; FRL-13344-01-R10]</DEPDOC>
                <SUBJECT>CERCLA Administrative Settlement Agreement With Prospective Purchaser and Covenants Not To Sue, McCormick &amp; Baxter Creosoting Company Superfund Site, Portland, Oregon</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed agreement; request for public comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given by the U.S. Environmental Protection Agency (EPA), Region 10, of a prospective purchaser settlement agreement embodied in an “Administrative Settlement Agreement with Prospective Purchaser and Covenants Not to Sue,” with EPA, and the prospective purchaser, Portland Botanical Gardens (“Purchaser”). This agreement provides for the payment of certain response costs incurred by the United States at or in connection with the property located at 6900 N. Edgewater Street in Portland, Oregon, which is part of the McCormick &amp; Baxter Creosoting Company Superfund Site.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The proposed agreement is available as a supporting document in the main rulemaking docket. Requests for a hard copy of the proposed agreement should be addressed to Stephanie Ebright, Assistant Regional Counsel, Office of Regional Counsel, Environmental Protection Agency, Region 10, M/S 11-C07, Seattle, Washington 98101, email address: 
                        <E T="03">ebright.stephanie@epa.gov</E>
                         and should reference the McCormick &amp; Baxter Creosoting Company Superfund Site.
                    </P>
                    <P>
                        Comments may be submitted electronically, identified by Docket ID No. EPA-R10-SFUND-2026-2674 to 
                        <E T="03">http://www.regulations.gov.</E>
                         Follow the online instructions for submitting comments.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Stephanie Ebright, Assistant Regional Counsel, Office of Regional Counsel, Environmental Protection Agency, Region 10, M/S 11-C07, Seattle, Washington 98101, telephone number: (206) 553-0774, email address: 
                        <E T="03">ebright.stephanie@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>For thirty (30) days following the date of publication of this document, the Agency will receive written comments relating to the agreement. The Agency will consider all comments received and may modify or withdraw its consent to the agreement if comments received disclose facts or considerations that indicate that the agreement is inappropriate, improper, or inadequate.</P>
                <P>
                    <E T="03">Authority:</E>
                     42 U.S.C. 9601-9657.
                </P>
                <SIG>
                    <NAME>Daniel Opalski,</NAME>
                    <TITLE>Division Director, Superfund and Emergency Management Division, Region 10.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15395 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OLEM-2018-0200; FRL-13470-01-OLEM]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Final Authorization for Hazardous Waste Management Programs, EPA ICR No. 0969.13, OMB Control No. 2050-0041</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Final Authorization for Hazardous Waste Management Programs” (EPA ICR No. 0969.13, OMB Control No. 2050-0041) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act (PRA). Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section. This is a proposed extension of the ICR, which is currently approved through March 31, 2027. This document allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID No. EPA-HQ-OLEM-2018-0200, to EPA online using 
                        <E T="03">https://www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, U.S. Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Peggy Vyas, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-0453; email address: 
                        <E T="03">vyas.peggy@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through March 31, 2027. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This document allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">https://www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is (202) 566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     document to announce the submission of the ICR to OMB and the 
                    <PRTPAGE P="48102"/>
                    opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     In order for a State to obtain final authorization for a State hazardous waste program or to revise its previously authorized program, it must submit an official application to the EPA Regional office for approval. The purpose of the application is to enable the EPA to properly determine whether the State's program meets the requirements of section 3006 of Resource Conservation and Recovery Act (RCRA). A State with an approved program may voluntarily transfer program responsibilities to EPA by notifying the EPA of the proposed transfer, as required by § 271.23. Further, the EPA may withdraw a State's authorized program under § 271.23.
                </P>
                <P>State program revision may be necessary when the controlling Federal or State statutory or regulatory authority is modified or supplemented. In the event that the State is revising its program by adopting new Federal requirements, the State shall prepare and submit modified revisions of the program description, Attorney General's statement, Memorandum of Agreement, or such other documents as the EPA determines to be necessary. The State shall inform the EPA of any proposed modifications to its basic statutory or regulatory authority in accordance with § 271.21. If a State is proposing to transfer all or any part of any program from the approved State agency to any other agency, it must notify the EPA in accordance with § 271.21 and submit revised organizational charts as required under § 271.6, in accordance with § 271.21. These paperwork requirements are mandatory under section 3006(a). The EPA will use the information submitted by the State in order to determine whether the State's program meets the statutory and regulatory requirements for authorization.</P>
                <P>
                    <E T="03">Form numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     State/territorial governments.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (RCRA section 3006(a)).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     50.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Annual.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     10,794 hours per year. Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $427,536 (per year), includes $0 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     The burden hours are likely to stay substantially the same.
                </P>
                <SIG>
                    <DATED>Dated: July 20, 2026.</DATED>
                    <NAME>Andrew Baca,</NAME>
                    <TITLE>Director, Office of Resource Conservation and Recovery.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15376 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-EPA-HQ-OW-2008-0719; FRL-13554-01-OMS]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; National Pollutant Discharge Elimination System Program (Renewal)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), National Pollutant Discharge Elimination System Program (Renewal) (EPA ICR No. 0229.27, OMB Control No. 2040-0004) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed renewal of the ICR, which is currently approved through July 31, 2026. Public comments were previously requested via the 
                        <E T="04">Federal Register</E>
                         on April 21, 2026 during a 60-day comment period. This notice allows for an additional 30 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number EPA-HQ-OW-2008-0719, to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method), by email to 
                        <E T="03">OW-Docket@epa.gov,</E>
                         or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Ave. NW, Washington, DC 20460.
                    </P>
                    <P>EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.</P>
                    <P>
                        Submit written comments and recommendations to OMB for the proposed information collection within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Doris Ihejirika, National Program Branch, Water Permits Division, Office of Wastewater Management, Mail Code: 4203M, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 564-2110; email address: 
                        <E T="03">Ihejirika.Doris@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed renewal of the ICR, which is currently approved through July 31, 2026. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on April 21, 2026 during a 60-day comment period (91 FR 21287). This notice allows for an additional 30 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">http://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     This Information Collection Request (ICR) renews the National Pollutant Discharge Elimination System (NPDES) Program ICR. It calculates the information collection burden and costs associated with the NPDES program, identifies the types of activities regulated under the NPDES program, describes the roles and responsibilities of state governments and the Agency, and presents the program areas that address the various types of regulated activities. This ICR renewal covers information collection burden and costs associated with activities previously reported in 22 NPDES program or NPDES-related ICRs. The Clean Water Act (CWA) provides that NPDES permits are required for the discharge of pollutants to waters of the United States. The CWA requires that EPA develop and implement the NPDES permit program. CWA section 402(b) allows states to acquire authority to administer the NPDES program, enabling them to issue NPDES permits for discharges within the state. At present, 47 states and the U.S. Virgin Islands are authorized to administer the 
                    <PRTPAGE P="48103"/>
                    NPDES permit program. In states that do not have authority for these programs, the Agency administers the program and issues NPDES permits. Because some permit applications are processed by states and some by EPA, this ICR calculates government burden and cost for both authorized states and EPA.
                </P>
                <P>
                    <E T="03">Form Numbers:</E>
                     EPA Form 3510-1; EPA Form 3510-2A; EPA Form 3510-2B; EPA Form 3510-2C; EPA Form 3510-2D; EPA Form 3510-2E; EPA Form 3510-2F; EPA Form 3510-2S;
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Any point source discharger of pollutants, including but not limited to publicly owned and privately owned treatment works (POTWs and PrOTWs), industrial dischargers to POTWs and PrOTWs, industrial and commercial dischargers to waters of the United States, sewage sludge management and disposal operations, dischargers of stormwater, construction sites, municipalities, pesticide applicators, local and state governments.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory, pursuant to sections 204, 208, 301, 302, 304, 306, 307, 308, 309, 316(a), 316(b), 401, 402, 403, 405, 501(a), and 510 of the Clean Water Act; the 1987 Water Quality Act (WQA) revisions to Clean Water Act section 402(p); 40 CFR parts 122, 123, 124, 125, 127, 129, 132, parts 501 and 503 for biosolids, part 403 for pretreatment; and the Great Lakes Critical Programs Act.
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     853,912 (total).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     The frequency of response varies depending on the specific response activity and can range from ongoing and monthly to once every five years.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     33,335,582 hours (per year). Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $2,301,814,621 (per year), which includes $38,342,314 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the Estimates:</E>
                     There is an increase of 2,192,078 hours in the total estimated respondent burden compared with the ICR currently approved by OMB. This increase is due to due to improved electronic data collection, leading to EPA's estimates of permittee respondents increasing from 9,310,277 in the current ICR to 10,836,245 in this ICR, a 16% increase. In addition, capital and O&amp;M cost burden increased due to inflation which impacted factors such as laboratory analytic and labor costs.
                </P>
                <SIG>
                    <NAME>Courtney Kerwin, </NAME>
                    <TITLE>Deputy Director, Data and Enterprise Programs Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15394 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OAR-2021-0276; FRL-13381-01-OAR]</DEPDOC>
                <SUBJECT>Multi-Agency Radiation Survey and Site Investigation Manual, Revision 2</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Department of Energy, Department of War, Environmental Protection Agency, and Nuclear Regulatory Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The U.S. Department of Energy (DOE), U.S. Department of War (DOW), U.S. Environmental Protection Agency (EPA), and the U.S. Nuclear Regulatory Commission (NRC) are announcing the availability for use of Revision 2 of the Multi-Agency Radiation Survey and Site Investigation Manual (MARSSIM). MARSSIM provides information on planning, conducting, evaluating, and documenting environmental radiological surveys of surface soils and building surfaces for demonstrating compliance with regulations. The manual has not been updated since 2001; updates prior to 2001 primarily consisted of minor non-technical edits. Revision 2 updates the science, clarifies methods, and implements lessons learned from over 25 years of use. MARSSIM Revision 2 is available from 
                        <E T="03">https://www.epa.gov/radiation/multi-agency-radiation-survey-and-site-investigation-manual-marssim.</E>
                    </P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Any of the following points of contact for each agency for technical information: DOE: H. Mike Stewart, Office of Environmental Compliance and Radiation Protection, EH-11, U.S. Department of Energy, 1000 Independence Avenue SW, Washington, DC 20585, telephone number: (202) 586-6444, email address: 
                        <E T="03">mike.stewart@hq.doe.gov;</E>
                         DOW: Gerald A. Falo, Defense Centers for Public Health-Aberdeen, DHA Public Health, 8977 Sibert Road, Building E-1570, Aberdeen Proving Ground, MD 21010, telephone number: (410) 436-4852, email address: 
                        <E T="03">gerald.a.falo.civ@health.mil;</E>
                         EPA: Kathryn Snead, Office of Air and Radiation, Mail Stop 6608T, Environmental Protection Agency, 1200 Pennsylvania Avenue NW, Washington, DC 20460-1000, telephone number: (202) 343-9228, email address: 
                        <E T="03">snead.kathryn@epa.gov;</E>
                         NRC: Joseph Kanney, U.S. Nuclear Regulatory Commission, Mail Stop O5-G10, Washington, DC 20555-0001, telephone number: (301) 415-1920, email address: 
                        <E T="03">joseph.kanney@nrc.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Table of Acronyms</HD>
                <EXTRACT>
                    <FP SOURCE="FP-1">CCD continuously collected data</FP>
                    <FP SOURCE="FP-1">DOE Department of Energy</FP>
                    <FP SOURCE="FP-1">DOW Department of War</FP>
                    <FP SOURCE="FP-1">EPA Environmental Protection Agency</FP>
                    <FP SOURCE="FP-1">LBGR lower bound of the gray region</FP>
                    <FP SOURCE="FP-1">MARSSIM multi-agency radiation survey and site investigation manual</FP>
                    <FP SOURCE="FP-1">MQOs measurement quality objectives</FP>
                    <FP SOURCE="FP-1">NRC Nuclear Regulatory Commission</FP>
                    <FP SOURCE="FP-1">SAB science advisory board</FP>
                    <FP SOURCE="FP-1">SI international system of units</FP>
                    <FP SOURCE="FP-1">TENORM technologically enhanced naturally occurring radioactive material</FP>
                </EXTRACT>
                <HD SOURCE="HD1">Table of Contents</HD>
                <GPOTABLE COLS="2" OPTS="L0,tp0,p0,8/9,g1,t1,i1" CDEF="s150,2">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">I. General Information</ENT>
                        <ENT>2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">A. Summary of Revisions</ENT>
                        <ENT>2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">B. How can I get copies of this document and other related information?</ENT>
                        <ENT>4</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">I. General Information</HD>
                <HD SOURCE="HD2">A. Summary of Revisions</HD>
                <P>MARSSIM provides information on planning, conducting, evaluating, and documenting environmental radiological surveys of surface soil and building surfaces for demonstrating compliance with regulations. MARSSIM, Revision 2, updates this multi-agency consensus document.</P>
                <P>
                    MARSSIM was originally developed by the technical staff of the four Federal agencies (DOE, DOW, EPA and NRC) having authority for control of radioactive materials.
                    <SU>1</SU>
                    <FTREF/>
                     The four agencies issued Revision 1 to MARSSIM in August 2000, and additional edits to Revision 1 in June 2001. MARSSIM has not been updated since 2001; updates prior to 2001 primarily consisted of minor non-technical edits. Revision 2 updates the science, clarifies methods, and implements lessons learned from over 25 years of use in industry.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         60 FR 12555 (Mar. 7, 1995).
                    </P>
                </FTNT>
                <P>
                    A summary of changes in MARSSIM Revision 2 includes but is not limited to the following: (1) added measurement quality objectives (MQOs) and measurement uncertainty, (2) expanded measurement methods to include site-specific scanning surveys, (3) updated survey instrumentation information, (4) added Scenario B (“assumed to meet the criteria until proven otherwise”), (5) added information on continuously 
                    <PRTPAGE P="48104"/>
                    collected data (CCD) surveys, (6) improved description of the lower bound of the gray region (LBGR), (7) increased information on manned and unmanned aerial radiological surveys, (8) updated references, (9) changed English units to International System of Units (SI), (10) removed the term “Area Factor,” (11) included additional examples, (12) reorganized information for clarity, (13) addressed comments on composite samples, surrogate ratios, and Technologically Enhanced Naturally Occurring Radioactive Material (TENORM), and (14) increased emphasis on regulator interface during survey design.
                </P>
                <P>
                    MARSSIM benefited from extensive internal, public, and technical peer review and comment. Before the publication of the draft for public comment, the four Federal agencies performed an extensive internal review that identified several key areas of needed improvement. After addressing internal comments, the four federal agencies announced a sixty-day open public comment period 
                    <SU>2</SU>
                    <FTREF/>
                     and an additional forty-five day open public comment period.
                    <SU>3</SU>
                    <FTREF/>
                     The document simultaneously received formal technical peer review under the auspices of the EPA Science Advisory Board (SAB). The four federal agencies completed additional changes to address public and technical peer review comments, resulting in MARSSIM, Revision 2.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         86 FR 32034 (June 16, 2021).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         86 FR 73757 (Dec. 28, 2021)
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Docket ID No. EPA-HQ-OAR-2021-0276.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. How can I get copies of this document and other related information?</HD>
                <P>
                    <E T="03">1. Docket.</E>
                     EPA has established a docket for this action under Docket ID No. EPA-HQ-OAR-2021-0276. Publicly available docket materials are available either electronically through 
                    <E T="03">www.regulations.gov</E>
                     or in hard copy at the EPA Docket Center, WJC West Building, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The Docket Center's hours of operations are 8:30 a.m.-4:30 p.m., Monday-Friday (except Federal Holidays). For further information on the EPA Docket Center services and the current status, see: 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">2. Electronic Access.</E>
                     You may access this 
                    <E T="04">Federal Register</E>
                     document electronically from 
                    <E T="03">https://www.federalregister.gov/documents/2021/06/16/2021-12654/multi-agency-radiation-survey-and-site-investigation-manual-revision-2.</E>
                </P>
                <SIG>
                    <NAME>Michael Silverman,</NAME>
                    <TITLE>Director, Office of Environmental Protection and ES&amp;H Reporting, Office of Environment, Health, Safety and Security, Department of Energy.</TITLE>
                    <NAME>Patricia Helene Passman,</NAME>
                    <TITLE>Colonel, U.S. Army, Director, Occupational and Environmental Safety, Office of the Under Secretary of War for Personnel and Readiness/Assistant Secretary of War for Readiness/Deputy Assistant Secretary of War for Safety and Occupational Health.</TITLE>
                    <NAME>Sharon White,</NAME>
                    <TITLE>Acting Director, Office of Radiation and Indoor Air, Environmental Protection Agency.</TITLE>
                    <NAME>John Tappert,</NAME>
                    <TITLE>Director, Office of Nuclear Regulatory Research, Nuclear Regulatory Commission.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15390 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OLEM-2018-0767; FRL-13474-01-OLEM]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Recordkeeping and Reporting—Solid Waste Disposal Facilities and Practices; EPA ICR No. 1381.14, OMB Control No. 2050-0122</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Recordkeeping and Reporting-Solid Waste Disposal Facilities and Practices” (EPA ICR No. 1381.14, OMB Control No. 2050-0122) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act (PRA). Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section. This is a proposed extension of the ICR, which is currently approved through March 31, 2027. This document allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID No. EPA-HQ-OLEM-2018-0767, to EPA online using 
                        <E T="03">https://www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, U.S. Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Peggy Vyas, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-0453; email address: 
                        <E T="03">vyas.peggy@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through March 31, 2027. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This document allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">https://www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is (202) 566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     document to announce the submission of the ICR to OMB and the 
                    <PRTPAGE P="48105"/>
                    opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     In order to effectively implement and enforce final changes to 40 CFR part 258 on a State level, owners/operators of municipal solid waste landfills have to comply with the final reporting and recordkeeping requirements. Respondents include owners or operators of new municipal solid waste landfills (MSWLFs), existing MSWLFs, and lateral expansions of existing MSWLFs. The respondents, in complying with 40 CFR part 258, are required to record information in the facility operating record, pursuant to § 258.29, as it becomes available. The operating record must be supplied to the State as requested until the end of the post-closure care period of the MSWLF. The information collected will be used by the State Director to confirm owner or operator compliance with the regulations under 40 CFR part 258. These owners or operators could include Federal, State, and local governments, and private waste management companies. Facilities in NAICS codes 9221, 5622, 3252, 3251 and 3253 may be affected by this rule.
                </P>
                <P>
                    <E T="03">Form numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Private sector as well as state and local governments.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     The respondents, in complying with 40 CFR part 258, are required to record information in the facility operating record, pursuant to § 258.29, as it becomes available.
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     3,800.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     On occasion.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     211,262 hours (per year). Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $17,286,006 (per year), which includes $15,075,153 in annualized labor and $2,210,856 in annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     The burden hours are likely to stay substantially the same.
                </P>
                <SIG>
                    <DATED>Dated: July 21, 2026.</DATED>
                    <NAME>Andrew Baca,</NAME>
                    <TITLE>Director, Office of Resource Conservation and Recovery.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15388 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OLEM-2018-0692; FRL-13476-01-OLEM]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Generator Standards Applicable to Laboratories Owned by Eligible Academic Entities, EPA ICR No. 2317.05, OMB Control No. 2050-0204</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Generator Standards Applicable to Laboratories Owned by Eligible Academic Entities” (EPA ICR No. 2317.05, OMB Control No. 2050-0204) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act (PRA). Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section. This is a proposed extension of the ICR, which is currently approved through March 31, 2027. This document allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID No. EPA-HQ-OLEM-2018-0692, to EPA online using 
                        <E T="03">https://www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, U.S. Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Peggy Vyas, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-0453; email address: 
                        <E T="03">vyas.peggy@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through March 31, 2027. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This document allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">https://www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is (202) 566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     document to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Subpart K within 40 CFR part 262 provides a flexible and protective set of regulations that address the specific nature of hazardous waste generation and accumulation in laboratories owned by colleges and universities, including teaching hospitals and non-profit research institutes that are either owned by or formally affiliated with a college or university. In addition, eligible academic entities have the discretion to determine the most appropriate and effective method of compliance with these requirements—by allowing them the choice of either managing their hazardous wastes in accordance with the alternative regulations as set forth in subpart K, or remaining subject to the existing generator regulations.
                </P>
                <P>
                    <E T="03">Form numbers:</E>
                     None.
                    <PRTPAGE P="48106"/>
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Business and other for-profit, as well as State, Local, and Tribal governments.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Required to obtain or retain a benefit (sections 2002, 3001, 3002, 3004 of RCRA).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     246.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     On occasion.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     146,160 hours per year. Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $8,088,511 (per year), which includes $255,758 in annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     The burden hours are likely to stay substantially the same.
                </P>
                <SIG>
                    <DATED>Dated: July 21, 2026. </DATED>
                    <NAME>Andrew Baca,</NAME>
                    <TITLE>Director, Office of Resource Conservation and Recovery.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15393 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OLEM-2018-0391; FRL-13475-01-OLEM]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Facility Ground-Water Monitoring Requirements, EPA ICR No. 0959.18, OMB Control No. 2050-0033</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Facility Ground-Water Monitoring Requirements (Renewal)” (EPA ICR No. 0959.18, OMB Control No. 2050-0033) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act (PRA). Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section. This is a proposed extension of the ICR, which is currently approved through March 31, 2027. This document allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID No. EPA-HQ-OLEM-2018-0391, to EPA online using 
                        <E T="03">https://www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, U.S. Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Peggy Vyas, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-0453; email address: 
                        <E T="03">vyas.peggy@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through March 31, 2027. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This document allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">https://www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave., NW, Washington, DC. The telephone number for the Docket Center is (202) 566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     document to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Subtitle C of the Resource Conservation and Recovery Act (RCRA) creates a comprehensive program for the safe management of hazardous waste. Section 3004 of RCRA requires owners and operators of facilities that treat, store, or dispose of hazardous waste to comply with standards established by EPA that are to protect the environment. Section 3005 provides for implementation of these standards under permits issued to owners and operators by EPA or authorized States. Section 3005 also allows owners and operators of facilities in existence when the regulations came into effect to comply with applicable notice requirements to operate until a permit is issued or denied. This statutory authorization to operate prior to permit determination is commonly known as “interim status.” Owners and operators of interim status facilities also must comply with standards set under section 3004.
                </P>
                <P>This ICR examines the ground-water monitoring standards for permitted and interim status facilities at 40 CFR parts 264 and 265, as specified. The ground-water monitoring requirements for regulated units follow a tiered approach whereby releases of hazardous contaminants are first detected (detection monitoring), then confirmed (compliance monitoring), and if necessary, are required to be cleaned up (corrective action). Each of these tiers requires collection and analysis of ground-water samples. Owners or operators that conduct ground-water monitoring are required to report information to the oversight agencies on releases of contaminants and to maintain records of ground-water monitoring data at their facilities. The goal of the ground-water monitoring program is to prevent and quickly detect releases of hazardous contaminants to groundwater, and to establish a program whereby any contamination is expeditiously cleaned up as necessary to protect human health and environment.</P>
                <P>
                    <E T="03">Form numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Business or other for-profit; and State, Local, or Tribal Governments.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (RCRA sections 3004 and 3005).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     774.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Quarterly, semi-annually, and annually.
                    <PRTPAGE P="48107"/>
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     100,701 hours per year. Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $22,470,710 (per year), which includes $15,430,083 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     The burden hours are likely to stay substantially the same.
                </P>
                <SIG>
                    <DATED>Dated: July 21, 2026.</DATED>
                    <NAME>Andrew Baca,</NAME>
                    <TITLE>Director, Office of Resource Conservation and Recovery.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15392 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OLEM-2018-0198; FRL-13472-01-OLEM]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Land Disposal Restrictions (Renewal), EPA ICR No. 1442.25, OMB Control No. 2050-0085</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Land Disposal Restrictions (Renewal)” (EPA ICR No. 1442.25, OMB Control No. 2050-0085) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act (PRA). Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section. This is a proposed extension of the ICR, which is currently approved through March 31, 2027. This document allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID No. EPA-HQ-OLEM-2018-0198, to EPA online using 
                        <E T="03">https://www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, U.S. Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Peggy Vyas, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-0453; email address: 
                        <E T="03">vyas.peggy@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through March 31, 2027. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This document allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">https://www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is (202) 566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     document to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Section 3004 of the Resource Conservation and Recovery Act (RCRA), as amended, requires that EPA develop standards for hazardous waste treatment, storage, and disposal as may be necessary to protect human health and the environment. Subsections 3004(d), (e), and (g) require EPA to promulgate regulations that prohibit the land disposal of hazardous waste unless it meets specified treatment standards described in subsection 3004(m).
                </P>
                <P>The regulations implementing these requirements are codified in the Code of Federal Regulations (CFR) Title 40, part 268. EPA requires that facilities maintain the data outlined in this ICR so that the Agency can ensure that land disposed waste meets the treatment standards. EPA strongly believes that the recordkeeping requirements are necessary for the agency to fulfill its congressional mandate to protect human health and the environment.</P>
                <P>
                    <E T="03">Form numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Private sector and State, Local, or Tribal governments.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (40 CFR part 268).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     77,612.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     On occasion.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     517,369 hours per year. Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $87,510,974 (per year), which includes $45,898,132 in annualized capital and operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     The burden hours are likely to stay substantially the same.
                </P>
                <SIG>
                    <DATED> Dated: July 20, 2026.</DATED>
                    <NAME>Andrew Baca,</NAME>
                    <TITLE>Director, Office of Resource Conservation and Recovery.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15379 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OECA-2011-0824; FRL—10651.1-01-OECA]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Application for Registration and Pesticide Report for Pesticide-Producing and Device-Producing Establishments</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) is planning to submit an information collection request (ICR), “Application for Registration and Pesticide Report for Pesticide-Producing 
                        <PRTPAGE P="48108"/>
                        and Device-Producing Establishments” (EPA ICR No. 0160.14, OMB Control No. 2070-0078) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. Before doing so, EPA is soliciting public comments on specific aspects of the proposed information collection as described below. This is a proposed extension of the ICR, which is currently approved through November 30, 2026. This notice allows for 60 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number EPA-HQ-OECA-2011-0824, to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method) or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Ave. NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Michelle Yaras, Office of Compliance, Compliance, Inspector, and Training Division, Pesticides, Waste, and Toxics Compliance Branch (2227A), Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 564-4153; email address: 
                        <E T="03">yaras.michelle@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through November 30, 2026. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    This notice allows 60 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">http://www.epa.gov/dockets.</E>
                </P>
                <P>
                    Pursuant to section 3506(c)(2)(A) of the PRA, EPA is soliciting comments and information to enable it to: (i) evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility; (ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (iii) enhance the quality, utility, and clarity of the information to be collected; and (iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate forms of information technology. EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval. At that time, EPA will issue another 
                    <E T="04">Federal Register</E>
                     notice to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) Section 7(a) requires that any person who produces pesticides, active ingredients or devices subject to the Act must register with the Administrator of EPA the establishment in which the pesticide, active ingredient or device is produced. This section further requires that applications for registration of any establishment shall include the name and address of the establishment and of the producer who operates such an establishment. EPA Form 3540-8, Application for Registration of Pesticide-Producing and Device-Producing Establishments, is used to collect the establishment registration information required by this section.
                </P>
                <P>FIFRA Section 7(c) requires that any producer operating an establishment registered under Section 7 report to the Administrator within 30 days after it is registered, and annually thereafter by March 1st for certain pesticide or device production and sales or distribution information. The producers must report which types and amounts of pesticides, active ingredients, or devices are currently being produced, were produced during the past year, sold or distributed in the past year. The supporting regulations at 40 CFR part 167 provide the requirements and time schedules for submitting production information. EPA Form 3540-16, Pesticide Report for Pesticide-Producing and Device-Producing Establishments, is used to collect the pesticide production information required by Section 7(c) of FIFRA.</P>
                <P>Establishment registration information, collected on EPA Form 3540-8, is a one-time requirement for all pesticide-producing and device-producing establishments. Pesticide and device production information, reported on EPA Form 3540-16, is required to be submitted within 30 days after the company is notified of its pesticide-producing or device-producing establishment number, and annually thereafter on or before March 1st. Pesticide-producing and device-producing establishments optionally can electronically enter and submit their establishment registration information and pesticide production information through EPA's Central Data Exchange (CDX).</P>
                <P>
                    <E T="03">Form Numbers:</E>
                     3540-8 and 3540-16.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Establishments producing pesticides.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (40 CFR part 167).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     20,762 (total).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Initial and Annually.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     33,307.19 hours (per year). Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $2,961,348.61 (per year), which includes $0 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the Estimates:</E>
                     There is no change in the estimated total burden per form compared with the prior ICR, but there is an increase in the estimated respondent burden due to an increase in the estimated labor costs (increase in hourly wages) and an increase in the number of respondents submitting each form increases the total hours (increase of 87.5 hours). The total estimated increase in respondent costs from increases in labor costs and total hours is $225,380.47.
                </P>
                <SIG>
                    <NAME>Loren Denton,</NAME>
                    <TITLE>Director, Compliance, Inspector, and Training Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15364 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">FEDERAL COMMUNICATIONS COMMISSION</AGENCY>
                <DEPDOC>[PSHSB &amp; OET: PS Docket No. 26-184; DA 26-742; FR ID 359713]</DEPDOC>
                <SUBJECT>Seeking Comment on Prohibiting the Importation and Marketing of Certain Covered UAS and UAS Critical Components and Equipment Listed in Section 1709 of FY2025 NDAA.</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Communications Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Request for comments.</P>
                </ACT>
                <SUM>
                    <PRTPAGE P="48109"/>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In this document, the Public Safety and Homeland Security Bureau (PSHSB) and the Office of Engineering and Technology (OET) seek comment on proposing to prohibit the continued importation and marketing of certain previously authorized equipment that has been determined to pose an unacceptable risk to the national security of the United States or to the and security of United States persons. Through Public Notice, acting pursuant to section 2.939 of the Federal Communications Commission's rules, PSHSB and OET propose to apply such prohibitions to certain previously-authorized foreign-produced uncrewed aircraft systems (UAS) and UAS critical components, and certain communications and video surveillance equipment listed in section 1709 of the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 (FY2025 NDAA), added to the Covered List in December 2025.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are due on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Pursuant to sections 1.415 and 1.419 of the Commission's rules, 47 CFR 1.415, 1.419, interested parties may file comments on or before the dates indicated on the first page of this document. You may submit comments, identified by PS Docket No. 26-184, by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal Communications Commission's website:</E>
                          
                        <E T="03">https://www.fcc.gov/ecfs.</E>
                         Follow the instructions for submitting comments. 
                        <E T="03">Electronic Filers:</E>
                         Comments may be filed electronically using the internet by accessing the ECFS: 
                        <E T="03">https://www.fcc.gov/ecfs.</E>
                    </P>
                    <P>
                        • 
                        <E T="03">Paper Filers:</E>
                         Parties who choose to file by paper must file an original and one copy of each filing.
                    </P>
                    <P>• Filings can be sent by hand or messenger delivery, by commercial courier, or by the U.S. Postal Service. All filings must be addressed to the Secretary, Federal Communications Commission.</P>
                    <P>• Hand-delivered or messenger-delivered paper filings for the Commission's Secretary are accepted between 8:00 a.m. and 4:00 p.m. by the FCC's mailing contractor at 9050 Junction Drive, Annapolis Junction, MD 20701. All hand deliveries must be held together with rubber bands or fasteners. Any envelopes and boxes must be disposed of before entering the building.</P>
                    <P>• Commercial courier deliveries (any deliveries not by the U.S. Postal Service) must be sent to 9050 Junction Drive, Annapolis Junction, MD 20701.</P>
                    <P>• Filings sent by U.S. Postal Service First-Class Mail, Priority Mail, and Priority Mail Express must be sent to 45 L Street NE, Washington, DC 20554.</P>
                    <P>
                        • 
                        <E T="03">People With Disabilities:</E>
                         Contact the FCC to request reasonable accommodations (accessible format documents, sign language interpreters, CART, etc.) by email: 
                        <E T="03">FCC504@fcc.gov</E>
                         or phone: 202-418-0530.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Matthew Chai, Attorney Advisor, Operations and Emergency Management Division, Public Safety and Homeland Security Bureau, (202) 418-1112 or 
                        <E T="03">Matthew.chai@fcc.gov.</E>
                    </P>
                    <P>
                        <E T="03">Authority:</E>
                         47 U.S.C. 151, 154, 229, 301, 302a(b), 303, 1004, 1601-1609; Secure Equipment Act of 2021, Pub. L. 117-55, 135 Stat. 423.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This is a summary of the Public Notice released on July 17, 2026 in PS Docket No. 26-184. The full text of this document is available at: 
                    <E T="03">https://docs.fcc.gov/public/attachments/DA-26-742A1.docx.</E>
                </P>
                <P>
                    In October 2025, the Commission adopted the 
                    <E T="03">EA Security Second R&amp;O</E>
                     (90 FR 53227) which established a procedure to limit the scope of an existing authorization of covered equipment to prohibit continued importation or marketing of such equipment, without revoking the underlying authorization. The Commission directed PSHSB and OET to “institute proceedings to determine whether to apply these prohibitions to some or all of the equipment currently on the Covered List” and it delegated authority to PSHSB and OET to apply such prohibitions pursuant to the framework and process outlined in the 
                    <E T="03">EA Security Second R&amp;O.</E>
                     Under section 2.939(e), PSHSB and OET “may place limitations on an existing authorization for covered equipment authorizations to prohibit continued importation or marketing” of such equipment.
                </P>
                <P>On December 22, 2025, PSHSB added all UAS and UAS critical components produced in a foreign country to the Covered List, and all communications and video surveillance equipment and services listed in section 1709 of the FY2025 NDAA, to the Covered List. These additions were based on a National Security Determination from an Executive Branch interagency body, including several appropriate national security agencies, determining (among other things) that such equipment and services pose an unacceptable risk to the national security of the United States and to the safety and security of United States persons.</P>
                <P>On March 30, 2026, the Enforcement Bureau (EB) opened an investigation and issued a Letter of Inquiry (LOI) to Xtra Technology LLC (Xtra), based on publicly available information that Xtra was producing hardware copies of certain communications and video surveillance equipment listed in section 1709 of the FY2025 NDAA, and that code from the equipment listed in section 1709 of the FY2025 NDAA was copied and pasted into Xtra devices. On May 8, 2026, EB opened an investigation and issued LOIs to Cogito Tech Company, Limited (Cogito); Fikaxo Technology Inc. (Fikaxo); Lyno Dynamics LLC (Lyno Dynamics); Skyhigh Tech LLC (Skyhigh Tech); Spatial Hover Inc (Spatial Hover); SZ Knowact Robot Technology Co., Ltd. (SZ Knowact); WaveGo Tech LLC (WaveGo), based on publicly available information that such companies produce UAS and UAS critical components that contain hardware copies of communications and video surveillance equipment listed in section 1709 of the FY2025 NDAA. All of these companies failed to respond to EB's March and May 2026 LOIs as directed in violation of Commission rules.</P>
                <P>On April 9, 2026, EB issued a Letter of Inquiry to Guangzhou Xaircraft Technology Co. Ltd (XAG), a company that manufactures UAS and UAS critical components in a foreign country, based on XAG's failure to provide updated United States agent for service of process information as required by section 2.929(c) of the Commission's rules. EB granted XAG's request for an extension of time to respond until May 26, 2026. On May 21, 2026, XAG sought an additional 60-day extension, asserting that certain requested information might be subject to export controls under the laws of the People's Republic of China (PRC) and that XAG needed time to obtain an official determination from the PRC Ministry of Commerce regarding whether it could respond to the FCC's inquiries. On July 16, 2026, OET temporarily deferred XAG's grantee code based on XAG's continued failure to provide updated United States agent for service of process information pursuant to section 2.929(c) of the Commission's rules.</P>
                <P>
                    Through this Public Notice, pursuant to section 2.939(e), PSHSB and OET propose to prohibit the continued importation and marketing of previously-authorized foreign-produced UAS and UAS critical components, and certain communications and video surveillance equipment listed in section 1709 of the FY2025 NDAA, added to the Covered List in December 2025. This would encompass all covered equipment produced by the following entities and their affiliates, subsidiaries, and other partners: Cogito; Fikaxo; Lyno 
                    <PRTPAGE P="48110"/>
                    Dynamics; Skyhigh Tech; Spatial Hover; SZ Knowact; WaveGo; Xtra; and XAG.
                </P>
                <P>We tentatively conclude that such equipment is covered equipment. Specifically, we propose to apply these prohibitions to the following covered equipment:</P>
                <P>(1) foreign-produced UAS and UAS critical components and white-labeled devices listed in section 1709 of the FY2025 NDAA produced by the following entities:</P>
                <P>• Cogito, including FCC IDs 2BCHV-TQFDUB2, 2BCHV-GL3323, and 2BCHV-TQFDUB1; </P>
                <P>• Fikaxo, including FCC IDs 2BRQB-FKABZF and 2BRQB-YZABFI; </P>
                <P>• Lyno Dynamics, including FCC IDs 2BQ98-LD2202508, 2BQ98-LD220RC, and 2BQ98-LD220RD; </P>
                <P>• Skyhigh Tech, including FCC IDs 2BLZI-T60X2411 and 2BLZI-YKBP22411; </P>
                <P>• Spatial Hover, including FCC IDs 2BQAI-S3T and 2BQAI-NRC01; </P>
                <P>• SZ Knowact, including FCC IDs 2BMUV-ARDCF25 and 2BMUV-AUDAFV25; and </P>
                <P>• WaveGo LLC, including FCC IDs 2BPFE-DD001 and 2BPFE-RC001.</P>
                <P>(2) communications and video surveillance equipment listed in section 1709 produced by Xtra, including FCC IDs 2BQH2-XCAMA01, 2BQH2-XCAMB01, 2BQH2-XCAMC01, 2BQH2-XCAMD01, and 2BQH2-XCAME01.</P>
                <P>(3) foreign-produced UAS and UAS critical components produced by XAG, including UAS and UAS critical components with FCC IDs beginning with the 2A46G grantee code.</P>
                <P>We tentatively conclude that such equipment is covered equipment. As stated above, public reporting indicates that equipment listed in categories (1) and (2) are exact hardware copies of certain communications and video surveillance equipment listed in section 1709 of the FY2025 NDAA. Even if the equipment is not an exact hardware copy, equipment that relies on substantial design, manufacture, assembly, or development by entities listed in section 1709 could still be considered “produced by” such entities. Additionally, as reflected in the materials submitted as part of the application for certification, three companies—Lyno Dynamics, Spatial Hover, and Skyhigh Tech—submitted equipment certification applications that still display branding of or reference companies listed in section 1709. Even if not produced by an entity named in section 1709, the equipment listed in categories (1) and (2) might still be produced by a “partner,” or entity “to which [a] named entity has a technology sharing or licensing agreement,” given the closeness of the designs. Moreover, publicly available equipment authorization records indicate that several of the UAS and UAS critical components in category (1) are in any event produced abroad, rendering them covered equipment even apart from the section 1709 connection. Equipment listed in category 3 is equipment produced in a foreign country. For example, XAG identified in its response to EB's April 9, 2026 LOI that its manufacturing facilities are located in a foreign country.</P>
                <P>This proposed prohibition would not apply to any other already-authorized covered equipment, nor to UAS and UAS critical components on the DCMA Blue UAS Cleared List, domestic end products under the Buy American Standard, or devices granted Conditional Approval by the Department of War or Department of Homeland Security. It also would not apply to importation or marketing for federal government use or for commercial testing and product development, and would not affect the continued use or operation of already-purchased equipment.</P>
                <P>We seek comment on our tentative conclusions that the above-referenced equipment is covered equipment. We invite commenters to provide specific evidence in response to our tentative conclusions. Below, we provide a brief analysis of the relevant factors that would justify limitation on the authorization of previously authorized “covered” equipment and tentatively conclude that prohibiting the continued importation and marketing of this previously authorized covered equipment serves the public interest.</P>
                <P>
                    <E T="03">National security impacts.</E>
                     As the Commission recognized in the 
                    <E T="03">EA Security Second R&amp;O,</E>
                     “it is obvious and unarguable that no governmental interest is more compelling than the security of the Nation.” The Commission further stated that older models of covered equipment, which continue to be widely sold in the United States, pose an unacceptable risk to national security when imported or marketed, “not only when such equipment is new to the market.” The Commission agreed with commenters who observed that certain previously authorized devices that are now considered covered equipment “likely remain[ ] marketable in the United States” and “may present continuing national security threats.”
                </P>
                <P>Subject to exceptions, an Executive Branch interagency body with appropriate national security expertise—including participation from appropriate national security agencies, one of which was the Department of War—specifically determined that UAS and UAS critical components produced in foreign countries, as well as communications and video surveillance equipment and services listed in section 1709 of the FY2025 NDAA, “pose unacceptable risks to the national security of the United States or to the safety and security of United States persons.” This determination of “unacceptable risks” was based on an assessment of “threats from unauthorized surveillance, sensitive data exfiltration, supply chain vulnerabilities, and other potential threats to the homeland.” We believe this national security determination to encompass all already-authorized covered equipment addressed in this Public Notice—namely, UAS and UAS critical components produced in foreign countries and/or communications and video surveillance equipment and services listed in section 1709 of the FY2025 NDAA. Consistent with the Commission's direction, we tentatively accept this determination and “give [it] particular weight.” We seek comment on this proposed analysis. We tentatively conclude that prohibiting the continued importation and marketing of previously authorized covered UAS and UAS critical components and communications and video surveillance equipment and services listed in section 1709 of the FY2025 NDAA as described above is necessary to protect national security by mitigating risks to the United States communications sector.</P>
                <P>
                    <E T="03">Economic and supply chain impacts.</E>
                     We seek comment on the potential economic and supply chain impacts of prohibiting the continued importation and marketing of already-authorized covered equipment. How would this proposed action affect the financial interests of consumers, providers, and manufacturers in the communications sector? What are the economic or supply chain considerations that weigh in favor of, or against taking this proposed action? We invite commenters to provide data that we should consider in our analysis.
                </P>
                <P>
                    We tentatively conclude that our proposed action would not have substantial economic and supply chain impacts, given that the devices subject to the proposed limitation represent a very small portion of the United States market. None of the companies identified in this Public Notice—Cogito, Fikaxo, Lyno Dynamics, Skyhigh Tech, Spatial Hover, SZ Knowact, WaveGo, XAG, or Xtra—appear in major industry market analyses or rankings. We seek comment on whether this assessment is accurate, whether other equipment 
                    <PRTPAGE P="48111"/>
                    could readily substitute for the covered equipment, whether the Conditional Approval process has provided an adequate source of trusted equipment, whether the proposed prohibition would be cost-effective for the public in terms of obtaining trusted equipment, and whether providers' compliance costs would decrease as they replaced covered equipment with trusted equipment. We strongly encourage commenters to submit data or other specific evidence regarding any economic costs.
                </P>
                <P>We also seek comment on potential economic benefits that may result from the proposed prohibitions. Following the initial update to the Covered List, domestic UAS producers have attracted billions of dollars in new investment, supporting thousands of United States manufacturing jobs, and additional billions have been committed to expanding domestic production of UAS and UAS critical components. These investments—supported by both domestic and foreign capital—are expected to generate further economic growth. We tentatively conclude that if the proposed prohibition results in any supply reductions, it may spur additional domestic investment that could offset or outweigh any negative economic effects. We request comment on the economic impacts of the likely investment in United States production driven by this proposed prohibition.</P>
                <P>
                    <E T="03">Public interest analysis.</E>
                     We tentatively conclude that prohibiting the continued importation and marketing of the previously authorized covered equipment identified in this Public Notice serves the public interest because it protects United States communications networks from devices that an Executive Branch interagency body has specifically determined to “pose an unacceptable risk to the national security of the United States or the security and safety of United States persons.” We further tentatively conclude that no countervailing public interest factors outweigh this finding with respect to the proposed prohibition. We seek comment on this analysis.
                </P>
                <P>
                    <E T="03">Existing authorizations.</E>
                     We clarify that, if this prohibition is adopted, the continued use or operation of previously authorized UAS and UAS critical components that are foreign-produced, as well as communications and video surveillance equipment listed in section 1709 of the FY2025 NDAA and addressed in this Public Notice, would remain permitted.
                </P>
                <P>
                    <E T="03">Implementation timeline.</E>
                     We propose that all parties must cease all importation and marketing activities within 30 days after publication in the 
                    <E T="04">Federal Register</E>
                    . We seek comment on the proposed timeline from the responsible parties and relevant manufacturers, importers, distributors, retailers, and other interested entities. In particular, we request comment on implementation considerations such as the quantity of devices already imported into the United States and available for—or being held for—marketing or sale; new or recently updated device models that are en route to the United States or pending shipment; and devices subject to executed distribution, marketing, or sales agreements that have not yet entered the supply chain.
                </P>
                <P>
                    <E T="03">Permit-but-disclose proceeding.</E>
                     The proceeding this Public Notice initiates shall be treated as a “permit-but-disclose” proceeding in accordance with the Commission's ex parte rules. Persons making ex parte presentations must file a copy of any written presentation or a memorandum summarizing any oral presentation within two business days after the presentation (unless a different deadline applicable to the Sunshine period applies). Persons making oral ex parte presentations are reminded that memoranda summarizing the presentation must (1) list all persons attending or otherwise participating in the meeting at which the ex parte presentation was made, and (2) summarize all data presented and arguments made during the presentation. If the presentation consisted in whole or in part of the presentation of data or arguments already reflected in the presenter's written comments, memoranda or other filings in the proceeding, the presenter may provide citations to such data or arguments in his or her prior comments, memoranda, or other filings (specifying the relevant page and/or paragraph numbers where such data or arguments can be found) in lieu of summarizing them in the memorandum. Documents shown or given to Commission staff during ex parte meetings are deemed to be written ex parte presentations and must be filed consistent with rule 1.1206(b). In proceedings governed by rule 1.49(f) or for which the Commission has made available a method of electronic filing, written ex parte presentations and memoranda summarizing oral ex parte presentations, and all attachments thereto, must be filed through the electronic comment filing system available for that proceeding, and must be filed in their native format (
                    <E T="03">e.g.,</E>
                     .doc, .xml, .ppt, searchable .pdf). Participants in this proceeding should familiarize themselves with the Commission's ex parte rules.
                </P>
                <SIG>
                    <FP>Federal Communications Commission.</FP>
                    <NAME>Zenji Nakazawa,</NAME>
                    <TITLE>Chief, Public Safety and Homeland Security Bureau.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15418 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6712-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">FEDERAL RESERVE SYSTEM</AGENCY>
                <SUBJECT>Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company</SUBJECT>
                <P>The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).</P>
                <P>
                    The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at 
                    <E T="03">https://www.federalreserve.gov/foia/request.htm.</E>
                     Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.
                </P>
                <P>Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.</P>
                <P>Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Benjamin W. McDonough, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than August 14, 2026.</P>
                <P>
                    <E T="03">A. Federal Reserve Bank of Kansas City</E>
                     (Jeffrey Imgarten, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001. Comments can also be sent electronically to 
                    <E T="03">KCApplicationComments@kc.frb.org:</E>
                </P>
                <P>
                    1. 
                    <E T="03">
                        The JVA Inheritance Trust for Terry V. Anderson, Terry V. Anderson, as 
                        <PRTPAGE P="48112"/>
                        trustee, both of Piedmont, Oklahoma; the JVA Inheritance Trust for John T. Anderson, John T. Anderson, as trustee, both of Crescent, Oklahoma; the JVA Inheritance Trust for Barry L. Anderson, Barry L. Anderson, as trustee, both of Guthrie, Oklahoma; and the JVA Inheritance Trust for Patti J. Rains, Patti J. Rains, as trustee, both of Oklahoma City, Oklahoma;
                    </E>
                     to join the Anderson Family Group, a group acting in concert, to acquire voting shares of F&amp;M Bancshares, Inc., Crescent, Oklahoma, and thereby indirectly acquire voting shares of F&amp;M Bank, Edmond, Oklahoma. Terry V. Anderson, John T.
                </P>
                <P>Anderson, Barry L. Anderson, and Patti J. Rains are members of the Anderson Family Group and were each previously permitted by the Federal Reserve System to acquire voting shares of F&amp;M Bancshares, Inc., in their individual capacities.</P>
                <SIG>
                    <P>Board of Governors of the Federal Reserve System.</P>
                    <NAME>Erin Cayce, </NAME>
                    <TITLE>Assistant Secretary of the Board.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15367 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6210-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Agency for Healthcare Research and Quality</SUBAGY>
                <SUBJECT>Agency Information Collection Activities: Proposed Collection; Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Agency for Healthcare Research and Quality, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Information collection notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the extension without change of the information collection project “Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery” (0935-0179).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on this notice must be received by August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments should be submitted to: Margie Shofer, Reports Clearance Officer, AHRQ, by email at 
                        <E T="03">REPORTSCLEARANCEOFFICER@ahrq.hhs.gov.</E>
                    </P>
                    <P>Copies of the proposed collection plans, data collection instruments, and specific details on the estimated burden can be obtained from the AHRQ Reports Clearance Officer.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Margie Shofer, AHRQ Reports Clearance Officer, (301) 427-1696, or by email at 
                        <E T="03">REPORTSCLEARANCEOFFICER@ahrq.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Proposed Project</HD>
                <HD SOURCE="HD2">Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery</HD>
                <P>The information collection activity will garner qualitative customer and stakeholder feedback in an efficient, timely manner, in accordance with the Administration's commitment to improving service delivery. By qualitative feedback we mean information that provides useful insights on perceptions and opinions, but are not statistical surveys that yield quantitative results that can be generalized to the population of study. This feedback will provide insights into customer or stakeholder perceptions, experiences, and expectations, provide an early warning of issues with service, or focus attention on areas where communication, training or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative and actionable communication between the Agency and its customers and stakeholders. It will also allow feedback to contribute directly to the improvement of program management. The current clearance was approved on November 7, 2023 (OMB Control Number 0935-0179) and will expire on November 30, 2026.</P>
                <HD SOURCE="HD1">Method of Collection</HD>
                <P>Feedback collected under this generic clearance will provide useful information, but it will not yield data that can be generalized to the overall population. This type of generic clearance for qualitative information will not be used for quantitative information collections that are designed to yield reliably actionable results, such as monitoring trends over time or documenting program performance. Such data uses require more rigorous designs that address: (1) the target population to which generalizations will be made; (2) the sampling frame; (3) the sample design (including stratification and clustering); (4) the precision requirements or power calculations that justify the proposed sample size; (5) the expected response rate; (6) methods for assessing potential nonresponse bias; (7) the protocols for data collection; (8) and any testing procedures that were or will be undertaken prior to fielding the study. Depending on the degree of influence the results are likely to have, such collections may still be eligible for submission for other generic mechanisms that are designed to yield quantitative results.</P>
                <HD SOURCE="HD1">Estimated Annual Respondent Burden</HD>
                <P>Exhibit 1 shows the estimated total burden hours for the respondents. Mail surveys are estimated to average 15 minutes, telephone surveys 40 minutes, web-based surveys 10 minutes, focus groups two hours, and in-person interviews are estimated to average 50 minutes. Mail surveys may also be sent to respondents via email and may include a telephone non-response follow-up. Telephone non-response follow-up for mailed surveys does not count as a telephone survey. The total burden hours for the 3 years of the clearance are estimated to be 10,900 hours.</P>
                <P>Exhibit 2 shows the estimated cost burden for the respondents. The total cost burden for the 3 years of the clearance is estimated to be $226,932.</P>
                <GPOTABLE COLS="5" OPTS="L2,i1" CDEF="s100,12,13,12,12">
                    <TTITLE>Exhibit 1—Estimated Burden Hours Over 3 Years</TTITLE>
                    <BOXHD>
                        <CHED H="1">Type of information collection</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of
                            <LI>responses per</LI>
                            <LI>respondent</LI>
                        </CHED>
                        <CHED H="1">
                            Hours per
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">
                            Total burden
                            <LI>hours</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Mail/email *</ENT>
                        <ENT>5,000</ENT>
                        <ENT>1</ENT>
                        <ENT>15/60</ENT>
                        <ENT>1,250</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Telephone</ENT>
                        <ENT>200</ENT>
                        <ENT>1</ENT>
                        <ENT>40/60</ENT>
                        <ENT>133</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Web-based</ENT>
                        <ENT>5,000</ENT>
                        <ENT>1</ENT>
                        <ENT>10/60</ENT>
                        <ENT>833</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Focus Groups</ENT>
                        <ENT>500</ENT>
                        <ENT>1</ENT>
                        <ENT>2.0</ENT>
                        <ENT>1,000</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">In-person</ENT>
                        <ENT>200</ENT>
                        <ENT>1</ENT>
                        <ENT>50/60</ENT>
                        <ENT>167</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="48113"/>
                        <ENT I="03">Total</ENT>
                        <ENT>10,900</ENT>
                        <ENT>N/A</ENT>
                        <ENT>N/A</ENT>
                        <ENT>3,383</ENT>
                    </ROW>
                    <TNOTE>* May include telephone non-response follow-up in which case the burden will not change.</TNOTE>
                </GPOTABLE>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,12,12,12,12,16">
                    <TTITLE>Exhibit 2—Estimated Cost Burden Over 3 Years</TTITLE>
                    <BOXHD>
                        <CHED H="1">Type of information collection</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Total burden
                            <LI>hours</LI>
                        </CHED>
                        <CHED H="1">
                            Average
                            <LI>hourly wage</LI>
                            <LI>rate *</LI>
                        </CHED>
                        <CHED H="1">
                            Adjusted
                            <LI>average</LI>
                            <LI>hourly wage</LI>
                            <LI>rate **</LI>
                        </CHED>
                        <CHED H="1">
                            Total cost burden
                            <LI>(total burden</LI>
                            <LI>hours × adjusted</LI>
                            <LI>average hourly</LI>
                            <LI>wage rate)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Mail/email</ENT>
                        <ENT>5,000</ENT>
                        <ENT>1,250</ENT>
                        <ENT>$33.54</ENT>
                        <ENT>$67.08</ENT>
                        <ENT>$83,850</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Telephone</ENT>
                        <ENT>200</ENT>
                        <ENT>133</ENT>
                        <ENT>33.54</ENT>
                        <ENT>67.08</ENT>
                        <ENT>8,922</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Web-based</ENT>
                        <ENT>5,000</ENT>
                        <ENT>833</ENT>
                        <ENT>33.54</ENT>
                        <ENT>67.08</ENT>
                        <ENT>55,878</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Focus Groups</ENT>
                        <ENT>500</ENT>
                        <ENT>1,000</ENT>
                        <ENT>33.54</ENT>
                        <ENT>67.08</ENT>
                        <ENT>67,080</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">In-person</ENT>
                        <ENT>200</ENT>
                        <ENT>167</ENT>
                        <ENT>33.54</ENT>
                        <ENT>67.08</ENT>
                        <ENT>11,202</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT>10,900</ENT>
                        <ENT>3,383</ENT>
                        <ENT>33.54</ENT>
                        <ENT>67.08</ENT>
                        <ENT>226,932</ENT>
                    </ROW>
                    <TNOTE>
                        * Bureau of Labor &amp; Statistics on “Occupational Employment and Wages, May 2025” 
                        <E T="03">for all occupations found at the following URL:</E>
                         National Occupational Employment and Wage Estimates (
                        <E T="03">bls.gov</E>
                        ) for the respondents.
                    </TNOTE>
                    <TNOTE>** Adjusted Average Hourly Wage Rate is 200% of the average hourly rate. It is a fully loaded rate that includes the benefit costs of respondents.</TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">Request for Comments</HD>
                <P>In accordance with the Paperwork Reduction Act, 44 U.S.C. 3501-3520, comments on AHRQ's information collection are requested with regard to any of the following: (a) whether the proposed collection of information is necessary for the proper performance of AHRQ's health care research and health care information dissemination functions, including whether the information will have practical utility; (b) the accuracy of AHRQ's estimate of burden (including hours and costs) of the proposed collection(s) of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.</P>
                <P>Comments submitted in response to this notice will be summarized and included in the Agency's subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Jeffrey Toven,</NAME>
                    <TITLE>Executive Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15326 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4160-90-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Agency for Healthcare Research and Quality</SUBAGY>
                <SUBJECT>Agency Information Collection Activities: Proposed Collection; Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Agency for Healthcare Research and Quality, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Information collection notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the extension with change of the currently approved information collection “AHRQ Consumer Assessment of Healthcare Providers and Systems (CAHPS) Database for Health Plans” (OMB Control number 0935-0165, last approved on December 31, 2023).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on this notice must be received by September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments should be submitted to: Margie Shofer, Reports Clearance Officer, AHRQ, by email at 
                        <E T="03">REPORTSCLEARANCEOFFICER@ahrq.hhs.gov.</E>
                    </P>
                    <P>Copies of the proposed collection plans, data collection instruments, and specific details on the estimated burden can be obtained from the AHRQ Reports Clearance Officer.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Margie Shofer, AHRQ Reports Clearance Officer, (301) 427-1696, or by email at 
                        <E T="03">REPORTSCLEARANCEOFFICER@ahrq.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The CAHPS Health Plan Database consists of data from the AHRQ CAHPS Health Plan Survey. Health plans in the U.S. are asked to voluntarily submit data from the survey to AHRQ, through its contractor, Westat. The CAHPS Health Plan Survey is a tool for collecting standardized information on enrollees' experiences with health plans and their services. The development of the CAHPS Health Plan Survey began in 1995 in response to requests from health plans, purchasers, and the Centers for Medicare and Medicaid Services (CMS) to provide comparative data to support public reporting of health plan ratings, health plan accreditation and quality improvement. Since that time, the survey has been refined and updated to reflect field feedback from industry experts; reports from health plan participants, data collection vendors (the organization that helps carry out the technical and operational parts of a survey and database submission), and other users; evidence from cognitive testing and focus groups; and extensive psychometric data analysis. Version 5.0 of the Health Plan Survey was released in 2012. The National Quality Forum endorsed the 5.0 version of the Health Plan Survey in 2015. Version 5.1 was released in 2020 to acknowledge the various ways in which enrollees may 
                    <PRTPAGE P="48114"/>
                    receive care: in person, by phone, or by video.
                </P>
                <P>The collection of information for the CAHPS Health Plan Database is being conducted through its contractor, Westat, pursuant to AHRQ's statutory authority to conduct and support research on health care and systems for the delivery of such care, including activities with respect to the quality, effectiveness, efficiency, appropriateness and value of health care services, quality measurement and development, and database development. See 42 U.S.C. 299a(a)(1), (2), and (8).</P>
                <HD SOURCE="HD1">Rationale for the Information Collection</HD>
                <P>The CAHPS Health Plan Database uses data from AHRQ's standardized CAHPS Health plan survey to provide results to health care purchasers, consumers, regulators and policy makers across the country. Voluntary participants include public and private employers, State Medicaid agencies, Children's Health Insurance Programs (CHIP), CMS, and individual health plans.</P>
                <P>This research seeks to answer the following questions:</P>
                <P>1. What are the key drivers of member experience in health plans?</P>
                <P>2. How do member experiences with health plans vary across the West, Midwest, South and Northeast regions?</P>
                <P>3. What are the highest and lowest scoring measures in specific areas of care for health plans?</P>
                <P>This research has the following goals:</P>
                <P>1. To maintain the CAHPS Health Plan database using data from AHRQ's standardized CAHPS Health Plan survey to provide results to health care purchasers, consumers, regulators and policy makers across the country.</P>
                <P>2. To offer several products and services, including aggregated results presented through summary chartbooks, custom analyses, and data for research purposes.</P>
                <P>
                    3. To provide state-level data to CMS for public reporting on 
                    <E T="03">Medicaid.gov</E>
                     and 
                    <E T="03">Data.Medicaid.gov</E>
                     that does not display the name of the health plans.
                </P>
                <HD SOURCE="HD1">Key Project Components</HD>
                <P>Each year State Medicaid agencies, and individual health plans decide whether to participate in the database and prepare their materials and dataset for submission to the CAHPS Health Plan Database. Participating organizations are typically State Medicaid agencies with multiple health plans. However, individual health plans are also encouraged to submit their data to the CAHPS Database. The number of data submissions per registrant varies from participant to participant and year to year because some participants submit data for multiple health plans, while others may only submit survey data for one plan.</P>
                <P>Each organization that decides to participate in the database must have their point-of-contact (POC) complete a registration form providing their contact information for access to the online data submission system, sign and submit a Data Use Agreement (DUA), and provide health plan characteristics such as health plan name, product type, type of population surveyed, health plan state, and plan name to appear in the reporting of their results.</P>
                <P>Each vendor that submits files on behalf of a Medicaid agency or individual health plan must also complete the registration form in order to obtain access to the online submission system. The vendor, on behalf of their client, may also complete additional information about survey administration, submit a copy of the questionnaire used, and submit one data file per health plan.</P>
                <HD SOURCE="HD1">Proposed Revisions</HD>
                <P>The only change to the data collection is a small increase in burden, which is based on an increase in data file submissions in 2025, the most recent reported data available. The individual data submission process did not have an increased burden but there was an increase in the total volume of data file submissions.</P>
                <HD SOURCE="HD1">Method of Collection</HD>
                <P>To achieve the goals of this project the following activities and data collections will be implemented:</P>
                <P>
                    1. Program Recruitment. Outreach will be conducted with the CAHPS Health Plan user community (including state agencies, independent health plans, survey vendors, etc.) to promote the database and its benefits, and to encourage voluntary contributions of survey data. A variety of communications will be used (
                    <E T="03">e.g.,</E>
                     GovDelivery announcements, personal email messages, conference and meeting presentations, etc.) to present the value case for the database and key dates and details about submitting data.
                </P>
                <P>2. Data Submission Platform. AHRQ's contractor currently provides a web-based user-friendly submission platform including data submission specifications; technical assistance and step-by-step instructions for participation; analysis programs for data cleaning and reporting; and DUA to protect the confidentiality of the participating organizations and their data.</P>
                <P>3. Submission Notifications and Instructions. Clear instructions and notifications are of paramount importance for successful submission of valid data, seamless report dissemination, and streamlined communication with survey vendors, state programs, or other submitters. Procedures for data submission through the data submission platform will include the following:</P>
                <P>a. Registration Form—The point-of-contact (POC), which is the sponsor from Medicaid agencies and health plans, and vendors complete a number of data submission steps and forms, beginning with the completion of the online registration form. The purpose of this form is to collect basic contact information about the organization and initiate the registration process.</P>
                <P>
                    b. Health Plan Information Form—The purpose of this form, completed by the participating sponsor organization, is to collect background characteristics of the health plan, such as the name of the plan, the product type (
                    <E T="03">e.g.,</E>
                     HMO, PPO), the population surveyed (
                    <E T="03">e.g.,</E>
                     adult Medicaid or child Medicaid). Each year, the prior year's plan data are preloaded in the plan table to lessen burden on the Sponsor. The Sponsor is responsible for updating the plan table to reflect the current year's plan information.
                </P>
                <P>c. DUA—The purpose of the DUA, completed by the participating sponsor organization, is to state how data submitted by health plans will be used and provide confidentiality assurances.</P>
                <P>d. Data Files Submission—POCs upload their data file using the Health Plan data file specifications to ensure that users submit standardized and consistent data in the way variables are named, coded, and formatted. Each submitter will provide a copy of their questionnaire and the survey data file in the required file format. Survey data files must conform to the data file layout specifications provided by the CAHPS Database. Submitters will upload one data file per health plan. Once a data file is uploaded the file will be checked automatically to ensure it conforms to the specifications and a data file status report will be produced and made available to the submitter. Submitters will review each report and will be expected to fix any errors in their data file and resubmit them if necessary.</P>
                <P>
                    4. Data Cleaning and Preparation. Thorough data cleaning and data preparation are extremely important in maintaining the integrity of the data and for analyzing the data in a valid and reliable way. During data submission, 
                    <PRTPAGE P="48115"/>
                    submitters and AHRQ's contractor's database team will review survey response frequencies to identify out-of-range values, missing variables, or other data anomalies such as when unexpected responses are detected (
                    <E T="03">e.g.,</E>
                     an unusually large proportion of “0” responses on a 0-10 response scale). A submission status report will inform submitters of such errors so that the file can be corrected and resubmitted. Once the data submission period closes, SAS® software will be used for data cleaning, analysis, and reporting.
                </P>
                <P>5. Data Analysis and Reporting. Using reporting systems, the contractor will develop reporting products with appropriate data visualization techniques to present results that are meaningful and useful.</P>
                <HD SOURCE="HD1">Estimated Annual Respondent Burden</HD>
                <P>Exhibit 1 shows the estimated burden hours for the respondent to participate in the database. The 129 POCs in Exhibit 1 are a combination of an estimated 114 State Medicaid agencies and individual health plans (sponsors), and 15 vendor organizations.</P>
                <P>Each sponsor (made up of state Medicaid agencies and health plans) and vendor will register online for submission. The Registration Form will require about 5 minutes to complete. Each sponsor will also complete a Health Plan Information Form which takes on average 30 minutes to complete per health plan with each POC completing the form for four plans on average. The DUA will be completed by the 114 participating State Medicaid agencies or individual health plans. Vendors do not sign or submit DUAs. The DUA requires about 5 minutes to sign and upload. Data File Submissions will be completed by either sponsors or vendors for the 114 participating submitters and will take about 1 hour to submit the data for each plan, and each POC will submit data for four plans on average. The total burden is estimated to be 893 hours annually.</P>
                <GPOTABLE COLS="5" OPTS="L2,i1" CDEF="s100,12,12,12,12">
                    <TTITLE>Exhibit 1—Estimated Annualized Burden Hours</TTITLE>
                    <BOXHD>
                        <CHED H="1">Form name</CHED>
                        <CHED H="1">
                            Number of 
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of 
                            <LI>responses per respondent</LI>
                        </CHED>
                        <CHED H="1">
                            Hours per 
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">Total burden hours</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Registration Form</ENT>
                        <ENT>129</ENT>
                        <ENT>1</ENT>
                        <ENT>5/60</ENT>
                        <ENT>11</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Health Plan Information Form</ENT>
                        <ENT>114</ENT>
                        <ENT>4</ENT>
                        <ENT>30/60</ENT>
                        <ENT>228</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Data Use Agreement</ENT>
                        <ENT>114</ENT>
                        <ENT>1</ENT>
                        <ENT>5/60</ENT>
                        <ENT>10</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Data Files Submission</ENT>
                        <ENT>114</ENT>
                        <ENT>5.65</ENT>
                        <ENT>1</ENT>
                        <ENT>644</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT>471</ENT>
                        <ENT>NA</ENT>
                        <ENT>NA</ENT>
                        <ENT>893</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Exhibit 2 shows the estimated annualized cost burden based on the respondents' time to complete one submission process. The cost burden is estimated to be $100,115 annually.</P>
                <GPOTABLE COLS="5" OPTS="L2,i1" CDEF="s100,12,12,12,12">
                    <TTITLE>Exhibit 2—Estimated Annualized Cost Burden</TTITLE>
                    <BOXHD>
                        <CHED H="1">Form name</CHED>
                        <CHED H="1">Total burden hours</CHED>
                        <CHED H="1">
                            Average 
                            <LI>hourly wage </LI>
                            <LI>rate *</LI>
                        </CHED>
                        <CHED H="1">
                            Adjusted 
                            <LI>hourly wage </LI>
                            <LI>rate **</LI>
                        </CHED>
                        <CHED H="1">
                            Total cost 
                            <LI>burden</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Registration Form</ENT>
                        <ENT>11</ENT>
                        <ENT>
                            <SU>a</SU>
                             67.77
                        </ENT>
                        <ENT>$135.54</ENT>
                        <ENT>1,491</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Health Plan Information Form</ENT>
                        <ENT>228</ENT>
                        <ENT>
                            <SU>a</SU>
                             67.77
                        </ENT>
                        <ENT>135.54</ENT>
                        <ENT>$30,903</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Data Use Agreement</ENT>
                        <ENT>10</ENT>
                        <ENT>
                            <SU>b</SU>
                             129.63
                        </ENT>
                        <ENT>259.26</ENT>
                        <ENT>2,593</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Data Files Submission</ENT>
                        <ENT>644</ENT>
                        <ENT>
                            <SU>c</SU>
                             50.56
                        </ENT>
                        <ENT>101.12</ENT>
                        <ENT>65,128</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT>893</ENT>
                        <ENT>NA</ENT>
                        <ENT>NA</ENT>
                        <ENT>100,115</ENT>
                    </ROW>
                    <TNOTE>* National Compensation Survey: Occupational wages in the United States May 2025, “U.S. Department of Labor, Bureau of Labor Statistics.”</TNOTE>
                    <TNOTE>** The Adjusted Hourly Rate was estimated at 200% of the hourly wage.</TNOTE>
                    <TNOTE>(a) Based on the mean hourly wage for Medical and Health Services Managers (11-9111).</TNOTE>
                    <TNOTE>(b) Based on the mean hourly wage for Chief Executives (11-1011).</TNOTE>
                    <TNOTE>(c) Based on the mean hourly wages for Computer Programmers (15-1251).</TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">Request for Comments</HD>
                <P>In accordance with the Paperwork Reduction Act, 44 U.S.C. 3501-3520, comments on AHRQ's information collection are requested with regard to any of the following: (a) whether the proposed collection of information is necessary for the proper performance of AHRQ's health care research and health care information dissemination functions, including whether the information will have practical utility; (b) the accuracy of AHRQ's estimate of burden (including hours and costs) of the proposed collection(s) of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.</P>
                <P>Comments submitted in response to this notice will be summarized and included in the Agency's subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.</P>
                <SIG>
                    <DATED>Dated: July 27, 2026.</DATED>
                    <NAME>Jeffrey Toven,</NAME>
                    <TITLE>Executive Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15324 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4160-90-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48116"/>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Centers for Disease Control and Prevention</SUBAGY>
                <SUBJECT>National Center for Health Statistics, Meeting of the ICD-10 Coordination and Maintenance Committee</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&amp;M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online registration is required.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The meeting will be held on September 15, 2026, from 9 a.m. to 5 p.m., EDT, and September 16, 2026, from 9 a.m. to 5 p.m., EDT.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        This is a virtual meeting. Register in advance for this webinar: 
                        <E T="03">https://cdc.zoomgov.com/webinar/register/WN_18C-Xz4MROugqMEWCew6YA.</E>
                         After registering, you will receive a confirmation email containing information about joining the webinar. Further information will be provided on each of the respective web pages when it comes available. For CDC, NCHS: 
                        <E T="03">https://www.cdc.gov/nchs/icd/icd-10-maintenance/meetings.html.</E>
                         For the Centers for Medicare &amp; Medicaid Services, Department of Health and Human Services: 
                        <E T="03">https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Traci Ramirez, Medical Classification Specialist, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782-2064. Telephone: (301) 458-4454; Email: 
                        <E T="03">TRamirez@cdc.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION: </HD>
                <P>The Secretary of Health and Human Services (HHS) is statutorily required to maintain the U.S. domestic standards with public input and in a way that minimizes disruption and cost of compliance as described at 42 U.S. Code §  1395ww(d)(5)(K).</P>
                <P>
                    <E T="03">Purpose:</E>
                     The ICD-10 Coordination and Maintenance (C&amp;M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification (CM) and ICD-10 Procedure Coding System (PCS).
                </P>
                <P>
                    <E T="03">Matters to be Considered:</E>
                     The tentative agenda will include discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda items are subject to change as priorities dictate. Please refer to the posted agenda for updates one month prior to the meeting.
                </P>
                <P>ICD-10-PCS Topics:</P>
                <FP SOURCE="FP-2">1. Extracorporeal Interstitial Fluid Removal</FP>
                <FP SOURCE="FP-2">2. Transcutaneous Spinal Cord Stimulation</FP>
                <FP SOURCE="FP-2">3. Visually Guided Pressure Offloading</FP>
                <FP SOURCE="FP-2">4. Percutaneous Irrigation for Intracranial Interventions</FP>
                <FP SOURCE="FP-2">5. Measurement of Volumetric Blood Flow in Peripheral Vessels</FP>
                <FP SOURCE="FP-2">6. Intraoperative Control of Pericardial Hemorrhage using Rapid Exchange Catheter</FP>
                <FP SOURCE="FP-2">7. Monitoring of Peritoneal Cavity using Electrode Sensors</FP>
                <FP SOURCE="FP-2">8. Labor Management</FP>
                <FP SOURCE="FP-2">9. Sirolimus-Coated Balloon Catheter for Percutaneous Coronary Intervention</FP>
                <FP SOURCE="FP-2">10. Computer-Aided Assessment of Acute Abdominopelvic Pathology</FP>
                <FP SOURCE="FP-2">11. Computer-Aided Monitoring of Fluid Volume</FP>
                <FP SOURCE="FP-2">12. Insertion of Brain Computer Interface Device</FP>
                <FP SOURCE="FP-2">13. Fragmentation of Carotid Arteries</FP>
                <FP SOURCE="FP-2">14. Computer-Aided Detection and Notification of Whole Body Positioning Status</FP>
                <FP SOURCE="FP-2">15. Bypass using Endovascular Transvenous Cerebrospinal Fluid Shunt</FP>
                <FP SOURCE="FP-2">16. Section X</FP>
                <FP SOURCE="FP-2">17. Addenda and Reference Key Updates</FP>
                <FP SOURCE="FP-2">18. Administration of cefepime-zidebactam</FP>
                <FP SOURCE="FP-2">19. Administration of tanruprubart</FP>
                <FP SOURCE="FP-2">20. Administration of ristoglogene autogetemcel</FP>
                <FP SOURCE="FP-2">21. Transfusion of Cryopreserved Organ Donor-derived Bone Marrow</FP>
                <FP SOURCE="FP-2">22. Administration of mivocabtagene autoleucel</FP>
                <FP SOURCE="FP-2">23. Administration of anzutresgene autoleucel</FP>
                <FP SOURCE="FP-2">24. Administration of imlifidase</FP>
                <P>CMS will not present the Fall 2026 ICD-10-PCS procedure code topics during a public meeting. Instead, CMS will post the procedure code topic materials and solicit public comments regarding any clinical questions or coding options. The deadline to submit comments for procedure code topics being considered for an April 1, 2027 implementation is October 16, 2026, and the deadline to submit comments for procedure code topics being considered for an October 1, 2027 implementation is November 13, 2026.</P>
                <P>
                    Members of the public should send any questions or comments related to the procedure code topics that are under consideration for an April 1, 2027 or an October 1, 2027 implementation to the CMS mailbox at: 
                    <E T="03">ICDProcedureCodeRequest@cms.hhs.gov</E>
                     by the respective deadline.
                </P>
                <P>
                    All procedure code topic materials and related documents will be made available on the CMS Website at 
                    <E T="03">https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials</E>
                    . Additionally, CMS will post a question-and-answer document to address any clinical or coding questions that members of the public submit by the respective deadline.
                </P>
                <P>ICD-10-CM Topics:</P>
                <FP SOURCE="FP-2">1. Adverse Childhood Experiences</FP>
                <FP SOURCE="FP-2">2. Amyloid-related imaging abnormalities (ARIA)</FP>
                <FP SOURCE="FP-2">3. Carotid Web</FP>
                <FP SOURCE="FP-2">4. Doxy PEP</FP>
                <FP SOURCE="FP-2">5. Encounter for Safety Counseling in the Home</FP>
                <FP SOURCE="FP-2">6. Extreme Immaturity of Newborns</FP>
                <FP SOURCE="FP-2">7. Limbal stem cell deficiency</FP>
                <FP SOURCE="FP-2">8. Macular telangiectasia</FP>
                <FP SOURCE="FP-2">9. Neonatal Supraventricular Tachycardia</FP>
                <FP SOURCE="FP-2">10. Organizing Principles for Classification of Ultra-rare and Genetic Conditions</FP>
                <FP SOURCE="FP-2">11. Presence of continuous glucose monitoring device</FP>
                <FP SOURCE="FP-2">12. Progressive myopia</FP>
                <FP SOURCE="FP-2">13. Sepsis</FP>
                <FP SOURCE="FP-2">14. Tenosynovial Giant Cell Tumor</FP>
                <FP SOURCE="FP-2">15. Addenda</FP>
                <P>
                    The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign 
                    <E T="04">Federal Register</E>
                     notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
                </P>
                <SIG>
                    <NAME>Kalwant Smagh,</NAME>
                    <TITLE>Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15323 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4163-18-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48117"/>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Administration for Children and Families</SUBAGY>
                <DEPDOC>[Assistance Listing Number: 93.356]</DEPDOC>
                <SUBJECT>Announcement of the Intent To Award Single-Source Grants (Multiple Recipients) for Necessary Expenses Directly Related to the Consequences of Hurricanes Fiona and Ian </SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Head Start (OHS), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of Issuance of Single-Source awards (multiple recipients).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>ACF/OHS announces its intent to award multiple single-source grants totaling $143,436,162 to select organizations operating a Head Start grant in Florida, South Carolina, and Puerto Rico who demonstrated Head Start services in the affective areas were either disrupted or impacted by Hurricanes Fiona and Ian. These awards are for necessary expenses directly related to the consequences of Hurricanes Fiona and Ian, including replacement of damaged or destroyed property and facilities, and increased mental health support.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>All funds must be expended by recipients within 36 months of their award date. </P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Shawna Pinckney, Acting Deputy Director, Office of Head Start, 330 C Street SW, Washington, DC 20201. Telephone: 1-866-763-6481, email: 
                        <E T="03">HeadStart@eclkc.info.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Consolidated Appropriations Act, 2023 (H.R. 2617), was signed into law on December 29, 2022. The Act provides $345,000,000 in emergency funding “for necessary expenses directly related to the consequences of Hurricanes Fiona and Ian, including activities authorized under section 319(a) of the Public Health Service Act.” Grants were effective starting November 1, 2023, and grant funds will continue to be distributed until September 30, 2027, or until the funding is exhausted.</P>
                <P>OHS announces the intent to award the following single-source award (for multiple recipients):</P>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s150,15">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Recipient</CHED>
                        <CHED H="1">Award amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Children First</ENT>
                        <ENT>$618,209</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wateree Community Action</ENT>
                        <ENT>432,038</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wateree Community Action</ENT>
                        <ENT>362,038</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fundacion Para El Desarrollo De Hogar Propio Incorporado (F.D.H.P.)</ENT>
                        <ENT>3,794,815</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Humacao</ENT>
                        <ENT>388,508</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fundacion Para El Desarrollo De Hogar Propio Incorporado (F.D.H.P.)</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Bayamon</ENT>
                        <ENT>1,603,600</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Mid Florida Community Services</ENT>
                        <ENT>26,361,394</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Md Florida Community Services</ENT>
                        <ENT>122,704</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Carolina</ENT>
                        <ENT>17,681,107</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Children First</ENT>
                        <ENT>951,033</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Humacao</ENT>
                        <ENT>1,564,999</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Guayama</ENT>
                        <ENT>1,458,192</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Ponce</ENT>
                        <ENT>945,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Guayama</ENT>
                        <ENT>2,808,818</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Red por los Derechos de la Ninezyla Juventude Puerto Rico</ENT>
                        <ENT>1,066,441</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Carolina</ENT>
                        <ENT>13,657,254</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fundacion Para El Desarrollo De Hogar Propio Incorporado (F.D.H.P.)</ENT>
                        <ENT>636,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Isabela</ENT>
                        <ENT>1,707,919</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Red por los Derechos de la Ninezyla Juventude Puerto Rico</ENT>
                        <ENT>22,662,122</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Humacao</ENT>
                        <ENT>2,482,572</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Orocovis</ENT>
                        <ENT>4,556,732</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wateree Community Action</ENT>
                        <ENT>1,376,510</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Yabuacoa</ENT>
                        <ENT>480,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Quintana Baptist Church Head Start Program</ENT>
                        <ENT>2,104,916</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Chesterfield Marlboro County Economic Opportunity Council, Inc</ENT>
                        <ENT>1,704,981</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Guaynabo</ENT>
                        <ENT>2,051,700</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Dorado</ENT>
                        <ENT>532,631</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Guayama</ENT>
                        <ENT>90,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Adjuntas</ENT>
                        <ENT>701,120</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Patillas</ENT>
                        <ENT>169,700</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Mid Florida Community Services</ENT>
                        <ENT>303,312</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">New York Foundling</ENT>
                        <ENT>5,615,651</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">East Coast Migrant</ENT>
                        <ENT>364,362</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Quebradillas</ENT>
                        <ENT>996,702</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Chesterfield Marlboro County Economic Opportunity Council, Inc</ENT>
                        <ENT>16,994,723</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Municipality of Guayama</ENT>
                        <ENT>3,978,361</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Children First</ENT>
                        <ENT>9,998</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT>143,436,162</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="48118"/>
                <P>
                    <E T="03">Statutory Authority:</E>
                     The Consolidated Appropriations Act, 2023 (H.R. 2617).
                </P>
                <SIG>
                    <NAME>Elizabeth Leo,</NAME>
                    <TITLE>Grants Policy Branch Chief, Office of Grants Policy, Office of Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15413 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4184-40-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7896]</DEPDOC>
                <SUBJECT>Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the FDA Food Safety Modernization Act (FSMA).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>These fees apply to the period from October 1, 2026, and will remain in effect through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        <E T="03">For questions related to FSMA program fees: FSMAFeeStaff@fda.hhs.gov.</E>
                          
                        <E T="03">For questions related to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Section 743 of the FD&amp;C Act (21 U.S.C. 379j-31) authorizes FDA to assess and collect fees from, in part: (1) the responsible party for each domestic facility and the U.S. agent for each foreign facility subject to a reinspection to cover reinspection-related costs; (2) the responsible party for a domestic facility and an importer who does not comply with a recall order to cover food recall activities associated with such order; and (3) each importer subject to a reinspection to cover reinspection-related costs (sections 743(a)(1)(A), (B), and (D) of the FD&amp;C Act). Section 743 of the FD&amp;C Act directs FDA to establish fees for each of these activities based on an estimate of 100 percent of the costs of each activity for each year (sections 743(b)(2)(A)(i), (ii), and (iv) of the FD&amp;C Act), and these fees must be made available solely to pay for the costs of each activity for which the fee was incurred (section 743(b)(3) of the FD&amp;C Act). These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027.</P>
                <P>In section 743(b)(2)(B)(iii) of the FD&amp;C Act, Congress directed FDA to develop a proposed set of guidelines in consideration of the burden of fee amounts on small businesses. FDA issued guidance on this subject in October 2011 (2011 Fee Provision Guidance) (FDA Guidance for Industry, “Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act” (October 2011)). As stated in our 2011 Fee Provision Guidance, FDA recognizes that the full cost recovery of FDA reinspection or recall oversight could impose severe economic hardship for small businesses (id.). Therefore, as the 2011 Fee Provision Guidance explains, FDA intends to consider reducing certain fees for those firms (id.). Consistent with the 2011 Fee Provision Guidance, FDA does not intend to issue invoices for reinspection or recall order fees until FDA publishes a separate guidance document outlining the process through which firms may request a reduction in fees.</P>
                <P>In addition, as stated in the 2011 Fee Provision Guidance, FDA is considering various issues associated with the assessment and collection of importer reinspection fees. The fee rates set forth in this notice will be used to determine any importer reinspection fees assessed in FY 2027.</P>
                <HD SOURCE="HD1">II. Estimating the Average Cost of a Supported Direct FDA Work Hour for FY 2027</HD>
                <P>FDA estimates 100 percent of its costs for each activity to establish fee rates for FY 2027 (see section 743(b)(2)(A) of the FD&amp;C Act).</P>
                <HD SOURCE="HD2">A. Estimating the Full Cost per Direct Work Hour in FY 2027</HD>
                <P>Full-time Equivalent (FTE) reflects the total number of regular straight-time hours—not including overtime or holiday hours—worked by employees, divided by the number of compensable hours applicable to each fiscal year. Annual leave, sick leave, compensatory time off, and other approved leave categories are considered “hours worked” for purposes of defining FTE employment.</P>
                <P>In general, the starting point for estimating the full cost per direct work hour is to estimate the cost of an FTE or paid staff year. Calculating an FDA-wide total cost per FTE requires three primary cost elements: payroll, nonpayroll, and rent.</P>
                <P>We used an average of past year cost elements to predict the FY 2027 cost. The FY 2027 FDA-wide average cost for payroll (salaries and benefits) is $244,029; non-payroll (including equipment, supplies, IT, general and administrative overhead) is $108,488; and rent (including cost allocation analysis and adjustments for other rent and rent-related costs) is $24,118 per paid staff year, excluding travel costs.</P>
                <P>Summing the average cost of an FTE for payroll, nonpayroll, and rent, brings the FY 2027 average fully supported cost to $376,635 (total includes rounding) per FTE, excluding travel costs. FDA will use this base unit fee in determining the hourly fee rate for reinspection and recall order fees for FY 2027 before including domestic or foreign travel costs as applicable for the activity.</P>
                <P>To calculate an hourly rate, we divide the FY 2027 average fully supported cost of $376,635 per FTE by the average number of supported direct FDA work hours in FY 2025 (the last fiscal year for which data are available). See table 1.</P>
                <GPOTABLE COLS="2" OPTS="L2,p1,nj,8/9,i1" CDEF="s150,15">
                    <TTITLE>Table 1—Supported Direct FDA Work Hours in a Paid Staff Year in FY 2025</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total number of hours in a paid staff year</ENT>
                        <ENT>2,080</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Less:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">11 paid holidays</ENT>
                        <ENT>−88</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">20 days of annual leave</ENT>
                        <ENT>−160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">10 days of sick leave</ENT>
                        <ENT>−80</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">12.5 days of training</ENT>
                        <ENT>−100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">22 days of general administration</ENT>
                        <ENT>−176</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">26.5 days of travel</ENT>
                        <ENT>−212</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">2 hours of meetings per week</ENT>
                        <ENT>−104</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="48119"/>
                        <ENT I="05">Net Supported Direct FDA Work Hours Available for Assignments</ENT>
                        <ENT>1,160</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Dividing the average fully supported FTE cost in FY 2027 ($376,635) by the total number of supported direct work hours available for assignment in FY 2025 (1,160) results in an average fully supported cost of $325 (rounded to the nearest dollar), excluding inspection travel costs, per supported direct work hour in FY 2027.</P>
                <HD SOURCE="HD2">B. Adjusting FY 2025 Travel Costs for Inflation To Estimate FY 2027 Travel Costs</HD>
                <P>
                    To adjust the hourly rate for FY 2027, we estimate the cost of inflation in each year for FY 2026 and FY 2027. FDA uses the method prescribed for estimating inflationary costs under the Prescription Drug User Fee Act (PDUFA) provisions of the FD&amp;C Act (section 736(c)(1) of the FD&amp;C Act (21 U.S.C. 379h(c)(1))), the statutory method for inflation adjustment in the FD&amp;C Act that FDA has used consistently. FDA previously determined the FY 2026 inflation rate to be 5.0313 percent; this rate was published in the FY 2026 PDUFA user fee rates notice in the 
                    <E T="04">Federal Register</E>
                     (90 FR 35866, July 30, 2025). Using the method set forth in section 736(c)(1) of the FD&amp;C Act, FDA calculated an inflation rate of 5.0313 percent for FY 2026 and 4.7210 percent for FY 2027, and FDA intends to use these inflation rates to make inflation adjustments for FY 2028 for several of its user fee programs.
                </P>
                <P>
                    In FY 2025, FDA's Office of Inspections and Investigation (OII) spent a total of $10,002,278 for domestic regulatory inspection travel costs and General Services Administration Vehicle costs related to FDA's Human Foods Program (HFP) and Center for Veterinary Medicine (CVM) field activities programs.
                    <SU>1</SU>
                    <FTREF/>
                     The total OII domestic travel costs spent is then divided by the 9,485 HFP and CVM domestic inspections, which averages a total of $1,055 (rounded) per inspection. These inspections average 40.76 hours per inspection. Dividing $1,055 per inspection by 40.76 hours per inspection results in a total and an additional cost of $26 (rounded to the nearest dollar) per hour spent for domestic inspection travel costs in FY 2025. To adjust for the $26 per hour additional domestic cost inflation increases for FY 2026 and FY 2027, we multiply the FY 2026 PDUFA inflation rate adjustor (1.050313) times the FY 2027 PDUFA inflation rate adjustor (1.047210) times the $26 additional domestic cost, which results in an estimated cost of $29 (rounded to the nearest dollar) per paid hour in addition to $325 for a total of $354 per paid hour ($325 plus $29) for each direct hour of work requiring domestic inspection travel. FDA will use these rates in charging fees in FY 2027 when domestic travel is required.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Effective October 1st, 2024, FDA implemented a reorganization to establish a unified Humans Foods Program and restructured its field operations, formerly the Office of Regulatory Affairs and now the Office of Inspections and Investigations (OII). The establishment of the Human Foods Program allows us to most effectively deliver on our mission to protect and promote public health through science-based approaches to prevent foodborne illness, reduce diet-related chronic disease, and ensure the safety of chemicals in our food. For more information, see 
                        <E T="03">https://www.fda.gov/news-events/press-announcements/fdas-unified-human-foods-program-new-model-field-operations-and-other-modernization-efforts-go.</E>
                    </P>
                </FTNT>
                <P>In FY 2025, OII spent a total of $2,689,902 on 277 foreign inspection trips related to FDA's HFP and CVM field activities programs, which averaged a total of $9,711 per foreign inspection trip. These trips averaged 3 weeks (or 120 paid hours) per trip. Dividing $9,711 per trip by 120 hours per trip results in a total and an additional cost of $81 (rounded to the nearest dollar) per paid hour spent for foreign inspection travel costs in FY 2025. To adjust $81 for inflationary increases in FY 2026, and FY 2027, FDA multiplies it by the same inflation factors mentioned previously in this document (1.050313 and 1.042710), which results in an estimated cost of $89 (rounded to the nearest dollar) per paid hour in addition to $325 for a total of $414 per paid hour ($325 plus $89) for each direct hour of work requiring foreign inspection travel. FDA will use these rates in charging fees in FY 2027 when foreign travel is required.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s50,12">
                    <TTITLE>Table 2—FSMA Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Fee rates
                            <LI>for FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Hourly rate if domestic travel is required</ENT>
                        <ENT>$354</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Hourly rate if foreign travel is required</ENT>
                        <ENT>414</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. Fees for Reinspections of Domestic or Foreign Facilities Under Section 743(a)(1)(A) of the FD&amp;C Act</HD>
                <HD SOURCE="HD2">A. What will cause this fee to be assessed?</HD>
                <P>
                    The fee will be assessed for a reinspection conducted under section 704 of the FD&amp;C Act (21 U.S.C. 374) to determine whether corrective actions have been implemented and are effective and compliance has been achieved to the Secretary of Health and Human Services' (the Secretary) (and, by delegation, FDA's) satisfaction at a facility that manufactures, processes, packs, or holds food for consumption necessitated as a result of a previous inspection (also conducted under section 704 of the FD&amp;C Act) of this facility, which had a final classification of Official Action Indicated (OAI) conducted by or on behalf of FDA, when FDA determined the noncompliance was materially related to food safety requirements of the FD&amp;C Act. FDA considers such noncompliance to include noncompliance with a statutory or regulatory requirement under section 402 of the FD&amp;C Act (21 U.S.C. 342) and section 403(w) of the FD&amp;C Act (21 U.S.C. 343(w)). However, FDA does not consider noncompliance that is materially related to a food safety requirement to include circumstances where the noncompliance is of a technical nature and not food safety related (
                    <E T="03">e.g.,</E>
                     failure to comply with a food standard or incorrect font size on a food label). Determining when noncompliance, other than under sections 402 and 403(w) of the FD&amp;C Act, is materially related to a food safety requirement of the FD&amp;C Act may depend on the facts of a particular situation. FDA intends to issue guidance to provide additional information about the circumstances under which FDA would consider noncompliance to be materially related to a food safety requirement of the FD&amp;C Act.
                </P>
                <P>Under section 743(a)(1)(A) of the FD&amp;C Act, FDA is directed to assess and collect fees from the responsible party for each domestic facility (as defined in section 415(b) of the FD&amp;C Act (21 U.S.C. 350d(b))) and the U.S. agent for each foreign facility subject to a reinspection to cover reinspection-related costs.</P>
                <P>
                    Section 743(a)(2)(A)(i) of the FD&amp;C Act defines the term “reinspection” with respect to domestic facilities as 1 or more inspections conducted under 
                    <PRTPAGE P="48120"/>
                    section 704 of the FD&amp;C Act subsequent to an inspection conducted under such provision which identified noncompliance materially related to a food safety requirement of this Act, specifically to determine whether compliance has been achieved to the Secretary's satisfaction.
                </P>
                <P>The FD&amp;C Act does not contain a definition of “reinspection” specific to foreign facilities. In order to give meaning to the language in section 743(a)(1)(A) of the FD&amp;C Act to collect fees from the U.S. agent of a foreign facility subject to a reinspection, we are using the following definition of “reinspection” for purposes of assessing and collecting fees under section 743(a)(1)(A) of the FD&amp;C Act, with respect to a foreign facility: “1 or more inspections conducted by officers or employees duly designated by the Secretary subsequent to such an inspection which identified noncompliance materially related to a food safety requirement of the FD&amp;C Act, specifically to determine whether compliance has been achieved to the Secretary's (and, by delegation, FDA's) satisfaction.”</P>
                <P>This definition allows FDA to fulfill the mandate to assess and collect fees from the U.S. agent of a foreign facility in the event that an inspection reveals noncompliance materially related to a food safety requirement of the FD&amp;C Act, causing one or more subsequent inspections to determine whether compliance has been achieved to the Secretary's (and, by delegation, FDA's) satisfaction. By requiring the initial inspection to be conducted by officers or employees duly designated by the Secretary, the definition ensures that a foreign facility would be subject to fees only in the event that FDA, or an entity designated to act on its behalf, has made the requisite identification at an initial inspection of noncompliance materially related to a food safety requirement of the FD&amp;C Act. The definition of “reinspection-related costs” in section 743(a)(2)(B) of the FD&amp;C Act relates to both a domestic facility reinspection and a foreign facility reinspection, as described in section 743(a)(1)(A) of the FD&amp;C Act.</P>
                <HD SOURCE="HD2">B. Who will be responsible for paying this fee?</HD>
                <P>The FD&amp;C Act states that this fee is to be paid by the responsible party for each domestic facility (as defined in section 415(b) of the FD&amp;C Act) and by the U.S. agent for each foreign facility (section 743(a)(1)(A) of the FD&amp;C Act). This is the party to whom FDA will send the invoice for any fees that are assessed under this section.</P>
                <HD SOURCE="HD2">C. How much will this fee be?</HD>
                <P>The fee is based on the number of direct hours spent on such reinspections, including time spent conducting the physical surveillance and/or compliance reinspection at the facility, or whatever components of such an inspection are deemed necessary, making preparations and arrangements for the reinspection, traveling to and from the facility, preparing any reports, analyzing any samples or examining any labels if required, and performing other activities as part of the OAI reinspection until the facility is again determined to be in compliance. The direct hours spent on each such reinspection will be billed at the appropriate hourly rate shown in table 2 of this document.</P>
                <HD SOURCE="HD1">IV. Fees for Noncompliance With a Recall Order Under Section 743(a)(1)(B) of the FD&amp;C Act</HD>
                <HD SOURCE="HD2">A. What will cause this fee to be assessed?</HD>
                <P>The fee will be assessed for not complying with a recall order under section 423(d) (21 U.S.C. 350l(d)) or section 412(f) of the FD&amp;C Act (21 U.S.C. 350a(f)) to cover food recall activities associated with such order performed by the Secretary (and by delegation, FDA) (section 743(a)(1)(B) of the FD&amp;C Act). Noncompliance may include the following: (1) not initiating a recall as ordered by FDA; (2) not conducting the recall in the manner specified by FDA in the recall order; or (3) not providing FDA with requested information regarding the recall, as ordered by FDA.</P>
                <HD SOURCE="HD2">B. Who will be responsible for paying this fee?</HD>
                <P>Section 743(a)(1)(B) of the FD&amp;C Act states that the fee is to be paid by the responsible party for a domestic facility (as defined in section 415(b) of the FD&amp;C Act) and an importer who does not comply with a recall order under section 423 or under section 412(f) of the FD&amp;C Act. In other words, the party paying the fee would be the party that received the recall order.</P>
                <HD SOURCE="HD2">C. How much will this fee be?</HD>
                <P>The fee is based on the number of direct hours spent taking action in response to the firm's failure to comply with a recall order. Types of activities could include conducting recall audit checks, reviewing periodic status reports, analyzing the status reports and the results of the audit checks, conducting inspections, traveling to and from locations, and monitoring product disposition. The direct hours spent on each such recall will be billed at the appropriate hourly rate shown in table 2 of this document.</P>
                <HD SOURCE="HD2">D. How must the fees be paid?</HD>
                <P>
                    Section 743(a)(1)(A) and (B) of the FD&amp;C Act require FDA to assess and collect reinspection and recall fees, as appropriate, from responsible parties for domestic and foreign food facilities. Further, section 743(a)(1)(D) requires FDA to assess and collect reinspection fees from importers. An invoice will be sent to the responsible party for paying the fee after FDA completes the work on which the invoice is based. Payments made to FDA must be made, within 30 days of the invoice date, in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov,</E>
                     a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov.</E>
                     Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts or U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the invoice number to ensure that the payment is applied to the correct fee(s). Without the invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>
                    FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 743(e)(2) 
                    <PRTPAGE P="48121"/>
                    of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.
                </P>
                <HD SOURCE="HD1">V. What are the consequences of not paying these fees?</HD>
                <P>Under section 743(e)(2) of the FD&amp;C Act and 45 CFR part 30, any fee that is not paid within 30 days after it is due shall be treated as a claim of the U.S. Government subject to provisions of subchapter II of chapter 37 of title 31, United States Code.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15336 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7559]</DEPDOC>
                <SUBJECT>Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the Over-the-Counter Monograph Drug User Fee Amendments (herein referred to as “OMUFA II”), authorizes the Food and Drug Administration (FDA, the Agency, or we) to assess and collect user fees from qualifying manufacturers of over-the-counter (OTC) monograph drugs and submitters of OTC monograph order requests (OMORs) for fiscal years 2026 through 2030. This notice publishes the OMUFA fee rates for fiscal year (FY) 2027.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For more information on OTC monograph drug fees, visit FDA's website at: 
                        <E T="03">https://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa. For questions relating to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>
                    Section 744M of the FD&amp;C Act (21 U.S.C. 379j-72), as amended by OMUFA II,
                    <SU>1</SU>
                    <FTREF/>
                     authorizes FDA to assess and collect, for each of fiscal years 2026 through 2030: (1) facility fees from qualifying owners of OTC monograph drug facilities and (2) fees from submitters of qualifying OMORs. These fees are to support FDA's OTC monograph drug activities, which are detailed in section 744L(6) of the FD&amp;C Act (21 U.S.C. 379j-71(6)) and include specified FDA activities associated with OTC monograph drugs. For OMUFA purposes:
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Over-the-Counter Monograph Drug User Fee Amendments, title V of Division F of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Pub. L. 119-37).
                    </P>
                </FTNT>
                <P>• An OTC monograph drug is a nonprescription drug without an approved new drug application that is governed by the provisions of section 505G of the FD&amp;C Act (21 U.S.C. 355h) (see section 744L(5) of the FD&amp;C Act);</P>
                <P>• An OTC monograph drug facility (MDF) is a foreign or domestic business or other entity that, in addition to meeting other criteria, is engaged in manufacturing or processing the finished dosage form of an OTC monograph drug (see section 744L(10) of the FD&amp;C Act); and</P>
                <P>• A contract manufacturing organization (CMO) facility is an OTC monograph drug facility where neither the owner nor any affiliate of the owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States (see section 744L(2) of the FD&amp;C Act).</P>
                <P>• An OMOR is a request for an administrative order, with respect to an OTC monograph drug, which is submitted under section 505G(b)(5) of the FD&amp;C Act (see section 744L(7) of the FD&amp;C Act).</P>
                <P>
                    Under section 744M(a)(1)(A) of the FD&amp;C Act, a facility fee for FY 2027 shall be assessed with respect to each facility that is identified as an OTC monograph drug facility during the fee-liable period from January 1, 2026, through September 30, 2026.
                    <SU>2</SU>
                    <FTREF/>
                     Consistent with the statute, FDA will assess and collect facility fees with respect to the two types of OTC monograph drug facilities—MDF and CMO facilities. A full facility fee will be assessed to each qualifying person that owns a facility identified as an MDF (see section 744M(a)(1)(A) of the FD&amp;C Act), and a reduced facility fee of two-thirds will be assessed to each qualifying person that owns a facility identified as a CMO facility (see section 744M(a)(1)(B)(ii) of the FD&amp;C Act). The facility fees for FY 2027 are due in two equal installments, in a first installment representing 50 percent of such fee due on October 1, 2026, and in a second installment representing the remaining 50 percent of such fee due on February 1, 2027 (see section 744M(a)(1)(D)(ii) of the FD&amp;C Act).
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Under section 744M(a)(1)(A)(i) of the FD&amp;C Act, “Each person that owns a facility identified as an OTC monograph drug facility at any time during the applicable period . . . for a fiscal year shall be assessed an annual fee for each such facility”. The applicable period for FY 2027 is the 9-month period ending September 30, 2026, per section 744M(a)(1)(A)(ii)(II) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Assuming that, as we anticipate, the FY 2027 fee appropriation will occur prior to October 1, 2026 for the first installment and prior to February 1, 2027, for the second installment of such fee. See section 744M(a)(1)(D)(ii) of the FD&amp;C Act with respect to the due date for the two payment installments in relation to the timing of an OMUFA fee appropriation for fiscal year 2027.
                    </P>
                </FTNT>
                <P>As discussed in greater detail below, OTC monograph drug facilities are exempt from FY 2027 facility fees if they had ceased OTC monograph drug activities, and updated their registration with FDA to that effect, prior to January 1, 2026 (see section 744M(a)(1)(B)(i)(I)(bb) of the FD&amp;C Act).</P>
                <P>
                    In addition to facility fees, the Agency is authorized to assess and collect fees from submitters of OMORs, except for OMORs that request certain safety-related changes (as discussed below). There are two levels of OMOR fees, based on whether the OMOR at issue is a Tier 1 or Tier 2 OMOR.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Under OMUFA, a Tier 1 OMOR is defined as any OMOR that is not a Tier 2 OMOR (see section 744L(8) of the FD&amp;C Act). Tier 2 OMORs are detailed in section 744L(9) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>
                    For FY 2027, the OMUFA fee rates are: MDF facility fees ($47,891), CMO facility fees ($31,927), Tier 1 OMOR fees ($614,608), and Tier 2 OMOR fees ($122,921). These fees are effective for the period from October 1, 2026, through September 30, 2027.
                    <SU>5</SU>
                    <FTREF/>
                     This document is issued pursuant to section 744M(a)(4) and 744M(c)(5) of the FD&amp;C Act and describes the calculations used to set the OMUFA facility fees and OMOR fees for FY 2027 in accordance with the directives in the statute.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         These OMUFA facility fees are for FY 2027, per section 744M(a) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Facility Fee Revenue Amount for FY 2027</HD>
                <P>
                    Under OMUFA, FDA sets annual facility fees to generate the total facility fee revenues for each fiscal year established by section 744M(b) of the FD&amp;C Act. The yearly base revenue amount is the starting point for setting annual facility fee rates. The base revenue for FY 2027 is the dollar amount of the total revenue amount for the previous fiscal year, without certain adjustments made for that previous 
                    <PRTPAGE P="48122"/>
                    year, and is $40,648,348 (see section 744M(b)(2)(B) of the FD&amp;C Act).
                </P>
                <HD SOURCE="HD2">A. FY 2027 Statutory Fee Revenue Adjustment for Inflation</HD>
                <P>Under OMUFA, the annual base revenue amount for facility fees is adjusted for inflation for FY 2027, per section 744M(c)(1) of the FD&amp;C Act. That provision states that the dollar amount of the inflation adjustment is equal to the product of the annual base revenue for the fiscal year and the inflation adjustment percentage. For FY 2027, the inflation adjustment percentage is equal to the sum of:</P>
                <P>• The average annual percent change in cost, per full-time equivalent (FTE) position of the FDA, of all personnel compensation and benefits (PC&amp;B) paid with respect to such positions for the first 3 years of the preceding 4 FYs, multiplied by the proportion of PC&amp;B costs to total costs of the OTC monograph drug activities for the first 3 years of the preceding 4 FYs (see section 744M(c)(1)(C)(i) of the FD&amp;C Act); and</P>
                <P>• The average annual percent change that occurred in the Consumer Price Index (CPI) for urban consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than PC&amp;B costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 FYs (see section 744M(c)(1)(C)(ii) of the FD&amp;C Act).</P>
                <P>Table 1 summarizes the actual cost and FTE data for the specified FYs, provides the percent changes from the previous FYs, and provides the average percent changes over the first 3 of the 4 FYs preceding FY 2027. The 3-year average is 5.7330 percent.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 1—FDA Personnel Compensation and Benefits (PC&amp;B) Each Fiscal Year and Percent Changes</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>3,436,513,000</ENT>
                        <ENT>3,791,729,000</ENT>
                        <ENT>3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTEs</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>183,486</ENT>
                        <ENT>192,601</ENT>
                        <ENT>202,515</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent Change From Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Under the statute, this 5.7330 percent is multiplied by the proportion of PC&amp;B costs to the total FDA costs of OTC monograph drug activities for the first 3 years of the preceding 4 FYs (see section 744M(c)(1)(C)(i) of the FD&amp;C Act).</P>
                <P>Table 2 shows the PC&amp;B and the total obligations for OTC monograph drug activities for the first 3 of the preceding 4 FYs.</P>
                <GPOTABLE COLS="5" OPTS="L2,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 2—PC&amp;B as a Percent of Total Cost of OTC Monograph Drug Activities</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>39,133,075</ENT>
                        <ENT>41,579,890</ENT>
                        <ENT>54,076,351</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>68,480,052</ENT>
                        <ENT>68,176,240</ENT>
                        <ENT>82,466,551</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B Percent</ENT>
                        <ENT>57.1452%</ENT>
                        <ENT>60.9888%</ENT>
                        <ENT>65.5737%</ENT>
                        <ENT>61.2359%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The payroll adjustment is 5.7330 percent from table 1 multiplied by 61.2359 percent from table 2, resulting in 3.5107 percent.</P>
                <P>
                    Table 3 provides the summary data for the percent changes in the specified CPI for the Washington-Arlington-Alexandria, DC-VA-MD-WV area.
                    <SU>6</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         These data are published by the Bureau of Labor Statistics on its website: 
                        <E T="03">https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&amp;series_id=CUURS35ASA0,CUUSS35ASA0.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 3—Annual and 3-Year Average Percent Change in CPI for Washington-Arlington-Alexandria, DC-VA-MD-WV Area</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>305.317</ENT>
                        <ENT>315.186</ENT>
                        <ENT>321.993</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.1069%</ENT>
                        <ENT>3.2324%</ENT>
                        <ENT>2.1597%</ENT>
                        <ENT>2.8330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The statute specifies that this 2.8330 percent be multiplied by the proportion of all costs other than PC&amp;B to total costs of OTC monograph drug activities (see section 744M(c)(1)(C)(ii) of the FD&amp;C Act). Because 61.2359 percent was obligated for PC&amp;B (as shown in table 2), 38.7641 percent is the portion of costs other than PC&amp;B (100 percent−61.2359 percent = 38.7641 percent). The non-payroll adjustment is 2.8330 percent × 38.7641 percent, or 1.0982 percent.</P>
                <P>Next, we add the payroll adjustment (3.5107 percent) to the non-payroll adjustment (1.0982 percent), for a total inflation adjustment of 4.6089 percent (rounded) for FY 2027.</P>
                <P>Pursuant to the statute, the FY 2027 base revenue of $40,648,348 is increased by the total inflation adjustment of 4.6089 percent, yielding an inflation adjusted base revenue amount of $42,521,790 for FY 2027 (see section 744M(c)(1)(A)).</P>
                <HD SOURCE="HD2">B. FY 2027 Statutory Additional Dollar Amounts Adjustment</HD>
                <P>
                    OMUFA II requires that the facility fee revenue be increased by an additional dollar amount for each of fiscal years 2026-2028. For FY 2027, the inflation adjusted revenue amount of $42,521,790 is increased by an additional dollar amount of $1,233,000 
                    <PRTPAGE P="48123"/>
                    as specified in the statute (see section 744M(b)(1)(E)(ii) of the FD&amp;C Act). This yields an adjusted fee revenue subtotal of $43,754,790.
                </P>
                <HD SOURCE="HD2">C. FY 2027 Statutory Fee Revenue Adjustment for Additional Direct Cost</HD>
                <P>Fee revenue is further adjusted for additional direct costs as specified in the statute. In FY 2027, $300,000 is added to the facility fee revenues to account for additional direct costs (see section 744M(c)(3)(B) of the FD&amp;C Act). Adding the additional direct costs amount of $300,000 to $43,754,790 yields an additional direct cost adjusted fee revenue of $44,054,790.</P>
                <HD SOURCE="HD2">D. FY 2027 Statutory Fee Revenue Adjustment for Operating Reserve</HD>
                <P>Under OMUFA, FDA may further increase the FY 2027 facility fee revenue and fees if such an adjustment is necessary to provide up to 10 weeks of operating reserves of carryover user fees for OTC monograph drug activities (see section 744M(c)(2)(A) of the FD&amp;C Act). Accordingly, in setting fees for FY 2027, the Agency must estimate its carryover for FY 2027 to ensure the Agency has sufficient operating reserves of carryover user fees to mitigate certain financial risks, such as under collections, unanticipated surges in program costs, or a lapse in appropriations. Under the statute, if FDA has carryover for OTC monograph drug activities that would exceed 10 weeks of such operating reserves, FDA is required to decrease FY 2027 fee revenues and fees to provide for not more than 10 weeks of operating reserves of carryover user fees (see section 744M(c)(2)(B) of the FD&amp;C Act).</P>
                <P>To determine the FY 2026 end-of-year operating reserves of carryover user fees, the Agency assessed the operating reserve of carryover user fees at the end of June 2026 and forecast collections and obligations for the remainder of FY 2026. FDA estimates the FY 2027 operating reserve of carryover user fees to be $15,554,437.</P>
                <P>To determine whether the carryover is within the 10-week limit for the operating reserve, the Agency starts with the additional direct cost adjusted fee revenue of 44,054,790 (calculated in section C), divides it by 52 to yield a weekly operating amount of $847,207, and then multiplies the weekly operating reserve amount ($847,207) by 10, resulting in an operating reserve limit of $8,472,075. Because the estimated FY 2027 carryover is above the 10-week threshold, FDA is applying a downward operating reserve adjustment of $7,082,362, equivalent to approximately 8 weeks, to bring the operating reserve of carryover user fees to the statutory limit for such operating reserves (see section 744M(c)(2)(B) of the FD&amp;C Act). The final FY 2027 OMUFA target facility fee revenue is $36,972,000 (rounded to the nearest thousand dollars).</P>
                <HD SOURCE="HD1">III. Facility Fee Calculations</HD>
                <HD SOURCE="HD2">A. Facility Fee Revenues and Fees</HD>
                <P>For FY 2027, facility fee rates are being established to generate a total target revenue amount, as determined under the statute, equal to $36,972,000 (rounded to the nearest thousand dollars). FDA used the methodology described below to determine the appropriate number of MDF and CMO facilities to be used in setting the OMUFA facility fees for FY 2027. FDA took into consideration that the CMO facility fee is equal to two-thirds of the amount of the MDF facility fee (see section 744M(a)(1)(B)(ii) of the FD&amp;C Act).</P>
                <HD SOURCE="HD2">B. Calculating the Number of Qualifying Facilities and Setting the Facility Fees</HD>
                <P>
                    For FY 2027, FDA utilized available data consisting of the number of facilities that at the time of fee-setting were registered in FDA's Electronic Drug Registration and Listing System (eDRLS) to manufacture human OTC drug products produced under a monograph 
                    <SU>7</SU>
                    <FTREF/>
                     during the FY 2027 fee-liable period (
                    <E T="03">i.e.,</E>
                     January 1, 2026, through September 30, 2026, and that paid prior FY OMUFA facility fees, as the primary sources for estimating the number of each facility fee type (
                    <E T="03">i.e.,</E>
                     MDF and CMO). In addition, the Agency considered data provided by firms regarding their operation as MDFs and CMOs during FY 2026 (
                    <E T="03">i.e.,</E>
                     October 1, 2025, through September 30, 2026) when they were submitting OTC Monograph User Fee Cover Sheets to pay the FY 2026 fee. This data supported FDA's estimate of the number of firms operating as MDF and CMO facilities during the FY 2027 fee-liable period (
                    <E T="03">i.e.,</E>
                     January 1, 2026, through September 30, 2026), and informed FDA's calculation of the number and ratio of MDF and CMO facilities used in determining the FY 2027 fee rates.
                    <SU>8</SU>
                    <FTREF/>
                     FDA's review of data also reflected input received during the FY 2027 fee-liable period from facilities whose manufacturing or processing practices meet the definition of fee-eligible OTC monograph drug facilities, to help capture those facilities that are in the market during the FY 2027 fee-liable period and intend to remain in the market during FY 2027.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         See section 744M(d) of the FD&amp;C Act. OTC monograph drug facilities had selected in the eDRLS the business operation qualifiers of “manufactures human over-the-counter drug products produced under a monograph” or “contract manufacturing for human over-the-counter drug products produced under a monograph” and indicated at least one of the following business operations: finished dosage form manufacture, label, manufacture, pack, relabel, or repack.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         FDA considers relabelers and repackagers to be a category of OTC monograph drug facilities subject to OMUFA facility fees. See section 744L(10)(A); see also section 744L(10)(A)(iii) of the FD&amp;C Act, excluding from the definition of “OTC monograph drug facility” those facilities whose manufacturing or processing consists solely of a narrow range of specified activities (
                        <E T="03">e.g.,</E>
                         placement of outer overpackaging on products already in final packaged form); 
                        <E T="03">cf</E>
                         section 744A(6)(A)(ii) of the FD&amp;C Act (which expressly excludes from the definition of “facility”, for purposes of Generic Drug User Fee Amendments facility fees, a business or other entity whose only manufacturing or processing activities are repackaging, relabeling, or testing). See also 21 CFR 207.1 (addressing drug establishment registration), stating that “[m]anufacture means each step in the manufacture, preparation, propagation, compounding, or processing of a drug,” and indicating that “the term `manufacture, preparation, propagation, compounding, or processing,' as used in section 510 of the Federal Food, Drug, and Cosmetic Act, includes relabeling, repackaging, and salvaging activities.”
                    </P>
                </FTNT>
                <P>Those facilities that only manufacture the active pharmaceutical ingredient of an OTC monograph drug do not meet the definition of an OTC monograph drug facility (see section 744L(10)(A)(i)(II)) of the FD&amp;C Act). Likewise, a facility is not an OTC monograph drug facility if its only manufacturing or processing activities are one or more of the following: (1) production of clinical research supplies; (2) testing; or (3) placement of outer packaging on packages containing multiple products, for such purposes as creating multipacks, when each monograph drug product contained within the overpackaging is already in a final packaged form prior to placement in the outer overpackaging (see section 744L(10)(A)(iii) of the FD&amp;C Act).</P>
                <P>
                    In undertaking the statutorily directed fee calculations for FY 2027 fees, the Agency also made certain assumptions, including that: (1) facilities that have deregistered in eDRLS have exited the market; (2) facilities that FDA believes registered incorrectly as OTC monograph drug facilities (for example, the associated drug listings for these facilities did not include OTC monograph drugs but instead indicated such products as nonprescription drug products marketed under an approved drug application or nonprescription animal drug products) were not engaged in manufacturing or processing the finished dosage form of an OTC monograph drug; (3) facilities that registered but did not have an active 
                    <PRTPAGE P="48124"/>
                    OTC monograph drug product listing associated in their registration profile were not manufacturing or processing such drug products; (4) additional facilities are estimated to register from the time of fee setting through the end of the FY 2027 fee liability period at the same rate as the prior 3 year average (
                    <E T="03">i.e.,</E>
                     FYs 2024-2026); (5) a portion of facilities that newly registered including projected numbers of new registrants during the fee liable period are estimated to be in arrears based on a detailed review of the prior 3-year average (
                    <E T="03">i.e.,</E>
                     FYs 2023-2025); and (6) facilities that remain on the arrears list for failure to satisfy the FY 2026 facility fee as of June 22, 2026 are likely to be placed on the FY 2027 arrears list as well.
                </P>
                <P>Based on the above-referenced factors and assumptions, FDA estimates there will be 905 OMUFA fee-paying units. The Agency estimates that 56 percent (905 × 0.56 = 507, rounded) will incur the MDF fee and 44 percent (905 × 0.44 = 398, rounded) will incur the CMO fee.</P>
                <P>
                    To determine the number of full fee-paying equivalents (the denominator) to be used in setting the OMUFA fees, FDA assigns a value of 1 to each MDF (507) and a value of 
                    <FR>2/3</FR>
                     to each CMO (398 × 
                    <FR>2/3</FR>
                     = 265) for a full facility equivalent of 772 (rounded). The target fee revenue of $36,972,000 is then divided by 772 for an MDF fee of $47,891 and a CMO fee of $31,927.
                </P>
                <HD SOURCE="HD1">IV. OMOR Fee Calculations</HD>
                <P>For FY 2027, the Tier 1 OMOR fee is $614,608 and the Tier 2 OMOR fee is $122,921, including an adjustment for inflation (see sections 744M(a)(2)(A)(i) and (ii) of the FD&amp;C Act, respectively). OMOR fees are not included in the OMUFA target revenue calculation, which is based on the facility fees (see section 744M(b) of the FD&amp;C Act).</P>
                <P>
                    An OMOR fee is generally assessed to each person who submits an OMOR (see section 744M(a)(2)(A) of the FD&amp;C Act). OMOR fees are due on the date of the submission of the OMOR (see section 744M(a)(2)(B) of the FD&amp;C Act). The payor should submit the OMOR fee that applies to the type of OMOR they are submitting (
                    <E T="03">i.e.,</E>
                     Tier 1 or Tier 2). FDA will determine whether the appropriate OMOR fee has been submitted following receipt of the OMOR and the fee.
                </P>
                <P>An OMOR fee will not be assessed if the OMOR seeks to make certain safety changes with respect to an OTC monograph drug. Specifically, no fee will be assessed if FDA finds that the OMOR seeks to change the drug facts labeling of an OTC monograph drug in a way that would add to or strengthen: (1) a contraindication, warning, or precaution; (2) a statement about risk associated with misuse or abuse; or (3) an instruction about dosage and administration that is intended to increase the safe use of the OTC monograph drug (see section 744M(a)(2)(C) of the FD&amp;C Act).</P>
                <P>Under section 744M(a)(2)(A) of the FD&amp;C Act, each person that submits a qualifying OMOR shall be subject to a fee for an OMOR. The amount of such fee shall be:</P>
                <P>(1) For a Tier 1 OMOR, $500,000, adjusted for inflation for the FY (see section 744M(a)(2)(A)(i) of the FD&amp;C Act); and</P>
                <P>(2) For a Tier 2 OMOR, $100,000, adjusted for inflation for the FY (see section 744M(a)(2)(A)(ii) of the FD&amp;C Act).</P>
                <P>In addition, under section 744M(c)(1)(B)(ii) of the FD&amp;C Act and for purposes of section 744M(a)(2) of the FD&amp;C Act, the inflation adjustment for the FY 2027 OMOR fee shall be equal to the product of:</P>
                <P>(1) the fee for FY 2026 under section 744M(a)(2) of the FD&amp;C Act; and</P>
                <P>(2) the inflation adjustment percentage under subparagraph (C) of section 744M(c)(1) of the FD&amp;C Act.</P>
                <P>
                    Therefore, for FY 2027, the base of OMOR fees taken from the preceding FY (
                    <E T="03">i.e.,</E>
                     FY 2026) are: Tier 1: $587,529 and Tier 2: $117,505. The FY 2027 inflation adjustment percentage is: 4.6089 percent.
                </P>
                <HD SOURCE="HD1">V. Fee Schedule for FY 2027</HD>
                <P>The fee rates for FY 2027 are displayed in Table 4.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s50,9">
                    <TTITLE>Table 4—Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>fee rates</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Facility:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">MDF</ENT>
                        <ENT>$47,891</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">CMO</ENT>
                        <ENT>31,927</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">OMOR:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">Tier 1</ENT>
                        <ENT>614,608</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">Tier 2</ENT>
                        <ENT>122,921</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">VI. Electronic Federal Payment Methods</HD>
                <P>The new facility fee rates are effective for the period from October 1, 2026, through September 30, 2027. To pay the MDF and CMO fees, use the OMUFA FY 2027 Facility Fee Invoice that will be issued by the Agency in August and December 2026 for the October 1st, 2026 and February 1st, 2027 installment due dates, respectively. The OTC Monograph Drug User Fee Cover Sheet will not be available for FY 2027 payments.</P>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov</E>
                    , a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice. Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online). Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the invoice number to ensure that the payment is applied to the correct fee(s). Without the invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfers: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No.: 75060099, Routing No.: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 744M(g) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collection.</P>
                <P>
                    If you are assessed an FY 2027 OMUFA facility fee and believe your facility is not an OTC monograph drug facility as described in this notice, please contact 
                    <E T="03">FDAUserFees@fda.hhs.gov.</E>
                </P>
                <SIG>
                    <NAME>Grace Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15344 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48125"/>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7709]</DEPDOC>
                <SUBJECT>Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        <E T="03">For questions related to FSMA program fees: FSMAFeeStaff@fda.hhs.gov.</E>
                          
                        <E T="03">For questions related to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Section 806 of the FD&amp;C Act (21 U.S.C. 384b) directs FDA to establish a program to provide for the expedited review and importation of food offered for importation by importers who have voluntarily agreed to participate in such program, and a process, consistent with section 808 of the FD&amp;C Act (21 U.S.C. 384d), for the issuance of a facility certification to accompany a food offered for importation by importers participating in VQIP.</P>
                <P>
                    Section 743 of the FD&amp;C Act (21 U.S.C. 379j-31) authorizes FDA to assess and collect fees from each importer participating in VQIP to cover FDA's costs of administering the program. Each fiscal year, fees are to be established based on an estimate of 100 percent of the costs for the year (section 743(b)(2)(A)(iii) of the FD&amp;C Act). The fee rates must be published in a 
                    <E T="04">Federal Register</E>
                     notice not later than 60 days before the start of each fiscal year (section 743(b)(1) of the FD&amp;C Act). After FDA approves a VQIP application, the user fee is to be paid before October 1, the start of the VQIP fiscal year, to begin receiving benefits for that VQIP fiscal year.
                </P>
                <P>The FY 2027 VQIP user fee will support benefits from October 1, 2026, through September 30, 2027.</P>
                <HD SOURCE="HD1">II. Estimating the Average Cost of a Supported Direct FDA Work Hour for FY 2027</HD>
                <P>FDA estimates 100 percent of its costs for each activity to establish fee rates for FY 2027 (see section 743(b)(2)(A) of the FD&amp;C Act).</P>
                <HD SOURCE="HD2">A. Estimating the Full Cost per Direct Work Hour in FY 2027</HD>
                <P>Full-time Equivalent (FTE) reflects the total number of regular straight-time hours—not including overtime or holiday hours—worked by employees, divided by the number of compensable hours applicable to each fiscal year. Annual leave, sick leave, compensatory time off, and other approved leave categories are considered “hours worked” for purposes of defining FTE employment.</P>
                <P>In general, the starting point for estimating the full cost per direct work hour is to estimate the cost of an FTE or paid staff year. Calculating an FDA-wide total cost per FTE requires three primary cost elements: payroll, non-payroll, and rent.</P>
                <P>We used an average of past year cost elements to predict the FY 2027 cost. The FY 2027 FDA-wide average cost for payroll (salaries and benefits) is $244,029; non-payroll—including equipment, supplies, IT, general and administrative overhead—is $108,488; and rent, including cost allocation analysis and adjustments for other rent and rent-related costs, is $24,118 per paid staff year, excluding travel costs.</P>
                <P>Summing the average cost of an FTE for payroll, non-payroll, and rent, brings the FY 2027 average fully supported cost to $376,635 (total includes rounding) per FTE, excluding travel costs. FDA will use this base unit fee in determining the hourly fee rate for VQIP fees for FY 2027 before including domestic or foreign travel costs as applicable for the activity.</P>
                <P>To calculate an hourly rate, we divide the FY 2027 average fully supported cost of $376,635 per FTE by the average number of supported direct FDA work hours in FY 2025—the last FY for which data are available. See table 1.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,p1,8/9,i1" CDEF="s150,12">
                    <TTITLE>Table 1—Supported Direct FDA Work Hours in a Paid Staff Year in FY 2025</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total number of hours in a paid staff year</ENT>
                        <ENT>2,080</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Less:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">11 paid holidays</ENT>
                        <ENT>−88</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">20 days of annual leave</ENT>
                        <ENT>−160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">10 days of sick leave</ENT>
                        <ENT>−80</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">12.5 days of training</ENT>
                        <ENT>−100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">22 days of general administration</ENT>
                        <ENT>−176</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">26.5 days of travel</ENT>
                        <ENT>−212</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">2 hours of meetings per week</ENT>
                        <ENT>−104</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Net Supported Direct FDA Work Hours Available for Assignments</ENT>
                        <ENT>1,160</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Dividing the average fully supported FTE cost in FY 2027 ($376,635) by the total number of supported direct work hours available for assignment in FY 2025 (1,160) results in an average fully supported cost of $325 (rounded to the nearest dollar), excluding inspection travel costs, per supported direct work hour in FY 2027.</P>
                <HD SOURCE="HD2">B. Adjusting FY 2025 Travel Costs for Inflation To Estimate FY 2027 Travel Costs</HD>
                <P>
                    To adjust the hourly rate for FY 2027, FDA estimates the cost of inflation in each year for FYs 2026 and 2027. FDA uses the method prescribed for estimating inflationary costs under the Prescription Drug User Fee Act (PDUFA) provisions of the FD&amp;C Act (section 736(c)(1) of the FD&amp;C Act (21 U.S.C. 379h(c)(1))), the statutory method for inflation adjustment in the FD&amp;C Act that FDA has used consistently. FDA previously determined the FY 2026 inflation rate to be 5.0313 percent; this rate was published in the FY 2026 PDUFA user fee rates notice in the 
                    <E T="04">Federal Register</E>
                     (July 30, 2025, 90 FR 35866). Using the method set forth in section 736(c)(1) of the FD&amp;C Act, FDA calculated an inflation rate of 5.0313 
                    <PRTPAGE P="48126"/>
                    percent for FY 2026 and 4.7210 percent for FY 2027, and FDA intends to use these inflation rates to make inflation adjustments for FY 2027.
                </P>
                <P>
                    In FY 2025, FDA's Office of Inspections and Investigation (OII) spent a total of $10,002,278 for domestic regulatory inspection travel costs and General Services Administration Vehicle costs related to FDA's Human Foods Program (HFP) and Center for Veterinary Medicine (CVM) field activities programs.
                    <SU>1</SU>
                    <FTREF/>
                     The total OII domestic travel costs spent is then divided by the 9,485 HFP and CVM domestic inspections, which averages a total of $1,055 per inspection. These inspections average 40.76 hours per inspection. Dividing $1,055 per inspection by 40.76 hours per inspection results in a total and an additional cost of $26 (rounded to the nearest dollar) per hour spent for domestic inspection travel costs in FY 2025. To adjust for the $26 per hour additional domestic cost inflation increases for FY 2026 and FY 2027, FDA multiplies the FY 2026 PDUFA inflation rate adjustor (1.050313) by the FY 2027 PDUFA inflation rate adjustor (1.047210) times the $26 additional domestic cost, which results in an estimated cost of $29 (rounded to the nearest dollar) per paid hour in addition to $325 for a total of $354 per paid hour ($325 plus $29) for each direct hour of work requiring domestic inspection travel. FDA will use these rates in charging fees in FY 2027 when domestic travel is required.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Effective October 1st, 2024, FDA implemented a reorganization to establish a unified Humans Foods Program and restructured its field operations, formerly the Office of Regulatory Affairs and now the Office of Inspections and Investigations (OII). The establishment of the Human Foods Program allows us to most effectively deliver on our mission to protect and promote public health through science-based approaches to prevent foodborne illness, reduce diet-related chronic disease, and ensure the safety of chemicals in our food. For more information, see 
                        <E T="03">https://www.fda.gov/news-events/press-announcements/fdas-unified-human-foods-program-new-model-field-operations-and-other-modernization-efforts-go</E>
                        .
                    </P>
                </FTNT>
                <P>In FY 2025, OII spent a total of $2,689,902 on 277 foreign inspection trips related to FDA's HFP and CVM field activities programs, which averaged a total of $9,711 per foreign inspection trip. These trips averaged 3 weeks (or 120 paid hours) per trip. Dividing $9,711 per trip by 120 hours per trip results in a total and an additional cost of $81 (rounded to the nearest dollar) per paid hour spent for foreign inspection travel costs in FY 2025. To adjust $81 for inflationary increases in FY 2026 and FY 2027, FDA multiplies it by the same inflation factors mentioned previously in this document (1.050313 and 1.047210), which results in an estimated cost of $89 (rounded to the nearest dollar) for each direct hour of work requiring foreign inspection travel. FDA will use these rates in charging fees in FY 2027 when foreign travel is required.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s25,9">
                    <TTITLE>Table 2—FSMA Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">Fee rates for FY 2027</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Hourly rate without travel</ENT>
                        <ENT>$325</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Hourly rate if domestic travel is required</ENT>
                        <ENT>354</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Hourly rate if foreign travel is required</ENT>
                        <ENT>414</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. Fees for Importers Approved To Participate in the Voluntary Qualified Importer Program Under Section 743 of the FD&amp;C Act</HD>
                <P>FDA assesses fees for VQIP annually. Table 3 provides an overview of the fees for FY 2027.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s25,9C">
                    <TTITLE>Table 3—FSMA VQIP User Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">Fee rates for FY 2027</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">VQIP User Fee</ENT>
                        <ENT>$9,994</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 743 of the FD&amp;C Act requires that each importer participating in VQIP pay a fee to cover FDA's costs of administering the program. This fee represents the estimated average cost of the work FDA performs in reviewing and evaluating a VQIP importer. At this time, FDA is not offering an adjusted fee for small businesses. As required by section 743(b)(2)(B)(iii) of the FD&amp;C Act, FDA published guidelines in consideration of the burden of the VQIP fee on small businesses and provided for a period of public comment on the guidelines (80 FR 32136, June 5, 2015). While we received some comments, the comments did not address the questions posed (that is, how a small business fee reduction should be structured, what percentage of fee reduction would be appropriate, or what alternative structures FDA might consider to indirectly reduce fees for small businesses by charging different fee amounts to different VQIP participants). Consistent with section 743(b)(2)(B)(iii) of the FD&amp;C Act, if we determine to provide for a small business fee reduction, we will adjust the fee schedule for small businesses only through notice and comment rulemaking.</P>
                <P>The fee is based on the fully supported FTE hourly rates and estimates of the number of hours it would take FDA to perform relevant activities. These estimates represent FDA's current thinking, and as the program evolves, FDA will reconsider the estimated hours. We estimate that it would take, on average, 39 person-hours to review a new VQIP application (including communication provided through the VQIP Importer's Help Desk), 28 person-hours to review a returning VQIP application (including communication provided through the VQIP Importer's Help Desk), 16 person-hours for an onsite performance evaluation of a domestic VQIP importer (including travel and other steps necessary for a fully supported FTE to complete and document an onsite assessment), and 34 person-hours for an onsite performance evaluation of a foreign VQIP importer (including travel and other steps necessary for a fully supported FTE to complete and document an onsite assessment).</P>
                <P>Based on updated data, FDA anticipates that there may be up to seven returning VQIP applicants and up to two new applicants this fiscal year. FDA employees are likely to review new VQIP applications from their worksites, so we use the fully supported FTE hourly rate excluding travel, $325/hour, to calculate the portion of the user fee attributable to those activities: $325/hour × (39 hours) = $12,675. FDA employees are likely to review returning VQIP applications from their worksites, so we use the fully supported FTE hourly rate excluding travel, $325/hour, to calculate the portion of the user fee attributable to those activities: $325/hour × (28 hours) = $9,100.</P>
                <P>FDA employees may conduct a VQIP inspection to verify the eligibility criteria and full implementation of the food safety and food defense systems established in the Quality Assurance Program. For FY 2027, FDA does not anticipate conducting dedicated VQIP inspections and will instead use existing inspection programs (such as the Foreign Supplier Verification Program and Hazard Analysis and Critical Control Point regulations) for program participants.</P>
                <P>
                    FDA employees are likely to prepare for and report on the performance evaluation of a domestic VQIP importer at an FTE's worksite, so we use the fully supported FTE hourly rate excluding travel, $325/hour, to calculate the portion of the user fee attributable to those activities: $325/hour × (8 hours) = $2,600. For the portion of the fee covering onsite evaluation of a domestic VQIP importer, we use the fully 
                    <PRTPAGE P="48127"/>
                    supported FTE hourly rate for work requiring domestic travel, $354/hour, to calculate the portion of the user fee attributable to those activities: $354/hour × 8 hours (
                    <E T="03">i.e.,</E>
                     one fully supported FTE × (1 day onsite × 8 hours)) = $2,832. Therefore, the total cost of conducting the domestic performance evaluation of a VQIP importer is determined to be $2,600 + $2,832 = $5,432.
                </P>
                <P>
                    Coordination of the onsite performance evaluation of a foreign VQIP importer is estimated to take place at an FTE's worksite, so we use the fully supported FTE hourly rate excluding travel, $325/hour, to calculate the portion of the user fee attributable to those activities: $325/hour × (10 hours) = $3,250. For the portion of the fee covering onsite evaluation of a foreign VQIP importer, we use the fully supported FTE hourly rate for work requiring foreign travel, $414/hour, to calculate the portion of the user fee attributable to those activities: $414/hour × 24 hours (
                    <E T="03">i.e.,</E>
                     one fully supported FTE × ((2 travel days × 8 hours) + (1 day onsite × 8 hours))) = $9,936. Therefore, the total cost of conducting the foreign performance evaluation of a VQIP importer is determined to be $3,250 + $9,936 = $13,186.
                </P>
                <P>
                    Therefore, the estimated average cost of the work FDA performs in total for approving an application for a VQIP importer in FY 2027 based on these figures would be ($12,675 × 
                    <FR>1/4</FR>
                    ) + ($9,100 × 
                    <FR>3/4</FR>
                    ) = $9,994.
                </P>
                <HD SOURCE="HD1">IV. How must the fee be paid?</HD>
                <P>Section 743(a)(1)(C) of the FD&amp;C Act requires FDA to assess and collect user fees from each importer participating in VQIP. An invoice will be sent to VQIP importers approved to participate in the program. Payment are to be made before October 1, 2026, to be eligible for VQIP participation for the benefit year beginning October 1, 2026. FDA will not refund the VQIP user fee for any reason.</P>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov</E>
                    , a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov.</E>
                     Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts or U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the invoice number to ensure that the payment is applied to the correct fee(s). Without the invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965.</P>
                <HD SOURCE="HD1">V. What are the consequences of not paying this fee?</HD>
                <P>
                    The consequences of not paying these fees are outlined in Section J of our Guidance for Industry, “FDA's Voluntary Qualified Importer Program” (November 2024) (available at 
                    <E T="03">https://www.fda.gov/media/92196/download</E>
                    ). If the user fee is not paid before October 1, a VQIP importer will not be eligible to participate in VQIP. For the first year a VQIP application is approved, if the user fee is not paid before October 1, 2026, you are not eligible to participate in VQIP. If you subsequently pay the user fee, FDA will begin your benefits after we receive the full payment. The user fee may not be paid after December 31, 2026. For a subsequent year, if you do not pay the user fee before October 1, FDA will send a Notice of Intent to Revoke your participation in VQIP. If you do not pay the user fee within 30 days of the date of the Notice of Intent to Revoke, we will revoke your participation in VQIP.
                </P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15345 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-2526]</DEPDOC>
                <SUBJECT>Butylated Hydroxytoluene (BHT); Request for Information; Reopening of Comment Period</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; request for information; reopening of comment period.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Food and Drug Administration (FDA or we) is reopening the comment period for the notice titled “Butylated Hydroxytoluene (BHT); Request for Information,” which published in the 
                        <E T="04">Federal Register</E>
                         of May 13, 2026. We are taking this action in response to a request from stakeholders to extend the comment period to allow additional time for interested parties to develop and submit data, other information, and comments for this request for information.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        FDA is reopening the comment period on the notice “Butylated Hydroxytoluene (BHT); Request for Information,” which published in the 
                        <E T="04">Federal Register</E>
                         on May 13, 2026 (91 FR 27054). Submit either electronic or written comments by August 31, 2026.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The 
                        <E T="03">https://www.regulations.gov</E>
                         electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of August 31, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.
                    </P>
                </ADD>
                <HD SOURCE="HD2">Electronic Submissions</HD>
                <P>Submit electronic comments in the following way:</P>
                <P>
                    • 
                    <E T="03">Federal eRulemaking Portal: https://www.regulations.gov.</E>
                     Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to 
                    <E T="03">https://www.regulations.gov</E>
                     will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that 
                    <PRTPAGE P="48128"/>
                    identifies you in the body of your comments, that information will be posted on 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <P>• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).</P>
                <HD SOURCE="HD2">Written/Paper Submissions</HD>
                <P>Submit written/paper submissions as follows:</P>
                <P>
                    • 
                    <E T="03">Mail/Hand Delivery/Courier (for written/paper submissions):</E>
                     Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
                </P>
                <P>• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”</P>
                <P>
                    <E T="03">Instructions:</E>
                     All submissions received must include the Docket No. FDA-2026-N-2526 for “Butylated Hydroxytoluene (BHT); Request for Information.” Received comments, those filed in a timely manner (see 
                    <E T="02">ADDRESSES</E>
                    ), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at 
                    <E T="03">https://www.regulations.gov</E>
                     or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
                </P>
                <P>
                    • 
                    <E T="03">Confidential Submissions</E>
                    —To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” We will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on 
                    <E T="03">https://www.regulations.gov.</E>
                     Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: 
                    <E T="03">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.</E>
                </P>
                <P>
                    <E T="03">Docket:</E>
                     For access to the docket to read background documents or the electronic and written/paper comments received, go to 
                    <E T="03">https://www.regulations.gov</E>
                     and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>John Steele, Office of Food Chemical Safety, Dietary Supplements, and Innovation, Human Foods Program, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 301-796-1976; or Lauren Kleinman, Office of Policy and International Engagement, Human Foods Program, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-2378.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    In the 
                    <E T="04">Federal Register</E>
                     of May 13, 2026 (91 FR 27054), FDA published a notice with a 60-day comment period to request information on the current uses and safety data for BHT in human food and as a food contact substance. We originally gave interested persons until July 13, 2026, to provide data and information.
                </P>
                <P>Following publication of the notice, FDA received a request to allow interested parties additional time to comment. The request asserted that 60 days was insufficient to allow impacted stakeholders to develop a complete and scientifically robust submission, particularly due to supply chain communications. We have considered this request, and, because the request came too late for us to extend the comment period before it expired, we are reopening the comment period for 30 days. FDA believes that these additional 30 days will allow time for interested parties to submit data and other information to support our post-market assessment of the safety of BHT in food and as a food contact substance.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15429 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7558]</DEPDOC>
                <SUBJECT>Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2027.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The application fee rates apply to applications submitted on or after October 1, 2026, and will remain in effect through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                         Visit FDA's website at: 
                        <E T="03">https://www.fda.gov/industry/fda-user-fee-programs/animal-drug-user-fee-act-adufa.</E>
                         For general questions, you may also email FDA's Center for Veterinary Medicine (CVM) at: 
                        <E T="03">cvmadufa@fda.hhs.gov. For questions relating to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Section 740(a) of the FD&amp;C Act (21 U.S.C. 379j-12), as amended by ADUFA V, establishes four different types of user fees: (1) fees for certain animal drug applications and supplemental animal drug applications; (2) annual fees for certain animal drug products; (3) annual fees for certain establishments where such products are made; and (4) annual fees for certain sponsors of animal drug applications and/or investigational animal drug submissions. When certain conditions are met, FDA will waive or reduce fees per section 740(d) of the FD&amp;C Act.</P>
                <P>
                    For FYs 2024 through 2028, section 740(b)(1) of the FD&amp;C Act establishes 
                    <PRTPAGE P="48129"/>
                    the base revenue amount for each fiscal year. Per section 740(c)(2) and (3) of the FD&amp;C Act, the base revenue amounts established for fiscal years after FY 2024 are subject to adjustment for inflation and workload. Beginning in FY 2025, the annual fee revenue amount is also subject to an operating reserve adjustment to allow FDA to adjust the fee revenue amount to maintain a specified operating reserve of carryover user fees, per section 740(c)(4) of the FD&amp;C Act. FDA may increase the fee revenue amount to maintain a 12-week minimum. If FDA has an excess operating reserve, FDA will decrease the fee revenue amount so that FDA has 22 weeks of operating reserve for FY 2025, 20 weeks for FY 2026, 18 weeks for FY 2027, and 16 weeks for FY 2028.
                </P>
                <P>Per section 740(b)(2) of the FD&amp;C Act, fees for applications, establishments, products, and sponsors are to be established each year by FDA so that the percentages of the total revenue that are derived from each type of user fee will be as follows: (1) revenue from application fees shall be 20 percent of total fee revenue; (2) revenue from product fees shall be 27 percent of total fee revenue; (3) revenue from establishment fees shall be 26 percent of total fee revenue; and (4) revenue from sponsor fees shall be 27 percent of total fee revenue. The target revenue amounts for each fee category for FY 2027 are as follows: for application fees, the target revenue amount is $6,465,600; for product fees, the target revenue amount is $8,728,560; for establishment fees, the target revenue amount is $8,405,280; and for sponsor fees, the target revenue amount is $8,728,560.</P>
                <P>For FY 2027, the animal drug user fee rates are: (1) $621,692 for an animal drug application; (2) $310,846 for a supplemental animal drug application for which safety or effectiveness data are required, for an animal drug application subject to the criteria set forth in section 512(d)(4) of the FD&amp;C Act (21 U.S.C. 360b), and for an application for conditional approval under section 571 of the FD&amp;C Act (21 U.S.C. 360ccc) for which an animal drug application submitted under section 512(b)(1) of the FD&amp;C Act has been previously approved under section 512(d)(1) of the FD&amp;C Act for another intended use; (3) $12,294 for the annual product fee; (4) $215,513 for the annual establishment fee; and (5) $145,476 for the annual sponsor fee. FDA will issue invoices for FY 2027 product, establishment, and sponsor fees by December 31, 2026, and payment will be due by January 31, 2027. The application fee rates are effective for applications submitted on or after October 1, 2026, and will remain in effect through September 30, 2027. Applications will not be accepted for review until FDA has received full payment of application fees and any other animal drug user fees owed under the ADUFA program.</P>
                <HD SOURCE="HD1">II. Fee Revenue Amount for FY 2027</HD>
                <HD SOURCE="HD2">A. Statutory Fee Revenue Amounts</HD>
                <P>Section 740(b)(1) of the FD&amp;C Act specifies that the base fee revenue amount for FY 2027 for all animal drug user fee categories totals $33,500,000.</P>
                <HD SOURCE="HD2">B. Inflation Adjustment to Fee Revenue Amount</HD>
                <P>Section 740(c)(2)(A)(ii) and (iii) of the FD&amp;C Act specifies that the annual fee revenue amount is to be adjusted for inflation increases for FY 2025 and subsequent fiscal years using two separate adjustments: one for personnel compensation and benefits (PC&amp;B) and one for non-PC&amp;B costs. Section 740(c)(2)(A)(ii) of the FD&amp;C Act specifies the component of the inflation adjustment for payroll costs shall be one plus the average annual percent change in the cost of all PC&amp;B paid per full-time equivalent position (FTE) at FDA for the first 3 of the 4 preceding fiscal years of available data, multiplied by the average proportion of PC&amp;B costs to total FDA costs for the first 3 of the 4 preceding fiscal years of available data. The data on total PC&amp;B paid and numbers of FTE paid, from which the average cost per FTE can be derived, are published in FDA's Justification of Estimates for Appropriations Committees.</P>
                <P>Table 1 summarizes the total PC&amp;B cost per FTE for the specified fiscal years, provides the percent change from the previous fiscal year, and provides the average percent change over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 1—FDA Personnel Compensation and Benefits (PC&amp;B) Each Year and Percentage Change</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT> </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTEs</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT> </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                        <ENT> </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percentage Change from Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 740(c)(2)(A)(ii) of the FD&amp;C Act specifies that this 5.7330 percent should be multiplied by the proportion of PC&amp;B costs to total FDA costs for the first 3 of the preceding 4 fiscal years for which data are available. Table 2 shows the amount of PC&amp;B and the total amount obligated by FDA for the same 3 fiscal years.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 2—PC&amp;B as a Percent of Total Cost at FDA</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT> </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>$6,654,058,000</ENT>
                        <ENT>$6,976,495,000</ENT>
                        <ENT>$6,809,369,000</ENT>
                        <ENT> </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B percent</ENT>
                        <ENT>51.6454%</ENT>
                        <ENT>54.3501%</ENT>
                        <ENT>56.9207%</ENT>
                        <ENT>54.3054%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The portion of the inflation adjustment relating to payroll costs is 5.7330 percent multiplied by 54.3054 percent, or 3.1133 percent.</P>
                <P>
                    Section 740(c)(2)(A)(iii) of the FD&amp;C Act specifies that the portion of the inflation adjustment for non-payroll costs is the average annual percent change that occurred in the Consumer Price Index (CPI) (Washington-Arlington-Alexandria, DC-VA-MD-WV; not seasonally adjusted; all items less food and energy; annual index) for the first 3 years of the preceding 4 years of 
                    <PRTPAGE P="48130"/>
                    available data multiplied by the average proportion of all costs other than PC&amp;B costs to total FDA costs for the first 3 years of the preceding 4 fiscal years. Table 3 provides the summary data for the percent change in the specified CPI for the Washington-Arlington-Alexandria area. The data from the Bureau of Labor Statistics are shown in table 3.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The data is published by the Bureau of Labor Statistics and can be found on its website at: 
                        <E T="03">https://data.bls.gov/timeseries/CUURS35ASA0L1E.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 3—Annual and 3-Year Average Percentage Change in CPI (Less Food and Energy) for Washington-Arlington-Alexandria Area</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>313.315</ENT>
                        <ENT>324.560</ENT>
                        <ENT>332.041</ENT>
                        <ENT> </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.5382%</ENT>
                        <ENT>3.5890%</ENT>
                        <ENT>2.3050%</ENT>
                        <ENT>3.1441%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 740(c)(2)(A)(iii) of the FD&amp;C Act specifies to calculate the inflation adjustment for non-payroll costs, we multiply 3.1441 percent by the average proportion of all costs other than PC&amp;B to total FDA costs for the first 3 years of the preceding 4 fiscal years. Since 54.3054 percent was obligated for PC&amp;B as shown in table 2, 45.6946 percent is the portion of costs other than PC&amp;B (100 percent minus the PC&amp;B percentage of 54.3054). The portion of the inflation adjustment relating to non-payroll costs is 3.1441 percent multiplied by 45.6946 percent, or 1.4367 percent.</P>
                <P>Next, we add the payroll component (3.1133 percent) to the non-payroll component (1.4367 percent), for an inflation adjustment of 4.5500 percent for FY 2027.</P>
                <P>Section 740(c)(2)(B) of the FD&amp;C Act provides for the inflation adjustment to be compounded each fiscal year after FY 2025. The inflation adjustment for FY 2027 (4.5500 percent) is compounded by adding 1 and then multiplying by 1 plus the inflation adjustment factor for FY 2026 (1.0896), which equals 1.1392 (rounded) (1.0896 multiplied by 1.0455). We then multiply the base revenue amount for FY 2027 ($33,500,000) by 1.1392, yielding an inflation adjusted amount of $38,163,368.</P>
                <HD SOURCE="HD2">C. Workload Adjustment to Inflation Adjusted Fee Revenue Amount</HD>
                <P>Section 740(c)(3)(A) of the FD&amp;C Act specifies that the annual fee revenue amounts in ADUFA V for FY 2025 and subsequent fiscal years are subject to adjustment to account for changes in FDA's review workload. The workload adjustment will be applied to the inflation adjusted fee revenue amount.</P>
                <P>To determine whether a workload adjustment applies, per ADUFA V commitments FDA calculates the weighted average of the change in the total number of each of the five types of applications and submissions specified in the workload adjustment provision (animal drug applications, supplemental animal drug applications for which data with respect to safety or efficacy are required, manufacturing supplemental animal drug applications, investigational animal drug study submissions, and investigational animal drug protocol submissions) received over the 5-year period that ended on September 30, 2025 (the base years; 2021 through 2025), and the average number of each of these types of applications and submissions over the most recent 5-year period that ended April 30, 2026.</P>
                <P>The results of these calculations are presented in the first two columns of table 4. Column 3 reflects the percent change in workload over the two 5-year periods. Column 4 shows the weighting factor for each type of application/submission, reflecting how much of the total FDA animal drug review workload was accounted for by each type of application or submission in the table during the most recent 5 years. Column 5 is the weighted percent change in each category of workload and was derived by multiplying the weighting factor in each line in column 4 by the percent change from the base years in column 3. At the bottom right of the table, the sum of the values in column 5 is calculated, reflecting a total change in workload of negative 4.8810 percent for FY 2027. This is the workload adjuster for FY 2027.</P>
                <GPOTABLE COLS="6" OPTS="L2,nj,i1" CDEF="s50,12,10,10,10,10">
                    <TTITLE>Table 4—Workload Adjuster Calculation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Application type</CHED>
                        <CHED H="1">Column 1</CHED>
                        <CHED H="2">
                            5-Year
                            <LI>average</LI>
                            <LI>(base years)</LI>
                        </CHED>
                        <CHED H="1">Column 2</CHED>
                        <CHED H="2">
                            Latest
                            <LI>5-year</LI>
                            <LI>average</LI>
                        </CHED>
                        <CHED H="1">Column 3</CHED>
                        <CHED H="2">
                            Percent
                            <LI>change</LI>
                        </CHED>
                        <CHED H="1">Column 4</CHED>
                        <CHED H="2">
                            Weighting
                            <LI>factor</LI>
                        </CHED>
                        <CHED H="1">Column 5</CHED>
                        <CHED H="2">
                            Weighted
                            <LI>percent</LI>
                            <LI>change</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">New Animal Drug Application (NADAs)</ENT>
                        <ENT>11.80</ENT>
                        <ENT>12.0</ENT>
                        <ENT>1.6949</ENT>
                        <ENT>0.0434</ENT>
                        <ENT>0.0735</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Supplemental NADAs With Safety or Efficacy Data</ENT>
                        <ENT>8.40</ENT>
                        <ENT>9.0</ENT>
                        <ENT>7.1429</ENT>
                        <ENT>0.0291</ENT>
                        <ENT>0.2077</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Manufacturing Supplements</ENT>
                        <ENT>369.20</ENT>
                        <ENT>349.2</ENT>
                        <ENT>−5.4171</ENT>
                        <ENT>0.2117</ENT>
                        <ENT>−1.1466</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Investigational Study Submissions</ENT>
                        <ENT>143.60</ENT>
                        <ENT>134.2</ENT>
                        <ENT>−6.5460</ENT>
                        <ENT>0.5911</ENT>
                        <ENT>−3.8692</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Investigational Protocol Submissions</ENT>
                        <ENT>136.40</ENT>
                        <ENT>134.8</ENT>
                        <ENT>−1.1730</ENT>
                        <ENT>0.1248</ENT>
                        <ENT>−0.1464</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">FY 2027 ADUFA V Workload Adjuster</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT>−4.8810</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    Section 740(c)(3)(B) of the FD&amp;C Act specifies that under no circumstances shall the workload adjustment result in fee revenues that are less than the base fee revenues for that fiscal year as adjusted for inflation. Additionally, section 740(c)(3)(A)(ii) states that the workload adjuster must be greater than 3 percent for a second fiscal year within ADUFA V before FDA can add the adjustment to the target revenue. For FY 2027 the workload adjuster is below the 3 percent statute threshold; therefore, no workload adjustment shall be applied.
                    <PRTPAGE P="48131"/>
                </P>
                <HD SOURCE="HD2">D. Operating Reserve Adjustment to Inflation and Workload Adjusted Fee Revenue Amount</HD>
                <P>Section 740(c)(4)(A) of the FD&amp;C Act specifies that for FY 2027, after the fee revenue amount established under section 740(b) of the FD&amp;C Act is adjusted for inflation and workload, the Secretary shall increase the fee revenue amount for such fiscal year, if necessary to provide an operating reserve of not less than 12 weeks or decrease the fee revenue amount for such fiscal year, if necessary to provide for not more than 18 weeks of operating reserves.</P>
                <P>To determine the dollar amounts for the 12-week and 18-week operating reserve thresholds, we divide the adjusted annual fee revenue amount ($38,163,368) by 52 weeks to generate a 1-week operating reserve amount of $733,911. The 1-week operating reserve amount is then multiplied by 12 and 18. This results in a 12-week minimum threshold of $8,806,932 and a 18-week maximum threshold of $13,210,398.</P>
                <P>To estimate the FY 2026 end-of-year operating reserve of carryover user fees, the Agency projected the user fee carryover amount at the end of July 2026 using forecasted obligations, collections, and estimated recoveries but not including carryover user fees that have not been appropriated. The operating reserve of carryover user fees is projected to be $19,048,886 or 25.96 weeks ($19,048,886 divided by $733,911).</P>
                <P>Because the estimated FY 2026 end-of-year operating reserve of carryover user fees is not below the 12-week threshold amount of $8,806,932, FDA will not increase the fee revenue amount and fees for FY 2027.</P>
                <P>However, because the estimated FY 2026 end-of-year operating reserve of carryover user fees of $19,048,886 exceeds the 18-week threshold of $13,210,398, FDA will apply an operating reserve adjustment of $5,834,940 to decrease the fee revenue and fees for FY 2027.</P>
                <P>With respect to target revenue for FY 2027, subtracting the operating reserve adjustment amount of $5,834,940 from the adjusted fee revenue amount of $38,163,368 results in a total target revenue amount of $32,328,000 (rounded) for FY 2027.</P>
                <HD SOURCE="HD2">E. FY 2027 Fee Revenue Amounts</HD>
                <P>The fee revenue amount for FY 2027 is $32,328,000 (rounded). Section 740(b)(2) of the FD&amp;C Act specifies that this revenue amount is to be divided as follows: 20 percent, or a total of $6,465,600 is to come from application fees; 27 percent, or a total of $8,728,560, is to come from product fees; 26 percent, or a total of $8,405,280 is to come from establishment fees; and 27 percent, or a total of $8,728,560 is to come from sponsor fees.</P>
                <HD SOURCE="HD1">III. Animal Drug Application Fee Calculations for FY 2027</HD>
                <HD SOURCE="HD2">A. Application Fee Revenues and Numbers of Fee-Paying Applications</HD>
                <P>Section 740(a)(1)(A) of the FD&amp;C Act states that each person that submits an animal drug application or a supplemental animal drug application shall be subject to an application fee, with limited exceptions. The term “animal drug application” means an application for approval of any new animal drug submitted under section 512(b)(1) of the FD&amp;C Act or an application for conditional approval of a new animal drug submitted under section 571 of the FD&amp;C Act. A “supplemental animal drug application” is defined as a request to FDA to approve a change in an approved animal drug application, or a request to FDA to approve a change to an application approved under section 512(c)(2) of the FD&amp;C Act for which data with respect to safety or effectiveness are required. Such applications are subject to ADUFA fees, except those fees may be waived under the circumstances described in sections 740(d)(1)(D) and 740(i) of the FD&amp;C Act.</P>
                <P>Furthermore, ADUFA V continues to provide an exception from application fees for animal drug applications submitted under section 512(b)(1) of the FD&amp;C Act by a sponsor who previously applied for conditional approval under section 571 of the FD&amp;C Act for the same product and paid an application fee at the time they applied for conditional approval. The purpose of this exception is to prevent sponsors of conditionally approved products from having to pay a second application fee at the time they apply for full approval of their products under section 512(b)(1) of the FD&amp;C Act, provided the sponsor's application for full approval is filed consistent with the timeframes established in section 571(h) of the FD&amp;C Act.</P>
                <P>The application fees are to be set so that they will generate $6,465,600 in fee revenue for FY 2027. The fee for a supplemental animal drug application for which safety or effectiveness data are required, for an animal drug application subject to criteria set forth in section 512(d)(4) of the FD&amp;C Act, and for an application for conditional approval under section 571 of the FD&amp;C Act of a new animal drug for which an animal drug application submitted under section 512(b)(1) of the FD&amp;C Act has been previously approved under section 512(d)(1) for another intended use is to be set at 50 percent of the animal drug application fee.</P>
                <P>To set animal drug application fees and supplemental animal drug application fees to realize $6,465,600, FDA must first make some assumptions about the number of fee-paying applications and supplemental applications the Agency will receive in FY 2027.</P>
                <P>The Agency knows the number of applications that have been submitted in previous fiscal years. That number fluctuates annually. In estimating the fee revenue to be generated by animal drug application fees in FY 2027, FDA is assuming that the number of applications for which fees will be paid in FY 2027 will equal the average number of applications over the five most recently completed fiscal years of the ADUFA program (FY 2021 to FY 2025).</P>
                <P>Over the 5 most recently completed fiscal years, the average number of animal drug applications subject to the full fee was 5.80. Over this same period, the average number of supplemental applications for which safety or effectiveness data are required, applications subject to the criteria set forth in section 512(d)(4) of the FD&amp;C Act, and applications for conditional approval of a new animal drug for which a section 512(b)(1) application has been previously approved for another intended use subject to half of the full fee was 9.20.</P>
                <P>Based on the previous assumptions, FDA is estimating that it will receive a total of 10.40 fee-paying animal drug applications in FY 2027 (5.80 applications paying a full fee and 9.20 applications paying a half fee).</P>
                <HD SOURCE="HD2">B. Application Fee Rates for FY 2027</HD>
                <P>
                    FDA must set the fee rates for FY 2027 so that the estimated 10.40 applications that pay the fee will generate a total of $6,465,600. To generate this amount, the fee for an animal drug application, rounded to the nearest dollar, will have to be $621,692, and the fee for a supplemental animal drug application for which safety or effectiveness data are required, for applications subject to the criteria set forth in section 512(d)(4) of the FD&amp;C Act, and for an application for conditional approval under section 571 of the FD&amp;C Act of a new animal drug for which an animal drug application submitted under section 512(b)(1) of the FD&amp;C Act has been previously approved under section 512(d)(1) for another intended use will have to be $310,846.
                    <PRTPAGE P="48132"/>
                </P>
                <HD SOURCE="HD1">IV. Animal Drug Product Fee Calculations for FY 2027</HD>
                <HD SOURCE="HD2">A. Product Fee Revenues and Numbers of Fee-Paying Products</HD>
                <P>Section 740(a)(2) of the FD&amp;C Act specifies that the animal drug product fee must be paid annually by the person named as the applicant in a new animal drug application or supplemental new animal drug application for an animal drug product submitted for listing under section 510 of the FD&amp;C Act (21 U.S.C. 360) and who had an animal drug application or supplemental animal drug application pending at FDA after September 1, 2003. The term “animal drug product” means each specific strength or potency of a particular active ingredient or ingredients in final dosage form marketed by a particular manufacturer or distributor, which is uniquely identified by the labeler code and product code portions of the National Drug Code, and for which an animal drug application or a supplemental animal drug application has been approved (see section 739(3) of the FD&amp;C Act). The product fees are to be set so that they will generate $8,728,560 in fee revenue for FY 2027.</P>
                <P>To set animal drug product fees to realize $8,728,560, FDA must make some assumptions about the number of products for which these fees will be paid in FY 2027. FDA developed data on all animal drug products that have been submitted for listing under section 510 of the FD&amp;C Act and matched this to the list of all persons who had an animal drug application or a supplemental animal drug application pending after September 1, 2003. As of May 2025, FDA estimates that there are 724 products submitted for listing by persons who had an animal drug application or supplemental animal drug application pending after September 1, 2003. Based on this, FDA estimates that a total of 724 products will be subject to this fee in FY 2027.</P>
                <P>In estimating the fee revenue to be generated by animal drug product fees in FY 2027, FDA is assuming that 2 percent of the products invoiced, or 14, will not pay fees in FY 2027, due to fee waivers and reductions. FDA has made this estimate at 2 percent this year, based on historical data over the past 5 completed fiscal years of the ADUFA program.</P>
                <P>Accordingly, the Agency estimates that a total of 710 (724 minus 14) products will be subject to product fees in FY 2027.</P>
                <HD SOURCE="HD2">B. Product Fee Rates for FY 2027</HD>
                <P>FDA must set the fee rates for FY 2027 so that the estimated 710 products for which fees are paid will generate a total of $8,728,560. To generate this amount will require the fee for an animal drug product, rounded to the nearest dollar, to be $12,294.</P>
                <HD SOURCE="HD1">V. Animal Drug Establishment Fee Calculations for FY 2027</HD>
                <HD SOURCE="HD2">A. Establishment Fee Revenues and Numbers of Fee-Paying Establishments</HD>
                <P>Section 740(a)(3) of the FD&amp;C Act states that the animal drug establishment fee must be paid annually by the person who: (1) owns or operates, directly or through an affiliate, an animal drug establishment; (2) is named as the applicant in an animal drug application or supplemental animal drug application for an animal drug product submitted for listing under section 510 of the FD&amp;C Act; (3) had an animal drug application or supplemental animal drug application pending at FDA after September 1, 2003; and (4) whose establishment engaged in the manufacture of the animal drug product during the fiscal year. An establishment subject to animal drug establishment fees is assessed only one such fee per fiscal year. The term “animal drug establishment” is defined as a foreign or domestic place of business at one general physical location, consisting of one or more buildings, all of which are within 5 miles of each other, at which one or more animal drug products are manufactured in final dosage form (see section 739(4) of the FD&amp;C Act). The establishment fees are to be set so that they will generate $8,405,280 in fee revenue for FY 2027.</P>
                <P>To set animal drug establishment fees to realize $8,405,280, FDA must make some assumptions about the number of establishments for which these fees will be paid in FY 2027. FDA developed data on all animal drug establishments and matched this to the list of all persons who had an animal drug application or supplemental animal drug application pending after September 1, 2003. As of May 2026, FDA estimates that there are a total of 41 establishments owned or operated by persons who had an animal drug application or supplemental animal drug application pending after September 1, 2003. Based on this, FDA believes that 41 establishments will be subject to this fee in FY 2027.</P>
                <P>In estimating the fee revenue to be generated by animal drug establishment fees in FY 2027, FDA is assuming that 5 percent of the establishments invoiced, or two, will not pay fees in FY 2027 due to fee waivers and reductions. FDA has made this estimate at 5 percent this year, based on historical data over the past 5 completed fiscal years.</P>
                <P>Accordingly, the Agency estimates that a total of 39 establishments (41 minus 2) will be subject to establishment fees in FY 2027.</P>
                <HD SOURCE="HD2">B. Establishment Fee Rates for FY 2027</HD>
                <P>FDA must set the fee rates for FY 2027 so that the fees paid for the estimated 39 establishments will generate a total of $8,405,280. To generate this amount will require the fee for an animal drug establishment, rounded to the nearest dollar, to be $215,520.</P>
                <HD SOURCE="HD1">VI. Animal Drug Sponsor Fee Calculations for FY 2027</HD>
                <HD SOURCE="HD2">A. Sponsor Fee Revenues and Numbers of Fee-Paying Sponsors</HD>
                <P>The animal drug sponsor fee must be paid annually by each person who: (1) is named as the applicant in an animal drug application, except for an approved application for which all subject products have been removed from listing under section 510 of the FD&amp;C Act, or has submitted an investigational animal drug submission that has not been terminated or otherwise rendered inactive and (2) had an animal drug application, supplemental animal drug application, or investigational animal drug submission pending at FDA after September 1, 2003 (see sections 739(6) and 740(a)(4) of the FD&amp;C Act). An animal drug sponsor is subject to only one such fee each fiscal year (see section 740(a)(4) of the FD&amp;C Act). The sponsor fees are to be set so that they will generate $8,728,560 in fee revenue for FY 2027.</P>
                <P>To set animal drug sponsor fees to realize $8,728,560, FDA must make some assumptions about the number of sponsors who will pay these fees in FY 2027. FDA developed data on all animal drug sponsors and matched this to the list of all sponsors who had pending submissions and applications after September 1, 2003. As of May 2026, FDA estimates that a total of 198 sponsors will meet this definition in FY 2027.</P>
                <P>In estimating the fee revenue to be generated by animal drug sponsor fees in FY 2027, FDA is assuming that 70 percent of the sponsors invoiced, or 138, will not pay sponsor fees in FY 2027 due to fee waivers and reductions. FDA has made this estimate at 70 percent this year, based on historical data over the past 5 completed fiscal years of the ADUFA program.</P>
                <P>
                    Accordingly, the Agency estimates that a total of 60 sponsors (198 minus 138) will be subject to and pay sponsor fees in FY 2027.
                    <PRTPAGE P="48133"/>
                </P>
                <HD SOURCE="HD2">B. Sponsor Fee Rates for FY 2027</HD>
                <P>FDA must set the fee rates for FY 2027 so that the estimated 60 sponsors that pay fees will generate a total of $8,728,560. To generate this amount will require the fee for an animal drug sponsor, rounded to the nearest dollar, to be $145,476.</P>
                <HD SOURCE="HD1">VII. Fee Schedule for FY 2027</HD>
                <P>The fee rates for FY 2027 are summarized in table 5.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,12">
                    <TTITLE>Table 5—FY 2027 Fee Rates</TTITLE>
                    <BOXHD>
                        <CHED H="1">Animal drug user fee category</CHED>
                        <CHED H="1">
                            Fee rate for
                            <LI>FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Animal Drug Application Fees:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Animal Drug Application</ENT>
                        <ENT>$621,692</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Supplemental Animal Drug Application for Which Safety or Effectiveness Data are Required,
                            <LI O="xl">Animal Drug Application Subject to the Criteria Set Forth in Section 512(d)(4) of the FD&amp;C Act, or</LI>
                            <LI O="xl">Application for Conditional Approval Under Section 571 of the FD&amp;C Act for Which an Animal Drug Application Submitted Under Section 512(b)(1) of the FD&amp;C Act Has Been Previously Approved Under Section 512(d)(1) for Another Intended Use.</LI>
                        </ENT>
                        <ENT>310,846</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Animal Drug Product Fee</ENT>
                        <ENT>12,294</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Animal Drug Establishment Fee 
                            <SU>1</SU>
                        </ENT>
                        <ENT>215,520</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Animal Drug Sponsor Fee 
                            <SU>2</SU>
                        </ENT>
                        <ENT>145,476</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         An animal drug establishment is subject to only one such fee each fiscal year.
                    </TNOTE>
                    <TNOTE>
                        <SU>2</SU>
                         An animal drug sponsor is subject to only one such fee each fiscal year.
                    </TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">VIII. Fee Waiver or Reduction; Exemption From Fees</HD>
                <P>The types of fee waivers, fee reductions, and exemptions from fees that applied during ADUFA IV still exist in ADUFA V, with one exception. After September 30, 2023, there is no longer an exemption for any person who submits to CVM a supplemental animal drug application relating to a new animal drug application approved under section 512 of the FD&amp;C Act, solely to add the application number to the labeling of the drug in the manner specified in section 503(w) of the FD&amp;C Act.</P>
                <P>Remaining waivers and reductions apply for the following: barriers to innovation; where fees will exceed the cost to review the animal drug application; if the application is related to certain free-choice medicated feeds; if the application is solely for a MUMS indication; or if the sponsor is a small business submitting its first animal drug application. See section 740(d)(1) of the FD&amp;C Act.</P>
                <HD SOURCE="HD2">A. Barrier to Innovation Waivers or Fee Reductions</HD>
                <P>
                    Under section 740(d)(1)(A) of the FD&amp;C Act, an animal drug applicant may qualify for a waiver or reduction of one or more ADUFA fees if the fee would present a significant barrier to innovation because of limited resources available to the applicant or other circumstances. CVM's guidance for industry (GFI) #170, entitled “Animal Drug User Fees and Fee Waivers and Reductions,” 
                    <SU>2</SU>
                    <FTREF/>
                     states that the Agency interprets this provision to mean that a waiver or reduction is appropriate when: (1) the product for which the waiver is being requested is innovative, or the requestor is otherwise pursuing innovative animal drug products or technology and (2) the fee would be a significant barrier to the applicant's ability to develop, manufacture, or market the innovative product or technology. Only those applicants that meet both criteria will qualify for a waiver or reduction in user fees under this provision (see GFI #170 at pp. 6-8). For purposes of determining whether the second criterion would be met based on limited financial resources available to the applicant, FDA has determined an applicant with financial resources of less than $20,000,000 (including the financial resources of the applicant's affiliates), adjusted annually for inflation, has limited resources available. Using the CPI for urban consumers (U.S. city average; not seasonally adjusted; all items; annual index), the inflation-adjusted level for FY 2027 will be $25,493,000; this level represents the financial resource ceiling that will be used to determine if there are limited resources available to an applicant requesting a Barrier to Innovation waiver on financial grounds for FY 2027. Requests for a waiver must be submitted in writing to FDA each fiscal year not later than 180 days from when the fees are due. A waiver granted on Barrier to Innovation grounds (or any of the other grounds listed in section 740(d)(1) of the FD&amp;C Act) is only valid for one fiscal year. If a sponsor is not granted a waiver, they are liable for the fees.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         CVM's GFI #170 is located at: 
                        <E T="03">https://www.fda.gov/media/69918/download.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Exemption or Exception From Fees</HD>
                <P>In addition to the waivers and fee reductions described above, one fee exemption and two exceptions still apply in ADUFA V.</P>
                <P>If an animal drug application, supplemental animal drug application, or investigational submission involves the intentional genomic alteration of an animal that is intended to produce a human medical product, any person who is the named applicant or sponsor of that application or submission will not be subject to sponsor, product, or establishment fees under ADUFA based solely on that application or submission (see section 740(d)(4) of the FD&amp;C Act).</P>
                <P>There is an exception from application fees for animal drug applications submitted under section 512(b)(1) of the FD&amp;C Act by a sponsor who previously applied for conditional approval under section 571 of the FD&amp;C Act for the same product and paid an application fee at the time they applied for conditional approval, provided the sponsor has submitted the application under section 512(b)(1) of the FD&amp;C Act within the timeframe specified in section 571(h) of the FD&amp;C Act. There is also an exception from application fees for previously filed applications that were not approved or were withdrawn (without waiver or refund). Both exceptions are detailed in section 740(a)(1)(C) of the FD&amp;C Act.</P>
                <HD SOURCE="HD1">IX. Procedures for Paying the FY 2027 Fees</HD>
                <HD SOURCE="HD2">A. Application Fees and Payment Instructions</HD>
                <P>
                    The FY 2027 fee established in the new fee schedule must be paid for an animal drug application or supplement subject to fees under ADUFA V that is submitted on or after October 1, 2026. Payments made to FDA must be made in U.S. currency drawn on a U.S. bank 
                    <PRTPAGE P="48134"/>
                    by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov</E>
                    , a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov</E>
                    . Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID or invoice number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID or invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 740(h) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <HD SOURCE="HD2">B. Application Cover Sheet Procedures</HD>
                <P>
                    <E T="03">Step One:</E>
                     Create a user account and password. Log on to the ADUFA website at 
                    <E T="03">https://www.fda.gov/industry/animal-drug-user-fee-act-adufa/</E>
                    animal-drug-user-fee-cover-sheet and, under Application Submission Information, click on “Create ADUFA User Fee Cover Sheet.” For security reasons, each firm applying will be assigned an organization identification number, and each user will also be required to set up a user account and password the first time you use this site. Online instructions will walk you through this process.
                </P>
                <P>
                    <E T="03">Step Two:</E>
                     Create an Animal Drug User Fee Cover Sheet, transmit it to the FDA, and print a copy. After logging into your account with your username and password, complete the steps required to create an Animal Drug User Fee Cover Sheet. One cover sheet is needed for each animal drug application or supplement. Once you are satisfied that the data on the cover sheet is accurate and you have finalized the cover sheet, you will be able to transmit it electronically to the FDA and you will be able to print a copy of your cover sheet showing your unique PIN.
                </P>
                <P>
                    <E T="03">Step Three:</E>
                     Send the payment for your application as described in section IX.A above.
                </P>
                <P>
                    <E T="03">Step Four:</E>
                     Submit your application.
                </P>
                <HD SOURCE="HD2">C. Product, Establishment, and Sponsor Fees</HD>
                <P>By December 31, 2026, FDA will issue invoices and payment instructions for product, establishment, and sponsor fees for FY 2027 using this fee schedule. Payment will be due by January 31, 2027. FDA will issue invoices in November 2027 for any products, establishments, and sponsors subject to fees for FY 2027 that qualify for fees after the December 2026 billing.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15339 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7492]</DEPDOC>
                <SUBJECT>Medical Device User Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov. For information on Medical Device User Fees:</E>
                          
                        <E T="03">https://www.fda.gov/industry/fda-user-fee-programs/medical-device-user-fee-amendments-mdufa.</E>
                          
                        <E T="03">For questions relating to the MDUFA Small Business Program, please visit the Center for Devices and Radiological Health's website:</E>
                          
                        <E T="03">https://www.fda.gov/medical-devices/premarket-submissions/reduced-medical-device-user-fees-small-business-determination-sbd-program.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>The FD&amp;C Act, as amended by MDUFA V, authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. Section 738 of the FD&amp;C Act (21 U.S.C. 379j) establishes fees for certain medical device applications, submissions, supplements, notices, and requests (for simplicity, this document refers to these collectively as “submissions” or “applications”); for periodic reporting on class III devices; and for the registration of certain establishments.</P>
                <P>
                    Under the FD&amp;C Act, the fee rate for each type of submission is set at a specified percentage of the standard fee for a premarket application (a premarket application is a premarket approval application (PMA), a product development protocol (PDP), or a biologics license application (BLA)). The FD&amp;C Act specifies the base fee for a premarket application for each year from FY 2023 through FY 2027; the base fee for a premarket application received by FDA during FY 2027 is $470,000. From this starting point, this document establishes FY 2027 fee rates for certain types of submissions, and for periodic reporting, by applying criteria specified in the FD&amp;C Act. Under statutorily defined conditions, a qualified applicant may receive a fee waiver or may pay a lower small business fee (see sections 738(a)(3)(B), 738(d) and 738(e) of the FD&amp;C Act). For more information on fee waivers, please see Section IX. Small Business Fee Reductions and Fee Waivers.
                    <PRTPAGE P="48135"/>
                </P>
                <P>The FD&amp;C Act specifies the base fee for establishment registration for each year from FY 2023 through FY 2027; the base fee for an establishment registration in FY 2027 is $8,465. Each establishment that is registered (or is required to register) with the Secretary of Health and Human Services under section 510 of the FD&amp;C Act, because such establishment is engaged in the manufacture, preparation, propagation, compounding, or processing of a device, is required to pay the annual fee for establishment registration.</P>
                <HD SOURCE="HD1">II. Total Revenue Amount for FY 2027</HD>
                <P>The total revenue amount for FY 2027 is $418,343,000, as set forth in the statute prior to the inflation adjustment (see section 738(b)(3) of the FD&amp;C Act). MDUFA V directs FDA to use the yearly total revenue amount as a starting point to set the standard fee rates for each fee type. The fee calculations for FY 2027 are described in this document.</P>
                <HD SOURCE="HD2">Inflation Adjustment</HD>
                <P>MDUFA specifies that the $418,343,000 is to be adjusted for inflation increases for FY 2027 using two separate adjustments: one for payroll costs and one for non-payroll costs (see 738(c)(2)). The base inflation adjustment for FY 2027 is the sum of one plus the two separate adjustments and is compounded as specified in the statute (see section 738(c)(2)(C) and 738(c)(2)(B) of the FD&amp;C Act).</P>
                <P>The component of the inflation adjustment for payroll costs is the average annual percent change in the cost of all personnel compensation and benefits (PC&amp;B) paid per full-time equivalent (FTE) position at FDA for the first 3 of the 4 preceding FYs, multiplied by 0.60, or 60 percent (see section 738(c)(2)(C)(i)(I) of the FD&amp;C Act).</P>
                <P>Table 1 summarizes the actual cost and FTE data for the specified FYs, provides the percent change from the previous fiscal year, and provides the average percent change over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent (rounded).</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,7">
                    <TTITLE>Table 1—FDA PC&amp;Bs Each Year and Percent Change</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">FY 2023</CHED>
                        <CHED H="1">FY 2024</CHED>
                        <CHED H="1">FY 2025</CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTE</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent change from previous year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The payroll adjustment is 5.7330 percent multiplied by 60 percent, resulting in 3.4398 percent. The statute specifies that the component of the inflation adjustment for non-payroll costs for FY 2027 is the average annual percent change that occurred in the Consumer Price Index (CPI) for urban consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; Not Seasonally Adjusted; All Items; Annual Index) for the first 3 of the preceding 4 years of available data multiplied by 0.40, or 40 percent (see section 738(c)(2)(C)(i)(II) of the FD&amp;C Act).</P>
                <P>
                    Table 2 provides the summary data and the 3-year average percent change in the specified CPI for the Washington-Arlington-Alexandria area.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         This data is published by the Bureau of Labor Statistics and can be found on its website at: 
                        <E T="03">https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&amp;series_id=CUURS35ASA0,CUUSS35ASA0.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,7">
                    <TTITLE>Table 2—Annual and 3-Year Average Percent Change in Washington-Arlington-Alexandria Area CPI</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>305.317</ENT>
                        <ENT>315.186</ENT>
                        <ENT>321.993</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.1069%</ENT>
                        <ENT>3.2324%</ENT>
                        <ENT>2.1597%</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">3-Year Average Percent Change in CPI</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT>2.8330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The non-payroll adjustment is 2.8330 percent multiplied by 40 percent, resulting in 1.1332 percent. Next, the payroll adjustment (3.4398 percent or 0.034398) is added to the non-payroll adjustment (1.1332 percent or 0.011332), for a total of 4.5730 percent (or 0.045730). To complete the inflation adjustment, 1 (100 percent or 1.0) is added for a total base inflation adjustment of 1.045730 for FY 2027. If the base inflation adjustment for a fiscal year is greater than 1.04, such adjustment shall be considered to be equal to 1.04 (see section 738(c)(2)(C)(ii)(II) of the FD&amp;C Act). The total base inflation adjustment for FY 2027 is 1.04.</P>
                <P>MDUFA V provides for this inflation adjustment to be compounded for FY 2023 and each subsequent fiscal year (see section 738(c)(2)(B) of the FD&amp;C Act). To complete the compounded inflation adjustment for FY 2027, the FY 2026 compounded adjustment (1.167391) is multiplied by the FY 2027 base inflation adjustment (1.040000) to reach the applicable inflation adjustment of 1.214087 (rounded) for FY 2027. We then multiply the total revenue amount for FY 2027 ($418,343,000) by 1.214087, yielding an inflation adjusted total revenue amount of $507,905,000 (rounded to the nearest thousand dollars).</P>
                <HD SOURCE="HD1">III. Adjustments to Base Fee Amounts for FY 2027</HD>
                <P>Under the FD&amp;C Act, all submission fees and the periodic reporting fee are set as a percentage of the standard (full) fee for a premarket application (see section 738(a)(2)(A) and (b)(1)).</P>
                <HD SOURCE="HD2">A. Inflation Adjustment</HD>
                <P>
                    MDUFA specifies that the base fees of $470,000 (premarket application) and $8,465 (establishment registration) are to be adjusted for FY 2027 using the same methodology as that for the total revenue inflation adjustment in section II (see section 738(c)(2)(D)(i) of the FD&amp;C Act). Multiplying the base fees by the compounded inflation adjustment of 
                    <PRTPAGE P="48136"/>
                    1.214087 yields inflation adjusted base fees of $570,621 (premarket application) and $10,277 (establishment registration).
                </P>
                <HD SOURCE="HD2">B. Further Adjustments To Generate the Inflation-Adjusted Total Revenue Amount</HD>
                <P>After the applicable inflation adjustment to fees is done, FDA may increase, if necessary to achieve the inflation adjusted total revenue amount, the base fee amounts on a uniform proportionate basis (see section 738(c)(2)(D)(ii) of the FD&amp;C Act). After this adjustment, if necessary, FDA may further increase the base establishment registration fees to generate the inflation-adjusted total revenue amount (see section 738(c)(3)).</P>
                <P>For FY 2027, further adjustments were required to meet the inflation adjusted total revenue amount of $507,905,000. After increasing base fees, on a uniform proportionate basis, and further increasing establishment registration fees, this yields inflation adjusted base fees of $636,732 (premarket application) and $11,693 (establishment registration).</P>
                <HD SOURCE="HD2">C. MDUFA V Adjustments Solely to Registration Fees</HD>
                <P>MDUFA V has three new potential adjustments that will not change the total revenue amount but may impact collections by increasing or decreasing establishment registration base fees only. These adjustments are the performance improvement adjustment, the hiring adjustment, and the operating reserve adjustment.</P>
                <HD SOURCE="HD3">1. Performance Improvement Adjustment</HD>
                <P>Beginning with FY 2025, this adjustment allows FDA to collect fees in addition to the total revenue amount in FYs 2025, 2026, and 2027, if the Agency meets certain performance goals in FYs 2023, 2024, and 2025. If applicable, this provision further increases base establishment registration fee amounts to achieve an increase in total fee collections equal to the applicable performance improvement adjustment amount, which is set forth in the statute (see section 738(c)(4)). FDA met the FY 2025 Pre-Submission Written Feedback goal and the FY 2024 De Novo Decision goal, which determine the amount of the performance improvement adjustment for FY 2027</P>
                <P>For FY 2027, the performance improvement adjustment amount is equal to the product of (1) the sum of the pre-submission amount in section 738(c)(4)(B)(i)(III)(cc), $40,572,600 and the de novo classification request amount in section 738(c)(4)(B)(ii)(II)(bb), $11,765,400 and (2) the applicable inflation adjustment under section 738(c)(2)(B), 1.214087. See section 738(c)(4)(A)(iii). Thus, for FY 2027, the performance improvement adjustment is equal to the product of $52,338,000 and 1.214087 which results in $63,542,885.</P>
                <HD SOURCE="HD3">2. Hiring Adjustment</HD>
                <P>Beginning with FY 2025, this adjustment provides for the reduction of base establishment registration fees in FYs 2025, 2026, and 2027, if specified hiring goals for FYs 2023, 2024, and 2025 are not met by a certain threshold. The hiring adjustment would serve to decrease the base establishment registration fee amounts, as necessary, to achieve a reduction in total fee collections equal to the hiring adjustment amount, which is set forth in the statute (see section 738(c)(5)).</P>
                <P>FDA met the FY 2025 statutory hiring threshold of 75 hires, so establishment registration fees will not need to be lowered by the hiring adjustment amount in FY 2027.</P>
                <HD SOURCE="HD3">3. Operating Reserve Adjustment</HD>
                <P>For FYs 2023 to 2027, the operating reserve adjustment requires FDA to decrease base establishment registration fees if the amount of operating reserves of carryover user fees exceeds the “designated amount”, and such reduction is necessary to provide for not more than such designated amount of operating reserves of carryover user fees (see section 738(c)(6)(A)).</P>
                <P>The designated amount is equal to the sum of 13 weeks of operating reserves of carryover user fees plus 1 month of operating reserves, as described in 738(c)(8) (see 738(c)(6)(B)).</P>
                <P>To determine the 13-week operating reserves of carryover user fees amount, the FY 2027 inflation-adjusted total revenue amount (from section II), $507,905,000, is added to the inflation-adjusted performance improvement adjustment amount (from section III.C.1), $63,542,885 resulting in $571,447,885. This amount is then divided by 52, and then multiplied by 13. The 13-week operating reserve amount for FY 2027 is $142,861,971.</P>
                <P>To determine the 1 month of operating reserves described in section 738(c)(8) of the FD&amp;C Act, the FY 2027 inflation-adjusted total revenue amount of $507,905,000 is added to the inflation-adjusted performance improvement adjustment amount of $63,542,885, resulting in $571,447,885. This amount is then divided by 12. The 1 month of operating reserves for FY 2027 is $47,620,657.</P>
                <P>For FY 2027, the designated amount is equal to the 13-week operating reserve of $142,861,971 plus the 1 month of operating reserves of $47,620,657, totaling $190,482,628.</P>
                <P>To determine the FY 2026 end-of-year operating reserves of carryover user fees amount, FDA combined the actual collections and obligations at the end of the third quarter (June 2026) and added the forecasted collections and obligations for the fourth quarter of FY 2026 to generate a full year estimate for FY 2026. The estimated end-of-year FY 2026 operating reserves of carryover user fees is $139,866,752 (Note, this amount includes the 1-month reserve).</P>
                <P>Note that under MDUFA V, for the purposes of calculating the operating reserve adjustment, this amount does not include user fee funds considered unappropriated ($26,680,243) or unearned revenue ($89,956,562).</P>
                <P>Because the estimated end-of-year FY 2026 MDUFA operating reserves of carryover user fees amount totaling $139,866,752 does not exceed the FY 2027 designated amount of $190,482,628 FDA will not decrease the base establishment registration fee amounts for FY 2027 to provide for not more than such designated amount.</P>
                <P>As there is a performance improvement adjustment for FY 2027, but no hiring adjustment or operating reserve adjustment, establishment registration fees are increased to achieve an increase in total fee collections for FY 2027 equal to the performance improvement adjustment amount of $63,542,885. After increasing establishment registration fees only, this yields fees of $636,732 (premarket application) and $13,785 (establishment registration).</P>
                <HD SOURCE="HD1">IV. Calculation of Fee Rates</HD>
                <P>As noted in section II, the total revenue amount after the applicable inflation adjustment is $507,905,000 (rounded to the nearest thousand dollars). As noted in section III, the performance improvement adjustment solely to registration fees for FY 2027 is $63,542,885. There is no hiring adjustment or operating reserve adjustment for FY 2027.</P>
                <P>
                    Table 3 provides fee-paying submission counts for the last 3 years and the 3-year average. Historically, FDA has estimated the total number of fee-paying submission counts it expects to receive during the next fiscal year by averaging the number of fee-paying submission counts received in the 3 most recently completed fiscal years; for FY 2027 fee-setting, this would be an average of FY 2023 through FY 2025.
                    <PRTPAGE P="48137"/>
                </P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s100,9,9,9,9">
                    <TTITLE>Table 3—Three-Year Average of Fee-Paying Submissions </TTITLE>
                    <TDESC>[Excluding establishment registration]</TDESC>
                    <BOXHD>
                        <CHED H="1">Application type</CHED>
                        <CHED H="1">
                            FY 2023
                            <LI>actual</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2024
                            <LI>actual</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2025
                            <LI>actual</LI>
                        </CHED>
                        <CHED H="1">
                            3 Yr.
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Full Fee applications</ENT>
                        <ENT>31</ENT>
                        <ENT>20</ENT>
                        <ENT>33</ENT>
                        <ENT>28</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>3</ENT>
                        <ENT>4</ENT>
                        <ENT>3</ENT>
                        <ENT>3</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Panel-Track Supplements</ENT>
                        <ENT>22</ENT>
                        <ENT>26</ENT>
                        <ENT>35</ENT>
                        <ENT>28</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>5</ENT>
                        <ENT>2</ENT>
                        <ENT>2</ENT>
                        <ENT>3</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">De Novo Classifications</ENT>
                        <ENT>26</ENT>
                        <ENT>26</ENT>
                        <ENT>13</ENT>
                        <ENT>22</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>68</ENT>
                        <ENT>47</ENT>
                        <ENT>49</ENT>
                        <ENT>55</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">180-Day Supplements</ENT>
                        <ENT>113</ENT>
                        <ENT>127</ENT>
                        <ENT>130</ENT>
                        <ENT>123</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>12</ENT>
                        <ENT>15</ENT>
                        <ENT>29</ENT>
                        <ENT>19</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Real-Time Supplements</ENT>
                        <ENT>138</ENT>
                        <ENT>157</ENT>
                        <ENT>145</ENT>
                        <ENT>147</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>28</ENT>
                        <ENT>35</ENT>
                        <ENT>42</ENT>
                        <ENT>35</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">510(k)s</ENT>
                        <ENT>1,943</ENT>
                        <ENT>1,754</ENT>
                        <ENT>1,883</ENT>
                        <ENT>1,860</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>2,031</ENT>
                        <ENT>2,066</ENT>
                        <ENT>2,204</ENT>
                        <ENT>2,100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">30-Day Notice (Note also includes counts for 135 Day Supplements)</ENT>
                        <ENT>825</ENT>
                        <ENT>854</ENT>
                        <ENT>893</ENT>
                        <ENT>857</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>53</ENT>
                        <ENT>62</ENT>
                        <ENT>55</ENT>
                        <ENT>57</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">513(g)(21 U.S.C. 360c(g)) Request for Classification Information</ENT>
                        <ENT>82</ENT>
                        <ENT>65</ENT>
                        <ENT>64</ENT>
                        <ENT>70</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>59</ENT>
                        <ENT>68</ENT>
                        <ENT>54</ENT>
                        <ENT>60</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Fee for Periodic Reporting</ENT>
                        <ENT>657</ENT>
                        <ENT>700</ENT>
                        <ENT>713</ENT>
                        <ENT>690</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>22</ENT>
                        <ENT>32</ENT>
                        <ENT>38</ENT>
                        <ENT>31</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Establishment Registrations</ENT>
                        <ENT>30,645</ENT>
                        <ENT>30,280</ENT>
                        <ENT>30,214</ENT>
                        <ENT>30,380</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The information in table 3 is necessary to estimate the amount of revenue that will be collected based on the fee amounts. Tables 4A and 4B display the FY 2027 base fees set in statute (column one) and the inflation adjusted base fees (per calculations in section III.A.) (column two). Using the inflation adjusted fees and the 3-year average of fee-paying submissions, collections are projected to total $449,060,062 which is $58,844,938 lower than the inflation adjusted total revenue amount (in section II). Accordingly, the next step in the fee setting process is to increase the base fee amounts on a uniform proportionate basis to generate the inflation adjusted total revenue amounts (see 738(c)(2)(D)(ii) and table 4A, column three).</P>
                <P>Applying these further adjusted fee rates to the 3-year average of fee-paying submissions, results in estimated total fee collections of $501,089,079 which is still $6,815,921 lower than the inflation adjusted total revenue amount (in Section II). The next step in the fee setting process, after the adjustment in (2)(D) is done, is to increase the base establishment registration fee amount as necessary for total fee collections to generate the inflation adjusted total revenue amount, as adjusted under paragraph (2) (see 738(c)(3)). Accordingly, the base establishment registration fee was increased by $225 for an establishment registration fee rate of $11,693 (see 738(c)(3) and table 4B, column three). The performance improvement adjustment amount is $63,542,885. Per statute, the establishment registration fee is further adjusted to account for the performance improvement adjustment amount. The inflation adjusted establishment registration fee is increased by $2,092 for an establishment registration fee of $13,785. The fees in column three in table 4A and column four in table 4B are those we are establishing for FY 2027, which are the standard fees.</P>
                <GPOTABLE COLS="6" OPTS="L2,nj,i1" CDEF="s50,11,9,14,11,13">
                    <TTITLE>Table 4A—Fees Needed To Achieve New FY 2027 Revenue Target</TTITLE>
                    <BOXHD>
                        <CHED H="1">Application type</CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>statutory</LI>
                            <LI>fees</LI>
                            <LI>(base fees)</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>inflation</LI>
                            <LI>adjusted</LI>
                            <LI>statutory</LI>
                            <LI>base fees</LI>
                        </CHED>
                        <CHED H="1">
                            2027 Fees
                            <LI>adjusted</LI>
                            <LI>to meet</LI>
                            <LI>revenue target</LI>
                            <LI>(uniform</LI>
                            <LI>proportionate</LI>
                            <LI>increase)</LI>
                        </CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average of</LI>
                            <LI>fee-paying</LI>
                            <LI>submissions</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>revenue from</LI>
                            <LI>adjusted fees</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Full Fee Application</ENT>
                        <ENT>$470,000</ENT>
                        <ENT>$570,621</ENT>
                        <ENT>$636,732</ENT>
                        <ENT>28</ENT>
                        <ENT>$17,828,496</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>117,500</ENT>
                        <ENT>142,655</ENT>
                        <ENT>159,183</ENT>
                        <ENT>3</ENT>
                        <ENT>477,549</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Panel-Track Supplement</ENT>
                        <ENT>376,000</ENT>
                        <ENT>456,497</ENT>
                        <ENT>509,386</ENT>
                        <ENT>28</ENT>
                        <ENT>14,262,808</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>94,000</ENT>
                        <ENT>114,124</ENT>
                        <ENT>127,347</ENT>
                        <ENT>3</ENT>
                        <ENT>382,041</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">De Novo Classification Request</ENT>
                        <ENT>141,000</ENT>
                        <ENT>171,186</ENT>
                        <ENT>191,020</ENT>
                        <ENT>22</ENT>
                        <ENT>4,202,440</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>35,250</ENT>
                        <ENT>42,797</ENT>
                        <ENT>47,755</ENT>
                        <ENT>55</ENT>
                        <ENT>2,626,525</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">180-Day Supplement</ENT>
                        <ENT>70,500</ENT>
                        <ENT>85,593</ENT>
                        <ENT>95,510</ENT>
                        <ENT>123</ENT>
                        <ENT>11,747,730</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>17,625</ENT>
                        <ENT>21,398</ENT>
                        <ENT>23,878</ENT>
                        <ENT>19</ENT>
                        <ENT>453,682</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Real-Time Supplement</ENT>
                        <ENT>32,900</ENT>
                        <ENT>39,943</ENT>
                        <ENT>44,571</ENT>
                        <ENT>147</ENT>
                        <ENT>6,551,937</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>8,225</ENT>
                        <ENT>9,986</ENT>
                        <ENT>11,143</ENT>
                        <ENT>35</ENT>
                        <ENT>390,005</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">510(k) Premarket Notification Submission</ENT>
                        <ENT>21,150</ENT>
                        <ENT>25,678</ENT>
                        <ENT>28,653</ENT>
                        <ENT>1,860</ENT>
                        <ENT>53,294,580</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>5,288</ENT>
                        <ENT>6,419</ENT>
                        <ENT>7,163</ENT>
                        <ENT>2,100</ENT>
                        <ENT>15,042,300</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">30-Day Notice</ENT>
                        <ENT>7,520</ENT>
                        <ENT>9,130</ENT>
                        <ENT>10,188</ENT>
                        <ENT>857</ENT>
                        <ENT>8,731,116</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>3,760</ENT>
                        <ENT>4,565</ENT>
                        <ENT>5,094</ENT>
                        <ENT>57</ENT>
                        <ENT>290,358</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">513(g) Request for Classification Information</ENT>
                        <ENT>6,345</ENT>
                        <ENT>7,703</ENT>
                        <ENT>8,596</ENT>
                        <ENT>70</ENT>
                        <ENT>601,720</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small Business</ENT>
                        <ENT>3,173</ENT>
                        <ENT>3,852</ENT>
                        <ENT>4,298</ENT>
                        <ENT>60</ENT>
                        <ENT>257,880</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Fee for Periodic Reporting</ENT>
                        <ENT>16,450</ENT>
                        <ENT>19,972</ENT>
                        <ENT>22,286</ENT>
                        <ENT>690</ENT>
                        <ENT>15,377,340</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <PRTPAGE P="48138"/>
                        <ENT I="03">Small Business</ENT>
                        <ENT>4,113</ENT>
                        <ENT>4,993</ENT>
                        <ENT>5,572</ENT>
                        <ENT>31</ENT>
                        <ENT>172,732</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT>152,691,239</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="7" OPTS="L2,nj,i1" CDEF="s50,11C,9C,24C,16C,11C,13C">
                    <TTITLE>Table 4B—Fees Needed To Achieve New FY 2027 Revenue Target Plus/Minus Adjustments</TTITLE>
                    <BOXHD>
                        <CHED H="1">Application type</CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>statutory</LI>
                            <LI>fees</LI>
                            <LI>(base fees)</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>inflation</LI>
                            <LI>adjusted</LI>
                            <LI>statutory</LI>
                            <LI>base fees</LI>
                        </CHED>
                        <CHED H="1">
                            Adjusted FY 2027 fees to
                            <LI>meet inflation adjusted</LI>
                            <LI>total revenue amount</LI>
                            <LI>(uniform proportionate</LI>
                            <LI>increase + further</LI>
                            <LI>adjustment to</LI>
                            <LI>establishment</LI>
                            <LI>registrations)</LI>
                        </CHED>
                        <CHED H="1">
                            Adjusted FY 2027
                            <LI>fees to meet</LI>
                            <LI>inflation</LI>
                            <LI>adjusted total</LI>
                            <LI>revenue +/−</LI>
                            <LI>adjustments</LI>
                        </CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average of</LI>
                            <LI>fee-paying</LI>
                            <LI>submissions</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>revenue from</LI>
                            <LI>adjusted fees</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Establishment Registrations</ENT>
                        <ENT>$8,465</ENT>
                        <ENT>$10,277</ENT>
                        <ENT>$11,693</ENT>
                        <ENT>$13,785</ENT>
                        <ENT>30,380</ENT>
                        <ENT>
                            $355,233,340 
                            <SU>1</SU>
                        </ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         Excludes additional collections from the performance improvement adjustment.
                    </TNOTE>
                </GPOTABLE>
                <P>The standard fee (adjusted base amount) for a premarket application, including a BLA, and for a premarket report and a BLA efficacy supplement, is $636,732 for FY 2027.</P>
                <P>The fees set by reference to the standard fee for a premarket application are:</P>
                <FP SOURCE="FP-1">• For a panel-track supplement, 80 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For a de novo classification request, 30 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For a 180-day supplement, 15 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For a real-time supplement, 7 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For an annual fee for periodic reporting concerning a class III device, 3.5 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For a 510(k) premarket notification, 4.5 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For a 30-day notice, 1.6 percent of the standard fee</FP>
                <FP SOURCE="FP-1">• For a 513(g) request for classification information, 1.35 percent of the standard fee</FP>
                <P>For all submissions other than a 30-day notice and a 513(g) request for classification information, the small business fee is 25 percent of the standard (full) fee for the submission (see 738(d)(2)(C) and (e)(2)(C)). For a 30-day notice and a 513(g) request for classification information, the small business fee is 50 percent of the standard (full) fee for the submission (see 738(d)(2)(C)).</P>
                <P>The annual fee for establishment registration, after adjustments, is set at $13,785 for FY 2027. For FY 2027, FDA may, but is not required to, grant a waiver of the fee for annual establishment registration (excluding the initial registration) to applicants that qualify as a small business if FDA finds that the establishment is a small business and paying the fee for such a year represents a financial hardship to the establishment as determined by FDA. For more information on reduced fees and waivers for small businesses, please see Section IX. Small Business Fee Reductions and Fee Waivers.</P>
                <P>Table 5 summarizes the FY 2027 rates for all medical device fees.</P>
                <GPOTABLE COLS="4" OPTS="L2,i1" CDEF="s150,r50,12,12">
                    <TTITLE>Table 5—Medical Device Fees for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Application fee type</CHED>
                        <CHED H="1">
                            Standard fee
                            <LI>(as a percentage of the standard fee for a premarket application)</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>standard fee</LI>
                        </CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>small</LI>
                            <LI>business fee</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Premarket Application (a PMA submitted under section 515(c)(1) of the FD&amp;C Act (21 U.S.C. 360e(c)(1)), a PDP submitted under section 515(f) of the FD&amp;C Act, or a BLA submitted under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262))</ENT>
                        <ENT>Base fee specified in statute</ENT>
                        <ENT>$636,732</ENT>
                        <ENT>$159,183</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Premarket Report (submitted under section 515(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>100%</ENT>
                        <ENT>636,732</ENT>
                        <ENT>159,183</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Efficacy Supplement (to an approved BLA under section 351 of the PHS Act)</ENT>
                        <ENT>100%</ENT>
                        <ENT>636,732</ENT>
                        <ENT>159,183</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Panel-Track Supplement</ENT>
                        <ENT>80%</ENT>
                        <ENT>509,386</ENT>
                        <ENT>127,347</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">De Novo Classification Request</ENT>
                        <ENT>30%</ENT>
                        <ENT>191,020</ENT>
                        <ENT>47,755</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">180-Day Supplement</ENT>
                        <ENT>15%</ENT>
                        <ENT>95,510</ENT>
                        <ENT>23,878</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Real-Time Supplement</ENT>
                        <ENT>7%</ENT>
                        <ENT>44,571</ENT>
                        <ENT>11,143</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">510(k) Premarket Notification Submission</ENT>
                        <ENT>4.5%</ENT>
                        <ENT>28,653</ENT>
                        <ENT>7,163</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">30-Day Notice</ENT>
                        <ENT>1.60%</ENT>
                        <ENT>10,188</ENT>
                        <ENT>5,094</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">513(g) Request for Classification Information</ENT>
                        <ENT>1.35%</ENT>
                        <ENT>8,596</ENT>
                        <ENT>4,298</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Annual Fee Type:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Annual Fee for Periodic Reporting on a class III device</ENT>
                        <ENT>3.50%</ENT>
                        <ENT>22,286</ENT>
                        <ENT>5,572</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="48139"/>
                        <ENT I="03">Annual Establishment Registration Fee (to be paid by the establishment engaged in the manufacture, preparation, propagation, compounding, or processing of a device, as defined by 21 U.S.C. 379i(14))</ENT>
                        <ENT>Base fee specified in statute</ENT>
                        <ENT>13,785</ENT>
                        <ENT>13,785</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">V. How To Qualify as a Small Business for Purposes of Medical Device Fees</HD>
                <P>
                    If your business, including your affiliates, has gross receipts or sales of no more than $100 million for your most recent tax year, you may qualify for reduced small business fees. If your business, including your affiliates, has gross receipts or sales of no more than $30 million for your most recent tax year, you may also qualify for a waiver of the fee for your first premarket application (
                    <E T="03">i.e.,</E>
                     PMA, PDP, or BLA) or premarket report. If you want to pay the small business fee rate for a submission or you want to receive a waiver of the fee for your first premarket application or premarket report, you must submit the materials showing you qualify as a small business at least 60 days before any applicable fee is due to FDA. For more information on fee waivers or reductions, please see Section IX. Small Business Fee Reductions and Fee Waivers.
                </P>
                <P>
                    For FY 2027, FDA may, but is not required to, grant a waiver of the annual establishment registration fee (excluding the initial registration) to applicants that qualify as a small business if FDA finds that the establishment is a small business and paying the fee for such a year represents a financial hardship to the establishment as determined by FDA. For the purpose of the annual registration fee waiver, a small business is defined as one with $1,000,000 or less in gross receipts or sales in the most recent Federal (U.S.) income tax return (including the returns of its affiliates).
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         See Medical Device User Fee Small Business Qualification and Determination guidance (
                        <E T="03">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-user-fee-small-business-qualification-and-determination</E>
                        ).
                    </P>
                </FTNT>
                <P>If your business qualified as a small business for FY 2026, your status as a small business will expire at the close of business on September 30, 2026. You must re-qualify for FY 2027 in order to pay small business fees during FY 2027.</P>
                <HD SOURCE="HD2">A. Domestic (U.S.) Businesses</HD>
                <P>If you are a domestic (U.S.) business and wish to qualify as a small business for FY 2027, submit the following to FDA:</P>
                <P>
                    <E T="03">1.</E>
                     A completed MDUFA Small Business Request form. The most current FDA Form may be found in the FDA Forms database: 
                    <E T="03">https://www.fda.gov/about-fda/reports-manuals-forms/forms.</E>
                </P>
                <P>2. A signed copy of your Federal (U.S.) income tax return for the most recent tax year. The most recent tax year will be 2026, except:</P>
                <P>• If you submit your MDUFA Small Business Request for FY 2027 before April 15, 2027, and you have not yet filed your return for 2026, you may use tax year 2025.</P>
                <P>• If you submit your MDUFA Small Business Request for FY 2027 on or after April 15, 2027, and have not yet filed your 2026 return because you obtained an extension, you may submit your most recent tax return filed prior to the extension.</P>
                <P>3. For each of your affiliates, either:</P>
                <P>• If the affiliate is a domestic (U.S.) business, a signed copy of the affiliate's Federal (U.S.) income tax return for the most recent tax year, or</P>
                <P>• If the affiliate is a foreign business and cannot submit a Federal (U.S.) income tax return, a National Taxing Authority Certification completed by, and bearing the official seal of, the National Taxing Authority, if extant, of the country in which the business is headquartered. The National Taxing Authority is the foreign equivalent of the U.S. Internal Revenue Service. This certification must show the amount of gross receipts or sales for the most recent tax year, in both U.S. dollars and the local currency of the country, the exchange rate used in converting the local currency to U.S. dollars, and the dates during which these receipts or sales were collected. The business must also submit a statement signed by the head of the business's firm or by its chief financial officer that the business has submitted certifications for all of its affiliates, identifying the name of each affiliate, or that the business has no affiliates.</P>
                <P>
                    • If your affiliate is headquartered in a country without a National Taxing Authority, please contact the Division of Industry and Consumer Education at 800-638-2041 or 301-796-7100 or email at 
                    <E T="03">DICE@fda.hhs.gov.</E>
                </P>
                <P>
                    4. Once you have completed and signed the most current FDA Form for a MDUFA Small Business Request, submit your form and your supporting documentation (copies of the Federal (U.S.) income tax returns), using the instructions which are available at the following website: 
                    <E T="03">https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm577696.htm.</E>
                </P>
                <P>
                    If you need assistance, please contact the Division of Industry and Consumer Education at 800-638-2041 or 301-796-7100 or email at 
                    <E T="03">DICE@fda.hhs.gov.</E>
                </P>
                <HD SOURCE="HD2">B. Foreign Businesses</HD>
                <P>If you are a foreign business, and wish to qualify as a small business for FY 2027, submit the following:</P>
                <P>
                    1. A completed MDUFA Small Business Request form. The most current FDA Form is provided in the FDA Forms database: 
                    <E T="03">https://www.fda.gov/about-fda/reports-manuals-forms/forms.</E>
                </P>
                <P>2. A National Taxing Authority Certification, completed by, and bearing the official seal of, the National Taxing Authority, if extant, of the country in which the business is headquartered. This certification must show the amount of gross receipts or sales for the most recent tax year, in both U.S. dollars and the local currency of the country, the exchange rate used in converting the local currency to U.S. dollars, and the dates during which these receipts or sales were collected.</P>
                <P>
                    If your business is headquartered in a country without a National Taxing Authority, please contact the Division of Industry and Consumer Education at 800-638-2041 or 301-796-7100 or email at 
                    <E T="03">DICE@fda.hhs.gov.</E>
                </P>
                <P>3. For each of your affiliates, either:</P>
                <P>• If the affiliate is a domestic (U.S.) business, a signed copy of the affiliate's Federal (U.S.) income tax return for the most recent tax year (2025 or later), or</P>
                <P>
                    • If the affiliate is a foreign business and cannot submit a Federal (U.S.) income tax return, a National Taxing Authority Certification completed by, and bearing the official seal of, the National Taxing Authority, if extant, of the country in which the business is headquartered. The National Taxing 
                    <PRTPAGE P="48140"/>
                    Authority is the foreign equivalent of the U.S. Internal Revenue Service. This certification must show the amount of gross receipts or sales for the most recent tax year, in both U.S. dollars and the local currency of the country, the exchange rate used in converting the local currency to U.S. dollars, and the dates during which these receipts or sales were collected. The business must also submit a statement signed by the head of the business's firm or by its chief financial officer that the applicant has submitted certifications for all of its affiliates, identifying the name of each affiliate, or that the business has no affiliates.
                </P>
                <P>
                    • If your affiliate is headquartered in a country without a National Taxing Authority, please contact the Division of Industry and Consumer Education at 800-638-2041 or 301-796-7100 or email at 
                    <E T="03">DICE@fda.hhs.gov.</E>
                </P>
                <P>
                    4. Once you have completed and signed the most current MDUFA Small Business request, submit your form and your supporting documentation, including the following, using the instructions which are available at the following website: 
                    <E T="03">https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm577696.htm.</E>
                </P>
                <P>• A copy of the most recent Federal (U.S.) income tax return for each of your affiliates headquartered in the U.S. and</P>
                <P>• A National Taxing Authority Certification for each of your foreign affiliates.</P>
                <P>
                    If you need assistance, please contact the Division of Industry and Consumer Education at 800-638-2041 or 301-796-7100 or email at 
                    <E T="03">DICE@fda.hhs.gov.</E>
                </P>
                <HD SOURCE="HD1">VI. Procedures for Paying Application Fees</HD>
                <P>If your application or submission is subject to a fee and your payment is received by FDA between October 1, 2026, and September 30, 2027, you must pay the fee in effect for FY 2027. To avoid delay in the review of your application, you should pay the application fee at the time you submit your application to FDA. The later of the date that the application is received in the reviewing center's document room or the date the U.S. Treasury recognizes the payment determines whether the fee rates for FY 2026 or FY 2027 apply. FDA must receive the correct fee at the time that an application is submitted, or the application will not be accepted for filing or review.</P>
                <P>FDA requests that you follow the steps below before submitting a medical device application subject to a fee to ensure that FDA links the fee with the correct application.</P>
                <HD SOURCE="HD2">A. Secure a Payment Identification Number (PIN) and Medical Device User Fee Cover Sheet From FDA Before Submitting Either the Application or the Payment</HD>
                <P>
                    Log into the User Fee System at: 
                    <E T="03">https://userfees.fda.gov/OA_HTML/mdufmaCAcdLogin.jsp.</E>
                     Complete the Medical Device User Fee cover sheet. Be sure you choose the correct application submission date range. (Two choices will be offered until October 1, 2026. One choice is for applications and fees that will be received on or before September 30, 2026, which are subject to FY 2026 fee rates. A second choice is for applications and fees received on or after October 1, 2026, which are subject to FY 2027 fee rates.) After completing data entry, print a copy of the Medical Device User Fee cover sheet and note the unique PIN located in the upper right-hand corner of the printed cover sheet.
                </P>
                <HD SOURCE="HD2">B. Electronically Transmit a Copy of the Printed Cover Sheet With the PIN</HD>
                <P>When you are satisfied that the data on the cover sheet is accurate, electronically transmit that data to FDA according to instructions on the screen. Applicants are required to set up a user account and password to assure data security in the creation and electronic submission of cover sheets.</P>
                <HD SOURCE="HD2">C. Submit Payment for the Completed Medical Device User Fee Cover Sheet</HD>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov,</E>
                     a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov.</E>
                     Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID or invoice number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID or invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the United States Government (see 738(i) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <P>FDA records the official application receipt date as the later of the following: (1) the date the application was received by the FDA Document Control Center for the reviewing Center or (2) the date the U.S. Treasury recognizes the payment.</P>
                <HD SOURCE="HD2">D. Submit Your Application to FDA With a Copy of the Completed Medical Device User Fee Cover Sheet</HD>
                <P>
                    Please submit your application and a copy of the completed Medical Device User Fee cover sheet to the address located at 
                    <E T="03">https://www.fda.gov/cdrhsubmissionaddress.</E>
                </P>
                <HD SOURCE="HD1">VII. Procedures for Paying the Annual Fee for Periodic Reporting</HD>
                <P>You will be invoiced at the end of the quarter in which your PMA Periodic Report is due. Invoices will be sent based on the details included on your PMA file. You are responsible for ensuring FDA has your current billing information, and you may update your contact information for the PMA by submitting an amendment to the pending PMA or a supplement to the approved PMA.</P>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, 
                    <PRTPAGE P="48141"/>
                    American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov,</E>
                     a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                    feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov</E>
                    . Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID or invoice number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID or invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the United States Government (see 738(i) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <HD SOURCE="HD1">VIII. Procedures for Paying Annual Establishment Registration Fees</HD>
                <P>
                    To pay the annual establishment registration fee, firms must access the Device Facility User Fee (DFUF) website at 
                    <E T="03">https://userfees.fda.gov/OA_HTML/furls.jsp.</E>
                     (FDA has verified the website address, but FDA is not responsible for any subsequent changes to the website address after this document is published in the 
                    <E T="04">Federal Register</E>
                    .) Create a DFUF order and you will be issued a PIN when you place your order. After payment has been processed, you will be issued a payment confirmation number (PCN). You will not be able to register your establishment if you do not have a PIN and a PCN. An establishment required to pay an annual establishment registration fee is not legally registered in FY 2027 until it has completed the steps below to register and pay any applicable fee (see 738(f)(2)).
                </P>
                <P>Companies that do not manufacture any product other than a licensed biologic are required to register in the Blood Establishment Registration (BER) system. FDA's Center for Biologics Evaluation and Research (CBER) will send establishment registration fee invoices annually to these companies.</P>
                <HD SOURCE="HD2">A. Submit a DFUF Order With a PIN From FDA Before Registering or Submitting Payment</HD>
                <P>To submit a DFUF Order, you must create or have previously created a user account and password for the user fee website listed previously in this section. After creating a username and password, log into the Establishment Registration User Fee FY 2027 store. Complete the DFUF order by entering the number of establishments you are registering that require payment. When you are satisfied that the information in the order is accurate, electronically transmit that data to FDA according to instructions on the screen. Print a copy of the final DFUF order and note the unique PIN located in the upper right-hand corner of the printed order.</P>
                <P>
                    If you have an approved small business waiver, please contact 
                    <E T="03">FDAUserFees@fda.hhs.gov</E>
                     for further instructions.
                </P>
                <HD SOURCE="HD2">B. Pay for Your DFUF Order</HD>
                <P>Unless paying by U.S. credit card, all payments must be in U.S. currency and drawn on a U.S. bank.</P>
                <P>
                    1. 
                    <E T="03">If paying by credit card or electronic check (ACH or eCheck):</E>
                     The DFUF order will include payment information, including details on how you can pay online using a credit card or electronic check. Follow the instructions provided to make an electronic payment.
                </P>
                <P>
                    2. 
                    <E T="03">If paying with a wire transfer:</E>
                     Wire transfers may also be used to pay annual establishment registration fees. To send a wire transfer, please read and comply with the following information:
                </P>
                <P>Include your order's unique PIN (in the upper right-hand corner of your completed DFUF order) in your wire transfer. Without the PIN, your payment may not be applied to your facility, and your registration may be delayed.</P>
                <P>The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the United States Government (see section 738(i) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <HD SOURCE="HD2">C. Complete the Information Online To Update Your Establishment's Annual Registration for FY 2027, or To Register a New Establishment for FY 2027</HD>
                <P>
                    Go to the Center for Devices and Radiological Health's website at 
                    <E T="03">https://www.fda.gov/medical-devices/how-study-and-market-your-device/device-registration-and-listing</E>
                     and click the “Access Electronic Registration” link on the left side of the page. This opens a new page with important information about the FDA Unified Registration and Listing System (FURLS). After reading this information, click on the “Access Electronic Registration” link in the middle of the page. This link takes you to an FDA Industry Systems page with tutorials that demonstrate how to create a new FURLS user account if your establishment did not create an account in FY 2026. Manufacturers of licensed biologics should register in the electronic Blood Establishment Registration (eBER) system at 
                    <E T="03">https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-establishment-registration.</E>
                </P>
                <P>
                    Enter your existing account ID and password to log into FURLS. From the FURLS/FDA Industry Systems menu, click on the Device Registration and Listing Module (DRLM) of FURLS button. New establishments will need to register, and existing establishments will update their annual registration using choices on the DRLM menu. When you choose to register or update your annual registration, the system will prompt you through the entry of information about your establishment and your devices. If you have any problems with this process, email: 
                    <E T="03">reglist@cdrh.fda.gov</E>
                     or call 301-796-7400 for assistance. (
                    <E T="03">Note:</E>
                     This email address and this telephone number are for assistance with establishment registration only; they are not to be used for questions related to other aspects of medical device user fees.) Problems with the eBER system should be directed to: 
                    <E T="03">
                        https://www.accessdata.fda.gov/scripts/email/
                        <PRTPAGE P="48142"/>
                        cber/bldregcontact.cfm
                    </E>
                     or call 240-402-8360.
                </P>
                <HD SOURCE="HD2">D. Enter Your DFUF Order PIN and PCN</HD>
                <P>After completing your annual or initial registration and device listing, you will be prompted to enter your DFUF order PIN and PCN, when applicable. This process does not apply to establishments engaged only in the manufacture, preparation, propagation, compounding, or processing of licensed biologic devices. CBER will send invoices for payment of the establishment registration fee to such establishments.</P>
                <HD SOURCE="HD1">IX. Small Business Fee Reductions and Fee Waivers</HD>
                <P>To qualify for reduced fees for small businesses or a small business fee waiver, please see the requirements for qualification provided in Section V. How To Qualify as a Small Business for Purposes of Medical Device Fees. The applicant should submit a MDUFA Small Business Request form and the supporting materials showing you qualify as a small business at least 60 days before any applicable fee is due to FDA. FDA will review your information and determine whether you qualify as a small business eligible for the reduced fee and/or fee waiver. If you make a submission before FDA finds that you qualify as a small business, you must pay the standard (full) fee for that submission.</P>
                <P>
                    If you need assistance, please contact the Division of Industry and Consumer Education at 800-638-2041 or 301-796-7100 or email at 
                    <E T="03">DICE@fda.hhs.gov.</E>
                </P>
                <HD SOURCE="HD2">A. Premarket Approval Fee Reduction or Waiver</HD>
                <P>A small business applicant may request to pay a reduced rate for premarket approval fees. An applicant may also request a fee waiver for their first premarket application or premarket report (738(d)).</P>
                <HD SOURCE="HD2">B. Premarket Notification Submission Fee Reduction</HD>
                <P>A small business applicant may request to pay a reduced rate for a premarket notification submission.</P>
                <HD SOURCE="HD2">C. Annual Establishment Registration Fee Waiver</HD>
                <P>For FY 2027, FDA may, but is not required to, grant a waiver of the annual establishment registration fee (excluding the initial registration) to applicants that qualify as a small business if FDA finds that the establishment is a small business and paying the fee for such a year represents a financial hardship to the establishment as determined by FDA.</P>
                <HD SOURCE="HD1">X. Refunds</HD>
                <P>To qualify for consideration for a refund, a person shall submit to FDA a written request for a refund not later than 180 days after such fee is due. For more information on qualifying and submitting a refund, see section 738(a)(2)(D) of the FD&amp;C Act (21 U.S.C. 379j(a)(2)(D)).</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15335 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7397]</DEPDOC>
                <SUBJECT>Outsourcing Facility Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). The FD&amp;C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2027 rates for the small business establishment fee ($7,142), the non-small business establishment fee ($22,074), and the reinspection fee ($21,427) for outsourcing facilities; provides information on how the fees for FY 2027 were determined; and describes the payment procedures outsourcing facilities should follow.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>These fee rates are effective October 1, 2026, and will remain in effect through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For more information on human drug compounding and outsourcing facility fees, visit FDA's website at: 
                        <E T="03">https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding. For questions relating to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Under section 503B of the FD&amp;C Act (21 U.S.C. 353b), a human drug compounder can register with FDA as an “outsourcing facility.” Outsourcing facilities, as defined in section 503B(d)(4), are, in part, facilities that meet all the conditions described in section 503B(a), including registering with FDA as an outsourcing facility and paying an annual establishment fee. If the conditions of section 503B are met, a drug compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility is exempt from three sections of the FD&amp;C Act: (1) section 502(f)(1) (21 U.S.C. 352(f)(1)), concerning the labeling of drugs with adequate directions for use; (2) section 505 (21 U.S.C. 355), concerning the approval of human drug products under new drug applications or abbreviated new drug applications; and (3) section 582 (21 U.S.C. 360eee-1), concerning drug supply chain security requirements. Drugs compounded in outsourcing facilities are not exempt from the requirements of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), concerning current good manufacturing practice requirements for drugs.</P>
                <P>Section 744K of the FD&amp;C Act (21 U.S.C. 379j-62) authorizes FDA to assess and collect the following fees associated with outsourcing facilities: (1) an annual establishment fee from each outsourcing facility and (2) a reinspection fee from each outsourcing facility subject to a reinspection (see section 744K(a)(1) of the FD&amp;C Act). Under statutorily defined conditions, a qualified applicant may pay a reduced small business establishment fee (see section 744K(c)(4) of the FD&amp;C Act).</P>
                <P>
                    FDA announced in the 
                    <E T="04">Federal Register</E>
                     of November 24, 2014 (79 FR 69856), the availability of a final guidance for industry entitled “Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&amp;C Act.” The guidance provides additional information on the annual fees for outsourcing facilities and adjustments required by law, reinspection fees, how to submit payment, the effect of failure to pay fees, and how to qualify as a small business to obtain a reduction of the annual establishment fee. This guidance can be accessed on FDA's website at: 
                    <E T="03">https://www.fda.gov/media/136683/download.</E>
                    <PRTPAGE P="48143"/>
                </P>
                <HD SOURCE="HD1">II. Fees for FY 2027</HD>
                <HD SOURCE="HD2">A. Methodology for Calculating FY 2027 Adjustment Factors</HD>
                <HD SOURCE="HD3">1. Inflation Adjustment Factor</HD>
                <P>Section 744K(c)(2) of the FD&amp;C Act specifies the annual inflation adjustment for outsourcing facility fees. The inflation adjustment has two components: one based on FDA's payroll costs and one based on FDA's non-payroll costs for the first 3 of the 4 previous fiscal years. The payroll component of the annual inflation adjustment is calculated by taking the average change in FDA's per full-time equivalent (FTE) personnel compensation and benefits (PC&amp;B) in the first 3 of the 4 previous fiscal years (see section 744K(c)(2)(A)(ii) of the FD&amp;C Act). FDA's total annual spending on PC&amp;B is divided by the total number of FTEs per fiscal year to determine the average PC&amp;B per FTE.</P>
                <P>Table 1 summarizes the actual cost and FTE data for the specified fiscal years and provides the percent change from the previous fiscal year and the average percent change over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 1—FDA PC&amp;Bs Each Year and Percent Change</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">FY 2023</CHED>
                        <CHED H="1">FY 2024</CHED>
                        <CHED H="1">FY 2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTEs</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent Change from Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 744K(c)(2)(A)(ii) of the FD&amp;C Act specifies that this 5.7330 percent should be multiplied by the proportion of PC&amp;B to total costs of an average FDA FTE for the same 3 fiscal years.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 2—FDA PC&amp;Bs as a Percent of FDA Total Costs of an Average FTE</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">FY 2023</CHED>
                        <CHED H="1">FY 2024</CHED>
                        <CHED H="1">FY 2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B (proportion of costs)</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>$6,654,058,000</ENT>
                        <ENT>$6,976,495,000</ENT>
                        <ENT>$6,809,369,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B percent</ENT>
                        <ENT>51.6454%</ENT>
                        <ENT>54.3501%</ENT>
                        <ENT>56.9207%</ENT>
                        <ENT>54.3054%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The payroll adjustment is 5.7330 percent multiplied by 54.3054 percent, or 3.1133 percent.</P>
                <P>Section 744K(c)(2)(A)(iii) of the FD&amp;C Act specifies that the portion of the inflation adjustment for non-payroll costs for FY 2027 is equal to the average annual percent change in the Consumer Price Index (CPI) for urban consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data, multiplied by the proportion of all non-PC&amp;B costs to total costs of an average FDA FTE for the same period.</P>
                <P>
                    Table 3 provides the summary data for the percent change in the specified CPI for U.S. cities. These data are published by the Bureau of Labor Statistics and can be found on its website: 
                    <E T="03">https://data.bls.gov/cgi-bin/surveymost?cu.</E>
                     The data can be viewed by checking the box marked “U.S. city average, All items—CUUR0000SA0” and then selecting “Retrieve Data.”
                </P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 3—Annual and 3-Year Average Percent Change in U.S. City Average CPI</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>304.702</ENT>
                        <ENT>313.689</ENT>
                        <ENT>321.943</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>4.1165%</ENT>
                        <ENT>2.9494%</ENT>
                        <ENT>2.6313%</ENT>
                        <ENT>3.2324%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 744K(c)(2)(A)(iii) of the FD&amp;C Act specifies that this 3.2324 percent should be multiplied by the proportion of all non-PC&amp;B costs to total costs of an average FTE for the same 3 fiscal years. The proportion of all non-PC&amp;B costs to total costs of an average FDA FTE for FYs 2023 to 2025 is 45.6946 percent (100 percent minus 54.3054 percent equals 45.6946 percent). Therefore, the non-pay adjustment is 3.2324 percent times 45.6946 percent, or 1.4770 percent.</P>
                <P>The PC&amp;B component (3.1133 percent) is added to the non-PC&amp;B component (1.4770 percent), for a total inflation adjustment of 4.5903 percent (rounded). Section 744K(c)(2)(A)(i) of the FD&amp;C Act specifies that one is added to that figure, making the inflation adjustment 1.045903.</P>
                <P>
                    Section 744K(c)(2)(B) of the FD&amp;C Act provides for this inflation adjustment to be compounded after FY 2015. This factor for FY 2027 (4.5903 percent) is compounded by adding one to it, and then multiplying it by one plus the inflation adjustment factor for FY 2026 (36.5750 percent), as published in the 
                    <E T="04">Federal Register</E>
                     on July 30, 2025 (90 FR 35903). The result of this multiplication of the inflation factors for the 12 years since FY 2015 (1.045903 × 1.365750) becomes the inflation adjustment for FY 2027. For FY 2027, the inflation adjustment is 42.8442 percent (rounded). We then add one, making the FY 2027 inflation adjustment factor 1.428442.
                </P>
                <HD SOURCE="HD3">2. Small Business Adjustment Factor</HD>
                <P>
                    Section 744K(c)(3) of the FD&amp;C Act specifies that in addition to the inflation adjustment factor, the establishment fee for non-small businesses is to be further adjusted for a small business adjustment factor. Section 744K(c)(3)(B) of the FD&amp;C Act provides that the small business adjustment factor is the adjustment to the establishment fee for non-small businesses that is necessary 
                    <PRTPAGE P="48144"/>
                    to achieve total fees equaling the amount that FDA would have collected if no entity qualified for the small business exception in section 744K(c)(4) of the FD&amp;C Act. Additionally, section 744K(c)(5)(A) states that in establishing the small business adjustment factor for a fiscal year, FDA shall provide for the crediting of fees from the previous year to the next year if FDA overestimated the amount of the small business adjustment factor for such previous fiscal year.
                </P>
                <P>
                    Therefore, to calculate the small business adjustment to the establishment fee for non-small businesses for FY 2027, FDA must estimate: (1) the number of outsourcing facilities that will pay the reduced fee for small businesses for FY 2027 and (2) the total fee revenue it would have collected if no entity had qualified for the small business exception (
                    <E T="03">i.e.,</E>
                     if each entity that registers as an outsourcing facility for FY 2027 were to pay the inflation-adjusted fee amount of $21,427).
                </P>
                <P>With respect to (1), FDA estimates that 8 entities will qualify for small business exceptions and will pay the reduced fee for FY 2027. With respect to (2), to estimate the total number of entities that will register as outsourcing facilities for FY 2027, FDA used data submitted by outsourcing facilities through the voluntary registration process, which began in December 2013. Accordingly, FDA estimates that 87 outsourcing facilities, including 8 small businesses, will be registered with FDA in FY 2027.</P>
                <P>If the projected 87 outsourcing facilities paid the full inflation-adjusted fee of $21,427, this would result in total revenue of $1,864,149 in FY 2027 ($21,427 × 87). However, 8 of the entities that are expected to register as outsourcing facilities for FY 2027 are projected to qualify for the small business exception and to pay one-third of the full fee ($7,142 × 8), totaling $57,136 instead of paying the full fee ($21,427 × 8), which would total $171,416. This would leave a potential shortfall of $114,280 ($171,416 minus $57,136).</P>
                <P>Additionally, section 744K(c)(5)(A) of the FD&amp;C Act states that in establishing the small business adjustment factor for a fiscal year, FDA shall provide for the crediting of fees from the previous year to the next year if FDA overestimated the amount of the small business adjustment factor for such previous fiscal year. FDA has determined that it is appropriate to credit excess fees collected from the last completed fiscal year, due to the inability to conclusively determine the amount of excess fees from the fiscal year that is in progress at the time this calculation is made. This crediting is done by comparing the small business adjustment factor for the last completed fiscal year, FY 2025 ($2,069), to what would have been the small business adjustment factor for FY 2025 ($1,342) if FDA had estimated perfectly.</P>
                <P>
                    The calculation for what the small business adjustment would have been if FDA had estimated perfectly begins by determining the total target collections (15,000 × [inflation adjustment factor] × [number of registrants]). For the most recent complete fiscal year, FY 2025, this was $1,868,640 ($19,465 × 96). The actual FY 2025 revenue from the 96 total registrants (
                    <E T="03">i.e.,</E>
                     87 registrants paying FY 2025 non-small business establishment fee and 9 small business registrants) paying establishment fees is $1,751,847. $1,751,847 is calculated as follows: (FY 2025 Non-Small Business Establishment Fee adjusted for inflation only) × (total number of registrants in FY 2025 paying Non-Small Business Establishment Fee) + (FY 2025 Small Business Establishment Fee) × (total number of small business registrants in FY 2025 paying Small Business Establishment Fee). $19,465 × 87 + $6,488 × 9 = $1,751,847. This left a shortfall of $116,793 from the estimated total target collection amount ($1,868,640 minus $1,751,847). This amount ($116,793) divided by the total number of registrants in FY 2025 paying Standard Establishment Fee (87) equals $1,342.
                </P>
                <P>The difference between the small business adjustment factor used in FY 2025 and the small business adjustment factor that would have been used had FDA estimated perfectly is $726 ($2,069 minus $1,342). The $726 is then multiplied by the number of actual registrants who paid the standard fee for FY 2025 (87), which provides a total excess collection of $63,192 (rounded to the nearest dollar) in FY 2025.</P>
                <P>Therefore, to calculate the small business adjustment factor for FY 2027, FDA subtracts $63,192 from the projected shortfall of $114,280 for FY 2027 to arrive at the numerator for the small business adjustment amount, which equals $51,088. This number divided by 79 (the number of expected non-small businesses for FY 2027), is the small business adjustment amount for FY 2027, which is $647 (rounded to the nearest dollar).</P>
                <HD SOURCE="HD2">B. FY 2027 Rates for Small Business Establishment Fee, Non-Small Business Establishment Fee, and Reinspection Fee</HD>
                <HD SOURCE="HD3">
                    1. Establishment Fee for Qualified Small Businesses 
                    <E T="51">1</E>
                </HD>
                <P>
                    The amount of the establishment fee for a qualified small business is equal to $15,000 multiplied by the inflation adjustment factor for that fiscal year, divided by 3 (see section 744K(c)(4)(A) and (c)(1)(A) of the FD&amp;C Act). The inflation adjustment factor for FY 2027 is 1.428442. See section II.A.1 of this document for the methodology used to calculate the FY 2027 inflation adjustment factor. Therefore, the establishment fee for a qualified small business for FY 2027 is one third of $21,427, which equals $7,142 (rounded to the nearest dollar).
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         To qualify for a small business reduction of the FY 2027 establishment fee, entities had to submit their exception requests by April 30, 2026. See section 744K(c)(4)(B) of the FD&amp;C Act. The time for requesting a small business exception for FY 2027 has now passed. An entity that wishes to request a small business exception for FY 2028 should consult section 744K(c)(4) of the FD&amp;C Act and section III.D of FDA's guidance for industry entitled “Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&amp;C Act,” which can be accessed on FDA's website at 
                        <E T="03">https://www.fda.gov/media/136683/download.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Establishment Fee for Non-Small Businesses</HD>
                <P>Under section 744K(c) of the FD&amp;C Act, the amount of the establishment fee for a non-small business is equal to $15,000 multiplied by the inflation adjustment factor for that fiscal year, plus the small business adjustment factor for that fiscal year, and plus or minus an adjustment factor to account for over or under collections due to the small business adjustment factor in the prior year. The inflation adjustment factor for FY 2027 is 1.428442. The small business adjustment amount for FY 2027 is $647. See section II.A.2 of this document for the methodology used to calculate the small business adjustment factor for FY 2027. Therefore, the establishment fee for a non-small business for FY 2027 is $15,000 multiplied by 1.428442 plus $647, which equals $22,074 (rounded to the nearest dollar).</P>
                <HD SOURCE="HD3">3. Reinspection Fee</HD>
                <P>
                    Section 744K(c)(1)(B) of the FD&amp;C Act provides that the amount of the FY 2027 reinspection fee is equal to $15,000, multiplied by the inflation adjustment factor for that fiscal year. The inflation adjustment factor for FY 2027 is 1.428442. Therefore, the reinspection fee for FY 2027 is $15,000 multiplied by 
                    <PRTPAGE P="48145"/>
                    1.428442, which equals $21,427 (rounded to the nearest dollar). There is no reduction in this fee for small businesses.
                </P>
                <HD SOURCE="HD2">C. Summary of FY 2027 Fee Rates</HD>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s25,9">
                    <TTITLE>Table 4—Outsourcing Facility Fees</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Fee
                            <LI>rates for</LI>
                            <LI>FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Qualified Small Business Establishment Fee</ENT>
                        <ENT>$7,142</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Small Business Establishment Fee</ENT>
                        <ENT>22,074</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Reinspection Fee</ENT>
                        <ENT>21,427</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. Fee Payment Options and Procedures</HD>
                <HD SOURCE="HD2">A. Establishment Fee</HD>
                <P>Once an entity submits registration information and FDA has determined that the information is complete, the entity will incur the annual establishment fee. FDA will send an invoice to the entity, via email to the email address indicated in the registration file. The invoice will contain information regarding the obligation incurred, the amount owed, and payment procedures. A facility will not be registered as an outsourcing facility until it has paid the annual establishment fee under section 744K of the FD&amp;C Act. Accordingly, it is important that facilities seeking to operate as outsourcing facilities pay all fees immediately upon receiving an invoice. If an entity does not pay the full invoiced amount within 15 calendar days after FDA issues the invoice, FDA will consider the submission of registration information to have been withdrawn and adjust the invoice to reflect that no fee is due.</P>
                <P>Outsourcing facilities that registered in FY 2026 and wish to maintain their status as an outsourcing facility in FY 2027 must register during the annual registration period that lasts from October 1, 2026, to December 31, 2026. Failure to register and complete payment by December 31, 2026, will result in a loss of status as an outsourcing facility on January 1, 2027. Entities should submit their registration information no later than December 10, 2026, to allow enough time for review of the registration information, invoicing, and payment of fees before the end of the registration period.</P>
                <HD SOURCE="HD2">B. Reinspection Fee</HD>
                <P>FDA will issue invoices for each reinspection after the conclusion of the reinspection, via email to the email address indicated in the registration file. Payments must be made within 30 days of the invoice date.</P>
                <HD SOURCE="HD2">C. Fee Payment Procedures</HD>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov,</E>
                     a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov</E>
                    . Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the invoice number to ensure that the payment is applied to the correct fee(s). Without the invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a Reinspection Fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 744K(g)(4) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15342 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7712]</DEPDOC>
                <SUBJECT>Food Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for recognized accreditation bodies and accredited certification bodies, and the initial and renewal fee rate for accreditation bodies applying to be recognized in the third-party certification program authorized by the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the FDA Food Safety Modernization Act (FSMA). We are also announcing the fee rate for certification bodies applying for direct FDA accreditation.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The fees apply from October 1, 2026, through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        <E T="03">For Questions Related to FSMA Program Fees: FSMAFeeStaff@fda.hhs.gov.</E>
                          
                        <E T="03">For Questions Related to This Notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Section 808(b)(1)(A) of the FD&amp;C Act (21 U.S.C. 384d(b)(1)(A)) directed FDA to establish a recognition system for entities that accredit third-party certification bodies to conduct food safety audits and issue food and facility certifications to eligible foreign entities. (For the reasons explained in the third-party certification final rule (80 FR 74570 at 74578 to 74579, November 27, 2015), and for consistency with our regulations for the third-party certification program in 21 CFR parts 1, 11, and 16, this notice uses the term “third-party certification body” rather than the term “third-party auditor” used in section 808 of the FD&amp;C Act.) Section 808(b)(1)(A)(ii) of the FD&amp;C Act also allowed us to directly accredit certain third-party certification bodies.</P>
                <P>
                    Section 808(c)(8) of the FD&amp;C Act directed FDA to establish a reimbursement (user fee) program by which we assess fees and require reimbursement for our work to administer the third-party certification 
                    <PRTPAGE P="48146"/>
                    program. Our regulations pertaining to the user fee program for the third-party certification program can be found at 21 CFR 1.700 through 1.725.
                </P>
                <P>The FY 2027 third-party certification program user fee rates announced in this notice is effective from October 1, 2026, through September 30, 2027.</P>
                <HD SOURCE="HD1">II. Estimating the Average Cost of a Supported Direct FDA Work Hour for FY 2027</HD>
                <P>FDA estimates its costs for each activity to establish fee rates (see 21 CFR 1.705(b)).</P>
                <HD SOURCE="HD2">A. Estimating the Full Cost per Direct Work Hour in FY 2027</HD>
                <P>Full-time Equivalent (FTE) reflects the total number of regular straight-time hours—not including overtime or holiday hours—worked by employees, divided by the number of compensable hours applicable to each fiscal year. Annual leave, sick leave, compensatory time off, and other approved leave categories are considered “hours worked” for purposes of defining FTE employment.</P>
                <P>In general, the starting point for estimating the full cost per direct work hour is to estimate the cost of an FTE or paid staff year. Calculating an FDA-wide total cost per FTE requires three primary cost elements: payroll, non-payroll, and rent.</P>
                <P>We used an average of past year cost elements to predict the FY 2027 cost. The FY 2027 FDA-wide average cost for payroll (salaries and benefits) is $244,029; non-payroll (including equipment, supplies, information technology, general and administrative overhead) is $108,488; and rent (including cost allocation analysis and adjustments for other rent and rent-related costs) is $24,118 per paid staff year, excluding travel costs.</P>
                <P>Summing the average cost of an FTE for payroll, non-payroll, and rent brings the FY 2027 average fully supported cost to $376,635 (total includes rounding) per FTE, excluding travel costs. FDA will use this base unit fee in determining the hourly fee rate for third-party certification user fees for FY 2027 before including travel costs as applicable for the activity.</P>
                <P>To calculate an hourly rate, we divide the FY 2027 average fully supported cost of $376,635 per FTE by the average number of supported direct FDA work hours in FY 2025 (the last FY for which data are available). See table 1.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,p1,8/9,i1" CDEF="s150,15">
                    <TTITLE>Table 1—Supported Direct FDA Work Hours in a Paid Staff Year in FY 2025</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total number of hours in a paid staff year</ENT>
                        <ENT>2,080</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Less:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">11 paid holidays</ENT>
                        <ENT>−88</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">20 days of annual leave</ENT>
                        <ENT>−160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">10 days of sick leave</ENT>
                        <ENT>−80</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">12.5 days of training</ENT>
                        <ENT>−100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">22 days of general administration</ENT>
                        <ENT>−176</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">26.5 days of travel</ENT>
                        <ENT>−212</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">2 hours of meetings per week</ENT>
                        <ENT>−104</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Net Supported Direct FDA Work Hours Available for Assignments</ENT>
                        <ENT>1,160</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Dividing the average fully supported FTE cost in FY 2027 ($376,635) by the total number of supported direct work hours available for assignment in FY 2025 (1,160) results in an average fully supported cost of $325 (rounded to the nearest dollar), excluding travel costs, per supported direct work hour in FY 2027.</P>
                <HD SOURCE="HD2">B. Adjusting FY 2025 Travel Costs for Inflation To Estimate FY 2027 Travel Costs</HD>
                <P>
                    To adjust the hourly rate for FY 2027, FDA estimates the cost of inflation in each year for FY 2026 and FY 2027. FDA uses the method prescribed for estimating inflationary costs under the Prescription Drug User Fee Act (PDUFA) provisions of the FD&amp;C Act (section 736(c)(1) of the FD&amp;C Act (21 U.S.C. 379h(c)(1))), the statutory method for inflation adjustment in the FD&amp;C Act. FDA previously determined the FY 2026 inflation rate to be 5.0313 percent; this rate was published in the FY 2026 PDUFA user fee rates notice in the 
                    <E T="04">Federal Register</E>
                     (July 30, 2025, 90 FR 35866). Using the method set forth in section 736(c)(1) of the FD&amp;C Act, FDA has calculated an inflation rate of 5.0313 percent for FY 2026 and 4.7210 percent for FY 2027, and FDA intends to use this inflation rate to make inflation adjustments for FY 2027.
                </P>
                <P>
                    For the purpose of estimating the fee, we are using the travel cost rate for foreign travel because the majority of onsite assessments made by FDA under this program will require foreign travel. In FY 2025, the Office of Inspections and Investigation (OII) spent a total of $2,689,902 on 277 foreign inspection trips (averaging $9,711 per foreign inspection trip) related to FDA's Human Foods Program and Center for Veterinary Medicine field activities programs.
                    <SU>1</SU>
                    <FTREF/>
                     These trips averaged 3 weeks (or 120 paid hours) per trip. Dividing $9,711 per trip by 120 hours per trip equals $81 (rounded to the nearest dollar) per paid hour spent for foreign inspection travel costs in FY 2025. To adjust $81 for inflation in FY 2026 and FY 2027, FDA multiplies it by the same inflation factors mentioned previously in this document (1.050313 and 1.047210), which results in an estimated cost of $89 per paid hour. That plus $325 in other costs per average supported direct work hour equals $414 per paid hour for each direct hour of work requiring foreign inspection travel. FDA will use this rate in charging fees in FY 2027 when travel is required for the third-party certification program.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Effective October 1st, 2024, FDA implemented a reorganization to establish a unified Humans Foods Program and restructured its field operations, formerly the Office of Regulatory Affairs and now the Office of Inspections and Investigations (OII). The establishment of the Human Foods Program allows us to most effectively deliver on our mission to protect and promote public health through science-based approaches to prevent foodborne illness, reduce diet-related chronic disease, and ensure the safety of chemicals in our food. For more information, see 
                        <E T="03">https://www.fda.gov/news-events/press-announcements/fdas-unified-human-foods-program-new-model-field-operations-and-other-modernization-efforts-go.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s50,12">
                    <TTITLE>Table 2—FSMA Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">Fee rates for FY 2027</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Hourly rate without travel</ENT>
                        <ENT>$325</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Hourly rate if travel is required</ENT>
                        <ENT>414</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. Fees for Accreditation Bodies and Certification Bodies in the Third-Party Certification Program Under Section 808(c)(8) of the FD&amp;C Act</HD>
                <P>
                    The third-party certification program assesses application fees and annual 
                    <PRTPAGE P="48147"/>
                    fees. Specifically, FDA can collect an initial application fee for accreditation bodies seeking recognition, an annual fee for recognized accreditation bodies, an annual fee for certification bodies accredited by a recognized accreditation body, an initial application fee for a certification body seeking direct accreditation from FDA, and a renewal application fee for recognized accreditation bodies. Table 3 provides an overview of the fees for FY 2027.
                </P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,15">
                    <TTITLE>Table 3—FSMA Third-Party Certification Program User Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Fee rates for
                            <LI>FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Initial Application Fee for Accreditation Body Seeking Recognition</ENT>
                        <ENT>$56,272</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Fee for Recognized Accreditation Body</ENT>
                        <ENT>2,612</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Fee for Accredited Certification Body</ENT>
                        <ENT>3,266</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Initial Application Fee for a Certification Body Seeking Direct Accreditation from FDA</ENT>
                        <ENT>56,272</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Renewal Application Fee for Recognized Accreditation Body</ENT>
                        <ENT>34,311</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">A. Application Fee for Accreditation Bodies Applying for Recognition in the Third-Party Certification Program Under Section 808(c)(8) of the FD&amp;C Act</HD>
                <P>Our regulations, at § 1.705(a)(1), require an application fee for accreditation bodies applying for recognition; that fee covers the estimated average cost of the work FDA performs in reviewing and evaluating applications for recognition of accreditation bodies.</P>
                <P>The fee is based on the fully supported FTE hourly rates and estimates of the number of hours it would take FDA to perform relevant activities. Based on our data since starting the program, we estimate that it would take, on average, 80 person-hours to review an accreditation body's application, 48 person-hours for an onsite performance evaluation of the applicant (including travel and other steps necessary for a fully supported FTE to complete an onsite assessment), and 32 person-hours to prepare a written report documenting the onsite assessment.</P>
                <P>
                    FDA employees review applications and prepare reports from their worksites, so we use the fully supported FTE hourly rate excluding travel ($325 per hour) to calculate the user fee attributable to those activities: $325/hour × (80 hours (application review) + 32 hours (written report)) = $36,400. We use the fully supported FTE hourly rate for work requiring travel ($414 per hour) to calculate the user fee for onsite performance evaluations, since historically most accreditation bodies are in foreign countries: $414/hour × 48 hours (
                    <E T="03">i.e.,</E>
                     two fully supported FTEs × ((2 travel days × 8 hours) + (1 day onsite × 8 hours))) = $19,872. The estimated average cost of our total work for reviewing an application for recognition for an accreditation body based on these figures would be $36,400 + $19,872 = $56,272. Therefore, the application fee for accreditation bodies applying for recognition in FY 2027 will be $56,272.
                </P>
                <HD SOURCE="HD2">B. Annual Fee for Accreditation Bodies Participating in the Third-Party Certification Program Under Section 808(c)(8) of the FD&amp;C Act</HD>
                <P>To calculate the annual fee for each recognized accreditation body, FDA takes the estimated average cost of our work to monitor performance of a single recognized accreditation body and annualizes that over the average term of recognition. We assume an average term of recognition of 5 years. We also assume that FDA will monitor 10 percent of recognized accreditation bodies onsite. We estimate that one performance evaluation of a recognized accreditation body would take, on average, 22 hours to conduct records review, 8 hours to prepare a report detailing the records review and onsite performance evaluation, and 8 hours of onsite performance evaluation. Using the fully supported FTE hourly rates in table 2, the estimated average cost of our work to monitor performance of a single recognized accreditation body would be $9,750 ($325/hour × (22 hours (records review) + 8 hours (written report))) plus $3,312 ($414/hour × 8 hours (onsite evaluation)), which is $13,062. Annualizing this amount over 5 years leads to an annual fee for recognized accreditation bodies of $2,612 for FY 2027.</P>
                <HD SOURCE="HD2">C. Annual Fee for Certification Bodies Accredited by a Recognized Accreditation Body in the Third-Party Certification Program Under Section 808(c)(8) of the FD&amp;C Act</HD>
                <P>To calculate the annual fee for a certification body accredited by a recognized accreditation body, FDA takes the estimated average cost of our work to monitor performance of a single certification body accredited by a recognized accreditation body and annualizes that over the average term of accreditation. We assume an average term of accreditation of 4 years. We estimate that FDA would conduct, on average, the same activities for the same amount of time to monitor certification bodies accredited by a recognized accreditation body as we would to monitor an accreditation body recognized by FDA. Using the fully supported FTE hourly rates in table 2, the estimated average cost of our work to monitor performance of a single accredited certification body would be $9,750 ($325/hour × (22 hours (records review) + 8 hours (written report))) plus $3,312 ($414/hour × 8 hours (onsite evaluation)), which is $13,062. Annualizing this amount over 4 years leads to an annual fee for accredited certification bodies of $3,266 for FY 2027.</P>
                <HD SOURCE="HD2">D. Initial Application Fee for Certification Bodies Seeking Direct Accreditation From FDA in the Third-Party Certification Program Under Section 808(c)(8) of the FD&amp;C Act</HD>
                <P>Our regulations, at § 1.705(a)(3), require an application fee for certification bodies applying for direct accreditation from FDA to cover the estimated average cost of our work to review and evaluating initial applications for direct accreditation of certification bodies.</P>
                <P>The fee is based on the fully supported FTE hourly rates and estimates of the number of hours it would take FDA to perform relevant activities. We estimate that it would take, on average, 80 person-hours to review a certification body's application, 48 person-hours for an onsite performance evaluation of the applicant, and 32 person-hours to prepare a written report documenting the onsite assessment.</P>
                <P>
                    FDA employees are likely to review applications and prepare reports from their worksites, so we use the fully supported FTE hourly rate excluding travel, $325 per hour, to calculate the portion of the user fee attributable to those activities: $325/hour × (80 hours (application review) + 32 hours (written report)) = $36,400. For the portion of the 
                    <PRTPAGE P="48148"/>
                    fee attributable to onsite performance evaluations, we use the fully supported FTE hourly rate for work requiring travel ($414 per hour) since historically most certification bodies are in foreign countries: $414/hour × 48 hours (
                    <E T="03">i.e.,</E>
                     two fully supported FTEs × ((2 travel days × 8 hours) + (1 day onsite × 8 hours))) = $19,872. The estimated average cost of our work to review an application for direct accreditation of a certification body is $36,400 + $19,872 = $56,272. Therefore, the application fee for certification bodies applying for direct accreditation from FDA in FY 2027 will be $56,272
                </P>
                <HD SOURCE="HD2">E. Renewal Application Fee for Accreditation Bodies Participating in the Third-Party Certification Program Under Section 808(c)(8) of the FD&amp;C Act</HD>
                <P>Our regulations, at § 1.705(a)(2), require a renewal application fee for recognized accreditation bodies to cover the estimated average cost of our work to review and evaluate renewal applications for recognition of accreditation bodies.</P>
                <P>The fee is based on the fully supported FTE hourly rates and estimates of the number of hours it would take FDA to perform relevant activities. We estimate that it would take, on average, 43 person-hours to review an accreditation body's submitted renewal application, 24 person-hours for an onsite performance evaluation of the applicant, and 32 person-hours to prepare a written report documenting the onsite assessment.</P>
                <P>
                    FDA employees are likely to review renewal applications and prepare reports from their worksites, so we use the fully supported FTE hourly rate excluding travel ($325 per hour) to calculate the portion of the user fee attributable to those activities: $325/hour × (43 hours (application review) + 32 hours (written report)) = $24,375. For the portion of the fee attributable to onsite performance evaluations, we use the fully supported FTE hourly rate for work requiring travel ($414 per hour) since historically most accreditation bodies are in foreign countries: $414/hour × 24 hours (
                    <E T="03">i.e.,</E>
                     fully supported FTE × ((2 travel days × 8 hours) + (1 day onsite × 8 hours))) = $9,936. The estimated average cost of our work for reviewing a renewal application for recognition of an accreditation body is $24,375 + $9,936 = $34,311. Therefore, the renewal application fee for recognized accreditation bodies in FY 2027 will be $34,311.
                </P>
                <HD SOURCE="HD1">IV. Estimated Fees for Accreditation Bodies and Certification Bodies in Other Fee Categories for FY 2027</HD>
                <P>Our regulations, at § 1.705(a)(4), require application fees for certification bodies applying for renewal of direct accreditation, while § 1.705(b)(2) requires annual fees for certification bodies directly accredited by FDA.</P>
                <P>Although to date we have not directly accredited any certification bodies under the Third-Party Certification Program, FDA notifies the public of the program fee schedule annually (21 CFR 1.710). Therefore, we are providing estimates of annual fees and renewal applications for directly accredited certification bodies, based on the fully supported FTE hourly rates for FY 2026 and estimates of the number of hours it would take FDA to perform relevant activities as outlined in the Final Regulatory Impact Analysis for the Third-Party Certification regulation. Table 4 provides an overview of the estimated fees for these other categories.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,20">
                    <TTITLE>Table 4—Estimated Fee Rates for Other Fee Categories Under the FSMA Third-Party Certification Program</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Estimated fee rates
                            <LI>for FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Renewal application fee for directly accredited certification body</ENT>
                        <ENT>$34,311</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual fee for certification body directly accredited by FDA</ENT>
                        <ENT>26,960</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">V. How must the fees be paid?</HD>
                <P>
                    Accreditation bodies seeking recognition must submit the application fee with the application (21 CFR 1.715(a)). For recognized accreditation bodies and accredited certification bodies, an invoice will be sent annually. Payments made to FDA must be made, within 30 days of the invoice date, in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov,</E>
                     a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov.</E>
                     Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts or U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the invoice number to ensure that the payment is applied to the correct fee(s). Without the invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965.</P>
                <HD SOURCE="HD1">VI. What are the consequences of not paying this fee?</HD>
                <P>
                    The consequences of not paying these fees are outlined in 21 CFR 1.725. If FDA does not receive an application fee with an application for recognition, the application will be considered incomplete, and FDA will not review the application. If a recognized accreditation body fails to submit its annual user fee within 30 days of the due date, we will suspend its recognition. If the recognized accreditation body fails to submit its annual user fee within 90 days of the due date, we will revoke its recognition. If an accredited certification body fails to pay its annual fee within 30 days of the due date, we will suspend its accreditation. If the accredited certification body fails to pay its annual 
                    <PRTPAGE P="48149"/>
                    fee within 90 days of the due date, we will withdraw its accreditation.
                </P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15337 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7498]</DEPDOC>
                <SUBJECT>Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (JINADs), and for certain submissions related to JINAD files. This notice establishes the fee rates for FY 2027.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The application fee rates are effective for all abbreviated applications for a generic new animal drug submitted on or after October 1, 2026, and will remain in effect through September 30, 2027. The fee rates for requests to establish a JINAD file, and for certain submissions to JINAD files established prior to October 1, 2023, are effective on October 1, 2026, and will remain in effect through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Visit FDA's website at: 
                        <E T="03">https://www.fda.gov/industry/fda-user-fee-programs/animal-generic-drug-user-fee-act-agdufa.</E>
                         For general questions, email FDA's Center for Veterinary Medicine (CVM) at: 
                        <E T="03">cvmagdufa@fda.hhs.gov. For questions relating to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Section 741(a) of the FD&amp;C Act (21 U.S.C. 379j-21(a)), establishes four different types of generic new animal drug user fees: (1) fees for certain abbreviated applications for generic new animal drugs; (2) annual fees for certain generic new animal drug products; (3) annual fees for certain sponsors of abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs; and (4) JINAD file fees. When certain conditions are met, section 741(d) of the FD&amp;C Act authorizes FDA to waive or reduce fees for generic new animal drugs intended solely to provide for a minor use or minor species indication.</P>
                <P>Section 741(b)(1) of the FD&amp;C Act establishes a base revenue amount for each fiscal year. Per section 741(c)(2) and (3) of the FD&amp;C Act, the base revenue amounts established for fiscal years after FY 2024 are subject to adjustment for inflation and workload. Beginning FY 2026, the annual fee revenue amounts are also subject to adjustment to reduce workload-based increases by the amount of certain excess collections. Section 741(b) of the FD&amp;C Act establishes fees each year so that the percentage allocations for each of the fee categories is as follows: 20 percent shall be derived from fees for abbreviated applications for a generic new animal drug and JINAD file fees; 40 percent shall be derived from fees for generic new animal drug products; and 40 percent shall be derived from fees for generic new animal drug sponsors. The target revenue amounts for each fee category for FY 2027 are as follows: for application and/or JINAD file fees, the target revenue amount is $5,696,000; for product fees, the target revenue amount is $11,392,000; and for sponsor fees, the target revenue amount is $11,392,000.</P>
                <P>For FY 2027, the AGDUFA rates are: $132,614 for each abbreviated application for a generic new animal drug other than those subject to the criteria in section 512(d)(4) of the FD&amp;C Act (21 U.S.C. 360b(d)(4)); $66,307 for each abbreviated application for a generic new animal drug subject to the criteria in section 512(d)(4) of the FD&amp;C Act; $50,000 for each JINAD file request or certain submissions to established JINAD files; $15,670 for each generic new animal drug product; $264,009 for each generic new animal drug sponsor paying 100 percent of the sponsor fee; $198,007 for each generic new animal drug sponsor paying 75 percent of the sponsor fee; and $132,005 for each generic new animal drug sponsor paying 50 percent of the sponsor fee. FDA will issue invoices for FY 2027 product and sponsor fees by December 31, 2026, and payment will be due by January 31, 2027. The application fee rates are effective for all abbreviated applications for a generic new animal drug submitted on or after October 1, 2026, and will remain in effect through September 30, 2027. The fee rate for requests to establish a JINAD file, and for certain submissions to JINAD files established prior to October 1, 2023, is effective on October 1, 2026, and will remain in effect through September 30, 2027.</P>
                <P>Applications will not be accepted for review until FDA has received full payment of application fees and any other fees owed under the AGDUFA program. Similarly, a request to establish a JINAD file or a submission to an existing JINAD file will not be accepted for action by FDA until FDA has received full payment of all fees owed under the AGDUFA program.</P>
                <HD SOURCE="HD1">II. Fee Revenue Amount for FY 2027</HD>
                <HD SOURCE="HD2">A. Statutory Fee Revenue Amounts</HD>
                <P>Section 741(b)(1) of the FD&amp;C Act specifies that the base fee revenue amount for FY 2027 for all generic animal drug user fee categories totals $25,000,000.</P>
                <HD SOURCE="HD2">B. Inflation Adjustment to Fee Revenue Amount</HD>
                <P>Section 741(c)(2)(A) of the FD&amp;C Act specifies that the annual fee revenue amount is to be adjusted for inflation increases for FY 2025 and subsequent fiscal years using two separate factors—one for personnel compensation and benefits (PC&amp;B) costs and one for non-PC&amp;B costs.</P>
                <P>Section 741(c)(2)(A)(ii) of the FD&amp;C Act specifies the component of the inflation adjustment for payroll costs shall be one plus the average annual percent change in the cost of all PC&amp;B, per full-time equivalent (FTE) position of FDA, for the first 3 of the preceding 4 fiscal years of available data, multiplied by the average proportion of PC&amp;B costs to total FDA costs for the first 3 of the 4 preceding fiscal years of available data. The data on total PC&amp;B paid and numbers of FTE paid, from which the average cost per FTE can be derived, are published in FDA's Justification of Estimates for Appropriations Committees.</P>
                <P>
                    Table 1 summarizes the total PC&amp;B costs per FTE for the specified fiscal years, provides the percentage change from the previous fiscal year, and provides the average percentage change over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent.
                    <PRTPAGE P="48150"/>
                </P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,15,15,15,15">
                    <TTITLE>Table 1—FDA Personnel Compensation and Benefits (PC&amp;B) Each Year and Percent Change</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTEs</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent Change from Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 741(c)(2)(A)(ii) of the FD&amp;C Act specifies that the 5.7330 percent should be multiplied by the average proportion of PC&amp;B costs to total FDA costs for the first 3 of the preceding 4 fiscal years for which data are available. Table 2 shows the amount of PC&amp;B and the total costs obligated by FDA for the same 3 fiscal years.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,15,15,15,15">
                    <TTITLE>Table 2—PC&amp;B as a Percent of Total Cost</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>$6,654,058,000</ENT>
                        <ENT>$6,976,495,000</ENT>
                        <ENT>$6,809,369,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B percent</ENT>
                        <ENT>51.6454%</ENT>
                        <ENT>54.3501%</ENT>
                        <ENT>56.9207%</ENT>
                        <ENT>54.3054%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The portion of the inflation adjustment relating to payroll costs is 5.7330 percent multiplied by 54.3054 percent, or 3.1133 percent.</P>
                <P>
                    Section 741(c)(2)(A)(iii) of the FD&amp;C Act specifies that the non-payroll costs adjustment factor is calculated by multiplying the average annual percentage change that occurred in the Consumer Price Index for Urban Consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; Not Seasonally Adjusted; All Items Less Food and Energy; Annual Index) for the first 3 years of the preceding 4 years of available data by the average proportion of all non-PC&amp;B costs to total FDA costs for the first 3 years of the preceding 4 fiscal years. Table 3 provides the summary data for the percentage change in the specified CPI for the Washington-Arlington-Alexandria area.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The data is published by the Bureau of Labor Statistics and can be found on its website at: 
                        <E T="03">https://data.bls.gov/timeseries/CUURS35ASA0L1E.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,15,15,15,15">
                    <TTITLE>Table 3—Annual and 3-Year Average Percent Change in CPI (Less Food and Energy) for Washington-Arlington-Alexandria Area</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>313.315</ENT>
                        <ENT>324.560</ENT>
                        <ENT>332.041</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.5382%</ENT>
                        <ENT>3.5890%</ENT>
                        <ENT>2.3050%</ENT>
                        <ENT>3.1441%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Section 741(c)(2)(A)(iii) of the FD&amp;C Act specifies to calculate the inflation adjustment for non-payroll costs, we multiply 3.1441 percent by the average proportion of all costs other than PC&amp;B to total FDA costs for the first 3 years of the preceding 4 fiscal years. Since 54.3054 percent was obligated for PC&amp;B as shown in table 2, 45.6946 percent is the portion of costs other than PC&amp;B (100 percent minus the PC&amp;B percentage of 54.3054). The portion of the inflation adjustment relating to non-payroll costs is 3.1441 percent multiplied by 45.6946 percent, or 1.4367 percent.</P>
                <P>Next, we add the payroll component (3.1133 percent) to the non-payroll component (1.4367 percent), for an inflation adjustment of 4.5500 percent for FY 2027.</P>
                <P>Section 741(c)(2)(B) of the FD&amp;C Act provides for the inflation adjustment to be compounded each fiscal year after FY 2025. The inflation adjustment for FY 2027 (4.5500 percent) is compounded by adding 1 and then multiplying by 1 plus the inflation adjustment factor for FY 2026 (1.0896), which equals 1.1392 (rounded) (1.0896 multiplied by 1.0455). We then multiply the base revenue amount for FY 2027 ($25,000,000) by 1.1392, yielding an inflation adjusted amount of $28,480,125.</P>
                <HD SOURCE="HD2">C. Workload Adjustment to Inflation Adjusted Fee Revenue Amount</HD>
                <P>Section 741(c)(3)(A) of the FD&amp;C Act specifies that fee revenue amounts for FY 2025 and subsequent fiscal years are subject to adjustment to account for changes in FDA's review workload. The workload adjustment would be applied to the inflation adjusted fee revenue amount.</P>
                <P>To determine whether a workload adjustment applies, per AGDUFA IV commitments FDA calculates the weighted average of the change in the total number of each of the six types of applications and submissions specified in the workload adjustment provision (abbreviated applications for generic new animal drugs, manufacturing supplemental abbreviated applications for generic new animal drugs, investigational generic new animal drug study submissions, investigational generic new animal drug protocol submissions, generic investigational new animal drug file requests, and generic investigational new animal drug meeting requests) received over the 5-year period that ended on September 30, 2025 (the base years; 2021 through 2025), and the average number of each of these types of applications and submissions over the most recent 5-year period that ended April 30, 2026.</P>
                <P>
                    The results of these calculations are presented in the first two columns of table 4. Column 3 reflects the percent change in workload over the two 5-year periods. Column 4 shows the weighting 
                    <PRTPAGE P="48151"/>
                    factor for each type of application/submission, reflecting how much of the total FDA generic new animal drug review workload was accounted for by each type of application or submission in the table during the most recent 5 years. Column 5 is the weighted percent change in each category of workload and was derived by multiplying the weighting factor in each line in column 4 by the percent change from the base years in column 3. At the bottom right of the table, the sum of the values in column 5 is calculated, reflecting a total change in workload of 1.5927 percent for FY 2027. This is the workload adjuster for FY 2027.
                </P>
                <GPOTABLE COLS="6" OPTS="L2,nj,i1" CDEF="s50,12,8,8,8,8">
                    <TTITLE>Table 4—Workload Adjuster Calculation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Application type</CHED>
                        <CHED H="1">Column 1</CHED>
                        <CHED H="2">
                            5-Year
                            <LI>average</LI>
                            <LI>(base years)</LI>
                        </CHED>
                        <CHED H="1">Column 2</CHED>
                        <CHED H="2">
                            Latest
                            <LI>5-year</LI>
                            <LI>average</LI>
                        </CHED>
                        <CHED H="1">Column 3</CHED>
                        <CHED H="2">
                            Percent
                            <LI>change</LI>
                        </CHED>
                        <CHED H="1">Column 4</CHED>
                        <CHED H="2">
                            Weighting
                            <LI>factor</LI>
                        </CHED>
                        <CHED H="1">Column 5</CHED>
                        <CHED H="2">
                            Weighted
                            <LI>percent</LI>
                            <LI>change</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Abbreviated Application for a Generic New Animal Drug (ANADAs)</ENT>
                        <ENT>31.00</ENT>
                        <ENT>33.00</ENT>
                        <ENT>6.4516</ENT>
                        <ENT>0.1135</ENT>
                        <ENT>0.7324</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Manufacturing Supplements ANADAs</ENT>
                        <ENT>263.80</ENT>
                        <ENT>269.80</ENT>
                        <ENT>2.2745</ENT>
                        <ENT>0.2509</ENT>
                        <ENT>0.5706</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Generic Investigational Study Submissions</ENT>
                        <ENT>173.00</ENT>
                        <ENT>170.20</ENT>
                        <ENT>−1.6185</ENT>
                        <ENT>0.4531</ENT>
                        <ENT>−0.7333</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Generic Investigational Protocol Submissions</ENT>
                        <ENT>50.00</ENT>
                        <ENT>52.60</ENT>
                        <ENT>5.2000</ENT>
                        <ENT>0.0980</ENT>
                        <ENT>0.5098</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Generic Investigational New Animal Drug File Requests (JINAD)</ENT>
                        <ENT>44.00</ENT>
                        <ENT>43.80</ENT>
                        <ENT>−0.4545</ENT>
                        <ENT>0.0168</ENT>
                        <ENT>−0.0076</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Generic Investigational New Animal Drug Meeting Requests (JINAD)</ENT>
                        <ENT>33.80</ENT>
                        <ENT>36.40</ENT>
                        <ENT>7.6923</ENT>
                        <ENT>0.0677</ENT>
                        <ENT>0.5208</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FY 2027 AGDUFA IV Workload Adjuster</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT>1.5927 </ENT>
                    </ROW>
                </GPOTABLE>
                <P>Per section 741(c)(3)(C) of the FD&amp;C Act under no circumstances shall the workload adjustment result in fee revenues that are less than the base fee revenues for that fiscal year as adjusted for inflation. For FY 2027 the workload adjustment would not result in fee revenues less than the base fee revenues as adjusted for inflation, therefore a workload adjustment of $453,574 shall be applied.</P>
                <P>Per section 741(c)(3)(B) of the FD&amp;C Act, for each of fiscal years 2026 through 2028, if application of the workload adjustment increases the fee revenue amounts otherwise established for the fiscal year, as adjusted for inflation, such fee revenue increase shall be reduced by the amount of any excess collections for the second preceding fiscal year, up to the amount of such fee revenue increase. The second preceding fiscal year for FY 2027 resulted in excess collections of $3,359,210, which is higher than the corresponding workload adjustment for FY 2027, and therefore, the workload adjustment is reduced to $0.</P>
                <HD SOURCE="HD2">D. FY 2027 Fee Revenue Amounts</HD>
                <P>AGDUFA IV specifies that the revenue amount of $28,480,000 (rounded) for FY 2027 is to be divided as follows: 20 percent, or a total of $5,696,000, is to come from application and/or JINAD file fees; 40 percent, or a total of $11,392,000, is to come from product fees; and 40 percent, or a total of $11,392,000 is to come from sponsor fees (See section 741(b) of the FD&amp;C Act).</P>
                <HD SOURCE="HD1">III. Abbreviated Application Fee and Generic Investigational New Animal Drug (JINAD) File Fee Calculations for FY 2027</HD>
                <HD SOURCE="HD2">A. Fee Revenues and Numbers of Fee-Paying Applications and Submissions</HD>
                <P>Section 741(a)(1)(A) of the FD&amp;C Act states that each person who submits an abbreviated application for a generic new animal drug shall be subject to an application fee, with limited exceptions. The term “abbreviated application for a generic new animal drug” means an abbreviated application for the approval of any generic new animal drug submitted under section 512(b)(2) of the FD&amp;C Act. FDA will assess fees related to JINAD files under section 741(a)(4)(A)(i) of the FD&amp;C Act when a person submits a request to establish a new JINAD file. FDA will assess a fee under section 741(a)(4)(A)(ii) and (iii) of the FD&amp;C Act for a person's first submission, as described below, to a JINAD file on or after October 1, 2023, where the JINAD file had been established prior to that date. The JINAD file fee is set in accordance with section 741(c)(1)(C) of the FD&amp;C Act at $50,000. FDA will set the abbreviated application fee so that such fees combined with the JINAD file fees will generate a combined total of $5,696,000 in fee revenue for FY 2027.</P>
                <P>To set fees for abbreviated applications for generic new animal drugs, FDA must first make some assumptions about the number of fee-paying abbreviated applications it will receive during FY 2027, the number of requests to establish new JINAD files it will receive during FY 2027, and the number of existing (prior to October 1, 2023) JINAD files to which it will receive submissions during FY 2027.</P>
                <P>Regarding the fee for a person's first submission to an existing (prior to October 1, 2023) JINAD file on or after October 1, 2023, FDA intends to assess a fee only for the first data (or “P”) submission to the Bioequivalence (BE) or Chemistry, Manufacturing, and Controls (CMC) technical sections of the JINAD file. The Agency has selected P submissions to the BE or CMC technical sections as the basis for assessing this fee because P submissions to these sections consistently entail the substantial use of FDA review hours during the phased review process.</P>
                <P>The Agency knows the numbers of applications and submissions that have been submitted in previous years. Those numbers fluctuate annually. In estimating the fee revenue to be generated by application and submission fees in FY 2027, FDA is assuming that the number of applications and submissions for which fees will be paid in FY 2027 will equal the average number of applications and submissions over the 5 most recently completed fiscal years of the AGDUFA program (FY 2021-FY 2025).</P>
                <P>In addition, under section 741(a)(1)(C)(ii) of the FD&amp;C Act an abbreviated application for a generic new animal drug subject to the criteria in section 512(d)(4) of the FD&amp;C Act and submitted on or after October 1, 2013, shall be subject to 50 percent of the fee applicable to all other abbreviated applications for a generic new animal drug.</P>
                <P>
                    The average number of original submissions of abbreviated applications for generic new animal drugs over the 5 most recently completed fiscal years is 
                    <PRTPAGE P="48152"/>
                    22.6 applications not subject to the criteria in section 512(d)(4) of the FD&amp;C Act and 3.0 submissions subject to the criteria in section 512(d)(4). Each of the submissions described under section 512(d)(4) of the FD&amp;C Act pays 50 percent of the fee paid by the other applications and will be counted as one half of a fee. Adding all of the applications not subject to the criteria in section 512(d)(4) of the FD&amp;C Act and 50 percent of the number that are subject to such criteria results in a total of 24.1 anticipated full fees.
                </P>
                <P>Based on the previous assumptions, FDA is estimating that it will receive a total of 24.1 fee-paying generic new animal drug applications in FY 2027 (22.6 original applications paying a full fee and 3.0 applications paying a half fee).</P>
                <P>For estimating the number of requests to establish a new JINAD file and the number of P submissions to the BE or CMC section of an existing (prior to October 1, 2023) JINAD file the Agency will receive in FY 2027, FDA took the number of new JINAD file requests and P submissions to the BE or CMC section of an existing JINAD file received in FY 2026. The number of requests to establish new JINAD files and P submissions to the BE or CMC section of existing JINAD files during FY 2026 as of June is 50.</P>
                <P>Based on the previous assumptions, FDA is estimating that it will receive a total of 50 fee-paying JINAD file submissions in FY 2027 (including both requests to establish new JINAD files and first P submissions to the BE or CMC section of existing (prior to October 1, 2023) JINAD files).</P>
                <HD SOURCE="HD2">B. Application Fee Rates for FY 2027</HD>
                <P>FDA must set the fee rates for FY 2027 so that the estimated 24.1 abbreviated application fees and 50 JINAD file fees will generate a total of $5,696,000. The fee for a new JINAD file request or the first submission to an existing (prior to October 1, 2023) JINAD file is $50,000 under section 741(c)(1)(C) of the FD&amp;C Act. Therefore, the JINAD fees will generate a total of $2,500,000. Abbreviated application fees will have to generate a total of $3,196,000.</P>
                <P>To generate this amount, the fee for a generic new animal drug application will be $132,614 and for those applications that are subject to the criteria set forth in section 512(d)(4) of the FD&amp;C Act, 50 percent of that amount, or $66,307.</P>
                <HD SOURCE="HD1">IV. Generic New Animal Drug Product Fee Calculations For FY 2027</HD>
                <HD SOURCE="HD2">A. Product Fee Revenues and Numbers of Fee-Paying Products</HD>
                <P>The generic new animal drug product fee must be paid annually by the person named as the applicant in an abbreviated application or supplemental abbreviated application for a generic new animal drug product submitted for listing under section 510 of the FD&amp;C Act (21 U.S.C. 360), and who had an abbreviated application or supplemental abbreviated application for a generic new animal drug product pending at FDA after September 1, 2008 (21 U.S.C. 379j-21(a)(2)). Section 741(k)(6) of FD&amp;C Act defines “generic new animal drug product” as a specific strength or potency of a particular active ingredient or ingredients in final dosage form marketed by a particular manufacturer or distributor, which is uniquely identified by the labeler code and product code portions of the National Drug Code, and for which an abbreviated application for a generic new animal drug or supplemental abbreviated application for a generic new animal drug has been approved. The product fees are to be set so that they will generate $11,392,000 in fee revenue for FY 2027.</P>
                <P>To set generic new animal drug product fees to realize $11,392,000, FDA must make some assumptions about the number of products for which these fees will be paid in FY 2027. FDA gathered data on all generic new animal drug products that have been submitted for listing under section 510 of the FD&amp;C Act and matched this to the list of all persons who FDA estimated would have a generic new animal drug application or supplemental abbreviated application pending after September 1, 2008. As of May 2026, FDA estimates that there is a total of 731 products submitted for listing by persons who had an abbreviated application for a generic new animal drug or supplemental abbreviated application for a generic new animal drug pending after September 1, 2008. Based on this, FDA believes that a total of 731 products will be subject to this fee in FY 2027.</P>
                <P>Per section 741(d) of the FD&amp;C Act in estimating the fee revenue to be generated by generic new animal drug product fees in FY 2027, FDA is estimating that 0.5 percent of the products invoiced, or 4 products, will not pay fees in FY 2027, due to fee waivers and reductions. FDA has made this estimate at 0.5 percent this year, based on historical data over the past 5 completed fiscal years of the AGDUFA program.</P>
                <P>Accordingly, the Agency estimates that a total of 727 (731 minus 4) products will be subject to product fees in FY 2027.</P>
                <HD SOURCE="HD2">B. Product Fee Rates for FY 2027</HD>
                <P>FDA must set the fee rates for FY 2027 so that the estimated 727 products for which fees are paid will generate a total of $11,392,000. To generate this amount will require the fee for a generic new animal drug product, rounded to the nearest dollar, to be $15,670.</P>
                <HD SOURCE="HD1">V. Generic New Animal Drug Sponsor Fee Calculations for FY 2027</HD>
                <HD SOURCE="HD2">A. Sponsor Fee Revenues and Numbers of Fee-Paying Sponsors</HD>
                <P>The generic new animal drug sponsor fee must be paid annually by each person who: (1) is named as the applicant in an abbreviated application for a generic new animal drug, except for an approved application for which all subject products have been removed from listing under section 510 of the FD&amp;C Act, or has submitted an investigational submission for a generic new animal drug that has not been terminated or otherwise rendered inactive; and (2) had an abbreviated application for a generic new animal drug, supplemental abbreviated application for a generic new animal drug, or investigational submission for a generic new animal drug pending at FDA after September 1, 2008. See section 741(k)(7) and (a)(3) of the FD&amp;C Act.</P>
                <P>Per section 741(a)(3)(C) of the FD&amp;C Act, a generic new animal drug sponsor is subject to only one such fee each fiscal year. Applicants with more than 6 approved abbreviated applications will pay 100 percent of the sponsor fee; applicants with more than 1 and fewer than 7 approved abbreviated applications will pay 75 percent of the sponsor fee; and applicants with 1 or fewer approved abbreviated applications will pay 50 percent of the sponsor fee. The sponsor fees are to be set so that they will generate $11,392,000 in fee revenue for FY 2027.</P>
                <P>
                    To set generic new animal drug sponsor fees to realize $11,392,000, FDA must make some assumptions about the number of sponsors who will pay these fees in FY 2027. FDA developed data on all generic new animal drug sponsors and matched this to the list of all sponsors who had pending submissions and applications after September 1, 2008. As of May, 2026, FDA estimates that in FY 2027, 18 sponsors will pay 100 percent fees, 15 sponsors will pay 75 percent fees, and 30 sponsors will pay 50 percent fees. The total of these 
                    <PRTPAGE P="48153"/>
                    figures is the equivalent of 44.25 full sponsor fees (18 times 100 percent or 18, plus 15 times 75 percent or 11.25 plus 30 times 50 percent or 15).
                </P>
                <P>FDA estimates that about 2.5 percent of the 44.25 effective full sponsors, or 1.10, will not pay fees in FY 2027, due to fee waivers and reductions. FDA has made the estimate of the percentage of sponsors that will not pay fees at 2.5 percent this year, based on historical data over the past 5 completed fiscal years of the AGDUFA program. See section 741(d) of the FD&amp;C Act.</P>
                <P>Accordingly, the Agency estimates that the equivalent of 43.15 full sponsor fees (44.25 minus 1.10) are likely to be paid in FY 2027.</P>
                <HD SOURCE="HD2">B. Sponsor Fee Rates for FY 2027</HD>
                <P>FDA must set the fee rates for FY 2027 so that the estimated equivalent of 43.15 full sponsor fees will generate a total of $11,392,000. To generate this amount will require the 100 percent fee for a generic new animal drug sponsor, rounded to the nearest dollar, to be $264,009. Accordingly, the fee for those paying 75 percent of the full sponsor fee will be $198,007, and the fee for those paying 50 percent of the full sponsor fee will be $132,005.</P>
                <HD SOURCE="HD1">VI. Fee Schedule for FY 2027</HD>
                <P>The fee rates for FY 2027 are summarized in table 5.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,17">
                    <TTITLE>Table 5—FY 2027 Fee Rates</TTITLE>
                    <BOXHD>
                        <CHED H="1">User fee category</CHED>
                        <CHED H="1">Fee rate for FY 2027</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Abbreviated Application Fee for Generic New Animal Drug except those subject to the criteria in section 512(d)(4)</ENT>
                        <ENT>$132,614</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Abbreviated Application Fee for Generic New Animal Drug subject to the criteria in section 512(d)(4)</ENT>
                        <ENT>66,307</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Generic Investigational New Animal Drug File Fee (JINAD)</ENT>
                        <ENT>50,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Generic New Animal Drug Product Fee</ENT>
                        <ENT>15,670</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            100% Generic New Animal Drug Sponsor Fee 
                            <SU>1</SU>
                        </ENT>
                        <ENT>264,009</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            75% Generic New Animal Drug Sponsor Fee 
                            <SU>1</SU>
                        </ENT>
                        <ENT>198,007</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            50% Generic New Animal Drug Sponsor Fee 
                            <SU>1</SU>
                        </ENT>
                        <ENT>132,005</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         An animal drug sponsor is subject to only one fee each fiscal year.
                    </TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">VII. Fee Waiver or Reduction; Exemption From Fees</HD>
                <P>Per section 741(d)(1), of the FD&amp;C Act the types of fees waivers and reductions that applied last fiscal year still exist for FY 2027. However, after September 30, 2023, there is no longer an exemption for any person who submits to CVM a supplemental abbreviated application relating to a generic new animal drug approved under section 512 of the FD&amp;C Act, solely to add the application number to the labeling of the drug in the manner specified in section 502(w)(3) of the FD&amp;C Act (21 U.S.C. 352(w)(3)).</P>
                <P>Waivers or reductions remain available for abbreviated applications for generic new animal drugs intended solely for a minor use/minor species indication; see section 741(d) of the FD&amp;C Act.</P>
                <HD SOURCE="HD1">VIII. Procedures for Paying the FY 2027 Fees</HD>
                <HD SOURCE="HD2">A. Abbreviated Application Fees, JINAD File Fees, and Payment Instructions</HD>
                <P>
                    The FY 2027 fees established in the new fee schedule must be paid for the following applications/submissions that are subject to fees under AGDUFA IV and submitted on or after October 1, 2026: a generic new animal drug application, a submission requesting to establish a JINAD file, or the first BE or CMC submission to a JINAD file that was established prior to October 1, 2023. Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov</E>
                    , a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov</E>
                    . Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID or invoice number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID or invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 741(h) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <HD SOURCE="HD2">B. Application and JINAD File Submission Cover Sheet Procedures</HD>
                <P>
                    <E T="03">Step One:</E>
                     Create a user account and password. Log onto the AGDUFA website at 
                    <E T="03">https://www.fda.gov/ForIndustry/UserFees/AnimalGenericDrugUserFeeActAGDUFA/ucm137049.htm</E>
                     and, under Application Submission Information, click on “Create AGDUFA User Fee Cover Sheet” and follow the directions. For security reasons, each firm submitting an application and/or a JINAD file submission will be assigned an organization identification number, and each user will also be required to set up a user account and password the first time you use this site. Online instructions will walk you through this process.
                </P>
                <P>
                    <E T="03">Step Two:</E>
                     Create an Animal Generic Drug User Fee Cover Sheet, transmit it to FDA, and print a copy. After logging into your account with your username and password, complete the steps required to create an Animal Generic Drug User Fee Cover Sheet. One cover sheet is needed for each abbreviated application for a generic new animal 
                    <PRTPAGE P="48154"/>
                    drug or JINAD file submission. Once you are satisfied that the data on the cover sheet is accurate and you have finalized the cover sheet, you will be able to transmit it electronically to FDA and you will be able to print a copy of your cover sheet showing your unique PIN.
                </P>
                <P>
                    <E T="03">Step Three:</E>
                     Send the payment for your application or JINAD file submission as described in section VIII.A.
                </P>
                <P>
                    <E T="03">Step Four:</E>
                     Submit your application or JINAD file submission.
                </P>
                <HD SOURCE="HD2">C. Product and Sponsor Fees</HD>
                <P>By December 31, 2026, FDA will issue invoices and payment instructions for product and sponsor fees for FY 2027 using this fee schedule. Payment will be due by January 31, 2027. FDA will issue invoices in November 2027 for any products and sponsors subject to fees for FY 2027 that qualify for fees after the December 2026 billing.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15341 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7398]</DEPDOC>
                <SUBJECT>Generic Drug User Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2027 rates for GDUFA III fees.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For more information on human generic drug fees, visit FDA's website at: 
                        <E T="03">https://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments. For questions relating to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>
                    Sections 744A and 744B of the FD&amp;C Act (21 U.S.C. 379j-41 and 379j-42), as amended by GDUFA III, authorize FDA to assess and collect fees associated with human generic drug products. Fees are assessed on: (1) certain types of applications for human generic drug products; (2) certain facilities where APIs and FDFs are produced; (3) certain DMFs associated with human generic drug products; and (4) generic drug applicants who own one or more approved ANDAs (the program fee) (see section 744B(a)(2) through (5) of the FD&amp;C Act). For more information about GDUFA III, please refer to the FDA website (
                    <E T="03">https://www.fda.gov/gdufa</E>
                    ).
                </P>
                <P>For FY 2027, the generic drug user fee rates are ANDA ($375,684), DMF ($109,899), domestic API facility ($39,680), foreign API facility ($54,680), domestic FDF facility ($230,033), foreign FDF facility ($245,033), domestic CMO facility ($55,208), foreign CMO facility ($70,208), large size operation generic drug applicant program ($1,927,291), medium size operation generic drug applicant program ($770,916), and small business generic drug applicant program ($192,729). These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027. The fee rates for FY 2027 are set out in table 1.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,15">
                    <TTITLE>Table 1—Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Fee rates
                            <LI>for FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Applications:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Abbreviated New Drug Application (ANDA)</ENT>
                        <ENT>$375,684</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Drug Master File (DMF)</ENT>
                        <ENT>109,899</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Facilities:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Active Pharmaceutical Ingredient (API)—Domestic</ENT>
                        <ENT>39,680</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">API—Foreign</ENT>
                        <ENT>54,680</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Finished Dosage Form (FDF)—Domestic</ENT>
                        <ENT>230,033</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FDF—Foreign</ENT>
                        <ENT>245,033</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Contract Manufacturing Organization (CMO)—Domestic</ENT>
                        <ENT>55,208</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">CMO—Foreign</ENT>
                        <ENT>70,208</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">GDUFA Program:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Large size operation generic drug applicant</ENT>
                        <ENT>1,927,291</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Medium size operation generic drug applicant</ENT>
                        <ENT>770,916</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small business generic drug applicant</ENT>
                        <ENT>192,729</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">II. Fee Revenue Amount for FY 2027</HD>
                <P>Under section 744B(b)(1)(B)(ii) of the FD&amp;C Act, the base revenue amount for FY 2027 for GDUFA III is $670,899,031. Under section 744B(c)(1) of the FD&amp;C Act, applicable inflation adjustments to base revenue shall be made beginning with FY 2024.</P>
                <P>Under section 744B(c)(2) of the FD&amp;C Act, for FY 2027, FDA shall, in addition to the inflation adjustment, apply a capacity planning adjustment to further adjust, as needed, the fee revenue and fees to reflect changes in the resource capacity needs of FDA for human generic drug activities.</P>
                <P>
                    Under section 744B(c)(3) of the FD&amp;C Act, for FY 2027, FDA may, in addition to the inflation and capacity planning adjustments, apply an operating reserve 
                    <PRTPAGE P="48155"/>
                    adjustment to further increase the fee revenue and fees if necessary to provide operating reserves of carryover user fees for human generic drug activities for not more than 10 weeks (or as applicable, shall apply such adjustment to decrease the fee revenues and fees to provide for not more than 12 weeks of such operating reserves).
                </P>
                <HD SOURCE="HD2">A. Inflation Adjustment</HD>
                <P>
                    As noted above, the base revenue amount for FY 2027 is $670,899,031. This is the total revenue amount specified for the prior fiscal year, FY 2026, pursuant to the statute (see section 744B(b)(1)(B) of the FD&amp;C Act).
                    <SU>1</SU>
                    <FTREF/>
                     GDUFA III specifies that the $670,899,031 is to be adjusted for inflation for FY 2027 using two separate adjustments: one for personnel compensation and benefits (PC&amp;B) and one for non-PC&amp;B costs (see sections 744B(c)(1)(B) and (C) of the FD&amp;C Act).
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Under section 744B(b)(1)(B)(ii) of the FD&amp;C Act, the base revenue amount for a fiscal year is equal to the total revenue amount established for the previous fiscal year, not including any adjustments for such previous fiscal year under section 744B(c)(3).
                    </P>
                </FTNT>
                <P>
                    The component of the inflation adjustment for PC&amp;B costs shall be the average annual percent change in the cost of all PC&amp;B paid per full-time equivalent (FTE) 
                    <SU>2</SU>
                    <FTREF/>
                     positions at FDA for the first 3 of the 4 preceding fiscal years, multiplied by the proportion of PC&amp;B costs to total FDA costs of human generic drug activities for the first 3 of the preceding 4 fiscal years (see section 744B(c)(1)(B) of the FD&amp;C Act).
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Full-time equivalents refer to a paid staff year, rather than a count of individual employees.
                    </P>
                </FTNT>
                <P>Table 2 summarizes the actual cost and total FTEs for the specified fiscal years and provides the percent change from the previous fiscal year and the average percent change over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,15,15,15,15">
                    <TTITLE>Table 2—FDA Personnel Compensation and Benefits (PC&amp;B) Each Year and Percent Change</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTEs</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent Change from Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The statute specifies that this 5.7330 percent should be multiplied by the proportion of PC&amp;B expended for human generic drug activities for the first 3 of the preceding 4 fiscal years. Table 3 shows the amount of PC&amp;B and the total amount obligated for human generic drug activities from FY 2023 through FY 2025.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,15,15,15,15">
                    <TTITLE>Table 3—PC&amp;B as a Percent of Fee Revenues Spent on Human Generic Drug Activities Over the Last 3 Years</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">PC&amp;B</ENT>
                        <ENT>$441,930,068</ENT>
                        <ENT>$479,495,256</ENT>
                        <ENT>$485,081,368</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-PC&amp;B</ENT>
                        <ENT>$301,930,017</ENT>
                        <ENT>$278,861,828</ENT>
                        <ENT>$248,716,445</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>$743,860,085</ENT>
                        <ENT>$758,357,084</ENT>
                        <ENT>$733,797,813</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B Percent</ENT>
                        <ENT>59.4104%</ENT>
                        <ENT>63.2282%</ENT>
                        <ENT>66.1056%</ENT>
                        <ENT>62.9147%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-PC&amp;B Percent</ENT>
                        <ENT>40.5896%</ENT>
                        <ENT>36.7718%</ENT>
                        <ENT>33.8944%</ENT>
                        <ENT>37.0853%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The payroll adjustment is 5.7330 percent multiplied by 62.9147 percent (or 3.6069 percent).</P>
                <P>
                    The statute specifies that the portion of the inflation adjustment for non-PC&amp;B costs for FY 2027 is the average annual percent change that occurred in the Consumer Price Index (CPI) for urban consumers (Washington-Arlington-Alexandria Area, DC-VA-MD-WV; not seasonally adjusted; all items; annual index) for the first 3 of the preceding 4 years of available data multiplied by the proportion of all costs other than PC&amp;B costs to total costs of human generic drug activities for the first 3 years of the preceding 4 fiscal years (see section 744B(c)(1)(C) of the FD&amp;C Act). Table 4 provides the summary data for the percent change in the specified CPI.
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The data are published by the Bureau of Labor Statistics and can be found on its website at: 
                        <E T="03">https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&amp;series_id=CUURS35ASA0,CUUSS35ASA0.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,12,12,12,12">
                    <TTITLE>Table 4—Annual and 3-Year Average Percent Change in CPI for Washington-Arlington-Alexandria Area</TTITLE>
                    <BOXHD>
                        <CHED H="1">Year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>305.317</ENT>
                        <ENT>315.186</ENT>
                        <ENT>321.993</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.1069%</ENT>
                        <ENT>3.2324%</ENT>
                        <ENT>2.1597%</ENT>
                        <ENT>2.8330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>To calculate the inflation adjustment for non-pay costs, we multiply the 3-year average percent change in the CPI (2.8330 percent) by the proportion of all costs other than PC&amp;B to total costs of human generic drug activities obligated. Because 62.9147 percent was obligated for PC&amp;B as shown in table 3, 37.0853 percent is the portion of costs other than PC&amp;B. The non-pay adjustment is 2.8330 percent times 37.0853 percent, or 1.0506 percent.</P>
                <P>
                    To complete the inflation adjustment for FY 2027, we add the PC&amp;B component (3.6069 percent) to the non-PC&amp;B component (1.0506 percent) for a total inflation adjustment of 4.6575 percent (rounded), and then add 1, 
                    <PRTPAGE P="48156"/>
                    making an inflation adjustment multiple of 1.046575. We then multiply the base revenue amount for FY 2027 ($670,899,031) by 1.046575, yielding an inflation-adjusted amount of $702,146,153.
                </P>
                <HD SOURCE="HD2">B. FY 2027 Statutory Fee Revenue Adjustments for Capacity Planning</HD>
                <P>
                    The statute specifies that after the base revenue amount for FY 2027 of $670,899,031 has been adjusted for inflation as described in section A above, the resulting amount shall be further adjusted to reflect changes in the resource capacity needs for human generic drug activities (see section 744B(c)(2) of the FD&amp;C Act). Following a process required in the statute, FDA established the capacity planning adjustment (CPA) methodology that is derived from the methodology and recommendations made in the report titled “Independent Evaluation of the GDUFA Resource Capacity Planning Adjustment Methodology: Evaluation and Recommendations” as announced in the 
                    <E T="04">Federal Register</E>
                     of August 3, 2020, and incorporating approaches and attributes determined appropriate by the Agency, except that the workload drivers are limited to those specified in the GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027 (GDUFA III Commitment Letter).
                    <SU>4</SU>
                    <FTREF/>
                     This methodology includes a continuous, iterative improvement approach, under which the Agency intends to refine its data and estimates for the core review activities to improve their accuracy over time.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Section 744B(c)(2)(B) of the FD&amp;C Act; see also section VIII.B.2.e. of the GDUFA III Commitment Letter available at 
                        <E T="03">https://www.fda.gov/media/153631/download.</E>
                    </P>
                </FTNT>
                <P>The CPA methodology consists of four steps:</P>
                <P>1. Forecast workload volumes: predictive models estimate the volume of workload for the upcoming FY.</P>
                <P>2. Forecast the resource needs: forecast algorithms are generated utilizing time reporting data. These algorithms estimate the required demand in FTEs for direct review-related effort. This is then compared to current available resources for the direct review-related workload.</P>
                <P>3. A managerial adjustment to assess the resource forecast in the context of additional internal factors: program leadership examines operational, financial, and resourcing data to assess whether FDA will be able to utilize additional funds during the fiscal year, and whether such funds are required to support additional review capacity. FTE amounts are adjusted, if needed.</P>
                <P>4. Convert the FTE need to dollars: utilizing FDA's fully loaded FTE cost model, the final feasible FTEs are converted to an equivalent dollar amount.</P>
                <P>Table 5 summarizes the forecasted workload volumes for the Center for Drug Evaluation and Research (CDER) for FY 2027 based on predictive models, as well as historical actuals from FY 2025 for comparison.</P>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s100,12,12">
                    <TTITLE>Table 5—CDER Actual FY 2025 Workload Volumes and Predicted FY 2027 Workload Volumes</TTITLE>
                    <BOXHD>
                        <CHED H="1">Workload driver category</CHED>
                        <CHED H="1">FY 2025 actuals</CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>predictions</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">
                            ANDA Originals 
                            <SU>1</SU>
                        </ENT>
                        <ENT>580</ENT>
                        <ENT>586</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            ANDA Supplements 
                            <SU>2</SU>
                        </ENT>
                        <ENT>11,383</ENT>
                        <ENT>11,916</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Pre-ANDA Meetings</ENT>
                        <ENT>114</ENT>
                        <ENT>106 </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Controlled Correspondences 
                            <SU>3</SU>
                        </ENT>
                        <ENT>3,722</ENT>
                        <ENT>3,655</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Suitability Petitions</ENT>
                        <ENT>95</ENT>
                        <ENT>100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            ANDA Annual Reports 
                            <SU>4</SU>
                        </ENT>
                        <ENT>14,223</ENT>
                        <ENT>14,655</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Active REMS Programs 
                            <SU>4</SU>
                             
                            <SU>5</SU>
                        </ENT>
                        <ENT>52</ENT>
                        <ENT>52</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         Excludes response to refused to receive (RTR) and Orig-2+. ANDA Original and Resubmissions/Amendments captured in time reporting data. The prediction consists of 122.3 complex ANDAs and 463.5 non-complex ANDAs.
                    </TNOTE>
                    <TNOTE>
                        <SU>2</SU>
                         Includes changes being effected (CBE) and prior approval supplement (PAS) Manufacturing and Labeling Supplements. PAS exclude response to RTRs, risk evaluation and mitigation strategies (REMS) and Bioequivalence Supplements. ANDA Supplement and Resubmissions/Amendments captured in time reporting data.
                    </TNOTE>
                    <TNOTE>
                        <SU>3</SU>
                         Includes all requesting controlled correspondences.
                    </TNOTE>
                    <TNOTE>
                        <SU>4</SU>
                         Data represents workload related to resource needs for post-marketing safety activities (developed in alignment with the methodology used in fee-setting under PDUFA (section 736 of the FD&amp;C Act) (21 U.S.C. 379h) and BsUFA (section 744H of the FD&amp;C Act) (21 U.S.C. 379j-52)), as applicable.
                    </TNOTE>
                    <TNOTE>
                        <SU>5</SU>
                         Represents the percentage of active REMS programs proportional to Center and User Fee by total number of qualifying products with the exclusion of the Opioid Shared System.
                    </TNOTE>
                </GPOTABLE>
                <P>FDA anticipates that any FTE gains could be funded through the expected FY 2027 collections amount without further adjustment from the CPA. As such, FDA determined that in FY 2027 the GDUFA fee amounts do not need adjustment from the CPA to provide funds for the program.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s100,15">
                    <TTITLE>
                        Table 6—Base Revenue Amount and Section 744B(
                        <E T="01">c</E>
                        )(1) and (2) Adjustment Amounts
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 744B(b)(1) of the FD&amp;C Act)</ENT>
                        <ENT>$670,899,031</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 744B(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>31,247,122</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (section 744B(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Revenue Amount after Adjustments in sections 744B(b)(1), 744B(c)(1), and 744B(c)(2) of the FD&amp;C Act</ENT>
                        <ENT>702,146,153</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="48157"/>
                <HD SOURCE="HD2">C. FY 2027 Statutory Fee Revenue Adjustments for Operating Reserve</HD>
                <P>Under section 744B(c)(3) of the FD&amp;C Act, for FY 2027, FDA may, in addition to the inflation and capacity planning adjustments, apply an operating reserve adjustment to further increase the fee revenue and fees if necessary to provide operating reserves of carryover user fees for human generic drug activities for not more than the number of weeks specified in such section (or as applicable, shall apply such adjustment to decrease the fee revenues and fees to provide for not more than 12 weeks of such operating reserves).</P>
                <P>The upward operating reserve adjustment is discretionary. For FY 2027, FDA may take an adjustment to provide for not more than 10 weeks of operating reserve. If carryover is more than 12 weeks of operating reserve, FDA must decrease the fee revenues and fees to provide for not more than 12 weeks of operating reserve. To calculate the 10-week and 12-week threshold amounts for the FY 2027 operating reserve adjustment, the FY 2027 adjusted revenue amount, $702,146,153 is divided by 52, resulting in a $13,502,811 cost of operation for 1 week. The 1-week value is then multiplied by 10 weeks to generate the 10-week operating reserve threshold amount for FY 2027 of $135,028,106. The 1-week value is multiplied by 12 to generate the 12-week operating reserve threshold amount for FY 2027 of $162,033,728.</P>
                <P>To determine the FY 2026 end-of-year operating reserves of carryover user fees, the Agency assessed the operating reserve of carryover user fees at the end of June 2026 and forecast collections and obligations in the fourth quarter of FY 2026 combined. This provides an estimated end-of-year FY 2026 operating reserve of carryover user fees of $198,194,080 which equates to 14.68 weeks of operations. As the estimated end-of-year FY 2026 operating reserve of carryover user fees exceeds the 12-week threshold of $162,033,728, FDA will apply an operating reserve adjustment of -$36,160,352 to reduce the FY 2027 fee revenue and fees under the statutory provision for operating reserve adjustments.</P>
                <P>Table 7 below summarizes FY 2027 fee revenue.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,15">
                    <TTITLE>Table 7—Total Estimated Adjusted Revenue Amount</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 744B(b)(1) of the FD&amp;C Act)</ENT>
                        <ENT>$670,899,031</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 744B(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>31,247,122</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (section 744B(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Operating Reserve Adjustment (section (744B(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>−36,160,352</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Revenue Amount (sections 744B(b)(1), 744B(c)(1), 744B(c)(2) and 744B(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>665,985,801</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Total Revenue Amount (rounded to the nearest thousand dollars)
                            <LI>(sections 744B(b)(1), 744B(c)(1), 744B(c)(2) and 744B(c)(3) of the FD&amp;C Act) (rounded to the nearest thousand)</LI>
                        </ENT>
                        <ENT>665,986,000</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. ANDA Filing Fee</HD>
                <P>
                    Under GDUFA III, the FY 2027 ANDA filing fee is owed by each applicant that submits an ANDA on or after October 1, 2026.
                    <SU>5</SU>
                    <FTREF/>
                     This fee is due on the submission date of the ANDA. Section 744B(b)(2)(B) of the FD&amp;C Act specifies that the ANDA fee will make up 33 percent of the $665,986,000, which is $219,775,380.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Section 744B(a)(3) of the FD&amp;C Act. The FY 2027 ANDA filing fee is owed for each ANDA submitted during FY 2027.
                    </P>
                </FTNT>
                <P>To calculate the ANDA fee, FDA estimated the number of full application equivalents (FAEs) that will be submitted in FY 2027. The submissions are broken down into three categories: new originals (submissions that have not been received by FDA previously), submissions that FDA RTR for reasons other than failure to pay fees, and applications that are resubmitted after an RTR decision for reasons other than failure to pay fees. An ANDA counts as one FAE; however, 75 percent of the fee paid for an ANDA that has been RTR shall be refunded according to GDUFA III if: (1) the ANDA is refused for a cause other than failure to pay fees or (2) the ANDA has been withdrawn prior to receipt (section 744B(a)(3)(D)(i) of the FD&amp;C Act). Therefore, an ANDA that is considered not to have been received by FDA due to reasons other than failure to pay fees or withdrawn prior to receipt counts as one-fourth of an FAE. After an ANDA has been RTR, the applicant has the option of resubmitting. For user fee purposes, these resubmissions are equivalent to new original submissions: ANDA resubmissions are charged the full amount for an application (one FAE).</P>
                <P>As shown in table 5, FDA estimates that 586 new original ANDAs will be submitted and incur filing fees in FY 2027. Not all the new original ANDAs will be received by FDA and some of those not received will be resubmitted in the same fiscal year. After accounting for these factors, FDA expects that the FAE count for ANDAs will be 585.28, rounded to 585 for FY 2027.</P>
                <P>The FY 2027 ANDA filing fee is estimated by dividing the number of FAEs that will incur the fee in FY 2027 (585) into the fee revenue amount to be derived from ANDA filing fees in FY 2027 ($219,775,380). The result, rounded to the nearest dollar, is a fee of $375,684 per ANDA.</P>
                <P>The statute provides that those ANDAs that include information about the production of APIs other than by reference to a DMF will pay an additional fee that is based on the number of such APIs and the number of facilities proposed to produce those ingredients, subject to certain conditions (see section 744B(a)(3)(F) of the FD&amp;C Act). FDA anticipates that this additional fee is unlikely to be assessed often; therefore, FDA has not included projections concerning the amount of this fee in calculating the fees for ANDAs.</P>
                <HD SOURCE="HD1">IV. DMF Fee</HD>
                <P>
                    Under GDUFA III, the DMF fee is owed by each person that owns a type II API DMF that is referenced, on or after October 1, 2012, in a generic drug submission by an initial letter of authorization.
                    <SU>6</SU>
                    <FTREF/>
                     This is a one-time fee for each DMF. This fee is due on the earlier of the date on which the first generic drug submission is submitted that references the associated DMF or the date on which the DMF holder requests the initial completeness assessment. Under section 744B(a)(2)(D)(iii) of the FD&amp;C Act, if a DMF has successfully undergone an initial completeness assessment and the fee is paid, the DMF will be placed on a publicly available list documenting DMFs available for reference.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         Section 744B(a)(2) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <PRTPAGE P="48158"/>
                <P>To calculate the DMF fee, FDA assessed the volume of DMF submissions over time. FDA assessed DMFs from October 1, 2023, to April 30, 2026, and concluded that averaging the number of fee-paying DMFs provided the most accurate model for predicting fee-paying DMFs for FY 2027. The monthly average of paid DMF submissions FDA received from FY 2024 through April 2026 is 25.23. To determine the FY 2027 projected number of fee-paying DMFs, the average of 25.23 DMF submissions is multiplied by 12 months, which results in 303 estimated FY 2027 fee-paying DMFs. FDA is estimating 303 fee-paying DMFs for FY 2027.</P>
                <P>The FY 2027 DMF fee is determined by dividing the DMF target revenue by the estimated number of fee-paying DMFs in FY 2027. Section 744B(b)(2)(A) of the FD&amp;C Act specifies that the DMF fees will make up 5 percent of the $665,986,000, which is $33,299,300. Dividing the DMF revenue amount ($33,299,300) by the estimated fee-paying DMFs (303), and rounding to the nearest dollar, yields a DMF fee of $109,899 for FY 2027.</P>
                <HD SOURCE="HD1">V. Foreign Facility Fee Differential</HD>
                <P>
                    Under GDUFA III, the annual fee (as discussed below) for a generic drug or API facility located outside the United States and its territories and possessions shall be $15,000 higher than the amount of the fee for a facility located in the United States and its territories and possessions.
                    <SU>7</SU>
                    <FTREF/>
                     The basis for this differential is the extra cost incurred by conducting an inspection outside the United States and its territories and possessions.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Section 744B(b)(2)(C) and (D) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">VI. FDF and CMO Facility Fees</HD>
                <P>
                    Under GDUFA III, the annual FDF facility fee is owed by each person who owns an FDF facility that is identified in at least one approved generic drug submission owned by that person or its affiliates.
                    <SU>8</SU>
                    <FTREF/>
                     The CMO facility fee is owed by each person who owns an FDF facility that is identified in at least one approved ANDA but is not identified in an approved ANDA held by the owner of that facility or its affiliates.
                    <SU>9</SU>
                    <FTREF/>
                     Section 744B(b)(2)(C) of the FD&amp;C Act specifies that the FDF and CMO facility fee revenue will make up 20 percent of the $665,986,000, which is $133,197,200.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Section 744B(a)(4)(A) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         Section 744A(5) and 744B(b)(2)(C) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>To calculate the fees, data from FDA's Integrity Services were utilized as the primary source of facility information for determining the denominators of each facility fee type. Integrity Services is the master data steward for all facility information provided in generic drug submissions received by FDA. A facility's reference status in an approved generic drug submission is extracted directly from submission data rather than relying on data from self-identification. This information provided the number of facilities referenced as FDF manufacturers in at least one approved generic drug submission. These findings were compared against facility statuses from FDA's Office of Inspections and Investigations (OII) to exclude facilities that are no longer operational.</P>
                <P>Based on these data, the FDF and CMO facility denominators are 156 FDF domestic, 332 FDF foreign, 92 CMO domestic, and 155 CMO foreign facilities for FY 2027.</P>
                <P>
                    GDUFA III specifies that the CMO facility fee is to be equal to 24 percent of the FDF facility fee.
                    <SU>10</SU>
                    <FTREF/>
                     Therefore, to generate the target collection revenue amount from FDF and CMO facility fees ($133,197,200), FDA must weight a CMO facility as 24 percent of an FDF facility. FDA set fees based on the estimate of 156 FDF domestic, 332 FDF foreign, 22.08 CMO domestic (92 multiplied by 24 percent), and 37.20 CMO foreign facilities (155 multiplied by 24 percent), which equals 547.28 total weighted FDF and CMO facilities for FY 2027.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Section 744B(b)(2)(C) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>To calculate the fee for domestic facilities, FDA first determines the total fee revenue that will result from the foreign facility differential by subtracting the fee revenue resulting from the foreign facility fee differential from the target collection revenue amount ($133,197,200) as follows: the foreign facility fee differential revenue equals the foreign facility fee differential ($15,000) multiplied by the number of FDF foreign facilities (332) plus the foreign facility fee differential ($15,000) multiplied by the number of CMO foreign facilities (155), totaling $7,305,000. This results in foreign fee differential revenue of $7,305,000 from the total FDF and CMO facility fee target collection revenue.</P>
                <P>Subtracting the foreign facility differential fee revenue ($7,305,000) from the total FDF and CMO facility target collection revenue ($133,197,200) results in a remaining facility fee revenue balance of $125,892,200. To determine the domestic FDF facility fee, FDA divides the $125,892,200 by the total weighted number of FDF and CMO facilities (547.28), which results in a domestic FDF facility fee of $230,033. The foreign FDF facility fee is $15,000 more than the domestic FDF facility fee, or $245,033.</P>
                <P>
                    According to GDUFA III, the domestic CMO fee is calculated as 24 percent of the amount of the domestic FDF facility fee.
                    <SU>11</SU>
                    <FTREF/>
                     Therefore, the domestic CMO fee is $55,208, rounded to the nearest dollar. The foreign CMO fee is calculated as the domestic CMO fee plus the foreign fee differential of $15,000. Therefore, the foreign CMO fee is $70,208.
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Section 744B(b)(2)(C) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">VII. API Facility Fee</HD>
                <P>
                    Under GDUFA III, the annual API facility fee is owed by each person who owns a facility that is identified in at least one approved generic drug submission in which the facility is approved to produce one or more API or in a Type II API DMF referenced in at least one approved generic drug submission.
                    <SU>12</SU>
                    <FTREF/>
                     Section 744B(b)(2)(D) of the FD&amp;C Act specifies the API facility fee will make up 6 percent of $665,986,000 in fee revenue, which is $39,959,160.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         Section 744B(a)(4)(A)(ii) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>To calculate the API facility fee, data from FDA's Integrity Services were utilized as the primary source of facility information for determining the denominator. As stated above, Integrity Services is the master data steward for all facility information provided in generic drug submissions received by FDA. A facility's reference status in an approved generic drug submission is extracted directly from submission data rather than relying on data from self-identification. This information provided the number of facilities referenced as API manufacturers in at least one approved generic drug submission. These findings were compared against facility statuses from FDA's OII to exclude facilities that are no longer operational.</P>
                <P>
                    Based on these data, the total number of API facilities identified was 753; of that number, 81 were domestic and 672 were foreign facilities. The foreign facility differential is $15,000. To calculate the fee for domestic facilities, FDA must first subtract the fee revenue that will result from the foreign facility fee differential. FDA takes the foreign facility differential ($15,000) and multiplies it by the number of foreign facilities (672) to determine the total fee revenue that will result from the foreign facility differential. As a result of this calculation, the foreign fee differential revenue will make up $10,080,000 of the total API fee revenue. Subtracting 
                    <PRTPAGE P="48159"/>
                    the foreign facility differential fee revenue ($10,080,000) from the total API facility target revenue ($39,959,160) results in a remaining balance of $29,879,160. To determine the domestic API facility fee, we divide the $29,879,160 by the total number of facilities (753), which gives us a domestic API facility fee of $39,680. The foreign API facility fee is $15,000 more than the domestic API facility fee, or $54,680.
                </P>
                <HD SOURCE="HD1">VIII. Generic Drug Applicant Program Fee</HD>
                <P>
                    Under GDUFA III, if a person and its affiliates own at least one but not more than five approved ANDAs on October 1, 2026, the person and its affiliates shall owe a small business generic drug applicant program fee.
                    <SU>13</SU>
                    <FTREF/>
                     If a person and its affiliates own at least 6 but not more than 19 approved ANDAs, the person and its affiliates shall owe a medium size operation generic drug applicant program fee.
                    <SU>14</SU>
                    <FTREF/>
                     If a person and its affiliates own at least 20 approved ANDAs, the person and its affiliates shall owe a large size operation generic drug applicant program fee.
                    <SU>15</SU>
                    <FTREF/>
                     Section 744B(b)(2)(E) of the FD&amp;C Act specifies the GDUFA program fee will make up 36 percent of $665,986,000 in fee revenue, which is $239,754,960.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         Sections 744B(a)(5)(A) and 744B(b)(2)(E)(i) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         Id.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         Id.
                    </P>
                </FTNT>
                <P>To determine the appropriate number of parent companies for each tier, FDA asked companies to claim their ANDAs and affiliates in the CDER NextGen Portal. The companies were able to confirm relationships currently present in FDA's records, while also reporting newly approved ANDAs, newly acquired ANDAs, and new affiliations.</P>
                <P>
                    In determining the appropriate number of approved ANDAs, FDA has factored in a number of variables that could affect the collection of the target revenue: (1) withdrawals of approved ANDAs by April 1: applicants who have submitted a written request for withdrawal of approval by April 1 of the previous fiscal year; 
                    <SU>16</SU>
                    <FTREF/>
                     (2) inactive ANDAs: applicants who have not submitted an annual report for one or more of their approved applications within the past 2 years; (3) CBER-approved ANDAs: applicants and their affiliates with CBER-approved ANDAs are added to CDER's population of approved ANDAs; (4) Program Fee Arrears List: parent companies that are on the arrears list for any fiscal year; (5) Out of Business companies: parent companies that are no longer in operation; and (6) Tier Adjustment: the frequency of large-tier, medium-tier, and small-tier companies moving to different tiers (or as applicable, dropping out of any tier) after the completion of the program fee methodology and tier determination.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         See section 744B(b)(2)(E)(ii) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>The list of original approved ANDAs from the Generic Drug Review Platform as of April 30, 2026, in addition to CBER's database, shows 229 applicants in the small business tier, 70 applicants in the medium size tier, and 85 applicants in the large size tier. Factoring in all the variables, we estimate there will be 196 applicants in the small business tier, 67 applicants in the medium size tier, and 78 applicants in the large size tier for FY 2027.</P>
                <P>
                    To calculate the GDUFA program fee, GDUFA III provides that large size operation generic drug applicants pay the full fee, medium size operation applicants pay two-fifths of the full fee, and small business applicants pay one-tenth of the full fee.
                    <SU>17</SU>
                    <FTREF/>
                     To generate the target collection revenue amount from GDUFA program fees ($239,754,960), we must weigh medium and small tiered applicants as a subset of a large size operation generic drug applicant. FDA will set fees based on the weighted estimate of 19.6 applicants in the small business tier (196 multiplied by 10 percent), 26.8 applicants in the medium size tier (67 multiplied by 40 percent), and 78 applicants in the large size tier, arriving at 124.4 total weighted applicants for FY 2027.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         Section 744B(b)(2)(E)(i) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>To generate the large size operation GDUFA program fee, FDA divides the target revenue amount of $239,754,960 by 124.4, which equals $1,927,291. The medium size operation GDUFA program fee is 40 percent of the full fee ($770,916), and the small business GDUFA program fee is 10 percent of the full fee ($192,729).</P>
                <HD SOURCE="HD1">IX. Fee Schedule for FY 2027</HD>
                <P>The fee rates for FY 2027 are displayed in table 8.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,15">
                    <TTITLE>Table 8—Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">Fee rates for FY 2027</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Applications:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Abbreviated New Drug Application (ANDA)</ENT>
                        <ENT>$375,684</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Drug Master File (DMF)</ENT>
                        <ENT>109,899</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Facilities:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Active Pharmaceutical Ingredient (API)—Domestic</ENT>
                        <ENT>39,680</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">API—Foreign</ENT>
                        <ENT>54,680</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Finished Dosage Form (FDF)—Domestic</ENT>
                        <ENT>230,033</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FDF—Foreign</ENT>
                        <ENT>245,033</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Contract Manufacturing Organization (CMO)—Domestic</ENT>
                        <ENT>55,208</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">CMO—Foreign</ENT>
                        <ENT>70,208</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">GDUFA Program:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Large size operation generic drug applicant</ENT>
                        <ENT>1,927,291</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Medium size operation generic drug applicant</ENT>
                        <ENT>770,916</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Small business generic drug applicant</ENT>
                        <ENT>192,729</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">X. Fee Payment Options and Procedures</HD>
                <P>The new fee rates are effective on October 1, 2026, and will remain in effect through September 30, 2027. Under sections 744B(a)(4) and (5) of the FD&amp;C Act, respectively, facility and program fees are generally due on the later of the first business day on or after October 1 of each fiscal year or the first business day after the enactment of an appropriations act providing for the collection and obligation of GDUFA fees for the fiscal year.</P>
                <P>
                    To pay the ANDA, DMF, API facility, FDF facility, CMO facility, and GDUFA program fees, complete the Generic Drug User Fee Cover Sheet, available at 
                    <PRTPAGE P="48160"/>
                    <E T="03">https://www.fda.gov/gdufa</E>
                     and 
                    <E T="03">https://userfees.fda.gov/OA_HTML/gdufaCAcdLogin.jsp,</E>
                     and generate a user fee identification (ID) number.
                </P>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov</E>
                    , a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov</E>
                    . Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID or invoice number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID or invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 744B(j) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15343 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-0007]</DEPDOC>
                <SUBJECT>Prescription Drug User Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for prescription drug user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the Prescription Drug User Fee Amendments of 2022 (PDUFA VII), authorizes FDA to collect application fees for certain applications for the review of human drug and biological products and prescription drug program fees for certain approved products. This notice establishes the fee rates for FY 2027.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>These fees apply to the period from October 1, 2026, through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For more information on prescription drug fees, visit FDA's website at: 
                        <E T="03">https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments. For questions relating to this notice:</E>
                         Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900; or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Sections 735 and 736 of the FD&amp;C Act (21 U.S.C. 379g and 379h) establish two different kinds of user fees. Fees are assessed as follows: (1) application fees are assessed on certain types of applications for the review of human drug and biological products and (2) prescription drug program fees are assessed on certain approved products (section 736(a) of the FD&amp;C Act). The statute also includes conditions under which such fees may be waived or reduced (section 736(d) of the FD&amp;C Act), or under which fee exceptions, refunds, or exemptions apply (sections 736(a)(1)(C) through (H), 736(a)(2)(B) through (C), and 736(k) of the FD&amp;C Act).</P>
                <P>
                    For FY 2023 through FY 2027, the base revenue amounts for the total revenues from all PDUFA fees are established by PDUFA VII. The base revenue amount for FY 2027 is $1,515,410,160. The FY 2027 base revenue amount is adjusted for (1) inflation, (2) strategic hiring and retention, and for (3) the resource capacity needs for the process for the review of human drug applications (the capacity planning adjustment (CPA)). This amount is further adjusted to include the additional dollar amount as specified in the statute (see section 736(b)(1)(G) of the FD&amp;C Act) to provide for additional full-time equivalent (FTE) 
                    <SU>1</SU>
                    <FTREF/>
                     positions to support PDUFA VII initiatives. If applicable, an operating reserve adjustment is added to provide sufficient operating reserves of carryover user fees. The amount from the preceding adjustments is then adjusted to provide for additional direct costs to fund PDUFA VII initiatives. Fee amounts are to be established each year so that revenues from application fees provide 20 percent of the total revenue, and prescription drug program fees provide 80 percent of the total revenue (see section 736(b)(2) of the FD&amp;C Act).
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Full-time equivalents refer to a paid staff year, rather than a count of individual employees.
                    </P>
                </FTNT>
                <P>
                    This document provides fee rates for FY 2027 for an application requiring covered clinical data 
                    <SU>2</SU>
                    <FTREF/>
                     ($4,600,753), for an application not requiring covered clinical data ($2,300,376), and for the prescription drug program fee ($416,857). These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027. For applications that are submitted on or after October 1, 2026, the new fee schedule must be used.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         As used herein, “covered clinical data” is “clinical data (other than bioavailability or bioequivalence studies) with respect to safety or effectiveness [that] are required for approval” (see section 736(a)(1)(A) of the FD&amp;C Act).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Fee Revenue Amount for FY 2027</HD>
                <P>The base revenue amount for FY 2027 is $1,515,410,160 (see section 736(b)(1)(A) and (b)(3) of the FD&amp;C Act). This amount is prior to any adjustments made for inflation, the strategic hiring and retention adjustment, CPA, additional dollar amount, operating reserve adjustment (if applicable), and additional direct costs (see section 736(b)(1) of the FD&amp;C Act).</P>
                <HD SOURCE="HD2">A. FY 2027 Statutory Fee Revenue Adjustments for Inflation</HD>
                <P>PDUFA VII specifies that the $1,515,410,160 is to be adjusted for inflation increases for FY 2027 using two separate adjustments: one for personnel compensation and benefits (PC&amp;B) and one for non-PC&amp;B costs (see section 736(c)(1) of the FD&amp;C Act).</P>
                <P>
                    The component of the inflation adjustment for payroll costs is the average annual percent change in the 
                    <PRTPAGE P="48161"/>
                    cost of all PC&amp;B paid per FTE position at FDA for the first 3 of the preceding 4 fiscal years, multiplied by the proportion of PC&amp;B costs to total FDA costs of the process for the review of human drug applications for the first 3 of the preceding 4 fiscal years (see section 736(c)(1)(A) and (B)(i) of the FD&amp;C Act).
                </P>
                <P>Table 1 summarizes the actual cost and FTE data for the specified fiscal years, provides the percent changes from the previous fiscal years, and provides the average percent changes over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,7">
                    <TTITLE>Table 1—FDA Personnel Compensation and Benefits (PC&amp;B) Each Year and Percent Changes</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTEs</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent Change from Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The statute specifies that this 5.7330 percent be multiplied by the proportion of PC&amp;B costs to the total FDA costs of the process for the review of human drug applications. Table 2 shows the PC&amp;B and the total obligations for the process for the review of human drug applications for the first 3 of the preceding 4 fiscal years.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,10">
                    <TTITLE>Table 2—PC&amp;B as a Percent of Total Cost of the Process for the Review of Human Drug Applications</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B (proportion of costs)</ENT>
                        <ENT>$1,040,590,183</ENT>
                        <ENT>$1,139,962,844</ENT>
                        <ENT>$1,218,505,064</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>$1,686,733,841</ENT>
                        <ENT>$1,772,198,497</ENT>
                        <ENT>$1,758,633,360</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B percent</ENT>
                        <ENT>61.6926%</ENT>
                        <ENT>64.3248%</ENT>
                        <ENT>69.2870%</ENT>
                        <ENT>65.1015%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The payroll adjustment is 5.7330 percent from table 1 multiplied by 65.1015 percent from table 2 resulting in 3.7323 percent.</P>
                <P>
                    The statute specifies that the portion of the inflation adjustment for non-payroll costs is the average annual percent change that occurred in the Consumer Price Index (CPI) for urban consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of the process for the review of human drug applications (as defined in section 735(6)) for the first 3 years of the preceding 4 fiscal years (see section 736(c)(1)(A) and (B)(ii)). Table 3 provides the summary data for the percent changes in the specified CPI for the Washington-Arlington-Alexandria area.
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The data are published by the Bureau of Labor Statistics and can be found on its website at: 
                        <E T="03">https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&amp;series_id=CUURS35ASA0,CUUSS35ASA0.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,10">
                    <TTITLE>Table 3—Annual and 3-Year Average Percent Change in CPI for Washington-Arlington-Alexandria Area</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">
                            3-Year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>305.317</ENT>
                        <ENT>315.186</ENT>
                        <ENT>321.993</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.1069%</ENT>
                        <ENT>3.2324%</ENT>
                        <ENT>2.1597%</ENT>
                        <ENT>2.8330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The statute specifies that this 2.8330 percent be multiplied by the proportion of all costs other than PC&amp;B to total costs of the process for the review of human drug applications. Because 65.1015 percent was obligated for PC&amp;B (as shown in table 2), 34.8985 percent is the portion of costs other than PC&amp;B (100 percent minus 65.1015 percent equals 34.8985 percent). The non-payroll adjustment is 2.8330 percent times 34.8985 percent, or 0.9887 percent.</P>
                <P>Next, we add the payroll adjustment (3.7323 percent) to the non-payroll adjustment (0.9887 percent), for a total inflation adjustment of 4.7210 percent (rounded) for FY 2027.</P>
                <P>We then multiply the base revenue amount for FY 2027 ($1,515,410,160) by 4.7210 percent, which produces an inflation adjustment amount of $71,542,514. Adding this amount to the base revenue amount yields an inflation-adjusted base revenue amount of $1,586,952,674.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,15">
                    <TTITLE>
                        Table 4—Base Revenue Amount and Section 736(
                        <E T="01">c</E>
                        )(1) Adjustment Amount
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 736(b)(3) of the FD&amp;C Act)</ENT>
                        <ENT>$1,515,410,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 736(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>71,542,514</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="48162"/>
                        <ENT I="01">Revenue Amount after Adjustments in sections 736(c)(1) of the FD&amp;C Act</ENT>
                        <ENT>1,586,952,674</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">B. FY 2027 Strategic Hiring and Retention Adjustment</HD>
                <P>For each fiscal year, after the annual base revenue established in section II is adjusted for inflation in accordance with section II.A, the statute directs FDA to further increase the fee revenue and fees to support strategic hiring and retention. For FY 2027, this amount is $4,000,000 (see section 736(c)(2)(A) of the FD&amp;C Act).</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,15">
                    <TTITLE>
                        Table 5—Base Revenue Amount and Section 736(
                        <E T="01">c</E>
                        )(1) Through (2) Adjustment Amounts
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 736(b)(3) of the FD&amp;C Act)</ENT>
                        <ENT>$1,515,410,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 736(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>71,542,514</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (section 736(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>4,000,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Revenue Amount after Adjustments in sections 736(c)(1) and (2) of the FD&amp;C Act</ENT>
                        <ENT>1,590,952,674</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">C. FY 2027 Statutory Fee Revenue Adjustments for Capacity Planning</HD>
                <P>
                    The statute specifies that after the base revenue amount for FY 2027 of $1,515,410,160 has been adjusted as described in sections II.A and II.B, this amount shall be further adjusted to reflect changes in the resource capacity needs for the process of human drug application reviews (see section 736(c)(3) of the FD&amp;C Act). Following a process agreed upon by FDA and industry during PDUFA VI reauthorization discussions and subsequently required in statute, FDA established a new CPA methodology and first applied it in the setting of FY 2021 fees. The establishment of this methodology is described in the 
                    <E T="04">Federal Register</E>
                     of August 3, 2020 (85 FR 46651). This methodology includes a continuous, iterative improvement approach, under which the Agency intends to refine its data and estimates for the core review activities to improve their accuracy over time. An adjustment for workload has been a critical aspect of the PDUFA program since PDUFA III in FY 2003 as it enables the program to adjust to shifts in review workload resulting from industry submissions to the Agency. The annual adjustment process allows greater accuracy than would be expected if workload adjustments were fixed at the start of the reauthorization period. The CPA is an evolution of the PDUFA workload adjuster and was implemented through a process agreed to by FDA and industry during PDUFA VI. The CPA builds on the concepts of the workload adjuster but realizes enhancements including the use of leading indicators of workload, use of full-time reporting data, the introduction of a managerial adjustment process as an internal check on the reasonableness of any adjustment, outputs measured in full-time equivalent employees, and the incorporation of adjustments into the base revenue amounts to ensure sustainability of payroll to support any new hires.
                </P>
                <P>The CPA methodology includes four steps:</P>
                <P>
                    1. 
                    <E T="03">Forecast workload volumes:</E>
                     predictive models estimate the volume of workload for the upcoming FY.
                </P>
                <P>
                    2. 
                    <E T="03">Forecast the resource needs:</E>
                     forecast algorithms are generated utilizing time reporting data. These algorithms estimate the required demand in FTEs for direct review-related effort. This is then compared to current available resources for the direct review-related workload.
                </P>
                <P>
                    3. 
                    <E T="03">A managerial adjustment to assess the resource forecast in the context of additional internal factors:</E>
                     program leadership examines operational, financial, and resourcing data to assess whether FDA will be able to utilize additional funds during the FY, and whether such funds are required to support additional review capacity. FTE amounts are adjusted, if needed.
                </P>
                <P>
                    4. 
                    <E T="03">Convert the FTE need to dollars:</E>
                     utilizing FDA's fully loaded FTE cost model, the final feasible FTEs are converted to an equivalent dollar amount.
                </P>
                <P>FDA calculated workload models for the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) individually. The final Center-level results were then combined to determine the total FY 2027 PDUFA CPA.</P>
                <P>Table 6 summarizes the forecasted workload volumes for CDER in FY 2027 based on predictive models, as well as historical actuals from FY 2025 for comparison.</P>
                <GPOTABLE COLS="3" OPTS="L2,i1" CDEF="s100,15,19">
                    <TTITLE>Table 6—CDER Actual FY 2025 Workload Volumes and Predicted FY 2027 Workload Volumes</TTITLE>
                    <BOXHD>
                        <CHED H="1">Workload category</CHED>
                        <CHED H="1">FY 2025 actuals</CHED>
                        <CHED H="1">FY 2027 predictions</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Efficacy Supplements</ENT>
                        <ENT>257</ENT>
                        <ENT>268</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Labeling Supplements</ENT>
                        <ENT>1,018</ENT>
                        <ENT>996</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Manufacturing Supplements</ENT>
                        <ENT>2,653</ENT>
                        <ENT>2,766</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            NDA/BLA 
                            <SU>1</SU>
                             Original
                        </ENT>
                        <ENT>145</ENT>
                        <ENT>131</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            PDUFA Industry Meetings (including WROs 
                            <SU>2</SU>
                            )
                        </ENT>
                        <ENT>4,107</ENT>
                        <ENT>4,505</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Active Commercial INDs 
                            <SU>3</SU>
                        </ENT>
                        <ENT>10,215</ENT>
                        <ENT>10,715</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Annual Reports 
                            <SU>4</SU>
                        </ENT>
                        <ENT>3,555</ENT>
                        <ENT>3,618</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            PMR/PMC-Related Documents 
                            <SU>4</SU>
                        </ENT>
                        <ENT>1,778</ENT>
                        <ENT>1,791</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Active REMS Programs 
                            <SU>4</SU>
                             
                            <SU>5</SU>
                        </ENT>
                        <ENT>24</ENT>
                        <ENT>23</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         New drug applications (NDA)/biological license applications (BLA).
                    </TNOTE>
                    <TNOTE>
                        <SU>2</SU>
                         Written responses only (WROs).
                        <PRTPAGE P="48163"/>
                    </TNOTE>
                    <TNOTE>
                        <SU>3</SU>
                         For purpose of the CPA, this is defined as an active commercial investigational new drug (IND) for which a document has been received in the past 18 months.
                    </TNOTE>
                    <TNOTE>
                        <SU>4</SU>
                         Represents activities related to the review of materials submitted to the application file after approval.
                    </TNOTE>
                    <TNOTE>
                        <SU>5</SU>
                         Represents the percentage of active risk evaluation and management strategy (REMS) programs proportional to Center and User Fee by total number of qualifying products with the exclusion of the Opioid Shared System.
                    </TNOTE>
                </GPOTABLE>
                <P>Table 7 summarizes the forecasted workload volumes for CBER in FY 2027 based on predictive models, as well as the corresponding historical actuals from 2025 for comparison.</P>
                <GPOTABLE COLS="3" OPTS="L2,i1" CDEF="s50,12,12">
                    <TTITLE>Table 7—CBER Actual FY 2025 Workload Volumes and Predicted FY 2027 Workload Volumes</TTITLE>
                    <BOXHD>
                        <CHED H="1">Workload category</CHED>
                        <CHED H="1">FY 2025 actuals</CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>predictions</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Efficacy Supplements</ENT>
                        <ENT>35</ENT>
                        <ENT>25</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Labeling Supplements</ENT>
                        <ENT>64</ENT>
                        <ENT>67</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Manufacturing Supplements</ENT>
                        <ENT>907</ENT>
                        <ENT>905</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            NDA/BLA 
                            <SU>1</SU>
                             Original
                        </ENT>
                        <ENT>11</ENT>
                        <ENT>13</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            PDUFA Industry Meetings (including WROs 
                            <SU>2</SU>
                            )
                        </ENT>
                        <ENT>1,029</ENT>
                        <ENT>1,116</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Active Commercial INDs 
                            <SU>3</SU>
                        </ENT>
                        <ENT>1,914</ENT>
                        <ENT>2,063</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Annual Reports 
                            <SU>4</SU>
                        </ENT>
                        <ENT>346</ENT>
                        <ENT>331</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            PMR/PMC-Related Documents 
                            <SU>4</SU>
                        </ENT>
                        <ENT>224</ENT>
                        <ENT>220</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Active REMS Programs 
                            <SU>4</SU>
                             
                            <SU>5</SU>
                        </ENT>
                        <ENT>0</ENT>
                        <ENT>1</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         New drug applications (NDA)/biological license applications (BLA).
                    </TNOTE>
                    <TNOTE>
                        <SU>2</SU>
                         Written responses only (WROs).
                    </TNOTE>
                    <TNOTE>
                        <SU>3</SU>
                         For purpose of the CPA, this is defined as an active commercial investigational new drug (IND) for which a document has been received in the past 18 months.
                    </TNOTE>
                    <TNOTE>
                        <SU>4</SU>
                         Represents activities related to the review of materials submitted to the application file after approval.
                    </TNOTE>
                    <TNOTE>
                        <SU>5</SU>
                         Represents the percentage of active REMS programs proportional to Center and User Fee by total number of qualifying products with the exclusion of the Opioid Shared System.
                    </TNOTE>
                </GPOTABLE>
                <P>FDA anticipates that any FTE gains could be funded through the expected FY 2027 collections amount without further adjustment from the CPA. As such, FDA determined that in FY 2027 the PDUFA fee amounts do not need adjustment from the CPA to provide funds for the program.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s25,12">
                    <TTITLE>Table 8—FY 2027 PDUFA CPA</TTITLE>
                    <BOXHD>
                        <CHED H="1">Center</CHED>
                        <CHED H="1">
                            FY 2027
                            <LI>PDUFA CPA</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">CDER</ENT>
                        <ENT>$0</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">CBER</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT>0</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,15">
                    <TTITLE>
                        Table 9—Base Revenue Amount and Section 736(
                        <E T="01">c</E>
                        )(1) Through (3) Adjustment Amounts
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 736(b)(3) of the FD&amp;C Act)</ENT>
                        <ENT>$1,515,410,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 736(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>71,542,514</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (section 736(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>4,000,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (section 736(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Revenue Amount after Adjustments in sections 736(c)(1), (2), and (3) of the FD&amp;C Act</ENT>
                        <ENT>1,590,952,674</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">D. FY 2027 Statutory Fee Revenue Adjustments for Additional Dollar Amounts</HD>
                <P>PDUFA VII provides an additional dollar amount for each of the 5 fiscal years covered by PDUFA VII for additional FTEs to support enhancements outlined in the PDUFA VII commitment letter. The additional dollar amount for FY 2027 as outlined in statute is $1,314,620 (see section 736(b)(1)(G)(v) of the FD&amp;C Act). This amount will be added to the total FY 2027 PDUFA VII revenue amount.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,15">
                    <TTITLE>
                        Table 10—Base Revenue Amount and Section 736(
                        <E T="01">c</E>
                        )(1) Through (3) Adjustment Amounts
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 736(b)(3) of the FD&amp;C Act)</ENT>
                        <ENT>$1,515,410,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 736(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>71,542,514</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (section 736(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>4,000,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (section 736(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Additional Dollar Amounts Adjustment (section 736(b)(1)(G) of the FD&amp;C Act)</ENT>
                        <ENT>1,314,620</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Cumulative Revenue Amount after Adjustments in sections 736(c)(1), (2), and (3) of the FD&amp;C Act</ENT>
                        <ENT>1,592,267,294</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="48164"/>
                <HD SOURCE="HD2">E. FY 2027 Statutory Fee Revenue Adjustments for Operating Reserve</HD>
                <P>PDUFA VII provides for an operating reserve adjustment that may result in an increase or decrease in fee revenue and fees for a given FY (see section 736(c)(4) of the FD&amp;C Act). For FY 2027, FDA is required to further increase fee revenue and fees if an adjustment is necessary to provide for at least 10 weeks of operating reserves of carryover user fees (see section 736(c)(4)(A)(iii) of the FD&amp;C Act). If FDA has carryover balances of user fees in excess of 14 weeks of operating reserves, FDA is required to decrease fee revenue and fees to provide for not more than 14 weeks of operating reserves of carryover user fees (see section 736(c)(4)(B) of the FD&amp;C Act).</P>
                <P>To determine the dollar amounts for the 10-week and 14-week operating reserve thresholds, the adjustments (inflation, strategic hiring and retention, capacity planning, and additional dollar amount) discussed in sections II.A, II.B, II.C, and II.D are applied to the FY 2027 base revenue (see section 736(c)(4)(A) of the FD&amp;C Act), resulting in $1,592,267,294. This amount is then divided by 52 to generate the 1-week operating amount of $30,620,525. The 1-week operating amount is then multiplied by 10 and 14. This results in a 10-week threshold amount of $306,205,250 and a 14-week threshold amount of $428,687,350.</P>
                <P>
                    To determine the FY 2026 end-of-year operating reserves of carryover user fees, the Agency assessed the operating reserve of carryover fees at the end of June 2026 and forecasted collections and obligations in the fourth quarter of FY 2026 combined. This provides an estimated end-of-year FY 2026 operating reserve of carryover user fees of $564,378,337, which equates to 18.43 weeks of operations.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         For purposes of the operating reserve adjustment under PDUFA VII, the operating reserve of carryover user fees includes only user fee funds that are available for obligation. FDA excludes from the operating reserve of carryover user fee funds that were collected prior to 2010 and that are held by FDA, but which are considered unavailable for obligation due to lack of an appropriation ($78,850,995).
                    </P>
                </FTNT>
                <P>Because the estimated FY 2026 end-of-year operating reserves of carryover user fees exceeds the 14-week threshold of $428,687,350, FDA will apply an operating reserve adjustment of −$135,690,987 to reduce the FY 2027 fee revenue and fees under the statutory provision for operating reserve adjustments.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s200,15">
                    <TTITLE>
                        Table 11—Base Revenue Amount and Section 736(
                        <E T="01">c</E>
                        )(1) Through (4) Adjustment Amounts
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 736(b)(3) of the FD&amp;C Act)</ENT>
                        <ENT>$1,515,410,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 736(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>71,542,514</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (section 736(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>4,000,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (section 736(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Additional Dollar Amounts Adjustment (section 736(b)(1)(G) of the FD&amp;C Act)</ENT>
                        <ENT>1,314,620</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Operating Reserve Adjustment (section (736(c)(4) of the FD&amp;C Act)</ENT>
                        <ENT>−135,690,987</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Cumulative Revenue Amount after Adjustments in sections 736(c)(1), (2), (3), and (4) of the FD&amp;C Act</ENT>
                        <ENT>1,456,576,307</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">F. FY 2027 Statutory Fee Revenue Adjustments for Additional Direct Cost</HD>
                <P>PDUFA VII specifies that an additional direct cost of $41,505,100 is to be added to the total FY 2027 PDUFA revenue amount (see sections 736(c)(5)(A)(ii) and 736(c)(5)(B)(iv) of the FD&amp;C Act). With respect to target revenue for FY 2027, adding the additional direct cost amount of $41,505,100 to the inflation, strategic hiring and retention, CPA, additional dollar amount, and operating reserve adjustment results in the total revenue amount of $1,498,081,000 (rounded to the nearest thousand dollars).</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,14">
                    <TTITLE>Table 12—Total Estimated Adjusted Revenue Amount</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Statutory Fee Revenue Base Amount (section 736(b)(3) of the FD&amp;C Act)</ENT>
                        <ENT>$1,515,410,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (section 736(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>71,542,514</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (section 736(c)(2)(B) of the FD&amp;C Act)</ENT>
                        <ENT>4,000,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (section 736(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Additional Dollar Amounts Adjustment (section 736(b)(1)(G) of the FD&amp;C Act)</ENT>
                        <ENT>1,314,620</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Operating Reserve Adjustment (section (736(c)(4) of the FD&amp;C Act)</ENT>
                        <ENT>−135,690,987</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Additional Direct Cost Adjustment (section 736(c)(5) of the FD&amp;C Act)</ENT>
                        <ENT>41,505,100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Cumulative Revenue Amount after Adjustments in sections 736(c)(1), (2), (3), (4), and (5) of the FD&amp;C Act</ENT>
                        <ENT>1,498,081,407</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Cumulative Revenue Amount after Adjustments in sections 736(c)(1), (2), (3), (4), and (5) of the FD&amp;C Act (rounded to the nearest thousand)</ENT>
                        <ENT>1,498,081,000</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. Application Fee Calculations</HD>
                <HD SOURCE="HD2">A. Application Fee Revenues and Application Fees</HD>
                <P>Application fees will be set to generate 20 percent of the total revenue amount, amounting to $299,616,200 in FY 2027.</P>
                <HD SOURCE="HD2">B. Estimate of the Number of Fee-Paying Applications and Setting the Application Fees</HD>
                <P>
                    FDA has estimated the total number of fee-paying full application equivalents (FAEs) it expects to receive during the next fiscal year by averaging the number of fee-paying FAEs received in the ten most recently completed fiscal years. For FY 2027 fee setting, the 10 relevant fiscal years are FY 2016-2025. Prior year FAE totals are updated annually to reflect refunds and waivers processed after the close of the fiscal year.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         In the PDUFA fee setting FRNs for FYs 2023 and 2024, this adjustment for refunds was erroneously excluded, resulting in an overstatement of the historical FAE data.
                    </P>
                </FTNT>
                <P>
                    In estimating the number of fee-paying FAEs, an application requiring 
                    <PRTPAGE P="48165"/>
                    covered clinical data 
                    <SU>6</SU>
                    <FTREF/>
                     counts as one FAE. An application not requiring covered clinical data counts as one-half of an FAE. An application that is withdrawn before filing, or refused for filing, counts as one-fourth of an FAE if the applicant initially paid a full application fee, or one-eighth of an FAE if the applicant initially paid one-half of the full application fee amount.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         As defined in section 736(a)(1)(A)(i) of the FD&amp;C Act.
                    </P>
                </FTNT>
                <P>As table 13 shows, the average number of fee-paying FAEs received annually in FY 2016 through FY 2025 is 65.123. FDA will set fees for FY 2027 based on this estimate as the number of full application equivalents that will be subject to fees.</P>
                <GPOTABLE COLS="12" OPTS="L2,nj,i1" CDEF="s50,6C,6C,6C,6C,6C,6C,6C,6C,6C,6C,7C">
                    <TTITLE>Table 13—Fee-Paying FAEs</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2016</CHED>
                        <CHED H="1">2017</CHED>
                        <CHED H="1">2018</CHED>
                        <CHED H="1">2019</CHED>
                        <CHED H="1">2020</CHED>
                        <CHED H="1">2021</CHED>
                        <CHED H="1">2022</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">
                            10-year
                            <LI>average</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Fee-Paying FAEs</ENT>
                        <ENT>70.483</ENT>
                        <ENT>79.75</ENT>
                        <ENT>68.875</ENT>
                        <ENT>81.25</ENT>
                        <ENT>56.75</ENT>
                        <ENT>78.875</ENT>
                        <ENT>45.125</ENT>
                        <ENT>49.5</ENT>
                        <ENT>52.875</ENT>
                        <ENT>67.75</ENT>
                        <ENT>65.123</ENT>
                    </ROW>
                    <TNOTE>
                        <E T="02">Note:</E>
                         Prior year FAE totals are updated annually to reflect refunds and waivers processed after the close of the fiscal year.
                    </TNOTE>
                </GPOTABLE>
                <P>The FY 2027 application fee is estimated by dividing the average number of full applications that paid fees from FY 2016 through FY 2025, 65.123, into the fee revenue amount to be derived from application fees in FY 2027, $299,616,200. The result is a fee of $4,600,753 per full application requiring clinical data, and $2,300,376 per application not requiring clinical data.</P>
                <HD SOURCE="HD1">IV. Fee Calculation for Prescription Drug Program Fees</HD>
                <P>PDUFA VII assesses prescription drug program fees for certain prescription drug products. Program fees will be set to generate 80 percent of the total target revenue, amounting to $1,198,464,800 in FY 2027.</P>
                <P>An applicant will not be assessed more than five program fees for a FY for prescription drug products identified in a single approved NDA or BLA (see section 736(a)(2)(C) of the FD&amp;C Act). Applicants are assessed a program fee for a FY for user fee eligible prescription drug products identified in a human drug application approved as of October 1 of such FY. Additionally, applicants are assessed a program fee for a product that is not a prescription drug product on October 1 because it is included in the discontinued section of the Orange Book or the CDER/CBER Billable Biologics List on that date, if the product becomes a fee-eligible prescription drug product during the FY.</P>
                <P>FDA estimates 3,031 program fees will be invoiced in FY 2027 before factoring in waivers, refunds, exceptions, and exemptions. FDA approximates that there will be 113 waivers and refunds granted. Additionally, FDA approximates that another 43 program fees will be exempted in FY 2027 based on the orphan drug exemption in section 736(k) of the FD&amp;C Act.</P>
                <P>FDA estimates 2,875 program fees in FY 2027, after allowing for an estimated 156 waivers and reductions, including the orphan drug exemptions, excepted and exempted fee-liable products. The FY 2027 prescription drug program fee rate is calculated by dividing the adjusted total revenue from program fees ($1,198,464,800) by the estimated 2,875 program fees, resulting in a FY 2027 program fee of $416,857 (rounded to the nearest dollar).</P>
                <HD SOURCE="HD1">V. Fee Schedule for FY 2027</HD>
                <P>The fee rates for FY 2027 are displayed in table 14.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s50,10">
                    <TTITLE>Table 14—Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Fee rates
                            <LI>for</LI>
                            <LI>FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Application:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Requiring clinical data</ENT>
                        <ENT>$4,600,753</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Not requiring clinical data</ENT>
                        <ENT>2,300,376</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Program</ENT>
                        <ENT>416,857</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">VI. Fee Payment Options and Procedures</HD>
                <HD SOURCE="HD2">A. Application Fees</HD>
                <P>
                    The appropriate application fee established in the new fee schedule must be paid for any application subject to fees under PDUFA VII that is submitted on or after October 1, 2026. To pay, complete the Prescription Drug User Fee Cover Sheet, available at 
                    <E T="03">https://userfees.fda.gov/OA_HTML/pdufaCAcdLogin.jsp,</E>
                     and generate a user fee identification (ID) number.
                </P>
                <P>
                    Payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov,</E>
                     a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov.</E>
                     Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID or invoice number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID or invoice number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>
                    FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 736(h) of the FD&amp;C Act and 45 CFR part 30), 
                    <PRTPAGE P="48166"/>
                    meaning the invoice balance due amount is referred to collections.
                </P>
                <HD SOURCE="HD2">B. Prescription Drug Program Fees</HD>
                <P>FDA will issue invoices and payment instructions for FY 2027 program fees under the new fee schedule in August 2026. Under section 736(a)(2)(A)(i) of the FD&amp;C Act, prescription drug program fees are due on October 1, 2026.</P>
                <P>FDA will issue invoices in December 2026 for products that qualify for FY 2027 program fee assessments after the October 2026 billing.</P>
                <HD SOURCE="HD2">C. Fee Waivers and Refunds</HD>
                <P>To qualify for consideration for a waiver or reduction under section 736(d) of the FD&amp;C Act, an exemption under section 736(k) of the FD&amp;C Act, or the return of an application or program fee paid under section 736 of the FD&amp;C Act, including if the fee is claimed to have been paid in error, a person must submit to FDA a written request justifying such waiver, reduction, exemption or return not later than 180 days after such fee is due (section 736(i) of the FD&amp;C Act). A request submitted under this paragraph must include any legal authorities under which the request is made.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15334 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2026-N-7707]</DEPDOC>
                <SUBJECT>Biosimilar User Fee Rates for Fiscal Year 2027</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for biosimilar user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological product approved in a biosimilar biological product application. BsUFA III directs FDA to establish, before the beginning of each fiscal year, the amount of initial and annual biosimilar biological product development (BPD) fees, the reactivation fee, and the biosimilar biological product application and program fees for such year.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>These fees apply to the period from October 1, 2026, through September 30, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301-796-7900, or 
                        <E T="03">FDAUserFees@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>Sections 744G, 744H, and 744I of the FD&amp;C Act (21 U.S.C. 379j-51, 379j-52, and 379j-53), as amended by BsUFA III, authorize the collection of fees for biosimilar biological products. Under section 744H(a)(1)(A) of the FD&amp;C Act, the initial BPD fee for a product is due when the sponsor submits an investigational new drug (IND) application that FDA determines is intended to support a biosimilar biological product application or within 7 calendar days after FDA grants the first BPD meeting, whichever occurs first. A sponsor who has paid the initial BPD fee is considered to be participating in FDA's BPD program for that product.</P>
                <P>Under section 744H(a)(1)(B) of the FD&amp;C Act, once a sponsor has paid the initial BPD fee for a product, the annual BPD fee is assessed beginning with the next fiscal year. The annual BPD fee is assessed for the product each fiscal year until the sponsor submits a marketing application for the product that is accepted for filing, the sponsor discontinues participation in FDA's BPD program for the product, or the sponsor has been administratively removed from the BPD program for the product.</P>
                <P>Under section 744H(a)(1)(D) of the FD&amp;C Act, if a sponsor has discontinued participation in FDA's BPD program or has been administratively removed from the BPD program for a product and wants to reengage with FDA on development of the product, the sponsor must pay all annual BPD fees previously assessed for such product and still owed, and a reactivation fee to resume participation in the program. The sponsor must pay the reactivation fee by the earlier of the following dates: (1) no later than 7 calendar days after FDA grants the sponsor's request for a BPD meeting for that product or (2) upon the date of submission by the sponsor of an IND describing an investigation that FDA determines is intended to support a biosimilar biological product application for that product. The sponsor will be assessed an annual BPD fee beginning in the next fiscal year after payment of the reactivation fee.</P>
                <P>BsUFA III also authorizes fees for certain biosimilar biological product applications and for each biosimilar biological product identified in an approved biosimilar biological product application (section 744H(a)(2) and (3) of the FD&amp;C Act). Under certain conditions, FDA will grant a small business a waiver of the biosimilar biological product application fee (section 744H(d)(1) of the FD&amp;C Act).</P>
                <P>For FY 2023 through FY 2027, the base revenue amounts for the total revenues from all BsUFA fees are established by BsUFA III. For FY 2027, the base revenue amount is the FY 2026 total revenue amount excluding any operating reserve adjustment, which equates to the amount of $58,926,749. The FY 2027 base revenue amount is to be adjusted by the inflation adjustment, strategic hiring and retention adjustment, capacity planning adjustment (CPA), operating reserve adjustment, and the additional dollar amount. Each of these adjustments will be discussed in the sections below.</P>
                <P>This document provides fee rates for FY 2027 for the initial and annual BPD fee ($10,000), for the reactivation fee ($20,000), for an application requiring clinical data ($1,124,936) for an application not requiring clinical data ($562,468) and for the program fee ($195,887). These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027. For applications that are submitted on or after October 1, 2026, the new fee schedule must be used.</P>
                <HD SOURCE="HD1">II. Fee Revenue Amount for FY 2027</HD>
                <P>The base revenue amount for FY 2027 is $58,926,749 prior to adjustments for inflation, strategic hiring and retention, capacity planning, operating reserves, and the additional dollar amount (see section 744H(b) and (c) of the FD&amp;C Act).</P>
                <HD SOURCE="HD2">A. FY 2027 Statutory Fee Revenue Adjustments for Inflation</HD>
                <P>BsUFA III specifies that the $58,926,749 is to be adjusted for inflation increases for FY 2027 using two separate adjustments: one for personnel compensation and benefits (PC&amp;B) and one for non-PC&amp;B costs (see section 744H(c)(1) of the FD&amp;C Act).</P>
                <P>
                    The component of the inflation adjustment for payroll costs shall be the average annual percent change in the cost of all PC&amp;B paid per full-time 
                    <PRTPAGE P="48167"/>
                    equivalent (FTE) 
                    <SU>1</SU>
                    <FTREF/>
                     positions at FDA for the first 3 of the preceding 4 fiscal years, multiplied by the proportion of PC&amp;B costs to total FDA costs of the process for the review of biosimilar biological product applications for the first 3 of the preceding 4 fiscal years (see section 744H(c)(1)(B) of the FD&amp;C Act).
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Full-time equivalents refer to a paid staff year, rather than a count of individual employees.
                    </P>
                </FTNT>
                <P>Table 1 summarizes the actual cost and FTE data for the specified fiscal years and provides the percent changes from the previous fiscal years and the average percent changes over the first 3 of the 4 fiscal years preceding FY 2027. The 3-year average is 5.7330 percent.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 1—FDA PC&amp;B Each Year and Percent Changes</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B</ENT>
                        <ENT>$3,436,513,000</ENT>
                        <ENT>$3,791,729,000</ENT>
                        <ENT>$3,875,940,000</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total FTE</ENT>
                        <ENT>18,729</ENT>
                        <ENT>19,687</ENT>
                        <ENT>19,139</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B per FTE</ENT>
                        <ENT>$183,486</ENT>
                        <ENT>$192,601</ENT>
                        <ENT>$202,515</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Percent Change from Previous Year</ENT>
                        <ENT>7.0838%</ENT>
                        <ENT>4.9677%</ENT>
                        <ENT>5.1474%</ENT>
                        <ENT>5.7330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The statute specifies that this 5.7330 percent be multiplied by the proportion of PC&amp;B costs to the total FDA costs of the process for the review of biosimilar biological product applications. Table 2 shows the PC&amp;B and the total obligations for the process for the review of biosimilar biological product applications for the first 3 of the preceding 4 fiscal years.</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 2—PC&amp;B as a Percent of Total Cost of the Process for the Review of Biosimilar Biological Product Applications</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Total PC&amp;B (proportion of costs)</ENT>
                        <ENT>$45,893,774</ENT>
                        <ENT>$55,198,837</ENT>
                        <ENT>$55,760,956</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Costs</ENT>
                        <ENT>$86,101,288</ENT>
                        <ENT>$91,066,972</ENT>
                        <ENT>$84,866,379</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">PC&amp;B percent</ENT>
                        <ENT>53.3021%</ENT>
                        <ENT>60.6135%</ENT>
                        <ENT>65.7044%</ENT>
                        <ENT>59.8733%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The payroll adjustment is 5.7330 percent from table 1 multiplied by 59.8733 percent (or 3.4325 percent).</P>
                <P>
                    The statute specifies that the portion of the inflation adjustment for nonpayroll costs is the average annual percent change that occurred in the Consumer Price Index (CPI) for urban consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; not seasonally adjusted; all items; annual index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than PC&amp;B costs to total costs of the process for the review of biosimilar biological product applications for the first 3 years of the preceding 4 fiscal years (see section 744H(c)(1)(B) of the FD&amp;C Act). Table 3 provides the summary data for the percent changes in the specified CPI for the Washington-Arlington-Alexandria area.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         The data are published by the Bureau of Labor Statistics and can be found on its website at: 
                        <E T="03">https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&amp;series_id=CUURS35ASA0,CUUSS35ASA0.</E>
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,14,14,14">
                    <TTITLE>Table 3—Annual and 3-Year Average Percent Change in CPI for Washington-Arlington-Alexandria Area</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fiscal year</CHED>
                        <CHED H="1">2023</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">3-Year average</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Annual CPI</ENT>
                        <ENT>305.317</ENT>
                        <ENT>315.186</ENT>
                        <ENT>321.993</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Percent Change</ENT>
                        <ENT>3.1069%</ENT>
                        <ENT>3.2324%</ENT>
                        <ENT>2.1597%</ENT>
                        <ENT>2.8330%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The statute specifies that this 2.8330 percent be multiplied by the proportion of all costs other than PC&amp;B to total costs of the process for the review of biosimilar biological product applications obligated. Since 59.8733 percent was obligated for PC&amp;B (as shown in table 2), 40.1267 percent is the portion of costs other than PC&amp;B (100 percent minus 59.8733 percent equals 40.1267 percent). The non-payroll adjustment is 2.8330 percent times 40.1267 percent, 1.1368 percent.</P>
                <P>Next, we add the payroll adjustment (3.4325 percent) to the nonpayroll adjustment (1.1368 percent), for a total inflation adjustment of 4.5693 percent (rounded) for FY 2027.</P>
                <P>We then multiply the base revenue amount for FY 2027 ($58,926,749) by the inflation adjustment percentage (4.5693 percent), yielding an inflation adjustment of $2,692,540. Adding this amount yields an inflation-adjusted amount of $61,619,289.</P>
                <HD SOURCE="HD2">B. Strategic Hiring and Retention Adjustment</HD>
                <P>The statute specifies that for each fiscal year, after the annual base revenue is adjusted for inflation, FDA shall further increase the fee revenue and fees by the strategic hiring and retention adjustment, which is $150,000 for FY 2027 (see section 744H(c)(2) of the FD&amp;C Act).</P>
                <HD SOURCE="HD2">C. FY 2027 Statutory Fee Revenue Adjustments for Capacity Planning</HD>
                <P>
                    The statute specifies that the fee revenue and fees shall be further adjusted to reflect changes in the resource capacity needs for the process for the review of biosimilar biological product applications (see section 744H(c)(3) of the FD&amp;C Act). Following a process agreed upon by FDA and industry during BsUFA II reauthorization discussions and subsequently required in statute, FDA established the capacity planning adjustment methodology and first applied it in the setting of FY 2021 fees. The establishment of this methodology 
                    <PRTPAGE P="48168"/>
                    is described in the 
                    <E T="04">Federal Register</E>
                     at 85 FR 47220. This methodology includes a continuous, iterative improvement approach, under which the Agency intends to refine its data and estimates for the core review activities to improve their accuracy over time.
                </P>
                <P>The CPA methodology consists of four steps:</P>
                <P>
                    1. 
                    <E T="03">Forecast workload volumes:</E>
                     predictive models estimate the volume of workload for the upcoming FY.
                </P>
                <P>
                    2. 
                    <E T="03">Forecast the resource needs:</E>
                     forecast algorithms are generated utilizing time reporting data. These algorithms estimate the required demand in FTEs for direct review-related effort. This is then compared to current available resources for the direct review-related workload.
                </P>
                <P>
                    3. 
                    <E T="03">A managerial adjustment to assess the resource forecast in the context of additional internal factors:</E>
                     program leadership examines operational, financial, and resourcing data to assess whether FDA will be able to utilize additional funds during the fiscal year and whether such funds are required to support additional review capacity. FTE amounts are adjusted, if needed.
                </P>
                <P>
                    4. 
                    <E T="03">Convert the FTE need to dollars:</E>
                     utilizing FDA's fully loaded FTE cost model, the final feasible FTEs are converted to an equivalent dollar amount.
                </P>
                <P>Table 4 summarizes the forecasted workload volumes for BsUFA III in FY 2027 based on predictive models, as well as historical actuals from FY 2025 for comparison.</P>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s50,15,19">
                    <TTITLE>Table 4—BsUFA III Actual FY 2025 Workload Volumes &amp; Predicted FY 2027 Workload Volumes</TTITLE>
                    <BOXHD>
                        <CHED H="1">Workload category</CHED>
                        <CHED H="1">FY 2025 actuals</CHED>
                        <CHED H="1">FY 2027 predictions</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">
                            Original Biosimilar Supplements 
                            <SU>1</SU>
                        </ENT>
                        <ENT>77</ENT>
                        <ENT>86</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Manufacturing Supplements</ENT>
                        <ENT>216</ENT>
                        <ENT>181</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Biosimilar Biological Product Applications</ENT>
                        <ENT>14</ENT>
                        <ENT>19</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">BsUFA Industry Meetings (BIA, BPD Type 1-4)</ENT>
                        <ENT>189</ENT>
                        <ENT>223</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Participating BPD Programs</ENT>
                        <ENT>144</ENT>
                        <ENT>178</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Annual Reports 
                            <SU>2</SU>
                        </ENT>
                        <ENT>69</ENT>
                        <ENT>91</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            PMR/PMC-Related Documents 
                            <SU>2</SU>
                        </ENT>
                        <ENT>53</ENT>
                        <ENT>41</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Active REMS Programs 
                            <E T="0731">2 3</E>
                        </ENT>
                        <ENT>3</ENT>
                        <ENT>3</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>1</SU>
                         Includes Supplements with Clinical Data and Labeling Supplements.
                    </TNOTE>
                    <TNOTE>
                        <SU>2</SU>
                         Represents activities related to the review of materials submitted to the application file after approval.
                    </TNOTE>
                    <TNOTE>
                        <SU>3</SU>
                         Represents the percentage of active REMS programs proportional to Center and User Fee by total number of qualifying products with the exclusion of the Opioid Shared System.
                    </TNOTE>
                </GPOTABLE>
                <P>FDA anticipates that any FTE gains could be funded through the expected FY 2027 collections amount without further adjustment from the CPA. As such, FDA determined that in FY 2027 the BsUFA fee amounts do not need adjustment from the CPA to provide funds for the program.</P>
                <HD SOURCE="HD2">D. FY 2027 Additional Dollar Amount</HD>
                <P>For FY 2023 and FY 2024, BsUFA III provided an additional dollar amount for additional FTE for the biosimilar biological product review program to support enhancements outlined in the BsUFA III Commitment Letter. For FY 2025, FY 2026, and FY 2027, no additional amount is specified in statute.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s150,12">
                    <TTITLE>Table 5—Base Revenue Amount and Adjustments Prior to Operating Reserve Adjustment</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Base Revenue Amount (Section 744H(b)-(c) of the FD&amp;C Act)</ENT>
                        <ENT>$58,926,749</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (Section 744H(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>2,692,540</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (Section 744H(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>150,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (Section 744H(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Additional Dollar Amount</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Cumulative Revenue Amount Prior to Operating Reserve Adjustment</ENT>
                        <ENT>61,769,289</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD2">E. FY 2027 Statutory Fee Revenue Adjustments for Operating Reserve</HD>
                <P>BsUFA III sets forth an operating reserve adjustment to the fee revenue and fees. Specifically, for FY 2027, the statute directs FDA: (1) to increase the fee revenue and fees if such an adjustment is necessary to provide for at least 10 weeks of operating reserves of carryover user fees for the process for the review of biosimilar biological product applications and (2) if FDA has carryover balances for such process in excess of 21 weeks of such operating reserves, to decrease such fee revenue and fees to provide for not more than 21 weeks of such operating reserves (see section 744H(c)(4) of the FD&amp;C Act).</P>
                <P>
                    To calculate the 10-week and 21-week threshold amounts for the FY 2027 operating reserve adjustment, the estimated adjusted revenue amount (
                    <E T="03">i.e.,</E>
                     the base revenue amount and adjustments prior to the operating reserve adjustment), $61,769,289 is divided by 52, resulting in a $1,187,871 cost of operation for 1 week (rounded to the nearest dollar). The 1-week value ($1,187,871) is then multiplied by 10 weeks to generate the 10-week operating reserve threshold amount for FY 2027 of $11,878,709. The 1-week value is multiplied by 21 to generate the 21-week operating reserve threshold amount for FY 2027 of $24,945,290.
                </P>
                <P>To calculate the estimated operating reserve of carryover user fees at the end of FY 2026, FDA assessed the operating reserves of carryover fees at the end of June 2026. The balance of operating reserves of carryover fees at the end of June 2026 is combined with the forecasted collections and obligations for the remainder of FY 2026 to generate a full year estimate for FY 2026. The estimated operating reserve of carryover user fees at the end of FY 2026 is $27,808,972.</P>
                <P>
                    The estimated operating reserve of carryover user fees at the end of FY 2026 of $27,808,972 is above the 21-
                    <PRTPAGE P="48169"/>
                    week threshold allowable operating reserve of carryover user fees for FY 2027 of $24,945,290. As such, FDA is applying a downward operating reserve adjustment of $2,863,682 (rounded to the nearest dollar), an amount equivalent to a reduction of approximately 2.41 weeks of operations, to bring the operating reserve of carryover user fees to $24,945,290 or 21 weeks of operations at the start of FY 2027. With this operating reserve adjustment, the estimated adjusted revenue amount of $61,769,289 will be lowered by $2,863,682, yielding the FY 2027 target revenue amount of $58,906,000 (rounded to the nearest thousand), summarized below.
                </P>
                <GPOTABLE COLS="2" OPTS="L2,i1" CDEF="s150,12">
                    <TTITLE>Table 6—Total Estimated Adjusted Revenue Amount for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">Amount</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Base Revenue Amount (Section 744H(b)-(c) of the FD&amp;C Act)</ENT>
                        <ENT>$58,926,749</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Inflation Adjustment (Section 744H(c)(1) of the FD&amp;C Act)</ENT>
                        <ENT>2,692,540</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Strategic Hiring and Retention Adjustment (Section 744H(c)(2) of the FD&amp;C Act)</ENT>
                        <ENT>150,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capacity Planning Adjustment (Section 744H(c)(3) of the FD&amp;C Act)</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Additional Dollar Amount</ENT>
                        <ENT>0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Operating Reserve Adjustment</ENT>
                        <ENT>(2,863,682)</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Revenue Amount in sections 744H(b)-(c), 744H(c)(1), (2), (3) of the FD&amp;C Act</ENT>
                        <ENT>58,905,607</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Total Revenue Amount in sections 744H(b)-(c), 744H(c)(1), (2), (3) of the FD&amp;C Act (rounded to the nearest thousand dollars)</ENT>
                        <ENT>58,906,000</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">III. Fee Amounts for FY 2027</HD>
                <P>Under section 744H(b)(2)(A) of the FD&amp;C Act, FDA must determine the percentage of the total revenue amount for a fiscal year to be derived from: (1) initial and annual BPD fees, and reactivation fees; (2) biosimilar biological product application fees; and (3) biosimilar biological product program fees. As described above, a downward operating reserve adjustment is required for FY 2027. The operating reserve adjustment in subsequent years may not be as large. As such, the target revenue in FY 2027 may be lower than in prior or future years, and thereby the fee amounts may also be lower than in prior or future years.</P>
                <HD SOURCE="HD2">A. Application Fees</HD>
                <P>To calculate the biosimilar biological product application fee, FDA estimated the number of full application equivalents (FAEs) that will be submitted in FY 2027. A filed original 351(k) BLA with clinical data counts as one FAE. A filed original 351(k) BLA without clinical data counts as one-half of an FAE. An original 351(k) BLA that is refused to file (RTF) or withdrawn before filing (WD), counts as one-fourth of an FAE if the application required clinical data, or one-eighth of an FAE if the application did not require clinical data. After an original 351(k) BLA has been RTF or WD, the applicant has the option of resubmitting. For user fee purposes, these resubmitted original 351(k) BLAs are equivalent to original 351(k) BLA submissions. Filed original 351(k) BLA resubmissions are charged the full amount for an application with clinical data (one FAE) or without clinical data (one-half FAE). Additionally, a filed original 351(k) BLA with or without clinical data that is granted a small business waiver (SBW) from the application fee counts as zero FAE.</P>
                <P>As discussed in II.C above, FDA estimates that 19 original 351(k) BLAs will be submitted in FY 2027. Based on recent years data regarding SBWs, original 351(k) BLAs with or without clinical data, original 351(k) BLAs that are RTF or WD, and considering that some of these applications may be resubmitted in the same fiscal year, it is assumed that the 19 submissions will equate to 17 FAEs.</P>
                <P>For FY 2027 the biosimilar biological product application fee for applications requiring clinical data is $1,124,936. Applications not requiring clinical data pay half that fee, or $562,468. This is estimated to provide a total of $19,123,912 representing 32 percent (rounded to the nearest whole number) of the FY 2027 target revenue amount.</P>
                <HD SOURCE="HD2">B. Biosimilar Biological Product Program Fee</HD>
                <P>Under BsUFA III, FDA assesses biosimilar biological product program fees (“program fees”). An applicant in a biosimilar biological product application shall not be assessed more than five program fees for a fiscal year for biosimilar biological products identified in a single biosimilar biological product application (see section 744H(a)(3)(D) of the FD&amp;C Act). Applicants are assessed a program fee for a fiscal year for biosimilar biological products that are identified in a biosimilar biological product application approved as of October 1 of such fiscal year; that may be dispensed only under prescription pursuant to section 503(b) of the FD&amp;C Act; and that, as of October 1 of such fiscal year, do not appear on a list developed and maintained by FDA of discontinued biosimilar biological products. An approved biosimilar biological product that appears on the list of discontinued biosimilar biological products as of October 1 of a fiscal year would also be assessed the program fee if it is removed from the discontinued list during the fiscal year and the other statutory criteria for fee assessment are satisfied (see section 744H(a)(3)(E)(iii) of the FD&amp;C Act).</P>
                <P>Based on available information, FDA estimates that 194 program fees will be invoiced for FY 2027. For products invoiced in the FY 2027 regular billing cycle, FDA anticipates that zero program fees will be refunded.</P>
                <P>For FY 2027, the biosimilar biological product program fee is $195,887. This is estimated to provide a total of $38,002,078, representing 65 percent (rounded to the nearest whole number) of the FY 2027 target revenue amount.</P>
                <HD SOURCE="HD2">C. Initial and Annual BPD Fees, and Reactivation Fees</HD>
                <P>To estimate the number of BPD fees to be paid in FY 2027, FDA must consider the number of new BPD programs, the number of current BPD programs, and the number of BPD programs that will be reactivated. These estimates provide information that, when aggregated, allows FDA to set BPD fees (initial BPD fees, annual BPD fees, reactivation fees).</P>
                <P>
                    FDA analyzed available data to estimate the total number of BPD programs for FY 2027. In FY 2027, FDA estimates approximately 36 new BPD programs, no reactivations (a single reactivation is weighted as two BPD fees), and 142 BPD programs to pay the annual BPD fee, yielding a rounded total estimated equivalent of 178 BPD fees to be collected in FY 2027. The remainder of the target revenue of $1,780,000 or 3 percent is to be collected from the BPD fees. Dividing this amount by the estimated 178 BPD fees to be paid equals an initial BPD and annual BPD 
                    <PRTPAGE P="48170"/>
                    fee amount of $10,000 (rounded to the nearest dollar). The reactivation fee is set at twice the initial/annual BPD amount at $20,000 (rounded to the nearest dollar).
                </P>
                <HD SOURCE="HD1">IV. Fee Schedule for FY 2027</HD>
                <P>The fee rates for FY 2027 are displayed in table 7.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,i1" CDEF="s50,10">
                    <TTITLE>Table 7—Fee Schedule for FY 2027</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee category</CHED>
                        <CHED H="1">
                            Fee rates 
                            <LI>for FY 2027</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Initial BPD</ENT>
                        <ENT>$10,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual BPD</ENT>
                        <ENT>10,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Reactivation</ENT>
                        <ENT>20,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Applications:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Requiring Clinical Data</ENT>
                        <ENT>1,124,936</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Not Requiring Clinical Data</ENT>
                        <ENT>562,468</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Program Fee</ENT>
                        <ENT>195,887</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">V. Fee Payment Options and Procedures</HD>
                <HD SOURCE="HD2">A. Initial BPD, Reactivation, and Application Fees</HD>
                <P>
                    The fees established in the new fee schedule apply to FY 2027, 
                    <E T="03">i.e.,</E>
                     the period from October 1, 2026, through September 30, 2027. The initial BPD fee for a product is due when the sponsor submits an IND that FDA determines is intended to support a biosimilar biological product application for the product or within 7 calendar days after FDA grants the first BPD meeting for the product, whichever occurs first. Sponsors who have discontinued participation in the BPD program for a product or have been administratively removed from the BPD program for a product, and seek to resume participation in the BPD program for the product must pay all annual BPD fees previously assessed for such product and still owed and the reactivation fee by the earlier of the following dates: no later than 7 calendar days after FDA grants the sponsor's request for a BPD meeting for that product, or upon the date of submission by the sponsor of an IND describing an investigation that FDA determines is intended to support a biosimilar biological product application for that product.
                </P>
                <P>The application fee for a biosimilar biological product is due upon submission of the application (see section 744H(a)(2)(C) of the FD&amp;C Act).</P>
                <P>
                    Initial BPD, reactivation, or application fee payments made to FDA must be made in U.S. currency drawn on a U.S. bank by electronic check, credit card, or wire transfer. The preferred method for payments to FDA is online using electronic check (Automated Clearing House (ACH), also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). FDA has partnered with the U.S. Department of the Treasury to utilize 
                    <E T="03">Pay.gov</E>
                    , a web-based payment application, for online electronic payment. The 
                    <E T="03">Pay.gov</E>
                     feature is available on the FDA website upon receipt of an invoice or after completing the User Fee Cover Sheet and generating the user fee ID number.
                </P>
                <P>
                    Secure electronic payments to FDA can be submitted using the User Fees Payment Portal at 
                    <E T="03">https://userfees.fda.gov/pay.</E>
                     (
                    <E T="03">Note:</E>
                     Only full payments are accepted; no partial payments can be made online.) Once an invoice or cover sheet is located, “Pay Now” should be selected to be redirected to 
                    <E T="03">Pay.gov</E>
                    . Electronic payment options are based on the balance due. Payment by credit card is available for balances less than $25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.
                </P>
                <P>For payments made by wire transfer, include the unique user fee ID number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Acct. No: 75060099, Routing No: 021030004, SWIFT: FRNYUS33.</P>
                <P>FDA's tax identification number is 53-0196965. If a fee is not paid in full, the fee will be treated as a claim of the U.S. Government (see section 744H(g) of the FD&amp;C Act and 45 CFR part 30), meaning the invoice balance due amount is referred to collections.</P>
                <HD SOURCE="HD2">B. Annual BPD and Program Fees</HD>
                <P>FDA will issue invoices with payment instructions for FY 2027 annual BPD and program fees under the new fee schedule in August 2026. Under sections 744H(a)(1)(B)(ii) and 744H(a)(3)(B) of the FD&amp;C Act, annual BPD and program fees will be due on October 1, 2026.</P>
                <P>If sponsors join the BPD program after the annual BPD invoices have been issued in August 2026, FDA will issue invoices in December 2026 to sponsors subject to fees for FY 2027 that qualify for the annual BPD fee after the August 2026 billing. FDA will issue invoices in December 2027 for any products that qualify for the annual program fee after the August 2026 billing.</P>
                <HD SOURCE="HD2">C. Waivers and Returns</HD>
                <P>To qualify for consideration for a small business waiver under section 744H(d) of the FD&amp;C Act, or the return of any fee paid under section 744H of the FD&amp;C Act, including if the fee is claimed to have been paid in error, a person shall submit to FDA a written request justifying such waiver or return and, except as otherwise specified in section 744H of the FD&amp;C Act, such written request shall be submitted to FDA not later than 180 days after such fee is due. Such written request shall include any legal authorities under which the request is made. See section 744H(h) of the FD&amp;C Act.</P>
                <SIG>
                    <NAME>Grace R. Graham,</NAME>
                    <TITLE>Deputy Commissioner for Policy, Legislation, and International Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15346 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Health Resources and Services Administration</SUBAGY>
                <SUBJECT>Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Health Center Program Forms—OMB No. 0915-0285—Revision</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Health Resources and Services Administration (HRSA), Department of Health and Human Services.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on this ICR should be received no later than September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments to 
                        <E T="03">paperwork@hrsa.gov</E>
                         or mail the HRSA Information Collection Clearance Officer, Room 13N82, 5600 Fishers Lane, Rockville, Maryland 20857.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        To request more information on the 
                        <PRTPAGE P="48171"/>
                        proposed project or to obtain a copy of the data collection plans and draft instruments, email 
                        <E T="03">paperwork@hrsa.gov</E>
                         or call Samantha Miller, the HRSA Information Collection Clearance Officer, at (301) 443-3983.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    <E T="03">Information Collection Request Title:</E>
                     Health Center Program Forms, OMB No. 0915-0285—Revision.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The Health Center Program, administered by HRSA, is authorized under Section 330 of the Public Health Service Act (42 U.S.C. 254b). Health centers are patient-directed organizations that deliver affordable, accessible, quality, and cost-effective primary health care services to patients and adjust fees based on income and family size. Nearly 1,400 health centers operate more than 16,000 service delivery sites that provide primary health care to more than 32 million people in every U.S. state, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and the Pacific Basin. HRSA uses forms for health centers to report progress and change their scope of project.
                </P>
                <P>
                    <E T="03">Need and Proposed Use of the Information:</E>
                     The information HRSA collects from health centers via the Health Center Program-specific forms is necessary for the agency's oversight of Health Center Program awards. HRSA uses the information for program monitoring and for evaluating award recipients' compliance with Health Center Program statutory and regulatory requirements. These forms were approved by OMB on May 31, 2026, following 60- and 30-day public comment periods. Eight forms that were previously approved are being updated and three forms are being added to facilitate monitoring, improve scope of project documentation and oversight, increase the efficiency of the change in scope process, and enhance the accuracy of change in scope requests.
                </P>
                <P>HRSA will modify the following forms to update and clarify data currently being collected:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s100,r100">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Forms proposed to be modified: number/name</CHED>
                        <CHED H="1">Description of modifications</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Form 5A: Services Provided</ENT>
                        <ENT>Update labels and categories of services.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 5B: Sites</ENT>
                        <ENT>Modify fields collecting site information.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Checklist for Form 5A Scope Adjustments</ENT>
                        <ENT>Revise checklist statements and questions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Checklist for Form 5B Scope Adjustments</ENT>
                        <ENT>Revise checklist statements and questions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Checklist for Deleting a Service Site from Scope
                            <LI O="xl">
                                <E T="03">Previously: Checklist for Deleting</E>
                                 Existing Service Delivery Site.
                            </LI>
                        </ENT>
                        <ENT>Revise checklist statements and questions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Checklist for Adding a Service Site to Scope
                            <LI O="xl">
                                <E T="03">Previously: Checklist for Adding a New Service Delivery Site</E>
                                .
                            </LI>
                        </ENT>
                        <ENT>Revise checklist statements and questions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Checklist for Adding a Service to Scope
                            <LI O="xl">
                                <E T="03">Previously Checklist for adding a new service.</E>
                            </LI>
                        </ENT>
                        <ENT>Revise checklist statements and questions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Checklist for Deleting a Service from Scope
                            <LI O="xl">
                                <E T="03">Previously: Checklist for deleting existing service</E>
                                .
                            </LI>
                        </ENT>
                        <ENT>Revise checklist statements and questions.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>HRSA will add the following forms necessary for data collection and change in scope requests to simplify the process:</P>
                <FP SOURCE="FP-1">• Checklist for Replacing a Service Site in Scope</FP>
                <FP SOURCE="FP-1">• Quality Improvement Fund (QIF) Final Report</FP>
                <FP SOURCE="FP-1">• Loan Guarantee Progress Report</FP>
                <P>
                    <E T="03">Likely Respondents:</E>
                     Health Center Program award recipients (those funded under section 330 of the Public Health Service Act) and Health Center Program look-alikes.
                </P>
                <P>
                    <E T="03">Burden Statement:</E>
                     Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.
                </P>
                <P>These updates will reduce the estimated annual burden by 1,483.50 hours compared with the burden approved in the ICR on May 31, 2026. This is due to the modification of existing forms that is expected to reduce burden. In the burden table below, new forms are indicated through bold text, and revised forms are indicated through italicized text. All other forms are unchanged.</P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s100,10,10,10,10,10">
                    <TTITLE>Total Estimated Annualized Burden Hours</TTITLE>
                    <BOXHD>
                        <CHED H="1">Form title</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of
                            <LI>responses per</LI>
                            <LI>respondent</LI>
                        </CHED>
                        <CHED H="1">
                            Total
                            <LI>responses</LI>
                        </CHED>
                        <CHED H="1">
                            Average
                            <LI>burden per</LI>
                            <LI>response</LI>
                            <LI>(hours)</LI>
                        </CHED>
                        <CHED H="1">
                            Total
                            <LI>burden</LI>
                            <LI>hours</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Form 5A: Services Provided</E>
                        </ENT>
                        <ENT>1,400</ENT>
                        <ENT>1</ENT>
                        <ENT>1,400</ENT>
                        <ENT>0.25</ENT>
                        <ENT>350.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Form 5B: Sites</E>
                        </ENT>
                        <ENT>1,400</ENT>
                        <ENT>1</ENT>
                        <ENT>1,400</ENT>
                        <ENT>0.25</ENT>
                        <ENT>350.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Checklist for Form 5A Scope Adjustments</E>
                        </ENT>
                        <ENT>1,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1,000</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,000.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Checklist for Form 5B Scope Adjustments</E>
                        </ENT>
                        <ENT>2,000</ENT>
                        <ENT>1</ENT>
                        <ENT>2,000</ENT>
                        <ENT>1.00</ENT>
                        <ENT>2,000.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">
                            <E T="03">Checklist for Deleting a Service Site from Scope</E>
                            .
                            <LI>
                                <E T="03">Previously: Checklist for Deleting Existing Service Delivery Site</E>
                            </LI>
                        </ENT>
                        <ENT>500</ENT>
                        <ENT>1</ENT>
                        <ENT>500</ENT>
                        <ENT>1.00</ENT>
                        <ENT>500.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">
                            <E T="03">Checklist for Adding a Service Site to Scope</E>
                            .
                            <LI>
                                <E T="03">Previously: Checklist for Adding a New Service Delivery Site</E>
                            </LI>
                        </ENT>
                        <ENT>1,250</ENT>
                        <ENT>1</ENT>
                        <ENT>1,250</ENT>
                        <ENT>1.50</ENT>
                        <ENT>1,875.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">
                            <E T="03">Checklist for Adding a Service to Scope</E>
                            .
                            <LI>
                                <E T="03">Previously: Checklist for adding a new service</E>
                            </LI>
                        </ENT>
                        <ENT>450</ENT>
                        <ENT>1</ENT>
                        <ENT>450</ENT>
                        <ENT>1.00</ENT>
                        <ENT>450.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">
                            <E T="03">Checklist for Deleting a Service from Scope</E>
                            .
                            <LI>
                                <E T="03">Previously: Checklist for deleting existing service</E>
                            </LI>
                        </ENT>
                        <ENT>500</ENT>
                        <ENT>1</ENT>
                        <ENT>500</ENT>
                        <ENT>1.00</ENT>
                        <ENT>500.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Checklist for Replacing a Service Site in Scope</ENT>
                        <ENT>250</ENT>
                        <ENT>1</ENT>
                        <ENT>250</ENT>
                        <ENT>0.75</ENT>
                        <ENT>187.50</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="48172"/>
                        <ENT I="01">QIF Final Report</ENT>
                        <ENT>25</ENT>
                        <ENT>1</ENT>
                        <ENT>25</ENT>
                        <ENT>3.00</ENT>
                        <ENT>75.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Loan Guarantee Progress Report</ENT>
                        <ENT>22</ENT>
                        <ENT>4</ENT>
                        <ENT>88</ENT>
                        <ENT>1.00</ENT>
                        <ENT>88.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Capital Semi-Annual Progress Report</ENT>
                        <ENT>500</ENT>
                        <ENT>2</ENT>
                        <ENT>1,000</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,000.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Equipment List</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>0.50</ENT>
                        <ENT>65.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Federal Object Class Categories Form</ENT>
                        <ENT>500</ENT>
                        <ENT>1</ENT>
                        <ENT>500</ENT>
                        <ENT>0.25</ENT>
                        <ENT>125.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Loan Guarantee Program Financial Performance Indicators</ENT>
                        <ENT>5</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>1.00</ENT>
                        <ENT>5.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 1A: General Information Worksheet</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1</ENT>
                        <ENT>1,370</ENT>
                        <ENT>0.75</ENT>
                        <ENT>1,027.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 1B: Funding Request Summary</ENT>
                        <ENT>900</ENT>
                        <ENT>1</ENT>
                        <ENT>900</ENT>
                        <ENT>0.75</ENT>
                        <ENT>675.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 1C: Documents on File</ENT>
                        <ENT>1,460</ENT>
                        <ENT>1</ENT>
                        <ENT>1,460</ENT>
                        <ENT>0.50</ENT>
                        <ENT>730.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 2: Staffing Profile</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,370.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 3: Income Analysis</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,370.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 5C: Other Activities/Locations</ENT>
                        <ENT>550</ENT>
                        <ENT>1</ENT>
                        <ENT>550</ENT>
                        <ENT>0.25</ENT>
                        <ENT>137.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 6A: Current Board Member Characteristics</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,370.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 6B: Request for Waiver of Board Member Requirements</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,370.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 8: Health Center Agreements</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1</ENT>
                        <ENT>1,370</ENT>
                        <ENT>1.00</ENT>
                        <ENT>1,370.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Form 12: Organization Contacts</ENT>
                        <ENT>970</ENT>
                        <ENT>1</ENT>
                        <ENT>970</ENT>
                        <ENT>0.50</ENT>
                        <ENT>485.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Funding Sources</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>0.50</ENT>
                        <ENT>65.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">FY 2022 Accelerating Cancer Screening Progress Report</ENT>
                        <ENT>29</ENT>
                        <ENT>1</ENT>
                        <ENT>29</ENT>
                        <ENT>1.50</ENT>
                        <ENT>43.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Grant Number Form</ENT>
                        <ENT>400</ENT>
                        <ENT>1</ENT>
                        <ENT>400</ENT>
                        <ENT>0.25</ENT>
                        <ENT>100.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HCCN Progress Report</ENT>
                        <ENT>50</ENT>
                        <ENT>1</ENT>
                        <ENT>50</ENT>
                        <ENT>0.50</ENT>
                        <ENT>25.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Health Center Program Progress Report</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>1.00</ENT>
                        <ENT>130.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HRSA Loan Guarantee Program Application</ENT>
                        <ENT>5</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>1.00</ENT>
                        <ENT>5.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Impact Form</ENT>
                        <ENT>400</ENT>
                        <ENT>1</ENT>
                        <ENT>400</ENT>
                        <ENT>1.00</ENT>
                        <ENT>400.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NHHCIA NCC Clinical Performance Measures</ENT>
                        <ENT>5</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>1.50</ENT>
                        <ENT>7.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NHHCIA NCC Financial Performance Measures</ENT>
                        <ENT>5</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>0.50</ENT>
                        <ENT>2.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NHHCIA NCC Income Analysis Form</ENT>
                        <ENT>5</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>0.15</ENT>
                        <ENT>0.75</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NHHCIA Sample Project Work Plan</ENT>
                        <ENT>2</ENT>
                        <ENT>1</ENT>
                        <ENT>2</ENT>
                        <ENT>0.15</ENT>
                        <ENT>0.30</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NH-NCC Project Work Plan Update</ENT>
                        <ENT>5</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>1.00</ENT>
                        <ENT>5.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Operational Plan</ENT>
                        <ENT>350</ENT>
                        <ENT>1</ENT>
                        <ENT>350</ENT>
                        <ENT>2.00</ENT>
                        <ENT>700.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Other Requirements for Sites</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>0.50</ENT>
                        <ENT>65.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Participating Health Centers List</ENT>
                        <ENT>90</ENT>
                        <ENT>1</ENT>
                        <ENT>90</ENT>
                        <ENT>1.00</ENT>
                        <ENT>90.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Project Cover Page</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>1.00</ENT>
                        <ENT>130.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Project Narrative Update</ENT>
                        <ENT>1,325</ENT>
                        <ENT>1</ENT>
                        <ENT>1,325</ENT>
                        <ENT>4.00</ENT>
                        <ENT>5,300.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Project Overview Form</ENT>
                        <ENT>500</ENT>
                        <ENT>1</ENT>
                        <ENT>500</ENT>
                        <ENT>1.00</ENT>
                        <ENT>500.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Project Qualification Criteria</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>0.50</ENT>
                        <ENT>65.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Project Work Plan</ENT>
                        <ENT>508</ENT>
                        <ENT>1</ENT>
                        <ENT>508</ENT>
                        <ENT>4.00</ENT>
                        <ENT>2,032.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Proposal Cover Page</ENT>
                        <ENT>130</ENT>
                        <ENT>1</ENT>
                        <ENT>130</ENT>
                        <ENT>1.00</ENT>
                        <ENT>130.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">QIF Evaluative Measures Report</ENT>
                        <ENT>25</ENT>
                        <ENT>2</ENT>
                        <ENT>50</ENT>
                        <ENT>1.50</ENT>
                        <ENT>75.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">QIF Progress Report</ENT>
                        <ENT>25</ENT>
                        <ENT>12</ENT>
                        <ENT>300</ENT>
                        <ENT>1.50</ENT>
                        <ENT>450.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">QIF TJI Evaluative Measures Report</ENT>
                        <ENT>54</ENT>
                        <ENT>10</ENT>
                        <ENT>540</ENT>
                        <ENT>1.50</ENT>
                        <ENT>810.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">QIF TJI Progress Report</ENT>
                        <ENT>54</ENT>
                        <ENT>10</ENT>
                        <ENT>540</ENT>
                        <ENT>1.50</ENT>
                        <ENT>810.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">QIF Project Plan Form</ENT>
                        <ENT>100</ENT>
                        <ENT>1</ENT>
                        <ENT>100</ENT>
                        <ENT>1.00</ENT>
                        <ENT>100.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Summary Page (New Access Point)</ENT>
                        <ENT>500</ENT>
                        <ENT>1</ENT>
                        <ENT>500</ENT>
                        <ENT>1.00</ENT>
                        <ENT>500.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Summary Page (Service Area Competition)</ENT>
                        <ENT>360</ENT>
                        <ENT>1</ENT>
                        <ENT>360</ENT>
                        <ENT>0.50</ENT>
                        <ENT>180.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">LAL Cover page</ENT>
                        <ENT>110</ENT>
                        <ENT>1</ENT>
                        <ENT>110</ENT>
                        <ENT>0.50</ENT>
                        <ENT>55.00</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Checklist for Adding a Transitional Care in a Carceral Setting Site to Scope</ENT>
                        <ENT>50</ENT>
                        <ENT>1</ENT>
                        <ENT>50</ENT>
                        <ENT>1.00</ENT>
                        <ENT>50.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Totals</ENT>
                        <ENT>27,769.00</ENT>
                        <ENT/>
                        <ENT>29,607.00</ENT>
                        <ENT/>
                        <ENT>31,302.05</ENT>
                    </ROW>
                </GPOTABLE>
                <P>HRSA specifically requests comments on: (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.</P>
                <SIG>
                    <NAME>Maria G. Button,</NAME>
                    <TITLE>Director, Executive Secretariat.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15419 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4165-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>Office of the Secretary; Amended Notice of Meeting</SUBJECT>
                <P>
                    Notice is hereby given of a change in the meeting of the Interagency Autism Coordinating Committee, July 31, 2026, 09:00 a.m. to 05:00 p.m. ET., National Institutes of Mental Health (NIMH), Neuroscience Center (NSC), 6001 Executive Boulevard, Rockville, MD 20852 which was published in the 
                    <PRTPAGE P="48173"/>
                    <E T="04">Federal Register</E>
                     on July 07, 2026, FR Doc. 2026-13714, 91 FR 41645.
                </P>
                <P>This Notice is being amended to change the meeting date to August 27, 2026, and to extend the public comment period through August 20, 2026. The meeting is open to the public.</P>
                <SIG>
                    <DATED>Dated: July 28, 2026.</DATED>
                    <NAME>Rosalind M. Niamke, </NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15425 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4167-05-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>Center for Scientific Review; Notice of Closed Meetings</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.</P>
                <P>The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         Center for Scientific Review Special Emphasis Panel; Cancer Center Support Grant.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         September 1-2, 2026.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 6:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Mukesh Kumar, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 809 C, Bethesda, MD 20892, (301) 451-0359, 
                        <E T="03">mukesh.kumar3@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         Center for Scientific Review Special Emphasis Panel; RFA Panel: BRAIN Initiative: Promoting Health for All Through BRAIN Technology Partnerships.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         September 2, 2026.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         1:00 p.m. to 5:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Aurea D. De Sousa, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, Bethesda, MD 20892, (301) 827-6829, 
                        <E T="03">aurea.desousa@nih.gov</E>
                        .
                    </P>
                    <FP>(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)</FP>
                </EXTRACT>
                <SIG>
                    <DATED> Dated: July 27, 2026.</DATED>
                    <NAME>Sterlyn H. Gibson,</NAME>
                    <TITLE>Program Specialist, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15330 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>Office of the Director, National Institutes of Health; Notice of Meeting</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Council of Councils.</P>
                <P>
                    The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link:
                    <E T="03">https://videocast.nih.gov/.</E>
                </P>
                <P>The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         Council of Councils.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         September 10-11, 2026.
                    </P>
                    <P>
                        <E T="03">Open:</E>
                         September 10, 2026, 9:00 a.m. to 12:15 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         Welcome and Opening Remarks; Reminders and Procedures; DPCPSI Reports and Other Business of the Committee.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         Office of the Director, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892, (In Person).
                    </P>
                    <P>
                        <E T="03">Closed:</E>
                         September 10, 2026, 12:15 p.m. to 1:15 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         Office of the Director, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (In Person).
                    </P>
                    <P>
                        <E T="03">Open:</E>
                         September 10, 2026, 1:15 p.m. to 5:15 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         NIH Updates and Other Business of the Committee.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         Office of the Director, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (In Person).
                    </P>
                    <P>
                        <E T="03">Open:</E>
                         September 11, 2026, 9:00 a.m. to 12:30 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         Welcome and Recap of Day 1; Program Updates and Other Business of the Committee.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         Office of the Director, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (In Person).
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Robin I. Kawazoe, Deputy Director, DPCPSI Division of Program Coordination, Planning, and Strategic Initiatives, Office of The Director, National Institutes of Health, Building 1, Room 260, Bethesda, MD 20892, 
                        <E T="03">kawazoer@mail.nih.gov.</E>
                    </P>
                </EXTRACT>
                <P>Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.</P>
                <P>
                    In the interest of security, NIH has procedures at 
                    <E T="03">https://security.nih.gov/visitors/Pages/visitor-campus-access.aspx</E>
                     for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.
                </P>
                <SIG>
                    <DATED>Dated: July 28, 2026.</DATED>
                    <NAME>Bruce A. George, </NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15427 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4167-05-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>Office of the Director, National Institutes of Health; Amended Notice of Meeting</SUBJECT>
                <P>
                    Notice is hereby given of a change in the meeting of the Advisory Committee on Research on Women's Health, October 20, 2026, 09:30 a.m. to October 20, 2026, 04:00 p.m., National Institutes of Health, 6707 Democracy Boulevard, 
                    <PRTPAGE P="48174"/>
                    Bethesda, MD 20892 which was published in the 
                    <E T="04">Federal Register</E>
                     on June 26, 2026, FR Doc. 2026-13175, 91 FR 39627.
                </P>
                <P>Correction of the terminal degree for the contact person has been updated. Contact information for the Executive Secretary of the October 20, 2026, meeting is:</P>
                <EXTRACT>
                    <P>
                        <E T="03">Contact Person:</E>
                         Lucia Hindorff, Ph.D., ACRWH Executive Secretary, Office of Research on Women's Health, National Institutes of Health, 6707 Democracy Boulevard, Room 400, Bethesda, MD 20892, (240) 271-1509, 
                        <E T="03">lucia.hindorff@nih.gov</E>
                        .
                    </P>
                </EXTRACT>
                <P>Information regarding the meeting to include agenda and additional information can be found using the following link: ACRWH web page.</P>
                <P>The number of minimum days to present/submit comments has been updated from 10 to 30 days in advance of the meeting:</P>
                <P>
                    To submit questions or request reasonable accommodations, please email 
                    <E T="03">ACRWH@nih.gov.</E>
                     Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 30 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
                </P>
                <SIG>
                    <DATED> Dated: July 27, 2026.</DATED>
                    <NAME>Margaret N. Vardanian,</NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15329 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4167-05-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>Federal Emergency Management Agency</SUBAGY>
                <DEPDOC>[Docket ID: FEMA-2025-0212; OMB No. 1660-0080]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities: Submission for OMB Review, Comment Request; Application for Surplus Federal Real Property Public Benefit Conveyance and BRAC Program for Emergency Management Use</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Emergency Management Agency, Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice of extension and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Federal Emergency Management Agency (FEMA) will submit the information collection abstracted below to the Office of Management and Budget for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. FEMA invites the general public to take this opportunity to comment on an extension of a currently approved information collection. In accordance with the requirements of the Paperwork Reduction Act of 1995, this notice seeks comments concerning the application process for the conveyance of Federal real property for public benefit. The purpose of this application is to implement the processes and procedures for the successful, lawful, and expeditious conveyance of real property from the Federal government to public entities such as State, local, city, town, or other like government bodies as it relates to emergency management response purposes, including fire and rescue services. Compliance will ensure that properties will be fully positioned to use at their highest and best potentials as required by General Services Administration (GSA) and Department of Defense (DOD)/Department of War (DOW) regulations, Federal law, Executive Orders, and the Code of Federal Regulations (CFR).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional information or copies of the information collection should be made to Director, Information Management Division, 500 C Street SW, Washington, DC 20472, email address 
                        <E T="03">FEMA-Information-Collections-Management@fema.dhs.gov</E>
                         or Justin Dowdy, Realty Specialist, Federal Emergency Management Agency, 202-735-6328, 
                        <E T="03">justin.dowdy@fema.dhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Excess Federal real property is defined as property that is no longer mission critical to the needs of the Federal government. The conveyance and disposal of excess real property is governed by the Federal Property and Administrative Services Act of 1949 (Property Act) as amended, 40 U.S.C. 541, 
                    <E T="03">et seq.,</E>
                     40 U.S.C. 553, and applicable regulations (41 CFR parts 102-75.750 through 102-75.815). Under the sponsorship of FEMA, the Property Act gives the GSA Administrator authority to convey Federal real and related surplus property (without monetary consideration) to units of State and local government for emergency management response purposes, including fire rescue services. The scope and philosophy of GSA's real property policies are contained in 41 CFR part 102-71.
                </P>
                <P>
                    This proposed information collection previously published in the 
                    <E T="04">Federal Register</E>
                     on February 11, 2026, at 91 FR 6235 with a 60-day public comment period. FEMA received two comments. Both comments discussed the Public Benefit Conveyance Program itself and while those comments are beyond the scope of the extension of this information collection, FEMA appreciates the input and engagement and is incorporating that feedback into the Program. One of the comments received also discussed the burden placed on the public, which FEMA appreciates as they recognize the efforts undertaken as part of this continual information collection renewal process where our usability testing led to an overall 9.33% decrease in the annual burden hours for respondents in our previous renewal in 2023. FEMA thanks both commentors for their time and feedback that will be used to continue our process improvements. The purpose of this notice is to notify the public that FEMA will submit the information collection abstracted below to the Office of Management and Budget for review and clearance.
                    <PRTPAGE P="48175"/>
                </P>
                <HD SOURCE="HD1">Collection of Information</HD>
                <P>
                    <E T="03">Title:</E>
                     Application for Surplus Federal Real Property Public Benefit Conveyance and BRAC Program for Emergency Management Use.
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     Extension of a currently approved information collection.
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1660-0080.
                </P>
                <P>
                    <E T="03">FEMA Forms:</E>
                     FEMA Form FF-119-FY-22-133, Application for Surplus Federal Real Property Public Benefit Conveyance.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Use of the Application for Surplus Federal Real Property Public Benefit Conveyance and Base Realignment and Closure (BRAC) Program for Emergency Management Use is necessary to implement the processes and procedures for the successful, lawful, and expeditious conveyance of real property from the Federal government to public entities such as State, local, county, city, town, or other like government bodies, as it relates to emergency management response purposes, including fire and rescue services. Utilization of this application will ensure that properties will be fully positioned for use at their highest and best potentials as required by GSA and DOD/DOW regulations, public law, Executive Orders, and the CFR.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     State, Local or Tribal Government.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     15.
                </P>
                <P>
                    <E T="03">Estimated Number of Responses:</E>
                     15.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     68.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Respondent Cost:</E>
                     $4,436.
                </P>
                <P>
                    <E T="03">Estimated Respondents' Operation and Maintenance Costs:</E>
                     $0.
                </P>
                <P>
                    <E T="03">Estimated Respondents' Capital and Start-Up Costs:</E>
                     $0.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Cost to the Federal Government:</E>
                     $4,003.
                </P>
                <HD SOURCE="HD1">Comments</HD>
                <P>
                    Comments may be submitted as indicated in the 
                    <E T="02">ADDRESSES</E>
                     caption above. Comments are solicited to (a) evaluate whether the proposed data collection is necessary for the proper performance of the Agency, including whether the information shall have practical utility; (b) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) enhance the quality, utility, and clarity of the information to be collected; and (d) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </P>
                <SIG>
                    <NAME>Russell R. Bard,</NAME>
                    <TITLE>Information Management Senior Director, Office of the Chief Administrative Officer, Mission Support, Federal Emergency Management Agency, Department of Homeland Security.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15333 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-19-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT</AGENCY>
                <DEPDOC>[Docket No. FR-7106-N-34]</DEPDOC>
                <SUBJECT>Privacy Act of 1974; System of Records</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Chief Information Security Officer, HUD.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of a new system of record.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the provisions of the Privacy Act of 1974, as amended, the Department of Housing and Urban Development (HUD), Office of Chief Information Security Officer (OCISO) is issuing public notice of its intent to create a new system of record titled Enterprise Identity and Credential Access Management (EICAM). The purpose of EICAM is to standardize user access controls, which provides support for users through self-service functions, and ensure only approved users may access HUD systems and data across the HUD enterprise. EICAM more efficiently reinforces the rules and controls governing the collection, maintenance, use, and sharing of information.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments will be accepted on or before August 31, 2026. This proposed action will be effective on the date following the end of the comment period unless comments are received which result in a contrary determination.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments, identified by the docket number or by one of the following methods:</P>
                    <P>
                        <E T="03">Federal e-Rulemaking Portal:</E>
                          
                        <E T="03">http://www.regulations.gov.</E>
                         Follow the instructions provided on that site to submit comments electronically.
                    </P>
                    <P>
                        <E T="03">Fax:</E>
                         202-619-8365.
                    </P>
                    <P>
                        <E T="03">Email:</E>
                          
                        <E T="03">privacy@hud.gov.</E>
                    </P>
                    <P>
                        <E T="03">Mail:</E>
                         Attention: Privacy Office; Kimberly Morton, Acting Chief Privacy Officer; Office of the Executive Secretariat; 451 7th Street SW, Room 10139; Washington, DC 20410-0001.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the agency name and docket number for this rulemaking. All comments received will be posted without change to 
                        <E T="03">http://www.regulations.gov</E>
                         including any personal information provided.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to the docket to read background documents or comments received go to 
                        <E T="03">http://www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Kimberly Morton, Acting Chief Privacy Officer; 451 7th Street SW, Room 10139; Washington, DC 20410-0001; telephone number (804) 822-4801 (this is not a toll-free number). HUD welcomes and is prepared to receive calls from individuals who are deaf or hard of hearing, as well as individuals with speech or communication disabilities. To learn more about how to make an accessible telephone call, please visit 
                        <E T="03">https://www.fcc.gov/consumers/guides/telecommunications-relay-service-trs.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>HUD is establishing the Enterprise Identity Credential Access Management (EICAM) records as a HUD-wide Privacy Act system of records. EICAM is a Framework developed by the Chief Information Officer/Chief Information Security Officer Program Office. The EICAM Framework is the centralized department-wide infrastructure designed to manage the full lifecycle of digital identities, credentials, and access permissions. Its foundational role within HUD is to enforce a Zero Trust Architecture (ZTA) in alignment with Executive Order 14028 and OMB M-22-09, while meeting the federal identity consolidation frameworks established under OMB M-19-17. EICAM ensures that the right individual has the right level of access to the right HUD resources, at the right time, and for the right reason. In accordance with HUD's WEB Access Security Subsystem (WASS) modernization directives, EICAM unifies fragmented legacy identities.</P>
                <P>A key component of the EICAM framework is the Web Access Security Subsystem (WASS). Currently, WASS facilitates secure access to HUD systems by managing authentication for both internal and external users through a combination of identity verification services, including multi-factor authentication.</P>
                <P>
                    EICAM manages user identities and access across the enterprise using Okta as the primary directory for HUD-defined PII, including usernames, contact details, and dates of birth. By utilizing unique identifiers, EICAM eliminates the need to store Social 
                    <PRTPAGE P="48176"/>
                    Security Numbers. Identity proofing is supported by Socure, a Software-as-a-Service (SaaS) platform that provides identity verification and fraud prevention solutions, with Okta profiles updated upon successful verification. Internal identity data is maintained within the HUD Active Directory, while sensitive financial and application-specific records remain in dedicated HUD databases. Furthermore, the system leverages the Federal Housing Administration Connection (FHAC) Authority to Operate (ATO) for external data collection, explicitly ensuring that Social Security Administration (SSA)-provided PII which is not shared with EICAM. As HUD evolves, these records will be increasingly consolidated into the Okta Universal Directory, which will serve as the centralized, cloud-based source of truth for all user and device identities.
                </P>
                <P>This system of records covers the agency's maintenance of records about individual users of the HUD network and information systems, to create a secure and trusted environment where users can access authorized resources. HUD uses a Federal Risk and Authorization Management Program (FedRAMP) authorized Identity-as-a-Service (IDaaS) cloud platform to secure and validate internal and external user identities. This platform integrates with device-level signals alongside identity information for resource access with flexible adaptive MFA integrations at the application layer. The platform supports the hybrid cloud model allowing authentication of on-premises resources and has over 7,500 integrations available to other capabilities. The platform has implemented MFA for access to HUD On-Premises or Cloud applications through the integration of Personal Identity Verification (PIV) smartcards for HUD internal users or a verification and a One-Time Passcode (OTP) authenticator for HUD internal or external users. Additionally, the platform supports Single Sign On (SSO). There are significant advantages in providing EICAM services at the enterprise level, including efficiencies in consolidating network services; improved security; cost savings; and enabling the creation of digital identities for a single individual for use across the enterprise.</P>
                <PRIACT>
                    <HD SOURCE="HD1">SYSTEM NAME AND NUMBER:</HD>
                    <P>Enterprise Identity, Credential, and Access Management (EICAM), HUD/OCIO-07.</P>
                    <HD SOURCE="HD2">SECURITY CLASSIFICATION:</HD>
                    <P>Unclassified.</P>
                    <HD SOURCE="HD2">SYSTEM LOCATION:</HD>
                    <P>The system files are maintained in the Okta GovCloud, the identity authentication cloud service environment located within the Amazon Web Services (AWS) GovCloud; Cloud infrastructure and perimeter security service routing are provided by third-party vendor Cloudflare, Inc., 101 Townsend Street, San Francisco, CA 94107. Records are transiently processed, routed, and cached across Cloudflare's geographically decentralized network of authorized FedRAMP Moderate points of presence. A comprehensive listing of domestic physical data center locations utilized within the FedRAMP boundary is maintained by the Cloudflare FedRAMP program management team.</P>
                    <HD SOURCE="HD2">SYSTEM MANAGER(S):</HD>
                    <P>Tarrazzia Martin, Zero Trust Architecture (ZTA) EICAM Program Manager, 451 7th Street SW, Washington, DC 20410, telephone number (202) 402-3410.</P>
                    <HD SOURCE="HD2">AUTHORITY FOR MAINTENANCE OF THE SYSTEM:</HD>
                    <P>
                        Federal Information Security Modernization Act of 2014, 44 U.S.C. 3551 
                        <E T="03">et seq.;</E>
                         Paperwork Reduction Act of 1995, 44 U.S.C. 3501 
                        <E T="03">et seq.;</E>
                         6 U.S.C. 1523(b)(1); 42 U.S.C. 3535(d); Homeland Security Presidential Directive (HSPD) 12: Policy for a Common Identification Standard for Federal Employees and Contractors (Aug. 2015); and OMB Memorandum M-19-17, Enabling Mission Delivery through Improved Identity, Credential, and Access Management (May 21, 2019); Executive Order 14028, Improving the Nation's Cybersecurity (May 12, 2021); and OMB Memorandum M-22-09, Moving the U.S. Government Toward Zero Trust Cybersecurity Principles (January 26, 2022).
                    </P>
                    <HD SOURCE="HD2">PURPOSES OF THE SYSTEM:</HD>
                    <P>The principal purpose of the EICAM system is to capture and maintain a record of names, digital signatures, approved access, and other identifiers from authoritative sources to provide and maintain a record of access management to agency systems and resources, to include Financial Management and Reporting Records and Information Systems Security records.</P>
                    <HD SOURCE="HD2">CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:</HD>
                    <P>Individuals who have been issued credentials for access to HUD data, systems, or facilities which may include HUD employees; former employees and retirees; contractors and grantees; state and local government partners; public housing authorities; private sector partners; lenders participating in HUD-insured loan programs; tenants and program beneficiaries.</P>
                    <HD SOURCE="HD2">CATEGORIES OF RECORDS IN THE SYSTEM:</HD>
                    <P>The records maintained within this system encompass a variety of data points necessary for identity management and secure operations. Personal identifying information includes basic biographical details such as full names, unique user identifiers (such as CID numbers for contractors and HUD numbers for employees), dates and places of birth, gender, citizenship, and mother's middle or maiden name. Additionally, the system may store contact and credentialing data, including email addresses, personal and work phone numbers, emergency contact information, photographs, race and ethnic origin, and details from government-issued identification such as driver's licenses or passports.</P>
                    <P>Employment and professional information are also collected to manage system roles and permissions. This includes the individual's employer and work address, employment status, duty position, grade, series, and office affiliation. To ensure users are qualified for specific access levels, the system tracks certifications, training completion records, and the specific access rights provisioned across various HUD applications.</P>
                    <P>To maintain a secure environment, the system processes authentication, device, and fraud prevention data. This involves identity verification materials, such as photographs of government IDs, self-photographs, and MFA elements like one-time passcodes and security questions. HUD also monitors technical metadata, including IP addresses, browser types, and usage patterns, alongside risk scores and transaction details provided by third-party identity proofing and fraud prevention services. Finally, system access and audit information—including login attempts, system usage logs, and data access records—is maintained to ensure accountability and monitor for unauthorized activity.</P>
                    <HD SOURCE="HD2">RECORD SOURCE CATEGORIES:</HD>
                    <P>
                        Records are obtained from the Web Access Security System (WASS), HUD Active Directory, the HUD Integrated Human Resources and Training System (HIHRTS), the HUD Intranet/LDAP services, the Okta Identity-as-a-Service (IDaaS) cloud platform, FHAC, and Socure.
                        <PRTPAGE P="48177"/>
                    </P>
                    <HD SOURCE="HD2">ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND PURPOSES OF SUCH USES:</HD>
                    <P>(1) To contractors, grantees, experts, consultants, students, and others performing or working on a contract, service, grant, cooperative agreement, or other assignment for the Federal government when necessary to accomplish an agency function related to this system of records.</P>
                    <P>(2) To appropriate Federal, State, local, tribal, or other governmental agencies or multilateral governmental organizations responsible for investigating or prosecuting the violations of, or for enforcing or implementing, a statute, rule, regulation, order, or license, where HUD determines that the information would assist in the enforcement of civil or criminal laws and when such records, either alone or in conjunction with other information, indicate a violation or potential violation of law.</P>
                    <P>(3) To any component of the Department of Justice or other Federal agency conducting litigation or in proceedings before any court, adjudicative, or administrative body, when HUD determines that the use of such records is relevant and necessary to the litigation and when any of the following is a party to the litigation or have an interest in such litigation: (1) HUD, or any component thereof; or (2) any HUD employee in his or her official capacity; or (3) any HUD employee in his or her individual capacity where the Department of Justice or agency conducting the litigation has agreed to represent the employee; or (4) the United States, or any agency thereof, where HUD determines that litigation is likely to affect HUD or any of its components.</P>
                    <P>(4) To a court, magistrate, administrative tribunal, or arbitrator in the course of presenting evidence, including disclosures to opposing counsel or witnesses or jurors in the course of civil discovery, litigation, mediation, or settlement negotiations, or in connection with criminal law proceedings; when HUD determines that use of such records is relevant and necessary to the litigation and when any of the following is a party to the litigation or have an interest in such litigation: (1) HUD, or any component thereof; or (2) any HUD employee in his or her official capacity; or (3) any HUD employee in his or her individual capacity where HUD has agreed to represent the employee; or (4) the United States, or any agency thereof, where HUD determines that litigation is likely to affect HUD or any of its components.</P>
                    <P>(5) To the National Archives and Records Administration (NARA) for the purpose of records management inspections conducted under the authority of 44 U.S.C. 2904 and 2906.</P>
                    <P>(6) To a Member of Congress or staff acting upon the Member's behalf when the Member or staff requests the information on behalf of, and at the request of, the individual who is the subject of the record.</P>
                    <P>(7) To appropriate agencies, entities, and persons when (1) HUD suspects or confirms a breach of the system of records; (2) HUD determines as a result of the suspected or confirmed breach there is a risk of harm to individuals, HUD (including its information systems, programs, and operations), the Federal Government, or national security; and (3) the disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with HUD's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm.</P>
                    <P>(8) To another Federal agency or Federal entity, when HUD determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in (1) responding to a suspected or confirmed breach or (2) preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity (including its information systems, programs and operations), the Federal Government, or national security, resulting from a suspected or confirmed breach.</P>
                    <P>(9) To another Federal, State or local agency for the purpose of comparing to the agency's system of records or to non-Federal records, in coordination with an Office of Inspector General in conducting an audit, investigation, inspection, evaluation, or some other review as authorized by the Inspector General Act of 1987, as amended.</P>
                    <P>(10) To Federal agencies and third parties for identity proofing, verification services, and fraud prevention services as necessary to detect fraud, investigate, and authenticate users for access to HUD systems or applications, including to provide redress to users.</P>
                    <P>(11) To third-party entities to conduct studies for secure sign-in service enhancements and demographic studies for equitable performance of new technologies and to guide service improvement.</P>
                    <P>(12) To the National Archives and Records Administration, Office of Government Information Services (OGIS), to the extent necessary to fulfill its responsibilities in 5 U.S.C. 552(h), to review administrative agency policies, procedures and compliance with the Freedom of Information Act (FOIA), and to facilitate OGIS' offering of mediation services to resolve disputes between persons making FOIA requests and administrative agencies.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR STORAGE OF RECORDS:</HD>
                    <P>Records are maintained in electronic format only. Electronic records are stored within HUD-authorized systems, utilizing industry-standard encryption and restricted-access directories to ensure data security.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS:</HD>
                    <P>Records may be retrieved from Okta by Username, Name, Address, Email, Date of Birth, and Phone Number.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS</HD>
                    <P>Records are managed in accordance with the General Records Schedule (GRS) 5.5, System Access Records, items 010, which cover Mail, Printing, and Telecommunication Service Management Records. These records are temporary and are destroyed when 3 years old, or 3 years after applicable agreement expires or is cancelled, as appropriate, but longer retention is authorized if required for business use.</P>
                    <HD SOURCE="HD2">ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS:</HD>
                    <P>HUD protects the records within this system through a multi-layered security strategy that adheres to all applicable federal rules, policies, and procedures. Administrative safeguards ensure that only authorized personnel interact with the data; this includes mandatory privacy and information assurance training for all users, strict adherence to “need-to-know” access principles, and continuous risk monitoring. To maintain system integrity, HUD conducts regular security assessments and maintains comprehensive incident response procedures to address potential breaches.</P>
                    <P>
                        Technical safeguards utilize industry-standard encryption to secure data both at rest and during transit. Access is strictly controlled through Multi-Factor Authentication (MFA), including the use of Personal Identity Verification (PIV) cards and complex password requirements. The system is further protected by robust account management, regular vulnerability patching, and intrusion detection systems. Additionally, HUD employs data masking and anonymization techniques to shield sensitive information and maintains detailed logs to monitor all system activities.
                        <PRTPAGE P="48178"/>
                    </P>
                    <P>Physical safeguards protect the hardware and facilities housing the system. Access to these data centers is restricted by multifactor physical controls, video surveillance, and alarm systems. All visitors are subject to logging and escort procedures to ensure facility security. Finally, HUD utilizes environmental controls—such as fire suppression and temperature regulation—to protect equipment, alongside secure disposal methods for electronic media to prevent any unauthorized recovery of data.</P>
                    <HD SOURCE="HD2">RECORD ACCESS PROCEDURES:</HD>
                    <P>Individuals requesting records of themselves should address written inquiries to the Department of Housing and Urban Development 451 7th Street SW Washington, DC 20410-0001. For verification, individuals should provide their full name, current address, and telephone number. In addition, the requester must provide either a notarized statement or an unsworn declaration made under 24 CFR 16.4.</P>
                    <HD SOURCE="HD2">CONTESTING RECORD PROCEDURES:</HD>
                    <P>The HUD rule for contesting the content of any record pertaining to the individual by the individual concerned is published in 24 CFR 16.8 or may be obtained from the system manager.</P>
                    <HD SOURCE="HD2">NOTIFICATION PROCEDURES:</HD>
                    <P>Individuals requesting notification of records of themselves should address written inquiries to the Department of Housing and Urban Development, 451 7th Street SW, Washington, DC 20410-0001. For verification purposes, individuals should provide their full name, office or organization where assigned, if applicable, and current address and telephone number. In addition, the requester must provide either a notarized statement or an unsworn declaration made under 24 CFR 16.4.</P>
                    <HD SOURCE="HD2">EXEMPTIONS PROMULGATED FOR THE SYSTEM:</HD>
                    <P>None.</P>
                    <HD SOURCE="HD2">HISTORY: </HD>
                    <P>None.</P>
                </PRIACT>
                <SIG>
                    <NAME>Kimberly Morton,</NAME>
                    <TITLE>Acting Chief Privacy Officer, Office of Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15428 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4210-67-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOUSING AND URBAN DEVELPMENT</AGENCY>
                <DEPDOC>[Docket No. FR-7106-N-33]</DEPDOC>
                <SUBJECT>Privacy Act of 1974; System of Records</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Chief Human Capital Officer (OCHCO), HUD.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of a new system of records.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the provisions of the Privacy Act of 1974, as amended, the Department of Housing and Urban Development (HUD), Office of the Chief Human Capital Officer (OCHCO) is issuing a public notice of its intent to establish a new Privacy Act System of Records Notice (SORN) titled, “Human Resources Service Delivery (HRSD)”. The system aims to streamline the federal hiring process and enhance data accuracy by automating information exchange between HUD's integrated core platforms and USA Staffing's integrated Data Application Programing Interfaces (API) like, New Hire Interconnection (NHI), and Request Processing Interconnection (RPI). These interfaces enhance HRSD's integration and data utilization across HUD systems and helps streamlines onboarding, transferring new hire data seamlessly, and helps to manage of the entire hiring process from requisition to onboarding, with bi-directional data exchange. The information maintained within Human Resources Service Delivery is sourced through the Office of Personnel Management's (OPM), USA Staffing.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments will be accepted on or before August 31, 2026. This proposed action will be effective on the date following the end of the comment period unless comments are received which result in a contrary determination.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by docket number or by one of the following methods:</P>
                    <P>
                        <E T="03">Federal e-Rulemaking Portal:</E>
                          
                        <E T="03">http://www.regulations.gov.</E>
                         Follow the instructions provided on that site to submit comments electronically.
                    </P>
                    <P>
                        <E T="03">Fax:</E>
                         202-619-8365.
                    </P>
                    <P>
                        <E T="03">Email:</E>
                          
                        <E T="03">privacy@hud.gov.</E>
                    </P>
                    <P>
                        <E T="03">Mail:</E>
                         Attention: The Privacy Office; Kimberly Morton, Acting Chief Privacy Officer; The Executive Secretariat; 451 7th Street SW, Room 10139; Washington, DC 20410-0001.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the agency name and docket number for this rulemaking. All comments received will be posted without change to 
                        <E T="03">http://www.regulations.gov,</E>
                         including any personal information provided.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to the docket to read background documents or comments received go to 
                        <E T="03">http://www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Kimberly Morton, Acting Chief Privacy Officer; 451 7th Street SW, Room 10139; Washington, DC 20410-0001; telephone number (804) 822-4801 (this is not a toll-free number). HUD welcomes and is prepared to receive calls from individuals who are deaf or hard of hearing, as well as individuals with speech or communication disabilities. To learn more about how to make an accessible telephone call, please visit 
                        <E T="03">https://www.fcc.gov/consumers/guides/telecommunications-relay-service-trs.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>HUD Office of the Chief Human Capital Officer (OCHCO) will implement the Human Resources Service Delivery (HRSD) system with case management capabilities to track and manage all HR service requests from initial submission to resolution. HUD seeks to reduce costs, streamline processes, and reduce the need for manual intervention. HRSD is designed to improve employee productivity through capabilities such as: Onboarding, Shared Certificates, Employee and Labor Relations, and Performance Recognition Management Solutions. HRSD collects and processes information through a structured data interconnection that streamlines employees onboarding and supports standardized workflows, reduces administrative burden, and enables faster resolution of requests, allowing employees to effectively locate information and answers independently. Additionally, HRSD will enhance the overall employee experience by providing a unified self-service portal to access HR services and HR information within the HUD cloud architecture through ServiceNow, a Government Community Cloud (GCC) offering that delivers the Now Platform and complies with stringent cloud security and privacy compliance requirements. The following capabilities address human resources requirements:</P>
                <P>
                    • 
                    <E T="03">Classification:</E>
                     Creating, managing, and tracking job requisitions and associated documentation.
                </P>
                <P>
                    • 
                    <E T="03">Recruiting:</E>
                     Managing recruitment actions, tracking job requisitions and maintaining related documentation.
                </P>
                <P>
                    • 
                    <E T="03">Workforce Planning:</E>
                     Supporting succession planning and future organizational structures to align current and future talent needs.
                </P>
                <P>
                    • 
                    <E T="03">Onboarding:</E>
                     Integrating new hires into existing human capital management (HCM) systems, including pay, position, and organizational data.
                    <PRTPAGE P="48179"/>
                </P>
                <P>
                    • 
                    <E T="03">Employee Relations:</E>
                     Maintaining HR processes, documentation, case records, and communications.
                </P>
                <P>
                    • 
                    <E T="03">Performance Management:</E>
                     Documenting commendations, concerns, and performance patterns for individual employees.
                </P>
                <P>
                    • 
                    <E T="03">Employee Self-Service:</E>
                     Providing a centralized portal for employees to access HR information, benefits, and programs without direct assistance.
                </P>
                <P>
                    • 
                    <E T="03">Case and Knowledge Management:</E>
                     Standardizing documentation, managing employee relations cases, and fulfilling HR service requests.
                </P>
                <P>
                    • 
                    <E T="03">Reporting and Analytics:</E>
                     Collecting and analyzing data about performance, payroll, workflows, and other HCM functions, and generating automated reports for internal HUD stakeholders.
                </P>
                <PRIACT>
                    <HD SOURCE="HD1">SYSTEM NAME AND NUMBER:</HD>
                    <P>Human Resources Service Delivery (HRSD), HUD/OCHCO-07.</P>
                    <HD SOURCE="HD2">SECURITY CLASSIFICATION:</HD>
                    <P>Unclassified.</P>
                    <HD SOURCE="HD2">SYSTEM LOCATION:</HD>
                    <P>HUD Headquarters, 451 7th Street SW, Washington, DC 20410-0001, and Bowhead UIC Government Services LLC, 6564 Loisdale CT, Suite 900 Springfield, VA 22150-1812.</P>
                    <HD SOURCE="HD2">SYSTEM MANAGER(S):</HD>
                    <P>Amy Spande, HR Specialist, Human Capital Information System Division (HCISD), Office of the Chief Human Capital Officer (OCHCO), HUD HQ, 451 7th Street SW, Washington, DC 20410-0001; (202) 402-5665.</P>
                    <HD SOURCE="HD2">AUTHORITY FOR MAINTENANCE OF THE SYSTEM:</HD>
                    <P>5 U.S.C. 1302, Regulations; 5 U.S.C.1402, Authority and functions of agency Chief Human Capital Officers; 5 U.S. C. 2951, Reports to the Office of Personnel Management; 5 U.S.C. 3301(a), Civil Service; 5 U.S.C. 3372, General Provisions; 5 U.S. C. 3393, Career appointments; 42 U.S.C. 3535(c), Employment Compensation, Authority, and Duties of Personnel; and 5 CFR 250.204, Agency Roles and Responsibilities.</P>
                    <HD SOURCE="HD2">PURPOSES OF THE SYSTEM:</HD>
                    <P>The purpose of the Human Resources Service Delivery (HRSD) system is to modernize and support enterprise-wide HR integration. HRSD improves the timeliness and accuracy of personnel data, reduces manual errors, enhances onboarding and hiring processes, and provides Program Offices with flexible reporting capabilities to support mission-driven decision making and meet HR management business needs.</P>
                    <HD SOURCE="HD2">CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:</HD>
                    <P>Current and former HUD employees.</P>
                    <HD SOURCE="HD2">CATEGORIES OF RECORDS IN THE SYSTEM:</HD>
                    <P>Full name, job title, HUD employee ID (HID), work and personal email addresses, employment status/history, work and personal phone numbers, user ID, work address, employee duty location, assigned program office, and employment status and history.</P>
                    <HD SOURCE="HD2">RECORD SOURCE CATEGORIES:</HD>
                    <P>Office of Personnel Management USA Staffing.</P>
                    <HD SOURCE="HD2">ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND PURPOSES OF SUCH USES:</HD>
                    <P>(1) To a congressional office from the record of an individual in response to an inquiry from the congressional office made at the request of that individual.</P>
                    <P>(2) To contractors, grantees, experts, consultants, Federal agencies, and non-Federal entities, including, but not limited to, State and local governments and other research institutions or their parties, and entities and their agents with whom HUD has a contract, service agreement, grant, cooperative agreement, or other agreement for the purposes of statistical analysis and research in support of program operations, management, performance monitoring, evaluation, risk management, and policy development, to support the Department's mission otherwise, or for other research and statistical purposes not otherwise prohibited by law or regulation. Records under this routine use may not be used in whole or in part to make decisions that affect the rights, benefits, or privileges of specific individuals. The entity receiving information under this routine use may not further disclose the records in an identifiable form.</P>
                    <P>(3) To contractors, grantees, experts, consultants, and their agents, or others performing or working under a contract, service, grant, or cooperative agreement with HUD or under contract to another agency when necessary to accomplish an agency function related to a system of records. Disclosure requirements are limited to only those data elements considered relevant to accomplishing an agency function.</P>
                    <P>(4) To appropriate agencies, entities, and persons when: (1) HUD suspects or has confirmed that there has been a breach of the system of records; (2) HUD has determined that as a result of the suspected or confirmed breach there is a risk of harm to individuals, HUD (including its information systems, programs, and operations), the Federal Government, or national security; and (3) The disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with HUD's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm.</P>
                    <P>(5) To another Federal agency or Federal entity, when HUD determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in (1) responding to a suspected or confirmed breach or (2) preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity (including its information systems, programs and operations), the Federal Government, or national security, resulting from a suspected or confirmed breach.</P>
                    <P>(6) To appropriate Federal, State, local, tribal, or governmental agencies or multilateral governmental organizations responsible for investigating or prosecuting the violations of, or for enforcing or implementing, a statute, rule, regulation, order, or license where HUD determines that the information would assist in the enforcement of civil or criminal laws and when such records, either alone or in conjunction with other information, indicate a violation or potential violation of law.</P>
                    <P>(7) To a court, magistrate, administrative tribunal, or arbitrator while presenting evidence, including disclosures to opposing counsel or witnesses during civil discovery, litigation, mediation, or settlement negotiations; or in connection with criminal law proceedings; when HUD determines that use of such records is relevant and necessary to the litigation and when any of the following is a party to the litigation or have an interest in such litigation: (1) HUD, or any component thereof; or (2) any HUD employee in his or her official capacity; or (3) any HUD employee in his or her individual capacity where HUD has agreed to represent the employee; or (4) the United States, or any agency thereof, where HUD determines that litigation is likely to affect HUD or any of its components.</P>
                    <P>
                        (8) To any component of the Department of Justice or other Federal agency conducting litigation or in proceedings before any court, adjudicative, or administrative body, when HUD determines that the use of such records is relevant and necessary to the litigation and when any of the following is a party to the litigation or have an interest in such litigation: (1) HUD, or any component thereof; or (2) any HUD employee in his or her official 
                        <PRTPAGE P="48180"/>
                        capacity; or (3) any HUD employee in his or her individual capacity where the Department of Justice or agency conducting the litigation has agreed to represent the employee; or (4) the United States, or any agency thereof, where HUD determines that litigation is likely to affect HUD or any of its components.
                    </P>
                    <P>(9) To officials of labor organizations recognized under the Civil Service Reform Act when relevant and necessary to their duties of exclusive representation concerning personnel policies, practices, and matters affecting work conditions.</P>
                    <P>(10) To the Office of Personnel Management (OPM), the Merit Systems Protection Board (and its office of the Special Counsel), the Federal Labor Relations Authority (and its General Counsel), or the Equal Employment Opportunity Commission when requested in performance of their authorized duties of exclusive representation concerning personnel policies, practices, and matters affecting work conditions.</P>
                    <P>(11) To the National Archives and Records Administration, Office of Government Information Services (OGIS), to the extent necessary to fulfill its responsibilities in 5 U.S.C. 552(h), to review administrative agency policies, procedures and compliance with the Freedom of Information Act (FOIA), and to facilitate OGIS' offering of mediation services to resolve disputes between persons making FOIA requests and administrative agencies.</P>
                    <P>(12) To the Department of Treasury and the National Finance Center, a component office of the U.S. Department of Agriculture, for the purposes of delivering human resource services in support of program operations and management functions which include recruiting, promoting, compiling management reports, and processing transactions to meet human capital and workforce information management needs.</P>
                    <P>(13) To the Office of Personnel Management's USA Staffing portal, for the purpose of receiving data requests from agency personnel processing systems, to provide those agency personnel systems with real-time status and updates relating to requests, vacancies, and job announcements.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR STORAGE OF RECORDS:</HD>
                    <P>Records are maintained in electronic format. The electrical files are stored in OCHCO designated shared drive. The shared drive is restricted to only those with a need-to-know.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS:</HD>
                    <P>Records are retrieved by Full Name.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS:</HD>
                    <P>General Record Schedule (GRS) 2.2 refers to Employee Management Records and Employee Incentive Award Records. The “temporary” destruction periods are listed to show how long records are kept. The agency's awards files include recommendations for awards, approved nominations, and correspondence about awards from other Federal agencies or non-Federal organizations. These files also provide reports about agency-sponsored cash and noncash awards, honorary awards, informal recognition awards, cost savings awards, and time off awards. Lump-sum cash awards are included for both current and former employees. These temporary records are destroyed 2 years after final actions have been completed, but longer retention periods are authorized if required for business use. Copies of Standard Forms (SF 50) Notifications of Personnel Actions documenting all hiring, promotions, transfers, and separation actions are kept only as long as needed for business use. Chronological files, fact sheets, general correspondence, and forms about pending personnel actions are maintained by the agency's Human Resources offices. Temporary records of performance appraisals of non-senior executive service employees are destroyed no sooner than 4 years after the date of the appraisal, while records of senior executive service employees are destroyed no sooner than 5 years after the date of appraisal. All performance appraisals are authorized to be kept longer, if required for business use. Supervisors' personnel files, known as working files and/or unofficial personnel files, consist of records on information relating to positions, training records, telework agreements and award recommendations. These records are not appropriate for inclusion in the Official Performance File (OPF). Outdated items are removed and all remaining records are destroyed 1 year after the employee leaves or transfers. Destruction instructions may be included in the system's Privacy Impact Assessment (PIA).</P>
                    <HD SOURCE="HD2">ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS:</HD>
                    <P>
                        <E T="03">For Electronic Records:</E>
                         Comprehensive electronic records are maintained and stored in an electronic encryption database system. These records can only be accessed based on the user's rights and privileges to the system. Electronic records are stored in the ServiceNow Enterprise environment on the department's network (HUD). This environment complies with the security and privacy controls and procedures under the Federal Information Security Management Act (FISMA), National Institute of Standards and Technology (NIST) Special Publications, and Federal Information Processing Standards (FIPS). Access to the HRSD requires a valid HSPD-12 ID Credential, access to HUD's LAN, a valid User ID and Password, and a Personalized Identification Number (PIN). Records are accessible only to authorized personnel who require access to perform official duties.
                    </P>
                    <P>
                        <E T="03">For Electronic Records (cloud-based):</E>
                         Electronic records are secured and maintained within a Federal Risk and Authorization Management Program (FedRAMP) authorized, and Federal Information Security Management Act (FISMA) Moderate cloud environment. All data stored in the cloud is protected by firewalls and encrypted both at rest and in transit, consistent with HUD encryption standards. Security mechanisms for handling data follow HUD's technical, administrative, and operational safeguards to ensure confidentiality, integrity, and availability.
                    </P>
                    <HD SOURCE="HD2">RECORD ACCESS PROCEDURES:</HD>
                    <P>Individuals requesting records of themselves should address written inquiries to the Department of Housing and Urban Development, 451 7th Street SW, Washington, DC, 20410-0001. For verification, individuals should provide their full name, current address, and telephone number. In addition, the requester must provide either a notarized statement or an unsworn declaration made under 24 CFR 16.4.</P>
                    <HD SOURCE="HD2">CONTESTING RECORD PROCEDURES:</HD>
                    <P>The HUD rule for contesting the content of any record pertaining to the individual by the individual concerned is published in 24 CFR 16.8 or may be obtained from the system manager.</P>
                    <HD SOURCE="HD2">NOTIFICATION PROCEDURES:</HD>
                    <P>
                        Individuals requesting notification of records of themselves should address written inquiries to the Department of Housing and Urban Development, 451 7th Street SW, Washington, DC, 20410-0001. For verification purposes, individuals should provide their full name, office or organization where assigned, if applicable, and current address and telephone number. In addition, the requester must provide either a notarized statement or an 
                        <PRTPAGE P="48181"/>
                        unsworn declaration made under 24 CFR 16.4.
                    </P>
                    <HD SOURCE="HD2">EXEMPTIONS PROMULGATED FOR THE SYSTEM:</HD>
                    <P>None.</P>
                    <HD SOURCE="HD2">HISTORY: None.</HD>
                </PRIACT>
                <SIG>
                    <NAME>Kimberly Morton,</NAME>
                    <TITLE>Acting Chief Privacy Officer, Office of Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15421 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4210-67-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>Bureau of Indian Affairs</SUBAGY>
                <DEPDOC>[267A2100DD/AAKC001030/A0A501010.000000]</DEPDOC>
                <SUBJECT>Rate Adjustments for Indian Irrigation Projects</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Indian Affairs, Interior.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Bureau of Indian Affairs (BIA) owns or has an interest in irrigation projects located on or associated with various Indian reservations throughout the United States. We are required to establish irrigation assessment rates to recover the costs to administer, operate, maintain, and rehabilitate these projects. We are notifying you that we have adjusted the irrigation assessment rates at several of our irrigation projects and facilities to reflect current costs of administration, operation, maintenance, and rehabilitation.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The 2027 Irrigation Assessment Rates are effective on January 1, 2027.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Leslie Underwood, Program Specialist, Division of Water and Power, Office of Trust Services, (406) 657-5985. For details about a particular BIA irrigation project, please use the tables in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section to contact the BIA regional or local office where the irrigation project is located. Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    A Notice of Proposed Rate Adjustment was published in the 
                    <E T="04">Federal Register</E>
                     on March 23, 2026 (91 FR 13856) to propose adjustments to the irrigation assessment rates at several BIA irrigation projects. The public and interested parties were provided an opportunity to submit written comments during the 60-day period that ended May 22, 2026.
                </P>
                <HD SOURCE="HD1">Did BIA defer or change any proposed rate increases?</HD>
                <P>No, BIA did not defer any proposed rate increases.</P>
                <HD SOURCE="HD1">Did BIA receive any comments on the proposed irrigation assessment rate adjustments?</HD>
                <P>Yes. BIA received a total of nine (9) written comments related to the proposed 2027 irrigation assessment rate adjustments: two related to the Colorado River Indian Irrigation Project (CRIP), which included comments from the Colorado River Indian Tribes (CRIT) and an individual; and seven related to the Flathead Indian Irrigation Project (FIIP), which included comments from six individuals and legal counsel for the Flathead Irrigation District. The comments were received by letter and email.</P>
                <HD SOURCE="HD1">What issues were of concern to the commenters?</HD>
                <P>BIA's summary of the issues and responses are provided below.</P>
                <P>The following comments are specific to the Colorado River Indian Irrigation Project (CRIP):</P>
                <P>
                    <E T="03">Comment:</E>
                     CRIT requests a lower assessment, raising concerns related to rates increasing too quickly and impacts on irrigators' budgets.
                </P>
                <P>
                    <E T="03">Response:</E>
                     As noted when rates were proposed in the 
                    <E T="04">Federal Register</E>
                     on March 23, 2026 (91 FR 13856) and at our January tribal consultation and February water user meeting, BIA is required to establish irrigation assessment rates that recover the costs to administer, operate, maintain, and rehabilitate our projects. BIA's projects are important economic contributors to the local communities they serve, and they contribute millions of dollars in crop value annually. However, the costs associated with operating and maintaining an irrigation project may increase independently of prices and costs that are realized by the irrigators. Historically, BIA tempered irrigation rates to demonstrate sensitivity and lessen economic impact on water users, but that past practice created rate deficiencies at several irrigation projects. Therefore, funding to operate and maintain these projects must come directly from the water users they serve.
                </P>
                <P>BIA's irrigation program has been the subject of several Office of Inspector General (OIG) and U.S. Government Accountability Office (GAO) audits. In the most recent OIG audit, No. 96-I-641, March 1996, the OIG concluded:</P>
                <P>
                    <E T="03">Operation and maintenance revenues were insufficient to maintain the projects, and some projects had deteriorated to the extent that their continued capability to deliver water was in doubt. This occurred because operation and maintenance rates were not based on the full cost of delivering irrigation water, including the costs of systematically rehabilitating and replacing project facilities and equipment, and because project personnel did not seek regular rate increases to cover the full cost of project operation.</E>
                </P>
                <P>To address these deficiencies, BIA must systematically review irrigation assessment rates and adjust them to reflect the full cost of operation and maintenance of project infrastructure and to ensure its safe and reliable operation. Failure to make timely rate adjustments allows deficiencies to accumulate, eventually requiring larger, more abrupt increases over shorter periods than would have been otherwise necessary. By adjusting rates with actual rising costs (such as inflation, labor, materials, and construction) CRIP can secure essential resources through strategies like long-term contracts and bulk purchasing, safeguard against future price increases, and ensure the timely maintenance and replacement of critical infrastructure. These financial adjustments also enable the agency to address high-priority needs promptly, maintain reserve funding, and invest in staff recruitment and training, all of which contribute to more reliable water delivery and improved project operations. Ultimately, increased O&amp;M revenues provide necessary funding to maintain and enhance infrastructure, ensuring dependable service to the irrigators, and support long-term agricultural productivity.</P>
                <P>CRIP's assessments increased minimally from 2004 and 2024. We must now increase assessments by larger increments to keep up with rising construction, inflation, and maintenance costs. Additional revenues are necessary to fill staffing vacancies and complete major rehabilitation activities identified in modernization studies. The CRIP budget was developed in accordance with BIA's financial guidelines. Based on increased costs associated with administrating, operating, maintaining, and rehabilitating the project, the proposed rate increase is clearly needed and justified.</P>
                <P>
                    We appreciate CRIT's participation in our public meetings and comments regarding how to improve CRIP, and we have sent a follow-up letter to CRIT with additional details.
                    <PRTPAGE P="48182"/>
                </P>
                <P>
                    <E T="03">Comment:</E>
                     CRIT is concerned about CRIP's deferred maintenance exceeding $145 million and requests funding from other sources other than irrigation assessment rates.
                </P>
                <P>
                    <E T="03">Response:</E>
                     Over the past several years, BIA has received $24 million in annual appropriations from Congress to help address the significant deferred maintenance needs across its 17 BIA-owned irrigation projects, which total an estimated $2.39 billion as of April 26, 2026. BIA will continue to allocate its limited appropriations among the projects using our priority ranking system. BIA recently spent a significant amount of its appropriations on priority deferred maintenance projects at CRIP by providing engineering, design, and construction funds to CRIP; from fiscal years 2022 through 2025, BIA allocated over $25 million in supplemental funding to CRIP for deferred maintenance projects. In addition, the Bureau of Reclamation committed up to $5 million in 2025 to CRIT to fund planning, design, and study of a Main Canal Re-Regulation Reservoir on the CRIT reservation. Also, CRIT received a $1.2 million grant from the Bureau of Reclamation in CY 2025 to complete an infrastructure assessment of CRIP, which BIA looks forward to reviewing.
                </P>
                <P>
                    <E T="03">Comment:</E>
                     CRIT is concerned with the high number of vacancies resulting in decreased irrigation service and requests authority to immediately fill all CRIP vacancies, pay staff higher wages, and assign an economist or accountant to assist with budgeting and rate calculations. Another commentor is concerned with chronic understaffing that leads to preventable failures and decreasing reliability in water service.
                </P>
                <P>
                    <E T="03">Response:</E>
                     BIA is similarly concerned with low staffing levels at CRIP and is taking all available steps to address these challenges within legal and regulatory limits. In 2025, CRIP experienced the departure of its project manager, program assistant, and two lead irrigation system operators (ditch riders).
                </P>
                <P>
                    Although BIA received an exemption from the federal hiring freeze in spring 2025 to fill two ditch rider positions, those positions remain vacant despite multiple advertisements on 
                    <E T="03">USAJOBS.com</E>
                    . While CRIP's staffing levels are low, existing staff continue to take on additional duties and work overtime to ensure water delivery to all irrigators. BIA's Western Region Irrigation and Utility Services Program also provides accounting and budgeting support through a Financial Analyst who serves all Western Region irrigation projects, including CRIP.
                </P>
                <P>Under Executive Order 14356, Ensuring Continued Accountability in Federal Hiring (Oct. 15, 2025), BIA is required to submit an Annual Staffing Plan to the U.S. Office of Personnel Management (OPM) and the White House's Office of Management and Budget. Several CRIP priority positions have been approved for recruitment in fiscal year 2026 and will be advertised until filled, with additional positions expected to be considered for approval in the fourth quarter of 2026. Federal wage rates, including those applicable to BIA employees, are set by OPM and governing statutes and cannot be adjusted by the agency.</P>
                <P>In January 2026, Congress authorized the Department of the Interior to recruit and directly appoint qualified individuals into the competitive service who are certified as maintaining a permanent and exclusive residence in the vicinity of the field unit into any position at or below grades GS-9. Public Law 119-74,  127 (Jan. 23, 2026). BIA plans to include “Field Unit Local Hiring” eligibility on CRIP job announcements at or below grades GS-9. We are optimistic this new authority will expedite BIA's hiring process.</P>
                <P>The 2027 CRIP budget includes funding for 13 vacant positions, including a project manager, program assistant, equipment operator, two supervisory ditch riders, and eight ditch riders. While BIA has not yet submitted its fiscal year 2027 Annual Staffing Plan, BIA anticipates requesting approval to fill all 13 funded vacant positions. If approval to advertise all positions is not granted for 2027, BIA will utilize contractors to perform necessary work. Any unspent personnel funds will be allocated to CRIP's emergency, sinking, and rehabilitation and replacement funds.</P>
                <P>
                    <E T="03">Comment:</E>
                     CRIT and another commenter object to CRIP's budget expense for purchasing new vehicles and equipment because cuts to staffing levels results in fewer people available to operate the equipment. The commenters recommend BIA instead sell old equipment.
                </P>
                <P>
                    <E T="03">Response:</E>
                     CRIP's 2027 budget does not include funding to purchase new equipment, rather it includes funding for maintenance of our existing equipment. Moreover, despite current staffing vacancies within CRIP, it remains important to procure vehicles for staff usage. Vehicles remain essential for field operations, and the Project must maintain sufficient fleet capacity for existing personnel to perform required duties. CRIP has historically leased all its vehicles, which results in higher long-term costs than ownership. To reduce recurring expenses, CRIP has budgeted to incrementally reduce its number of leased vehicles over the next several years to government-owned vehicles, which accounts for the higher vehicle-related funding in the 2027 budget compared to 2025 actual leasing costs. Once the Project transitions to owning vehicles, CRIP's annual vehicle expense will decrease and result in long-term budget savings.
                </P>
                <P>
                    <E T="03">Comment:</E>
                     One commentor requests implementation of a formal work order and tracking system.
                </P>
                <P>
                    <E T="03">Response:</E>
                     CRIP utilizes an established asset management system known as Maximo, which is used across all BIA programs. Maximo is the Department of the Interior's (DOI) enterprise software for facilities and asset management and is used to track and manage facility maintenance, dam safety, operations and maintenance, deferred maintenance, work orders, and asset-related reporting. CRIP creates and closes Maximo work orders for rehabilitation, replacement, and maintenance of project facilities and equipment.
                </P>
                <P>In addition to Maximo, the BIA Division of Water and Power recently launched a pilot electronic water ticketing system at CRIP. Phase 1 of the water ticketing system provides CRIP staff with access to an electronic database to record irrigators' water ticket requests and BIA water deliveries. Potential future functions, subject to the availability of appropriations for system development, include integration with BIA's irrigation billing system, improved scheduling of water deliveries, and customer water request portal. The water ticketing system is designed to streamline and improve communication, documentation, and responsiveness. After completing the pilot with CRIP, BIA Division of Water and Power plans to eventually implement the water ticketing system at all BIA irrigation projects.</P>
                <P>The following comments are specific to the Flathead Indian Irrigation Project (FIIP):</P>
                <P>
                    <E T="03">Comment:</E>
                     Three commentors express concerns about lack of maintenance and deferred maintenance and object to rate increases until quality of service improves.
                </P>
                <P>
                    <E T="03">Response:</E>
                     Because BIA does not have discretionary funds to subsidize the BIA irrigation projects, funding to operate and maintain these projects comes primarily from operations and assessment revenues. Several Government Accountability Office (GAO) reports and Inspector General (IG) audits have found BIA irrigation assessment rates need to increase 
                    <PRTPAGE P="48183"/>
                    significantly. (
                    <E T="03">see, e.g.,</E>
                     IG Report No. 96-641, March 1996; GAO Report 06-314, February 2006). In 2008, in response to these audits, BIA published updated regulations for its irrigation projects and declared its intent to “systematically review and evaluate [operation and maintenance] rates and adjust them, when necessary, to reflect the full costs to properly operate and perform all appropriate maintenance . . . to ensure safe and reliable operation” and to avoid the accumulation of further rate deficiencies (73 FR 32043, 32044). Since 2013 when BIA reassumed FIIP operation and maintenance, BIA has repeatedly acknowledged the need to increase operation and maintenance assessments and routinely noticed its intent to raise assessments.
                </P>
                <P>Assessment rates are commensurate with our quality of irrigation service, so we must increase rates to improve service. The proposed 2027 rate increase would allow FIIP to rebuild staffing levels, pay for increased pumping costs, account for rising inflation and construction costs, and replenish its depleted reserve account for emergencies. Achieving a higher level of service by efficiently carrying out infrastructure repairs and maintenance requires recruitment and retention of experienced and qualified personnel. Historically, BIA tempered O&amp;M rates to demonstrate sensitivity to the economic impact on water users, but that practice resulted in rate deficiencies at some projects including FIIP. FIIP's O&amp;M rates have not kept up with costs, resulting in a growing backlog of deferred maintenance. The proposed assessment increases have been projected and noticed for several years to ensure FIIP can keep up with these financial demands and maintain reliable service for water users.</P>
                <P>
                    <E T="03">Comment:</E>
                     Two commentors object to the proposed $220 parcel minimum charge because they do not use water service from FIIP.
                </P>
                <P>
                    <E T="03">Response:</E>
                     5 U.S.C. 301, the Act of August 14, 1914 (38 Stat. 583; 25 U.S.C. 385), and FIIP-specific statutes authorize the Secretary to fix operation and maintenance charges for irrigable lands within FIIP. The Secretary has in turn delegated this authority to the Assistant Secretary for Indian Affairs under part 209, chapter 8.1A, of the Department of the Interior's Departmental Manual. Land classification is a process by which land is surveyed and classified as irrigable or non-irrigable, and irrigable means lands to which water for irrigation purposes can be delivered, upon request, within a reasonable amount of time (Pub. L. 66-141 (41 Stat. 409), Feb. 14, 1920). A landowner's failure to provide internal ditches, perform minor leveling, or remove vegetation are not considered factors that alter classification of lands as irrigable or prevent irrigation or assessment of FIIP lands.
                </P>
                <P>FIIP's land tracts were originally authorized to be between 40 and 160 acre parcels (Pub. L. 58-159 (33 Stat. 302), Apr. 23, 1904; Pub. L. 60-156 (35 Stat. 444, 448-50), May 29, 1908). Each tract with no less than 40 acres is served by a farm turnout structure designed to deliver water via gravity flow from a ditch. Over time, subdivision of tracts has resulted in an approximately 60% increase in the total number of FIIP assessable tracts, with a significant portion now less than 4.78 acres in size. The increased number of tracts requires greater staff time for administrative and operational activities, including updating and maintaining land records, processing annual O&amp;M billings, revenue collection, taking and adjusting water orders, accounting of water deliveries, resolving water issues, responding to user inquiries or complaints, permitting, and addressing encroachment. From 2015 through 2025, FIIP's minimum charge remained $75 annually and did not keep up with actual expenses for servicing these smaller tracts. When rates are delayed, subsequent increases will necessarily be larger. The proposed $220 minimum charge is structured to cover increased operational and administrative costs associated with serving these smaller tracts.</P>
                <P>
                    Irrigators do not have to pay their annual operation and maintenance assessment if they are granted an Annual Assessment Waiver or the land is re-designated as Temporarily or Permanently Non-Assessable. An annual assessment waiver will be granted if our facilities are not capable of delivering any water to your land for the entire year. 25 CFR 171.705-710. Inadequate water supply due to natural conditions or climate is not justification for an annual assessment waiver. The Annual Assessment Waiver Application is available at 
                    <E T="03">https://www.bia.gov/sites/default/files/media_document/1076-0141_bia-dwp-irr-103-assessment-waiver_exp-04-30-29_508.pdf.</E>
                     If landowners believe their lands cannot be cultivated profitably due to a present lack of water supply, proper drainage facilities, or need of additional construction work, they can apply to have their lands declared temporarily non-assessable for up to 5 years (25 U.S.C. 389 
                    <E T="03">et seq</E>
                    ). If landowners believe their lands are permanently non-assessable, they may apply for a Permanently Non-Assessable designation (25 U.S.C. 389b 
                    <E T="03">et seq</E>
                    ). Changed land use, however, is not sufficient reason to re-designate land to permanently non-assessable. A permanent change in land status may reduce the value of the property and diminish resale value as well as potentially impact water rights. The Land Classification/Designation application is available at 
                    <E T="03">https://www.bia.gov/sites/default/files/media_document/1076-0141_bia-dwp-irr-105_land-classification-and-designation-application_exp-04-30-29_508.pdf.</E>
                </P>
                <P>
                    <E T="03">Comment:</E>
                     Two commentors object to the rate increase because they depend on overflow from ditches to flood irrigate their property and have not received sufficient overflow in the past two years. One of these commentors objects to an across-the-board rate increase because of inequity in water deliveries and receiving poorer water service than other parts of the FIIP.
                </P>
                <P>
                    <E T="03">Response:</E>
                     The quantity of water provided to each tract is determined by the irrigator's request, the legal entitlement, and the available water supply in accordance with 25 CFR 171.205. FIIP's mission is to deliver water equitably to all farm units at their respective designated turnout. Once water passes through the farm turnout, the responsibility for means and methods of irrigation rests solely with the irrigator. It is up to each irrigator to manage how that irrigation water is applied to their land for effective irrigation.
                </P>
                <P>
                    Future water shortages may exist due to climatic conditions, and hydrology varies across the Project. However, inadequate water supply due to natural conditions or climate is not justification for the BIA to delay an assessment increase. The costs BIA assesses for O&amp;M—covering personnel, equipment, maintenance, rehabilitation, 
                    <E T="03">etc.</E>
                    —persist regardless of drought conditions. 
                    <E T="03">See</E>
                     25 CFR 171.500 and 25 CFR 171.705.
                </P>
                <P>
                    <E T="03">Comment:</E>
                     Three commentors express concerns over FIIP's low staffing levels and inadequacy of emergency hires. Commentors believe FIIP has excess funds due to staffing shortages and recommend reducing the rate increase until the hiring freeze is lifted and FIIP is approved to fill vacancies.
                </P>
                <P>
                    <E T="03">Response:</E>
                     For the last several summers, FIIP has relied on Confederated Salish and Kootenai Tribes (CSKT) staff—referred to as “emergency hires”—to assist with carrying out essential irrigation operations, administrative functions, and maintenance activities. FIIP provides CSKT with funding to hire 
                    <PRTPAGE P="48184"/>
                    irrigation staff through CSKT's self-governance compact with BIA, whereby Intergovernmental Personnel Act agreements may be entered into for each employee. As of June 2026, FIIP operates with 26 full-time BIA employees and 14 CSKT staff for a total current staff level of 40 employees. Around 50% of the CSKT staff are retired BIA personnel, some with decades of FIIP experience and expertise. These CSKT staff are tremendously helpful, and without them BIA may not be able to deliver water to all FIIP irrigators. Even though staffing levels have fallen below ideal thresholds, FIIP has maintained full operational continuity as a result of dedicated personnel working overtime, soliciting contractors to do work BIA previously performed, and assuming extra administrative work to support land records management, billing, revenue collection, water delivery, issue resolution, permitting, and encroachment responses.
                </P>
                <P>BIA is no longer subject to the federal hiring freeze in place for most of 2025. Starting with fiscal year 2026, BIA must submit an Annual Staffing Plan to OPM and the White House's Office of Management and Budget. Exec. Order No. 14356 (Oct. 15, 2025). A few of FIIP's requested priority positions have been approved to hire in fiscal year 2026 and will be advertised this summer until filled. Additional FIIP positions may be approved for hiring in the fourth quarter of 2026. As explained above, BIA was recently authorized to recruit and directly appoint qualified individuals into the competitive service who are certified as maintaining a permanent and exclusive residence in the vicinity of the field unit, into any position at or below grades GS-9 (Pub. L. 119-74, section 127 (Jan. 23, 2026)). We are optimistic this new authority will expedite FIIP's hiring process.</P>
                <P>The FIIP 2027 budget includes funding for its current 40 staff plus 8 vacant positions including a Project Manager, Civil Engineering Technician, Supervisory Civil Engineer, GIS Specialist, Hydrologist/Fish Biologist, Irrigation System Operator, Utility Systems Operator, and Maintenance Worker. The 2027 budget does not include funding for 6 vacant positions in the Project's organizational chart. The 2027 budget and assessment rate will allow BIA to hire necessary personnel to improve irrigation service and address maintenance across the Project. While BIA has not yet submitted its fiscal year 2027 Annual Staffing Plan, BIA anticipates requesting approval to hire the 8 funded vacant FIIP positions as well as the positions temporarily filled by CSKT staff. Any unspent personnel funds will be allocated to FIIP's emergency, sinking, and rehabilitation and replacement funds.</P>
                <P>FIIP did not have any carryover funds in 2025. BIA's budget (prepared two years in advance) estimated personnel costs of $3.21 million and actual personnel costs was $3.16 million. The unspent portion allowed FIIP to purchase equipment. Because FIIP's total 2025 expenses exceeded revenue, FIIP used reserve funds to cover the balance of expenses. Given the same expenses and level of service will cost more in 2027, FIIP's rate assessment increase is necessary.</P>
                <HD SOURCE="HD1">Does this notice affect me?</HD>
                <P>This notice affects you if you own or lease land within the assessable acreage of one of our irrigation projects or if you have a carriage agreement with one of our irrigation projects.</P>
                <HD SOURCE="HD1">Where can I get information on the regulatory and legal citations in this notice?</HD>
                <P>
                    You can contact the appropriate office(s) stated in the tables for the irrigation project that serves you, or you can use the internet site for the Government Publishing Office at 
                    <E T="03">www.gpo.gov.</E>
                </P>
                <HD SOURCE="HD1">What authorizes you to issue this notice?</HD>
                <P>Our authority to issue this notice is vested in the Secretary of the Interior (Secretary) by 5 U.S.C. 301 and the Act of August 14, 1914 (38 Stat. 583; 25 U.S.C. 385). The Secretary has in turn delegated this authority to the Assistant Secretary—Indian Affairs under part 209, chapter 8.1A, of the Department of the Interior's Departmental Manual.</P>
                <HD SOURCE="HD1">Whom can I contact for further information?</HD>
                <P>The following tables are the regional and project/agency contacts for our irrigation facilities.</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,p1,8/9,i1" CDEF="s50,r150">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Northwest Region Contacts</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="22">Kurt Fredenburg, Acting Regional Director, Bureau of Indian Affairs, Northwest Regional Office, 911 NE 11th Avenue, Portland, OR 97232-4169. Telephone: (505) 220-9252.</ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Flathead Indian Irrigation Project</ENT>
                        <ENT>Gene “Bear” Hughes, Acting Superintendent, Dominick Belcourt, Acting Irrigation Project Manager, 220 Project Drive, St. Ignatius, MT 59865. Telephones: Superintendent (406) 675-2700; Irrigation Project Manager (406) 745-2661.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Hall Irrigation Project</ENT>
                        <ENT>Tim Gardner, Acting Irrigation Project Manager, 36 Bannock Avenue, Fort Hall, ID 83203-0220. Telephone: (208) 238-1992.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Wapato Irrigation Project</ENT>
                        <ENT>Pete Plant, Project Administrator, 413 South Camas Avenue, Wapato, WA 98951-0220. Telephone: (509) 877-3155.</ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Rocky Mountain Region Contacts</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="22">Jodi Camrud, Acting Regional Director, Bureau of Indian Affairs, Rocky Mountain Regional Office, 2021 4th Avenue North, Billings, MT 59101. Telephone: (406) 247-7943.</ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Blackfeet Irrigation Project</ENT>
                        <ENT>Kenneth Bird, Superintendent, Edward Chief All Over, Acting Irrigation Project Manager, P.O. Box 880, Browning, MT 59417. Telephones: Superintendent (406) 338-7544; Irrigation Project Manager (406) 338-7519.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Crow Irrigation Project</ENT>
                        <ENT>Harold “Jess” Brien, Superintendent, Richard Taptto, Acting Irrigation Project Manager (BIA), (Project O&amp;M performed by Water Users Association), P.O. Box 69, Crow Agency, MT 59022. Telephones: Superintendent (406) 638-2672; Acting Irrigation Project Manager (406) 698-5631.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Belknap Irrigation Project</ENT>
                        <ENT>Mark Azure, Superintendent, Richard Taptto, Acting Irrigation Project Manager (BIA), (Project O&amp;M contracted to Tribes under Pub. L. 93-638),158 Tribal Way, Suite B, Harlem, MT 59526. Telephones: Superintendent (406) 353-2901; Irrigation Project Manager, Tribal Office (406) 353-8454.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Peck Irrigation Project</ENT>
                        <ENT>Megan Gourneau, Superintendent, Richard Taptto, Acting Irrigation Project Manager (BIA), (Project O&amp;M performed by Fort Peck Water Users Association), P.O. Box 637, Poplar, MT 59255. Telephones: Superintendent (406) 768-5312; Acting Irrigation Project Manager (406) 698-5631.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <PRTPAGE P="48185"/>
                        <ENT I="01">Wind River Irrigation Project</ENT>
                        <ENT>Antonio Pingree, Superintendent, Richard Taptto, Acting Irrigation Project Manager (BIA), (Project O&amp;M for Little Wind, Johnstown, and Lefthand Units contracted to Tribes under Pub. L. 93-638; Upper Wind Units O&amp;M performed by A Canal, and Crowheart Water Users Associations), P.O. Box 158, Fort Washakie, WY 82514. Telephones: Superintendent (307) 332-7810; Acting Irrigation Project Manager (406) 698-5631.</ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Southwest Region Contacts</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="22">Dan Galvin, Acting Regional Director, Bureau of Indian Affairs, Southwest Regional Office, 1001 Indian School Road NW, Albuquerque, NM 87104. Telephone: (505) 563-3100.</ENT>
                    </ROW>
                    <ROW EXPSTB="00" RUL="s">
                        <ENT I="01">Pine River Irrigation Project</ENT>
                        <ENT>Priscilla Bancroft, Superintendent, Vickie Begay, Irrigation Project Manager, P.O. Box 315, Ignacio, CO 81137-0315. Telephones: Superintendent (970) 200-8613; Irrigation Project Manager (970) 236-4161.</ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Western Region Contacts</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="22">Jessie Durham, Regional Director, Bureau of Indian Affairs, Western Regional Office, 2600 North Central Avenue, 4th Floor Mailroom, Phoenix, AZ 85004. Telephone: (480) 535-1552.</ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Colorado River Irrigation Project</ENT>
                        <ENT>Davetta Ameelyenah, Superintendent, Irrigation Project Manager (Vacant), (Portions of Project O&amp;M contracted to Colorado River Indian Tribes under Pub. L. 93-638), 12124 1st Avenue, Parker, AZ 85344. Telephones: Superintendent (928) 669-7111; Irrigation Project Manager (928) 662-4392; Water Resources/Irrigation Department of Colorado River Indian Tribes (928) 669-1312.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Duck Valley Irrigation Project</ENT>
                        <ENT>Jane Jackson-Bear,Superintendent, (Project O&amp;M compacted to Shoshone-Paiute Tribes under Pub. L. 93-638), 2719 Argent Avenue, Suite 4, Gateway Plaza, Elko, NV 89801. Telephones: Superintendent (775) 738-5165; Tribal Office (208) 759-3100.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Yuma Project, Indian Unit</ENT>
                        <ENT>Davetta Ameelyenah, Acting Superintendent, BOR owns the Project and is responsible for O&amp;M), 256 South Second Avenue, Suite D, Yuma, AZ 85364. Telephones: Superintendent (928) 782-1202; BOR Area Office Manager (928) 343-8100.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">San Carlos Irrigation Project (Indian Works and Joint Works)</ENT>
                        <ENT>Cathy Wilson, Acting General Manager, Irrigation and Utility Services (BIA), Kyle Varvel, Civil Engineer, Irrigation Division (BIA), (Portions of Indian Works O&amp;M compacted to Gila River Indian Community under Pub. L. 93-638; Joint Control Board is responsible for portions of Joint Works maintenance pursuant to Gila River Indian Community Water Rights Settlement Act of 2004, 118 Stat. 3499), 13805 North Arizona Boulevard, Coolidge, AZ 85128. Telephones: General Manager (480) 744-5368; Civil Engineer (520) 562-3372; Gila River Indian Irrigation &amp; Drainage District (520) 562-6720; Joint Control Board (520) 562-9760, (520) 723-5408.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Uintah Irrigation Project</ENT>
                        <ENT>Seann Woster, Acting Superintendent, Sam Johnson, Irrigation System Manager, (Project O&amp;M performed by Uintah Indian Irrigation Project Operation and Maintenance Company), P.O. Box 130, Fort Duchesne, UT 84026. Telephones: Superintendent (435) 722-4300; Uintah Indian Irrigation Operation and Maintenance Company (435) 724-5200.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Walker River Irrigation Project</ENT>
                        <ENT>James Gatzke, Acting Superintendent, 311 East Washington Street, Carson City, NV 89701. Telephone: (775) 887-3500.</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">What irrigation assessments or charges are adjusted by this notice?</HD>
                <P>The rate table below contains final rates for the 2026 and 2027 calendar years for all irrigation projects where we recover costs of administering, operating, maintaining, and rehabilitating them. An asterisk immediately following the rate category notes irrigation projects where 2026 rates are different from the 2027 rates.</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,tp0,i1" CDEF="s100,r75,12,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Project name</CHED>
                        <CHED H="1">Rate category</CHED>
                        <CHED H="1">
                            Final
                            <LI>2026 rate</LI>
                        </CHED>
                        <CHED H="1">
                            Final
                            <LI>2027 rate</LI>
                        </CHED>
                    </BOXHD>
                    <ROW EXPSTB="03" RUL="s">
                        <ENT I="21">
                            <E T="02">Northwest Region Rate Table</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Flathead Irrigation Project (See Note #1)</ENT>
                        <ENT>Basic per acre—A *</ENT>
                        <ENT>$39.00</ENT>
                        <ENT>$46.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Basic per acre—B *</ENT>
                        <ENT>19.50</ENT>
                        <ENT>23.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Minimum Charge per tract *</ENT>
                        <ENT>200.00</ENT>
                        <ENT>220.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Hall Irrigation Project</ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>68.00</ENT>
                        <ENT>68.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Minimum Charge per tract *</ENT>
                        <ENT>44.50</ENT>
                        <ENT>45.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Hall Irrigation Project—Minor Units</ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>46.50</ENT>
                        <ENT>47.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Minimum Charge per tract *</ENT>
                        <ENT>44.50</ENT>
                        <ENT>45.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Hall Irrigation Project—Michaud Unit</ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>77.50</ENT>
                        <ENT>78.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Pressure per acre *</ENT>
                        <ENT>120.00</ENT>
                        <ENT>122.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Minimum Charge per tract *</ENT>
                        <ENT>44.50</ENT>
                        <ENT>45.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wapato Irrigation Project—Toppenish/Simcoe Units</ENT>
                        <ENT>Minimum Charge per bill *</ENT>
                        <ENT>28.00</ENT>
                        <ENT>28.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>28.00</ENT>
                        <ENT>28.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wapato Irrigation Project—Ahtanum Units</ENT>
                        <ENT>Minimum Charge per bill *</ENT>
                        <ENT>35.00</ENT>
                        <ENT>36.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>35.00</ENT>
                        <ENT>36.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wapato Irrigation Project—Satus Unit</ENT>
                        <ENT>Minimum Charge per bill *</ENT>
                        <ENT>100.00</ENT>
                        <ENT>120.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>“A” Basic per acre *</ENT>
                        <ENT>86.00</ENT>
                        <ENT>89.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>“B” Basic per acre *</ENT>
                        <ENT>92.00</ENT>
                        <ENT>95.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wapato Irrigation Project—Additional Works</ENT>
                        <ENT>Minimum Charge per bill *</ENT>
                        <ENT>100.00</ENT>
                        <ENT>120.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>87.00</ENT>
                        <ENT>90.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wapato Irrigation Project—Water Rental</ENT>
                        <ENT>Minimum Charge per bill *</ENT>
                        <ENT>100.00</ENT>
                        <ENT>120.00</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <PRTPAGE P="48186"/>
                        <ENT I="22"> </ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>100.00</ENT>
                        <ENT>125.00</ENT>
                    </ROW>
                    <ROW EXPSTB="03" RUL="s">
                        <ENT I="21">
                            <E T="02">Rocky Mountain Region Rate Table</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Blackfeet Irrigation Project</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>22.00</ENT>
                        <ENT>22.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Crow Irrigation Project—Willow Creek O&amp;M (includes Agency, Lodge Grass #1, Lodge Grass #2, Reno, Upper Little Horn, and Forty Mile Units)</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>34.00</ENT>
                        <ENT>34.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Crow Irrigation Project—All Others (includes Bighorn, Soap Creek, and Pryor Units)</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>34.00</ENT>
                        <ENT>34.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Two Leggins Irrigation District Unit—Servicing Crow Trust lands (See Note #2)</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>17.00</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Two Leggins Drainage District—Servicing Crow Trust lands (See Note #2)</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>5.00</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Belknap Irrigation Project</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>25.00</ENT>
                        <ENT>25.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fort Peck Irrigation Project</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>35.00</ENT>
                        <ENT>35.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wind River Irrigation Project—Units 2, 3 and 4</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>28.00</ENT>
                        <ENT>28.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wind River Irrigation Project—Unit 6</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>28.00</ENT>
                        <ENT>28.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">LeClair Irrigation District—Servicing Wind River Trust lands (See Note #3)</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>47.00</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wind River Irrigation Project—Crow Heart Unit</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>17.50</ENT>
                        <ENT>17.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Wind River Irrigation Project—A Canal Unit</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>17.50</ENT>
                        <ENT>17.50</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Riverton Valley Irrigation District—Servicing Wind River Trust lands (See Note #3)</ENT>
                        <ENT>Basic-per acre</ENT>
                        <ENT>30.65</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                    <ROW EXPSTB="03" RUL="s">
                        <ENT I="21">
                            <E T="02">Southwest Region Rate Table</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Pine River Irrigation Project (See Note #4)</ENT>
                        <ENT>Minimum Charge per tract</ENT>
                        <ENT>75.00</ENT>
                        <ENT>75.00</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="22"> </ENT>
                        <ENT>Basic-per acre *</ENT>
                        <ENT>24.50</ENT>
                        <ENT>25.00</ENT>
                    </ROW>
                    <ROW EXPSTB="03" RUL="s">
                        <ENT I="21">
                            <E T="02">Western Region Rate Table</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Colorado River Irrigation Project</ENT>
                        <ENT>Basic per acre up to 5.75 acre-feet *</ENT>
                        <ENT>85.00</ENT>
                        <ENT>93.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Excess Water per acre-foot over 5.75 acre-feet</ENT>
                        <ENT>18.00</ENT>
                        <ENT>18.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Duck Valley Irrigation Project</ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>12.00</ENT>
                        <ENT>13.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Yuma Project, Indian Unit (See Note #5)</ENT>
                        <ENT>Basic per acre up to 5.0 acre-feet</ENT>
                        <ENT>222.50</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Excess Water per acre-foot over 5.0 acre-feet</ENT>
                        <ENT>35.00</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Basic per acre up to 5.0 acre-feet (Ranch 5)</ENT>
                        <ENT>222.50</ENT>
                        <ENT>( + )</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="5" OPTS="L2(0,,),ns,nj,tp0,p1,8/9,i1" CDEF="s100,r50,r50,r50,r50">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW RUL="n,s">
                        <ENT I="01">San Carlos Irrigation Project (Joint Works) (See Note #6)</ENT>
                        <ENT A="L01">Basic per acre *</ENT>
                        <ENT>28.00</ENT>
                        <ENT>24.00</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="22"> </ENT>
                        <ENT A="L03">Final 2027 Construction Water Rate Schedule:</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT O="oi0" O1="xl">
                            Off project 
                            <LI O="oi0" O1="xl">construction</LI>
                        </ENT>
                        <ENT O="oi0" O1="xl">
                            On project 
                            <LI O="oi0" O1="xl">construction—</LI>
                            <LI O="oi0" O1="xl">gravity water</LI>
                        </ENT>
                        <ENT O="oi0" O1="xl">
                            On Project 
                            <LI O="oi0" O1="xl">construction—</LI>
                            <LI O="oi0" O1="xl">pump water</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Administrative Fee</ENT>
                        <ENT>300.00</ENT>
                        <ENT>300.00</ENT>
                        <ENT>300.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Usage Fee</ENT>
                        <ENT>250.00 per month</ENT>
                        <ENT>No Fee</ENT>
                        <ENT>100.00 per acre foot</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Excess Water Rate †</ENT>
                        <ENT>5.00 per 1,000 gal.</ENT>
                        <ENT>No Charge</ENT>
                        <ENT>No Charge</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="4" OPTS="L2,ns,nj,tp0,i1" CDEF="s100,r75,12,12">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Project name</CHED>
                        <CHED H="1">Rate category</CHED>
                        <CHED H="1">
                            Final
                            <LI>2026 rate</LI>
                        </CHED>
                        <CHED H="1">
                            Final
                            <LI>2027 rate</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">San Carlos Irrigation Project (Indian Works) (See Note #7)</ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>98.85</ENT>
                        <ENT>94.85</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Uintah Irrigation Project</ENT>
                        <ENT>Basic per acre</ENT>
                        <ENT>25.00</ENT>
                        <ENT>25.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Minimum Bill</ENT>
                        <ENT>25.00</ENT>
                        <ENT>25.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Walker River Irrigation Project</ENT>
                        <ENT>Basic per acre *</ENT>
                        <ENT>32.00</ENT>
                        <ENT>34.00</ENT>
                    </ROW>
                    <TNOTE>* Notes irrigation projects where rates are adjusted.</TNOTE>
                    <TNOTE>+ These rates have not yet been determined.</TNOTE>
                    <TNOTE>† The excess water rate applies to all water used in excess of 50,000 gallons in any one month.</TNOTE>
                    <TNOTE>Note #1: The Minimum Charge per tract for Flathead Irrigation Project for 2027 will apply to parcels sized 4.78 acres or smaller.</TNOTE>
                    <TNOTE>Note #2: The O&amp;M rates for Two Leggins Irrigation District Unit and Two Leggins Drainage District pertain to Trust lands serviced by each respective irrigation district. The Two Leggins Irrigation District Unit and Two Leggins Drainage District are privately owned and operated, co-located with the BIA Crow Irrigation Project. The annual O&amp;M rates are determined by the districts annually. BIA is retracting the proposed 2027 rates because the final budgets for 2027 have not yet been determined by the districts.</TNOTE>
                    <TNOTE>
                        Note #3: The O&amp;M rates for LeClair Irrigation District and Riverton Valley Irrigation District apply to Trust lands serviced by each irrigation district. The districts are privately owned and operated, co-located with the BIA Wind River Irrigation Project. The annual O&amp;M rates are determined by the LeClair and Riverton Valley Irrigation Districts, respectively. BIA is retracting the proposed 2027 rates for these two districts because the final budgets for 2027 rates have not yet been determined.
                        <PRTPAGE P="48187"/>
                    </TNOTE>
                    <TNOTE>Note #4: The Minimum Charge per tract for Pine River Irrigation Project for 2027 will apply to any parcel with an assessment under $75.00, whereby a flat fee of $75.00 will be charged.</TNOTE>
                    <TNOTE>Note #5: The O&amp;M rate for the Yuma Project, Indian Unit has two components. The first component of the O&amp;M rate is established by the Bureau of Reclamation (BOR), the owner and operator of the Project; the BOR rate is $218 for 2026 but has not been established for 2027. The second component of the O&amp;M rate is established by BIA to cover administrative costs, which includes billing and collections for the Project. The Final 2026 BIA rate component is $4.50 per acre. The Final 2027 BIA rate component is $4.50 per acre.</TNOTE>
                    <TNOTE>Note #6: The Construction Water Rate Schedule identifies fees assessed for use of irrigation water for non-irrigation purposes.</TNOTE>
                    <TNOTE>Note #7: The O&amp;M rate for the San Carlos Irrigation Project—Indian Works has three components. The first component is established by BIA San Carlos Irrigation Project—Indian Works; the final 2026 rate is $55.85 per acre and the Final 2027 rate is $55.85. The second component is established by BIA San Carlos Irrigation Project—Joint Works; the final 2026 rate is $28.00 per acre and the 2027 Final rate is $24.00. The third component is established by the San Carlos Irrigation Project Joint Control Board (comprised of representatives from the Gila River Indian Community and the San Carlos Irrigation and Drainage District); the 2026 and 2027 rate is $15.00 per acre.</TNOTE>
                </GPOTABLE>
                <HD SOURCE="HD1">Consultation and Coordination With Tribal Governments (Executive Order 13175)</HD>
                <P>The Department of the Interior strives to strengthen its government-to-government relationship with Indian Tribes through a commitment to consultation with Indian Tribes and recognition of their right to self-governance and Tribal sovereignty. We have evaluated this notice under the Department's consultation policy and under the criteria of Executive Order 13175 and have determined there to be substantial direct effects on federally recognized Tribes because the irrigation projects are located on or associated with Indian reservations. To fulfill its consultation responsibility to Tribes and Tribal organizations, BIA communicates, coordinates, and consults on a continuing basis with these entities on issues of water delivery, water availability, and costs of administration, operation, maintenance, and rehabilitation of projects that concern them. This is accomplished at the individual irrigation project by project, agency, and regional representatives, as appropriate, in accordance with local protocol and procedures. This notice is one component of our overall coordination and consultation process to provide notice to, and request comments from, these entities when we adjust irrigation assessment rates.</P>
                <HD SOURCE="HD1">Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use (Executive Order 13211)</HD>
                <P>These rate adjustments are not a significant energy action under the definition in Executive Order 13211. A statement of energy effects is not required.</P>
                <HD SOURCE="HD1">Regulatory Planning and Review (Executive Order 12866)</HD>
                <P>These rate adjustments are not a significant regulatory action and do not need to be reviewed by the Office of Management and Budget under Executive Order 12866.</P>
                <HD SOURCE="HD1">Regulatory Flexibility Act</HD>
                <P>These rate adjustments are not a rule for the purposes of the Regulatory Flexibility Act because they establish “a rule of particular applicability relating to rates.” 5 U.S.C. 601(2).</P>
                <HD SOURCE="HD1">Unfunded Mandates Reform Act of 1995</HD>
                <P>
                    These rate adjustments do not impose an unfunded mandate on State, local, or Tribal governments in the aggregate, or on the private sector, of more than $130 million per year. They do not have a significant or unique effect on State, local, or Tribal governments or the private sector. Therefore, the Department is not required to prepare a statement containing the information required by the Unfunded Mandates Reform Act (2 U.S.C. 1531 
                    <E T="03">et seq.</E>
                    ).
                </P>
                <HD SOURCE="HD1">Takings (Executive Order 12630)</HD>
                <P>These rate adjustments do not effect a taking of private property or otherwise have “takings” implications under Executive Order 12630. The rate adjustments do not deprive the public, State, or local governments of rights or property.</P>
                <HD SOURCE="HD1">Federalism (Executive Order 13132)</HD>
                <P>Under the criteria in section 1 of Executive Order 13132, these rate adjustments do not have sufficient federalism implications to warrant the preparation of a federalism summary impact statement because they will not affect the States, the relationship between the national government and the States, or the distribution of power and responsibilities among the various levels of government. A federalism summary impact statement is not required.</P>
                <HD SOURCE="HD1">Civil Justice Reform (Executive Order 12988)</HD>
                <P>This notice complies with the requirements of Executive Order 12988. Specifically, in issuing this notice, the Department has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct as required by section 3 of Executive Order 12988.</P>
                <HD SOURCE="HD1">Paperwork Reduction Act of 1995</HD>
                <P>These rate adjustments do not affect the collections of information which have been approved by the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. The OMB Control Number is 1076-0141 and expires April 30, 2029.</P>
                <HD SOURCE="HD1">National Environmental Policy Act</HD>
                <P>
                    The Department has determined that these rate adjustments do not constitute a major Federal action significantly affecting the quality of the human environment. A detailed statement under the National Environmental Policy Act of 1969 (NEPA) is not required because the rate adjustments are of an administrative, financial, legal, technical, or procedural nature. (For further information 
                    <E T="03">see</E>
                     43 CFR 46.210(i)). We have also determined that the rate adjustments would not involve any of the extraordinary circumstances listed in 43 CFR 46.215 that would require further analysis under NEPA.
                </P>
                <SIG>
                    <NAME>William Henry Kirkland III,</NAME>
                    <TITLE>Assistant Secretary—Indian Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15360 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4337-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>Bureau of Indian Affairs</SUBAGY>
                <DEPDOC>[267A2100DD/AAMM001010/A0A600000.000000]</DEPDOC>
                <SUBJECT>Notice of Public Meetings of the Advisory Board for Exceptional Children</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Indian Affairs, Interior.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of public meetings.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Bureau of Indian Education (BIE) is publishing this notice to announce that the Advisory Board for Exceptional Children (Advisory Board) will meet as indicated below. The purpose of the meetings is to meet the mandates of the Individuals with Disabilities Education Act of 2004 
                        <PRTPAGE P="48188"/>
                        (IDEA) for Indian children with disabilities.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The BIE Advisory Board will meet virtually on Wednesday, August 12, 2026, and Thursday, August 13, 2026, from 8:00 a.m. to 4:00 p.m., Mountain Daylight Time (MDT) and in-person and virtually on Thursday, September 10, 2026, and Friday, September 11, 2026, from 8:00 a.m. to 4:30 p.m. (MDT).</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The Advisory Board meeting on August 12-13, 2026, will be held virtually. The Advisory Board meeting on September 10-11, 2026, will be held in-person and virtually. The in-person meeting location will be at the National Indian Training Center, 1011 Indian School Rd. NW, Albuquerque, NM 87104. To attend virtually, participants may use this link to register:
                        <E T="03"> https://www.zoomgov.com/meeting/register/3Rm19uumRAeHIQJjnzx2MQ.</E>
                    </P>
                    <P>Attendees register once and can attend one or both meeting events. After registering, you will receive a confirmation email containing information about joining the meeting.</P>
                    <P>
                        <E T="03">Comments:</E>
                         Public comments can be emailed to the Designated Federal Officer (DFO), Jennifer Davis, at 
                        <E T="03">Jennifer.Davis@bie.edu;</E>
                         or faxed to (602) 265-0293 Attention: Jennifer Davis, DFO; or mailed or hand delivered to the Bureau of Indian Education, Attention: Jennifer Davis, DFO, 2600 N Central Ave., 12th floor, Suite 250, Phoenix, AZ 85004.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Jennifer Davis, Designated Federal Officer, Bureau of Indian Education, 2600 N Central Ave., 12th floor, Suite 250, Phoenix, AZ 85004, 
                        <E T="03">Jennifer.Davis@bie.edu,</E>
                         or mobile phone (202) 860-7845. Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The meetings are being held under the provisions of the FACA of 1972 (5 U.S.C. Ch. 10), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR part 102-3. The Advisory Board was established under the Individuals with Disabilities Act of 2004 (20 U.S.C. 1400 
                    <E T="03">et seq.</E>
                    ) to advise the Secretary of the Interior, through the Assistant Secretary-Indian Affairs, on the needs of Indian children with disabilities. All meetings, including virtual sessions, are open to the public in their entirety.
                </P>
                <HD SOURCE="HD1">Meeting Agenda Items</HD>
                <P>The agenda items for the August 12-13, 2026 meetings:</P>
                <P>• BIE Central Office Updates.</P>
                <P>• Office of Head Start, Administration for Children and Families Updates.</P>
                <P>• Family and Child Education Program (FACE) Panel Discussion.</P>
                <P>• BIE's Division of Performance and Accountability Updates.</P>
                <P>• Advisory Board Work Sessions.</P>
                <P>• Public Comments.</P>
                <P>○ On Wednesday, August 12, 2026, two sessions will be held at 9:30 a.m. to 9:45 a.m. (MDT) and 2:30 p.m. to 2:40 p.m. (MDT).</P>
                <P>○ On Thursday, August 13, 2026, one session (15 minutes) will be provided, 11:00 a.m. to 11:15 a.m. (MDT).</P>
                <P>
                    ○ Public comments can be provided verbally 
                    <E T="03">via</E>
                     webinar or in writing using the chat box.
                </P>
                <P>
                    ○ Public comments can also be emailed to the DFO (
                    <E T="03">see</E>
                      
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                    ).
                </P>
                <P>The agenda items for the September 10-11, 2026 meetings:</P>
                <P>• BIE Special Education Updates.</P>
                <P>• BIE School Operations/Division of Budget and Finance Updates.</P>
                <P>• Advisory Board Work Sessions.</P>
                <P>• Public Comments.</P>
                <P>○ On Thursday, September 10, 2026, one session (10 minutes) will be provided, 9:30 a.m. to 9:40 a.m. (MDT) and Friday, September 11, 2026, from 8:30 a.m. to 11:30 a.m. (MDT) and 1:00 p.m. to 4:30 p.m. (MDT) during the Advisory Board's work sessions.</P>
                <P>○ Public comments can be provided verbally via webinar or in writing using the chat box.</P>
                <P>
                    ○ Public comments can also be emailed to the DFO (
                    <E T="03">see</E>
                      
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                    ).
                </P>
                <P>
                    The final agendas and meeting materials will be posted to the Advisory Board's website prior to the meeting at 
                    <E T="03">https://www.bie.edu/DPA/SpecialEducationAdvisoryBoard.</E>
                </P>
                <P>
                    <E T="03">Request for Accommodations:</E>
                     Please make requests in advance for sign language interpreter services, assistive listening devices, or other reasonable accommodations. Please contact the person listed in the section (
                    <E T="03">see</E>
                      
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                    ) at least seven (7) business days prior to the meeting to give the Department of the Interior sufficient time to process your request. All reasonable accommodation requests are managed on a case-by-case basis.
                </P>
                <P>
                    <E T="03">Public Disclosure of Comments:</E>
                     Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     5 U.S.C. Ch. 10.
                </P>
                <SIG>
                    <NAME>William Henry Kirkland III,</NAME>
                    <TITLE>Assistant Secretary—Indian Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15361 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4337-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">INTERNATIONAL TRADE COMMISSION</AGENCY>
                <DEPDOC>[Investigation Nos. 701-TA-758 and 731-TA-1739 (Final)]</DEPDOC>
                <SUBJECT>Fiberglass Door Panels From China; Determinations</SUBJECT>
                <P>
                    On the basis of the record 
                    <SU>1</SU>
                    <FTREF/>
                     developed in the subject investigations, the United States International Trade Commission (“Commission”) determines, pursuant to the Tariff Act of 1930 (“the Act”), that an industry in the United States is materially injured by reason of imports of fiberglass door panels from China, provided for in subheading 3925.20.00 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (“Commerce”) to be sold in the United States at less than fair value (“LTFV”), and imports of the subject merchandise from China that have been found to be subsidized by the government of China.
                    <E T="51">2 3</E>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The record is defined in § 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         91 FR 35960 and 35963 (June 15, 2026).
                    </P>
                    <P>
                        <SU>3</SU>
                         Chairman Brett W. Doyle did not participate in this proceeding.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    The Commission instituted these investigations effective March 20, 2025, following receipt of petitions filed with the Commission and Commerce by the American Fiberglass Door Coalition, the members of which are Therma-Tru Corporation, Maumee, Ohio; PlastPro Doors Inc., Los Angeles, California; and Owens Corning, Toledo, Ohio. The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by Commerce that imports of fiberglass door panels from China were subsidized within the meaning of section 703(b) of the Act (19 
                    <PRTPAGE P="48189"/>
                    U.S.C. 1671b(b)) and sold at LTFV within the meaning of 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission's investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the 
                    <E T="04">Federal Register</E>
                     on February 6, 2026 (91 FR 5510). The Commission conducted its hearing on June 9, 2026. All persons who requested the opportunity were permitted to participate.
                </P>
                <P>
                    The Commission made these determinations pursuant to §§ 705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on July 30, 2026. The views of the Commission are contained in USITC Publication 5766 (July 2026), entitled 
                    <E T="03">Fiberglass Door Panels from China: Investigation Nos. 701-TA-758 and 731-TA-1739 (Final).</E>
                </P>
                <SIG>
                    <P>By order of the Commission.</P>
                    <DATED>Issued: July 28, 2026.</DATED>
                    <NAME>Lisa Barton,</NAME>
                    <TITLE>Secretary to the Commission.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15423 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7020-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">INTERNATIONAL TRADE COMMISSION</AGENCY>
                <DEPDOC>[Investigation No. 337-TA-1494]</DEPDOC>
                <SUBJECT>Certain TOPCon Solar Cells, Modules, Panels, Components Thereof, and Products Containing Same; Notice of a Commission Determination Not To Review an Initial Determination Granting the Motion To Intervene of IC Star Solar (USA) LLC D/B/A Imperial Star</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. International Trade Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (“ID”) (Order No. 18) of the presiding administrative law judge (“ALJ”) granting a motion to intervene filed by non-party IC Star Solar (USA) LLC d/b/a Imperial Star (“Imperial”).</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Edward S. Jou, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-3316. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at 
                        <E T="03">https://edis.usitc.gov.</E>
                         For help accessing EDIS, please email 
                        <E T="03">EDIS3Help@usitc.gov.</E>
                         General information concerning the Commission may also be obtained by accessing its internet server at 
                        <E T="03">https://www.usitc.gov.</E>
                         Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The Commission instituted this investigation on March 30, 2026, based on a complaint, as supplemented, filed by First Solar, Inc. (“First Solar”) of Phoenix, Arizona. 91 FR 15632-34 (Mar. 30, 2026). The complaint, as supplemented, alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation into the United States and the sale of certain TOPCon solar cells, modules, panels, components thereof, and products containing same by reason of the infringement of certain claims of U.S. Patent No. 9,130,074. 
                    <E T="03">Id.</E>
                     at 15632. The complaint, as supplemented, further alleged that an industry in the United States exists or is in the process of being established. 
                    <E T="03">Id.</E>
                     The Commission's notice of investigation named as respondents AXITEC, LLC of Radnor, Pennsylvania; AXITEC Energy GmbH &amp; Co. KG of Böblingen, Germany; AXITEC SOLAR, LLC of Newark, Delaware; Canadian Solar Inc. of Ontario, Canada; CSI Solar Co., Ltd. of Suzhou, China; Canadian Solar (USA) Inc. of Walnut Creek, California; Canadian Solar Manufacturing (Thailand) Co., Ltd. of Bo Win, Thailand; Canadian Solar US Module Manufacturing Corporation of Mesquite, Texas; Canadian Solar International Ltd. of Kowloon, Hong Kong; JA Solar Technology Co., Ltd. of Beijing, China; JA Solar USA, Inc. of San Jose, California; JA Solar AZ, LLC of Phoenix, Arizona; JA Solar International, Ltd. of Kowloon, Hong Kong; JA Solar Vietnam Co., Ltd. of Bac Giang, Vietnam; JinkoSolar Holding Co., Ltd. of Jiangxi Province, China; Jinko Solar Co., Ltd. of Jiangxi Province, China; Jinko Solar (Vietnam) Industries Co. Ltd. of Quang Ninh, Vietnam; Jinko Solar Technology Sdn. Bhd. of Pulau Pinang, Malaysia; Zhejiang Jinko Solar Co., Ltd. of Zhejiang Province, China; JinkoSolar (U.S.) Inc. of Campbell, California; JinkoSolar (U.S.) Manufacturing Inc. of Dover, Delaware; JinkoSolar (U.S.) Industries Inc. of Jacksonville, Florida; Mundra Solar PV Limited of Gujarat, India; Mundra Solar Energy Ltd. of Gujarat, India; Adani Green Energy Ltd. of Gujarat, India; Philadelphia Solar LLC of Amman, Jordan; Philadelphia Solar USA Inc. of San Mateo, California; Hanwha Q CELLS USA Inc. of Dalton, Georgia; Hanwha Q CELLS America Inc. of Irvine, California; Hanwha Q CELLS USA Corp. of Irvine, California; Hanwha Solutions Corporation of Seoul, Korea; Jiangsu Runergy New Energy Technology Co., Ltd. of Jiangsu Province, China; Runergy USA Inc. of Pleasanton, California; Runergy Alabama Inc. of Huntsville, Alabama; Runergy USA Trading LLC of Dover, Delaware; Runergy PV Technology (Thailand) Co., Ltd. of Rayong, Thailand; Trina Solar Co., Ltd. of Jiangsu Province, China; Trina Solar (U.S.), Inc. of Fremont, California; Trina Solar Energy Development Co., Ltd. of Thai Nguyen Province, Vietnam; Changzhou Trina Solar Energy Co., Ltd. of Zhejiang, China; Trina Solar Yiwu Technology Co., Ltd. of Zhejiang; China; Tl Energy, Inc. of Austin, Texas; Tl Gl Dallas Solar Module LLC of Wilmer, Texas; Vietnam Sunergy Joint Stock Company of Bac Giang Province, Vietnam; VSUN Solar USA Inc. of Fremont, California; Toyo Co., Ltd. of Tokyo, Japan; and Toyo Solar Texas, LLC of Humble, Texas. 
                    <E T="03">Id.</E>
                     at 15633. The Office of Unfair Import Investigations (“OUII”) is also a party in this investigation. 
                    <E T="03">Id.</E>
                </P>
                <P>
                    Respondents BYD America LLC and Tesla, Inc. were added to the investigation by intervention. Order No. 7 (Apr. 27, 2026), 
                    <E T="03">unreviewed by</E>
                     Comm'n Notice (May 27, 2026), 91 FR 32434-35 (June 1, 2026); Order No. 10 (May 11, 2026), 
                    <E T="03">unreviewed by</E>
                     Comm'n Notice (June 10, 2026), 91 FR 36000-01 (June 15, 2026). The complaint and notice of investigation were amended to change the name of respondent JA Solar AZ, LLC to American Panel Solutions LLC. Order No. 13 (May 28, 2026), 
                    <E T="03">unreviewed by</E>
                     Comm'n Notice (June 23, 2026), 91 FR 38455-56 (June 25, 2026). Respondents Mundra Solar Energy Ltd., Adani Green Energy Ltd., Philadelphia Solar USA Inc., and Changzhou Trina Solar Energy Co, Ltd. were terminated from the investigation by withdrawal of the complaint. Order No. 14 (May 28, 2026), 
                    <E T="03">unreviewed by</E>
                     Comm'n Notice (June 24, 2026); Order No. 17 (June 24, 2026), 
                    <E T="03">unreviewed by</E>
                     Comm'n Notice (July 24, 2026).
                </P>
                <P>
                    On May 29, 2026, Imperial filed a motion to intervene as a respondent pursuant to Commission Rule 210.19, 19 CFR 210.19. On June 10, 2026, First Solar filed a response that did not oppose the intervention if the procedural schedule was extended. Also 
                    <PRTPAGE P="48190"/>
                    on June 10, 2026, OUII filed a response in support of the motion. On June 24, 2026, the ALJ granted a motion filed by First Solar amending the procedural schedule and extending the target date. Order No. 16 (June 24, 2026), 
                    <E T="03">unreviewed by</E>
                     Comm'n Notice (July 24, 2026).
                </P>
                <P>On June 25, 2026, the ALJ issued the subject ID (Order No. 18) granting Imperial's motion to intervene. No petitions for review of the ID were filed.</P>
                <P>The Commission has determined not to review the subject ID.</P>
                <P>The Commission vote for this determination took place on July 27, 2026.</P>
                <P>The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).</P>
                <SIG>
                    <P>By order of the Commission.</P>
                    <DATED>Issued: July 28, 2026.</DATED>
                    <NAME>Lisa Barton,</NAME>
                    <TITLE>Secretary to the Commission.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15426 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7020-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF JUSTICE</AGENCY>
                <SUBAGY>Drug Enforcement Administration</SUBAGY>
                <SUBJECT>Joan Rubinger, N.P.; Decision and Order</SUBJECT>
                <HD SOURCE="HD1">I. Introduction</HD>
                <P>
                    On June 17, 2024, the Drug Enforcement Administration (DEA or Government) issued an Order to Show Cause and Immediate Suspension of Registration (OSC/ISO) to Joan Rubinger, N.P., of Stockton, California (Respondent). OSC/ISO, at 1. The OSC/ISO informed Respondent of the immediate suspensions of her DEA Certificates of Registration, Nos. MM3336422 (based in California) and MR5666106 (based in New York), alleging that Respondent's continued registration constitutes “ `an imminent danger to the public health or safety.' ” 
                    <E T="03">Id.</E>
                     (quoting 21 U.S.C. 824(d)). The OSC/ISO proposed the revocation of both of Respondent's registrations because Respondent has committed such acts as would render her registrations inconsistent with the public interest. 
                    <E T="03">Id.</E>
                     (citing 21 U.S.C. 823(g)(1); 824(a)(4)).
                </P>
                <P>
                    Specifically, the OSC/ISO alleged that from 2019 until 2024, Respondent prescribed over 2,500 controlled substance prescriptions without proper state authority. 
                    <E T="03">Id.</E>
                     at 2, 3-4. In addition, the OSC/ISO alleged that Respondent prescribed controlled substances to a patient knowing that those substances were being diverted to another individual. 
                    <E T="03">Id.</E>
                     at 2, 4. Lastly, the OSC/ISO alleged that Respondent failed to maintain adequate and accurate records regarding the over 2,500 controlled substance prescriptions that she issued to patients.
                    <SU>1</SU>
                    <FTREF/>
                      
                    <E T="03">Id.</E>
                     at 4. The OSC/ISO alleged that Respondent's above-described misconduct violated federal and state law. 
                    <E T="03">Id.</E>
                     at 2-4 (citing 21 CFR 1306.04(a); Cal. Bus &amp; Prof. Code § 2242(a); Cal. Health &amp; Safety Code § 11150; Cal. Health &amp; Safety Code § 11154; Cal. Bus &amp; Prof. Code § 2836.1(d); Cal. Code Regs. tit. 16, § 1474).
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Because of the substantial evidence of Respondent's unlawful dispensing, which includes acts of intentional diversion, this Decision and Order does not address the Government's recordkeeping allegations. The Agency has found that intentional acts of diversion “strike[ ] at the CSA's core purpose of preventing the abuse and diversion of controlled substances,” and that “proof of a single act of intentional diversion is sufficient to support the revocation of a registration.” 
                        <E T="03">See Samuel Mintlow, M.D.,</E>
                         80 FR 3630, 3653 (2015) (citing 
                        <E T="03">Dewey C. MacKay, M.D.,</E>
                         75 FR 49956, 49977 (2010).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         The Agency need not adjudicate the criminal violations alleged in the OSC/ISO. 
                        <E T="03">Ruan</E>
                         v. 
                        <E T="03">United States,</E>
                         597 U.S. 450 (2022) (decided in the context of criminal proceedings).
                    </P>
                </FTNT>
                <P>
                    An initial hearing was conducted on September 25, 2024. On September 26, 2024, Administrative Law Judge Paul E. Soeffing (the ALJ) issued an Order continuing the hearing and staying the proceedings pending resolution of an interlocutory appeal by the Government concerning the tribunal's rulings regarding four of the Government's exhibits.
                    <SU>3</SU>
                    <FTREF/>
                     The hearing was ultimately resumed and further conducted on December 10, 2024, and December 12, 2024.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Order Continuing Hearing, Staying Proceedings, and For Briefing of Government's Interlocutory Appeal.
                    </P>
                </FTNT>
                <P>
                    On March 7, 2025, the ALJ issued his Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision of the Administrative Law Judge (Recommended Decision or RD). The RD recommended that the Agency revoke Respondent's registrations. RD, at 80.
                    <SU>4</SU>
                    <FTREF/>
                     On April 3, 2025, Respondent filed Exceptions to the RD. The Agency adopts and hereby incorporates by reference the ALJ's credibility findings,
                    <SU>5</SU>
                    <FTREF/>
                     findings of fact, conclusions of law, sanctions analysis, and recommended sanction, and summarizes and clarifies portion thereof herein.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         On March 20, 2025, Respondent voluntarily surrendered for cause both her California and New York DEA registrations. On April 1, 2025, Respondent filed a Motion to Dismiss or Terminate Administrative Proceedings Based on Voluntary Surrender for Cause (Motion to Dismiss), arguing that the case was moot because Respondent had surrendered her DEA registrations. On April 3, 2025, the Government filed a motion requesting that the ALJ deny Respondent's Motion to Dismiss and continue the proceedings. 
                        <E T="03">See</E>
                         Government's Motion Requesting the Tribunal Certify the Record to DEA's Acting Administrator. On April 3, 2025, the ALJ issued an Order denying Respondent's Motion to Dismiss. 
                        <E T="03">See</E>
                         Order Denying Respondent's Motion to Dismiss or Terminate Proceedings. Respondent renewed her mootness arguments in her Exceptions.
                    </P>
                    <P>
                        The Agency agrees with the ALJ's denial of Respondent's motion to dismiss and rejects Respondent's exception regarding mootness. The Agency has determined that its jurisdiction to adjudicate a matter to finality is not dependent on whether the respondent has an active DEA registration. 
                        <E T="03">Jeffrey D. Olsen,</E>
                         84 FR 68474, 68475-80 (2019). Instead, the Agency's jurisdiction in an administrative action is over the 
                        <E T="03">registrant,</E>
                         not the 
                        <E T="03">registration. See Abdul Naushad, M.D.,</E>
                         89 FR 54059, 54060 (2024) (“[O]ne way that the Administrator carries out the CSA is by investigating and administratively adjudicating 
                        <E T="03">a registrant's</E>
                         CSA-relevant actions and inactions. When the registrant's actions or inactions call for it, the sanction may be suspension or revocation of the registrant's registration. 21 U.S.C. 824(a). While the sanction involves the registration, the sanction is levied on the 
                        <E T="03">registrant</E>
                         and remains in the record throughout the rest of the registrant-Agency relationship, regardless of whether that relationship is either continuous or intermittent”) (emphasis added). When it serves the Agency's and the registrant's interests to litigate an expired registration to finality—for example, when a respondent intends to engage in regulated activity in the future, and memorializing a registrant's compliance (or non-compliance) with the CSA will aid the Agency's future relationship with the registrant—the Agency has determined that issuing a final order may be done in a manner that is with the Constitution, the CSA, applicable legal authority, and sound law enforcement principles. 
                        <E T="03">Jeffrey D. Olsen,</E>
                         84 FR at 68475-80.
                    </P>
                    <P>
                        Here, adjudicating the matter to finality will achieve similar goals as in 
                        <E T="03">Olsen;</E>
                         it will support future interactions between the Agency and Respondent, inform current and prospective members of the registrant community about the Agency's expectations, provide continuing education to all DEA personnel, help coordinate law enforcement efforts, and informs stakeholders, such as legislators and the public, about the Agency's work. 
                        <E T="03">Olsen,</E>
                         84 FR at 68479. Moreover, where, as here, a registrant has surrendered her registration after availing herself of the hearing process and receiving an unfavorable decision, the Agency has determined that failing to adjudicate the matter to finality “would be contrary to [the Agency's] duties under the CSA [and] allow the usurpation of the Agency's enforcement mission.” 
                        <E T="03">Kotsonis, 85 FR</E>
                         at 85668-69.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         The Agency adopts the ALJ's summary of each witness's testimony, as well as the ALJ's assessment of each witness's credibility. 
                        <E T="03">See</E>
                         RD, at 3-41.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Public Interest Determination</HD>
                <HD SOURCE="HD2">A. Overview of Law</HD>
                <P>
                    Congress enacted the Controlled Substances Act (CSA) “to conquer drug abuse and control the legitimate and illegitimate traffic in controlled substances.” 
                    <E T="03">Gonzales</E>
                     v. 
                    <E T="03">Raich,</E>
                     545 U.S. 1, 12 (2005). A particular concern of Congress was “the need to prevent the diversion of drugs from legitimate to illicit channels,” and it “devised a closed regulatory system making it 
                    <PRTPAGE P="48191"/>
                    unlawful to manufacture, distribute, dispense, or possess any controlled substance except in a manner authorized by the CSA.” 
                    <E T="03">Id.</E>
                     at 12-13.
                </P>
                <P>
                    The CSA's requirements under this closed regulatory system include that “every person who dispenses, or who proposes to dispense, any controlled substance, shall obtain from the [DEA] a registration.” 21 U.S.C. 822(a)(2); 
                    <E T="03">see also Gonzales</E>
                     v. 
                    <E T="03">Raich,</E>
                     545 U.S. at 27-28. To protect the American people and ensure compliance with the CSA, Congress empowered the Agency to deny, suspend, or revoke a registration if it would be inconsistent with the public interest. 21 U.S.C. 823(g)(1); 21 U.S.C. 824(a)(4); 
                    <E T="03">Gonzales</E>
                     v. 
                    <E T="03">Oregon,</E>
                     546 U.S. 243, 251 (2006).
                </P>
                <P>
                    In determining whether registrant's registration is inconsistent with the public interest, the Agency analyzes five statutorily established “public interest factors.” 
                    <E T="03">Gonzales</E>
                     v. 
                    <E T="03">Oregon,</E>
                     546 U.S. at 251; 21 U.S.C. 823(g)(1)(A-E). The five factors are:
                </P>
                <EXTRACT>
                    <P>(A) The recommendation of the appropriate State licensing board or professional disciplinary authority.</P>
                    <P>(B) The [registrant's] experience in dispensing, or conducting research with respect to controlled substances.</P>
                    <P>(C) The [registrant's] conviction record under Federal or State laws relating to the manufacture, distribution, or dispensing of controlled substances.</P>
                    <P>(D) Compliance with applicable State, Federal, or local laws relating to controlled substances.</P>
                    <P>(E) Such other conduct which may threaten the public health and safety.</P>
                </EXTRACT>
                <P>21 U.S.C. 823(g)(1)(A-E).</P>
                <P>
                    These five public interest factors are considered in the disjunctive. 
                    <E T="03">Gonzales</E>
                     v. 
                    <E T="03">Oregon,</E>
                     546 U.S. at 292-93 (Scalia, J., dissenting); 
                    <E T="03">Robert A. Leslie, M.D.,</E>
                     68 FR 15227, 15230 (2003). Each factor is weighed on a case-by-case basis. 
                    <E T="03">David H. Gillis, M.D.,</E>
                     58 FR 37507, 37508 (1993). Any one factor, or combination of factors, may be decisive, 
                    <E T="03">David H. Gillis, M.D.,</E>
                     58 FR at 37508, and the Agency “may give each factor the weight . . . deem[ed] appropriate in determining whether a registration should be revoked or an application for registration denied.” 
                    <E T="03">Morall</E>
                     v. 
                    <E T="03">Drug Enf't Admin.,</E>
                     412 F.3d 165, 185 n.2 (D.C. Cir. 2005) (Henderson, J., concurring) (quoting 
                    <E T="03">Robert A. Smith, M.D.,</E>
                     70 FR 33207, 33208 (2007)); 
                    <E T="03">see also Penick Corp.</E>
                     v. 
                    <E T="03">Drug Enf't Admin.,</E>
                     491 F.3d 483, 490 (D.C. Cir. 2007).
                </P>
                <P>
                    Moreover, while the Agency is required to consider each of the factors, it “need not make explicit findings as to each one.” 
                    <E T="03">MacKay</E>
                     v. 
                    <E T="03">Drug Enf't Admin.,</E>
                     664 F.3d 808, 816 (10th Cir. 2011) (quoting 
                    <E T="03">Volkman</E>
                     v. 
                    <E T="03">U. S. Drug Enf't Admin.,</E>
                     567 F.3d 215, 222 (6th Cir. 2009)); 
                    <E T="03">Jones Total Health Care Pharmacy, LLC</E>
                     v. 
                    <E T="03">Drug Enf't Admin.,</E>
                     881 F.3d 823, 830 (11th Cir. 2018); 
                    <E T="03">Hoxie</E>
                     v. 
                    <E T="03">Drug Enf't Admin.,</E>
                     419 F.3d 477, 482 (6th Cir. 2005). “In short, . . . the Agency is not required to mechanically count up the factors and determine how many favor the Government and how many favor the registrant. Rather, it is an inquiry which focuses on protecting the public interest; what matters is the seriousness of the registrant's misconduct.” 
                    <E T="03">Jayam Krishna-Iyer, M.D.,</E>
                     74 FR 459, 462 (2009). Accordingly, Agency decisions have explained that findings under a single factor can support the revocation of a registration. 
                    <E T="03">MacKay,</E>
                     664 F.3d at 821.
                </P>
                <P>
                    The Government has the burden of proof in this proceeding, 21 CFR 1301.44(e), and the Agency must make its findings based on “substantial [record] evidence.” 5 U.S.C. 556(d); 
                    <E T="03">see also</E>
                     5 U.S.C. 706(2); 21 U.S.C. 877. If the Government meets its burden of establishing a 
                    <E T="03">prima facie</E>
                     case that Respondent's registration is not in the public interest, then the burden shifts to the Respondent to rebut the Government's case. 
                    <E T="03">Pharmacy Doctor Enterprises,</E>
                     789 Fed. Appx. at 729 (citing 
                    <E T="03">Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 830).
                </P>
                <P>
                    In this matter, the Government's evidence is confined to Factors B and D. ALJX 1, at 3. Evidence is considered under Factors B and D when it reflects experience dispensing controlled substances and compliance or non-compliance with laws related to controlled substances. 
                    <E T="03">Kareem Hubbard, M.D.,</E>
                     87 FR 21156, 21162 (2022). To determine whether Respondent's continued registration is in the public interest, the Agency has evaluated the Government's allegations of Respondent's non-compliance with applicable federal and state laws.
                </P>
                <HD SOURCE="HD2">B. Allegation That Respondent Unlawfully Prescribed Controlled Substances</HD>
                <HD SOURCE="HD3">i. Applicable Law and Standard of Care</HD>
                <P>
                    According to the CSA's implementing regulations, a lawful controlled substance prescription is one that is “issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.” 21 CFR 1306.04(a); 
                    <E T="03">see Gonzales</E>
                     v. 
                    <E T="03">Oregon,</E>
                     546 U.S. 243, 274 (2006); 
                    <E T="03">United States</E>
                     v. 
                    <E T="03">Hayes,</E>
                     595 F.2d 258 (5th Cir. 1979), 
                    <E T="03">rehearing den.,</E>
                     598 F.2d 620 (5th Cir. 1979), 
                    <E T="03">cert. denied,</E>
                     444 U.S. 866 (1979). “A practitioner must establish and maintain a 
                    <E T="03">bona fide</E>
                     doctor-patient relationship in order to act `in the usual course of . . . professional practice' and to issue a prescription for a `legitimate medical purpose.' ” 
                    <E T="03">Dewey C. MacKay, M.D.,</E>
                     75 FR 49956, 49973 (2010).
                </P>
                <P>
                    Similarly, California regulations prohibit practitioners from “knowingly prescrib[ing] . . . or furnish[ing] a controlled substance to or for any person . . . not under [their] treatment for a pathology or condition other than addiction to a controlled substance.” Cal. Health &amp; Safety Code § 11154(a). California regulations also define unprofessional conduct to include “[p]rescribing, dispensing, or furnishing [controlled substances] without an appropriate prior examination and a medical indication.” Cal. Bus. &amp; Prof. Code § 2242(a).
                    <SU>6</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         This code section was amended in October 2019, during the timeframe that the relevant misconduct in this case took place; however, there were no relevant, substantive modifications to this regulation in 2019.
                    </P>
                </FTNT>
                <P>
                    Regarding the basic requirements for nurse practitioners to prescribe controlled substances, California regulations state that nurse practitioners may only issue prescriptions if they are acting within the scope of Cal. Bus. &amp; Prof. Code § 2836.1, which requires “physician . . . supervision.” Cal. Health &amp; Safety Code § 11150. Physician supervision includes: “(1) collaboration on the development of the standardized procedure, (2) approval of the standardized procedure, and (3) availability by telephonic contact at the time of patient examination by the nurse practitioner.” 
                    <SU>7</SU>
                    <FTREF/>
                     Cal. Bus. &amp; Prof. Code § 2836.1(d). California regulations outline the requirements of the standardized procedure including, among other things, that it be in “writing, dated, and signed”; specify the functions the nurse may perform; “establish a method for initial and continuing evaluation of the [nurse's] competence”; specify patient recordkeeping requirements; and provide for periodic review. Cal. Code Reg. tit. 16, § 1474(b)(1), (10). The standardized procedure must also “specify which nurse practitioners may furnish or order drugs or devices, which drugs or devices may be furnished or ordered, [and] under what circumstances.” Cal. Bus. &amp; Prof. Code § 2836.1(c)(1).
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         “Physician . . . supervision” does not require the physician to be physically present.
                    </P>
                </FTNT>
                <P>
                    For Schedule II drugs, the standardized procedure “shall address the diagnosis of the illness, injury, or condition for which the Schedule II controlled substance is to be furnished.” 
                    <E T="03">Id.</E>
                     at § 2836.1(c)(2). Further, when 
                    <PRTPAGE P="48192"/>
                    Schedule II or III controlled substances are “furnished or ordered by a nurse practitioner, the controlled substances shall be furnished or ordered in accordance with a patient-specific protocol approved by the treating or supervising physician” and “[a] copy of the section of the nurse practitioner's standardized procedure relating to controlled substances shall be provided, upon request, to any licensed pharmacist who dispenses drugs or devices, when there is uncertainty about the nurse practitioner furnishing the order.” 
                    <E T="03">Id.</E>
                     at § 2836.1(f)(2).
                </P>
                <P>
                    The Government's expert witness, Ms. Guijo,
                    <SU>8</SU>
                    <FTREF/>
                     testified in more detail about standardized procedures. Ms. Guijo testified that in California, nurses are considered “registered nurses” until they implement standardized procedures, at which time they are considered “nurse practitioners” authorized to prescribe controlled substances.
                    <SU>9</SU>
                    <FTREF/>
                     Tr. 253; RD, at 13. Consistent with the California Code summarized above, Ms. Guijo testified that a standardized procedure is a “contractual agreement, or a formal agreement, that is in written form” and “dated and signed by the organized healthcare system personnel authorized to approve it . . . [which] would include the supervising physician.” Tr. 252, 263-64; RD, at 13-14. Ms. Guijo testified that pursuant to the applicable laws, standardized procedures must outline the scope of the medical practice, the policy for the relevant department or organization, and protocols based on the specialty of the nurse practitioner. Tr. 262; GX 10(c); RD, at 13, 13 n.53.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Ms. Guijo is a certified family nurse practitioner in California, specializing in addiction medicine. Tr. 235-37; RD, at 11-12.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         Respondent acknowledged that nurse practitioners must have a standardized procedure with a physician and testified about the components of a standardized procedure. Tr. 421-24, 427-28; RD, at 27. Respondent also acknowledged that a standardized procedure is an important document that should be kept “close by.” Tr. 423, 428; RD, at 27.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">ii. Findings of Fact</HD>
                <P>Respondent is a board-certified nurse practitioner registered with DEA in California and New York. Tr. 367; RD, at 22. Respondent testified that she considers her practice to be a “concierge practice” where she primarily treats athletes, travels frequently, and sets up treatment locations in hotels or at her home residence. Tr. 40, 399-401; RD, at 4, 24.</P>
                <HD SOURCE="HD3">1. Respondent Was Not Authorized To Prescribe Controlled Substances in California Because She Did Not Have a Standardized Procedure or a Supervising Physician</HD>
                <P>
                    Although Respondent testified that she had a “collaborating physician,” 
                    <SU>10</SU>
                    <FTREF/>
                     Dr. W.,
                    <SU>11</SU>
                    <FTREF/>
                     and they had a standardized procedure that included all the necessary information, Tr. 374, 376, 423-24, 428; RD, at 25, 27, Respondent testified that the standardized procedure was implemented “well over ten years ago” and she had lost her copy. Tr. 374-75, 423, 42; RD, at 25, 27. Respondent testified that this document was “informal[,] . . . just a single piece of paper . . . with many bullet points outlining” Dr. W.'s role, including “offering input and feedback, taking a look at images, consulting on more complicated issues or cases[,] . . . taking referrals of patients, talking with [Respondent] and [her] patients[,] . . . [and] participating in [patient] care if needed.” Tr. 374-75; RD, at 25.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Respondent testified that she considered a “collaborating physician” to be a supervising practitioner that offers input and feedback when asked, is available “if and when need[ed]” for consultation on complicated cases, can provide opinions on “imaging studies,” and otherwise “participate[s] in a free exchange of ideas regarding patient care.” Tr. 279; RD, at 25 n.86.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Dr. R. W. is an orthopedic surgeon licensed and registered in California who has been practicing medicine for approximately 34 years. Tr. 180-81; RD, at 7.
                    </P>
                </FTNT>
                <P>
                    Dr. W. testified at the hearing and denied ever having a formal supervisory relationship with Respondent or a standardized procedure with Respondent. 
                    <E T="03">E.g.,</E>
                     Tr. 188; RD, at 9 (Dr. W. testifying that he “[does not] believe that [he] was ever a supervising physician, other than to agree to occasional calls and conversations about specific patients”). Dr. W. testified that Respondent shadowed him for three months about 10 or 15 years ago and they had stayed in contact since.
                    <SU>12</SU>
                    <FTREF/>
                     Tr. 183-84; RD, at 7-8. Dr. W. testified that he communicated with Respondent approximately every three to six months when she “would occasionally send [him] either an x-ray, or sometimes a video, of the people that she would be seeing in her job.” Tr. 185; RD, at 8, 26; 
                    <E T="03">see also</E>
                     Tr. 379-80 (Respondent's testimony about frequent collaboration with Dr. W. on complicated issues). Dr. W. testified that “there were a couple of occasions where [he and Respondent] had three-way phone calls, or text message chains that went back and forth, from patients that she had seen somewhere.” Tr. 186; RD, at 8. Dr. W. testified that he gave Respondent his opinion about x-rays “probably twice,” and on one occasion he provided a signature authorizing radiology testing for one of Respondent's patients. Tr. 216-18, 224-25; RX 1, at 5; RD, at 9-10, 10 n.39.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         Dr. W. allowed Respondent to have items mailed to his office and Respondent stopped by periodically to pick up such mail. Tr. 184-85; RD, at 8.
                    </P>
                </FTNT>
                <P>
                    Dr. W. testified that he was only aware of one prescription 
                    <SU>13</SU>
                    <FTREF/>
                     that Respondent issued between the time when she first began her practice until December 2023 and he was not aware of any prescriptions written by Respondent after December 2023. Tr. 226-30; RD, at 10-11. Dr. W. testified that he consulted with Respondent because of their personal relationship 
                    <SU>14</SU>
                    <FTREF/>
                     and because he trusted her judgment. Tr. 225-26; RD, at 10. Dr. W. agreed that he and Respondent had “a working dialogue and free exchange of ideas” about Respondent's patients but reiterated that it was limited to “about every six months.” Tr. 222; RD, at 10.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         Dr. W. testified that he had a text message conversation with Respondent regarding a prescription for oxycodone-acetaminophen (a Schedule II opioid) for one of Respondent's patients. Tr. 226-27; RD, at 3 (stip. 10), 10 n.43. This conversation occurred after he was contacted by an Ohio pharmacy because the pharmacy was unable to fill an out-of-state prescription written by Respondent. Tr. 228; RX 1, at 19; RD, at 10 n.43. Dr. W. testified that he did not know why the prescription was written, did not know who the patient was, and was unsure of how the pharmacy received his contact information. Tr. 227-29; RD, at 10 n.43. He speculated that it was because Respondent printed his name and practice information on her prescription pads and noted that he did not know why Respondent had his name and practice information on her prescription pads. 
                        <E T="03">Id.</E>
                         When told that Respondent had prescribed drugs such as phentermine and dextroamphetamine, Dr. W. testified that he did not know anything about those drugs other than knowing that phentermine was used for weight loss. Tr. 230; RD, at 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         Respondent testified that she and Dr. W. “had a friendship” and she “knew his wife and kids.” Tr. 381; RD, at 26. Respondent also testified that she would gift Dr. W. things like signed jerseys, paraphernalia from athletes, game tickets, “and that sort of thing as a thank you for all that he [had] done as a supervisor.” Tr. 371; RD, at 26.
                    </P>
                </FTNT>
                <P>
                    Dr. W. testified that he did not recall reviewing any medical records for Respondent's patients other than specific records she sent over text message. Tr. 187, 480; RD, at 8, 36. Dr. W. testified that he and Respondent had an agreement that Respondent could call him anytime to “talk about whatever situations [came] up,” but he “[did not] recall any kind of formal agreement saying, yes, I will be your collaborator, or supervisor.” 
                    <SU>15</SU>
                    <FTREF/>
                     Tr. 196; 
                    <PRTPAGE P="48193"/>
                    RD, at 9. Dr. W. testified that he only learned of the requirements for nurse practitioners to maintain a standardized procedure a few months before the hearing and that he had never discussed with Respondent his responsibilities with respect to her practice as a nurse practitioner; never had anything in writing with Respondent outlining a professional relationship; never had anything in writing with respect to how Respondent should keep medical records; never had an agreement concerning continuing evaluation of Respondent; and never evaluated Respondent or her medical practice. Tr. 189-90, RD, at 9. Tr. 188-90; RD, at 8-9.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         Respondent testified that her standardized procedures with Dr. W. were implemented over a decade ago and thus likely “hard to recall . . . for him.” Tr. 523; RD, at 39. Respondent reiterated that the standardized procedures were “simple” and were an outline of the practice arrangement. Tr. 523-24; RD, at 39. Respondent testified that she believes that “maybe at some point [Dr. W.] and 
                        <PRTPAGE/>
                        [her] were looking at the same thing through two different lenses . . . and . . . [Dr. W.] may have had a different impression of [the] arrangement.” Tr. 405; RD, at 26. Respondent also testified that her text messages with Dr. W. do not reference him as her supervising physician because “that agreement was made in 2014, [but the] text messages only go back to 2017.” Tr. 410-11; RX 1; RD, at 26. Respondent testified that Dr. W. trusted her judgment and she and Dr. W. did not see any reason to do an annual review or update the practice arrangement. Tr. 524; RD, at 39. Respondent reiterated her belief that “it was just two people having a different impression of the arrangement . . . [and] it just comes down to a simple misunderstanding.” Tr. 524; RD, at 39.
                    </P>
                </FTNT>
                <P>
                    Ms. Guijo testified that, in her opinion, Respondent lacked authority to prescribe controlled substances in California because Dr. W. was not her supervising physician and Respondent lacked a “formal agreement, which is the standardized procedure.” Tr. 264; RD, at 14. Ms. Guijo's testimony is consistent with California's regulations, which require that standardized procedures be in writing and outline the terms and scope of the professional relationship. 
                    <E T="03">See supra,</E>
                     II.B.i. (citing Cal. Code Reg. tit. 16, § 1474(b)(1), (10)). Ms. Guijo's testimony is also consistent with Dr. W.'s credible testimony that he did not have a formalized supervisory relationship with Respondent or a standardized procedure with Respondent.
                </P>
                <P>
                    Respondent testified in depth about the circumstances surrounding her relationship with Dr. W. that led her to view Dr. W. as her “collaborating physician”—which she equated with a “supervising physician”—such as Dr. W. allowing her to use his office address on her DEA registration and prescription pads, Dr. W.'s willingness to consult on difficult cases, and his occasional review of x-rays and medical files. 
                    <E T="03">See</E>
                     RD, at 24-28. However, California requires a formalized, written agreement between the registered nurse and supervising physician, which must be available upon pharmacist request when Schedule II controlled substances are prescribed. Respondent's failure to produce a standardized procedure, highly exculpatory evidence, supports a presumption that this document does not exist or would be unfavorable to her if produced. 
                    <E T="03">See, e.g., Huthnance</E>
                     v. 
                    <E T="03">DC,</E>
                     722 F.3d 371, 378 (D.C. Cir. 2013) (“Respondent's decision not to provide records gives rise to an inference that any such evidence is unfavorable to Respondent.”)), 
                    <E T="03">Int'l Union, United Auto., Aerospace &amp; Agric. Implement Workers of Am. (UAW)</E>
                     v. 
                    <E T="03">Nat'l Labor Relations Bd.,</E>
                     459 F.2d 1329, 1336 (D.C. Cir. 1972) (“Simply stated, the rule provides that when a party has relevant evidence within his control which he fails to produce, that failure gives rise to an inference that the evidence is unfavorable to him.”); 
                    <E T="03">Gulf Med Pharmacy,</E>
                     86 FR 72694, 72729 (2021) (inferring that the “failure to provide highly exculpatory documentation [showing that red flags were resolved] suggests it does not exist”); RD, at 54-55, 58 (drawing an adverse inference based on Respondent's failure to produce a standardized procedure). This presumption is supported by Dr. W.'s credible testimony that he did not have a formalized supervisory relationship with Respondent and that they never executed a standardized procedure.
                </P>
                <P>
                    Additionally, as the ALJ discussed in depth in the RD, it was clear from Dr. W.'s testimony that he did not conduct the supervision required under a standardized procedure, such as evaluating Respondent's competence, conducting a periodic review of the standardized procedure, or implementing procedures related to Respondent's controlled substance prescribing. RD, at 52-58. Indeed, Dr. W. was not even aware of the controlled substances that Respondent was prescribing other than one single prescription for which he received a call from the pharmacy. Tr. 226-30; RD, at 56-57. Accordingly, while Respondent may have valued Dr. W.'s feedback and viewed him as a resource to support her practice, Respondent did not have the requisite standardized procedure or formal supervisory relationship to be authorized to prescribe controlled substances in California. 
                    <E T="03">See</E>
                     RD, at 47, 52-58. As the ALJ observes, “A supervising physician is not a position that one stumbles into on account of their relationship with a nurse practitioner. It is a statutory and contractual designation, which requires not only collaboration and availability for consultation, but also “approval of . . . standardized procedure[s].” RD, at 58 (citing Cal. Bus. &amp; Prof. Code § 2836.1(d)).
                </P>
                <P>Accordingly, the Agency agrees with the ALJ and concludes, based on substantial record evidence, that Respondent did not have a supervising physician or a standardized procedure during the timeframe at issue (April 2019 to April 2024), and, therefore, that Respondent was not authorized to prescribe controlled substances in California. RD, at 52-55.</P>
                <HD SOURCE="HD3">2. Respondent Issued Over 2,500 Prescriptions Without State Authority Between April 2019 and March 2024</HD>
                <P>
                    Respondent issued over 2,500 prescriptions for controlled substances between April 2019 and March 2024. GX 5(a), (b); RD, at 29, 44-45, 58, 68-69; 
                    <E T="03">see also</E>
                     Tr. 428-29; (Respondent's testimony acknowledging that she issued these prescriptions). These prescriptions included Schedule IV stimulants (
                    <E T="03">e.g.,</E>
                     phentermine), Schedule IV benzodiazepines (
                    <E T="03">e.g.,</E>
                     alprazolam), and Schedule II opioids (
                    <E T="03">e.g.,</E>
                     oxycodone, methadone, hydrocodone-acetaminophen). GX 5(a), (b), 8(a); ALJX 13 at 4, Stip. 6; RD, at 29, 68-69. Accordingly, the Agency agrees with the ALJ, and finds based on substantial record evidence, that Respondent issued over 2,500 prescriptions for controlled substances without state authority between April 2019 and March 2024. The Agency further agrees with the ALJ, and finds based on substantial record evidence, that these prescriptions were issued outside the usual course of professional practice.
                    <SU>16</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         “A [practitioner] who engages in the unauthorized practice of [his profession] is not a `practitioner acting in the usual course of professional practice.' ” 
                        <E T="03">United Prescription Servs., Inc.,</E>
                         72 FR 50397, 50407 (2007). “A controlled-substance prescription issued by a [practitioner] who lacks the license necessary to practice [his profession] within a State is therefore unlawful under the CSA.” 
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Respondent Issued at Least 23 Prescriptions to K.D. Knowing That They Would Be Diverted</HD>
                <P>
                    One of Respondent's patients, T.D., is a retired professional athlete. Tr. 328; RD, at 18. T.D.'s wife, K.D., testified at the hearing about Respondent's relationship with T.D. K.D. testified that she learned about Respondent around September or October of 2019 when she and T.D. moved to California and she saw Respondent's name on medicine bottles prescribed to T.D.
                    <SU>17</SU>
                    <FTREF/>
                     Tr. 329-30, 334; RD, at 18-19, 19 n.66. T.D. told K.D. that Respondent “was a doctor for a lot of athletes” and that he had met her through another professional 
                    <PRTPAGE P="48194"/>
                    athlete. Tr. 329-30; RD, at 19.
                    <SU>18</SU>
                    <FTREF/>
                     K.D. testified that T.D. continued to receive treatment from Respondent after they moved to North Carolina. Tr. 331; RD, at 19. At some point after the move, K.D. researched Respondent and realized that she was not a doctor. 
                    <E T="03">Id.</E>
                     T.D. offered for K.D. to meet Respondent “since [she did not] think that [Respondent] actually exist[ed] or that [Respondent was] a doctor.” Tr. 331-32; RD, at 19.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         The investigation into Respondent's prescribing was initiated based on a tip submitted by K.D. to DEA's tip line. Tr. 30-31; RD, at 3-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         K.D. testified that T.D. initially referred to Respondent as “his chiropractor” and that Respondent treated T.D. for injuries received during his career as a professional athlete. Tr. 347; RD, at 19. K.D. reiterated that T.D. did not tell her that Respondent was a nurse practitioner. Tr. 348; RD, at 19.
                    </P>
                </FTNT>
                <P>
                    K.D. testified that she met Respondent once, in June 2020, at a Marriott hotel in Charlotte, North Carolina,
                    <SU>19</SU>
                    <FTREF/>
                     when she accompanied T.D. for his appointment. Tr. 331-32, 334, 348-49; RD, at 19, 19 n.67-68. K.D. passed another professional athlete in the hallway leading to the hotel room where she met with Respondent. 
                    <E T="03">Id.</E>
                     K.D. testified that in the hotel room, she met Respondent and her son, and the room “was a whole set up with . . . IV things and suitcases with stuff in them and medicine, little syringes and bottles and things like that.” Tr. 332-33; RD, at 19-20.
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         Respondent admitted that she was not registered with DEA in North Carolina nor was she licensed as a medical professional in North Carolina. Tr. 467. Although Respondent ultimately admitted that it was unlawful for her to use her California license to issue prescriptions outside of California, she testified that it was difficult for her to know what was “improper” because pharmacies filled her out-of-state prescriptions. Tr. 522, 526; RD, at 40-41.
                    </P>
                </FTNT>
                <P>
                    K.D. testified that she was in the hotel room for about 15 minutes while she asked questions about Respondent's practice and the injections Respondent was giving T.D. Tr. 333; RD, at 20, 20 n.69. K.D. testified that during this conversation, T.D. told her to disclose to Respondent shoulder and back pain she had been experiencing, to which Respondent stated that she could “give [K.D.] a shot to help.” Tr. 333; RD, at 20. K.D. testified that although she was hesitant to receive the injection, she ultimately did so. Tr. 333, 348; RD, at 20. K.D. testified that Respondent did not perform a physical examination or inquire about her medical history,
                    <SU>20</SU>
                    <FTREF/>
                     and K.D. did not receive any paperwork in connection with this encounter.
                    <SU>21</SU>
                    <FTREF/>
                     Tr. 334, 346-47; RD, at 20, 20 n.71. K.D. testified that the June 2020 meeting was the only time she met Respondent and Respondent never treated her via telehealth or over the phone.
                    <SU>22</SU>
                    <FTREF/>
                     Tr. 331, 334, 348; RD, at 19, 19 n.67.
                </P>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         Respondent testified that she physically examined K.D. and took “a little bit of a history.” Tr. 396-97; RD, at 31, 31 n.97. The Agency, like the ALJ, credits K.D.'s consistent and reliable testimony that Respondent did not examine her or take a history. RD, at 22, 35 n.111, 35-36, 47, 71.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         K.D. further testified that she found out from her chiropractor that the injection she received was an anti-inflammatory medication. Tr. 333-34; RD, at 20 n.70. K.D. testified that she was not aware that Respondent had prescribed her further anti-inflammatory medication after this visit. Tr. 349; RD, at 21.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         Respondent offered inconsistent and self-serving testimony about when and how many times she met with Respondent. 
                        <E T="03">See</E>
                         RD, at 30-33. The Agency agrees with the ALJ that Respondent's testimony about K.D. was internally inconsistent, conflicted with the documentary evidence, and conflicted with K.D.'s consistent and credible testimony that K.D. only met Respondent once. RD, at 22, 35 n.111, 35-36, 47, 63-64, 71.
                    </P>
                </FTNT>
                <P>About two years after her initial encounter with Respondent, K.D. learned that Respondent had been issuing regular opioid prescriptions in her name without her knowledge. In February of 2022, K.D. went to the emergency room of a hospital in Waxhaw, North Carolina with extreme chest pain, fainting spells, and headaches. Tr. 335-36, 339; RD, at 20. While undergoing testing at the hospital, K.D. was informed by a doctor at the hospital that she would “not get[] any more pain medicine.” Tr. 335; RD, at 20. K.D. testified that, upon further inquiry, the doctor reiterated that the hospital would not prescribe her “any more pain medication,” but would “run some more tests.” Tr. 336; RD, at 20. K.D. was confused by the doctor's statement and informed the doctor that she had not come to the hospital for pain medication. Tr. 336; RD, at 20. K.D. testified that a nurse, seeing her apparent confusion, informed K.D. that she was “red flagged for having been written too many pain medication prescriptions.” Tr. 337. The nurse brought K.D. a printout showing prescriptions dispensed to K.D. over the past year by pharmacies in the vicinity of the hospital. Tr. 337; GX 7; RD, at 20. The record demonstrates that Respondent issued at least 23 prescriptions to K.D. for oxycodone-acetaminophen 10-325mg (a Schedule II opioid) between November 2019 and February 2022. GX 5(a), at 7-33; RD, at 59. Four of these prescriptions were written for K.D. before K.D. met Respondent in June 2020. GX 5(a), at 1-12; GX 6(b); RD, at 65 n.150. K.D. testified that the prescriptions were unfamiliar to her and she had not authorized Respondent to write prescriptions for her. Tr. 342; GX 6(a), (c); RD, at 21. K.D. further testified that the Walgreens and CVS prescriptions contained cell phone numbers belonging to T.D. and that none of the numbers were associated with her. Tr. 342-45; GX 6(a) at 8, 16; RD, at 21.</P>
                <P>
                    K.D. testified that she started crying, showed T.D. a picture of the printout, and immediately contacted Respondent using the social media app Instagram because she did not have Respondent's telephone number. Tr. 337, 339-40, 506; RD, at 21. Through Instagram, K.D. told Respondent that she had just found out that Respondent had been writing prescriptions in her name, and wrote, “This is insane. I can't believe you. You clearly know [T.D.] has a problem. Why would you do this? ” GX 18, at 1. Respondent apologized and said she “thought [T.D.] had cleared this with [her],” assured K.D. that she was prescribing T.D. “a very stable number per month,” asked K.D. “[p]lease don't punish me,” and gave K.D. her phone number. 
                    <E T="03">Id.</E>
                     K.D. also called Respondent and asked her why she had written prescriptions in her name because she had never been Respondent's patient. Tr. 346; RD, at 21.
                </P>
                <P>K.D. testified that she had observed bottles prescribed by Respondent bearing T.D.'s name but had never seen any bottles bearing her own name. Tr. 349; RD, at 21. K.D. testified that she knew of the pharmacies where the prescriptions issued to her were filled, but none of them had ever contacted her regarding the prescriptions. Tr. 349-50; RD, at 21. K.D. further testified that she does not know who picked up the prescriptions. Tr. 350; RD, at 21.</P>
                <P>
                    Although Respondent generally maintained that the prescriptions she issued to K.D. were based on a legitimate practitioner-patient relationship and multiple examinations, Respondent admits to one instance where she issued a prescription to K.D. knowing that the prescription would be diverted to T.D. Tr. 456; RD, at 34. Respondent testified that this occasion involved a “severe issue” and a “very unique circumstance” in which T.D. called Respondent in “severe distress” while he was traveling for his broadcasting job. Tr. 456-57; RD, at 34. T.D. called Respondent and indicated that he had “lost the medication or left his medication in a hotel or something, [and] couldn't access it,” and “practically begged” Respondent to write a prescription in K.D.'s name because otherwise he would have to “wait for his next fill” for another 25 to 26 days. Tr. 457; RD, at 34. Respondent testified that she told T.D. that she would write the prescription “as long as . . . [K.D. was] okay with it.” Tr. 457. Respondent acknowledged that this was “not necessarily a kosher thing to do,” 
                    <PRTPAGE P="48195"/>
                    but “being a paraplegic,
                    <SU>23</SU>
                    <FTREF/>
                     [she is] very sensitive to the issue of pain” and was just “trying to help.” Tr. 457. Respondent also testified that her emergency room experience allows her to recognize drug-seeking behavior and she does not “take on patients that appear to be drug seekers.” Tr. 458. Respondent testified that T.D.'s excuse was “legitimate” and he was “in severe distress and pain.” Tr. 458. Respondent testified that T.D. suffered from life-long pain from his career as a professional football player. Tr. 457; RD, at 34.
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         Respondent suffered a serious injury in August of 2015 that resulted in paralysis from the chest down. Tr. 384; RD, at 22 n.77.
                    </P>
                </FTNT>
                <P>Respondent testified that this was the “only occasion [she has] ever put medication in someone else's name,” and that all of the other prescriptions she issued to K.D. were for K.D. Tr. 458; RD, at 35. She further testified that if the prescriptions “were being diverted, [she] was completely unaware.” Tr. 458-59; RD, at 35. When asked why she did not issue a replacement prescription in T.D.'s own name upon learning of his issue, Respondent stated that “because he was fairly early in his cycle . . . [he] [could not] fill controlled substances for . . . a 30-day period . . . [so] [h]e would have had to wait another 25, 26 days or so for a refill.” Tr. 460. Respondent testified that she did not speak with K.D. personally, but that T.D. represented multiple times that K.D. was “cool with” the prescription for T.D. to be written in her name. Tr. 459-60; RD, at 61. Respondent also acknowledged that, even if she had received permission from K.D., it was still unlawful to issue a prescription for T.D. in K.D.'s name. Tr. 461; RD, at 34 n.110.</P>
                <P>
                    The Agency agrees with the ALJ and finds based on substantial record evidence that Respondent issued at least 23 prescriptions to K.D. without K.D.'s knowledge, without a 
                    <E T="03">bona fide</E>
                     practitioner-patient relationship, and to a patient not under Respondent's care. The Agency finds based on substantial record evidence that Respondent issued at least four of these prescriptions before meeting K.D. in June 2020, and, therefore, without an appropriate prior examination or medical indication. 
                    <E T="03">See</E>
                     RD, at 64-66. The Agency finds that on at least one occasion, Respondent issued a prescription to K.D. knowing that it would be diverted to T.D. Finally, the Agency agrees with the ALJ and finds that all 23 prescriptions that Respondent issued to K.D. were issued outside the usual course of professional practice.
                    <SU>24</SU>
                    <FTREF/>
                     RD, at 66.
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         Respondent did not have a 
                        <E T="03">bona fide</E>
                         practitioner-patient relationship with K.D. and, therefore, was not acting “as a physician.” Accordingly, these prescriptions were issued outside the usual course of professional practice and in violation of 21 CFR 1306.04. 
                        <E T="03">See, e.g., United States</E>
                         v. 
                        <E T="03">Moore,</E>
                         423 U.S. 122 (1975) (“Implicit in the registration of a physician is the understanding that he is authorized only to act `as a physician.' ”).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">iii. Conclusions of Law</HD>
                <P>The Agency found above that between 2019 and 2024, Respondent issued over 2,500 prescriptions for controlled substances without a supervising physician or standardized procedure, and, therefore, without state authority. The Agency further found that these prescriptions were issued outside the usual course of professional practice.</P>
                <P>
                    Additionally, the Agency found that Respondent issued at least 23 prescriptions to K.D. without K.D.'s knowledge, without a 
                    <E T="03">bona fide</E>
                     practitioner-patient relationship, and to a patient not under Respondent's care. The Agency found that these prescriptions were issued outside the usual course of professional practice. Finally, the Agency found that on at least one occasion, Respondent issued a prescription to K.D. knowing that it would be diverted to T.D., and on at least four occasions, Respondent issued prescriptions to K.D. without an appropriate prior examination or medical indication. Accordingly, the Agency finds substantial record evidence that Respondent violated 21 CFR 1306.04(a); Cal. Health &amp; Safety Code § 11150; Cal. Health &amp; Safety Code § 11154; Cal. Bus &amp; Prof. Code § 2836.1(d); Cal. Code Regs. tit. 16, § 1474). The Agency also finds that Respondent engaged in unprofessional conduct under California law. Cal. Bus &amp; Prof. Code § 2242(a).
                    <SU>25</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         Each of Respondent's CSA violations provides a sufficient basis for the Agency to revoke her registration. The Agency has found that intentional acts of diversion—such as Respondent's prescription to K.D. that Respondent knew would be diverted to T.D.—“strike[ ] at the CSA's core purpose of preventing the abuse and diversion of controlled substances,” and that “proof of a single act of intentional diversion is sufficient to support the revocation of a registration.” 
                        <E T="03">See Samuel Mintlow, M.D.,</E>
                         80 FR 3630, 3653 (2015) (citing 
                        <E T="03">Dewey C. MacKay, M.D.,</E>
                         75 FR 49956, 49977 (2010).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Public Interest Conclusion</HD>
                <P>
                    While the Agency considered all the public interest factors of 21 U.S.C. 823(g)(1), its findings are relevant to Factor B (experience dispensing controlled substances) and Factor D (compliance or non-compliance with laws related to controlled substances). 21 U.S.C. 823(g)(1); 
                    <E T="03">Kareem Hubbard, M.D.,</E>
                     87 FR at 21162 (2022). Accordingly, the Agency finds that after considering the public interest factors, the Government satisfied its 
                    <E T="03">prima facie</E>
                     burden of showing that Respondent's continued registration would be “inconsistent with the public interest.” 21 U.S.C. 824(a)(4). The Agency further finds that there is insufficient mitigating evidence to rebut the Government's 
                    <E T="03">prima facie</E>
                     case. Thus, the only remaining issue is whether revocation of Respondent's registration is the appropriate sanction.
                </P>
                <HD SOURCE="HD1">III. Sanction</HD>
                <P>
                    Where, as here, the Government has met the burden of showing that Respondent's registration is inconsistent with the public interest, the burden shifts to Respondent to show why she can be entrusted with a registration. 
                    <E T="03">Morall,</E>
                     412 F.3d. at 174; 
                    <E T="03">Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 823, 830; 
                    <E T="03">Garrett Howard Smith, M.D.,</E>
                     83 FR 18882, 18904 (2018). The issue of trust is necessarily a fact-dependent determination based on the circumstances presented by the individual registrant. 
                    <E T="03">Jeffrey Stein, M.D.,</E>
                     84 FR 46968, 46972 (2019); 
                    <E T="03">see also Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 833. Moreover, as past performance is the best predictor of future performance, the Agency requires that a registrant who has committed acts inconsistent with the public interest accept responsibility for those acts and demonstrate that he will not engage in future misconduct. 
                    <E T="03">See Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 833; 
                    <E T="03">ALRA Labs, Inc.</E>
                     v. 
                    <E T="03">Drug Enf't Admin.,</E>
                     54 F.3d 450, 452 (7th Cir. 1995). The Agency requires a registrant's unequivocal acceptance of responsibility. 
                    <E T="03">Janet S. Pettyjohn, D.O.,</E>
                     89 FR 82639, 82641 (2024); 
                    <E T="03">Mohammed Asgar, M.D.,</E>
                     83 FR 29569, 29573 (2018); 
                    <E T="03">see also Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 830-31. In addition, a registrant's candor during the investigation and hearing is an important factor in determining acceptance of responsibility and the appropriate sanction. 
                    <E T="03">See Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 830-31; 
                    <E T="03">Hoxie,</E>
                     419 F.3d at 483-84. Further, the Agency considers the egregiousness and extent of the misconduct as significant factors in determining the appropriate sanction. 
                    <E T="03">See Jones Total Health Care Pharmacy,</E>
                     881 F.3d at 834 &amp; n.4. The Agency also considers the need to deter similar acts by a registrant and by the community of registrants. 
                    <E T="03">Jeffrey Stein, M.D.,</E>
                     84 FR at 46972-73.
                </P>
                <P>
                    Here, the Agency agrees with the ALJ that Respondent did not unequivocally accept responsibility for her misconduct. RD, at 73-78. As the ALJ 
                    <PRTPAGE P="48196"/>
                    observed, “DEA precedent is clear that `[c]andor to the court is of paramount important.' ” 
                    <E T="03">Stephen E. Owusu, D.P.M.,</E>
                     87 FR 3343, 3349 (2022); RD, at 74. “[I]mplausible aspects of Respondent's testimony . . . demonstrate a lack of candor.” 
                    <E T="03">Id.</E>
                     at 3350; RD, at 74. As already discussed, Respondent offered testimony that was wholly inconsistent with the testimony of other witnesses with significantly less at stake in these proceedings. Although Respondent acknowledged these discrepancies, she classified them as “misunderstanding[s]” or mere differences in recollection. Tr. 405, 448, 524; RD, at 74.
                </P>
                <P>For example, Respondent testified that Dr. W. must have forgotten that they had implemented a standardized procedure because it was over a decade ago. Tr. 374-75, 423; RD, at 25, 27, 74. Respondent also dismissed Dr. W.'s testimony that he was not aware of Respondent's controlled substance prescribing, testifying that “nurse practitioner supervision [is] a lot [looser] than . . . physician assistant supervision” and emphasizing that Dr. W. had access to her patient records and could review them if he wanted to. Tr. 412-13; RD, at 26-27. Dr. W. denied having access to Respondent's records, but even so, Respondent's testimony that nurse practitioner supervision is “loose” directly conflicts with California's detailed Standardized Procedure Guidelines. These guidelines, jointly promulgated by the Medical Board of California and the Board of Registered Nursing, require a written and signed agreement that includes specific components, including “specify[ing] . . . which drugs or devices may be furnished or ordered, under what circumstances.” Cal. Bus. &amp; Prof. Code § 2836.1(c)(1).</P>
                <P>
                    Despite having issued over 2,500 unlawful controlled substance prescriptions, Respondent asserted that pain medications comprise a “super teeny, teeny, tiny, percentage of the practice in terms of volume of patients over the year,” and testified that over her entire career, she had only issued controlled substances to “around 100 people.” Tr. 382-83, 428-29, 465; RD, at 28, 29, 30. Respondent's attempts to minimize an extraordinarily high volume of controlled substance prescriptions is extremely concerning. 
                    <E T="03">See, e.g., Medical Pharmacy,</E>
                     86 FR 72030, 72054 (2021) (“[T]he agency has long considered statements that are aimed at minimizing the egregiousness of . . . conduct to weigh against a finding of acceptance of full responsibility.”); RD, at 77.
                </P>
                <P>Respondent also downplayed the discrepancies between K.D.'s repeated testimony that she only met Respondent once and her own self-serving and inconsistent testimony that they had met multiple times and conducted telehealth appointments. Tr. 189, 331, 334, 346, 348, 505; RD, at 74. Respondent again insisted that it was a misunderstanding, but also testified that she could not understand “how [K.D.] wouldn't know that she has pain medication [written] in her name” because she should have heard from the pharmacy that her prescriptions were ready to fill. Tr. 397-98, 448; RD, at 31, 32. Further, when testifying about the incident in which Respondent prescribed medication in K.D.'s name knowing that it would be diverted to T.D., Respondent emphasized that it was a “very unique circumstance”, that T.D. was in a lot of pain and distress, that she believed she had permission from K.D., and that T.D. did not appear to be engaging in any drug-seeking behavior. Tr. 456-57, 458, 459-60; RD, at 34-35, 34 n.110. Respondent also testified that if prescriptions “were being diverted, [she] was completely unaware.” Tr. 458-59; RD, at 35.</P>
                <P>
                    As the ALJ recognized, “Respondent frequently acknowledged and did not dispute the legal requirements governing her practice” and “acknowledged that her intentional diversion to T.D. was unlawful and wrong.” Tr. 421-23, 427-28, 430-31, 433-34, 458, 461, 526-27; RD, at 77. However, Respondent also repeatedly attempted to shift blame for her misconduct and offered incredulous and inconsistent testimony downplaying and justifying her repeated instances of improper prescribing and intentional diversion. 
                    <E T="03">See Owusu,</E>
                     87 FR at 3351 (“[I]t would strain all bounds of reasonable jurisprudence to find that Respondent has accepted responsibility for his actions, despite his trivialization of his misconduct . . . his implausible testimony, and his own view of himself as a victim.”); RD, at 77. Respondent's attempts to justify acts of intentional and knowing diversion are particularly concerning and demonstrate that the Agency cannot trust her with a registration. Accordingly, the Agency finds based on substantial record evidence that Respondent failed to unequivocally accept responsibility for her misconduct.
                    <SU>26</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         Where a registrant has not accepted responsibility, it is not necessary to consider evidence of the registrant's remedial measures. 
                        <E T="03">Ajay S. Ahuja, M.D.,</E>
                         84 FR 5479, 5498 n.33 (2019) (citing 
                        <E T="03">Jones Total Health Care Pharmacy,</E>
                         81 FR at 79,202-03). As the ALJ observed, Respondent presented no evidence of remedial measures during the hearing, and only in her post hearing brief did she first indicate that she has since (1) “engaged a new supervising physician, rather than Dr. Winter,” (2) “implemented updated standardized procedures,” (3) “transitioned to a new electronic health record system,” (4) dismissed all of her controlled substance patients,” and (5) “completed continuing education on prescribing.” ALJX 38, at 4, 15. The Agency agrees with the ALJ that even if Respondent had accepted responsibility for her actions, these statements related to remedial measures would receive little (if any) weight. They were provided after the hearing without any supporting testimony or documentary evidence, and without the opportunity for the Government to question Respondent regarding these actions. RD, at 18 n.169. Respondent's statements in her Exceptions that she has “taken concrete steps to address issues raised, particularly concerning recordkeeping, prescribing practices, and supervision compliance,” receive no weight for the same reasons. Accordingly, the Agency rejects Respondent's Exceptions.
                    </P>
                </FTNT>
                <P>
                    Acceptance of responsibility and remedial measures are assessed in the context of the “egregiousness of the violations and the [DEA's] interest in deterring similar misconduct by [the] Respondent in the future as well as on the part of others.” 
                    <E T="03">Daniel A. Glick, D.D.S.,</E>
                     80 FR 74800, 74810 (2015); 
                    <E T="03">OakmontScript Limited Partnership,</E>
                     87 FR 21546, 21545 (2022). Here, the Agency agrees with the ALJ that the egregiousness of Respondent's misconduct favors revocation. RD, at 78-79. For a period of about five years, Respondent issued over 2,500 prescriptions for highly abused and diverted Schedule II, III, and IV controlled substance prescriptions without possessing proper state authority. Respondent blatantly flouted her obligations as a DEA registrant by prescribing Schedule II opioids to K.D., an individual she had never met, knowing that these prescriptions would be diverted by T.D. Although Respondent testified that T.D. never exhibited any drug-seeking behavior, she admitted that he “practically begged” her to issue the prescription, and K.D. wrote to Respondent through Instagram, “[y]ou clearly know he has a problem.” Respondent showed no remorse for her acts of intentional diversion to an individual with potential substance abuse problems and instead portrayed it as a “very unique circumstance.”
                </P>
                <P>
                    Considerations of specific and general deterrence also militate in favor of revocation. RD, at 79-80. When testifying as to the allegations, Respondent rarely admitted fault and clearly did not appreciate the gravity of her misconduct or the potential harm to her patients and the community at large. Respondent's attempts to downplay and justify acts of intentional diversion demonstrate that she has not been deterred from violating the CSA in the 
                    <PRTPAGE P="48197"/>
                    future. Interests of general deterrence also support a sanction of revocation, as any sanction less than revocation would signal to the registrant community that intentional diversion and repeated acts of unlawful prescribing can be excused, even in cases where a registrant has failed to accept responsibility for such misconduct.
                </P>
                <P>In sum, Respondent has not offered sufficient credible evidence on the record to rebut the Government's case for revocation and Respondent has not demonstrated that she can be entrusted with the responsibility of registration. Accordingly, the Agency will order that Respondent's registrations be revoked.</P>
                <HD SOURCE="HD1">Order</HD>
                <P>
                    Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a) and 21 U.S.C. 823(g)(1), I hereby revoke DEA Certificates of Registration Nos. MM3336422 and MR5666106 issued to Joan Rubinger, N.P. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(g)(1), I hereby deny any pending applications of Joan Rubinger, N.P., to renew or modify these registrations, as well as any other pending application of Joan Rubinger, N.P., for additional registration in California and/or New York.
                    <SU>27</SU>
                    <FTREF/>
                     This Order is effective August 31, 2026.
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         The Agency may revoke Respondent's New York registration based on Respondent's egregious misconduct in California. 
                        <E T="03">See, e.g., Roberto Zayas, M.D.,</E>
                         82 FR 21410, 21430 (2017) (revoking the respondent's Florida registration and denying his Texas renewal application based on misconduct in Texas). The Administrator's determination that Respondent may not be trusted with a registration disqualifies her for current DEA registration in all states. 
                        <E T="03">See Suntree Pharmacy and Suntree Medical Equipment, LLC,</E>
                         85 FR 73753, 73755 (2020) (“If a practitioner holding multiple registrations cannot be entrusted with one, it would be difficult to justify entrusting the same practitioner with another in a separate location.”).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Signing Authority</HD>
                <P>
                    This document of the Drug Enforcement Administration was signed on July 24, 2026, by DEA Administrator Terrance C. Cole. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Heather Achbach,</NAME>
                    <TITLE>Federal Register Liaison Officer, Drug Enforcement Administration.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15328 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-09-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <SUBJECT>Notice of Lodging of Proposed Consent Decree Under the Clean Air Act</SUBJECT>
                <P>On July 24, 2026, the Department of Justice lodged a proposed Consent Decree in the United States District Court for the Western District of Arkansas in the lawsuit entitled United States, et al. v. Domtar A.W., LLC, Case No. 4:26-cv-04059-JTS.</P>
                <P>The United States filed this action with Arkansas Department of Energy&amp; Environment, Division of Environmental Quality against the Defendant for violations of the Clean Air Act and the Arkansas Water and Air Pollution Control Act. The complaint alleges that the Defendant violated the New Source Performance Standards and the National Emission Standards for Hazardous Air Pollutants at its kraft paper/pulp mill in Ashdown, Arkansas. Under the proposed Consent Decree, the Defendant has agreed to pay a penalty of $1,500,000 and perform injunctive relief, including two mitigation projects to resolve the governments' claims.</P>
                <P>The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States, et al. v. Domtar A.W., LLC, D.J. Ref. No. 90-5-2-1-12655. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:</P>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="xs50,r50">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1" O="L">
                            <E T="03">To submit comments:</E>
                        </CHED>
                        <CHED H="1" O="L">
                            <E T="03">Send them to:</E>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">By email</ENT>
                        <ENT>
                            <E T="03">pubcomment-ees.enrd@usdoj.gov.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">By mail</ENT>
                        <ENT>Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Any comments submitted in writing may be filed by the United States in whole or in part on the public court docket without notice to the commenter.</P>
                <P>
                    During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department website: 
                    <E T="03">http://www.usdoj.gov/enrd/Consent_Decrees.html.</E>
                     If you require assistance accessing the consent decree, you may request assistance by email or by mail to the addresses provided above for submitting comments.
                </P>
                <SIG>
                    <NAME>Jeffrey Sands,</NAME>
                    <TITLE>Deputy Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15402 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF LABOR</AGENCY>
                <SUBJECT>Agency Information Collection Activities; Submission for OMB Review; Comment Request; Attestation for Employers Seeking To Employ H-2B Nonimmigrant Workers Under Section 105 of Division G, Title I of the Further Consolidated Appropriations Act, 2024, Public Law 118-47, as Extended by Public Law 119-37</SUBJECT>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Labor (DOL) is submitting this Employment and Training Administration (ETA)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The OMB will consider all written comments that the agency receives on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Michael Howell by telephone at 202-693-6782, or by email at 
                        <E T="03">DOL_PRA_PUBLIC@dol.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This information collection request (ICR) supports the Temporary Final Rule (TFR), Exercise of Time-Limited Authority to Increase the Numerical Limitation for Fiscal Year 2026 for H-2B Temporary Nonagricultural Worker Program and Portability Flexibility for H-2B Workers Seeking To Change Employers, which is being promulgated 
                    <PRTPAGE P="48198"/>
                    by the Department of Labor (DOL or Department) and the Department of Homeland Security (DHS) (collectively, the Departments). The regulatory requirements will be codified at 8 CFR part 214 and 20 CFR part 655. The ICR includes a new form, Attestation for Employers Seeking to Employ H-2B Nonimmigrant Workers under Section 105 of Division G, Title I of the Further Consolidated Appropriations Act, 2024, Public Law 118-47, as extended by Public Law 119-37, Form ETA-9142-B-CAA-10 (Form ETA-9142-B-CAA-10). For additional substantive information about this ICR, see the related notice published in the 
                    <E T="04">Federal Register</E>
                     on February 3, 2026 (91 FR 5040).
                </P>
                <P>
                    <E T="03">Comments are invited on:</E>
                     (1) whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; (2) the accuracy of the agency's estimates of the burden and cost of the collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility and clarity of the information collection; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of automated collection techniques or other forms of information technology.
                </P>
                <P>
                    This information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless the OMB approves it and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person shall generally be subject to penalty for failing to comply with a collection of information that does not display a valid OMB Control Number. 
                    <E T="03">See</E>
                     5 CFR 1320.5(a) and 1320.6.
                </P>
                <P>DOL seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOL notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <P>
                    <E T="03">Agency:</E>
                     DOL-ETA.
                </P>
                <P>
                    <E T="03">Title of Collection:</E>
                     Attestation for Employers Seeking to Employ H-2B Nonimmigrant Workers under Section 105 of Division G, Title I of the Further Consolidated Appropriations Act, 2024, Public Law 118-47, as extended by Public Law 119-37.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     1205-0564.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Private Sector (businesses or other for-profits).
                </P>
                <P>
                    <E T="03">Total Estimated Number of Respondents:</E>
                     16,382.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Responses:</E>
                     16,382.
                </P>
                <P>
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     25,248 hours.
                </P>
                <P>
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <EXTRACT>
                    <FP>(Authority: 44 U.S.C. 3507(a)(1)(D))</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Michael Howell,</NAME>
                    <TITLE>Senior Paperwork Reduction Act Analyst.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15424 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4510-FN-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">NUCLEAR REGULATORY COMMISSION</AGENCY>
                <DEPDOC>[Docket No. 40-8943; NRC-2025-0976]</DEPDOC>
                <SUBJECT>Crow Butte Resources, Inc.; Crow Butte Project and Marsland Expansion Area; Environmental Assessment and Finding of No Significant Impact</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Nuclear Regulatory Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; issuance.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Nuclear Regulatory Commission (NRC) is considering renewal of Crow Butte Resources, Inc.'s (CBR or the licensee), source and byproduct materials license SUA-1534 for continued in situ recovery (ISR) of uranium at the Crow Butte Project and for construction and operation of a satellite facility and support operations at the Marsland Expansion Area in Crawford, Nebraska, for an additional 20 years. The NRC staff is issuing an environmental assessment (EA) and finding of no significant impact (FONSI).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The EA and FONSI referenced in this document are available on July 30, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Please refer to Docket ID NRC-2025-0976 when contacting the NRC about the availability of information regarding this document. You may obtain publicly available information related to this document using any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal Rulemaking Website:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov</E>
                         and search for Docket ID NRC-2025-0976. Address questions about Docket IDs in 
                        <E T="03">Regulations.gov</E>
                         to Bridget Curran; telephone: 301-415-1003; email: 
                        <E T="03">Bridget.Curran@nrc.gov.</E>
                         For technical questions, contact the individual(s) listed in the 
                        <E T="02">For Further Information Contact</E>
                         section of this document.
                    </P>
                    <P>
                        • 
                        <E T="03">NRC's Agencywide Documents Access and Management System (ADAMS):</E>
                         You may obtain publicly available documents online in the ADAMS Public Documents collection at 
                        <E T="03">https://www.nrc.gov/reading-rm/adams.html.</E>
                         To begin the search, select “Begin ADAMS Public Search.” For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, at 301-415-4737, or by email to 
                        <E T="03">PDR.Resource@nrc.gov.</E>
                    </P>
                    <P>
                        • 
                        <E T="03">NRC's PDR:</E>
                         The PDR, where you may examine and order copies of publicly available documents, is open by appointment. To make an appointment to visit the PDR, please send an email to 
                        <E T="03">PDR.Resource@nrc.gov</E>
                         or call 1-800-397-4209 or 301-415-4737, between 8 a.m. and 4 p.m. eastern time (ET), Monday through Friday, except Federal holidays.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Christine Pineda, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; telephone: 301-415-6789; email: 
                        <E T="03">Christine.Pineda@nrc.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>The NRC is making available to the public the “Environmental Assessment for the Proposed Renewal of Crow Butte Resources, Inc.'s License for In-Situ Uranium Recovery at the Crow Butte Project and Marsland Expansion Area in Dawes County, Nebraska.” The EA is available in ADAMS under Accession No. ML26204A421.</P>
                <HD SOURCE="HD1">II. Introduction</HD>
                <P>The NRC is considering the renewal of source and byproduct materials license SUA-1534 for CBR's ISR project in Dawes County, Nebraska at the Crow Butte Project (CBP) and Marsland Expansion Area (MEA) sites for an additional 20 years. CBR plans to continue recovering uranium and producing yellowcake using the ISR process. The CBP is an operating facility that has been in standby since 2018. The MEA has not yet been constructed. Yellowcake, the uranium oxide product of the ISR process, is used in the production of fuel for commercially operated nuclear power reactors.</P>
                <P>
                    The NRC staff has prepared an EA for this proposed licensing action in accordance with NRC regulations in part 51 of title 10 of the 
                    <E T="03">Code of Federal Regulations</E>
                     (10 CFR), “Environmental Protection Regulations for Domestic Licensing and Related Regulatory Functions,” which implement the National Environmental Policy Act of 1969, as amended (NEPA). Based on the EA, the NRC has concluded that a FONSI is appropriate. Therefore, in 
                    <PRTPAGE P="48199"/>
                    accordance with paragraph 10 CFR 51.31(a), “Determinations based on environmental assessment,” the NRC has determined that preparation of an environmental impact statement is not warranted for the proposed action. The NRC is issuing a FONSI at this time.
                </P>
                <HD SOURCE="HD1">III. Summary of the Environmental Assessment</HD>
                <HD SOURCE="HD2">Description of the Proposed Action</HD>
                <P>The proposed Federal action is approval of CBR's application for license renewal. If the NRC does decide to renew the license, CBR would continue ISR operations at the CBP and could construct and operate a satellite facility and support operations at the MEA. Other licensed activities include aquifer restoration and decommissioning activities. The NRC will renew license SUA-1534 (ADAMS Accession No. ML25259A241), under 10 CFR part 40, “Domestic Licensing of Source Material,” if the NRC concludes that CBR has demonstrated it will continue to meet NRC requirements for operation at the CBP and for construction and operation at the MEA.</P>
                <P>The CBP license area occupies approximately 2,840 acres, and the area disturbed over the estimated life of the project is approximately 1,265 acres. The ISR project at the CBP consists of processing facilities and 11 sequentially-developed wellfields (mine units), a central processing facility, two nonhazardous Class I deep injection (disposal) wells, a Class V septic disposal well, evaporation ponds, and associated infrastructure and support facilities. Currently, only aquifer restoration activities are ongoing at the CBP (no uranium recovery). If Crow Butte restarts operations at the CBP, uranium would continue to be recovered from the Basal Chadron Sandstone at a depth that varies from 400 to 900 feet below the ground surface. The maximum flow rate of the processing facility is 9,000 gpm, excluding restoration flow, and total annual yellowcake production is limited to 2 million pounds.</P>
                <P>The MEA license area encompasses approximately 4,622 acres, and Crow Butte estimates that the area to be disturbed would be approximately 1,754 acres. At the MEA, facilities would include wellfields, a satellite ion exchange facility, two nonhazardous Class I deep disposal wells, a Class V well for septic disposals, and support facilities and infrastructure. Crow Butte has not started construction of the ISR facilities at the MEA.</P>
                <P>After operations at a wellfield in the CBP or the MEA cease, CBR would begin aquifer restoration to return groundwater quality within the production zone of wellfields to standards consistent with NRC requirements at 10 CFR part 40, Appendix A, Criterion 5B(5) and, if applicable, 5B(6). After groundwater restoration, CBR would proceed with reclamation and decommissioning. CBR's goal in reclamation and decommissioning is to return disturbed lands back to conditions that are at least equal in quality to pre-ISR conditions.</P>
                <HD SOURCE="HD2">Purpose and Need for the Proposed Action</HD>
                <P>The purpose of the proposed license renewal is to enable Crow Butte to continue ISR operations for an additional 20 years. In regulating uranium milling and the ISR process, the NRC is meeting its obligations under the Atomic Energy Act of 1954, as amended, (AEA), to allow and ensure the safe possession and use of radioactive materials. This definition of “purpose and need” reflects the Commission's recognition that, unless there are negative findings in the NRC's safety review required by the AEA, or findings under NEPA that would lead the NRC to reject the license renewal application, the NRC has no role in a company's decision to construct and operate an ISR facility at a particular location.</P>
                <HD SOURCE="HD2">Environmental Impacts of the Proposed Action</HD>
                <P>The NRC staff has assessed the potential environmental impacts of the proposed action. The results of the NRC's environmental review can be found in the EA. The NRC staff assessed the potential impacts on land use; visual and scenic resources; noise; air quality; geology and soils; water resources; ecological resources; historic and cultural resources; socioeconomics; transportation; public and occupational health and safety; and waste management.</P>
                <P>The proposed action would not change the current and expected land use at the CBP. No significant changes in operations and no new construction at the CBP site, including roads, are planned or expected. Traffic is not expected to increase from current conditions (during full operations). The NRC staff has determined that impacts to water resources would not be significant, as discussed in detail in the EA. During the 20-year term of the license renewal, CBR would continue to operate in accordance with NRC, State, and other requirements to minimize impacts to water resources. There would be no significant impacts to public radiological and non-radiological health, and CBR would continue to operate in accordance with NRC and State requirements to minimize radiological and non-radiological impacts.</P>
                <P>The proposed action at the MEA likewise would not result in a significant increase in short-term or long-term radiological risk to public health or the environment. Certain construction impacts could be noticeable, including impacts from noise (temporary impacts to the nearest resident to the MEA during construction) and impacts on ecological resources (localized and temporary impacts resulting from the loss and slow recovery of forest habitat). While potential noticeable impacts would be expected for specific aspects of these resource areas, the construction impacts are short-term and temporary. Impacts from MEA operations would not be significant, as described in section 3 of the EA. After construction, CBR would operate the MEA during the 20-year license renewal term in accordance with NRC, State, and other requirements to minimize impacts to water resources. The NRC staff does not expect significant impacts from MEA operation to public radiological and non-radiological health, and CBR would operate the MEA in accordance with NRC and State requirements to minimize radiological and non-radiological impacts.</P>
                <P>In accordance with the Endangered Species Act, the NRC staff evaluated potential impacts to federally protected ecological resources that may result from the proposed action. As discussed in section 1.6.2 of the EA, the U.S. Fish and Wildlife Service concurred with NRC staff's effect determinations of “may affect but is not likely to adversely affect” the monarch butterfly, Suckley's cuckoo bumble bee, and western regal fritillary.</P>
                <P>
                    In accordance with the National Historic Preservation Act, the NRC staff evaluated potential impacts to historic and cultural resources at the CBP and the MEA. The NRC staff consulted with Federally recognized Indian Tribes, and the Nebraska State Historic Preservation Office, as described in section 1.6.1 of the EA. Based on the staff's assessment and the results of consultation, the NRC staff concludes that impacts from licensed activities at the CBP and MEA during the proposed license renewal period on unevaluated sites, sites eligible for listing in the National Register of Historic Places (NRHP), and Federally recognized Indian tribal sites not eligible for listing in the NRHP but 
                    <PRTPAGE P="48200"/>
                    of significance to Federally recognized Indian Tribes will not be significant.
                </P>
                <HD SOURCE="HD2">Environmental Impacts of the Alternative to the Proposed Action</HD>
                <P>As an alternative to the proposed license renewal for the Crow Butte ISR project at the CBP and the MEA, the NRC considered the no-action alternative. Under the no-action alternative, the NRC would not renew license SUA-1534. CBR would not be able to continue operations at the CBP, and would not be able to pursue construction and operation at the MEA. For the CBP site, CBR would need to submit a decommissioning plan for NRC approval. Decommissioning would commence only after the NRC has conducted parallel safety and environmental reviews and approved the decommissioning plan. The potential impacts of the no-action alternative would therefore be the same as the impacts resulting from decommissioning activities. Section 2.1.5 of the EA provides a general description of decommissioning activities.</P>
                <P>At the MEA site under the no-action alternative, there would be no environmental impacts on land use, transportation, geology and soils, air quality, water resources, ecological resources, noise, historic and cultural resources, visual and scenic resources, waste management, and public and occupational health and safety. Drill holes associated with MEA preconstruction activities would be properly plugged and abandoned, and the wells would be decommissioned.</P>
                <P>Additionally, the uranium minerals present in the Crow Butte area would not be made available to support the U.S. nuclear fuel supply chain with domestically produced uranium.</P>
                <HD SOURCE="HD2">Agencies and Persons Consulted</HD>
                <P>On May 26, 2026, the NRC provided the draft EA to the State of Nebraska's Department of Water, Energy, and Environment. The NRC received no comments on the draft EA.</P>
                <P>Under Section 106 of the National Historic Preservation Act, the NRC staff consulted with the Nebraska State Historic Preservation Office, CBR, and 28 Federally recognized Indian Tribes, as described in section 1.6.1 of the EA. Under the Endangered Species Act, the NRC staff consulted with the U.S. Fish and Wildlife Service, as described in section 1.6.2 of the EA.</P>
                <HD SOURCE="HD1">IV. Finding of No Significant Impact</HD>
                <P>In accordance with the requirements in 10 CFR part 51, the NRC staff has concluded that the proposed action will not significantly affect the quality of the human environment. Therefore, the NRC staff has determined, pursuant to 10 CFR 51.31, “Determinations based on environmental assessment,” that preparation of an EIS is not required for the proposed action, and pursuant to 10 CFR 51.32, “Finding of no significant impact,” a FONSI is appropriate. Consistent with 10 CFR 51.32(a)(4), this FONSI incorporates by reference the EA described in this notice.</P>
                <P>
                    <E T="03">Authority:</E>
                     42 U.S.C. 2011 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: July 24, 2026</DATED>
                    <P>For the Nuclear Regulatory Commission.</P>
                    <NAME>Robert Sun,</NAME>
                    <TITLE>Chief, Environmental Review Materials Branch, Division of Spent Fuel Storage and Transportation, Office of Nuclear Material Safety and Safeguards.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15338 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7590-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">POSTAL REGULATORY COMMISSION</AGENCY>
                <DEPDOC>[Docket Nos. MC2026-322 and K2026-317; MC2026-323 and K2026-318]</DEPDOC>
                <SUBJECT>New Postal Products</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Postal Regulatory Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Commission is noticing a recent Postal Service filing for the Commission's consideration concerning a negotiated service agreement. This notice informs the public of the filing, invites public comment, and takes other administrative steps.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Comments are due:</E>
                         August 4, 2026.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit comments electronically via the Commission's Filing Online system at 
                        <E T="03">https://www.prc.gov.</E>
                         Those who cannot submit comments electronically should contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section by telephone for advice on filing alternatives.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>David A. Trissell, General Counsel, at 202-789-6820.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Introduction</FP>
                    <FP SOURCE="FP-2">II. Public Proceeding(s)</FP>
                    <FP SOURCE="FP-2">III. Summary Proceeding(s)</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Introduction</HD>
                <P>Pursuant to 39 CFR 3041.405, the Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to Competitive negotiated service agreement(s). The request(s) may propose the addition of a negotiated service agreement from the Competitive product list or the modification of an existing product currently appearing on the Competitive product list.</P>
                <P>
                    The public portions of the Postal Service's request(s) can be accessed via the Commission's website (
                    <E T="03">http://www.prc.gov</E>
                    ). Non-public portions of the Postal Service's request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3011.301.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See</E>
                         Docket No. RM2018-3, Order Adopting Final Rules Relating to Non-Public Information, June 27, 2018, Attachment A at 19-22 (Order No. 4679).
                    </P>
                </FTNT>
                <P>Section II identifies the docket number(s) associated with each Postal Service request, if any, that will be reviewed in a public proceeding as defined by 39 CFR 3010.101(p), the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. For each such request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 and 39 CFR 3000.114 (Public Representative). The Public Representative does not represent any individual person, entity or particular point of view, and, when Commission attorneys are appointed, no attorney-client relationship is established. Section II also establishes comment deadline(s) pertaining to each such request.</P>
                <P>The Commission invites comments on whether the Postal Service's request(s) identified in Section II, if any, are consistent with the policies of title 39. Applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3035, and 39 CFR part 3041. Comment deadline(s) for each such request, if any, appear in Section II.</P>
                <P>
                    Section III identifies the docket number(s) associated with each Postal Service request, if any, to add a standardized distinct product to the Competitive product list or to amend a standardized distinct product, the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. Standardized distinct products are negotiated service agreements that are variations of one or more Competitive products, and for which financial models, minimum rates, and classification criteria have undergone advance Commission review. 
                    <E T="03">See</E>
                     39 CFR 3041.110(n); 39 CFR 3041.205(a). Such requests are reviewed in summary 
                    <PRTPAGE P="48201"/>
                    proceedings pursuant to 39 CFR 3041.325(c)(2) and 39 CFR 3041.505(f)(1). Pursuant to 39 CFR 3041.405(c)-(d), the Commission does not appoint a Public Representative or request public comment in proceedings to review such requests.
                </P>
                <HD SOURCE="HD1">II. Public Proceeding(s)</HD>
                <P>
                    1. 
                    <E T="03">Docket No(s).:</E>
                     MC2026-322 and K2026-317; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express International, Priority Mail International &amp; First-Class Package International Service Contract 119 to Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     July 27, 2026; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Maxine Bradley; 
                    <E T="03">Comments Due:</E>
                     August 4, 2026.
                </P>
                <HD SOURCE="HD1">III. Summary Proceeding(s)</HD>
                <P>
                    1. 
                    <E T="03">Docket No(s).:</E>
                     MC2026-323 and K2026-318; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add New Fulfillment Standardized Distinct Product, PM-GA Contract 1053, and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     July 27, 2026; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642 and 3633, 39 CFR 3035.105, and 39 CFR 3041.325.
                </P>
                <P>
                    This Notice will be published in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Danielle LeFlore,</NAME>
                    <TITLE>Legal Assistant.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15366 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7710-FW-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-105980; File No. S7-2026-26]</DEPDOC>
                <SUBJECT>Notice of an Application of the Securities Industry and Financial Markets Association for an Exemption Pursuant to Section 36 of the Securities Exchange Act of 1934 From Certain Conditions of Note H to Exchange Act Rule 15c3-3a</SUBJECT>
                <DATE>July 24, 2026.</DATE>
                <P>
                    On June 24, 2026, the Securities Industry and Financial Markets Association (“SIFMA”), a trade association for broker-dealers, investment banks, and asset managers operating in the U.S. and global capital markets, filed an application with the Securities and Exchange Commission (“Commission”), to obtain an exemption pursuant to section 36 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (“Exchange Act”),
                    <SU>2</SU>
                    <FTREF/>
                     in accordance with the procedures set forth in Exchange Act Rule 0-12.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, SIFMA is requesting relief, on behalf of its broker-dealer members, from the application of Exchange Act section 15(c)(3) 
                    <SU>4</SU>
                    <FTREF/>
                     and Rule 15c3-3a, Note H(b)(1) and (2)(i) thereunder, to permit broker-dealers to include a debit in their reserve computations for customers and the proprietary securities accounts of other broker-dealers (“PAB”) 
                    <SU>5</SU>
                    <FTREF/>
                     (collectively “reserve computations”) for margin required and on deposit with a qualified clearing agency resulting from transactions in U.S. Treasury securities in customer accounts that have been cleared, settled, and novated by the clearing agency in cases where the broker-dealer has delivered the margin collateral on a net, omnibus, basis, rather than on a gross, customer-by-customer basis, subject to certain conditions discussed below.
                    <SU>6</SU>
                    <FTREF/>
                     The Commission is publishing this notice to provide interested persons with an opportunity to comment.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78mm. Section 36(a)(1) of the Exchange Act gives the Commission the authority to exempt any person, security or transaction or any class or classes of persons, securities or transactions, conditionally or unconditionally, from any Exchange Act provision by rule, regulation or order, to the extent that the exemption is necessary or appropriate in the public interest and consistent with the protection of investors.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a 
                        <E T="03">et seq.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.0-12. Exchange Act Rule 0-12 sets forth procedures for filing applications for orders for exemptive relief pursuant to section 36. The application will not appear in the 
                        <E T="04">Federal Register</E>
                         (“Application”). The Application is available on the Commission's internet website at 
                        <E T="03">www.sec.gov.</E>
                         Defined terms in this notice are the same as used in the Application, unless we note otherwise.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78o(c)(3).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         17 CFR 15c3-3(a)(16) (defining PAB account as a proprietary securities account of a broker-dealer (which includes a foreign broker-dealer, or a foreign bank acting as a broker-dealer) other than a delivery-versus-payment account or a receipt-versus-payment account. The term does not include an account that has been subordinated to the claims of creditors of the carrying broker-dealer.)
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.15c3-3a, Note H(b)(2)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Background</HD>
                <P>
                    Rule 15c3-3 under the Exchange Act, known as the broker-dealer customer protection rule, requires broker-dealers that hold customer cash and securities (“carrying broker-dealers”) to treat these assets in a manner that facilitates their prompt return to customers if the broker-dealer fails financially.
                    <SU>7</SU>
                    <FTREF/>
                     To meet this objective, Rule 15c3-3 requires a carrying broker-dealer to take two primary steps to safeguard customer assets, which are designed to protect customers by segregating their securities and cash from the carrying broker-dealer's proprietary business activities.
                    <SU>8</SU>
                    <FTREF/>
                     The first step requires a carrying broker-dealer to maintain physical possession or control over customers' fully paid and excess margin securities.
                    <SU>9</SU>
                    <FTREF/>
                     The second step requires that a carrying broker-dealer maintain a reserve bank account that must hold cash or qualified securities (
                    <E T="03">e.g.,</E>
                     U.S. Treasury securities) in an amount determined by a computation of the net cash owed to the carrying broker-dealer's customers pursuant to a formula set forth in Exchange Act Rule 15c3-3a, the customer reserve computation.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Daily Computation of Customer and Broker-Dealer Reserve Requirements Under the Broker-Dealer Customer Protection Rule,</E>
                         Exchange Act Release No. 102022 (Dec. 20, 2024) [90 FR 2790 (Jan. 13, 2025)] (“Daily Rule 15c3-3 Reserve Computation Final Rule”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See id.</E>
                         at 2794.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.15c3-3(d).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         Daily Rule 15c3-3 Reserve Computation Final Rule, 90 FR at 2794. 
                        <E T="03">See also Financial Responsibility Rules for Broker-Dealers; Final Rule,</E>
                         Exchange Act Release No. 70072 (July 30, 2013) [78 FR 51824, 51826 (Aug. 21, 2013)] (“Financial Responsibility Rules for Broker-Dealers; Final Rule”). 
                        <E T="03">See also</E>
                         17 CFR 240.15c3-3a (Formula for determination of customer and PAB account reserve requirements of broker-dealers under Rule 15c3-3.).
                    </P>
                </FTNT>
                <P>
                    Under the customer reserve computation, the broker-dealer adds up customer credit items (for example, credit balances in customer securities accounts and cash obtained through the use of customer margin securities) and subtracts customer debit items (for example, margin loans). The goal of Rule 15c3-3 is to place a broker-dealer in a position where it is able to wind down in an orderly self-liquidation without the need of financial assistance provided by the Securities Investor Protection Corporation through a formal proceeding under the Securities Investor Protection Act of 1970.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Financial Responsibility Rules for Broker-Dealers; Final Rule, 78 FR at 51869; Daily Rule 15c3-3 Reserve Computation Final Rule, 90 FR at 2791.
                    </P>
                </FTNT>
                <P>
                    On December 13, 2023, the Commission adopted rules under the Exchange Act to amend the standards applicable to certain clearing agencies to enhance risk management practices for central counterparties in the U.S. Treasury market and facilitate additional clearing of U.S. Treasury securities.
                    <SU>12</SU>
                    <FTREF/>
                     Included in the Treasury Clearing Adopting Release, the Commission also adopted amendments to Rule 15c3-3a to permit margin required and on deposit at qualified clearing agencies providing central counterparty services for U.S. Treasury securities to be included by broker-
                    <PRTPAGE P="48202"/>
                    dealers as a debit in their customer reserve computation, subject to certain conditions.
                    <SU>13</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See Standards for Covered Clearing Agencies for U.S. Treasury Securities and Application of the Broker-Dealer Customer Protection Rule With Respect to U.S. Treasury Securities,</E>
                         Exchange Act Release No. 99149 (Dec. 13, 2023), [89 FR 2714 (Jan. 16, 2024)] (“Treasury Clearing Adopting Release”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See id.</E>
                         at 2760-68. 
                        <E T="03">See also</E>
                         17 CFR 240.15c3-3a, Note H. As discussed in the Treasury Clearing Adopting Release, the debit in Item 15 of Rule 15c3-3a, and the related requirements of Note H apply to both the customer and PAB reserve computations. 
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 89 FR at 2768.
                    </P>
                </FTNT>
                <P>
                    Included among these conditions is paragraph (b)(1) to Note H, which requires that in order to include a debit in Item 15 of its customer reserve computation, a broker-dealer must deliver customer cash, U.S. Treasury securities, or qualified customer securities 
                    <SU>14</SU>
                    <FTREF/>
                     to a qualified clearing agency on a customer-by-customer basis, or otherwise temporarily prefund a specific customer's margin requirement with proprietary U.S. Treasury securities, subject to certain conditions.
                    <SU>15</SU>
                    <FTREF/>
                     Another condition, in paragraph (b)(2)(i) of Note H, requires that any customer margin required and on deposit at the qualified clearing agency is treated in accordance with rules requiring the qualified clearing agency to calculate a separate margin amount for each customer of the broker-dealer, and the broker-dealer to deliver that amount of margin for each customer on a gross basis.
                    <SU>16</SU>
                    <FTREF/>
                     The Commission adopted this requirement to ensure that the risk of one customer's positions could not be offset by the risk of another customer's positions in determining the amount of customer margin the broker-dealer would need to have on deposit at the qualified clearing agency.
                    <SU>17</SU>
                    <FTREF/>
                     Thus, under existing Note H requirements, a broker-dealer is not permitted to deliver assets belonging to one customer to meet the margin requirement of another customer, and margin must be calculated and delivered on a gross basis.
                    <SU>18</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.15c3-3a, Note H(c) (defining “qualified customer securities” to mean the securities of a customer of the broker-dealer (other than U.S. Treasury securities) that are held in custody by the broker-dealer for the customer and that under the rules of the qualified clearing agency are eligible to be used to margin U.S. Treasury securities positions of the customer that are cleared, settled, and novated by the qualified clearing agency).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.15c3-3a, Note H(b)(1). The Commission permitted broker-dealers to temporarily prefund a specific customer's margin requirement to address instances where a qualified clearing agency may call for margin arising from a customer's cleared U.S. Treasury securities transactions before the customer can deliver the requisite margin to the broker-dealer, but limited the permissible proprietary assets the broker-dealer could use exclusively to U.S. Treasury securities to ensure that only the safest, most liquid securities of the broker-dealer are commingled with the customer cash and securities in the account. 
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 89 FR at 2763. For further discussion on the Commission's reasoning in permitting a broker-dealer's use of proprietary assets to temporarily prefund a margin requirement resulting from a customer's U.S. Treasury securities positions cleared, settled, and novated at the qualified clearing agency, 
                        <E T="03">see id.</E>
                         at 2762-63.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.15c3-3a, Note H(b)(1) and (b)(2)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 89 FR at 2764. For a discussion of the Commission's consideration of the alternative of tailoring the requirement to permit a debit based on a margin amount posted to the qualified clearing agency that is calculated on a net basis across all the broker-dealer's customers, as is the case under Item 13 and Note F in Rule 15c3-3a for margin required and on deposit with the Options Clearing Corporation (“OCC”) for all option contracts written or purchased in customer accounts, 
                        <E T="03">see id.</E>
                         at 2764-65.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 89 FR at 2764.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Summary of the Application and Proposed Conditions</HD>
                <P>
                    In the Application, SIFMA requests that, pursuant to section 36 of the Exchange Act, the Commission grant exemptive relief from section 15(c)(3) of the Exchange Act and Rule 15c3-3a, Note H(b)(1) and (2)(i) thereunder to permit broker-dealers to include a debit in their reserve computations for customer margin required and on deposit with a qualified clearing agency resulting from transactions in U.S. Treasury securities in customer accounts that have been cleared, settled, and novated by the clearing agency, in cases where the broker-dealer has delivered the margin collateral on a net, omnibus, basis, rather than on a gross, customer-by-customer basis, subject to certain conditions.
                    <SU>19</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         Application, at pp.1-2.
                    </P>
                </FTNT>
                <P>
                    In its Application, SIFMA stated that as broker-dealers have commenced implementing the operational and system changes necessary to comply with the gross (
                    <E T="03">i.e.,</E>
                     customer-by-customer) margin calculation and posting requirements connected with Note H, it has become apparent that such an approach entails more significant drawbacks than anticipated at the time of the Commission's proposal and subsequent adoption of Note H. In particular, SIFMA stated in the Application that a strict customer-by-customer framework requires highly granular systems to map positions, margin requirements, and collateral flows to individual customers across clearing, settlement, and internal records, as well as complex intraday reconciliation and enhanced data infrastructure that SIFMA stated is not aligned with the existing omnibus-based operational models used in Treasury intermediation.
                </P>
                <P>
                    Further, SIFMA stated that customer-by-customer gross margining and collateral delivery requirements applied within the evolving U.S. Treasury clearing model become increasingly difficult to scale as clearing expands to a broader set of market participants and intermediated relationships, and may introduce significant operational complexity and capital inefficiencies.
                    <SU>20</SU>
                    <FTREF/>
                     SIFMA additionally stated that these inefficiencies and operational complexities associated with a gross margin calculation and delivery requirement may impair broker-dealers' ability to efficiently intermediate access to centrally cleared U.S. Treasury markets, particularly for smaller or indirect participants, and may therefore undermine the Commission's objective of broadening participation in central clearing. In its Application, SIFMA stated that for broker-dealers that elect not to implement the full systems and processes necessary to support scalable gross, customer-level margining, the resulting reserve computation treatment may not reflect the economic substance of customer facilitation activity in U.S. Treasury clearing, instead giving rise to duplicative capital and liquidity requirements that are misaligned with actual risk exposure and the manner in which broker-dealers intermediate customer access to central clearing.
                    <SU>21</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         Application, at p.4. 
                        <E T="03">See also</E>
                         Letter from Kevin Zambrowicz, Deputy General (Institutional) &amp; Managing Director, SIFMA, to the Honorable Gary Gensler, Chair, Commission (Oct. 23, 2024) (Application of the Broker-Dealer Customer Protection Rule with Respect to U.S. Treasury Securities Clearing), 
                        <E T="03">available at: https://www.sec.gov/comments/S7-23-22/s72322-834280-2549193.pdf;</E>
                         and Letter from Kevin Zambrowicz, Deputy General Counsel, SIFMA, to the Honorable Paul Atkins, Chair, Commission (Nov. 19, 2025) (Treasury Clearing—The OCC-Model Approach under Rule 15c3-3), 
                        <E T="03">available at: https://www.sec.gov/comments/S7-23-22/s72322-834300-2549193.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Application, at p.4. SIFMA further stated that these constraints may have the unintended effect of increasing the cost of clearing intermediation and reducing broker-dealers' willingness or ability to facilitate customer access to centrally cleared U.S. Treasury markets, with a disproportionate impact on smaller or less frequent market participants that choose not to access central clearing on a gross margining basis due to participation costs and related operational requirements. Further, SIFMA stated that over time, these frictions could reduce participation and liquidity in the U.S. Treasury market and undermine the policy objectives of expanded central clearing by discouraging efficient access pathways and increasing operational burdens without a corresponding reduction in systemic risk.
                    </P>
                </FTNT>
                <P>
                    In its Application, SIFMA stated that one well-established model for facilitating omnibus-based intermediary clearing activity is the customer clearing structure used by the OCC.
                    <SU>22</SU>
                    <FTREF/>
                     Specifically, SIFMA stated that under the OCC framework, broker-dealer clearing members intermediate customer access to centrally cleared markets through omnibus customer 
                    <PRTPAGE P="48203"/>
                    accounts, with margin and risk managed at the clearing member level in a manner that promotes operational efficiency while preserving strict customer protection standards, including segregation of customer assets and strong default management protections.
                    <SU>23</SU>
                    <FTREF/>
                     SIFMA requests in its Application that the Commission provide exemptive relief to permit either (1) the calculation and delivery of customer margin on a net (
                    <E T="03">i.e.,</E>
                     omnibus) basis; or (2) the calculation of margin on a gross (
                    <E T="03">i.e.,</E>
                     customer-by-customer) basis and the delivery of margin on a net (
                    <E T="03">i.e.,</E>
                     omnibus) basis.
                    <SU>24</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See</E>
                         Application, at p.4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See id.</E>
                         SIFMA further stated that this structure has supported broad participation in centrally cleared markets, including by smaller market participants that would otherwise lack direct access to central clearing.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See</E>
                         Application, at p.4.
                    </P>
                </FTNT>
                <P>
                    SIFMA stated in the Application that this relief would enable broker-dealers to more efficiently intermediate access to centrally cleared U.S. Treasury markets, while remaining consistent with the customer protection and reserve computation framework under Rule 15c3-3.
                    <SU>25</SU>
                    <FTREF/>
                     SIFMA has further stated that the current customer-by-customer, gross margining and delivery requirement may impose disproportionate capital and operational burdens when broker-dealers serve smaller customers, particularly given applicable minimum cash margin requirements. SIFMA stated that the requested relief would provide broker-dealers with greater flexibility and alleviate these constraints, thereby supporting broader market access, enhancing liquidity, and advancing the Commission's objective of promoting a deep, resilient, and inclusive U.S. Treasury market.
                    <SU>26</SU>
                    <FTREF/>
                     Additionally, SIFMA stated that this approach would take into account the various customer account types that clearing agencies currently offer to market participants for clearing transactions in U.S. Treasury securities, and as such, would help facilitate a smoother implementation of the Commission's 2023 amendments from the Treasury Clearing Adopting Release.
                    <SU>27</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See id.</E>
                         Specifically, SIFMA stated that recognizing net (omnibus) customer margin collateral delivered to a qualified clearing agency for U.S. Treasury securities as a debit in the customer reserve computation aligns reserve formula treatment with the protections provided through central clearing, and that absent such treatment, the customer reserve computation would impose duplicative requirements on assets already subject to segregation and risk management within a regulated clearing environment. 
                        <E T="03">See</E>
                         Application, at p.6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         Application, at p.4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    Further, SIFMA stated in the Application that the proposed “lesser of” framework (which is found within the proposed conditions for the requested relief, as discussed further below), reflects a conservative approach that ties the debit treatment directly to actual customer-related exposures to prevent any overstatement of debits, and preserve the integrity of the broker-dealer's customer reserve computation.
                    <SU>28</SU>
                    <FTREF/>
                     More specifically, SIFMA stated in its Application that each of the three caps reflected within the proposed “lesser of” framework serves a distinct risk-limiting function: (i) the customer margin collected cap limits recognition to customer-derived funds; (ii) the margin delivered cap confines limits recognition to amounts actually transferred to the qualified clearing agency; and (iii) the qualified clearing agency margin requirement cap ensures that any margin collected or posted in excess of the clearing agency's required customer margin amount is not recognized in the customer reserve computation and is effectively “pulled back” by the broker-dealer.
                    <SU>29</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See</E>
                         Application, at p.6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See</E>
                         Application, at p.6. Relatedly, SIFMA stated in its Application that because the Item 15 debit is limited to margin required and on deposit at the qualified clearing agency, the broker-dealer has an incentive to obtain the prompt return of excess margin collateral held by the qualified clearing agency that is in the form of securities. Specifically, the amount of the excess margin would remain a credit in the customer reserve computation with no offsetting debit if the excess margin amount is no longer required by the qualified clearing agency. 
                        <E T="03">See</E>
                         Application, at p.6, n.16. 
                        <E T="03">See also</E>
                         Treasury Clearing Adopting Release, 89 FR at 2765 and 2767.
                    </P>
                </FTNT>
                <P>
                    SIFMA proposes certain conditions in the Application in support of its request for exemptive relief from certain conditions of Rule 15c3-3a, Note H.
                    <SU>30</SU>
                    <FTREF/>
                     Specifically, SIFMA proposes that:
                </P>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         
                        <E T="03">See</E>
                         section II. of the Application.
                    </P>
                </FTNT>
                <EXTRACT>
                    <P>
                        1. 
                        <E T="03">Eligibility Limitation:</E>
                         The relief applies solely to margin required and on deposit with a qualified clearing agency in connection with the following types of transactions in U.S. Treasury securities in customer accounts that have been cleared, settled, and novated by the qualified clearing agency: (i) purchases and sales of U.S. Treasury securities; and (ii) repurchase and reverse repurchase agreements in U.S. Treasury securities.
                    </P>
                    <P>2. The broker-dealer delivers the following cash and securities to the qualified clearing agency to meet the customer margin requirement:</P>
                    <P>(i) Proprietary or customer cash;</P>
                    <P>(ii) Proprietary or customer U.S. Treasury securities;</P>
                    <P>(iii) Qualified customer securities; or</P>
                    <P>(iv) Any combination of clauses (i) through (iii) above.</P>
                    <P>
                        3. 
                        <E T="03">Permitted Debit:</E>
                         The amount the broker-dealer includes in the Item 15 debit in the customer reserve computation must equal the lesser of:
                    </P>
                    <P>(i) The amount of margin collected from customers in connection with U.S. Treasury securities transactions of the broker-dealer's customers that are cleared, settled, and novated by the qualified clearing agency;</P>
                    <P>(ii) The amount of margin required for U.S. Treasury securities positions of the broker-dealer's customers that are cleared, settled, and novated by the qualified clearing agency; or</P>
                    <P>(iii) The total of: (A) customer cash, (B) customer U.S. Treasury securities, and (C) qualified customer securities, delivered by the broker-dealer to the qualified clearing agency to meet margin requirements arising from U.S. Treasury securities positions of the broker-dealer's customers that are cleared, settled and novated by the qualified clearing agency.</P>
                    <P>
                        4. 
                        <E T="03">Documentation:</E>
                         The broker-dealer must maintain books and records sufficient to identify the amount of customer margin collected and delivered to the qualified clearing agency.
                    </P>
                    <P>
                        5. 
                        <E T="03">Qualified Clearing Agency Rulebook Amendments:</E>
                         The rules of the qualified clearing agency must comply with the conditions of any exemptive order the Commission may issue in response to the Application.
                    </P>
                    <P>
                        6. 
                        <E T="03">Procedures:</E>
                         The broker-dealer must adopt and implement written policies and procedures reasonably designed to ensure ongoing compliance with the conditions of any exemptive order the Commission may issue in response to the Application.
                    </P>
                    <P>7. To the extent a broker-dealer delivers margin to a qualified clearing agency pursuant to the Application, such margin remains subject to the other applicable conditions of Note H not exempted by the Commission pursuant to the Application, including paragraphs (b)(2)(ii) through (v).</P>
                </EXTRACT>
                <P>
                    Finally, SIFMA requested that the relief in any exemptive order the Commission may issue pursuant to its Application provide broker-dealers with the same relief as to their PAB account holders and PAB reserve computation under Rule 15c3-3a, subject to the same conditions as those proposed above to the customer reserve computation.
                    <SU>31</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         
                        <E T="03">See</E>
                         section II. of the Application.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">III. Request for Comment</HD>
                <P>We request and encourage any interested person to submit comments regarding the Application, including whether the Commission should grant the request. In particular, we solicit comment on the following questions:</P>
                <EXTRACT>
                    <P>
                        1. Do commenters agree with SIFMA's reasons described in the Application 
                        <SU>32</SU>
                        <FTREF/>
                         in support of the Commission finding that the exemptive relief is consistent with section 36 of the Exchange Act? If so, why or why not.
                    </P>
                    <FTNT>
                        <P>
                            <SU>32</SU>
                             
                            <E T="03">See, e.g.,</E>
                             sections I. and III. of the Application; 
                            <E T="03">see also</E>
                             section II. of this notice.
                        </P>
                    </FTNT>
                    <P>
                        2. Are there other or alternative conditions not outlined in the Application, or modifications to the conditions proposed 
                        <PRTPAGE P="48204"/>
                        within the Application, that the Commission should consider? If so, please describe those conditions or modifications.
                    </P>
                    <P>
                        3. In connection with proposed condition (i) under “Permitted Debit” above,
                        <SU>33</SU>
                        <FTREF/>
                         are broker-dealers currently capable of tracking and recording the portion of any margin required and on deposit with a qualified clearing agency that is attributable to customers in connection with transactions in U.S. Treasury securities that have been cleared, settled, and novated by the qualified clearing agency? If so, how does a broker-dealer track and record this margin? For example, do broker-dealers generally record repurchase and reverse repurchase transactions in U.S. Treasury securities in a separate securities account for each customer? If broker-dealers cannot track and record this portion of any margin required and on deposit with a qualified clearing agency that is attributable to customers in connection with transactions in U.S. Treasury securities that have been cleared, settled, and novated by the qualified clearing agency, will they need to modify their current operational systems to comply with the conditions proposed in this Application? If so, how?
                    </P>
                    <FTNT>
                        <P>
                            <SU>33</SU>
                             
                            <E T="03">See</E>
                             proposed condition (3)(i) in Application, at p.5.
                        </P>
                    </FTNT>
                    <P>
                        4. Does the relief proposed in the Application to permit broker-dealers to include a debit in their reserve computations for margin required and on deposit with a qualified clearing agency resulting from transactions in U.S. Treasury securities that have been cleared, settled, and novated by the qualified clearing agency, when the broker-dealer has delivered the margin collateral on a net, omnibus, basis, rather than a gross, customer-by-customer, basis raise any potential customer protection concerns or risks? 
                        <SU>34</SU>
                        <FTREF/>
                         If so, please describe. What modifications to the proposed conditions, or additional conditions, if any, should the Commission consider to address any potential risks posed by the requested relief?
                    </P>
                    <FTNT>
                        <P>
                            <SU>34</SU>
                             
                            <E T="03">See, e.g.,</E>
                             Treasury Clearing Adopting Release, 89 FR at 2764-65 (discussing the Commission's rationale for requiring margin to be calculated and delivered on a gross, customer-by-customer basis under Note H, rather than, in response to a commenter's suggestion, modifying this requirement to be consistent with the requirements of Item 13 and Note F to the customer reserve computation, which covers margin required and on deposit with OCC where the permitted debit is based on a margin amount posted to OCC that is calculated on a net basis across all the broker-dealer's customers with listed options.)
                        </P>
                    </FTNT>
                    <P>
                        5. Is the relief requested in the Application more relevant to a particular type of U.S. Treasury securities transaction (
                        <E T="03">e.g.,</E>
                         cash U.S. Treasury securities transactions or U.S. Treasury securities repurchase and reverse repurchase agreements, etc.)? If so, how?
                    </P>
                    <P>6. What are the operational issues, if any, that broker-dealers face that stem from the existing requirements to calculate and deliver margin on a gross, customer-by-customer basis, as required by Rule 15c3-3a, Note H? How would the relief requested in the Application address these issues?</P>
                    <P>7. Do commenters agree with SIFMA that the gross, customer-by-customer margin requirement approach causes disproportionate capital and operational constraints that may result in duplicative capital and liquidity requirements? If so, would the exemptive relief proposed in the Application relieve those constraints? If so, how?</P>
                    <P>8. How much time would be necessary, and what steps would be needed, for qualified clearing agencies to modify their own rulebooks and systems to be able to conduct operations consistent with the exemptive relief requested in the Application?</P>
                    <P>9. In considering whether to issue an exemptive order requested in the Application, should the Commission also consider clarifying the application of any Notice H notices issued or that the Commission may issue under paragraph (b)(3) under Rule 15c3-3a, Note H, as they relate to the proposed conditions in the Application? If so, how?</P>
                    <P>10. Would the exemption requested in the Application have a competitive impact—either positive or negative—on broker-dealers and their customers in the context of clearing for U.S. Treasury securities? What would be the potential benefits and costs of this exemptive relief? Would the exemption and conditions impact investor protection? If so, what would those impacts be?</P>
                </EXTRACT>
                <P>Comments should be received on or before August 31, 2026. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/comments/s7-2026-26/notice-application-securities-industry-financial-markets-association-exemption-pursuant-section-36</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include File Number S7-2026-26 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to File Number S7-2026-26. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method of submission. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules-regulations/public-comments/s7-2026-26</E>
                    ). Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection.
                </FP>
                <P>For further information, you may contact Raymond A. Lombardo, Acting Associate Director; Sheila Dombal Swartz, Senior Special Counsel; or James Wintering, Special Counsel at (202) 551-5500, Office of Broker-Dealer Finances, Division of Trading and Markets, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-7010.</P>
                <SIG>
                    <P>By the Commission.</P>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15320 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-105995; File No. SR-NASDAQ-2026-032]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Order Granting Approval of a Proposed Rule Change, as Modified by Amendment No. 1, To Amend Nasdaq Rule 5711(d) (Commodity-Based Trust Shares)</SUBJECT>
                <DATE>July 27, 2026.</DATE>
                <HD SOURCE="HD1">I. Introduction</HD>
                <P>
                    On April 14, 2026, The Nasdaq Stock Market LLC (“Exchange”) filed with the Securities and Exchange Commission (“Commission”), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder (“Rule 19b-4”),
                    <SU>2</SU>
                    <FTREF/>
                     a proposed rule change to amend Nasdaq Rule 5711(d) to modify the generic listing standards for Commodity-Based Trust Shares. The proposed rule change was published for comment in the 
                    <E T="04">Federal Register</E>
                     on April 28, 2026.
                    <SU>3</SU>
                    <FTREF/>
                     On June 9, 2026, the Exchange filed Amendment No. 1 to the proposed rule change, which replaced and superseded the original proposed rule change in its entirety. On June 11, 2026, the Commission published notice of the proposed rule change, as modified by Amendment No. 1 (“Proposal”), and extended the time for Commission action on the Proposal.
                    <SU>4</SU>
                    <FTREF/>
                     This order approves the Proposal.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 105293 (Apr. 23, 2026), 91 FR 22883.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 105672, 91 FR 36185 (June 16, 2026) (“Notice”) (designating July 27, 2026, as the date by which the Commission shall either approve the Proposal, disapprove the Proposal, or institute proceedings to determine whether the Proposal should be disapproved). The Commission has received no comments on the Proposal.
                    </P>
                </FTNT>
                <PRTPAGE P="48205"/>
                <HD SOURCE="HD1">II. Description of the Proposal</HD>
                <P>
                    The Commission previously approved Nasdaq Rule 5711(d), which sets forth generic listing standards 
                    <SU>5</SU>
                    <FTREF/>
                     for Commodity-Based Trust Shares 
                    <SU>6</SU>
                    <FTREF/>
                     on the Exchange.
                    <SU>7</SU>
                    <FTREF/>
                     As described in more detail in the Notice,
                    <SU>8</SU>
                    <FTREF/>
                     the Exchange proposes to amend Nasdaq Rule 5711(d) to modify certain aspects of the generic listing standards for Commodity-Based Trust Shares.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Generic listing standards for Commodity-Based Trust Shares permit the Exchange, pursuant to Rule 19b-4(e) under the Act (“Rule 19b-4(e)”), to list and trade Commodity-Based Trust Shares without first submitting a proposed rule change with the Commission pursuant to Section 19(b) of the Act. 
                        <E T="03">See</E>
                         17 CFR 240.19b-4(e). The Exchange, however, is required to submit a rule filing with the Commission when seeking to list and trade Commodity-Based Trust Shares that do not meet the generic listing standards set forth in Nasdaq Rule 5711(d).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         Pursuant to the current rule, the term “Commodity-Based Trust Shares” is defined as a security that: (1) is issued by a trust, limited liability company, partnership, or other similar entity (“trust”) that, if applicable, is operated by a registered commodity pool operator pursuant to the Commodity Exchange Act (“CEA”), and is not registered as an investment company pursuant to the Investment Company Act of 1940 (“1940 Act”), or series or class thereof; (2) is designed to reflect the performance of one or more reference assets or an index of reference assets, less expenses and other liabilities; (3) in order to reflect such performance, is issued by a trust that holds (a) one or more commodities or commodity-based assets, and (b) in addition to such commodities or commodity-based assets, may hold securities, cash, and cash equivalents; (4) is issued by such trust in a specified aggregate minimum number in return for a deposit of (a) a specified quantity of the underlying commodities, commodity-based assets, securities, cash, and/or cash equivalents, or (b) a cash amount with a value based on the next determined net asset value (“NAV”) per trust share; and (5) when aggregated in the same specified minimum number, may be redeemed at a holder's request by such trust which will deliver to the redeeming holder (a) the specified quantity of the underlying commodities, commodity-based assets, securities, cash, and/or cash equivalents, or (b) a cash amount with a value based on the next determined NAV per trust share. 
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iii)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 103995 (Sept. 17, 2025), 90 FR 45414 (Sept. 22, 2025) (SR-NASDAQ-2025-056; SR-CboeBZX-2025-104; SR-NYSEARCA-2025-54) (Order Granting Accelerated Approval of Proposed Rule Changes, as Modified by Amendments Thereto, to Adopt Generic Listing Standards for Commodity-Based Trust Shares) (“Generics Approval Order”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         Notice, 
                        <E T="03">supra</E>
                         note 4.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">A. Proposed Amendment To Allow a 15% Buffer for Certain Assets</HD>
                <P>
                    Currently, Nasdaq Rule 5711(d)(iv) sets forth eligibility criteria that the holdings of Commodity-Based Trust Shares must meet for the shares to be listed and traded pursuant to the generic listing standards. Specifically, Nasdaq Rule 5711(d)(iv)(A) requires that each commodity,
                    <SU>9</SU>
                    <FTREF/>
                     or commodity that underlies a commodity-based asset,
                    <SU>10</SU>
                    <FTREF/>
                     held by a trust must meet at least one of the following criteria:
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         The term “commodity” is as defined in Section 1a(9) of the CEA that is not an “excluded commodity” as defined in Section 1a(19) of the CEA. 
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iii)(B).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         The term “commodity-based asset” means any future, option, or swap on a commodity. 
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iii)(C).
                    </P>
                </FTNT>
                <P>
                    • On an initial and continuing basis, the commodity trades on a market that is an Intermarket Surveillance Group (“ISG”) member, provided that the Exchange may obtain information about trading in such commodity from the ISG member; 
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iv)(A)(1).
                    </P>
                </FTNT>
                <P>
                    • On an initial and continuing basis, the commodity underlies a futures contract that has been made available to trade on a designated contract market (“DCM”) for at least six months; provided that the Exchange has a comprehensive surveillance sharing agreement, whether directly or through common membership in ISG, with such DCM; 
                    <SU>12</SU>
                    <FTREF/>
                     or
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iv)(A)(2).
                    </P>
                </FTNT>
                <P>
                    • On an initial basis only, an exchange-traded fund (“ETF”) 
                    <SU>13</SU>
                    <FTREF/>
                     designed to provide economic exposure of no less than 40% of its NAV to the commodity lists and trades on a national securities exchange.
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         The term “exchange-traded fund” means an open-end management investment company or a unit investment trust as defined in Section 4(2) of the 1940 Act or series or class thereof, the shares of which are listed and traded on a national securities exchange, and that has formed and operates under an exemptive order under the 1940 Act or in reliance on an exemptive rule adopted by the Commission. 
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iii)(G).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iv)(A)(3).
                    </P>
                </FTNT>
                <P>
                    In addition, to the extent a trust holds securities, (i) each equity security held by the trust must meet the requirements set forth in the Exchange's rules for equity component securities underlying Managed Fund Shares generically listed on the Exchange; 
                    <SU>15</SU>
                    <FTREF/>
                     (ii) each fixed income security held by the trust must meet the requirements set forth in the Exchange's rules for fixed income component securities underlying Managed Fund Shares generically listed on the Exchange,
                    <SU>16</SU>
                    <FTREF/>
                     and (iii) if the security is a listed option, it must trade on an ISG market.
                    <SU>17</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5735(b)(1)(A) (Managed Fund Shares).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5735(b)(1)(B) (Managed Fund Shares).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iv)(B).
                    </P>
                </FTNT>
                <P>
                    The Exchange proposes to amend Nasdaq Rule 5711(d)(iv) to adopt a new paragraph (C) in Nasdaq Rule 5711(d)(iv). As proposed, Nasdaq Rule 5711(d)(iv)(C) would provide that, notwithstanding the eligibility criteria set forth in Nasdaq Rules 5711(d)(iv)(A) and (B), up to 15% of the Commodity-Based Trust Shares' NAV in the aggregate may consist of (i) “digital commodities” 
                    <SU>18</SU>
                    <FTREF/>
                     that do not meet the criteria for commodities set forth in Nasdaq Rule 5711(d)(iv)(A), or (ii) securities that do not meet the criteria for securities set forth in Nasdaq Rule 5711(d)(iv)(B) (referred to herein as the “15% Buffer”).
                    <SU>19</SU>
                    <FTREF/>
                     For purposes of calculating this 15% Buffer, any derivative held by the trust would be calculated based on its gross notional value.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         The Exchange proposes to define the term “digital commodity” to mean a commodity that is a digital asset and is intrinsically linked to and derives its value from the programmatic operation of a functional crypto system, as well as supply and demand dynamics, rather than from the expectation of profits from the essential managerial efforts of others. 
                        <E T="03">See</E>
                         proposed Nasdaq Rule 5711(d)(iii)(D). The Exchange states that this proposed definition is informed by the joint interpretative guidance issued by the Commission and the Commodity Futures Trading Commission. 
                        <E T="03">See</E>
                         Notice at 36187 (citing “Application of the Federal Securities Laws to Certain Types of Crypto Assets and Certain Transactions Involving Crypto Assets,” Securities Exchange Act Release No. 105020 (Mar. 17, 2026), 91 FR 13714 (Mar. 23, 2026)). The Exchange states that, to the extent legislation is enacted defining “digital commodity” or a substantially similar term, the Exchange will submit a rule filing to conform the definition of “digital commodity” in the Commodity-Based Trust Shares generic listing standards to the statutory definition. 
                        <E T="03">See id.</E>
                         The Exchange also states that the generic listing standards “are not intended to apply to novel products or materially distinct structures that were not considered when the standards were adopted,” and the Proposal “would effectively exclude other commodities such as non-fungible assets or non-fungible collectibles from being included in the 15% [B]uffer for generically listed Commodity-Based Trust Shares.” 
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         proposed Nasdaq Rule 5711(d)(iv)(C).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See id.</E>
                         The Exchange states that it similarly calculates percentage limitations on derivatives in its Managed Fund Shares rule based on the aggregate gross notional value of derivatives. 
                        <E T="03">See</E>
                         Notice at 36186 n.10 (citing to Nasdaq Rules 5735(b)(1)(D) and (E) (Managed Fund Shares)).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Proposed Amendment To Allow Actively Managed Commodity-Based Trust Shares</HD>
                <P>
                    Currently, Nasdaq Rule 5711(d)(iii)(A) defines a “Commodity-Based Trust Share” to mean, in part, a security that “is designed to reflect the performance of one or more reference assets or an index of reference assets, less expenses and other liabilities.” 
                    <SU>21</SU>
                    <FTREF/>
                     Thus, Nasdaq Rule 5711(d) currently precludes actively managed Commodity-Based Trust Shares from being eligible to list and trade pursuant to the generic listing standards (
                    <E T="03">i.e.,</E>
                     without a rule filing pursuant to Section 19(b) of the Act).
                    <SU>22</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(iii)(A)(2). 
                        <E T="03">See also</E>
                          
                        <E T="03">supra</E>
                         note 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release Nos. 105681 (June 12, 2026), 91 FR 36629 (June 17, 2026) (NYSEARCA-2025-77) (Order Granting Approval of a Proposed Rule Change, as Modified by Amendment No. 2 Thereto, To List and Trade Shares of the T. Rowe Price Active Crypto ETF under NYSE Arca Rule 8.201-E (Generic) 
                        <PRTPAGE/>
                        Commodity-Based Trust Shares) (“T. Rowe Order”) at 36630 n. 20; 105582 (May 29, 2026), 91 FR 33252 (June 3, 2026) (NASDAQ-2025-085) (Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment No. 1 Thereto, To List and Trade Shares of the iShares Bitcoin Premium Income ETF Under Nasdaq Rule 5711(d) (Commodity-Based Trust Shares)) (“iShares Order”) at 33252 n. 15.
                    </P>
                </FTNT>
                <PRTPAGE P="48206"/>
                <P>
                    The Exchange now proposes to amend Nasdaq Rule 5711(d) to allow for the generic listing and trading of actively managed Commodity-Based Trust Shares that otherwise meet the generic listing standards, as proposed to be amended.
                    <SU>23</SU>
                    <FTREF/>
                     In particular, the Exchange proposes to amend the definition of “Commodity-Based Trust Shares” to remove the requirement that Commodity-Based Trust Shares be “designed to reflect the performance of one or more reference assets or an index of reference assets, less expenses and other liabilities” and to add a requirement that a trust's holdings be “consistent with [its] investment objective and policies.” 
                    <SU>24</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See</E>
                         Notice at 36188-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See</E>
                         proposed Nasdaq Rule 5711(d)(iii)(A).
                    </P>
                </FTNT>
                <P>
                    In connection with this amendment to the definition of “Commodity-Based Trust Shares,” the Exchange also proposes to adopt certain additional trading halt and firewall requirements.
                    <SU>25</SU>
                    <FTREF/>
                     First, if the Exchange becomes aware that the information required by paragraph (v)(A) of Nasdaq Rule 5711(d) 
                    <SU>26</SU>
                    <FTREF/>
                     (
                    <E T="03">i.e.,</E>
                     the Commodity-Based Trust Shares' portfolio information) is not disseminated to all market participants at the same time, it will halt trading in the Commodity-Based Trust Shares until such time as the required information is available to all market participants.
                    <SU>27</SU>
                    <FTREF/>
                     Second, any person associated with, or that is an agent of, the trust (including the Reporting Authority) 
                    <SU>28</SU>
                    <FTREF/>
                     who has access to non-public information regarding the portfolio of the Commodity-Based Trust Shares, including any change thereto, must be subject to procedures designed to prevent the use and dissemination of material non-public information regarding the portfolio.
                    <SU>29</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         These additional proposed requirements would apply in addition to what is already required under Nasdaq Rules 5711(d)(ix) and (x). 
                        <E T="03">See</E>
                         Notice at 36188-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         Nasdaq Rule 5711(d)(v)(A)(v) requires that the trust disclose prominently on its website, which is publicly available and free of charge, before the opening of regular trading on the Exchange, for the trust's commodities, commodity-based assets, securities, cash and cash equivalent, to the extent applicable: (1) ticker symbol; (2) identifier; (3) description of the holding; (4) the quantity of each commodity, commodity-based asset, security, cash, and cash equivalent held; and (5) percentage weighting of the trust's assets.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See</E>
                         proposed Nasdaq Rules 5711(d)(ix)(A)(3); 5711(d)(ix)(B). The Exchange states that this additional requirement is substantively identical to a requirement in the Exchange's rule governing the listing and trading of actively managed ETFs. 
                        <E T="03">See</E>
                         Notice at 36189 (citing Nasdaq Rule 5735(d)(2)(D) (Managed Fund Shares)).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         The Exchange proposes to define the term “Reporting Authority” with respect to Commodity-Based Trust Shares to mean an institution or reporting service designated by the Exchange or the trust as the official source for calculating and reporting information relating to the Commodity-Based Trust Share, including, but not limited to, its portfolio, the amount of any cash distribution to holders of Commodity-Based Trust Shares, NAV, or other information relating to the issuance, redemption or trading of Commodity-Based Trust Shares. Each Commodity-Based Trust Shares may have more than one Reporting Authority, each having different functions. 
                        <E T="03">See</E>
                         proposed Nasdaq Rule 5711(d)(iii)(L). The Exchange states that Nasdaq Rule 5735(c)(4) (Managed Fund Shares) includes a similar definition of “Reporting Authority.” 
                        <E T="03">See</E>
                         Notice at 36188 n. 18. 
                        <E T="03">See also</E>
                         Nasdaq Rules 5704(a)(1)(C) (Exchange Traded Fund Shares); 5750(c)(3) (Proxy Portfolio Shares).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See</E>
                         proposed Nasdaq Rule 5711(d)(x)(3). The Exchange states that this additional requirement is substantively rooted in the current prohibitions against the use and dissemination of material non-public information within the Exchange's rules governing actively-managed ETFs, and would apply to anyone associated with, or is an agent of, the trust who has access to non-public information regarding the trust's portfolio. 
                        <E T="03">See</E>
                         Notice at 36188-9 (citing Nasdaq Rules 5735(g) (Managed Fund Shares); 5704(b)(1)(B)(i) and (ii) (Exchange Traded Fund Shares)).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">III. Discussion and Commission Findings</HD>
                <P>
                    After careful review, the Commission finds that the Proposal is consistent with the Act and rules and regulations thereunder applicable to a national securities exchange.
                    <SU>30</SU>
                    <FTREF/>
                     In particular, the Commission finds that the Proposal is consistent with Section 6(b)(5) of the Act,
                    <SU>31</SU>
                    <FTREF/>
                     which requires, among other things, that the Exchange's rules be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest and are not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         In approving the Proposal, the Commission has considered the Proposal's impacts on efficiency, competition, and capital formation. 
                        <E T="03">See</E>
                         15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>
                    Since the Generics Approval Order, the Commission has approved Commodity-Based Trust Shares that hold up to 15% of the portfolio in digital assets not previously approved by the Commission as permissible investments of an exchange-traded product (“ETP”).
                    <SU>32</SU>
                    <FTREF/>
                     In each of the Grayscale Order and the Bitwise Order, the Commission stated that the risks associated with fraud and manipulation are sufficiently mitigated if an ETP holds at least 80% of the investments in assets that do not raise concerns relating to fraud and manipulation.
                    <SU>33</SU>
                    <FTREF/>
                     Accordingly, the Commission found that the requirement that each ETP holds at least 85% of its investments in commodities approved by the Commission to underlie an ETP as primary investments will enable adequate surveillance of the shares on the listing exchange.
                    <SU>34</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release Nos. 103996 (Sept. 17, 2025), 90 FR 45440 (Sept. 22, 2025) (SR-NYSEARCA-2024-87) (Order Setting Aside Action by Delegated Authority and Approving a Proposed Rule Change, as Modified by Amendment No. 1, to Amend NYSE Arca Rule 8.500-E (Trust Units) and to List and Trade Shares of the Grayscale Digital Large Cap Fund LLC under Amended NYSE Arca Rule 8.500-E (Trust Units)) (“Grayscale Order”); and 104212 (Nov. 18, 2025), 90 FR 52724 (Nov. 21, 2025) (SR-NYSEARCA-2024-98) (Order Setting Aside Action by Delegated Authority and Approving a Proposed Rule Change, as Modified by Amendment No. 1, to Amend NYSE Arca Rule 8.500-E (Trust Units) and to List and Trade Shares of the Bitwise 10 Crypto Index ETF under Amended NYSE Arca Rule 8.500-E (Trust Units)) (“Bitwise Order”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         
                        <E T="03">See</E>
                         Grayscale Order at 45443; Bitwise Order at 52726.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         
                        <E T="03">See id.</E>
                         In each case, 85% of the ETP's holdings were in bitcoin and/or ether and the remainder of its holdings were in other digital assets.
                    </P>
                </FTNT>
                <P>
                    Likewise, since the Generics Approval Order, the Commission has approved Commodity-Based Trust Shares that are not “designed to reflect the performance of one or more reference assets or an index of reference assets” but are actively managed.
                    <SU>35</SU>
                    <FTREF/>
                     In each of the iShares Order and the T. Rowe Order, the Commission stated that, in the context of ETFs registered under the 1940 Act, the mere addition of active management to a portfolio that would otherwise qualify for generic listing as an index-based ETF does not affect the portfolio's susceptibility to manipulation or the availability of arbitrage between the ETF and its underlying portfolio.
                    <SU>36</SU>
                    <FTREF/>
                     The Commission stated that this principle also holds true for Commodity-Based Trust Shares.
                    <SU>37</SU>
                    <FTREF/>
                     Further, the Commission stated that consistently applying listing standards across products with economic exposures to the same underlying commodities levels the playing field between issuers, which should promote 
                    <PRTPAGE P="48207"/>
                    competition and would more readily afford investors greater investment options.
                    <SU>38</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         iShares Order, 
                        <E T="03">supra</E>
                         note 22; T. Rowe Order, 
                        <E T="03">supra</E>
                         note 22.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See</E>
                         iShares Order at 33252-3; T. Rowe Order at 36630. 
                        <E T="03">See also</E>
                         Securities Exchange Act Release Nos. 78396 (July 22, 2016), 81 FR 49698, 49702 (July 28, 2016) (SR-BATS-2015-100) (Order Approving Generic Listing Standards for Managed Fund Shares); and 78397 (July 22, 2016), 81 FR 49320, 49324-25 (July 27, 2016) (SR-NYSEArca-2015-110) (Order Approving Generic Listing Standards for Managed Fund Shares).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See</E>
                         iShares Order at 33253; T. Rowe Order at 36630.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">See id.</E>
                          
                        <E T="03">See also</E>
                         Generics Approval Order at 45419.
                    </P>
                </FTNT>
                <P>
                    Rule 19b-4(e) provides that the listing and trading of a new derivative securities product by a national securities exchange shall not be deemed a proposed rule change pursuant to paragraph (c)(1) of Rule 19b-4 
                    <SU>39</SU>
                    <FTREF/>
                     if the Commission has approved, pursuant to Section 19(b) of the Act,
                    <SU>40</SU>
                    <FTREF/>
                     the exchange's trading rules, procedures, and listing standards for the product class that would include the new derivative securities product, and the exchange has a surveillance program for the product class.
                    <SU>41</SU>
                    <FTREF/>
                     The Exchange proposes to amend its generic listing standards for Commodity-Based Trust Shares to include the 15% Buffer and active-management that the Commission has previously considered and approved in separate Rule 19b-4 filings. Accordingly, the Proposal fulfills the intended objective of Rule 19b-4(e) by permitting Commodity-Based Trust Shares that satisfy the requirements previously found to be consistent with the Act to commence trading without public comment and Commission approval.
                    <SU>42</SU>
                    <FTREF/>
                     The Exchange's ability to rely on Rule 19b-4(e) to list and trade additional Commodity-Based Trust Shares that meet the applicable requirements and minimum standards will reduce the time frame for bringing the shares to market and thereby reduce the burdens on issuers and other market participants, while also promoting competition.
                    <SU>43</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         17 CFR 240.19b-4(c)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         15 U.S.C. 78s(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.19b-4(e). 
                        <E T="03">See also</E>
                          
                        <E T="03">supra</E>
                         note 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         The failure of any particular Commodity-Based Trust Shares to satisfy the proposed generic listing standards pursuant to Rule 19b-4(e) would not preclude the Exchange from submitting a separate filing pursuant to Section 19(b) to list and trade those Commodity-Based Trust Shares. 
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         Nasdaq Rule 5711(d), as modified by the Proposal, also continues to require the Exchange to maintain surveillance procedures for Commodity-Based Trust Shares, consistent with the requirements of Rule 19b-4(e). 17 CFR 240.19b-4(e). 
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(viii)(B).
                    </P>
                </FTNT>
                <P>
                    Similarly, the Exchange's proposed additional trading halt and firewall provisions are consistent with the Act.
                    <SU>44</SU>
                    <FTREF/>
                     Because Nasdaq Rule 5711(d) currently contemplates only passive management,
                    <SU>45</SU>
                    <FTREF/>
                     the Exchange proposes changes designed to address active management of Commodity-Based Trust Shares, namely provisions related to (1) trading halts if Commodity-Based Trust Shares' portfolio information 
                    <SU>46</SU>
                    <FTREF/>
                     is not disseminated to all market participants at the same time,
                    <SU>47</SU>
                    <FTREF/>
                     and (2) procedures designed to prevent the use and dissemination of material non-public portfolio information.
                    <SU>48</SU>
                    <FTREF/>
                     The Exchange's proposed changes are substantively identical to Nasdaq's rule governing the listing and trading of actively managed ETFs,
                    <SU>49</SU>
                    <FTREF/>
                     and apply in addition to what is already required under Nasdaq Rule 5711(d)(ix). The additional trading halt provision will help to ensure that all market participants have transparency relating to the Commodity-Based Trust Shares' underlying portfolio, which information is key to pricing the shares and that no market participant has an unfair informational advantage. Ensuring such transparency relating to the underlying portfolio for all market participants will help facilitate a fair and orderly market for the Commodity-Based Trust Shares, as well as help to ensure that the Commodity-Based Trust Shares are not susceptible to manipulation. Likewise, the additional firewall provision will provide additional protection against the potential misuse of material, non-public information relating to a Commodity-Based Trust Share's actively-managed portfolio.
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Nasdaq Rules 5711(d)(viii)(B)(2) and 5711(d)(ix)(A)(1), requiring the Exchange to initiate delisting procedures and halt trading if the value of the underlying reference asset(s) or index is not made widely available on at least a 15-second basis from a source unaffiliated with the sponsor or the trust; Nasdaq Rule 5711(d)(x)(1), requiring that if the value of a Commodity-Based Trust Share is based on an index that is maintained by a broker-dealer, the broker-dealer erect and maintain a firewall around the personnel responsible for the maintenance of such index or who have access to information concerning changes and adjustments to the index; and Nasdaq Rule 5711(d)(x)(2), requiring that any advisory committee, supervisory board, or similar entity that advises an index licensor or administrator or that makes decisions regarding the index composition, methodology, and related matters must implement and maintain, or be subject to, procedures designed to prevent the use and dissemination of material, non-public information regarding the applicable index.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         
                        <E T="03">See supra</E>
                         note 26.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         
                        <E T="03">See supra</E>
                         note 27 and accompanying text.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See supra</E>
                         note 29 and accompanying text.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rules 5735(d)(2)(D) (Managed Fund Shares) (setting forth trading halt requirement if certain information with respect to a series of Managed Fund Shares is not disseminated to all market participants at the same time); 5750(d)(2)(D)(ii) (Proxy Portfolio Shares) (setting forth trading halt requirement if certain information with respect to a series of Proxy Portfolio Shares is not being made available to all market participants at the same time). 
                        <E T="03">See also</E>
                         Nasdaq Rules 5735(g) (Managed Fund Shares) (setting forth firewall and procedure requirements that apply to the investment adviser to the investment company issuing Managed Fund Shares and to personnel who make decisions on the investment company's portfolio composition); 5704(b)(1)(B)(i) (Exchange Traded Fund Shares) (setting forth firewall and procedure requirements that apply to the investment adviser to an Exchange Traded Fund and to personnel who make decisions on the Exchange Traded Fund's portfolio composition), 5704(b)(1)(B)(ii) (Exchange Traded Fund Shares) (setting forth procedure requirements that apply to the “Reporting Authority” that provides information relating to the Exchange Traded Fund's portfolio) and 5750(b)(6) (Proxy Portfolio Shares) (setting forth procedure and firewall requirements that apply to any person or entity, including a Reporting Authority, who has access to nonpublic information regarding the fund's portfolio). Further, these requirements are substantially similar to requirements applicable to actively-managed Commodity-Based Trust Shares previously approved by the Commission. 
                        <E T="03">See</E>
                         iShares Order at 33253-4; T. Rowe Order at 36630-1.
                    </P>
                </FTNT>
                <P>
                    Finally, Commodity-Based Trust Shares listed pursuant to Nasdaq Rule 5711(d), as modified by the Proposal, would be required to comply with all applicable requirements of Nasdaq Rule 5711(d). In addition, all Commodity-Based Trust Shares listed under Nasdaq Rule 5711(d) will be subject to the rules and procedures of the Exchange that currently govern the trading of equity securities on the Exchange.
                    <SU>50</SU>
                    <FTREF/>
                     The Exchange would continue to be required to submit a rule filing with the Commission when seeking to list and trade Commodity-Based Trust Shares that do not meet the generic listing standards under Nasdaq Rule 5711(d), as proposed to be modified.
                </P>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         
                        <E T="03">See</E>
                         Nasdaq Rule 5711(d)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Conclusion</HD>
                <P>
                    This approval order is based on all of the Exchange's representations and descriptions in the Proposal, which the Commission has evaluated as discussed above. For the reasons set forth above, the Commission finds, pursuant to Section 19(b)(2) of the Act,
                    <SU>51</SU>
                    <FTREF/>
                     that the Proposal is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange, and in particular, with Section 6(b)(5) of the Act.
                    <SU>52</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>
                    <E T="03">It is therefore ordered,</E>
                     pursuant to Section 19(b)(2) of the Act,
                    <SU>53</SU>
                    <FTREF/>
                     that the proposed rule change, as modified by Amendment No. 1 (SR-NASDAQ-2026-032), be, and hereby is, approved.
                </P>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>54</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>54</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2026-15327 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48208"/>
                <AGENCY TYPE="N">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <SUBJECT>Notice of Availability of the Final Programmatic Environmental Assessment and FONSI/ROD</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Federal Aviation Administration (FAA) announces the availability of the Final Programmatic Environmental Assessment (PEA) and Finding of No Significant Impact (FONSI)/Record of Decision (ROD), following the FAA's evaluation of the potential environmental effects of its decision related to unmanned aircraft systems (UAS) (drone) package delivery operations in the United States.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For questions concerning this action, contact AFS-700 Emerging Technologies Division, Office of Safety Standards, Flight Standards Service; email: 
                        <E T="03">9-FAA-Drone-Environmental@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The final PEA evaluates the reasonably foreseeable environmental impacts of UAS (drone) package delivery operations in the United States. The proposed action analyzed in the final PEA is for drone operators conducting commercial drone package deliveries under 14 Code of Federal Regulations (CFR) part 135.</P>
                <P>
                    The FAA prepared the final PEA in accordance with the National Environmental Policy Act (NEPA) (42 United States Code [U.S.C.] 4321 
                    <E T="03">et seq.</E>
                    ), USDOT Order 5610.1D 
                    <E T="03">DOT's Procedures for Considering Environmental Impacts,</E>
                     and FAA Order 1050.1G 
                    <E T="03">FAA National Environmental Policy Act Implementing Procedures.</E>
                     The final PEA evaluates the potential impacts of the proposed action and no action alternative to all environmental impact categories identified in FAA Order 1050.1.G. A notice of availability of the draft PEA and request for comments was published in the 
                    <E T="04">Federal Register</E>
                     on December 9, 2025. Upon request, the public comment period was extended by fifteen days for a total of forty-five days, ending on January 23, 2026. Based on the FAA's review and analysis and consideration of comments, the FAA has determined that, with implementation of the mitigation measures provided in the final PEA, the proposed action would not result in significant impacts.
                </P>
                <P>
                    The FONSI/ROD and final PEA are available to view and download electronically at 
                    <E T="03">https://www.faa.gov/uas/advanced_operations/nepa_and_drones/.</E>
                     The documentation is available from any internet access including from computers freely available at public libraries.
                </P>
                <SIG>
                    <DATED>Issued in Washington, DC, on July 28, 2026.</DATED>
                    <NAME>Derek W. Hufty,</NAME>
                    <TITLE>Manager, General Aviation and Commercial Branch, Emerging Technologies Division, Office of Safety Standards, Flight Standards Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15417 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Motor Carrier Safety Administration</SUBAGY>
                <DEPDOC>[Docket No. FMCSA-2019-0069]</DEPDOC>
                <SUBJECT>Parts and Accessories Necessary for Safe Operation; Application for Exemption Renewal From Charles Machine Works, Inc.</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of application for renewal of exemption; withdrawal.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>FMCSA withdraws its January 16, 2026, notice that requested public comment on an application from Charles Machine Works, Inc. (CMW) seeking renewal of a five-year exemption from the Agency's prohibition against the use of gravity-fed or siphon-fed fuel systems on commercial motor vehicles (CMVs). FMCSA has determined that the Agency's February 19, 2026, final rule titled “Parts and Accessories Necessary for Safe Operation; Auxiliary Fuel Tanks,” provided the requested relief by amending the relevant regulation in a way that resolves the concerns outlined in CMW's original exemption request. Consequently, the exemption is now unnecessary, not only for CMW but also for any other entities that might have planned to request an exemption from the prohibition on gravity-fed or siphon-fed fuel systems on CMVs.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Mr. Jose Cestero, Mechanical Engineer, FMCSA, Vehicle and Roadside Operations Division, Office of Carrier, Driver, and Vehicle Safety Standards; (202) 366-5541; 
                        <E T="03">MCPSV@dot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>Section 393.65 of the Federal Motor Carrier Safety Regulations (49 CFR 393.65) establishes requirements applicable to all CMV fuel systems, including those supplying fuel to auxiliary equipment. These requirements apply to systems used for containing and supplying fuel for the operation of (1) motor vehicles or (2) auxiliary equipment installed on, or used in connection with, motor vehicles. Specifically, § 393.65(d) generally prohibits a fuel system from supplying fuel by gravity or siphon feed directly to the carburetor or injectors.</P>
                <P>On September 16, 2020, FMCSA published a notice of final disposition granting CMW's application for a five-year exemption from § 393.65(d) to allow the use of gravity or syphon-fed fuel systems for auxiliary equipment that operates only when the CMV is stationary (85 FR 57928).</P>
                <P>
                    On January 16, 2026, FMCSA published a notice in the 
                    <E T="04">Federal Register</E>
                     requesting public comments on CMW's application for renewal of its exemption (91 FR 2271),
                </P>
                <P>FMCSA subsequently issued a final rule titled “Parts and Accessories Necessary for Safe Operation; Auxiliary Fuel Tanks,” published on February 19, 2026 (91 FR 7890). The final rule amended 49 CFR 393.65(d) to add an exception to the prohibition on gravity and siphon feeds for auxiliary pumps with a nominal fuel tank capacity of not more than five gallons mounted on the trailer chassis frame or trailer bed, for purposes other than the operation of the motor vehicle, that are operated only when the motor vehicle is not in motion.</P>
                <P>As a result of the regulatory amendment, motor carriers and equipment manufacturers may operate in accordance with the revised requirements in 49 CFR 393.65(d) without the need for an exemption. Because the amended regulation provides the regulatory relief sought by CMW, the exemption is no longer necessary. Accordingly, FMCSA considers CMW's request for a renewal of the exemption to be closed, as of March 23, 2026, the effective date of February 19, 2026, final rule rendering the requested exemption unnecessary. Therefore, FMCSA withdraws its January 16, 2026, notice.</P>
                <SIG>
                    <NAME>Larry W. Minor,</NAME>
                    <TITLE>Associate Administrator for Policy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15431 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-EX-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="48209"/>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Motor Carrier Safety Administration</SUBAGY>
                <DEPDOC>[Docket No. FMCSA-2026-1520]</DEPDOC>
                <SUBJECT>Hours of Service (HOS) of Drivers: Precision Fireworks LLC; Application for Exemption</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of application for exemption; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>FMCSA requests public comment on Precision Fireworks LLC's (Precision) application for exemption from the HOS requirement that drivers of commercial motor vehicles (CMVs) must not drive following the 14th hour after coming on duty. FMCSA is required by statute to publish a notice explaining each exemption request. This notice does not indicate what decision FMCSA will ultimately reach on the request. After reviewing the application, safety analyses, and public comments submitted, FMCSA will grant or deny the exemption.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by Docket Number FMCSA 2026-1520 by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal: www.regulations.gov.</E>
                         See the Public Participation and Request for Comments section below for further information.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Dockets Operations, U.S. Department of Transportation, 1200 New Jersey Avenue SE, W58-213, West Building, Washington, DC 20590-0001.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery or Courier:</E>
                         1200 New Jersey Avenue SE, W58-213, West Building, Washington, DC 20590-0001, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         (202) 493-2251. Each submission must include the Agency name and the docket number (FMCSA-2026-1520) for this notice. Note that DOT posts all comments received without change to 
                        <E T="03">www.regulations.gov,</E>
                         including any personal information included in a comment. Please see the Privacy Act heading below.
                    </P>
                    <P>
                        <E T="03">Privacy Act:</E>
                         In accordance with 49 U.S.C. 31315(b), DOT solicits comments from the public to better inform its exemption process. DOT posts these comments, including any personal information the commenter provides, to 
                        <E T="03">www.regulations.gov,</E>
                         as described in the system of records notice DOT/ALL-14 FDMS (Federal Docket Management System (FDMS)), which can be reviewed at 
                        <E T="03">https://www.transportation.gov/individuals/privacy/privacy-act-system-records-notices.</E>
                         The comments are posted without edit and are searchable by the name of the submitter.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Ms. Pearlie Robinson, FMCSA Driver and Carrier Operations Division; Office of Carrier, Driver and Vehicle Safety Standards; 
                        <E T="03">pearlie.robinson@dot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Public Participation and Request for Comments</HD>
                <P>FMCSA encourages you to participate by submitting comments and related materials.</P>
                <HD SOURCE="HD2">A. Submitting Comments</HD>
                <P>If you submit a comment, please include the docket number for this notice (FMCSA-2026-1520), indicate the specific section of this document to which the comment applies, and provide a reason for your suggestions or recommendations. You may submit your comments and material online or by fax, mail, or hand delivery, but please use only one of these means. FMCSA recommends that you include your name and a mailing address, an email address, or a phone number in the body of your document so the Agency can contact you if it has questions regarding your submission.</P>
                <P>
                    To submit your comment online, go to 
                    <E T="03">https://www.regulations.gov/docket/FMCSA-2026-1520/document,</E>
                     click on this notice, click “Comment,” and type your comment into the text box on the following screen.
                </P>
                <P>
                    If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8
                    <FR>1/2</FR>
                     by 11 inches, suitable for copying and electronic filing.
                </P>
                <P>FMCSA will consider all comments and material received during the comment period. Comments received after the comment closing date will be filed in the public docket and will be considered to the extent practicable.</P>
                <HD SOURCE="HD2">B. Confidential Business Information (CBI)</HD>
                <P>
                    CBI is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments responsive to the notice contain commercial or financial information that is customarily treated as private, that you actually treat as private, and that is relevant or responsive to the notice, it is important that you clearly designate the submitted comments as CBI. Please mark each page of your submission that constitutes CBI as “PROPIN” to indicate it contains proprietary information. FMCSA will treat such marked submissions as confidential under the Freedom of Information Act, and they will not be placed in the public docket of the notice. Submissions containing CBI should be sent to Brian Dahlin, Chief, Regulatory Evaluation Division, Office of Policy, FMCSA, 1200 New Jersey Avenue SE, Washington, DC 20590-0001 or via email at 
                    <E T="03">brian.g.dahlin@dot.gov.</E>
                     At this time, you need not send a duplicate hardcopy of your electronic CBI submissions to FMCSA headquarters. Any comments FMCSA receives not specifically designated as CBI will be placed in the public docket for this notice.
                </P>
                <HD SOURCE="HD2">C. Viewing Comments and Documents</HD>
                <P>
                    To view comments, as well as any documents mentioned in this preamble as being available in the docket, go to 
                    <E T="03">https://www.regulations.gov,</E>
                     insert FMCSA-2026-1520 in the keyword box, select the document tab and choose the document to review. To view comments, click this notice, then click “Browse Comments.” If you do not have access to the internet, you may view the docket by visiting Dockets Operations in Room W58-213 of the DOT West Building, 1200 New Jersey Avenue SE, West Building, Washington, DC 20590-0001, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                </P>
                <HD SOURCE="HD1">II. Legal Basis</HD>
                <P>
                    FMCSA has authority under 49 U.S.C. 31136(e) and 31315(b) to grant exemptions from the Federal Motor Carrier Safety Regulations (FMCSRs). FMCSA must publish a notice of each exemption request in the 
                    <E T="04">Federal Register</E>
                     (49 CFR 381.315(a)). The Agency must provide the public an opportunity to inspect the information relevant to the application, including the applicant's safety analysis. The Agency must provide an opportunity for public comment on the request.
                </P>
                <P>
                    The Agency reviews the application, safety analyses, and public comments submitted and determines whether granting the exemption would likely achieve a level of safety equivalent to, or greater than, the level that would be achieved absent such exemption, pursuant to the standard set forth in 49 U.S.C. 31315(b)(1). The Agency must publish its decision in the 
                    <E T="04">Federal Register</E>
                     (49 CFR 381.315(b)). If granted, the notice will identify the regulatory provision(s) from which the exempted party will be exempt, the effective 
                    <PRTPAGE P="48210"/>
                    period, and all terms and conditions of the exemption (49 CFR 381.315(c)(1)). If the exemption is denied, the notice will explain the reason for the denial (49 CFR 381.315(c)(2)). The exemption may be renewed (49 CFR 381.300(b)).
                </P>
                <HD SOURCE="HD1">III. Applicant's Request</HD>
                <HD SOURCE="HD2">Current Regulatory Requirements</HD>
                <P>The HOS rule in 49 CFR 395.3(a)(2) prohibits a property-carrying CMV driver from driving a CMV after the 14th hour after coming on duty following 10 consecutive hours off duty.</P>
                <HD SOURCE="HD2">Applicant's Request</HD>
                <P>Precision, USDOT # 3129980, is a fireworks display company that employs CMV drivers who hold commercial driver's licenses (CDL) with hazardous materials endorsements to transport Division 1.1G, 1.3G and 1.4G fireworks in conjunction with the setup of firework displays for Independence Day. The applicant seeks an exemption from the 14-hour rule in 49 CFR 395.3(a)(2) so that drivers would be allowed to exclude off-duty and sleeper-berth time of any length from the calculation of the 14 hours. The exemption, if granted, would apply to approximately 5 drivers of 5 CMVs employed by the applicant in conjunction with staging fireworks displays celebrating Independence Day during the period June 28-July 8, for the next five years (2026-2031) inclusive. As a condition for operating under the requested exemption, drivers would not be allowed to drive after accumulating a total of 14 hours of on-duty time, following 10 consecutive hours off duty, and would continue to be subject to the 11-hour driving time limit, and the 60- and 70-hour on-duty limits.</P>
                <P>The applicant asserts that denial of the exemption would create significant economic hardship and public safety risks. Without the exemption the applicant would be unable to provide professional fireworks displays for Texas, New Mexico and Missouri because it cannot find sufficient CDL-qualified, hazmat-endorsed seasonal drivers to meet the demand within the strict 14-hour window. Furthermore, it would lead to the unsecure parking of hazardous materials (Division 1.1G, 1.3G and 1.4G products) in public areas.</P>
                <HD SOURCE="HD2">Applicant's Equivalent Level of Safety</HD>
                <P>According to the application for exemption, “Precision Fireworks LLC will ensure a level of safety equivalent to or greater than the current regulations by:</P>
                <P>
                    • 
                    <E T="03">Short-Distance Routes:</E>
                     Our routes during this period are typically, but not limited to, within 150 miles from our distribution point to the display site.
                </P>
                <P>
                    • 
                    <E T="03">Mandatory Rest Periods:</E>
                     Drivers are required to take significant off-duty rest periods at the show site during the afternoon and early evening while waiting for the display to begin.
                </P>
                <P>
                    • 
                    <E T="03">Early Morning Driving:</E>
                     Most transit occurs in the early morning when traffic density is lowest.
                </P>
                <P>
                    • 
                    <E T="03">Safety Record:</E>
                     Our company has zero reportable crashes in the last 10 years while operating during the Independence Day season.”
                </P>
                <P>A copy of the applicant's application for exemption is available for review in the docket for this notice.</P>
                <HD SOURCE="HD1">IV. Request for Comments</HD>
                <P>In accordance with 49 U.S.C. 31315(b), FMCSA requests public comment from all interested persons on Precision Fireworks LLC's application for an exemption from the requirement of 49 CFR 395.3(a)(2). All comments received before the close of business on the comment closing date will be considered and will be available for examination in the docket at the location listed under the Addresses section of this notice. Comments received after the comment closing date will be filed in the public docket and will be considered to the extent practicable. In addition to late comments, FMCSA will also continue to file, in the public docket, relevant information that becomes available after the comment closing date. Interested persons should continue to examine the public docket for new material.</P>
                <SIG>
                    <NAME>Larry W. Minor,</NAME>
                    <TITLE>Associate Administrator of Policy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15430 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-EX-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Motor Carrier Safety Administration</SUBAGY>
                <DEPDOC>[Docket No. FMCSA-2026-0859]</DEPDOC>
                <SUBJECT>Parts and Accessories Necessary for Safe Operation; Application for Exemption From Transit Solutions, LLC</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of application for exemption; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>FMCSA requests public comments on an application for exemption submitted by Transit Solutions, LLC (dba TSI Video) to allow motor carriers to operate commercial motor vehicles (CMV) equipped with TSI's ClearView E-Mirror camera monitor system (CMS) installed as an alternative to the two rear-vision mirrors required by the Federal Motor Carrier Safety Regulations (FMCSRs). FMCSA is required by statute to publish a notice explaining each exemption request and such notice does not indicate what decision FMCSA will ultimately reach on the request. After reviewing the application, safety analyses, and public comments submitted, FMCSA will grant or deny the exemption.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by Docket Number FMCSA-2026-0859 by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                          
                        <E T="03">www.regulations.gov.</E>
                         See the Public Participation and Request for Comments section below for further information.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Dockets Operations, U.S. Department of Transportation, 1200 New Jersey Avenue SE, W58-213, West Building, Washington, DC 20590-0001.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery or Courier:</E>
                         1200 New Jersey Avenue SE, W58-213, West Building, Washington, DC 20590-0001 between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         (202) 493-2251.
                    </P>
                    <P>
                        Each submission must include the Agency name and the docket number (FMCSA-2026-0859) for this notice. Note that DOT posts all comments received without change to 
                        <E T="03">www.regulations.gov,</E>
                         including any personal information included in a comment. Please see the Privacy Act heading below.
                    </P>
                    <P>
                        <E T="03">Privacy Act:</E>
                         In accordance with 49 U.S.C. 31315(b), DOT solicits comments from the public to better inform its exemption process. DOT posts these comments, including any personal information the commenter provides, to 
                        <E T="03">www.regulations.gov,</E>
                         as described in the system of records notice DOT/ALL-14 FDMS (Federal Docket Management System (FDMS)), which can be reviewed at 
                        <E T="03">https://www.transportation.gov/individuals/privacy/privacy-act-system-records-notices.</E>
                         The comments are posted without edit and are searchable by the name of the submitter.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Mr. Jose Moreno, Vehicle and Roadside Operations Division, Office of Carrier, Driver, and Vehicle Safety, FMCSA; (202)-961-1373, or by email at 
                        <E T="03">MCPSV@dot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">
                    SUPPLEMENTARY INFORMATION:
                    <PRTPAGE P="48211"/>
                </HD>
                <HD SOURCE="HD1">I. Public Participation and Request for Comments</HD>
                <P>FMCSA encourages you to participate by submitting comments and related materials.</P>
                <HD SOURCE="HD2">A. Submitting Comments</HD>
                <P>If you submit a comment, please include the docket number for this notice (FMCSA-2026-0859), indicate the specific section of this document to which the comment applies, and provide a reason for your suggestions or recommendations. You may submit your comments and material online or by fax, mail, or hand delivery, but please use only one of these means. FMCSA recommends that you include your name and a mailing address, an email address, or a phone number in the body of your document so the Agency can contact you if it has questions regarding your submission.</P>
                <P>
                    To submit your comment online, go to 
                    <E T="03">https://www.regulations.gov/docket/FMCSA-2026-0859/document,</E>
                     click on this notice, click “Comment,” and type your comment into the text box on the following screen.
                </P>
                <P>
                    If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8
                    <FR>1/2</FR>
                     by 11 inches, suitable for copying and electronic filing.
                </P>
                <P>FMCSA will consider all comments and material received during the comment period. Comments received after the comment closing date will be filed in the public docket and will be considered to the extent practicable.</P>
                <HD SOURCE="HD2">B. Confidential Business Information (CBI)</HD>
                <P>
                    CBI is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments responsive to the notice contain commercial or financial information that is customarily treated as private, that you actually treat as private, and that is relevant or responsive to the notice, it is important that you clearly designate the submitted comments as CBI. Please mark each page of your submission that constitutes CBI as “PROPIN” to indicate it contains proprietary information. FMCSA will treat such marked submissions as confidential under the Freedom of Information Act, and they will not be placed in the public docket of the notice. Submissions containing CBI should be sent to Brian Dahlin, Chief, Regulatory Evaluation Division, Office of Policy, FMCSA, 1200 New Jersey Avenue SE, Washington, DC 20590-0001 or via email at 
                    <E T="03">brian.g.dahlin@dot.gov.</E>
                     At this time, you need not send a duplicate hardcopy of your electronic CBI submissions to FMCSA headquarters. Any comments FMCSA receives not specifically designated as CBI will be placed in the public docket for this notice.
                </P>
                <HD SOURCE="HD2">C. Viewing Comments and Documents</HD>
                <P>
                    To view comments, as well as any documents mentioned in this preamble as being available in the docket, go to 
                    <E T="03">https://www.regulations.gov,</E>
                     insert FMCSA-2026-0859 in the keyword box, select the document tab and choose the document to review. To view comments, click this notice, then click “Browse Comments.” If you do not have access to the internet, you may view the docket by visiting Dockets Operations in room W58-213 of the DOT West Building, 1200 New Jersey Avenue SE, West Building, Washington, DC 20590-0001, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                </P>
                <HD SOURCE="HD1">II. Legal Basis</HD>
                <P>
                    FMCSA has authority under 49 U.S.C. 31136(e) and 31315(b) to grant exemptions from the Federal Motor Carrier Safety Regulations (FMCSRs). FMCSA must publish a notice of each exemption request in the 
                    <E T="04">Federal Register</E>
                     (49 CFR 381.315(a)). The Agency must provide the public an opportunity to inspect the information relevant to the application, including the applicant's safety analysis. The Agency must provide an opportunity for public comment on the request.
                </P>
                <P>
                    The Agency reviews the application, safety analyses, and public comments submitted and determines whether granting the exemption would likely achieve a level of safety equivalent to, or greater than, the level that would be achieved absent such exemption, pursuant to the standard set forth in 49 U.S.C. 31315(b)(1). The Agency must publish its decision in the 
                    <E T="04">Federal Register</E>
                     (49 CFR 381.315(b)). If granted, the notice will identify the regulatory provision(s) from which the exempted party will be exempt, the effective period, and all terms and conditions of the exemption (49 CFR 381.315(c)(1)). If the exemption is denied, the notice will explain the reason for the denial (49 CFR 381.315(c)(2)). The exemption may be renewed (49 CFR 381.300(b)).
                </P>
                <HD SOURCE="HD1">III. Applicant's Request</HD>
                <HD SOURCE="HD2">Current Regulatory Requirements</HD>
                <P>Section 393.80(a) of the FMCSRs requires that each bus, truck, and truck-tractor operating in interstate commerce be equipped with two rear-vision mirrors, one at each side. The mirrors must be positioned to reflect to the driver a view of the highway to the rear and the area along both sides of the CMV. Section 393.80(a) cross-references the National Highway Traffic Safety Administration's standards for mirrors on motor vehicles (49 CFR 571.111, Federal Motor Vehicle Safety Standard (FMVSS) No. 111). Paragraph S7.1 of FMVSS No. 111 provides requirements for mirrors on multipurpose passenger vehicles and trucks with a gross vehicle weight rating (GVWR) greater than 4,536 kg and less than 11,340 kg and each bus, other than a school bus, with a GVWR of more than 4,536 kg. Paragraph S8.1 provides requirements for mirrors on multipurpose passenger vehicles and trucks with a GVWR of 11,340 kg or more.</P>
                <HD SOURCE="HD2">Applicant's Request</HD>
                <P>TSI Video has applied for an exemption from § 393.80(a) to allow motor carriers (including operators of public transit buses) to equip their fleets with the company's “TSI ClearView E-Mirror” installed as an alternative to the two rear-vision mirrors required by the FMCSRs. This technology is generally considered a camera-based rear visibility system, or Camera Monitor System (CMS). According to TSI Video, its system provides an equal or greater level of safety than traditional mirrors through an expanded field of view, improved low-light/glare performance, blind-spot reduction, and fail-safe diagnostics and driver alerts.</P>
                <P>TSI Video states its ClearView E-Mirror meets or exceeds FMVSS 111 safety standards by providing a more comprehensive field of view that covers Class II, IV, and V requirements, in addition to international standards such as UNECE R46. TSI Video also states that its ClearView E-Mirror also improves driver situational awareness by offering a superior field of view and higher image quality than conventional mirror assemblies. Further, TSI Video states its ClearView E-mirror uses high-dynamic-range cameras and advanced sensors, ensuring the system provides reliable visibility by mitigating glare from light sources and maintaining high object definition in low-light environments.</P>
                <P>
                    TSI Video also uses optimized AI models for edge detection and object classification to continuously identify pedestrians and obstacles in the vehicle's environment. This real-time detection capability alerts drivers via the in-cab monitor and LED indicators, significantly improving safety during 
                    <PRTPAGE P="48212"/>
                    complex maneuvers and in low-visibility conditions.
                </P>
                <P>Public transit buses are generally not subject to the FMCSRs because they operate in intrastate commerce. Further, transit operations that do operate in interstate commerce are generally not subject to the FMCSRs as they are covered by the exception for transportation performed by a State or any political subdivision of a State under 49 CFR 390.3T(f)(2). TSI Video confirmed to FMCSA staff that its camera system would be used in CMVs subject to the FMCSRs.</P>
                <P>A copy of TSI Video's application for exemption, and all supporting materials, are available for review in the docket for this notice.</P>
                <HD SOURCE="HD1">IV. Request for Comments</HD>
                <P>In accordance with 49 U.S.C. 31315(b), FMCSA requests public comment from all interested persons on TSI Video's application for a 5-year exemption from 49 CFR 393.80(a). All comments received before the close of business on the comment closing date will be considered and will be available for examination in the docket at the location listed under the Addresses section of this notice. Comments received after the comment closing date will be filed in the public docket and will be considered to the extent practicable. In addition to late comments, FMCSA will also continue to file, in the public docket, relevant information that becomes available after the comment closing date. Interested persons should continue to examine the public docket for new material.</P>
                <SIG>
                    <NAME>Larry W. Minor,</NAME>
                    <TITLE>Associate Administrator for Policy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15414 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-EX-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Maritime Administration</SUBAGY>
                <DEPDOC>[Docket No. MARAD-2026-1160]</DEPDOC>
                <SUBJECT>Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V APERITIVO</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Maritime Administration (MARAD), U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Secretary of Transportation, as represented by MARAD, is authorized to make determinations regarding the coastwise use of foreign built; certain U.S. built; and U.S. and foreign rebuilt vessels that solely carry no more than twelve passengers for hire. MARAD has received such a determination request and is publishing this notice to solicit comments to assist with determining whether the proposed use of the vessel set forth in the request would have an adverse effect on U.S. vessel builders or U.S. coastwise trade businesses that use U.S.-built vessels in those businesses. Information about the requestor's vessel, including a description of the proposed service, is in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section below.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by DOT Docket Number MARAD-2026-1160 by any one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Search the above DOT Docket Number and follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail or Hand Delivery:</E>
                         Docket Management Facility is in the West Building, Ground Floor of the U.S. Department of Transportation. The Docket Management Facility location address is U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except on Federal holidays.
                    </P>
                    <P>
                        <E T="03">Note:</E>
                         If you mail or hand-deliver your comments, we recommend that you include the DOT Docket Number, your name and a mailing address, an email address or a telephone number in the body of your document so that we can contact you if we have questions regarding your submission.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the agency name and specific DOT Docket Number. All comments received will be posted without change to the docket at 
                        <E T="03">www.regulations.gov,</E>
                         including any personal information provided. For detailed instructions on submitting comments, or to submit comments that are confidential in nature, see the section entitled Public Participation.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Patricia Hagerty, U.S. Department of Transportation, Maritime Administration, 1200 New Jersey Avenue SE, Mail Stop 2, MAR-620, Washington, DC 20590. Telephone: (202) 366-5400. Email: 
                        <E T="03">smallvessels@dot.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Pursuant to 46 U.S.C. 12121(b), the U.S. Coast Guard may issue a certificate of documentation with a coastwise trade endorsement for eligible, small passenger vessels authorized to carry no more than 12 passengers for hire if MARAD, after notice and an opportunity for public comment, determines the use of the small passenger vessel in the coastwise trade will not adversely affect United States vessel builders or the coastwise trade business of any person that employs vessels built in the United States in that business.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The U.S. Coast Guard and MARAD have authority under 46 U.S.C. 12121(b) through the Secretary of the Department of Homeland Security and the Secretary of the Department of Transportation, respectively.
                    </P>
                </FTNT>
                <P>
                    MARAD has received an eligibility determination request. Further details about the requester's vessel and its proposed operations may be found in the determination request posted in the DOT Docket Number listed in the 
                    <E T="02">ADDRESSES</E>
                     section above at 
                    <E T="03">https://www.regulations.gov.</E>
                     Interested parties may comment on the undue adverse effect this action may have on U.S. vessel builders or coastwise trade businesses in the U.S. that employ U.S.-built vessels in those businesses. Comments should refer to the vessel name, state the commenter's interest in the request, and demonstrate, with supporting documentation, the undue adverse effect on U.S. vessel builders and coastwise trade businesses.
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <HD SOURCE="HD2">How do I submit comments?</HD>
                <P>
                    Please submit comments, including the attachments, following the instructions provided under the above heading entitled 
                    <E T="02">ADDRESSES</E>
                    . It may take a few hours or even days for comments to be reflected on the docket. Comments must be written in English. Provide concise comments and attach additional documents as necessary. There is no limit on the length of the attachments.
                </P>
                <HD SOURCE="HD2">Where do I go to read public comments, and find supporting information?</HD>
                <P>
                    The docket online is located at 
                    <E T="03">https://www.regulations.gov,</E>
                     keyword search the DOT Docket Number list in the 
                    <E T="02">ADDRESSES</E>
                     section above or visit the Docket Management Facility (see 
                    <E T="02">ADDRESSES</E>
                     for hours of operation). Please periodically check the Docket for new submissions and supporting material.
                </P>
                <HD SOURCE="HD2">Will my comments be made available to the public?</HD>
                <P>
                    Yes. Your entire comment, including your personal identifying information, will be made publicly available.
                    <PRTPAGE P="48213"/>
                </P>
                <HD SOURCE="HD2">May I submit comments confidentially?</HD>
                <P>
                    You may request that MARAD treat your comments as commercially confidential by submitting them to 
                    <E T="03">SmallVessels@dot.gov.</E>
                     Include in the email subject heading “Contains Confidential Commercial Information” or “Contains CCI” and state in your submission, with specificity, the basis for any such confidential treatment highlighting the CCI portions. If possible, please provide a summary of your submission that can be made available to the public.
                </P>
                <P>If MARAD receives a Freedom of Information Act (FOIA) request for the information, procedures described in the Department's FOIA regulation at 49 CFR 7.29 will be followed. Only information that is ultimately determined to be confidential under those procedures will be exempt from disclosure under FOIA.</P>
                <HD SOURCE="HD1">Privacy Act</HD>
                <P>
                    Anyone can search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). For information on DOT's compliance with the Privacy Act, please visit 
                    <E T="03">https://www.transportation.gov/privacy.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 46 U.S.C. 12121, 49 CFR 1.93(a).)</FP>
                </EXTRACT>
                <SIG>
                    <FP>By Order of the Maritime Administrator.</FP>
                    <NAME>T. Mitchell Hudson, Jr.,</NAME>
                    <TITLE>Secretary, Maritime Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15382 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-81-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Maritime Administration</SUBAGY>
                <DEPDOC>[Docket No. MARAD-2026-1157]</DEPDOC>
                <SUBJECT>Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V LYNX</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Maritime Administration (MARAD), U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Secretary of Transportation, as represented by MARAD, is authorized to make determinations regarding the coastwise use of foreign built; certain U.S. built; and U.S. and foreign rebuilt vessels that solely carry no more than twelve passengers for hire. MARAD has received such a determination request and is publishing this notice to solicit comments to assist with determining whether the proposed use of the vessel set forth in the request would have an adverse effect on U.S. vessel builders or U.S. coastwise trade businesses that use U.S.-built vessels in those businesses. Information about the requestor's vessel, including a description of the proposed service, is in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section below.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>ou may submit comments identified by DOT Docket Number MARAD-2026-1157 by any one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Search the above DOT Docket Number and follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail or Hand Delivery:</E>
                         Docket Management Facility is in the West Building, Ground Floor of the U.S. Department of Transportation. The Docket Management Facility location address is U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except on Federal holidays.
                    </P>
                    <P>
                        <E T="03">Note:</E>
                         If you mail or hand-deliver your comments, we recommend that you include the DOT Docket Number, your name and a mailing address, an email address or a telephone number in the body of your document so that we can contact you if we have questions regarding your submission.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the agency name and specific DOT Docket Number. All comments received will be posted without change to the docket at 
                        <E T="03">www.regulations.gov,</E>
                         including any personal information provided. For detailed instructions on submitting comments, or to submit comments that are confidential in nature, see the section entitled Public Participation.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Patricia Hagerty, U.S. Department of Transportation, Maritime Administration, 1200 New Jersey Avenue SE, Mail Stop 2, MAR-620, Washington, DC 20590. Telephone: (202) 366-5400. Email: 
                        <E T="03">smallvessels@dot.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Pursuant to 46 U.S.C. 12121(b), the U.S. Coast Guard may issue a certificate of documentation with a coastwise trade endorsement for eligible, small passenger vessels authorized to carry no more than 12 passengers for hire if MARAD, after notice and an opportunity for public comment, determines the use of the small passenger vessel in the coastwise trade will not adversely affect United States vessel builders or the coastwise trade business of any person that employs vessels built in the United States in that business.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The U.S. Coast Guard and MARAD have authority under 46 U.S.C. 12121(b) through the Secretary of the Department of Homeland Security and the Secretary of the Department of Transportation, respectively.
                    </P>
                </FTNT>
                <P>
                    MARAD has received an eligibility determination request. Further details about the requester's vessel and its proposed operations may be found in the determination request posted in the DOT Docket Number listed in the 
                    <E T="02">ADDRESSES</E>
                     section above at 
                    <E T="03">https://www.regulations.gov.</E>
                     Interested parties may comment on the undue adverse effect this action may have on U.S. vessel builders or coastwise trade businesses in the U.S. that employ U.S.-built vessels in those businesses. Comments should refer to the vessel name, state the commenter's interest in the request, and demonstrate, with supporting documentation, the undue adverse effect on U.S. vessel builders and coastwise trade businesses.
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <HD SOURCE="HD2">How do I submit comments?</HD>
                <P>
                    Please submit comments, including the attachments, following the instructions provided under the above heading entitled 
                    <E T="02">ADDRESSES</E>
                    . It may take a few hours or even days for comments to be reflected on the docket. Comments must be written in English. Provide concise comments and attach additional documents as necessary. There is no limit on the length of the attachments.
                </P>
                <HD SOURCE="HD2">Where do I go to read public comments, and find supporting information?</HD>
                <P>
                    The docket online is located at 
                    <E T="03">https://www.regulations.gov,</E>
                     keyword search the DOT Docket Number list in the 
                    <E T="02">ADDRESSES</E>
                     section above or visit the Docket Management Facility (see 
                    <E T="02">ADDRESSES</E>
                     for hours of operation). Please periodically check the Docket for new submissions and supporting material.
                </P>
                <HD SOURCE="HD2">Will my comments be made available to the public?</HD>
                <P>Yes. Your entire comment, including your personal identifying information, will be made publicly available.</P>
                <HD SOURCE="HD2">May I submit comments confidentially?</HD>
                <P>
                    You may request that MARAD treat your comments as commercially confidential by submitting them to 
                    <E T="03">SmallVessels@dot.gov.</E>
                     Include in the 
                    <PRTPAGE P="48214"/>
                    email subject heading “Contains Confidential Commercial Information” or “Contains CCI” and state in your submission, with specificity, the basis for any such confidential treatment highlighting the CCI portions. If possible, please provide a summary of your submission that can be made available to the public.
                </P>
                <P>If MARAD receives a Freedom of Information Act (FOIA) request for the information, procedures described in the Department's FOIA regulation at 49 CFR 7.29 will be followed. Only information that is ultimately determined to be confidential under those procedures will be exempt from disclosure under FOIA.</P>
                <HD SOURCE="HD1">Privacy Act</HD>
                <P>
                    Anyone can search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). For information on DOT's compliance with the Privacy Act, please visit 
                    <E T="03">https://www.transportation.gov/privacy.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 46 U.S.C. 12121, 49 CFR 1.93(a).)</FP>
                </EXTRACT>
                <SIG>
                    <P>By Order of the Maritime Administrator.</P>
                    <NAME>T. Mitchell Hudson, Jr.,</NAME>
                    <TITLE>Secretary, Maritime Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15386 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-81-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Maritime Administration</SUBAGY>
                <DEPDOC>[Docket No. MARAD-2026-1159]</DEPDOC>
                <SUBJECT>Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V DOS PARA UNO</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Maritime Administration (MARAD), U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Secretary of Transportation, as represented by MARAD, is authorized to make determinations regarding the coastwise use of foreign built; certain U.S. built; and U.S. and foreign rebuilt vessels that solely carry no more than twelve passengers for hire. MARAD has received such a determination request and is publishing this notice to solicit comments to assist with determining whether the proposed use of the vessel set forth in the request would have an adverse effect on U.S. vessel builders or U.S. coastwise trade businesses that use U.S.-built vessels in those businesses. Information about the requestor's vessel, including a description of the proposed service, is in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section below.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by DOT Docket Number MARAD-2026-1159 by any one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Search the above DOT Docket Number and follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail or Hand Delivery:</E>
                         Docket Management Facility is in the West Building, Ground Floor of the U.S. Department of Transportation. The Docket Management Facility location address is U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except on Federal holidays.
                    </P>
                </ADD>
                <NOTE>
                    <HD SOURCE="HED">Note:</HD>
                    <P> If you mail or hand-deliver your comments, we recommend that you include the DOT Docket Number, your name and a mailing address, an email address or a telephone number in the body of your document so that we can contact you if we have questions regarding your submission.</P>
                </NOTE>
                <P>
                    <E T="03">Instructions:</E>
                     All submissions received must include the agency name and specific DOT Docket Number. All comments received will be posted without change to the docket at 
                    <E T="03">www.regulations.gov,</E>
                     including any personal information provided. For detailed instructions on submitting comments, or to submit comments that are confidential in nature, see the section entitled Public Participation.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Patricia Hagerty, U.S. Department of Transportation, Maritime Administration, 1200 New Jersey Avenue SE, Mail Stop 2, MAR-620, Washington, DC 20590. Telephone: (202) 366-5400. Email: 
                        <E T="03">smallvessels@dot.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Pursuant to 46 U.S.C. 12121(b), the U.S. Coast Guard may issue a certificate of documentation with a coastwise trade endorsement for eligible, small passenger vessels authorized to carry no more than 12 passengers for hire if MARAD, after notice and an opportunity for public comment, determines the use of the small passenger vessel in the coastwise trade will not adversely affect United States vessel builders or the coastwise trade business of any person that employs vessels built in the United States in that business.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The U.S. Coast Guard and MARAD have authority under 46 U.S.C. 12121(b) through the Secretary of the Department of Homeland Security and the Secretary of the Department of Transportation, respectively.
                    </P>
                </FTNT>
                <P>
                    MARAD has received an eligibility determination request. Further details about the requester's vessel and its proposed operations may be found in the determination request posted in the DOT Docket Number listed in the 
                    <E T="02">ADDRESSES</E>
                     section above at 
                    <E T="03">https://www.regulations.gov.</E>
                     Interested parties may comment on the undue adverse effect this action may have on U.S. vessel builders or coastwise trade businesses in the U.S. that employ U.S.-built vessels in those businesses. Comments should refer to the vessel name, state the commenter's interest in the request, and demonstrate, with supporting documentation, the undue adverse effect on U.S. vessel builders and coastwise trade businesses.
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <HD SOURCE="HD2">How do I submit comments?</HD>
                <P>
                    Please submit comments, including the attachments, following the instructions provided under the above heading entitled 
                    <E T="02">ADDRESSES</E>
                    . It may take a few hours or even days for comments to be reflected on the docket. Comments must be written in English. Provide concise comments and attach additional documents as necessary. There is no limit on the length of the attachments.
                </P>
                <HD SOURCE="HD2">Where do I go to read public comments, and find supporting information?</HD>
                <P>
                    The docket online is located at 
                    <E T="03">https://www.regulations.gov,</E>
                     keyword search the DOT Docket Number list in the 
                    <E T="02">ADDRESSES</E>
                     section above or visit the Docket Management Facility (see 
                    <E T="02">ADDRESSES</E>
                     for hours of operation). Please periodically check the Docket for new submissions and supporting material.
                </P>
                <HD SOURCE="HD2">Will my comments be made available to the public?</HD>
                <P>Yes. Your entire comment, including your personal identifying information, will be made publicly available.</P>
                <HD SOURCE="HD2">May I submit comments confidentially?</HD>
                <P>
                    You may request that MARAD treat your comments as commercially confidential by submitting them to 
                    <E T="03">SmallVessels@dot.gov.</E>
                     Include in the email subject heading “Contains Confidential Commercial Information” or “Contains CCI” and state in your submission, with specificity, the basis for any such confidential treatment 
                    <PRTPAGE P="48215"/>
                    highlighting the CCI portions. If possible, please provide a summary of your submission that can be made available to the public.
                </P>
                <P>If MARAD receives a Freedom of Information Act (FOIA) request for the information, procedures described in the Department's FOIA regulation at 49 CFR 7.29 will be followed. Only information that is ultimately determined to be confidential under those procedures will be exempt from disclosure under FOIA.</P>
                <HD SOURCE="HD1">Privacy Act</HD>
                <P>
                    Anyone can search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). For information on DOT's compliance with the Privacy Act, please visit 
                    <E T="03">https://www.transportation.gov/privacy.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 46 U.S.C. 12121, 49 CFR 1.93(a).)</FP>
                </EXTRACT>
                <SIG>
                    <P>By Order of the Maritime Administrator.</P>
                    <NAME>T. Mitchell Hudson, Jr.,</NAME>
                    <TITLE>Secretary, Maritime Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15383 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-81-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Maritime Administration</SUBAGY>
                <DEPDOC>[Docket No. MARAD-2026-1158]</DEPDOC>
                <SUBJECT>Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V CORMORANT</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Maritime Administration (MARAD), U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Secretary of Transportation, as represented by MARAD, is authorized to make determinations regarding the coastwise use of foreign built; certain U.S. built; and U.S. and foreign rebuilt vessels that solely carry no more than twelve passengers for hire. MARAD has received such a determination request and is publishing this notice to solicit comments to assist with determining whether the proposed use of the vessel set forth in the request would have an adverse effect on U.S. vessel builders or U.S. coastwise trade businesses that use U.S.-built vessels in those businesses. Information about the requestor's vessel, including a description of the proposed service, is in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section below.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by DOT Docket Number MARAD-2026-1158 by any one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Search the above DOT Docket Number and follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail or Hand Delivery:</E>
                         Docket Management Facility is in the West Building, Ground Floor of the U.S. Department of Transportation. The Docket Management Facility location address is U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except on Federal holidays.
                    </P>
                </ADD>
                <NOTE>
                    <HD SOURCE="HED">Note:</HD>
                    <P> If you mail or hand-deliver your comments, we recommend that you include the DOT Docket Number, your name and a mailing address, an email address or a telephone number in the body of your document so that we can contact you if we have questions regarding your submission.</P>
                </NOTE>
                <P>
                    <E T="03">Instructions:</E>
                     All submissions received must include the agency name and specific DOT Docket Number. All comments received will be posted without change to the docket at 
                    <E T="03">www.regulations.gov,</E>
                     including any personal information provided. For detailed instructions on submitting comments, or to submit comments that are confidential in nature, see the section entitled Public Participation.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Patricia Hagerty, U.S. Department of Transportation, Maritime Administration, 1200 New Jersey Avenue SE, Mail Stop 2, MAR-620, Washington, DC 20590. Telephone: (202) 366-5400. Email: 
                        <E T="03">smallvessels@dot.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Pursuant to 46 U.S.C. 12121(b), the U.S. Coast Guard may issue a certificate of documentation with a coastwise trade endorsement for eligible, small passenger vessels authorized to carry no more than 12 passengers for hire if MARAD, after notice and an opportunity for public comment, determines the use of the small passenger vessel in the coastwise trade will not adversely affect United States vessel builders or the coastwise trade business of any person that employs vessels built in the United States in that business.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The U.S. Coast Guard and MARAD have authority under 46 U.S.C. 12121(b) through the Secretary of the Department of Homeland Security and the Secretary of the Department of Transportation, respectively.
                    </P>
                </FTNT>
                <P>
                    MARAD has received an eligibility determination request. Further details about the requester's vessel and its proposed operations may be found in the determination request posted in the DOT Docket Number listed in the 
                    <E T="02">ADDRESSES</E>
                     section above at 
                    <E T="03">https://www.regulations.gov.</E>
                     Interested parties may comment on the undue adverse effect this action may have on U.S. vessel builders or coastwise trade businesses in the U.S. that employ U.S.-built vessels in those businesses. Comments should refer to the vessel name, state the commenter's interest in the request, and demonstrate, with supporting documentation, the undue adverse effect on U.S. vessel builders and coastwise trade businesses.
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <HD SOURCE="HD2">How do I submit comments?</HD>
                <P>
                    Please submit comments, including the attachments, following the instructions provided under the above heading entitled 
                    <E T="02">ADDRESSES</E>
                    . It may take a few hours or even days for comments to be reflected on the docket. Comments must be written in English. Provide concise comments and attach additional documents as necessary. There is no limit on the length of the attachments.
                </P>
                <HD SOURCE="HD2">Where do I go to read public comments, and find supporting information?</HD>
                <P>
                    The docket online is located at 
                    <E T="03">https://www.regulations.gov,</E>
                     keyword search the DOT Docket Number list in the 
                    <E T="02">ADDRESSES</E>
                     section above or visit the Docket Management Facility (see 
                    <E T="02">ADDRESSES</E>
                     for hours of operation). Please periodically check the Docket for new submissions and supporting material.
                </P>
                <HD SOURCE="HD2">Will my comments be made available to the public?</HD>
                <P>Yes. Your entire comment, including your personal identifying information, will be made publicly available.</P>
                <HD SOURCE="HD2">May I submit comments confidentially?</HD>
                <P>
                    You may request that MARAD treat your comments as commercially confidential by submitting them to 
                    <E T="03">SmallVessels@dot.gov.</E>
                     Include in the email subject heading “Contains Confidential Commercial Information” or “Contains CCI” and state in your submission, with specificity, the basis for any such confidential treatment 
                    <PRTPAGE P="48216"/>
                    highlighting the CCI portions. If possible, please provide a summary of your submission that can be made available to the public.
                </P>
                <P>If MARAD receives a Freedom of Information Act (FOIA) request for the information, procedures described in the Department's FOIA regulation at 49 CFR 7.29 will be followed. Only information that is ultimately determined to be confidential under those procedures will be exempt from disclosure under FOIA.</P>
                <HD SOURCE="HD1">Privacy Act</HD>
                <P>
                    Anyone can search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). For information on DOT's compliance with the Privacy Act, please visit 
                    <E T="03">https://www.transportation.gov/privacy.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 46 U.S.C. 12121, 49 CFR 1.93(a).)</FP>
                </EXTRACT>
                <SIG>
                    <P>By Order of the Maritime Administrator.</P>
                    <NAME>T. Mitchell Hudson, Jr.,</NAME>
                    <TITLE>Secretary, Maritime Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15384 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-81-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Maritime Administration</SUBAGY>
                <DEPDOC>[Docket No. MARAD-2026-1123]</DEPDOC>
                <SUBJECT>Request for Comments on the Renewal of a Previously Approved Information Collection: Application and Reporting Elements for Participation in the Tanker Security Program</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Maritime Administration (MARAD), U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        MARAD invites public comments on its intention to request Office of Management and Budget (OMB) approval to renew an information collection in accordance with the Paperwork Reduction Act of 1995. The proposed collection OMB 2133-0554 (Application and Reporting Elements for Participation in the Tanker Security Program) is used to evaluate the eligibility of applicants for participation in the Tanker Security Program (TSP). Since the last renewal, the application form for this collection is being updated to include minor clerical amendments regarding the authorizing statute and electronic submission procedures. MARAD is required to publish this notice in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments identified by Docket No. MARAD-2026-1123 through one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal: www.regulations.gov.</E>
                         Search using the above DOT docket number and follow the online instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail or Hand Delivery:</E>
                         Docket Management Facility, U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except on Federal holidays.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions must include the agency name and docket number for this rulemaking.
                    </P>
                </ADD>
                <NOTE>
                    <HD SOURCE="HED">Note:</HD>
                    <P>
                        All comments received will be posted without change to 
                        <E T="03">www.regulations.gov</E>
                         including any personal information provided.
                    </P>
                </NOTE>
                <P>
                    <E T="03">Comments are invited on:</E>
                     (a) whether the proposed collection of information is reasonable for the Department's performance; (b) the accuracy of the estimated burden; (c) ways for the Department to enhance the quality, utility, and clarity of the information collection; and (d) ways that the burden could be lessened without reducing the quality of the collected information. The agency will summarize or include your comments in the request for OMB's clearance of this information collection.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Richard Wanerman, 202-366-2306, Office of Sealift Support, Maritime Administration, 1200 New Jersey Avenue SE, Room W23-103, Mail Stop 2, Washington, DC 20590, 
                        <E T="03">Richard.Wanerman@dot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    <E T="03">Title:</E>
                     Application and Reporting Elements for Participation in the Tanker Security Program.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     2133-0554.
                </P>
                <P>
                    <E T="03">Type of Request:</E>
                     Extension with change of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     46 U.S.C. Chapter 534 established the Tanker Security Program (TSP) as a fleet of active, commercially viable, militarily useful, privately owned product tank vessels to meet national defense and other security requirements and maintain a United States presence in international commercial shipping. TSP provides for enrollment of eligible tank vessels in the program for FY 2022 through FY 2040. Applications and amendments will be used to select vessels for the fleet. Periodic reporting will be used to monitor adherence of participants to program parameters.
                </P>
                <P>
                    <E T="03">Respondents:</E>
                     Product tanker operators.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Business or other for profit.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     10.
                </P>
                <P>
                    <E T="03">Estimated Number of Responses:</E>
                     160.
                </P>
                <P>
                    <E T="03">Estimated Hours per Response:</E>
                     1-6.
                </P>
                <P>
                    <E T="03">Annual Estimated Total Annual Burden Hours:</E>
                     280.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     Monthly/Annually.
                </P>
                <EXTRACT>
                    <FP>(Authority: The Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended; and 49 CFR 1.49.)</FP>
                </EXTRACT>
                <SIG>
                    <P>By Order of the Maritime Administrator.</P>
                    <NAME>T. Mitchell Hudson, Jr.,</NAME>
                    <TITLE>Secretary, Maritime Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15378 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-81-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Maritime Administration</SUBAGY>
                <DEPDOC>[Docket No. MARAD-2026-1156]</DEPDOC>
                <SUBJECT>Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V WHITE STAR</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Maritime Administration (MARAD), U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Secretary of Transportation, as represented by MARAD, is authorized to make determinations regarding the coastwise use of foreign built; certain U.S. built; and U.S. and foreign rebuilt vessels that solely carry no more than twelve passengers for hire. MARAD has received such a determination request and is publishing this notice to solicit comments to assist with determining whether the proposed use of the vessel set forth in the request would have an adverse effect on U.S. vessel builders or U.S. coastwise trade businesses that use U.S.-built vessels in those businesses. Information about the requestor's vessel, including a description of the proposed service, is in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section below.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        You may submit comments identified by DOT Docket Number MARAD-2026-1156 by any one of the following methods:
                        <PRTPAGE P="48217"/>
                    </P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Search the above DOT Docket Number and follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail or Hand Delivery:</E>
                         Docket Management Facility is in the West Building, Ground Floor of the U.S. Department of Transportation. The Docket Management Facility location address is U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Room W12-140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except on Federal holidays.
                    </P>
                </ADD>
                <NOTE>
                    <HD SOURCE="HED">Note:</HD>
                    <P> If you mail or hand-deliver your comments, we recommend that you include the DOT Docket Number, your name and a mailing address, an email address or a telephone number in the body of your document so that we can contact you if we have questions regarding your submission.</P>
                </NOTE>
                <P>
                    <E T="03">Instructions:</E>
                     All submissions received must include the agency name and specific DOT Docket Number. All comments received will be posted without change to the docket at 
                    <E T="03">www.regulations.gov,</E>
                     including any personal information provided. For detailed instructions on submitting comments, or to submit comments that are confidential in nature, see the section entitled Public Participation.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Patricia Hagerty, U.S. Department of Transportation, Maritime Administration, 1200 New Jersey Avenue SE, Mail Stop 2, MAR-620, Washington, DC 20590. Telephone: (202) 366-5400. Email: 
                        <E T="03">smallvessels@dot.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Pursuant to 46 U.S.C. 12121(b), the U.S. Coast Guard may issue a certificate of documentation with a coastwise trade endorsement for eligible, small passenger vessels authorized to carry no more than 12 passengers for hire if MARAD, after notice and an opportunity for public comment, determines the use of the small passenger vessel in the coastwise trade will not adversely affect United States vessel builders or the coastwise trade business of any person that employs vessels built in the United States in that business.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The U.S. Coast Guard and MARAD have authority under 46 U.S.C. 12121(b) through the Secretary of the Department of Homeland Security and the Secretary of the Department of Transportation, respectively.
                    </P>
                </FTNT>
                <P>
                    MARAD has received an eligibility determination request. Further details about the requester's vessel and its proposed operations may be found in the determination request posted in the DOT Docket Number listed in the 
                    <E T="02">ADDRESSES</E>
                     section above at 
                    <E T="03">https://www.regulations.gov.</E>
                     Interested parties may comment on the undue adverse effect this action may have on U.S. vessel builders or coastwise trade businesses in the U.S. that employ U.S.-built vessels in those businesses. Comments should refer to the vessel name, state the commenter's interest in the request, and demonstrate, with supporting documentation, the undue adverse effect on U.S. vessel builders and coastwise trade businesses.
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <HD SOURCE="HD2">How do I submit comments?</HD>
                <P>
                    Please submit comments, including the attachments, following the instructions provided under the above heading entitled 
                    <E T="02">ADDRESSES</E>
                    . It may take a few hours or even days for comments to be reflected on the docket. Comments must be written in English. Provide concise comments and attach additional documents as necessary. There is no limit on the length of the attachments.
                </P>
                <HD SOURCE="HD2">Where do I go to read public comments, and find supporting information?</HD>
                <P>
                    The docket online is located at 
                    <E T="03">https://www.regulations.gov,</E>
                     keyword search the DOT Docket Number list in the 
                    <E T="02">ADDRESSES</E>
                     section above or visit the Docket Management Facility (see 
                    <E T="02">ADDRESSES</E>
                     for hours of operation). Please periodically check the Docket for new submissions and supporting material.
                </P>
                <HD SOURCE="HD2">Will my comments be made available to the public?</HD>
                <P>Yes. Your entire comment, including your personal identifying information, will be made publicly available.</P>
                <HD SOURCE="HD2">May I submit comments confidentially?</HD>
                <P>
                    You may request that MARAD treat your comments as commercially confidential by submitting them to 
                    <E T="03">SmallVessels@dot.gov.</E>
                     Include in the email subject heading “Contains Confidential Commercial Information” or “Contains CCI” and state in your submission, with specificity, the basis for any such confidential treatment highlighting the CCI portions. If possible, please provide a summary of your submission that can be made available to the public.
                </P>
                <P>If MARAD receives a Freedom of Information Act (FOIA) request for the information, procedures described in the Department's FOIA regulation at 49 CFR 7.29 will be followed. Only information that is ultimately determined to be confidential under those procedures will be exempt from disclosure under FOIA.</P>
                <HD SOURCE="HD1">Privacy Act</HD>
                <P>
                    Anyone can search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). For information on DOT's compliance with the Privacy Act, please visit 
                    <E T="03">https://www.transportation.gov/privacy.</E>
                </P>
                <EXTRACT>
                    <FP>(Authority: 46 U.S.C. 12121, 49 CFR 1.93(a).)</FP>
                </EXTRACT>
                <SIG>
                    <P>By Order of the Maritime Administrator.</P>
                    <NAME>T. Mitchell Hudson, Jr.,</NAME>
                    <TITLE>Secretary, Maritime Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15385 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-81-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>National Highway Traffic Safety Administration</SUBAGY>
                <SUBJECT>National Emergency Medical Services Advisory Council Notice of Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Highway Traffic Safety Administration, U.S. Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of public meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This notice announces a meeting of the National Emergency Medical Services Advisory Council (NEMSAC).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This meeting will be transmitted via virtual interface and is scheduled to be held on August 5, 2026, from 1:00 p.m. to 5:00 p.m. ET. Pre-registration is required to attend the meeting. Once registered, a link permitting access to the meeting will be distributed to registrants by email. If you wish to speak during the meeting, you must submit a written copy of your remarks to DOT by July 29, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        General information about the Council is available on the NEMSAC internet website at 
                        <E T="03">www.ems.gov.</E>
                         The registration portal and meeting agenda will be available on the NEMSAC internet website at 
                        <E T="03">www.ems.gov</E>
                         at least one week in advance of the meeting.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Clary Mole, EMS Specialist, National Highway Traffic Safety Administration, U.S. Department of Transportation is available by phone at (202) 868-3275 or by email at 
                        <E T="03">Clary.Mole@dot.gov.</E>
                         Any committee-related requests should be sent to the person listed in this section.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>
                    NEMSAC is authorized under Section 31108 of the Moving Ahead for Progress 
                    <PRTPAGE P="48218"/>
                    in the 21st Century (MAP-21) Act of 2012, codified at 42 U.S.C. 300d-4 as a Federal Advisory Committee. The purpose of NEMSAC is to serve as a nationally recognized council of emergency medical services (EMS) representatives to provide advice and consult with:
                </P>
                <P>a. The Federal Interagency Committee on Emergency Medical Services (FICEMS) on matters relating to EMS issues; and</P>
                <P>b. The Secretary of Transportation on matters relating to EMS issues affecting DOT.</P>
                <P>The NEMSAC provides an important national forum for the non-Federal deliberation of national EMS issues and serves as a platform for advice on DOT's national EMS activities. NEMSAC also provides advice and recommendations to the FICEMS.</P>
                <HD SOURCE="HD1">II. Agenda</HD>
                <P>At the meeting, the agenda will cover the following topics:</P>
                <FP SOURCE="FP-1">• NHTSA Initiatives</FP>
                <FP SOURCE="FP-1">• Updates from Federal Partners</FP>
                <FP SOURCE="FP-1">• Council Chair and Vice Chair Announcement</FP>
                <FP SOURCE="FP-1">• Subcommittee Names and Purposes Announcement</FP>
                <FP SOURCE="FP-1">• Solicitation of Subcommittee Chairperson Candidate Nominations</FP>
                <FP SOURCE="FP-1">• General Informational Sessions</FP>
                <FP SOURCE="FP-1">• Strategic Planning for NEMSAC</FP>
                <FP SOURCE="FP-1">• Public Comment Period</FP>
                <HD SOURCE="HD1">III. Public Participation</HD>
                <P>
                    This meeting will be open to the public. We are committed to providing equal access to this meeting for all participants. People with disabilities in need of accommodation should send a request to the individual in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this notice no later than July 29, 2026.
                </P>
                <P>
                    A period of time will be allotted for comments from members of the public attending the meeting. Members of the public may present questions and comments to the Council using the live chat feature available during the meeting. Members of the public may also submit materials, questions, and comments in advance to the individual listed in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this notice.
                </P>
                <P>
                    Members of the public wishing to reserve time to speak directly to the Council during the meeting must submit a request. The request must include the name, contact information (address, phone number, and email address), and organizational affiliation of the individual wishing to address NEMSAC; it must also include a written copy of prepared remarks and must be forwarded to the individual listed in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section of this notice no later than July 29, 2026.
                </P>
                <P>All advance submissions will be reviewed by the Council Chairperson and Designated Federal Officer. If approved, advance submissions shall be circulated to NEMSAC representatives for review prior to the meeting. All advance submissions will become part of the official record of the meeting.</P>
                <EXTRACT>
                    <FP>(Authority: 42 U.S.C. 300d-4(b); 49 CFR Part 1.95(i)(4).)</FP>
                </EXTRACT>
                <SIG>
                    <P>Issued in Washington, DC.</P>
                    <NAME>Angie Wang,</NAME>
                    <TITLE>Acting Associate Administrator, Research and Program Development.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15332 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-59-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>National Highway Traffic Safety Administration</SUBAGY>
                <DEPDOC>[Docket No. NHTSA-2024-0099; Notice 1]</DEPDOC>
                <SUBJECT>Toyota Motor North America, Receipt of Petition for Decision of Inconsequential Noncompliance</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Highway Traffic Safety Administration (NHTSA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Receipt of petition.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        Toyota Motor North America, Inc. (Toyota), on behalf of Toyota Motor corporation (TMC) (collectively referred to as “Toyota”), has determined that certain Joyson Safety Systems Seat Belt Assemblies do not fully comply with Federal Motor Vehicle Safety Standard (FMVSS) No. 209, 
                        <E T="03">Seat Belt Assemblies.</E>
                         Toyota filed a noncompliance report dated November 13, 2024, and subsequently petitioned NHTSA (the “Agency”) on December 6, 2024, for a decision that the subject noncompliance is inconsequential as it relates to motor vehicle safety. This document announces receipt of Toyota's petition.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Send comments on or before August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Interested persons are invited to submit written data, views, and arguments on this petition. Comments must refer to the docket and notice number cited in the title of this notice and may be submitted by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Send comments by mail addressed to the U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery:</E>
                         Deliver comments by hand to the U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590. The Docket Section is open on weekdays from 10 a.m. to 5 p.m. except for Federal Holidays.
                    </P>
                    <P>
                        • 
                        <E T="03">Electronically:</E>
                         Submit comments electronically by logging onto the Federal Docket Management System (FDMS) website at 
                        <E T="03">https://www.regulations.gov/.</E>
                         Follow the online instructions for submitting comments.
                    </P>
                    <P>• Comments may also be faxed to (202) 493-2251.</P>
                    <P>
                        Comments must be written in the English language, and be no greater than 15 pages in length, although there is no limit to the length of necessary attachments to the comments. If comments are submitted in hard copy form, please ensure that two copies are provided. If you wish to receive confirmation that comments you have submitted by mail were received, please enclose a stamped, self-addressed postcard with the comments. Note that all comments received will be posted without change to 
                        <E T="03">https://www.regulations.gov,</E>
                         including any personal information provided.
                    </P>
                    <P>All comments and supporting materials received before the close of business on the closing date indicated above will be filed in the docket and will be considered. All comments and supporting materials received after the closing date will also be filed and will be considered to the fullest extent possible.</P>
                    <P>
                        When the petition is granted or denied, notice of the decision will also be published in the 
                        <E T="04">Federal Register</E>
                         pursuant to the authority indicated at the end of this notice.
                    </P>
                    <P>
                        All comments, background documentation, and supporting materials submitted to the docket may be viewed by anyone at the address and times given above. The documents may also be viewed on the internet at 
                        <E T="03">https://www.regulations.gov</E>
                         by following the online instructions for accessing the dockets. The docket ID number for this petition is shown in the heading of this notice.
                    </P>
                    <P>
                        DOT's complete Privacy Act Statement is available for review in a 
                        <E T="04">Federal Register</E>
                         notice published on April 11, 2000 (65 FR 19477-78).
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Kelley Adams-Campos, Safety Compliance Engineer, NHTSA, Office of Vehicle Safety Compliance, (202) 366-7479.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    <PRTPAGE P="48219"/>
                </P>
                <P>
                    <E T="03">I. Overview:</E>
                     Toyota determined that certain replacement seat belt assemblies intended for use in certain MY 2003-2025 Toyota and MY 2016-2024 Lexus vehicles do not fully comply with paragraphs 4.1(k) and 4.1(l) of FMVSS No. 209, 
                    <E T="03">Seat Belt Assemblies</E>
                     (49 CFR 571.209) and filed a noncompliance report on November 13, 2024, pursuant to 49 CFR part 573, 
                    <E T="03">Defect and Noncompliance Responsibility and Reports.</E>
                     Toyota petitioned NHTSA on December 6, 2024, for an exemption from the notification and remedy requirements of 49 U.S.C. Chapter 301 on the basis that this noncompliance is inconsequential as it relates to motor vehicle safety, pursuant to 49 U.S.C. 30118(d) and 30120(h) and 49 CFR part 556, 
                    <E T="03">Exemption for Inconsequential Defect or Noncompliance.</E>
                </P>
                <P>This notice of receipt of Toyota's petition is published under 49 U.S.C. 30118 and 30120 and does not represent any agency decision or another exercise of judgment concerning the merits of the petition.</P>
                <P>
                    <E T="03">II. Equipment Involved:</E>
                     Approximately 12,216 seat belt assemblies, manufactured between July 1, 2020, and July 3, 2024, by Joyson Safety Systems, were reported by the manufacturer.
                </P>
                <P>
                    <E T="03">III. Rule Requirements:</E>
                     Paragraphs 4.1(k) and 4.1(l) of FMVSS No. 209 include the requirements relevant to this petition. S4.1(k) 
                    <E T="03">Installation Instructions</E>
                     specifies that a seat belt assembly, other than a seat belt assembly installed in a motor vehicle by an automobile manufacturer, shall be accompanied by an instruction sheet providing sufficient information for installing the assembly in a motor vehicle. If the assembly is for use only in specifically stated motor vehicles, the assembly shall either be permanently and legibly marked or labeled with the following statement, or the instruction sheet shall include the following statement:
                </P>
                <EXTRACT>
                    <P>
                        “This seat belt assembly is for use only in [insert specific seating position(s), 
                        <E T="03">e.g.,</E>
                         “front right”] in [insert specific vehicle make(s) and model(s)].”
                    </P>
                </EXTRACT>
                <P>Paragraph 4.1(l) of FMVSS No. 209 requires, in part, that a seat belt assembly shall be accompanied by written instructions for the proper use of the assembly, stressing particularly the importance of wearing the assembly snugly and properly located on the body, and on the maintenance of the assembly and periodic inspection of all components.</P>
                <P>
                    <E T="03">IV. Noncompliance:</E>
                     Toyota explains that approximately 12,216 seat belt assemblies sold as replacement equipment are missing the required installation instruction sheets or are accompanied by incorrect installation instruction sheets required by FMVSS 209 S4.1(k) and S4.1(l).
                </P>
                <P>
                    <E T="03">V. Summary of Toyota's Petition:</E>
                     The following views and arguments presented in this section, “V. Summary of Toyota's Petition,” are the views and arguments provided by Toyota. They have not been evaluated by the Agency and do not reflect the views of the Agency. Toyota describes the subject noncompliance and contends that the noncompliance is inconsequential as it relates to motor vehicle safety.
                </P>
                <P>In its petition, Toyota states that the noncompliance is inconsequential to motor vehicle safety for the following reasons:</P>
                <P>
                    <E T="03">I. The subject seat belt assemblies were sold only by Toyota dealerships. Improper replacement seat belt assembly selection would not likely occur due to the dealerships' replacement parts ordering system and the parts packaging.</E>
                </P>
                <P>Toyota contends it is unlikely that the subject seat belt assemblies would be selected for an incorrect seating position because the subject seat belt assemblies were only sold by Toyota dealerships. Toyota further states that the parts ordering system clearly indicates the part, enabling identification of the appropriate model vehicle and seating position for which the assembly is intended to be installed. Toyota explains how a replacement part can be searched in its “robust” part ordering system, using VIN, part number and vehicle model. Toyota also states the part can be identified by the label on the box, which specifies the part number and the part description. See Figure 1 of Toyota's petition for an example label on a part box. Because of the parts ordering system and package labeling, Toyota believes the missing or incorrect installation instruction sheet “has no effect on a dealership's ability to provide the correct replacement part ordered or on the installer's ability to correctly identify the appropriate replacement part.”</P>
                <P>
                    <E T="03">II. Improper installation of the seat belt assembly is unlikely. Dealership technicians and third-party installers can access Toyota's electronic repair manual and other aftermarket manuals.</E>
                </P>
                <P>Toyota states that it is unlikely that an improper installation of a replacement seat belt would occur as a result of a “missing or incorrect” instruction sheet. First, because an incorrect instruction sheet, which specifies the vehicle model and an image of the [seat belt assembly's] seating position, would be noticed by the purchaser. Toyota contends this would result in the purchaser obtaining the correct installation information from a different source or return the part to the dealer. Second, an installer who returns the part with the incorrect installation instruction sheet to the dealer would request the correct installation instructions from the dealer. Toyota states that technicians at Toyota dealerships have access to Toyota's electronic repair manual and that third party installers have access to various aftermarket repair manuals and can obtain access to Toyota's electronic repair manual. Toyota states that the “instructions would be provided free of charge” to an installer requesting a copy from Toyota. Furthermore, Toyota argues, that the seat belt assemblies “have characteristics that discourage incorrect installation,” and that “the installation procedure is the reverse of part removal.” Toyota also explains that the torque value for mounting the seat belt assemblies “is correct regardless of which instruction sheet is used” such that “even if the technician uses the torque values from the wrong installation instruction sheet, the torque value will still be correct.” See Toyota's petition for its audit findings on the subject seat belt assemblies.</P>
                <P>
                    <E T="03">III. The replacement seat belt assemblies are intended to replace the original equipment seat belts. The owner's manual for each vehicle contains the seat belt usage and maintenance instructions.</E>
                </P>
                <P>The affected seat belt assemblies are designed to replace the originally equipped seat belts in specific Toyota vehicles, according to Toyota. Toyota argues that an owner of a vehicle for which the subject seat belt assemblies were designed would not need to refer to the instruction sheet for usage and maintenance instructions because this information is contained in those vehicles' accompanying owner's manual.</P>
                <P>
                    <E T="03">IV. The seat belts comply with all other requirements of FMVSS No. 209.</E>
                </P>
                <P>
                    Toyota states that the “missing or incorrect” instruction sheets have “no bearing on the materials or performance of the replacement seatbelt [
                    <E T="03">sic</E>
                    ] assembly itself.” Toyota further contends that there is no impact to “performance, functionality, or occupant safety.”
                </P>
                <P>
                    <E T="03">V. Toyota is unaware of complaints of missing or incorrect instruction sheets.</E>
                </P>
                <P>
                    Toyota states that as of 11/13/2024 it found no “owner complaints, field reports, warranty claims, legal claims, or dealer technical assistance call records concerning the missing or incorrect installation instructions.”
                    <PRTPAGE P="48220"/>
                </P>
                <P>
                    <E T="03">VI. NHTSA has granted petitions for inconsequential noncompliance relating to the subject requirement of FMVSS No. 209.</E>
                </P>
                <P>Toyota lists the following inconsequential noncompliance petitions for missing or incorrect instruction sheets for certain replacement seat belt assemblies granted by NHTSA and believes the reasons they were granted apply to the subject Toyota replacement seat belt assemblies:</P>
                <FP SOURCE="FP-1">• FCA US LLC (84 FR 20948, May 3, 2019)</FP>
                <FP SOURCE="FP-1">• Mitsubishi Motors North America, Inc., (77 FR 24762, Apr. 25, 2012)</FP>
                <FP SOURCE="FP-1">• Bentley Motors Inc. (76 FR 58343, Sept. 20, 2011)</FP>
                <FP SOURCE="FP-1">• Hyundai Motor Company (74 FR 9125, Mar. 2, 2009)</FP>
                <FP SOURCE="FP-1">• Ford Motor Company, (73 FR 11462, Mar. 3, 2008)</FP>
                <FP SOURCE="FP-1">• Mazda North American Operations (73 FR 11464, Mar. 3, 2008)</FP>
                <FP SOURCE="FP-1">• Subaru of America, Inc., (65 FR 67471, Nov. 9, 2000)</FP>
                <P>NHTSA notes that the statutory provisions (49 U.S.C. 30118(d) and 30120(h)) that permit manufacturers to file petitions for a determination of inconsequentiality allow NHTSA to exempt manufacturers only from the duties found in sections 30118 and 30120, respectively, to notify owners, purchasers, and dealers of a defect or noncompliance and to remedy the defect or noncompliance. Therefore, any decision on this petition only applies to the subject equipment that Toyota no longer controlled at the time it determined that the noncompliance existed. However, any decision on this petition does not relieve equipment distributors and dealers of the prohibitions on the sale, offer for sale, or introduction or delivery for introduction into interstate commerce of the noncompliant equipment under their control after Toyota notified them that the subject noncompliance existed.</P>
                <EXTRACT>
                    <FP>(Authority: 49 U.S.C. 30118, 30120; delegations of authority at 49 CFR 1.95 and 501.8)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Otto G. Matheke III,</NAME>
                    <TITLE>Director, Office of Vehicle Safety Compliance.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15347 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-59-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Office of the Secretary</SUBAGY>
                <DEPDOC>[Docket No. DOT-OST-2026-1981]</DEPDOC>
                <SUBJECT>Privacy Act of 1974; System of Records</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Departmental Chief Information Officer, Office of the Secretary of Transportation, Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of a modified system of records.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In accordance with the Privacy Act of 1974, the Department of Transportation (DOT) proposes to rename, update, and reissue an existing system of records notice currently titled “Department of Transportation, Federal Aviation Administration, DOT/FAA 828 Physiological Training System.” The name of this system of records notice will be changed to “DOT/FAA 828 Physiological Training Records.” The modified system of records notice (hereafter referred to as “Notice” or “SORN”) covers records related to the management of physiological and post-crash survival training, inclusive of determining eligibility and enrolling students in training.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments on or before August 31, 2026. The Department may publish an amended Systems of Records Notice considering any comments received. This modified system will be effective immediately upon publication. The routine uses will be effective August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments, identified by docket number DOT-OST-2026-1981 by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal e-Rulemaking Portal: https://www.regulations.gov.</E>
                         Follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Docket Management Facility, U.S. Department of Transportation, 1200 New Jersey Ave. SE, West Building Ground Floor, Room W12-140, Washington, DC 20590-0001.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery or Courier:</E>
                         West Building Ground Floor, Room W12-140, 1200 New Jersey Ave. SE, between 9 a.m. and 5 p.m. ET, Monday through Friday, except Federal Holidays.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         (202) 493-2251.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         You must include the agency name and docket number DOT-OST-2026-1981. All comments received will be posted without change to 
                        <E T="03">https://www.regulations.gov,</E>
                         including any personal information provided. You may review the Department of Transportation's complete Privacy Act statement in the 
                        <E T="04">Federal Register</E>
                         published on April 11, 2000 (65 FR 19477-78).
                    </P>
                    <P>
                        <E T="03">Privacy Act:</E>
                         Anyone is able to search the electronic form of all comments received in any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). You may review the Department of Transportation's complete Privacy Act statement in the 
                        <E T="04">Federal Register</E>
                         published on April 11, 2000 (65 FR 19477-78), or you may visit 
                        <E T="03">http://DocketsInfo.dot.gov. Docket:</E>
                         For access to the docket to read background documents or comments received, go to 
                        <E T="03">http://www.regulations.gov</E>
                         or to the street address listed above. Follow the online instructions for accessing the docket.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For questions, please contact: Karyn Gorman, Departmental Chief Privacy Officer, Privacy Office, Department of Transportation, Washington, DC 20590; 
                        <E T="03">privacy@dot.gov;</E>
                         or 202-603-8321.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Notice Updates</HD>
                <P>This Notice update includes substantive and non-substantive changes to the previously published Notice. The substantive changes include updates to purpose, categories of individuals, categories of records, record source categories, routine uses of records, retention and disposal of records, and the administrative, technical and physical safeguards which are new to this Notice.</P>
                <P>Non-substantive changes have been made to system manager, storage of records, retrieval of records, record access procedures, contesting record procedures and notification procedures.</P>
                <HD SOURCE="HD1">Background</HD>
                <P>In accordance with the Privacy Act of 1974, 5 U.S.C. 552a, the Department of Transportation (DOT)/Federal Aviation Administration (FAA) proposes to update and reissue a DOT Privacy Act System of Records currently titled, “DOT/FAA 828 Physiological Training System.”</P>
                <P>
                    This Notice covers records related to the management of physiological and post-crash survival training, inclusive of determining eligibility and enrolling students in training. A “student” is described as follows: individuals such as pilots, flight engineers, technicians, parachutists, aviation medical examiners, physicians, and private individuals with a requirement (
                    <E T="03">i.e.</E>
                     regulation or FAA orders) or desire to 
                    <PRTPAGE P="48221"/>
                    participate in either of the training courses described below.
                </P>
                <P>There are two main training courses, physiological training and post-crash survival training, covered in this Notice. Under Code of Federal Regulations, Title 14, Part 61.31 (g)(1-3), pilots in command of a pressurized aircraft flying above 25,000 feet must receive physiological training from an authorized instructor who certifies that the individual has satisfactorily completed the training. Under FAA Order 4040.9E, FAA Order 4040.26C and Aircraft Certification Service (AIR)'s Flight Test Operations Manual (FTOM) (Chapter 5 Tables 5-1, 5-2 and 5-3), qualified flight test crew members have a requirement for physiological and survival training.</P>
                <P>Physiological training provides educational information and experience in the effects pertaining to the human body. Specifically, aerospace physiology relates to the effects of altitude experienced during flight with a primary focus on hypoxia as a problem that results from reduced barometric pressure limiting the availability of oxygen. To complete physiological training, a student must have a current FAA Class 1, 2 or 3 Aviation Medical or BasicMed Certificate to be allowed to enter a reduced oxygen environment to experience hypoxia. Students who do not possess the medical qualification may attend the training and receive academic information; however, these students cannot participate in the hypoxia exercise. Included in this training is spatial disorientation training, which provides educational information and experience in the effects of loss of situational awareness. Specifically, spatial disorientation relates to the effects of disorientation as it occurs in flight with a focus on illusions that can result in loss of aircraft control. To complete spatial disorientation training, a student must be a pilot or student pilot. Students who do not meet that requirement can attend the training and receive academic information; however, these students cannot participate in spatial disorientation demonstrations.</P>
                <P>Post-crash survival training provides educational information and experience regarding the tools and skills needed to stay alive. Specifically, post-crash survival training prepares aircrew for a survival situation resulting from an accident. To complete post-crash survival training, a student must be 18 years of age or older. Students that do not meet that requirement may attend the training and receive academic information; however, these students cannot participate in any dynamic training.</P>
                <P>
                    Students provide personal information to enroll in the desired training course which includes name, date of birth, phone number, email address, mailing address and point of contact. Additional information collected for the physiological training course on the day of consists of responses from students on their medical history (
                    <E T="03">i.e.,</E>
                     medications, nasal congestion, ear infections, upset stomach, hospitalizations, blood donations, altitude sickness, surgeries) which helps in the determination of whether the student can participate in the hypoxia exercise.
                </P>
                <P>The FAA does not maintain training files for these students, nor does it track their certificates. The agency provides the training and a course certificate to the students for them to track their training or provide to their employers. Information related to completion of the training courses is retained in the system to allow for reprinting of a course certificate should the original be lost/a duplicate be needed.</P>
                <P>The FAA is updating this existing Notice to make the following substantive changes:</P>
                <P>
                    1. 
                    <E T="03">Purpose:</E>
                     This Notice updates the purpose to better reflect the different uses of the system. One of these uses includes the eligibility and enrollment of students to attend the physiological or post-crash survival training course conducted at the Civil Aerospace Medical Institute (CAMI) in Oklahoma City, OK.
                </P>
                <P>
                    2. 
                    <E T="03">Categories of Individuals:</E>
                     This Notice updates the categories of individuals to expand the coverage from certificated airmen to FAA employees/contractors to include non-FAA individuals including pilots, flight engineers, technicians, parachutists, aviation medical examiners, physicians, and private individuals (collectively defined as students) with a requirement or desire to participate in the physiological or post-crash survival training course.
                </P>
                <P>
                    3. 
                    <E T="03">Categories of Records:</E>
                     This Notice updates the categories of records to include data elements captured to determine eligibility and to enroll students in the physiological or post-crash survival training program. Any reference to monetary funds were deleted from this Notice as these records are no longer required due to a change in the scope of the program. Payment is no longer required to attend these training programs.
                </P>
                <P>
                    4. 
                    <E T="03">Record Source Categories:</E>
                     This Notice updates the record source categories to clarify that covered individuals are the students who are registered and approved for the physiological or post-crash survival training program. Additional records sources include the people coordinating the training on behalf of the students, such as employers, college/university faculty, etc.
                </P>
                <P>
                    5. 
                    <E T="03">Routine Uses of Records:</E>
                     The Notice updates the routine uses to include the Department of Transportation's general routine uses applicable to this Notice as they were previously only incorporated by reference. The Office of Management and Budget (OMB) Memorandum A-108 recommends that agencies include all routine uses in one notice rather than incorporating general routine uses by reference. Therefore, the Department is replacing the statement in DOT/FAA 828 that referenced the “Prefatory Statement of General Routine Uses” with the general routine uses that apply to this system of records. The reference to transferring of training funds is removed as payment is no longer required for training. Additional references to determining individual training qualifications and maintaining records of training completion are removed as they are purposes of the system and do not constitute actual sharing of records with an individual or entity.
                </P>
                <P>
                    6. 
                    <E T="03">Retention and Disposal of Records:</E>
                     This Notice updates the retention section to reflect that a new records schedule is being drafted for this system. The retention period for the records is still to be determined. The FAA will maintain these records indefinitely until the new schedule is approved by the National Archives and Records Administration (NARA).
                </P>
                <P>
                    7. 
                    <E T="03">Administrative, Technical and Physical Safeguards:</E>
                     This Notice adds the administrative, technical and physical safeguards section to identify the current physical access requirements for the data covered under this Notice in an effort to minimize inadvertent release of information to unauthorized personnel. Electronic access is limited to those with an approved password and Personal Identification Verification (PIV) enabled credentials. This section was not required in the previously published Notice.
                </P>
                <P>The FAA is updating this Notice to make the following non-substantive changes:</P>
                <P>
                    8. 
                    <E T="03">System Manager:</E>
                     This Notice updates the system manager to include current contact information for the system.
                </P>
                <P>
                    9. 
                    <E T="03">Storage of Records:</E>
                     This Notice updates the records storage to clarify 
                    <PRTPAGE P="48222"/>
                    how electronic and hard copy files are maintained, including the description of the physical controls to the data.
                </P>
                <P>
                    10. 
                    <E T="03">Retrieval of Records:</E>
                     This Notice updates retrievability to add training year in addition to name, and to remove the location of training as this would not necessarily retrieve records about individuals.
                </P>
                <P>
                    11. 
                    <E T="03">Record Access Procedures:</E>
                     This Notice updates the record access procedures to include the redress guidance for students who wish to amend, access, or contest records covered under this Notice.
                </P>
                <P>
                    12. 
                    <E T="03">Contesting Record Procedures:</E>
                     This Notice updates the contesting record procedures section to include specific contesting record content guidance to students wishing to do so.
                </P>
                <P>
                    13. 
                    <E T="03">Notification Procedure:</E>
                     This Notice updates the notification procedures section to refer the student to the record access procedures section for guidance.
                </P>
                <HD SOURCE="HD2">Privacy Act</HD>
                <P>
                    The Privacy Act (5 U.S.C. 552a) governs the means by which the Federal Government collects, maintains, and uses personally identifiable information (PII) in a System of Records. A “System of Records” is a group of any records under the control of a Federal agency from which information about individuals is retrieved by name or other personal identifier. The Privacy Act requires each agency to publish in the 
                    <E T="04">Federal Register</E>
                     a System of Records Notice (SORN) identifying and describing each System of Records the agency maintains, including the purposes for which the agency uses PII in the system, the routine uses for which the agency discloses such information outside the agency, and how individuals to whom a Privacy Act record pertains can exercise their rights under the Privacy Act (
                    <E T="03">e.g.,</E>
                     to determine if the system contains information about them and to contest inaccurate information). In accordance with 5 U.S.C. 552a(r), DOT has provided a report of this system of records to the Office of Management and Budget and to Congress.
                </P>
                <PRIACT>
                    <HD SOURCE="HD1">SYSTEM NAME AND NUMBER:</HD>
                    <P>Department of Transportation, Federal Aviation Administration, DOT/FAA 828 Physiological Training Records.</P>
                    <HD SOURCE="HD2">SECURITY CLASSIFICATION: </HD>
                    <P>Unclassified</P>
                    <HD SOURCE="HD2">SYSTEM LOCATION:</HD>
                    <P>Aeromedical Education Division, AAM-400, FAA Civil Aerospace Medical Institute, Mike Monroney Aeronautical Center, 6500 S. MacArthur Blvd., P.O. Box 25082, Oklahoma City, OK 73125.</P>
                    <HD SOURCE="HD2">SYSTEM MANAGER(S):</HD>
                    <P>
                        Manager, Aeromedical Education Division, AAM-400, FAA Civil Aerospace Medical Institute, Mike Monroney Aeronautical Center, 6500 S. MacArthur Blvd., P.O. Box 25082, Oklahoma City, OK 73125; 
                        <E T="03">airmanedtraining@faa.gov;</E>
                         (405) 954-4837.
                    </P>
                    <HD SOURCE="HD2">AUTHORITY FOR MAINTENANCE OF THE SYSTEM:</HD>
                    <P>49 U.S.C. 44703 and 14 CFR 61.31(g)(1-2).</P>
                    <HD SOURCE="HD2">PURPOSE(S) OF THE SYSTEM:</HD>
                    <P>The three-fold purpose of the system is as follows: (1) Determine eligibility and enroll students who seek to participate in physiological or post-crash survival training; (2) Identify and maintain appropriate documentation on students who participated in physiological or post-crash survival training; and 93) Generate course completion certificates for students.</P>
                    <HD SOURCE="HD2">CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:</HD>
                    <P>FAA employees/contractors as well as non-FAA students.</P>
                    <HD SOURCE="HD2">CATEGORIES OF RECORDS IN THE SYSTEM:</HD>
                    <P>Records necessary to establish the eligibility of students to receive physiological or post-crash survival training and provide proper evidence of training that has been completed. Personal information collected on students includes name, date of birth, age, height, weight, citizenship, mailing address, phone number, email address, medical questions/history (with brief explanations for “Yes” responses), FAA medical certificate number and date, and signature. Employment/training related information collected on students includes classification of student, FAA organizational affiliation, duty routing symbol, company name, flight crew position, number of flight hours and prior number of chamber experiences. Other data collected includes point of contact, BasicMed physician's name and medical certificate examiner's designation number or form control number.</P>
                    <HD SOURCE="HD2">RECORD SOURCE CATEGORIES:</HD>
                    <P>Students who are registering for the physiological or post-crash survival training program, and people coordinating the training for the students, such as employers and college/university faculty.</P>
                    <HD SOURCE="HD2">ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES:</HD>
                    <P>In addition to those disclosures generally permitted under 5 U.S.C. 552a(b) of the Privacy Act, all or a portion of the records or information contained in this system may be disclosed outside of DOT/FAA as a routine use pursuant to 5 U.S.C. 552a(b)(3) as follows:</P>
                    <P>1. In the event that a system of records maintained by DOT to carry out its functions indicates a violation or potential violation of law, whether civil, criminal or regulatory in nature, and whether arising by general statute or particular program pursuant thereto, the relevant records in the system of records may be referred, as a routine use, to the appropriate agency, whether Federal, State, local or foreign, charged with the responsibility of investigating or prosecuting such violation or charged with enforcing or implementing the statute, or rule, regulation, or order issued pursuant thereto.</P>
                    <P>2. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local agency maintaining civil, criminal, or other relevant enforcement information or other pertinent information, such as current licenses, if necessary to obtain information relevant to a DOT decision concerning the hiring or retention of an employee, the issuance of a security clearance, the letting of a contract, or the issuance of a license, grant or other benefit.</P>
                    <P>3. A record from this system of records may be disclosed, as a routine use, to a Federal agency, in response to its request, in connection with the hiring or retention of an employee, the issuance of a security clearance, the reporting of an investigation of an employee, the letting of a contract, or the issuance of a license, grant, or other benefit by the requesting agency, to the extent that the information is relevant and necessary to the requesting agency's decision on the matter.</P>
                    <P>
                        4a. Routine Use for Disclosure for Use in Litigation. It shall be a routine use of the records in this system of records to disclose them to the Department of Justice or other Federal agency conducting litigation when (a) DOT, or any agency thereof, or (b) Any employee of DOT or any agency thereof, in his/her official capacity, or (c) Any employee of DOT or any agency thereof, in his/her individual capacity where the Department of Justice has agreed to represent the employee, or (d) The United States or any agency thereof, where DOT determines that litigation is likely to affect the United States, is a 
                        <PRTPAGE P="48223"/>
                        party to litigation or has an interest in such litigation, and the use of such records by the Department of Justice or other Federal agency conducting the litigation is deemed by DOT to be relevant and necessary in the litigation, provided, however, that in each case, DOT determines that disclosure of the records in the litigation is a use of the information contained in the records that is compatible with the purpose for which the records were collected.
                    </P>
                    <P>4b. Routine Use for Agency Disclosure in Other Proceedings. It shall be a routine use of records in this system to disclose them in proceedings before any court or adjudicative or administrative body before which DOT or any agency thereof, appears, when (a) DOT, or any agency thereof, or (b) Any employee of DOT or any agency thereof in his/her official capacity, or (c) Any employee of DOT or any agency thereof in his/her individual capacity where DOT has agreed to represent the employee, or (d) The United States or any agency thereof, where DOT determines that the proceeding is likely to affect the United States, is a party to the proceeding or has an interest in such proceeding, and DOT determines that use of such records is relevant and necessary in the proceeding, provided, however, that in each case, DOT determines that disclosure of the records in the proceeding is a use of the information contained in the records that is compatible with the purpose for which the records were collected.</P>
                    <P>5. The information contained in this system of records will be disclosed to the Office of Management and Budget in connection with the review of private relief legislation as set forth in OMB Circular No. A-19 at any stage of the legislative coordination and clearance process as set forth in that Circular.</P>
                    <P>6. Disclosure may be made to a Congressional office from the record of an individual in response to an inquiry from the Congressional office made at the request of that individual. In such cases, however, the Congressional office does not have greater rights to records than the individual. Thus, the disclosure may be withheld from delivery to the individual where the file contains investigative or actual information or other materials which are being used, or are expected to be used, to support prosecution or fines against the individual for violations of a statute, or of regulations of the Department based on statutory authority. No such limitations apply to records requested for Congressional oversight or legislative purposes; release is authorized under 49 CFR 10.35(a)(9).</P>
                    <P>7. One or more records from a system of records may be disclosed routinely to the National Archives and Records Administration in records management inspections being conducted under the authority of 44 U.S.C. 2904 and 2906.</P>
                    <P>8a. To appropriate agencies, entities, and persons when (1) DOT suspects or has confirmed that there has been a breach of the system of records; (2) DOT has determined that as a result of the suspected or confirmed breach there is a risk of harm to individuals, DOT (including its information systems, programs, and operations), the Federal Government, or national security; and (3) the disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with DOT's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm.</P>
                    <P>8b. To another Federal agency or Federal entity, when DOT determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in (1) responding to a suspected or confirmed breach or (2) preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity (including its information systems, programs, and operations), the Federal Government, or national security, resulting from a suspected or confirmed breach.</P>
                    <P>9. DOT may disclose records from this system, as a routine use, to the Office of Government Information Services for the purpose of (a) resolving disputes between FOIA requesters and Federal agencies and (b) reviewing agencies' policies, procedures, and compliance in order to recommend policy changes to Congress and the President.</P>
                    <P>10. DOT may disclose records from this system, as a routine use, to contractors and their agents, experts, consultants, and others performing or working on a contract, service, cooperative agreement, or other assignment for DOT, when necessary to accomplish an agency function related to this system of records.</P>
                    <P>11. DOT may disclose records from this system, as a routine use, to an agency, organization, or individual for the purpose of performing audit or oversight operations related to this system of records, but only such records as are necessary and relevant to the audit or oversight activity. This routine use does not apply to intra-agency sharing authorized under section (b)(1) of the Privacy Act.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR STORAGE OF RECORDS:</HD>
                    <P>Data required to enroll, establish eligibility, manage and provide evidence of training is maintained in an electronic database. Records are also maintained in hard copy within a filing cabinet with restricted access.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS:</HD>
                    <P>Records are retrieved by training year and last name.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS:</HD>
                    <P>A new retention schedule is being drafted for these records. The records will be maintained indefinitely until NARA approves the new schedule.</P>
                    <HD SOURCE="HD2">ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS:</HD>
                    <P>The data is password protected and limited to approved personnel in the Aeromedical</P>
                    <P>Education Division. The supervising official of the physiological training program updates passwords every 30 days in an effort to mitigate unauthorized access to the system. All FAA computers are controlled by FAA group policy, which forces the computer to lock down after 15 minutes of inactivity. Only an authorized user can restore access. The electronic data is protected behind a firewall in an FAA (Office of Information Technology) Enterprise Data Center. Access is limited to those with password and PIV enabled credentials. Additionally, hard copy files are maintained in a filing cabinet with restricted access.</P>
                    <HD SOURCE="HD2">RECORD ACCESS PROCEDURES:</HD>
                    <P>Individuals seeking notification of whether this system of records contains information about them may contact the System Manager at the address provided in the section “System Manager.” When seeking records about yourself from this system of records or any other Departmental system of records, your request must conform to the Privacy Act regulations set forth in 49 CFR part 10. You must sign your request, and your signature must either be notarized or submitted in accordance with 28 U.S.C. 1746, a law that permits statements to be made under penalty of perjury as a substitute for notarization. If your request is seeking records pertaining to another living individual, you must include a statement from that individual certifying his/her agreement for you to access his/her records.</P>
                    <HD SOURCE="HD2">CONTESTING RECORDS PROCEDURES:</HD>
                    <P>
                        Individuals seeking to contest the content of any record pertaining to him 
                        <PRTPAGE P="48224"/>
                        or her in the system of records may contact the System Manager and follow the Privacy Act procedures in 49 CFR part 10, subpart E, Correction of Records. You must sign your request, and your signature must either be notarized or submitted in accordance with 28 U.S.C. 1746, a law that permits statements to be made under penalty of perjury as a substitute for notarization. If your request contests the content of records pertaining to another living individual, you must include a statement from that individual certifying his/her agreement for you to access his/her records.
                    </P>
                    <HD SOURCE="HD2">NOTIFICATION PROCEDURES:</HD>
                    <P>See “Record Access Procedures” above.</P>
                    <HD SOURCE="HD2">EXEMPTIONS PROMULGATED FOR THE SYSTEM:</HD>
                    <P>No exemptions claimed.</P>
                    <HD SOURCE="HD2">HISTORY:</HD>
                    <P>
                        A full notice of this system of records, DOT/FAA 828 Physiological Training Records, was published in the 
                        <E T="04">Federal Register</E>
                         on April 11, 2000 (65 FR 19524).
                    </P>
                </PRIACT>
                <SIG>
                    <P>Issued in Washington, DC.</P>
                    <NAME>Karyn Gorman,</NAME>
                    <TITLE>Departmental Chief Privacy Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15359 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-9X-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF THE TREASURY</AGENCY>
                <SUBAGY>Office of Foreign Assets Control</SUBAGY>
                <SUBJECT>Notice of OFAC Sanctions Action</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Foreign Assets Control, Treasury.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) is publishing the names of one or more persons that have been placed on OFAC's Specially Designated Nationals and Blocked Persons List (SDN List) based on OFAC's determination that one or more applicable legal criteria were satisfied. All property and interests in property subject to U.S. jurisdiction of these persons are blocked, and U.S. persons are generally prohibited from engaging in transactions with them.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        This action was issued on July 22, 2026. See 
                        <E T="02">Supplementary Information</E>
                         for relevant dates.
                    </P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        OFAC: Associate Director for Global Targeting, 202-622-2420; Assistant Director for Licensing, 202-622-2480; Assistant Director for Sanctions Compliance, 202-622-2490 or 
                        <E T="03">https://ofac.treasury.gov/contact-ofac.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Electronic Availability</HD>
                <P>
                    The SDN List and additional information concerning OFAC sanctions programs are available on OFAC's website: 
                    <E T="03">https://ofac.treasury.gov.</E>
                </P>
                <HD SOURCE="HD1">Notice of OFAC Actions</HD>
                <P>On July 24, 2026, OFAC determined that the property and interests in property subject to U.S. jurisdiction of the following persons are blocked under the relevant sanctions authorities listed below.</P>
                <HD SOURCE="HD1">Individuals</HD>
                <BILCOD>BILLING CODE 4810-AL-P</BILCOD>
                <GPH SPAN="3" DEEP="604">
                    <PRTPAGE P="48225"/>
                    <GID>EN30JY26.005</GID>
                </GPH>
                <HD SOURCE="HD1">Entities</HD>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="48226"/>
                    <GID>EN30JY26.006</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="48227"/>
                    <GID>EN30JY26.007</GID>
                </GPH>
                <GPH SPAN="3" DEEP="218">
                    <PRTPAGE P="48228"/>
                    <GID>EN30JY26.008</GID>
                </GPH>
                <EXTRACT>
                    <FP>(Authority: E.O. 13902)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Bradley T. Smith,</NAME>
                    <TITLE>Director, Office of Foreign Assets Control.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15356 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4810-AL-C</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <DEPDOC>[OMB Control No. 2900-0321]</DEPDOC>
                <SUBJECT>Agency Information Collection Activity Under OMB Review: Appointment of Veterans Service Organization as Claimant's Representative and Appointment of Individual as Claimant's Representative</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Veterans Benefits Administration, Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the Paperwork Reduction Act (PRA) of 1995, this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden, and it includes the actual data collection instrument.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments and recommendations for the proposed information collection should be sent by August 31, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        To submit comments and recommendations for the proposed information collection, please type the following link into your browser: 
                        <E T="03">www.reginfo.gov/public/do/PRAMain,</E>
                         select “Currently under Review—Open for Public Comments”, then search the list for the information collection by Title or “OMB Control No. 2900-0321.”
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        <E T="03">VA PRA information:</E>
                         Dorothy Glasgow, 202-461-1084, 
                        <E T="03">VAPRA@va.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    <E T="03">Title:</E>
                     Appointment of Veterans Service Organization as Claimant's Representative and Appointment of Individual as Claimant's Representative (VA Form 21-22 and 21-22a).
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     2900-0321 
                    <E T="03">https://www.reginfo.gov/public/do/PRASearch.</E>
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     VA Forms 21-22 and 21-22a are used to collect the information needed to determine whom claimants have appointed to represent them in the preparation, presentation, and prosecution of claims for VA benefits. The information is also used to determine the extent of representatives' access to claimants' records. Without this information VA would be unable to determine whom claimants have appointed to represent them in the prosecution of VA claims, the extent of such representation, and access to appropriate records. The burden has increased since the previous approval due to the increase in the estimated number of receivables by respondents averaged over the past year.
                </P>
                <P>
                    An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The 
                    <E T="04">Federal Register</E>
                     Notice with a 60-day comment period soliciting comments on this collection of information was published at insert citation date: 91 FR 31525, May 2026.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals or Households.
                </P>
                <P>
                    <E T="03">Estimated Annual Burden:</E>
                     87,176 hours.
                </P>
                <P>
                    <E T="03">Estimated Average Burden per Respondent:</E>
                     5 minutes.
                </P>
                <P>
                    <E T="03">Frequency of Response: example:</E>
                     One time.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     1,046,113 per year.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <NAME>Shunda Willis,</NAME>
                    <TITLE>Alternate, VA PRA Clearance Officer, Office of Information Technology/Data Governance Analytics, Department of Veterans Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15375 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <DEPDOC>[OMB Control No. 2900-0663]</DEPDOC>
                <SUBJECT>Agency Information Collection Activity: PayVA (Pay Now Enter Info Page)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Debt Management Center, Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        Debt Management Center (DMC), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the 
                        <E T="04">Federal Register</E>
                         concerning each 
                        <PRTPAGE P="48229"/>
                        proposed collection of information, including each proposed extension of a currently approved collection, and allow 60 days for public comment in response to the notice. 
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Comments must be submitted through 
                        <E T="03">www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        <E T="03">Program-Specific information:</E>
                         Morgen Egesdal, 612-725-4353, 
                        <E T="03">Morgen.Egesdal@va.gov.</E>
                    </P>
                    <P>
                        <E T="03">VA PRA information:</E>
                         Dorothy Glasgow, 202-461-1084, 
                        <E T="03">VAPRA@va.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Under the PRA of 1995, Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.</P>
                <P>With respect to the following collection of information, DMC invites comments on: (1) whether the proposed collection of information is necessary for the proper performance of DMC's functions, including whether the information will have practical utility; (2) the accuracy of DMC's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.</P>
                <P>
                    <E T="03">Title:</E>
                     PayVA (Pay Now Enter Info Page).
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     2900-0663. 
                    <E T="03">https://www.reginfo.gov/public/do/PRASearch</E>
                     (Once at this link, you can enter the OMB Control Number to find the historical versions of this Information Collection).
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     PayVA (Pay Now Enter Info Page—
                    <E T="03">pay.va.gov</E>
                    ) is used by the VA Debt Management Center (DMC) to verify debts that are active at DMC before the indebted person makes a payment. PayVA collects basic debt information from the respondent and redirects them to 
                    <E T="03">pay.gov</E>
                     (a Department of Treasury website) for online payments. PayVA then collects responses from 
                    <E T="03">pay.gov</E>
                     to verify payment.
                </P>
                <P>The change in burden was the result of more payments being made electronically through the pay.va platform and a higher number of overall overpayment debts owed to the VA.</P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals.
                </P>
                <P>
                    <E T="03">Estimated Annual Burden:</E>
                     42,878 hours.
                </P>
                <P>
                    <E T="03">Estimated Average Burden per Respondent:</E>
                     10 minutes.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     On occasion.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     257,266.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <NAME>Shunda Willis,</NAME>
                    <TITLE>Alternate, VA PRA Clearance Officer, Office of Information Technology, Data Governance Analytics, Department of Veterans Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15354 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <DEPDOC>[OMB Control No. 2900-0165]</DEPDOC>
                <SUBJECT>Agency Information Collection Activity: Financial Status Report</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Debt Management Center, Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        Debt Management Center (DMC), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the 
                        <E T="04">Federal Register</E>
                         concerning each proposed collection of information, including each proposed extension of a currently approved collection, and allow 60 days for public comment in response to the notice. 
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Comments must be submitted through 
                        <E T="03">www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        <E T="03">Program-Specific information:</E>
                         Morgen Egesdal, 612-725-4353, 
                        <E T="03">Morgen.Egesdal@va.gov.</E>
                    </P>
                    <P>
                        <E T="03">VA PRA information:</E>
                         Dorothy Glasgow, 202-461-1084, 
                        <E T="03">VAPRA@va.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Under the PRA of 1995, Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.</P>
                <P>With respect to the following collection of information, DMC invites comments on: (1) whether the proposed collection of information is necessary for the proper performance of DMC's functions, including whether the information will have practical utility; (2) the accuracy of DMC's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.</P>
                <P>
                    <E T="03">Title:</E>
                     Financial Status Report, VA Form 5655.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     2900-0165. 
                    <E T="03">https://www.reginfo.gov/public/do/PRASearch</E>
                     (Once at this link, you can enter the OMB Control Number to find the historical versions of this Information Collection).
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The major use of the form is to document and support the eligibility determinations for waivers of collection, for the consideration of compromise offers, determine financial hardship suspensions, and/or for assisting in the development of repayment plans for overpayment debts owed to the VA.
                </P>
                <P>The burden has increased since the previous approval due to the resumption of collections of debts that were suspended during the Coronavirus 2019 (COVID-19) Pandemic. Collection was paused on new debts effective April 2020 at the Debt Management Center (DMC). Collection action resumed beginning May 2022 for suspended debts, and additional debts continue to be created, returning operations to normal.</P>
                <P>Additionally, DMC also no longer requires VA Form 5655 to approve repayment plans extending 60 months or fewer. Previously, VA Form 5655 was required to approve repayment plans extending greater than 12 months. Repayment plans on compensation and pension benefit overpayments now also automatically extend for 36 months instead of 12 months when over the minimum monthly payment threshold.</P>
                <P>Form usage has fluctuated due to the above-mentioned policy changes and collections restarting.</P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals
                </P>
                <P>
                    <E T="03">Estimated Annual Burden:</E>
                     150,871 hours.
                </P>
                <P>
                    <E T="03">Estimated Average Burden per Respondent:</E>
                     60 minutes.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     On occasion and/or annually.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     150,871.
                    <PRTPAGE P="48230"/>
                </P>
                <P>
                    <E T="03">Authority:</E>
                     44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <NAME>Shunda Willis,</NAME>
                    <TITLE>Alternate, VA PRA Clearance Officer, Office of Information Technology, Data Governance Analytics, Department of Veterans Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15355 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <DEPDOC>[OMB Control No. 2900-0161]</DEPDOC>
                <SUBJECT>Agency Information Collection Activity: Medical Expense Report</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Veterans Benefits Administration, Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        Veterans Benefits Administration, Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the 
                        <E T="04">Federal Register</E>
                         concerning each proposed collection of information, including each proposed extension of a currently approved collection, and allow 60 days for public comment in response to the notice. 
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before September 28, 2026.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Comments must be submitted through 
                        <E T="03">www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Program-Specific information: Kendra Mccleave, 202-461-9568, 
                        <E T="03">kendra.mccleave@va.gov.</E>
                         VA PRA information: Dorothy Glasgow, 202-461-1084, 
                        <E T="03">VAPRA@va.gov</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Under the PRA of 1995, Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.</P>
                <P>With respect to the following collection of information, VBA invites comments on: (1) whether the proposed collection of information is necessary for the proper performance of VBA's functions, including whether the information will have practical utility; (2) the accuracy of VBA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.</P>
                <P>
                    <E T="03">Title:</E>
                     21P-8416, Medical Expense Report.
                </P>
                <P>
                    <E T="03">OMB Control Number: 2900-0161. https://www.reginfo.gov/public/do/PRASearch</E>
                     (Once at this link, you can enter the OMB Control Number to find the historical versions of this Information Collection).
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     VA Form 21P-8416 allows claimants and beneficiaries to report unreimbursed medical expenses to reduce their countable income for needs-based benefit programs, such as VA Pension and Parents' Dependency and Indemnity Compensation (DIC). These expenses are deducted from otherwise countable income to determine eligibility for income-based benefits and the rate payable. Veteran Service Representatives use the information on the form to adjust benefits.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals and households.
                </P>
                <P>
                    <E T="03">Estimated Annual Burden:</E>
                     30,000 hours.
                </P>
                <P>
                    <E T="03">Estimated Average Burden per Respondent:</E>
                     30 minutes.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     One time.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     60,000.
                </P>
                <EXTRACT>
                    <FP>
                        (Authority: 44 U.S.C. 3501 
                        <E T="03">et seq.</E>
                        )
                    </FP>
                </EXTRACT>
                <SIG>
                    <NAME>Shunda Willis,</NAME>
                    <TITLE>Alternate, VA PRA Clearance Officer, Office of Information Technology/Data Governance Analytics, Department of Veterans Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2026-15353 Filed 7-29-26; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
    </NOTICES>
</FEDREG>
